

SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 80.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.

THIS PAGE BLANK (USPTO)
THIS PAGE BLANK (USPTO)

107 13.8 0.3 17 1 US-09-585-664B-1348 Sequence 1348, Ap
108 13.8 0.3 17 1 US-09-585-664B-3603 Sequence 3603, Ap
109 13.8 0.3 17 1 US-09-554-267-2 Sequence 2, Appl
110 13.8 0.3 17 1 US-09-554-267-21 Sequence 21, Appl
111 13.8 0.3 17 1 US-09-554-267-40 Sequence 40, Appl
112 13.8 0.3 17 1 PCT-US93-00977-96 Sequence 96, Appl
113 13.8 0.3 17 1 PCT-US95-07744A-30 Sequence 30, Appl
114 13.4 0.3 17 1 US-08-182-968A-3 Sequence 3, Appl
115 13.4 0.3 15 1 US-08-319-492B-95 Sequence 95, Appl
116 13.4 0.3 15 1 US-08-291-932A-95 Sequence 95, Appl
117 13.4 0.3 15 1 US-08-291-932A-96 Sequence 96, Appl
118 13.4 0.3 15 1 US-08-291-932A-244 Sequence 244, App
119 13.4 0.3 15 1 US-08-291-932A-284 Sequence 284, App
120 13.4 0.3 15 1 US-08-291-932A-285 Sequence 285, App
121 13.4 0.3 15 1 US-08-774-306A-3 Sequence 3, Appl
122 13.4 0.3 15 1 US-08-585-684B-2264 Sequence 2264, Ap
123 13.4 0.3 15 1 US-08-585-684B-2265 Sequence 2265, Ap
124 13.4 0.3 15 1 US-08-585-684B-2266 Sequence 2266, Ap
125 13.4 0.3 15 1 US-08-757-024-889 Sequence 889, App
126 13.4 0.3 15 1 US-08-757-024-946 Sequence 946, App
127 13.4 0.3 15 1 US-09-064-156A-3 Sequence 3, Appl
128 13.4 0.3 15 1 US-09-038-073-2264 Sequence 2264, Ap
129 13.4 0.3 15 1 US-09-038-073-2265 Sequence 2265, Ap
130 13.4 0.3 15 1 US-09-038-073-2266 Sequence 2266, Ap
131 13.4 0.3 15 1 US-09-081-646-122 Sequence 122, App
132 13.4 0.3 15 1 US-09-081-646-870 Sequence 870, App
133 13.4 0.3 15 1 US-09-093-972C-889 Sequence 889, App
134 13.4 0.3 15 1 US-09-093-972C-946 Sequence 946, App
135 13.4 0.3 16 1 US-08-757-024-882 Sequence 882, App
136 13.4 0.3 16 1 US-08-757-024-945 Sequence 945, App
137 13.4 0.3 16 1 US-09-413-452-25 Sequence 25, Appl
138 13.4 0.3 16 1 US-09-413-068-25 Sequence 25, Appl
139 13.4 0.3 16 1 US-09-060-299-433 Sequence 433, App
140 13.4 0.3 16 1 US-09-402-923A-433 Sequence 433, App
141 13.4 0.3 16 1 US-09-787-069-6 Sequence 6, Appl
142 13.4 0.3 16 1 US-09-914-841A-5 Sequence 5, Appl
143 13.4 0.3 16 1 US-09-093-972C-882 Sequence 882, App
144 13.4 0.3 16 1 US-09-093-972C-945 Sequence 945, App
145 13.4 0.3 16 1 US-10-110-502-2 Sequence 2, Appl

ALIGNMENTS

RESULT 1
US-09-140-378A-3/c
; Sequence 3, Application US/09140378A
; Patent No. 6627733
; GENERAL INFORMATION:
; APPLICANT: Johnson, Jeffrey D.
; APPLICANT: Rutter, William J.
; APPLICANT: Edman, Jeffrey C.
; APPLICANT: The Regents of the University of California
; TITLE OF INVENTION: Receptor Tyrosine Kinase With a Discoidin-Type Binding
; TITLE OF INVENTION: Domain
; FILE REFERENCE: 023070-079010US
; CURRENT APPLICATION NUMBER: US/09/140,378A
; CURRENT FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: US 08/077,254
; PRIOR FILING DATE: 1993-06-14
; PRIOR APPLICATION NUMBER: US 08/292,299
; PRIOR FILING DATE: 1994-08-16
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 3
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: antisense
; OTHER INFORMATION: oligonucleotide
US-09-140-378A-3

Query Match 0.5%; Score 20.4; DB 1; Length 24;
Best Local Similarity 75.0%; Pred. No. 6,9;
Matches 18; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 2587 CACCGAGACCTGGCTGCTCGCAAC 2610
Db 24 CAYCGGAVCTGGCYGCGSAAC 1
||:||||:||||:||||:||||:||||:
||:||||:||||:||||:||||:||||:

RESULT 2
US-09-396-196G-24487
; Sequence 24487, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24487
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-24487

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 8,4;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3005 TGATCCGGAACCCCGCCAGCTCAA 3029
Db 1 TGATCCGAACCCCAACAGCTCAA 25
|||||:|||||:|||||:|||||:|||||:
|||||:|||||:|||||:|||||:|||||:

RESULT 3
US-09-396-196G-37489/c
; Sequence 37489, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 37489
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-37489

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 8,4;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1940 ATCACAGCCAGACCCCACTGGATGA 1964
Db 25 ATCACAGCCAGACCCCAACAGGAAGA 1
|||||:|||||:|||||:|||||:|||||:
|||||:|||||:|||||:|||||:|||||:

```
RESULT 4
US-09-593-711A-41
; Sequence 41, Application US/09593711A
; Patent No. 6271030
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF C/EBP BETA EXPRESSION
; FILE REFERENCE: RTS-0118
; CURRENT APPLICATION NUMBER: US/09/593,711A
; CURRENT FILING DATE: 2000-06-14
; NUMBER OF SEQ ID NOS: 244
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-593-711A-41

Query Match          0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 18;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      214 GCCGCGCGCGGTGCGCCG 232
Db      1   GCCGCGCGCGCGCGCCG 19

RESULT 5
US-09-226-012-91/c
; Sequence 91, Application US/09226012
; Patent No. 6207383
; GENERAL INFORMATION:
; APPLICANT: Keating, Mark T.
; APPLICANT: Splawski, Igor
; TITLE OF INVENTION: MUTATIONS IN AND GENOMIC STRUCTURE OF HERG - A LONG QT
; TITLE OF INVENTION: SYNDROME GENE
; FILE REFERENCE: 2323-136
; CURRENT APPLICATION NUMBER: US/09/226,012
; CURRENT FILING DATE: 1999-01-06
; EARLIER APPLICATION NUMBER: 09/122,847
; EARLIER FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 91
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-226-012-91

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 26;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2018 GTGTGTCCTGCTGCTGCTG 2037
Db      20   GTCTGGTCCAGGTCCTGCTG 1

RESULT 6
US-09-630-706-22/c
; Sequence 22, Application US/09630706
; Patent No. 6277640
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF HER-3 EXPRESSION
; FILE REFERENCE: RTS-0053
; CURRENT APPLICATION NUMBER: US/09/630,706
; CURRENT FILING DATE: 2000-08-01
; NUMBER OF SEQ ID NOS: 94
```

```
; SEQ ID NO 22
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-630-706-22

Query Match          0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 22;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      105 ACCCCAACTCCAGCCAG 122
Db      18   ACACCAACTCCAGCCAG 1

RESULT 7
US-09-475-947A-333
; Sequence 333, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; APPLICANT: Minna, John D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 333
; LENGTH: 18
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-333

Query Match          0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 22;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1069 GGCCCCCAGCCCGCCTC 1086
Db      1   GGCCCCCAGCTCCAGCCTC 18

RESULT 8
US-08-204-697-6/c
; Sequence 6, Application US/08204697
; Patent No. 5648482
; GENERAL INFORMATION:
; APPLICANT: Meyer, Urs A
; TITLE OF INVENTION: DETECTION OF POOR METABOLIZERS OF DRUGS
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/204,697
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/716,500
; FILING DATE: 17-JUN-1991
```

```
; APPLICATION NUMBER: EP 90810467.2
; FILING DATE: 22-JUN-1990
; PRIOR APPLICATION DATA: EP 91108867.2
; FILING DATE: 29-MAY-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Schlager, John J.
; REGISTRATION NUMBER: 20942
; REFERENCE/DOCKET NUMBER: RAN 4095/3
; TELEPHONE: 201-235-2863
; TELEFAX: 201-235-3500
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-204-697-6

Query Match      0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 28;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3722 AGAAGGGGTGTCAGGGCC 3739
Db      20 AGAAGGAGTGTTCAGGGCC 3

RESULT 9
US-08-445-291-3/c
; Sequence 3, Application US/08445291
; Patent No. 5649638
; GENERAL INFORMATION:
; APPLICANT: Polushin, Nikolai N.
; APPLICANT: Efimov, Vladimir A.
; APPLICANT: Moroch, Alan M.
; APPLICANT: Cohen, Jack S.
; TITLE OF INVENTION: DEPROTECTION OF OLIGONUCLEOTIDES AND
; TITLE OF INVENTION: ANALOGS
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oliff & Berridge
; STREET: P.O. Box 19928
; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22320
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/445,291
; FILING DATE:
; CLASSIFICATION: 102
; ATTORNEY/AGENT INFORMATION:
; NAME: Berridge, William P.
; REGISTRATION NUMBER: 30,024
; REFERENCE/DOCKET NUMBER: WPB/J-267
; TELEPHONE: (703)836-6400
; TELEFAX: (703)836-2787
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-204-697-6

Query Match      0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 28;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3722 AGAAGGGGTGTCAGGGCC 3739
Db      20 AGAAGGAGTGTTCAGGGCC 3

RESULT 11
US-09-198-452A-2100/c
; Sequence 2100, Application US/09198452A
```

```
US-08-445-291-3
Query Match      0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 28;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3722 AGAAGGGGTGTCAGGGCC 3739
Db      20 AGAAGGAGTGTTCAGGGCC 3

RESULT 10
US-08-744-332-6/c
; Sequence 6, Application US/08744332
; Patent No. 5844108
; GENERAL INFORMATION:
; APPLICANT: Meyer, Urs A.
; TITLE OF INVENTION: DETECTION OF POOR METABOLIZERS OF DRUGS
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/744,332
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/716,500
; FILING DATE: 17-JUN-1991
; APPLICATION NUMBER: EP 90810467.2
; FILING DATE: 22-JUN-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 91108867.2
; FILING DATE: 29-MAY-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Schlager, John J.
; REGISTRATION NUMBER: 20942
; REFERENCE/DOCKET NUMBER: RAN 4095/3
; TELEPHONE: 201-235-2863
; TELEFAX: 201-235-3500
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-744-332-6

Query Match      0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 28;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3722 AGAAGGGGTGTCAGGGCC 3739
Db      20 AGAAGGAGTGTTCAGGGCC 3

RESULT 11
US-09-198-452A-2100/c
; Sequence 2100, Application US/09198452A
```

```
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 2100
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-2100

Query Match      0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 28;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3134 AAATGGGAAGATACGAAG 3151
Db 19 AAATGGGAAGATCCGAAG 2
|||||

RESULT 12
US-09-696-791-72/c
; Sequence 72, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 72
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cdk1 ribozyme binding site
US-09-696-791-72

Query Match      0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4188 CTTTTCGTATAAATAA 4203
Db 19 CTTTTCGTATAAATAA 4
|||||

RESULT 13
US-09-696-791-73/c
; Sequence 73, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 73
; LENGTH: 19
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cdk1 ribozyme binding site
US-09-696-791-73

Query Match      0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 29;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4188 CTTTTCGTATAAATAA 4203
Db 17 CTTTTCGTATAAATAA 2
|||||

RESULT 14
US-08-359-705B-22
; Sequence 22, Application US/08359705B
; Patent No. 5844092
; GENERAL INFORMATION:
; APPLICANT: Presta, Leonard G.
; APPLICANT: Shelton, David L.
; APPLICANT: Urfer, Roman
; TITLE OF INVENTION: Human trk Receptors and Neurotrophic Factor Inhibitors
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatIn (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/359,705B
; FILING DATE: 20-Dec-1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286846
; FILING DATE: 08/10/94
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/215139
; FILING DATE: 03/18/94
; ATTORNEY/AGENT INFORMATION:
; NAME: Torchia, Ph.D., Timothy E.
; REGISTRATION NUMBER: 36,700
; REFERENCE/DOCKET NUMBER: P0873P2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-8674
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
US-08-359-705B-22

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 32;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3539 ACTCCAGACCAAGGTGAG 3557
Db 1 ACGCCAGGCCAAGGTGAG 19
|||||

RESULT 15
US-08-286-846A-22
; Sequence 22, Application US/08286846A
```

```
; Patent No. 5877016
; GENERAL INFORMATION:
; APPLICANT: Presta, Leonard G.
; APPLICANT: Shelton, David L.
; APPLICANT: Urfer, Roman
; TITLE OF INVENTION: Human trk Receptors and Neurotrophic Factor Inhibitors
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatIn (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/286,846A
; FILING DATE: 05-Aug-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Torchia, Phd., Timothy E.
; REGISTRATION NUMBER: 36,700
; REFERENCE/DOCKET NUMBER: P0873P1
; TELEPHONE: 415/225-8674
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; US-08-286-846A-22

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 32;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3539 ACTCCAGACCAAGGTGAG 3557
Db 1 ACGCCAGGCCAGGGTGAG 19

RESULT 16
US-08-457-880A-22
; Sequence 22, Application US/08457880A
; Patent No. 5910574
; GENERAL INFORMATION:
; APPLICANT: Leonard G. Presta
; APPLICANT: David L. Shelton
; APPLICANT: Roman Urfer
; TITLE OF INVENTION: HUMAN trk RECEPTORS AND NEUROTROPHIC FACTOR
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatIn (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/457,880A
; FILING DATE: 19-May-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286846
; FILING DATE: 5
; ATTORNEY/AGENT INFORMATION:
; NAME: Torchia, Phd., Timothy E.
; REGISTRATION NUMBER: 36,700
; REFERENCE/DOCKET NUMBER: P0873P1C3
; TELEPHONE: 650/225-8674
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; US-08/457,880A
```

```
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/444,622
; FILING DATE: 19-May-1995
; APPLICATION NUMBER: 08/286846
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Torchia, Phd., Timothy E.
; REGISTRATION NUMBER: 36,700
; REFERENCE/DOCKET NUMBER: P0873P1C3
; TELEPHONE: 650/225-8674
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; US-08-457-880A-22

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 32;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3539 ACTCCAGACCAAGGTGAG 3557
Db 1 ACGCCAGGCCAGGGTGAG 19

RESULT 17
US-08-444-622A-22
; Sequence 22, Application US/08444622A
; Patent No. 6025166
; GENERAL INFORMATION:
; APPLICANT: Leonard G. Presta
; APPLICANT: David L. Shelton
; APPLICANT: Roman Urfer
; TITLE OF INVENTION: HUMAN trk RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatIn (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/444,622A
; FILING DATE: 19-May-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286846
; FILING DATE: 5
; ATTORNEY/AGENT INFORMATION:
; NAME: Torchia, Phd., Timothy E.
; REGISTRATION NUMBER: 36,700
; REFERENCE/DOCKET NUMBER: P0873P1C3
; TELEPHONE: 650/225-8674
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; US-08/444,622A
```


US-10-083-246A-83

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 32;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1068 TGGCCCCAGCCCGAGCTC 1086

DB 19 TTGTCCAGCCCGAGCTC 1

RESULT 21

US-08-292-620A-1948
; Sequence 1948, Application US/08292620A
; Patent No. 5837542

; GENERAL INFORMATION:

; APPLICANT: Susan Grimm

; APPLICANT: Dan T. Stinchcomb

; APPLICANT: James McSwiggen

; APPLICANT: Sean Sullivan

; APPLICANT: Kenneth G. Draper

; TITLE OF INVENTION: RIBOZYME TREATMENT OF

; TITLE OF INVENTION: DISEASES OR CONDITIONS

; TITLE OF INVENTION: RELATED TO LEVELS OF

; TITLE OF INVENTION: INTRACELLULAR ADHESION

; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

; NUMBER OF SEQUENCES: 2390

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; STREET: Suite 4700

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071-2066

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: Word Perfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/292,620A

; FILING DATE: August 17, 1994

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; PRIOR APPLICATION DATA: including application

; PRIOR APPLICATION DATA: described below:

; APPLICATION NUMBER: 08/008,895

; FILING DATE: January 19, 1993

; APPLICATION NUMBER: 07/989,849

; FILING DATE: December 7, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 208/149

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 1948:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-292-620A-1948

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 30;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1218 AGAAGGTCCTGCCAGC 1234

DB 1 AGAAGGTCCTGCCAGC 17

RESULT 22

US-09-071-845-1948

; Sequence 1948, Application US/09071845

; Patent No. 6132967

; GENERAL INFORMATION:

; APPLICANT: Susan Grimm

; APPLICANT: Dan T. Stinchcomb

; APPLICANT: James McSwiggen

; APPLICANT: Sean Sullivan

; APPLICANT: Kenneth G. Draper

; TITLE OF INVENTION: RIBOZYME TREATMENT OF

; TITLE OF INVENTION: DISEASES OR CONDITIONS

; TITLE OF INVENTION: RELATED TO LEVELS OF

; TITLE OF INVENTION: INTRACELLULAR ADHESION

; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)

; NUMBER OF SEQUENCES: 2390

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; STREET: Suite 4700

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071-2066

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: Word Perfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/071,845

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US/08/292,620

; FILING DATE: August 17, 1994

; APPLICATION NUMBER: 08/008,895

; FILING DATE: January 19, 1993

; APPLICATION NUMBER: 07/989,849

; FILING DATE: December 7, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 208/149

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 1948:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-09-071-845-1948

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 30;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1218 AGAAGGTCCTGCCAGC 1234

DB 1 AGAAGGTCCTGCCAGC 17

RESULT 23

US-09-866-108A-1653/c

; Sequence 1653, Application US/09866108A


```
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEONICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1653
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1653

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 30;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3966 TATGGCCTCCTTTGCC 3982
Db 17 TCTGGCCTCCTTTGCC 1

RESULT 24
US-09-866-108A-1654/c
; Sequence 1654, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEONICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
```

```
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1654
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1654

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 30;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3965 CTATGGCCTCCTTTGCC 3981
Db 17 CTCTGGCCTCCTTTGCC 1

RESULT 25
US-09-818-875-3946
; Sequence 3946, Application US/09818875
; Patent No. 6936467
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3946
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3946

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 30;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2319 CCTGAAGGGTGGCTACA 2335
Db 1 CCTGAAGGGTGGCTACA 17

RESULT 26
```

```
US-09-818-875-3947/c
; Sequence 3947, Application US/09818875
; Patent No. 6936467
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamber, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Stranded Oligonucleotides
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3947
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
;
US-09-818-875-3947

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 30;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 CCTGAAGGGTGGGTACA 2335
Db 17 CCTGGAGGGTGGGTACA 1

RESULT 27
US-08-937-063-15/c
; Sequence 15, Application US/08937063
; Patent No. 6187534
; GENERAL INFORMATION:
; APPLICANT: STROM, TERRY B.
; APPLICANT: VASCONCELLOS, LAURO
; APPLICANT: SUTHANTHIRAN, MANIKKAM
; TITLE OF INVENTION: METHODS OF EVALUATING TRANSPLANT
; TITLE OF INVENTION: REJECTION
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HAMILTON, BROOK, SMITH & REYNOLDS
; STREET: TWO MILITIA DRIVE
; CITY: LEXINGTON
; STATE: MASSACHUSETTS
; COUNTRY: UNITED STATES
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/937,063
; FILING DATE: 24-SEP-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: GRANAHAN, PATRICIA
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: BIDMC97-01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (781) 861-6240
; TELEFAX: (781) 861-9540
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
```

```
;
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-937-063-15

Query Match      0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3961 TTCACTATGGCCTCC 3975
Db 15 TTCACTATGGCCTCC 1

RESULT 28
US-09-371-772B-5010
; Sequence 5010, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: Levels of Vascular Endothelial Growth Factor Receptor
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5010
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5010

Query Match      0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 35;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2894 CCCC GCCC CCGAGACT 2908
Db 3 CCCC GCCC CCGAGACU 17

RESULT 29
US-09-371-772B-5011
; Sequence 5011, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: Levels of Vascular Endothelial Growth Factor Receptor
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5011
```

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5011

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 35;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2894 CCCCGCCCCCAGACT 2908
|||||
Db 2 CCCCGCCCCCAGACU 16

RESULT 30

US-09-371-772B-5012
; Sequence 5012, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEBH00, 876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5012
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5012

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 35;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2894 CCCCGCCCCCAGACT 2908
|||||
Db 1 CCCCGCCCCCAGACU 15

RESULT 31

US-09-866-108A-1651/c
; Sequence 1651, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: Ji, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1651
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1651

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3968 TGGCCTCTCTTGCCC 3982
|||||
Db 17 TGGCCTCTCTTGCCC 3

RESULT 32

US-09-866-108A-1652/c
; Sequence 1652, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: Ji, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1652

```
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1652

Query Match          0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3968 TGGCCTCCTTTGCC 3982
Db      |||||
        TGGCCTCCTTTGCC 2

RESULT 33
US-09-777-732A-15/c
; Sequence 15, Application US/09777732A
; Patent No. 6900015
; GENERAL INFORMATION:
; APPLICANT: Avihinganon, Yingyos
; APPLICANT: Ma, Malli
; APPLICANT: Strom, Terry
; APPLICANT: Soares, Miguel C.
; APPLICANT: Ferran, Chrisiane
; APPLICANT: Manikkam, Suchanthiran
; TITLE OF INVENTION: MEASUREMENT OF PROTECTIVE GENES IN ALLOGRAFT REJECTION
; FILE REFERENCE: 01948-059001
; CURRENT APPLICATION NUMBER: US/09/777,732A
; CURRENT FILING DATE: 2001-02-06
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: Fast-SEQ for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetically generated primer
US-09-777-732A-15

Query Match          0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3961 TTCACATGGCCCTCC 3975
Db      |||||
        TTCACATGGCCCTCC 1

RESULT 34
US-08-584-040-3042
; Sequence 3042, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
```

```
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3042:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-3042

Query Match          0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 40;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2894 CCCCGCCCCCAGACT 2908
Db      |||||
        CCCCGCCCCCAGACU 18

RESULT 35
US-09-371-772B-1470
; Sequence 1470, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1470
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1470

Query Match          0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 40;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2894 CCCCGCCCCCAGACT 2908
Db      |||||
        CCCCGCCCCCAGACU 18

RESULT 36
```

```
US-09-685-664B-1470
; Sequence 1470, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1470
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1470

Query Match 0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 40;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2894 CCCGCCCCCAGACT 2508
Db 4 CCCGCCCCCAGACU 18

RESULT 37
US-09-161-015-29
; Sequence 29, Application US/09161015A
; Patent No. 5965370
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF RHO G EXPRESSION
; FILE REFERENCE: RTS-0015
; CURRENT APPLICATION NUMBER: US/09/161,015A
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 29
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-161-015-29

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 658 CTCGAGTGCCTGTCCTG 675
Db 1 CGCGAGTGCCTGGCCCTG 18

RESULT 38
US-09-387-341-172
; Sequence 172, Application US/09387341
; Patent No. 6410523
; GENERAL INFORMATION:
; APPLICANT: Roberts, M. Luisa
; APPLICANT: Cowsett, Lex M.
; TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
```

```
; TITLE OF INVENTION: Expression
; FILE REFERENCE: ISPH-0404
; CURRENT APPLICATION NUMBER: US/09/387,341
; CURRENT FILING DATE: 1999-08-31
; EARLIER APPLICATION NUMBER: 09/156,424
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,979
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,807
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/161,015
; EARLIER FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 233
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 172
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-387-341-172

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 658 CTCGAGTGCCTGTCCTG 675
Db 1 CGCGAGTGCCTGGCCCTG 18

RESULT 39
US-09-920-760-12
; Sequence 12, Application US/09920760
; Patent No. 6492173
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF CYCLIN D2 EXPRESSION
; FILE REFERENCE: RTS-0275
; CURRENT APPLICATION NUMBER: US/09/920,760
; CURRENT FILING DATE: 2001-08-01
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 12
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-920-760-12

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2481 CTCCTTCCTCGCGCTAAA 2498
Db 1 CTCCTTCCTTGGCTAAA 18

RESULT 40
US-09-544-398B-517
; Sequence 517, Application US/09544398B
; Patent No. 6770461
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-013
; CURRENT APPLICATION NUMBER: US/09/544,398B
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: US 09/229,319
```

; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 517
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-544-398B-517

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3093 CTCAGCTTTGGCTCTGT 3110
||| ||||| ||||| |||||
Db 1 CTGAGCTTTGGCACTGT 18

RESULT 41
US-09-543-771B-517
; Sequence 517, Application US/09543771B
; Patent No. 6780609
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-014
; CURRENT APPLICATION NUMBER: US/09/543,771B
; CURRENT FILING DATE: 2000-04-05
; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 517
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-543-771B-517

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3093 CTCAGCTTTGGCTCTGT 3110
||| ||||| ||||| |||||
Db 1 CTGAGCTTTGGCACTGT 18

RESULT 42
US-09-060-299-432/c
; Sequence 432, Application US/09060299
; Patent No. 6545137
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; APPLICANT: Hess, John W
; APPLICANT: Caskey, Charles T
; APPLICANT: Cox, Roger D
; APPLICANT: Gerhold, David
; APPLICANT: Hammond, Holly
; APPLICANT: Hey, Patricia
; APPLICANT: Kawaguchi, Yoshihiko
; APPLICANT: Merriman, Tony R
; APPLICANT: Metzker, Michael L

; TITLE OF INVENTION: No. 6545137el Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. 6545137th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia
; COUNTRY: US
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/060,299
; FILING DATE: 15-APR-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-35
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 432:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
US-09-060-299-432

Query Match 0.3%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 40;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1705 CGGCTCTCACCAGCA 1720
||| ||||| ||||| |||||
Db 16 CGGCCCTCACCAGCA 1

RESULT 43
US-09-402-923A-432/c
; Sequence 432, Application US/09402923A
; Patent No. 6555654
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; Hess, John W
; Caskey, Charles T
; Cox, Roger D
; Gerhold, David
; Hammond, Holly
; Hey, Patricia
; Kawaguchi, Yoshihiko
; Merriman, Tony R
; Metzker, Michael L
; TITLE OF INVENTION: No. 6555654el LDL-Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. 6555654th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia
; COUNTRY: US
; ZIP: VA 2201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk

QY 2932 ATGCTGGACTGTTGGC 2947
||:|:|:|:|:|:|:
Db 1 AUGCUGGACUGCUGGC 16

RESULT 46
US-09-866-108A-905
? Sequence 905, Application US/09866108A
? Patent No. 6686188
? GENERAL INFORMATION:
? APPLICANT: GU, Yizhong
? APPLICANT: JI, Yonggang
? APPLICANT: PENN, Sharron G.
? APPLICANT: HANZEL, David K.
? APPLICANT: RANK, David R.
? APPLICANT: CHEN, Wensheng
? APPLICANT: SHANNON, Mark
? TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
? FILE REFERENCE: A6OMICA-7
? CURRENT APPLICATION NUMBER: US/09/866,108A
? CURRENT FILING DATE: 2001-05-25
? PRIOR APPLICATION NUMBER: US 60/207,456
? PRIOR FILING DATE: 2000-05-26
? PRIOR APPLICATION NUMBER: GB 24263.6
? PRIOR FILING DATE: 2000-10-04
? PRIOR APPLICATION NUMBER: US 60/236,359
? PRIOR FILING DATE: 2000-09-27
? PRIOR APPLICATION NUMBER: PCT/US01/00666
? PRIOR FILING DATE: 2001-01-30
? PRIOR APPLICATION NUMBER: PCT/US01/00667
? PRIOR FILING DATE: 2001-01-30
? PRIOR APPLICATION NUMBER: PCT/US01/00664
? PRIOR FILING DATE: 2001-01-30
? PRIOR APPLICATION NUMBER: PCT/US01/00669
? PRIOR FILING DATE: 2001-01-30
? PRIOR APPLICATION NUMBER: PCT/US01/00665
? PRIOR FILING DATE: 2001-01-30
? PRIOR APPLICATION NUMBER: PCT/US01/00668
? PRIOR FILING DATE: 2001-01-30
? PRIOR APPLICATION NUMBER: PCT/US01/00663
? PRIOR FILING DATE: 2001-01-30

; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2647
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2647

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 46;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1222 GGGTCTCTGGCAGCCAT 1237
|||||
Db 2 GGGTCTCTGGCAGCCAT 17

RESULT 50

US-09-866-108A-2648
; Sequence 2648, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2648
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2648

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 46;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1222 GGGTCTCTGGCAGCCAT 1237
|||||
Db 1 GGGTCTCTGGCAGCCAT 16

RESULT 51

US-07-796-106-13
; Sequence 13, Application US/07796106
; Patent No. 5389529
; GENERAL INFORMATION:
; APPLICANT: PANAYOTATOS, NIKOS
; APPLICANT: FANDL, JAMES P.
; TITLE OF INVENTION: Production and Recovery of Recombinant
; TITLE OF INVENTION: Neurotrophins
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/796,106
; FILING DATE: 19911121
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Misrock, S. Leslie
; REGISTRATION NUMBER: 18,872
; REFERENCE/DOCKET NUMBER: 6526-081
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 790-9090
; TELEFAX: (212) 8698864/9741
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
US-07-796-106-13

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 52;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1100 ATGCCAGTGGCCGA 1115
|||||
Db 2 ATGCCAGTGGCCGA 17

RESULT 52

```
US-09-199-859-46
; Sequence 46, Application US/09199859
; Patent No. 6069008
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF NF-KAPPA-B P65 SUBUNIT EXPRESSION
; FILE REFERENCE: RTS-0025
; CURRENT APPLICATION NUMBER: US/09/199,859
; CURRENT FILING DATE: 1998-11-25
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 46
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-199-859-46
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 52;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2669 TGGAGGAGAACTCTTC 2684
||| ||||| |||||
Db 2 TGGAGGAGAACTCTTC 17
RESULT 53
US-09-213-719-82/c
; Sequence 82, Application US/09213719B
; Patent No. 6150162
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD44 EXPRESSION
; FILE REFERENCE: RTS-0006
; CURRENT APPLICATION NUMBER: US/09/213,719B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 91
; SEQ ID NO 82
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-213-719-82
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 52;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2702 GCTCCCTGGGAGGAAA 2717
||| ||||| |||||
Db 16 GGTCCCTGGGAGGAAA 1
RESULT 54
US-09-044-602-2
; Sequence 2, Application US/09044602
; Patent No. 6613750
; GENERAL INFORMATION:
; APPLICANT: Depinho, Robert A.
; TITLE OF INVENTION: A METHOD OF INHIBITING CELL PROLIFERATION USING AN ANTI-ONCOGENE
; FILE REFERENCE: 96700/469
; CURRENT APPLICATION NUMBER: US/09/044,602
; CURRENT FILING DATE: 1998-03-19
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer for MDM2 mutant
US-10-424-630-2
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 52;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer for MDM2 mutant
US-09-044-602-2
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 52;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 3598 GAAGTCCCCAACATCT 3613
||| ||||| |||||
Db 2 GAAGGCCCAACATCT 17
RESULT 55
US-09-856-747-46
; Sequence 46, Application US/09856747
; Patent No. 6656688
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; APPLICANT: ISIS PHARMACEUTICALS, INC.
; TITLE OF INVENTION: ANTISENSE MODULATION OF NF-KAPPA-B P65 SUBUNIT EXPRESSION
; FILE REFERENCE: RTSP-0116
; CURRENT APPLICATION NUMBER: US/09/856,747
; CURRENT FILING DATE: 2001-05-24
; PRIOR APPLICATION NUMBER: US 09/199,859
; PRIOR FILING DATE: 1998-11-25
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 46
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-856-747-46
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 52;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2669 TGGAGGAGAACTCTTC 2684
||| ||||| |||||
Db 2 TGGAGGAGAACTCTTC 17
RESULT 56
US-10-424-630-2
; Sequence 2, Application US/10424630
; Patent No. 6897197
; GENERAL INFORMATION:
; APPLICANT: Depinho, Robert A.
; TITLE OF INVENTION: A METHOD OF INHIBITING CELL PROLIFERATION USING AN ANTI-ONCOGENE
; FILE REFERENCE: 96700/469
; CURRENT APPLICATION NUMBER: US/10/424,630
; CURRENT FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: US/09/044,602
; PRIOR FILING DATE: 1998-03-19
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer for MDM2 mutant
US-10-424-630-2
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 52;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

Qy 3598 GAAGTGGCCCACTCT 3613
|||||
Db 2 GAAGGGCCCACTCT 17

RESULT 57

US-08-050-073-184/c
; Sequence 184, Application US/08050073
; Patent No. 5567809
; GENERAL INFORMATION:
; APPLICANT: Apple, Raymond J.
; APPLICANT: Begovich, Ann B.
; APPLICANT: Bugawan, Teodorica L.
; APPLICANT: Brlich, Henry A.
; APPLICANT: Griffith, Robert L.
; APPLICANT: Scharf, Stephen J.
; TITLE OF INVENTION: Methods and Reagents for HLA DRBeta DNA
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 315
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/050,073
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Petry, Douglas A.
; REGISTRATION NUMBER: 35,321
; REFERENCE/DOCKET NUMBER: 8769
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (510) 814-2977
; TELEFAX: (510) 814-2977
; INFORMATION FOR SEQ ID NO: 184:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: genomic DNA
; US-08-050-073-184

Query Match 0.3%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2963 CCGGCGCCCGCTTC 2976
|||||
Db 14 CCGGCGCCCGCTTC 1

RESULT 58

US-08-009-075-1
; Sequence 1, Application US/08009075
; Patent No. 5300436
; GENERAL INFORMATION:
; APPLICANT: GOLDSTEIN, Menek
; APPLICANT: Wu, Jing
; APPLICANT: FILER, David
; APPLICANT: FRIEDHOFF, Arnold J.
; TITLE OF INVENTION: GENETICALLY MODIFIED TYROSINE
; TITLE OF INVENTION: HYDROXYLASE AND USES THEREOF
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: BROWDY and NEIMARK
; STREET: 419 Seventh Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/009,075
; FILING DATE: 19930126
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: TOWNSEND, GUY K.
; REGISTRATION NUMBER: 34,033
; REFERENCE/DOCKET NUMBER: GOLDSTEIN=1A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-628-5197
; TELEFAX: 202-737-3528
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-009-075-1

Query Match 0.3%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2111 GACAGTATCTCATC 2124
|||||
Db 2 GACAGTATCTCATC 15

RESULT 59

US-08-050-073-167/c
; Sequence 167, Application US/08050073
; Patent No. 5567809
; GENERAL INFORMATION:
; APPLICANT: Apple, Raymond J.
; APPLICANT: Begovich, Ann B.
; APPLICANT: Bugawan, Teodorica L.
; APPLICANT: Erlich, Henry A.
; APPLICANT: Griffith, Robert L.
; APPLICANT: Scharf, Stephen J.
; TITLE OF INVENTION: Methods and Reagents for HLA DRBeta DNA
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 315
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/050,073
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Petry, Douglas A.
; REGISTRATION NUMBER: 35,321

Patent No. 6461810
 GENERAL INFORMATION:
 APPLICANT: JOHNSON, Marion D.
 APPLICANT: FRESCO, Jacques R.
 TITLE OF INVENTION: TRIPLEX IN-SITU HYBRIDIZATION
 FILE REFERENCE: 2448-103
 CURRENT APPLICATION NUMBER: US/09/531,000
 PRIOR FILING DATE: 2000-09-08
 PCT/US98/23765
 PRIOR FILING DATE: 1998-11-10
 PRIOR APPLICATION NUMBER: 60/064,997
 PRIOR FILING DATE: 1997-11-10
 NUMBER OF SEQ ID NOS: 77
 SOFTWARE: PatentIn Ver. 2.1
 SEQ ID NO 23
 LENGTH: 16
 TYPE: DNA
 ORGANISM: Artificial Sequence
 FEATURE:
 OTHER INFORMATION: Description of Artificial Sequence: Target
 OTHER INFORMATION: sequences
 US-09-531-000-23

Query Match 0.3%; Score 14; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 48;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3587 CAGAGGAAAGGAA 3600
 Db 2 CAGAGGAAAGGAA 15
 |||||

RESULT 64
 US-08-050-073-75
 Sequence 75, Application US/08050073
 Patent No. 5567809
 GENERAL INFORMATION:
 APPLICANT: Apple, Raymond J.
 APPLICANT: Begovich, Ann B.
 APPLICANT: Bugawan, Teodorica L.
 APPLICANT: Erlich, Henry A.
 APPLICANT: Griffith, Robert L.
 APPLICANT: Scharf, Stephen J.
 TITLE OF INVENTION: Methods and Reagents for HLA DRBeta DNA
 TITLE OF INVENTION: Typing
 NUMBER OF SEQUENCES: 315
 CORRESPONDENCE ADDRESS:
 ADDRESS: Hoffmann-La Roche Inc.
 STREET: 340 Kingsland Street
 CITY: Nutley
 STATE: New Jersey
 COUNTRY: U.S.A.
 ZIP: 07110
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION NUMBER: US/08/050,073
 FILING DATE:
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Petry, Douglas A.
 REGISTRATION NUMBER: 35,321
 REFERENCE/DOCKET NUMBER: 8769
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (510) 814-2974
 TELEFAX: (510) 814-2977
 INFORMATION FOR SEQ ID NO: 75:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 17 base pairs
 TYPE: nucleic acid

STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: genomic DNA
 US-08-050-073-75
 Query Match 0.3%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 54;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 2963 CCGGGCCCCGCTTC 2976
 Db 3 CCGGGCCCCGCTTC 16
 |||||

RESULT 65
 US-08-050-073-149/c
 Sequence 149, Application US/08050073
 Patent No. 5567809
 GENERAL INFORMATION:
 APPLICANT: Apple, Raymond J.
 APPLICANT: Begovich, Ann B.
 APPLICANT: Bugawan, Teodorica L.
 APPLICANT: Erlich, Henry A.
 APPLICANT: Griffith, Robert L.
 APPLICANT: Scharf, Stephen J.
 TITLE OF INVENTION: Methods and Reagents for HLA DRBeta DNA
 TITLE OF INVENTION: Typing
 NUMBER OF SEQUENCES: 315
 CORRESPONDENCE ADDRESS:
 ADDRESS: Hoffmann-La Roche Inc.
 STREET: 340 Kingsland Street
 CITY: Nutley
 STATE: New Jersey
 COUNTRY: U.S.A.
 ZIP: 07110
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION NUMBER: US/08/050,073
 FILING DATE:
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Petry, Douglas A.
 REGISTRATION NUMBER: 35,321
 REFERENCE/DOCKET NUMBER: 8769
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (510) 814-2974
 TELEFAX: (510) 814-2977
 INFORMATION FOR SEQ ID NO: 149:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 17 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: genomic DNA
 US-08-050-073-149
 Query Match 0.3%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 54;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 2963 CCGGGCCCCGCTTC 2976
 Db 15 CCGGGCCCCGCTTC 2
 |||||

RESULT 66
 US-09-160-496-6/c
 Sequence 6, Application US/09160496
 Patent No. 6346613

```
; GENERAL INFORMATION:
; APPLICANT: O'Mahony, Daniel J
; APPLICANT: Cagney, Gerard
; TITLE OF INVENTION: Composition and Method for Enhancing Paracellular
; TITLE OF INVENTION: Transport across Cell Layers
; FILE REFERENCE: Docket No. 6346613: 98.1070.US
; CURRENT APPLICATION NUMBER: US/09/160,496
; CURRENT FILING DATE: 1998-09-24
; EARLIER APPLICATION NUMBER: US 60/059,644
; EARLIER FILING DATE: 1997-09-24
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Human occludin
; OTHER INFORMATION: scrambled oligonucleotide
US-09-160-496-6

Query Match          0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 54;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1561 CTAGTCCTGACTT 1574
DB 16 CTAGTCCTGACTT 3

RESULT 67
US-09-371-772B-5013
; Sequence 5013, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5013
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5013

Query Match          0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 54;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2895 CCGGCCCGGAGCT 2908
DB 1 CCGGCCCGGAGACU 14

RESULT 68
US-09-866-108A-1650/C
; Sequence 1650, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
```

```
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1650
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1650

Query Match          0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 54;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3969 GGCCTCCTTTGCC 3982
DB 17 GGCCTCCTTTGCC 4

RESULT 69
5182195-67/C
; Patent No. 5182195
; APPLICANT: NAKAHAMA, KAZUO;KAISHO, YOSHIHIKO;YOSHIMURA, KOJI
; TITLE OF INVENTION: METHOD FOR INCREASING USING PROTEASE
; DEFICIENT YEASTS
; NUMBER OF SEQUENCES: 71
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/269,140
; FILING DATE: 09-NOV-1988
; SEQ ID NO:67;
; LENGTH: 17
5182195-67

Query Match          0.3%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 54;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3848 TGAAGGTTTTTGAG 3861
DB 15 TGAAGGTTTTTGAG 2

RESULT 70
US-08-379-078-482
```

; Sequence 482, Application US/08379078
; Patent No. 5639612
; GENERAL INFORMATION:
; APPLICANT: Mitsuhashi, Masato
; TITLE OF INVENTION: Gene Detection System
; NUMBER OF SEQUENCES: 726
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: KNOBBE, MARTENS, OLSON AND BEAR
; STREET: 620 Newport Center Drive 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08379,078
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/974,406
; FILING DATE: 12-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Altman, Daniel E.
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.011CP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 482:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to mRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-379-078-482

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 149 CCACCTGCCAGCAGCTC 165
Db 1 CCACCTGCCACATGCTC 17

RESULT 71
US-08-261-822A-30/c
; Sequence 30, Application US/08261822A
; Patent No. 5650553
; GENERAL INFORMATION:
; APPLICANT: Ecker, Joseph R. et al.
; TITLE OF INVENTION: Plant Genes for Sensitivity to Ethylene
; TITLE OF INVENTION: and Pathogens
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & No. 5650553ris
; STREET: One Liberty Place, 46th floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/261,822A
; FILING DATE: 17-JUN-1994
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Beardell, Lori Y.
; REGISTRATION NUMBER: 34,293
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-08-261-822A-30

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2586 CCACCGAGACCTGGCTG 2602
Db 17 CCACCAAGACCTGGGTG 1

RESULT 72
US-08-955-138-48
; Sequence 48, Application US/08955138A
; Patent No. 5977435
; GENERAL INFORMATION:
; APPLICANT: Lefebvre, Daniel D.
; APPLICANT: Gellatly, Kevin S.
; TITLE OF INVENTION: PLANT PHOSPHATASES
; FILE REFERENCE: PPL97-01
; CURRENT APPLICATION NUMBER: US/08/955,138A
; CURRENT FILING DATE: 1997-10-21
; NUMBER OF SEQ ID NOS: 119
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 48
; LENGTH: 17
; TYPE: DNA
; ORGANISM: SOLANUM TUBEROSUM
; US-08-955-138-48

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3839 CCTTCATATTGAAGTTT 3855
Db 1 CCTTCATTTGAAGTTT 17

RESULT 73
US-08-985-162-326
; Sequence 326, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:

```
/
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq for Windows 2.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/985,162
/ FILING DATE: 04 December 1997
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 60/036,476
/ FILING DATE: 31 January 1997
/ ATTORNEY/AGENT INFORMATION:
/ NAME: warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 230/107
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 326:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-985-162-326

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 59;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2776 AGTGATGCGCTGGAGTTA 2792
||:|:|:|:|:|:|
Db 1 AGUGAUGUCUGGAGCUA 17

RESULT 74
US-07-974-409C-96
; Sequence 96, Application US/07974409C
; Patent No. 6300058
; GENERAL INFORMATION:
; APPLICANT: Akitaya, Tatsuo
; APPLICANT: Mitsuhashi, Masato
; APPLICANT: Cooper, Allan
; TITLE OF INVENTION: METHOD AND REAGENT
; TITLE OF INVENTION: FOR MEASURING MESSENGER RNA
; NUMBER OF SEQUENCES: 457
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson, and Bear
; STREET: 620 Newport Center Dr. Sixteenth Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/974,409C
; FILING DATE: 12-NOV-1992
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Altman, Daniel E.
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.006CEP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 96:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA to mRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-07-974-409C-96

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 149 CCACCTGCCAGCAGCTC 165
|||||
Db 1 CCACCTGCCAACATGCTC 17

RESULT 75
US-08-584-040-2794/c
; Sequence 2794, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2794:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
```


TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-2794

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3870 TTGGTCTTAATTTTCT 3886
Db 17 TTTTCTTAATTTTCT 1

RESULT 76
US-08-584-040-2824
; Sequence 2824, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2824:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-2824

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 17.6%; Pred. No. 59;
Matches 3; Conservative 12; Mismatches 2; Indels 0; Gaps 0;

Qy 3892 TTCCCTTTTGTCTTCTT 3908
Db 1 UUCACUUUUUGUUUU 17

RESULT 77
US-08-584-040-7819
; Sequence 7819, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7819:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7819

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 11.8%; Pred. No. 59;
Matches 2; Conservative 13; Mismatches 2; Indels 0; Gaps 0;

Qy 3854 TTTTGTGATTTTGT 3870
Db 1 UUUUGUUUUUGUUUU 17

RESULT 78
US-09-673-809-98/c
; Sequence 98, Application US/09673809
; Patent No. 6528261
; GENERAL INFORMATION:
; APPLICANT: INNOGENETICS N.V.
; TITLE OF INVENTION: Method for typing of HLA alleles.
; FILE REFERENCE: PCT99.86.HLA
; CURRENT APPLICATION NUMBER: US/09/673,809
; CURRENT FILING DATE: 2000-10-20

; PRIOR APPLICATION NUMBER: 98870088.6
; PRIOR FILING DATE: 1998-04-20
; NUMBER OF SEQ ID NOS: 107
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 98
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-673-809-98

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2628 CCTCGTCTGCAAGTGT 2644
| | | | | | | | | | | | | | | | | | | | |
DB 17 CATCGTCTGCCAAGTGT 1

RESULT 79
US-09-474-432B-535
; Sequence 535, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 535
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-535

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 59;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2776 AGTGATCGCTGGAGTTA 2792
| | | | | | | | | | | | | | | | | | | | |
DB 1 AGUGAUGUGUGAGAGUUA 17

RESULT 80
US-09-474-432B-559
; Sequence 559, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David

; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleoti
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 559
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-559

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 17.6%; Pred. No. 59;
Matches 3; Conservative 12; Mismatches 2; Indels 0; Gaps 0;

QY 3907 TTCGTTTCTTTTCTA 3923
| | | | | | | | | | | | | | | | | | | | |
DB 1 UTUGUUUUUUUUUUA 17

RESULT 81
US-09-371-772B-1318/C
; Sequence 1318, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1318
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1318

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3870 TTGGTCTTAATTTTCT 3886
| | | | | | | | | | | | | | | | | | | | |
DB 17 TTTTCTTAATTTTCT 1

RESULT 82
US-09-371-772B-1348
; Sequence 1348, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam

RESULT 86
US-09-371-772B-5092
; Sequence 5092, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: MCSwigen, Jim
; APPLICANT: Stinchcomb, Dan

```
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5092
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5092

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 59;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3521 CCCAGCCACCTCGGG 3537
    |||||
Db 1 CCCCGCCACCUCAGGG 17

RESULT 87
US-09-371-772B-5545/c
; Sequence 5545, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5545
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5545

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4175 TTTAAAAAAGTAACCTT 4191
    |||||
Db 17 TGTATAAAAGTAACCTT 1

RESULT 88
US-09-371-772B-5599
; Sequence 5599, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
```

```
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5599
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5599

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 29.4%; Pred. No. 59;
Matches 5; Conservative 10; Mismatches 2; Indels 0; Gaps 0;

QY 3889 CCGTTCCTCTTTGTTT 3905
    ||:|:|:|:|:|:|
Db 1 CCUUCACUUUUUUUUU 17

RESULT 89
US-09-371-772B-6785
; Sequence 6785, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6785
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6785

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 59;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2924 ACCAGCTATGCTGAC 2940
    |||||
Db 1 ACCAGACCAUGCUGGAC 17

RESULT 90
US-09-476-387-534
; Sequence 534, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, Dave
```

```

; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MBH00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 534
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-534

```

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 59;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2776 AGTGATGCCCTGGAGTTA 2792
||:|:|:|:|:|:|:|:
Db 1 AGUGAUGUGUGGAGUUA 17

RESULT 91
 US-09-476-387-558 ; Sequence 558, Application US/09476387
 ; Patent No. 6617438
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Beigelman, Leo
 ; APPLICANT: Beaudry, Amber
 ; APPLICANT: Karpeisky, Alex
 ; APPLICANT: Adamic, Jasenka Matulic
 ; APPLICANT: Sweedler, Dave
 ; APPLICANT: Zinnen, Shawn
 ; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
 ; FILE REFERENCE: MHB00-831-C (249/073)
 ; CURRENT APPLICATION NUMBER: US/09/476,387
 ; CURRENT FILING DATE: 2001-04-04
 ; PRIOR APPLICATION NUMBER: 09/474,432
 ; PRIOR FILING DATE: 1999-12-29
 ; PRIOR APPLICATION NUMBER: 09/301,511
 ; PRIOR FILING DATE: 1999-04-28
 ; PRIOR APPLICATION NUMBER: 09/186,675
 ; PRIOR FILING DATE: 1998-11-04
 ; PRIOR APPLICATION NUMBER: 60/083,727
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/064,866
 ; PRIOR FILING DATE: 1997-11-05
 ; NUMBER OF SEQ ID NOS: 1524
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 558
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-476-387-558

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 17.6%; Pred. No. 59;
Matches 3; Conservative 12; Mismatches 2; Indels 0; Gaps 0;

Qy 3907 TTCGTTTGTCTTA 3923
Dd 1 UUUGUUUUGUUUUUA 17

RESULT 92
US-09-401-063-326
; Sequence 326, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Fastseq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 326:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-401-063-326

Query Match	0.3%	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	64.7%	Pred. No. 59;		
Matches 11; Conservative		4; Mismatches	2; Indels	0; Gaps

Qy 2776 AGTGATGCCCTGGAGTTA 2792
||:|:|:|:|:|:|:
pb 1 AGUGAUGUCUGGAGCUA 17

RESULT 93
US-09-827-998-504
Sequence 504, Application US/09827998
Patent No. 6656700
GENERAL INFORMATION:
APPLICANT: Gu, Yizhong
APPLICANT: Shannon, Mark
TITLE OF INVENTION: NOVEL ISOFORMS OF
FILE REFERENCE: MDMP-8
CURRENT APPLICATION NUMBER: US/09/827

; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 504
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-504

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2700 GAGCTCCCTGGGAGGAA 2716
||||| |||||||
Db 1 GAGCTTCTGGGAGGAA 17

RESULT 94
US-09-827-998-505
; Sequence 505, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDhMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 505
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-505

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2701 AGCTCCCTGGGAGGAA 2717
||||| |||||||
Db 1 AGCTTCTGGGAGGAA 17

RESULT 95
US-09-747-391-84/c
; Sequence 84, Application US/09747391
; Patent No. 6670124
; GENERAL INFORMATION:
; APPLICANT: Chow, Robert
; APPLICANT: Tonai, Richard
; APPLICANT: StemCyt, Inc.
; TITLE OF INVENTION: High Throughput Methods of HLA Typing
; FILE REFERENCE: 020035-000210US
; CURRENT APPLICATION NUMBER: US/09/747,391
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: US 60/172,768
; PRIOR FILING DATE: 1999-12-20
; NUMBER OF SEQ ID NOS: 278
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 84

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-747-391-84

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 161 CGCTCGGGCGCGCGC 177
||||| |||||||
Db 17 CGCTCTGTGACGCGGC 1

RESULT 96
US-09-866-108A-2316/c
; Sequence 2316, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2316
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2316

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 CCATGGAGCTCCGGGTG 390
||||| |||||||
Db 17 CCATGGAGAACCGGTG 1

RESULT 97
US-09-866-108A-2464
; Sequence 2464, Application US/09866108A
; Patent No. 6686188

```
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2464
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2464

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3428 GCTGGATTGCACTTTGA 3444
Db 1 GCTGGATTGCACTTTGA 17

RESULT 98
US-09-866-108A-2778
; Sequence 2778, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2464
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2464
```

```
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: PCT/US01/00666
; CURRENT FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2778
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2778

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1194 GGGCACCTTCAAGCCCC 1210
Db 1 GGGCACCTTCAAGCACC 17

RESULT 99
US-09-866-108A-6262/c
; Sequence 6262, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
```

```
; SEQ ID NO 6262
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6262

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 564 GCAGCGTGGCCCGGCC 580
Db 17 GCAGCTTGGCCCGGCC 1

RESULT 100
US-09-866-108A-9235/c
; Sequence 9235, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9235
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9236

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2878 CAGGACTACCGCTGCC 2894
Db 17 CAGGACTGCAGGCTGCC 1

RESULT 102
US-09-866-108A-10354/c
; Sequence 10354, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9235
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9235

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2879 AGGACTACCGCTGCC 2895
Db 17 AGGACTGCAGGCTGCC 1

RESULT 101
US-09-866-108A-9236/c
; Sequence 9236, Application US/09866108A
```



```
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10354
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10354

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1342 CCTCCTTGGGCTCGCG 1358
Db 17 CCTCCTTGGGCTCGCG 1

RESULT 103
US-09-866-108A-10529/c
; Sequence 10529, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10354
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10354
```

```
; Patent No. 6686188
; SEQ ID NO 10529
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10529

Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2603 CTCGCAACATCCTAGTC 2619
Db 17 CTCGCAACATCCTAGTC 1

RESULT 104
US-09-866-108A-10530/c
; Sequence 10530, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10530
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10530
```

```
Query Match      0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2602 GCTCGCAACATCCTAGT 2618
Db 17 GCTCGCAACATCCTAGT 1

RESULT 105
US-09-866-108A-10531/c
```

; Sequence 10531, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10531
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10531

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2601 TGCTCGCAACATCCTAG 2617
Db 17 TGCTCGCAACATCGTCG 1

RESULT 106
US-09-685-664B-1318/c
; Sequence 1318, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772

; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1318
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1318

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3870 TTGGTCTTAATTTTCT 3886
Db 17 TTTTCTTAATTTTCT 1

RESULT 107
US-09-685-664B-1348
; Sequence 1348, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1348
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1348

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 17.6%; Pred. No. 59;
Matches 3; Conservative 12; Mismatches 2; Indels 0; Gaps 0;

Qy 3892 TTCCTTTTGTCTT 3908
Db 1 UUCACUUUUUGUUGU 17

RESULT 108
US-09-685-664B-3603
; Sequence 3603, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3603
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
; US-09-685-664B-3603

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 11.8%; Pred. No. 59;
Matches 2; Conservative 13; Mismatches 2; Indels 0; Gaps 0;

Qy 3854 TTTTGGAGTTTGTGTTT 3870
Db 1 UUUUGUUUUUUUUU 17

RESULT 109
US-09-554-267-2
; Sequence 2, Application US/09554267
; Patent No. 6878547
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, ANUSCHIRWAN
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: WEISER, CAROLINE
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES AGAINST TENASCIN FOR
; TITLE OF INVENTION: TREATING VITILIGO
; FILE REFERENCE: 02481.1669
; CURRENT APPLICATION NUMBER: US/09/554.267
; CURRENT FILING DATE: 2000-07-24
; PRIOR APPLICATION NUMBER: PCT/EP98/06868
; PRIOR FILING DATE: 1998-10-29
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-09-554-267-2

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2239 GGTGCAGGTGAGTTGG 2255
Db 1 GGTGCAGGTGAGTTGG 17

RESULT 110
US-09-554-267-21
; Sequence 21, Application US/09554267
; Patent No. 6878547
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, ANUSCHIRWAN
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: WEISER, CAROLINE
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES AGAINST TENASCIN FOR
; TITLE OF INVENTION: TREATING VITILIGO
; FILE REFERENCE: 02481.1669
; CURRENT APPLICATION NUMBER: US/09/554.267
; CURRENT FILING DATE: 2000-07-24
; PRIOR APPLICATION NUMBER: PCT/EP98/06868
; PRIOR FILING DATE: 1998-10-29
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 21
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-09-554-267-21

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2239 GGTGCAGGTGAGTTGG 2255
Db 1 GGTGCAGGTGAGTTGG 17

RESULT 111
US-09-554-267-40
; Sequence 40, Application US/09554267
; Patent No. 6878547
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, ANUSCHIRWAN
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: WEISER, CAROLINE
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES AGAINST TENASCIN FOR
; TITLE OF INVENTION: TREATING VITILIGO
; FILE REFERENCE: 02481.1669
; CURRENT APPLICATION NUMBER: US/09/554.267
; CURRENT FILING DATE: 2000-07-24
; PRIOR APPLICATION NUMBER: PCT/EP98/06868
; PRIOR FILING DATE: 1998-10-29
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 40
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-09-554-267-40

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2239 GGTGCAGGTGAGTTGG 2255
Db 1 GGTGCAGGTGAGTTGG 17

RESULT 112
PCT-US93-00977-96
; Sequence 96, Application PC/TUS9300977
; GENERAL INFORMATION:
; TITLE OF INVENTION: METHOD AND REAGENT FOR MEASURING MESSENGER RNA
; NUMBER OF SEQUENCES: 711
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson, and Bear
; STREET: 620 Newport Center Dr. Sixteenth Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/00977

```
;
; FILING DATE: 19930129
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Alcmán, Daniel E.
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.006H
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 96:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17
; TYPE: NUCLEIC ACID
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cdna to mRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
PCT-US93-00977-96

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 149 CCACTGCCAGCAGCTC 165
Db 1 CCACTGCCACATGCTC 17

RESULT 113
PCT-US95-07744A-30/c
; Sequence 30, Application PC/TUS9507744A
; GENERAL INFORMATION:
; APPLICANT: Trustees of The University of Pennsylvania
; TITLE OF INVENTION: Plant Genes for Sensitivity to Ethylene
; TITLE OF INVENTION: and Pathogens
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & Norris
; STREET: One Liberty Place, 46th floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/07744A
; FILING DATE: 15-JUNE-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/261,822
; FILING DATE: June 17, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Beardell, Lori Y.
; REGISTRATION NUMBER: 34,293
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
PCT-US95-07744A-30
```

```
;
; FILING DATE: 19930129
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Alcmán, Daniel E.
; REGISTRATION NUMBER: 34,115
; REFERENCE/DOCKET NUMBER: HITACHI.006H
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-760-0404
; TELEFAX: 714-760-9502
; INFORMATION FOR SEQ ID NO: 96:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17
; TYPE: NUCLEIC ACID
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cdna to mRNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
PCT-US93-00977-96

Query Match 0.3%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2586 CCACCGAGACCTGGCTG 2602
Db 17 CCACCAAGACCTGGGTG 1

RESULT 114
US-08-182-968A-3/c
; Sequence 3, Application US/08182968A
; Patent No. 5610054
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/182,968A
; FILING DATE: 13-JANUARY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/882,888
; FILING DATE: 14-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 205/277
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-182-968A-3

Query Match 0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 54;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 CTCGAGGGAGGGGGG 42
Db 15 CTCGAGGGAGGGGGG 1

RESULT 115
US-08-319-492B-95/c
; Sequence 95, Application US/08319492B
; Patent No. 5616488
; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
```

```

; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OF IL-5
; NUMBER OF SEQUENCES: 751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

```

```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/319,492B
; FILING DATE: October 7, 1994
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/276
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 95:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-319-492B-95

```

Two

```

Query Match 0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 54;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Oy 4166 TAAATTATTTTAAA 4180
Db 15 TAAATTATTTGAAA 1
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

```

RESULT 116

```

US-08-291-932A-95/c
; Sequence 95, Application US/08291932A
; Patent No. 5658780

```

```

; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

```

```

; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/291,932A
; FILING DATE: August 15, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/157
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 95:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-291-932A-95

```

Two

```

Query Match 0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 54;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Oy 2670 GGAGGAGGACTCTTC 2684
Db 15 GGAGGAGGAGTCTTC 1

```

RESULT 117

```

US-08-291-932A-96/c
; Sequence 96, Application US/08291932A
; Patent No. 5658780

```

```

; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/291,932A
; FILING DATE: August 15, 1994

```

CLASSIFICATION: 514
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 96:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-291-932A-96

Query Match 0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 54;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2669 TGGAGGAGAACTCTT 2683
Db 15 TCGAGGAGAACTCTT 1

RESULT 118

US-08-291-932A-244
Sequence 244, Application US/08291932A
Patent No. 5658780
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth G.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: NP-KB
NUMBER OF SEQUENCES: 830
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/291,932A
FILING DATE: August 15, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.

Two

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 244:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-291-932A-244

Query Match 0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 54;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1474 GGAGGCTCTGTGCG 1488
Db 1 GCAGGCCUCCUGGCG 15

RESULT 119

US-08-291-932A-284/c
Sequence 284, Application US/08291932A
Patent No. 5658780
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth G.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: NP-KB
NUMBER OF SEQUENCES: 830
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/291,932A
FILING DATE: August 15, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 284:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid

Two

; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-291-932A-284

Query Match 0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 54;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2670 GGAGGAGGAGTCTTC 2684
Db 15 GGAGGAGGAGTCTTC 1

RESULT 120
US-08-291-932A-285/c
; Sequence 285, Application US/08291932A
; Patent No. 5658780
; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/291,932A
; FILING DATE: August 15, 1994
; CLASSIFICATION: 514

; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994

; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/157
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 285:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-291-932A-285

Query Match 0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 54;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2669 TGGAGGAGGAGTCTT 2683
Db 15 TGGAGGAGGAGTCTT 1

Db 15 TGGAGGAGGAGTCTT 1

RESULT 121

US-08-774-306A-3/c
; Sequence 3, Application US/08774306A
; Patent No. 5869253
; GENERAL INFORMATION:

; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,306A
; FILING DATE: December 26, 1996
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/227
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-774-306A-3

Query Match 0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 54;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 CTCGAGGAGGAGG 42
Db 15 CTCGAGGAGGAGG 1

RESULT 122

US-08-585-684B-2264
; Sequence 2264, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:

```
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2264:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-2264

Query Match 0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 54;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

OY 552 AGTGTGTGACGTGCA 566
||:|:|:|:|:|
Db 1 AGUGUGUACGUGCA 15

RESULT 123
US-08-585-684B-2265
; Sequence 2265, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2266:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-2266
```

```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2265:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-2265

Query Match 0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 54;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

OY 552 AGTGTGTGACGTGCA 566
||:|:|:|:|:|
Db 1 AGUGUGUACGUGCA 15

RESULT 124
US-08-585-684B-2266
; Sequence 2266, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2266:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-2266
```



```

; TOPOLOGY: linear
US-08-585-684B-2266

Query Match      0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 54;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0

QY 553 GTGTGTGACGTGCAG 567
   |:|: |||:||||
Db 1 GUGUGUACGUGCAG 15

RESULT 125
US-08-757-024-889/c
; Sequence 889, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 889:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-757-024-889

Query Match      0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 54;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1178 GCCGAGCCTGTGCC 1192
   ||| ||||| |||||
Db 15 GCCGAGCCTGTGCC 1

RESULT 126
US-08-757-024-946/c
; Sequence 946, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: NYCE, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009

```

```
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 234/083
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-064-156A-3

Query Match 0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 54;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 CTCGAGGAGGGGG 42
DB 15 CTCGCGGAGGGGG 1

RESULT 128
US-09-038-073-2264
; Sequence 2264, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2264:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-2264
```

```
Query Match 0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 54;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 552 AGTGTGTGACGTGCA 566
DB 1 AGUGUGUACGUGCA 15

RESULT 129
US-09-038-073-2265
; Sequence 2265, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2265:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-2265

Query Match 0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 66.7%; Pred. No. 54;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 552 AGTGTGTGACGTGCA 566
DB 1 AGUGUGUACGUGCA 15

RESULT 130
US-09-038-073-2266
; Sequence 2266, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
```


; FILING DATE: 26-11-1996
; APPLICATION NUMBER: US 08/472,527
; FILING DATE: 7-June-1995
; APPLICATION NUMBER: US 09/016,464
; FILING DATE: 30-January-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EP1-00672
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 889:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 889:
US-09-093-972C-889

Query Match 0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 54;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1178 GCCGAGCCTGTGCC 1192
||| |||||
Db 15 GCCCAGCCTGTGCC 1

RESULT 134
US-09-093-972C-946/c
; Sequence 946, Application US/09093972C
; Patent No. 6825174
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
; BRONCHOCOSTRUCTION, ALLERGY (IBS) & INFLAMMATION
; NUMBER OF SEQUENCES: 996
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/093,972C
; FILING DATE: 09-Jun-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/472,527
; FILING DATE: 7-June-1995
; APPLICATION NUMBER: US 08/757,024
; FILING DATE: 26-11-1996
; APPLICATION NUMBER: US 08/472,527
; FILING DATE: 7-June-1995
; APPLICATION NUMBER: US 09/016,464
; FILING DATE: 30-January-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EP1-00672
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035

; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 946:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 946:
US-09-093-972C-946

Query Match 0.3%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 54;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1178 GCCGAGCCTGTGCC 1192
||| |||||
Db 15 GCCCAGCCTGTGCC 1

RESULT 135
US-08-757-024-882/c
; Sequence 882, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 882:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-757-024-882

Query Match 0.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 62;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1178 GCCGAGCCTGTGCC 1192
||| |||||
Db 16 GCCCAGCCTGTGCC 2

RESULT 136
US-08-757-024-945/c

```

; Sequence 945, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 945:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-757-024-945

Query Match      0.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 62;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1178 GCCGAGCCTGTGCC 1192
Db      16 GCCGAGCCTGTGCC 2

RESULT 137
US-09-413-452-25
; Sequence 25, Application US/09413452
; Patent No. 6083540
; GENERAL INFORMATION:
; APPLICANT: Christensen, T.
; APPLICANT: Thorsoe, H.
; APPLICANT: Kreiberg, J.
; APPLICANT: Buchholt, H.
; TITLE OF INVENTION: PROCESS FOR STABILIZING PROTEINS IN AN
; FILE REFERENCE: DYOUL4.001APC
; CURRENT APPLICATION NUMBER: US/09/413,452
; EARLIER FILING DATE: 1999-10-06
; EARLIER FILING DATE: 1998-05-18
; EARLIER FILING DATE: 1996-07-12
; NUMBER OF SEQ ID NOS: 56
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 25
; LENGTH: 16
; TYPE: DNA
; ORGANISM: UNI (M13-20 primer)
US-09-413-452-25

```

```

Query Match      0.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 62;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2495 TAAACGACGACGACGT 2509
Db      2 TAAACGACGACGACGT 16

RESULT 138
US-09-413-068-25
; Sequence 25, Application US/09413068
; Patent No. 6268195
; GENERAL INFORMATION:
; APPLICANT: Christensen, T.
; APPLICANT: Thorsoe, H.
; APPLICANT: Kreiberg, J.
; APPLICANT: Buchholt, H.
; TITLE OF INVENTION: PROCESS FOR STABILIZING PROTEINS IN AN
; FILE REFERENCE: DYOUL4.001APC
; CURRENT APPLICATION NUMBER: US/09/413,068
; CURRENT FILING DATE: 1999-06-06
; EARLIER APPLICATION NUMBER: 08/983364
; EARLIER FILING DATE: 1998-05-18
; EARLIER APPLICATION NUMBER: PCT/EP96/03051
; EARLIER FILING DATE: 1996-07-12
; NUMBER OF SEQ ID NOS: 56
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 25
; LENGTH: 16
; TYPE: DNA
; ORGANISM: UNI (M13-20 primer)
US-09-413-068-25

Query Match      0.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 62;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      2495 TAAACGACGACGACGT 2509
Db      2 TAAACGACGACGACGT 16

RESULT 139
US-09-060-299-433/c
; Sequence 433, Application US/09060299
; Patent No. 6545137
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; APPLICANT: Hess, John W
; APPLICANT: Caskey, Charles T
; APPLICANT: Cox, Roger D
; APPLICANT: Gerhold, David
; APPLICANT: Hammond, Holly
; APPLICANT: Hey, Patricia
; APPLICANT: Kawaguchi, Yoshihiko
; APPLICANT: Merriman, Tony R
; APPLICANT: Metzker, Michael L
; TITLE OF INVENTION: No. 6545137el Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. 6545137th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia
; COUNTRY: US
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25 (BPO)

```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/060,299
; FILING DATE: 15-APR-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; PRIOR APPLICATION DATA: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-35
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 433:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; US-09-060-299-433

Query Match 0.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 62;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3336 CTGACCTGCAGGAAC 3350
DB 15 CTGACCTGCATGAAC 1
|||||

RESULT 140
US-09-402-923A-433/c
; Sequence 433, Application US/09402923A
; Patent No. 6555654
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; HESS, John W
; Caskey, Charles T
; Cox, Roger D
; Gerhold, David
; Hammond, Holly
; Hey, Patricia
; Kawaguchi, Yoshihiko
; Merriman, Tony R
; Metzker, Michael L
; TITLE OF INVENTION: No. 6555654el LDL-Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. 6555654th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia
; COUNTRY: US
; ZIP: VA 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/402,923A
; FILING DATE: 14-Feb-2001
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB98/01102
; FILING DATE: 15-APR-1998
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997

```

```

; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-81
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 433:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 433:
; US-09-402-923A-433

Query Match 0.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 62;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3336 CTGACCTGCAGGAAC 3350
DB 15 CTGACCTGCATGAAC 1
|||||

RESULT 141
US-09-787-069-6
; Sequence 6, Application US/09787069
; Patent No. 6627429
; GENERAL INFORMATION:
; APPLICANT: Danisco A/S
; APPLICANT: Christensen, Tove MIE
; APPLICANT: Pedersen, Anette A
; APPLICANT: Brunstedt, Janne
; APPLICANT: Mikkelsen, Jorn D
; TITLE OF INVENTION: Process
; FILE REFERENCE: P005380WO CTH
; CURRENT APPLICATION NUMBER: US/09/787,069
; CURRENT FILING DATE: 2001-07-16
; PRIOR APPLICATION NUMBER: GB 9820195.7
; PRIOR FILING DATE: 1998-09-16
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 6
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
; US-09-787-069-6

Query Match 0.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 62;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2495 TAAACGACGACAGT 2509
DB 2 TAAACGACGACAGT 16
|||||

RESULT 142
US-09-914-841A-5
; Sequence 5, Application US/09914841A
; Patent No. 6645750
; GENERAL INFORMATION:
; APPLICANT: Amano Enzyme Inc.
; TITLE OF INVENTION: Beta-PRIMEVEROSIDASE GENE
; FILE REFERENCE: 066072
; CURRENT APPLICATION NUMBER: US/09/914,841A
; CURRENT FILING DATE: 2001-09-04
; PRIOR APPLICATION NUMBER: P. Hei. 11-056299
; PRIOR FILING DATE: 1999-03-04
; PRIOR APPLICATION NUMBER: PCT/JP00/01242

```

;; PRIOR FILING DATE: 2000-03-02
;; NUMBER OF SEQ ID NOS: 15
;; SOFTWARE: PatentIn version 3.1
;; SEQ ID NO 5
;; LENGTH: 16
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic DNA PCR primer
US-09-914-841A-5

Query Match 0.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 62;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2495 TAAACGACGGACAGT 2509
||| ||||| |||||
Db 2 TAAACGACGGCCAGT 16

RESULT 143

US-09-093-972C-882/c
; Sequence 882, Application US/09093972C
; Patent No. 6825174
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION

NUMBER OF SEQUENCES: 996
CORRESPONDENCE ADDRESS:
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
STREET: 7 Clarke Drive
CITY: Cranbury
STATE: New Jersey
COUNTRY: USA
ZIP: 08512

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/093,972C
FILING DATE: 09-Jun-1998
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 08/757,024
FILING DATE: 26-11-1996
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 09/016,464
FILING DATE: 30-January-1998
ATTORNEY/AGENT INFORMATION:
NAME: Anzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-00672
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 882:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 882:
US-09-093-972C-882

Query Match 0.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 62;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1178 GCCGAGCCTGTGCC 1192
||| ||||| |||||
Db 16 GCCGAGCCTGTGCC 2

RESULT 144

US-09-093-972C-945/c
; Sequence 945, Application US/09093972C
; Patent No. 6825174
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION

NUMBER OF SEQUENCES: 996
CORRESPONDENCE ADDRESS:
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
STREET: 7 Clarke Drive
CITY: Cranbury
STATE: New Jersey
COUNTRY: USA
ZIP: 08512

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/093,972C
FILING DATE: 09-Jun-1998
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 08/757,024
FILING DATE: 26-11-1996
APPLICATION NUMBER: US 08/472,527
FILING DATE: 7-June-1995
APPLICATION NUMBER: US 09/016,464
FILING DATE: 30-January-1998
ATTORNEY/AGENT INFORMATION:
NAME: Anzel, Viviana
REGISTRATION NUMBER: 30,930
REFERENCE/DOCKET NUMBER: EPI-00672
TELECOMMUNICATION INFORMATION:
TELEPHONE: 609-409-3035
TELEFAX: 413-254-9245
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 945:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 945:
US-09-093-972C-945

Query Match 0.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 62;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1178 GCCGAGCCTGTGCC 1192
||| ||||| |||||
Db 16 GCCGAGCCTGTGCC 2

RESULT 145

US-10-110-502-2

```

; Sequence 2, Application US/10110502
; Patent No. 6872870
; GENERAL INFORMATION:
; APPLICANT: Iturriaga de la Fuente, Gabriel
; APPLICANT: Thevelein, Johan M.
; APPLICANT: Van Dijk, Patrick
; APPLICANT: Mascorro-Gallardo, Jose Oscar
; APPLICANT: Van Vaec, Christophe
; TITLE OF INVENTION: Specific Genetic Modification Of The Activity of
; TITLE OF INVENTION: Trehalose-6-Phosphate Synthase And Expression in a
; FILE REFERENCE: 702-020635
; CURRENT APPLICATION NUMBER: US/10/110,502
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: PCT/EP99/07913
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: Microsoft Word 97 SR-2
; SEQ ID NO 2
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Universal primer
US-10-110-502-2

Query Match      0.3%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 62;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2495 TAAACGACGGACAGT 2509
Db 2 TAAACGACGGCCAGT 16

```

Search completed: March 23, 2006, 11:12:26
Job time : 8 secs

GenCore version 5.1.7

Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 23, 2006, 11:22:19 ; Search time 0.001 Seconds
(without alignments)

2981.440 Million cell updates/sec

Title: US-10-800-077-392

Perfect score: 4235

Sequence: 1 ctgcggccgcggcgagc.....cgtgccagctccaggggt 4235

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 18 seqs, 352 residues

Total number of hits satisfying chosen parameters: 36

Minimum DB seq length: 5

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 18 summaries

Database : fetch392rst.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
C 1	16.8	0.4	20	1	CF306206
C 2	16.8	0.4	20	1	CF306357
C 3	16.8	0.4	20	1	CF307027
C 4	16.8	0.4	20	1	CF307105
C 5	16.8	0.4	20	1	CF307109
C 6	16.8	0.4	20	1	CF307258
C 7	16.8	0.4	21	1	CF306412
C 8	16.8	0.4	21	1	CF306419
C 9	16.8	0.4	21	1	CF306998
C 10	16.8	0.4	21	1	CF307416
C 11	16.8	0.4	21	1	CF307437
C 12	15.8	0.4	19	1	AI383415
C 13	15.8	0.4	19	1	CF307006
C 14	15.8	0.4	19	1	CF307304
C 15	15.8	0.4	19	1	CF307439
C 16	15.8	0.4	19	1	C2283815
C 17	13.4	0.3	16	1	BM394080
C 18	12.8	0.3	16	1	AI560058

ALIGNMENTS

RESULT 1
CF306206/c
LOCUS
DEFINITION HDAl--03-A04 g1 OshDACL-overexpressing transgenic rice lambda phage
cDNA library I (HDAl) Oryza sativa (japonica cultivar-group) cDNA
clone HDAl--03-A04, mRNA sequence.
CF306206
CF306206.1 GI:33677967
EST.
Oryza sativa (japonica cultivar-group)

ORGANISM

Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.

REFERENCE

1. (bases 1 to 20)
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,
Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.

TITLE

Large-scale Sequencing Analysis of Rice ESTs

JOURNAL

Unpublished (2003)

COMMENT

Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhnm@bio.com, bnhnm@bio.myongji.ac.kr.

FEATURES

source

1..20
Location/Qualifiers
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HDAl--03-A04"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli SOLR"
/clone_lib="OshDACL-overexpressing transgenic rice lambda
phage cDNA library I (HDAl)"
/notes="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2:
XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
was inserted into lambda Uni-ZAP XR vector at 5' end with
EcoRI and 3' end with XhoI site. mRNA was derived from
rice Histone Deacetylase overexpression line."

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.2;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3526 GCCACCTCGGGGACTCCAG 3545

Db 20 GCCACCGCGGGAGCTCCAG 1

RESULT 2

CF306357/c

LOCUS

DEFINITION

CF306357 20 bp mRNA linear EST 15-AUG-2003
HDAl--03-J04.g1 OshDACL-overexpressing transgenic rice lambda phage
cDNA library I (HDAl) Oryza sativa (japonica cultivar-group) cDNA
clone HDAl--03-J04, mRNA sequence.

ACCESSION

CF306357

VERSION

CF306357.1 GI:33678118

KEYWORDS

EST.

SOURCE

ORGANISM

Oryza sativa (japonica cultivar-group)

Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales;
Ehrhartoideae; Oryzeae; Oryza.

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhnm@bio.com, bnhnm@bio.myongji.ac.kr.

FEATURES

source

1..20
Location/Qualifiers
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"

```

/cultivar="Nackdong"
/db xref="taxon:39947"
/clones="HDAL--03-J04"
/tissue_type="callus"
/dev stage="proliferated callus on 2N6 media for 2 weeks"
/lab host="E.coli SOLR"
/clone lib="OshDACL1-overexpressing transgenic rice lambda
phase cDNA library I (HDAL)"
/notes="vector: pBluescript SK(+); Site 1: EcoRI; Site 2:
XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
was inserted into lambda Uni-ZAP XR vector at 5' end with
EcoRI and 3' end with XhoI site. mRNA was derived from
rice Histone Deacetylase overexpression line."

Query Match          0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.2;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3526 GCCACCTCGGGGAGCTCCAG 3545
      ||||| ||||| ||||| |||||
Db 20 GCCACCGGGGAGCTCCAG 1

RESULT 3
CF307027/c
LOCUS
DEFINITION
HDAL--05-I10.g1 OshDACL1-overexpressing transgenic rice lambda phage
cDNA library I (HDAL) Oryza sativa (japonica cultivar-group) cDNA
clone HDAL--05-I10, mRNA sequence.
CF307027
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE
1 (bases 1 to 20)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhahm@bio.com, bnhahm@bio.myongji.ac.kr.
Location/Qualifiers
1..20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HDAL--05-I10"
/tissue_type="callus"
/dev stage="proliferated callus on 2N6 media for 2 weeks"
/clone lib="OshDACL1-overexpressing transgenic rice lambda
phase cDNA library I (HDAL)"
/notes="vector: pBluescript SK(+); Site 1: EcoRI; Site 2:
XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
was inserted into lambda Uni-ZAP XR vector at 5' end with
EcoRI and 3' end with XhoI site. mRNA was derived from
rice Histone Deacetylase overexpression line."

Query Match          0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.2;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3526 GCCACCTCGGGGAGCTCCAG 3545
      ||||| ||||| ||||| |||||
Db 20 GCCACCGGGGAGCTCCAG 1

RESULT 5
CF307109/c
LOCUS
DEFINITION
HDAL--05-M12.g1 OshDACL1-overexpressing transgenic rice lambda phage
cDNA library I (HDAL) Oryza sativa (japonica cultivar-group) cDNA
clone HDAL--05-M12, mRNA sequence.
CF307109
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE
1 (bases 1 to 20)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhahm@bio.com, bnhahm@bio.myongji.ac.kr.
Location/Qualifiers
1..20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HDAL--05-I10"
/tissue_type="callus"
/dev stage="proliferated callus on 2N6 media for 2 weeks"
/clone lib="OshDACL1-overexpressing transgenic rice lambda
phase cDNA library I (HDAL)"
/notes="vector: pBluescript SK(+); Site 1: EcoRI; Site 2:
XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
was inserted into lambda Uni-ZAP XR vector at 5' end with
EcoRI and 3' end with XhoI site. mRNA was derived from
rice Histone Deacetylase overexpression line."

Query Match          0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.2;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3526 GCCACCTCGGGGAGCTCCAG 3545
      ||||| ||||| ||||| |||||
Db 20 GCCACCGGGGAGCTCCAG 1

```

```

Db 20 GCCACCGGGGAGCTCCAG 1

RESULT 4
CF307105/c
LOCUS
DEFINITION
HDAL--05-M06.g1 OshDACL1-overexpressing transgenic rice lambda phage
cDNA library I (HDAL) Oryza sativa (japonica cultivar-group) cDNA
clone HDAL--05-M06, mRNA sequence.
CF307105
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE
1 (bases 1 to 20)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhahm@bio.com, bnhahm@bio.myongji.ac.kr.
Location/Qualifiers
1..20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HDAL--05-M06"
/tissue_type="callus"
/dev stage="proliferated callus on 2N6 media for 2 weeks"
/clone lib="OshDACL1-overexpressing transgenic rice lambda
phase cDNA library I (HDAL)"
/notes="vector: pBluescript SK(+); Site 1: EcoRI; Site 2:
XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
was inserted into lambda Uni-ZAP XR vector at 5' end with
EcoRI and 3' end with XhoI site. mRNA was derived from
rice Histone Deacetylase overexpression line."

Query Match          0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.2;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3526 GCCACCTCGGGGAGCTCCAG 3545
      ||||| ||||| ||||| |||||
Db 20 GCCACCGGGGAGCTCCAG 1

RESULT 5
CF307109/c
LOCUS
DEFINITION
HDAL--05-M12.g1 OshDACL1-overexpressing transgenic rice lambda phage
cDNA library I (HDAL) Oryza sativa (japonica cultivar-group) cDNA
clone HDAL--05-M12, mRNA sequence.
CF307109
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE
1 (bases 1 to 20)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhahm@bio.com, bnhahm@bio.myongji.ac.kr.
Location/Qualifiers
1..20
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HDAL--05-M06"
/tissue_type="callus"
/dev stage="proliferated callus on 2N6 media for 2 weeks"
/clone lib="OshDACL1-overexpressing transgenic rice lambda
phase cDNA library I (HDAL)"
/notes="vector: pBluescript SK(+); Site 1: EcoRI; Site 2:
XhoI; Callus was treated with ABA(20um) for 1hour. cDNA
was inserted into lambda Uni-ZAP XR vector at 5' end with
EcoRI and 3' end with XhoI site. mRNA was derived from
rice Histone Deacetylase overexpression line."

Query Match          0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.2;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3526 GCCACCTCGGGGAGCTCCAG 3545
      ||||| ||||| ||||| |||||
Db 20 GCCACCGGGGAGCTCCAG 1

```

TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193

Fax: 82 31 321 6355

Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source

Location/Qualifiers

1..20

/organism="Oryza sativa (japonica cultivar-group)"

/mol_type="mRNA"

/cultivar="Nackdong"

/db_xref="taxon:39947"

/clone="HDAL--05-M12"

/tissue_type="callus"

/dev_stage="proliferated callus on 2N6 media for 2 weeks"

/lab_host="E.coli SOLR"

/clone_lib="OshDAC1-overexpressing transgenic rice lambda

phage cDNA library I (HDAL)"

/note="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2:

XhoI; Callus was treated with ABA(20um) for 1hour. cDNA

was inserted into lambda Uni-ZAP XR vector at 5' end with

EcoRI and 3' end with XhoI site. mRNA was derived from

rice Histone Deacetylase overexpression line."

Query Match

Best Local Similarity 0.4%; Score 16.8; DB 1; Length 20;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy

3526 GCCACCTCGGGGAAGTCCAG 3545

Db 20 GCCACCGGGGAGCTCCAG 1

RESULT 6

CF307258/c

LOCUS

DEFINITION HDAL--06-D04.g1 OshDAC1-overexpressing transgenic rice lambda phage
cDNA library I (HDAL) Oryza sativa (japonica cultivar-group) cDNA
clone HDAL--06-D04, mRNA sequence.

ACCESSION CF307258

VERSION CF307258.1 GI:33679019

KEYWORDS EST.

SOURCE

ORGANISM

Oryza sativa (japonica cultivar-group)

Oryza sativa (japonica cultivar-group)

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;

Ehrhartoideae; Oryzaeae; Oryza.

1 (bases 1 to 20)

Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,

Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.

Large-scale Sequencing Analysis of Rice ESTs

Unpublished (2003)

Contact: Nahm B.H.

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division

of Bioscience and Bioinformatics, Myongji University

Yongin, Kyeonggi, Korea

Tel: 82 31 330 6193

Fax: 82 31 321 6355

Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source

1..20

/organism="Oryza sativa (japonica cultivar-group)"

/mol_type="mRNA"

/cultivar="Nackdong"

/db_xref="taxon:39947"

/clone="HDAL--06-D04"

/tissue_type="callus"

/dev_stage="proliferated callus on 2N6 media for 2 weeks"

/lab_host="E.coli SOLR"

/clone_lib="OshDAC1-overexpressing transgenic rice lambda

phage cDNA library I (HDAL)"

/note="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2:

XhoI; Callus was treated with ABA(20um) for 1hour. cDNA

was inserted into lambda Uni-ZAP XR vector at 5' end with

EcoRI and 3' end with XhoI site. mRNA was derived from

rice Histone Deacetylase overexpression line."

Query Match

Best Local Similarity 0.4%; Score 16.8; DB 1; Length 20;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy

3526 GCCACCTCGGGGAAGTCCAG 3545

Db 20 GCCACCGGGGAGCTCCAG 1

RESULT 7

CF306412/c

LOCUS

DEFINITION HDAL--03-M07.g1 OshDAC1-overexpressing transgenic rice lambda phage
cDNA library I (HDAL) Oryza sativa (japonica cultivar-group) cDNA
clone HDAL--03-M07, mRNA sequence.

ACCESSION CF306412

VERSION CF306412.1 GI:33678173

KEYWORDS EST.

SOURCE

ORGANISM

Oryza sativa (japonica cultivar-group)

Oryza sativa (japonica cultivar-group)

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;

Ehrhartoideae; Oryzaeae; Oryza.

1 (bases 1 to 21)

Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,

Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.

Large-scale Sequencing Analysis of Rice ESTs

Unpublished (2003)

Contact: Nahm B.H.

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division

of Bioscience and Bioinformatics, Myongji University

Yongin, Kyeonggi, Korea

Tel: 82 31 330 6193

Fax: 82 31 321 6355

Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source

1..21

/organism="Oryza sativa (japonica cultivar-group)"

/mol_type="mRNA"

/cultivar="Nackdong"

/db_xref="taxon:39947"

/clone="HDAL--03-M07"

/tissue_type="callus"

/dev_stage="proliferated callus on 2N6 media for 2 weeks"

/lab_host="E.coli SOLR"

/clone_lib="OshDAC1-overexpressing transgenic rice lambda

phage cDNA library I (HDAL)"

/note="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2:

XhoI; Callus was treated with ABA(20um) for 1hour. cDNA

was inserted into lambda Uni-ZAP XR vector at 5' end with

EcoRI and 3' end with XhoI site. mRNA was derived from

rice Histone Deacetylase overexpression line."

Query Match

Best Local Similarity 0.4%; Score 16.8; DB 1; Length 21;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy

3526 GCCACCTCGGGGAAGTCCAG 3545

Db 21 GCCACCGGGGAGCTCCAG 2

RESULT 8

CF306419/c

LOCUS

DEFINITION HDAL--03-M17.g1 OshDAC1-overexpressing transgenic rice lambda phage
cDNA library I (HDAL) Oryza sativa (japonica cultivar-group) cDNA
clone HDAL--03-M17, mRNA sequence.

REFERENCE	AUTHORS	TITLE	JOURNAL	COMMENT
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnamh@bio.com, bhnamh@bio.myongji.ac.kr.

FEATURES

source

1. .19
Location/Qualifiers
/organism="Oryza sativa (japonica cultivar-group)"

/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HDAL-05-H09"
/tissue_type="callus"

/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli SOLR"
/clone_lib="OSHDA1-overexpressing transgenic rice lambda phage cDNA library I (HDAL)"
/notes="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2: XhoI; Callus was treated with ABA(20um) for 1hour. cDNA was inserted into lambda Uni-ZAP XR vector at 5' end with EcoRI and 3' end with XhoI site. mRNA was derived from rice Histone Deacetylase overexpression line."

Query Match

Best Local Similarity 0.4%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3526 GCCACCTCGGGGAACTCCA 3544

||||| ||||| |||||

Db 19 GCCACCACGGGGAGCTCCA 1

RESULT 14

CF307304/c

LOCUS

DEFINITION HDAL-06-F05.g1 OshDAC1-overexpressing transgenic rice lambda phage cDNA library I (HDAL) Oryza sativa (japonica cultivar-group) cDNA clone HDAL-06-F05, mRNA sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzeae; Oryza.

REFERENCE

AUTHORS

Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.

TITLE

JOURNAL

COMMENT

Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea

Tel: 82 31 330 6193

Fax: 82 31 321 6355

Email: bhnamh@bio.com, bhnamh@bio.myongji.ac.kr.

FEATURES

source

1. .19
Location/Qualifiers
/organism="Oryza sativa (japonica cultivar-group)"

/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HDAL-06-F05"
/tissue_type="callus"

/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli SOLR"
/clone_lib="OSHDA1-overexpressing transgenic rice lambda phage cDNA library I (HDAL)"
/notes="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2: XhoI; Callus was treated with ABA(20um) for 1hour. cDNA was inserted into lambda Uni-ZAP XR vector at 5' end with EcoRI and 3' end with XhoI site. mRNA was derived from

rice Histone Deacetylase overexpression line."

Query Match

Best Local Similarity 0.4%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3526 GCCACCTCGGGGAACTCCA 3544

||||| ||||| |||||

Db 19 GCCACCACGGGGAGCTCCA 1

RESULT 15

CF307439/c

LOCUS

DEFINITION HDAL-06-L09.g1 OshDAC1-overexpressing transgenic rice lambda phage cDNA library I (HDAL) Oryza sativa (japonica cultivar-group) cDNA clone HDAL-06-L09, mRNA sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzeae; Oryza.

REFERENCE

AUTHORS

Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C., Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.

TITLE

JOURNAL

COMMENT

Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea

Tel: 82 31 330 6193

Fax: 82 31 321 6355

Email: bhnamh@bio.com, bhnamh@bio.myongji.ac.kr.

FEATURES

source

1. .19
Location/Qualifiers
/organism="Oryza sativa (japonica cultivar-group)"

/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="HDAL-06-L09"
/tissue_type="callus"

/dev_stage="proliferated callus on 2N6 media for 2 weeks"
/lab_host="E.coli SOLR"
/clone_lib="OSHDA1-overexpressing transgenic rice lambda phage cDNA library I (HDAL)"
/note="Vector: pBluescript SK(+); Site 1: EcoRI; Site 2: XhoI; Callus was treated with ABA(20um) for 1hour. cDNA was inserted into lambda Uni-ZAP XR vector at 5' end with EcoRI and 3' end with XhoI site. mRNA was derived from rice Histone Deacetylase overexpression line."

Query Match

Best Local Similarity 0.4%; Score 15.8; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3526 GCCACCTCGGGGAACTCCA 3544

||||| ||||| |||||

Db 19 GCCACCACGGGGAGCTCCA 1

RESULT 16

CZ283815

LOCUS

DEFINITION cp31h12.f Candida parapsilosis Random Genomic Library Candida parapsilosis genomic clone cp31h12, genomic survey sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

Candida parapsilosis

```

ORGANISM      Candida parapsilosis
REFERENCE      Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
AUTHORS        Saccharomycetales; mitosporic Saccharomycetales; Candida.
TITLE          1 (bases 1 to 19)
JOURNAL        Logue, M.E., Wong, S., Wolfe, K.H. and Butler, G.
PUBMED         A genome sequence survey shows that the pathogenic yeast Candida
                parapsilosis has a defective MTL1 allele at its mating type locus
                Eukaryot. Cell 4 (6), 1009-1017 (2005)
COMMENT        15947193
                Contact: Logue M
                Department of Biochemistry, Conway Institute of Biomolecular and
                Biomedical Research
                University College Dublin
                Dublin 4, Ireland
                Tel: +353 1 7166885
                Fax: +353 1 2837211
                Email: mary.e.logue@ucd.ie
                Class: plasmid ends.
FEATURES       Location/Qualifiers
                source
                1..19
                /organism="Candida parapsilosis"
                /mol_type="genomic DNA"
                /strain="CU428.1"
                /db_xref="taxon:5480"
                /clone="cp31h12"
                /clone_lib="Candida parapsilosis Random Genomic Library"

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.9;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      320 GGGGGGGCGAGGCCCCCC 338
Db      1 GGGGGGGCGAGGCCCCCC 19

RESULT 17
BM394080/c      16 bp mRNA linear EST 17-JAN-2002
LOCUS          50072-2-12-H02.r.1 Chilcoat/Turkewitz cDNA (large fraction)
DEFINITION     Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION      BM394080
VERSION        BM394080.1 GI:18194133
KEYWORDS       EST.
SOURCE         Tetrahymena thermophila
ORGANISM       Tetrahymena thermophila
REFERENCE      Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
AUTHORS        Hymenostomatida; Tetrahymenina; Tetrahymenidae; Tetrahymena.
                1 (bases 1 to 16)
                Turkewitz, A.P., Karrer, K.M., Jahn, C., Orias, E., Kirk, K.E.,
                Frankel, J. and Klobutcher, L.
TITLE          EST from Tetrahymena thermophila, strain CU428.1, growing cells
JOURNAL        Unpublished (2002)
COMMENT        Contact: Turkewitz AP
                Molecular Genetics and Cell Biology
                University of Chicago
                920 E. 58th Street, Chicago, IL 60637, USA
                Tel: 773 702 4374
                Fax: 773 702 3172
                Email: apturkew@midway.uchicago.edu
                Seq primer: T3.
FEATURES       Location/Qualifiers
                source
                1..16
                /organism="Tetrahymena thermophila"
                /mol_type="mRNA"
                /strain="CU428.1"
                /db_xref="taxon:5911"
                /clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
                /note="Vector: Bluescript2 SK+; Details on library
                preparation can be found in Chilcoat and Turkewitz (2001)
                Proc. Natl. Acad. Sci USA, 98: 8709-8713."

Query Match      0.3%; Score 13.4; DB 1; Length 16;

```

```

Best Local Similarity 93.3%; Pred. No. 21;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2404 ATCCGCTGTGAGGCG 2418
Db      16 ATCCGCTGTGAGGCG 2
                ||||| |||||
                ||||| |||||

RESULT 18
AI560058/c      16 bp mRNA linear EST 13-MAY-1999
LOCUS          tq38h11.x1 NCI CGAP Ucl Homo sapiens cDNA clone IMAGE:221141.3,
DEFINITION     similar to TR:Q04154 Q04154 SALIVARY PROLINE-RICH PROTEIN RP15
                PRECURSOR. ; contains MSR1.t2 MSR1 repetitive element ;, mRNA
                sequence.
ACCESSION      AI560058
VERSION        AI560058.1 GI:4510263
KEYWORDS       EST.
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
                Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;
                Hominidae; Homo.
REFERENCE      1 (bases 1 to 16)
AUTHORS        NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE          National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
                Tumor Gene Index
                Unpublished (1997)
JOURNAL        Contact: Robert Strausberg, Ph.D.
COMMENT        Email: cgapsb@emall.nih.gov
                Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.
                Emmert-Buck, M.D., Ph.D.
                CDNA Library Preparation: Life Technologies, Inc.
                CDNA Library Arrayed by: Greg Lennon, Ph.D.
                DNA Sequencing by: Washington University Genome Sequencing Center
                Clone distribution: NCI-CGAP clone distribution information can be
                found through the I.M.A.G.E. Consortium/LLNL at:
                www-bio.llnl.gov/bbrp/image/image.html

Trace considered overall poor quality
Insert Length: 2104 Std Error: 0.00
Seq primer: -40UP from Gibco
High quality sequence stop: 1
POLYA=No.
FEATURES       Location/Qualifiers
                source
                1..16
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="taxon:9606"
                /clone="IMAGE:221141"
                /tissue_type="well-differentiated endometrial
                adenocarcinoma, 7 pooled tumors"
                /lab_host="DH10B"
                /clone_lib="NCI CGAP Ucl1"
                /note="Organ: uterus; Vector: pCMV-SPORT6; Site 1: SalI;
                Site 2: NotI; Cloned unidirectionally. Primer: Oligo dT.
                Average insert size 1.75 kb. Life Technologies catalog #:
                11538-014"

Query Match      0.3%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 25;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      66 CCCCCGCCACCCGGG 81
Db      16 CCCCCGCCACCCGGG 1
                ||||| |||||
                ||||| |||||

Search completed: March 23, 2006, 11:22:21
Job time : 1 secs

```

THIS PAGE BLANK (00P10)

107	25	0.6	25	1	US-11-060-756-242200	Sequence 242200,	180	21	0.5	21	1	US-10-800-350-237	Sequence 237, App
108	25	0.6	25	1	US-11-060-756-243194	Sequence 243194,	181	21	0.5	21	1	US-10-800-350-238	Sequence 238, App
109	25	0.6	25	1	US-11-060-756-244973	Sequence 244973,	182	21	0.5	21	1	US-10-800-350-239	Sequence 239, App
110	25	0.6	25	1	US-11-060-756-247996	Sequence 247996,	183	21	0.5	21	1	US-10-800-350-240	Sequence 240, App
111	25	0.6	25	1	US-11-060-756-248716	Sequence 248716,	184	21	0.5	21	1	US-10-800-350-241	Sequence 241, App
112	25	0.6	25	1	US-11-060-756-254719	Sequence 254719,	185	21	0.5	21	1	US-10-800-350-242	Sequence 242, App
113	25	0.6	25	1	US-11-060-756-260910	Sequence 260910,	186	21	0.5	21	1	US-10-800-350-243	Sequence 243, App
114	25	0.6	25	1	US-11-060-756-262582	Sequence 262582,	187	21	0.5	21	1	US-10-800-350-244	Sequence 244, App
115	25	0.6	25	1	US-11-060-756-262926	Sequence 262926,	188	21	0.5	21	1	US-10-800-350-245	Sequence 245, App
116	25	0.6	25	1	US-11-060-756-263974	Sequence 263974,	189	21	0.5	21	1	US-10-800-350-246	Sequence 246, App
117	25	0.6	25	1	US-11-060-756-264417	Sequence 264417,	190	21	0.5	21	1	US-10-800-350-247	Sequence 247, App
118	25	0.6	25	1	US-11-060-756-264508	Sequence 264508,	191	21	0.5	21	1	US-10-800-350-248	Sequence 248, App
119	25	0.6	25	1	US-11-060-756-264553	Sequence 264553,	192	21	0.5	21	1	US-10-800-350-249	Sequence 249, App
120	25	0.6	25	1	US-11-060-756-265308	Sequence 265308,	193	21	0.5	21	1	US-10-800-350-250	Sequence 250, App
121	25	0.6	25	1	US-11-060-756-265308	Sequence 265308,	194	21	0.5	21	1	US-10-800-350-251	Sequence 251, App
122	25	0.6	25	1	US-11-060-756-266195	Sequence 266195,	195	21	0.5	21	1	US-10-800-350-252	Sequence 252, App
123	25	0.6	25	1	US-11-060-756-266335	Sequence 266335,	196	21	0.5	21	1	US-10-800-350-253	Sequence 253, App
124	25	0.6	25	1	US-11-060-756-266889	Sequence 266889,	197	21	0.5	21	1	US-10-800-350-254	Sequence 254, App
125	25	0.6	25	1	US-11-060-756-267083	Sequence 267083,	198	21	0.5	21	1	US-10-800-350-255	Sequence 255, App
126	25	0.6	25	1	US-11-060-756-268063	Sequence 268063,	199	21	0.5	21	1	US-10-800-350-256	Sequence 256, App
127	25	0.6	25	1	US-11-060-756-268427	Sequence 268427,	200	21	0.5	21	1	US-10-800-350-257	Sequence 257, App
128	25	0.6	25	1	US-11-060-756-270798	Sequence 270798,	201	21	0.5	21	1	US-10-800-350-258	Sequence 258, App
129	25	0.6	25	1	US-11-060-756-271627	Sequence 271627,	202	21	0.5	21	1	US-10-800-350-259	Sequence 259, App
130	25	0.6	25	1	US-11-060-756-275773	Sequence 275773,	203	21	0.5	21	1	US-10-800-350-260	Sequence 260, App
131	25	0.6	25	1	US-11-060-756-275774	Sequence 275774,	204	21	0.5	21	1	US-10-800-350-261	Sequence 261, App
132	25	0.6	25	1	US-11-060-756-285057	Sequence 285057,	205	21	0.5	21	1	US-10-800-350-262	Sequence 262, App
133	25	0.6	25	1	US-11-060-756-286007	Sequence 286007,	206	21	0.5	21	1	US-10-800-350-263	Sequence 263, App
134	25	0.6	25	1	US-11-060-756-286495	Sequence 286495,	207	21	0.5	21	1	US-10-800-350-264	Sequence 264, App
135	25	0.6	25	1	US-11-060-756-291576	Sequence 291576,	208	21	0.5	21	1	US-10-800-350-265	Sequence 265, App
136	25	0.6	25	1	US-11-060-756-291577	Sequence 291577,	209	21	0.5	21	1	US-10-800-350-266	Sequence 266, App
137	25	0.6	25	1	US-11-060-756-294522	Sequence 294522,	210	21	0.5	21	1	US-10-800-350-267	Sequence 267, App
138	25	0.6	25	1	US-11-060-756-294810	Sequence 294810,	211	21	0.5	21	1	US-10-800-350-268	Sequence 268, App
139	25	0.6	25	1	US-11-060-756-300396	Sequence 300396,	212	21	0.5	21	1	US-10-800-350-269	Sequence 269, App
140	25	0.6	25	1	US-11-060-756-300512	Sequence 300512,	213	21	0.5	21	1	US-10-800-350-270	Sequence 270, App
141	25	0.6	25	1	US-11-060-756-301519	Sequence 301519,	214	21	0.5	21	1	US-10-800-350-271	Sequence 271, App
142	24.2	0.6	29	1	US-10-800-350-1	Sequence 1, Appl	215	21	0.5	21	1	US-10-800-350-272	Sequence 272, App
143	24.2	0.6	29	1	US-10-800-350-1	Sequence 1, Appl	216	21	0.5	21	1	US-10-800-350-273	Sequence 273, App
144	23.4	0.6	25	1	US-10-956-157-160391	Sequence 160391,	217	21	0.5	21	1	US-10-800-350-274	Sequence 274, App
145	22.4	0.5	25	1	US-10-956-157-208204	Sequence 208204,	218	21	0.5	21	1	US-10-800-350-275	Sequence 275, App
146	22.4	0.5	25	1	US-11-036-317-409480	Sequence 409480,	219	21	0.5	21	1	US-10-800-350-276	Sequence 276, App
147	21.8	0.5	25	1	US-10-719-956-644851	Sequence 644851,	220	21	0.5	21	1	US-10-800-350-277	Sequence 277, App
148	21.8	0.5	25	1	US-10-956-157-189189	Sequence 189189,	221	21	0.5	21	1	US-10-800-350-278	Sequence 278, App
149	21.8	0.5	25	1	US-11-036-317-15098	Sequence 15098, A	222	21	0.5	21	1	US-10-800-350-279	Sequence 279, App
150	21.8	0.5	25	1	US-11-060-756-124745	Sequence 124745,	223	21	0.5	21	1	US-10-800-350-280	Sequence 280, App
c 151	21.8	0.5	25	1	US-11-060-756-152377	Sequence 152377,	224	21	0.5	21	1	US-10-800-350-281	Sequence 281, App
c 152	21.8	0.5	25	1	US-11-060-756-152378	Sequence 152378,	225	21	0.5	21	1	US-10-800-350-282	Sequence 282, App
153	21.8	0.5	25	1	US-11-060-756-152378	Sequence 152378,	226	21	0.5	21	1	US-10-800-350-283	Sequence 283, App
154	21.4	0.5	25	1	US-11-036-317-39029	Sequence 39029, A	227	21	0.5	21	1	US-10-800-350-284	Sequence 284, App
c 155	21	0.5	21	1	US-10-800-350-20	Sequence 20, Appl	228	21	0.5	21	1	US-10-800-350-285	Sequence 285, App
c 156	21	0.5	21	1	US-10-800-350-35	Sequence 35, Appl	c 229	21	0.5	21	1	US-10-800-077-20	Sequence 20, Appl
c 157	21	0.5	21	1	US-10-800-350-35	Sequence 35, Appl	c 230	21	0.5	21	1	US-10-800-077-35	Sequence 35, Appl
c 158	21	0.5	21	1	US-10-800-350-39	Sequence 39, Appl	c 231	21	0.5	21	1	US-10-800-077-37	Sequence 37, Appl
c 159	21	0.5	21	1	US-10-800-350-41	Sequence 41, Appl	c 232	21	0.5	21	1	US-10-800-077-39	Sequence 39, Appl
c 160	21	0.5	21	1	US-10-800-350-42	Sequence 42, Appl	c 233	21	0.5	21	1	US-10-800-077-41	Sequence 41, Appl
c 161	21	0.5	21	1	US-10-800-350-44	Sequence 44, Appl	c 234	21	0.5	21	1	US-10-800-077-42	Sequence 42, Appl
c 162	21	0.5	21	1	US-10-800-350-45	Sequence 45, Appl	c 235	21	0.5	21	1	US-10-800-077-44	Sequence 44, Appl
c 163	21	0.5	21	1	US-10-800-350-46	Sequence 46, Appl	c 236	21	0.5	21	1	US-10-800-077-45	Sequence 45, Appl
c 164	21	0.5	21	1	US-10-800-350-49	Sequence 49, Appl	c 237	21	0.5	21	1	US-10-800-077-46	Sequence 46, Appl
c 165	21	0.5	21	1	US-10-800-350-50	Sequence 50, Appl	c 238	21	0.5	21	1	US-10-800-077-49	Sequence 49, Appl
c 166	21	0.5	21	1	US-10-800-350-52	Sequence 52, Appl	c 239	21	0.5	21	1	US-10-800-077-50	Sequence 50, Appl
c 167	21	0.5	21	1	US-10-800-350-70	Sequence 70, Appl	c 240	21	0.5	21	1	US-10-800-077-52	Sequence 52, Appl
c 168	21	0.5	21	1	US-10-800-350-73	Sequence 73, Appl	c 241	21	0.5	21	1	US-10-800-077-70	Sequence 70, Appl
c 169	21	0.5	21	1	US-10-800-350-222	Sequence 222, App	c 242	21	0.5	21	1	US-10-800-077-73	Sequence 73, Appl
c 170	21	0.5	21	1	US-10-800-350-224	Sequence 224, App	c 243	21	0.5	21	1	US-10-800-077-222	Sequence 222, App
c 171	21	0.5	21	1	US-10-800-350-225	Sequence 225, App	c 244	21	0.5	21	1	US-10-800-077-224	Sequence 224, App
c 172	21	0.5	21	1	US-10-800-350-226	Sequence 226, App	c 245	21	0.5	21	1	US-10-800-077-225	Sequence 225, App
c 173	21	0.5	21	1	US-10-800-350-229	Sequence 229, App	c 246	21	0.5	21	1	US-10-800-077-226	Sequence 226, App
c 174	21	0.5	21	1	US-10-800-350-230	Sequence 230, App	c 247	21	0.5	21	1	US-10-800-077-229	Sequence 229, App
c 175	21	0.5	21	1	US-10-800-350-232	Sequence 232, App	c 248	21	0.5	21	1	US-10-800-077-230	Sequence 230, App
176	21	0.5	21	1	US-10-800-350-233	Sequence 233, App	c 249	21	0.5	21	1	US-10-800-077-232	Sequence 232, App
177	21	0.5	21	1	US-10-800-350-234	Sequence 234, App	250	21	0.5	21	1	US-10-800-077-233	Sequence 233, App
178	21	0.5	21	1	US-10-800-350-235	Sequence 235, App	251	21	0.5	21	1	US-10-800-077-234	Sequence 234, App
179	21	0.5	21	1	US-10-800-350-236	Sequence 236, App	252	21	0.5	21	1	US-10-800-077-235	Sequence 235, App

253	21	0.5	21	1	US-10-800-077-236	Sequence 236, App	326	20.2	0.5	25	1	US-11-036-317-456404	Sequence 456404,
254	21	0.5	21	1	US-10-800-077-237	Sequence 237, App	327	20.2	0.5	25	1	US-11-036-317-528469	Sequence 528469,
255	21	0.5	21	1	US-10-800-077-238	Sequence 238, App	328	20.2	0.5	25	1	US-11-060-756-18552	Sequence 18552, A
256	21	0.5	21	1	US-10-800-077-239	Sequence 239, App	329	20.2	0.5	25	1	US-11-060-756-18556	Sequence 18556, A
257	21	0.5	21	1	US-10-800-077-240	Sequence 240, App	330	20.2	0.5	25	1	US-11-060-756-18557	Sequence 18557, A
258	21	0.5	21	1	US-10-800-077-241	Sequence 241, App	331	20.2	0.5	25	1	US-11-060-756-18562	Sequence 18562, A
259	21	0.5	21	1	US-10-800-077-242	Sequence 242, App	332	20.2	0.5	25	1	US-11-060-756-18564	Sequence 18564, A
260	21	0.5	21	1	US-10-800-077-243	Sequence 243, App	333	20.2	0.5	25	1	US-11-060-756-18574	Sequence 18574, A
261	21	0.5	21	1	US-10-800-077-244	Sequence 244, App	334	20.2	0.5	25	1	US-11-060-756-18578	Sequence 18578, A
262	21	0.5	21	1	US-10-800-077-245	Sequence 245, App	335	20.2	0.5	25	1	US-11-060-756-84138	Sequence 84138, A
263	21	0.5	21	1	US-10-800-077-246	Sequence 246, App	336	20.2	0.5	25	1	US-11-060-756-84139	Sequence 84139, A
264	21	0.5	21	1	US-10-800-077-247	Sequence 247, App	337	20.2	0.5	25	1	US-11-060-756-84144	Sequence 84144, A
265	21	0.5	21	1	US-10-800-077-248	Sequence 248, App	338	20.2	0.5	25	1	US-11-060-756-123826	Sequence 123826,
266	21	0.5	21	1	US-10-800-077-249	Sequence 249, App	339	20.2	0.5	25	1	US-11-060-756-126430	Sequence 126430,
267	21	0.5	21	1	US-10-800-077-250	Sequence 250, App	340	20.2	0.5	25	1	US-11-060-756-144910	Sequence 144910,
268	21	0.5	21	1	US-10-800-077-251	Sequence 251, App	341	20.2	0.5	25	1	US-11-060-756-163426	Sequence 163426,
269	21	0.5	21	1	US-10-800-077-252	Sequence 252, App	342	20.2	0.5	25	1	US-11-060-756-163426	Sequence 163426,
270	21	0.5	21	1	US-10-800-077-253	Sequence 253, App	343	20.2	0.5	25	1	US-11-060-756-166073	Sequence 166073,
271	21	0.5	21	1	US-10-800-077-254	Sequence 254, App	344	20.2	0.5	25	1	US-11-060-756-166074	Sequence 166074,
272	21	0.5	21	1	US-10-800-077-255	Sequence 255, App	345	20.2	0.5	25	1	US-11-060-756-166073	Sequence 166073,
273	21	0.5	21	1	US-10-800-077-256	Sequence 256, App	346	20.2	0.5	25	1	US-11-060-756-168023	Sequence 168023,
274	21	0.5	21	1	US-10-800-077-257	Sequence 257, App	347	20.2	0.5	25	1	US-11-060-756-170191	Sequence 170191,
275	21	0.5	21	1	US-10-800-077-258	Sequence 258, App	348	20.2	0.5	25	1	US-11-060-756-170358	Sequence 170358,
276	21	0.5	21	1	US-10-800-077-259	Sequence 259, App	349	20.2	0.5	25	1	US-11-060-756-170359	Sequence 170359,
277	21	0.5	21	1	US-10-800-077-260	Sequence 260, App	350	20.2	0.5	25	1	US-11-060-756-171498	Sequence 171498,
278	21	0.5	21	1	US-10-800-077-261	Sequence 261, App	351	20.2	0.5	25	1	US-11-060-756-171499	Sequence 171499,
279	21	0.5	21	1	US-10-800-077-262	Sequence 262, App	352	20.2	0.5	25	1	US-11-060-756-182311	Sequence 182311,
280	21	0.5	21	1	US-10-800-077-263	Sequence 263, App	353	20.2	0.5	25	1	US-11-060-756-192323	Sequence 192323,
281	21	0.5	21	1	US-10-800-077-264	Sequence 264, App	354	20.2	0.5	25	1	US-11-060-756-227416	Sequence 227416,
282	21	0.5	21	1	US-10-800-077-265	Sequence 265, App	355	20.2	0.5	25	1	US-11-060-756-239848	Sequence 239848,
283	21	0.5	21	1	US-10-800-077-266	Sequence 266, App	356	20.2	0.5	25	1	US-11-060-756-245548	Sequence 245548,
284	21	0.5	21	1	US-10-800-077-267	Sequence 267, App	357	20.2	0.5	25	1	US-11-060-756-248252	Sequence 248252,
285	21	0.5	21	1	US-10-800-077-268	Sequence 268, App	358	20.2	0.5	25	1	US-11-060-756-261475	Sequence 261475,
286	21	0.5	21	1	US-10-800-077-269	Sequence 269, App	359	20.2	0.5	25	1	US-11-060-756-265730	Sequence 265730,
287	21	0.5	21	1	US-10-800-077-270	Sequence 270, App	360	20.2	0.5	25	1	US-11-060-756-266448	Sequence 266448,
288	21	0.5	21	1	US-10-800-077-271	Sequence 271, App	361	20.2	0.5	25	1	US-11-060-756-269583	Sequence 269583,
289	21	0.5	21	1	US-10-800-077-272	Sequence 272, App	362	20.2	0.5	25	1	US-11-060-756-282968	Sequence 282968,
290	21	0.5	21	1	US-10-800-077-273	Sequence 273, App	363	20.2	0.5	25	1	US-11-060-756-283106	Sequence 283106,
291	21	0.5	21	1	US-10-800-077-274	Sequence 274, App	364	20.2	0.5	25	1	US-11-060-756-283608	Sequence 283608,
292	21	0.5	21	1	US-10-800-077-275	Sequence 275, App	365	20.2	0.5	25	1	US-11-060-756-283741	Sequence 283741,
293	21	0.5	21	1	US-10-800-077-276	Sequence 276, App	366	20.2	0.5	25	1	US-11-060-756-301070	Sequence 301070,
294	21	0.5	21	1	US-10-800-077-277	Sequence 277, App	367	20.2	0.5	25	1	US-11-060-756-301071	Sequence 301071,
295	21	0.5	21	1	US-10-800-077-278	Sequence 278, App	368	20	0.5	20	1	US-10-800-350-19	Sequence 19, Appl
296	21	0.5	21	1	US-10-800-077-279	Sequence 279, App	369	20	0.5	20	1	US-10-800-350-21	Sequence 21, Appl
297	21	0.5	21	1	US-10-800-077-280	Sequence 280, App	370	20	0.5	20	1	US-10-800-350-25	Sequence 25, Appl
298	21	0.5	21	1	US-10-800-077-281	Sequence 281, App	371	20	0.5	20	1	US-10-800-350-27	Sequence 27, Appl
299	21	0.5	21	1	US-10-800-077-282	Sequence 282, App	372	20	0.5	20	1	US-10-800-350-32	Sequence 32, Appl
300	21	0.5	21	1	US-10-800-077-283	Sequence 283, App	373	20	0.5	20	1	US-10-800-350-33	Sequence 33, Appl
301	21	0.5	21	1	US-10-800-077-284	Sequence 284, App	374	20	0.5	20	1	US-10-800-350-51	Sequence 51, Appl
302	21	0.5	21	1	US-10-800-077-285	Sequence 285, App	375	20	0.5	20	1	US-10-800-350-55	Sequence 55, Appl
303	20.8	0.5	25	1	US-10-719-956-629839	Sequence 629839,	376	20	0.5	20	1	US-10-800-350-56	Sequence 56, Appl
304	20.8	0.5	25	1	US-10-719-956-629840	Sequence 629840,	377	20	0.5	20	1	US-10-800-350-74	Sequence 74, Appl
305	20.8	0.5	25	1	US-11-036-317-47943	Sequence 47943, A	378	20	0.5	20	1	US-10-800-350-75	Sequence 75, Appl
306	20.8	0.5	25	1	US-11-036-317-133760	Sequence 133760,	379	20	0.5	20	1	US-10-800-350-76	Sequence 76, Appl
307	20.8	0.5	25	1	US-11-036-317-479532	Sequence 479532,	380	20	0.5	20	1	US-10-800-350-77	Sequence 77, Appl
308	20.8	0.5	25	1	US-11-060-756-121062	Sequence 121062,	381	20	0.5	20	1	US-10-800-350-78	Sequence 78, Appl
309	20.8	0.5	25	1	US-11-060-756-121063	Sequence 121063,	382	20	0.5	20	1	US-10-800-350-79	Sequence 79, Appl
310	20.8	0.5	25	1	US-11-060-756-142612	Sequence 142612,	383	20	0.5	20	1	US-10-800-350-80	Sequence 80, Appl
311	20.8	0.5	25	1	US-11-060-756-142613	Sequence 142613,	384	20	0.5	20	1	US-10-800-350-81	Sequence 81, Appl
312	20.8	0.5	25	1	US-11-060-756-180539	Sequence 180539,	385	20	0.5	20	1	US-10-800-350-82	Sequence 82, Appl
313	20.8	0.5	25	1	US-11-060-756-256243	Sequence 256243,	386	20	0.5	20	1	US-10-800-350-83	Sequence 83, Appl
314	20.4	0.5	22	1	US-10-800-350-59	Sequence 59, Appl	387	20	0.5	20	1	US-10-800-350-84	Sequence 84, Appl
315	20.4	0.5	22	1	US-10-800-077-59	Sequence 59, Appl	388	20	0.5	20	1	US-10-800-350-85	Sequence 85, Appl
316	20.4	0.5	24	1	US-09-140-378A-3	Sequence 3, Appl	389	20	0.5	20	1	US-10-800-350-86	Sequence 86, Appl
317	20.2	0.5	25	1	US-10-719-956-644852	Sequence 644852,	390	20	0.5	20	1	US-10-800-350-87	Sequence 87, Appl
318	20.2	0.5	25	1	US-10-809-189-24487	Sequence 24487, A	391	20	0.5	20	1	US-10-800-350-88	Sequence 88, Appl
319	20.2	0.5	25	1	US-10-809-189-37489	Sequence 37489, A	392	20	0.5	20	1	US-10-800-350-89	Sequence 89, Appl
320	20.2	0.5	25	1	US-11-036-317-105366	Sequence 105366,	393	20	0.5	20	1	US-10-800-350-90	Sequence 90, Appl
321	20.2	0.5	25	1	US-11-036-317-210541	Sequence 210541,	394	20	0.5	20	1	US-10-800-350-91	Sequence 91, Appl
322	20.2	0.5	25	1	US-11-036-317-341458	Sequence 341458,	395	20	0.5	20	1	US-10-800-350-92	Sequence 92, Appl
323	20.2	0.5	25	1	US-11-036-317-370869	Sequence 370869,	396	20	0.5	20	1	US-10-800-350-93	Sequence 93, Appl
324	20.2	0.5	25	1	US-11-036-317-373537	Sequence 373537,	397	20	0.5	20	1	US-10-800-350-94	Sequence 94, Appl
325	20.2	0.5	25	1	US-11-036-317-411187	Sequence 411187,	398	20	0.5	20	1	US-10-800-350-95	Sequence 95, Appl

691	19.8	0.5	23	1	US-10-962-898-2237	Sequence 2237, Ap	764	16.8	0.4	21	1	US-10-847-918-4062	Sequence 4062, Ap
692	19.8	0.5	23	1	US-10-944-611-2237	Sequence 2237, Ap	765	16.4	0.4	19	1	US-10-665-951-2244	Sequence 2244, Ap
693	19.4	0.5	21	1	US-10-800-350-43	Sequence 43, Appl	765	16.4	0.4	19	1	US-10-665-951-2245	Sequence 2245, Ap
C 694	19.4	0.5	21	1	US-10-800-350-223	Sequence 223, Appl	767	16.4	0.4	19	1	US-10-758-155-2244	Sequence 2244, Ap
C 695	19.4	0.5	21	1	US-10-800-077-43	Sequence 43, Appl	768	16.4	0.4	19	1	US-10-758-155-2265	Sequence 2265, Ap
C 696	19.4	0.5	21	1	US-10-800-077-223	Sequence 223, Appl	769	16.4	0.4	19	1	US-10-758-155-2266	Sequence 2266, Ap
C 697	19.4	0.5	22	1	US-10-635-780-16	Sequence 16, Appl	770	16.4	0.4	19	1	US-10-758-155-2263	Sequence 2263, Ap
C 698	19.2	0.5	24	1	US-10-309-775A-26	Sequence 26, Appl	771	16.4	0.4	19	1	US-10-758-155-2265	Sequence 2265, Ap
699	19.2	0.5	24	1	US-10-309-775A-73	Sequence 73, Appl	772	16.4	0.4	19	1	US-10-758-155-2265	Sequence 2265, Ap
700	19	0.4	19	1	US-10-440-464-41	Sequence 41, Appl	773	16.4	0.4	19	1	US-10-758-155-2234	Sequence 2234, Ap
701	19	0.4	21	1	US-10-800-350-22	Sequence 22, Appl	774	16.4	0.4	19	1	US-10-758-155-2237	Sequence 2237, Ap
702	19	0.4	21	1	US-10-800-350-23	Sequence 23, Appl	775	16.4	0.4	19	1	US-10-831-620-2244	Sequence 2244, Ap
703	19	0.4	21	1	US-10-800-350-34	Sequence 34, Appl	776	16.4	0.4	19	1	US-10-831-620-2265	Sequence 2265, Ap
704	19	0.4	21	1	US-10-800-350-36	Sequence 36, Appl	777	16.4	0.4	19	1	US-10-831-620-2262	Sequence 2262, Ap
705	19	0.4	21	1	US-10-800-350-40	Sequence 40, Appl	778	16.4	0.4	19	1	US-10-831-620-2263	Sequence 2263, Ap
706	19	0.4	21	1	US-10-800-350-69	Sequence 69, Appl	779	16.4	0.4	19	1	US-10-831-620-2265	Sequence 2265, Ap
707	19	0.4	21	1	US-10-800-350-286	Sequence 286, App	780	16.4	0.4	19	1	US-10-831-620-2279	Sequence 2279, Ap
708	19	0.4	21	1	US-10-800-350-287	Sequence 287, App	781	16.4	0.4	19	1	US-10-831-620-2734	Sequence 2734, Ap
709	19	0.4	21	1	US-10-800-350-289	Sequence 289, App	782	16.4	0.4	19	1	US-10-831-620-2737	Sequence 2737, Ap
710	19	0.4	21	1	US-10-800-350-290	Sequence 290, App	783	16.4	0.4	19	1	US-10-844-076-2244	Sequence 2244, Ap
711	19	0.4	21	1	US-10-800-077-22	Sequence 22, Appl	784	16.4	0.4	19	1	US-10-844-076-2265	Sequence 2265, Ap
712	19	0.4	21	1	US-10-800-077-34	Sequence 34, Appl	785	16.4	0.4	19	1	US-10-844-076-2262	Sequence 2262, Ap
713	19	0.4	21	1	US-10-800-077-36	Sequence 36, Appl	786	16.4	0.4	19	1	US-10-844-076-2263	Sequence 2263, Ap
714	19	0.4	21	1	US-10-800-077-40	Sequence 40, Appl	787	16.4	0.4	19	1	US-10-844-076-2265	Sequence 2265, Ap
715	19	0.4	21	1	US-10-800-077-69	Sequence 69, Appl	788	16.4	0.4	19	1	US-10-844-076-2279	Sequence 2279, Ap
716	19	0.4	21	1	US-10-800-077-286	Sequence 286, App	789	16.4	0.4	19	1	US-10-844-076-2734	Sequence 2734, Ap
717	19	0.4	21	1	US-10-800-077-287	Sequence 287, App	790	16.4	0.4	19	1	US-10-844-076-2737	Sequence 2737, Ap
718	19	0.4	21	1	US-10-800-077-289	Sequence 289, App	791	16.4	0.4	19	1	US-10-968-898-2293	Sequence 2293, Ap
719	19	0.4	21	1	US-10-800-077-290	Sequence 290, App	792	16.4	0.4	19	1	US-10-968-898-2421	Sequence 2421, Ap
720	19	0.4	21	1	US-10-800-077-290	Sequence 290, App	793	16.4	0.4	19	1	US-10-944-611-2293	Sequence 2293, Ap
721	18.8	0.4	22	1	US-10-411-954-268	Sequence 268, App	794	16.4	0.4	20	1	US-10-944-611-2421	Sequence 2421, Ap
722	18.8	0.4	22	1	US-10-411-954-339	Sequence 339, App	C 795	16.4	0.4	20	1	US-10-021-707-19	Sequence 19, Appl
723	18.8	0.4	22	1	US-10-321-039-737	Sequence 737, App	C 796	16.4	0.4	20	1	US-10-126-355-83	Sequence 83, Appl
724	18.8	0.4	22	1	US-10-617-070-268	Sequence 268, App	C 797	16.4	0.4	20	1	US-10-289-762-2100	Sequence 2100, Ap
725	18.8	0.4	22	1	US-10-617-070-339	Sequence 339, App	C 798	16.4	0.4	20	1	US-10-673-063-1929	Sequence 19, Appl
726	18.8	0.4	22	1	US-10-956-507-268	Sequence 268, App	799	16	0.4	19	1	US-10-333-429-417	Sequence 417, App
727	18.8	0.4	22	1	US-10-956-507-339	Sequence 339, App	800	15.8	0.4	19	1	US-09-880-732-4	Sequence 4, Appl
728	18.8	0.4	23	1	US-10-758-155-2627	Sequence 2627, Ap	801	15.8	0.4	19	1	US-09-966-147-22	Sequence 22, Appl
729	18.8	0.4	23	1	US-10-758-155-2639	Sequence 2639, Ap	C 802	15.8	0.4	19	1	US-09-904-968A-63	Sequence 63, Appl
730	18.8	0.4	23	1	US-10-831-620-2627	Sequence 2627, Ap	C 803	15.8	0.4	19	1	US-10-083-246A-83	Sequence 83, Appl
731	18.8	0.4	23	1	US-10-831-620-2639	Sequence 2639, Ap	804	15.8	0.4	19	1	US-10-374-469-22	Sequence 22, Appl
732	18.8	0.4	23	1	US-10-844-076-2627	Sequence 2627, Ap	805	15.8	0.4	19	1	US-10-163-598-18	Sequence 18, Appl
733	18.8	0.4	23	1	US-10-844-076-2639	Sequence 2639, Ap	806	15.8	0.4	19	1	US-10-698-597-22	Sequence 22, Appl
734	18.8	0.4	23	1	US-10-962-898-2232	Sequence 2232, Ap	807	15.8	0.4	19	1	US-10-665-951-1677	Sequence 1677, Ap
735	18.8	0.4	23	1	US-10-962-898-2242	Sequence 2242, Ap	C 808	15.8	0.4	19	1	US-10-665-951-1924	Sequence 1924, Ap
736	18.8	0.4	23	1	US-10-944-611-2232	Sequence 2232, Ap	809	15.8	0.4	19	1	US-10-665-951-2245	Sequence 2245, Ap
737	18.8	0.4	23	1	US-10-944-611-2242	Sequence 2242, Ap	810	15.8	0.4	19	1	US-10-683-990-87	Sequence 87, Appl
C 738	18	0.4	18	1	US-10-800-350-47	Sequence 47, Appl	C 811	15.8	0.4	19	1	US-10-683-990-184	Sequence 184, App
C 739	18	0.4	18	1	US-10-800-350-48	Sequence 48, Appl	812	15.8	0.4	19	1	US-10-758-155-1677	Sequence 1677, Ap
C 740	18	0.4	18	1	US-10-800-350-227	Sequence 227, App	C 813	15.8	0.4	19	1	US-10-758-155-1924	Sequence 1924, Ap
C 741	18	0.4	18	1	US-10-800-350-228	Sequence 228, App	814	15.8	0.4	19	1	US-10-758-155-2245	Sequence 2245, Ap
C 742	18	0.4	18	1	US-10-800-077-47	Sequence 47, Appl	815	15.8	0.4	19	1	US-10-758-155-2268	Sequence 2268, Ap
C 743	18	0.4	18	1	US-10-800-077-48	Sequence 48, Appl	816	15.8	0.4	19	1	US-10-758-155-2711	Sequence 2711, Ap
C 744	18	0.4	18	1	US-10-800-077-227	Sequence 227, App	817	15.8	0.4	19	1	US-10-758-155-2717	Sequence 2717, Ap
C 745	18	0.4	18	1	US-10-800-077-228	Sequence 228, App	818	15.8	0.4	19	1	US-10-758-155-2723	Sequence 2723, Ap
C 746	17.8	0.4	21	1	US-10-712-363-25	Sequence 25, Appl	819	15.8	0.4	19	1	US-10-758-155-2738	Sequence 2738, Ap
C 747	17.8	0.4	21	1	US-10-810-976-5	Sequence 5, Appl	C 820	15.8	0.4	19	1	US-10-411-915-83	Sequence 83, Appl
748	17.4	0.4	19	1	US-10-411-954-236	Sequence 236, App	821	15.8	0.4	19	1	US-10-831-620-1677	Sequence 1677, Ap
749	17.4	0.4	19	1	US-10-617-070-236	Sequence 236, App	C 822	15.8	0.4	19	1	US-10-831-620-1924	Sequence 1924, Ap
750	17.4	0.4	19	1	US-10-617-070-361	Sequence 361, App	823	15.8	0.4	19	1	US-10-831-620-2245	Sequence 2245, Ap
751	17.4	0.4	19	1	US-10-758-155-2735	Sequence 2735, Ap	824	15.8	0.4	19	1	US-10-831-620-2668	Sequence 2668, Ap
752	17.4	0.4	19	1	US-10-831-620-2735	Sequence 2735, Ap	825	15.8	0.4	19	1	US-10-831-620-2711	Sequence 2711, Ap
753	17.4	0.4	19	1	US-10-844-076-2735	Sequence 2735, App	826	15.8	0.4	19	1	US-10-831-620-2717	Sequence 2717, Ap
754	17.4	0.4	19	1	US-10-956-507-236	Sequence 236, App	827	15.8	0.4	19	1	US-10-831-620-2723	Sequence 2723, Ap
755	17.4	0.4	20	1	US-10-188-359-361	Sequence 13, Appl	828	15.8	0.4	19	1	US-10-831-620-2738	Sequence 2738, Ap
756	17.4	0.4	20	1	US-10-188-359-13	Sequence 13, Appl	C 829	15.8	0.4	19	1	US-10-923-522-544	Sequence 544, App
C 757	17	0.4	19	1	US-10-800-350-60	Sequence 60, Appl	830	15.8	0.4	19	1	US-10-923-522-863	Sequence 863, App
C 758	17	0.4	19	1	US-10-800-077-60	Sequence 60, Appl	831	15.8	0.4	19	1	US-10-844-076-1677	Sequence 1677, Ap
C 759	16.8	0.4	20	1	US-09-888-361-53	Sequence 53, Appl	C 832	15.8	0.4	19	1	US-10-844-076-1924	Sequence 1924, Ap
C 760	16.8	0.4	20	1	US-10-705-715-53	Sequence 53, Appl	833	15.8	0.4	19	1	US-10-844-076-2245	Sequence 2245, Ap
C 761	16.8	0.4	20	1	US-10-776-013-6	Sequence 6, Appl	834	15.8	0.4	19	1	US-10-844-076-2268	Sequence 2268, Ap
C 762	16.8	0.4	21	1	US-09-735-995-91	Sequence 91, Appl	835	15.8	0.4	19	1	US-10-844-076-2711	Sequence 2711, Ap
C 763	16.8	0.4	21	1	US-10-696-708-91	Sequence 91, Appl	836	15.8	0.4	19	1	US-10-844-076-2717	Sequence 2717, Ap

```
837 15.8 0.4 19 1 US-10-844-076-2723 Sequence 2723, Ap Sequence 1651, Ap
838 15.8 0.4 19 1 US-10-844-076-2738 Sequence 2738, Ap Sequence 1652, Ap
839 15.8 0.4 19 1 US-10-962-898-1677 Sequence 1677, Ap Sequence 1654, Ap
840 15.8 0.4 19 1 US-10-962-898-1924 Sequence 1924, Ap Sequence 1655, Ap
841 15.8 0.4 19 1 US-10-962-898-2294 Sequence 2294, Ap Sequence 1656, Ap
842 15.8 0.4 19 1 US-10-944-611-1677 Sequence 1677, Ap Sequence 1657, Ap
843 15.8 0.4 19 1 US-10-944-611-1924 Sequence 1924, Ap Sequence 1658, Ap
844 15.8 0.4 19 1 US-10-944-611-2294 Sequence 2294, Ap Sequence 1659, Ap
845 15.4 0.4 17 1 US-09-866-108-1653 Sequence 1653, Ap Sequence 1660, Ap
846 15.4 0.4 17 1 US-09-866-108-1654 Sequence 1654, Ap Sequence 1661, Ap
847 15.4 0.4 17 1 US-09-866-108-1655 Sequence 1655, Ap Sequence 1662, Ap
848 15.4 0.4 17 1 US-09-866-108-1656 Sequence 1656, Ap Sequence 1663, Ap
849 15.4 0.4 17 1 US-09-866-108-1657 Sequence 1657, Ap Sequence 1664, Ap
850 15.4 0.4 17 1 US-10-209-787-3946 Sequence 3946, Ap Sequence 1665, Ap
851 15.4 0.4 17 1 US-10-209-787-3947 Sequence 3947, Ap Sequence 1666, Ap
852 15.4 0.4 17 1 US-10-261-185-3947 Sequence 3947, Ap Sequence 1667, Ap
853 15.4 0.4 17 1 US-10-138-674-7739 Sequence 7739, Ap Sequence 1668, Ap
854 15.4 0.4 17 1 US-10-138-674-7740 Sequence 7740, Ap Sequence 1669, Ap
855 15.4 0.4 17 1 US-10-287-949A-7739 Sequence 7739, Ap Sequence 1670, Ap
856 15.4 0.4 17 1 US-10-287-949A-7740 Sequence 7740, Ap Sequence 1671, Ap
857 15.4 0.4 17 1 US-10-723-361-1653 Sequence 1653, Ap Sequence 1672, Ap
858 15.4 0.4 17 1 US-10-723-361-1654 Sequence 1654, Ap Sequence 1673, Ap
859 15.4 0.4 17 1 US-10-723-361-1655 Sequence 1655, Ap Sequence 1674, Ap
860 15.4 0.4 17 1 US-10-681-074-3946 Sequence 3946, Ap Sequence 1675, Ap
861 15.4 0.4 17 1 US-10-681-074-3947 Sequence 3947, Ap Sequence 1676, Ap
862 15.4 0.4 17 1 US-10-712-633-822 Sequence 822, Ap Sequence 1677, Ap
863 15.4 0.4 17 1 US-10-712-633-823 Sequence 823, Ap Sequence 1678, Ap
864 15.4 0.4 17 1 US-10-712-633-8238 Sequence 8238, Ap Sequence 1679, Ap
865 15.4 0.4 18 1 US-09-969-373-1642 Sequence 1642, Ap Sequence 1680, Ap
866 15.4 0.4 18 1 US-10-770-538-51 Sequence 51, Appl Sequence 1681, Ap
867 15.4 0.4 19 1 US-10-665-951-895 Sequence 895, Appl Sequence 1682, Ap
868 15.4 0.4 19 1 US-10-665-951-1219 Sequence 1219, Ap Sequence 1683, Ap
869 15.4 0.4 19 1 US-10-665-951-2264 Sequence 2264, Ap Sequence 1684, Ap
870 15.4 0.4 19 1 US-10-635-780-19 Sequence 19, Appl Sequence 1685, Ap
871 15.4 0.4 19 1 US-10-758-155-895 Sequence 895, Appl Sequence 1686, Ap
872 15.4 0.4 19 1 US-10-758-155-1219 Sequence 1219, Ap Sequence 1687, Ap
873 15.4 0.4 19 1 US-10-758-155-2264 Sequence 2264, Ap Sequence 1688, Ap
874 15.4 0.4 19 1 US-10-758-155-2671 Sequence 2671, Ap Sequence 1689, Ap
875 15.4 0.4 19 1 US-10-758-155-2728 Sequence 2728, Ap Sequence 1690, Ap
876 15.4 0.4 19 1 US-10-758-155-2731 Sequence 2731, Ap Sequence 1691, Ap
877 15.4 0.4 19 1 US-10-831-620-895 Sequence 895, Appl Sequence 1692, Ap
878 15.4 0.4 19 1 US-10-831-620-1219 Sequence 1219, Ap Sequence 1693, Ap
879 15.4 0.4 19 1 US-10-831-620-2264 Sequence 2264, Ap Sequence 1694, Ap
880 15.4 0.4 19 1 US-10-831-620-2669 Sequence 2669, Ap Sequence 1695, Ap
881 15.4 0.4 19 1 US-10-831-620-2671 Sequence 2671, Ap Sequence 1696, Ap
882 15.4 0.4 19 1 US-10-831-620-2728 Sequence 2728, Ap Sequence 1697, Ap
883 15.4 0.4 19 1 US-10-831-620-2731 Sequence 2731, Ap Sequence 1698, Ap
884 15.4 0.4 19 1 US-10-844-076-895 Sequence 895, Appl Sequence 1699, Ap
885 15.4 0.4 19 1 US-10-844-076-1219 Sequence 1219, Ap Sequence 1700, Ap
886 15.4 0.4 19 1 US-10-844-076-2264 Sequence 2264, Ap Sequence 1701, Ap
887 15.4 0.4 19 1 US-10-844-076-2669 Sequence 2669, Ap Sequence 1702, Ap
888 15.4 0.4 19 1 US-10-844-076-2671 Sequence 2671, Ap Sequence 1703, Ap
889 15.4 0.4 19 1 US-10-844-076-2728 Sequence 2728, Ap Sequence 1704, Ap
890 15.4 0.4 19 1 US-10-844-076-2731 Sequence 2731, Ap Sequence 1705, Ap
891 15.4 0.4 19 1 US-10-962-898-895 Sequence 895, Appl Sequence 1706, Ap
892 15.4 0.4 19 1 US-10-962-898-1219 Sequence 1219, Ap Sequence 1707, Ap
893 15.4 0.4 19 1 US-10-962-898-2420 Sequence 2420, Ap Sequence 1708, Ap
894 15.4 0.4 19 1 US-10-962-898-3371 Sequence 3371, Ap Sequence 1709, Ap
895 15.4 0.4 19 1 US-10-944-611-895 Sequence 895, Appl Sequence 1710, Ap
896 15.4 0.4 19 1 US-10-944-611-1219 Sequence 1219, Ap Sequence 1711, Ap
897 15.4 0.4 19 1 US-10-944-611-2420 Sequence 2420, Ap Sequence 1712, Ap
898 15.4 0.4 19 1 US-10-944-611-3371 Sequence 3371, Ap Sequence 1713, Ap
899 15 0.4 15 1 US-10-440-464-42 Sequence 42, Appl Sequence 1714, Ap
900 15 0.4 17 1 US-09-866-108-1651 Sequence 1651, Ap Sequence 1715, Ap
901 15 0.4 17 1 US-09-866-108-1652 Sequence 1652, Ap Sequence 1716, Ap
902 15 0.4 17 1 US-09-777-732-15 Sequence 15, Appl Sequence 1717, Ap
903 15 0.4 17 1 US-09-778-013-15 Sequence 15, Appl Sequence 1718, Ap
904 15 0.4 17 1 US-10-138-674-5010 Sequence 5010, Ap Sequence 1719, Ap
905 15 0.4 17 1 US-10-138-674-5011 Sequence 5011, Ap Sequence 1720, Ap
906 15 0.4 17 1 US-10-138-674-5012 Sequence 5012, Ap Sequence 1721, Ap
907 15 0.4 17 1 US-10-287-949A-5010 Sequence 5010, Ap Sequence 1722, Ap
908 15 0.4 17 1 US-10-287-949A-5011 Sequence 5011, Ap Sequence 1723, Ap
909 15 0.4 17 1 US-10-287-949A-5012 Sequence 5012, Ap Sequence 1724, Ap
```

ALIGNMENTS

RESULT 1

```
US-10-776-399A-217
; Sequence 217, Application US/10776399A
; Publication No. US20050026172A1
; GENERAL INFORMATION:
; APPLICANT: Li, Henry
; APPLICANT: Chatterton, Jon E.
; APPLICANT: Fan, Wufang
; APPLICANT: Ke, Ning
; APPLICANT: Wong-Staal, Flossie
; TITLE OF INVENTION: siRNA Libraries Optimized for Predetermined
; TITLE OF INVENTION: Protein Families
; FILE REFERENCE: 016556-003610US
; CURRENT APPLICATION NUMBER: US/10776,399A
; CURRENT FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: US 60/446,714
; PRIOR FILING DATE: 2003-02-11
; NUMBER OF SEQ ID NOS: 314
; SOFTWARE: PatentIn version 2.1
; SEQ ID NO 217
; LENGTH: 48
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:variant 5
; OTHER INFORMATION: tyrosine kinase family portion of catalytic domain
US-10-776-399A-217
```

Query Match 1.1%; Score 48; DB 1; Length 48;
Best Local Similarity 100.0%; Pred. No. 2.1;
Matches 48; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 2575 ATGAGTACGTCCACGAGACCTGGTCTCGCAACATCTAGTCAAC 2622
      |||||
Db 1 ATGAGTACGTCCACGAGACCTGGTCTCGCAACATCTAGTCAAC 48
```

RESULT 2

```
US-10-776-399A-197
; Sequence 197, Application US/10776399A
; Publication No. US20050026172A1
; GENERAL INFORMATION:
; APPLICANT: Li, Henry
; APPLICANT: Chatterton, Jon E.
; APPLICANT: Fan, Wufang
; APPLICANT: Ke, Ning
; APPLICANT: Wong-Staal, Flossie
; TITLE OF INVENTION: siRNA Libraries Optimized for Predetermined
; TITLE OF INVENTION: Protein Families
```



```
; FILE REFERENCE: 016556-003610US
; CURRENT APPLICATION NUMBER: US/10/776,399A
; CURRENT FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: US 60/446,714
; PRIOR FILING DATE: 2003-02-11
; NUMBER OF SEQ ID NOS: 314
; SOFTWARE: PatentIn version 2.1
; SEQ ID NO 197
; LENGTH: 48
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:variant 5
; OTHER INFORMATION: tyrosine kinase family portion of catalytic domain
US-10-776-399A-197

Query Match          0.9%; Score 40; DB 1; Length 48;
Best Local Similarity 89.6%; Pred. No. 14;
Matches 43; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 2575 ATGAGCTACGTCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 2622
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1 ATGAATATGTGACCGCGACCTGGCTGCTCGCAACATCCTTGTCAAC 48

RESULT 3
US-10-776-399A-183
; Sequence 183, Application US/10776399A
; Publication No. US20050026172A1
; GENERAL INFORMATION:
; APPLICANT: Li, Henry
; APPLICANT: Chatterton, Jon E.
; APPLICANT: Fan, Wufang
; APPLICANT: Ke, Ning
; APPLICANT: Wong-Staal, Flossie
; TITLE OF INVENTION: siRNA Libraries Optimized for Predetermined
; FILE REFERENCE: 016556-003610US
; CURRENT APPLICATION NUMBER: US/10/776,399A
; CURRENT FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: US 60/446,714
; PRIOR FILING DATE: 2003-02-11
; NUMBER OF SEQ ID NOS: 314
; SOFTWARE: PatentIn version 2.1
; SEQ ID NO 183
; LENGTH: 48
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:variant 5
; OTHER INFORMATION: tyrosine kinase family portion of catalytic domain
US-10-776-399A-183

Query Match          0.9%; Score 38.4; DB 1; Length 48;
Best Local Similarity 87.5%; Pred. No. 21;
Matches 42; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2575 ATGAGCTACGTCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 2622
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1 ATGAATATGTGACCGCGACCTGGCTGCTCGCAACATCCTTGTCAAC 48

RESULT 4
US-10-776-399A-195
; Sequence 195, Application US/10776399A
; Publication No. US20050026172A1
; GENERAL INFORMATION:
; APPLICANT: Li, Henry
; APPLICANT: Chatterton, Jon E.
; APPLICANT: Fan, Wufang
; APPLICANT: Ke, Ning
; APPLICANT: Wong-Staal, Flossie
; TITLE OF INVENTION: siRNA Libraries Optimized for Predetermined
```

```
; TITLE OF INVENTION: Protein Families
; FILE REFERENCE: 016556-003610US
; CURRENT APPLICATION NUMBER: US/10/776,399A
; CURRENT FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: US 60/446,714
; PRIOR FILING DATE: 2003-02-11
; NUMBER OF SEQ ID NOS: 314
; SOFTWARE: PatentIn version 2.1
; SEQ ID NO 195
; LENGTH: 48
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:variant 5
; OTHER INFORMATION: tyrosine kinase family portion of catalytic domain
US-10-776-399A-195

Query Match          0.9%; Score 38.4; DB 1; Length 48;
Best Local Similarity 87.5%; Pred. No. 21;
Matches 42; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2575 ATGAGCTACGTCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 2622
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1 ATGAATATGTGACCGCGACCTGGCTGCTCGCAACATCCTTGTCAAC 48

RESULT 5
US-10-800-350-2/c
; Sequence 2, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-2

Query Match          0.7%; Score 29; DB 1; Length 36;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 TGGATGAGAGCGAGGCTGGCGGAGCAG 1986
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 36 TGGATGAGAGCGAGGCTGGCGGAGCAG 8

RESULT 6
US-10-800-077-2/c
; Sequence 2, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
```



```
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-2

Query Match          0.7%; Score 29; DB 1; Length 36;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 TGGATGAGCGGCGGCTGCGGAGCAG 1986
      |||||
Db 36 TGGATGAGCGGCGGCTGCGGAGCAG 8

RESULT 7
US-10-440-464-40
; Sequence 40, Application US/10440464
; Publication No. US20040018528A1
; GENERAL INFORMATION:
; APPLICANT: DEPRIMO, SAMUEL
; APPLICANT: O'FARRELL, ANNE-MARIE
; APPLICANT: MORIMOTO, ALYSSA
; APPLICANT: SMOLICH, BEVERLY
; APPLICANT: MANNING, WILLIAM
; APPLICANT: WALTER, SARAH
; APPLICANT: CHERRINGTON, JULIE
; APPLICANT: SCHILLING, JIM
; TITLE OF INVENTION: NOVEL BIOMARKERS OF TYROSINE KINASE INHIBITOR EXPOSURE
; FILE REFERENCE: 038602/1592
; CURRENT APPLICATION NUMBER: US/10/440,464
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: 60/380,872
; PRIOR FILING DATE: 2002-05-17
; PRIOR APPLICATION NUMBER: 60/448,922
; PRIOR FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: 60/448,874
; PRIOR FILING DATE: 2003-02-24
; NUMBER OF SEQ ID NOS: 185
; SOFTWARE: PatentIn ver. 2.1
; SEQ ID NO 40
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-440-464-40

Query Match          0.6%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3920 TCTACCGTCCTTGTGCATAACTTTGTG 3945
      |||||
Db 1 TCTACCGTCCTTGTGCATAACTTTGTG 26

RESULT 8
US-11-060-756-97792
; Sequence 97792, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97792
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97792

Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3918 TTCTACCGTCCTTGTGCATAACTTT 3942
      |||||
Db 1 TTCTACCGTCCTTGTGCATAACTTT 25

RESULT 9
US-11-060-756-97793
; Sequence 97793, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97793
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97793

Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3919 TTCTACCGTCCTTGTGCATAACTTTG 3943
      |||||
Db 1 TTCTACCGTCCTTGTGCATAACTTTG 25

RESULT 10
US-11-060-756-97794
; Sequence 97794, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97794
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97794
```

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3134 AATGGGAAGATACGAGAAAGTTT 3158
|||||
Db 1 AATGGGAAGATACGAGAAAGTTT 25

RESULT 11
US-11-060-756-97795
; Sequence 97795, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97795
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97795

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3921 CTACCGTCCTTGTCATAACTTTGTG 3945
|||||
Db 1 CTACCGTCCTTGTCATAACTTTGTG 25

RESULT 12
US-11-060-756-97796
; Sequence 97796, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97796
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97796

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3920 TCTACCGTCCTTGTCATAACTTTGT 3944
|||||
Db 1 TCTACCGTCCTTGTCATAACTTTGT 25

RESULT 13
US-11-060-756-97797
; Sequence 97797, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97797
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97797

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3135 AATGGGAAGATACGAGAAAGTTTC 3159
|||||
Db 1 AATGGGAAGATACGAGAAAGTTTC 25

RESULT 14
US-11-060-756-97798
; Sequence 97798, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97798
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97798

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3780 CTGTCACCACCAACTCAATCATTT 3804
|||||
Db 1 CTGTCACCACCAACTCAATCATTT 25

RESULT 15
US-11-060-756-97799
; Sequence 97799, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97799
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97799

```
Query Match      0.6%  Score 25;  DB 1;  Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3922 TACCGTCTTGTGCATAACTTTGTGT 3946
DB 1 TACCGTCTTGTGCATAACTTTGTGT 25
|||||
|||||

RESULT 16
US-11-060-756-97800
; Sequence 97800, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97800
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97800

Query Match      0.6%  Score 25;  DB 1;  Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3931 TGTGCATAACTTTGTGTGGAGGGA 3955
DB 1 TGTGCATAACTTTGTGTGGAGGGA 25
|||||
|||||

RESULT 17
US-11-060-756-97803
; Sequence 97803, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97803
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97803

Query Match      0.6%  Score 25;  DB 1;  Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3932 GTGCATAACTTTGTGTGGAGGGA 3956
DB 1 GTGCATAACTTTGTGTGGAGGGA 25
|||||
|||||

RESULT 18
US-11-060-756-97801
; Sequence 97801, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97801
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97801

Query Match      0.6%  Score 25;  DB 1;  Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3929 CTTGTGCATAACTTTGTGTGGAGG 3953
DB 1 CTTGTGCATAACTTTGTGTGGAGG 25
|||||
|||||

RESULT 19
US-11-060-756-97804
; Sequence 97804, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97804
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97804

Query Match      0.6%  Score 25;  DB 1;  Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3930 TTGTGCATAACTTTGTGTGGAGGGA 3954
DB 1 TTGTGCATAACTTTGTGTGGAGGGA 25
|||||
|||||

RESULT 20
US-11-060-756-97804
; Sequence 97804, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97804
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97804

Query Match      0.6%  Score 25;  DB 1;  Length 25;
```

```
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97807
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97807

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3927 TCCTTGTCAATACTTGTGTGGAG 3951
|||||
Db 1 TCCTTGTCAATACTTGTGTGGAG 25

RESULT 21
US-11-060-756-97805
; Sequence 97805, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97805
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97805

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3925 CGTCTTGTCAATACTTGTGTGG 3949
|||||
Db 1 CGTCTTGTCAATACTTGTGTGG 25

RESULT 22
US-11-060-756-97806
; Sequence 97806, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97806
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97806

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3924 CCGTCTTGTCAATACTTGTGTG 3948
|||||
Db 1 CCGTCTTGTCAATACTTGTGTG 25

RESULT 23
US-11-060-756-97807
; Sequence 97807, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
```

```
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97807
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97807

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3926 GTCTTGTCAATACTTGTGTGGA 3950
|||||
Db 1 GTCTTGTCAATACTTGTGTGGA 25

RESULT 24
US-11-060-756-97808
; Sequence 97808, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97808
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97808

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3462 TTGGCAATTTGGAGACAGGATTT 3486
|||||
Db 1 TTGGCAATTTGGAGACAGGATTT 25

RESULT 25
US-11-060-756-97809
; Sequence 97809, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97809
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97809

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
```

```
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3928 CCTGTGCATACTTTGTGTGGAGG 3952
Db 1 CCTGTGCATACTTTGTGTGGAGG 25

RESULT 26
US-11-060-756-97810
; Sequence 97810, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97810
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97810

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3923 ACCGTCCTTGTGCATACTTTGTGT 3947
Db 1 ACCGTCCTTGTGCATACTTTGTGT 25

RESULT 27
US-11-060-756-97811
; Sequence 97811, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97811
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97811

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3933 TCATAACTTTTGTGTGGAGGGAACC 3957
Db 1 TCATAACTTTTGTGTGGAGGGAACC 25

RESULT 28
US-11-060-756-97812
; Sequence 97812, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
```

```
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97812
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97812

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3917 TTTTCTACCGTCCTTGTGCATACTT 3941
Db 1 TTTTCTACCGTCCTTGTGCATACTT 25

RESULT 29
US-11-060-756-97813
; Sequence 97813, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97813
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97813

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3132 CAAAATGGGAAGATACGAAGAAGT 3156
Db 1 CAAAATGGGAAGATACGAAGAAGT 25

RESULT 30
US-11-060-756-97814
; Sequence 97814, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97814
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97814

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 3131 TCAAAATGGGAAGATACGAGAAAG 3155
|||||
Db 1 TCAAAATGGGAAGATACGAGAAAG 25

RESULT 31
US-11-060-756-97815
; Sequence 97815, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97815
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97815

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4150 TGCTTGAGGGGTTCTTAATTTATA 4174
|||||
Db 1 TGCTTGAGGGGTTCTTAATTTATA 25

RESULT 32
US-11-060-756-97816
; Sequence 97816, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97816
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97816

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3133 AAAATGGGAAGATACGAGAAAGTT 3157
|||||
Db 1 AAAATGGGAAGATACGAGAAAGTT 25

RESULT 33
US-11-060-756-97817
; Sequence 97817, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes

; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97817
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97817

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3461 GTTGGCAATTTGGAGAGACAGGATT 3485
|||||
Db 1 GTTGGCAATTTGGAGAGACAGGATT 25

RESULT 34
US-11-060-756-97818
; Sequence 97818, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97818
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97818

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3129 CATCAAAATGGGAAGATACGAGAA 3153
|||||
Db 1 CATCAAAATGGGAAGATACGAGAA 25

RESULT 35
US-11-060-756-97819
; Sequence 97819, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97819
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97819

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4149 GTGCTTGAGGGTCTTAAATAT 4173
|||||
Db 1 GTGCTTGAGGGTCTTAAATAT 25

RESULT 36
US-11-060-756-97820
; Sequence 97820, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97820
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97820

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3130 ATCAAAATGGGAAGATACGAGAA 3154
|||||
Db 1 ATCAAAATGGGAAGATACGAGAA 25

RESULT 37
US-11-060-756-97821
; Sequence 97821, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97821
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97821

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3781 TGTCAACCAAACTCAATCATTTT 3805
|||||
Db 1 TGTCAACCAAACTCAATCATTTT 25

RESULT 38
US-11-060-756-97822
; Sequence 97822, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)

; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97822
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97822

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3935 ATAACCTTGTGTGGAGGGAACCTG 3959
|||||
Db 1 ATAACCTTGTGTGGAGGGAACCTG 25

RESULT 39
US-11-060-756-97823
; Sequence 97823, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97823
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97823

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3934 CATAACTTTGTGTGGAGGGAACCT 3958
|||||
Db 1 CATAACTTTGTGTGGAGGGAACCT 25

RESULT 40
US-11-060-756-97824
; Sequence 97824, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97824
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97824

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4151 GCTTGGAGGGTCTTAAATATAT 4175

```
|||||
Db      1  GCTGGAGGGTCTTAATAATAT 25

RESULT 41
US-11-060-756-97825
; Sequence 97825, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97825
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97825

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3463  TGGCAATTTGGAGAGACAGGATTG 3487
|||||
Db      1  TGGCAATTTGGAGAGACAGGATTG 25

RESULT 42
US-11-060-756-97826
; Sequence 97826, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97826
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97826

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3492  TTCTGCCATAATAGGAGGGGAAAAAT 3516
|||||
Db      1  TTCTGCCATAATAGGAGGGGAAAAAT 25

RESULT 43
US-11-060-756-97827
; Sequence 97827, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3493  TCTGCCATAATAGGAGGGGAAAAATC 3517
|||||
Db      1  TCTGCCATAATAGGAGGGGAAAAATC 25

RESULT 44
US-11-060-756-97828
; Sequence 97828, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97828
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97828

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3779  GCTGTCAACCAACCAACTCAATCATT 3803
|||||
Db      1  GCTGTCAACCAACCAACTCAATCATT 25

RESULT 45
US-11-060-756-97829
; Sequence 97829, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97829
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97829

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3945  GTTGGAGGGACCTGTTTCATTATG 3969
|||||
```



```
Db      1 GTTGGAGGGAACCTGTTTCACTATG 25

RESULT 46
US-11-060-756-97830
; Sequence 97830, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97830
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97830

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3494 CTGTCATAATAGGAGGGAATCA 3518
      |||||
Db      1 CTGTCATAATAGGAGGGAATCA 25

RESULT 47
US-11-060-756-97831
; Sequence 97831, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97831
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97831

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3494 CTGTCATAATAGGAGGGAATCA 3518
      |||||
Db      1 CTGTCATAATAGGAGGGAATCA 25

RESULT 48
US-11-060-756-97832
; Sequence 97832, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97832
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97832

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3495 TGGCATAATAGGAGGGAATCAC 3519
      |||||
Db      1 TGGCATAATAGGAGGGAATCAC 25

RESULT 49
US-11-060-756-97833
; Sequence 97833, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97833
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97833

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3491 GTTCTGCATAATAGGAGGGAATA 3515
      |||||
Db      1 GTTCTGCATAATAGGAGGGAATA 25

RESULT 50
US-11-060-756-97834
; Sequence 97834, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97834
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97834

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3460 AGTTGGCAATTTGGAGAGACAGGAT 3484
      |||||
Db      1 AGTTGGCAATTTGGAGAGACAGGAT 25
```

```
RESULT 51
US-11-060-756-97835
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 129097
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-129097
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 97835
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-97835
Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3465 GCAATTGGAGACAGGATTGGG 3489
      |||
Db      1 GCAATTGGAGACAGGATTGGG 25

RESULT 52
US-11-060-756-125249
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 125249
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-125249
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 125249
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-125249
Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4007 ATGCTGTTCCAGACAGTGCTT 4031
      |||
Db      1 ATGCTGTTCCAGACAGTGCTT 25

RESULT 53
US-11-060-756-129097
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 129097
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-129097
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 129097
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-129097
Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3950 AGGGAACCTGTTTCACTATGGCCTC 3974
      |||
Db      1 AGGGAACCTGTTTCACTATGGCCTC 25

RESULT 54
US-11-060-756-129098
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 129098
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-129098
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 129098
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-129098
Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3950 AGGGAACCTGTTTCACTATGGCCTC 3974
      |||
Db      1 AGGGAACCTGTTTCACTATGGCCTC 25

RESULT 55
US-11-060-756-132097
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 132097
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-132097
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 132097
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-132097
Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3984 AGTTGAACAGGGGCCCATCATCAT 4008
      |||
Db      1 AGTTGAACAGGGGCCCATCATCAT 25
```

1

```

RESULT 61
US-11-060-756-153404
; Sequence 153404, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 153404
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-153404

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3721 AAGAGGGGTGTGAGGGCCAGTGA 3745
|||||
Db 1 AAGAGGGGTGTGAGGGCCAGTGA 25

RESULT 62
US-11-060-756-155302
; Sequence 155302, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 155302
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-155302

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3983 AAGTTGAACAGGGGCCCATCATCA 4007
|||||
Db 1 AAGTTGAACAGGGGCCCATCATCA 25

RESULT 63
US-11-060-756-161865
; Sequence 161865, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 161865

```

```

; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-161865

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4134 CAGAAACGAGCGCGGTGCTGGAG 4158
|||||
Db 1 CAGAAACGAGCGCGGTGCTGGAG 25

RESULT 64
US-11-060-756-162190
; Sequence 162190, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 162190
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-162190

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3665 CAAGAGAGTGTGACTCCCTTGCCA 3689
|||||
Db 1 CAAGAGAGTGTGACTCCCTTGCCA 25

RESULT 65
US-11-060-756-165621
; Sequence 165621, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 165621
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-165621

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3192 CAGCCAGATCTCTGTGAGGACCTG 3216
|||||
Db 1 CAGCCAGATCTCTGTGAGGACCTG 25

RESULT 66

```



```
; Sequence 183482, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 183482
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-183482

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3532 TCGGGGAACCTCCAGACCAAGGGTGA 3556
      |||||
Db 1 TCGGGGAACCTCCAGACCAAGGGTGA 25

RESULT 72
US-11-060-756-183957
; Sequence 183957, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 183957
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-183957

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3652 CGTTCGCGCAGACCAAGAGAGTGT 3676
      |||||
Db 1 CGTTCGCGCAGACCAAGAGAGTGT 25

RESULT 73
US-11-060-756-184429
; Sequence 184429, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 184429
; LENGTH: 25
; TYPE: DNA
US-11-060-756-184429

; Sequence 183482, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 183482
; LENGTH: 25
; TYPE: DNA
US-11-060-756-183482

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3925 CGTCCTTGTCACTTAACCTTTGCTTGG 3949
      |||||
Db 1 CGTCCTTGTCACTTAACCTTTGCTTGG 25

RESULT 74
US-11-060-756-184632
; Sequence 184632, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 184632
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-184632

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3220 CGAATCGGAGTCACCTCGCGGGAC 3244
      |||||
Db 1 CGAATCGGAGTCACCTCGCGGGAC 25

RESULT 75
US-11-060-756-185040
; Sequence 185040, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 185040
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-185040

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4132 CCCAGAAACGACGCGCGTGTGG 4156
      |||||
Db 1 CCCAGAAACGACGCGCGTGTGG 25

RESULT 76
US-11-060-756-185041
; Sequence 185041, Application US/11060756
```

```
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 185041
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
;
US-11-060-756-185041

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      4132 CCCGAAACGACGACCGCGTGTGG 4156
Db      1 CCCGAAACGACGACCGCGTGTGG 25
|||||

RESULT 77
US-11-060-756-186082
; Sequence 186082, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 186082
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
;
US-11-060-756-186082

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      4112 GCGCGTAGTTGGTGTGAACCCAG 4136
Db      1 GCGCGTAGTTGGTGTGAACCCAG 25
|||||

RESULT 78
US-11-060-756-186108
; Sequence 186108, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 186108
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
;
US-11-060-756-186108

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      4112 GCGCGTAGTTGGTGTGAACCCAG 4136
Db      1 GCGCGTAGTTGGTGTGAACCCAG 25
|||||

RESULT 79
US-11-060-756-186568
; Sequence 186568, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 186568
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
;
US-11-060-756-186568

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      4064 CCCCCAAGCTGTGTCTATGAAGG 4088
Db      1 CCCCCAAGCTGTGTCTATGAAGG 25
|||||

RESULT 80
US-11-060-756-187404
; Sequence 187404, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 187404
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
;
US-11-060-756-187404

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      3998 CCCATCATCATGTCTGTTCAGAA 4022
Db      1 CCCATCATCATGTCTGTTCAGAA 25
|||||

RESULT 81
US-11-060-756-188249
; Sequence 188249, Application US/11060756
; Publication No. US20050221354A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 188249
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-188249

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3038 CCCGGGAGATGGCGGCTTACA 3062
      |||||
Db 1 CCCGGGAGATGGCGGCTTACA 25

RESULT 82
US-11-060-756-189304
; Sequence 189304, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 189304
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-189304

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4133 CCAGAACGGACCGCGTCTTGA 4157
      |||||
Db 1 CCAGAACGGACCGCGTCTTGA 25

RESULT 83
US-11-060-756-189708
; Sequence 189708, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 189708
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-189708
```

```
Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3024 CCTCAAAATCGTGGCCGGGAGAT 3048
      |||||
Db 1 CCTCAAAATCGTGGCCGGGAGAT 25

RESULT 84
US-11-060-756-190188
; Sequence 190188, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 190188
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-190188

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3924 CCGTCCTTGTCAATACTTTGTGTG 3948
      |||||
Db 1 CCGTCCTTGTCAATACTTTGTGTG 25

RESULT 85
US-11-060-756-190605
; Sequence 190605, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 190605
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-190605

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3371 CTCCTCCCATTTTCGGGGCAGAGTG 3395
      |||||
Db 1 CTCCTCCCATTTTCGGGGCAGAGTG 25

RESULT 86
US-11-060-756-191833
; Sequence 191833, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
```



```
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 191833
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-191833

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 2919 CCTCACCAGCTCATGCTGGAGTGT 2943
Db 1 CCTCACCAGCTCATGCTGGAGTGT 25

RESULT 87
US-11-060-756-193142
; Sequence 193142, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 193142
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-193142

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 3928 CCTGTGTCATACTTGTGTTGGAGG 3952
Db 1 CCTGTGTCATACTTGTGTTGGAGG 25

RESULT 88
US-11-060-756-193756
; Sequence 193756, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 193756
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-193756
```

```
Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 2870 CCATTGAACAGGACTACCGGCTGCC 2894
Db 1 CCATTGAACAGGACTACCGGCTGCC 25

RESULT 89
US-11-060-756-195383
; Sequence 195383, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 195383
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-195383

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 3829 CCAGCTGCTGCCTTCATATTGAAGG 3853
Db 1 CCAGCTGCTGCCTTCATATTGAAGG 25

RESULT 90
US-11-060-756-197318
; Sequence 197318, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 197318
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-197318

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 3686 GCCAGCTCCAGAGTGGGGGGCTGT 3710
Db 1 GCCAGCTCCAGAGTGGGGGGCTGT 25

RESULT 91
US-11-060-756-201466
; Sequence 201466, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

```

; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 201466
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-201466

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3113 GCGAGTGGCTTCGGGCCATCAAAAT 3137
Db 1 GCGAGTGGCTTCGGGCCATCAAAAT 25

RESULT 92
US-11-060-756-205476
; Sequence 205476, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 205476
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-205476

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4151 GCTTGGAGGGTCTCTTAATTATAT 4175
Db 1 GCTTGGAGGGTCTCTTAATTATAT 25

RESULT 93
US-11-060-756-207856
; Sequence 207856, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 207856
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-207856

Query Match          0.6%; Score 25; DB 1; Length 25;

```

```
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 216810
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-216810

Query Match
Best Local Similarity 100.0%; Pred. No. 1.2e+02; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3988 GAAACAGGGGCCCATCATCATGCTCT 4012
Db 1 GAAACAGGGGCCCATCATCATGCTCT 25

RESULT 97
US-11-060-756-216811
; Sequence 216811, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 216811
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-216811

Query Match
Best Local Similarity 100.0%; Pred. No. 1.2e+02; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3988 GAAACAGGGGCCCATCATCATGCTCT 4012
Db 1 GAAACAGGGGCCCATCATCATGCTCT 25

RESULT 98
US-11-060-756-223922
; Sequence 223922, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 223922
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-223922

Query Match
Best Local Similarity 100.0%; Pred. No. 1.2e+02; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3475 GAGACAGGATTTGGGGTTCGTGCCA 3499
Db 1 GAGACAGGATTTGGGGTTCGTGCCA 25

RESULT 99
US-11-060-756-225785
; Sequence 225785, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 225785
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-225785

Query Match
Best Local Similarity 100.0%; Pred. No. 1.2e+02; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3949 GAGGGAACCTGTTTCACTATGGCCT 3973
Db 1 GAGGGAACCTGTTTCACTATGGCCT 25

RESULT 100
US-11-060-756-232888
; Sequence 232888, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 232888
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-232888

Query Match
Best Local Similarity 100.0%; Pred. No. 1.2e+02; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3985 GTTGAAACAGGGGCCCATCATCATG 4009
Db 1 GTTGAAACAGGGGCCCATCATCATG 25

RESULT 101
US-11-060-756-233025
; Sequence 233025, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
```

```
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 233025
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-233025

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3945 GTTGGAGGGAACTGTTTCACTATG 3969
      |||
Db 1 GTTGGAGGGAACTGTTTCACTATG 25

RESULT 102
US-11-060-756-235734
; Sequence 235734, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 235734
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-235734

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4013 GTTTCAGAACAGTGCCTTGTCAT 4037
      |||
Db 1 GTTTCAGAACAGTGCCTTGTCAT 25

RESULT 103
US-11-060-756-236369
; Sequence 236369, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 236369
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-236369

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4101 GTAGTGAAGGCGGTAGTTGGTG 4125
      |||
Db 1 GTAGTGAAGGCGGTAGTTGGTG 25

RESULT 104
US-11-060-756-240888
; Sequence 240888, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 240888
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-240888

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4009 GTCGTTTCCAGAACAGTGCCTTGG 4033
      |||
Db 1 GTCGTTTCCAGAACAGTGCCTTGG 25

RESULT 105
US-11-060-756-241193
; Sequence 241193, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 241193
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-241193

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4104 GTGAAAAGGCGGTAGTTGGTG 4128
      |||
Db 1 GTGAAAAGGCGGTAGTTGGTG 25

RESULT 106
US-11-060-756-241337
; Sequence 241337, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
```

; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 241337
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-241337

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3926 GTCCTTGCATCAACTTGTGTGGA 3950
DB 1 GTCCTTGCATCAACTTGTGTGGA 25

RESULT 107

US-11-060-756-242200
; Sequence 242200, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug

; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 242200
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-242200

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4149 GTGCTTGAGGGGTTCTTAATTAT 4173
DB 1 GTGCTTGAGGGGTTCTTAATTAT 25

RESULT 108

US-11-060-756-243194
; Sequence 243194, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug

; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 243194
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-243194

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3943 GTCTTGAGGGAACCTGTTTCACTA 3967
DB 1 GTCTTGAGGGAACCTGTTTCACTA 25

RESULT 109

US-11-060-756-244973
; Sequence 244973, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug

; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 244973
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-244973

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3449 GTGGGGTGAGGAGTTGGCAATTGG 3473
DB 1 GTGGGGTGAGGAGTTGGCAATTGG 25

RESULT 110

US-11-060-756-247996
; Sequence 247996, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug

; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 247996
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-247996

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3487 GGGGGTTCTGCCATAATAGAGGGG 3511
DB 1 GGGGGTTCTGCCATAATAGAGGGG 25

RESULT 111

US-11-060-756-248716
; Sequence 248716, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug

; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)

3705 GGCTGTCCACGGGGCAAGAAAGGG 3729

```
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 263974
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-263974

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3947 TGGAGGGAACCTGTTTCACTATGCG 3971
      |||||||||||||||||||||||||
Db 1 TGGAGGGAACCTGTTTCACTATGCG 25

RESULT 117
US-11-060-756-264417
; Sequence 264417, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 264417
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-264417

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4124 TGGTGGAAACCCAGAAACGGACGCG 4148
      |||||||||||||||||||||||||
Db 1 TGGTGGAAACCCAGAAACGGACGCG 25

RESULT 118
US-11-060-756-264508
; Sequence 264508, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 264508
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-264508

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2984 TGGTCAGCGCCCTGGACAAGATGAT 3008
      |||||||||||||||||||||||||
Db 1 TGGTCAGCGCCCTGGACAAGATGAT 25

RESULT 119
US-11-060-756-264553
; Sequence 264553, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 264553
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-264553

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3942 TGTGTTGGAGGGAACCTGTTTCACT 3966
      |||||||||||||||||||||||||
Db 1 TGTGTTGGAGGGAACCTGTTTCACT 25

RESULT 120
US-11-060-756-265308
; Sequence 265308, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 265308
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-265308

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3755 TGGGGTTTGTAGTCCCAACTTGCTG 3779
      |||||||||||||||||||||||||
Db 1 TGGGGTTTGTAGTCCCAACTTGCTG 25

RESULT 121
US-11-060-756-266195
; Sequence 266195, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
```

```
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 266195
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-266195

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3920 TCTACCGTCTTGTCTAATCTTGT 3944
      |||||
Db 1 TCTACCGTCTTGTCTAATCTTGT 25

RESULT 122
US-11-060-756-266335
; Sequence 266335, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 266335
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-266335

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4073 TGTGTCCTATGAAGGGGTGTGGGGT 4097
      |||||
Db 1 TGTGTCCTATGAAGGGGTGTGGGGT 25

RESULT 123
US-11-060-756-266889
; Sequence 266889, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 266889
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-266889

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4075 TGTCTATGAAGGGGTGTGGGGTGA 4099
      |||||
Db 1 TGTCTATGAAGGGGTGTGGGGTGA 25

RESULT 124
US-11-060-756-267083
; Sequence 267083, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 267083
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-267083

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3781 TGTCCACCACCAACTCAATCATTTT 3805
      |||||
Db 1 TGTCCACCACCAACTCAATCATTTT 25

RESULT 125
US-11-060-756-268063
; Sequence 268063, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 268063
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-268063

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4012 TGTTCCTCCAGACAGTGCCTTGTC 4036
      |||||
Db 1 TGTTCCTCCAGACAGTGCCTTGTC 25

RESULT 126
US-11-060-756-268427
; Sequence 268427, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
```



```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 268427
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-268427

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3944 TGTGGAGGGAACCTGTTCACTAT 3968
      |||||||
Db 1 TGTGGAGGGAACCTGTTCACTAT 25

RESULT 127
US-11-060-756-270798
; Sequence 270798, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 270798
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-270798

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4105 TGAAGAGGGCGGTAGTTGGTGGTGG 4129
      |||||||
Db 1 TGAAGAGGGCGGTAGTTGGTGGTGG 25

RESULT 128
US-11-060-756-271627
; Sequence 271627, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 271627
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-271627

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3987 TGAACAGGGGGCCCATCATCATGTC 4011
      |||||||
Db 1 TGAACAGGGGGCCCATCATCATGTC 25

RESULT 129
US-11-060-756-275773
; Sequence 275773, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 275773
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-275773

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4016 TCCAGAACAGTGCCTTGGTCATCCC 4040
      |||||||
Db 1 TCCAGAACAGTGCCTTGGTCATCCC 25

RESULT 130
US-11-060-756-275774
; Sequence 275774, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 275774
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-275774

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4016 TCCAGAACAGTGCCTTGGTCATCCC 4040
      |||||||
Db 1 TCCAGAACAGTGCCTTGGTCATCCC 25

RESULT 131
US-11-060-756-285057
; Sequence 285057, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
```

; SEQ ID NO 285057
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-285057

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3087 TCACTACTCAGCTTTGGCTCTGTG 3111
|||||
Db 1 TCACTACTCAGCTTTGGCTCTGTG 25

RESULT 132

US-11-060-756-286007
; Sequence 286007, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 286007
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-286007

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3795 TCAATCATTTTTTCCCTGTGTAAT 3819
|||||
Db 1 TCAATCATTTTTTCCCTGTGTAAT 25

RESULT 133

US-11-060-756-286495
; Sequence 286495, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 286495
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-286495

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3922 TACGTCCTTGTGCATAACTTTGTG 3946
|||||
Db 1 TACGTCCTTGTGCATAACTTTGTG 25

RESULT 134

US-11-060-756-291576
; Sequence 291576, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 291576
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-291576

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3919 TTCTACCGTCCTTGTGCATAACTTTG 3943
|||||
Db 1 TTCTACCGTCCTTGTGCATAACTTTG 25

RESULT 135

US-11-060-756-291577
; Sequence 291577, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 291577
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-291577

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3919 TTCTACCGTCCTTGTGCATAACTTTG 3943
|||||
Db 1 TTCTACCGTCCTTGTGCATAACTTTG 25

RESULT 136

US-11-060-756-294522
; Sequence 294522, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 294522

```
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-294522

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4014 TTTCAGACAGTCGCTTGGTCATC 4038
Db 1 TTTCAGACAGTCGCTTGGTCATC 25

RESULT 137
US-11-060-756-294810
; Sequence 294810, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 294810
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-294810

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3564 TTTCCTCAGACAGTCGGGTGACCA 3588
Db 1 TTTCCTCAGACAGTCGGGTGACCA 25

RESULT 138
US-11-060-756-300396
; Sequence 300396, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 300396
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-300396

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4015 TTCCAGACAGTCGCTTGGTCATCC 4039
Db 1 TTCCAGACAGTCGCTTGGTCATCC 25

RESULT 139
US-11-060-756-300512
; Sequence 300512, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 300512
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-300512

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3977 TTGCCCAAGTTGAAACAGGGGCCCA 4001
Db 1 TTGCCCAAGTTGAAACAGGGGCCCA 25

RESULT 140
US-11-060-756-301519
; Sequence 301519, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 301519
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-301519

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3930 TTTCATAACTTTGTGTGGAGGGA 3954
Db 1 TTTCATAACTTTGTGTGGAGGGA 25

RESULT 141
US-11-060-756-301875
; Sequence 301875, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 301875
; LENGTH: 25
```

; TYPE: DNA
; ORGANISM: probe
US-11-060-756-301875

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3434 TTGCACCTTTGAGCCCGTGGGTGAG 3458
|||
Db 1 TTGCACCTTTGAGCCCGTGGGTGAG 25

RESULT 142

US-10-800-350-1

; Sequence 1, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parakash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-1

Query Match 0.6%; Score 24.2; DB 1; Length 29;
Best Local Similarity 89.7%; Pred. No. 1.9e+02;
Matches 26; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 367 GCGCGGCCCATGGAGCTCCGGGTGCTGCT 395
|||
Db 1 GGATCCGCATGGAGCTCCGGGTGCTGCT 29

RESULT 143

US-10-800-077-1

; Sequence 1, Application US/10800077
; Publication No. US20050164955A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parakash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Unknown

; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-1

Query Match 0.6%; Score 24.2; DB 1; Length 29;
Best Local Similarity 89.7%; Pred. No. 1.9e+02;
Matches 26; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 367 GCGCGGCCCATGGAGCTCCGGGTGCTGCT 395
|||
Db 1 GGATCCGCATGGAGCTCCGGGTGCTGCT 29

RESULT 144

US-10-956-157-160391

; Sequence 160391, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 160391
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-160391

Query Match 0.6%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2927 AGCTCATGCTGGACTGTGGCAGAA 2951
|||
Db 1 AACTCATGCTGGACTGTGGCAGAA 25

RESULT 145

US-10-956-157-208204

; Sequence 208204, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 208204
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-208204

Query Match 0.5%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2934 GCTGGACTGTTGGCAGAAAGACCG 2957
|||
Db 1 GCTGGACTGTTGGCAGAGGACCG 24

RESULT 146

US-11-036-317-409480

```
; Sequence 409480, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036.317
; CURRENT FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; PRIOR FILING DATE: 2004-01-13
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 409480
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-409480

Query Match          0.5%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2313 CAAGACCTCTGAAGGCTGCTACAC 2336
      ||||| ||||| ||||| ||||| |||||
Db 1 CAAGACTCTGAAGGCTGCTACAC 24

RESULT 147
US-10-719-956-644851
; Sequence 644851, Application US/10719956
; Publication No. US20040145910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 644851
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-644851

Query Match          0.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3781 TGTCAACCAACCAATCAATCAATTTT 3805
      ||||| ||||| ||||| ||||| |||||
Db 1 TGTCAACCAACCAAGGCAATCAATTTT 25

RESULT 148
US-10-956-157-188189
; Sequence 188189, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 188189
; LENGTH: 25
```

```
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-188189

Query Match          0.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2920 CTCACCACTCATGCTGGACTGTT 2944
      ||||| ||||| ||||| ||||| |||||
Db 1 CTCACCAACTCATGCTGGACTGTT 25

RESULT 149
US-11-036-317-15098
; Sequence 15098, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; CURRENT FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; PRIOR FILING DATE: 2004-01-13
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 15098
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-15098

Query Match          0.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2926 CAGCTCATGCTGCAGCTGTTGGCAGA 2950
      ||||| ||||| ||||| ||||| |||||
Db 1 CAGCTAATGCTGGATTGTTGGCAGA 25

RESULT 150
US-11-060-756-124745
; Sequence 124745, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 124745
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-124745

Query Match          0.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2867 ATGCCATTGACAGGACTACCGGCT 2891
      ||||| ||||| ||||| ||||| |||||
Db 1 ATGCCATCGACGAGGACTACCGGCT 25

RESULT 151
```


Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 928 ATGGCCCTGCTATCCCTGCAC 948
Db 21 ATGGCCCTGCTATCCCTGCAC 1

RESULT 156

US-10-800-350-35/c
; Sequence 35, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 35
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-35

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 425 AAGAGACCTGCTGAACACAA 445
Db 21 AAGAGACCTGCTGAACACAA 1

RESULT 157

US-10-800-350-37/c
; Sequence 37, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 37
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-800-350-37

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 847 AAGGTGAATGTCAGACGCTG 867
Db 21 AAGGTGAATGTCAGACGCTG 1

RESULT 158

US-10-800-350-39/c
; Sequence 39, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 39
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-39

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1937 AACATCACAGCCAGACCCCAAC 1957
Db 21 AACATCACAGCCAGACCCCAAC 1

RESULT 159

US-10-800-350-41/c
; Sequence 41, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 41
; LENGTH: 21
; TYPE: RNA

```

; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-41

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2677 AACTTTCGATCCACCTTAC 2697
Db 21 AACTTTCGATCCACCTTAC 1

RESULT 160
US-10-800-350-42/c
; Sequence 42, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 42
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-42

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 928 ATGGCCCTGCTATCCCTGCAC 948
Db 21 ATGGCCCTGCTATCCCTGCAC 1

RESULT 161
US-10-800-350-44/c
; Sequence 44, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 44
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-44

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1381 GGCTCCTCCCTGCACCTGGAA 1401
Db 21 GGCTCCTCCCTGCACCTGGAA 1

RESULT 162
US-10-800-350-45/c
; Sequence 45, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 45
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-45

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1641 TGAGCCTGTCAATGTCACCAC 1661
Db 21 TGAGCCTGTCAATGTCACCAC 1

RESULT 163
US-10-800-350-46/c
; Sequence 46, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 46
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-46

```


; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 46
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-46

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1931 GCCAGGAACATCACAGCAGA 1951
Db 21 GCCAGGAACATCACAGCAGA 1

RESULT 164

US-10-800-350-49/c
; Sequence 49, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 49
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-49

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 784 AAGGTGGACACGGTGGCGCG 804
Db 21 AAGGTGGACACGGTGGCGCG 1

RESULT 165

US-10-800-350-50/c
; Sequence 50, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12

; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 50
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-50

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2305 GTGGCAATCAAGACCCCTGAAG 2325
Db 21 GTGGCAATCAAGACCCCTGAAG 1

RESULT 166

US-10-800-350-52/c
; Sequence 52, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 52
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-52

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2515 GTCATCAGCTCGTGGCATG 2535
Db 21 GTCATCAGCTCGTGGCATG 1

RESULT 167

US-10-800-350-70/c
; Sequence 70, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12

```

; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 70
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-70

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 425 AAGAGACCCCTGCTGAACACAA 445
Db 21 AAGAGACCCCTGCTGAACACAA 1

RESULT 168
US-10-800-350-73/c
; Sequence 73, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 73
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-73

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3319 GGACCGCCCGCCGAGTACTGA 3339
Db 21 GGACCGCCCGCCGAGTACTGA 1

RESULT 169
US-10-800-350-222/c
; Sequence 222, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 224
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-224

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1381 GGCTCCTCCCTGCACCTGAA 1401
Db 21 GGCTCCTCCCTGCACCTGAA 1

RESULT 171
US-10-800-350-225/c
; Sequence 225, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 224
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-224

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 928 ATGGCCCTGCTATCCCTGCAC 948
Db 21 ATGGCCCTGCTATCCCTGCAC 1

RESULT 170
US-10-800-350-224/c
; Sequence 224, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 224
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-224

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 928 ATGGCCCTGCTATCCCTGCAC 948
Db 21 ATGGCCCTGCTATCCCTGCAC 1

```

; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 225
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-800-350-225

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1641 TGAGCCTGTCAATGTCACCAC 1661
|||||
DB 21 TGAGCCTGTCAATGTCACCAC 1

RESULT 172

US-10-800-350-226/c
; Sequence 226, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 226
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-800-350-226

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1931 GCCAGGAACATCAGCCAGCA 1951
|||||
DB 21 GCCAGGAACATCAGCCAGCA 1

RESULT 173

US-10-800-350-229/c
; Sequence 229, Application US/10800350

; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 229
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-800-350-229

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 784 AAGTGGACACGGTGGCCGG 804
|||||
DB 21 AAGTGGACACGGTGGCCGG 1

RESULT 174

US-10-800-350-230/c
; Sequence 230, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 230
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-800-350-230

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2305 GTGGCAATCAAGACCTGAAG 2325
|||||
DB 21 GTGGCAATCAAGACCTGAAG 1

RESULT 175
US-10-800-350-232/c
; Sequence 232, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 232
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-232

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2515 GTCATCCAGCTCGTGGCATG 2535
|||||
DB 21 GTCATCCAGCTCGTGGCATG 1

RESULT 176
US-10-800-350-233
; Sequence 233, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 233
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-233

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 445 AAATTGGAACTGCTGATCTG 465
|||||

Db 1 AAATTGGAACTGCTGATCTG 21

RESULT 177
US-10-800-350-234
; Sequence 234, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 234
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-234

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 446 AATTGGAACTGCTGATCTGA 466
|||||
DB 1 AATTGGAACTGCTGATCTGA 21

RESULT 178
US-10-800-350-235
; Sequence 235, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 235
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-235

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Query Match	0.5%; Score 21; DB 1; Length 21;	Best Local Similarity 100.0%; Pred. No. 2e+02;	Mismatches 0; Indels 0; Gaps 0;
QY 452	AAACTGCTGATCTGAAGTGGG 472		
DB 1	AAACTGCTGATCTGAAGTGGG 21		
RESULT 179			
US-10-800-350-236			
; Sequence 236, Application US/10800350			
; Publication No. US20050084873A1			
; GENERAL INFORMATION:			
; APPLICANT: Krasnoperov, Valery			
; APPLICANT: Zozulya, Sergey			
; APPLICANT: Kertesz, Nathalie			
; APPLICANT: Reddy, Ramachandra			
; APPLICANT: Gill, Parkash			
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING			
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH			
; FILE REFERENCE: VASG-P01-002			
; CURRENT APPLICATION NUMBER: US/10/800,350			
; CURRENT FILING DATE: 2004-03-12			
; PRIOR APPLICATION NUMBER: US 60/454,432			
; PRIOR FILING DATE: 2003-03-12			
; PRIOR APPLICATION NUMBER: US 60/454,300			
; PRIOR FILING DATE: 2003-03-12			
; NUMBER OF SEQ ID NOS: 396			
; SOFTWARE: FastSeq for Windows Version 4.0			
; SEQ ID NO 236			
; LENGTH: 21			
; TYPE: DNA			
; ORGANISM: Unknown			
; FEATURE:			
; OTHER INFORMATION: Oligonucleotide			
US-10-800-350-236			
Query Match 0.5%; Score 21; DB 1; Length 21;			
Best Local Similarity 100.0%; Pred. No. 2e+02;			
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY 453	AACTGCTGATCTGAAGTGGG 473		
DB 1	AACTGCTGATCTGAAGTGGG 21		
RESULT 180			
US-10-800-350-237			
; Sequence 237, Application US/10800350			
; Publication No. US20050084873A1			
; GENERAL INFORMATION:			
; APPLICANT: Krasnoperov, Valery			
; APPLICANT: Zozulya, Sergey			
; APPLICANT: Kertesz, Nathalie			
; APPLICANT: Reddy, Ramachandra			
; APPLICANT: Gill, Parkash			
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING			
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH			
; FILE REFERENCE: VASG-P01-002			
; CURRENT APPLICATION NUMBER: US/10/800,350			
; CURRENT FILING DATE: 2004-03-12			
; PRIOR APPLICATION NUMBER: US 60/454,432			
; PRIOR FILING DATE: 2003-03-12			
; PRIOR APPLICATION NUMBER: US 60/454,300			
; PRIOR FILING DATE: 2003-03-12			
; NUMBER OF SEQ ID NOS: 396			
; SOFTWARE: FastSeq for Windows Version 4.0			
; SEQ ID NO 237			
; LENGTH: 21			
; TYPE: DNA			
; ORGANISM: Unknown			
; FEATURE:			
; OTHER INFORMATION: Oligonucleotide			
US-10-800-350-237			

```
;
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-239

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 847 AAGGTGAATGTCAGACGCTG 867
Db 1 AAGGTGAATGTCAGACGCTG 21

RESULT 183
US-10-800-350-240
; Sequence 240, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 240
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-240

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 AAGGAGACCTTCACCGTCTTC 717
Db 1 AAGGAGACCTTCACCGTCTTC 21

RESULT 184
US-10-800-350-241
; Sequence 241, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 241
; LENGTH: 21

;
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-242

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1246 AATAGCCACTCTAACACCACTT 1266
Db 1 AATAGCCACTCTAACACCACTT 21

RESULT 186
US-10-800-350-243
; Sequence 243, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 242
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-242

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 958 AAAAAGTGGCCCCAGCTGACT 978
Db 1 AAAAAGTGGCCCCAGCTGACT 21

RESULT 185
US-10-800-350-242
; Sequence 242, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 242
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-242

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 958 AAAAAGTGGCCCCAGCTGACT 978
Db 1 AAAAAGTGGCCCCAGCTGACT 21
```

```
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 243
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-243

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1258 AACACCATGGATCAGCGTC 1278
|||||
Db 1 AACACCATGGATCAGCGTC 21

RESULT 187
US-10-800-350-244
; Sequence 244, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 244
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-244

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1651 AATGTCACCTGACCGAGAG 1671
|||||
Db 1 AATGTCACCTGACCGAGAG 21

RESULT 188
US-10-800-350-245
; Sequence 245, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
```

```
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 245
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-245

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1783 AAATACCATGAGAAAGCGGCC 1803
|||||
Db 1 AAATACCATGAGAAAGCGGCC 21

RESULT 189
US-10-800-350-246
; Sequence 246, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 246
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-246

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1831 AAGACGTCAGAAAACCGGCA 1851
|||||
Db 1 AAGACGTCAGAAAACCGGCA 21

RESULT 190
US-10-800-350-247
; Sequence 247, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
```

```
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 247
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-247

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1937 AACATCAGCCGACCCCAAC 1957
Db 1 AACATCAGCCGACCCCAAC 21

RESULT 191
US-10-800-350-248
; Sequence 248, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 248
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-248

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2068 AACGAGCAATGGGAGAGAA 2088
Db 1 AAGCAGAGCAATGGGAGAGAA 21

RESULT 192
US-10-800-350-249
; Sequence 249, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
```

```
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 249
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-249

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2077 AATGGAGAGAGCAGCAATAT 2097
Db 1 AATGGAGAGAGCAGCAATAT 21

RESULT 193
US-10-800-350-250
; Sequence 250, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 250
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-250

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2087 AAGCAGCAATATTCGACAAAC 2107
Db 1 AAGCAGCAATATTCGACAAAC 21

RESULT 194
US-10-800-350-251
; Sequence 251, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
```


; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 251
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-251

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2093 AATATTCGACAAACACGGAC 2113
|||||
Db 1 AATATTCGACAAACACGGAC 21

RESULT 195
US-10-800-350-252
; Sequence 252, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 252
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-252

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2104 AAACACGACAGTATCTCATC 2124
|||||
Db 1 AAACACGACAGTATCTCATC 21

RESULT 196
US-10-800-350-253
; Sequence 253, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:

; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 253
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-253

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2105 AACACGACAGTATCTCATCG 2125
|||||
Db 1 AACACGACAGTATCTCATCG 21

RESULT 197
US-10-800-350-254
; Sequence 254, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 254
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-254

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2196 AAAAGAGATCGATGCTCTCTA 2216
|||||
Db 1 AAAAGAGATCGATGCTCTCTA 21

RESULT 198
US-10-800-350-255

```
; Sequence 255, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 255
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-255

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2173 AATGAGGCTGTGAGGGAATTT 2193
Db 1 AATGAGGCTGTGAGGGAATTT 21

RESULT 199
US-10-800-350-256
; Sequence 256, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 256
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-256

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2165 AAGACCCCTAATGAGGCTGTGA 2185
Db 1 AAGACCCCTAATGAGGCTGTGA 21

RESULT 200
US-10-800-350-257
; Sequence 257, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 257
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-257

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2197 AAAGAGATCGATGTCTCTCTAC 2217
Db 1 AAAGAGATCGATGTCTCTCTAC 21

RESULT 201
US-10-800-350-258
; Sequence 258, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 258
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-258

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2198 AAAGATCGATGTCTCTCTACG 2218
```

```
Db      1 AAGAGTCGATGTCTCCTACG 21
|||||
RESULT 202
US-10-800-350-259
; Sequence 259, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 259
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-259

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2228 AAGAGGTGATTGGTCAGGTG 2248
|||||
Db      1 AAGAGGTGATTGGTCAGGTG 21
|||||
RESULT 203
US-10-800-350-260
; Sequence 260, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 260
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-260

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2228 AAGAGGTGATTGGTCAGGTG 2248
|||||
Db      1 AAGAGGTGATTGGTCAGGTG 21
|||||
RESULT 204
US-10-800-350-261
; Sequence 261, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 261
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-261

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2428 AACAGCATGCCGTCATGATT 2448
|||||
Db      1 AACAGCATGCCGTCATGATT 21
|||||
RESULT 205
US-10-800-350-262
; Sequence 262, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 262
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-262

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2221 AAGATTGAAGAGGTGATTGTT 2241
|||||
Db      1 AAGATTGAAGAGGTGATTGTT 21
|||||
```

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2290 AAGAAGGAGAGCTGTGTGGCA 2310
|||||
Db 1 AAGAAGGAGAGCTGTGTGGCA 21

RESULT 206

US-10-800-350-263

; Sequence 263, Application US/10800350

; Publication No. US20050084873A1

; GENERAL INFORMATION:

; APPLICANT: Krasnoperov, Valery

; APPLICANT: Zozulya, Sergey

; APPLICANT: Kertesz, Nathalie

; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING

; FILE REFERENCE: VASG-P01-002

; CURRENT APPLICATION NUMBER: US/10/800,350

; PRIOR FILING DATE: 2004-03-12

; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300

; NUMBER OF SEQ ID NOS: 396

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 263

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: Oligonucleotide

US-10-800-350-263

Query Match

0.5%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 2e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2293 AAGGAGAGCTGTGTGGCAATC 2313
|||||
Db 1 AAGGAGAGCTGTGTGGCAATC 21

RESULT 207

US-10-800-350-264

; Sequence 264, Application US/10800350

; Publication No. US20050084873A1

; GENERAL INFORMATION:

; APPLICANT: Krasnoperov, Valery

; APPLICANT: Zozulya, Sergey

; APPLICANT: Kertesz, Nathalie

; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING

; FILE REFERENCE: VASG-P01-002

; CURRENT APPLICATION NUMBER: US/10/800,350

; PRIOR FILING DATE: 2004-03-12

; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300

; NUMBER OF SEQ ID NOS: 396

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 264

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-800-350-264

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2310 AATCAAGACCCCTGAAGGGTGG 2330
|||||
Db 1 AATCAAGACCCCTGAAGGGTGG 21

RESULT 208

US-10-800-350-265

; Sequence 265, Application US/10800350

; Publication No. US20050084873A1

; GENERAL INFORMATION:

; APPLICANT: Krasnoperov, Valery

; APPLICANT: Zozulya, Sergey

; APPLICANT: Kertesz, Nathalie

; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING

; FILE REFERENCE: VASG-P01-002

; CURRENT APPLICATION NUMBER: US/10/800,350

; PRIOR FILING DATE: 2004-03-12

; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300

; NUMBER OF SEQ ID NOS: 396

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 265

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: Oligonucleotide

US-10-800-350-265

Query Match

0.5%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 2e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2496 AAACGACGACAGTTCACAGT 2516
|||||
Db 1 AAACGACGACAGTTCACAGT 21

RESULT 209

US-10-800-350-266

; Sequence 266, Application US/10800350

; Publication No. US20050084873A1

; GENERAL INFORMATION:

; APPLICANT: Krasnoperov, Valery

; APPLICANT: Zozulya, Sergey

; APPLICANT: Kertesz, Nathalie

; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING

; FILE REFERENCE: VASG-P01-002

; CURRENT APPLICATION NUMBER: US/10/800,350

; PRIOR FILING DATE: 2004-03-12

; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300

; NUMBER OF SEQ ID NOS: 396

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 266

```
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-266

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2497 AACGACGGACAGTTCACAGTC 2517
Db 1 AACGACGGACAGTTCACAGTC 21

RESULT 210
US-10-800-350-267
; Sequence 267, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 267
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-267

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2608 AACATCCTAGTCAACAGCAAC 2628
Db 1 AACATCCTAGTCAACAGCAAC 21

RESULT 211
US-10-800-350-268
; Sequence 268, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
```

```
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 268
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-268

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2620 AACAGCAACCTCGTCTGCAAA 2640
Db 1 AACAGCAACCTCGTCTGCAAA 21

RESULT 212
US-10-800-350-269
; Sequence 269, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 269
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-269

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2677 AACTCTTCGATCCACCTAC 2697
Db 1 AACTCTTCGATCCACCTAC 21

RESULT 213
US-10-800-350-270
; Sequence 270, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
```

```
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 270
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-270

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2639 AAGTGTCTGACTTTGGCCTT 2659
|||||
Db 1 AAGTGTCTGACTTTGGCCTT 21

RESULT 214
US-10-800-350-271
; Sequence 271, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 271
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-271

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2626 AACCTGCTGCAAGTGCT 2646
|||||
Db 1 AACCTGCTGCAAGTGCT 21

RESULT 215
US-10-800-350-272
; Sequence 272, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
```

```
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 272
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-272

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2638 AAAGTGTCTGACTTTGGCCTT 2658
|||||
Db 1 AAAGTGTCTGACTTTGGCCTT 21

RESULT 216
US-10-800-350-273
; Sequence 273, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 273
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-273

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2851 AATCAGGACGTGATCAATGCC 2871
|||||
Db 1 AATCAGGACGTGATCAATGCC 21

RESULT 217
US-10-800-350-274
; Sequence 274, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
```

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 274
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-274

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2715 AAAGATTCCCATCCGATGGAC 2735
|||||
Db 1 AAAGATTCCCATCCGATGGAC 21

RESULT 218
US-10-800-350-275
; Sequence 275, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 275
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-275

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2716 AAAGATTCCCATCCGATGGACT 2736
|||||
Db 1 AAAGATTCCCATCCGATGGACT 21

RESULT 219
US-10-800-350-276
; Sequence 276, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey

; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 276
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-276

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2761 AAGTTCACTTCCCGCAGTGAT 2781
|||||
Db 1 AAGTTCACTTCCCGCAGTGAT 21

RESULT 220
US-10-800-350-277
; Sequence 277, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 277
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-277

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3141 AAGATACGAAGAAAGTTTCGC 3161
|||||
Db 1 AAGATACGAAGAAAGTTTCGC 21

RESULT 221
US-10-800-350-278
; Sequence 278, Application US/10800350
; Publication No. US20050084873A1

US-10-800-350-278

GENERAL INFORMATION:

APPLICANT: Krasnoperov, Valery

APPLICANT: Zozulya, Sergey

APPLICANT: Kertesz, Nathalie

APPLICANT: Reddy, Ramachandra

APPLICANT: Gill, Parkash

TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING

FILE REFERENCE: VASG-P01-002

CURRENT APPLICATION NUMBER: US/10/800,350

PRIOR FILING DATE: 2004-03-12

PRIOR APPLICATION NUMBER: US 60/454,432

PRIOR FILING DATE: 2003-03-12

PRIOR APPLICATION NUMBER: US 60/454,300

PRIOR FILING DATE: 2003-03-12

NUMBER OF SEQ ID NOS: 396

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 278

LENGTH: 21

TYPE: DNA

ORGANISM: Unknown

FEATURE:

OTHER INFORMATION: Oligonucleotide

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3135 AATGGGAAGATACGAGAAAG 3155
|||||

Db 1 AATGGGAAGATACGAGAAAG 21

RESULT 222

US-10-800-350-279

Sequence 279, Application US/108000350

Publication No. US20050084873A1

GENERAL INFORMATION:

APPLICANT: Krasnoperov, Valery

APPLICANT: Zozulya, Sergey

APPLICANT: Kertesz, Nathalie

APPLICANT: Reddy, Ramachandra

APPLICANT: Gill, Parkash

TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING

FILE REFERENCE: VASG-P01-002

CURRENT APPLICATION NUMBER: US/10/800,350

PRIOR FILING DATE: 2004-03-12

PRIOR APPLICATION NUMBER: US 60/454,432

PRIOR FILING DATE: 2003-03-12

PRIOR APPLICATION NUMBER: US 60/454,300

PRIOR FILING DATE: 2003-03-12

NUMBER OF SEQ ID NOS: 396

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 279

LENGTH: 21

TYPE: DNA

ORGANISM: Unknown

FEATURE:

OTHER INFORMATION: Oligonucleotide

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2866 AATGCCATTGAACAGGACTAC 2886
|||||

Db 1 AATGCCATTGAACAGGACTAC 21

RESULT 223

US-10-800-350-280

Sequence 280, Application US/108000350

Publication No. US20050084873A1

GENERAL INFORMATION:

APPLICANT: Krasnoperov, Valery

APPLICANT: Zozulya, Sergey

APPLICANT: Kertesz, Nathalie

APPLICANT: Reddy, Ramachandra

APPLICANT: Gill, Parkash

TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING

FILE REFERENCE: VASG-P01-002

CURRENT APPLICATION NUMBER: US/10/800,350

PRIOR FILING DATE: 2004-03-12

PRIOR APPLICATION NUMBER: US 60/454,432

PRIOR FILING DATE: 2003-03-12

PRIOR APPLICATION NUMBER: US 60/454,300

PRIOR FILING DATE: 2003-03-12

NUMBER OF SEQ ID NOS: 396

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 280

LENGTH: 21

TYPE: DNA

ORGANISM: Unknown

FEATURE:

OTHER INFORMATION: Oligonucleotide

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3028 AAAATCGTGGCCCGGAGAAAT 3048
|||||

Db 1 AAAATCGTGGCCCGGAGAAAT 21

RESULT 224

US-10-800-350-281

Sequence 281, Application US/108000350

Publication No. US20050084873A1

GENERAL INFORMATION:

APPLICANT: Krasnoperov, Valery

APPLICANT: Zozulya, Sergey

APPLICANT: Kertesz, Nathalie

APPLICANT: Reddy, Ramachandra

APPLICANT: Gill, Parkash

TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING

FILE REFERENCE: VASG-P01-002

CURRENT APPLICATION NUMBER: US/10/800,350

PRIOR FILING DATE: 2004-03-12

PRIOR APPLICATION NUMBER: US 60/454,432

PRIOR FILING DATE: 2003-03-12

PRIOR APPLICATION NUMBER: US 60/454,300

PRIOR FILING DATE: 2003-03-12

NUMBER OF SEQ ID NOS: 396

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 281

LENGTH: 21

TYPE: DNA

ORGANISM: Unknown

FEATURE:

OTHER INFORMATION: Oligonucleotide

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3253 AAAATCTTGGCCAGTGTCAG 3273
|||||

Db 1 AAAATCTTGGCCAGTGTCAG 21

RESULT 225
US-10-800-350-282
; Sequence 282, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 282
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-282
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3254 AAATCTTGGCCAGTGTCAGC 3274
DB 1 AAATCTTGGCCAGTGTCAGC 21
RESULT 226
US-10-800-350-283
; Sequence 283, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 283
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-283
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3149 AAGAAAGTTTCGACGCGCTG 3169
DB 1 AAGAAAGTTTCGACGCGCTG 21
RESULT 227
US-10-800-350-284
; Sequence 284, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 284
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-284
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3250 AAGAAATCTTGGCCAGTGTC 3270
DB 1 AAGAAATCTTGGCCAGTGTC 21
RESULT 228
US-10-800-350-285
; Sequence 285, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 285
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-285
Query Match 0.5%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 2e+02; 0; Mismatches 0; Gaps 0; Indels 0;

Matches 21; Conservative 0; Gaps 0; Indels 0;

QY 3255 AATCTTGGCAGTGTCCAGCA 3275

Db 1 AATCTTGGCAGTGTCCAGCA 21

RESULT 229

US-10-800-077-20/c

; Sequence 20, Application US/108000077

; Publication No. US20050164965A1

; GENERAL INFORMATION:

; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING

; FILE REFERENCE: VASG-P01-001

; CURRENT APPLICATION NUMBER: US/10/800,077

; PRIOR FILING DATE: 2004-03-12

; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300

; NUMBER OF SEQ ID NOS: 396

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 20

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: Oligonucleotide

US-10-800-077-20

Query Match

Best Local Similarity 0.5%; Score 21; DB 1; Length 21;

Matches 21; Conservative 0; Mismatches 0; Gaps 0; Indels 0;

QY 928 ATGGCCCTGCTATCCCTGCAC 948

Db 21 ATGGCCCTGCTATCCCTGCAC 1

RESULT 230

US-10-800-077-35/c

; Sequence 35, Application US/108000077

; Publication No. US20050164965A1

; GENERAL INFORMATION:

; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING

; FILE REFERENCE: VASG-P01-001

; CURRENT APPLICATION NUMBER: US/10/800,077

; PRIOR FILING DATE: 2004-03-12

; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300

; NUMBER OF SEQ ID NOS: 396

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 35

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: Oligonucleotide

US-10-800-077-35

Query Match

Best Local Similarity 0.5%; Score 21; DB 1; Length 21;

Matches 21; Conservative 0; Mismatches 0; Gaps 0; Indels 0;

QY 425 AAGAGACCCCTGCTGAACACAA 445

Db 21 AAGAGACCCCTGCTGAACACAA 1

RESULT 231

US-10-800-077-37/c

; Sequence 37, Application US/108000077

; Publication No. US20050164965A1

; GENERAL INFORMATION:

; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING

; FILE REFERENCE: VASG-P01-001

; CURRENT APPLICATION NUMBER: US/10/800,077

; PRIOR FILING DATE: 2004-03-12

; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300

; PRIOR FILING DATE: 2003-03-12

; NUMBER OF SEQ ID NOS: 396

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 37

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: Oligonucleotide

US-10-800-077-37

Query Match

Best Local Similarity 0.5%; Score 21; DB 1; Length 21;

Matches 21; Conservative 100.0%; Pred. No. 2e+02; 0; Mismatches 0; Indels 0; Gaps 0;

QY 847 AAGGTGAATGTCAAGACGCTG 867

Db 21 AAGGTGAATGTCAAGACGCTG 1

RESULT 232

US-10-800-077-39/c

; Sequence 39, Application US/108000077

; Publication No. US20050164965A1

; GENERAL INFORMATION:

; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING

; FILE REFERENCE: VASG-P01-001

; CURRENT APPLICATION NUMBER: US/10/800,077

; PRIOR FILING DATE: 2004-03-12

; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300

; PRIOR FILING DATE: 2003-03-12

; NUMBER OF SEQ ID NOS: 396

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 39

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: Oligonucleotide

US-10-800-077-39

Query Match

Best Local Similarity 0.5%; Score 21; DB 1; Length 21;

Matches 21; Conservative 100.0%; Pred. No. 2e+02; 0; Mismatches 0; Indels 0; Gaps 0;

QY 1937 AACATCAGCCAGCCCAAC 1957

Db 21 AACATCAGCCAGCCCAAC 1

```
RESULT 233
US-10-800-077-41/c
; Sequence 41, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 41
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-41
Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2677 AACTCTTCGGATCCCACTAC 2697
Db 21 AACTCTTCGGATCCCACTAC 1

RESULT 234
US-10-800-077-42/c
; Sequence 42, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 42
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-42
Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 928 ATGGCCCTGCTATCCCTGCAC 948
Db 21 ATGGCCCTGCTATCCCTGCAC 1

RESULT 235
```

```
US-10-800-077-44/c
; Sequence 44, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 44
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-44
Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1381 GGCTCTCCCTGCACCTGGAA 1401
Db 21 GGCTCTCCCTGCACCTGGAA 1

RESULT 236
US-10-800-077-45/c
; Sequence 45, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 45
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-45
Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1641 TGAGCCTGTCAATGTCCACAC 1661
Db 21 TGAGCCTGTCAATGTCCACAC 1

RESULT 237
US-10-800-077-46/c
; Sequence 46, Application US/10800077
; Publication No. US20050164965A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 46
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-46
```

```
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1931 GCCAGGAACATCACAGCCAGA 1951
Db 21 GCCAGGAACATCACAGCCAGA 1
```

```
RESULT 238
US-10-800-077-49/c
; Sequence 49, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 49
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-49
```

```
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 784 AAGGTGGACACGGTGGCCGCG 804
Db 21 AAGGTGGACACGGTGGCCGCG 1
```

```
RESULT 239
US-10-800-077-50/c
; Sequence 50, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
```

```
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 50
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-50
```

```
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2305 GTGCAATCAAGACCCCTGAAG 2325
Db 21 GTGCAATCAAGACCCCTGAAG 1
```

```
RESULT 240
US-10-800-077-52/c
; Sequence 52, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 52
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-52
```

```
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2515 GTCATCCAGCTCGTGGCATG 2535
Db 21 GTCATCCAGCTCGTGGCATG 1
```

```
RESULT 241
US-10-800-077-70/c
; Sequence 70, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
```

; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 70
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-70

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 425 AAGAGACCTGCTGAACAA 445
Db 21 AAGAGACCTGCTGAACAA 1

RESULT 242
US-10-800-077-73/c
; Sequence 73, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 73
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-73

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3319 GGACGGCCCGCAGTACTGA 3339
Db 21 GGACGGCCCGCAGTACTGA 1

RESULT 243
US-10-800-077-222/c
; Sequence 222, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 222
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-222

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 928 ATGGCCCTGCTATCCCTGCAC 948
Db 21 ATGGCCCTGCTATCCCTGCAC 1

RESULT 244
US-10-800-077-224/c
; Sequence 224, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 224
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-224

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1381 GGCTCTCCCTGCACCTGGAA 1401
Db 21 GGCTCTCCCTGCACCTGGAA 1

RESULT 245
US-10-800-077-225/c
; Sequence 225, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12

```
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 225
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-225

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1641 TGAGCCTGTCAATGTCACAC 1661
Db 21 TGAGCCTGTCAATGTCACAC 1

RESULT 246
US-10-800-077-226/c
; Sequence 226, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 226
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-226

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1931 GCCAGGAACATCAGCCAGA 1951
Db 21 GCCAGGAACATCAGCCAGA 1

RESULT 247
US-10-800-077-229/c
; Sequence 229, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 229

; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 225
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-225

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1641 TGAGCCTGTCAATGTCACAC 1661
Db 21 TGAGCCTGTCAATGTCACAC 1

RESULT 246
US-10-800-077-226/c
; Sequence 226, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 226
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-226

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1931 GCCAGGAACATCAGCCAGA 1951
Db 21 GCCAGGAACATCAGCCAGA 1

RESULT 247
US-10-800-077-229/c
; Sequence 229, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 229

; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 225
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-229

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 784 AAGGTGGACACGGTGGCCGCG 804
Db 21 AAGGTGGACACGGTGGCCGCG 1

RESULT 248
US-10-800-077-230/c
; Sequence 230, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 230
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-230

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2305 GTGGCAATCAAGACCCCTGAAG 2325
Db 21 GTGGCAATCAAGACCCCTGAAG 1

RESULT 249
US-10-800-077-232/c
; Sequence 232, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 232
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
```

;
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-232

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2515 GTCATCCAGCTCGTGGCATG 2535
Db 21 GTCATCCAGCTCGTGGCATG 1

RESULT 250
US-10-800-077-233
; Sequence 233, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 233
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-233

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 445 AAATTGGAACCTGCTGATCTG 465
Db 1 AAATTGGAACCTGCTGATCTG 21

RESULT 251
US-10-800-077-234
; Sequence 234, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 234
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-234

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 446 AATTGGAACCTGCTGATCTGA 466
Db 1 AATTGGAACCTGCTGATCTGA 21

RESULT 252
US-10-800-077-235
; Sequence 235, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 235
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-235

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 452 AAATCTGCTGATCTGAAGTGGG 472
Db 1 AAATCTGCTGATCTGAAGTGGG 21

RESULT 253
US-10-800-077-236
; Sequence 236, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 236
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-236

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;

```
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 453 AACTGCTGATCTCAAGTGGGT 473
Db 1 AACTGCTGATCTCAAGTGGGT 21

RESULT 254
US-10-800-077-237
; Sequence 237, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 237
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-237

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 853 AATGTCAAGACGCTGCGTCTG 873
Db 1 AATGTCAAGACGCTGCGTCTG 21

RESULT 255
US-10-800-077-238
; Sequence 238, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 238
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-238

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 466 AAGTGGGTGACATTCCTCAG 486
```

```
Db 1 AAGTGGGTGACATTCCTCAG 21

RESULT 256
US-10-800-077-239
; Sequence 239, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 239
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-239

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 847 AAGGTCAATGTCAAGACGCTG 867
Db 1 AAGGTCAATGTCAAGACGCTG 21

RESULT 257
US-10-800-077-240
; Sequence 240, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 240
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-240

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 AAGGACCTTCACCGTCTTC 717
Db 1 AAGGACCTTCACCGTCTTC 21
```



```

; Sequence 243, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 243
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-243

Query Match      0.5%; Score 21; DB 1; Length 2
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0;

QY 1258 AACACCATTTGGATCAGCCGTC 1278
      |||||
DB 1 AACACCATTTGGATCAGCCGTC 21

RESULT 261
US-10-800-077-244
; Sequence 244, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 244
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-244

Query Match      0.5%; Score 21; DB 1; Length 2
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0;

QY 1651 AATGTCACCACTCAGCCGAG 1671
      |||||
DB 1 AATGTCACCACTCAGCCGAG 21

RESULT 262
US-10-800-077-245
; Sequence 245, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:

```

```
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 245
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-245

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1783 AAATACCATGAGAGGGCGCC 1803
Db 1 AAATACCATGAGAGGGCGCC 21

RESULT 263
US-10-800-077-246
; Sequence 246, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 246
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-246

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1831 AAGACGTGTCAGAAAACCGGGCA 1851
Db 1 AAGACGTGTCAGAAAACCGGGCA 21

RESULT 264
US-10-800-077-247
; Sequence 247, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
```

```
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 247
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-247

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1937 AACATCAGCCAGCCCAAC 1957
Db 1 AACATCAGCCAGCCCAAC 21

RESULT 265
US-10-800-077-248
; Sequence 248, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 248
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-248

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2068 AAGCAGCAATGGGAGAGAA 2088
Db 1 AAGCAGCAATGGGAGAGAA 21

RESULT 266
US-10-800-077-249
; Sequence 249, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
```

; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 249
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-249

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2077 AATGGAGAGAGCAGGAATAT 2097
|||||
Db 1 AATGGAGAGAGCAGGAATAT 21

RESULT 267
US-10-800-077-250
; Sequence 250, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 250
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-250

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2087 AAGCAGAAATATTCGACAAAC 2107
|||||
Db 1 AAGCAGAAATATTCGACAAAC 21

RESULT 268
US-10-800-077-251
; Sequence 251, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 251
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-251

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2093 AATATTCGGACAAACACGGAC 2113
|||||
Db 1 AATATTCGGACAAACACGGAC 21

RESULT 269
US-10-800-077-252
; Sequence 252, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 252
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-252

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2104 AAACACGGACAGTATCTCATC 2124
|||||
Db 1 AAACACGGACAGTATCTCATC 21

RESULT 270
US-10-800-077-253
; Sequence 253, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396

```
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 253
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-253

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2105 AACACGACAGTATCTCATCG 2125
      |||||||||||||||||||
Db 1 AACACGACAGTATCTCATCG 21

RESULT 271
US-10-800-077-254
; Sequence 254, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 254
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-254

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2196 AAAAGAGATCGATGCTCTCCTA 2216
      |||||||||||||||||||
Db 1 AAAAGAGATCGATGCTCTCCTA 21

RESULT 272
US-10-800-077-255
; Sequence 255, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 255
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-255

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2165 AAGACCCTTAATGAGCGTGGA 2185
      |||||||||||||||||||
Db 1 AAGACCCTTAATGAGCGTGGA 21

RESULT 274
US-10-800-077-257
; Sequence 257, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 257
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-256

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2173 AATGAGGCTGTGAGGGAATTT 2193
      |||||||||||||||||||
Db 1 AATGAGGCTGTGAGGGAATTT 21

RESULT 273
US-10-800-077-256
; Sequence 256, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 256
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-256

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

OTHER INFORMATION: Oligonucleotide
US-10-800-077-257

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2197 AAGAGATCGATGTCCTAC 2217
|||||
Db 1 AAGAGATCGATGTCCTAC 21

RESULT 275

US-10-800-077-258
; Sequence 258, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 258
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-800-077-258

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2198 AAGATCGATGTCCTAC 2218
|||||
Db 1 AAGATCGATGTCCTAC 21

RESULT 276

US-10-800-077-259
; Sequence 259, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 259
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-800-077-259

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2228 AAGAGTGTGTCAGGTG 2248
|||||
Db 1 AAGAGTGTGTCAGGTG 21

RESULT 277

US-10-800-077-260
; Sequence 260, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 260
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-800-077-260

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2221 AAGATGAAGGTGTTGGT 2241
|||||
Db 1 AAGATGAAGGTGTTGGT 21

RESULT 278

US-10-800-077-261
; Sequence 261, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 261
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-800-077-261

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY      2428 AACAGCATGCCGTCATGATT 2448
Db      1 AACAGCATGCCGTCATGATT 21

RESULT 279
US-10-800-077-262
; Sequence 262, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 262
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-262

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2290 AAGAGGAGCTGTGTGGCA 2310
Db      1 AAGAGGAGCTGTGTGGCA 21

RESULT 280
US-10-800-077-263
; Sequence 263, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 263
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-263

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2293 AAGGAGAGCTGTGTGGCAATC 2313
Db      1 AAGGAGAGCTGTGTGGCAATC 21

RESULT 281
US-10-800-077-264
; Sequence 264, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 264
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-264

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2310 AATCAAGACCTGGAAGGGTGG 2330
Db      1 AATCAAGACCTGGAAGGGTGG 21

RESULT 282
US-10-800-077-265
; Sequence 265, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 265
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-265

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2496 AAACGACGACAGTTCACAGT 2516
Db      1 AAACGACGACAGTTCACAGT 21

```

```
RESULT 283
US-10-800-077-266
; Sequence 266, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 266
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-266

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2497 AACGACGGACAGTTCACAGTC 2517
DB 1 AACGACGGACAGTTCACAGTC 21

RESULT 284
US-10-800-077-267
; Sequence 267, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 267
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-267

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2608 AACATCCTAGTCAACAGCAAC 2628
DB 1 AACATCCTAGTCAACAGCAAC 21

RESULT 285
US-10-800-077-268
; Sequence 268, Application US/10800077
```

```
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 268
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-268

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2620 AACAGCAACCTCGTCGCAAA 2640
DB 1 AACAGCAACCTCGTCGCAAA 21

RESULT 286
US-10-800-077-269
; Sequence 269, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 269
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-269

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2677 AACTCTCCGATCCACCTAC 2697
DB 1 AACTCTCCGATCCACCTAC 21

RESULT 287
US-10-800-077-270
; Sequence 270, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
```

```
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 270
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-270

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2639 AAGTGTCTGACTTTGGCCTTT 2659
      |||||
Db 1 AAGTGTCTGACTTTGGCCTTT 21

RESULT 288
US-10-800-077-271
; Sequence 271, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 271
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-271

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2626 AACCTGCTCTGCAAGTGCT 2646
      |||||
Db 1 AACCTGCTCTGCAAGTGCT 21

RESULT 289
US-10-800-077-272
; Sequence 272, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
```

```
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 272
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-272

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2638 AAAGTGTCTGACTTTGGCCTT 2658
      |||||
Db 1 AAAGTGTCTGACTTTGGCCTT 21

RESULT 290
US-10-800-077-273
; Sequence 273, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 273
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-273

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2851 AATCAGGACGTGATCAATGCC 2871
      |||||
Db 1 AATCAGGACGTGATCAATGCC 21

RESULT 291
US-10-800-077-274
; Sequence 274, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
```


; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 274
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-274

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2715 AAGATTCCCATCCGATGGAC 2735
Db 1 AAGATTCCCATCCGATGGAC 21

RESULT 292
US-10-800-077-275
; Sequence 275, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 275
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-275

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2716 AAGATTCCCATCCGATGGACT 2736
Db 1 AAGATTCCCATCCGATGGACT 21

RESULT 293
US-10-800-077-276
; Sequence 276, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300

; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 276
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-276

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2761 AAGTTCACTTCGCCCACTGAT 2781
Db 1 AAGTTCACTTCGCCCACTGAT 21

RESULT 294
US-10-800-077-277
; Sequence 277, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 277
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-277

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3141 AAGATACGAAGAAGTTTCGC 3161
Db 1 AAGATACGAAGAAGTTTCGC 21

RESULT 295
US-10-800-077-278
; Sequence 278, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0

```
; SEQ ID NO 278
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-278

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3135 AATGGGAAGATACGAAGAAAG 3155
      |||||
Db 1 AATGGGAAGATACGAAGAAAG 21

RESULT 296
US-10-800-077-279
; Sequence 279, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 279
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-279

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2866 AATGCCATTGAACAGGACTAC 2886
      |||||
Db 1 AATGCCATTGAACAGGACTAC 21

RESULT 297
US-10-800-077-280
; Sequence 280, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 280
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-280

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3253 AAAATCTTGGCCAGTGTCCAG 3273
      |||||
Db 1 AAAATCTTGGCCAGTGTCCAG 21

RESULT 298
US-10-800-077-281
; Sequence 281, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 281
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-281

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3253 AAAATCTTGGCCAGTGTCCAG 3273
      |||||
Db 1 AAAATCTTGGCCAGTGTCCAG 21

RESULT 299
US-10-800-077-282
; Sequence 282, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 282
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-282
```

US-10-800-077-282

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGTCAGC 3274
|||||
Db 1 AAATCTTGGCCAGTGTCAGC 21

RESULT 300

US-10-800-077-283
; Sequence 283, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 283
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-283

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3149 AAGAAAGTTTCGACGCGCTG 3169
|||||
Db 1 AAGAAAGTTTCGACGCGCTG 21

RESULT 301

US-10-800-077-284
; Sequence 284, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 284
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-284

Query Match 0.5%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3250 AAGAAATCTTGGCCAGTGTC 3270
|||||
Db 1 AAGAAATCTTGGCCAGTGTC 21

RESULT 302

US-10-800-077-285
; Sequence 285, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 285
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-285

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3255 AATCTTGGCCAGTGTCAGCA 3275
|||||
Db 1 AATCTTGGCCAGTGTCAGCA 21

RESULT 303

US-10-719-956-629839
; Sequence 629839, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 659466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 629839
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-629839

Query Match 0.5%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 767 TCGAGAACCCCTACATCAAGTGG 790
|||||
Db 1 TGGAGAACACCTCCATCAAGGTGG 24

RESULT 304

```

US-10-719-956-629840
; Sequence 629840, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 629840
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-629840

Query Match      0.5%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 767 TGGAGAACCCCTACATCAAGGTGG 790
      ||||| ||||| ||||| ||||| |||||
Db 1 TGGAGAACACCTGCATCAGGTGG 24

RESULT 305
US-11-036-317-47943
; Sequence 47943, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; CURRENT FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; PRIOR FILING DATE: 2004-01-13
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 47943
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-47943

Query Match      0.5%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2457 GTTCATGGAGAACGGCGCCCTGGA 2480
      ||||| ||||| ||||| ||||| |||||
Db 1 GTTCATGGAGAAATGGAGCCCTGGA 24

RESULT 306
US-11-036-317-133760
; Sequence 133760, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; CURRENT FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; PRIOR FILING DATE: 2004-01-13
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

```

```

; SEQ ID NO 133760
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-133760

Query Match      0.5%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTTCATGGAGAACGGCG 2473
      ||||| ||||| ||||| ||||| |||||
Db 1 TCACAGACTACATGGAGAACGGCG 24

RESULT 307
US-11-036-317-479532
; Sequence 479532, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; CURRENT FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; PRIOR FILING DATE: 2004-01-13
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 479532
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-479532

Query Match      0.5%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2572 GAGATGAGCTAGTCCACCGAGAC 2595
      ||||| ||||| ||||| ||||| |||||
Db 2 GAAATGAGCTATGTCCACCGAGAC 25

RESULT 308
US-11-060-756-121062/c
; Sequence 121062, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 121062
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-121062

Query Match      0.5%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2769 TTCGCCGAGTGTGCTGGAGTTA 2792
      ||||| ||||| ||||| ||||| |||||
Db 25 TTCTGCCAGTGTGCTGGAGTTA 2

```

```
RESULT 309
US-11-060-756-121063/c
; Sequence 121063, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 121063
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-121063

Query Match      0.5%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2769 TTCCGCCAGTGCCTGGAGTTA 2792
||| ||||| ||||| ||||| ||||| |||||
Db 25 TTCTGCCAGTGCCTGGAGTTA 2

RESULT 310
US-11-060-756-142612/c
; Sequence 142612, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 142612
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-142612

Query Match      0.5%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2767 ACTTCCGCCAGTGCCTGGAGT 2790
||||| ||||| ||||| ||||| ||||| |||||
Db 24 ACTTCTGCCAGTGCCTGGAGT 1

RESULT 311
US-11-060-756-142613/c
; Sequence 142613, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
```

```
; SEQ ID NO 142613
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-142613

Query Match      0.5%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2767 ACTTCCGCCAGTGCCTGGAGT 2790
||||| ||||| ||||| ||||| ||||| |||||
Db 24 ACTTCTGCCAGTGCCTGGAGT 1

RESULT 312
US-11-060-756-180539
; Sequence 180539, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 180539
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-180539

Query Match      0.5%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2634 CTGCAAAAGTGTCTGATTTGGCAT 2657
||||| ||||| ||||| ||||| ||||| |||||
Db 1 CTGCAAAAGTGTCTGATTTGGCAT 24

RESULT 313
US-11-060-756-256243
; Sequence 256243, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 256243
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-256243

Query Match      0.5%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2937 GGACTGTGGCAGAAAGACGGAA 2960
||||| ||||| ||||| ||||| ||||| |||||
Db 1 GGACTGTGGCAGAAAGACGGAA 24
```

```
RESULT 314
US-10-800-350-59
; Sequence 59, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 59
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
;
US-10-800-350-59

Query Match      0.5%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 2.5e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1587 TGAGGTCACCTGCATTGAACGGG 1608
Db 1 TCAGGTCACCTGCATTGAACGGG 22

RESULT 315
US-10-800-077-59
; Sequence 59, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 59
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
;
US-10-800-077-59

Query Match      0.5%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 2.5e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1587 TGAGGTCACCTGCATTGAACGGG 1608
Db 1 TCAGGTCACCTGCATTGAACGGG 22
```

```
RESULT 316
US-09-140-378A-3/c
; Sequence 3, Application US/09140378A
; Publication No. US20030124133A1
; GENERAL INFORMATION:
; APPLICANT: Johnson, Jeffrey D.
; APPLICANT: Rutter, William J.
; APPLICANT: Edman, Jeffrey C.
; APPLICANT: The Regents of the University of California
; TITLE OF INVENTION: Receptor Tyrosine Kinase with a Discoidin-Type Binding
; TITLE OF INVENTION: Domain
; FILE REFERENCE: 023070-079010US
; CURRENT APPLICATION NUMBER: US/09/140,378A
; CURRENT FILING DATE: 1998-08-26
; PRIOR APPLICATION NUMBER: US 08/077,254
; PRIOR FILING DATE: 1993-06-14
; PRIOR APPLICATION NUMBER: US 08/292,299
; PRIOR FILING DATE: 1994-08-16
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: antisense
; OTHER INFORMATION: oligonucleotide
;
US-09-140-378A-3

Query Match      0.5%; Score 20.4; DB 1; Length 24;
Best Local Similarity 75.0%; Pred. No. 3e+02;
Matches 18; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 2587 CACCGAGACCTGGCTGCTCGCAAC 2610
Db 24 CAYCGGAYCTGGCYGCGYCGSAAC 1

RESULT 317
US-10-719-956-644852
; Sequence 644852, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 644852
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
;
US-10-719-956-644852

Query Match      0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3781 TGTCCACCACCAACTCAATCATTTT 3805
Db 1 TGTCCACCACCAATGGCAATCATTTT 25

RESULT 318
US-10-809-189-24487
; Sequence 24487, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
;
```

; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24487
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-24487

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3005 TGATCCGGAACCCCGCCAGCCTCAA 3029
||||| ||||| ||||| ||||| |||||
Db 1 TGATCCGGAACCCCGCCAGCCTCAA 25

RESULT 319
US-10-809-189-37489/c
; Sequence 37489, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mitmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 37489
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-37489

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1940 ATCAGCCAGACCAACTGATGA 1964
||||| ||||| ||||| ||||| |||||
Db 25 ATCAACACAGACCAACAGGAAGA 1

RESULT 320
US-11-036-317-105366
; Sequence 105366, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; CURRENT FILING DATE: 2005-01-13

; PRIOR APPLICATION NUMBER: US 60/536,639
; PRIOR FILING DATE: 2004-01-13
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 105366
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-105366

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 769 GAGAACCCCTACATCAAGGTGGACA 793
||||| ||||| ||||| ||||| |||||
Db 1 GAGAACCCCTACATCAAGGTGGACA 25

RESULT 321
US-11-036-317-210541
; Sequence 210541, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; CURRENT FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; PRIOR FILING DATE: 2004-01-13
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 210541
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-210541

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2845 ATGACCAATCAGGACGTCATGATG 2869
||||| ||||| ||||| ||||| |||||
Db 1 ATGACCAATCAGGACGTCATGATG 25

RESULT 322
US-11-036-317-341458
; Sequence 341458, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; CURRENT FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; PRIOR FILING DATE: 2004-01-13
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 341458
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-341458

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; CURRENT FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; PRIOR FILING DATE: 2004-01-13
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 370869
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-370869

Query Match      0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2233 GTGATTGGTGCAGGTGAGTTGGCG 2257
Db      1 GTGATTGGTGCAGGAGAAATTTGGAG 25

RESULT 323
US-11-036-317-370869
; Sequence 370869, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; CURRENT FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; PRIOR FILING DATE: 2004-01-13
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 370869
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-370869

Query Match      0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2846 TGAGCAATCAGGACGTGATCAATGC 2870
Db      1 TGACCAATCAGGATGTGATCAAGGC 25

RESULT 324
US-11-036-317-373537
; Sequence 373537, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; CURRENT FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; PRIOR FILING DATE: 2004-01-13
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 373537
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-373537

Query Match      0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2234 TGATTGGTGCAGGTGAGTTGGCGA 2258
Db      1 TGATTGGTGCAGGAGAAATTTGGAGA 25

RESULT 325
US-11-036-317-411187
; Sequence 411187, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
```

```
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; CURRENT FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; PRIOR FILING DATE: 2004-01-13
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 411187
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-411187

Query Match      0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      441 CACAAAATTGGAACCTGCTGATCTG 465
Db      1 CACAAAATCGGAACCGCGGATCTG 25

RESULT 326
US-11-036-317-456404
; Sequence 456404, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; CURRENT FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; PRIOR FILING DATE: 2004-01-13
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 456404
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-456404

Query Match      0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      850 GTGAATGTCAAGACGCTGCTCTGG 874
Db      1 GTTAATATCAAGACGCTGCGCTGG 25

RESULT 327
US-11-036-317-528469
; Sequence 528469, Application US/11036317
; Publication No. US20050214823A1
; GENERAL INFORMATION:
; APPLICANT: Williams, Alan
; APPLICANT: Blume, John
; TITLE OF INVENTION: Method of Analysis of Alternative Splicing in Mouse
; FILE REFERENCE: 3654.1
; CURRENT APPLICATION NUMBER: US/11/036,317
; CURRENT FILING DATE: 2005-01-13
; PRIOR APPLICATION NUMBER: US 60/536,639
; PRIOR FILING DATE: 2004-01-13
; NUMBER OF SEQ ID NOS: 991174
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 528469
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-11-036-317-528469
```



```
Query Match      0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2390 AGCACCCCAATATCATCCGCTGGA 2414
      |||||
Db 1 AGCACCCCAATATCTCGGCTGGA 25

RESULT 328
US-11-060-756-18552/c
; Sequence 18552, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18552
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-18552

Query Match      0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2762 AGTTCACTTCGCCAGTGATGCTG 2786
      |||||
Db 25 AGTTTACTTCTGCCAGTGATGCTG 1

RESULT 331
US-11-060-756-18562/c
; Sequence 18562, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18562
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-18562

Query Match      0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2757 CCGAAGTTTCACCTTCGCCAGTGAT 2781
      |||||
Db 25 CCGAAGTTTACTTCGCCAGTGAT 1

RESULT 332
US-11-060-756-18564/c
; Sequence 18564, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18564
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-18564

Query Match      0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2758 CGGAAGTTCACTTCGCCAGTGATG 2782
      |||||
Db 25 CGAAGTTTACTTCTGCCAGTGATG 1

RESULT 330
US-11-060-756-18557/c
; Sequence 18557, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
```

```
Query Match          0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2755 TTCCGGAAGTTCACTTCCGCCAGTG 2779
Db 25 TTCCGGAAGTTACTTCTGCCAGTG 1

RESULT 333
US-11-060-756-18574/c
; Sequence 18574, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18574
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-18574

Query Match          0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2756 TCCGGAAGTTCACTTCCGCCAGTGA 2780
Db 25 TCCGGAAGTTACTTCTGCCAGTGA 1

RESULT 334
US-11-060-756-18578/c
; Sequence 18578, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18578
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-18578

Query Match          0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2774 CCAGTGATGCTCGGAGTTACGGGAT 2798
Db 25 CCAGTGATGCTCGGAGTTATGGAAT 1

RESULT 335
US-11-060-756-84138
; Sequence 84138, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

```
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 84138
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-84138

Query Match          0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2746 GCATTGCTTCCGGAAGTTCACTT 2770
Db 1 GCCATAGCCTATCGGAAGTTCACTT 25

RESULT 336
US-11-060-756-84139
; Sequence 84139, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 84139
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-84139

Query Match          0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2845 ATGAGCAATCAGGACGTGATCAATG 2869
Db 1 ATGAGCAACCAGGATGTCATCAATG 25

RESULT 337
US-11-060-756-84144
; Sequence 84144, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 84144
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-84144

Query Match          0.5%; Score 20.2; DB 1; Length 25;
```

[illegible]

```
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2755 TTCCGGAAGTTCACTCCGCCAGTG 2779
||||| ||||| ||||| ||||| |||||
Db 25 TTCCGGAAGTTTACTTCTGCCAGTG 1

RESULT 343
US-11-060-756-163426/c
; Sequence 163426, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 163426
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-163426

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2755 TTCCGGAAGTTCACTCCGCCAGTG 2779
||||| ||||| ||||| ||||| |||||
Db 25 TTCCGGAAGTTTACTTCTGCCAGTG 1

RESULT 344
US-11-060-756-166073/c
; Sequence 166073, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 166073
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-166073

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2762 AGTTCACTTCGCCAGTGATGCCTG 2786
||||| ||||| ||||| ||||| |||||
Db 25 AGTTTACTTCTGCCAGTGATGCTG 1

RESULT 345
US-11-060-756-166074/c
; Sequence 166074, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
```

```
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 166074
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-166074

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2762 AGTTCACTTCGCCAGTGATGCCTG 2786
||||| ||||| ||||| ||||| |||||
Db 25 AGTTTACTTCTGCCAGTGATGCTG 1

RESULT 346
US-11-060-756-168023
; Sequence 168023, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 168023
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-168023

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2243 CAGGTGAGTTTGGCGAGTGTCCTG 2267
||||| ||||| ||||| ||||| |||||
Db 1 CAGGGGAGTTTGGCGAGGTCTGCAG 25

RESULT 347
US-11-060-756-170191
; Sequence 170191, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 170191
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-170191

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 2931 CATGCTGGACTGTTGGCAGAAAGAC 2955
      |||||
Db 1 CATGCTGGACTGCGGACAAAGAC 25

RESULT 348
US-11-060-756-170358/c
; Sequence 170358, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 170358
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-170358

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2758 CGGAAGTTCACTTCGCCAGTGATG 2782
      |||||
Db 25 CGAAGTTACTTCTGCCAGTGATG 1

RESULT 349
US-11-060-756-170359/c
; Sequence 170359, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 170359
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-170359

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2758 CGGAAGTTCACTTCGCCAGTGATG 2782
      |||||
Db 25 CGAAGTTACTTCTGCCAGTGATG 1

RESULT 350
US-11-060-756-171498/c
; Sequence 171498, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 171498
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-171498

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2770 TCCGCCAGTGATGCTGGAGTTACG 2794
      |||||
Db 25 TCTGCCAGTGATGCTGGAGTTATG 1

RESULT 351
US-11-060-756-171499/c
; Sequence 171499, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 171499
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-171499

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2770 TCCGCCAGTGATGCTGGAGTTACG 2794
      |||||
Db 25 TCTGCCAGTGATGCTGGAGTTATG 1

RESULT 352
US-11-060-756-182311
; Sequence 182311, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 182311
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-182311

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 2995 CTGCAACAGATGATCGGAACCCG 3019
|||||
Db 1 CTGGACAGCTTATCGGAATCCG 25

RESULT 353

US-11-060-756-193223/c
; Sequence 193223, Application US/11060756
; Publication No. US20050221354A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 193223
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-193223

Query Match 0.5%; Score 20.2; DB 1; Length 25;

Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2771 CCGCCAGTGATGCTCGAGTTACGG 2795
|||||
Db 25 CTGCCAGTGATGCTCGAGTTATGG 1

RESULT 354

US-11-060-756-227416
; Sequence 227416, Application US/11060756
; Publication No. US20050221354A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 227416
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-227416

Query Match 0.5%; Score 20.2; DB 1; Length 25;

Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3003 GATGATCCGGAACCCGCCAGCTC 3027
|||||
Db 1 GATGATCCGGAACCCGCCAGTCTC 25

RESULT 355

US-11-060-756-239848
; Sequence 239848, Application US/11060756
; Publication No. US20050221354A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)

; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 239848
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-239848

Query Match 0.5%; Score 20.2; DB 1; Length 25;

Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2800 GTGATGTGGAGTGCATGTCATTGG 2824
|||||
Db 1 GTCATGTGGGAAGTCATGTCATTGG 25

RESULT 356

US-11-060-756-245548
; Sequence 245548, Application US/11060756
; Publication No. US20050221354A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 245548
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-245548

Query Match 0.5%; Score 20.2; DB 1; Length 25;

Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2805 GTGGGAGTGCATGTCATTGGGAG 2829
|||||
Db 1 GTGGGAGTGCATGTCATTGGAGAG 25

RESULT 357

US-11-060-756-248252
; Sequence 248252, Application US/11060756
; Publication No. US20050221354A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 248252
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-248252

Query Match 0.5%; Score 20.2; DB 1; Length 25;

Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2840 GGGACATGAGCAATCAGGACGTGAT 2864

```

||||| ||||||| ||||||| ||||||| |||||||
Db 1 GGGAGATGAGCAATCAGGAGGTAT 25

RESULT 358
US-11-060-756-261475
; Sequence 261475, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 261475
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-261475

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2745 GGCAATTCCTCCGGAGTTCACT 2769
||||| ||||||| ||||||| ||||||| |||||||
Db 1 GGCCATAGCTATCGGAAGTTCACT 25

RESULT 359
US-11-060-756-265730
; Sequence 265730, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 265730
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-265730

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2806 TGGGAGGTGATGTCATTTGGGGAGA 2830
||||| ||||||| ||||||| ||||||| |||||||
Db 1 TGGGAAGTCATGTCATTTGGGAGAGA 25

RESULT 360
US-11-060-756-266448
; Sequence 266448, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 266448
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-266448

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2804 TGTGGGAGGTGATGTCATTTGGGGAGA 2828
||||| ||||||| ||||||| ||||||| |||||||
Db 1 TGTGGGAAGTCATGTCATTTGGGAGA 25

RESULT 361
US-11-060-756-269583
; Sequence 269583, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 269583
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-269583

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3005 TGATCCGGAACCCCGCAGCTCAA 3029
||||| ||||||| ||||||| ||||||| |||||||
Db 1 TGATCCGGAACCCCGCAAGTCTCAA 25

RESULT 362
US-11-060-756-282968
; Sequence 282968, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 282968
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-282968

Query Match 0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2861 TGATCAATGCCATTGAACAGGACTA 2885
||||| ||||||| ||||||| ||||||| |||||||

```

```
Db      1  TCATCAATGCCATCGAGCAGGACTA 25
;
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 283741
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-283741

Query Match      0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2801  TCATGTGGGAGGTGATGTCATTGG 2825
Db      1  TCATGTGGGAGGTGATGTCATTGG 25

RESULT 366
US-11-060-756-301070/c
; Sequence 301070, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 301070
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-301070

Query Match      0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2773  GCCAGTGTGCTCGGAGTTACGGGA 2797
Db      25  GCCAGTGTGCTCGGAGTTATGGA 1

RESULT 367
US-11-060-756-301071/c
; Sequence 301071, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
; NUMBER OF SEQ ID NOS: 303284
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 301071
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe
US-11-060-756-301071

Query Match      0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.4e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2773  GCCAGTGTGCTCGGAGTTACGGGA 2797
Db      25  GCCAGTGTGCTCGGAGTTATGGA 1

RESULT 365
US-11-060-756-283741
; Sequence 283741, Application US/11060756
; Publication No. US20050221354A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William Martin
; TITLE OF INVENTION: Nucleic Acid Arrays for Monitoring Expression Profiles of Drug
; TITLE OF INVENTION: Target Genes
; FILE REFERENCE: AM101083 (031896-042000)
; CURRENT APPLICATION NUMBER: US/11/060,756
; CURRENT FILING DATE: 2005-02-18
```


RESULT 368
US-10-800-350-19
; Sequence 19, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-19

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 691 TCTGCAAGGAGACCTTCAC 710
Db 1 TCTGCAAGGAGACCTTCAC 20

RESULT 369
US-10-800-350-21/c
; Sequence 21, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-21

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2356 TTCTGAGCGAGCGCTCCAT 2375
Db 20 TTCTGAGCGAGCGCTCCAT 1
RESULT 370
US-10-800-350-25
; Sequence 25, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-25

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 697 AAGGAGACCTTCACCGCTTT 716
Db 1 AAGGAGACCTTCACCGCTTT 20

RESULT 371
US-10-800-350-27/c
; Sequence 27, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-27

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.3e+02; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 974 TGACTGTGAACCTGACTCGA 993
Db 20 TGACTGTGAACCTGACTCGA 1
|||||

RESULT 372
US-10-800-350-32
; Sequence 32, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-32

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 419 CTTTGGAGAGACCCCTGCTG 438
Db 1 CTTTGGAGAGACCCCTGCTG 20
|||||

RESULT 373
US-10-800-350-33/c
; Sequence 33, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-800-350-33
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 696 CAAGGAGACCTTCACCGTCT 715
Db 20 CAAGGAGACCTTCACCGTCT 1
|||||

RESULT 374
US-10-800-350-51/c
; Sequence 51, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-51

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2356 TTTCTGAGCGAGGCTCCAT 2375
Db 20 TTTCTGAGCGAGGCTCCAT 1
|||||

RESULT 375
US-10-800-350-55
; Sequence 55, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA

; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-55

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 419 CTTTGGAGAGACCTGCTG 438
|||||
Db 1 CTTTGGAGAGACCTGCTG 20

RESULT 376
US-10-800-350-56/c
; Sequence 56, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-56

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 696 CAAGGAGACCTTCCCGTCT 715
|||||
Db 20 CAAGGAGACCTTCCCGTCT 1

RESULT 377
US-10-800-350-74/c
; Sequence 74, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-74

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3299 GAACCCCGGCGGACAGGA 3318
|||||
Db 20 GAACCCCGGCGGACAGGA 1

RESULT 378
US-10-800-350-75/c
; Sequence 75, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-75

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3279 GAAGTCCCGCCAGCCG 3298
|||||
Db 20 GAAGTCCCGCCAGCCG 1

RESULT 379
US-10-800-350-76/c
; Sequence 76, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0

<pre>; PRIOR FILING DATE: 2003-03-12 ; NUMBER OF SEQ ID NOS: 396 ; SOFTWARE: FastSeq for Windows Version 4.0 ; SEQ ID NO 76 ; LENGTH: 20 ; TYPE: DNA ; ORGANISM: Unknown ; FEATURE: ; OTHER INFORMATION: Oligonucleotide US-10-800-350-76</pre>	<pre>Query Match 0.5%; Score 20; DB 1; Length 20; Best Local Similarity 100.0%; Pred.No. 2.3e+02; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;</pre>
<pre>QY 3259 TTGGCCAGTGTCACGACAT 3278 Db 20 TTGCCAGTGTCCAGCACAAT 1</pre>	
<pre>RESULT 380 US-10-800-350-77/c Sequence 77, Application US/10800350 Publication No. US20050084873A1 GENERAL INFORMATION: APPLICANT: Krasnoperov, Valery APPLICANT: Zozulya, Sergey APPLICANT: Kertesz, Nathalie APPLICANT: Reddy, Ramachandra APPLICANT: Gill, Parkash TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING FILE REFERENCE: VASG-P01-002 CURRENT APPLICATION NUMBER: US/10/800,350 PRIOR FILING DATE: 2004-03-12 PRIOR APPLICATION NUMBER: US 60/454,432 PRIOR FILING DATE: 2003-03-12 PRIOR APPLICATION NUMBER: US 60/454,300 NUMBER OF SEQ ID NOS: 396 SOFTWARE: FastSeq for Windows Version 4.0 SEQ ID NO 77 LENGTH: 20 TYPE: DNA ORGANISM: Unknown FEATURE: OTHER INFORMATION: Oligonucleotide US-10-800-350-77</pre>	<pre>Query Match 0.5%; Score 20; DB 1; Length 20; Best Local Similarity 100.0%; Pred.No. 2.3e+02; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;</pre>
<pre>QY 3239 CGGCACCAGCAAGAATAATC 3258 Db 20 CGGCACCAGCAAGAATAATC 1</pre>	
<pre>RESULT 381 US-10-800-350-78/c Sequence 78, Application US/10800350 Publication No. US20050084873A1 GENERAL INFORMATION: APPLICANT: Krasnoperov, Valery APPLICANT: Zozulya, Sergey APPLICANT: Kertesz, Nathalie APPLICANT: Reddy, Ramachandra APPLICANT: Gill, Parkash TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING FILE REFERENCE: VASG-P01-002 CURRENT APPLICATION NUMBER: US/10/800,350 CURRENT FILING DATE: 2004-03-12</pre>	<pre>Query Match 0.5%; Score 20; DB 1; Length 20; Best Local Similarity 100.0%; Pred.No. 2.3e+02; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;</pre>
<pre>QY 3239 CGGCACCAGCAAGAATAATC 3258 Db 20 CGGCACCAGCAAGAATAATC 1</pre>	
<pre>RESULT 383 US-10-800-350-80/c Sequence 80, Application US/10800350 Publication No. US20050084873A1 GENERAL INFORMATION: APPLICANT: Krasnoperov, Valery APPLICANT: Zozulya, Sergey APPLICANT: Kertesz, Nathalie APPLICANT: Reddy, Ramachandra APPLICANT: Gill, Parkash TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING FILE REFERENCE: VASG-P01-002 CURRENT APPLICATION NUMBER: US/10/800,350 CURRENT FILING DATE: 2004-03-12</pre>	<pre>Query Match 0.5%; Score 20; DB 1; Length 20; Best Local Similarity 100.0%; Pred.No. 2.3e+02; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;</pre>
<pre>QY 3199 ATCTCTGCTGAGGACCTGCT 3218 Db 20 ATCTCTGCTGAGGACCTGCT 1</pre>	
<pre>RESULT 382 US-10-800-350-79/c Sequence 79, Application US/10800350 Publication No. US20050084873A1 GENERAL INFORMATION: APPLICANT: Krasnoperov, Valery APPLICANT: Zozulya, Sergey APPLICANT: Kertesz, Nathalie APPLICANT: Reddy, Ramachandra APPLICANT: Gill, Parkash TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING FILE REFERENCE: VASG-P01-002 CURRENT APPLICATION NUMBER: US/10/800,350 CURRENT FILING DATE: 2004-03-12 PRIOR APPLICATION NUMBER: US 60/454,432 PRIOR FILING DATE: 2003-03-12 PRIOR APPLICATION NUMBER: US 60/454,300 NUMBER OF SEQ ID NOS: 396 SOFTWARE: FastSeq for Windows Version 4.0 SEQ ID NO 79 LENGTH: 20 TYPE: DNA ORGANISM: Unknown FEATURE: OTHER INFORMATION: Oligonucleotide US-10-800-350-79</pre>	<pre>Query Match 0.5%; Score 20; DB 1; Length 20; Best Local Similarity 100.0%; Pred.No. 2.3e+02; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;</pre>
<pre>QY 3219 CCGAATCGGAGTCACTCTGG 3238 Db 20 CCGAATCGGAGTCACTCTGG 1</pre>	

; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-80

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3179 CCTTCGAGCTGCTCAGCCAG 3198
Db 20 CCTTCGAGCTGCTCAGCCAG 1

RESULT 384
US-10-800-350-81/c
; Sequence 81, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 81
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-81

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3159 CGCAGCGCTGGCTTTGGCT 3178
Db 20 CGCAGCGCTGGCTTTGGCT 1

RESULT 385
US-10-800-350-82/c
; Sequence 82, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 82
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-82

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3139 GGAAGATACGAAGAAAGTTT 3158
Db 20 GGAAGATACGAAGAAAGTTT 1

RESULT 386
US-10-800-350-83/c
; Sequence 83, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-83

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3119 GGCTTCGGCCATCAAAATG 3138
Db 20 GGCTTCGGCCATCAAAATG 1

RESULT 387
US-10-800-350-84/c
; Sequence 84, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery

```
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-84

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3099 TTTTGGCTCTGTGGCGAGT 3118
Db 20 TTTTGGCTCTGTGGCGAGT 1

RESULT 388
US-10-800-350-85/c
; Sequence 85, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 85
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-85

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3079 CGGCGAGCTCACTACTCAGC 3098
Db 20 CGGCGAGCTCACTACTCAGC 1

RESULT 389
US-10-800-350-86/c
; Sequence 86, Application US/10800350
```

```
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 86
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-86

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3059 CACACCTCTCTGTGGACCAG 3078
Db 20 CACACCTCTCTGTGGACCAG 1

RESULT 390
US-10-800-350-87/c
; Sequence 87, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 87
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-87

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3039 CCGGAGAAATGCGGGCCT 3058
Db 20 CCGGAGAAATGCGGGCCT 1
```

RESULT 391
US-10-800-350-88/c
; Sequence 88, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 88
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-88

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3019 GCCAGCCTCAAAATCGTGGC 3038
Db 20 GCCAGCCTCAAAATCGTGGC 1

RESULT 392
US-10-800-350-89/c
; Sequence 89, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 89
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-89

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2999 ACAAGATGATCCGGAACCCC 3018
Db 20 ACAAGATGATCCGGAACCCC 1

Db 20 ACAAGATGATCCGGAACCCC 1
RESULT 393
US-10-800-350-90/c
; Sequence 90, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 90
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-90

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2979 CCAGGTGGTCAGCGCCCTGG 2998
Db 20 CCAGGTGGTCAGCGCCCTGG 1

RESULT 394
US-10-800-350-91/c
; Sequence 91, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 91
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-91

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 2959 AATGCCGGCGCCGCTTCCC 2978
Db 20 AATGCCGGCGCCGCTTCCC 1

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 395
US-10-800-350-92/c
; Sequence 92, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 92
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-92

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2939 ACTGTTGGCAGAAAGACCGG 2958
Db 20 ACTGTTGGCAGAAAGACCGG 1

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 396
US-10-800-350-93/c
; Sequence 93, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 93
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-93

QY 2919 CCTCCACCAGCTCATGCTGG 2938
Db 20 CCTCCACCAGCTCATGCTGG 1

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 397
US-10-800-350-94/c
; Sequence 94, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-94

QY 2899 CCCCAGACTGCCCCACCTC 2918
Db 20 CCCCAGACTGCCCCACCTC 1

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 398
US-10-800-350-95/c
; Sequence 95, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 95
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-95
```



```
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-95

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2879 AGGACTACCGGCTGCCCGC 2898
Db 20 AGGACTACCGGCTGCCCGC 1

RESULT 399
US-10-800-350-96/c
; Sequence 96, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 96
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-96

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2859 CGTGATCAATGCCATTGAAC 2878
Db 20 CGTGATCAATGCCATTGAAC 1

RESULT 400
US-10-800-350-97/c
; Sequence 97, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 97
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-97

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2839 TGGGACATGAGCAATCAGGA 2858
Db 20 TGGGACATGAGCAATCAGGA 1

RESULT 401
US-10-800-350-98/c
; Sequence 98, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-98

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2819 CATTGGGGAGAGGCCCGTAC 2838
Db 20 CATTGGGGAGAGGCCCGTAC 1

RESULT 402
US-10-800-350-99/c
; Sequence 99, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 99
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-99
```

```
Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 2799 TGTGATCTGGAGCTGATGT 2818
Db 20 TGTGATCTGGAGCTGATGT 1
```

RESULT 403

```
US-10-800-350-100/c
; Sequence 100, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 100
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-100
```

```
Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 2779 GATGCTTGGAGTTACGGAT 2798
Db 20 GATGCTTGGAGTTACGGAT 1
```

RESULT 404

```
US-10-800-350-101/c
; Sequence 101, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
```

```
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 101
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-101
```

```
Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 2759 GGAAGTTCACCTCCGCCAGT 2778
Db 20 GGAAGTTCACCTCCGCCAGT 1
```

RESULT 405

```
US-10-800-350-102/c
; Sequence 102, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 102
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-102
```

```
Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 2739 CCCGAGGCCATTGCTTCC 2758
Db 20 CCCGAGGCCATTGCTTCC 1
```

RESULT 406

```
US-10-800-350-103/c
; Sequence 103, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
```

```

RESULT 408
US-10-800-350-105/c
; Sequence 105, Application US/10800350
; Publication No. US2005008487A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Korteaz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS

```

RESULT 410
US-10-800-350-107/c
; Sequence 107, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Korteiz, Nathalie
; APPLICANT: Korteiz, Nathalie

; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-107

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2639 AAGTGCTGACTTTGGCCTT 2658
|||||
Db 20 AAGTGCTGACTTTGGCCTT 1

RESULT 411
US-10-800-350-108/c
; Sequence 108, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 108
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-108

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2618 TCAACAGCAACCTCGTCTGC 2637
|||||
Db 20 TCAACAGCAACCTCGTCTGC 1

RESULT 412
US-10-800-350-109/c
; Sequence 109, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:

; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-109

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2598 GGCTGCTGCAACATCCTAG 2617
|||||
Db 20 GGCTGCTGCAACATCCTAG 1

RESULT 413
US-10-800-350-110/c
; Sequence 110, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 110
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-110

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2578 AGCTACGTCCACCGAGACCT 2597
|||||
Db 20 AGCTACGTCCACCGAGACCT 1

RESULT 414
US-10-800-350-111/c

; Sequence 111, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 111
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-111

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2558 TGGCGTACCTTGGCGAGATG 2577
Db 20 TGGCGTACCTTGGCGAGATG 1

RESULT 415
US-10-800-350-112/c
; Sequence 112, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 112
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-112

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2538 GCGGGGATCGCCTCGGCA 2557
Db 20 GCGGGGATCGCCTCGGCA 1

RESULT 416
US-10-800-350-113/c
; Sequence 113, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 113
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-113

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2518 ATCCAGCTCGTGGCATGCT 2537
Db 20 ATCCAGCTCGTGGCATGCT 1

RESULT 417
US-10-800-350-114/c
; Sequence 114, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 114
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-114

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2498 ACGACGACAGTTCACAGTC 2517

```
Db      20 ACCAGCGACAGTTCACAGTC 1
|||||
RESULT 418
US-10-800-350-115/c
; Sequence 115, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 115
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-115

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2478 GGACTCCTTCCTCGGCTAA 2497
|||||
Db      20 GGACTCCTTCCTCGGCTAA 1

RESULT 419
US-10-800-350-116/c
; Sequence 116, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 116
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-116

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db      20 ACCATGGAGACGCGCCCT 1
|||||
Qy      2458 TTTCATGGAGACGCGCCCT 2477
|||||
Db      20 TTTCATGGAGACGCGCCCT 1

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 420
US-10-800-350-117/c
; Sequence 117, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 117
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-117

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2438 CCGTCATGATTCACAGAG 2457
|||||
Db      20 CCGTCATGATTCACAGAG 1

RESULT 421
US-10-800-350-118/c
; Sequence 118, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 118
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-118
```

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2418 CGTGTACCAACAGCATGC 2437
| | | | | | | | | | | | | | | | | | | | | |
Db 20 CGTGTACCAACAGCATGC 1

RESULT 422

US-10-800-350-119/c
; Sequence 119, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 119
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-119

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2398 AATATCATCCCGTGAGGG 2417
| | | | | | | | | | | | | | | | | | | | | |
Db 20 AATATCATCCCGTGAGGG 1

RESULT 423

US-10-800-350-120/c
; Sequence 120, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 120
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown

; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-120

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2378 TGGGCCAGTTCGAGCACCCC 2397
| | | | | | | | | | | | | | | | | | | | | |
Db 20 TGGGCCAGTTCGAGCACCCC 1

RESULT 424

US-10-800-350-121/c
; Sequence 121, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 121
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-121

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2358 TCTGAGCGAGGCTCCATCA 2377
| | | | | | | | | | | | | | | | | | | | | |
Db 20 TCTGAGCGAGGCTCCATCA 1

RESULT 425

US-10-800-350-122/c
; Sequence 122, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 122

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-122

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2338 GAGCGGCGAGCGGCTGAGTT 2357
      |||||
Db 20 GAGCGGCGAGCGGCTGAGTT 1

RESULT 426
US-10-800-350-123/c
; Sequence 123, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 123
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-123

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2318 CCTGAAGGCTGCTACAG 2337
      |||||
Db 20 CCTGAAGGCTGCTACAG 1

RESULT 427
US-10-800-350-124/c
; Sequence 124, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
```

```
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 124
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-124

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2298 GAGCTGTGTGCAATCAAGA 2317
      |||||
Db 20 GAGCTGTGTGCAATCAAGA 1

RESULT 428
US-10-800-350-125/c
; Sequence 125, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-125

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2278 AAGGCCCGGAGGAGGGA 2297
      |||||
Db 20 AAGGCCCGGAGGAGGGA 1

RESULT 429
US-10-800-350-126/c
; Sequence 126, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
```


; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 126
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-126

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2258 AGGTGTCGGGGCGGCTC 2277
| | | | | | | | | | | | | | | | | | | | | |
Db 20 AGGTGTCGGGGCGGCTC 1

RESULT 430

US-10-800-350-127/c
; Sequence 127, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 127
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-127

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2238 TGGTGACAGTGAGTTGGCG 2257
| | | | | | | | | | | | | | | | | | | | | |
Db 20 TGGTGACAGTGAGTTGGCG 1

RESULT 431

US-10-800-350-128/c
; Sequence 128, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002

; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 128
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-128

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2218 GTCAGATTGAAGGTTGAT 2237
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GTCAGATTGAAGGTTGAT 1

RESULT 432

US-10-800-350-129/c
; Sequence 129, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 129
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-129

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2198 AAGAGATCGATGTCCTAC 2217
| | | | | | | | | | | | | | | | | | | | | |
Db 20 AAGAGATCGATGTCCTAC 1

RESULT 433

US-10-800-350-130/c
; Sequence 130, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash

```
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 130
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-130

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2178 GGCTGTGAGGGAATTTGCCA 2197
Db 20 GGCTGTGAGGGAATTTGCCA 1

RESULT 434
US-10-800-350-131/c
; Sequence 131, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 131
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-131

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2158 ACTTATGAAGACCCCTAATGA 2177
Db 20 ACTTATGAAGACCCCTAATGA 1

RESULT 435
US-10-800-350-132/c
; Sequence 132, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
```

```
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 132
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-132

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2138 AGGCTCATCGACCCCTTC 2157
Db 20 AGGCTCATCGACCCCTTC 1

RESULT 436
US-10-800-350-133/c
; Sequence 133, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 133
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-133

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2118 TCTCATCGACATCGTACTA 2137
Db 20 TCTCATCGACATCGTACTA 1

RESULT 437
US-10-800-350-134/c
; Sequence 134, Application US/10800350
; Publication No. US20050084873A1
```

GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 134
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-134

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2098 TCGGACAAACACGGACAGTA 2117
|||||
Db 20 TCGGACAAACACGGACAGTA 1

RESULT 438

US-10-800-350-135/c
; Sequence 135, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 135
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-135

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2078 ATGGGAGAGACGAGATAT 2097
|||||
Db 20 ATGGGAGAGACGAGATAT 1

RESULT 439

US-10-800-350-136/c
; Sequence 136, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 136
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-136

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2058 CTGCCTCAGAGCAGCA 2077
|||||
Db 20 CTGCCTCAGAGCAGCA 1

RESULT 440

US-10-800-350-137/c
; Sequence 137, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 137
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-137

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2038 GTCATTGTGTCGAGTTCT 2057
|||||
Db 20 GTCATTGTGTCGAGTTCT 1

RESULT 441
US-10-800-350-139/c
; Sequence 138, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 138
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-138

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2018 GTGTGGTCTCTGGTCCCTGGTG 2037
|||||
Db 20 GTGTGGTCTCTGGTCCCTGGTG 1

RESULT 442
US-10-800-350-139/c
; Sequence 139, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 139
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-139

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1998 TCGGGGACGCGAGTCGTGG 2017
|||||
Db 20 TCGGGGACGCGAGTCGTGG 1
RESULT 443
US-10-800-350-140/c
; Sequence 140, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 140
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-140

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1978 CGGAGCAGCTGGCCCTGAT 1997
|||||
Db 20 CGGAGCAGCTGGCCCTGAT 1

RESULT 444
US-10-800-350-141/c
; Sequence 141, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 141
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-141

Query Match 0.5%; Score 20; DB 1; Length 20;

```

/
/ LENGTH: 20
/
/ TYPE: DNA
/
/ ORGANISM: Unknown
/
/ FEATURE:
/
/ OTHER INFORMATION: oligonucleotide
/

```

```

; NUMBER OF SEQ AS REQ: 310
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 145
; LENGTH: 20
; TYPE: DNA

```

```
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-145

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1878 CAGCTACCTGGTGCAGGTAC 1897
    |||||
Db 20 CAGCTACCTGGTGCAGGTAC 1

RESULT 449
US-10-800-350-146/c
; Sequence 146, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 146
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-146

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1858 CGGGGGCTGAAGCGGGGAGC 1877
    |||||
Db 20 CGGGGGCTGAAGCGGGGAGC 1

RESULT 450
US-10-800-350-147/c
; Sequence 147, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 147
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-147

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1838 CAGAAAACCGGGCAGAGCTG 1857
    |||||
Db 20 CAGAAAACCGGGCAGAGCTG 1

RESULT 451
US-10-800-350-148/c
; Sequence 148, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 148
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-148

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1818 CGTGGCGTTCCTGAAGACGT 1837
    |||||
Db 20 CGTGGCGTTCCTGAAGACGT 1

RESULT 452
US-10-800-350-149/c
; Sequence 149, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; SOFTWARE: FastSeq for Windows Version 4.0
```

; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 149
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-149

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1798 GCGCCGAGGCTCCAGCAG 1817
|||
Db 20 GCGCCGAGGCTCCAGCAG 1

RESULT 453

US-10-800-350-150/c
; Sequence 150, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 150
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-150

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1778 AGGTCAATACCATGAGAAG 1797
|||
Db 20 AGGTCAATACCATGAGAAG 1

RESULT 454

US-10-800-350-151/c
; Sequence 151, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12

; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 151
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-151

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1758 TGGGGCTGTCTGGACTACG 1777
|||
Db 20 TGGGGCTGTCTGGACTACG 1

RESULT 455

US-10-800-350-152/c
; Sequence 152, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 152
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-152

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1738 GCTGTTCCTCCGGCACCAC 1757
|||
Db 20 GCTGTTCCTCCGGCACCAC 1

RESULT 456

US-10-800-350-153/c
; Sequence 153, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12

; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 153
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-153

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1718 GCAGCTTGACCTGGCGCTGG 1737
Db 20 GCAGCTTGACCTGGCGCTGG 1

RESULT 457

US-10-800-350-154/c
; Sequence 154, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 154
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-154

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1698 GGTGACGCGGTCTCTCACCCA 1717
Db 20 GGTGACGCGGTCTCTCACCCA 1

RESULT 458

US-10-800-350-155/c
; Sequence 155, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 155
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-155

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1678 CCTGCAGTGTCTGACATCCG 1697
Db 20 CCTGCAGTGTCTGACATCCG 1

RESULT 459

US-10-800-350-156/c
; Sequence 156, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 156
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-156

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1658 CCACTGACGAGAGGTACCT 1677
Db 20 CCACTGACGAGAGGTACCT 1

RESULT 460

US-10-800-350-157/c
; Sequence 157, Application US/108000350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery

; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 157
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 159
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-800-350-157
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1638 ATTTGAGCCTGTCAATGTCA 1637
Db 20 ATTTGAGCCTGTCAATGTCA 1

RESULT 461
US-10-800-350-158/c
; Sequence 158, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 158
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-800-350-158
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1598 CATTGAACGGGTATCTCTCC 1617
Db 20 CATTGAACGGGTATCTCTCC 1

RESULT 463
US-10-800-350-160/c
; Sequence 160, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 160
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-800-350-160
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1578 CTATACCTTTGAGGTCACTG 1597
Db 20 CTATACCTTTGAGGTCACTG 1

RESULT 462
US-10-800-350-159/c
; Sequence 159, Application US/10800350

US-10-800-350-159
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1618 TTAGCCAGGGCGCGTCC 1637
Db 20 TTAGCCAGGGCGCGTCC 1

RESULT 464
US-10-800-350-161/c
; Sequence 161, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 161
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-161

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1558 GGGCTAGCTCCTGACTTCAC 1577
|||||
Db 20 GGGCTAGCTCCTGACTTCAC 1

RESULT 465
US-10-800-350-162/c
; Sequence 162, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 162
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-162

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1538 AGCCCTGGGTGGTGGTTCCA 1557
|||||

Db 20 AGCCCTGGGTGGTGGTTCCA 1

RESULT 466
US-10-800-350-163/c
; Sequence 163, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 163
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-163

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1518 CGGCCCCCGGACCTGGTGG 1537
|||||
Db 20 CGGCCCCCGGACCTGGTGG 1

RESULT 467
US-10-800-350-164/c
; Sequence 164, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 164
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-164

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1498 GGAGACCTGACTTTTGACCC 1517
      |||||
Db 20 GGAGACCTGACTTTTGACCC 1

RESULT 468
US-10-800-350-165/c
; Sequence 165, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 165
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-165

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1478 GCTCCTGTGGCCCTCGGGG 1497
      |||||
Db 20 GCTCCTGTGGCCCTCGGGG 1

RESULT 469
US-10-800-350-166/c
; Sequence 166, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 166
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-166

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1478 GTCACCTAGCCCTCCGCTG 1457
      |||||
Db 20 CTCACCTAGCCCTCCGCTG 1

RESULT 471
US-10-800-350-168/c
; Sequence 168, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 168
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-168

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1458 CCGGAGTGCCGACCCGGAG 1477
      |||||
Db 20 CCGGAGTGCCGACCCGGAG 1

RESULT 470
US-10-800-350-167/c
; Sequence 167, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 167
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-167

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1438 CTCACCTAGCCCTCCGCTG 1457
      |||||
Db 20 CTCACCTAGCCCTCCGCTG 1
```

```
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-168

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1418 AGTCTGGTGGCCGAGGAC 1437
      |||||
Db 20 AGTCTGGTGGCCGAGGAC 1

RESULT 472
US-10-800-350-169/c
; Sequence 169, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 169
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-169

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1398 GGAATGGAGTGCCCCCTGG 1417
      |||||
Db 20 GGAATGGAGTGCCCCCTGG 1

RESULT 473
US-10-800-350-170/c
; Sequence 170, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 170
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-170/c

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1398 GGAATGGAGTGCCCCCTGG 1417
      |||||
Db 20 GGAATGGAGTGCCCCCTGG 1

RESULT 474
US-10-800-350-171/c
; Sequence 171, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 171
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-171

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1378 AACGGCTCTCCCTGCACCT 1397
      |||||
Db 20 AACGGCTCTCCCTGCACCT 1

RESULT 475
US-10-800-350-172/c
; Sequence 172, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 172
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-172
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 172
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-172

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1338 CACCCCTCCTTGGCTCCGC 1357
      |||||
Db 20 CACCCCTCCTTGGCTCCGC 1

RESULT 476
US-10-800-350-173/c
; Sequence 173, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 173
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-173

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CCCCAGGTGACCCCTGCAC 1337
      |||||
Db 20 CCCCAGGTGACCCCTGCAC 1

RESULT 477
US-10-800-350-174/c
; Sequence 174, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
```

```
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 174
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-174

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1298 ACTTCGGGCACGCACGAC 1317
      |||||
Db 20 ACTTCGGGCACGCACGAC 1

RESULT 478
US-10-800-350-175/c
; Sequence 175, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 175
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-175

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1278 CTGCCAGTCCGCTCGGCT 1297
      |||||
Db 20 CTGCCAGTCCGCTCGGCT 1

RESULT 479
US-10-800-350-176/c
; Sequence 176, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2003-03-12
```

```
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 176
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-176

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1258 AACACCATTTGGATCAGCCGT 1277
Db 20 AACACCATTTGGATCAGCCGT 1

RESULT 480
US-10-800-350-177/c
; Sequence 177, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 177
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-177

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1238 GCCCAGCCCAATGCCACTCT 1257
Db 20 GCCCAGCCCAATGCCACTCT 1

RESULT 481
US-10-800-350-178/c
; Sequence 178, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
```

```
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 178
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-178

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1218 AGAAGGGTCTGCCAGCCAT 1237
Db 20 AGAAGGGTCTGCCAGCCAT 1

RESULT 482
US-10-800-350-179/c
; Sequence 179, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 179
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-179

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1198 ACCTTCAGCCCTGTCTCAGG 1217
Db 20 ACCTTCAGCCCTGTCTCAGG 1

RESULT 483
US-10-800-350-180/c
; Sequence 180, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
```

; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 180
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-180

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1178 GCCGAGCTGTGCCAGGC 1197
|||
Db 20 GCCGAGCTGTGCCAGGC 1

RESULT 484

US-10-800-350-181/c
; Sequence 181, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 181
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-181

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1158 AGCTGAGGGGAACCAAGT 1177
|||
Db 20 AGCTGAGGGGAACCAAGT 1

RESULT 485

US-10-800-350-182/c
; Sequence 182, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:

; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 182
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-182

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1138 TGTGCTCCGGGTTTCGAGC 1157
|||
Db 20 TGTGCTCCGGGTTTCGAGC 1

RESULT 486

US-10-800-350-183/c
; Sequence 183, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 183
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-183

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1118 AGCCGGTCACGGGTCGAGC 1137
|||
Db 20 AGCCGGTCACGGGTCGAGC 1

RESULT 487

US-10-800-350-184/c

```
; Sequence 184, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 184
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-184
```

```
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1098 GGATGGCCAGTGGCCGAAC 1117
DB 20 GGATGGCCAGTGGCCGAAC 1
```

RESULT 488

```
US-10-800-350-185/c
; Sequence 185, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 185
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-185
```

```
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1078 CCCAGCCTTACTGCGGTGA 1097
DB 20 CCCAGCCTTACTGCGGTGA 1
```

```
RESULT 489
US-10-800-350-186/c
; Sequence 186, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 186
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-186
```

```
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1058 TCCCCGCCCCCTGGCCCCAGC 1077
DB 20 TCCCCGCCCCCTGGCCCCAGC 1
```

RESULT 490

```
US-10-800-350-187/c
; Sequence 187, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 187
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-187
```

```
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1038 TAGCTGCGTGTGGATGCG 1057
```



```

Db      20 TAGCTGCGTGGTGGATCGG 1
|||||
RESULT 491
US-10-800-350-189/c
; Sequence 188, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 188
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-188

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1018 CTGTTGTGCCCGGCCGG 1037
|||||
Db      20 CTGTTGTGCCCGGCCGG 1

RESULT 492
US-10-800-350-189/c
; Sequence 189, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 189
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-189

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      998 CGGAGACTGTGCTCGGGAG 1017
|||||
Db      20 CGGAGACTGTGCTCGGGAG 1

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 493
US-10-800-350-190/c
; Sequence 190, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 190
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-190

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      978 TGTGAACCTGACTCGATTCC 997
|||||
Db      20 TGTGAACCTGACTCGATTCC 1

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 494
US-10-800-350-191/c
; Sequence 191, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 191
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-191

```

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 958 AAAAGTGGCCCGAGTGTAC 977
|||||
Db 20 AAAAGTGGCCCGAGTGTAC 1

RESULT 495

US-10-800-350-192/c
; Sequence 192, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 192
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-192

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 938 TATCCCTGGACCTTCTAC 957
|||||
Db 20 TATCCCTGGACCTTCTAC 1

RESULT 496

US-10-800-350-193/c
; Sequence 193, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 193
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown

; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-193

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 918 GGGTGGCTGCATGGCCCTGC 937
|||||
Db 20 GGGTGGCTGCATGGCCCTGC 1

RESULT 497

US-10-800-350-194/c
; Sequence 194, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 194
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-194

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 898 TACCTGGCCTTCCAGACCA 917
|||||
Db 20 TACCTGGCCTTCCAGACCA 1

RESULT 498

US-10-800-350-195/c
; Sequence 195, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 195

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-195

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 878 CGCTCAGCAGGCTGGCTTC 897
Db 20 CGCTCAGCAGGCTGGCTTC 1

RESULT 499
US-10-800-350-196/c
; Sequence 196, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 196
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-196

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 858 CAAGACGCTGCGTCTGGAC 877
Db 20 CAAGACGCTGCGTCTGGAC 1

RESULT 500
US-10-800-350-197/c
; Sequence 197, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12

; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 197
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-197

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 838 GCCACCGGGAAGTGAATGT 857
Db 20 GCCACCGGGAAGTGAATGT 1

RESULT 501
US-10-800-350-198/c
; Sequence 198, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 198
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-198

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 818 GGAAGCGCCTGGGCGGAG 837
Db 20 GGAAGCGCCTGGGCGGAG 1

RESULT 502
US-10-800-350-199/c
; Sequence 199, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
```

```

; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 199
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-199

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 798 GGCGCGGAGCATCTCACCC 817
Db 20 GGCGCGGAGCATCTCACCC 1

RESULT 503
US-10-800-350-200/c
; Sequence 200, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 200
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-200

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 778 TACATCAAGTGGACACGGT 797
Db 20 TACATCAAGTGGACACGGT 1

RESULT 504
US-10-800-350-201/c
; Sequence 201, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002

```

```

; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 201
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-201

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 758 CAGCCTGGATGGAGAACCCC 777
Db 20 CAGCCTGGATGGAGAACCCC 1

RESULT 505
US-10-800-350-202/c
; Sequence 202, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 202
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-202

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 738 CACGGCCACGGCCCTCACGC 757
Db 20 CACGGCCACGGCCCTCACGC 1

RESULT 506
US-10-800-350-203/c
; Sequence 203, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash

```

```

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 203
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-203

```

```

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 718 TACTATGAGACGATGCGGA 737
    |||||
Db 20 TACTATGAGACGATGCGGA 1

```

```

RESULT 507
US-10-800-350-204/c
; Sequence 204, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 204
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-204

```

```

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 698 AGGAGACCTTCACCGCTTTC 717
    |||||
Db 20 AGGAGACCTTCACCGCTTTC 1

```

```

RESULT 508
US-10-800-350-205/c
; Sequence 205, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey

```

```

; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 205
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-205

```

```

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 678 TCGGGCTGGGGCTCTCGCA 697
    |||||
Db 20 TCGGGCTGGGGCTCTCGCA 1

```

```

RESULT 509
US-10-800-350-206/c
; Sequence 206, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 206
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-206

```

```

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 658 CTCGAGTGCCTGTCCCTGCC 677
    |||||
Db 20 CTCGAGTGCCTGTCCCTGCC 1

```

```

RESULT 510
US-10-800-350-207/c
; Sequence 207, Application US/10800350
; Publication No. US20050084873A1

```

```
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 207
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-207

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 638 CCAGCTGCGCTTCACCATG 657
DB 20 CCAGCTGCGCTTCACCATG 1

RESULT 511
US-10-800-350-208/c
; Sequence 208, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 208
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-208

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 618 GGGCGCGCTCCAGCTGTACG 637
DB 20 GGGCGCGCTCCAGCTGTACG 1

RESULT 512
```

```
US-10-800-350-209/c
; Sequence 209, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 209
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-209

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 598 ACAGTTGGTCCACGGCG 617
DB 20 ACAGTTGGTCCACGGCG 1

RESULT 513
US-10-800-350-210/c
; Sequence 210, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 210
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-210

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 578 GCCAGGCCCACTGGCTTCGC 597
DB 20 GCCAGGCCCACTGGCTTCGC 1
```

RESULT 514
US-10-800-350-211/c
; Sequence 211, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 211
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-211

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 558 TGACGTGCAGCGTCCCCGG 577
Db 20 TGACGTGCAGCGTCCCCGG 1

RESULT 515
US-10-800-350-212/c
; Sequence 212, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 212
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-212

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 538 GTGGCACCTACGAAGTGTG 557
Db 20 GTGGCACCTACGAAGTGTG 1

RESULT 516
US-10-800-350-213/c
; Sequence 213, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 213
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-213

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 518 TGGATGAGGACACGACG 537
Db 20 TGGATGAGGACACGACG 1

RESULT 517
US-10-800-350-214/c
; Sequence 214, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 214
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-214

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 498 GTGGGAGGAAGTGGCGGC 517
|||||
Db 20 GTGGGAGGAAGTGGCGGC 1

RESULT 518

US-10-800-350-215/c
; Sequence 215, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 215
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-215

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 478 TTCCTCAGGTGACGGCA 497
|||||
Db 20 TTCCTCAGGTGACGGCA 1

RESULT 519

US-10-800-350-216/c
; Sequence 216, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 216
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-800-350-216

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 458 CTGATCTGAAGTGGGTGACA 477
|||||
Db 20 CTGATCTGAAGTGGGTGACA 1

RESULT 520

US-10-800-350-217/c
; Sequence 217, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 217
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-217

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 438 GAACACAAAATTGGAACATG 457
|||||
Db 20 GAACACAAAATTGGAACATG 1

RESULT 521

US-10-800-350-218/c
; Sequence 218, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 218
; LENGTH: 20
; TYPE: DNA


```
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-218

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 418 GCTTTGGAAGAGACCCCTGCT 437
Db 20 GCTTTGGAAGAGACCCCTGCT 1

RESULT 522
US-10-800-350-219/c
; Sequence 219, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 219
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-219

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 398 GCTGGGCTTCGTTGGCGCA 417
Db 20 GCTGGGCTTCGTTGGCGCA 1

RESULT 523
US-10-800-350-220/c
; Sequence 220, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 220
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-220

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 376 ATGGAGCTCCGGGTGCTGCT 395
Db 20 ATGGAGCTCCGGGTGCTGCT 1

RESULT 525
US-10-800-350-231/c
; Sequence 231, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 221
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-221

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 378 GGAGCTCCGGGTGCTGCTCT 397
Db 20 GGAGCTCCGGGTGCTGCTCT 1

RESULT 524
US-10-800-350-221/c
; Sequence 221, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 221
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-221

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 376 ATGGAGCTCCGGGTGCTGCT 395
Db 20 ATGGAGCTCCGGGTGCTGCT 1

RESULT 525
US-10-800-350-231/c
; Sequence 231, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
```

```
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 231
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-231

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2356 TTCTGAGCGAGGCTCCAT 2375
Db 20 TTCTGAGCGAGGCTCCAT 1

RESULT 526
US-10-800-077-19
; Sequence 19, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-19

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 691 TCCTGCAAGGAGACCTTCAC 710
Db 1 TCCTGCAAGGAGACCTTCAC 20

RESULT 527
US-10-800-077-21/c
; Sequence 21, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-21/c

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 AAGGAGACCTTCACCGTCTT 716
Db 1 AAGGAGACCTTCACCGTCTT 20

RESULT 529
US-10-800-077-27/c
; Sequence 27, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-25

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 AAGGAGACCTTCACCGTCTT 716
Db 1 AAGGAGACCTTCACCGTCTT 20

RESULT 529
US-10-800-077-27/c
; Sequence 27, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-25
```

```
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-27

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 974 TGACTGTGAACCTGACTCGA 993
Db 20 TGACTGTGAACCTGACTCGA 1

RESULT 530
US-10-800-077-32
; Sequence 32, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-32

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 419 CTTTGAAGAGACCCCTGCTG 438
Db 1 CTTTGAAGAGACCCCTGCTG 20

RESULT 531
US-10-800-077-33/c
; Sequence 33, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-33/c

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2356 TTCTGAGCGAGCGCTCCAT 2375
Db 20 TTCTGAGCGAGCGCTCCAT 1

RESULT 533
US-10-800-077-55
; Sequence 55, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-55

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2356 TTCTGAGCGAGCGCTCCAT 2375
Db 20 TTCTGAGCGAGCGCTCCAT 1

RESULT 533
US-10-800-077-55
; Sequence 55, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-55

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Best Local Similarity 100.0%; Pred. No. 2.3e+02; Indels 0; Mismatches 0; Gaps 0;
Matches 20; Conservative 0;
QY 419 CTTTGAAGAGACCCCTGCTG 438
Db 1 CTTTGAAGAGACCCCTGCTG 20

RESULT 534
US-10-800-077-56/c
; Sequence 56, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-56

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 696 CAAGGAGACCTTCACCGTCT 715
Db 20 CAAGGAGACCTTCACCGTCT 1

RESULT 535
US-10-800-077-74/c
; Sequence 74, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-74

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3299 GAACCCCGGTGGGACAGCA 3318
Db 20 GAACCCCGGTGGGACAGCA 1

RESULT 536
US-10-800-077-75/c
; Sequence 75, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-75

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3279 GAAGTCCCGAGCCCAAGCCGG 3298
Db 20 GAAGTCCCGAGCCCAAGCCGG 1

RESULT 537
US-10-800-077-76/c
; Sequence 76, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-76

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3259 TTGGCCAGTGTCCAGCACAT 3278
Db 20 TTGGCCAGTGTCCAGCACAT 1

RESULT 538

US-10-800-077-77/c

; Sequence 77, Application US/10800077

; Publication No. US20050164965A1

; GENERAL INFORMATION:

; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING

; FILE REFERENCE: VASG-P01-001

; CURRENT APPLICATION NUMBER: US/10/800,077

; CURRENT FILING DATE: 2004-03-12

; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300

; PRIOR FILING DATE: 2003-03-12

; NUMBER OF SEQ ID NOS: 396

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 77

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: Oligonucleotide

US-10-800-077-77

Query Match

Best Local Similarity 0.5%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3239 CGGGACACCGAGAAAATC 3258

DB 20 CGGGACACCGAGAAAATC 1

RESULT 539

US-10-800-077-78/c

; Sequence 78, Application US/10800077

; Publication No. US20050164965A1

; GENERAL INFORMATION:

; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING

; FILE REFERENCE: VASG-P01-001

; CURRENT APPLICATION NUMBER: US/10/800,077

; CURRENT FILING DATE: 2004-03-12

; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300

; PRIOR FILING DATE: 2003-03-12

; NUMBER OF SEQ ID NOS: 396

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 78

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: Oligonucleotide

US-10-800-077-78

Query Match

Best Local Similarity 0.5%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3219 CCGAATCGGAGTCACTCTGG 3238

DB 20 CCGAATCGGAGTCACTCTGG 1

RESULT 540

US-10-800-077-79/c

; Sequence 79, Application US/10800077

; Publication No. US20050164965A1

; GENERAL INFORMATION:

; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING

; FILE REFERENCE: VASG-P01-001

; CURRENT APPLICATION NUMBER: US/10/800,077

; CURRENT FILING DATE: 2004-03-12

; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300

; PRIOR FILING DATE: 2003-03-12

; NUMBER OF SEQ ID NOS: 396

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 79

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: Oligonucleotide

US-10-800-077-79

Query Match

Best Local Similarity 0.5%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3199 ATCTCTGCTGAGGACCTGCT 3218

DB 20 ATCTCTGCTGAGGACCTGCT 1

RESULT 541

US-10-800-077-80/c

; Sequence 80, Application US/10800077

; Publication No. US20050164965A1

; GENERAL INFORMATION:

; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING

; FILE REFERENCE: VASG-P01-001

; CURRENT APPLICATION NUMBER: US/10/800,077

; CURRENT FILING DATE: 2004-03-12

; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300

; PRIOR FILING DATE: 2003-03-12

; NUMBER OF SEQ ID NOS: 396

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 80

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: Oligonucleotide

US-10-800-077-80

Query Match

Best Local Similarity 0.5%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3179 CCTTCGAGCTGGTCACCCAG 3198

DB 20 CCTTCGAGCTGGTCACCCAG 1

```
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 81
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-81

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3159 CGCAGCGGCTGGCTTTGGCT 3178
Db 20 CGCAGCGGCTGGCTTTGGCT 1

RESULT 543
US-10-800-077-82/c
; Sequence 82, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 82
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-82

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3139 GGAAGTACGAGAAAGTTT 3158
Db 20 GGAAGTACGAGAAAGTTT 1

RESULT 544
US-10-800-077-83/c
; Sequence 83, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
```

```
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-83

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3119 GGCCTCGGGCCCATCAAAATG 3138
Db 20 GGCCTCGGGCCCATCAAAATG 1

RESULT 545
US-10-800-077-84/c
; Sequence 84, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-84

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3099 TTTTGGCTCTGTGGCGAGT 3118
Db 20 TTTTGGCTCTGTGGCGAGT 1

RESULT 546
US-10-800-077-85/c
; Sequence 85, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
```

; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 85
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-85

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3079 CGGCAGCCTCACTACTCAGC 3098
Db 20 CGGCAGCCTCACTACTCAGC 1

RESULT 547
US-10-800-077-86/c
; Sequence 86, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 86
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-86

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3059 CACACCCCTCTCTGGACCAG 3078
Db 20 CACACCCCTCTCTGGACCAG 1

RESULT 548
US-10-800-077-87/c
; Sequence 87, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 87
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-87

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3039 CCGGAGAAATGGCGGGCCT 3058
Db 20 CCGGAGAAATGGCGGGCCT 1

RESULT 549
US-10-800-077-88/c
; Sequence 88, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 88
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-88

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3019 GCCAGCCTCAAAATCGTGC 3038
Db 20 GCCAGCCTCAAAATCGTGC 1

RESULT 550
US-10-800-077-89/c
; Sequence 89, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12

```
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 89
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-89

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2999 ACAAGATGATCCGGAACCCC 3018
Db 20 ACAAGATGATCCGGAACCCC 1

RESULT 551
US-10-800-077-90/c
; Sequence 90, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 90
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-90

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2979 CCAGGTGGTCAGCGCCCTGG 2998
Db 20 CCAGGTGGTCAGCGCCCTGG 1

RESULT 552
US-10-800-077-91/c
; Sequence 91, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 91

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-91

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2939 ACTGTTGCAGAAAGACCGG 2958
Db 20 ACTGTTGCAGAAAGACCGG 1

RESULT 554
US-10-800-077-93/c
; Sequence 93, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 93
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
```


; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-93

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2919 CCTCCACGCTCATGCTGG 2938
Db 20 CCTCCACGCTCATGCTGG 1

RESULT 555
US-10-800-077-94/c
; Sequence 94, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-94

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2899 CCCCCAGACTGTCACCTC 2918
Db 20 CCCCCAGACTGTCACCTC 1

RESULT 556
US-10-800-077-95/c
; Sequence 95, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 95
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-95

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2879 AGGACTACCGCTGCCCCCG 2898
Db 20 AGGACTACCGCTGCCCCCG 1

RESULT 557
US-10-800-077-96/c
; Sequence 96, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 96
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-96

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2859 CGTGATCAATGCCATTGAAC 2878
Db 20 CGTGATCAATGCCATTGAAC 1

RESULT 558
US-10-800-077-97/c
; Sequence 97, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 97
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-97

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2839 TGGACATGAGCAATCAGGA 2858
Db 20 TGGACATGAGCAATCAGGA 1

RESULT 559
US-10-800-077-98/c
; Sequence 98, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-98

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2819 CATTGGGGAGGCCGTAC 2838
Db 20 CATTGGGGAGGCCGTAC 1

RESULT 560
US-10-800-077-99/c
; Sequence 99, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 99
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-99

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2799 TGTGATGTGGAGGTGATGT 2818

Db 20 TGTGATGTGGAGGTGATGT 1

RESULT 561
US-10-800-077-100/c
; Sequence 100, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 100
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-100

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2779 GATGCTGGAGTTACGGGAT 2798
Db 20 GATGCTGGAGTTACGGGAT 1

RESULT 562
US-10-800-077-101/c
; Sequence 101, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 101
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-101

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2759 GGAAGTTCACCTCCGCCAGT 2778
Db 20 GGAAGTTCACCTCCGCCAGT 1

RESULT 563
US-10-800-077-102/c
; Sequence 102, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 102
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-102

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2739 CCCGAGGCCATTGCTTCC 2758
Db 20 CCCGAGGCCATTGCTTCC 1

RESULT 564
US-10-800-077-103/c
; Sequence 103, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 103
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-103

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2719 ATCCCATCCGATGCTGTC 2738
Db 20 ATCCCATCCGATGCTGTC 1

RESULT 565
US-10-800-077-104/c

; Sequence 104, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 104
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-104

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2699 CGAGCTCCCTGGGAGGAAAG 2718
Db 20 CGAGCTCCCTGGGAGGAAAG 1

RESULT 566
US-10-800-077-105/c
; Sequence 105, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 105
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-105

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2679 CTCTCCGATCCACCTACA 2698
Db 20 CTCTCCGATCCACCTACA 1

RESULT 567
US-10-800-077-106/c
; Sequence 106, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:

```
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-106

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2659 TCCCGATTCTCGGAGGAA 2678
      |||||
Db 20 TCCCGATTCTCGGAGGAA 1

RESULT 568
US-10-800-077-107/c
; Sequence 107, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-107

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2639 AAGTGCTGACTTGGCCTT 2658
      |||||
Db 20 AAGTGCTGACTTGGCCTT 1

RESULT 569
US-10-800-077-108/c
; Sequence 108, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
```

```
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 108
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-108

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2618 TCAACAGCAACCTCGTCTGC 2637
      |||||
Db 20 TCAACAGCAACCTCGTCTGC 1

RESULT 570
US-10-800-077-109/c
; Sequence 109, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-109

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2598 GGCTGCTCGCAACATCCTAG 2617
      |||||
Db 20 GGCTGCTCGCAACATCCTAG 1

RESULT 571
US-10-800-077-110/c
; Sequence 110, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
```

```
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 110
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-110

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2578 AGCTACGTCCACCGAGACCT 2597
Db 20 AGCTACGTCCACCGAGACCT 1

RESULT 572
US-10-800-077-111/c
; Sequence 111, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 111
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-111

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2558 TGGGTACCTTGGCGAGATG 2577
Db 20 TGGGTACCTTGGCGAGATG 1

RESULT 573
US-10-800-077-112/c
; Sequence 112, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
```

```
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 112
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-112

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2538 GCGGGCATCGCTCGGGCA 2557
Db 20 GCGGGCATCGCTCGGGCA 1

RESULT 574
US-10-800-077-113/c
; Sequence 113, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 113
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-113

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2518 ATCCAGCTCGTGGCATGCT 2537
Db 20 ATCCAGCTCGTGGCATGCT 1

RESULT 575
US-10-800-077-114/c
; Sequence 114, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 114
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-114

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2498 ACGACGACAGTTCACAGTC 2517
      |||||||
Db 20 ACGACGACAGTTCACAGTC 1

RESULT 576
US-10-800-077-115/c
; Sequence 115, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 115
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-115

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2478 GGACTCCTTCCTCGGCTAA 2497
      |||||||
Db 20 GGACTCCTTCCTCGGCTAA 1

RESULT 577
US-10-800-077-116/c
; Sequence 116, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 116
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-116

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2438 CCGTCATGATTCACAGAG 2457
      |||||||
Db 20 CCGTCATGATTCACAGAG 1

RESULT 579
US-10-800-077-118/c
; Sequence 118, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 118
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-117

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2458 TTCATGGAGACGGCGCCT 2477
      |||||||
Db 20 TTCATGGAGACGGCGCCT 1

RESULT 578
US-10-800-077-117/c
; Sequence 117, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 117
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-117
```

; OTHER INFORMATION: Oligonucleotide
US-10-800-077-118

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0;

QY 2418 CGTGGTCACCAACAGCATGC 2437
|||||
Db 20 CGTGGTCACCAACAGCATGC 1

RESULT 580

US-10-800-077-119/c
; Sequence 119, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 119
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-119

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0;

QY 2398 AATATCATCGCCTGGAGGG 2417
|||||
Db 20 AATATCATCGCCTGGAGGG 1

RESULT 581

US-10-800-077-120/c
; Sequence 120, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 120
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-120

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0;

QY 2378 TGGCCAGTTCGAGCACCCC 2397
|||||
Db 20 TGGCCAGTTCGAGCACCCC 1

RESULT 582

US-10-800-077-121/c
; Sequence 121, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 121
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-121

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0;

QY 2358 TCTGAGCGAGGCTCCATCA 2377
|||||
Db 20 TCTGAGCGAGGCTCCATCA 1

RESULT 583

US-10-800-077-122/c
; Sequence 122, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 122
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-122

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0;

```
QY 2338 GAGCGGAGCGGGTGAGTT 2357
Db 20 GAGCGGAGCGGGTGAGTT 1

RESULT 584
US-10-800-077-123/c
; Sequence 123, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; SOFTWARE: FastSeq for Windows Version 4.0
; NUMBER OF SEQ ID NOS: 396
; SEQ ID NO 123
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-123

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2318 CCCTGAAGGTTGGCTACAG 2337
Db 20 CCCTGAAGGTTGGCTACAG 1

RESULT 585
US-10-800-077-124/c
; Sequence 124, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; SOFTWARE: FastSeq for Windows Version 4.0
; NUMBER OF SEQ ID NOS: 396
; SEQ ID NO 124
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-124

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2298 GAGCTGTGGCAATCAAGA 2317
Db 20 GAGCTGTGGCAATCAAGA 1

RESULT 586
US-10-800-077-125/c
; Sequence 125, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; SOFTWARE: FastSeq for Windows Version 4.0
; NUMBER OF SEQ ID NOS: 396
; SEQ ID NO 125
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-125

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2278 AAGGCCCGAGGAGAGGA 2297
Db 20 AAGGCCCGAGGAGAGGA 1

RESULT 587
US-10-800-077-126/c
; Sequence 126, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; SOFTWARE: FastSeq for Windows Version 4.0
; NUMBER OF SEQ ID NOS: 396
; SEQ ID NO 126
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-126

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2258 AGGTGTCCGGGGCGGCTC 2277
Db 20 AGGTGTCCGGGGCGGCTC 1
```



```
RESULT 588
US-10-800-077-127/c
; Sequence 127, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 127
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-127

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2238 TGGTGCAGGTGAGTTTGGCG 2257
Db 20 TGGTGCAGGTGAGTTTGGCG 1

RESULT 589
US-10-800-077-128/c
; Sequence 128, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 128
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-128

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2218 GTCAAGATTGAAGAGGTGAT 2237
Db 20 GTCAAGATTGAAGAGGTGAT 1

RESULT 590
US-10-800-077-129/c
; Sequence 129, Application US/10800077
```

```
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 129
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-129

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2198 AAGAGATCGATGTCCTTAC 2217
Db 20 AAGAGATCGATGTCCTTAC 1

RESULT 591
US-10-800-077-130/c
; Sequence 130, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 130
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-130

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2178 GGCTGTGAGGGAATTTGCAA 2197
Db 20 GGCTGTGAGGGAATTTGCAA 1

RESULT 592
US-10-800-077-131/c
; Sequence 131, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
```

```
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 131
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-131

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2158 ACTTATGAGACCCCTAATGA 2177
Db 20 ACTTATGAGACCCCTAATGA 1

RESULT 593
US-10-800-077-132/c
; Sequence 132, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 132
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-132

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2138 AGGTCTACATCGACCCCTTC 2157
Db 20 AGGTCTACATCGACCCCTTC 1

RESULT 594
US-10-800-077-133/c
; Sequence 133, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
```

```
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 133
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-133

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2118 TCTCATCGACATGCTACTA 2137
Db 20 TCTCATCGACATGCTACTA 1

RESULT 595
US-10-800-077-134/c
; Sequence 134, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 134
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-134

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2098 TCGGACAAACACGGACAGTA 2117
Db 20 TCGGACAAACACGGACAGTA 1

RESULT 596
US-10-800-077-135/c
; Sequence 135, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
```

; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 135
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-135

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2078 ATGGGAGAGAGCAGAGATAT 2097
|||||
DB 20 ATGGGAGAGAGCAGAGATAT 1

RESULT 597
US-10-800-077-136/c
; Sequence 136, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 136
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-136

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2058 CTGCCTCAGGAGCAGACGA 2077
|||||
DB 20 CTGCCTCAGGAGCAGACGA 1

RESULT 598
US-10-800-077-137/c
; Sequence 137, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0

; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 137
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-137

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2038 GTCATTGTGTCGCACTTCT 2057
|||||
DB 20 GTCATTGTGTCGCACTTCT 1

RESULT 599
US-10-800-077-138/c
; Sequence 138, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 138
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-138

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2018 GTGTGTCCTGTCCTGGTG 2037
|||||
DB 20 GTGTGTCCTGTCCTGGTG 1

RESULT 600
US-10-800-077-139/c
; Sequence 139, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0

```
; SEQ ID NO 139
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-139

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1998 TCGGGCAGCGCAGTCGTGG 2017
      |||||
Db 20 TCGGGCAGCGCAGTCGTGG 1

RESULT 601
US-10-800-077-140/c
; Sequence 140, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 140
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-140

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1978 CGGGAGCAGCTGGCCCTGTAT 1997
      |||||
Db 20 CGGGAGCAGCTGGCCCTGTAT 1

RESULT 602
US-10-800-077-141/c
; Sequence 141, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 141
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-141

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 TCGATGAGAGCGAGGCTGG 1977
      |||||
Db 20 TCGATGAGAGCGAGGCTGG 1

RESULT 603
US-10-800-077-142/c
; Sequence 142, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 142
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-142

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 ACATCAGCCAGCCCAAC 1957
      |||||
Db 20 ACATCAGCCAGCCCAAC 1

RESULT 604
US-10-800-077-143/c
; Sequence 143, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 143
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-143
```

US-10-800-077-143

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1918 TACGGGCCCTTCGGCCAGGA 1937
| | | | | | | | | | | | | | | | | | | | | |
Db 20 TACGGGCCCTTCGGCCAGGA 1

RESULT 605

US-10-800-077-144/c
; Sequence 144, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 144
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-144

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1898 GGGCGCGCTCTGAGCGCGC 1917
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GGGCGCGCTCTGAGCGCGC 1

RESULT 606

US-10-800-077-145/c
; Sequence 145, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 145
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-145

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1878 CAGTACCTCGTCAGGTAC 1897
| | | | | | | | | | | | | | | | | | | | | |
Db 20 CAGTACCTCGTCAGGTAC 1

RESULT 607

US-10-800-077-146/c
; Sequence 146, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 146
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-146

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1858 CGGGGGCTGAAGCGGGGAGC 1877
| | | | | | | | | | | | | | | | | | | | | |
Db 20 CGGGGGCTGAAGCGGGGAGC 1

RESULT 608

US-10-800-077-147/c
; Sequence 147, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 147
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-147

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1838 CAGAAAACCGGCAGAGCTG 1857
|||||
Db 20 CAGAAAACCGGCAGAGCTG 1

RESULT 609
US-10-800-077-148/c
; Sequence 148, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 148
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-148

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1818 CGTGGGTTCTCGAGACGT 1837
|||||
Db 20 CGTGGGTTCTCGAGACGT 1

RESULT 610
US-10-800-077-149/c
; Sequence 149, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 149
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-149

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1798 GGC GCCGAGGTC CCGAGCAG 1817
|||||
Db 20 GGC GCCGAGGTC CCGAGCAG 1

RESULT 611
US-10-800-077-150/c
; Sequence 150, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 150
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-150

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1778 AGGTCAATACCATGAGAAG 1797
|||||
Db 20 AGGTCAATACCATGAGAAG 1

RESULT 612
US-10-800-077-151/c
; Sequence 151, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 151
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-151

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1758 TGGGGCTGTGCTGGACTACG 1777
|||||
Db 20 TGGGGCTGTGCTGGACTACG 1

RESULT 613

US-10-800-077-152/c
; Sequence 152, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 152
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-152

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1738 GCTGTTCCCGGCGACCCAG 1757
|||
Db 20 GCTGTTCCCGGCGACCCAG 1

RESULT 614
US-10-800-077-153/c
; Sequence 153, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 153
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-153

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1718 GCAGCTTGAGCGCTGCGCTGG 1737
|||
Db 20 GCAGCTTGAGCGCTGCGCTGG 1

RESULT 615
US-10-800-077-154/c
; Sequence 154, Application US/10800077
; Publication No. US20050164965A1

; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 154
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-154

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1698 GGTGACGCGTCTCTCACCCA 1717
|||
Db 20 GGTGACGCGTCTCTCACCCA 1

RESULT 616
US-10-800-077-155/c
; Sequence 155, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 155
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-155

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1678 CCTGCAGTGTCTGACATCCG 1697
|||
Db 20 CCTGCAGTGTCTGACATCCG 1

RESULT 617
US-10-800-077-156/c
; Sequence 156, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash

; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 160
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-160

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1578 CTATACCTTTGAGGTCACTG 1597
Db 20 CTATACCTTTGAGGTCACTG 1

RESULT 622

US-10-800-077-161/c
; Sequence 161, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 161
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-161

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1558 GGGCTACGTCCTGACTTCAC 1577
Db 20 GGGCTACGTCCTGACTTCAC 1

RESULT 623

US-10-800-077-162/c
; Sequence 162, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12

; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 162
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-162

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1538 AGCCCTGGGTGGTTCGA 1557
Db 20 AGCCCTGGGTGGTTCGA 1

RESULT 624

US-10-800-077-163/c
; Sequence 163, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 163
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-163

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1518 CGGCCCCCGGACCTGGTGG 1537
Db 20 CGGCCCCCGGACCTGGTGG 1

RESULT 625

US-10-800-077-164/c
; Sequence 164, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 164

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-164

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1498 GGAGACCTGACTTTTGACCC 1517
Db 20 GGAGACCTGACTTTTGACCC 1

RESULT 626
US-10-800-077-165/c
; Sequence 165, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 165
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-165

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1478 GCTCCTGTGCGCCCTCGCGG 1497
Db 20 GCTCCTGTGCGCCCTCGCGG 1

RESULT 627
US-10-800-077-166/c
; Sequence 166, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 166
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-166

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1478 CTCACCTAGCCCTCCGCTG 1457
Db 20 CTCACCTAGCCCTCCGCTG 1

RESULT 629
US-10-800-077-168/c
; Sequence 168, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 168
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-168
```

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1418 AGTCTGGTGGCCGAGAGAC 1437
| | | | | | | | | | | | | | | | | |
Db 20 AGTCTGGTGGCCGAGAGAC 1

RESULT 630
US-10-800-077-169/c
; Sequence 169, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 169
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-169

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1398 GGAATGGAGTGGCCCTGG 1417
| | | | | | | | | | | | | | | | | |
Db 20 GGAATGGAGTGGCCCTGG 1

RESULT 631
US-10-800-077-170/c
; Sequence 170, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 170
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-170

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1378 AACGGCTCTCTCCCTGCACCT 1397
| | | | | | | | | | | | | | | | | |
Db 20 AACGGCTCTCTCCCTGCACCT 1

RESULT 632
US-10-800-077-171/c
; Sequence 171, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 171
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-171

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1358 GGAGCGTGGTTTCCCGCCTG 1377
| | | | | | | | | | | | | | | | | |
Db 20 GGAGCGTGGTTTCCCGCCTG 1

RESULT 633
US-10-800-077-172/c
; Sequence 172, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 172
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-172

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1338 CACCCCTCTTCGGCTCCG 1357

```
Db      20  CACCCCTCCTTCGGCTCCGC 1
|||||
RESULT 634
US-10-800-077-173/c
; Sequence 173, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 173
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-173
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1318  CCCCGGGGTGCACCCCTGCAC 1337
|||||
Db      20  CCCCGGGGTGCACCCCTGCAC 1

RESULT 635
US-10-800-077-174/c
; Sequence 174, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 174
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-174
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1298  ACTTCGGGCACGCACAGAC 1317
|||||
Db      20  ACTTCGGGCACGCACAGAC 1

RESULT 636
US-10-800-077-175/c
; Sequence 175, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 175
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-175
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1278  CTGCCAGTCCCGCTCGGGT 1297
|||||
Db      20  CTGCCAGTCCCGCTCGGGT 1

RESULT 637
US-10-800-077-176/c
; Sequence 176, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 176
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-176
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1258  AACACATTGGATCAGCCGT 1277
|||||
Db      20  AACACATTGGATCAGCCGT 1

RESULT 638
US-10-800-077-177/c
```

; Sequence 177, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 177
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; US-10-800-077-177

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1238 GCCAGGCCAATAGCCACTCT 1257
DB 20 GCCAGGCCAATAGCCACTCT 1

RESULT 639

US-10-800-077-178/c
; Sequence 178, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 178
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; US-10-800-077-178

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1218 AGAAGGGTCCTGCCAGCCAT 1237
DB 20 AGAAGGGTCCTGCCAGCCAT 1

RESULT 640

US-10-800-077-179/c
; Sequence 179, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:

; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 179
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; US-10-800-077-179

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1198 ACCTTCAAGCCCTGTCTCAGG 1217
DB 20 ACCTTCAAGCCCTGTCTCAGG 1

RESULT 641

US-10-800-077-180/c
; Sequence 180, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 180
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; US-10-800-077-180

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1178 GCCGAGCCTGTGCCAGGGC 1197
DB 20 GCCGAGCCTGTGCCAGGGC 1

RESULT 642

US-10-800-077-181/c
; Sequence 181, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING

```
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; SOFTWARE: FastSeq for Windows Version 4.0
; NUMBER OF SEQ ID NOS: 396
; SEQ ID NO 181
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-181

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1158 AGCTGAGGGGAACACCAAGT 1177
      |||||
Db 20 AGCTGAGGGGAACACCAAGT 1

RESULT 643
US-10-800-077-182/c
; Sequence 182, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; SOFTWARE: FastSeq for Windows Version 4.0
; NUMBER OF SEQ ID NOS: 396
; SEQ ID NO 182
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-182

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1138 TGTGCTCCGGGTTGAGGC 1157
      |||||
Db 20 TGTGCTCCGGGTTGAGGC 1

RESULT 644
US-10-800-077-183/c
; Sequence 183, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
```

```
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 183
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-183

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1118 AGCCGGTCACGGGCTGCAGC 1137
      |||||
Db 20 AGCCGGTCACGGGCTGCAGC 1

RESULT 645
US-10-800-077-184/c
; Sequence 184, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 184
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-184

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1098 GGATGCCAGTGGGCCGAAC 1117
      |||||
Db 20 GGATGCCAGTGGGCCGAAC 1

RESULT 646
US-10-800-077-185/c
; Sequence 185, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
```

; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 185
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-185

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1078 CCCAGCCTCTACTCCCGTGA 1097
DB 20 CCCAGCCTCTACTCCCGTGA 1

RESULT 647

US-10-800-077-186/c
; Sequence 186, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 186
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-186

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1058 TCCCCGCCCTGGCCCCCAGC 1077
DB 20 TCCCCGCCCTGGCCCCCAGC 1

RESULT 648

US-10-800-077-187/c
; Sequence 187, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396

; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 187
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-187

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TAGCTCGGTGGTGGATGCCG 1057
DB 20 TAGCTCGGTGGTGGATGCCG 1

RESULT 649

US-10-800-077-188/c
; Sequence 188, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 188
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-188

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1018 CTGGTTGTGCCCGTGCCCG 1037
DB 20 CTGGTTGTGCCCGTGCCCG 1

RESULT 650

US-10-800-077-189/c
; Sequence 189, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 189
; LENGTH: 20

```
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-189
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 998 CCGAGACTGTGCTCGGAG 1017
      |||||
Db 20 CCGAGACTGTGCTCGGAG 1

RESULT 651
US-10-800-077-190/c
; Sequence 190, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 190
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-190
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 978 TGTGAACCTGACTCGATTCC 997
      |||||
Db 20 TGTGAACCTGACTCGATTCC 1

RESULT 652
US-10-800-077-191/c
; Sequence 191, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 191
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-191
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 938 TATCCCTGCACCTCTTCTAC 957
      |||||
Db 20 TATCCCTGCACCTCTTCTAC 1

RESULT 654
US-10-800-077-193/c
; Sequence 193, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 193
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-193
```


Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 918 GGGTGCCTGCATGGCCCTGC 937
Db 20 GGGTGCCTGCATGGCCCTGC 1

RESULT 655

US-10-800-077-194/c
; Sequence 194, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 194
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-194

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 998 TACCTGGCCTTCCAGGACCA 917
Db 20 TACCTGGCCTTCCAGGACCA 1

RESULT 656

US-10-800-077-195/c
; Sequence 195, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 195
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-195

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 878 CGCTCAGCAAGGCTGGCTTC 897
Db 20 CGCTCAGCAAGGCTGGCTTC 1

RESULT 657

US-10-800-077-196/c
; Sequence 196, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 196
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-196

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 858 CAAGACGCTCGTCTGGGAC 877
Db 20 CAAGACGCTCGTCTGGGAC 1

RESULT 658

US-10-800-077-197/c
; Sequence 197, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 197
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-197

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 838 GCCACCGGGAAGGTGAATGT 857
Db 20 GCCACCGGGAAGGTGAATGT 1

```
Db      20 GCCACCGGGAAGTGAATGT 1

RESULT 659
US-10-800-077-198/c
; Sequence 198, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 198
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
;
US-10-800-077-198

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      818 GGAAGCGCCCTGGGCGCGAG 837
      |||||
Db      20 GGAAGCGCCCTGGGCGCGAG 1

RESULT 660
US-10-800-077-199/c
; Sequence 199, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 199
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
;
US-10-800-077-199

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      798 GGCGCGGAGCATCTCACC 817
      |||||
Db      20 GGCGCGGAGCATCTCACC 1

RESULT 661
US-10-800-077-200/c
; Sequence 200, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 200
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
;
US-10-800-077-200

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      778 TACATCAAGGTGGACACGGT 797
      |||||
Db      20 TACATCAAGGTGGACACGGT 1

RESULT 662
US-10-800-077-201/c
; Sequence 201, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 201
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
;
US-10-800-077-201

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      758 CAGCCTGGATGGAGAACCCC 777
      |||||
Db      20 CAGCCTGGATGGAGAACCCC 1

RESULT 663
US-10-800-077-202/c
; Sequence 202, Application US/10800077
```

```
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 202
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-202

Query Match      0.5%  Score 20;  DB 1;  Length 20;
Best Local Similarity 100.0%;  Pred. No. 2.3e+02;
Matches 20;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;

QY 738 CACGGCCACGGCCCTCAGC 757
Db 20 CACGGCCACGGCCCTCAGC 1

RESULT 664
US-10-800-077-203/c
; Sequence 203, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 203
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-203

Query Match      0.5%  Score 20;  DB 1;  Length 20;
Best Local Similarity 100.0%;  Pred. No. 2.3e+02;
Matches 20;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;

QY 718 TACTATGAGCGATGCGGA 737
Db 20 TACTATGAGCGATGCGGA 1

RESULT 665
US-10-800-077-204/c
; Sequence 204, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 204
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-204

Query Match      0.5%  Score 20;  DB 1;  Length 20;
Best Local Similarity 100.0%;  Pred. No. 2.3e+02;
Matches 20;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;

QY 678 TCGGGCTGGGGCGCTCCTGCA 697
Db 20 TCGGGCTGGGGCGCTCCTGCA 1

RESULT 667
US-10-800-077-206/c
; Sequence 206, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 205
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-205

Query Match      0.5%  Score 20;  DB 1;  Length 20;
Best Local Similarity 100.0%;  Pred. No. 2.3e+02;
Matches 20;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;

QY 698 AGGAGACCTTCACCGTCTTC 717
Db 20 AGGAGACCTTCACCGTCTTC 1

RESULT 666
US-10-800-077-205/c
; Sequence 205, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 205
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-205

Query Match      0.5%  Score 20;  DB 1;  Length 20;
Best Local Similarity 100.0%;  Pred. No. 2.3e+02;
Matches 20;  Conservative 0;  Mismatches 0;  Indels 0;  Gaps 0;

QY 698 AGGAGACCTTCACCGTCTTC 717
Db 20 AGGAGACCTTCACCGTCTTC 1
```

; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 206
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-206

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 658 CTCGAGTGCCTGCTCCCTGCC 677
|||
Db 20 CTCGAGTGCCTGCTCCCTGCC 1

RESULT 668
US-10-800-077-207/c
; Sequence 207, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 207
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-207

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 638 CCACGCTGCGCTTCACCATG 657
|||
Db 20 CCACGCTGCGCTTCACCATG 1

RESULT 669
US-10-800-077-208/c
; Sequence 208, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12

; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 208
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-208

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 618 GGGCGCGCTCCACGTGTACG 637
|||
Db 20 GGGCGCGCTCCACGTGTACG 1

RESULT 670
US-10-800-077-209/c
; Sequence 209, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 209
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-209

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 598 ACAGGTTGGTCCCGCGCG 617
|||
Db 20 ACAGGTTGGTCCCGCGCG 1

RESULT 671
US-10-800-077-210/c
; Sequence 210, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300

; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 210
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-210

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 578 GCCAGGCCCACTGGCTTCGC 597
Db 20 GCCAGGCCCACTGGCTTCGC 1

RESULT 672

US-10-800-077-211/c
; Sequence 211, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 211
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-211

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 558 TGACGTGACGCGTCCCGG 577
Db 20 TGACGTGACGCGTCCCGG 1

RESULT 673

US-10-800-077-212/c
; Sequence 212, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 212
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-212

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 538 GTGGGCACCTACCAAGTGTG 557
Db 20 GTGGGCACCTACCAAGTGTG 1

RESULT 674

US-10-800-077-213/c
; Sequence 213, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 213
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-213

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 518 TGGATGAGGAACACGACGAGC 537
Db 20 TGGATGAGGAACACGACGAGC 1

RESULT 675

US-10-800-077-214/c
; Sequence 214, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 214
; LENGTH: 20
; TYPE: DNA

```
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-214

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 498 GTGGAGGAACTGAGCGGCC 517
Db 20 GTGGAGGAACTGAGCGGCC 1

RESULT 676
US-10-800-077-215/c
; Sequence 215, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 215
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-215

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 478 TTCCCTCAGGTGACGGCA 497
Db 20 TTCCCTCAGGTGACGGCA 1

RESULT 677
US-10-800-077-216/c
; Sequence 216, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 216
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-216

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 478 TTCCCTCAGGTGACGGCA 497
Db 20 TTCCCTCAGGTGACGGCA 1

RESULT 679
US-10-800-077-218/c
; Sequence 218, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 218
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-218

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 438 GAACACAAAATTGGAACTG 457
Db 20 GAACACAAAATTGGAACTG 1

RESULT 678
US-10-800-077-217/c
; Sequence 217, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 217
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-217

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 438 GAACACAAAATTGGAACTG 457
Db 20 GAACACAAAATTGGAACTG 1

RESULT 679
US-10-800-077-218/c
; Sequence 218, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 218
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-218

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 438 GAACACAAAATTGGAACTG 457
Db 20 GAACACAAAATTGGAACTG 1
```

Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 418 GCTTTGGAAGAGACCTGCT 437
Db 20 GCTTTGGAAGAGACCTGCT 1

RESULT 680

US-10-800-077-219/c
; Sequence 219, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 219
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-219

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 398 GCTGGGCTTCGTTGCCGCA 417
Db 20 GCTGGGCTTCGTTGCCGCA 1

RESULT 681

US-10-800-077-220/c
; Sequence 220, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 220
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-220

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 378 GGAGCTCCGGGTGCTGCTCT 397
Db 20 GGAGCTCCGGGTGCTGCTCT 1

RESULT 682

US-10-800-077-221/c
; Sequence 221, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 221
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-221

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 376 ATCGAGCTCCGGGTGCTGCT 395
Db 20 ATCGAGCTCCGGGTGCTGCT 1

RESULT 683

US-10-800-077-231/c
; Sequence 231, Application US/108000077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 231
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-231

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2356 TTCTGAGCGAGCCTCCAT 2375
Db 20 TTCTGAGCGAGCCTCCAT 1

```
RESULT 684
US-10-800-350-38
; Sequence 38, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 38
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-38

Query Match          0.5%; Score 20; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1939 CATCAGCGCAGACCCCAACT 1958
DB 1 CAUCACAGCCAGACCCCAACU 20

RESULT 685
US-10-800-350-288
; Sequence 288, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 288
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-288

Query Match          0.5%; Score 20; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1939 CATCAGCGCAGACCCCAACT 1958
DB 1 CAUCACAGCCAGACCCCAACU 20

RESULT 686
US-10-800-077-38
; Sequence 38, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 38
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-38

Query Match          0.5%; Score 20; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1939 CATCAGCGCAGACCCCAACT 1958
DB 1 CAUCACAGCCAGACCCCAACU 20

RESULT 687
US-10-800-077-288
; Sequence 288, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 288
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-288

Query Match          0.5%; Score 20; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1939 CATCAGCGCAGACCCCAACT 1958
DB 1 CAUCACAGCCAGACCCCAACU 20
```



```

RESULT 688
US-10-758-155-2633
; Sequence 2633, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2633
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2633

Query Match 0.5%; Score 19.8; DB 1; Length 23;
Best Local Similarity 69.6%; Pred. No. 3.1e+02;
Matches 16; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2926 CAGCTCATGCTGGACTGTGGCA 2948
Db 1 CAGAUCAGCUGGACUGCGGCA 23

RESULT 689
US-10-831-620-2633
; Sequence 2633, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957

```

```

; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2633
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2633

Query Match 0.5%; Score 19.8; DB 1; Length 23;
Best Local Similarity 69.6%; Pred. No. 3.1e+02;
Matches 16; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2926 CAGCTCATGCTGGACTGTGGCA 2948
Db 1 CAGAUCAGCUGGACUGCGGCA 23

RESULT 690
US-10-844-076-2633
; Sequence 2633, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668

```

; PRIOR FILING DATE: 2003-09-18
; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 2633

; LENGTH: 23

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-844-076-2633

Query Match 0.5%; Score 19.8; DB 1; Length 23;

Best Local Similarity 69.8%; Pred.No. 3.1e+02;

Matches 16; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2926 CAGCTCATGCTGGACTGTTGGCA 2948

||||:||||:||||:||||:

Db 1 CAGAUCAUGCUGGACUGGCA 23

RESULT 691

US-10-962-898-2237

; Sequence 2237, Application US/10962898

; Publication No. US20050222066A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: Richards, Ivan

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial

; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor

; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)

; FILE REFERENCE: 400/236 (MBH02-742-U)

; CURRENT APPLICATION NUMBER: US/10/962,898

; CURRENT FILING DATE: 2004-10-12

; PRIOR APPLICATION NUMBER: US 10/944,644

; PRIOR FILING DATE: 2004-09-16

; PRIOR APPLICATION NUMBER: US 10/844,076

; PRIOR FILING DATE: 2004-05-11

; PRIOR APPLICATION NUMBER: US 10/831,620

; PRIOR FILING DATE: 2004-04-23

; PRIOR APPLICATION NUMBER: US 10/764,957

; PRIOR FILING DATE: 2004-01-26

; PRIOR APPLICATION NUMBER: US 10/670,011

; PRIOR FILING DATE: 2003-09-23

; PRIOR APPLICATION NUMBER: US 10/665,255

; PRIOR FILING DATE: 2003-09-16

; PRIOR APPLICATION NUMBER: US 10/664,767

; PRIOR FILING DATE: 2003-09-16

; PRIOR APPLICATION NUMBER: PCT/US03/05022

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/393,796

; PRIOR FILING DATE: 2002-07-03

; PRIOR APPLICATION NUMBER: US 60/399,348

; PRIOR FILING DATE: 2002-07-29

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 4252

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 2237

; LENGTH: 23

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
US-10-962-898-2237

Query Match 0.5%; Score 19.8; DB 1; Length 23;

Best Local Similarity 69.8%; Pred.No. 3.1e+02;

Matches 16; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2926 CAGCTCATGCTGGACTGTTGGCA 2948

||||:||||:||||:||||:

Db 1 CAGAUCAUGCUGGACUGGCA 23

```

; Sequence 16, Application US/10033780
; Publication No. US20050032070A1
;
; GENERAL INFORMATION:
;
; APPLICANT: EPIDAUROS Biotechnologie AG
;
; TITLE OF INVENTION: Polymorphisms in the human gene for CYP2D6 and their use in
;
; TITLE OF INVENTION: diagnostic and therapeutic applications
;
; FILE REFERENCE: VOS-43
;
; CURRENT APPLICATION NUMBER: US/10/635,780
;
; CURRENT FILING DATE: 2003-08-05
;
; NUMBER OF SEQ ID NOS: 23
;
; SOFTWARE: PatentIn version 3.1
;
; SEQ ID NO 16

```



```
US-10-800-350-22
Query Match          0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 3.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 849 GGTGAATGTCAAGACGCTG 867
||:||||:||||:|
Db 1 GGUGAUGUCAAGACGUG 19

RESULT 702
US-10-800-350-23
; Sequence 23, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-23

Query Match          0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 3.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2679 CTCCTCCGATCCACCTAC 2697
|:||||:||||:|
Db 1 CUCUCCGAUCCACCUAC 19

RESULT 703
US-10-800-350-34
; Sequence 34, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 34
; LENGTH: 21
; TYPE: RNA
```

```
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-34

Query Match          0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 427 GAGACCTCTGTAACAA 445
|||||:||||:|
Db 1 GAGACCCUGCUGAACAA 19

RESULT 704
US-10-800-350-36
; Sequence 36, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 36
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-36

Query Match          0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 3.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 849 GGTGAATGTCAAGACGCTG 867
||:||||:||||:|
Db 1 GGUGAUGUCAAGACGUG 19

RESULT 705
US-10-800-350-40
; Sequence 40, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSEQ for Windows Version 4.0
```

```

; SEQ ID NO 40
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-40

Query Match          0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 3.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2679 CTCCTCCGATCCACCTAC 2697
Db 1 CUCUCCCGAUCGCCACCCOAC 19

RESULT 706
US-10-800-350-69
; Sequence 69, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 69
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-69

Query Match          0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 427 GAGACCCCTGCTGAACACAA 445
Db 1 GAGACCCUGCUGAACACAA 19

RESULT 707
US-10-800-350-286
; Sequence 286, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300

```

```

; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 286
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-286

Query Match          0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 427 GAGACCCCTGCTGAACACAA 445
Db 1 GAGACCCUGCUGAACACAA 19

RESULT 708
US-10-800-350-287
; Sequence 287, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 287
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-287

Query Match          0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 3.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 849 GGTGAATGTCAAGACGCTG 867
Db 1 GGUGAUGUCAGACGCGUG 19

RESULT 709
US-10-800-350-289
; Sequence 289, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12

```

; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 289
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-289

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 3.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2679 CTCTTCGATCCACCTAC 2697
|:|||||:|||||:
Db 1 CUCUCCGAUCCACCUAC 19

RESULT 710
US-10-800-350-290
; Sequence 290, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 290
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-290

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 3.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2679 CTCTTCGATCCACCTAC 2697
|:|||||:|||||:
Db 1 CUCUCCGAUCCACCUAC 19

RESULT 711
US-10-800-077-22
; Sequence 22, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12

; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-22

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 78.3%; Pred. No. 3.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 849 GGTGAATGTCAGACGCTG 867
|:|||||:|||||:
Db 1 GGUGAUGUCACGACGUG 19

RESULT 712
US-10-800-077-23
; Sequence 23, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-23

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 3.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2679 CTCTTCGATCCACCTAC 2697
|:|||||:|||||:
Db 1 CUCUCCGAUCCACCUAC 19

RESULT 713
US-10-800-077-34
; Sequence 34, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300

```
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 34
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-34

Query Match          0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 427 GAGACCTGCTGAACACAA 445
      |||||:|:|:|:|:|:|
Db 1 GAGACCCUGUGAACACAA 19

RESULT 714
US-10-800-077-36
; Sequence 36, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 36
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-36

Query Match          0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 3.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 849 GGTGAATGTCAGACGCTG 867
      ||:|:|:|:|:|:|:|
Db 1 GGUGAAUGUCAAGACGCGUG 19

RESULT 715
US-10-800-077-40
; Sequence 40, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 40
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-40

Query Match          0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 3.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2679 CTTTCCGATCCACCTAC 2697
      |:|:|:|:|:|:|:|
Db 1 CUCUCCGUAUCCACCUCAC 19

RESULT 716
US-10-800-077-69
; Sequence 69, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 69
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-69

Query Match          0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 427 GAGACCTGCTGAACACAA 445
      |||||:|:|:|:|:|:|
Db 1 GAGACCCUGUGAACACAA 19

RESULT 717
US-10-800-077-286
; Sequence 286, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 286
; LENGTH: 21
; TYPE: RNA
```


ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: Oligonucleotide
US-10-800-077-286

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 427 GAGACCTGCTGACACAA 445
Db 1 GAGACCCGCGGACACAA 19

RESULT 718
US-10-800-077-287
Sequence 287, Application US/10800077
Publication No. US20050164965A1
GENERAL INFORMATION:
APPLICANT: Reddy, Ramachandra
APPLICANT: Gill, Parkash
TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
FILE REFERENCE: VASG-P01-001
CURRENT APPLICATION NUMBER: US/10/800,077
PRIOR FILING DATE: 2004-03-12
PRIOR APPLICATION NUMBER: US 60/454,432
PRIOR FILING DATE: 2003-03-12
PRIOR APPLICATION NUMBER: US 60/454,300
PRIOR FILING DATE: 2003-03-12
NUMBER OF SEQ ID NOS: 396
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 287
LENGTH: 21
TYPE: RNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: Oligonucleotide
US-10-800-077-287

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 3.1e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 849 GGTGAATGCTCAAGACGCTG 867
Db 1 GGUGAUGUCAAAGACGCG 19

RESULT 719
US-10-800-077-289
Sequence 289, Application US/10800077
Publication No. US20050164965A1
GENERAL INFORMATION:
APPLICANT: Reddy, Ramachandra
APPLICANT: Gill, Parkash
TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
FILE REFERENCE: VASG-P01-001
CURRENT APPLICATION NUMBER: US/10/800,077
PRIOR FILING DATE: 2004-03-12
PRIOR APPLICATION NUMBER: US 60/454,432
PRIOR FILING DATE: 2003-03-12
PRIOR APPLICATION NUMBER: US 60/454,300
PRIOR FILING DATE: 2003-03-12
NUMBER OF SEQ ID NOS: 396
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 289
LENGTH: 21
TYPE: RNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: Oligonucleotide

US-10-800-077-289
Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 3.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 2679 CTCTTCGATCCACCTAC 2697
Db 1 CUCUCCGAUCCCAUAC 19

RESULT 720
US-10-800-077-290
Sequence 290, Application US/10800077
Publication No. US20050164965A1
GENERAL INFORMATION:
APPLICANT: Reddy, Ramachandra
APPLICANT: Gill, Parkash
TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
FILE REFERENCE: VASG-P01-001
CURRENT APPLICATION NUMBER: US/10/800,077
PRIOR FILING DATE: 2004-03-12
PRIOR APPLICATION NUMBER: US 60/454,432
PRIOR FILING DATE: 2003-03-12
PRIOR APPLICATION NUMBER: US 60/454,300
PRIOR FILING DATE: 2003-03-12
NUMBER OF SEQ ID NOS: 396
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 290
LENGTH: 21
TYPE: RNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: Oligonucleotide
US-10-800-077-290

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 3.1e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 2679 CTCTTCGATCCACCTAC 2697
Db 1 CUCUCCGAUCCCAUAC 19

RESULT 721
US-10-411-954-268
Sequence 268, Application US/10411954
Publication No. US20030235848A1
GENERAL INFORMATION:
APPLICANT: Neville, Matt
APPLICANT: de Arruda Indig, Monika
TITLE OF INVENTION: Characterization of CYP2D6 Alleles
FILE REFERENCE: FORS-07897
CURRENT APPLICATION NUMBER: US/10/411,954
CURRENT FILING DATE: 2003-04-11
PRIOR APPLICATION NUMBER: 60/371,819
PRIOR FILING DATE: 2002-04-11
NUMBER OF SEQ ID NOS: 356
SOFTWARE: PatentIn version 3.2
SEQ ID NO 268
LENGTH: 22
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
US-10-411-954-268

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3716 GGGGCAAGAGGGGTGTCAGGG 3737
| | | | | | | | | | | | | | | | | |
Db 1 GAGGCAAGAAGGAGTGTTCAGGG 22

RESULT 722
US-10-411-954-339
; Sequence 339, Application US/10411954
; Publication No. US20030235848A1
; GENERAL INFORMATION:
; APPLICANT: Neville, Matt
; APPLICANT: de Arruda Indig, Monika
; TITLE OF INVENTION: Characterization of CYP2D6 Alleles
; FILE REFERENCE: FORS-07897
; CURRENT APPLICATION NUMBER: US/10/411,954
; CURRENT FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/371,819
; PRIOR FILING DATE: 2002-04-11
; NUMBER OF SEQ ID NOS: 356
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 339
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-411-954-339

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3716 GGGGCAAGAGGGGTGTCAGGG 3737
| | | | | | | | | | | | | | | | | |
Db 1 GAGGCAAGAAGGAGTGTTCAGGG 22

RESULT 723
US-10-321-039-737
; Sequence 737, Application US/10321039
; Publication No. US20040014067A1
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Lukowiak, Andrew
; APPLICANT: Jarvis, Nancy
; APPLICANT: Kurensky, David
; TITLE OF INVENTION: Amplification Methods and Compositions
; FILE REFERENCE: FORS-06960
; CURRENT APPLICATION NUMBER: US/10/321,039
; CURRENT FILING DATE: 2002-12-17
; PRIOR APPLICATION NUMBER: 09/998,157
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: 60/329,113
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/360,489
; PRIOR FILING DATE: 2001-10-19
; NUMBER OF SEQ ID NOS: 759
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 737
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-321-039-737

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3716 GGGGCAAGAGGGGTGTCAGGG 3737
| | | | | | | | | | | | | | | | | |
Db 1 GAGGCAAGAAGGAGTGTTCAGGG 22

RESULT 724
US-10-617-070-268
; Sequence 268, Application US/10617070
; Publication No. US20040096874A1
; GENERAL INFORMATION:
; APPLICANT: Neville, Matt
; APPLICANT: de Arruda Indig, Monika
; APPLICANT: Cao, Feng
; APPLICANT: Oldenburg, Mary C.
; APPLICANT: Koelbl, Jim C.
; APPLICANT: Aizenstein, Brian D.
; APPLICANT: Davey, Keith
; TITLE OF INVENTION: Characterization of CYP2D6 Genotypes
; FILE REFERENCE: FORS-08195
; CURRENT APPLICATION NUMBER: US/10/617,070
; CURRENT FILING DATE: 2003-07-10
; PRIOR APPLICATION NUMBER: 10/411,954
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/371,819
; PRIOR FILING DATE: 2002-04-11
; NUMBER OF SEQ ID NOS: 529
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 268
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-070-268

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3716 GGGGCAAGAGGGGTGTCAGGG 3737
| | | | | | | | | | | | | | | | | |
Db 1 GAGGCAAGAAGGAGTGTTCAGGG 22

RESULT 725
US-10-617-070-339
; Sequence 339, Application US/10617070
; Publication No. US20040096874A1
; GENERAL INFORMATION:
; APPLICANT: Neville, Matt
; APPLICANT: de Arruda Indig, Monika
; APPLICANT: Cao, Feng
; APPLICANT: Oldenburg, Mary C.
; APPLICANT: Koelbl, Jim C.
; APPLICANT: Aizenstein, Brian D.
; APPLICANT: Davey, Keith
; TITLE OF INVENTION: Characterization of CYP2D6 Genotypes
; FILE REFERENCE: FORS-08195
; CURRENT APPLICATION NUMBER: US/10/617,070
; CURRENT FILING DATE: 2003-07-10
; PRIOR APPLICATION NUMBER: 10/411,954
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/371,819
; PRIOR FILING DATE: 2002-04-11
; NUMBER OF SEQ ID NOS: 529
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 339
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-070-339

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 3.6e+02;

```

/ FILE REFERENCE: FOKS-061935
/ CURRENT APPLICATION NUMBER: US/10/956,507
/ CURRENT FILING DATE: 2004-10-01
/ PRIOR APPLICATION NUMBER: US/10/617,070
/ PRIOR FILING DATE: 2003-07-10
/ PRIOR APPLICATION NUMBER: 10/411,954
/ PRIOR FILING DATE: 2003-04-11
/ PRIOR APPLICATION NUMBER: 60/371,819
/ PRIOR FILING DATE: 2002-04-11
/ NUMBER OF SEQ ID NOS: 529
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 339

```

RESULT 729
US-10-758-155-2639

```
; Sequence 2639, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2639
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2639

Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 68.2%; Pred. No. 3.9e+02;
Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2927 AGCTCATGCTGGACTGTGGCA 2948
||| :||:||||:|||||
Db 1 AGAUCAGUCGACUGCUGGCA 22

RESULT 730
US-10-831-620-2627
; Sequence 2627, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
```

```
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2627
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2627

Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 68.2%; Pred. No. 3.9e+02;
Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2926 CAGCTCATGCTGGACTGTGGC 2947
||| :||:||||:|||||
Db 2 CAGAUCAGUCGACUGCUGGC 23

RESULT 731
US-10-831-620-2639
; Sequence 2639, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
```

```
; SEQ ID NO 2639
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2639

Query Match          0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 68.2%; Pred. No. 3.9e+02;
Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2927 AGCTCATGCTGGACTGTTGCCA 2948
      |||:|||||:|||||:|||||
Db 1 AGAUCAGCUGGACUGCUGGCA 22

RESULT 732
US-10-844-076-2627
; Sequence 2627, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2639
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-844-076-2639

Query Match          0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 68.2%; Pred. No. 3.9e+02;
Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2927 AGCTCATGCTGGACTGTTGCCA 2948
      |||:|||||:|||||:|||||
Db 1 AGAUCAGCUGGACUGCUGGCA 22

RESULT 734
US-10-962-898-2232
; Sequence 2232, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
```

```
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2232
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
US-10-962-898-2232

Query Match          0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 68.2%; Pred. No. 3.9e+02;
Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2926 CAGCTCATGCTGGACTGTGGC 2947
      ||| :|||:|||||:|:|
Db 2 CAGCAUCGUGGACUGCUGGC 23

RESULT 735
US-10-962-898-2242
; Sequence 2242, Application US/10962898
; Publication No. US2005022066A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBH02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2242
```

```
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
US-10-962-898-2242

Query Match          0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 68.2%; Pred. No. 3.9e+02;
Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2927 AGCTCATGCTGGACTGTGGCA 2948
      ||| :|||:|||||:|:|
Db 1 AGCAUCGUGGACUGCUGGC 22

RESULT 736
US-10-944-611-2232
; Sequence 2232, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBH02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2232
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
US-10-944-611-2232

Query Match          0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 68.2%; Pred. No. 3.9e+02;
Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2926 CAGCTCATGCTGGACTGTGGC 2947
      ||| :|||:|||||:|:|
Db 2 CAGCAUCGUGGACUGCUGGC 23
```

```

; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 47
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-47

Query Match          0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 499 TGGGAGGAACTGAGCGGC 516
      |||||||
Db 18 TGGGAGGAACTGAGCGGC 1

RESULT 739
US-10-800-350-48/c
; Sequence 48, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 48
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-48

Query Match          0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 692 CCTGCAAGGAGACCTTCA 709
      |||||||
Db 18 CCTGCAAGGAGACCTTCA 1

RESULT 740
US-10-800-350-227/c
; Sequence 227, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002

```

```
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 227
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-227
```

```
Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 499 TGGGAGGAACTGAGCGGC 516
Db 18 TGGGAGGAACTGAGCGGC 1
```

```
RESULT 741
US-10-800-350-228/c
; Sequence 228, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnopetrov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 228
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-228
```

```
Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 692 CCTGCAAGGAGACCTTCA 709
Db 18 CCTGCAAGGAGACCTTCA 1
```

```
RESULT 742
US-10-800-077-47/c
; Sequence 47, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
```

```
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 47
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-47
```

```
Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 499 TGGGAGGAACTGAGCGGC 516
Db 18 TGGGAGGAACTGAGCGGC 1
```

```
RESULT 743
US-10-800-077-48/c
; Sequence 48, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 48
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-48
```

```
Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 692 CCTGCAAGGAGACCTTCA 709
Db 18 CCTGCAAGGAGACCTTCA 1
```

```
RESULT 744
US-10-800-077-227/c
; Sequence 227, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
```


; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 227
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-227

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 499 TGGGAGGAAGTACGGGC 516
|||
Db 18 TGGGAGGAAGTACGGGC 1

RESULT 745

US-10-800-077-228/c
; Sequence 228, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: Gill, Parkash
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 228
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-228

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 692 CCTGCAAGGAGACCTTCA 709
|||
Db 18 CCTGCAAGGAGACCTTCA 1

RESULT 746

US-10-712-363-25
; Sequence 25, Application US/10712363
; Publication No. US20040072235A1
; GENERAL INFORMATION:
; APPLICANT: Dawson, Elliot P.
; TITLE OF INVENTION: CYTOCHROME P450 GENETIC VARIATIONS
; FILE REFERENCE: 13744-2
; CURRENT APPLICATION NUMBER: US/10/712,363
; CURRENT FILING DATE: 2003-11-12
; PRIOR APPLICATION NUMBER: US 60/306,675
; PRIOR FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 10/360,790
; PRIOR FILING DATE: 2002-07-18
; PRIOR APPLICATION NUMBER: PCT/US03/21468
; PRIOR FILING DATE: 2003-07-09

; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic primer
US-10-712-363-25

Query Match 0.4%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3715 GGGGGCAAGAGGGGTGTCTAG 3735
|||
Db 1 GGAGGCAAGAGGGGTGTCTAG 21

RESULT 747

US-10-810-976-5/c
; Sequence 5, Application US/10810976
; Publication No. US20040191873A1
; GENERAL INFORMATION:
; APPLICANT: Young, Won-Bin
; APPLICANT: Link, Charles J.
; TITLE OF INVENTION: METHODS FOR HIGH THROUGHPUT ELUCIDATION OF TRANSCRIPTIONAL
; FILE REFERENCE: P05768US01
; CURRENT APPLICATION NUMBER: US/10/810,976
; CURRENT FILING DATE: 2004-03-26
; PRIOR APPLICATION NUMBER: US 60/458,152
; PRIOR FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Nested primer
US-10-810-976-5

Query Match 0.4%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2410 CTGGAGGGCGTGTCTACCAAC 2430
|||
Db 21 CTGGAGGGCGTGTCTACCAAC 1

RESULT 748

US-10-411-954-236
; Sequence 236, Application US/10411954
; Publication No. US20030235848A1
; GENERAL INFORMATION:
; APPLICANT: Neville, Matt
; APPLICANT: de Arruda Indig, Monika
; TITLE OF INVENTION: Characterization of CYP2D6 Alleles
; FILE REFERENCE: FORS-07897
; CURRENT APPLICATION NUMBER: US/10/411,954
; CURRENT FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/371,819
; PRIOR FILING DATE: 2002-04-11
; NUMBER OF SEQ ID NOS: 356
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 236
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic


```
; Sequence 2735, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siRNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2735
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2735

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 3.6e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 2930 TCATGCTGGACTGTTGGCA 2948
:||||:||||:||||:
Db 1 UCAUGCUGGACUGCUGCA 19

RESULT 753
US-10-844-076-2735
; Sequence 2735, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siRNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
```

```
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2735
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-844-076-2735

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 3.6e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 2930 TCATGCTGGACTGTTGGCA 2948
:||||:||||:||||:
Db 1 UCAUGCUGGACUGCUGCA 19

RESULT 754
US-10-956-507-236
; Sequence 236, Application US/10956507
; Publication No. US20050196771A1
; GENERAL INFORMATION:
; APPLICANT: Neville, Matt
; APPLICANT: de Arruda Indig, Monika
; APPLICANT: Cao, Feng
; APPLICANT: Oldenburg, Mary C.
; APPLICANT: Koelbl, Jim C.
; APPLICANT: Aizenstein, Brian D.
; APPLICANT: Davey, Keith
; TITLE OF INVENTION: Characterization of CYP2D6 Genotypes
; FILE REFERENCE: FORS-08195
; CURRENT APPLICATION NUMBER: US/10/956,507
; CURRENT FILING DATE: 2004-10-01
; PRIOR APPLICATION NUMBER: US/10/617,070
; PRIOR FILING DATE: 2003-07-10
; PRIOR APPLICATION NUMBER: 10/411,954
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/371,819
; PRIOR FILING DATE: 2002-04-11
; NUMBER OF SEQ ID NOS: 529
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 236
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-956-507-236

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3719 GCAAGAGGGGCTGTCCAGGG 3737
||||||| |||||||
```

```
Db      1  GCAAGAAGGAGTGTCTCAGG 19

RESULT 755
US-10-956-507-361
; Sequence 361, Application US/10956507
; Publication No. US20050196771A1
; GENERAL INFORMATION:
; APPLICANT: Neville, Matt
; APPLICANT: de Arruda Indig, Monika
; APPLICANT: Cao, Feng
; APPLICANT: Oldenburg, Mary C.
; APPLICANT: Koelbl, Jim C.
; APPLICANT: Aizenstein, Brian D.
; APPLICANT: Davey, Keith
; TITLE OF INVENTION: Characterization of CYP2D6 Genotypes
; FILE REFERENCE: FORS-08195
; CURRENT APPLICATION NUMBER: US/10/956,507
; CURRENT FILING DATE: 2004-10-01
; PRIOR APPLICATION NUMBER: US/10/617,070
; PRIOR FILING DATE: 2003-07-10
; PRIOR APPLICATION NUMBER: 10/411,954
; PRIOR FILING DATE: 2003-04-11
; PRIOR APPLICATION NUMBER: 60/371,819
; PRIOR FILING DATE: 2002-04-11
; NUMBER OF SEQ ID NOS: 529
; SOFTWARE: Patentcin version 3.2
; SEQ ID NO 361
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-956-507-361

Query Match      0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3719  GCAAGAAGGAGTGTCTCAGG 3737
          |||||
Db      1  GCAAGAAGGAGTGTCTCAGG 19

RESULT 756
US-10-188-359-13
; Sequence 13, Application US/10188359
; Publication No. US20030215819A1
; GENERAL INFORMATION:
; APPLICANT: DNA Print Genomics, Inc.
; APPLICANT: FRUDAKIS, Tony N.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR INFERRING A RESPONSE TO A STATIN
; FILE REFERENCE: DNAL150-3
; CURRENT APPLICATION NUMBER: US/10/188,359
; CURRENT FILING DATE: 2002-07-01
; PRIOR APPLICATION NUMBER: US 60/301,867
; PRIOR FILING DATE: 2001-06-29
; PRIOR APPLICATION NUMBER: US 60/310,783
; PRIOR FILING DATE: 2001-08-07
; PRIOR APPLICATION NUMBER: US 60/322,478
; PRIOR FILING DATE: 2001-09-13
; NUMBER OF SEQ ID NOS: 234
; SOFTWARE: Patentcin version 3.1
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-188-359-13

Query Match      0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 4e+02;

Db      1  GCAAGAAGGAGTGTCTCAGG 19

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3718  GCAAGAAGGAGTGTCTCAGG 3736
          |||||
Db      2  GCAAGAAGGAGTGTCTCAGG 20

RESULT 757
US-10-800-350-60/c
; Sequence 60, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 60
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-60

Query Match      0.4%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1955  AACTGATGAGAGCGAG 1971
          |||||
Db      19  AACTGATGAGAGCGAG 3

RESULT 758
US-10-800-077-60/c
; Sequence 60, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; CURRENT FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 60
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-60

Query Match      0.4%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4e+02;
```


Db 20 GTCTGTCAGGTCCTGGTG 1

RESULT 763

US-10-696-708-91/c
; Sequence 91, Application US/10696708
; Publication No. US20040078833A1
; GENERAL INFORMATION:
; APPLICANT: Keating, Mark T.
; APPLICANT: Splawski, Igor
; TITLE OF INVENTION: MUTATIONS IN AND GENOMIC STRUCTURE OF HERG - A LONG QT
; TITLE OF INVENTION: SYNDROME GENE
; FILE REFERENCE: 2323-164
; CURRENT APPLICATION NUMBER: US/10/696,708
; PRIOR FILING DATE: 2003-10-30
; PRIOR APPLICATION NUMBER: US 09/735,995
; PRIOR FILING DATE: 2000-12-14
; PRIOR APPLICATION NUMBER: US 09/226,012
; PRIOR FILING DATE: 1999-01-06
; PRIOR APPLICATION NUMBER: 09/122,847
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 91
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-696-708-91

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2018 GTGTGTCCTGGTCCTGGTG 2037

Db 20 GTCTGTCAGGTCCTGGTG 1

RESULT 764

US-10-847-918-4062
; Sequence 4062, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4062
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-847-918-4062

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 5e+02;
Matches 13; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 3823 CCTCCCCAGCTGCTGCTT 3842

Db 2 CCUCCUCCAGCUCGUCGUU 21

RESULT 765

US-10-665-951-2244

; Sequence 2244, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBH02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-08-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2244
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-665-951-2244
Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
QY 2931 CATGCTGGACTGTGGCA 2948
Db 1 CAUGCUGGACUCUGGCA 18
RESULT 766
US-10-665-951-2265
; Sequence 2265, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MBH02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348

```
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2265
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
```

Query Match 0.4%; Score 16.4; DB 1; Length 19;

Best Local Similarity 72.2%; Pred. No. 4.5e+02;

Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTGGCA 2948

Db 2 CAUGCUGGACUGCGGCA 19

RESULT 767

```
; US-10-758-155-2244
; Sequence 2244, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/141 (MRHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2265
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
```

```
; SEQ ID NO 2244
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
```

US-10-758-155-2244

Query Match 0.4%; Score 16.4; DB 1; Length 19;

Best Local Similarity 72.2%; Pred. No. 4.5e+02;

Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTGGCA 2948

Db 1 CAUGCUGGACUGCGGCA 18

RESULT 768

```
; US-10-758-155-2265
; Sequence 2265, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/141 (MRHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2265
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
```

US-10-758-155-2265

Query Match 0.4%; Score 16.4; DB 1; Length 19;

Best Local Similarity 72.2%; Pred. No. 4.5e+02;

Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTGGCA 2948

Db 2 CAUGCUGGACUGCGGCA 19

RESULT 769

```
US-10-758-155-2662
; Sequence 2662, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2662
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2662

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTGGCA 2948
Db 1 CAUGCUGGACUGGCA 18

RESULT 771
US-10-758-155-2665
; Sequence 2665, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2662
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2662

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTGGCA 2948
Db 1 CAUGCUGGACUGGCA 18

RESULT 770
US-10-758-155-2663
; Sequence 2663, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
```


; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2737
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2737

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTGGCA 2948
||:|||||:||||
Db 2 CAUGCUGGACUGCGGCA 19

RESULT 775
US-10-831-620-2244
; Sequence 2244, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2737
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2737

; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2244
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-831-620-2244

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTGGCA 2948
||:|||||:||||
Db 1 CAUGCUGGACUGCGGCA 18

RESULT 776
US-10-831-620-2265
; Sequence 2265, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2265
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-831-620-2265

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTGGCA 2948
||:|||||:||||
Db 2 CAUGCUGGACUGCGGCA 19

```
RESULT 777
; Sequence 2662, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2662
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2662

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATCTGGAGCTGTGGCA 2948
Db 1 CAUGCUGGACUGCGCA 18

RESULT 779
US-10-831-620-2665
; Sequence 2665, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2662
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2662

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATCTGGAGCTGTGGCA 2948
Db 1 CAUGCUGGACUGCGCA 18

RESULT 778
US-10-831-620-2663
; Sequence 2663, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
```

```
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2663
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2663

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATCTGGAGCTGTGGCA 2948
Db 1 CAUGCUGGACUGCGCA 18

RESULT 779
US-10-831-620-2665
; Sequence 2665, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
```

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 2751

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 2665

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: target sequence

US-10-831-620-2665

Query Match 0.4%; Score 16.4; DB 1; Length 19;

Best Local Similarity 72.2%; Pred. No. 4.5e+02;

Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTGGCA 2948

||:|||||:||||

Db 1 CAUGCUGGACUGCGCA 18

RESULT 780

US-10-831-620-2729

; Sequence 2729, Application US/10831620

; Publication No. US20050148530A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; APPLICANT: Beigelman, Leonid

; APPLICANT: Pavco, Pamela

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial

; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor

; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)

; FILE REFERENCE: 400/152 (MHB02-742-Q)

; CURRENT APPLICATION NUMBER: US/10/831,620

; CURRENT FILING DATE: 2004-04-23

; PRIOR APPLICATION NUMBER: US 10/764,957

; PRIOR FILING DATE: 2004-01-26

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-14

; PRIOR APPLICATION NUMBER: US 10/758,155

; PRIOR FILING DATE: 2004-01-12

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/712,633

; PRIOR FILING DATE: 2003-11-13

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/670,011

; PRIOR FILING DATE: 2003-09-23

; PRIOR APPLICATION NUMBER: US 10/665,951

; PRIOR FILING DATE: 2003-09-18

; PRIOR APPLICATION NUMBER: US 10/664,668

; PRIOR FILING DATE: 2003-09-16

; PRIOR APPLICATION NUMBER: US 10/665,255

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 2751

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 2729

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: target sequence

US-10-831-620-2729

Query Match 0.4%; Score 16.4; DB 1; Length 19;

Best Local Similarity 66.7%; Pred. No. 4.5e+02;

Matches 12; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 2930 TCATGCTGGACTGTGGC 2947

||:|||||:||||

Db 2 UCAUGCUGGACUGCGGC 19

RESULT 781

US-10-831-620-2734

; Sequence 2734, Application US/10831620

; Publication No. US20050148530A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; APPLICANT: Beigelman, Leonid

; APPLICANT: Pavco, Pamela

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial

; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor

; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)

; FILE REFERENCE: 400/152 (MHB02-742-Q)

; CURRENT APPLICATION NUMBER: US/10/831,620

; CURRENT FILING DATE: 2004-04-23

; PRIOR APPLICATION NUMBER: US 10/764,957

; PRIOR FILING DATE: 2004-01-26

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-14

; PRIOR APPLICATION NUMBER: US 10/758,155

; PRIOR FILING DATE: 2004-01-12

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/712,633

; PRIOR FILING DATE: 2003-11-13

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/670,011

; PRIOR FILING DATE: 2003-09-23

; PRIOR APPLICATION NUMBER: US 10/665,951

; PRIOR FILING DATE: 2003-09-18

; PRIOR APPLICATION NUMBER: US 10/664,668

; PRIOR FILING DATE: 2003-09-16

; PRIOR APPLICATION NUMBER: US 10/665,255

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 2751

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 2734

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: target sequence

US-10-831-620-2734

Query Match 0.4%; Score 16.4; DB 1; Length 19;

Best Local Similarity 72.2%; Pred. No. 4.5e+02;

Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTGGCA 2948

||:|||||:||||

Db 2 CAUGCUGGACUGCGCA 19

RESULT 782

US-10-831-620-2737

; Sequence 2737, Application US/10831620

; Publication No. US20050148530A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; APPLICANT: Beigelman, Leonid

; APPLICANT: Pavco, Pamela

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial

; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor

; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)

; FILE REFERENCE: 400/152 (MHB02-742-Q)

; CURRENT APPLICATION NUMBER: US/10/831,620

; CURRENT FILING DATE: 2004-04-23

; PRIOR APPLICATION NUMBER: US 10/764,957

; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2737
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2737

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACTGTTGGCA 2948
||:|||||:||||
Db 2 CAUGCUGACUGCGGCA 19

RESULT 783
US-10-844-076-2244
; Sequence 2244, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-13
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2265
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re

; PRIOR FILING DATE: 2003-09-18
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2244
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-844-076-2244

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACTGTTGGCA 2948
||:|||||:||||
Db 1 CAUGCUGACUGCGGCA 18

RESULT 784
US-10-844-076-2265
; Sequence 2265, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2265
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-844-076-2265

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACTGTTGGCA 2948
||:|||||:||||

```
Db          2 CAUGCUGGACUGCGGCA 19

RESULT 785
US-10-844-076-2662
; Sequence 2662, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844, 076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2662
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-844-076-2662

Query Match          0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      2931 CATGCTGGACTGTGGCA 2948
        ||:||:||:||:||:||
Db       1 CAUGCUGGACUGCGGCA 18

RESULT 787
US-10-844-076-2665
; Sequence 2665, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844, 076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2662
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-844-076-2662

Query Match          0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      2931 CATGCTGGACTGTGGCA 2948
        ||:||:||:||:||:||
Db       1 CAUGCUGGACUGCGGCA 18

RESULT 786
US-10-844-076-2663
; Sequence 2663, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844, 076
; CURRENT FILING DATE: 2004-05-11
```

;; PRIOR APPLICATION NUMBER: US 10/664,668
;; PRIOR FILING DATE: 2003-09-18
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 2755
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 2665
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-844-076-2665

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACTGTTGGCA 2948
||:|||||:||||
Db 1 CAUGCUGGACUGCGGCA 18

RESULT 788

US-10-844-076-2729
;; Sequence 2729, Application US/10844076
;; Publication No. US20050171039A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; APPLICANT: McSwiggen, James
;; APPLICANT: Beigelman, Leonid
;; APPLICANT: Pavco, Pamela
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
;; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
;; FILE REFERENCE: 400/159 (MBHB02-742-R)
;; CURRENT APPLICATION NUMBER: US/10/844,076
;; CURRENT FILING DATE: 2004-05-11
;; PRIOR APPLICATION NUMBER: US 10/831,620
;; PRIOR FILING DATE: 2004-04-23
;; PRIOR APPLICATION NUMBER: US 10/764,957
;; PRIOR FILING DATE: 2004-01-26
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/758,155
;; PRIOR FILING DATE: 2004-01-12
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/712,633
;; PRIOR FILING DATE: 2003-11-13
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/670,011
;; PRIOR FILING DATE: 2003-09-23
;; PRIOR APPLICATION NUMBER: US 10/665,951
;; PRIOR FILING DATE: 2003-09-18
;; PRIOR APPLICATION NUMBER: US 10/664,668
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 2755
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 2729
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-844-076-2729

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 4.5e+02;
Matches 12; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 2930 TCATGCTGGACTGTTGGC 2947

Db 2 UCAUGCUGGACUGCGGC 19
||:|||||:||||

RESULT 789

US-10-844-076-2734
;; Sequence 2734, Application US/10844076
;; Publication No. US20050171039A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; APPLICANT: McSwiggen, James
;; APPLICANT: Beigelman, Leonid
;; APPLICANT: Pavco, Pamela
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
;; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
;; FILE REFERENCE: 400/159 (MBHB02-742-R)
;; CURRENT APPLICATION NUMBER: US/10/844,076
;; CURRENT FILING DATE: 2004-05-11
;; PRIOR APPLICATION NUMBER: US 10/831,620
;; PRIOR FILING DATE: 2004-04-23
;; PRIOR APPLICATION NUMBER: US 10/764,957
;; PRIOR FILING DATE: 2004-01-26
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-14
;; PRIOR APPLICATION NUMBER: US 10/758,155
;; PRIOR FILING DATE: 2004-01-12
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/712,633
;; PRIOR FILING DATE: 2003-11-13
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/670,011
;; PRIOR FILING DATE: 2003-09-23
;; PRIOR APPLICATION NUMBER: US 10/665,951
;; PRIOR FILING DATE: 2003-09-18
;; PRIOR APPLICATION NUMBER: US 10/664,668
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 2755
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 2734
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-844-076-2734

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACTGTTGGCA 2948
||:|||||:||||
Db 2 CAUGCUGGACUGCGGCA 19

RESULT 790

US-10-844-076-2737
;; Sequence 2737, Application US/10844076
;; Publication No. US20050171039A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; APPLICANT: McSwiggen, James
;; APPLICANT: Beigelman, Leonid
;; APPLICANT: Pavco, Pamela
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
;; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
;; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
;; FILE REFERENCE: 400/159 (MBHB02-742-R)
;; CURRENT APPLICATION NUMBER: US/10/844,076

```
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2737
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-844-076-2737
```

```
Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2931 CATGCTGGACTGTGGCA 2948
||:|||||:|||||
Db 2 CAUGCUGGACUGCUGGCA 19
```

```
RESULT 791
US-10-962-898-2293
; Sequence 2293, Application US/10962898
; Publication No. US2005022066A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
```

```
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2293
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-962-898-2293
```

```
Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2931 CATGCTGGACTGTGGCA 2948
||:|||||:|||||
Db 1 CAUGCUGGACUGCUGGCA 18
```

```
RESULT 792
US-10-962-898-2421
; Sequence 2421, Application US/10962898
; Publication No. US2005022066A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2421
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-962-898-2421
```

```
Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2931 CATGCTGGACTGTGGCA 2948
||:|||||:|||||
```


Db 2 CAUGCUGGACUGCGCA 19

RESULT 793

US-10-944-611-2293
; Sequence 2293, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2293
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense sense
US-10-944-611-2293

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACTGTGGCA 2948

Db 1 CAUGCUGGACUGCGCA 18

RESULT 794

US-10-944-611-2421
; Sequence 2421, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor

; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2421
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense sense
US-10-944-611-2421

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.5e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACTGTGGCA 2948

Db 2 CAUGCUGGACUGCGCA 19

RESULT 795

US-10-021-707-19/c
; Sequence 19, Application US/10021707
; Publication No. US20030186903A1
; GENERAL INFORMATION:
; APPLICANT: James Karras
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF MYD88 EXPRESSION
; FILE REFERENCE: RTS-0330
; CURRENT APPLICATION NUMBER: US/10/021,707
; CURRENT FILING DATE: 2001-11-23
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-021-707-19

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2595 CCTGGCTGCTCGCAACAT 2612

Db 19 CCTGGCTGCTCGCAACAT 2

```
RESULT 796
US-10-126-355-83/c
; Sequence 83, Application US/10126355
; Publication No. US20030198965A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF HYDROXYSTEROID
; TITLE OF INVENTION: 11-BETA DEHYDROGENASE 1 EXPRESSION
; FILE REFERENCE: RTS-0428
; CURRENT APPLICATION NUMBER: US/10/126,355
; CURRENT FILING DATE: 2002-04-19
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-126-355-83

Query Match          0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2067 GAAGCAGAGCAATGGCAG 2084
    |||||
Db 19 GAAGCAGAGCAATGGCAG 2

RESULT 797
US-10-289-762-2100/c
; Sequence 2100, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griflais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 2100
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-2100

Query Match          0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3134 AAATGGGAAGATACGAAG 3151
    |||||
Db 19 AAATGGGAAGATCCGAAG 2

RESULT 798
US-10-673-063-19/c
; Sequence 19, Application US/10673063
; Publication No. US20040038926A1
; GENERAL INFORMATION:
; APPLICANT: James Karras
; APPLICANT: Kenneth Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF MYD88 EXPRESSION
; FILE REFERENCE: RTS-0330
; CURRENT APPLICATION NUMBER: US/10/673,063
; CURRENT FILING DATE: 2003-09-26
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-673-063-19

Query Match          0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2595 CCTGGCTGCTCGCAACAT 2612
    |||||
Db 19 CCTGGCTGCTCTCAACAT 2

RESULT 799
US-10-333-429-417
; Sequence 417, Application US/10333429
; Publication No. US20040048265A1
; GENERAL INFORMATION:
; APPLICANT: GENSET
; TITLE OF INVENTION: Obesity Associated Biallelic Marker Maps
; FILE REFERENCE: G-083US02PCT
; CURRENT APPLICATION NUMBER: US/10/333,429
; CURRENT FILING DATE: 2003-01-17
; PRIOR APPLICATION NUMBER: PCT/IB01/01477
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: US 60/219,704
; PRIOR FILING DATE: 2000-07-18
; NUMBER OF SEQ ID NOS: 579
; SOFTWARE: Patent.pm
; SEQ ID NO 417
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; LOCATION: 1..19
; OTHER INFORMATION: downstream amplification primer 99-38897 for SEQ 75, in complement
US-10-333-429-417

Query Match          0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4117 TAGTTGGTGGTGGGAAC 4132
    |||||
Db 1 TAGTTGGTGGTGGGAAC 16

RESULT 800
US-09-880-732-4
; Sequence 4, Application US/09880732
; Patent No. US20020127561A1
; GENERAL INFORMATION:
; APPLICANT: GENICON SCIENCES CORPORATION
; APPLICANT: BEE, Gary
; APPLICANT: KOHNE, David E.
; APPLICANT: KORB, Linda
; APPLICANT: PETERSON, Todd
; APPLICANT: YGUERABIDE, Juan
; TITLE OF INVENTION: ASSAY FOR GENETIC POLYMORPHISMS USING SCATTERED LIGHT DETECTABLE I
; FILE REFERENCE: 089498/0403
; CURRENT APPLICATION NUMBER: US/09/880,732
; CURRENT FILING DATE: 2001-09-17
; PRIOR APPLICATION NUMBER: US 60/210,988
; PRIOR FILING DATE: 2000-06-12
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

; NAME/KEY: misc feature
; OTHER INFORMATION: Primer
US-09-880-732-4

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1947 CCAGACCAACTGGATGAG 1965
||| ||||| ||||| |||||
Db 1 CCTGACCCAGCTGGATGAG 19

RESULT 801

US-09-966-147-22
; Sequence 22 Application US/09966147
; Patent No. US20020146416A1
; GENERAL INFORMATION:
; APPLICANT: Presta, Leonard G.
; Shelton, David L.
; Urfer, Roman

; TITLE OF INVENTION: HUMAN trk RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Knobbe, Martens, Olson & Bear, LLP
; STREET: 620 Newport Center Drive, 16th Floor
; CITY: Newport Beach
; STATE: California
; COUNTRY: USA
; ZIP: 92660

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatIn (Genentech)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/966.147
; FILING DATE: 27-Sep-2000
; CLASSIFICATION: <unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/446172
; FILING DATE: 19-MAY-1995
; APPLICATION NUMBER: 08/286846
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: 08/215139
; FILING DATE: 18-MAR-1994

; ATTORNEY/AGENT INFORMATION:

; NAME: Dregger, Ginger
; REGISTRATION NUMBER: 33,055
; REFERENCE/DOCKET NUMBER: GENENT.33CPC4C

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (415) 954-4114
; TELEFAX: (415) 954-4111

; INFORMATION FOR SEQ ID NO: 22:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 19 base pairs

; TYPE: Nucleic Acid

; STRANDEDNESS: Single

; TOPOLOGY: Linear

; SEQUENCE DESCRIPTION: SEQ ID NO: 22:

US-09-966-147-22

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3539 ACTCCAGCAAGGGGTGAG 3557
||| ||||| ||||| |||||
Db 1 ACGCAGCCCAAGGGGTGAG 19

RESULT 802

US-09-904-968A-63/c

; Sequence 63, Application US/09904968A
; Publication No. US20030008288A1
; GENERAL INFORMATION:

; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

; APPLICANT: GERMINO, Gregory

; APPLICANT: WATNICK, Terry

; APPLICANT: PHAKDEEKITCHAROEN, Bunyong

; TITLE OF INVENTION: DETECTION AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE

; FILE REFERENCE: JH01680-2

; CURRENT APPLICATION NUMBER: US/09/904,968A

; CURRENT FILING DATE: 2001-07-13

; PRIOR APPLICATION NUMBER: US 60/283,691

; PRIOR FILING DATE: 2001-07-13

; PRIOR APPLICATION NUMBER: US 60/218,261

; PRIOR FILING DATE: 2000-07-13

; NUMBER OF SEQ ID NOS: 113

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 63

; LENGTH: 19

; TYPE: DNA

; ORGANISM: Artificial sequence

; FEATURE:

; OTHER INFORMATION: PCR primer 13R

US-09-904-968A-63

Query Match 0.4%; Score 15.8; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 5.1e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1068 TGGCCCCAGCCCCAGCCTC 1086

||| ||||| ||||| |||||

Db 19 TTGTCCAGCCCCAGCCTC 1

RESULT 803

US-10-083-246A-83/c

; Sequence 83, Application US/10083246A

; Publication No. US20030152936A1

; GENERAL INFORMATION:

; APPLICANT: Athena Diagnostics

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR GENETIC ANALYSIS OF POLYCYSTIC KIDNEY

; FILE REFERENCE: 1133/2002

; CURRENT APPLICATION NUMBER: US/10/083,246A

; CURRENT FILING DATE: 2002-10-15

; NUMBER OF SEQ ID NOS: 168

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 83

; LENGTH: 19

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (1)..(19)

; OTHER INFORMATION: Synthetic primer

US-10-083-246A-83

Query Match 0.4%; Score 15.8; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 5.1e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1068 TGGCCCCAGCCCCAGCCTC 1086

||| ||||| ||||| |||||

Db 19 TTGTCCAGCCCCAGCCTC 1

RESULT 804

US-10-374-469-22

; Sequence 22, Application US/10374469

; Publication No. US20030157099A1

; GENERAL INFORMATION:

; APPLICANT: Presta, Leonard G.

; Shelton, David L.

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 2455

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 2245

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-665-951-2245

Query Match 0.4%; Score 15.8; DB 1; Length 19;

Best Local Similarity 68.4%; Pred. No. 5.1e+02;

Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2932 ATGCTGAGTGTGGCAGA 2950

|||||:|||||

Db 1 AUGCUGAGCUGCUGGCACA 19

RESULT 810

US-10-683-990-87

; Sequence 87, Application US/10683990

; Publication No. US20040198682A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics

; APPLICANT: McSwiggen, James

; APPLICANT: Usman, Nassim

; APPLICANT: Pavco, Pamela

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor

; FILE REFERENCE: 400/134 (02-742-H)

; CURRENT APPLICATION NUMBER: US/10/683,990

; CURRENT FILING DATE: 2003-10-10

; PRIOR APPLICATION NUMBER: PCT/US03/05022

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 60/393,796

; PRIOR FILING DATE: 2002-07-03

; PRIOR APPLICATION NUMBER: US 60/399,348

; PRIOR FILING DATE: 2002-07-29

; PRIOR APPLICATION NUMBER: US 60/406,784

; PRIOR FILING DATE: 2002-08-29

; PRIOR APPLICATION NUMBER: US 60/408,378

; PRIOR FILING DATE: 2002-09-05

; PRIOR APPLICATION NUMBER: US 60/409,293

; PRIOR FILING DATE: 2002-09-09

; PRIOR APPLICATION NUMBER: US 60/440,129

; PRIOR FILING DATE: 2003-01-15

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 256

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 87

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-683-990-87

Query Match 0.4%; Score 15.8; DB 1; Length 19;

Best Local Similarity 84.2%; Pred. No. 5.1e+02;

Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 519 GGATGAGGAACAGCAGCAGC 537

|||||:|||||

Db 1 GGAUGAGAAACAGCUCAGC 19

RESULT 811

US-10-683-990-184/c

; Sequence 184, Application US/10683990

; Publication No. US20040198682A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics

; APPLICANT: McSwiggen, James

; APPLICANT: Usman, Nassim

; APPLICANT: Pavco, Pamela

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor

; FILE REFERENCE: 400/134 (02-742-H)

; CURRENT APPLICATION NUMBER: US/10/683,990

; CURRENT FILING DATE: 2003-10-10

; PRIOR APPLICATION NUMBER: PCT/US03/05022

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 60/393,796

; PRIOR FILING DATE: 2002-07-03

; PRIOR APPLICATION NUMBER: US 60/399,348

; PRIOR FILING DATE: 2002-07-29

; PRIOR APPLICATION NUMBER: US 60/406,784

; PRIOR FILING DATE: 2002-08-29

; PRIOR APPLICATION NUMBER: US 60/408,378

; PRIOR FILING DATE: 2002-09-05

; PRIOR APPLICATION NUMBER: US 60/409,293

; PRIOR FILING DATE: 2002-09-09

; PRIOR APPLICATION NUMBER: US 60/440,129

; PRIOR FILING DATE: 2003-01-15

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 256

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 184

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-683-990-184

Query Match 0.4%; Score 15.8; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 5.1e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 519 GGATGAGGAACAGCAGC 537

|||||:|||||

Db 19 GGATGAGGAACAGCTCAGC 1

RESULT 812

US-10-758-155-1677

; Sequence 1677, Application US/10758155

; Publication No. US20050075304A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; APPLICANT: Beigelman, Leonid

; APPLICANT: Pavco, Pamela

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial

; FILE REFERENCE: 400/141 (WBH02742-N)

; CURRENT APPLICATION NUMBER: US/10/758,155

; CURRENT FILING DATE: 2004-01-12

; PRIOR APPLICATION NUMBER: US 10/665,951

; PRIOR FILING DATE: 2003-09-18

; PRIOR APPLICATION NUMBER: US 10/664,668

```

; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1677
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-758-155-1677

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2596 CTGGCTGCTCGCACATCC 2614
      |||||:||||:||||:|
DB 1 CUGGCGUCGCGGACAUUC 19

RESULT 813
US-10-758-155-1924/C
; Sequence 1924, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1677
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-758-155-1677

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2596 CTGGCTGCTCGCACATCC 2614
      |||||:||||:||||:|
DB 1 CUGGCGUCGCGGACAUUC 19

RESULT 814
US-10-758-155-2245
; Sequence 2245, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2245
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-758-155-2245

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2932 ATGCTGACTGTGGCAGA 2950
      |:|:|:|:|:|:|:|:|
DB 1 AUGCUGACUCGUGGCACA 19

```

```

; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1924
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-758-155-1924

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2596 CTGGCTGCTCGCACATCC 2614
      |||||:||||:||||:|
DB 19 CTGGCTGCTCGGACATTC 1

RESULT 814
US-10-758-155-2245
; Sequence 2245, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2245
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-758-155-2245

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2932 ATGCTGACTGTGGCAGA 2950
      |:|:|:|:|:|:|:|:|
DB 1 AUGCUGACUCGUGGCACA 19

```

```
RESULT 815
US-10-758-155-2668
; Sequence 2668, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MEHB02742-N)
; CURRENT APPLICATION NUMBER: US/10758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2668
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2668

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2932 ATGCTGACTGTTGGCACA 2950
|||:|||||:|||||
Db 1 AUGCUGACUGCUGGCACA 19

RESULT 816
US-10-758-155-2711
; Sequence 2711, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MEHB02742-N)
; CURRENT APPLICATION NUMBER: US/10758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
```

```
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2711
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2711

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 5.1e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2926 CAGCTCATGCTGGACTGTT 2944
|||:|||||:|||||
Db 1 CAGAUCAUGCUGGACUGCU 19

RESULT 817
US-10-758-155-2717
; Sequence 2717, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MEHB02742-N)
; CURRENT APPLICATION NUMBER: US/10758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
```


; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 2751

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 2717

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: target sequence

US-10-758-155-2717

Query Match

Best Local Similarity 0.4%; Score 15.8; DB 1; Length 19;

Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2927 AGCTCATGCTGGACTGTGG 2945

||:||||:||||:|

Db 1 AGAUCGUGGACUGCUG 19

RESULT 818

US-10-758-155-2723

; Sequence 2723, Application US/10758155

; Publication No. US20050075304A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; APPLICANT: Beigelman, Leonid

; APPLICANT: Pavco, Pamela

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial

; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor

; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)

; FILE REFERENCE: 400/141 (MBHB02742-N)

; CURRENT APPLICATION NUMBER: US/10/758,155

; PRIOR FILING DATE: 2004-01-12

; PRIOR APPLICATION NUMBER: US 10/665,951

; PRIOR FILING DATE: 2003-09-18

; PRIOR APPLICATION NUMBER: US 10/664,668

; PRIOR FILING DATE: 2003-09-18

; PRIOR APPLICATION NUMBER: PCT/US 03/05022

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/399,348

; PRIOR FILING DATE: 2002-07-29

; PRIOR APPLICATION NUMBER: US 60/393,796

; PRIOR FILING DATE: 2002-07-03

; PRIOR APPLICATION NUMBER: US 10/287,949

; PRIOR FILING DATE: 2002-11-04

; PRIOR APPLICATION NUMBER: US 10/306,747

; PRIOR FILING DATE: 2002-11-27

; PRIOR APPLICATION NUMBER: PCT/US 02/17674

; PRIOR FILING DATE: 2002-05-29

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 2751

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 2723

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: target sequence

US-10-758-155-2723

Query Match

Best Local Similarity 0.4%; Score 15.8; DB 1; Length 19;

Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2928 GCTCATGCTGGACTGTGG 2946

||:||||:||||:|

Db 1 GAUCAUGGACUGCUGG 19

RESULT 819

US-10-758-155-2738

; Sequence 2738, Application US/10758155

; Publication No. US20050075304A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; APPLICANT: Beigelman, Leonid

; APPLICANT: Pavco, Pamela

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial

; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor

; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)

; FILE REFERENCE: 400/141 (MBHB02742-N)

; CURRENT APPLICATION NUMBER: US/10/758,155

; PRIOR FILING DATE: 2004-01-12

; PRIOR APPLICATION NUMBER: US 10/665,951

; PRIOR FILING DATE: 2003-09-18

; PRIOR APPLICATION NUMBER: US 10/664,668

; PRIOR FILING DATE: 2003-09-18

; PRIOR APPLICATION NUMBER: PCT/US 03/05022

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/399,348

; PRIOR FILING DATE: 2002-07-29

; PRIOR APPLICATION NUMBER: US 60/393,796

; PRIOR FILING DATE: 2002-07-03

; PRIOR APPLICATION NUMBER: US 10/287,949

; PRIOR FILING DATE: 2002-11-04

; PRIOR APPLICATION NUMBER: US 10/306,747

; PRIOR FILING DATE: 2002-11-27

; PRIOR APPLICATION NUMBER: PCT/US 02/17674

; PRIOR FILING DATE: 2002-05-29

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 2751

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 2738

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: target sequence

US-10-758-155-2738

Query Match

Best Local Similarity 0.4%; Score 15.8; DB 1; Length 19;

Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2930 TCATGCTGGACTGTGGCA 2948

||:||||:||||:|

Db 1 UCAUGCUGGAUUGCUGGCA 19

RESULT 820

US-10-411-915-83/c

; Sequence 83, Application US/10411915

; Publication No. US20050100898A1

; GENERAL INFORMATION:

; APPLICANT: Athena Diagnostics

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR GENETIC ANALYSIS OF POLYCYSTIC KIDNEY

; TITLE OF INVENTION: DISEASE

; FILE REFERENCE: 1133/2005

; CURRENT APPLICATION NUMBER: US/10/411,915

; CURRENT FILING DATE: 2003-04-11

; PRIOR APPLICATION NUMBER: US 10/083,246

; PRIOR FILING DATE: 2002-02-26

; PRIOR APPLICATION NUMBER: US 60/328,739

; PRIOR FILING DATE: 2001-10-12

; NUMBER OF SEQ ID NOS: 172

```
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 83
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: Synthetic primer
US-10-411-915-83

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1068 TGGCCCGAGCCCGAGCTC 1086
      |||
Db 19 TTGTCCGAGCCCGAGCTC 1

RESULT 821
US-10-831-620-1677
; Sequence 1677, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MEHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/665,255
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1924
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-831-620-1924

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2596 CTGGCTGCTCGCAACATCC 2614
      |||
Db 19 CTGGCTGCTCGGAACATTC 1

RESULT 823
US-10-831-620-2245
; Sequence 2245, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MEHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
```

```

; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2245
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-831-620-2245

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy      2932 ATGCTGACTGTGGCAGA 2950
      |||:||||:|:|||||
Db      1 AUGCUGACUGCUGGCACA 19

RESULT 824
US-10-831-620-2668
; Sequence 2668, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/665,255
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2711
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2711

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 5.1e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy      2926 CAGCTCATGCTGACTGTT 2944
      |||:||||:|||||

```

```

; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2668
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2668

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy      2932 ATGCTGACTGTGGCAGA 2950
      |||:||||:|:|||||
Db      1 AUGCUGACUGCUGGCACA 19

RESULT 825
US-10-831-620-2711
; Sequence 2711, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2711
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2711

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 5.1e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy      2926 CAGCTCATGCTGACTGTT 2944
      |||:||||:|||||

```



```
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2738
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2738

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 5.1e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2930 TCATGCTGAGCTGTGGCA 2948
      :||:|||||:|:|||||
Db 1 UCAUGCUGGAUUGCGGCA 19

RESULT 829
US-10-923-522-544/c
; Sequence 544, Application US/10923522
; Publication No. US20050159381A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Chowrira, Bharat
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
; FILE REFERENCE: 400/192 (MHB03-026-B)
; CURRENT APPLICATION NUMBER: US/10/923,522
; PRIOR FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: PCT/US 03/05234
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/439,922
; PRIOR FILING DATE: 2003-01-14
; PRIOR APPLICATION NUMBER: US 60/404,039
; PRIOR FILING DATE: 2002-08-15
; PRIOR APPLICATION NUMBER: PCT/US 04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1779
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 544
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-923-522-544

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 155 CCAGCAGCTCCGGGCCG 173
      ||||| || ||||| |||||
```

```
Db 19 CCAGCTCGGTCCGGGCCG 1

RESULT 830
US-10-923-522-863
; Sequence 863, Application US/10923522
; Publication No. US20050159381A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Chowrira, Bharat
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
; FILE REFERENCE: 400/192 (MHB03-026-B)
; CURRENT APPLICATION NUMBER: US/10/923,522
; PRIOR FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: PCT/US 03/05234
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/439,922
; PRIOR FILING DATE: 2003-01-14
; PRIOR APPLICATION NUMBER: US 60/404,039
; PRIOR FILING DATE: 2002-08-15
; PRIOR APPLICATION NUMBER: PCT/US 04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1779
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 863
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-923-522-863

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 5.1e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 155 CCAGCAGCTCCGGGCCG 173
      ||||| || ||||| |||||
Db 1 CCAGCUGGUGCGGCCG 19

RESULT 831
US-10-844-076-1677
; Sequence 1677, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/159 (MHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
```



```
Db      1 AUGCUGGACUGGCGACA 19

RESULT 834
US-10-844-076-2668
; Sequence 2668, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2711
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-844-076-2711

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 5.1e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy      2926 CAGCTCATGCTGGACTGTT 2944
      ||| :|||:||||:|
Db      1 CAGAUCAUGGCGGACUGCU 19

RESULT 836
US-10-844-076-2717
; Sequence 2717, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2668
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-844-076-2668

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy      2932 ATGCTGGACTGTTGGCAGA 2950
      |||:|||||:|||||
Db      1 AUGCUGGACUGGCGACA 19

RESULT 835
US-10-844-076-2711
; Sequence 2711, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
```

;; PRIOR APPLICATION NUMBER: US 10/664,668
;; PRIOR FILING DATE: 2003-09-18
;; Remaining Prior Application data removed - See File Wrapper or PALM.

;; NUMBER OF SEQ ID NOS: 2755
;; SOFTWARE: PatentIn version 3.3

;; SEQ ID NO 2717

;; LENGTH: 19

;; TYPE: RNA

;; ORGANISM: Artificial Sequence

;; FEATURE:

;; OTHER INFORMATION: Description of Artificial Sequence: target sequence

US-10-844-076-2717

Query Match 0.4%; Score 15.8; DB 1; Length 19;

Best Local Similarity 63.2%; Pred.No. 5.1e+02;

Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2927 AGCTCATGCTGGACTGTTG 2945

||:||||:||||:|

Db 1 AGAUCGUGGACUGCUG 19

RESULT 837

US-10-844-076-2723

;; Sequence 2723, Application US/10844076

;; Publication No. US20050171039A1

;; GENERAL INFORMATION:

;; APPLICANT: Sirna Therapeutics, Inc.

;; APPLICANT: McSwiggen, James

;; APPLICANT: Beigelman, Leonid

;; APPLICANT: Pavco, Pamela

;; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial

;; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor

;; FILE REFERENCE: 400/159 (MBH02-742-R)

;; CURRENT APPLICATION NUMBER: US/10/844,076

;; CURRENT FILING DATE: 2004-05-11

;; PRIOR APPLICATION NUMBER: US 10/831,620

;; PRIOR FILING DATE: 2004-04-23

;; PRIOR APPLICATION NUMBER: US 10/764,957

;; PRIOR FILING DATE: 2004-01-26

;; PRIOR APPLICATION NUMBER: US 10/757,803

;; PRIOR FILING DATE: 2004-01-14

;; PRIOR APPLICATION NUMBER: US 10/758,155

;; PRIOR FILING DATE: 2004-01-12

;; PRIOR APPLICATION NUMBER: US 10/720,448

;; PRIOR FILING DATE: 2003-11-24

;; PRIOR APPLICATION NUMBER: US 10/712,633

;; PRIOR FILING DATE: 2003-11-13

;; PRIOR APPLICATION NUMBER: US 10/693,059

;; PRIOR FILING DATE: 2003-10-23

;; PRIOR APPLICATION NUMBER: US 10/670,011

;; PRIOR FILING DATE: 2003-09-23

;; PRIOR APPLICATION NUMBER: US 10/665,951

;; PRIOR FILING DATE: 2003-09-18

;; PRIOR APPLICATION NUMBER: US 10/664,668

;; PRIOR FILING DATE: 2003-09-18

;; Remaining Prior Application data removed - See File Wrapper or PALM.

;; NUMBER OF SEQ ID NOS: 2755

;; SOFTWARE: PatentIn version 3.3

;; SEQ ID NO 2723

;; LENGTH: 19

;; TYPE: RNA

;; ORGANISM: Artificial Sequence

;; FEATURE:

;; OTHER INFORMATION: Description of Artificial Sequence: target sequence

US-10-844-076-2723

Query Match 0.4%; Score 15.8; DB 1; Length 19;

Best Local Similarity 63.2%; Pred.No. 5.1e+02;

Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2928 GCTCATGCTGGACTGTTGG 2946

Db 1 GAUCAUGGUGGACUGCUG 19

||:||||:||||:|

RESULT 838

US-10-844-076-2738

;; Sequence 2738, Application US/10844076

;; Publication No. US20050171039A1

;; GENERAL INFORMATION:

;; APPLICANT: Sirna Therapeutics, Inc.

;; APPLICANT: McSwiggen, James

;; APPLICANT: Beigelman, Leonid

;; APPLICANT: Pavco, Pamela

;; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial

;; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor

;; FILE REFERENCE: 400/159 (MBH02-742-R)

;; CURRENT APPLICATION NUMBER: US/10/844,076

;; CURRENT FILING DATE: 2004-05-11

;; PRIOR APPLICATION NUMBER: US 10/831,620

;; PRIOR FILING DATE: 2004-04-23

;; PRIOR APPLICATION NUMBER: US 10/764,957

;; PRIOR FILING DATE: 2004-01-26

;; PRIOR APPLICATION NUMBER: US 10/757,803

;; PRIOR FILING DATE: 2004-01-14

;; PRIOR APPLICATION NUMBER: US 10/758,155

;; PRIOR FILING DATE: 2004-01-12

;; PRIOR APPLICATION NUMBER: US 10/720,448

;; PRIOR FILING DATE: 2003-11-24

;; PRIOR APPLICATION NUMBER: US 10/712,633

;; PRIOR FILING DATE: 2003-11-13

;; PRIOR APPLICATION NUMBER: US 10/693,059

;; PRIOR FILING DATE: 2003-10-23

;; PRIOR APPLICATION NUMBER: US 10/670,011

;; PRIOR FILING DATE: 2003-09-23

;; PRIOR APPLICATION NUMBER: US 10/665,951

;; PRIOR FILING DATE: 2003-09-18

;; PRIOR APPLICATION NUMBER: US 10/664,668

;; PRIOR FILING DATE: 2003-09-18

;; Remaining Prior Application data removed - See File Wrapper or PALM.

;; NUMBER OF SEQ ID NOS: 2755

;; SOFTWARE: PatentIn version 3.3

;; SEQ ID NO 2738

;; LENGTH: 19

;; TYPE: RNA

;; ORGANISM: Artificial Sequence

;; FEATURE:

;; OTHER INFORMATION: Description of Artificial Sequence: target sequence

US-10-844-076-2738

Query Match 0.4%; Score 15.8; DB 1; Length 19;

Best Local Similarity 63.2%; Pred.No. 5.1e+02;

Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2930 TCATGCTGGACTGTTGGCA 2948

||:||||:||||:|

Db 1 UCAUCGUGAUGCUGGCA 19

RESULT 839

US-10-962-898-1677

;; Sequence 1677, Application US/10962898

;; Publication No. US2005022066A1

;; GENERAL INFORMATION:

;; APPLICANT: Sirna Therapeutics, Inc.

;; APPLICANT: Richards, Ivan

;; APPLICANT: McSwiggen, James

;; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial

;; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor

;; FILE REFERENCE: 400/236 (MBH02-742-U)

;; CURRENT APPLICATION NUMBER: US/10/962,898

;; CURRENT FILING DATE: 2004-10-12


```

; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/931,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1677
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-962-898-1677

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2596 CTGGCTGCTCGCAACATCC 2614
Db 1 CUGGCGUGCUGGACAUUC 19

RESULT 840
US-10-962-898-1924/c
; Sequence 1924, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2294
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-962-898-2294

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2932 ATGCTGACCTGTTGGCAGA 2950
Db 1 AUGCUGGACUGGCGGACA 19

```

```

; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1924
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-962-898-1924

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 5.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2596 CTGGCTGCTCGCAACATCC 2614
Db 19 CTGGCTGCTCGGACATTC 1

RESULT 841
US-10-962-898-2294
; Sequence 2294, Application US/10962898
; Publication No. US20050222066A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2294
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-962-898-2294

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2932 ATGCTGACCTGTTGGCAGA 2950
Db 1 AUGCUGGACUGGCGGACA 19

```

```

; FILE REFERENCE: 400/235 (NEHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1924
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-944-611-1924

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred.No.5.le+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2596 CTGGCTGCTCGCAACATCC 2614
|||:|||||:|||||
DB 19 CTGGCTGCTCGCAACATTC 1

RESULT 844
US-10-944-611-2294
; Sequence 2294, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (NEHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1677
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-944-611-1677

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred.No.5.le+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2596 CTGGCTGCTCGCAACATCC 2614
|:|||||:|||||
DB 1 CUGGUGUGCGGAAUUC 19

RESULT 843
US-10-944-611-1924/c
; Sequence 1924, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (NEHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1677
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-944-611-1677

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred.No.5.le+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2596 CTGGCTGCTCGCAACATCC 2614
|:|||||:|||||
DB 1 CUGGUGUGCGGAAUUC 19

RESULT 843
US-10-944-611-1924/c
; Sequence 1924, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (NEHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1677
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-944-611-1677

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred.No.5.le+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2596 CTGGCTGCTCGCAACATCC 2614
|:|||||:|||||
DB 1 CUGGUGUGCGGAAUUC 19

RESULT 843
US-10-944-611-1924/c
; Sequence 1924, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (NEHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1677
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-944-611-1677

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred.No.5.le+02;
Matches 13; Conservative 4; Mismatches 2; Ind
```

```
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2294
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense x
US-10-944-611-2294

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 5.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2932 ATGCTGACGTGTGGCACA 2950
      |||:|||||:|||||
Db 1 AUGCUGACUGCGGCACA 19

RESULT 845
US-09-866-108-1653/c
; Sequence 1653, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1654
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1654
```

```
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1653
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1653

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3966 TATGGCTCTTTGCC 3982
      |||:|||||:|||||
Db 17 TCTGGCTCTTTGCC 1

RESULT 846
US-09-866-108-1654/c
; Sequence 1654, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1654
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1654

Query Match      0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
```

```
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3965 CTATGGCTCTCTTTGCC 3981
Db 17 CTCTGGCTCTCTTTGCC 1

RESULT 847
US-09-818-875-3946
; Sequence 3946, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3946
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3946

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 CCTGAAGGGTGGCTACA 2335
Db 1 CCTGGAGGGTGGCTACA 17

RESULT 848
US-09-818-875-3947/c
; Sequence 3947, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3947
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-3947
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 CCTGAAGGGTGGCTACA 2335
Db 17 CCTGGAGGGTGGCTACA 1

RESULT 849
US-10-209-787-3946
; Sequence 3946, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; PRIOR FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3946
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3946

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 CCTGAAGGGTGGCTACA 2335
Db 1 CCTGGAGGGTGGCTACA 17

RESULT 850
US-10-209-787-3947/c
; Sequence 3947, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; PRIOR FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
```

; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3947
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-3947

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 CCTGAAGGTTGGCTACA 2335
|||||
Db 17 CCTGAGGTTGGCTACA 1

RESULT 851

US-10-261-185-3946
; Sequence 3946, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3946
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3946

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 CCTGAAGGTTGGCTACA 2335
|||||
Db 1 CCTGAGGTTGGCTACA 17

RESULT 852

US-10-261-185-3947/c
; Sequence 3947, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176

; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 3947
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-3947

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2319 CCTGAAGGTTGGCTACA 2335
|||||
Db 17 CCTGAGGTTGGCTACA 1

RESULT 853

US-10-138-674-7739
; Sequence 7739, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7739
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7739

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2926 CAGCTCATGCTGACTG 2942
|||||
Db 1 CAGAUCAUGCUGGACUG 17

RESULT 854

US-10-138-674-7740
; Sequence 7740, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 7740
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7740

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTGGC 2947
||:|||||:|:|
Db 1 CAUGCUGACUGCUGC 17

RESULT 855

US-10-287-949A-7739
; Sequence 7739, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7739
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7739

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2926 CAGCTCATGCTGGACTG 2942
|||:|||||:|:|
Db 1 CAGAUCAUGCUGACUG 17

RESULT 856

US-10-287-949A-7740
; Sequence 7740, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7740
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7740

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTGGC 2947
||:|||||:|:|
Db 1 CAUGCUGACUGCUGC 17

RESULT 857

US-10-723-361-1653/c
; Sequence 1653, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1653
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1653

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3966 TATGGCCTCTTTGCC 3982
|:|||||:|:|
Db 17 TCTGGCCTCTTTGCC 1

RESULT 858

US-10-723-361-1654/c
; Sequence 1654, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI

```
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1654
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1654

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3965 CTATGGCTCTCTTGCC 3981
Db 17 CTCTGGCTCTCTTGCC 1

RESULT 859
US-10-681-074-3946
; Sequence 3946, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3946
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3946

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2319 CCTGAAGGGTGGCTACA 2335
Db 1 CCTGGAGGGTGGCTACA 17

RESULT 861
US-10-712-633-822
; Sequence 822, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTO
; FILE REFERENCE: MBHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 822
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-822

Query Match          0.4%; Score 15.4; DB 1; Length 17;
```

```
RESULT 860
US-10-681-074-3947/c
; Sequence 3947, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; FILE REFERENCE: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3947
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-3947

Query Match          0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2319 CCTGAAGGGTGGCTACA 2335
Db 17 CCTGGAGGGTGGCTACA 1

RESULT 861
US-10-712-633-822
; Sequence 822, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTO
; FILE REFERENCE: MBHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 822
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-822

Query Match          0.4%; Score 15.4; DB 1; Length 17;
```

```
Best Local Similarity 70.6%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2926 CAGCTCATGCTGACTG 2942
|||:||||:||||:|
Db 1 CAGACUAGCUGCUGC 17

RESULT 862
US-10-712-633-823
; Sequence 823, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MEHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 823
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-823

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTTGGC 2947
|||:||||:||||:|
Db 1 CAUGCUGACUGCUGGC 17

RESULT 864
US-09-969-373-1642/c
; Sequence 1642, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 1642
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-1642

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3473 GAGACACAGGATTTGGG 3489
|||||:|||||:|||||
Db 17 GAGACACAGGATTTGGG 1

RESULT 865
US-10-770-538-51
; Sequence 51, Application US/10770538
; Publication No. US20040241714A1
; GENERAL INFORMATION:
; APPLICANT: BRANCH, ROBERT A.
; APPLICANT: ROMKES, MARJORIE
; TITLE OF INVENTION: METHODS OF ASSESSMENT OF DRUG METABOLIZING ENZYMES
; TITLE OF INVENTION: FIELD OF THE INVENTION
; FILE REFERENCE: 12405/4
; CURRENT APPLICATION NUMBER: US/10/770,538
```

```
Best Local Similarity 70.6%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2926 CAGCTCATGCTGACTG 2942
|||:||||:||||:|
Db 1 CAGACUAGCUGCUGC 17

RESULT 862
US-10-712-633-823
; Sequence 823, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MEHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 823
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-823

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 4.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTTGGC 2947
|||:||||:||||:|
Db 1 CAUGCUGACUGCUGGC 17

RESULT 863
US-10-712-633-4238
; Sequence 4238, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MEHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
```


; CURRENT FILING DATE: 2004-02-04
; PRIOR APPLICATION NUMBER: US 60/444,656
; PRIOR FILING DATE: 2003-02-04
; NUMBER OF SEQ ID NOS: 225
; SOFTWARE: PatentIn ver. 3.2
; SEQ ID NO 51
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-770-538-51

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 5e+02; Mismatches 0; Indels 0; Gaps 0;

Qy 3718 GGCAGAGGGGTGCTCA 3734
|||||
Db 2 GGCAGAGGAGTGTCA 18

RESULT 866
US-10-665-951-895/c
; Sequence 895, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 895
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-665-951-895

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 5.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3860 AGTTTGTGTTTGTCT 3876
|||||
Db 18 AGTTTGTGTTTGTCT 2

RESULT 867
US-10-665-951-1219
; Sequence 1219, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1219
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-665-951-1219

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 29.4%; Pred. No. 5.5e+02;
Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;

Qy 3860 AGTTTGTGTTTGTCT 3876
|||||
Db 2 AGUUUUUUUUUUUUUCU 18

RESULT 868
US-10-665-951-2264
; Sequence 2264, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (MBHB02-742-F)

```
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2264
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense x
US-10-665-951-2264
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2931 CATGCTGGAGCTGTGGC 2947
||:|||||:||||
Db 3 CAUGCUGGACUGCGGC 19
```

```
RESULT 869
US-10-635-780-19/c
; Sequence 19, Application US/10635780
; Publication No. US20050032070A1
; GENERAL INFORMATION:
; APPLICANT: EPIDAUROS Biotechnologie AG
; TITLE OF INVENTION: Polymorphisms in the human gene for CYP2D6 and their use in
; FILE REFERENCE: VOS-43
; CURRENT APPLICATION NUMBER: US/10/635,780
; CURRENT FILING DATE: 2003-08-05
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 19
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-635-780-19
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 5.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 3723 GAAGGGGTGTGAGGGCC 3739
|||||
Db 19 GAAGGAGTGTGAGGGCC 3
```

```
RESULT 870
US-10-758-155-895/c
; Sequence 895, Application US/10758155
```

```
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 895
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-758-155-895

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 5.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3860 AGTTTGTGTTTGTGCT 3876
|||||
Db 18 AGTTTGTGTTTGTGCT 2

RESULT 871
US-10-758-155-1219
; Sequence 1219, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
```

```
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1219
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-758-155-1219
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 29.4%; Pred. No. 5.5e+02;
Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 3860 AGTTTGTGTTTGTCT 3876
||:||||:|:|
Db 2 AGUUUGUUUUUGUUCU 18
```

```
RESULT 872
US-10-758-155-2264
; Sequence 2264, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US/10/758,155
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2264
```

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-758-155-2264
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2931 CATGCTGGACTGTGGC 2947
||:||||:|:|
Db 3 CAUGCUGGACUGCUGGC 19
```

```
RESULT 873
US-10-758-155-2669
; Sequence 2669, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US/10/758,155
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2669
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2669
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2932 ATGCTGGACTGTGGCA 2948
||:||||:|:|
Db 1 AUGCUGGACUGCUGGC 17
```

```
RESULT 874
US-10-758-155-2671
```

```
; Sequence 2671, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2671
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2671

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.Se+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2932 ATGCTGGACTGTTGGCA 2948
||:|||||:|:||||
Db 1 AUGCUGGACUGCGGCA 17

RESULT 875
US-10-758-155-2728
; Sequence 2728, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2671
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2671

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.Se+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2932 ATGCTGGACTGTTGGCA 2948
||:|||||:|:||||
Db 1 AUGCUGGACUGCGGCA 17

RESULT 876
US-10-758-155-2731
; Sequence 2731, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2728
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-758-155-2728

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.Se+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTTGGC 2947
||:|||||:|:||||
Db 3 CAUGCUGGACUGCGGC 19

RESULT 876
US-10-758-155-2731
; Sequence 2731, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
```

```
; SEQ ID NO 2731
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-895
Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACGTGGC 2947
      |||:|||||:|
Db 3 CAUGCUGGACUGCGC 19

RESULT 877
US-10-831-620-895/c
; Sequence 895, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 895
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-831-620-895
Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 5.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3860 AGTTTGTGTTTGTCT 3876
      |||:|||||:|
Db 18 AGTTTGTGTTTGTCT 2

RESULT 878
US-10-831-620-895/c
; Sequence 895, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 895
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-831-620-895
```

```
US-10-831-620-1219
; Sequence 1219, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1219
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-831-620-1219
Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 29.4%; Pred. No. 5.5e+02;
Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;

Qy 3860 AGTTTGTGTTTGTCT 3876
      |||:|||||:|
Db 2 AGUUUUUUUUUUUUU 18

RESULT 879
US-10-831-620-2264
; Sequence 2264, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
```

```
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2264
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-831-620-2264

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      2931 CATGCTGGACTGTGGC 2947
Db      3 CAUGCUGGACUGCUGGC 19

RESULT 880
US-10-831-620-2669
; Sequence 2669, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
```

```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2669
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2669

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      2932 ATGCTGGACTGTGGCA 2948
Db      1 AUGCUGGACUGCUGGCA 17

RESULT 881
US-10-831-620-2671
; Sequence 2671, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2671
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2671

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      2932 ATGCTGGACTGTGGCA 2948
Db      1 AUGCUGGACUGCUGGCA 17
```

RESULT 882

US-10-831-620-2728
; Sequence 2728, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBH02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2728
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2728

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACTGTGGC 2947
||:|||||:|:
Db 3 CAUGCUGGACUGCGGC 19

RESULT 883

US-10-831-620-2731
; Sequence 2731, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBH02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2731
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-831-620-2731

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACTGTGGC 2947
||:|||||:|:
Db 3 CAUGCUGGACUGCGGC 19

RESULT 884

US-10-844-076-895/c
; Sequence 895, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBH02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 895
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-844-076-895

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 5.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3860 AGTTTGTGTTTGGTCT 3876
|||||
DB 18 AGTTTGTGTTTGGTCT 2

RESULT 885
US-10-844-076-1219
; Sequence 1219, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBH02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1219
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-844-076-1219

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 29.4%; Pred. No. 5.5e+02;
Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;

QY 3860 AGTTTGTGTTTGGTCT 3876
|||||
DB 2 AGUUUUGUUUGUUCU 18

RESULT 886
US-10-844-076-2264
; Sequence 2264, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBH02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2264
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-844-076-2264

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGACACTGTGGC 2947
|||||
DB 3 CAUGCUGACUGCUGGC 19

RESULT 887
US-10-844-076-2669
; Sequence 2669, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBH02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23

;; PRIOR APPLICATION NUMBER: US 10/664,668
: PRIOR FILING DATE: 2003-09-18

```
RESULT 890
US-10-844-076-2731
; Sequence 2731, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2731
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: target sequence
US-10-844-076-2731

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTGGC 2947
||:|||||:|
3 CAUGCUGACUGCGGC 19

Db

RESULT 891
US-10-962-898-895/c
; Sequence 895, Application US/10962898
; Publication No. US2005022066A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; CURRENT APPLICATION NUMBER: US 10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 895
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-962-898-895

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 5.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3860 AGTTTGTGTTTGTC 3876
|||||
Db 18 AGTTTGTGTTTGTC 2

RESULT 892
US-10-962-898-1219
; Sequence 1219, Application US/10962898
; Publication No. US2005022066A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; CURRENT APPLICATION NUMBER: US 10/962,898
; CURRENT FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1219
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-962-898-1219

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 29.4%; Pred. No. 5.5e+02;
Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;

Qy 3860 AGTTTGTGTTTGTCT 3876
    |||::|::|::|::|::|
Db 2 AGUUUUUUUUUUUUUCU 18

RESULT 893
US-10-962-898-2420
; Sequence 2420, Application US/10962898
; Publication No. US2005022066A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3371
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (2)..(3)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (4)..(5)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (7)..(8)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (9)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (12)..(13)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature

US-10-962-898-2420
; Query Match          0.4%; Score 15.4; DB 1; Length 19;
; Best Local Similarity 70.6%; Pred. No. 5.5e+02;
; Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGACTGTGGC 2947
    |||:|||||:|
Db 3 CAUGCUGACUGCGGC 19
```

```
RESULT 894
US-10-962-898-3371/c
; Sequence 3371, Application US/10962898
; Publication No. US2005022066A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3371
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (2)..(3)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (4)..(5)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (7)..(8)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (9)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (12)..(13)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
```

LOCATION: (14)..(14)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-O-methyl
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
NAME/KEY: misc_feature
LOCATION: (17)..(18)
OTHER INFORMATION: 2'-O-methyl
US-10-962-898-3371

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 5.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTGGC 2947
Db 17 CATGCTGGACTGTGGC 1

RESULT 895
US-10-944-611-895/c
Sequence 895, Application US/10944611
Publication No. US20050233998A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Jadhav, Vasant
APPLICANT: Kossen, Karl
APPLICANT: Zinnen, Shawn
APPLICANT: Vaish, Narendra
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
FILE REFERENCE: 400/235 (MBH02-742-S)
CURRENT APPLICATION NUMBER: US/10/944,611
CURRENT FILING DATE: 2004-09-16
PRIOR APPLICATION NUMBER: US 10/844,076
PRIOR FILING DATE: 2004-05-11
PRIOR APPLICATION NUMBER: US 10/831,620
PRIOR FILING DATE: 2004-04-23
PRIOR APPLICATION NUMBER: US 10/764,957
PRIOR FILING DATE: 2004-01-26
PRIOR APPLICATION NUMBER: US 10/670,011
PRIOR FILING DATE: 2003-09-23
PRIOR APPLICATION NUMBER: US 10/665,255
PRIOR FILING DATE: 2003-09-16
PRIOR APPLICATION NUMBER: US 10/664,767
PRIOR FILING DATE: 2003-09-16
PRIOR APPLICATION NUMBER: PCT/US03/05022
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/393,796
PRIOR FILING DATE: 2002-07-03
PRIOR APPLICATION NUMBER: US 60/399,348
PRIOR FILING DATE: 2002-07-29
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 4252
SOFTWARE: PatentIn version 3.3
SEQ ID NO 895
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-944-611-895

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 5.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3860 AGTTTGTGTTTGGTCT 3876
Db 18 AGTTTGTGTTTGGTCT 2

RESULT 896
US-10-944-611-1219
Sequence 1219, Application US/10944611
Publication No. US20050233998A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Jadhav, Vasant
APPLICANT: Kossen, Karl
APPLICANT: Zinnen, Shawn
APPLICANT: Vaish, Narendra
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
FILE REFERENCE: 400/235 (MBH02-742-S)
CURRENT APPLICATION NUMBER: US/10/944,611
CURRENT FILING DATE: 2004-09-16
PRIOR APPLICATION NUMBER: US 10/844,076
PRIOR FILING DATE: 2004-05-11
PRIOR APPLICATION NUMBER: US 10/831,620
PRIOR FILING DATE: 2004-04-23
PRIOR APPLICATION NUMBER: US 10/764,957
PRIOR FILING DATE: 2004-01-26
PRIOR APPLICATION NUMBER: US 10/670,011
PRIOR FILING DATE: 2003-09-23
PRIOR APPLICATION NUMBER: US 10/665,255
PRIOR FILING DATE: 2003-09-16
PRIOR APPLICATION NUMBER: US 10/664,767
PRIOR FILING DATE: 2003-09-16
PRIOR APPLICATION NUMBER: PCT/US03/05022
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/393,796
PRIOR FILING DATE: 2002-07-03
PRIOR APPLICATION NUMBER: US 60/399,348
PRIOR FILING DATE: 2002-07-29
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 4252
SOFTWARE: PatentIn version 3.3
SEQ ID NO 1219
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-944-611-1219

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 29.4%; Pred. No. 5.5e+02;
Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;
QY 3860 AGTTTGTGTTTGGTCT 3876
Db 2 AGUUUUUUUUUUUUUCU 18

RESULT 897
US-10-944-611-2420
Sequence 2420, Application US/10944611
Publication No. US20050233998A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Jadhav, Vasant

```
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2420
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense x
US-10-944-611-2420

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. NO. 5.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATCGTGACGTGTGGC 2947
||:|||||:|
Db 3 CAUGCUGACUGCUGGC 19

RESULT 898
US-10-944-611-3371/c
; Sequence 3371, Application US/10944611
; Publication No. US20050233998A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
```

```
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3371
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (2)..(3)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (4)..(5)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (7)..(8)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (9)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (12)..(13)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)..(16)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (17)..(18)
; OTHER INFORMATION: 2'-O-methyl
; US-10-944-611-3371

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. NO. 5.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY 2931 CATGCTGGACTGTGGC 2947
Db 17 CATGCTGGACTGTGGC 1

RESULT 899
US-10-440-464-42
; Sequence 42, Application US/10440464
; Publication No. US20040018528A1
; GENERAL INFORMATION:
; APPLICANT: DEPRIMO, SAMUEL
; APPLICANT: O'FARRELL, ANNE-MARIE
; APPLICANT: MORIMOTO, ALYSSA
; APPLICANT: SNOLICH, BEVERLY
; APPLICANT: MANNING, WILLIAM
; APPLICANT: WALTER, SARAH
; APPLICANT: CHERINGTON, JULIE
; APPLICANT: SCHILLING, JIM
; TITLE OF INVENTION: NOVEL BIOMARKERS OF TYROSINE KINASE INHIBITOR EXPOSURE
; TITLE OF INVENTION: AND ACTIVITY IN MAMMALS
; FILE REFERENCE: 038602/1592
; CURRENT APPLICATION NUMBER: US/10/440,464
; CURRENT FILING DATE: 2003-05-19
; PRIOR APPLICATION NUMBER: 60/380,872
; PRIOR FILING DATE: 2002-05-17
; PRIOR APPLICATION NUMBER: 60/448,922
; PRIOR FILING DATE: 2003-02-24
; PRIOR APPLICATION NUMBER: 60/448,874
; PRIOR FILING DATE: 2003-02-24
; NUMBER OF SEQ ID NOS: 185
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Probe
US-10-440-464-42

Query Match 0.4%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3974 CCTTTGCCCAAGTTG 3988
Db 1 CCTTTGCCCAAGTTG 15

RESULT 900
US-09-866-108-1651/c
; Sequence 1651, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1651
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1651

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3968 TGGCCTCTTTGCC 3982
Db 17 TGGCCTCTTTGCC 3

RESULT 901
US-09-866-108-1652/c
; Sequence 1652, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1652
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1652

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3968 TGGCTCTCTTGGCC 3982
||| ||||| ||||| |||||
Db 16 TGGCTCTCTTGGCC 2

RESULT 902
US-09-777-732-15/c
; Sequence 15, Application US/0977732
; Patent No. US20020132235A1
; GENERAL INFORMATION:
; APPLICANT: Avihingsanon, Yingyos
; APPLICANT: Ma, Nalli
; APPLICANT: Strom, Terry
; APPLICANT: Soares, Miguel C.
; APPLICANT: Ferran, Chrisiane
; APPLICANT: Manikam, Suchanthiran
; TITLE OF INVENTION: MEASUREMENT OF PROTECTIVE GENES IN ALLOGRAFT REJECTION
; FILE REFERENCE: 01948-059001
; CURRENT APPLICATION NUMBER: US/09/777.732
; CURRENT FILING DATE: 2001-02-06
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetically generated primer
US-09-777-732-15

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3961 TTCACTATGGCCTCC 3975
||| ||||| ||||| |||||
Db 15 TTCACTATGGCCTCC 1

RESULT 903
US-09-778-013-15/c
; Sequence 15, Application US/09778013
; Publication No. US20030104371A1
; GENERAL INFORMATION:
; APPLICANT: Strom, Terry B.
; APPLICANT: Suchanthiran, Manikkam
; APPLICANT: Vasconcellos, Lauro
; TITLE OF INVENTION: METHOD OF EVALUATING TRANSPLANT REJECTION
; FILE REFERENCE: 01948-061001
; CURRENT APPLICATION NUMBER: US/09/778.013

; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US 60/199,327
; PRIOR FILING DATE: 2000-04-24
; PRIOR APPLICATION NUMBER: US 60/240,735
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: US 60/240,735
; PRIOR FILING DATE: 2000-10-12
; PRIOR APPLICATION NUMBER: US 60/238,718
; PRIOR FILING DATE: 2000-10-06
; PRIOR APPLICATION NUMBER: US 08/937,063
; PRIOR FILING DATE: 1997-09-24
; NUMBER OF SEQ ID NOS: 57
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: sense primer
US-09-778-013-15

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3961 TTCACTATGGCCTCC 3975
||| ||||| ||||| |||||
Db 15 TTCACTATGGCCTCC 1

RESULT 904
US-10-138-674-5010
; Sequence 5010, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5010
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5010

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.9e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2894 CCCCCCCCCCAGACT 2908
||| ||||| ||||| |||||
Db 3 CCCCCCCCCCAGACU 17

RESULT 905
US-10-138-674-5011
; Sequence 5011, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5011
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5011

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.9e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2894 CCCCGCCCCCAGACT 2908
|||||||
Db 2 CCCCGCCCCCAGACU 16

RESULT 906

US-10-138-674-5012
; Sequence 5012, Application US/10138674
; Publication No. US2004007565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5012
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5012

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.9e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2894 CCCCGCCCCCAGACT 2908
|||||||
Db 1 CCCCGCCCCCAGACU 15

RESULT 907

US-10-287-949A-5010
; Sequence 5010, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5010
; LENGTH: 17
; TYPE: RNA

; ORGANISM: Homo sapiens
US-10-287-949A-5010

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.9e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2894 CCCCGCCCCCAGACT 2908
|||||||
Db 3 CCCCGCCCCCAGACU 17

RESULT 908

US-10-287-949A-5011
; Sequence 5011, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5011
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5011

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.9e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2894 CCCCGCCCCCAGACT 2908
|||||||
Db 2 CCCCGCCCCCAGACU 16

RESULT 909

US-10-287-949A-5012
; Sequence 5012, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5012
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5012

Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 4.9e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2894 CCCCGCCCCCAGACT 2908
|||||||

Db 1 CCCCCCCCCCAGACU 15

RESULT 910

US-10-723-361-1651/c

; Sequence 1651, Application US/107233361

; Publication No. US20040137589A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

; FILE REFERENCE: PB0105

; CURRENT APPLICATION NUMBER: US/10/723,361

; CURRENT FILING DATE: 2003-11-26

; PRIOR APPLICATION NUMBER: US 09/866,108

; PRIOR FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aeomica Sequence Listing Engine

; SEQ ID NO 1651

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-723-361-1651

Query Match 0.4%; Score 15; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 4.9e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3968 TGGCCTCCTTTGCC 3982

Db 17 TGGCCTCCTTTGCC 3

RESULT 911

US-10-723-361-1652/c

; Sequence 1652, Application US/107233361

; Publication No. US20040137589A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

; FILE REFERENCE: PB0105

; CURRENT APPLICATION NUMBER: US/10/723,361

; CURRENT FILING DATE: 2003-11-26

; PRIOR APPLICATION NUMBER: US 09/866,108

; PRIOR FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aeomica Sequence Listing Engine

; SEQ ID NO 1652

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-723-361-1652

Query Match 0.4%; Score 15; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 4.9e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3968 TGGCCTCCTTTGCC 3982

Db 16 TGGCCTCCTTTGCC 2

RESULT 912

US-10-138-674-1470

; Sequence 1470, Application US/10138674

; Publication No. US20040077565A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MEH000-876-N(400/049)

; CURRENT APPLICATION NUMBER: US/10/138,674

; CURRENT FILING DATE: 2002-05-03

; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1470

; LENGTH: 18

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-138-674-1470

Query Match 0.4%; Score 15; DB 1; Length 18;

Best Local Similarity 93.3%; Pred. No. 5.5e+02;

Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2894 CCCCCCCCCCAGACT 2908

Db 4 CCCCCCCCCCAGACU 18

RESULT 913

US-10-287-949A-1470

; Sequence 1470, Application US/10287949A

```
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1470
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1470

Query Match          0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 5.5e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2894 CCCCGCCCCCAGACT 2908
Db 4 CCCCGCCCCCAGACU 18

RESULT 914
US-10-951-303-1470
; Sequence 1470, Application US/10951303
; Publication No. US20050227937A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00-876-K (400/021)
; CURRENT FILING DATE: 2004-09-27
; NUMBER OF SEQ ID NOS: 10951,303
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1470
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-951-303-1470

Query Match          0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 5.5e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2894 CCCCGCCCCCAGACT 2908
Db 4 CCCCGCCCCCAGACU 18

RESULT 915
US-10-719-956-629839/c
; Sequence 629839, Application US/10719956
; Publication No. US20040146910A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 629839
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-629839

Query Match          0.4%; Score 15; DB 1; Length 25;
Best Local Similarity 78.3%; Pred. No. 8.9e+02;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 3636 CTCACCTTGATGGTGGCTTCCC 3658
Db 25 CCCACCTTGATGGAGGTGTTCTC 3

RESULT 916
US-09-969-373-3074/c
; Sequence 3074, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Ebertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 3074
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-3074

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2225 TTGAAGAGGTGATTGGTG 2242
Db 18 TTGAGGAGGTGTTGGTG 1

RESULT 917
US-10-178-325-172
; Sequence 172, Application US/10178325
; Publication No. US20030199467A1
; GENERAL INFORMATION:
; APPLICANT: Roberts, M. Luisa
; APPLICANT: Cowser, Lex M.
; TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
; FILE REFERENCE: ISPH-0404
; CURRENT APPLICATION NUMBER: US/10/178,325
; CURRENT FILING DATE: 2002-06-21
; PRIOR APPLICATION NUMBER: US/09/387,341
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 09/156,424
```

; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 09/156,979
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 09/156,807
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 09/161,015
; PRIOR FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 233
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 172
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-178-325-172

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 658 CTCGAGTGCCTGTCCTG 675
| | | | | | | | | | | | | | | |
Db 1 CGCGAGTGCCTGCGCCTG 18

RESULT 918
US-10-409-786-13/c
; Sequence 13, Application US/10409786
; Publication No. US20040023855A1
; GENERAL INFORMATION:
; APPLICANT: John, Constance
; APPLICANT: Unger, Gretchen
; TITLE OF INVENTION: BIOLOGIC MODULATIONS WITH NANOPARTICLES
; FILE REFERENCE: 3157.00009
; CURRENT APPLICATION NUMBER: US/10/409,786
; CURRENT FILING DATE: 2003-04-08
; PRIOR APPLICATION NUMBER: 10/378,044
; PRIOR FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: 60/394,315
; PRIOR FILING DATE: 2002-07-08
; PRIOR APPLICATION NUMBER: 60/370,882
; PRIOR FILING DATE: 2002-04-08
; PRIOR APPLICATION NUMBER: 60/428,296
; PRIOR FILING DATE: 2002-11-22
; PRIOR APPLICATION NUMBER: 09/877,790
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: WO 02/100343
; PRIOR FILING DATE: 2002-06-10
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: CK2alpha Antisense
US-10-409-786-13

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1223 GGTCTGCTGCACGCGCATGCC 1240
| | | | | | | | | | | | | | | |
Db 18 GGTCCCGCCGCGCATGCC 1

RESULT 919
US-10-378-044-8/c
; Sequence 8, Application US/10378044
; Publication No. US20040038303A1
; GENERAL INFORMATION:

; APPLICANT: Geneseeques, Inc.
; TITLE OF INVENTION: Biological Modulations with Nanoparticles
; FILE REFERENCE: 3193.03US02
; CURRENT APPLICATION NUMBER: US/10/378,044
; CURRENT FILING DATE: 2003-02-28
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: CK2alpha Antisense
US-10-378-044-8

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1223 GGTCTGCTGCACGCGCATGCC 1240
| | | | | | | | | | | | | | | |
Db 18 GGTCCCGCCGCGCATGCC 1

RESULT 920
US-10-416-111-10
; Sequence 10, Application US/10416111
; Publication No. US20040048278A1
; GENERAL INFORMATION:
; APPLICANT: OLEK, Alexander
; APPLICANT: PIEPENBROCK, Christian
; APPLICANT: BERLIN, Kurt
; TITLE OF INVENTION: Diagnosis of Diseases Associated with the Human C-mos Gene
; FILE REFERENCE: 5013.1017
; CURRENT APPLICATION NUMBER: US/10/416,111
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: PCT/EP01/12831
; PRIOR FILING DATE: 2001-11-06
; PRIOR APPLICATION NUMBER: DE 10054972.1
; PRIOR FILING DATE: 2000-11-06
; NUMBER OF SEQ ID NOS: 20
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: chemically treated genomic DNA (Homo sapiens)
US-10-416-111-10

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3782 GTCACCAACCAACTCAAT 3799
| | | | | | | | | | | | | | | |
Db 1 GTTACCACCAACTCCAT 18

RESULT 921
US-10-731-739-517
; Sequence 517, Application US/10731739
; Publication No. US20040176582A1
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-013
; CURRENT APPLICATION NUMBER: US/10/731,739
; CURRENT FILING DATE: 2003-12-10
; PRIOR APPLICATION NUMBER: US/09/544,398B
; PRIOR FILING DATE: 2002-06-10

; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 517
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-731-739-517

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3093 CTCAGCTTTTGGCTCTGT 3110
||| ||||| ||||| |||||
Db 1 CTGAGCTTTTGGCACTGT 18

RESULT 922
US-10-660-122-104
; Sequence 104, Application US/10660122
; Publication No. US20040219517A1
; GENERAL INFORMATION:
; APPLICANT: Ecker, David J.
; APPLICANT: Griffey, Richard H.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Hofstadler, Steven
; APPLICANT: McNeil, John
; APPLICANT: Crooke, Stanley T.
; TITLE OF INVENTION: Methods For Rapid Identification Of Pathogens In Humans And Anima
; FILE REFERENCE: IBIS0061-100
; CURRENT APPLICATION NUMBER: US/10/660,122
; CURRENT FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 10/323,233
; PRIOR FILING DATE: 2002-12-18
; PRIOR APPLICATION NUMBER: 09/798,007
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/431,319
; PRIOR FILING DATE: 2002-12-06
; PRIOR APPLICATION NUMBER: 60/443,443
; PRIOR FILING DATE: 2003-01-29
; PRIOR APPLICATION NUMBER: 60/443,788
; PRIOR FILING DATE: 2003-01-30
; PRIOR APPLICATION NUMBER: 60/447,529
; PRIOR FILING DATE: 2003-02-14
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 104
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-660-122-104

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 636 CGGCACGCTGGCTTTCAC 653
||| ||||| ||||| |||||
Db 1 CGAGCGCTGGCTTTCAC 18

RESULT 923
US-10-477-238A-517
; Sequence 517, Application US/10477238A
; Publication No. US20040221326A1

; GENERAL INFORMATION:
; APPLICANT: Babi, Philip
; APPLICANT: Yaworsky, Paul
; APPLICANT: Bex, Frederick J. III
; APPLICANT: Bodine, Peter Van Nest
; TITLE OF INVENTION: Transgenic Animal Model of Bone Mass Modulation
; FILE REFERENCE: 032796-212
; CURRENT APPLICATION NUMBER: US/10/477,238A
; CURRENT FILING DATE: 2003-11-10
; PRIOR APPLICATION NUMBER: US 60/290,071
; PRIOR FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: US 60/291,311
; PRIOR FILING DATE: 2001-05-17
; PRIOR APPLICATION NUMBER: US 60/353,058
; PRIOR FILING DATE: 2002-02-01
; PRIOR APPLICATION NUMBER: US 60/361,293
; PRIOR FILING DATE: 2002-03-04
; NUMBER OF SEQ ID NOS: 812
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 517
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-477-238A-517

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3093 CTCAGCTTTTGGCTCTGT 3110
||| ||||| ||||| |||||
Db 1 CTGAGCTTTTGGCACTGT 18

RESULT 924
US-10-473-126-1246
; Sequence 1246, Application US/10473126
; Publication No. US20040234973A1
; GENERAL INFORMATION:
; APPLICANT: Epigenomics AG
; TITLE OF INVENTION: Methods and nucleic acids for the analysis of hematopoietic cell
; TITLE OF INVENTION: proliferative disorders
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/473,126
; CURRENT FILING DATE: 2003-09-26
; NUMBER OF SEQ ID NOS: 1258
; SEQ ID NO 1246
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Detection oligonucleotide for Humos
US-10-473-126-1246

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3782 GTCACCACCAACTCAAT 3799
||| ||||| ||||| |||||
Db 1 GTTACCACCAACTCCAT 18

RESULT 925
US-10-680-287A-517
; Sequence 517, Application US/10680287A
; Publication No. US2004024069A1
; GENERAL INFORMATION:
; APPLICANT: Babi, Philip
; APPLICANT: Yaworsky, Paul
; APPLICANT: Bex, Frederick J. III
; APPLICANT: Bodine, Peter Van Nest
; TITLE OF INVENTION: Transgenic Animal Model of Bone Mass Modulation

; FILE REFERENCE: 032796-179
; CURRENT APPLICATION NUMBER: US/10/680,287A
; CURRENT FILING DATE: 2003-10-08
; PRIOR APPLICATION NUMBER: PCT/US02/14876
; PRIOR FILING DATE: 2002-05-13
; PRIOR APPLICATION NUMBER: US 60/290,071
; PRIOR FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: US 60/291,311
; PRIOR FILING DATE: 2001-05-17
; PRIOR APPLICATION NUMBER: US 60/353,058
; PRIOR FILING DATE: 2002-02-01
; PRIOR APPLICATION NUMBER: US 60/361,293
; PRIOR FILING DATE: 2002-03-04
; NUMBER OF SEQ ID NOS: 812
; SOFTWARE: PastSeq for Windows Version 4.0
; SEQ ID NO 517
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-680-287A-517

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3093 CTCAGCTTTTGGCTCTGT 3110
||| ||||| ||||| |||||
Db 1 CTGAGCTTTTGGCAGCTGT 18

RESULT 926

US-10-477-173-517
; Sequence 517, Application US/10477173
; Publication No. US20050070699A1
; GENERAL INFORMATION:
; APPLICANT: Genome Therapeutics Corporation and
; APPLICANT: Allen, Kristina M.
; APPLICANT: Yaworsky, Paul
; APPLICANT: Morales, Arturo J.
; APPLICANT: Graham, James R.
; APPLICANT: Anisowicz, Anthony
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: HBM Variants that Modulate Bone Mass and Lipid Levels
; FILE REFERENCE: 032796-135
; CURRENT APPLICATION NUMBER: US/10/477,173
; CURRENT FILING DATE: 2003-11-10
; PRIOR APPLICATION NUMBER: US 60/290,071
; PRIOR FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: US 60/291,311
; PRIOR FILING DATE: 2001-05-17
; PRIOR APPLICATION NUMBER: US 60/353,058
; PRIOR FILING DATE: 2002-02-01
; PRIOR APPLICATION NUMBER: US 60/361,293
; PRIOR FILING DATE: 2002-03-04
; NUMBER OF SEQ ID NOS: 1086
; SOFTWARE: PastSeq for Windows Version 4.0
; SEQ ID NO 517
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-477-173-517

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3093 CTCAGCTTTTGGCTCTGT 3110
||| ||||| ||||| |||||
Db 1 CTGAGCTTTTGGCAGCTGT 18

RESULT 927

US-10-182-049-49/c

; Sequence 49, Application US/10182049
; Publication No. US20050113322A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION
; FILE REFERENCE: RTSP-0360
; CURRENT APPLICATION NUMBER: US/10/182,049
; CURRENT FILING DATE: 2002-07-27
; PRIOR APPLICATION NUMBER: 09/490,208
; PRIOR FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 182
; SEQ ID NO 49
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-182-049-49

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 511 AGCGGCTGATCAGGAA 528
||| ||||| ||||| |||||
Db 18 AGCTGCTGGAGGAGAA 1

RESULT 928

US-10-834-377-517
; Sequence 517, Application US/10834377
; Publication No. US20050142617A1
; GENERAL INFORMATION:
; APPLICANT: Carulli, John P.
; APPLICANT: Little, Randall D.
; APPLICANT: Recker, Robert R.
; APPLICANT: Johnson, Mark L.
; TITLE OF INVENTION: High bone mass gene of 11q13.3
; FILE REFERENCE: 032796-014
; CURRENT APPLICATION NUMBER: US/10/834,377
; CURRENT FILING DATE: 2004-04-29
; PRIOR APPLICATION NUMBER: US/09/543,771B
; PRIOR FILING DATE: 2000-04-05
; PRIOR APPLICATION NUMBER: US 09/229,319
; PRIOR FILING DATE: 1999-01-13
; PRIOR APPLICATION NUMBER: US 60/071,449
; PRIOR FILING DATE: 1998-01-13
; PRIOR APPLICATION NUMBER: US 60/105,511
; PRIOR FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 641
; SOFTWARE: PastSeq for Windows Version 4.0
; SEQ ID NO 517
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-834-377-517

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 5.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3093 CTCAGCTTTTGGCTCTGT 3110
||| ||||| ||||| |||||
Db 1 CTGAGCTTTTGGCAGCTGT 18

Search completed: March 23, 2006, 11:15:52
Job time : 56 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.7
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: March 23, 2006, 11:19:39 ; Search time 84 Seconds
(without alignments)

3.337 Million cell updates/sec

Title: US-10-800-077-392

Perfect score: 4235

Sequence: 1 ctggccggcgccgagc.....cgtgtcccgctccaggggt 4235

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 1699 seqs, 33094 residues

Total number of hits satisfying chosen parameters: 3398

Minimum DB seq length: 5

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 1700 summaries

Database : fetch392rnpbn.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
C 1	29	0.7	36	1	US-10-949-720-2
C 2	27	0.6	27	1	US-10-310-914A-153230
C 3	27	0.6	27	1	US-10-310-914A-153273
C 4	27	0.6	27	1	US-10-310-914A-153276
C 5	26	0.6	26	1	US-10-310-914A-153271
C 6	26	0.6	26	1	US-10-310-914A-153279
C 7	25	0.6	25	1	US-10-310-914A-153226
C 8	25	0.6	25	1	US-10-310-914A-153237
C 9	25	0.6	25	1	US-10-310-914A-153292
C 10	25	0.6	25	1	US-11-121-849-151566
C 11	25	0.6	25	1	US-11-121-849-151567
C 12	25	0.6	25	1	US-11-121-849-151568
C 13	25	0.6	25	1	US-11-121-849-151569
C 14	25	0.6	25	1	US-11-121-849-151570
C 15	25	0.6	25	1	US-11-121-849-151571
C 16	25	0.6	25	1	US-11-121-849-151572
C 17	25	0.6	25	1	US-11-121-849-151573
C 18	25	0.6	25	1	US-11-121-849-151575
C 19	25	0.6	25	1	US-11-121-849-151576
C 20	25	0.6	25	1	US-11-121-849-302682
C 21	25	0.6	25	1	US-11-121-849-302683
C 22	25	0.6	25	1	US-11-121-849-302684
C 23	25	0.6	25	1	US-11-121-849-302685
C 24	25	0.6	25	1	US-11-121-849-302686
C 25	25	0.6	25	1	US-11-121-849-302687
C 26	25	0.6	25	1	US-11-121-849-302688
C 27	25	0.6	25	1	US-11-121-849-302689
C 28	25	0.6	25	1	US-11-121-849-302690
C 29	25	0.6	25	1	US-11-121-849-302691
C 30	25	0.6	25	1	US-11-121-849-302692
C 31	25	0.6	27	1	US-10-310-914A-153255
C 32	24.2	0.6	29	1	US-10-949-720-1
C 33	24.2	0.6	29	1	US-10-949-720-397
C 34	24	0.6	24	1	US-10-949-720-2
C 35	24	0.6	24	1	US-10-949-720-35
C 36	24	0.6	24	1	US-10-949-720-37
C 37	24	0.6	24	1	US-10-949-720-39
C 38	24	0.6	24	1	US-10-949-720-41
C 39	24	0.6	24	1	US-10-949-720-42
C 40	24	0.6	24	1	US-10-949-720-44
C 41	24	0.6	24	1	US-10-949-720-45
C 42	24	0.6	24	1	US-10-949-720-46
C 43	24	0.6	24	1	US-10-949-720-49
C 44	23.4	0.6	24	1	US-10-949-720-50
C 45	23	0.5	23	1	US-10-949-720-52
C 46	23	0.5	23	1	US-10-949-720-55
C 47	23	0.5	23	1	US-10-949-720-73
C 48	23	0.5	23	1	US-10-949-720-222
C 49	23	0.5	23	1	US-10-949-720-224
C 50	23	0.5	23	1	US-10-949-720-225
C 51	23	0.5	23	1	US-10-949-720-226
C 52	23	0.5	23	1	US-10-949-720-229
C 53	23	0.5	23	1	US-10-949-720-230
C 54	23	0.5	23	1	US-10-949-720-232
C 55	23	0.5	23	1	US-10-949-720-233
C 56	23	0.5	23	1	US-10-949-720-234
C 57	22.8	0.5	22	1	US-10-949-720-236
C 58	22	0.5	22	1	US-10-949-720-237
C 59	22	0.5	22	1	US-10-949-720-238
C 60	22	0.5	22	1	US-10-949-720-239
C 61	22	0.5	22	1	US-10-949-720-240
C 62	22	0.5	22	1	US-10-949-720-241
C 63	22	0.5	22	1	US-10-949-720-242
C 64	22	0.5	22	1	US-10-949-720-243
C 65	22	0.5	22	1	US-10-949-720-244
C 66	22	0.5	22	1	US-10-949-720-245
C 67	21.8	0.5	25	1	US-11-136-527-49340
C 68	21.8	0.5	25	1	US-11-136-527-49341
C 69	21.8	0.5	25	1	US-11-136-527-243931
C 70	21.8	0.5	25	1	US-11-136-527-243933
C 71	21.8	0.5	25	1	US-11-136-527-243939
C 72	21.8	0.5	26	1	US-10-310-914A-153283
C 73	21.4	0.5	23	1	US-10-310-914A-153286
C 74	21.4	0.5	25	1	US-10-310-914A-207826
C 75	21	0.5	25	1	US-10-310-914A-916482
C 76	21	0.5	21	1	US-10-949-720-35
C 77	21	0.5	21	1	US-10-949-720-37
C 78	21	0.5	21	1	US-10-949-720-39
C 79	21	0.5	21	1	US-10-949-720-41
C 80	21	0.5	21	1	US-10-949-720-42
C 81	21	0.5	21	1	US-10-949-720-44
C 82	21	0.5	21	1	US-10-949-720-45
C 83	21	0.5	21	1	US-10-949-720-46
C 84	21	0.5	21	1	US-10-949-720-49
C 85	21	0.5	21	1	US-10-949-720-50
C 86	21	0.5	21	1	US-10-949-720-52
C 87	21	0.5	21	1	US-10-949-720-70
C 88	21	0.5	21	1	US-10-949-720-73
C 89	21	0.5	21	1	US-10-949-720-222
C 90	21	0.5	21	1	US-10-949-720-224
C 91	21	0.5	21	1	US-10-949-720-225
C 92	21	0.5	21	1	US-10-949-720-226
C 93	21	0.5	21	1	US-10-949-720-229
C 94	21	0.5	21	1	US-10-949-720-230
C 95	21	0.5	21	1	US-10-949-720-232
C 96	21	0.5	21	1	US-10-949-720-233
C 97	21	0.5	21	1	US-10-949-720-234
C 98	21	0.5	21	1	US-10-949-720-236
C 99	21	0.5	21	1	US-10-949-720-237
C 100	21	0.5	21	1	US-10-949-720-238
C 101	21	0.5	21	1	US-10-949-720-239
C 102	21	0.5	21	1	US-10-949-720-240
C 103	21	0.5	21	1	US-10-949-720-241
C 104	21	0.5	21	1	US-10-949-720-242
C 105	21	0.5	21	1	US-10-949-720-243
C 106	21	0.5	21	1	US-10-949-720-244
C 107	21	0.5	21	1	US-10-949-720-245
C 108	21	0.5	21	1	US-10-949-720-246
C 109	21	0.5	21	1	US-10-949-720-247
C 110	21	0.5	21	1	US-10-949-720-248
C 111	21	0.5	21	1	US-10-949-720-249
C 112	21	0.5	21	1	US-10-949-720-250
C 113	21	0.5	21	1	US-10-949-720-251
C 114	21	0.5	21	1	US-10-949-720-252
C 115	21	0.5	21	1	US-10-949-720-253
C 116	21	0.5	21	1	US-10-949-720-254
C 117	21	0.5	21	1	US-10-949-720-255
C 118	21	0.5	21	1	US-10-949-720-256
C 119	21	0.5	21	1	US-10-949-720-257
C 120	21	0.5	21	1	US-10-949-720-258
C 121	21	0.5	21	1	US-10-949-720-259
C 122	21	0.5	21	1	US-10-949-720-260
C 123	21	0.5	21	1	US-10-949-720-261
C 124	21	0.5	21	1	US-10-949-720-262
C 125	21	0.5	21	1	US-10-949-720-263
C 126	21	0.5	21	1	US-10-949-720-264
C 127	21	0.5	21	1	US-10-949-720-265
C 128	21	0.5	21	1	US-10-949-720-266
C 129	21	0.5	21	1	US-10-949-720-267
C 130	21	0.5	21	1	US-10-949-720-268
C 131	21	0.5	21	1	US-10-949-720-269
C 132	21	0.5	21	1	US-10-949-720-270
C 133	21	0.5	21	1	US-10-949-720-271
C 134	21	0.5	21	1	US-10-949-720-272
C 135	21	0.5	21	1	US-10-949-720-273
C 136	21	0.5	21	1	US-10-949-720-274
C 137	21	0.5	21	1	US-10-949-720-275
C 138	21	0.5	21	1	US-10-949-720-276
C 139	21	0.5	21	1	US-10-949-720-277
C 140	21	0.5	21	1	US-10-949-720-278
C 141	21	0.5	21	1	US-10-949-720-279
C 142	21	0.5	21	1	US-10-949-720-280
C 143	21	0.5	21	1	US-10-949-720-281
C 144	21	0.5	21	1	US-10-949-720-282
C 145	21	0.5	21	1	US-10-949-720-283
C 146	21	0.5	21	1	US-10-949-720-284
C 147	21	0.5	21	1	US-10-949-720-285
C 148	21	0.5	21	1	US-10-949-720-286
C 149	21	0.5	21	1	US-10-949-720-287
C 150	21	0.5	21	1	US-10-949-720-288
C 151	21	0.5	21	1	US-10-949-720-289
C 152	21	0.5	21	1	US-10-949-720-290
C 153	21	0.5	21	1	US-10-949-720-291
C 154	21	0.5	21	1	US-10-949-720-292
C 155	21	0.5	21	1	US-10-949-720-293
C 156	21	0.5	21	1	US-10-949-720-294
C 157	21	0.5	21	1	US-10-949-720-295
C 158	21	0.5	21	1	US-10-949-720-296
C 159	21	0.5	21	1	US-10-949-720-297
C 160	21	0.5	21	1	US-10-949-720-298
C 161	21	0.5	21	1	US-10-949-720-299
C 162	21	0.5	21	1	US-10-949-720-300
C 163	21	0.5	21	1	US-10-949-720-301
C 164	21	0.5	21	1	US-10-949-720-302
C 165	21	0.5	21	1	US-10-949-720-303
C 166	21	0.5	21	1	US-10-949-720-304
C 167	21	0.5	21	1	US-10-949-720-305
C 168	21	0.5	21	1	US-10-949-720-306
C 169	21	0.5	21	1	US-10-949-720-307
C 170	21	0.5	21	1	US-10-949-720-308
C 171	21	0.5	21	1	US-10-949-720-309
C 172	21	0.5	21	1	US-10-949-720-310
C 173	21	0.5	21	1	US-10-949-720-311
C 174	21	0.5	21	1	US-10-949-720-312
C 175	21	0.5	21	1	US-

C 253	20	0.5	20	1	US-10-949-720-146	Sequence 146, App	C 326	20	0.5	20	1	US-10-949-720-219	Sequence 219, App
C 254	20	0.5	20	1	US-10-949-720-147	Sequence 147, App	C 327	20	0.5	20	1	US-10-949-720-220	Sequence 220, App
C 255	20	0.5	20	1	US-10-949-720-148	Sequence 148, App	C 328	20	0.5	20	1	US-10-949-720-221	Sequence 221, App
C 256	20	0.5	20	1	US-10-949-720-149	Sequence 149, App	C 329	20	0.5	20	1	US-10-949-720-231	Sequence 231, App
C 257	20	0.5	20	1	US-10-949-720-150	Sequence 150, App	C 330	20	0.5	20	1	US-10-949-720-421	Sequence 421, App
C 258	20	0.5	20	1	US-10-949-720-151	Sequence 151, App	C 331	20	0.5	20	1	US-10-310-914A-153225	Sequence 153225,
C 259	20	0.5	20	1	US-10-949-720-152	Sequence 152, App	C 332	20	0.5	20	1	US-10-310-914A-153251	Sequence 153251,
C 260	20	0.5	20	1	US-10-949-720-153	Sequence 153, App	C 333	20	0.5	20	1	US-10-310-914A-153252	Sequence 153252,
C 261	20	0.5	20	1	US-10-949-720-154	Sequence 154, App	C 334	20	0.5	20	1	US-10-310-914A-153263	Sequence 153263,
C 262	20	0.5	20	1	US-10-949-720-155	Sequence 155, App	C 335	20	0.5	20	1	US-10-310-914A-153284	Sequence 153284,
C 263	20	0.5	20	1	US-10-949-720-156	Sequence 156, App	C 336	20	0.5	21	1	US-10-949-720-38	Sequence 38, Appl
C 264	20	0.5	20	1	US-10-949-720-157	Sequence 157, App	C 337	20	0.5	21	1	US-10-949-720-288	Sequence 288, App
C 265	20	0.5	20	1	US-10-949-720-158	Sequence 158, App	C 338	20	0.5	21	1	US-10-770-726-17477	Sequence 17477, A
C 266	20	0.5	20	1	US-10-949-720-159	Sequence 159, App	C 339	20	0.5	21	1	US-10-310-914A-153253	Sequence 153253,
C 267	20	0.5	20	1	US-10-949-720-160	Sequence 160, App	C 340	20	0.5	22	1	US-10-310-914A-1353080	Sequence 1353080,
C 268	20	0.5	20	1	US-10-949-720-161	Sequence 161, App	C 341	20	0.5	23	1	US-10-310-914A-95660	Sequence 95660, A
C 269	20	0.5	20	1	US-10-949-720-162	Sequence 162, App	C 342	19.8	0.5	23	1	US-10-310-914A-478410	Sequence 478410,
C 270	20	0.5	20	1	US-10-949-720-163	Sequence 163, App	C 343	19.8	0.5	23	1	US-10-310-914A-1141553	Sequence 1141553,
C 271	20	0.5	20	1	US-10-949-720-164	Sequence 164, App	C 344	19.8	0.5	24	1	US-10-310-914A-556544	Sequence 556544,
C 272	20	0.5	20	1	US-10-949-720-165	Sequence 165, App	C 345	19.4	0.5	21	1	US-10-949-720-43	Sequence 43, Appl
C 273	20	0.5	20	1	US-10-949-720-166	Sequence 166, App	C 346	19.4	0.5	21	1	US-10-949-720-223	Sequence 223, App
C 274	20	0.5	20	1	US-10-949-720-167	Sequence 167, App	C 347	19.4	0.5	21	1	US-10-770-726-16892	Sequence 16892, A
C 275	20	0.5	20	1	US-10-949-720-168	Sequence 168, App	C 348	19.4	0.5	21	1	US-10-770-726-16916	Sequence 16916, A
C 276	20	0.5	20	1	US-10-949-720-169	Sequence 169, App	C 349	19.4	0.5	21	1	US-10-770-726-17495	Sequence 17495, A
C 277	20	0.5	20	1	US-10-949-720-170	Sequence 170, App	C 350	19.4	0.5	21	1	US-10-770-726-17498	Sequence 17498, A
C 278	20	0.5	20	1	US-10-949-720-171	Sequence 171, App	C 351	19.4	0.5	21	1	US-10-770-726-17501	Sequence 17501, A
C 279	20	0.5	20	1	US-10-949-720-172	Sequence 172, App	C 352	19.4	0.5	21	1	US-10-770-726-17534	Sequence 17534, A
C 280	20	0.5	20	1	US-10-949-720-173	Sequence 173, App	C 353	19.4	0.5	21	1	US-10-770-726-17540	Sequence 17540, A
C 281	20	0.5	20	1	US-10-949-720-174	Sequence 174, App	C 354	19.4	0.5	21	1	US-10-770-726-17543	Sequence 17543, A
C 282	20	0.5	20	1	US-10-949-720-175	Sequence 175, App	C 355	19.4	0.5	21	1	US-10-310-914A-161882	Sequence 161882,
C 283	20	0.5	20	1	US-10-949-720-176	Sequence 176, App	C 356	19.4	0.5	22	1	US-10-310-914A-161883	Sequence 161883,
C 284	20	0.5	20	1	US-10-949-720-177	Sequence 177, App	C 357	19.4	0.5	22	1	US-10-310-914A-311206	Sequence 311206,
C 285	20	0.5	20	1	US-10-949-720-178	Sequence 178, App	C 358	19.2	0.5	24	1	US-10-310-914A-390963	Sequence 390963,
C 286	20	0.5	20	1	US-10-949-720-179	Sequence 179, App	C 359	19.2	0.5	24	1	US-10-310-914A-686978	Sequence 686978,
C 287	20	0.5	20	1	US-10-949-720-180	Sequence 180, App	C 360	19.2	0.5	24	1	US-11-178-086-26	Sequence 26, Appl
C 288	20	0.5	20	1	US-10-949-720-181	Sequence 181, App	C 361	19.2	0.5	24	1	US-11-178-086-73	Sequence 73, Appl
C 289	20	0.5	20	1	US-10-949-720-182	Sequence 182, App	C 362	19	0.4	19	1	US-10-310-914A-153218	Sequence 153218,
C 290	20	0.5	20	1	US-10-949-720-183	Sequence 183, App	C 363	19	0.4	19	1	US-10-310-914A-153220	Sequence 153220,
C 291	20	0.5	20	1	US-10-949-720-184	Sequence 184, App	C 364	19	0.4	19	1	US-10-310-914A-153222	Sequence 153222,
C 292	20	0.5	20	1	US-10-949-720-185	Sequence 185, App	C 365	19	0.4	19	1	US-10-310-914A-153224	Sequence 153224,
C 293	20	0.5	20	1	US-10-949-720-186	Sequence 186, App	C 366	19	0.4	19	1	US-10-310-914A-153227	Sequence 153227,
C 294	20	0.5	20	1	US-10-949-720-187	Sequence 187, App	C 367	19	0.4	19	1	US-10-310-914A-153244	Sequence 153244,
C 295	20	0.5	20	1	US-10-949-720-188	Sequence 188, App	C 368	19	0.4	19	1	US-10-310-914A-153245	Sequence 153245,
C 296	20	0.5	20	1	US-10-949-720-189	Sequence 189, App	C 369	19	0.4	19	1	US-10-310-914A-153250	Sequence 153250,
C 297	20	0.5	20	1	US-10-949-720-190	Sequence 190, App	C 370	19	0.4	19	1	US-10-310-914A-153258	Sequence 153258,
C 298	20	0.5	20	1	US-10-949-720-191	Sequence 191, App	C 371	19	0.4	19	1	US-10-310-914A-153268	Sequence 153268,
C 299	20	0.5	20	1	US-10-949-720-192	Sequence 192, App	C 372	19	0.4	19	1	US-10-310-914A-153272	Sequence 153272,
C 300	20	0.5	20	1	US-10-949-720-193	Sequence 193, App	C 373	19	0.4	19	1	US-10-310-914A-153282	Sequence 153282,
C 301	20	0.5	20	1	US-10-949-720-194	Sequence 194, App	C 374	19	0.4	19	1	US-10-310-914A-153290	Sequence 153290,
C 302	20	0.5	20	1	US-10-949-720-195	Sequence 195, App	C 375	19	0.4	19	1	US-10-310-914A-153291	Sequence 153291,
C 303	20	0.5	20	1	US-10-949-720-196	Sequence 196, App	C 376	19	0.4	19	1	US-11-101-244-685	Sequence 685, App
C 304	20	0.5	20	1	US-10-949-720-197	Sequence 197, App	C 377	19	0.4	19	1	US-11-101-244-686	Sequence 686, App
C 305	20	0.5	20	1	US-10-949-720-198	Sequence 198, App	C 378	19	0.4	19	1	US-11-101-244-687	Sequence 687, App
C 306	20	0.5	20	1	US-10-949-720-199	Sequence 199, App	C 379	19	0.4	19	1	US-11-101-244-688	Sequence 688, App
C 307	20	0.5	20	1	US-10-949-720-200	Sequence 200, App	C 380	19	0.4	19	1	US-11-101-244-158892	Sequence 158892,
C 308	20	0.5	20	1	US-10-949-720-201	Sequence 201, App	C 381	19	0.4	19	1	US-11-101-244-159283	Sequence 159283,
C 309	20	0.5	20	1	US-10-949-720-202	Sequence 202, App	C 382	19	0.4	19	1	US-11-101-244-159284	Sequence 159284,
C 310	20	0.5	20	1	US-10-949-720-203	Sequence 203, App	C 383	19	0.4	19	1	US-11-101-244-159285	Sequence 159285,
C 311	20	0.5	20	1	US-10-949-720-204	Sequence 204, App	C 384	19	0.4	19	1	US-11-101-244-159287	Sequence 159287,
C 312	20	0.5	20	1	US-10-949-720-205	Sequence 205, App	C 385	19	0.4	19	1	US-11-101-244-159288	Sequence 159288,
C 313	20	0.5	20	1	US-10-949-720-206	Sequence 206, App	C 386	19	0.4	19	1	US-11-101-244-159289	Sequence 159289,
C 314	20	0.5	20	1	US-10-949-720-207	Sequence 207, App	C 387	19	0.4	19	1	US-11-101-244-159290	Sequence 159290,
C 315	20	0.5	20	1	US-10-949-720-208	Sequence 208, App	C 388	19	0.4	19	1	US-11-101-244-159291	Sequence 159291,
C 316	20	0.5	20	1	US-10-949-720-209	Sequence 209, App	C 389	19	0.4	19	1	US-11-101-244-159292	Sequence 159292,
C 317	20	0.5	20	1	US-10-949-720-210	Sequence 210, App	C 390	19	0.4	19	1	US-11-101-244-159293	Sequence 159293,
C 318	20	0.5	20	1	US-10-949-720-211	Sequence 211, App	C 391	19	0.4	19	1	US-11-101-244-159294	Sequence 159294,
C 319	20	0.5	20	1	US-10-949-720-212	Sequence 212, App	C 392	19	0.4	19	1	US-11-101-244-159295	Sequence 159295,
C 320	20	0.5	20	1	US-10-949-720-213	Sequence 213, App	C 393	19	0.4	19	1	US-11-101-244-159296	Sequence 159296,
C 321	20	0.5	20	1	US-10-949-720-214	Sequence 214, App	C 394	19	0.4	19	1	US-11-101-244-159297	Sequence 159297,
C 322	20	0.5	20	1	US-10-949-720-215	Sequence 215, App	C 395	19	0.4	19	1	US-11-101-244-159298	Sequence 159298,
C 323	20	0.5	20	1	US-10-949-720-216	Sequence 216, App	C 396	19	0.4	19	1	US-11-101-244-159299	Sequence 159299,
C 324	20	0.5	20	1	US-10-949-720-217	Sequence 217, App	C 397	19	0.4	19	1	US-11-101-244-159300	Sequence 159300,
C 325	20	0.5	20	1	US-10-949-720-218	Sequence 218, App	C 398	19	0.4	19	1	US-11-101-244-159301	Sequence 159301,

545	19	0.4	19	1	US-11-083-784-159348	Sequence 159348,	618	18	0.4	19	1	US-11-101-244-159271	Sequence 159271,
546	19	0.4	19	1	US-11-083-784-159349	Sequence 159349,	619	18	0.4	19	1	US-11-101-244-159286	Sequence 159286,
547	19	0.4	19	1	US-11-083-784-159350	Sequence 159350,	620	18	0.4	19	1	US-11-083-784-159271	Sequence 159271,
548	19	0.4	19	1	US-11-083-784-159351	Sequence 159351,	621	18	0.4	19	1	US-11-083-784-159286	Sequence 159286,
549	19	0.4	19	1	US-11-083-784-159352	Sequence 159352,	622	18	0.4	21	1	US-10-770-726-17478	Sequence 17478, A
550	19	0.4	19	1	US-11-083-784-159353	Sequence 159353,	623	18	0.4	21	1	US-10-770-726-17544	Sequence 17544, A
551	19	0.4	19	1	US-11-083-784-159354	Sequence 159354,	624	18	0.4	22	1	US-10-310-914A-871069	Sequence 871069,
552	19	0.4	19	1	US-11-083-784-159355	Sequence 159355,	625	17.8	0.4	21	1	US-10-770-726-16904	Sequence 16893, A
553	19	0.4	19	1	US-11-083-784-159356	Sequence 159356,	626	17.8	0.4	21	1	US-10-770-726-16904	Sequence 16904, A
554	19	0.4	19	1	US-11-083-784-159357	Sequence 159357,	627	17.8	0.4	21	1	US-10-770-726-16911	Sequence 16911, A
555	19	0.4	19	1	US-11-083-784-159358	Sequence 159358,	628	17.8	0.4	21	1	US-10-770-726-17474	Sequence 17474, A
556	19	0.4	19	1	US-11-083-784-159359	Sequence 159359,	629	17.8	0.4	21	1	US-10-770-726-17504	Sequence 17504, A
557	19	0.4	19	1	US-11-083-784-159360	Sequence 159360,	630	17.8	0.4	21	1	US-10-770-726-17507	Sequence 17507, A
558	19	0.4	19	1	US-11-083-784-159361	Sequence 159361,	631	17.8	0.4	21	1	US-10-770-726-17531	Sequence 17531, A
559	19	0.4	19	1	US-11-083-784-159362	Sequence 159362,	632	17.8	0.4	21	1	US-10-770-726-17537	Sequence 17537, A
560	19	0.4	19	1	US-11-083-784-159363	Sequence 159363,	633	17.8	0.4	21	1	US-10-770-726-18030	Sequence 18030, A
561	19	0.4	19	1	US-11-083-784-159365	Sequence 159365,	634	17.8	0.4	21	1	US-10-770-726-18074	Sequence 18074, A
562	19	0.4	19	1	US-11-083-784-159366	Sequence 159366,	635	17.8	0.4	21	1	US-10-770-726-18089	Sequence 18089, A
563	19	0.4	19	1	US-11-083-784-159367	Sequence 159367,	636	17.8	0.4	21	1	US-10-770-726-18458	Sequence 18458, A
564	19	0.4	19	1	US-11-083-784-159368	Sequence 159368,	637	17.8	0.4	21	1	US-10-770-726-18662	Sequence 18662, A
565	19	0.4	19	1	US-11-083-784-159369	Sequence 159369,	638	17.8	0.4	21	1	US-10-770-726-18723	Sequence 18723, A
566	19	0.4	19	1	US-11-083-784-159370	Sequence 159370,	c 639	17.8	0.4	21	1	US-10-770-726-18723	Sequence 44767, A
567	19	0.4	19	1	US-11-083-784-159372	Sequence 159372,	640	17.8	0.4	21	1	US-10-310-914A-432291	Sequence 332291,
568	19	0.4	19	1	US-11-083-784-159373	Sequence 159373,	641	17.8	0.4	21	1	US-10-310-914A-332482	Sequence 332482,
569	19	0.4	19	1	US-11-083-784-159374	Sequence 159374,	642	17.8	0.4	21	1	US-10-310-914A-471965	Sequence 471965,
570	19	0.4	19	1	US-11-083-784-159375	Sequence 159375,	643	17.8	0.4	21	1	US-10-310-914A-556552	Sequence 556552,
571	19	0.4	19	1	US-11-083-784-159376	Sequence 159376,	644	17.8	0.4	21	1	US-10-310-914A-1213089	Sequence 1213089,
572	19	0.4	19	1	US-11-083-784-159377	Sequence 159377,	c 645	17.8	0.4	21	1	US-10-310-914A-1341719	Sequence 1341719,
573	19	0.4	19	1	US-11-083-784-159378	Sequence 159378,	646	17.8	0.4	22	1	US-10-310-914A-174984	Sequence 174984,
574	19	0.4	19	1	US-11-083-784-159379	Sequence 159379,	647	17.8	0.4	22	1	US-10-310-914A-175001	Sequence 175001,
575	19	0.4	19	1	US-11-083-784-159380	Sequence 159380,	c 648	17.8	0.4	22	1	US-10-310-914A-371300	Sequence 371300,
576	19	0.4	19	1	US-11-083-784-159381	Sequence 159381,	c 649	17.8	0.4	22	1	US-10-310-914A-494111	Sequence 494111,
577	19	0.4	19	1	US-11-083-784-159382	Sequence 159382,	650	17.8	0.4	22	1	US-10-310-914A-497206	Sequence 497206,
578	19	0.4	21	1	US-10-949-720-22	Sequence 22, Appl	651	17.8	0.4	22	1	US-10-310-914A-59823	Sequence 59823,
579	19	0.4	21	1	US-10-949-720-23	Sequence 23, Appl	652	17.8	0.4	22	1	US-10-310-914A-765177	Sequence 765177,
580	19	0.4	21	1	US-10-949-720-34	Sequence 34, Appl	653	17.8	0.4	22	1	US-10-310-914A-1224324	Sequence 1224324,
581	19	0.4	21	1	US-10-949-720-36	Sequence 36, Appl	654	17.4	0.4	22	1	US-10-310-914A-1224348	Sequence 1224348,
582	19	0.4	21	1	US-10-949-720-40	Sequence 40, Appl	655	17.4	0.4	19	1	US-10-310-914A-1294342	Sequence 1294342,
583	19	0.4	21	1	US-10-949-720-69	Sequence 69, Appl	656	17.4	0.4	19	1	US-11-101-244-153337	Sequence 153337,
584	19	0.4	21	1	US-10-949-720-86	Sequence 86, App	657	17.4	0.4	19	1	US-11-101-244-153343	Sequence 153343,
585	19	0.4	21	1	US-10-949-720-287	Sequence 287, App	658	17.4	0.4	19	1	US-11-101-244-153383	Sequence 153383,
586	19	0.4	21	1	US-10-949-720-289	Sequence 289, App	659	17.4	0.4	19	1	US-11-101-244-153389	Sequence 153389,
587	19	0.4	21	1	US-10-949-720-290	Sequence 290, App	660	17.4	0.4	19	1	US-11-101-244-158363	Sequence 158363,
588	19	0.4	21	1	US-10-770-726-16917	Sequence 16917, A	661	17.4	0.4	19	1	US-11-101-244-158571	Sequence 158571,
589	19	0.4	21	1	US-10-770-726-17547	Sequence 17547, A	662	17.4	0.4	19	1	US-11-101-244-158800	Sequence 158800,
590	18.8	0.4	21	1	US-10-770-726-17547	Sequence 17547, A	663	17.4	0.4	19	1	US-11-101-244-158823	Sequence 158823,
c 591	18.8	0.4	22	1	US-10-310-914A-1216690	Sequence 1216690,	664	17.4	0.4	19	1	US-11-101-244-158867	Sequence 158867,
c 592	18.8	0.4	22	1	US-10-310-914A-207817	Sequence 207817,	665	17.4	0.4	19	1	US-11-101-244-158987	Sequence 158987,
593	18.8	0.4	22	1	US-10-310-914A-287071	Sequence 287071,	666	17.4	0.4	19	1	US-11-101-244-159004	Sequence 159004,
594	18.8	0.4	23	1	US-10-310-914A-1125431	Sequence 1125431,	667	17.4	0.4	19	1	US-11-101-244-159040	Sequence 159040,
c 595	18.8	0.4	23	1	US-10-310-914A-200253	Sequence 200253,	668	17.4	0.4	19	1	US-11-101-244-159054	Sequence 159054,
596	18.8	0.4	23	1	US-10-310-914A-458565	Sequence 458565,	669	17.4	0.4	19	1	US-11-101-244-159086	Sequence 159086,
597	18.8	0.4	23	1	US-10-310-914A-497207	Sequence 497207,	670	17.4	0.4	19	1	US-11-101-244-159086	Sequence 159086,
598	18.4	0.4	20	1	US-10-310-914A-1141590	Sequence 1141590,	671	17.4	0.4	19	1	US-11-101-244-159129	Sequence 159129,
c 599	18.4	0.4	20	1	US-10-310-914A-161881	Sequence 161881,	672	17.4	0.4	19	1	US-11-101-244-159138	Sequence 159138,
600	18.4	0.4	20	1	US-10-310-914A-914666	Sequence 914666,	673	17.4	0.4	19	1	US-11-101-244-159213	Sequence 159213,
601	18.4	0.4	21	1	US-10-770-726-16895	Sequence 16895, A	674	17.4	0.4	19	1	US-11-101-244-159231	Sequence 159231,
602	18.4	0.4	21	1	US-10-770-726-16910	Sequence 16910, A	675	17.4	0.4	19	1	US-11-101-244-159248	Sequence 159248,
603	18.4	0.4	21	1	US-10-770-726-16913	Sequence 16913, A	676	17.4	0.4	19	1	US-11-101-244-159274	Sequence 159274,
604	18.4	0.4	21	1	US-10-770-726-17541	Sequence 17541, A	677	17.4	0.4	19	1	US-11-101-244-159309	Sequence 159309,
605	18.4	0.4	21	1	US-10-770-726-18401	Sequence 18401, A	678	17.4	0.4	19	1	US-11-101-244-159364	Sequence 159364,
606	18.4	0.4	22	1	US-10-310-914A-161858	Sequence 161858,	679	17.4	0.4	19	1	US-11-101-244-159371	Sequence 159371,
607	18.4	0.4	22	1	US-10-310-914A-161859	Sequence 161859,	680	17.4	0.4	19	1	US-11-101-244-1212014	Sequence 1212014,
c 608	18	0.4	18	1	US-10-949-720-47	Sequence 47, Appl	681	17.4	0.4	19	1	US-11-083-784-153337	Sequence 153337,
c 609	18	0.4	18	1	US-10-949-720-227	Sequence 48, Appl	682	17.4	0.4	19	1	US-11-083-784-153343	Sequence 153343,
c 610	18	0.4	18	1	US-10-949-720-227	Sequence 227, App	683	17.4	0.4	19	1	US-11-083-784-153383	Sequence 153383,
c 611	18	0.4	18	1	US-10-949-720-228	Sequence 228, App	684	17.4	0.4	19	1	US-11-083-784-153389	Sequence 153389,
c 612	18	0.4	18	1	US-10-310-914A-153257	Sequence 153257,	685	17.4	0.4	19	1	US-11-083-784-15363	Sequence 158363,
c 613	18	0.4	18	1	US-10-310-914A-153262	Sequence 153262,	686	17.4	0.4	19	1	US-11-083-784-158571	Sequence 158571,
c 614	18	0.4	18	1	US-10-310-914A-153275	Sequence 153275,	687	17.4	0.4	19	1	US-11-083-784-158800	Sequence 158800,
c 615	18	0.4	18	1	US-10-310-914A-153278	Sequence 153278,	688	17.4	0.4	19	1	US-11-083-784-158823	Sequence 158823,
c 616	18	0.4	18	1	US-10-310-914A-153288	Sequence 153288,	689	17.4	0.4	19	1	US-11-083-784-158867	Sequence 158867,
c 617	18	0.4	18	1	US-10-310-914A-153289	Sequence 153289,	690	17.4	0.4	19	1	US-11-083-784-159897	Sequence 159897,

691	17.4	0.4	19	1	US-11-083-784-159004	Sequence 159004,	c 764	16.8	0.4	20	1	US-10-310-914A-1332047	Sequence 1332047,
692	17.4	0.4	19	1	US-11-083-784-159040	Sequence 159040,	c 765	16.8	0.4	20	1	US-10-310-914A-1341732	Sequence 1341732,
693	17.4	0.4	19	1	US-11-083-784-159054	Sequence 159054,	c 766	16.8	0.4	20	1	US-11-043-752-2628	Sequence 2628, Ap
694	17.4	0.4	19	1	US-11-083-784-159086	Sequence 159086,	c 767	16.8	0.4	21	1	US-10-770-726-16898	Sequence 16898, A
695	17.4	0.4	19	1	US-11-083-784-159100	Sequence 159100,	c 768	16.8	0.4	21	1	US-10-770-726-17246	Sequence 17246, A
696	17.4	0.4	19	1	US-11-083-784-159129	Sequence 159129,	c 769	16.8	0.4	21	1	US-10-770-726-17508	Sequence 17508, A
697	17.4	0.4	19	1	US-11-083-784-159138	Sequence 159138,	c 770	16.8	0.4	21	1	US-10-770-726-18041	Sequence 18041, A
698	17.4	0.4	19	1	US-11-083-784-159213	Sequence 159213,	c 771	16.8	0.4	21	1	US-10-770-726-18090	Sequence 18090, A
699	17.4	0.4	19	1	US-11-083-784-159231	Sequence 159231,	c 772	16.8	0.4	21	1	US-10-770-726-18104	Sequence 18104, A
700	17.4	0.4	19	1	US-11-083-784-159248	Sequence 159248,	c 773	16.8	0.4	21	1	US-10-770-726-18107	Sequence 18107, A
701	17.4	0.4	19	1	US-11-083-784-159274	Sequence 159274,	c 774	16.8	0.4	21	1	US-10-770-726-26045	Sequence 26045, A
702	17.4	0.4	19	1	US-11-083-784-159309	Sequence 159309,	c 775	16.8	0.4	21	1	US-10-310-914A-43024	Sequence 43024, A
703	17.4	0.4	19	1	US-11-083-784-159364	Sequence 159364,	c 776	16.8	0.4	21	1	US-10-310-914A-94223	Sequence 94223, A
704	17.4	0.4	19	1	US-11-083-784-159371	Sequence 159371,	c 777	16.8	0.4	21	1	US-10-310-914A-147724	Sequence 147724, A
705	17.4	0.4	20	1	US-11-083-784-1212014	Sequence 1212014,	c 778	16.8	0.4	21	1	US-10-310-914A-175830	Sequence 175830,
706	17.4	0.4	20	1	US-10-297-056-41	Sequence 41, Appl	c 779	16.8	0.4	21	1	US-10-310-914A-239772	Sequence 239772,
707	17.4	0.4	20	1	US-10-310-914A-52199	Sequence 52199, A	c 780	16.8	0.4	21	1	US-10-310-914A-271797	Sequence 271797,
708	17.4	0.4	20	1	US-10-310-914A-173994	Sequence 173994,	c 781	16.8	0.4	21	1	US-10-310-914A-271798	Sequence 271798,
709	17.4	0.4	20	1	US-10-310-914A-173995	Sequence 173995,	c 782	16.8	0.4	21	1	US-10-310-914A-310403	Sequence 310403,
710	17.4	0.4	20	1	US-10-310-914A-409848	Sequence 409848,	c 783	16.8	0.4	21	1	US-10-310-914A-329952	Sequence 329952,
711	17.4	0.4	20	1	US-10-310-914A-1224349	Sequence 1224349,	c 784	16.8	0.4	21	1	US-10-310-914A-340669	Sequence 340669,
712	17.4	0.4	21	1	US-10-770-726-17471	Sequence 17471, A	c 785	16.8	0.4	21	1	US-10-310-914A-406263	Sequence 406263,
713	17.4	0.4	21	1	US-10-770-726-17472	Sequence 17472, A	c 786	16.8	0.4	21	1	US-10-310-914A-426861	Sequence 426861,
714	17.4	0.4	21	1	US-10-770-726-17496	Sequence 17496, A	c 787	16.8	0.4	21	1	US-10-310-914A-481749	Sequence 481749,
715	17.4	0.4	21	1	US-10-770-726-17499	Sequence 17499, A	c 788	16.8	0.4	21	1	US-10-310-914A-497146	Sequence 497146,
716	17.4	0.4	21	1	US-10-770-726-17502	Sequence 17502, A	c 789	16.8	0.4	21	1	US-10-310-914A-513444	Sequence 513444,
717	17.4	0.4	21	1	US-10-770-726-17535	Sequence 17535, A	c 790	16.8	0.4	21	1	US-10-310-914A-562705	Sequence 562705,
718	17.4	0.4	21	1	US-10-770-726-18459	Sequence 18459, A	c 791	16.8	0.4	21	1	US-10-310-914A-572916	Sequence 572916,
719	17.4	0.4	21	1	US-10-310-914A-145348	Sequence 145348,	c 792	16.8	0.4	21	1	US-10-310-914A-628965	Sequence 628965,
720	17.4	0.4	21	1	US-10-310-914A-176222	Sequence 176222,	c 793	16.8	0.4	21	1	US-10-310-914A-700668	Sequence 700668,
721	17.4	0.4	21	1	US-10-310-914A-589336	Sequence 589336,	c 794	16.8	0.4	21	1	US-10-310-914A-711740	Sequence 711740,
722	17.4	0.4	18	1	US-10-310-914A-153211	Sequence 153211,	c 795	16.8	0.4	21	1	US-10-310-914A-711741	Sequence 711741,
723	17.4	0.4	18	1	US-10-310-914A-255656	Sequence 255656,	c 796	16.8	0.4	21	1	US-10-310-914A-712558	Sequence 712558,
724	17.4	0.4	18	1	US-10-310-914A-687613	Sequence 687613,	c 797	16.8	0.4	21	1	US-10-310-914A-849350	Sequence 849350,
725	17.4	0.4	19	1	US-10-949-720-60	Sequence 60, Appl	c 798	16.8	0.4	21	1	US-10-310-914A-853726	Sequence 853726,
726	17.4	0.4	19	1	US-11-101-244-4697	Sequence 4697, Ap	c 799	16.8	0.4	21	1	US-10-310-914A-964814	Sequence 964814,
727	17.4	0.4	19	1	US-11-083-784-4697	Sequence 4697, Ap	c 800	16.8	0.4	21	1	US-10-310-914A-1044788	Sequence 1044788,
728	17.4	0.4	20	1	US-10-750-185-12781	Sequence 12781, A	c 801	16.8	0.4	21	1	US-10-310-914A-1044846	Sequence 1044846,
729	17.4	0.4	20	1	US-10-750-623-12781	Sequence 12781, A	c 802	16.8	0.4	21	1	US-10-310-914A-1141569	Sequence 1141569,
730	17.4	0.4	21	1	US-10-770-726-17261	Sequence 17261, A	c 803	16.8	0.4	21	1	US-10-310-914A-1329403	Sequence 1329403,
731	17.4	0.4	21	1	US-10-770-726-17262	Sequence 17262, A	c 804	16.4	0.4	18	1	US-10-750-623-14487	Sequence 14487, A
732	17.4	0.4	21	1	US-10-310-914A-746199	Sequence 746199,	c 805	16.4	0.4	18	1	US-10-750-623-14487	Sequence 14487, A
733	16.8	0.4	20	1	US-10-831-286A-34263	Sequence 34263, A	c 806	16.4	0.4	18	1	US-10-310-914A-44706	Sequence 44706, A
734	16.8	0.4	20	1	US-10-310-914A-103507	Sequence 103507,	c 807	16.4	0.4	18	1	US-10-310-914A-161816	Sequence 161816,
735	16.8	0.4	20	1	US-10-310-914A-183395	Sequence 183395,	c 808	16.4	0.4	18	1	US-10-310-914A-215870	Sequence 215870,
736	16.8	0.4	20	1	US-10-310-914A-231085	Sequence 231085,	c 809	16.4	0.4	18	1	US-10-310-914A-239735	Sequence 239735,
737	16.8	0.4	20	1	US-10-310-914A-231831	Sequence 231831,	c 810	16.4	0.4	18	1	US-10-310-914A-263974	Sequence 263974,
738	16.8	0.4	20	1	US-10-310-914A-243576	Sequence 243576,	c 811	16.4	0.4	18	1	US-10-310-914A-346833	Sequence 346833,
739	16.8	0.4	20	1	US-10-310-914A-244194	Sequence 244194,	c 812	16.4	0.4	18	1	US-10-310-914A-486562	Sequence 486562,
740	16.8	0.4	20	1	US-10-310-914A-268244	Sequence 268244,	c 813	16.4	0.4	18	1	US-10-310-914A-562588	Sequence 562588,
741	16.8	0.4	20	1	US-10-310-914A-310780	Sequence 310780,	c 814	16.4	0.4	18	1	US-10-310-914A-702467	Sequence 702467,
742	16.8	0.4	20	1	US-10-310-914A-332290	Sequence 332290,	c 815	16.4	0.4	18	1	US-10-310-914A-806755	Sequence 806755,
743	16.8	0.4	20	1	US-10-310-914A-332481	Sequence 332481,	c 816	16.4	0.4	18	1	US-10-310-914A-915915	Sequence 915915,
744	16.8	0.4	20	1	US-10-310-914A-359152	Sequence 359152,	c 817	16.4	0.4	18	1	US-10-310-914A-916487	Sequence 916487,
745	16.8	0.4	20	1	US-10-310-914A-409640	Sequence 409640,	c 818	16.4	0.4	18	1	US-10-310-914A-937535	Sequence 937535,
746	16.8	0.4	20	1	US-10-310-914A-436758	Sequence 436758,	c 819	16.4	0.4	18	1	US-10-310-914A-1079798	Sequence 1079798,
747	16.8	0.4	20	1	US-10-310-914A-478404	Sequence 478404,	c 820	16.4	0.4	18	1	US-10-310-914A-1251971	Sequence 1251971,
748	16.8	0.4	20	1	US-10-310-914A-543126	Sequence 543126,	c 821	16.4	0.4	19	1	US-10-310-914A-161839	Sequence 161839,
749	16.8	0.4	20	1	US-10-310-914A-549822	Sequence 549822,	c 822	16.4	0.4	19	1	US-10-310-914A-161840	Sequence 161840,
750	16.8	0.4	20	1	US-10-310-914A-628964	Sequence 628964,	c 823	16.4	0.4	19	1	US-10-310-914A-225326	Sequence 225326,
751	16.8	0.4	20	1	US-10-310-914A-657369	Sequence 657369,	c 824	16.4	0.4	19	1	US-10-310-914A-329935	Sequence 329935,
752	16.8	0.4	20	1	US-10-310-914A-763042	Sequence 763042,	c 825	16.4	0.4	19	1	US-10-310-914A-481752	Sequence 481752,
753	16.8	0.4	20	1	US-10-310-914A-824483	Sequence 824483,	c 826	16.4	0.4	19	1	US-10-310-914A-562468	Sequence 562468,
754	16.8	0.4	20	1	US-10-310-914A-834462	Sequence 834462,	c 827	16.4	0.4	19	1	US-10-310-914A-910660	Sequence 910660,
755	16.8	0.4	20	1	US-10-310-914A-846714	Sequence 846714,	c 828	16.4	0.4	19	1	US-10-310-914A-917658	Sequence 917658,
756	16.8	0.4	20	1	US-10-310-914A-930332	Sequence 930332,	c 829	16.4	0.4	19	1	US-10-310-914A-1011800	Sequence 1011800,
757	16.8	0.4	20	1	US-10-310-914A-1024937	Sequence 1024937,	c 830	16.4	0.4	19	1	US-10-310-914A-1024936	Sequence 1024936,
758	16.8	0.4	20	1	US-10-310-914A-1025973	Sequence 1025973,	c 831	16.4	0.4	19	1	US-10-310-914A-1182295	Sequence 1182295,
759	16.8	0.4	20	1	US-10-310-914A-1125430	Sequence 1125430,	c 832	16.4	0.4	19	1	US-10-310-914A-1313753	Sequence 1313753,
760	16.8	0.4	20	1	US-10-310-914A-1209003	Sequence 1209003,	c 833	16.4	0.4	19	1	US-10-310-914A-132386	Sequence 132386,
761	16.8	0.4	20	1	US-10-310-914A-1230235	Sequence 1230235,	c 834	16.4	0.4	19	1	US-11-101-244-17533	Sequence 17533,
762	16.8	0.4	20	1	US-10-310-914A-1290463	Sequence 1290463,	c 835	16.4	0.4	19	1	US-11-101-244-158322	Sequence 158322,
763	16.8	0.4	20	1	US-10-310-914A-1290469	Sequence 1290469,	c 836	16.4	0.4	19	1	US-11-101-244-159024	Sequence 159024,

837	19	1	US-11-101-244-159117	Sequence 159117,	C 910	15.8	0.4	19	1	US-10-310-914A-143645	Sequence 143645,
838	19	1	US-11-101-244-159229	Sequence 159229,	C 911	15.8	0.4	19	1	US-10-310-914A-152768	Sequence 152768,
839	19	1	US-11-101-244-159279	Sequence 159279,	C 912	15.8	0.4	19	1	US-10-310-914A-175809	Sequence 175809,
840	19	1	US-11-101-244-159796	Sequence 159796,	C 913	15.8	0.4	19	1	US-10-310-914A-209753	Sequence 209753,
841	19	1	US-11-101-244-258796	Sequence 258796,	C 914	15.8	0.4	19	1	US-10-310-914A-242649	Sequence 242649,
c 842	19	1	US-11-101-244-258802	Sequence 258802,	C 915	15.8	0.4	19	1	US-10-310-914A-271792	Sequence 271792,
843	19	1	US-11-101-244-317987	Sequence 317987,	C 916	15.8	0.4	19	1	US-10-310-914A-376173	Sequence 376173,
844	19	1	US-11-101-244-325732	Sequence 325732,	C 917	15.8	0.4	19	1	US-10-310-914A-402475	Sequence 402475,
845	19	1	US-11-101-244-495967	Sequence 495967,	C 918	15.8	0.4	19	1	US-10-310-914A-436755	Sequence 436755,
846	19	1	US-11-101-244-520914	Sequence 520914,	C 919	15.8	0.4	19	1	US-10-310-914A-427119	Sequence 427119,
847	19	1	US-11-101-244-521180	Sequence 521180,	C 920	15.8	0.4	19	1	US-10-310-914A-454195	Sequence 454195,
848	19	1	US-11-101-244-931315	Sequence 931315,	C 921	15.8	0.4	19	1	US-10-310-914A-462107	Sequence 462107,
849	19	1	US-11-101-244-1104821	Sequence 1104821,	C 922	15.8	0.4	19	1	US-10-310-914A-477363	Sequence 477363,
c 850	19	1	US-11-101-244-174362	Sequence 174362,	C 923	15.8	0.4	19	1	US-10-310-914A-481676	Sequence 481676,
c 851	19	1	US-11-101-244-193142	Sequence 193142,	C 924	15.8	0.4	19	1	US-10-310-914A-496772	Sequence 496772,
852	19	1	US-11-101-244-1494874	Sequence 1494874,	C 925	15.8	0.4	19	1	US-10-310-914A-497205	Sequence 497205,
853	19	1	US-11-101-244-1529001	Sequence 1529001,	C 926	15.8	0.4	19	1	US-10-310-914A-502422	Sequence 502422,
854	19	1	US-11-083-784-117533	Sequence 117533,	C 927	15.8	0.4	19	1	US-10-310-914A-543953	Sequence 543953,
855	19	1	US-11-083-784-158322	Sequence 158322,	C 928	15.8	0.4	19	1	US-10-310-914A-616709	Sequence 616709,
856	19	1	US-11-083-784-159024	Sequence 159024,	C 929	15.8	0.4	19	1	US-10-310-914A-691544	Sequence 691544,
857	19	1	US-11-083-784-159117	Sequence 159117,	C 930	15.8	0.4	19	1	US-10-310-914A-701274	Sequence 701274,
858	19	1	US-11-083-784-159229	Sequence 159229,	C 931	15.8	0.4	19	1	US-10-310-914A-735391	Sequence 735391,
859	19	1	US-11-083-784-159279	Sequence 159279,	C 932	15.8	0.4	19	1	US-10-310-914A-764359	Sequence 764359,
860	19	1	US-11-083-784-258796	Sequence 258796,	C 933	15.8	0.4	19	1	US-10-310-914A-778757	Sequence 778757,
c 861	19	1	US-11-083-784-258802	Sequence 258802,	C 934	15.8	0.4	19	1	US-10-310-914A-933487	Sequence 933487,
862	19	1	US-11-083-784-317987	Sequence 317987,	C 935	15.8	0.4	19	1	US-10-310-914A-990363	Sequence 990363,
863	19	1	US-11-083-784-325732	Sequence 325732,	C 936	15.8	0.4	19	1	US-10-310-914A-1040857	Sequence 1040857,
864	19	1	US-11-083-784-495967	Sequence 495967,	C 937	15.8	0.4	19	1	US-10-310-914A-1099801	Sequence 1099801,
865	19	1	US-11-083-784-520914	Sequence 520914,	C 938	15.8	0.4	19	1	US-10-310-914A-1147060	Sequence 1147060,
866	19	1	US-11-083-784-521180	Sequence 521180,	C 939	15.8	0.4	19	1	US-10-310-914A-1160786	Sequence 1160786,
867	19	1	US-11-083-784-931315	Sequence 931315,	C 940	15.8	0.4	19	1	US-10-310-914A-1167297	Sequence 1167297,
c 868	19	1	US-11-083-784-1104821	Sequence 1104821,	C 941	15.8	0.4	19	1	US-10-310-914A-1249167	Sequence 1249167,
c 869	19	1	US-11-083-784-1393142	Sequence 1393142,	C 942	15.8	0.4	19	1	US-10-310-914A-1257401	Sequence 1257401,
c 870	19	1	US-11-083-784-1494874	Sequence 1494874,	C 943	15.8	0.4	19	1	US-11-101-244-611	Sequence 611, App
871	19	1	US-11-083-784-1529001	Sequence 1529001,	C 944	15.8	0.4	19	1	US-11-101-244-31906	Sequence 31906, A
c 872	19	1	US-10-310-914A-385316	Sequence 385316,	C 945	15.8	0.4	19	1	US-11-101-244-51586	Sequence 51586, A
c 873	19	1	US-10-310-914A-916483	Sequence 916483,	C 946	15.8	0.4	19	1	US-11-101-244-88135	Sequence 88135, A
c 874	19	1	US-10-310-914A-1192704	Sequence 1192704,	C 947	15.8	0.4	19	1	US-11-101-244-108278	Sequence 108278,
875	19	1	US-10-310-914A-81546	Sequence 81546, A	C 948	15.8	0.4	19	1	US-11-101-244-108374	Sequence 108374,
876	19	1	US-10-310-914A-443869	Sequence 443869,	C 949	15.8	0.4	19	1	US-11-101-244-108473	Sequence 108473,
c 877	19	1	US-10-310-914A-916489	Sequence 916489,	C 950	15.8	0.4	19	1	US-11-101-244-108571	Sequence 108571,
878	19	1	US-10-310-914A-983472	Sequence 983472,	C 951	15.8	0.4	19	1	US-11-101-244-108671	Sequence 108671,
c 879	19	1	US-10-310-914A-1088339	Sequence 1088339,	C 952	15.8	0.4	19	1	US-11-101-244-113648	Sequence 113648,
c 880	19	1	US-10-310-914A-1346847	Sequence 1346847,	C 953	15.8	0.4	19	1	US-11-101-244-149446	Sequence 149446,
881	19	1	US-10-310-914A-196336	Sequence 196336,	C 954	15.8	0.4	19	1	US-11-101-244-153349	Sequence 153349,
882	19	1	US-10-310-914A-482672	Sequence 482672,	C 955	15.8	0.4	19	1	US-11-101-244-158289	Sequence 158289,
c 883	19	1	US-10-310-914A-1295091	Sequence 1295091,	C 956	15.8	0.4	19	1	US-11-101-244-158376	Sequence 158376,
c 884	19	1	US-10-310-914A-1343420	Sequence 1343420,	C 957	15.8	0.4	19	1	US-11-101-244-158377	Sequence 158377,
c 885	19	1	US-11-101-244-31908	Sequence 31908, A	C 958	15.8	0.4	19	1	US-11-101-244-158451	Sequence 158451,
886	19	1	US-11-101-244-159280	Sequence 159280,	C 959	15.8	0.4	19	1	US-11-101-244-158521	Sequence 158521,
c 887	19	1	US-11-101-244-704088	Sequence 704088,	C 960	15.8	0.4	19	1	US-11-101-244-158525	Sequence 158525,
c 888	19	1	US-11-101-244-704181	Sequence 704181,	C 961	15.8	0.4	19	1	US-11-101-244-158535	Sequence 158535,
889	19	1	US-11-101-244-931267	Sequence 931267,	C 962	15.8	0.4	19	1	US-11-101-244-158948	Sequence 158948,
c 890	19	1	US-11-101-244-931277	Sequence 931277,	C 963	15.8	0.4	19	1	US-11-101-244-158952	Sequence 158952,
c 891	19	1	US-11-101-244-1365774	Sequence 1365774,	C 964	15.8	0.4	19	1	US-11-101-244-158958	Sequence 158958,
c 892	19	1	US-11-083-784-31908	Sequence 31908, A	C 965	15.8	0.4	19	1	US-11-101-244-159005	Sequence 159005,
893	19	1	US-11-083-784-159280	Sequence 159280,	C 966	15.8	0.4	19	1	US-11-101-244-159035	Sequence 159035,
c 894	19	1	US-11-083-784-704088	Sequence 704088,	C 967	15.8	0.4	19	1	US-11-101-244-159068	Sequence 159068,
c 895	19	1	US-11-083-784-704181	Sequence 704181,	C 968	15.8	0.4	19	1	US-11-101-244-159101	Sequence 159101,
896	19	1	US-11-083-784-931267	Sequence 931267,	C 969	15.8	0.4	19	1	US-11-101-244-159124	Sequence 159124,
c 897	19	1	US-11-083-784-931277	Sequence 931277,	C 970	15.8	0.4	19	1	US-11-101-244-159148	Sequence 159148,
c 898	19	1	US-11-083-784-1365774	Sequence 1365774,	C 971	15.8	0.4	19	1	US-11-101-244-159210	Sequence 159210,
899	19	1	US-10-831-286A-34811	Sequence 34811, A	C 972	15.8	0.4	19	1	US-11-101-244-159219	Sequence 159219,
c 900	19	1	US-10-831-286A-37357	Sequence 37357, A	C 973	15.8	0.4	19	1	US-11-101-244-159481	Sequence 159481,
901	19	1	US-10-831-286A-40915	Sequence 40915, A	C 974	15.8	0.4	19	1	US-11-101-244-182879	Sequence 182879,
c 902	19	1	US-10-831-286A-48457	Sequence 48457, A	C 975	15.8	0.4	19	1	US-11-101-244-183246	Sequence 183246,
903	19	1	US-10-310-914A-196337	Sequence 196337,	C 976	15.8	0.4	19	1	US-11-101-244-215222	Sequence 215222,
c 904	19	1	US-10-922-761-87	Sequence 87, App	C 977	15.8	0.4	19	1	US-11-101-244-247832	Sequence 247832,
c 905	19	1	US-10-922-761-184	Sequence 184, App	C 978	15.8	0.4	19	1	US-11-101-244-256851	Sequence 256851,
c 906	19	1	US-10-310-914A-50195	Sequence 50195, A	C 979	15.8	0.4	19	1	US-11-101-244-351839	Sequence 351839,
c 907	19	1	US-10-310-914A-74610	Sequence 74610, A	C 980	15.8	0.4	19	1	US-11-101-244-351938	Sequence 351938,
c 908	19	1	US-10-310-914A-81513	Sequence 81513, A	C 981	15.8	0.4	19	1	US-11-101-244-351938	Sequence 351938,
c 909	19	1	US-10-310-914A-143107	Sequence 143107,	C 982	15.8	0.4	19	1	US-11-101-244-351977	Sequence 351977,

983	15.8	0.4	19	1	US-11-101-244-358726	Sequence 358726,	1056	15.8	0.4	19	1	US-11-083-784-108278	Sequence 108278,
984	15.8	0.4	19	1	US-11-101-244-358909	Sequence 358909,	1057	15.8	0.4	19	1	US-11-083-784-108374	Sequence 108374,
985	15.8	0.4	19	1	US-11-101-244-367347	Sequence 367347,	1058	15.8	0.4	19	1	US-11-083-784-108473	Sequence 108473,
986	15.8	0.4	19	1	US-11-101-244-368735	Sequence 368735,	1059	15.8	0.4	19	1	US-11-083-784-108571	Sequence 108571,
987	15.8	0.4	19	1	US-11-101-244-401647	Sequence 401647,	1060	15.8	0.4	19	1	US-11-083-784-108671	Sequence 108671,
988	15.8	0.4	19	1	US-11-101-244-463025	Sequence 463025,	c1061	15.8	0.4	19	1	US-11-083-784-113648	Sequence 113648,
989	15.8	0.4	19	1	US-11-101-244-463025	Sequence 520652,	1062	15.8	0.4	19	1	US-11-083-784-149446	Sequence 149446,
990	15.8	0.4	19	1	US-11-101-244-553895	Sequence 553895,	1063	15.8	0.4	19	1	US-11-083-784-153349	Sequence 153349,
991	15.8	0.4	19	1	US-11-101-244-558451	Sequence 558451,	1064	15.8	0.4	19	1	US-11-083-784-158289	Sequence 158289,
992	15.8	0.4	19	1	US-11-101-244-588523	Sequence 588523,	1065	15.8	0.4	19	1	US-11-083-784-158376	Sequence 158376,
993	15.8	0.4	19	1	US-11-101-244-602297	Sequence 602297,	1066	15.8	0.4	19	1	US-11-083-784-158377	Sequence 158377,
994	15.8	0.4	19	1	US-11-101-244-632602	Sequence 632602,	1067	15.8	0.4	19	1	US-11-083-784-158451	Sequence 158451,
c 995	15.8	0.4	19	1	US-11-101-244-633003	Sequence 633003,	1068	15.8	0.4	19	1	US-11-083-784-158521	Sequence 158521,
c 996	15.8	0.4	19	1	US-11-101-244-645883	Sequence 645883,	1069	15.8	0.4	19	1	US-11-083-784-158525	Sequence 158525,
c 997	15.8	0.4	19	1	US-11-101-244-665485	Sequence 665485,	1070	15.8	0.4	19	1	US-11-083-784-158535	Sequence 158535,
998	15.8	0.4	19	1	US-11-101-244-669877	Sequence 669877,	1071	15.8	0.4	19	1	US-11-083-784-158548	Sequence 158548,
c 999	15.8	0.4	19	1	US-11-101-244-707935	Sequence 707935,	1072	15.8	0.4	19	1	US-11-083-784-158952	Sequence 158952,
c1000	15.8	0.4	19	1	US-11-101-244-722881	Sequence 722881,	1073	15.8	0.4	19	1	US-11-083-784-158958	Sequence 158958,
1001	15.8	0.4	19	1	US-11-101-244-729514	Sequence 729514,	1074	15.8	0.4	19	1	US-11-083-784-159005	Sequence 159005,
c 1002	15.8	0.4	19	1	US-11-101-244-729613	Sequence 729613,	1075	15.8	0.4	19	1	US-11-083-784-159035	Sequence 159035,
1003	15.8	0.4	19	1	US-11-101-244-748070	Sequence 748070,	1076	15.8	0.4	19	1	US-11-083-784-159068	Sequence 159068,
c1004	15.8	0.4	19	1	US-11-101-244-748086	Sequence 748086,	1077	15.8	0.4	19	1	US-11-083-784-159101	Sequence 159101,
1005	15.8	0.4	19	1	US-11-101-244-814212	Sequence 814212,	1078	15.8	0.4	19	1	US-11-083-784-159124	Sequence 159124,
1006	15.8	0.4	19	1	US-11-101-244-815617	Sequence 815617,	1079	15.8	0.4	19	1	US-11-083-784-159148	Sequence 159148,
c1007	15.8	0.4	19	1	US-11-101-244-829676	Sequence 829676,	1080	15.8	0.4	19	1	US-11-083-784-159210	Sequence 159210,
1008	15.8	0.4	19	1	US-11-101-244-858962	Sequence 858962,	1081	15.8	0.4	19	1	US-11-083-784-159219	Sequence 159219,
1009	15.8	0.4	19	1	US-11-101-244-871328	Sequence 871328,	1082	15.8	0.4	19	1	US-11-083-784-159481	Sequence 159481,
c1010	15.8	0.4	19	1	US-11-101-244-889071	Sequence 889071,	1083	15.8	0.4	19	1	US-11-083-784-182879	Sequence 182879,
1011	15.8	0.4	19	1	US-11-101-244-903949	Sequence 903949,	c1084	15.8	0.4	19	1	US-11-083-784-183246	Sequence 183246,
c1012	15.8	0.4	19	1	US-11-101-244-931273	Sequence 931273,	1085	15.8	0.4	19	1	US-11-083-784-215222	Sequence 215222,
1013	15.8	0.4	19	1	US-11-101-244-931865	Sequence 931865,	c1086	15.8	0.4	19	1	US-11-083-784-247832	Sequence 247832,
1014	15.8	0.4	19	1	US-11-101-244-943735	Sequence 943735,	c1087	15.8	0.4	19	1	US-11-083-784-256851	Sequence 256851,
1015	15.8	0.4	19	1	US-11-101-244-953149	Sequence 953149,	c1088	15.8	0.4	19	1	US-11-083-784-314443	Sequence 314443,
1016	15.8	0.4	19	1	US-11-101-244-959179	Sequence 959179,	1089	15.8	0.4	19	1	US-11-083-784-351839	Sequence 351839,
c1017	15.8	0.4	19	1	US-11-101-244-965862	Sequence 965862,	1090	15.8	0.4	19	1	US-11-083-784-351938	Sequence 351938,
1018	15.8	0.4	19	1	US-11-101-244-1012356	Sequence 1012356,	1091	15.8	0.4	19	1	US-11-083-784-351977	Sequence 351977,
1019	15.8	0.4	19	1	US-11-101-244-1012356	Sequence 1012356,	1092	15.8	0.4	19	1	US-11-083-784-358726	Sequence 358726,
c1020	15.8	0.4	19	1	US-11-101-244-1029052	Sequence 1029052,	1093	15.8	0.4	19	1	US-11-083-784-358909	Sequence 358909,
1021	15.8	0.4	19	1	US-11-101-244-1030733	Sequence 1030733,	1094	15.8	0.4	19	1	US-11-083-784-367347	Sequence 367347,
c1022	15.8	0.4	19	1	US-11-101-244-1033475	Sequence 1033475,	1095	15.8	0.4	19	1	US-11-083-784-368735	Sequence 368735,
1023	15.8	0.4	19	1	US-11-101-244-1104856	Sequence 1104856,	1096	15.8	0.4	19	1	US-11-083-784-401647	Sequence 401647,
1024	15.8	0.4	19	1	US-11-101-244-1110635	Sequence 1110635,	1097	15.8	0.4	19	1	US-11-083-784-463025	Sequence 463025,
1025	15.8	0.4	19	1	US-11-101-244-1110844	Sequence 1110844,	1098	15.8	0.4	19	1	US-11-083-784-520652	Sequence 520652,
1026	15.8	0.4	19	1	US-11-101-244-111066	Sequence 111066,	1099	15.8	0.4	19	1	US-11-083-784-553895	Sequence 553895,
1027	15.8	0.4	19	1	US-11-101-244-1111265	Sequence 1111265,	1100	15.8	0.4	19	1	US-11-083-784-558451	Sequence 558451,
1028	15.8	0.4	19	1	US-11-101-244-1111461	Sequence 1111461,	1101	15.8	0.4	19	1	US-11-083-784-588523	Sequence 588523,
1029	15.8	0.4	19	1	US-11-101-244-1111653	Sequence 1111653,	1102	15.8	0.4	19	1	US-11-083-784-602297	Sequence 602297,
1030	15.8	0.4	19	1	US-11-101-244-1111863	Sequence 1111863,	1103	15.8	0.4	19	1	US-11-083-784-632602	Sequence 632602,
1031	15.8	0.4	19	1	US-11-101-244-1112048	Sequence 1112048,	1104	15.8	0.4	19	1	US-11-083-784-633003	Sequence 633003,
1032	15.8	0.4	19	1	US-11-101-244-1112255	Sequence 1112255,	1105	15.8	0.4	19	1	US-11-083-784-645883	Sequence 645883,
1033	15.8	0.4	19	1	US-11-101-244-1112450	Sequence 1112450,	1106	15.8	0.4	19	1	US-11-083-784-665485	Sequence 665485,
1034	15.8	0.4	19	1	US-11-101-244-1112549	Sequence 1112549,	1107	15.8	0.4	19	1	US-11-083-784-669877	Sequence 669877,
1035	15.8	0.4	19	1	US-11-101-244-1112749	Sequence 1112749,	1108	15.8	0.4	19	1	US-11-083-784-707935	Sequence 707935,
1036	15.8	0.4	19	1	US-11-101-244-1112941	Sequence 1112941,	c1109	15.8	0.4	19	1	US-11-083-784-722881	Sequence 722881,
1037	15.8	0.4	19	1	US-11-101-244-1113149	Sequence 1113149,	1110	15.8	0.4	19	1	US-11-083-784-729514	Sequence 729514,
1038	15.8	0.4	19	1	US-11-101-244-1113350	Sequence 1113350,	1111	15.8	0.4	19	1	US-11-083-784-729613	Sequence 729613,
1039	15.8	0.4	19	1	US-11-101-244-1113545	Sequence 1113545,	1112	15.8	0.4	19	1	US-11-083-784-748070	Sequence 748070,
1040	15.8	0.4	19	1	US-11-101-244-1113749	Sequence 1113749,	c1113	15.8	0.4	19	1	US-11-083-784-748086	Sequence 748086,
1041	15.8	0.4	19	1	US-11-101-244-1113949	Sequence 1113949,	1114	15.8	0.4	19	1	US-11-083-784-814212	Sequence 814212,
1042	15.8	0.4	19	1	US-11-101-244-1114149	Sequence 1114149,	1115	15.8	0.4	19	1	US-11-083-784-815617	Sequence 815617,
c1043	15.8	0.4	19	1	US-11-101-244-1116288	Sequence 1162888,	c1116	15.8	0.4	19	1	US-11-083-784-829676	Sequence 829676,
1044	15.8	0.4	19	1	US-11-101-244-11175693	Sequence 1175693,	1117	15.8	0.4	19	1	US-11-083-784-858962	Sequence 858962,
1045	15.8	0.4	19	1	US-11-101-244-1207595	Sequence 1207595,	1118	15.8	0.4	19	1	US-11-083-784-871328	Sequence 871328,
1046	15.8	0.4	19	1	US-11-101-244-1277041	Sequence 1277041,	c1119	15.8	0.4	19	1	US-11-083-784-889071	Sequence 889071,
1047	15.8	0.4	19	1	US-11-101-244-1315734	Sequence 1315734,	1120	15.8	0.4	19	1	US-11-083-784-903949	Sequence 903949,
c1048	15.8	0.4	19	1	US-11-101-244-1355528	Sequence 1355528	c1121	15.8	0.4	19	1	US-11-083-784-931273	Sequence 931273,
1049	15.8	0.4	19	1	US-11-101-244-1377429	Sequence 1377429,	1122	15.8	0.4	19	1	US-11-083-784-931865	Sequence 931865,
c1050	15.8	0.4	19	1	US-11-101-244-1380520	Sequence 1380520,	1123	15.8	0.4	19	1	US-11-083-784-943735	Sequence 943735,
1051	15.8	0.4	19	1	US-11-101-244-1563938	Sequence 1563938,	1124	15.8	0.4	19	1	US-11-083-784-959149	Sequence 959149,
1052	15.8	0.4	19	1	US-11-083-784-611	Sequence 611, App	1125	15.8	0.4	19	1	US-11-083-784-959179	Sequence 959179,
1053	15.8	0.4	19	1	US-11-083-784-31906	Sequence 31906, A	c1126	15.8	0.4	19	1	US-11-083-784-965862	Sequence 965862,
1054	15.8	0.4	19	1	US-11-083-784-51586	Sequence 51586, A	1127	15.8	0.4	19	1	US-11-083-784-1012257	Sequence 1012257,
c1055	15.8	0.4	19	1	US-11-083-784-88135	Sequence 88135, A	1128	15.8	0.4	19	1	US-11-083-784-1012356	Sequence 1012356,

c1129	15.8	0.4	19	1	US-11-083-784-1029052	Sequence 1029052,	c1202	15.4	0.4	18	1	US-10-310-914A-1312670	Sequence 1312670,
1130	15.8	0.4	19	1	US-11-083-784-1030733	Sequence 1030733,	c1203	15.4	0.4	19	1	US-10-310-914A-42828	Sequence 42828, A
c1131	15.8	0.4	19	1	US-11-083-784-1033475	Sequence 1033475,	c1204	15.4	0.4	19	1	US-10-310-914A-42829	Sequence 42829, A
1132	15.8	0.4	19	1	US-11-083-784-104856	Sequence 104856,	1205	15.4	0.4	19	1	US-10-310-914A-44524	Sequence 44524, A
1133	15.8	0.4	19	1	US-11-083-784-1110635	Sequence 1110635,	c1206	15.4	0.4	19	1	US-10-310-914A-47332	Sequence 47332, A
1134	15.8	0.4	19	1	US-11-083-784-1110844	Sequence 1110844,	c1207	15.4	0.4	19	1	US-10-310-914A-66712	Sequence 66712, A
1135	15.8	0.4	19	1	US-11-083-784-1111066	Sequence 1111066,	c1208	15.4	0.4	19	1	US-10-310-914A-76028	Sequence 76028, A
1136	15.8	0.4	19	1	US-11-083-784-1111265	Sequence 1111265,	1209	15.4	0.4	19	1	US-10-310-914A-124041	Sequence 124041,
1137	15.8	0.4	19	1	US-11-083-784-1111461	Sequence 1111461,	c1210	15.4	0.4	19	1	US-10-310-914A-141479	Sequence 141479,
1138	15.8	0.4	19	1	US-11-083-784-1111653	Sequence 1111653,	c1211	15.4	0.4	19	1	US-10-310-914A-164314	Sequence 164314,
1139	15.8	0.4	19	1	US-11-083-784-1111863	Sequence 1111863,	c1212	15.4	0.4	19	1	US-10-310-914A-165319	Sequence 165319,
1140	15.8	0.4	19	1	US-11-083-784-1112048	Sequence 1112048,	c1213	15.4	0.4	19	1	US-10-310-914A-165325	Sequence 165325,
1141	15.8	0.4	19	1	US-11-083-784-1112255	Sequence 1112255,	1214	15.4	0.4	19	1	US-10-310-914A-174508	Sequence 174508,
1142	15.8	0.4	19	1	US-11-083-784-1112450	Sequence 1112450,	c1215	15.4	0.4	19	1	US-10-310-914A-260318	Sequence 260318,
1143	15.8	0.4	19	1	US-11-083-784-1112549	Sequence 1112549,	1216	15.4	0.4	19	1	US-10-310-914A-332383	Sequence 332383,
1144	15.8	0.4	19	1	US-11-083-784-1112749	Sequence 1112749,	c1217	15.4	0.4	19	1	US-10-310-914A-368914	Sequence 368914,
1145	15.8	0.4	19	1	US-11-083-784-1112941	Sequence 1112941,	1218	15.4	0.4	19	1	US-10-310-914A-450885	Sequence 450885,
1146	15.8	0.4	19	1	US-11-083-784-1113149	Sequence 1113149,	c1219	15.4	0.4	19	1	US-10-310-914A-476139	Sequence 476139,
1147	15.8	0.4	19	1	US-11-083-784-1113350	Sequence 1113350,	1220	15.4	0.4	19	1	US-10-310-914A-478635	Sequence 478635,
1148	15.8	0.4	19	1	US-11-083-784-1113354	Sequence 1113354,	c1221	15.4	0.4	19	1	US-10-310-914A-567126	Sequence 567126,
1149	15.8	0.4	19	1	US-11-083-784-1113749	Sequence 1113749,	c1222	15.4	0.4	19	1	US-10-310-914A-568323	Sequence 568323,
1150	15.8	0.4	19	1	US-11-083-784-1113949	Sequence 1113949,	1223	15.4	0.4	19	1	US-10-310-914A-580849	Sequence 580849,
1151	15.8	0.4	19	1	US-11-083-784-1114149	Sequence 1114149,	c1224	15.4	0.4	19	1	US-10-310-914A-591068	Sequence 591068,
c1152	15.8	0.4	19	1	US-11-083-784-1162888	Sequence 1162888,	c1225	15.4	0.4	19	1	US-10-310-914A-621832	Sequence 621832,
1153	15.8	0.4	19	1	US-11-083-784-1175693	Sequence 1175693,	1226	15.4	0.4	19	1	US-10-310-914A-632545	Sequence 632545,
1154	15.8	0.4	19	1	US-11-083-784-1207595	Sequence 1207595,	c1227	15.4	0.4	19	1	US-10-310-914A-656960	Sequence 656960,
1155	15.8	0.4	19	1	US-11-083-784-1277041	Sequence 1277041,	1228	15.4	0.4	19	1	US-10-310-914A-693048	Sequence 693048,
1156	15.8	0.4	19	1	US-11-083-784-1315734	Sequence 1315734,	1229	15.4	0.4	19	1	US-10-310-914A-693049	Sequence 693049,
c1157	15.8	0.4	19	1	US-11-083-784-1355528	Sequence 1355528,	c1230	15.4	0.4	19	1	US-10-310-914A-724817	Sequence 724817,
c1158	15.8	0.4	19	1	US-11-083-784-1377429	Sequence 1377429,	c1231	15.4	0.4	19	1	US-10-310-914A-725516	Sequence 725516,
c1159	15.8	0.4	19	1	US-11-083-784-1380520	Sequence 1380520,	1232	15.4	0.4	19	1	US-10-310-914A-738648	Sequence 738648,
c1160	15.8	0.4	19	1	US-11-083-784-1563938	Sequence 1563938,	1233	15.4	0.4	19	1	US-10-310-914A-757318	Sequence 757318,
c1161	15.4	0.4	18	1	US-10-310-914A-76027	Sequence 76027, A	1234	15.4	0.4	19	1	US-10-310-914A-773116	Sequence 773116,
c1162	15.4	0.4	18	1	US-10-310-914A-88249	Sequence 88249, A	1235	15.4	0.4	19	1	US-10-310-914A-796345	Sequence 796345,
c1163	15.4	0.4	18	1	US-10-310-914A-142074	Sequence 142074,	c1236	15.4	0.4	19	1	US-10-310-914A-814718	Sequence 814718,
c1164	15.4	0.4	18	1	US-10-310-914A-194147	Sequence 194147,	1237	15.4	0.4	19	1	US-10-310-914A-842885	Sequence 842885,
c1165	15.4	0.4	18	1	US-10-310-914A-196436	Sequence 196436,	c1238	15.4	0.4	19	1	US-10-310-914A-885145	Sequence 885145,
1166	15.4	0.4	18	1	US-10-310-914A-215704	Sequence 215704,	c1239	15.4	0.4	19	1	US-10-310-914A-900173	Sequence 900173,
c1167	15.4	0.4	18	1	US-10-310-914A-233017	Sequence 233017,	1240	15.4	0.4	19	1	US-10-310-914A-906770	Sequence 906770,
c1168	15.4	0.4	18	1	US-10-310-914A-239452	Sequence 239452,	1241	15.4	0.4	19	1	US-10-310-914A-912740	Sequence 912740,
c1169	15.4	0.4	18	1	US-10-310-914A-277041	Sequence 277041,	1242	15.4	0.4	19	1	US-10-310-914A-933011	Sequence 933011,
1170	15.4	0.4	18	1	US-10-310-914A-291755	Sequence 291755,	1243	15.4	0.4	19	1	US-10-310-914A-949706	Sequence 949706,
c1171	15.4	0.4	18	1	US-10-310-914A-309547	Sequence 309547,	c1244	15.4	0.4	19	1	US-10-310-914A-966440	Sequence 966440,
c1172	15.4	0.4	18	1	US-10-310-914A-319145	Sequence 319145,	c1245	15.4	0.4	19	1	US-10-310-914A-1044765	Sequence 1044765,
1173	15.4	0.4	18	1	US-10-310-914A-337636	Sequence 337636,	c1246	15.4	0.4	19	1	US-10-310-914A-1127249	Sequence 1127249,
c1174	15.4	0.4	18	1	US-10-310-914A-402474	Sequence 402474,	1247	15.4	0.4	19	1	US-10-310-914A-1150255	Sequence 1150255,
c1175	15.4	0.4	18	1	US-10-310-914A-482383	Sequence 482383,	1248	15.4	0.4	19	1	US-10-310-914A-1150285	Sequence 1150285,
c1176	15.4	0.4	18	1	US-10-310-914A-493585	Sequence 493585,	1249	15.4	0.4	19	1	US-10-310-914A-1154760	Sequence 1154760,
1177	15.4	0.4	18	1	US-10-310-914A-509676	Sequence 509676,	c1250	15.4	0.4	19	1	US-10-310-914A-1187331	Sequence 1187331,
c1178	15.4	0.4	18	1	US-10-310-914A-510078	Sequence 510078,	c1251	15.4	0.4	19	1	US-10-310-914A-1283822	Sequence 1283822,
c1179	15.4	0.4	18	1	US-10-310-914A-562505	Sequence 562505,	1252	15.4	0.4	19	1	US-11-101-244-51	Sequence 51, Appl
c1180	15.4	0.4	18	1	US-10-310-914A-572035	Sequence 572035,	1253	15.4	0.4	19	1	US-11-101-244-14393	Sequence 14393, A
c1181	15.4	0.4	18	1	US-10-310-914A-572960	Sequence 572960,	1254	15.4	0.4	19	1	US-11-101-244-14433	Sequence 14433, A
c1182	15.4	0.4	18	1	US-10-310-914A-621831	Sequence 621831,	1255	15.4	0.4	19	1	US-11-101-244-38758	Sequence 38758, A
c1183	15.4	0.4	18	1	US-10-310-914A-705359	Sequence 705359,	c1256	15.4	0.4	19	1	US-11-101-244-47494	Sequence 47494, A
c1184	15.4	0.4	18	1	US-10-310-914A-726118	Sequence 726118,	1257	15.4	0.4	19	1	US-11-101-244-88064	Sequence 88064, A
c1185	15.4	0.4	18	1	US-10-310-914A-736049	Sequence 736049,	1258	15.4	0.4	19	1	US-11-101-244-95866	Sequence 95866, A
c1186	15.4	0.4	18	1	US-10-310-914A-743243	Sequence 743243,	1259	15.4	0.4	19	1	US-11-101-244-124920	Sequence 124920,
1187	15.4	0.4	18	1	US-10-310-914A-839587	Sequence 839587,	1260	15.4	0.4	19	1	US-11-101-244-158311	Sequence 158311,
c1188	15.4	0.4	18	1	US-10-310-914A-842880	Sequence 842880,	1261	15.4	0.4	19	1	US-11-101-244-158978	Sequence 158978,
c1189	15.4	0.4	18	1	US-10-310-914A-876761	Sequence 876761,	c1262	15.4	0.4	19	1	US-11-101-244-165037	Sequence 165037,
c1190	15.4	0.4	18	1	US-10-310-914A-877410	Sequence 877410,	c1263	15.4	0.4	19	1	US-11-101-244-165057	Sequence 165057,
1191	15.4	0.4	18	1	US-10-310-914A-904313	Sequence 904313,	c1264	15.4	0.4	19	1	US-11-101-244-165136	Sequence 165136,
1192	15.4	0.4	18	1	US-10-310-914A-924563	Sequence 924563,	c1265	15.4	0.4	19	1	US-11-101-244-165156	Sequence 165156,
1193	15.4	0.4	18	1	US-10-310-914A-966189	Sequence 966189,	c1266	15.4	0.4	19	1	US-11-101-244-165238	Sequence 165238,
1194	15.4	0.4	18	1	US-10-310-914A-1029714	Sequence 1029714,	c1267	15.4	0.4	19	1	US-11-101-244-165258	Sequence 165258,
c1195	15.4	0.4	18	1	US-10-310-914A-1043266	Sequence 1043266,	1268	15.4	0.4	19	1	US-11-101-244-165337	Sequence 165337,
1196	15.4	0.4	18	1	US-10-310-914A-1071301	Sequence 1071301,	c1269	15.4	0.4	19	1	US-11-101-244-165357	Sequence 165357,
c1197	15.4	0.4	18	1	US-10-310-914A-1175377	Sequence 1175377,	c1270	15.4	0.4	19	1	US-11-101-244-165439	Sequence 165439,
1198	15.4	0.4	18	1	US-10-310-914A-1199690	Sequence 1199690,	c1271	15.4	0.4	19	1	US-11-101-244-165462	Sequence 165462,
c1199	15.4	0.4	18	1	US-10-310-914A-1214992	Sequence 1214992,	1272	15.4	0.4	19	1	US-11-101-244-223107	Sequence 223107,
1200	15.4	0.4	18	1	US-10-310-914A-1253300	Sequence 1253300,	c1273	15.4	0.4	19	1	US-11-101-244-249657	Sequence 249657,
c1201	15.4	0.4	18	1	US-10-310-914A-1296340	Sequence 1296340,	1274	15.4	0.4	19	1	US-11-101-244-249676	Sequence 249676,

1275	15.4	0.4	19	1	US-11-101-244-376141	Sequence 376141,	c1348	15.4	0.4	19	1	US-11-083-784-165238	Sequence 165238,
1276	15.4	0.4	19	1	US-11-101-244-384878	Sequence 384878,	c1349	15.4	0.4	19	1	US-11-083-784-165258	Sequence 165258,
1277	15.4	0.4	19	1	US-11-101-244-388710	Sequence 388710,	c1350	15.4	0.4	19	1	US-11-083-784-165337	Sequence 165337,
c1278	15.4	0.4	19	1	US-11-101-244-393275	Sequence 393275,	c1351	15.4	0.4	19	1	US-11-083-784-165357	Sequence 165357,
1279	15.4	0.4	19	1	US-11-101-244-405137	Sequence 405137,	c1352	15.4	0.4	19	1	US-11-083-784-165439	Sequence 165439,
1280	15.4	0.4	19	1	US-11-101-244-405183	Sequence 405183,	c1353	15.4	0.4	19	1	US-11-083-784-165462	Sequence 165462,
1281	15.4	0.4	19	1	US-11-101-244-440347	Sequence 440347,	c1354	15.4	0.4	19	1	US-11-083-784-223107	Sequence 223107,
c1282	15.4	0.4	19	1	US-11-101-244-442932	Sequence 442932,	c1355	15.4	0.4	19	1	US-11-083-784-249657	Sequence 249657,
c1283	15.4	0.4	19	1	US-11-101-244-446199	Sequence 446199,	c1356	15.4	0.4	19	1	US-11-083-784-249676	Sequence 249676,
c1284	15.4	0.4	19	1	US-11-101-244-448936	Sequence 448936,	c1357	15.4	0.4	19	1	US-11-083-784-376141	Sequence 376141,
1285	15.4	0.4	19	1	US-11-101-244-466442	Sequence 466442,	c1358	15.4	0.4	19	1	US-11-083-784-384878	Sequence 384878,
c1286	15.4	0.4	19	1	US-11-101-244-478703	Sequence 478703,	c1359	15.4	0.4	19	1	US-11-083-784-388710	Sequence 388710,
1287	15.4	0.4	19	1	US-11-101-244-488729	Sequence 488729,	c1360	15.4	0.4	19	1	US-11-083-784-393275	Sequence 393275,
1288	15.4	0.4	19	1	US-11-101-244-499341	Sequence 499341,	c1361	15.4	0.4	19	1	US-11-083-784-405137	Sequence 405137,
1289	15.4	0.4	19	1	US-11-101-244-536642	Sequence 536642,	c1362	15.4	0.4	19	1	US-11-083-784-405183	Sequence 405183,
c1290	15.4	0.4	19	1	US-11-101-244-586431	Sequence 586431,	c1363	15.4	0.4	19	1	US-11-083-784-440347	Sequence 440347,
c1291	15.4	0.4	19	1	US-11-101-244-593515	Sequence 593515,	c1364	15.4	0.4	19	1	US-11-083-784-442932	Sequence 442932,
c1292	15.4	0.4	19	1	US-11-101-244-604134	Sequence 604134,	c1365	15.4	0.4	19	1	US-11-083-784-446199	Sequence 446199,
c1293	15.4	0.4	19	1	US-11-101-244-618691	Sequence 618691,	c1366	15.4	0.4	19	1	US-11-083-784-448936	Sequence 448936,
1294	15.4	0.4	19	1	US-11-101-244-710189	Sequence 710189,	c1367	15.4	0.4	19	1	US-11-083-784-466442	Sequence 466442,
c1295	15.4	0.4	19	1	US-11-101-244-772658	Sequence 772658,	c1368	15.4	0.4	19	1	US-11-083-784-478703	Sequence 478703,
1296	15.4	0.4	19	1	US-11-101-244-778427	Sequence 778427,	c1369	15.4	0.4	19	1	US-11-083-784-488729	Sequence 488729,
1297	15.4	0.4	19	1	US-11-101-244-778438	Sequence 778438,	c1370	15.4	0.4	19	1	US-11-083-784-499341	Sequence 499341,
1298	15.4	0.4	19	1	US-11-101-244-788952	Sequence 788952,	c1371	15.4	0.4	19	1	US-11-083-784-536642	Sequence 536642,
1299	15.4	0.4	19	1	US-11-101-244-789052	Sequence 789052,	c1372	15.4	0.4	19	1	US-11-083-784-586431	Sequence 586431,
1300	15.4	0.4	19	1	US-11-101-244-789152	Sequence 789152,	c1373	15.4	0.4	19	1	US-11-083-784-593515	Sequence 593515,
1301	15.4	0.4	19	1	US-11-101-244-789248	Sequence 789248,	c1374	15.4	0.4	19	1	US-11-083-784-604134	Sequence 604134,
1302	15.4	0.4	19	1	US-11-101-244-789347	Sequence 789347,	c1375	15.4	0.4	19	1	US-11-083-784-618691	Sequence 618691,
1303	15.4	0.4	19	1	US-11-101-244-789447	Sequence 789447,	c1376	15.4	0.4	19	1	US-11-083-784-710189	Sequence 710189,
c1304	15.4	0.4	19	1	US-11-101-244-834453	Sequence 834453,	c1377	15.4	0.4	19	1	US-11-083-784-772658	Sequence 772658,
1305	15.4	0.4	19	1	US-11-101-244-837999	Sequence 837999,	c1378	15.4	0.4	19	1	US-11-083-784-778427	Sequence 778427,
1306	15.4	0.4	19	1	US-11-101-244-855576	Sequence 855576,	c1379	15.4	0.4	19	1	US-11-083-784-778438	Sequence 778438,
c1307	15.4	0.4	19	1	US-11-101-244-927801	Sequence 927801,	c1380	15.4	0.4	19	1	US-11-083-784-788952	Sequence 788952,
1308	15.4	0.4	19	1	US-11-101-244-1039444	Sequence 1039444,	c1381	15.4	0.4	19	1	US-11-083-784-789052	Sequence 789052,
c1309	15.4	0.4	19	1	US-11-101-244-1036594	Sequence 1036594,	c1382	15.4	0.4	19	1	US-11-083-784-789152	Sequence 789152,
1310	15.4	0.4	19	1	US-11-101-244-1071237	Sequence 1071237,	c1383	15.4	0.4	19	1	US-11-083-784-789248	Sequence 789248,
1311	15.4	0.4	19	1	US-11-101-244-1071275	Sequence 1071275,	c1384	15.4	0.4	19	1	US-11-083-784-789347	Sequence 789347,
1312	15.4	0.4	19	1	US-11-101-244-1104410	Sequence 1104410,	c1385	15.4	0.4	19	1	US-11-083-784-789447	Sequence 789447,
1313	15.4	0.4	19	1	US-11-101-244-1104472	Sequence 1104472,	c1386	15.4	0.4	19	1	US-11-083-784-834453	Sequence 834453,
1314	15.4	0.4	19	1	US-11-101-244-1134517	Sequence 1134517,	c1387	15.4	0.4	19	1	US-11-083-784-83453	Sequence 83453,
1315	15.4	0.4	19	1	US-11-101-244-1261573	Sequence 1261573,	c1388	15.4	0.4	19	1	US-11-083-784-855576	Sequence 855576,
1316	15.4	0.4	19	1	US-11-101-244-1267573	Sequence 1267573,	c1389	15.4	0.4	19	1	US-11-083-784-855576	Sequence 855576,
1317	15.4	0.4	19	1	US-11-101-244-1259838	Sequence 1259838,	c1390	15.4	0.4	19	1	US-11-083-784-1019444	Sequence 1019444,
c1318	15.4	0.4	19	1	US-11-101-244-1263543	Sequence 1263543,	c1391	15.4	0.4	19	1	US-11-083-784-1036594	Sequence 1036594,
c1319	15.4	0.4	19	1	US-11-101-244-1263597	Sequence 1263597,	c1392	15.4	0.4	19	1	US-11-083-784-1071237	Sequence 1071237,
c1320	15.4	0.4	19	1	US-11-101-244-1268095	Sequence 1268095,	c1393	15.4	0.4	19	1	US-11-083-784-1071275	Sequence 1071275,
c1321	15.4	0.4	19	1	US-11-101-244-1319444	Sequence 1319444,	c1394	15.4	0.4	19	1	US-11-083-784-1104410	Sequence 1104410,
c1322	15.4	0.4	19	1	US-11-101-244-1323046	Sequence 1323046,	c1395	15.4	0.4	19	1	US-11-083-784-1104472	Sequence 1104472,
c1323	15.4	0.4	19	1	US-11-101-244-1334142	Sequence 1334142,	c1396	15.4	0.4	19	1	US-11-083-784-1134517	Sequence 1134517,
1324	15.4	0.4	19	1	US-11-101-244-1366776	Sequence 1366776,	c1397	15.4	0.4	19	1	US-11-083-784-1136133	Sequence 1136133,
c1325	15.4	0.4	19	1	US-11-101-244-1372964	Sequence 1372964,	c1398	15.4	0.4	19	1	US-11-083-784-1207573	Sequence 1207573,
1326	15.4	0.4	19	1	US-11-101-244-1401474	Sequence 1401474,	c1399	15.4	0.4	19	1	US-11-083-784-1259838	Sequence 1259838,
c1327	15.4	0.4	19	1	US-11-101-244-141103	Sequence 141103,	c1400	15.4	0.4	19	1	US-11-083-784-1263543	Sequence 1263543,
c1328	15.4	0.4	19	1	US-11-101-244-1444645	Sequence 1444645,	c1401	15.4	0.4	19	1	US-11-083-784-1363597	Sequence 1363597,
c1329	15.4	0.4	19	1	US-11-101-244-1459620	Sequence 1459620,	c1402	15.4	0.4	19	1	US-11-083-784-1368095	Sequence 1368095,
c1330	15.4	0.4	19	1	US-11-101-244-1495899	Sequence 1495899,	c1403	15.4	0.4	19	1	US-11-083-784-1319444	Sequence 1319444,
1331	15.4	0.4	19	1	US-11-101-244-152077	Sequence 1512077,	c1404	15.4	0.4	19	1	US-11-083-784-1323046	Sequence 1323046,
c1332	15.4	0.4	19	1	US-11-101-244-1525042	Sequence 1525042,	c1405	15.4	0.4	19	1	US-11-083-784-1334142	Sequence 1334142,
c1333	15.4	0.4	19	1	US-11-101-244-1575806	Sequence 1575806,	c1406	15.4	0.4	19	1	US-11-083-784-1366776	Sequence 1366776,
1334	15.4	0.4	19	1	US-11-083-784-51	Sequence 51, Appl	c1407	15.4	0.4	19	1	US-11-083-784-1372964	Sequence 1372964,
1335	15.4	0.4	19	1	US-11-083-784-14393	Sequence 14393, A	c1408	15.4	0.4	19	1	US-11-083-784-1401474	Sequence 1401474,
1336	15.4	0.4	19	1	US-11-083-784-14433	Sequence 14433, A	c1409	15.4	0.4	19	1	US-11-083-784-1441103	Sequence 1441103,
1337	15.4	0.4	19	1	US-11-083-784-38758	Sequence 38758, A	c1410	15.4	0.4	19	1	US-11-083-784-1444645	Sequence 1444645,
c1338	15.4	0.4	19	1	US-11-083-784-47494	Sequence 47494, A	c1411	15.4	0.4	19	1	US-11-083-784-1469620	Sequence 1469620,
1339	15.4	0.4	19	1	US-11-083-784-88064	Sequence 88064, A	c1412	15.4	0.4	19	1	US-11-083-784-1495899	Sequence 1495899,
1340	15.4	0.4	19	1	US-11-083-784-95986	Sequence 95986, A	c1413	15.4	0.4	19	1	US-11-083-784-1512077	Sequence 1512077,
1341	15.4	0.4	19	1	US-11-083-784-124920	Sequence 124920,	c1414	15.4	0.4	19	1	US-11-083-784-1525042	Sequence 1525042,
1342	15.4	0.4	19	1	US-11-083-784-158311	Sequence 158311,	c1415	15.4	0.4	19	1	US-11-083-784-1575806	Sequence 1575806,
1343	15.4	0.4	19	1	US-11-083-784-158978	Sequence 158978,	c1416	15	0.4	18	1	US-10-310-914A-326990	Sequence 326990,
c1344	15.4	0.4	19	1	US-11-083-784-165037	Sequence 165037,	c1417	15	0.4	18	1	US-10-310-914A-350180	Sequence 350180,
c1345	15.4	0.4	19	1	US-11-083-784-165057	Sequence 165057,	c1418	15	0.4	18	1	US-10-310-914A-392825	Sequence 392825,
c1346	15.4	0.4	19	1	US-11-083-784-165136	Sequence 165136,	c1419	15	0.4	18	1	US-10-310-914A-439882	Sequence 439882,
c1347	15.4	0.4	19	1	US-11-083-784-165156	Sequence 165156,	c1420	15	0.4	18	1	US-10-310-914A-492615	Sequence 492615,

c1421	15	0.4	18	1	US-10-310-914A-736192	Sequence 736192,	c1494	14.8	0.3	18	1	US-10-310-914A-592815	Sequence 592815,
1422	15	0.4	18	1	US-10-310-914A-746225	Sequence 746225,	c1495	14.8	0.3	18	1	US-10-310-914A-609105	Sequence 609105,
1423	15	0.4	18	1	US-10-310-914A-1154193	Sequence 1154193,	1496	14.8	0.3	18	1	US-10-310-914A-655587	Sequence 655587,
c1424	15	0.4	18	1	US-10-310-914A-1198207	Sequence 1198207,	c1497	14.8	0.3	18	1	US-10-310-914A-661057	Sequence 661057,
1425	15	0.4	18	1	US-10-310-914A-1202821	Sequence 1202821,	c1498	14.8	0.3	18	1	US-10-310-914A-675735	Sequence 675735,
c1426	15	0.4	18	1	US-10-310-914A-1218422	Sequence 1218422,	c1499	14.8	0.3	18	1	US-10-310-914A-702256	Sequence 702256,
c1427	14.8	0.3	18	1	US-10-958-999-8	Sequence 8, Appli	1500	14.8	0.3	18	1	US-10-310-914A-716395	Sequence 716395,
1428	14.8	0.3	18	1	US-10-310-914A-41560	Sequence 41560, A	1501	14.8	0.3	18	1	US-10-310-914A-728016	Sequence 728016,
c1429	14.8	0.3	18	1	US-10-310-914A-41561	Sequence 41561, A	1502	14.8	0.3	18	1	US-10-310-914A-747222	Sequence 747222,
1430	14.8	0.3	18	1	US-10-310-914A-41786	Sequence 41786, A	c1503	14.8	0.3	18	1	US-10-310-914A-761086	Sequence 761086,
1431	14.8	0.3	18	1	US-10-310-914A-41980	Sequence 41980, A	1504	14.8	0.3	18	1	US-10-310-914A-765180	Sequence 765180,
1432	14.8	0.3	18	1	US-10-310-914A-44001	Sequence 44001, A	c1505	14.8	0.3	18	1	US-10-310-914A-771537	Sequence 771537,
1433	14.8	0.3	18	1	US-10-310-914A-49283	Sequence 49283, A	1506	14.8	0.3	18	1	US-10-310-914A-778728	Sequence 778728,
1434	14.8	0.3	18	1	US-10-310-914A-58832	Sequence 58832, A	c1507	14.8	0.3	18	1	US-10-310-914A-785986	Sequence 785986,
c1435	14.8	0.3	18	1	US-10-310-914A-58832	Sequence 58832, A	1508	14.8	0.3	18	1	US-10-310-914A-787511	Sequence 787511,
c1436	14.8	0.3	18	1	US-10-310-914A-64741	Sequence 64741, A	1509	14.8	0.3	18	1	US-10-310-914A-804096	Sequence 804096,
1437	14.8	0.3	18	1	US-10-310-914A-67513	Sequence 67513, A	c1509	14.8	0.3	18	1	US-10-310-914A-847270	Sequence 847270,
1438	14.8	0.3	18	1	US-10-310-914A-73628	Sequence 73628, A	1510	14.8	0.3	18	1	US-10-310-914A-871270	Sequence 871270,
1439	14.8	0.3	18	1	US-10-310-914A-73629	Sequence 73629, A	1511	14.8	0.3	18	1	US-10-310-914A-894247	Sequence 894247,
c1440	14.8	0.3	18	1	US-10-310-914A-74614	Sequence 74614, A	1512	14.8	0.3	18	1	US-10-310-914A-894280	Sequence 894280,
c1441	14.8	0.3	18	1	US-10-310-914A-76058	Sequence 76058, A	1513	14.8	0.3	18	1	US-10-310-914A-897142	Sequence 897142,
c1442	14.8	0.3	18	1	US-10-310-914A-79264	Sequence 79264, A	c1514	14.8	0.3	18	1	US-10-310-914A-907233	Sequence 907233,
c1443	14.8	0.3	18	1	US-10-310-914A-85575	Sequence 85575, A	1515	14.8	0.3	18	1	US-10-310-914A-958358	Sequence 958358,
c1444	14.8	0.3	18	1	US-10-310-914A-95682	Sequence 95682, A	c1516	14.8	0.3	18	1	US-10-310-914A-958514	Sequence 958514,
c1445	14.8	0.3	18	1	US-10-310-914A-98379	Sequence 98379, A	1517	14.8	0.3	18	1	US-10-310-914A-967635	Sequence 967635,
c1446	14.8	0.3	18	1	US-10-310-914A-99217	Sequence 99217, A	c1518	14.8	0.3	18	1	US-10-310-914A-974099	Sequence 974099,
c1447	14.8	0.3	18	1	US-10-310-914A-107712	Sequence 107712,	1519	14.8	0.3	18	1	US-10-310-914A-1009356	Sequence 1009356,
c1448	14.8	0.3	18	1	US-10-310-914A-11236	Sequence 11236,	c1520	14.8	0.3	18	1	US-10-310-914A-1014756	Sequence 1014756,
c1449	14.8	0.3	18	1	US-10-310-914A-138164	Sequence 138164,	c1521	14.8	0.3	18	1	US-10-310-914A-1026764	Sequence 1026764,
1450	14.8	0.3	18	1	US-10-310-914A-149256	Sequence 149256,	1522	14.8	0.3	18	1	US-10-310-914A-1030192	Sequence 1030192,
1451	14.8	0.3	18	1	US-10-310-914A-150479	Sequence 150479,	1523	14.8	0.3	18	1	US-10-310-914A-1059710	Sequence 1059710,
c1452	14.8	0.3	18	1	US-10-310-914A-157171	Sequence 157171,	1524	14.8	0.3	18	1	US-10-310-914A-1067192	Sequence 1067192,
c1453	14.8	0.3	18	1	US-10-310-914A-168059	Sequence 168059,	1525	14.8	0.3	18	1	US-10-310-914A-1067193	Sequence 1067193,
1454	14.8	0.3	18	1	US-10-310-914A-168733	Sequence 168733,	1526	14.8	0.3	18	1	US-10-310-914A-1077647	Sequence 1077647,
1455	14.8	0.3	18	1	US-10-310-914A-182752	Sequence 182752,	1527	14.8	0.3	18	1	US-10-310-914A-1077648	Sequence 1077648,
1456	14.8	0.3	18	1	US-10-310-914A-185749	Sequence 185749,	c1528	14.8	0.3	18	1	US-10-310-914A-1079848	Sequence 1079848,
1457	14.8	0.3	18	1	US-10-310-914A-200249	Sequence 200249,	1529	14.8	0.3	18	1	US-10-310-914A-1085525	Sequence 1085525,
1458	14.8	0.3	18	1	US-10-310-914A-200570	Sequence 200570,	c1530	14.8	0.3	18	1	US-10-310-914A-1087279	Sequence 1087279,
c1459	14.8	0.3	18	1	US-10-310-914A-223919	Sequence 223919,	1531	14.8	0.3	18	1	US-10-310-914A-1087936	Sequence 1087936,
1460	14.8	0.3	18	1	US-10-310-914A-245025	Sequence 245025,	1532	14.8	0.3	18	1	US-10-310-914A-1090451	Sequence 1090451,
c1461	14.8	0.3	18	1	US-10-310-914A-258670	Sequence 258670,	c1533	14.8	0.3	18	1	US-10-310-914A-1091850	Sequence 1091850,
1462	14.8	0.3	18	1	US-10-310-914A-274408	Sequence 274408,	1534	14.8	0.3	18	1	US-10-310-914A-1108672	Sequence 1108672,
1463	14.8	0.3	18	1	US-10-310-914A-289024	Sequence 289024,	c1535	14.8	0.3	18	1	US-10-310-914A-1115627	Sequence 1115627,
c1464	14.8	0.3	18	1	US-10-310-914A-312199	Sequence 312199,	1536	14.8	0.3	18	1	US-10-310-914A-1134670	Sequence 1134670,
c1465	14.8	0.3	18	1	US-10-310-914A-316348	Sequence 316348,	1537	14.8	0.3	18	1	US-10-310-914A-1141714	Sequence 1141714,
c1466	14.8	0.3	18	1	US-10-310-914A-318062	Sequence 318062,	c1538	14.8	0.3	18	1	US-10-310-914A-1150343	Sequence 1150343,
1467	14.8	0.3	18	1	US-10-310-914A-321907	Sequence 321907,	1539	14.8	0.3	18	1	US-10-310-914A-1160776	Sequence 1160776,
c1468	14.8	0.3	18	1	US-10-310-914A-322050	Sequence 322050,	c1540	14.8	0.3	18	1	US-10-310-914A-1161317	Sequence 1161317,
c1469	14.8	0.3	18	1	US-10-310-914A-340689	Sequence 340689,	c1541	14.8	0.3	18	1	US-10-310-914A-1168846	Sequence 1168846,
c1470	14.8	0.3	18	1	US-10-310-914A-343588	Sequence 343588,	c1542	14.8	0.3	18	1	US-10-310-914A-1183773	Sequence 1183773,
c1471	14.8	0.3	18	1	US-10-310-914A-343589	Sequence 343589,	c1543	14.8	0.3	18	1	US-10-310-914A-1187035	Sequence 1187035,
c1472	14.8	0.3	18	1	US-10-310-914A-353955	Sequence 353955,	1544	14.8	0.3	18	1	US-10-310-914A-1197636	Sequence 1197636,
c1473	14.8	0.3	18	1	US-10-310-914A-370347	Sequence 370347,	1545	14.8	0.3	18	1	US-10-310-914A-1200184	Sequence 1200184,
c1474	14.8	0.3	18	1	US-10-310-914A-374108	Sequence 374108,	c1546	14.8	0.3	18	1	US-10-310-914A-1201161	Sequence 1201161,
c1475	14.8	0.3	18	1	US-10-310-914A-392819	Sequence 392819,	c1547	14.8	0.3	18	1	US-10-310-914A-1212176	Sequence 1212176,
c1476	14.8	0.3	18	1	US-10-310-914A-394234	Sequence 394234,	c1548	14.8	0.3	18	1	US-10-310-914A-1214147	Sequence 1214147,
1477	14.8	0.3	18	1	US-10-310-914A-399085	Sequence 399085,	c1549	14.8	0.3	18	1	US-10-310-914A-1214571	Sequence 1214571,
c1478	14.8	0.3	18	1	US-10-310-914A-401700	Sequence 401700,	c1550	14.8	0.3	18	1	US-10-310-914A-1214779	Sequence 1214779,
c1479	14.8	0.3	18	1	US-10-310-914A-407421	Sequence 407421,	1551	14.8	0.3	18	1	US-10-310-914A-1228679	Sequence 1228679,
c1480	14.8	0.3	18	1	US-10-310-914A-472391	Sequence 472391,	c1552	14.8	0.3	18	1	US-10-310-914A-1228949	Sequence 1228949,
c1481	14.8	0.3	18	1	US-10-310-914A-479651	Sequence 479651,	1553	14.8	0.3	18	1	US-10-310-914A-1253710	Sequence 1253710,
c1482	14.8	0.3	18	1	US-10-310-914A-485967	Sequence 485967,	c1554	14.8	0.3	18	1	US-10-310-914A-1258332	Sequence 1258332,
c1483	14.8	0.3	18	1	US-10-310-914A-487136	Sequence 487136,	1555	14.8	0.3	18	1	US-10-310-914A-1260027	Sequence 1260027,
c1484	14.8	0.3	18	1	US-10-310-914A-490510	Sequence 490510,	c1556	14.8	0.3	18	1	US-10-310-914A-1263719	Sequence 1263719,
c1485	14.8	0.3	18	1	US-10-310-914A-494389	Sequence 494389,	c1557	14.8	0.3	18	1	US-10-310-914A-1284973	Sequence 1284973,
c1486	14.8	0.3	18	1	US-10-310-914A-510815	Sequence 510815,	1558	14.8	0.3	18	1	US-10-310-914A-1287424	Sequence 1287424,
c1487	14.8	0.3	18	1	US-10-310-914A-519334	Sequence 519334,	1559	14.8	0.3	18	1	US-10-310-914A-1296859	Sequence 1296859,
c1488	14.8	0.3	18	1	US-10-310-914A-521199	Sequence 521199,	1560	14.8	0.3	18	1	US-10-310-914A-1302290	Sequence 1302290,
c1489	14.8	0.3	18	1	US-10-310-914A-523963	Sequence 523963,	1561	14.8	0.3	18	1	US-10-310-914A-1302291	Sequence 1302291,
c1490	14.8	0.3	18	1	US-10-310-914A-540325	Sequence 540325,	c1562	14.8	0.3	18	1	US-10-310-914A-1303787	Sequence 1303787,
c1491	14.8	0.3	18	1	US-10-310-914A-552910	Sequence 552910,	1563	14.8	0.3	18	1	US-10-310-914A-1305050	Sequence 1305050,
c1492	14.8	0.3	18	1	US-10-310-914A-559267	Sequence 559267,	1564	14.8	0.3	18	1	US-10-310-914A-1305749	Sequence 1305749,
1493	14.8	0.3	18	1	US-10-310-914A-560682	Sequence 560682,	c1565	14.8	0.3	18	1	US-10-310-914A-1307300	Sequence 1307300,
							c1566	14.8	0.3	18	1	US-10-310-914A-1313757	Sequence 1313757,

c1567	14.8	0.3	18	1	US-10-310-914A-1322817	Sequence 1322817,	c1640	14.4	0.3	18	1	US-10-310-914A-733252	Sequence 733252,
c1568	14.8	0.3	18	1	US-10-310-914A-1330318	Sequence 1330318,	c1641	14.4	0.3	18	1	US-10-310-914A-736940	Sequence 736940,
c1569	14.8	0.3	18	1	US-10-310-914A-1345129	Sequence 1345129,	c1642	14.4	0.3	18	1	US-10-310-914A-737419	Sequence 737419,
c1570	14.8	0.3	18	1	US-10-310-914A-1360221	Sequence 1360221,	c1643	14.4	0.3	18	1	US-10-310-914A-738114	Sequence 738114,
c1571	14.8	0.3	18	1	US-10-310-914A-1362557	Sequence 1362557,	c1644	14.4	0.3	18	1	US-10-310-914A-750442	Sequence 750442,
c1572	14.8	0.3	18	1	US-10-310-914A-1368458	Sequence 1368458,	c1645	14.4	0.3	18	1	US-10-310-914A-759572	Sequence 759572,
c1573	14.8	0.3	18	1	US-10-310-914A-1374377	Sequence 1374377,	c1646	14.4	0.3	18	1	US-10-310-914A-778291	Sequence 778291,
c1574	14.8	0.3	18	1	US-10-310-914A-1375900	Sequence 1375900,	c1647	14.4	0.3	18	1	US-10-310-914A-790616	Sequence 790616,
c1575	14.8	0.3	18	1	US-11-069-908-5922	Sequence 5922, Ap	c1648	14.4	0.3	18	1	US-10-310-914A-791845	Sequence 791845,
c1576	14.6	0.3	25	1	US-11-121-849-151576	Sequence 151576,	c1649	14.4	0.3	18	1	US-10-310-914A-802146	Sequence 802146,
c1577	14.4	0.3	17	1	US-10-858-341-1384	Sequence 1384, Ap	c1650	14.4	0.3	18	1	US-10-310-914A-829295	Sequence 829295,
c1578	14.4	0.3	18	1	US-10-310-914A-41907	Sequence 41907, A	c1651	14.4	0.3	18	1	US-10-310-914A-833421	Sequence 833421,
c1579	14.4	0.3	18	1	US-10-310-914A-56011	Sequence 56011, A	c1652	14.4	0.3	18	1	US-10-310-914A-841274	Sequence 841274,
c1580	14.4	0.3	18	1	US-10-310-914A-64680	Sequence 64680, A	c1653	14.4	0.3	18	1	US-10-310-914A-847213	Sequence 847213,
c1581	14.4	0.3	18	1	US-10-310-914A-79204	Sequence 79204, A	c1654	14.4	0.3	18	1	US-10-310-914A-847214	Sequence 847214,
c1582	14.4	0.3	18	1	US-10-310-914A-91195	Sequence 91195, A	c1655	14.4	0.3	18	1	US-10-310-914A-853825	Sequence 853825,
c1583	14.4	0.3	18	1	US-10-310-914A-98349	Sequence 98349, A	c1656	14.4	0.3	18	1	US-10-310-914A-873006	Sequence 873006,
c1584	14.4	0.3	18	1	US-10-310-914A-111218	Sequence 111218,	c1657	14.4	0.3	18	1	US-10-310-914A-878489	Sequence 878489,
c1585	14.4	0.3	18	1	US-10-310-914A-148286	Sequence 148286,	c1658	14.4	0.3	18	1	US-10-310-914A-892826	Sequence 892826,
c1586	14.4	0.3	18	1	US-10-310-914A-169474	Sequence 169474,	c1659	14.4	0.3	18	1	US-10-310-914A-893437	Sequence 893437,
c1587	14.4	0.3	18	1	US-10-310-914A-173307	Sequence 173307,	c1660	14.4	0.3	18	1	US-10-310-914A-895138	Sequence 895138,
c1588	14.4	0.3	18	1	US-10-310-914A-174618	Sequence 174618,	c1661	14.4	0.3	18	1	US-10-310-914A-906603	Sequence 906603,
c1589	14.4	0.3	18	1	US-10-310-914A-176334	Sequence 176334,	c1662	14.4	0.3	18	1	US-10-310-914A-912483	Sequence 912483,
c1590	14.4	0.3	18	1	US-10-310-914A-213603	Sequence 213603,	c1663	14.4	0.3	18	1	US-10-310-914A-912486	Sequence 912486,
c1591	14.4	0.3	18	1	US-10-310-914A-213974	Sequence 213974,	c1664	14.4	0.3	18	1	US-10-310-914A-914942	Sequence 914942,
c1592	14.4	0.3	18	1	US-10-310-914A-213993	Sequence 213993,	c1665	14.4	0.3	18	1	US-10-310-914A-916502	Sequence 916502,
c1593	14.4	0.3	18	1	US-10-310-914A-216815	Sequence 216815,	c1666	14.4	0.3	18	1	US-10-310-914A-916886	Sequence 916886,
c1594	14.4	0.3	18	1	US-10-310-914A-216816	Sequence 216816,	c1667	14.4	0.3	18	1	US-10-310-914A-922634	Sequence 922634,
c1595	14.4	0.3	18	1	US-10-310-914A-218402	Sequence 218402,	c1668	14.4	0.3	18	1	US-10-310-914A-929594	Sequence 929594,
c1596	14.4	0.3	18	1	US-10-310-914A-223481	Sequence 223481,	c1669	14.4	0.3	18	1	US-10-310-914A-964748	Sequence 964748,
c1597	14.4	0.3	18	1	US-10-310-914A-225022	Sequence 225022,	c1670	14.4	0.3	18	1	US-10-310-914A-966408	Sequence 966408,
c1598	14.4	0.3	18	1	US-10-310-914A-246025	Sequence 246025,	c1671	14.4	0.3	18	1	US-10-310-914A-968397	Sequence 968397,
c1599	14.4	0.3	18	1	US-10-310-914A-247428	Sequence 247428,	c1672	14.4	0.3	18	1	US-10-310-914A-989400	Sequence 989400,
c1600	14.4	0.3	18	1	US-10-310-914A-260616	Sequence 260616,	c1673	14.4	0.3	18	1	US-10-310-914A-999098	Sequence 999098,
c1601	14.4	0.3	18	1	US-10-310-914A-279451	Sequence 279451,	c1674	14.4	0.3	18	1	US-10-310-914A-999099	Sequence 999099,
c1602	14.4	0.3	18	1	US-10-310-914A-281381	Sequence 281381,	c1675	14.4	0.3	18	1	US-10-310-914A-999100	Sequence 999100,
c1603	14.4	0.3	18	1	US-10-310-914A-283866	Sequence 283866,	c1676	14.4	0.3	18	1	US-10-310-914A-1002209	Sequence 1002209,
c1604	14.4	0.3	18	1	US-10-310-914A-302300	Sequence 302300,	c1677	14.4	0.3	18	1	US-10-310-914A-1013145	Sequence 1013145,
c1605	14.4	0.3	18	1	US-10-310-914A-312334	Sequence 312334,	c1678	14.4	0.3	18	1	US-10-310-914A-1022764	Sequence 1022764,
c1606	14.4	0.3	18	1	US-10-310-914A-345359	Sequence 345359,	c1679	14.4	0.3	18	1	US-10-310-914A-1027936	Sequence 1027936,
c1607	14.4	0.3	18	1	US-10-310-914A-360426	Sequence 360426,	c1680	14.4	0.3	18	1	US-10-310-914A-1041898	Sequence 1041898,
c1608	14.4	0.3	18	1	US-10-310-914A-365250	Sequence 365250,	c1681	14.4	0.3	18	1	US-10-310-914A-1060050	Sequence 1060050,
c1609	14.4	0.3	18	1	US-10-310-914A-366631	Sequence 366631,	c1682	14.4	0.3	18	1	US-10-310-914A-1101002	Sequence 1101002,
c1610	14.4	0.3	18	1	US-10-310-914A-384932	Sequence 384932,	c1683	14.4	0.3	18	1	US-10-310-914A-1124096	Sequence 1124096,
c1611	14.4	0.3	18	1	US-10-310-914A-400399	Sequence 400399,	c1684	14.4	0.3	18	1	US-10-310-914A-117722	Sequence 117722,
c1612	14.4	0.3	18	1	US-10-310-914A-405260	Sequence 405260,	c1685	14.4	0.3	18	1	US-10-310-914A-1187158	Sequence 1187158,
c1613	14.4	0.3	18	1	US-10-310-914A-409851	Sequence 409851,	c1686	14.4	0.3	18	1	US-10-310-914A-1187485	Sequence 1187485,
c1614	14.4	0.3	18	1	US-10-310-914A-416008	Sequence 416008,	c1687	14.4	0.3	18	1	US-10-310-914A-1219995	Sequence 1219995,
c1615	14.4	0.3	18	1	US-10-310-914A-434918	Sequence 434918,	c1688	14.4	0.3	18	1	US-10-310-914A-1222014	Sequence 1222014,
c1616	14.4	0.3	18	1	US-10-310-914A-444628	Sequence 444628,	c1689	14.4	0.3	18	1	US-10-310-914A-1264272	Sequence 1264272,
c1617	14.4	0.3	18	1	US-10-310-914A-449233	Sequence 449233,	c1690	14.4	0.3	18	1	US-10-310-914A-1264496	Sequence 1264496,
c1618	14.4	0.3	18	1	US-10-310-914A-470179	Sequence 470179,	c1691	14.4	0.3	18	1	US-10-310-914A-1279584	Sequence 1279584,
c1619	14.4	0.3	18	1	US-10-310-914A-476504	Sequence 476504,	c1692	14.4	0.3	18	1	US-10-310-914A-1289326	Sequence 1289326,
c1620	14.4	0.3	18	1	US-10-310-914A-477521	Sequence 477521,	c1693	14.4	0.3	18	1	US-10-310-914A-1289327	Sequence 1289327,
c1621	14.4	0.3	18	1	US-10-310-914A-477522	Sequence 477522,	c1694	14.4	0.3	18	1	US-10-310-914A-1295076	Sequence 1295076,
c1622	14.4	0.3	18	1	US-10-310-914A-502238	Sequence 502238,	c1695	14.4	0.3	18	1	US-10-310-914A-1296315	Sequence 1296315,
c1623	14.4	0.3	18	1	US-10-310-914A-541085	Sequence 541085,	c1696	14.4	0.3	18	1	US-10-310-914A-1315876	Sequence 1315876,
c1624	14.4	0.3	18	1	US-10-310-914A-543962	Sequence 543962,	c1697	14.4	0.3	18	1	US-10-310-914A-1347485	Sequence 1347485,
c1625	14.4	0.3	18	1	US-10-310-914A-545257	Sequence 545257,	c1698	14.4	0.3	18	1	US-10-310-914A-137485	Sequence 137485,
c1626	14.4	0.3	18	1	US-10-310-914A-551594	Sequence 551594,	c1699	14.4	0.3	18	1	US-10-310-914A-1353530	Sequence 1353530,
c1627	14.4	0.3	18	1	US-10-310-914A-608856	Sequence 608856,	c1700	14.4	0.3	18	1	US-10-310-914A-1353530	Sequence 1353530,
c1628	14.4	0.3	18	1	US-10-310-914A-615451	Sequence 615451,						Sequence 1263, Ap	
c1629	14.4	0.3	18	1	US-10-310-914A-632129	Sequence 632129,						Sequence 3629, Ap	
c1630	14.4	0.3	18	1	US-10-310-914A-637489	Sequence 637489,							
c1631	14.4	0.3	18	1	US-10-310-914A-640184	Sequence 640184,							
c1632	14.4	0.3	18	1	US-10-310-914A-647639	Sequence 647639,							
c1633	14.4	0.3	18	1	US-10-310-914A-694211	Sequence 694211,							
c1634	14.4	0.3	18	1	US-10-310-914A-696304	Sequence 696304,							
c1635	14.4	0.3	18	1	US-10-310-914A-703730	Sequence 703730,							
c1636	14.4	0.3	18	1	US-10-310-914A-709308	Sequence 709308,							
c1637	14.4	0.3	18	1	US-10-310-914A-715655	Sequence 715655,							
c1638	14.4	0.3	18	1	US-10-310-914A-722201	Sequence 722201,							
c1639	14.4	0.3	18	1	US-10-310-914A-732299	Sequence 73							

ALIGNMENTS

RESULT 1

US-10-949-720-2/c

; Sequence 2, Application US/10949720

; Publication No. US20050249736A1

; GENERAL INFORMATION:

; APPLICANT: Krasnoperov, Valery

; APPLICANT: Zozulya, Sergey

; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-2

Query Match 0.7%; Score 29; DB 1; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 TGGATGAGCGAGCGCTGGCGGAGCAG 1986
DB 36 TGGATGAGCGAGCGCTGGCGGAGCAG 8

RESULT 2

US-10-914A-153230/c
; Sequence 153230, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153230
; LENGTH: 27
; TYPE: RNA
; ORGANISM: Human
US-10-914A-153230

Query Match 0.6%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3896 CTTTTTGTTCCTCGTTTGTTCCT 3922
DB 27 CTTTTTGTTCCTCGTTTGTTCCT 1

RESULT 3

US-10-914A-153273/c
; Sequence 153273, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153273
; LENGTH: 27
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153273

Query Match 0.6%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3486 TGGGGGTTCTGCCATAATAGAGGGGA 3512
DB 27 TGGGGGTTCTGCCATAATAGAGGGGA 1

RESULT 4

US-10-310-914A-153276/c
; Sequence 153276, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153276
; LENGTH: 27
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153276

Query Match 0.6%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3644 GATGGGTGCGTTCGCCGACACCAAGA 3670
DB 27 GATGGGTGCGTTCGCCGACACCAAGA 1

RESULT 5

US-10-310-914A-153271/c
; Sequence 153271, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153271
; LENGTH: 26
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153271

Query Match 0.6%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3419 CTGTGCCCCGCTGATTGCACTTTGA 3444
|||||

```

Db      26 CTGTGCCCCGCTGGATTGCACCTTGA 1

RESULT 6
US-10-310-914A-153279/c
; Sequence 153279, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153279
; LENGTH: 26
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153279

Query Match      0.6%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4011 CTGTTTCCAGAACAGTGCCTTGTCAT 4036
        |||||||
Db      26 CTGTTTCCAGAACAGTGCCTTGTCAT 1

RESULT 7
US-10-310-914A-153226/c
; Sequence 153226, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153226
; LENGTH: 25
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153226

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3907 TTCGTTTGTGTTTCTACCGTCCTT 3931
        |||||||
Db      25 TTCGTTTGTGTTTCTACCGTCCTT 1

RESULT 8
US-10-310-914A-153237/c
; Sequence 153237, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06

```

```

; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153237
; LENGTH: 25
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153237

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3432 GATTGCACCTTGGAGCCCGTGGGGTG 3456
        |||||||
Db      25 GATTGCACCTTGGAGCCCGTGGGGTG 1

RESULT 9
US-10-310-914A-153292/c
; Sequence 153292, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153292
; LENGTH: 25
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153292

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4046 CCGGACCCCGCTGGGACCCCCAA 4070
        |||||||
Db      25 CCGGACCCCGCTGGGACCCCCAA 1

RESULT 10
US-11-121-849-151566
; Sequence 151566, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded Sa
; TITLE OF INVENTION: Microarrays
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151566
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-151566

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3912 TTGTTTCTACCGTCCTTGTCAT 3936
        |||||||

```

```
Db      1 TTTGTTTTCTACCGTCCTTGTCAT 25

RESULT 11
US-11-121-849-151567
; Sequence 151567, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraaffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151567
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-151567

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      3921 CTACCGTCCTTGTCATACTTTGTG 3945
|||||
Db      1 CTACCGTCCTTGTCATACTTTGTG 25

RESULT 12
US-11-121-849-151568
; Sequence 151568, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraaffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151568
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-151568

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      3926 GTCCTTGTCATACTTTGTGTTGGA 3950
|||||
Db      1 GTCCTTGTCATACTTTGTGTTGGA 25

RESULT 13
US-11-121-849-151569
; Sequence 151569, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraaffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
```

```
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151569
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-151569

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      3941 TTGTGTTGGAGGGAACCTGTTTCAC 3965
|||||
Db      1 TTGTGTTGGAGGGAACCTGTTTCAC 25

RESULT 14
US-11-121-849-151570
; Sequence 151570, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraaffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151570
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-151570

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      3949 GAGGGAACCTGTTTCACTATGCGCT 3973
|||||
Db      1 GAGGGAACCTGTTTCACTATGCGCT 25

RESULT 15
US-11-121-849-151571
; Sequence 151571, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraaffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151571
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-151571

Query Match      0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      3949 GAGGGAACCTGTTTCACTATGCGCT 3973
|||||
Db      1 GAGGGAACCTGTTTCACTATGCGCT 25
```

```
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3954 AACCTGTTTCACATATGGCTCTCTTT 3978
      |||||||
Db 1 AACCTGTTTCACATATGGCTCTCTTT 25

RESULT 16
US-11-121-849-151572
; Sequence 151572, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151572
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-151572

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4124 TGGTGGAAACCCAGAAACGACGCCG 4148
      |||||||
Db 1 TGGTGGAAACCCAGAAACGACGCCG 25

RESULT 19
US-11-121-849-151576
; Sequence 151576, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151576
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-151576

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4131 ACCCAGAAACGACGCCGCTGCTTG 4155
      |||||||
Db 1 ACCCAGAAACGACGCCGCTGCTTG 25

RESULT 20
US-11-121-849-302682
; Sequence 302682, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302682
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-302682

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4013 GTTTCAGAACAGTGCCTTGTCAT 4037
      |||||||
Db 1 GTTTCAGAACAGTGCCTTGTCAT 25

RESULT 18
US-11-121-849-151575
; Sequence 151575, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
```

```
US-11-121-849-302682
Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3648 GGTGGTTCCCGCAGACCAAGAGAG 3672
|||||
Db 1 GGTGGTTCCCGCAGACCAAGAGAG 25

RESULT 21
US-11-121-849-302683
; Sequence 302683, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; TITLE OF INVENTION: Microarrays
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302683
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-302683

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3649 GTGGTTCCCGCAGACCAAGAGAG 3673
|||||
Db 1 GTGGTTCCCGCAGACCAAGAGAG 25

RESULT 22
US-11-121-849-302684
; Sequence 302684, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; TITLE OF INVENTION: Microarrays
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302684
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-302684

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3651 GCGTTCCCGCAGACCAAGAGAGTG 3675
|||||
Db 1 GCGTTCCCGCAGACCAAGAGAGTG 25

RESULT 23
US-11-121-849-302685
```

```
; Sequence 302685, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; TITLE OF INVENTION: Microarrays
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302685
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-302685

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3653 GTTCCCGCAGACCAAGAGAGTG 3677
|||||
Db 1 GTTCCCGCAGACCAAGAGAGTG 25

RESULT 24
US-11-121-849-302686
; Sequence 302686, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; TITLE OF INVENTION: Microarrays
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302686
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-302686

Query Match          0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3655 TCCCGCAGACCAAGAGAGTG 3679
|||||
Db 1 TCCCGCAGACCAAGAGAGTG 25

RESULT 25
US-11-121-849-302687
; Sequence 302687, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; TITLE OF INVENTION: Microarrays
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
```

; SEQ ID NO 302687
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-302687

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3661 AGACCAAGAGAGTGTGACTCCCTT 3685
|||||
Db 1 AGACCAAGAGAGTGTGACTCCCTT 25

RESULT 26

US-11-121-849-302688
; Sequence 302688, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma

; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302688
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-302688

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3668 AGAGAGTGTGACTCCCTTGCAGCT 3692
|||||
Db 1 AGAGAGTGTGACTCCCTTGCAGCT 25

RESULT 27

US-11-121-849-302689
; Sequence 302689, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma

; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302689
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-302689

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3734 AGGCCCCAGTGACAAATCATTTGGG 3758
|||||
Db 1 AGGCCCCAGTGACAAATCATTTGGG 25

RESULT 28

US-11-121-849-302690
; Sequence 302690, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma

; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302690
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-302690

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3762 TGTAGTCCCAACTTGTGCTGTGCAC 3786
|||||
Db 1 TGTAGTCCCAACTTGTGCTGTGCAC 25

RESULT 29

US-11-121-849-302691
; Sequence 302691, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma

; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302691
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-302691

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3828 CCCAGCTGCTGCCTTCATATTGAAG 3852
|||||
Db 1 CCCAGCTGCTGCCTTCATATTGAAG 25

RESULT 30

US-11-121-849-302692
; Sequence 302692, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma

; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03

; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 302692
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-302692

Query Match 0.6%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3829 CCAGCTGCTGCCTTCATATTGAAGG 3853
Db 1 CCAGCTGCTGCCTTCATATTGAAGG 25

RESULT 31

US-10-310-914A-153255/c
; Sequence 153255, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; PRIOR FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153255
; LENGTH: 27
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153255

Query Match 0.6%; Score 25; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3537 GAATCCAGACCAAGGGTGAGGGCG 3561
Db 25 GAATCCAGACCAAGGGTGAGGGCG 1

RESULT 32

US-10-949-720-1
; Sequence 1, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 29

; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-1

Query Match 0.6%; Score 24.2; DB 1; Length 29;
Best Local Similarity 89.7%; Pred. No. 2.6e+02;
Matches 26; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 367 GCGGGCGCCATGAGCTCCGGGTGCTGCT 395
Db 1 GGATCCGCCATGAGCTCCGGGTGCTGCT 29

RESULT 33

US-10-949-720-397
; Sequence 397, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 397
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
US-10-949-720-397

Query Match 0.6%; Score 24.2; DB 1; Length 29;
Best Local Similarity 89.7%; Pred. No. 2.6e+02;
Matches 26; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 367 GCGGGCGCCATGAGCTCCGGGTGCTGCT 395
Db 1 GGATCCGCCATGAGCTCCGGGTGCTGCT 29

RESULT 34

US-10-310-914A-153219/c
; Sequence 153219, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153219
; LENGTH: 24
; TYPE: RNA
; ORGANISM: Human

US-10-310-914A-153219

Query Match 0.6%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3860 AGTTTGTGTTTTCGTCCTAAATTT 3883
|||||
DB 24 AGTTTGTGTTTTCGTCCTAAATTT 1

RESULT 35

US-10-310-914A-153221/c
; Sequence 153221, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 153221

; LENGTH: 24

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-153221

Query Match 0.6%; Score 24; DB 1; Length 24;

Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3846 ATTGAAGGTTTTTGAGTTTGTTT 3869
|||||
DB 24 ATTGAAGGTTTTTGAGTTTGTTT 1

RESULT 36

US-10-310-914A-153229/c
; Sequence 153229, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 153229

; LENGTH: 24

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-153229

Query Match 0.6%; Score 24; DB 1; Length 24;

Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3899 TTTGTTTCTTCGTTTGTGTTTCT 3922
|||||
DB 24 TTTGTTTCTTCGTTTGTGTTTCT 1

RESULT 37

US-10-310-914A-153235/c
; Sequence 153235, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 153235

; LENGTH: 24

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-153235

Query Match 0.6%; Score 24; DB 1; Length 24;

Best Local Similarity 100.0%; Pred. No. 2e+02;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4075 TGTCTATGAAGGGGTGTGGGGTG 4098
|||||
DB 24 TGTCTATGAAGGGGTGTGGGGTG 1

RESULT 38

US-10-310-914A-153238/c
; Sequence 153238, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 153238

; LENGTH: 24

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-153238

Query Match 0.6%; Score 24; DB 1; Length 24;

Best Local Similarity 100.0%; Pred. No. 2e+02;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4068 CAAGCTGTGCTCTATGAAGGGTG 4091
|||||
DB 24 CAAGCTGTGCTCTATGAAGGGTG 1

RESULT 39

US-10-310-914A-153248/c
; Sequence 153248, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 153248

; LENGTH: 24

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-153248

```
Query Match
Best Local Similarity 0.6%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 303 CAGGAGAGTGCAGCTGGGGGG 326
| | | | | | | | | | | | | | | | | |
DB 24 CAGGAGAGTGCAGCTGGGGGG 1

RESULT 40
US-10-310-914A-153254/c
; Sequence 153254, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153254
; LENGTH: 24
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153254

Query Match
Best Local Similarity 0.6%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4064 CCCCCAAGCTGTCTATGAAGG 4087
| | | | | | | | | | | | | | | | | |
DB 24 CCCCCAAGCTGTCTATGAAGG 1

RESULT 41
US-10-310-914A-153270/c
; Sequence 153270, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153270
; LENGTH: 24
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153270

Query Match
Best Local Similarity 0.6%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3837 TGCCTTCATATGAAGTTTGA 3860
| | | | | | | | | | | | | | | | | |
DB 24 TGCCTTCATATGAAGTTTGA 1

RESULT 42
US-10-310-914A-153280/c
; Sequence 153280, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153280
; LENGTH: 24
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153280

Query Match
Best Local Similarity 0.6%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3981 CCAAGTTGAACAGGGCCCATCA 4004
| | | | | | | | | | | | | | | | | |
DB 24 CCAAGTTGAACAGGGCCCATCA 1

RESULT 43
US-10-310-914A-153287/c
; Sequence 153287, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153287
; LENGTH: 24
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153287

Query Match
Best Local Similarity 0.6%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3392 AGTGGGACTCAGAGGCCCA 3415
| | | | | | | | | | | | | | | | | |
DB 24 AGTGGGACTCAGAGGCCCA 1

RESULT 44
US-11-121-849-151574
; Sequence 151574, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151574
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-151574
```

```
Query Match          0.6%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 2.5e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4060 GGGACCCCCCAAGCTGTGCTCATGA 4084
      |||||
Db 1 GGGACCCCCCAAGATGTGCTCATGA 25

RESULT 45
US-10-310-914A-153217/c
; Sequence 153217, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153217
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153217

Query Match          0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3897 TTTTGTCTTCCTGTTTGT 3919
      |||||
Db 23 TTTTGTCTTCCTGTTTGT 1

RESULT 46
US-10-310-914A-153223/c
; Sequence 153223, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153223
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153223

Query Match          0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3882 TTTCTCCCCGTTCCCTTTTGT 3904
      |||||
Db 23 TTTCTCCCCGTTCCCTTTTGT 1

RESULT 47
US-10-310-914A-153239/c
; Sequence 153239, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153239
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153239

Query Match          0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3474 AGAGACAGGATTTGGGGTTCTG 3496
      |||||
Db 23 AGAGACAGGATTTGGGGTTCTG 1

RESULT 48
US-10-310-914A-153242/c
; Sequence 153242, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153242
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153242

Query Match          0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3556 AGGGCGCCTTTCCTCAGGACTG 3578
      |||||
Db 23 AGGGCGCCTTTCCTCAGGACTG 1

RESULT 49
US-10-310-914A-153256/c
; Sequence 153256, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153256
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153256
```

```
Query Match          0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3869 TTGGTCTTAATTTTCTCCCG 3891
DB 23 TTGGTCTTAATTTTCTCCCG 1

RESULT 50
US-10-310-914A-153259/c
; Sequence 153259, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153259
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153259

Query Match          0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3523 CCAGCCACTCGGGAACTCCAG 3545
DB 23 CCAGCCACTCGGGAACTCCAG 1

RESULT 51
US-10-310-914A-153260/c
; Sequence 153260, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153260
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153260

Query Match          0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 327 CGAGGGCCCCCAACTCAGTTC 349
DB 23 CGAGGGCCCCCAACTCAGTTC 1

RESULT 52
US-10-310-914A-153261/c
; Sequence 153261, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
```

```
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153261
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153261

Query Match          0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3716 GGGGCAAGAGGGGTGTCTCAGGC 3738
DB 23 GGGGCAAGAGGGGTGTCTCAGGC 1

RESULT 53
US-10-310-914A-153265/c
; Sequence 153265, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153265
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153265

Query Match          0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3344 CAGGAACCTCCCACTCCAGGAC 3366
DB 23 CAGGAACCTCCCACTCCAGGAC 1

RESULT 54
US-10-310-914A-153266/c
; Sequence 153266, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153266
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153266

Query Match          0.5%; Score 23; DB 1; Length 23;
```



```
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3435 TGCACCTTTGACCCCTGGGGTG 3456
Db 22 TGCACCTTTGACCCCTGGGGTG 1

RESULT 60
US-10-310-914A-153246/c
; Sequence 153246, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153246
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153246

Query Match 0.5%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3469 TTTGGAGAGACAGGATTTGGGG 3490
Db 22 TTTGGAGAGACAGGATTTGGGG 1

RESULT 61
US-10-310-914A-153267/c
; Sequence 153267, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153267
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153267

Query Match 0.5%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3946 TTGGAGGGAACCTGTTTCACTA 3967
Db 22 TTGGAGGGAACCTGTTTCACTA 1

RESULT 62
US-10-310-914A-153269/c
; Sequence 153269, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
```

```
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153269
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153269

Query Match 0.5%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3916 TTTTCTACCGCTCTGTGTCTATA 3937
Db 22 TTTTCTACCGCTCTGTGTCTATA 1

RESULT 63
US-10-310-914A-153277/c
; Sequence 153277, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153277
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153277

Query Match 0.5%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3943 GTGTTGGAGGGAACCTGTTTCA 3964
Db 22 GTGTTGGAGGGAACCTGTTTCA 1

RESULT 64
US-10-310-914A-153281/c
; Sequence 153281, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153281
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153281

Query Match 0.5%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 3417 CCCTGTGCCCGCTGGATTGCA 3438
Db 22 CCCTGTGCCCGCTGGATTGCA 1

RESULT 65
US-10-310-914A-153283/c
; Sequence 153283, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153283
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153283

Query Match 0.5%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3668 AGAGAGTGTGACTCCCTTGCCA 3689
Db 22 AGAGAGTGTGACTCCCTTGCCA 1

RESULT 66
US-10-310-914A-153286/c
; Sequence 153286, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153286
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153286

Query Match 0.5%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3394 TGGGGACTCACAGAGGCCCA 3415
Db 22 TGGGGACTCACAGAGGCCCA 1

RESULT 67
US-10-310-914A-556532
; Sequence 556532, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153286
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-556532

Query Match 0.5%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 556532
; LENGTH: 25
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-556532

Query Match 0.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 3.7e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1059 CCCCCTGCTGGCCCGCCAGCCCGC 1083
Db 1 CCCCCTGCTGGCCCGCCAGCCCGC 25

RESULT 68
US-11-136-527-49340
; Sequence 49340, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49340
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-49340

Query Match 0.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 3.7e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3805 TTTTCCCTTGTAATGCCCTCCCTCC 3829
Db 1 TTTTCCCTTGTAATGCTCCTTCCC 25

RESULT 69
US-11-136-527-243931
; Sequence 243931, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 243931
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
```


US-11-136-527-243931

Query Match 0.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 3.7e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 3837 TGCCTTCATATTGAAGGTTTCTGAG 3861
Db 1 TGCCTTCATATTGAAGGTTCTGAG 25

RESULT 70

US-11-136-527-243935
; Sequence 243935, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 243935
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-243935

Query Match 0.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 3.7e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 3839 CCTTCATATTGAAGGTTTCTGAGTT 3863
Db 1 CCTTCATATTGAAGGTTCTGAGTT 25

RESULT 71

US-11-136-527-243939
; Sequence 243939, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 243939
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-243939

Query Match 0.5%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 3.7e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 3838 GCCTTCATATTGAAGGTTTCTGAGT 3862
Db 1 GCCTTCATATTGAAGGTTCTGAGT 25

RESULT 72

US-10-310-914A-556499
; Sequence 556499, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 556499
; LENGTH: 26
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-556499

Query Match 0.5%; Score 21.8; DB 1; Length 26;
Best Local Similarity 92.0%; Pred. No. 3.9e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1059 CCCGCCCTGGCCCGCCAGCCCGC 1083
Db 2 CCCGCCCTGGCCCGCCAGCCCGC 26

RESULT 73

US-10-310-914A-207826/C
; Sequence 207826, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 207826
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-207826

Query Match 0.5%; Score 21.4; DB 1; Length 23;
Best Local Similarity 95.7%; Pred. No. 3.5e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 3897 TTTTGTCTCTCGTTTGT 3919
Db 23 TTTTGTCTCTGTGTGT 1

RESULT 74

US-10-310-914A-916482/C
; Sequence 916482, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402

```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 916482
; LENGTH: 25
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-916482

Query Match          0.5%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 4e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1064 CCCTGGCCCCCAGCCCGCCTC 1086
Db 24 CCCTGGCCCCCAGCCCGCCTC 2

RESULT 75
US-10-949-720-20/c
; Sequence 20, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-20

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 928 ATGGCCCTGCTATCCCTGCAC 948
Db 21 ATGGCCCTGCTATCCCTGCAC 1

RESULT 76
US-10-949-720-35/c
; Sequence 35, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
```

```
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 35
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-35

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 425 AAGAGACCCCTGCTGAACACAA 445
Db 21 AAGAGACCCCTGCTGAACACAA 1

RESULT 77
US-10-949-720-37/c
; Sequence 37, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 37
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-37

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 847 AAGTGCAATGTCAGACGCTG 867
Db 21 AAGTGCAATGTCAGACGCTG 1

RESULT 78
US-10-949-720-39/c
; Sequence 39, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
```

```

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 39
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-39

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1937 AACATCACAGCCAGCCCAAC 1957
DB 21 AACATCACAGCCAGCCCAAC 1

RESULT 79
US-10-949-720-41/c
; Sequence 41, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 41
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-41

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2677 AACTCTTCGATCCCACTTAC 2697
DB 21 AACTCTTCGATCCCACTTAC 1

RESULT 80
US-10-949-720-42/c
; Sequence 42, Application US/10949720

```

```

; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 42
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-42

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 928 ATGGCCCTGCTATCCCTGCAC 948
DB 21 ATGGCCCTGCTATCCCTGCAC 1

RESULT 81
US-10-949-720-44/c
; Sequence 44, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 44
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-44

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1381 GGCTCCTCCCTGCACCTGGAA 1401

```

```
Db      21  GGCTCTCTCCCTGCACCTGGAA 1
|||||
RESULT 82
US-10-949-720-45/c
; Sequence 45, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 45
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-45

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db      21  TGAGCCTGTCAATGTCCACCAC 1661
|||||
RESULT 83
US-10-949-720-46/c
; Sequence 46, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 46
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-46

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db      21  TGAGCCTGTCAATGTCCACCAC 1
|||||
RESULT 84
US-10-949-720-49/c
; Sequence 49, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 49
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-49

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db      21  AAGGTGGACACGGTGGCCGCG 804
|||||
RESULT 85
US-10-949-720-50/c
; Sequence 50, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 50
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-50

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db      21  AAGGTGGACACGGTGGCCGCG 1
|||||
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 50
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-50

Query Match
Best Local Similarity 0.5%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2305 GTGGCAATCAAGACCTGAG 2325
Db 21 GTGGCAATCAAGACCTGAG 1

RESULT 86
US-10-949-720-52/c
; Sequence 52, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 52
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-52

Query Match
Best Local Similarity 0.5%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2515 GTCATCCAGCTCGTGGCATG 2535
Db 21 GTCATCCAGCTCGTGGCATG 1

RESULT 87
US-10-949-720-70/c
; Sequence 70, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
```

```
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 70
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-70

Query Match
Best Local Similarity 0.5%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 425 AAGAGACCTGCTGACACAA 445
Db 21 AAGAGACCTGCTGACACAA 1

RESULT 88
US-10-949-720-73/c
; Sequence 73, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 73
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-73

Query Match
Best Local Similarity 0.5%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3319 GGACCGCGCCCGCAGTACTGA 3339
Db 21 GGACCGCGCCCGCAGTACTGA 1

RESULT 89
US-10-949-720-222/c
; Sequence 222, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
```

; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 222
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-222

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 928 ATGGCCCTGCTATCCCTGCAC 948
|||||
Db 21 ATGGCCCTGCTATCCCTGCAC 1

RESULT 90
US-10-949-720-224/c
; Sequence 224, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 224
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-224

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1381 GGCTCCTCCCTGCACCTGGAA 1401
|||||
Db 21 GGCTCCTCCCTGCACCTGGAA 1

RESULT 91

US-10-949-720-225/c
; Sequence 225, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 225
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-225

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1641 TGAGCCTGTCAATGTCAACCAC 1661
|||||
Db 21 TGAGCCTGTCAATGTCAACCAC 1

RESULT 92
US-10-949-720-226/c
; Sequence 226, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 226
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-226

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1931 GCCAGGAACATCACAGCCAGA 1951
      |||||
Db 21 GCCAGGAACATCACAGCCAGA 1

RESULT 93
US-10-949-720-229/c
; Sequence 229, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 229
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-229

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 784 AAGGTGGACACGGTGGCCGCG 804
      |||||
Db 21 AAGGTGGACACGGTGGCCGCG 1

RESULT 94
US-10-949-720-230/c
; Sequence 230, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 230
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-230

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2515 GTCATCCAGCTCGTGGGCATG 2535
      |||||
Db 21 GTCATCCAGCTCGTGGGCATG 1

RESULT 96
US-10-949-720-233
; Sequence 233, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 233
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-233

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2305 GTGGCAATCAAGACCCCTGAAG 2325
      |||||
Db 21 GTGGCAATCAAGACCCCTGAAG 1

RESULT 95
US-10-949-720-232/c
; Sequence 232, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 232
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-232
```

; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 233
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-233

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 445 AATTGGAAACTGCTGATCTG 465
|||||
DB 1 AATTGGAAACTGCTGATCTG 21

RESULT 97

US-10-949-720-234
; Sequence 234, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 234
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-234

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 446 AATTGGAAACTGCTGATCTGA 466
|||||
DB 1 AATTGGAAACTGCTGATCTGA 21

RESULT 98

US-10-949-720-235
; Sequence 235, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002

; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 235
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-235

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 452 AAATCTCTGATCTGAAGTGGG 472
|||||
DB 1 AAATCTCTGATCTGAAGTGGG 21

RESULT 99

US-10-949-720-236
; Sequence 236, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 236
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-236

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 453 AACTGCTGATCTGAAGTGGGT 473
|||||
DB 1 AACTGCTGATCTGAAGTGGGT 21

RESULT 100

US-10-949-720-237
; Sequence 237, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery


```

; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 237
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-237

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 853 AATGTCAGAGCGCTGCTG 873
      |||||||
Db 1 AATGTCAGAGCGCTGCTG 21

RESULT 101
US-10-949-720-238
; Sequence 238, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 238
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-238

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 466 AAGTGGGTGACATTCCTCAG 486
      |||||||
Db 1 AAGTGGGTGACATTCCTCAG 21
```

```

RESULT 102
US-10-949-720-239
; Sequence 239, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 239
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-239

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 847 AAGGTGAATGTCAGAGCGCTG 867
      |||||||
Db 1 AAGGTGAATGTCAGAGCGCTG 21

RESULT 103
US-10-949-720-240
; Sequence 240, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 240
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-240

Query Match          0.5%; Score 21; DB 1; Length 21;
```

Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels

Qy 697 AAGGAGACCTTCACCGTCTTC 717
 |||||
 Db 1 AAGGAGACCTTCACCGTCTTC 21

RESULT 104

```

US-10-949-720-241
; Sequence 241, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; CURRENT APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 241
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-241

```

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels

Qy 958 AAAAGTGC GCCCAGCTGACT 978
|||||
db 1 AAAAGTGC GCCCAGCTGACT 21

RESULT 105

```

US-10-949-720-242
; Sequence 242, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 241
; LENGTH: 21

```

```

; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-242

```

```

Query Match      0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels

Qy      1246  AATAGCCACTCTAACACCACTT 1266
          |||||
Db      1  AATAGCCACTCTAACACCACTT 21

```

PRECIT.T 106

```

US-10-949-720-243
; Sequence 243, Application US/10949720
; Publication No. US20050249736A1
;
; GENERAL INFORMATION:
;
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
;
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
;
; FILE REFERENCE: VASG-P02-002
;
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
;
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
;
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
;
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
;
; NUMBER OF SEQ ID NOS: 425
;
; SOFTWARE: Fast-Seq for Windows Version 4.0
;
; SEQ ID NO 243
;
; LENGTH: 21
;
; TYPE: DNA
;
; ORGANISM: Unknown
;
; FEATURE:
;
; OTHER INFORMATION: Oligonucleotide
;
US-10-949-720-243

```

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21: Conservative 0; Mismatches 0; Indels

Qy	1258	AACACCATTTGGATCAGCCGTC	1278
Dβ	1	AACACCATTTGGATCAGCCGTC	21

PRECIPIT. 107

US-10-949-720-244
; Sequence 244, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300

; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 244
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-244

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1651 AATGTCACCACTGACCGAGAG 1671
|||||
Db 1 AATGTCACCACTGACCGAGAG 21

RESULT 108
US-10-949-720-245
; Sequence 245, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 245
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-245

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1783 AAATACCATGAGAGGGGCC 1803
|||||
Db 1 AAATACCATGAGAGGGGCC 21

RESULT 109
US-10-949-720-246
; Sequence 246, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING

; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 246
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-246

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1831 AAGACGTCAGAAAACCGGCA 1851
|||||
Db 1 AAGACGTCAGAAAACCGGCA 21

RESULT 110
US-10-949-720-247
; Sequence 247, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 247
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-247

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1937 AACATCAGCCAGACCCCAAC 1957
|||||
Db 1 AACATCAGCCAGACCCCAAC 21

RESULT 111
US-10-949-720-248
; Sequence 248, Application US/10949720
; Publication No. US20050249736A1

```
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 248
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-248

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2068 AAGCAGAGCAATCGGAGAGAA 2088
      |||||
Db 1 AAGCAGAGCAATCGGAGAGAA 21

RESULT 112
US-10-949-720-249
; Sequence 249, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 249
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-249

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2077 AATGGGAGAGAAAGCAGAAATAT 2097
      |||||
```

```
Db 1 AATGGGAGAGAAAGCAGAAATAT 21

RESULT 113
US-10-949-720-250
; Sequence 250, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 250
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-250

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2087 AAGCAGAAATATTCGGACAAAC 2107
      |||||
Db 1 AAGCAGAAATATTCGGACAAAC 21

RESULT 114
US-10-949-720-251
; Sequence 251, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 251
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-251
```

```
Query Match
Best Local Similarity 0.5%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2093 AATATTCGACAAACACGGAC 2113
DB 1 AATATTCGACAAACACGGAC 21

RESULT 115
US-10-949-720-252
; Sequence 252, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 252
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-252

Query Match
Best Local Similarity 0.5%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2104 AAACACGGACAGTATCTCATC 2124
DB 1 AAACACGGACAGTATCTCATC 21

RESULT 116
US-10-949-720-253
; Sequence 253, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
```

```
; SEQ ID NO 253
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-253

Query Match
Best Local Similarity 0.5%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2105 AACACGGACAGTATCTCATCG 2125
DB 1 AACACGGACAGTATCTCATCG 21

RESULT 117
US-10-949-720-254
; Sequence 254, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 254
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-254

Query Match
Best Local Similarity 0.5%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2196 AAAAGAGATCGATGCTCCTA 2216
DB 1 AAAAGAGATCGATGCTCCTA 21

RESULT 118
US-10-949-720-255
; Sequence 255, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
```

; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 255
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-255

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2173 AATGAGGCTGTGAGGGAATTT 2193
Db 1 AATGAGGCTGTGAGGGAATTT 21

RESULT 119

US-10-949-720-256
; Sequence 256, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 256
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-256

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2165 AAGACCCCTAATGAGGCTGTGA 2185
Db 1 AAGACCCCTAATGAGGCTGTGA 21

RESULT 120

US-10-949-720-257
; Sequence 257, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 257
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-257

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2197 AAAGATCGATGTCCTCTAC 2217
Db 1 AAAGATCGATGTCCTCTAC 21

RESULT 121

US-10-949-720-258
; Sequence 258, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 258
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-258

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2198 AAGATCGATGTCCTCTACG 2218
Db 1 AAGATCGATGTCCTCTACG 21

RESULT 122

US-10-949-720-259

; Sequence 259, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 259
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-259

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2228 AAGAGTGATGTCAGGTG 2248
Db 1 AAGAGTGATGTCAGGTG 21

RESULT 123
US-10-949-720-260
; Sequence 260, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 260
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-260

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2221 AAGATTGAAGAGGTGATTGGT 2241
Db 1 AAGATTGAAGAGGTGATTGGT 21

RESULT 124
US-10-949-720-261
; Sequence 261, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 261
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-261

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2428 AACAGCATGCCGTCATGATT 2448
Db 1 AACAGCATGCCGTCATGATT 21

RESULT 125
US-10-949-720-262
; Sequence 262, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 262
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
US-10-949-720-262

```
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-262

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2290 AAGAAGGAGAGCTGTGTGGCA 2310
      |||||
Db 1 AAGAAGGAGAGCTGTGTGGCA 21

RESULT 126
US-10-949-720-263
; Sequence 263, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 263
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-263

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2293 AAGGAGAGCTGTGTGGCAATC 2313
      |||||
Db 1 AAGGAGAGCTGTGTGGCAATC 21

RESULT 127
US-10-949-720-264
; Sequence 264, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
```

```
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 264
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-264

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2310 AATCAAGACCTGAAGGGTGG 2330
      |||||
Db 1 AATCAAGACCTGAAGGGTGG 21

RESULT 128
US-10-949-720-265
; Sequence 265, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 265
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-265

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2496 AAACGACGGACAGTTCACAGT 2516
      |||||
Db 1 AAACGACGGACAGTTCACAGT 21

RESULT 129
US-10-949-720-266
; Sequence 266, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
```


; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 266
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-266

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2497 AACGACGACAGTTCACAGTC 2517
Db 1 AACGACGACAGTTCACAGTC 21

RESULT 130
US-10-949-720-267
; Sequence 267, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 267
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-267

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2608 AACATCCTAGTCAACAGCAAC 2628
Db 1 AACATCCTAGTCAACAGCAAC 21

RESULT 131
US-10-949-720-268
; Sequence 268, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey

; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 268
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-268

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2620 AACAGCAACCTCGTCTGCAAA 2640
Db 1 AACAGCAACCTCGTCTGCAAA 21

RESULT 132
US-10-949-720-269
; Sequence 269, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 269
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-269

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2677 AACTCTTCGATCCACCTAC 2697
Db 1 AACTCTTCGATCCACCTAC 21

```
RESULT 133
US-10-949-720-270
; Sequence 270, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 270
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-270

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2639 AAGTGTCTGACTTTGGCCTTT 2659
Db      1 AAGTGTCTGACTTTGGCCTTT 21

RESULT 134
US-10-949-720-271
; Sequence 271, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 271
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-271

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2626 AACCTGCTCTGCAAAAGTGCT 2646
Db      1 AACCTGCTCTGCAAAAGTGCT 21

RESULT 135
US-10-949-720-272
; Sequence 272, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 272
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-272

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2638 AAAGTGTCTGACTTTGGCCTT 2658
Db      1 AAAGTGTCTGACTTTGGCCTT 21

RESULT 136
US-10-949-720-273
; Sequence 273, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 273
; LENGTH: 21
; TYPE: DNA
```

```
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-273

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2851 AATCAGGACGTCGATCAATGCC 2871
Db 1 AATCAGGACGTCGATCAATGCC 21

RESULT 137
US-10-949-720-274
; Sequence 274, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 274
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-274

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2715 AAAGATTCCTCCATCCGATGGAC 2735
Db 1 AAAGATTCCTCCATCCGATGGAC 21

RESULT 138
US-10-949-720-275
; Sequence 275, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
```

```
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 275
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-275

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2716 AAGATTCCTCCATCCGATGGACT 2736
Db 1 AAGATTCCTCCATCCGATGGACT 21

RESULT 139
US-10-949-720-276
; Sequence 276, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 276
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-276

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2761 AAGTTCACTTCCGCCAGTGAT 2781
Db 1 AAGTTCACTTCCGCCAGTGAT 21

RESULT 140
US-10-949-720-277
; Sequence 277, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
```

; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 277
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-277

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3141 AAGATACGAAGAAGTTTCGC 3161
|||||
Db 1 AAGATACGAAGAAGTTTCGC 21

RESULT 141
US-10-949-720-278
; Sequence 278, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 278
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-278

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3135 AATCGGAAGATACGAAGAAG 3155
|||||
Db 1 AATCGGAAGATACGAAGAAG 21

RESULT 142
US-10-949-720-279
; Sequence 279, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:

; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 279
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-279

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2866 AATGCCATTGAACAGGACTAC 2886
|||||
Db 1 AATGCCATTGAACAGGACTAC 21

RESULT 143
US-10-949-720-280
; Sequence 280, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 280
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-280

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3028 AAAATCGTGGCCCGGAGAAAT 3048
|||||
Db 1 AAAATCGTGGCCCGGAGAAAT 21

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGTCAGC 3274
Db 1 AAATCTTGGCCAGTGTCAGC 21

RESULT 146

US-10-949-720-283
; Sequence 283, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 283
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-283

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3149 AAGAAAGTTTCGACGCGCTG 3169
Db 1 AAGAAAGTTTCGACGCGCTG 21

RESULT 147

US-10-949-720-284
; Sequence 284, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 284

RESULT 144

US-10-949-720-281
; Sequence 281, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 281
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-281

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3253 AAAATCTTGGCCAGTGTCAG 3273
Db 1 AAAATCTTGGCCAGTGTCAG 21

RESULT 145

US-10-949-720-282
; Sequence 282, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 282
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-282

```
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-284

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3250 AAGAAATCTTGGCCAGTGC 3270
    |||||
Db 1 AAGAAATCTTGGCCAGTGC 21

RESULT 148
US-10-949-720-285
; Sequence 285 Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenopetrov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 285
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-285

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3255 AATCTGGCCAGTGTCCAGCA 3275
    |||||
Db 1 AATCTGGCCAGTGTCCAGCA 21

RESULT 149
US-10-770-726-17546
; Sequence 17546 Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17546
; LENGTH: 21
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17546

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTCTTGGCAGAA 2951
    |||||
Db 1 CATGCTGGACTCTTGGCAGAA 21

RESULT 150
US-10-310-914A-153232/c
; Sequence 153232 Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153232
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153232

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4145 GCCGGTGCTTGGAGGGTTCT 4165
    |||||
Db 21 GCCGGTGCTTGGAGGGTTCT 1

RESULT 151
US-10-310-914A-153233/c
; Sequence 153233 Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153233
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153233

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3916 TTTTCTACCGTCCTTGTGCAT 3936
    |||||
Db 21 TTTTCTACCGTCCTTGTGCAT 1

RESULT 152
US-10-310-914A-153234/c
```

```
; Sequence 153234, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153234
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153234

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3444 AGCCCGTGGGTGAGGAGTTG 3464
Db 21 AGCCCGTGGGTGAGGAGTTG 1

RESULT 153
US-10-310-914A-153240/c
; Sequence 153240, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153240
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153240

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3411 CCCAGCCCTGTGCCCCGCTG 3431
Db 21 CCCAGCCCTGTGCCCCGCTG 1

RESULT 154
US-10-310-914A-153241/c
; Sequence 153241, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153241
; LENGTH: 21
; TYPE: RNA
```

```
; ORGANISM: Human
US-10-310-914A-153241

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3939 CTTTGTGTGGAGGGGAACCTG 3959
Db 21 CTTTGTGTGGAGGGGAACCTG 1

RESULT 155
US-10-310-914A-153243/c
; Sequence 153243, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153243
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153243

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3445 GCCCGTGGGTGAGGAGTTGG 3465
Db 21 GCCCGTGGGTGAGGAGTTGG 1

RESULT 156
US-10-310-914A-153247/c
; Sequence 153247, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153247
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153247

Query Match          0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3471 TGGAGACACAGGATTGGGGG 3491
Db 21 TGGAGACACAGGATTGGGGG 1

RESULT 157
US-10-310-914A-153249/c
; Sequence 153249, Application US/10310914A
```

Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153249
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153249

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 21; Conservative 0;

Qy 3699 TGGGGGGCTGTCCAGGGG 3719
Db 21 TGGGGGGCTGTCCAGGGG 1

RESULT 158

US-10-310-914A-153264/c
; Sequence 153264, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153264
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153264

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 21; Conservative 0;

Qy 3767 TCCCACTTGTGTGTCC 3787
Db 21 TCCCACTTGTGTGTCC 1

RESULT 159

US-10-310-914A-153293/c
; Sequence 153293, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153293
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human

US-10-310-914A-153293

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.3e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 21; Conservative 0;

Qy 4149 GTGCTTGGAGGGTCTTAAA 4169
Db 21 GTGCTTGGAGGGTCTTAAA 1

RESULT 160

US-10-310-914A-1141554
; Sequence 1141554, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1141554
; LENGTH: 25
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1141554

Query Match 0.5%; Score 20.8; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 4.6e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 21; Conservative 1;

Qy 826 CTGTGGGCGGAGCCACCGGAAG 849
Db 1 CCUGGGCGGAGGCCACCCGGAAG 24

RESULT 161

US-11-136-527-49332
; Sequence 49332, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49332
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-49332

Query Match 0.5%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 4.6e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 22; Conservative 0;

Qy 3806 TTTCCCTTGTAAATGCCCTCCCC 3829
Db 1 TTTCCCTTGTAAATGCTCTTCCC 24

RESULT 162

US-11-136-527-49335
 ; Sequence 49335, Application US/11136527
 ; Publication No. US20050287570A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Wyeth
 ; APPLICANT: Mounts, William M
 ; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
 ; FILE REFERENCE: 031896-041000 (AM101086)
 ; CURRENT APPLICATION NUMBER: US/11/136,527
 ; CURRENT FILING DATE: 2005-05-25
 ; PRIOR APPLICATION NUMBER: US 60/574,294
 ; PRIOR FILING DATE: 2005-05-26
 ; NUMBER OF SEQ ID NOS: 362830
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 49335
 ; LENGTH: 25
 ; TYPE: DNA
 ; ORGANISM: Artificial
 ; FEATURE:
 ; OTHER INFORMATION: Probe
 US-11-136-527-49335

Query Match 0.5%; Score 20.8; DB 1; Length 25;
 Best Local Similarity 91.7%; Pred. No. 4.6e+02;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3805 TTTTCCCTGTAAATGCCCTCC 3828
 |||||
 DB 2 TTTTCCCTGTAAATGCTCCTCC 25

RESULT 163
 US-10-949-720-59
 ; Sequence 59, Application US/10949720
 ; Publication No. US20050249736A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Krasnopetrov, Valery
 ; APPLICANT: Zozulya, Sergey
 ; APPLICANT: Kertesz, Nathalie
 ; APPLICANT: Reddy, Ramachandra
 ; APPLICANT: Gill, Parkash
 ; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
 ; FILE REFERENCE: VASG-P02-002
 ; CURRENT APPLICATION NUMBER: US/10/949,720
 ; CURRENT FILING DATE: 2004-09-23
 ; PRIOR APPLICATION NUMBER: US 60/454,432
 ; PRIOR FILING DATE: 2003-03-12
 ; PRIOR APPLICATION NUMBER: US 60/454,300
 ; PRIOR FILING DATE: 2003-03-12
 ; PRIOR APPLICATION NUMBER: US 10/800,350
 ; PRIOR FILING DATE: 2004-03-12
 ; NUMBER OF SEQ ID NOS: 425
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 59
 ; LENGTH: 22
 ; TYPE: DNA
 ; ORGANISM: Unknown
 ; FEATURE:
 ; OTHER INFORMATION: Oligonucleotide
 US-10-949-720-59

Query Match 0.5%; Score 20.4; DB 1; Length 22;
 Best Local Similarity 95.5%; Pred. No. 4.1e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1587 TGAGGTCACTGCATTGAACGGG 1608
 |||||
 DB 1 TCAGGTCACTGCATTGAACGGG 22

RESULT 164
 US-10-310-914A-161890

; Sequence 161890, Application US/10310914A
 ; Publication No. US20060003322A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bentwich, Isaac
 ; APPLICANT: Shiler, Kuzat
 ; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
 ; FILE REFERENCE: 06087.0200.CPUS01
 ; CURRENT APPLICATION NUMBER: US/10/310,914A
 ; CURRENT FILING DATE: 2002-12-06
 ; NUMBER OF SEQ ID NOS: 1388402
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 161890
 ; LENGTH: 22
 ; TYPE: RNA
 ; ORGANISM: Human
 US-10-310-914A-161890

Query Match 0.5%; Score 20.4; DB 1; Length 22;
 Best Local Similarity 81.8%; Pred. No. 4.1e+02;
 Matches 18; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3604 CCCAACATCTCCAGCCTCC 3625
 ||||| : : : : : : : : : :
 DB 1 CCCAACCCUCCAGCCUCC 22

RESULT 165
 US-10-310-914A-161891
 ; Sequence 161891, Application US/10310914A
 ; Publication No. US20060003322A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bentwich, Isaac
 ; APPLICANT: Shiler, Kuzat
 ; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
 ; FILE REFERENCE: 06087.0200.CPUS01
 ; CURRENT APPLICATION NUMBER: US/10/310,914A
 ; CURRENT FILING DATE: 2002-12-06
 ; NUMBER OF SEQ ID NOS: 1388402
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 161891
 ; LENGTH: 22
 ; TYPE: RNA
 ; ORGANISM: Human
 US-10-310-914A-161891

Query Match 0.5%; Score 20.4; DB 1; Length 22;
 Best Local Similarity 81.8%; Pred. No. 4.1e+02;
 Matches 18; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3604 CCCAACATCTCCAGCCTCC 3625
 ||||| : : : : : : : : : :
 DB 1 CCCAACCCUCCAGCCUCC 22

RESULT 166
 US-10-310-914A-916479/c
 ; Sequence 916479, Application US/10310914A
 ; Publication No. US20060003322A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bentwich, Isaac
 ; APPLICANT: Shiler, Kuzat
 ; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
 ; FILE REFERENCE: 06087.0200.CPUS01
 ; CURRENT APPLICATION NUMBER: US/10/310,914A
 ; CURRENT FILING DATE: 2002-12-06
 ; NUMBER OF SEQ ID NOS: 1388402
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 916479
 ; LENGTH: 22
 ; TYPE: RNA

```
; ORGANISM: Human
US-10-310-914A-916479

Query Match          0.5%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 4.1e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1065 CCCTGGCCCGAGCCCGCCGCTC 1086
      ||||| ||||| ||||| ||||| |||||
Db 22 CCCTGGCCCGAGCCCGCCGCTC 1

RESULT 167
US-10-932-182A-21431/c
; Sequence 21431, Application US/10932182A
; Publication No. US20060046253A1
; GENERAL INFORMATION:
; APPLICANT: NAKAO, YOSHIHIRO
; APPLICANT: NAKAMURA, NORIHIISA
; APPLICANT: KODAMA, YUKIKO
; APPLICANT: FUJIMURA, TOMOKO
; APPLICANT: ASHIKARI, TOSHIHIKO
; TITLE OF INVENTION: METHODS FOR ANALYZING GENES OF INDUSTRIAL YEASTS
; FILE REFERENCE: 030685-043
; CURRENT APPLICATION NUMBER: US/10/932,182A
; CURRENT FILING DATE: 2004-09-02
; NUMBER OF SEQ ID NOS: 197023
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 21431
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Saccharomyces pastorianus
US-10-932-182A-21431

Query Match          0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 5.3e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2074 AGCAATGGGATAGGAAGCAGATATT 2098
      ||||| ||||| ||||| ||||| |||||
Db 25 AGCAATGGGATAGGAAGCAGATATT 1

RESULT 168
US-11-136-527-146486
; Sequence 146486, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 146486
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-146486

Query Match          0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 5.3e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2836 TACTGGGACATGAGCAATCAGGAGC 2860
      ||||| ||||| ||||| ||||| |||||
Db 1 TACTGGGACATGAGCAATCAGGAGC 25

RESULT 169
US-11-136-527-146488
; Sequence 146488, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 146488
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-146488

Query Match          0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 5.3e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2834 CGTACTGGGACATGAGCAATCAGGA 2858
      ||||| ||||| ||||| ||||| |||||
Db 1 CCTACTGGGACATGAGCAATCAGGA 25

RESULT 170
US-11-136-527-146494
; Sequence 146494, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes
; FILE REFERENCE: 031896-041000 (AM101086)
; CURRENT APPLICATION NUMBER: US/11/136,527
; CURRENT FILING DATE: 2005-05-25
; PRIOR APPLICATION NUMBER: US 60/574,294
; PRIOR FILING DATE: 2005-05-26
; NUMBER OF SEQ ID NOS: 362830
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 146494
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Probe
US-11-136-527-146494

Query Match          0.5%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 5.3e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2837 ACTGGGACATGAGCAATCAGGAGCT 2861
      ||||| ||||| ||||| ||||| |||||
Db 1 ACTGGGACATGAGCAATCAGGAGCT 25

RESULT 171
US-11-136-527-146507
; Sequence 146507, Application US/11136527
; Publication No. US20050287570A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William M
```

; TITLE OF INVENTION: Probe Arrays For Expression Profiling of Rat Genes

; FILE REFERENCE: 031896-041000 (AM101086)

; CURRENT APPLICATION NUMBER: US/11/136,527

; CURRENT FILING DATE: 2005-05-25

; PRIOR APPLICATION NUMBER: US 60/574,294

; PRIOR FILING DATE: 2005-05-26

; NUMBER OF SEQ ID NOS: 362830

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 146507

; TYPE: DNA

; ORGANISM: Artificial

; FEATURE:

; OTHER INFORMATION: Probe

US-11-136-527-146507

Query Match 0.5%; Score 20.2; DB 1; Length 25;

Best Local Similarity 88.0%; Pred. No. 5.3e+02;

Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2833 CGTACTGGACATGAGCAATCAGG 2857

Db 1 CCCTACTGGAATGACCAATCAGG 25

RESULT 172

US-10-949-720-19

; Sequence 19, Application US/10949720

; Publication No. US20050249736A1

; GENERAL INFORMATION:

; APPLICANT: Krasnoperov, Valery

; APPLICANT: Zozulya, Sergey

; APPLICANT: Kertesz, Nathalie

; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING

; FILE REFERENCE: VASG-P02-002

; CURRENT APPLICATION NUMBER: US/10/949,720

; CURRENT FILING DATE: 2004-09-23

; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 10/800,350

; PRIOR FILING DATE: 2004-03-12

; NUMBER OF SEQ ID NOS: 425

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 19

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: Oligonucleotide

US-10-949-720-19

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 3.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 691 TCCTGCAAGGAGACCTTCAC 710

Db 1 TCCTGCAAGGAGACCTTCAC 20

RESULT 173

US-10-949-720-21/c

; Sequence 21, Application US/10949720

; Publication No. US20050249736A1

; GENERAL INFORMATION:

; APPLICANT: Krasnoperov, Valery

; APPLICANT: Zozulya, Sergey

; APPLICANT: Kertesz, Nathalie

; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING

; FILE REFERENCE: VASG-P02-002

; CURRENT APPLICATION NUMBER: US/10/949,720

; CURRENT FILING DATE: 2004-09-23

; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 10/800,350

; PRIOR FILING DATE: 2004-03-12

; NUMBER OF SEQ ID NOS: 425

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 21

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: Oligonucleotide

US-10-949-720-21

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 3.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2356 TTCTGAGCGAGGCTCCAT 2375

Db 20 TTCTGAGCGAGGCTCCAT 1

RESULT 174

US-10-949-720-25

; Sequence 25, Application US/10949720

; Publication No. US20050249736A1

; GENERAL INFORMATION:

; APPLICANT: Krasnoperov, Valery

; APPLICANT: Zozulya, Sergey

; APPLICANT: Kertesz, Nathalie

; APPLICANT: Reddy, Ramachandra

; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING

; FILE REFERENCE: VASG-P02-002

; CURRENT APPLICATION NUMBER: US/10/949,720

; CURRENT FILING DATE: 2004-09-23

; PRIOR APPLICATION NUMBER: US 60/454,432

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300

; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 10/800,350

; PRIOR FILING DATE: 2004-03-12

; NUMBER OF SEQ ID NOS: 425

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 25

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: Oligonucleotide

US-10-949-720-25

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 3.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 697 AAGGAGACCTTCACCGTCTT 716

Db 1 AAGGAGACCTTCACCGTCTT 20

RESULT 175

US-10-949-720-27/c
; Sequence 27, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-27

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 974 TGACTGTGAACCTGACTCGA 993
Db 20 TGACTGTGAACCTGACTCGA 1

RESULT 176
US-10-949-720-32
; Sequence 32, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-32

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 419 CTTTGAAGAGACCCCTGCTG 438
Db 1 CTTTGAAGAGACCCCTGCTG 20

RESULT 177
US-10-949-720-33/c
; Sequence 33, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-33

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 696 CAAGGAGACCTTCACCGTCT 715
Db 20 CAAGGAGACCTTCACCGTCT 1

RESULT 178
US-10-949-720-51/c
; Sequence 51, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown

```
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-51

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2356 TTCTGAGCGAGGCTCCAT 2375
DB 20 TTCTGAGCGAGGCTCCAT 1

RESULT 179
US-10-949-720-55
; Sequence 55, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-55

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 419 CTTTGGAGAGACCTGCTG 438
DB 1 CTTTGGAGAGACCTGCTG 20

RESULT 180
US-10-949-720-56/c
; Sequence 56, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350

; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-55

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 419 CTTTGGAGAGACCTGCTG 438
DB 1 CTTTGGAGAGACCTGCTG 20

RESULT 181
US-10-949-720-74/c
; Sequence 74, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-74

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3299 GAACCCCGGTGGACAGGA 3318
DB 20 GAACCCCGGTGGACAGGA 1

RESULT 182
US-10-949-720-75/c
; Sequence 75, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
```

```
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-75

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3279 GAAGTCCCGAGCCCAAGCCG 3298
      ||||||||||||||||||
Db 20 GAAGTCCCGAGCCCAAGCCG 1

RESULT 183
US-10-949-720-76/c
; Sequence 76, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-76

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3259 TTGGCCAGTGTCCAGCACAT 3278
      ||||||||||||||||||
Db 20 TTGGCCAGTGTCCAGCACAT 1

RESULT 184
US-10-949-720-77/c
; Sequence 77, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
```

```
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-77

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3239 CGGGACACCCAGAGAAATC 3258
      ||||||||||||||||||
Db 20 CGGGACACCCAGAGAAATC 1

RESULT 185
US-10-949-720-78/c
; Sequence 78, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-78

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3219 CCGAATCGGAGTCACCTCTGG 3238
      ||||||||||||||||||
Db 20 CCGAATCGGAGTCACCTCTGG 1
```

```
RESULT 186
US-10-949-720-79/c
; Sequence 79, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 79
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-79

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3199 ATCTCTGCTGAGGACCTGCT 3218
DB 20 ATCTCTGCTGAGGACCTGCT 1

RESULT 187
US-10-949-720-80/c
; Sequence 80, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-80

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3159 CGCAGCCGCTGGCTTTGGCT 3178
DB 20 CGCAGCCGCTGGCTTTGGCT 1

RESULT 188
US-10-949-720-81/c
; Sequence 81, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 81
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-81

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3179 CCTTCGAGCTGCTCAGCCAG 3198
DB 20 CCTTCGAGCTGCTCAGCCAG 1

RESULT 189
US-10-949-720-82/c
; Sequence 82, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 82
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-82

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3139 GGAAGATACGAAGAAGACTTT 3158
Db      20 GGAAGATACGAAGAAGACTTT 1

RESULT 190
US-10-949-720-83/c
; Sequence 83, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-83

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3119 GGCTTCGGGCATCAAAATG 3138
Db      20 GGCTTCGGGCATCAAAATG 1

RESULT 191
US-10-949-720-84/c
; Sequence 84, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
```

```
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-84

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3099 TTTTGGCTCTGTGGCGAGT 3118
Db      20 TTTTGGCTCTGTGGCGAGT 1

RESULT 192
US-10-949-720-85/c
; Sequence 85, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 85
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-85

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3079 CGGCAGCCTCACTACTCAGC 3098
Db      20 CGGCAGCCTCACTACTCAGC 1

RESULT 193
US-10-949-720-86/c
; Sequence 86, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
```



```
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 86
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-86

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3059 CACACCTCTCTCTGGACCAG 3078
Db 20 CACACCTCTCTCTGGACCAG 1

RESULT 194
US-10-949-720-87/c
; Sequence 87, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 87
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-87

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3039 CCGGAGAGATGGCGGGGCT 3058
Db 20 CCGGAGAGATGGCGGGGCT 1

RESULT 195
US-10-949-720-88/c
; Sequence 88, Application US/10949720
; Publication No. US20050249736A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 88
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-88

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3019 GCCAGCCTCAAAATCGTGGC 3038
Db 20 GCCAGCCTCAAAATCGTGGC 1

RESULT 196
US-10-949-720-89/c
; Sequence 89, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 89
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-89

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2999 ACAAGATGATCCGGAACCCC 3018
Db 20 ACAAGATGATCCGGAACCCC 1
```

Query Match	0.5%;	Score 20;	DB 1;	Length 20;	
Best Local Similarity	100.0%;	Pred. No. 3.9e+02;			
Matches 20;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0	

QY	2959	AATGCCCGCGCCCGCTTCCC	2978	
Db	20	AATGCCCGCGCCCGCTTCCC	1	


```

RESULT 199
US-10-949-720-92/c
; Sequence 92, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 92
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-92

```


Query Match	0.5%;	Score 20;	DB 1;	Length 20;	
Best Local Similarity	100.0%;	Pred. No. 3.9e+02;			
Matches 20;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0	

QY	2939	ACTGTTGGCAGAAAGACCGG	2958	
Db	20	ACTGTTGGCAGAAAGACCGG	1	


```

RESULT 200
US-10-949-720-93/c
; Sequence 93, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
US-10-949-720-93

```

```
; SEQ ID NO 93
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-93

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2919 CCTCCACGAGTCTGCTGG 2938
      |||||
Db 20 CCTCCACGAGTCTGCTGG 1

RESULT 201
US-10-949-720-94/c
; Sequence 94, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-94

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2899 CCCCAGAGTGTCCACCTC 2918
      |||||
Db 20 CCCCAGAGTGTCCACCTC 1

RESULT 202
US-10-949-720-95/c
; Sequence 95, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
```

```
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 95
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-95

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2879 AGGACTACCGCTGCCCGG 2898
      |||||
Db 20 AGGACTACCGCTGCCCGG 1

RESULT 203
US-10-949-720-96/c
; Sequence 96, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 96
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-96

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2859 CGTGATCAATGCCATTGAAC 2878
      |||||
Db 20 CGTGATCAATGCCATTGAAC 1

RESULT 204
US-10-949-720-97/c
; Sequence 97, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
```

; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 10/949,720
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 97
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-97

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2839 TGGGACATGAGCAATCAGGA 2858
Db 20 TGGGACATGAGCAATCAGGA 1
|||||

RESULT 205
US-10-949-720-98/c
; Sequence 98, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 98
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-98

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2819 CATTGGGAGAGCCGCTAC 2838
Db 20 CATTGGGAGAGCCGCTAC 1
|||||

RESULT 206
US-10-949-720-99/c

; Sequence 99, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 99
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-99

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2799 TGTGATGTGGAGGTGATGT 2818
Db 20 TGTGATGTGGAGGTGATGT 1
|||||

RESULT 207
US-10-949-720-100/c
; Sequence 100, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertes, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 100
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-100

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy 2779 GATGCTGGAGTTACGGCAT 2798
|||||
Db 20 GATGCTGGAGTTACGGCAT 1

RESULT 208
US-10-949-720-101/c
; Sequence 101, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 101
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-101

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2759 GGAAGTTCACCTCCGCCAGT 2778
|||||
Db 20 GGAAGTTCACCTCCGCCAGT 1

RESULT 209
US-10-949-720-102/c
; Sequence 102, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 102
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-102
```

```
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-102

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2739 CCGGAGGCCATTGCCCTTC 2758
|||||
Db 20 CCGGAGGCCATTGCCCTTC 1

RESULT 210
US-10-949-720-103/c
; Sequence 103, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 103
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-103

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2719 ATCCCATCCGATGACTGC 2738
|||||
Db 20 ATCCCATCCGATGACTGC 1

RESULT 211
US-10-949-720-104/c
; Sequence 104, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
```

```
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 104
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-104

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2699 CGAGCTCCCTGGGAGGAAG 2718
Db 20 CGAGCTCCCTGGGAGGAAG 1

RESULT 212
US-10-949-720-105/c
; Sequence 105, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 105
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-105

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2679 CTCTTCCGATCCACCTACA 2698
Db 20 CTCTTCCGATCCACCTACA 1

RESULT 213
US-10-949-720-106/c
; Sequence 106, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
```

```
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-106

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2659 TCCCGATTCCTGGAGAGAA 2678
Db 20 TCCCGATTCCTGGAGAGAA 1

RESULT 214
US-10-949-720-107/c
; Sequence 107, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-107

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2639 AAGTGTCTGACTTGGCCTT 2658
Db 20 AAGTGTCTGACTTGGCCTT 1

RESULT 215
US-10-949-720-108/c
; Sequence 108, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
```

; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US 10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 108
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-108

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2618 TCAACAGCACTCTCTGCG 2637
Db 20 TCAACAGCACTCTCTGCG 1

RESULT 216

US-10-949-720-109/c
; Sequence 109, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US 10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-109

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2598 GGCTGCTGCAACATCCTAG 2617
Db 20 GGCTGCTGCAACATCCTAG 1

RESULT 217
US-10-949-720-110/c
; Sequence 110, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US 10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 110
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-110

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2578 AGCTACGTCACCGAGACCT 2597
Db 20 AGCTACGTCACCGAGACCT 1

RESULT 218

US-10-949-720-111/c
; Sequence 111, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US 10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 111
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-111

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;


```
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 115
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-115

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2478 GGACTCCTTCTCGCGCTAA 2497
Db 20 GGACTCCTTCTCGCGCTAA 1

RESULT 223
US-10-949-720-116/c
; Sequence 116, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 116
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-116

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2458 TTCATGGAGACGGCGCCCT 2477
Db 20 TTCATGGAGACGGCGCCCT 1

RESULT 224
US-10-949-720-117/c
; Sequence 117, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
```

```
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 117
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-117

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2438 CCGTCATGATTCACAGAG 2457
Db 20 CCGTCATGATTCACAGAG 1

RESULT 225
US-10-949-720-118/c
; Sequence 118, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 118
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-118

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2418 CGTGGTCACCAACAGCATGC 2437
Db 20 CGTGGTCACCAACAGCATGC 1

RESULT 226
US-10-949-720-119/c
; Sequence 119, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 119
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-119

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2398 AATATCATCGCCTGGAGGG 2417
      |||||
Db 20 AATATCATCGCCTGGAGGG 1
```

```
RESULT 227
US-10-949-720-120/c
; Sequence 120, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 120
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-120

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2378 TGGGCCAGTTCGAGCACCCC 2397
      |||||
Db 20 TGGGCCAGTTCGAGCACCCC 1
```

```
RESULT 228
US-10-949-720-121/c
; Sequence 121, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 121
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-121

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2358 TCTGAGCGAGGCTCCATCA 2377
      |||||
Db 20 TCTGAGCGAGGCTCCATCA 1
```

```
RESULT 229
US-10-949-720-122/c
; Sequence 122, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 122
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-122
```


; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 126
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-126

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2258 AGGTGTCGGGGCGGCTC 2277
|||||
DB 20 AGGTGTCGGGGCGGCTC 1

RESULT 234

US-10-949-720-127/c
; Sequence 127, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002

; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 127
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-127

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2238 TGGTGCAGGTGAGTTGGCG 2257
|||||
DB 20 TGGTGCAGGTGAGTTGGCG 1

RESULT 235

US-10-949-720-128/c
; Sequence 128, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 128
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-128

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2218 GTCAGATTGAAGAGGTGAT 2237
|||||
DB 20 GTCAGATTGAAGAGGTGAT 1

RESULT 236

US-10-949-720-129/c
; Sequence 129, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002

; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 129
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-129

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2198 AAGAGTCGATGTCCTAC 2217
|||||
DB 20 AAGAGTCGATGTCCTAC 1

RESULT 237

US-10-949-720-130/c
; Sequence 130, Application US/10949720

Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 130
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-130

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2178 GGCTGTGAGGGAATTGCAA 2197
DB 20 GGCTGTGAGGGAATTGCAA 1

RESULT 238
US-10-949-720-131/c
; Sequence 131, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 131
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-131

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2158 ACTTATGAGACCCCTAATGA 2177

DB 20 ACTTATGAGACCCCTAATGA 1

RESULT 239
US-10-949-720-132/c
; Sequence 132, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 132
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-132

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2138 AGTCTACATCGACCCCTTC 2157
DB 20 AGTCTACATCGACCCCTTC 1

RESULT 240
US-10-949-720-133/c
; Sequence 133, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 133
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide

US-10-949-720-133

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2118 TCTCATCGGACATGGTACTA 2137
|||||
Db 20 TCTCATCGGACATGGTACTA 1

RESULT 241

US-10-949-720-134/c
; Sequence 134, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 134
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-134

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2098 TCGGACAAACACGGACAGTA 2117
|||||
Db 20 TCGGACAAACACGGACAGTA 1

RESULT 242

US-10-949-720-135/c
; Sequence 135, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425

; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 135
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-135

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2078 ATGGGAGAGAGCAGCAATAT 2097
|||||
Db 20 ATGGGAGAGAGCAGCAATAT 1

RESULT 243

US-10-949-720-136/c
; Sequence 136, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 136
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-136

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2058 CTGCCTCAGGAGCAGCA 2077
|||||
Db 20 CTGCCTCAGGAGCAGCA 1

RESULT 244

US-10-949-720-137/c
; Sequence 137, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23

```
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 137
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-137

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2038 GTCATTGTGTCGCGAGTTCT 2057
Db 20 GTCATTGTGTCGCGAGTTCT 1

RESULT 245
US-10-949-720-138/c
; Sequence 138, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 138
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-138

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2018 GTGTGGTCTGTCGTCGTGGT 2037
Db 20 GTGTGGTCTGTCGTCGTGGT 1

RESULT 246
US-10-949-720-139/c
; Sequence 139, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
```

```
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 139
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-139

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1998 TGGGGCAGCGCAGTCGTGG 2017
Db 20 TGGGGCAGCGCAGTCGTGG 1

RESULT 247
US-10-949-720-140/c
; Sequence 140, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 140
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-140

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1978 CCGGAGCAGCTGGCCCTGAT 1997
Db 20 CCGGAGCAGCTGGCCCTGAT 1

RESULT 248
```

US-10-949-720-141/c
; Sequence 141, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 141
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-141

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1958 TGGATGAGCGCGGGCTGG 1977
Db 20 TGGATGAGCGCGGGCTGG 1

RESULT 249
US-10-949-720-142/c
; Sequence 142, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 142
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-142

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1938 ACATCAGCCAGCCAC 1957
Db 20 ACATCAGCCAGCCAC 1

RESULT 250
US-10-949-720-143/c
; Sequence 143, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 143
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-143

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1918 TACGGGCGCTTCGGCCAGGA 1937
Db 20 TACGGGCGCTTCGGCCAGGA 1

RESULT 251
US-10-949-720-144/c
; Sequence 144, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 144
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown

[illegible]

```
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 148
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-148

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1818 CGTGGCGTTCTCTGAAGACGT 1837
      |||||
Db 20 CGTGGCGTTCTCTGAAGACGT 1

RESULT 256
US-10-949-720-149/c
; Sequence 149, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 149
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-149

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1798 GCGCGCCGAGGGTCCACGAG 1817
      |||||
Db 20 GCGCGCCGAGGGTCCACGAG 1

RESULT 257
US-10-949-720-150/c
; Sequence 150, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
```

```
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 150
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-150

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1778 AGGTCAATATACCATGAGAAG 1797
      |||||
Db 20 AGGTCAATATACCATGAGAAG 1

RESULT 258
US-10-949-720-151/c
; Sequence 151, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 151
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-151

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1758 TGGGCTGTGCTGGACTACG 1777
      |||||
Db 20 TGGGCTGTGCTGGACTACG 1
```

RESULT 259
US-10-949-720-152/c
; Sequence 152, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 152
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-152
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1738 GCTGTTCCCGGACCCAG 1757
Db 20 GCTGTTCCCGGACCCAG 1
RESULT 260
US-10-949-720-153/c
; Sequence 153, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 153
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-153
Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1718 GCAGCTTGAGCCTGGCCTGG 1737
Db 20 GCAGCTTGAGCCTGGCCTGG 1
RESULT 261
US-10-949-720-154/c
; Sequence 154, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 154
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-154
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1698 GGTGACGCGGTCTCACCCA 1717
Db 20 GGTGACGCGGTCTCACCCA 1
RESULT 262
US-10-949-720-155/c
; Sequence 155, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 155
; LENGTH: 20

```
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-155

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1678 CCTGACGTGCTGACATCCG 1697
      |||||
Db 20 CCTGACGTGCTGACATCCG 1

RESULT 263
US-10-949-720-156/c
; Sequence 156, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 156
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-156

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1658 CCACTGACCGAGGTACCT 1677
      |||||
Db 20 CCACTGACCGAGGTACCT 1

RESULT 264
US-10-949-720-157/c
; Sequence 157, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
```

```
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 157
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-157

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1638 ATTTGAGCCTGTCAATGTCA 1657
      |||||
Db 20 ATTTGAGCCTGTCAATGTCA 1

RESULT 265
US-10-949-720-158/c
; Sequence 158, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 158
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-158

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1618 TTAGCCACGGGCCCGTCCC 1637
      |||||
Db 20 TTAGCCACGGGCCCGTCCC 1

RESULT 266
US-10-949-720-159/c
; Sequence 159, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
```

; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 159
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-159

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1598 CATTGAACGGGTATCTCC 1617
|||||
Db 20 CATTGAACGGGTATCTCC 1

RESULT 267
US-10-949-720-160/c
; Sequence 160, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 160
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-160

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1578 CTATACCTTTGAGGTCACTG 1597
|||||
Db 20 CTATACCTTTGAGGTCACTG 1

RESULT 268
US-10-949-720-161/c
; Sequence 161, Application US/10949720
; Publication No. US20050249736A1

; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 161
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-161

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1558 GGGCTACGTCCTGACTTCAC 1577
|||||
Db 20 GGGCTACGTCCTGACTTCAC 1

RESULT 269
US-10-949-720-162/c
; Sequence 162, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 162
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-162

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1538 AGCCCTGGGTGGTTCGA 1557
|||||

```
Db      20 AGCCTGGGTGGTGTTCGA 1

RESULT 270
US-10-949-720-163/c
; Sequence 163, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 163
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-163

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1518 CGGCCCGGGACCTGTGG 1537
Db      20 CGGCCCGGGACCTGTGG 1

RESULT 271
US-10-949-720-164/c
; Sequence 164, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 164
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-164

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1478 GTCCTGTGGCGCCTCGGG 1497
Db      20 GTCCTGTGGCGCCTCGGG 1

RESULT 273
US-10-949-720-166/c
; Sequence 166, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 165
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-165

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1498 GGAGACCTGACTTTTGACCC 1517
Db      20 GGAGACCTGACTTTTGACCC 1

RESULT 272
US-10-949-720-165/c
; Sequence 165, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 165
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-165
```

```
; SEQ ID NO 166
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-166

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1458 CCGGAGTGCCGACCCGGAG 1477
      |||||
Db 20 CCGGAGTGCCGACCCGGAG 1

RESULT 274
US-10-949-720-167/c
; Sequence 167, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 167
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-167

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1438 CTCACCTACGCCCTCGCTG 1457
      |||||
Db 20 CTCACCTACGCCCTCGCTG 1

RESULT 275
US-10-949-720-168/c
; Sequence 168, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
```

```
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 168
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-168

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1418 AGTCTGGTGGCCGAGAGGAC 1437
      |||||
Db 20 AGTCTGGTGGCCGAGAGGAC 1

RESULT 276
US-10-949-720-169/c
; Sequence 169, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 169
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-169

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1398 GGAATGGAGTGCCCGCCCTGG 1417
      |||||
Db 20 GGAATGGAGTGCCCGCCCTGG 1

RESULT 277
US-10-949-720-170/c
; Sequence 170, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
```

; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 170
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-170

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1378 AACGGCTCTCCCTGCACCT 1397
|||
Db 20 AACGGCTCTCCCTGCACCT 1

RESULT 278

US-10-949-720-171/c
; Sequence 171, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 171
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-171

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1358 GGACGCTGGTTTCCCGCTG 1377
|||
Db 20 GGACGCTGGTTTCCCGCTG 1

RESULT 279

US-10-949-720-172/c

; Sequence 172, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 172
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-172

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1338 CACCCCTCTTCGGCTCCGC 1357
|||
Db 20 CACCCCTCTTCGGCTCCGC 1

RESULT 280

US-10-949-720-173/c
; Sequence 173, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 173
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-173

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;


```
QY 1318 CCCCGGGGTGCACCTGCAC 1337
      |||||
Db 20 CCCCGGGGTGCACCTGCAC 1

RESULT 281
US-10-949-720-174/c
; Sequence 174, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 174
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-174

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1298 ACTTCGGGCACGCACACAC 1317
      |||||
Db 20 ACTTCGGGCACGCACACAC 1

RESULT 282
US-10-949-720-175/c
; Sequence 175, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 175
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-175

QY 1318 CCCCGGGGTGCACCTGCAC 1337
      |||||
Db 20 CCCCGGGGTGCACCTGCAC 1

RESULT 281
US-10-949-720-174/c
; Sequence 174, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 174
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-174

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1298 ACTTCGGGCACGCACACAC 1317
      |||||
Db 20 ACTTCGGGCACGCACACAC 1

RESULT 282
US-10-949-720-175/c
; Sequence 175, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 175
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-175

QY 1278 CTGCCAGTGCCTCGCGGT 1297
      |||||
Db 20 CTGCCAGTGCCTCGCGGT 1

RESULT 283
US-10-949-720-176/c
; Sequence 176, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 176
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-176

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1258 AACACCATTCGATCAGCCGT 1277
      |||||
Db 20 AACACCATTCGATCAGCCGT 1

RESULT 284
US-10-949-720-177/c
; Sequence 177, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 177
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-177
```

```
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 177
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-177

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1238 GCCCAGCCCAATAGCCACTCT 1257
Db 20 GCCCAGCCCAATAGCCACTCT 1

RESULT 285
US-10-949-720-178/c
; Sequence 178, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 178
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-178

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1218 AGAAGGGTCTGCGCCAGCCAT 1237
Db 20 AGAAGGGTCTGCGCCAGCCAT 1

RESULT 286
US-10-949-720-179/c
; Sequence 179, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
```

```
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 179
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-179

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1198 ACCTTCAAGCCCTGTCTCAGG 1217
Db 20 ACCTTCAAGCCCTGTCTCAGG 1

RESULT 287
US-10-949-720-180/c
; Sequence 180, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 180
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-180

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1178 GCCGAGCCTGTGCCCAGGGC 1197
Db 20 GCCGAGCCTGTGCCCAGGGC 1

RESULT 288
US-10-949-720-181/c
; Sequence 181, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
```

APPLICANT: Kertesz, Nathalie
APPLICANT: Reddy, Ramachandra
APPLICANT: Gill, Parkash
TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
FILE REFERENCE: VASG-P02-002
CURRENT APPLICATION NUMBER: US/10/949,720
PRIOR FILING DATE: 2004-09-23
PRIOR APPLICATION NUMBER: US 60/454,432
PRIOR FILING DATE: 2003-03-12
PRIOR APPLICATION NUMBER: US 60/454,300
PRIOR FILING DATE: 2003-03-12
PRIOR APPLICATION NUMBER: US 10/800,350
PRIOR FILING DATE: 2004-03-12
NUMBER OF SEQ ID NOS: 425
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 181
LENGTH: 20
TYPE: DNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: Oligonucleotide
US-10-949-720-181

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1158 AGCTGAGGGGAACACCAAGT 1177
|||||
DB 20 AGCTGAGGGGAACACCAAGT 1

RESULT 289

US-10-949-720-182/c
Sequence 182, Application US/10949720
Publication No. US20050249736A1
GENERAL INFORMATION:
APPLICANT: Krasnoperov, Valery
APPLICANT: Zozulya, Sergey
APPLICANT: Kertesz, Nathalie
APPLICANT: Reddy, Ramachandra
APPLICANT: Gill, Parkash
TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
FILE REFERENCE: VASG-P02-002
CURRENT APPLICATION NUMBER: US/10/949,720
CURRENT FILING DATE: 2004-09-23
PRIOR APPLICATION NUMBER: US 60/454,432
PRIOR FILING DATE: 2003-03-12
PRIOR APPLICATION NUMBER: US 60/454,300
PRIOR FILING DATE: 2003-03-12
PRIOR APPLICATION NUMBER: US 10/800,350
PRIOR FILING DATE: 2004-03-12
NUMBER OF SEQ ID NOS: 425
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 182
LENGTH: 20
TYPE: DNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: Oligonucleotide
US-10-949-720-182

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1138 TGTGCTCCGGGTTTCGAGGC 1157
|||||
DB 20 TGTGCTCCGGGTTTCGAGGC 1

RESULT 290
US-10-949-720-183/c
Sequence 183, Application US/10949720
Publication No. US20050249736A1
GENERAL INFORMATION:
APPLICANT: Krasnoperov, Valery
APPLICANT: Zozulya, Sergey
APPLICANT: Kertesz, Nathalie
APPLICANT: Reddy, Ramachandra
APPLICANT: Gill, Parkash
TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
FILE REFERENCE: VASG-P02-002
CURRENT APPLICATION NUMBER: US/10/949,720
CURRENT FILING DATE: 2004-09-23
PRIOR APPLICATION NUMBER: US 60/454,432
PRIOR FILING DATE: 2003-03-12
PRIOR APPLICATION NUMBER: US 60/454,300
PRIOR FILING DATE: 2003-03-12
PRIOR APPLICATION NUMBER: US 10/800,350
PRIOR FILING DATE: 2004-03-12
NUMBER OF SEQ ID NOS: 425
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 183
LENGTH: 20
TYPE: DNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: Oligonucleotide
US-10-949-720-183

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1118 AGCCGGTCACGGGCTGCAGC 1137
|||||
DB 20 AGCCGGTCACGGGCTGCAGC 1

RESULT 291

US-10-949-720-184/c
Sequence 184, Application US/10949720
Publication No. US20050249736A1
GENERAL INFORMATION:
APPLICANT: Krasnoperov, Valery
APPLICANT: Zozulya, Sergey
APPLICANT: Kertesz, Nathalie
APPLICANT: Reddy, Ramachandra
APPLICANT: Gill, Parkash
TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
FILE REFERENCE: VASG-P02-002
CURRENT APPLICATION NUMBER: US/10/949,720
CURRENT FILING DATE: 2004-09-23
PRIOR APPLICATION NUMBER: US 60/454,432
PRIOR FILING DATE: 2003-03-12
PRIOR APPLICATION NUMBER: US 60/454,300
PRIOR FILING DATE: 2003-03-12
PRIOR APPLICATION NUMBER: US 10/800,350
PRIOR FILING DATE: 2004-03-12
NUMBER OF SEQ ID NOS: 425
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 184
LENGTH: 20
TYPE: DNA
ORGANISM: Unknown
FEATURE:
OTHER INFORMATION: Oligonucleotide
US-10-949-720-184

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1098 GGATGGCCAGTGGCCGAAC 1117
Db 20 GGATGGCCAGTGGCCGAAC 1

RESULT 292

US-10-949-720-185/c
; Sequence 185, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 185
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-185

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1078 CCCAGCCTCTACTGCCGTGA 1057
Db 20 CCCAGCCTCTACTGCCGTGA 1

RESULT 293

US-10-949-720-186/c
; Sequence 186, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 186
; LENGTH: 20
; TYPE: DNA

; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-186

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1058 TCCCCGCCCTGGCCCCAGC 1077
Db 20 TCCCCGCCCTGGCCCCAGC 1

RESULT 294

US-10-949-720-187/c
; Sequence 187, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 187
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-187

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TAGCTCGGTGGTGGATCCG 1057
Db 20 TAGCTCGGTGGTGGATCCG 1

RESULT 295

US-10-949-720-188/c
; Sequence 188, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12

; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 190
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-188

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1018 CTGGTTGTGCCCGTGGCGG 1037
|||||
Db 20 CTGGTTGTGCCCGTGGCGG 1

RESULT 296
US-10-949-720-189/c
; Sequence 189, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 189
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-189

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 998 CGGAGACTGTGCTCGGGAG 1017
|||||
Db 20 CGGAGACTGTGCTCGGGAG 1

RESULT 297
US-10-949-720-190/c
; Sequence 190, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH

; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 190
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-190

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 978 TGTGAACCTGACTCGATTCC 997
|||||
Db 20 TGTGAACCTGACTCGATTCC 1

RESULT 298
US-10-949-720-191/c
; Sequence 191, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 191
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-191

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 958 AAAAAGTGGCCCGAGCTGAC 977
|||||
Db 20 AAAAAGTGGCCCGAGCTGAC 1

RESULT 299
US-10-949-720-192/c
; Sequence 192, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:

```
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 192
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-192

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 938 TATCCCTGCACCTCTTCTAC 957
Db 20 TATCCCTGCACCTCTTCTAC 1

RESULT 300
US-10-949-720-193/c
; Sequence 193, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 193
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-193

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 918 GGGTGCCTGCATGGCCCTGC 937
Db 20 GGGTGCCTGCATGGCCCTGC 1
```

```
RESULT 301
US-10-949-720-194/c
; Sequence 194, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 194
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-194

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 898 TACCTGGCCTTCCAGGACCA 917
Db 20 TACCTGGCCTTCCAGGACCA 1

RESULT 302
US-10-949-720-195/c
; Sequence 195, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 195
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-195
```

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 878 CGCTCAGCAGCTGGCTTC 897
Db 20 CGCTCAGCAGCTGGCTTC 1

RESULT 303

US-10-949-720-196/c
; Sequence 196, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenopero, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 196
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-196

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 858 CAAGACGCTGCTGGGAC 877
Db 20 CAAGACGCTGCTGGGAC 1

RESULT 304

US-10-949-720-197/c
; Sequence 197, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenopero, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 197

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-197

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 838 GCCACCGGAGGTGAATGT 857
Db 20 GCCACCGGAGGTGAATGT 1

RESULT 305

US-10-949-720-198/c
; Sequence 198, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenopero, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 198
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-198

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 818 GGAAGCCCTGGGGCCGAG 837
Db 20 GGAAGCCCTGGGGCCGAG 1

RESULT 306

US-10-949-720-199/c
; Sequence 199, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenopero, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12

; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 199
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-199

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 798 GCGCGGAGCAGCTCACCC 817
|||
Db 20 GCGCGGAGCAGCTCACCC 1

RESULT 307

US-10-949-720-200/c
; Sequence 200, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 200
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-200

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 778 TACATCAAGGTGGACACGGT 797
|||
Db 20 TACATCAAGGTGGACACGGT 1

RESULT 308

US-10-949-720-201/c
; Sequence 201, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash

; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 201
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-201

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 758 CAGCCTGGATGGAGAACCCC 777
|||
Db 20 CAGCCTGGATGGAGAACCCC 1

RESULT 309

US-10-949-720-202/c
; Sequence 202, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 202
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-202

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 738 CACGGCCACGGCCTCACGC 757
|||
Db 20 CACGGCCACGGCCTCACGC 1

RESULT 310

US-10-949-720-203/c
; Sequence 203, Application US/10949720


```
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 203
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-204
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 718 TACTATGAGCGATGCGGA 737
DB 20 TACTATGAGCGATGCGGA 1
|||||
RESULT 311
US-10-949-720-204/c
; Sequence 204, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 204
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-204
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 698 AGGAGACCTTCACCGCTCTTC 717
```

```
|||||
DB 20 AGGAGACCTTCACCGCTCTTC 1
|||||
RESULT 312
US-10-949-720-205/c
; Sequence 205, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 205
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-205
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 678 TCGGGCTGGGGCTCCTGCA 697
DB 20 TCGGGCTGGGGCTCCTGCA 1
|||||
RESULT 313
US-10-949-720-206/c
; Sequence 206, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 206
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-206
```

```
US-10-949-720-206
Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 658 CTCGAGTGCCTGCTCCCGCC 677
Db 20 CTCGAGTGCCTGCTCCCGCC 1

RESULT 314
US-10-949-720-207/c
; Sequence 207, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 207
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-207

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 638 CCACGCTGCGCTTCACCATG 657
Db 20 CCACGCTGCGCTTCACCATG 1

RESULT 315
US-10-949-720-208/c
; Sequence 208, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 208
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-208

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 598 ACAGGTTGGTCCCGCCGCG 617
Db 20 ACAGGTTGGTCCCGCCGCG 1

RESULT 317
US-10-949-720-210/c
; Sequence 210, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 209
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-209

Query Match          0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 618 GGGCGCCGTCACGTGTACG 637
Db 20 GGGCGCCGTCACGTGTACG 1

RESULT 316
US-10-949-720-209/c
; Sequence 209, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 209
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-209
```

; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 210
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-210

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 578 GCCAGGCCCACTGGCTTCGC 597
Db 20 GCCAGGCCCACTGGCTTCGC 1

RESULT 318

US-10-949-720-211/c
; Sequence 211, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 211
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-211

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 558 TGACGTGACGCTGCCCGG 577
Db 20 TGACGTGACGCTGCCCGG 1

RESULT 319

US-10-949-720-212/c
; Sequence 212, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie

; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 212
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-212

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 538 GTGCGCACCTACGAAGTGTG 557
Db 20 GTGCGCACCTACGAAGTGTG 1

RESULT 320

US-10-949-720-213/c
; Sequence 213, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 213
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-213

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 518 TGGATGAGGAACACACAGC 537
Db 20 TGGATGAGGAACACACAGC 1

RESULT 321

```
US-10-949-720-214/c
; Sequence 214, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 214
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-214
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 498 GTGGGAGGAAGTGTGCGGCC 517
Db 20 GTGGGAGGAAGTGTGCGGCC 1

RESULT 322
US-10-949-720-215/c
; Sequence 215, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 215
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-215
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 478 TTCCCTCAGGTGACGGCA 497
Db 20 TTCCCTCAGGTGACGGCA 1

RESULT 323
US-10-949-720-216/c
; Sequence 216, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 216
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-216
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 458 CTGATCTGAAGTGGGTGACA 477
Db 20 CTGATCTGAAGTGGGTGACA 1

RESULT 324
US-10-949-720-217/c
; Sequence 217, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 217
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
```

Feature	Prior Filing Date	2004-03-12	Number of Seq ID NOS	425	Software: FastSeq for Windows Version	4.0	Seq ID No	219	Length	20	Type	DNA	Organism	Unknown	Feature	Other Information: Oligonucleotide	US-10-949-720-219	Query Match	Score	20	DB 1	Length	20	Best Local Similarity	100.0%	Pred. No.	3.9e+02	Mismatches	0	Indels	0	Gaps	0											
Query Match	0.5%	Score 20	DB 1	Length 20	Best Local Similarity	100.0%	Pred. No.	3.9e+02	Mismatches	0	Indels	0	Gaps	0																														
Matches	20	Conservative	0	Mismatches	0	Indels	0	Gaps	0																																			
QY	438	GAACACAAAATTGGAACCTG	457	DB	20	GAACACAAAATTGGAACCTG	1																																					
RESULT 325	US-10-949-720-218/c	Sequence 218, Application US/10949720	Publication No. US20050249736A1	GENERAL INFORMATION:	APPLICANT: Krasnoperov, Valery	APPLICANT: Zozulya, Sergey	APPLICANT: Kertesz, Nathalie	APPLICANT: Reddy, Ramachandra	APPLICANT: Gill, Parkash	TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING	TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH	FILE REFERENCE: VASG-P02-002	CURRENT APPLICATION NUMBER: US/10/949,720	PRIOR FILING DATE: 2004-09-23	PRIOR APPLICATION NUMBER: US 60/454,432	PRIOR FILING DATE: 2003-03-12	PRIOR APPLICATION NUMBER: US 60/454,300	PRIOR FILING DATE: 2003-03-12	PRIOR APPLICATION NUMBER: US 10/800,350	PRIOR FILING DATE: 2004-03-12	NUMBER OF SEQ ID NOS: 425	SOFTWARE: FastSeq for Windows Version 4.0	SEQ ID NO 218	LENGTH: 20	TYPE: DNA	ORGANISM: Unknown	FEATURE:	OTHER INFORMATION: Oligonucleotide	US-10-949-720-218	Query Match	0.5%	Score 20	DB 1	Length 20	Best Local Similarity	100.0%	Pred. No.	3.9e+02	Mismatches	0	Indels	0	Gaps	0
Matches	20	Conservative	0	Mismatches	0	Indels	0	Gaps	0																																			
QY	418	GCTTTGGAAGAGACCTGCT	437	DB	20	GCTTTGGAAGAGACCTGCT	1																																					
RESULT 326	US-10-949-720-219/c	Sequence 219, Application US/10949720	Publication No. US20050249736A1	GENERAL INFORMATION:	APPLICANT: Krasnoperov, Valery	APPLICANT: Zozulya, Sergey	APPLICANT: Kertesz, Nathalie	APPLICANT: Reddy, Ramachandra	APPLICANT: Gill, Parkash	TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING	TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH	FILE REFERENCE: VASG-P02-002	CURRENT APPLICATION NUMBER: US/10/949,720	PRIOR FILING DATE: 2004-09-23	PRIOR APPLICATION NUMBER: US 60/454,432	PRIOR FILING DATE: 2003-03-12	PRIOR APPLICATION NUMBER: US 60/454,300	PRIOR FILING DATE: 2003-03-12	PRIOR APPLICATION NUMBER: US 10/800,350	PRIOR FILING DATE: 2004-03-12	NUMBER OF SEQ ID NOS: 425	SOFTWARE: FastSeq for Windows Version 4.0	SEQ ID NO 219	LENGTH: 20	TYPE: DNA	ORGANISM: Unknown	FEATURE:	OTHER INFORMATION: Oligonucleotide	US-10-949-720-219	Query Match	0.5%	Score 20	DB 1	Length 20	Best Local Similarity	100.0%	Pred. No.	3.9e+02	Mismatches	0	Indels	0	Gaps	0
Matches	20	Conservative	0	Mismatches	0	Indels	0	Gaps	0																																			
QY	378	GGAGCTCCGGTGCTGCTCT	397	DB	20	GGAGCTCCGGTGCTGCTCT	1																																					
RESULT 328	US-10-949-720-221/c	Sequence 221, Application US/10949720	Publication No. US20050249736A1	GENERAL INFORMATION:	APPLICANT: Krasnoperov, Valery	APPLICANT: Zozulya, Sergey	APPLICANT: Kertesz, Nathalie	APPLICANT: Reddy, Ramachandra	APPLICANT: Gill, Parkash	TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING	TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH	FILE REFERENCE: VASG-P02-002	CURRENT APPLICATION NUMBER: US/10/949,720	PRIOR FILING DATE: 2004-09-23	PRIOR APPLICATION NUMBER: US 60/454,432	PRIOR FILING DATE: 2003-03-12	PRIOR APPLICATION NUMBER: US 60/454,300	PRIOR FILING DATE: 2003-03-12	PRIOR APPLICATION NUMBER: US 10/800,350	PRIOR FILING DATE: 2004-03-12	NUMBER OF SEQ ID NOS: 425	SOFTWARE: FastSeq for Windows Version 4.0	SEQ ID NO 220	LENGTH: 20	TYPE: DNA	ORGANISM: Unknown	FEATURE:	OTHER INFORMATION: Oligonucleotide	US-10-949-720-220	Query Match	0.5%	Score 20	DB 1	Length 20	Best Local Similarity	100.0%	Pred. No.	3.9e+02	Mismatches	0	Indels	0	Gaps	0
Matches	20	Conservative	0	Mismatches	0	Indels	0	Gaps	0																																			
QY	378	GGAGCTCCGGTGCTGCTCT	397	DB	20	GGAGCTCCGGTGCTGCTCT	1																																					

; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 221
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-221

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 376 ATGGAGCTCCGGGTGCTGCT 395
Db 20 ATGGAGCTCCGGGTGCTGCT 1

RESULT 329

US-10-949-720-231/c
; Sequence 231, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 231
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-231

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2356 TTTCTGAGCGAGGCTTCAT 2375
Db 20 TTTCTGAGCGAGGCTTCAT 1

RESULT 330

US-10-949-720-421
; Sequence 421, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery

; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 421
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
US-10-949-720-421

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1263 CATTGGATCAGCGCTGCTGCC 1282
Db 1 CATTGGATCAGCGCTGCTGCC 20

RESULT 331

US-10-310-914A-153225/c
; Sequence 153225, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153225
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153225

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3893 TCCCTTTTGTTCCTTCGTT 3912
Db 20 TCCCTTTTGTTCCTTCGTT 1

RESULT 332

US-10-310-914A-153251/c
; Sequence 153251, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153251
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153251

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 312 TCAGACCTGGGGGGGCGAGG 331
DB 20 TCAGACCTGGGGGGGCGAGG 1

RESULT 333

US-10-310-914A-153252/c
; Sequence 153252, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153252
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153252

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3573 GGACTGGGTGTGACACGAGG 3592
DB 20 GGACTGGGTGTGACACGAGG 1

RESULT 334

US-10-310-914A-153263/c
; Sequence 153263, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153263
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153263

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3394 TGGGGACTCACAGAGGCCCC 3413

DB 20 TGGGGACTCACAGAGGCCCC 1

RESULT 335

US-10-310-914A-153284/c
; Sequence 153284, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153284
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153284

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3964 ACTATGGCCTCTTTTGCCCA 3983
DB 20 ACTATGGCCTCTTTTGCCCA 1

RESULT 336

US-10-949-720-38
; Sequence 38, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 38
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-38

Query Match 0.5%; Score 20; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 4.2e+02;
Matches 18; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1939 CATCAGCCAGCCCACT 1958
DB 1 CAUCACAGCCAGCCCAACU 20

```
RESULT 337
US-10-949-720-288
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Kraenopetrov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 288
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-288

Query Match      0.5%; Score 20; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 4.2e+02;
Matches 18; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1939 CATCACAGCCAGACCCCACT 1958
DB 1 CAUCACAGCCAGACCCCACTU 20

RESULT 338
US-10-770-726-17477
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17477
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17477

Query Match      0.5%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2506 CAGTTCACAGTCATCCAGCT 2525
DB 1 CAGTTCACAGTCATCCAGCT 20

RESULT 339
US-10-310-914A-153253/c
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153253
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153253

Query Match      0.5%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3463 TGGCAATTTGGAGACAGG 3482
DB 20 TGGCAATTTGGAGACAGG 1

RESULT 340
US-10-310-914A-1353080/c
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1353080
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1353080

Query Match      0.5%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1065 CCCTGGCCCCCAGCCCGCC 1084
DB 22 CCCTGGCCCCCAGCCCGCC 3

RESULT 341
US-10-310-914A-95660
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 95660
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-95660
```


; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: ANGIOGENESIS AND TUMOR GROWTH
; CURRENT APPLICATION NUMBER: VASG-P02-002
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US/10/949,720
; PRIOR FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 223
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-223

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 4.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1328 CACCGTGACACCCCTCCCTT 1348
|||||
Db 21 CACCGTGACACCCCTCCCTT 1

RESULT 347

US-10-770-726-16892
; Sequence 16892, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16892
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-16892

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 4.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2608 AACATCCTCGTCAACAGCAAC 2628
|||||
Db 1 AACATCCTCGTCAACAGCAAC 21

RESULT 348

US-10-770-726-16916
; Sequence 16916, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)

; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16916
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-16916

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 4.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2927 AGCTCATGCTGGACTGTTGGC 2947
|||||
Db 1 AACTCATGCTGGACTGTTGGC 21

RESULT 349

US-10-770-726-17495
; Sequence 17495, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17495
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17495

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 4.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2607 CAACATCCTCGTCAACAGCAA 2627
|||||
Db 1 CAACATCCTCGTCAACAGCAA 21

RESULT 350

US-10-770-726-17498
; Sequence 17498, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17498
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17498

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 4.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
QY 2610 CATCCTAGTCAACAGCAACT 2630
||||| ||||||| |||||||
Db 1 CATCCTGCTCAACAGCAACT 21

RESULT 351
US-10-770-726-17501
; Sequence 17501, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17501
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17501

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 4.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2619 CAACAGCAACCTCGTCTGCAA 2639
||||| ||||||| |||||||
Db 1 CAACAGCAACCTGCTGCAA 21

RESULT 352
US-10-770-726-17534
; Sequence 17534, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17534
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17534

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 4.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2865 CAATGCCATTGACAGGACTA 2885
||||| ||||||| |||||||
Db 1 CAATGCCATTGACAGGACTA 21

RESULT 353
US-10-770-726-17540
; Sequence 17540, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
```

```
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17540
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17540

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 4.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2923 CACCAGCTCATGCTGGACTGT 2943
||||| ||||||| |||||||
Db 1 CACCAGCTCATGCTGGACTGT 21

RESULT 354
US-10-770-726-17543
; Sequence 17543, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17543
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17543

Query Match 0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 4.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2926 CAGCTCATGCTGGACTGTGG 2946
||||| ||||||| |||||||
Db 1 CAACTCATGCTGGACTGTGG 21

RESULT 355
US-10-310-914A-161882
; Sequence 161882, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kruzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CFUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161882
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-161882
```

```

Query Match          0.5%; Score 19.4; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 4.8e+02;
Matches 17; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3605 CCAACATCTCCAGCTCCCC 3625
      ||||| :|||:|||||
Db 1 CCAACCUCCAGCCUCCCC 21

RESULT 356
US-10-310-914A-161883
; Sequence 161883, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161883
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-161883

Query Match          0.5%; Score 19.4; DB 1; Length 22;
Best Local Similarity 81.0%; Pred. No. 5.2e+02;
Matches 17; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3605 CCAACATCTCCAGCTCCCC 3625
      ||||| :|||:|||||
Db 1 CCAACCUCCAGCCUCCCC 21

RESULT 357
US-10-310-914A-311206/c
; Sequence 311206, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 311206
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-311206

Query Match          0.5%; Score 19.4; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 5.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3929 CTTGTCATACTTGTGTTGG 3949
      ||||| ||||| ||||| |||||
Db 21 CTTGTCATACTTGTGTTGG 1

RESULT 358
US-10-310-914A-390963
; Sequence 390963, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
```

```

; APPLICANT: Shiller, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 390963
; LENGTH: 24
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-390963

Query Match          0.5%; Score 19.2; DB 1; Length 24;
Best Local Similarity 8.3%; Pred. No. 6.3e+02;
Matches 2; Conservative 19; Mismatches 3; Indels 0; Gaps 0;

QY 3897 TTTTGTTCCTTCGTTTGTGTTT 3920
      :|||: |||: |||: |||: |||:
Db 1 UUUUUUUUUUUUUUUUUUUUUUU 24

RESULT 359
US-10-310-914A-686978/c
; Sequence 686978, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 686978
; LENGTH: 24
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-686978

Query Match          0.5%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 6.3e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3897 TTTTGTTCCTTCGTTTGTGTTT 3920
      ||||| ||| ||| ||| ||| ||| |||
Db 24 TTTTGTTCCTTCCTTTTGTGTTT 1

RESULT 360
US-11-178-086-26
; Sequence 26, Application US/11178086
; Publication No. US20050276789A1
; GENERAL INFORMATION:
; APPLICANT: LOPEZ, Ricardo A.
; TITLE OF INVENTION: IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 2901/OM327
; CURRENT FILING DATE: 2005-07-08
; PRIOR APPLICATION NUMBER: US/10/309,775
; PRIOR FILING DATE: 2002-12-04
; PRIOR APPLICATION NUMBER: CA 2,388,049
; PRIOR FILING DATE: 2002-05-30
; NUMBER OF SEQ ID NOS: 74
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

OTHER INFORMATION: PCR primer
US-11-178-086-26

Query Match 0.5%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 6.3e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3897 TTTTGTCTTCGTTTGTGTTTT 3920
||||| ||||| ||||| ||||| |||||
Db 1 TTTTGTCTTCATTTGTGTTTT 24

RESULT 361

US-11-178-086-73
; Sequence 73, Application US/11178086
; Publication No. US20050276789A1
; GENERAL INFORMATION:
; APPLICANT: LOPEZ, Ricardo A.
; TITLE OF INVENTION: IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 2901/0M327
; CURRENT APPLICATION NUMBER: US/11/178,086
; CURRENT FILING DATE: 2005-07-08
; PRIOR APPLICATION NUMBER: US/10/309,775
; PRIOR FILING DATE: 2002-12-04
; PRIOR APPLICATION NUMBER: CA 2,388,049
; PRIOR FILING DATE: 2002-05-30
; NUMBER OF SEQ ID NOS: 74
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 73
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-11-178-086-73

Query Match 0.5%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 6.3e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3897 TTTTGTCTTCGTTTGTGTTTT 3920
||||| ||||| ||||| ||||| |||||
Db 1 TTTTGTCTTCATTTGTGTTTT 24

RESULT 362

US-10-310-914A-153218/c
; Sequence 153218, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153218
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153218

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3852 GGTTCGAGTTTGTGTTTT 3870
||||| ||||| ||||| ||||| |||||
Db 19 GGTTCGAGTTTGTGTTTT 1

RESULT 363

US-10-310-914A-153220/c
; Sequence 153220, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153220
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153220

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3887 CCCGTTCCCTTTTGTGTTT 3905
||||| ||||| ||||| ||||| |||||
Db 19 CCCGTTCCCTTTTGTGTTT 1

RESULT 364

US-10-310-914A-153222/c
; Sequence 153222, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153222
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153222

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4159 GGGTCTCTAAATATATTTT 4177
||||| ||||| ||||| ||||| |||||
Db 19 GGGTCTCTAAATATATTTT 1

RESULT 365

US-10-310-914A-153224/c
; Sequence 153224, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3

```
; SEQ ID NO 153224
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153224

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3899 TTGTTTCCTCGTTTGT 3917
    |||||||
Db 19 TTGTTTCCTCGTTTGT 1

RESULT 366
US-10-310-914A-153227/c
; Sequence 153227, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153227
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153227

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3885 CTCCTCCCTTCCTTTTGT 3903
    |||||||
Db 19 CTCCTCCCTTCCTTTTGT 1

RESULT 367
US-10-310-914A-153244/c
; Sequence 153244, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153244
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153244

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3414 CAGCCCTGTGCCCGCTGG 3432
    |||||||
Db 19 CAGCCCTGTGCCCGCTGG 1

RESULT 368
US-10-310-914A-153245/c
; Sequence 153245, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153245
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153245

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3471 TGGAGAGACAGGATTGGG 3489
    |||||||
Db 19 TGGAGAGACAGGATTGGG 1

RESULT 369
US-10-310-914A-153250/c
; Sequence 153250, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153250
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153250

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3700 GGGGGGGCTGTCCAGGGG 3718
    |||||||
Db 19 GGGGGGGCTGTCCAGGGG 1

RESULT 370
US-10-310-914A-153258/c
; Sequence 153258, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153258
```

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153258

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4082 TGAAGGGGTGGGGGTGAG 4100
Db 19 TGAAGGGGTGGGGGTGAG 1

RESULT 371
US-10-310-914A-153268/c
; Sequence 153268, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153268
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153268

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3828 CCCAGCTGCTGCCTTCATA 3846
Db 19 CCCAGCTGCTGCCTTCATA 1

RESULT 372
US-10-310-914A-153272/c
; Sequence 153272, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153272
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153272

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4112 GCGCGTAGTTCGGTGTGA 4130
Db 19 GCGCGTAGTTCGGTGTGA 1

RESULT 373
```

```
US-10-310-914A-153282/c
; Sequence 153282, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153282
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153282

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3671 GAGTGTGACTCCCTTGCCA 3689
Db 19 GAGTGTGACTCCCTTGCCA 1

RESULT 374
US-10-310-914A-153290/c
; Sequence 153290, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153290
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153290

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3799 TCATTTTTTCCCTTGTA 3817
Db 19 TCATTTTTTCCCTTGTA 1

RESULT 375
US-10-310-914A-153291/c
; Sequence 153291, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153291
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153291

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 4004 ATCATGTCGTGTTCCAGAA 4022
|||||
DB 19 ATCATGTCGTGTTCCAGAA 1
```

```
RESULT 376
US-11-101-244-685
; Sequence 685, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 685
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-685
```

```
Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 GGACAAACACGACGACGTAT 2118
|||||
DB 1 GGACAAACACGACGACAGUAT 19
```

```
RESULT 377
US-11-101-244-686
; Sequence 686, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 686
; LENGTH: 19
; TYPE: RNA
```

```
; ORGANISM: Homo sapiens
US-11-101-244-686

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2132 GTACTAAGGCTCTACATCGA 2150
|||||
DB 1 GUACUAAAGGUCUACAUCCA 19
```

```
RESULT 378
US-11-101-244-687
; Sequence 687, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 687
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-687
```

```
Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2081 GGAGAGACGACGAATATTC 2099
|||||
DB 1 GGAGAGACGACGAUAUUC 19
```

```
RESULT 379
US-11-101-244-688
; Sequence 688, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 688
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
```


US-11-101-244-688

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1243 GCCAATAGCCACTCTAACA 1261
|||||:|||||:|:|||||
Db 1 GCCAUAAGCCACUCUAACA 19

RESULT 380

US-11-101-244-158892
; Sequence 158892, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158892
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-11-101-244-158892

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTCATGGAGAA 2468
:|||||:|:|||||
Db 1 UCACAGAGUUCAGGAGAA 19

RESULT 381

US-11-101-244-159283
; Sequence 159283, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159283
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-11-101-244-159283

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3786 CCACCAACTCAATCATTT 3804
|||||:|||||:|:|||||
Db 1 CCACCAACUCAAUAUUU 19

RESULT 382

US-11-101-244-159284
; Sequence 159284, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159284
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-11-101-244-159284

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3949 GAGGGAACCTGTTTCACTA 3967
|||||:|||||:|:|||||
Db 1 GAGGGAACUUGUUCACUA 19

RESULT 383

US-11-101-244-159285
; Sequence 159285, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159285
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-11-101-244-159285

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2100 GGACAAACACGGACAGTAT 2118
|||||:|||||:|:
Db 1 GGACAAACACGGACAGUAU 19

RESULT 384
US-11-101-244-159287
; Sequence 159287, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159287
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159287

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTTCATGGAGAA 2468
:|||||:|:|||||
Db 1 UCACAGAGUUCAGGAGAA 19

RESULT 385
US-11-101-244-159288
; Sequence 159288, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159288
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159288

Query Match 0.4%; Score 19; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 424 GAAGAGACCCCTGCTGAACA 442
|||||:|||||:|:
Db 1 GAAGAGACCCUGCUGAACA 19

RESULT 386
US-11-101-244-159289
; Sequence 159289, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159289
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159289

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2132 GTACTAAGGTCTACATCGA 2150
|:|:|:|:|:|:|:|:
Db 1 GUACUAAGGUCUACAUCGA 19

RESULT 387
US-11-101-244-159290
; Sequence 159290, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159290
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159290

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;

	Matches	15;	Conservative	4;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	450	GGAAACTGCTGATCTGAAG	468							
		: : : : :								
Db	1	GGAAACUGCUGAUCUGAAG	19							

```

RESULT 388
US-11-101-244-159291
; Sequence 159291, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Reynolds, Devin
; APPLICANT: Leake, William
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13498US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159291
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159291

```

```

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels

QY      2081 GGAGAGAAGCAGAAATATTC 2099
      |||||
Db      1 GGAGAGAAGCAGAAUAUUC 19

```

```

RESULT 389
US-11-101-244-159292
; Sequence 159292, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional sirna
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159292
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159292

```

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. NO. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels

Qy	3333	GTACTGACCTGCAGGA	ACT 3351
		: : : : : : : : :	
Db	1	GUACUGACCUGCAGGA	CU 19

RESULT 390

US-11-101-244-159293	
Sequence 159293, Application US/11101244	
Publication No. US20050246794A1	
GENERAL INFORMATION:	
APPLICANT: Dharmakon, Inc.	
APPLICANT: Khvorova, Anastasia	
APPLICANT: Reynolds, Angela	
APPLICANT: Leake, Devin	
APPLICANT: Marshall, William	
APPLICANT: Scaringe, Stephen	
TITLE OF INVENTION: Functional and Hyperfunctional sirna	
FILE REFERENCE: 134990S	
CURRENT APPLICATION NUMBER: US/11/101,244	
CURRENT FILING DATE: 2005-04-07	
PRIOR APPLICATION NUMBER: 60/502,050	
PRIOR FILING DATE: 2003-09-10	
PRIOR APPLICATION NUMBER: 60/426,137	
PRIOR FILING DATE: 2002-11-14	
NUMBER OF SEQ ID NOS: 1591911	
SOFTWARE: Proprietary	
SEQ ID NO 159293	
LENGTH: 19	
TYPE: RNA	
ORGANISM: Homo sapiens	
US-11-101-244-159293	

```
Query Match      0.4%; Score 19; DB 1; Length 19;  
Best Local Similarity 68.4%; Pred. NO. 4.5e+02;  
Matches 13; Conservative 6; Mismatches 0; Indels
```

```
Qy    3454   GTGAGGAGTTGGCAATTG 3472  
       |||||:::|||:::  
Db     1    GUGAGGAGUUGGCAAUUUG 19
```

```

RESULT 391
US-11-101-244-159294
; Sequence 159294, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159294
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159294

```

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels

```
QY 3453 GGTGAGGAGTTGGCAATTT 3471
Db 1 GGUGAGGAGUUGGCAUUU 19

RESULT 392
US-11-101-244-159295
; Sequence 159295, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159295
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159295

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4.5e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2070 GCAGAGCAATGGGAGAGAA 2088
Db 1 GCAGAGCAUUGGAGAGAA 19

RESULT 393
US-11-101-244-159296
; Sequence 159296, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159296
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159296

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 3832 GCTGCTGCCTTCATATTGA 3850

QY 3453 GGTGAGGAGTTGGCAATTT 3471
Db 1 GGUGAGGAGUUGGCAUUU 19

RESULT 394
US-11-101-244-159297
; Sequence 159297, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159297
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159297

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2361 GAGCGAGGCGCTCCATCATG 2379
Db 1 GAGCGAGGCGCCUCCAUCAUG 19

RESULT 395
US-11-101-244-159298
; Sequence 159298, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159298
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159298

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 4020 GAACAGTGCCTTGGTCATC 4038
```

Db 1 GAACAGUGCCUUGUCAUC 19

RESULT 396

US-11-101-244-159299
; Sequence 159299, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/101,244

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 159299

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-159299

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1243 GCCAATAGCCACTTAACA 1261

|||||:|||||:|||||

Db 1 GCCAAUAGCCACUACA 19

RESULT 397

US-11-101-244-159300
; Sequence 159300, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/101,244

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 159300

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-159300

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1770 GGACTACGAGGTCAATAC 1788

|||||:|||||:|||||

Db 1 GGACUACGAGGCUACAAC 19

RESULT 398

US-11-101-244-159301
; Sequence 159301, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/101,244

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 159301

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-159301

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 2804 TGCGGAGGTGATCTCAT 2822

:|:|||||:|||||:|:|

Db 1 UGUGGAGGUGUGUCAU 19

RESULT 399

US-11-101-244-159302
; Sequence 159302, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/101,244

; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 159302

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-101-244-159302

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2493 GCTAAACGACGACAGTTC 2511

|:|:|:|:|:|:|:|:|:|

Db 1 GCUAAGCAGGACAGUUC 19

RESULT 400
US-11-101-244-159303
; Sequence 159303, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159303
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159303

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 1496 GGGGAGACCTGACTTTGA 1514
|||||||:|:|:|:|:|:|
Db 1 GGGGAGACCTGACUUGA 19

RESULT 401
US-11-101-244-159304
; Sequence 159304, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159304
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159304

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 965 GCGCCGACCTGACTGTGAA 983
|||||||:|:|:|:|:|:|
Db 1 GCGCCGACCTGACUGUGAA 19

RESULT 402
US-11-101-244-159305
; Sequence 159305, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159305
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159305

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
QY 4156 GAGGGTCTCTAAATTATA 4174
|||||||:|:|:|:|:|:|
Db 1 GAGGGUUCUUAUAUA 19

RESULT 403
US-11-101-244-159306
; Sequence 159306, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159306
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159306

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 4065 CCCAAGCTGTGCTCTATGA 4084
|||||||:|:|:|:|:|:|
Db 1 CCCAAGCTGTGCTCTATGA 19

RESULT 404

```
US-11-101-244-159307
; Sequence 159307, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159307
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159307
```

```
Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2082 GAGAGAAGCAGAAATATTCG 2100
    |||||
DB 1 GAGAGAGCAGAAUAUUCG 19
```

```
RESULT 405
US-11-101-244-159308
; Sequence 159308, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159308
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159308
```

```
Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1777 GAGGTCAAAATACCATGAGA 1795
    |||||
DB 1 GAGGCAAAAUACCAUGAGA 19
```

```
RESULT 406
US-11-101-244-159310
```

```
; Sequence 159310, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159310
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159310
```

```
Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1779 GGTCAAAATACCATGAGAAG 1797
    |||||
DB 1 GGCAAAAUACCAUGAGAAG 19
```

```
RESULT 407
US-11-101-244-159311
; Sequence 159311, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159311
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159311
```

```
Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 69.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 3951 GGGAACTGTTCACATATG 3969
    |||||
DB 1 GGGAACTGTTCACATATG 19
```

```
RESULT 408
US-11-101-244-159312
; Sequence 159312, Application US/11101244
```



```

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159316
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159316

```

```

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      2090 CAGAAATATTCGACAAACA 2108
      |||||:|||||
Db      1 CAGAAUAUUCGACAAACA 19

```

```

RESULT 413
US-11-101-244-159317
; Sequence 159317, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159317
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159317

```

```

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1981 GAGCAGCTGCCCTGATTG 1999
      |||||:|||||
Db      1 GAGCAGCUGGCCCUAUG 19

```

```

RESULT 414
US-11-101-244-159318
; Sequence 159318, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.

```

```

; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159318
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159318

```

```

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      460 GATCTGAAGTGGTGACAT 478
      |||:|||||:|||||
Db      1 GAUCUGAUGUGGUGACAU 19

```

```

RESULT 415
US-11-101-244-159319
; Sequence 159319, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159319
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159319

```

```

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      2500 GACGACAGTTCACAGTCA 2518
      |||||:|||||
Db      1 GACGACAGUUCACAGUCA 19

```

```

RESULT 416
US-11-101-244-159320
; Sequence 159320, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia

```

```
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159320
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159320
```

```
Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2121 CATCGGACATGGTACTAAG 2139
Db ||:|||||:||||:||||:||||
```

```
RESULT 417
US-11-101-244-159321
; Sequence 159321, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159321
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159321
```

```
Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1583 CCTTTGAGGTCACATGCATT 1601
Db ||:|||||:||||:||||:||||
```

```
RESULT 418
US-11-101-244-159322
; Sequence 159322, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
```

```
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159322
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159322
```

```
Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 428 AGACCCCTGCTGAACACAAA 446
Db ||:|||||:||||:||||:||||
```

```
RESULT 419
US-11-101-244-159323
; Sequence 159323, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159323
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159323
```

```
Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 542 GCACCTACGAGTGCTGTA 560
Db ||:|||||:||||:||||:||||
```

```
RESULT 420
US-11-101-244-159324
; Sequence 159324, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
```

```
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159324
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159324

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 4154 TGGAGGGGTTCTTAATAA 4172
Db 1 UGGAGGGGUGUCUAAAUUA 19
```

```
RESULT 421
US-11-101-244-159325
; Sequence 159325, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159325
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159325
```

```
Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 2807 GGGAGGTGATCTCATTTGG 2825
Db 1 GGGAGGUGAUGCAUUGG 19
```

```
RESULT 422
US-11-101-244-159326
; Sequence 159326, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
```

```
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159326
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159326
```

```
Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2621 ACAGCAACCTGCTCTGCAA 2639
Db 1 ACAGCAACCCGUCUGCAA 19
```

```
RESULT 423
US-11-101-244-159327
; Sequence 159327, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159327
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159327
```

```
Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 2116 TATCTCATCGACATGGTA 2134
Db 1 UAUCUCAUCGACAUUGUA 19
```

```
RESULT 424
US-11-101-244-159328
; Sequence 159328, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
```

```
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159328
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159328

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1570 GACTTGACCTATACCTTTG 1588
      |||:|||||:|||||:|
Db 1 GACUUCACCUAUCUUUG 19

RESULT 425
US-11-101-244-159329
; Sequence 159329, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159329
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159329

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 4068 CAAGCTGTGCTTATGAAG 4086
      |||:|||||:|||||:|
Db 1 CAAGCUGUGCUAUGAAG 19

RESULT 426
US-11-101-244-159330
; Sequence 159330, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159330
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159330

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 3952 GGACCTGTTTCACTATGG 3970
      |||:|||||:|||||:|
Db 1 GGACCCUGUUCACUAUGG 19

RESULT 427
US-11-101-244-159331
; Sequence 159331, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159331
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159331

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 3078 GCGGCAGCTCACTACTCA 3096
      |||:|||||:|||||:|
Db 1 GCGGCAGCCUACUACUCA 19

RESULT 428
US-11-101-244-159332
; Sequence 159332, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
```

; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159332
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159332

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
QY 2441 TCATGATTCTCACAGAGTT 2459
:||||:|||||:
Db 1 UCAUGAUUCACAGUU 19

RESULT 429
US-11-101-244-159333
; Sequence 159333, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159333
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159333

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
QY 2235 GATTGGTCAGGTGAGTTT 2253
||:|||||:
Db 1 GAUUGUGCAGGUGAGUU 19

RESULT 430
US-11-101-244-159334
; Sequence 159334, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990US
; CURRENT APPLICATION NUMBER: US/11/101,244

; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159334
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159334

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 1602 GAACGGGGTATCTCTCTTA 1620
|||||:||||:
Db 1 GAACGGGGUAUCCUUA 19

RESULT 431
US-11-101-244-159335
; Sequence 159335, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159335
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159335

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 2934 GCTGGACTGTGGCAGAAA 2952
||:|||||:
Db 1 GCUGGACUGUGGCAGAAA 19

RESULT 432
US-11-101-244-159336
; Sequence 159336, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159336
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159336

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2156 TCACCTATGAGACCCTAA 2174
:||||:|||||||:
Db 1 UCACUUAUGAAGACCCTAA 19

RESULT 433
US-11-101-244-159337
; Sequence 159337, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159337
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159337

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1587 TGAGGTCACTGCATTGAAC 1605
:||||:|||||||:
Db 1 UGAGGUCACUGCAUGAAC 19

RESULT 434
US-11-101-244-159338
; Sequence 159338, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159338
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159338

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 707 TCACCGCTCTTCTACTATGA 725
:||||:|||||||:
Db 1 UCACCGUCUUCUACUANGA 19

RESULT 435
US-11-101-244-159339
; Sequence 159339, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159339
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159339

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 2789 GTTACGGGATTGTGATGTG 2807
:||||:|||||||:
Db 1 GUUACGGGAUGUGAUGUG 19

RESULT 436
US-11-101-244-159340
; Sequence 159340, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159340
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159340

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2079 TGGGAGAGCAGCAATAT 2097
:|||||:|||||:|||||:|||||:
Db 1 UGGGAGAGCAGCAUAU 19

RESULT 437

US-11-101-244-159341
; Sequence 159341, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159341
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159341

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 4.5e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 3932 GTCATACCTTTGTGTGGA 3950
|:|:|:|:|:|:|:|:|:|:|:|:|:
Db 1 GUCAUAACUUUGUGUUGA 19

RESULT 438

US-11-101-244-159342
; Sequence 159342, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159342
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159342

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 3426 CCGCTGCGATTGCACTTTGA 3444
|||||:|||||:|||||:|||||:
Db 1 CCGCUGGAGUUGCACUUGA 19

RESULT 439

US-11-101-244-159343
; Sequence 159343, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159343
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159343

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2606 GCAACATCCTCTAGTCAACAG 2624
|||||:|||||:|||||:|||||:
Db 1 GCAACAUCUUGGUCACAG 19

RESULT 440

US-11-101-244-159344
; Sequence 159344, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14

```
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159344
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159344

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 1248 TAGCCACTTAACACCACTT 1266
      :|||||:-:|||||:-:
Db 1 UAGCCACUUAACACCAU 19

RESULT 441
US-11-101-244-159345
; Sequence 159345, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159345
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159345

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1241 CAGCCAAATAGCCACTCTAA 1259
      :|||||:-:|||||:-:
Db 1 CAGCCAAUAGCCACCUAA 19

RESULT 442
US-11-101-244-159346
; Sequence 159346, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
US-11-101-244-159346

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 3206 CTGAGGACCTGCTCCGAAT 3224
      :|||||:-:|||||:-:
Db 1 CUGAGGACCGCUGCCGAU 19

RESULT 443
US-11-101-244-159347
; Sequence 159347, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159347
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159347

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 3206 CTGAGGACCTGCTCCGAAT 3224
      :|||||:-:|||||:-:
Db 1 CUGAGGACCGCUGCCGAU 19

RESULT 444
US-11-101-244-159348
; Sequence 159348, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
US-11-101-244-159348
```



```
; SEQ ID NO 159348
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159348

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2987 TCAGCGCCCTGCACAGAT 3005
      :|||||:|||||:
Db 1 UCAGCGCCCGGACAGAU 19

RESULT 445
US-11-101-244-159349
; Sequence 159349, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159349
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159349

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2625 CAACCTCGTCTGCAAGTG 2643
      |||||:|||||:
Db 1 CAACCCGCGUCGCAAGUG 19

RESULT 446
US-11-101-244-159350
; Sequence 159350, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159350

; SEQ ID NO 159348
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159348

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2987 TCAGCGCCCTGCACAGAT 3005
      :|||||:|||||:
Db 1 UCAGCGCCCGGACAGAU 19

RESULT 445
US-11-101-244-159349
; Sequence 159349, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159349
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159349

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2625 CAACCTCGTCTGCAAGTG 2643
      |||||:|||||:
Db 1 CAACCCGCGUCGCAAGUG 19

RESULT 446
US-11-101-244-159350
; Sequence 159350, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159350
```

; TYPE: RNA		; ORGANISM: Homo sapiens	
US-11-101-244-159352		US-11-101-244-159354	
Query Match		Query Match	
Best Local Similarity 73.7%; Pred. No. 4.5e+02;		Best Local Similarity 78.9%; Pred. No. 4.5e+02;	
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;		Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;	
QY 2220 CAAGATTGAAGAGTGATT 2238		QY 4106 GAAAGGGCGGTAGTTGGT 4124	
: : :		: : :	
Db 1 CAAGAUGAAGAGGUGAUU 19		Db 1 GAAAGGGCGGUGAUGGU 19	
RESULT 449		RESULT 451	
US-11-101-244-159353		US-11-101-244-159355	
; Sequence 159353, Application US/11101244		; Sequence 159355, Application US/11101244	
; Publication No. US20050246794A1		; Publication No. US20050246794A1	
; GENERAL INFORMATION:		; GENERAL INFORMATION:	
; APPLICANT: Dharmacon, Inc.		; APPLICANT: Dharmacon, Inc.	
; APPLICANT: Khvorova, Anastasia		; APPLICANT: Khvorova, Anastasia	
; APPLICANT: Reynolds, Angela		; APPLICANT: Reynolds, Angela	
; APPLICANT: Leake, Devin		; APPLICANT: Leake, Devin	
; APPLICANT: Marshall, William		; APPLICANT: Marshall, William	
; APPLICANT: Scaringe, Stephen		; APPLICANT: Scaringe, Stephen	
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA		; TITLE OF INVENTION: Functional and Hyperfunctional siRNA	
; FILE REFERENCE: 13499US		; FILE REFERENCE: 13499US	
; CURRENT APPLICATION NUMBER: US/11/101,244		; CURRENT APPLICATION NUMBER: US/11/101,244	
; CURRENT FILING DATE: 2005-04-07		; CURRENT FILING DATE: 2005-04-07	
; PRIOR APPLICATION NUMBER: 60/502,050		; PRIOR APPLICATION NUMBER: 60/502,050	
; PRIOR FILING DATE: 2003-09-10		; PRIOR FILING DATE: 2003-09-10	
; PRIOR APPLICATION NUMBER: 60/426,137		; PRIOR APPLICATION NUMBER: 60/426,137	
; PRIOR FILING DATE: 2002-11-14		; PRIOR FILING DATE: 2002-11-14	
; NUMBER OF SEQ ID NOS: 1591911		; NUMBER OF SEQ ID NOS: 1591911	
; SOFTWARE: Proprietary		; SOFTWARE: Proprietary	
; SEQ ID NO 159353		; SEQ ID NO 159355	
; LENGTH: 19		; LENGTH: 19	
; TYPE: RNA		; TYPE: RNA	
; ORGANISM: Homo sapiens		; ORGANISM: Homo sapiens	
US-11-101-244-159353		US-11-101-244-159355	
Query Match		Query Match	
Best Local Similarity 84.2%; Pred. No. 4.5e+02;		Best Local Similarity 63.2%; Pred. No. 4.5e+02;	
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;		Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;	
QY 2104 AACACGGACAGTATCTCA 2122		QY 3758 GGTTTGTAGTCCCAACTTG 3776	
: : :		: : :	
Db 1 AACACGGACAGUAUCUA 19		Db 1 GGUUUGUAGUCCCAACUUG 19	
RESULT 450		RESULT 452	
US-11-101-244-159354		US-11-101-244-159356	
; Sequence 159354, Application US/11101244		; Sequence 159356, Application US/11101244	
; Publication No. US20050246794A1		; Publication No. US20050246794A1	
; GENERAL INFORMATION:		; GENERAL INFORMATION:	
; APPLICANT: Dharmacon, Inc.		; APPLICANT: Dharmacon, Inc.	
; APPLICANT: Khvorova, Anastasia		; APPLICANT: Khvorova, Anastasia	
; APPLICANT: Reynolds, Angela		; APPLICANT: Reynolds, Angela	
; APPLICANT: Leake, Devin		; APPLICANT: Leake, Devin	
; APPLICANT: Marshall, William		; APPLICANT: Marshall, William	
; APPLICANT: Scaringe, Stephen		; APPLICANT: Scaringe, Stephen	
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA		; TITLE OF INVENTION: Functional and Hyperfunctional siRNA	
; FILE REFERENCE: 13499US		; FILE REFERENCE: 13499US	
; CURRENT APPLICATION NUMBER: US/11/101,244		; CURRENT APPLICATION NUMBER: US/11/101,244	
; CURRENT FILING DATE: 2005-04-07		; CURRENT FILING DATE: 2005-04-07	
; PRIOR APPLICATION NUMBER: 60/502,050		; PRIOR APPLICATION NUMBER: 60/502,050	
; PRIOR FILING DATE: 2003-09-10		; PRIOR FILING DATE: 2003-09-10	
; PRIOR APPLICATION NUMBER: 60/426,137		; PRIOR APPLICATION NUMBER: 60/426,137	
; PRIOR FILING DATE: 2002-11-14		; PRIOR FILING DATE: 2002-11-14	
; NUMBER OF SEQ ID NOS: 1591911		; NUMBER OF SEQ ID NOS: 1591911	
; SOFTWARE: Proprietary		; SOFTWARE: Proprietary	
; SEQ ID NO 159354		; SEQ ID NO 159356	
; LENGTH: 19		; LENGTH: 19	
; TYPE: RNA		; TYPE: RNA	
; ORGANISM: Homo sapiens		; ORGANISM: Homo sapiens	

US-11-101-244-159356

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 422 TGAAGAGACCCCTGTGAA 440
:|||||:|||||:
Db 1 UGAGAGAGACCCUGGAA 19

RESULT 453

US-11-101-244-159357
; Sequence 159357, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159357
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159357

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 411 GGCCGCGAGCTTTGGAAGAG 429
|||||:|||||:
Db 1 GGCCGCGAGCUUGGAGAG 19

RESULT 454

US-11-101-244-159358
; Sequence 159358, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159358
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159358

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 702 GACCTTCACCGTCTTCTAC 720
|||||:|||||:
Db 1 GACCUACACCGUCUCUAC 19

RESULT 455

US-11-101-244-159359
; Sequence 159359, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159359
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159359

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 977 CTGTGAACCTGACTCGATT 995
||:|||||:|||||:
Db 1 CUGUGAACCTGACUCGAUU 19

RESULT 456

US-11-101-244-159360
; Sequence 159360, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159360
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159360

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2786 GGAGTTACGGGATTGTGAT 2804
||||:|||||:|:|:
Db 1 GGAGUUAACGGGUAUUGAU 19

RESULT 457
US-11-101-244-159361
; Sequence 159361, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101.244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159361
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159361

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2159 CTTATGAAGACCCCTAATGA 2177
|:|:|||||:|:|:
Db 1 CUUAUGAAGAGCCCUAUGA 19

RESULT 458
US-11-101-244-159362
; Sequence 159362, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101.244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159362
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159362

Query Match 0.4%; Score 19; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2101 GACAAACACGACGATC 2119
|||||:|||||:|:|:
Db 1 GACAAACACGACGUAUC 19

RESULT 459
US-11-101-244-159363
; Sequence 159363, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101.244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159363
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159363

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1769 TGGACTACGAGTCAATA 1787
:|:|:|:|:|:|:|:|:
Db 1 UGGACUACGAGGUCAAUA 19

RESULT 460
US-11-101-244-159365
; Sequence 159365, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101.244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159365
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159365

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 4.5e+02;

Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 3998 CCATCATCTGCTGTTT 4016
||||:||||:||||:|
Db 1 CCCAUCACUAGUCUGUU 19

RESULT 461
US-11-101-244-159366
; Sequence 159366, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159366
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159366

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 3262 GCCAGTGTCCAGCACATGA 3280
||||:||||:||||:|
Db 1 GCCAGUGUCCAGCACAU 19

RESULT 462
US-11-101-244-159367
; Sequence 159367, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159367
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159367

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3082 CAGCTCACTACTCAGCTT 3100
||||:||||:||||:|
Db 1 CAGCCUACUACUCAGCUU 19

RESULT 463
US-11-101-244-159368
; Sequence 159368, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159368
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159368

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2559 GCGTACCTTGCCGAGATG 2577
||||:||||:||||:|
Db 1 GCGGUACUUGCCGAGAU 19

RESULT 464
US-11-101-244-159369
; Sequence 159369, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159369
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159369

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 452 AAATGCTGATCTGAAGTG 470
|||||:|:|:|:|:|:|:|:|:|
Db 1 AAACUGCUGAUCUGAAGUG 19

RESULT 465
US-11-101-244-159370
; Sequence 159370, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159370
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159370

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 423 GGAAGAGACCTGCTGAAC 441
|||||:|:|:|:|:|:|:|:|:|
Db 1 GGAAGAGACCCUGCUGAAC 19

RESULT 466
US-11-101-244-159372
; Sequence 159372, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159372
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159372

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2183 TGAGGGAATTTGCAAAAGA 2201

Db 1 UGAGGGAAUUUGCAAAAGA 19
:|:|:|:|:|:|:|:|:|:|:|:|

RESULT 467
US-11-101-244-159373
; Sequence 159373, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159373
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159373

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 3969 GGCTCTTTTGCCCAAGTT 3987
|||:|:|:|:|:|:|:|:|:|
Db 1 GGCCUCCUUUGCCCAAGUU 19

RESULT 468
US-11-101-244-159374
; Sequence 159374, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159374
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159374

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 3779 GCTGTCACCACCAAACTCA 3797
||:|:|:|:|:|:|:|:|:|

Db 1 GCUGUACACCAACAUCUA 19

RESULT 469

US-11-101-244-159375
; Sequence 159375, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159375
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159375

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2622 CAGCAACTCGTCTCCAAA 2640

Db 1 CAGCAACCCUGCUGCAAA 19
|||||||:|:|:|:|:|

RESULT 470

US-11-101-244-159376
; Sequence 159376, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159376
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159376

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2088 AGCAGAAATATTCGGACAAA 2106

Db 1 AGCAGAAUATUUCGGACAAA 19
|||||||:|:|:|:|:|

RESULT 471

US-11-101-244-159377
; Sequence 159377, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159377
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159377

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 4136 GAAACGACGCGCGTCTT 4154

Db 1 GAAACGACGCGCGUGCUU 19
|||||||:|:|:|:|:|

RESULT 472

US-11-101-244-159378
; Sequence 159378, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159378
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159378

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 3593 AAAAGGAAGTCCCAACAT 3611

Db 1 AAAAGGAAGUGCCCAACAU 19
|||||||:|:|:|:|:|

RESULT 473
US-11-101-244-159379
; Sequence 159379, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159379
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159379

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 845 GGAAGGTGAATGTCAAGAC 863
|||||:||||:|||||
Db 1 GGAAGGUGAAGUCACAGAC 19

RESULT 474
US-11-101-244-159380
; Sequence 159380, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159380
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159380

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 504 GGAAGTGAAGCGCTGGAT 522
|||||:|||||:|||||
Db 1 GGAACUGAGCGCCUGGAU 19

RESULT 475
US-11-101-244-159381
; Sequence 159381, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159381
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159381

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 540 GGCACCTACGAAGTGTGT 558
|||||:|||||:|||||
Db 1 GGCACCTACGAAGUGUGU 19

RESULT 476
US-11-101-244-159382
; Sequence 159382, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159382
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159382

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 2063 TCAGGAAGCAGAGCAATGG 2081
:|||||:|||||:|||||
Db 1 UCAGGAAGCAGAGCAAUUG 19

RESULT 477


```
QY 1243 GCCAATAGCCACTTCAACA 1261
      |||||:|||||:|||||:
Db 1 GCCAAUAGCCACCUCAACA 19

RESULT 481
US-11-083-784-158892
; Sequence 158892, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158892
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158892

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTCATGAGAA 2468
      :|||||:|||||:|||||:
Db 1 UCACAGAGUUCAGGAGAA 19

RESULT 482
US-11-083-784-159283
; Sequence 159283, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159283
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159283

Query Match 0.4%; Score 19; DB 1; Length 19;

QY 3786 CCACCAACTCAATCATTT 3804
      |||||:|||||:|||||:
Db 1 CCACCAACUCUAUUAUU 19

RESULT 483
US-11-083-784-159284
; Sequence 159284, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159284
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159284

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3949 GAGGGAACCTGTTTCACTA 3967
      |||||:|||||:|||||:
Db 1 GAGGGAACCUUUCACUA 19

RESULT 484
US-11-083-784-159285
; Sequence 159285, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159285
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159285

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```

US-11-083-784-159285
Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2100 GGACAAACACGACGAGTAT 2118
    |||||:|||||:|:|
Db 1 GGACAAACACGACGAGAU 19

RESULT 485
US-11-083-784-159287
; Sequence 159287, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159287
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159287

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 2450 TCACAGAGTTCATGAGAA 2468
    :|||||:|:|
Db 1 UCACAGAGUUCAGGAGAA 19

RESULT 486
US-11-083-784-159288
; Sequence 159288, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159288

```

```

; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159288

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 424 GAAGAGACCTGCTGAACA 442
    |||||:|||||:|:|
Db 1 GAAGAGACCTGCTGAACA 19

RESULT 487
US-11-083-784-159289
; Sequence 159289, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159289
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159289

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 2132 GTACTAAGTCTACATCGA 2150
    |:|:|:|:|:|:|:|
Db 1 GUACUAGGUCUACAUGCA 19

RESULT 488
US-11-083-784-159290
; Sequence 159290, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14

```

[illegible]

```
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159294
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159294

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 3453 GGTGAGGAGTTGGCAATTT 3471
||:|||||:|||||:|
Db 1 GGUGAGGAGUUGGCAAUU 19

RESULT 493
US-11-083-784-159295
; Sequence 159295, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159295
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159295

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4.5e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2070 GCAGAGCAATCGGAGAGAA 2088
|||||||:|||||
Db 1 GCAGAGCAUUGGAGAGAA 19

RESULT 494
US-11-083-784-159296
; Sequence 159296, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159296
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159296

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 3832 GCTGCTGCCTTCATATTGA 3850
||:|||||:|:|:|
Db 1 GCUGCGCCUUCAUUGA 19

RESULT 495
US-11-083-784-159297
; Sequence 159297, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159297
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159297

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2361 GAGCGAGCCCTCCATCATG 2379
|||||||:|:|:|
Db 1 GAGCGAGCCUCCAUUGA 19

RESULT 496
US-11-083-784-159298
; Sequence 159298, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
```

```
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159298
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159298
```

```
Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 4020 GAACAGTGCCTTGTCATC 4038
|||||:||||:||||:||||:
Db 1 GAACAGGCCUUGGUCAU 19
```

```
RESULT 497
US-11-083-784-159299
; Sequence 159299, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159299
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159299
```

```
Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1243 GCCAATAGCCCTTACCA 1261
|||||:||||:||||:||||:
Db 1 GCCAAUAGCCACUCUACA 19
```

```
RESULT 498
US-11-083-784-159300
; Sequence 159300, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
```

```
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159300
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159300
```

```
Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1770 GGACTACGAGGTCAATAC 1788
|||||:||||:||||:||||:
Db 1 GGACUACGAGGUCAAUAC 19
```

```
RESULT 499
US-11-083-784-159301
; Sequence 159301, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159301
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159301
```

```
Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 2804 TGTGGGAGGTGATTCATT 2822
|||||:||||:||||:||||:
Db 1 UGUGGCGGAGGUGAUCAUU 19
```

```
RESULT 500
US-11-083-784-159302
; Sequence 159302, Application US/11083784
```

```
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159302
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159302

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2493 GCTAAACGACGACAGTTC 2511
Db 1 GCUAAACGACGACAGUUC 19
```

```
RESULT 501
US-11-083-784-159303
; Sequence 159303, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159303
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159303

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 1496 GGGGAGACCTGACTTTGA 1514
Db 1 GGGGAGACCGACUUGA 19
```

```
RESULT 502
US-11-083-784-159304
; Sequence 159304, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159304
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159304
```

```
Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 965 GCGCCAGCTGACTGTGAA 983
Db 1 GCGCCAGCTGACUGUGAA 19
```

```
RESULT 503
US-11-083-784-159305
; Sequence 159305, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159305
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159305
```

```
Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 4156 GAGGGTTCTTAATATA 4174
```

Db 1 GAGGGGUUCUAAAUUAUA 19

RESULT 504

US-11-083-784-159306

; Sequence 159306, Application US/11083784

; Publication No. US20050245475A1

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/083,784

; CURRENT FILING DATE: 2005-03-18

; PRIOR FILING DATE: US/10/714,333

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 159306

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-083-784-159306

Query Match 0.4%; Score 19; DB 1; Length 19;

Best Local Similarity 73.7%; Pred. No. 4.5e+02;

Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 4066 CCCAAGCTGTCTCATGA 4084

|||||:|:|:|:|:|:|:|:|

Db 1 CCCAAGCUGUGUCCUAUGA 19

RESULT 505

US-11-083-784-159307

; Sequence 159307, Application US/11083784

; Publication No. US20050245475A1

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/083,784

; CURRENT FILING DATE: 2005-03-18

; PRIOR FILING DATE: US/10/714,333

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 159307

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-083-784-159307

Query Match 0.4%; Score 19; DB 1; Length 19;

Best Local Similarity 84.2%; Pred. No. 4.5e+02;

Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2082 GAGAGAAGCAGATATTCG 2100

|||||:|:|:|:|:|:|:|:|

Db 1 GAGAGAAGCAGAAUUCG 19

RESULT 506

US-11-083-784-159308

; Sequence 159308, Application US/11083784

; Publication No. US20050245475A1

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/083,784

; CURRENT FILING DATE: 2005-03-18

; PRIOR FILING DATE: US/10/714,333

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 159308

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-083-784-159308

Query Match 0.4%; Score 19; DB 1; Length 19;

Best Local Similarity 84.2%; Pred. No. 4.5e+02;

Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1777 GAGTCAAAATACCATGAGA 1795

|||||:|:|:|:|:|:|:|:|

Db 1 GAGGUCAAAAUCCCAUGAGA 19

RESULT 507

US-11-083-784-159310

; Sequence 159310, Application US/11083784

; Publication No. US20050245475A1

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/083,784

; CURRENT FILING DATE: 2005-03-18

; PRIOR FILING DATE: US/10/714,333

; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 159310

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-083-784-159310

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1779 GGTCAATACCATGAGAG 1797
||:||||:||||:|||||
DB 1 GGCAAAUACCAUGAGAAG 19

RESULT 508
US-11-083-784-159311
; Sequence 159311, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159311
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159311

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 3951 GGGAACTGTTTCACTAG 3969
||||||:|:|:|:|
DB 1 GGGAACTGUUUCACUAG 19

RESULT 509
US-11-083-784-159312
; Sequence 159312, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159312
; LENGTH: 19
; TYPE: RNA

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1779 GGTCAATACCATGAGAG 1797
||:||||:||||:|||||
DB 1 GGCAAAUACCAUGAGAAG 19

RESULT 508
US-11-083-784-159311
; Sequence 159311, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159311
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159311

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 3951 GGGAACTGTTTCACTAG 3969
||||||:|:|:|:|
DB 1 GGGAACTGUUUCACUAG 19

RESULT 509
US-11-083-784-159312
; Sequence 159312, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159312
; LENGTH: 19
; TYPE: RNA

; ORGANISM: Homo sapiens
US-11-083-784-159312

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 3363 GGACACGCTCCCATTT 3381
|||||:|:|:|:|
DB 1 GGACACGCCUCCCAUUD 19

RESULT 510
US-11-083-784-159313
; Sequence 159313, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159313
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159313

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2295 GGAGAGCTGTGCGCAATC 2313
|||||:|:|:|:|
DB 1 GGAGAGCUGUGGCAUUC 19

RESULT 511
US-11-083-784-159314
; Sequence 159314, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159318
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159318

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 460 GATCTGAAGTGGTACAT 478
||:||||:||||:|
Db 1 GAUCUGAAGUGGUGACAU 19

RESULT 516

US-11-083-784-159319
; Sequence 159319, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159319
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159319

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2500 GACGACAGTTCACAGTCA 2518
|||||||:||||:|
Db 1 GACGACAGUUCACAGUCA 19

RESULT 517

US-11-083-784-159320
; Sequence 159320, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784

; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159320
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159320

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 2121 CATCGGACATGGTACTAAG 2139
||:||||:||||:|
Db 1 CAUCGGACUGGUCUAAG 19

RESULT 518

US-11-083-784-159321
; Sequence 159321, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159321
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159321

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 1583 CCTTTGAGTCACTGCATT 1601
||:||||:||||:|
Db 1 CCUUGAGGUCACUGCAU 19

RESULT 519

US-11-083-784-159322
; Sequence 159322, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

```
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159322
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159322

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 428 AGACCTGCTGAACACAAA 446
|||||:|||||
Db 1 AGACCCUGUGACACAAA 19

RESULT 520
US-11-083-784-159323
; Sequence 159323, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159323
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159323

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 542 GCACCTACGAAGTGTGA 560
|||||:|||||
Db 1 GCACCUACGAAGUGUGA 19

RESULT 521
US-11-083-784-159324
; Sequence 159324, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
```

```
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159324
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159324

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 4154 TCGAGGGGTTCTTAATTA 4172
|||||:|||||
Db 1 UGGAGGGGUUCUAAAUUA 19

RESULT 522
US-11-083-784-159325
; Sequence 159325, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159325
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159325

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2807 GCGAGGTGATGTCATTGG 2825
|||||:|||||
Db 1 GCGAGGUGAUGUCAUUGG 19

RESULT 523
US-11-083-784-159326
; Sequence 159326, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159326
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159326

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2621 ACAGCAACCTGCTGTGCAA 2639
Db 1 ACAGCAACCTGCTGTGCAA 19

RESULT 524
US-11-083-784-159327
; Sequence 159327, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159327
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159327

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2116 TATCTCATCGGACATGGTA 2134
Db 1 UAUCUACUGGACUGGUA 19

RESULT 525
US-11-083-784-159328
```

```
; Sequence 159328, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159328
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159328

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1570 GACTTCACCTATACCTTTG 1588
Db 1 GACUUCACCUAUACCUUG 19

RESULT 526
US-11-083-784-159329
; Sequence 159329, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159329
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159329

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 4068 CAAGCTGTGTCCTATGAAG 4086
Db 1 CAAGCUGUGUCCUAUGAAG 19
```

```
RESULT 527
US-11-083-784-159330
; Sequence 159330, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159330
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159330

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy      3952  GGAACCTGTTTCACTATGG 3970
          |||||:|:|:|:|:|:|:|
Db      1  GGAACCUUUUUCACUAGG 19

RESULT 528
US-11-083-784-159331
; Sequence 159331, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159331
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159331

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy      3078  GCGCAGCGCTCACTACTCA 3096
          |||||:|:|:|:|:|:|:|
Db      1  GCGCAGCCUUCACUACUCA 19

RESULT 529
US-11-083-784-159332
; Sequence 159332, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159332
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159332

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy      2441  TCATGATTCTCACAGAGTT 2459
          :|:|:|:|:|:|:|:|:|:|
Db      1  UCAUGAUUUCUCACAGAGUU 19

RESULT 530
US-11-083-784-159333
; Sequence 159333, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159333
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159333

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
```

Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 2235 GATTGTCGAGTGAGTTT 2253
||:||||:||||:|
DB 1 GAUUGUGCAGGUGAGUUU 19

RESULT 531

US-11-083-784-159334
; Sequence 159334, Application US/11083784
; Publication No. US20050245475A1

; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18

; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159334

; LENGTH: 19
; TYPE: RNA

; ORGANISM: Homo sapiens
US-11-083-784-159334

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1602 GAACGGGTATCTTCCTTA 1620
|||||||:||||:|
DB 1 GAACGGGGUAUCCUCCUA 19

RESULT 532

US-11-083-784-159335

; Sequence 159335, Application US/11083784
; Publication No. US20050245475A1

; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18

; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159335

; LENGTH: 19
; TYPE: RNA

; ORGANISM: Homo sapiens
US-11-083-784-159335

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2934 GCTGGACTGTTGGCAGAA 2952
||:||||:||||:|
DB 1 GCUGGACUGUUGGCAGAA 19

RESULT 533

US-11-083-784-159336

; Sequence 159336, Application US/11083784
; Publication No. US20050245475A1

; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18

; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159336

; LENGTH: 19
; TYPE: RNA

; ORGANISM: Homo sapiens
US-11-083-784-159336

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2156 TCACCTTATGAAGACCCCTAA 2174
||:||||:||||:|
DB 1 UCACUUAUGAAGACCCUA 19

RESULT 534

US-11-083-784-159337

; Sequence 159337, Application US/11083784
; Publication No. US20050245475A1

; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18

; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159337

; LENGTH: 19

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159337

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 1587 TGAGGTCACTGCATTTGAAC 1605
      :||||:||||:||||:
Db 1 UGAGGUCACUGCAUGAAC 19

RESULT 535
US-11-083-784-159338
; Sequence 159338, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159338
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159338

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 707 TCACCGTCTTCTACTATGA 725
      :||||:||||:||||:
Db 1 UCACCGUCUCUACUAUGA 19

RESULT 536
US-11-083-784-159339
; Sequence 159339, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary
; SEQ ID NO 159339
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159339

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2079 TGGGAGAGAGCAGCATAT 2097
      :||||:||||:||||:
Db 1 UGGGAGAGAGCAGCAUAU 19

RESULT 538
US-11-083-784-159341
; Sequence 159341, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
```



```

; PRIOR APPLICATION NUMBER: 60/426,137
;
; PRIOR FILING DATE: 2002-11-14
;
; NUMBER OF SEQ ID NOS: 1591911
;
; SOFTWARE: Proprietary
;
; SEQ ID NO 159341
;
; LENGTH: 19
;
; TYPE: RNA
;
; ORGANISM: Homo sapiens
US-11-083-784-159341

```

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%;
Matches 11; Conservative 8; Mismatches 0; Indels
Pred. No. 4.5e+02;

Qy 3932 GTCATAACTTTGTGTTGA 3950
| : | : | : | : | : | :
Db 1 GUCAUACUUUGUGUUGGA 19

RESULT 539
US-11-083-784-159342

```

: Sequence 159342, Application US/11083784
: Publication No. US20050245475A1
: GENERAL INFORMATION:
: APPLICANT: Dharmacon, Inc.
: APPLICANT: Khvorova, Anastasia
: APPLICANT: Reynolds, Angela
: APPLICANT: Leake, Devin
: APPLICANT: Marshall, William
: APPLICANT: Scaringe, Stephen
: TITLE OF INVENTION: Functional and Hyper
: FILE REFERENCE: I3499US
: CURRENT APPLICATION NUMBER: US/11/083,7
: CURRENT FILING DATE: 2005-03-18
: PRIOR APPLICATION NUMBER: US/10/714,333
: PRIOR FILING DATE: 2003-11-14
: PRIOR APPLICATION NUMBER: 60/502,050
: PRIOR FILING DATE: 2003-09-10
: PRIOR APPLICATION NUMBER: 60/426,137
: PRIOR FILING DATE: 2002-11-14
: NUMBER OF SEQ ID NOS: 1591911
: SOFTWARE: Proprietary
: SEQ ID NO 159342
: LENGTH: 19
: TYPE: RNA
: ORGANISM: Homo sapiens
US-11-083-784-159342

```

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. NO. 4.5e+02;
Matches 13; Conservative 6; Mismatches 0; Indels

Qy 3426 CCGCTGGATTGCACCTTGA 3444
Db 1 CCGCUGGAUUGCACUUUGA 19

```

RESULT 540
US-11-083-784-159343
; Sequence 159343, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khivrotova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsinge, Stephen
; TITLE OF INVENTION: Functional and Hyper
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,7
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333

```

```

, PRIOR FILING DATE: 2003-11-14
, PRIOR APPLICATION NUMBER: 60/502,050
, PRIOR FILING DATE: 2003-09-10
, PRIOR APPLICATION NUMBER: 60/426,137
, PRIOR FILING DATE: 2002-11-14
, NUMBER OF SEQ ID NOS: 1591911
, SOFTWARE: Proprietary
, SEQ ID NO 159343
, LENGTH: 19
, TYPE: RNA
, ORGANISM: Homo sapiens
US-11-083-784-159343

```

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels

Qy 2606 GCAACATCCTAGTCAACAG 2624
|||||:|:|:|
db 1 GCAACAUCCUAGUCAACAG 19

RESULT 541

```

US-11-083-784-159344
; Sequence 159344, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsinge, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159344
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159344

```

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14: Conservative 5: Mismatches 0: Indels

OY 1248 TAGCCACTCTAACACCATT 1266
:
DQ 1 UAGCCACUCUAAACACCAUU 19

RESULT 542

```

RES001 312
US-11-083-784-159345
; Sequence 159345, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsge, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US

```

```
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159345
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159345

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1241 CAGCCAAATAGCCACTCTAA 1259
      |||||:|||||:|:|
Db 1 CAGCCAAUAGCCACUCUA 19

RESULT 543
US-11-083-784-159346
; Sequence 159346, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159346
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159346

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 842 CCGGAAGGTGAATGTCAA 860
      |||||:|||||:|:|
Db 1 CCGGAGGAGUGAUGUCAA 19

RESULT 544
US-11-083-784-159347
; Sequence 159347, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
```

```
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159347
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159347

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 3206 CTGAGGACCTGCTCCGAAT 3224
      |:|||||:|:|:|
Db 1 CUGAGGAGCCUGCCGAAU 19

RESULT 545
US-11-083-784-159348
; Sequence 159348, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159348
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159348

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2987 TCAGCGCCCTGGACAGAT 3005
      :|||||:|:|:|
Db 1 UCAGCGCCUGGACAGAU 19

RESULT 546
US-11-083-784-159349
; Sequence 159349, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
```

; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159349
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159349

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 2625 CAACCTCGTCTGCAAGTG 2643
|||||:|:|:|:|:|:|:|:
Db 1 CAACCCUGCUGCAAGUG 19

RESULT 547

US-11-083-784-159350
; Sequence 159350, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159350
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159350

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 2602 GCTCGCAACATCTTAGTCA 2620
|||||:|:|:|:|:|:|:|:
Db 1 GCUGGCAACAUCCUAGUCA 19

RESULT 548

US-11-083-784-159351
; Sequence 159351, Application US/11083784
; Publication No. US20050245475A1

; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159351
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159351

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 2126 GACATGGTACTAAGTCTA 2144
|||||:|:|:|:|:|:|:|:
Db 1 GACAUGGUAACUAGGUCA 19

RESULT 549

US-11-083-784-159352
; Sequence 159352, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159352
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159352

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 2220 CAAGTTGAAGAGTGATT 2238
|||||:|:|:|:|:|:|:|:
Db 1 CAAGAUGAAGAGGUCAU 19

RESULT 550

```
US-11-083-784-159353
; Sequence 159353, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159353
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159353

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2104 AAACACGGACAGTATCTCA 2122
      |||||:|||||:|:|:|
Db 1 AAACACGGACAGUAUCUA 19

RESULT 551
US-11-083-784-159354
; Sequence 159354, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159354
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159354

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 4106 GAAAGGCGCGTAGTGTGGT 4124
      |||||:|||||:|:|:|
Db 1 GAAAGGCGCGGAGUUGGU 19
```

```
RESULT 552
US-11-083-784-159355
; Sequence 159355, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159355
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159355

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 4.5e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 3758 GGTTCGTAGTCCCACTTG 3776
      ||::|:|:|:|:|:|:|
Db 1 GGUUGAGUCCCAACUUG 19

RESULT 553
US-11-083-784-159356
; Sequence 159356, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159356
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159356

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```



```
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159365
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159365

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 4.5e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 3998 CCCATCATCATGTCGTGTTT 4016
      |||||:||||:||||:|:|:|:|:|:|:|
Db 1 CCCAUCAUCAUCUGUCUGUUU 19

RESULT 562
US-11-083-784-159366
; Sequence 159366, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159366
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159366

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 3262 GCCAGTGTCGACGACATCA 3280
      |||||:||||:||||:|:|:|:|:|:|:|
Db 1 GCCAGUGUCCAGCACAUCA 19

RESULT 563
US-11-083-784-159367
; Sequence 159367, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
```

```
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159367
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159367

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3082 CAGCCTCACTACTCAGCTT 3100
      |||||:||||:||||:|:|:|:|:|:|:|
Db 1 CAGCCUACUACUCAGCUU 19

RESULT 564
US-11-083-784-159368
; Sequence 159368, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159368
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159368

Query Match          0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2559 GCGGTACCTTCCGAGATG 2577
      |||||:||||:||||:|:|:|:|:|:|:|
Db 1 GCGGUACCUUGCCGAGAUG 19

RESULT 565
US-11-083-784-159369
; Sequence 159369, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
```

[illegible]

; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159374
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159374

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 3779 GCTGTCACCACTCA 3797
||:|||||||:|
DB 1 GCUGUACCAACUACA 19

RESULT 570
US-11-083-784-159375
; Sequence 159375, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159375
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159375

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2622 CAGCAACCTGCTCTCAAA 2640
||:|||||||:|
DB 1 CAGCAACCTGCTCTCAAA 19

RESULT 571
US-11-083-784-159376
; Sequence 159376, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159376
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159376

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2088 AGCAGATATTCGACAAA 2106
||:|||||||:|
DB 1 AGCAGATATTCGACAAA 19

RESULT 572
US-11-083-784-159377
; Sequence 159377, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159377
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159377

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 4136 GAAACGACCGCGTGCTT 4154
||:|||||||:|
DB 1 GAAACGACCGCGTGCTT 19

RESULT 573
US-11-083-784-159378
; Sequence 159378, Application US/11083784

```

; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: US/10/714,333
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159378
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159378

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 4.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 3593 AAAAGGAAGTGCACCAACAT 3611
Db 1 AAAAGGAAGUGCCCAACAU 19

```

```

RESULT 574
US-11-083-784-159379
; Sequence 159379, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: US/10/714,333
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159379
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159379

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 845 GGAAGGTGAATGTCAAGAC 863
Db 1 GGAAGGUGAAGUCACAGAC 19

```

```

RESULT 575
US-11-083-784-159380
; Sequence 159380, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: US/10/714,333
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159380
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159380

```

```

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.5e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 504 GGAACGTGACGGCCTGGAT 522
Db 1 GGAACUGAGCGGCCUGGAU 19

```

```

RESULT 576
US-11-083-784-159381
; Sequence 159381, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: US/10/714,333
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159381
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159381

```

```

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.5e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 540 GCGCACCTACGAAGTGTGT 558

```

Query Match 0.4% Score 19 DB 1: Length 21:

```
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-34

Query Match      0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      427 GAGACCCCTGCTGACACAA 445
      |||||:|:|:|:|:|:|
Db      1 GAGACCCUGUGACACAA 19

RESULT 581
US-10-949-720-36
; Sequence 36, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 36
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-36

Query Match      0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 5.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      849 GGTGAATGTCAGACGCTG 867
      |||||:|:|:|:|:|:|
Db      1 GGUGAUGUGACAGCGCUG 19

RESULT 582
US-10-949-720-40
; Sequence 40, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 36
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-40

Query Match      0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      427 GAGACCCCTGCTGACACAA 445
      |||||:|:|:|:|:|:|
Db      1 GAGACCCUGUGACACAA 19

RESULT 584
US-10-949-720-286
; Sequence 286, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 69
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-69

Query Match      0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      2679 CTCCTCCGATCCACCTAC 2697
      |:|:|:|:|:|:|:|:|
Db      1 CUCUCCGACUCCACCUAC 19

RESULT 583
US-10-949-720-69
; Sequence 69, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 69
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-69

Query Match      0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      2679 CTCCTCCGATCCACCTAC 2697
      |:|:|:|:|:|:|:|:|
Db      1 CUCUCCGACUCCACCUAC 19
```

; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 286
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-286

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 427 GAGACCTGCTCAACACAA 445
|||||:|:|:|:|:|:|
DB 1 GAGACCCUGUGAACACAA 19

RESULT 585
US-10-949-720-287
; Sequence 287, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 287
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-287

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 5.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 849 GGTGAATGTCAAGACGCTG 867
|||||:|:|:|:|:|:|
DB 1 GGUGAUGUCAGACGCTG 19

RESULT 586
US-10-949-720-289
; Sequence 289, Application US/10949720
; Publication No. US20050249736A1

; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 289
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-289

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2679 CTCCTCCGATCCACCTAC 2697
|:|:|:|:|:|:|:|:|:|:|:|:|
DB 1 CUCUCCGAUCCACCUAC 19

RESULT 587
US-10-949-720-290
; Sequence 290, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 290
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-290

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2679 CTCCTCCGATCCACCTAC 2697
|:|:|:|:|:|:|:|:|:|:|:|:|

```
Db      1  CUCUUCGACUCCACCACUAC 19

RESULT 588
US-10-770-726-16917
; Sequence 16917, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16917
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-770-726-16917

Query Match      0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      2929  CTCATGCTGGACTGTGGC 2947
          |::|::|::|::|::|::|::|
Db      1  CUCAUGCUGACUGUGGC 19

RESULT 589
US-10-770-726-17547
; Sequence 17547, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17547
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-770-726-17547

Query Match      0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      2933  TGTGGACTGTGGCAGAA 2951
          :|::|::|::|::|::|::|
Db      1  UGCUGGACUGUGGCAGAA 19

RESULT 590
US-10-914A-1216690
; Sequence 1216690, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01

QY      1414  CTGGAGTCTGGTGGCCGAGAGG 1435
```

```
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1216690
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1216690

Query Match      0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      3407  AGGCCCCCAGCCCTGTGCC 3425
          |||::|::|::|::|::|::|
Db      3  AGGCCCCCAGCCCGUGGCC 21

RESULT 591
US-10-310-914A-207817/c
; Sequence 207817, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 207817
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-207817

Query Match      0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 6e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3901  TGTTCCTTCGTTTGTCTTCT 3922
          |||::|::|::|::|::|::|
Db      22  TGTTCCTTCGTTTGTCTTCT 1

RESULT 592
US-10-310-914A-287071/c
; Sequence 287071, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 287071
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-287071

Query Match      0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 6e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Db 22 CTAGAGTCTGGCGGCCGAGAGG 1

RESULT 593

```

US-10-310-914A-1125431
; Sequence 1125431, Application US/10310914A
; Publication No. US20060000322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvoznat
; TITLE OF INVENTION: Bioinformatically determined
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1386402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1125431
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1125431

```

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 13.6%; Pred. No. 6e+02;
Matches 3; Conservative 17; Mismatches 2; Indels 0; Gaps 0;

Qy 3897 TTTTGTTCCTCGTTTGTT 3918
:::|::: : |:::|:::
Dd 1 UUUUGUUUUGUUUGUU 22

RESULT 594

```

US-10-310-914A-200253
; Sequence 200253, Application US/10310914A
; Publication NO. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically derived
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200 CPU501
; CURRENT APPLICATION NUMBER: US/10/310,914
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 200253
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-200253

```

Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 81.8%; Pred. No. 6.4e+02;
Matches 18; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 3614 CCCAGCCTCCCCAGGTGCCCC 3635
|||||:|||||:|||||
Db 1 CCCACCTTCCCCCAGCUGCCCC 22

RESULT 595

US-1031-393
US-1031-914A-456565/c
; Sequence 456565, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kyzat
; TITLE OF INVENTION: Bioinformatically deter
; TITLE OF INVENTION: use thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10310.914A

```

; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
;
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 456565
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-456565

```

Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 90.9%; Pred. No. 6.4e+02;
Matches 20; Conservative 0; Mismatches 2; Indels

Qy 1572 CTTACCTATACCTTTGAGGTC 1593
| | | | | | | | | |
Db 23 CATCAACCAATACCTTTGAGGTC 2

RESULT 596

```

US-10-310-914A-497207
; Sequence 497207, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuzat
; TITLE OF INVENTION: Bioinformatically de
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,91
; CURRENT FILING DATE: 2008-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 497207
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-497207

```

Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 6.4e+02;
Matches 19: Conservative 1; Mismatches 2; Indels

Qy 1064 CCCCTGGCCCCCAGCCCCAGCCT 1085
 |||||
 1 CCCCCAGCCCCCAGCCCCAGCCU 22
 Db

RESULT 597

```

US-10-310-914A-1141590
; Sequence 1141590, Application US/10310914A
; Publication NO. US20060030322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwitch, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically deter
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087, 0200 CPUs01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 1141590
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Human
; US-10-310-914A-1141590

```

Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 86.4%; Pred. No. 6.4e+02;
Matches 19: Conservative 1; Mismatches 2; Indels

Qy 828 TGGGCCGAGGCCACCGGAAG 849

Db 1 UGGGGCGAGGGCCACCCCGAAG 22

RESULT 598

US-10-310-914A-161881

; Sequence 161881, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvazat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087, 0200, CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 161881

; LENGTH: 20

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-161881

Query Match 0.4%; Score 18.4; DB 1; Length 20;

Best Local Similarity 80.0%; Pred. No. 5.7e+02;

Matches 16; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3605 CCAACATCTCCAGCCTCC 3624

|||||:|||||:|||||

Db 1 CCAACCUCCAGCCTCC 20

RESULT 599

US-10-310-914A-914666/c

; Sequence 914666, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvazat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087, 0200, CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 914666

; LENGTH: 20

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-914666

Query Match 0.4%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 5.7e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 170 CCGCGCGCGCGCGCGCGG 189

|||||:|||||:|||||

Db 20 CCGCGCGCGCGCGCGCGG 1

RESULT 600

US-10-770-726-16895

; Sequence 16895, Application US/10770726

; Publication No. US20050266409A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Brown, Eugene

; APPLICANT: Liu, Wei

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING

; TITLE OF INVENTION: CANCERS

; FILE REFERENCE: AM101079 (031896-010000)

; CURRENT APPLICATION NUMBER: US/10/770,726

; CURRENT FILING DATE: 2004-02-04

; NUMBER OF SEQ ID NOS: 48640

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 16913

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-770-726-16913

Query Match 0.4%; Score 18.4; DB 1; Length 21;

Best Local Similarity 95.0%; Pred. No. 6.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

; CURRENT FILING DATE: 2004-02-04

; NUMBER OF SEQ ID NOS: 48640

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 16895

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-770-726-16895

Query Match 0.4%; Score 18.4; DB 1; Length 21;

Best Local Similarity 95.0%; Pred. No. 6.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2620 AACAGCAACCTGCTCTGCAA 2639

|||||:|||||:|||||

Db 1 AACAGCAACCTGCTCTGCAA 20

RESULT 601

US-10-770-726-16910

; Sequence 16910, Application US/10770726

; Publication No. US20050266409A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Brown, Eugene

; APPLICANT: Liu, Wei

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING

; TITLE OF INVENTION: CANCERS

; FILE REFERENCE: AM101079 (031896-010000)

; CURRENT APPLICATION NUMBER: US/10/770,726

; CURRENT FILING DATE: 2004-02-04

; NUMBER OF SEQ ID NOS: 48640

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 16910

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-770-726-16910

Query Match 0.4%; Score 18.4; DB 1; Length 21;

Best Local Similarity 95.0%; Pred. No. 6.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2863 ATCAATGCCATTGAACAGGA 2882

|||||:|||||:|||||

Db 2 ATCAATGCCATTGAACAGGA 21

RESULT 602

US-10-770-726-16913

; Sequence 16913, Application US/10770726

; Publication No. US20050266409A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Brown, Eugene

; APPLICANT: Liu, Wei

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING

; TITLE OF INVENTION: CANCERS

; FILE REFERENCE: AM101079 (031896-010000)

; CURRENT APPLICATION NUMBER: US/10/770,726

; CURRENT FILING DATE: 2004-02-04

; NUMBER OF SEQ ID NOS: 48640

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 16913

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-770-726-16913

Query Match 0.4%; Score 18.4; DB 1; Length 21;

Best Local Similarity 95.0%; Pred. No. 6.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;


```
Qy 2866 AATGCCATTGACAGGACTA 2885
      |||||
Db 1 AATGCCATTGACAGGACTA 20

RESULT 603
US-10-770-726-17541
; Sequence 17541, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17541
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-770-726-17541

Query Match 0.4%; Score 18.4; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 6.1e+02;
Matches 13; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 2925 CCAGTCATGCTGGACTGTT 2944
      |||||
Db 1 CCAACUCAUGCGACUGUU 20

RESULT 604
US-10-770-726-18110
; Sequence 18110, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18110
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-18110

Query Match 0.4%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 6.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2938 GACTGTTGGCAGAGGACCG 2957
      |||||
Db 1 GACTGTTGGCAGAGGACCG 20

RESULT 605
US-10-770-726-18401
; Sequence 18401, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18401
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-18401

Query Match 0.4%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 6.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 898 TACCTGGCCTTCAGGACCA 917
      |||||
Db 1 TACCTGGCCTTCAGGACCA 20

RESULT 606
US-10-310-914A-161858
; Sequence 161858, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161858
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-161858

Query Match 0.4%; Score 18.4; DB 1; Length 22;
Best Local Similarity 80.0%; Pred. No. 6.6e+02;
Matches 16; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 3606 CAACATCTCCAGCCTCCCC 3625
      |||||
Db 1 CAACCTUCGCCAGCCUCCCC 20

RESULT 607
US-10-310-914A-161859
; Sequence 161859, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161859
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-161859

Query Match 0.4%; Score 18.4; DB 1; Length 22;
Best Local Similarity 80.0%; Pred. No. 6.6e+02;
Matches 16; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
Matches 16; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3606 CAACATCTCCAGGCTCCCC 3625
    |||| :||:|||||:||||
Db 1 CAACCCUCCCGCCGCCGCC 20

RESULT 608
US-10-949-720-47/c
; Sequence 47, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 47
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-47

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 499 TGGGAGGAACCTGAGCGGC 516
    |||||:|||||:|||||
Db 18 TGGGAGGAACCTGAGCGGC 1

RESULT 609
US-10-949-720-48/c
; Sequence 48, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 48
; LENGTH: 18
; TYPE: DNA
```

```
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-48

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 692 CCTGCAAGGAGACCTTCA 709
    |||||:|||||:|||||
Db 18 CCTGCAAGGAGACCTTCA 1

RESULT 610
US-10-949-720-227/c
; Sequence 227, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 227
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-227

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 499 TGGGAGGAACCTGAGCGGC 516
    |||||:|||||:|||||
Db 18 TGGGAGGAACCTGAGCGGC 1

RESULT 611
US-10-949-720-228/c
; Sequence 228, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; TITLE OF INVENTION: ANGIOGENESIS AND TUMOR GROWTH
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2003-03-12
```

; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 228
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-228

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 692 CCTGAAGGAGACCTTCA 709
Db 18 CCTGAAGGAGACCTTCA 1
|||||

RESULT 612

US-10-310-914A-153257/c
; Sequence 153257, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153257
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153257

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4039 CCACATCCCGGACCCG 4056
Db 18 CCACATCCCGGACCCG 1
|||||

RESULT 613

US-10-310-914A-153262/c
; Sequence 153262, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153262
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153262

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3358 CCCAGGGACCCGCTCC 3375
Db 18 CCCAGGGACCCGCTCC 1
|||||

RESULT 614

US-10-310-914A-153275/c
; Sequence 153275, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153275
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153275

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3459 GAGTTGGCAATTTGGAGA 3476
Db 18 GAGTTGGCAATTTGGAGA 1
|||||

RESULT 615

US-10-310-914A-153278/c
; Sequence 153278, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153278
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153278

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3827 CCCAGCTGCTGCCTTCA 3844
Db 18 CCCAGCTGCTGCCTTCA 1
|||||

RESULT 616

US-10-310-914A-153288/c
; Sequence 153288, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153288
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153288

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
; FILE REFERENCE: 06087, 0200 CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153288
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153288

Query Match      0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3508 GGGGAAATCACCACCCCA 3525
Db 18 GGGGAAATCACCACCCCA 1

RESULT 617
US-10-310-914A-153289/c
; Sequence 153289, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuvatz
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087, 0200 CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153289
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153289

Query Match      0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3344 CAGGAACCTCCACCCCA 3361
Db 18 CAGGAACCTCCACCCCA 1

RESULT 618
US-11-101-244-159271
; Sequence 159271, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159271
; LENGTH: 19
; TYPE: RNA
```

```
; ORGANISM: Homo sapiens
US-11-101-244-159271

Query Match      0.4%; Score 18; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 5.7e+02;
Matches 15; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2362 AGCGAGGCTCCATCATG 2379
Db 2 AGCGAGGCCUCCAUG 19

RESULT 619
US-11-101-244-159286
; Sequence 159286, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159286
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159286

Query Match      0.4%; Score 18; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.7e+02;
Matches 11; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 1570 GACTTCACCTATACCTTT 1587
Db 2 GACUCCACCUAUACCUU 19

RESULT 620
US-11-083-784-159271
; Sequence 159271, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159271
; LENGTH: 19
```

; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159271

Query Match 0.4%; Score 18; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 5.7e+02;
Matches 15; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 2362 AGCGAGGCTCCATCATG 2379
Db 2 AGCGAGGCCUCCAUCAUG 19

RESULT 621

US-11-083-784-159286
; Sequence 159286, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159286
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159286

Query Match 0.4%; Score 18; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 5.7e+02;
Matches 11; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 1570 GACTTCACCTATACCTTT 1587
Db 2 GACUUCACCUAUACCUU 19

RESULT 622

US-10-770-726-17478
; Sequence 17478, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17478
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-770-726-17478

Query Match 0.4%; Score 18; DB 1; Length 21;

Best Local Similarity 72.2%; Pred. No. 6.7e+02;
Matches 13; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 2508 GTTCACAGTCATCCAGCT 2525
Db 1 GUUCACAGUCAUCCAGCU 18

RESULT 623

US-10-770-726-17544
; Sequence 17544, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17544
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-770-726-17544

Query Match 0.4%; Score 18; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 6.7e+02;
Matches 12; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 2929 CTCATGCTGACTGTTCG 2946
Db 2 CUCAUGCUGACUGUUGG 19

RESULT 624

US-10-310-914A-871069
; Sequence 871069, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 871069
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-871069

Query Match 0.4%; Score 18; DB 1; Length 22;
Best Local Similarity 88.9%; Pred. No. 7.2e+02;
Matches 16; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1070 GCCCCAGCCCCAGCCTCT 1087
Db 5 GCCCCAGCCCCAGCCUCU 22

RESULT 625

US-10-770-726-16893
; Sequence 16893, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

```

US-10-770-726-16911

Query Match      0.4%; Score 17.8; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 7e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY    2864   TCAATGCCATTGACAGGACT 2884
DB          :|||:|||:|||:|||:|||:
           1 UCAAUGCCAUGAGCAGGAUU 21

RESULT 628
US-10-770-726-17474
; Sequence 17474, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17474
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17474

Query Match      0.4%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY    2451   CACAGAGTTCATCGAGAAGG 2471
DB          ||| ||||||||| ||| ||
           1 CACCGAGTTCATCGAGAATGG 21

RESULT 629
US-10-770-726-17504
; Sequence 17504, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17504
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17504

Query Match      0.4%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY    2622   CAGCAACCTCGTCTGCAAAGT 2642
DB          ||||||||| ||||||||| ||
           1 CAGCAACCTCGTCTGCAAAGT 21

RESULT 630
US-10-770-726-17507

```

```
; Sequence 17507, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17507
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17507

Query Match
Best Local Similarity 0.4%; Score 17.8; DB 1; Length 21;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2625 CAACCTGCTGTCGAAGTGTC 2645
      ||||| ||||| ||||| |||||
Db 1 CAACCTGCTGTCGAAGTGTC 21

RESULT 631
US-10-770-726-17531
; Sequence 17531, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17531
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17531

Query Match
Best Local Similarity 0.4%; Score 17.8; DB 1; Length 21;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2854 CAGGACGTGATCAATGCCATT 2874
      ||||| ||||| ||||| |||||
Db 1 CAGGATGTAATCAATGCCATT 21

RESULT 632
US-10-770-726-17537
; Sequence 17537, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
```

```
; SEQ ID NO 17537
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17537

Query Match
Best Local Similarity 0.4%; Score 17.8; DB 1; Length 21;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2871 CATTGAACAGGACTATCGGCT 2891
      ||||| ||||| ||||| |||||
Db 1 CATTGACGAGGACTATCGGCT 21

RESULT 633
US-10-770-726-18030
; Sequence 18030, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18030
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-770-726-18030

Query Match
Best Local Similarity 0.4%; Score 17.8; DB 1; Length 21;
Matches 12; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 2141 TCTACATCGACCCCTTCACCTT 2161
      :|||: ||| :|||:
Db 1 UCUAUCAUGCAUCCUUCACUU 21

RESULT 634
US-10-770-726-18074
; Sequence 18074, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18074
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-18074

Query Match
Best Local Similarity 0.4%; Score 17.8; DB 1; Length 21;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2455 GAGTTCATGGAGAACGCGCC 2475
      ||||| ||||| ||||| |||||
Db 1 GAGTTCATGGAGAACGCGCTCC 21
```

<div><div>RESULT 635</div><div>US-10-770-726-18089</div><div><div>Sequence 18089, Application US/10770726</div><div>Publication No. US20050266409A1</div><div>GENERAL INFORMATION:</div><div>APPLICANT: Wyeth</div><div>APPLICANT: Brown, Eugene</div><div>APPLICANT: Liu, Wei</div><div>TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING</div><div>TITLE OF INVENTION: CANCERS</div><div>FILE REFERENCE: AM101079 (031896-010000)</div><div>CURRENT APPLICATION NUMBER: US/10/770,726</div><div>CURRENT FILING DATE: 2004-02-04</div><div>NUMBER OF SEQ ID NOS: 48640</div><div>SOFTWARE: PatentIn version 3.2</div><div>SEQ ID NO 18089</div><div>LENGTH: 21</div><div>TYPE: DNA</div><div>ORGANISM: Homo sapiens</div></div></div> <div>US-10-770-726-18089</div> <div><div>Query Match</div><div>Best Local Similarity 0.4%; Score 17.8; DB 1; Length 21;</div><div>Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</div></div> <div><div>QY</div><div>2760 GAAGTTCACCTCGCCAGTGA 2780</div><div> </div><div>Db</div><div>1 GAAGTTCACCTCGCCAGTGA 21</div></div> <div><div>RESULT 636</div><div>US-10-770-726-18458</div><div><div>Sequence 18458, Application US/10770726</div><div>Publication No. US20050266409A1</div><div>GENERAL INFORMATION:</div><div>APPLICANT: Wyeth</div><div>APPLICANT: Brown, Eugene</div><div>APPLICANT: Liu, Wei</div><div>TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING</div><div>TITLE OF INVENTION: CANCERS</div><div>FILE REFERENCE: AM101079 (031896-010000)</div><div>CURRENT APPLICATION NUMBER: US/10/770,726</div><div>CURRENT FILING DATE: 2004-02-04</div><div>NUMBER OF SEQ ID NOS: 48640</div><div>SOFTWARE: PatentIn version 3.2</div><div>SEQ ID NO 18458</div><div>LENGTH: 21</div><div>TYPE: DNA</div><div>ORGANISM: Homo sapiens</div></div><div>US-10-770-726-18458</div><div><div>Query Match</div><div>Best Local Similarity 0.4%; Score 17.8; DB 1; Length 21;</div><div>Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</div></div><div><div>QY</div><div>2861 TGATCAATGCCATTGAACAGG 2881</div><div> </div><div>Db</div><div>1 TAATCAATGCCATTGACAGG 21</div></div><div><div>RESULT 637</div><div>US-10-770-726-18662</div><div><div>Sequence 18662, Application US/10770726</div><div>Publication No. US20050266409A1</div><div>GENERAL INFORMATION:</div><div>APPLICANT: Wyeth</div><div>APPLICANT: Brown, Eugene</div><div>APPLICANT: Liu, Wei</div><div>TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING</div><div>TITLE OF INVENTION: CANCERS</div><div>FILE REFERENCE: AM101079 (031896-010000)</div></div><div>US-10-770-726-18662</div><div><div>Query Match</div><div>Best Local Similarity 0.4%; Score 17.8; DB 1; Length 21;</div><div>Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</div></div><div><div>QY</div><div>2861 TGATCAATGCCATTGAACAGG 2881</div><div> </div><div>Db</div><div>1 TAATCAATGCCATTGACAGG 21</div></div></div></div>	<div><div>CURRENT APPLICATION NUMBER: US/10/770,726</div><div>CURRENT FILING DATE: 2004-02-04</div><div>NUMBER OF SEQ ID NOS: 48640</div><div>SOFTWARE: PatentIn version 3.2</div><div>SEQ ID NO 18662</div><div>LENGTH: 21</div><div>TYPE: DNA</div><div>ORGANISM: Homo sapiens</div><div>US-10-770-726-18662</div><div><div>Query Match</div><div>Best Local Similarity 0.4%; Score 17.8; DB 1; Length 21;</div><div>Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</div></div><div><div>QY</div><div>2871 CATTGAACAGGACTACCGGCT 2891</div><div> </div><div>Db</div><div>1 CATTGACGAGGACTATCGGCT 21</div></div><div><div>RESULT 638</div><div>US-10-770-726-18723</div><div><div>Sequence 18723, Application US/10770726</div><div>Publication No. US20050266409A1</div><div>GENERAL INFORMATION:</div><div>APPLICANT: Wyeth</div><div>APPLICANT: Liu, Wei</div><div>APPLICANT: Brown, Eugene</div><div>TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING</div><div>TITLE OF INVENTION: CANCERS</div><div>FILE REFERENCE: AM101079 (031896-010000)</div><div>CURRENT APPLICATION NUMBER: US/10/770,726</div><div>CURRENT FILING DATE: 2004-02-04</div><div>NUMBER OF SEQ ID NOS: 48640</div><div>SOFTWARE: PatentIn version 3.2</div><div>SEQ ID NO 18723</div><div>LENGTH: 21</div><div>TYPE: RNA</div><div>ORGANISM: RNAI</div><div>US-10-770-726-18723</div><div><div>Query Match</div><div>Best Local Similarity 0.4%; Score 17.8; DB 1; Length 21;</div><div>Matches 12; Conservative 7; Mismatches 2; Indels 0; Gaps 0;</div></div><div><div>QY</div><div>2141 TCTACATCGACCCCTTCACTT 2161</div><div>: : </div><div>Db</div><div>1 UCUACAUGAUCUUUCACUU 21</div></div><div><div>RESULT 639</div><div>US-10-310-914A-44767/c</div><div><div>Sequence 44767, Application US/10310914A</div><div>Publication No. US20060003322A1</div><div>GENERAL INFORMATION:</div><div>APPLICANT: Bentwich, Isaac</div><div>APPLICANT: Shiller, Kvuza</div><div>TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and</div><div>TITLE OF INVENTION: uses thereof</div><div>FILE REFERENCE: 06087.0200.CPUS01</div><div>CURRENT APPLICATION NUMBER: US/10/310,914A</div><div>CURRENT FILING DATE: 2002-12-06</div><div>NUMBER OF SEQ ID NOS: 1388402</div><div>SOFTWARE: PatentIn version 3.3</div><div>SEQ ID NO 44767</div><div>LENGTH: 21</div><div>TYPE: RNA</div><div>ORGANISM: Human</div><div>US-10-310-914A-44767</div><div><div>Query Match</div><div>Best Local Similarity 0.4%; Score 17.8; DB 1; Length 21;</div><div>Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</div></div></div></div></div></div></div>
---	--

Db 21 AAGGTTTTTGTGTTGTTT 1
|||||

RESULT 645
US-10-310-914A-1341719/c
; Sequence 1341719, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1341719
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1341719

Query Match 0.4%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 7e+02; 2; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 665 GCCTGTCCCTGCCTCGGGCTG 685
|||||

Db 21 GCCTGTCCCTGCCTCGAGCTG 1
|||||

RESULT 646
US-10-310-914A-174984
; Sequence 174984, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 174984
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-174984

Query Match 0.4%; Score 17.8; DB 1; Length 22;
Best Local Similarity 81.0%; Pred. No. 7.5e+02;
Matches 17; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 3521 CCCAGCCACTCGGGAACT 3541
|||||

Db 1 CCCAGCCACCUCGGGACCU 21
|||||

RESULT 647
US-10-310-914A-175001
; Sequence 175001, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 175001
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-175001

Query Match 0.4%; Score 17.8; DB 1; Length 22;
Best Local Similarity 81.0%; Pred. No. 7.5e+02;
Matches 17; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 3521 CCCAGCCACTCGGGAACT 3541
|||||

Db 2 CCCAGCCACCUCGGGACCU 22
|||||

RESULT 648
US-10-310-914A-371300/c
; Sequence 371300, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 371300
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-371300

Query Match 0.4%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 7.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4189 TTTTGTATATAAAGAAA 4209
|||||

Db 21 TTTTGTATATAAAGAAA 1
|||||

RESULT 649
US-10-310-914A-494111/c
; Sequence 494111, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 494111
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-494111

Query Match 0.4%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 7.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1939 CATCAGCCAGCCCAACTG 1959
|||||

Db 21 CATCACACCCAGACCCACGG 1

RESULT 650

US-10-310-914A-497206
; Sequence 497206, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kruzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 497206
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-497206

Query Match 0.4%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 7.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1064 CCCTGCGCCCGCCAGCC 1084
||||| ||||| ||||| |||||
Db 1 CCCCCAGCCCGCCAGCC 21

RESULT 651

US-10-310-914A-549823
; Sequence 549823, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kruzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 549823
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-549823

Query Match 0.4%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 7.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1064 CCCTGCGCCCGCCAGCC 1084
||||| ||||| ||||| |||||
Db 1 CCCCCAGCCCGCCAGCC 21

RESULT 652

US-10-310-914A-765177
; Sequence 765177, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kruzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 765177
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-765177

Query Match 0.4%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 7.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1059 CCCGCGCCCTGGCCCGCCAGCC 1079
||||| ||||| ||||| |||||
Db 2 CCGCGACCCCGCCCGCCAGCC 22

RESULT 653

US-10-310-914A-1224324
; Sequence 1224324, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kruzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1224324
; LENGTH: 22
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1224324

Query Match 0.4%; Score 17.8; DB 1; Length 22;
Best Local Similarity 61.9%; Pred. No. 7.5e+02;
Matches 13; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 3158 TCGCAGCCGCTGGCTTTGGCT 3178
:||||| |:|||||:
Db 2 UCCGAGCGCCGCGCUUGGCU 22

RESULT 654

US-10-310-914A-1224348
; Sequence 1224348, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kruzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes; and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1224348
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1224348

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.6e+02;
Matches 16; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1852 GAGCTCGGGGGCTGAAGC 1870
||||| ||||| ||||| |||||
Db 1 GAGCUCUGGGGCGUGAAGC 19

```
RESULT 655
US-10-310-914A-1294342
; Sequence 1294342, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvsat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1294342
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1294342

Query Match          0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 3336 CTGACCTGCAGGAACCTCCC 3354
|||:|:|||||:|:|:|
Db 1 CUGAGCUGCAGGAACUCGCC 19

RESULT 656
US-11-101-244-153337
; Sequence 153337, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 153337
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-153337

Query Match          0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2606 GCAACATCTTAGTCAACAG 2624
|||:|:|||||:|:|:|
Db 1 GCAACAUCUCGUCACACAG 19

RESULT 657
US-11-101-244-153343
; Sequence 153343, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
```

```
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 153343
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-153343

Query Match          0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2621 ACAGCAACCTCGCTCGCAA 2639
|||:|:|||||:|:|:|
Db 1 ACAGCAACCCUGGUCUGCAA 19

RESULT 658
US-11-101-244-153383
; Sequence 153383, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 153383
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-153383

Query Match          0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 6.6e+02;
Matches 12; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 2636 GCAAGCTGCTGACTTTGG 2654
|||:|:|||||:|:|:|
Db 1 GCAAGGUGUGUCACUUGG 19

RESULT 659
US-11-101-244-153389
; Sequence 153389, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
```

RESULT 663
US-11-101-244-158823
; Sequence 158823, Application US/11101244
; Publication NO. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacon, Inc.
; APPLICANT: Khivotova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin

```

; APPLICANT: Marshall, William
; APPLICANT: Scavage, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158823
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158823

```

```

Query Match      0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+00;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      2621 ACAGCAACCTCGTCTGCAA 2639
        |||||||||:|:|:|
Db      1 ACAGCAACCTGGUCGCAA 19

```

```

RESULT 664
US-11-101-244-158867
; Sequence 158867, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsinge, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101.244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158867
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158867

```

```
Query Match      0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 57.9%; Pred.No.6.6e+00;
Matches 11; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
```

RESULT 665
US-11-101-244-159987
; Sequence 159987, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William

```

; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13490S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 15897
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158987

```

```

Query Match      0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      2361 GAGCGAGGGCCTCCATCATG 2379
Db      1 GAGCGAGGCCUCCAUG 19

```

```

RESULT 666
US-11-101-244-159004
; Sequence 159004, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional sirRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101.244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159004
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159004

```

```

Query Match      0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.6e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      2450 TCACAGAGTTTCATCGGAA 2468
      :|||:|||:|||:|||
Db      1 UCACCGAGUUCAUUGGAA 19

```

RESULT 667
US-11-101-244-159040
; Sequence 159040, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

```
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159040
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159040
```

```
Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2606 GCAACATCCTAGTCAACAG 2624
      |||||::|::|::|::|::|
Db 1 GCAACAUCGUGCAACAG 19
```

```
RESULT 668
US-11-101-244-159054
; Sequence 159054, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159054
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159054
```

```
Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2621 ACAGCAACCTCGTCTGCAA 2639
      |||||::|::|::|::|
Db 1 ACAGCAACGUGGUGCAAC 19
```

```
RESULT 669
US-11-101-244-159086
; Sequence 159086, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159086
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159086
```

```
Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2361 GAGCGAGGCTCCATCATG 2379
      |||||::|::|::|::|
Db 1 GAGCGAGCCUCCAUG 19
```

```
RESULT 670
US-11-101-244-159100
; Sequence 159100, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159100
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159100
```

```
Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.6e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2450 TCACAGAGTTTCATGGAGAA 2468
      :|||::|::|::|::|
Db 1 UCACCGAGUUCUGGAGAA 19
```

```
RESULT 671
US-11-101-244-159129
; Sequence 159129, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
```

```
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159129
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159129
```

```
Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2606 GCAACATCCTAGTCAACAG 2624
      |||||:|:|:|:|:|:|
Db 1 GCAACAUCUUGUCACAG 19
```

RESULT 672

```
US-11-101-244-159138
; Sequence 159138, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159138
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159138
```

```
Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2621 ACAGCAACCTCGTCTGCAA 2639
      |||||:|:|:|:|:|:|
Db 1 ACAGCAACUUGUCACAG 19
```

RESULT 673

```
US-11-101-244-159213
; Sequence 159213, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
```

```
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159213
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159213
```

```
Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2606 GCAACATCCTAGTCAACAG 2624
      |||||:|:|:|:|:|:|
Db 1 GCAACAUCUUGUCACAG 19
```

RESULT 674

```
US-11-101-244-159231
; Sequence 159231, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159231
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159231
```

```
Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2621 ACAGCAACCTCGTCTGCAA 2639
      |||||:|:~|:|:|:|:|
Db 1 ACAGCAACUUGUCACAG 19
```

RESULT 675

```
US-11-101-244-159248
; Sequence 159248, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
```


; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159248
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159248

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.6e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2602 GCTGCAACATCCTAGTCA 2620
||:|||||||:|:|
Db 1 GCUCGCAACUCCUGUCA 19

RESULT 676

US-11-101-244-159274
; Sequence 159274, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159274
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159274

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.6e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2624 GCAACCTCGTCTGCAAGT 2642
|||||:|:|||||
Db 1 GCAACCGUGUCGCAAGU 19

RESULT 677

US-11-101-244-159309
; Sequence 159309, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159309
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159309

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.6e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1564 CGTCCTGACTTCACCTATA 1582
||:|:|:|:|:|:|:|
Db 1 CGUCCGACUCCUACCUAUA 19

RESULT 678

US-11-101-244-159364
; Sequence 159364, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159364
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159364

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.6e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 546 CTAGCAAGTGTGTGACGTG 564
|:|:|:|:|:|:|:|
Db 1 CUACGAAGUGUGUGAAGUG 19

RESULT 679

US-11-101-244-159371
; Sequence 159371, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10

```
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159371
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159371

Query Match      0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.6e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1565 GTCCTGACTTCACTATAC 1583
      ||| |||: |||: |||
Db 1 GUCGCGACUCCUACUAC 19

RESULT 680
US-11-101-244-1212014
; Sequence 1212014, Application US/1101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1212014
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1212014

Query Match      0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.6e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 941 CCCTGCACCTCTTCTACAA 959
      |||: |||: |||: |||
Db 1 CCCUGGACCUUCUACUACAA 19

RESULT 681
US-11-083-784-153337
; Sequence 153337, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050

Query Match      0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2621 ACAGCAACCTCGTCTGCAA 2639
      ||| |||: |||: |||
Db 1 ACAGCAACCTCGUCUGCAA 19

RESULT 682
US-11-083-784-153343
; Sequence 153343, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 153343
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-153343

Query Match      0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2621 ACAGCAACCTCGTCTGCAA 2639
      ||| |||: |||: |||
Db 1 ACAGCAACCTCGUCUGCAA 19

RESULT 683
US-11-083-784-153383
; Sequence 153383, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
```

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 153383
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-153383

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 6.6e+02;
Matches 12; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 2636 GCAAAGTGTCTGACTTTGG 2654
||||| |:|:|:|:|:|:|:|
Db 1 GCAAGGUGUCGACUUGG 19

RESULT 684
US-11-083-784-153389
; Sequence 153389, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 153389
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-153389

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 6.6e+02;
Matches 11; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

Qy 2633 TCTGCAAAAGTGTCTGACTT 2651
:|:|:|:| |:|:|:|:|:|:|
Db 1 UCUGCAAGGUGUCUGACUU 19

RESULT 685
US-11-083-784-158363
; Sequence 158363, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158363
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158363

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 6.6e+02;
Matches 12; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 2636 GCAAAGTGTCTGACTTTGG 2654
||||| |:|:|:|:|:|:|
Db 1 GCAAGGUGUCGACUUGG 19

RESULT 686
US-11-083-784-158571
; Sequence 158571, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158571
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158571

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 6.6e+02;
Matches 11; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

Qy 2633 TCTGCAAAAGTGTCTGACTT 2651
:|:|:|:| |:|:|:|:|:|:|
Db 1 UCUGCAAGGUGUCUGAUUU 19

RESULT 687
US-11-083-784-158800
; Sequence 158800, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin

```
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 158800
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158800
```

```
Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2361 GAGCGAGCGCTCCATCATG 2379
Db 1 GAGCGAGCGGUCCAUCAUG 19
```

```
RESULT 688
US-11-083-784-158823
; Sequence 158823, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 158823
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158823
```

```
Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2621 ACAGCAACCTCGTCTGCAA 2639
Db 1 ACAGCAACCGUGUCGCAA 19
```

```
RESULT 689
US-11-083-784-158867
; Sequence 158867, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
```

```
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 158867
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158867
```

```
Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 6.6e+02;
Matches 11; Conservative 7; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2633 TCTGCAAGTGCTGACTT 2651
Db 1 UCUGCAAGGUGUGACUU 19
```

```
RESULT 690
US-11-083-784-158987
; Sequence 158987, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO: 158987
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158987
```

```
Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2361 GAGCGAGCGCTCCATCATG 2379
Db 1 GAGCGAGCGGUCCAUCAUG 19
```

```
RESULT 691
US-11-083-784-159004
; Sequence 159004, Application US/11083784
```

```

; Publication No. US20050245475A1
;
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159004
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-11-083-784-159004

```


Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2606 GCAACATCCTGCTGCAAG 2624
|||:||||:|:|:|||||
DB 1 GCAACAUCUUGUCAACAG 19

RESULT 699
US-11-083-784-159231
; Sequence 159231, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159231
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159231

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.6e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2621 ACAGCAACCTGCTGCAA 2639
|||:||||:|:|:|||||
DB 1 ACAGCAACUUGUCUGCAA 19

RESULT 700
US-11-083-784-159248
; Sequence 159248, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159248
; LENGTH: 19
; TYPE: RNA

; ORGANISM: Homo sapiens
US-11-083-784-159248

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.6e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2602 GCTCGCAACATCCTAGTCA 2620
|||:||||:|:|:|||||
DB 1 GCTCGCAACUUGUCA 19

RESULT 701
US-11-083-784-159274
; Sequence 159274, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159274
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159274

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.6e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2624 GCAACCTGCTGCAAGT 2642
|||:||||:|:|:|||||
DB 1 GCAACCTGUGUCGCAAGU 19

RESULT 702
US-11-083-784-159309
; Sequence 159309, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary

```
; SEQ ID NO 159309
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159309

Query Match      0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.6e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1564 CGTCTGACTTCACCTATA 1582
    ||| ||| ||| ||| ||| ||| ||| |||
Db 1 CGUCGGACUUCACCUAUA 19

RESULT 703
US-11-083-784-159364
; Sequence 159364, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159364
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159364

Query Match      0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.6e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 546 CTACGAAGTGTGTGACGTG 564
    ||| ||| ||| ||| ||| ||| ||| |||
Db 1 CUACGAAGUGUGUGAAGUG 19

RESULT 704
US-11-083-784-159371
; Sequence 159371, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
```

```
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159371
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159371

Query Match      0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.6e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1565 GTCCTGACTTCACCTATAC 1583
    ||| ||| ||| ||| ||| ||| ||| |||
Db 1 GUCCGGACUUCACCUAUA 19

RESULT 705
US-11-083-784-1212014
; Sequence 1212014, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1212014
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1212014

Query Match      0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.6e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 941 CCCTGCACCTCTTCTACAA 959
    ||| ||| ||| ||| ||| ||| ||| |||
Db 1 CCUGGACCUUCUUCUACAA 19

RESULT 706
US-10-297-056-41
; Sequence 41, Application US/10297056
; Publication No. US20060030045A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Madeline M. Butler
; APPLICANT: Jacqueline Wyatt
; APPLICANT: Isis Pharmaceuticals, Inc.
; TITLE OF INVENTION: ANTISENSE MODULATION OF C/EBP BETA EXPRESSION
; FILE REFERENCE: RTSP-0150
; CURRENT APPLICATION NUMBER: US/10/297,056
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 09/593,711
; PRIOR FILING DATE: 2000-06-13
; NUMBER OF SEQ ID NOS: 244
; SEQ ID NO 41
```



```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-297-056-41

Query Match          0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 7.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 214 GCCGCGCGCGCGTCCCG 232
    |||||
Db 1 GCCGCGCGCGCGCGCGCG 19

RESULT 707
US-10-310-914A-52199/c
; Sequence 52199, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 52199
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-52199

Query Match          0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 7.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 138 GCCGCGCGCGCCACTGCC 156
    |||||
Db 20 GCCGCGCGCGCCACTGCC 2

RESULT 708
US-10-310-914A-173994/c
; Sequence 173994, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 173994
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-173994

Query Match          0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 7.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1069 GGCCCCAGCCCCAGCCTCT 1087
    |||||
Db 19 GGCCCCAGCCCCAGCCTCT 1
```

```
RESULT 709
US-10-310-914A-173995/c
; Sequence 173995, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 173995
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-173995

Query Match          0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 7.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1069 GGCCCCAGCCCCAGCCTCT 1087
    |||||
Db 19 GGCCCCAGCCCCAGCCTCT 1

RESULT 710
US-10-310-914A-409848/c
; Sequence 409848, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 409848
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-409848

Query Match          0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 7.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1069 GGCCCCAGCCCCAGCCTCT 1087
    |||||
Db 19 GGCCCCAGCCCCAGCCTCT 1

RESULT 711
US-10-310-914A-1224349
; Sequence 1224349, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1224349
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1224349

Query Match          0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 7.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1069 GGCCCCAGCCCCAGCCTCT 1087
    |||||
Db 19 GGCCCCAGCCCCAGCCTCT 1
```

; SEQ ID NO 1224349
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1224349

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 7.1e+02;
Matches 16; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1852 GAGCTGCGGGGCTGAAGC 1870
|||||:|||||:|||||
Db 1 GAGCUGCGGGGCGUGAAGC 19

RESULT 712

US-10-770-726-17471
; Sequence 17471, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17471
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17471

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 7.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTTCATGAGAA 2468
|||||:|||||:|||||
Db 3 TCACCGAGTTTCATGAGAA 21

RESULT 713

US-10-770-726-17472
; Sequence 17472, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17472
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-770-726-17472

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 7.7e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTTCATGAGAA 2468
:|||||:|||||:|||||
Db 1 UCACCGAGUUCGAGGAA 19

RESULT 714

US-10-770-726-17496
; Sequence 17496, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17496
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-770-726-17496

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 7.7e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2609 ACATCTAGTCAACAGCAA 2627
|||||:|||||:|||||
Db 1 ACAUCCUGCUCAACAGCAA 19

RESULT 715

US-10-770-726-17499
; Sequence 17499, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17499
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-770-726-17499

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 7.7e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2612 TCCTAGTCAACAGCAACCT 2630
:|||||:|||||:|||||
Db 1 UCCUCGCUCAACAGCAACCU 19

RESULT 716

US-10-770-726-17502
; Sequence 17502, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)

; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17502
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-770-726-17502

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 7.7e+02;
Matches 15; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2621 ACAGCAACTCGTCGCAA 2639
| | | | | | | | | | | | | | | | | | | | |
Db 1 ACAGCACUUGUCGCAA 19

RESULT 717
US-10-770-726-17535
; Sequence 17535, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Liu, Wei
; APPLICANT: Brown, Eugene
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17535
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-770-726-17535

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 7.7e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2667 ATGCATTGACAGACTA 2885
| | | | | | | | | | | | | | | | | | | | |
Db 1 AUGCCAUGAGCAGACUA 19

RESULT 718
US-10-770-726-18459
; Sequence 18459, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Liu, Wei
; APPLICANT: Brown, Eugene
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18459
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-770-726-18459

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 7.7e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2863 ATCAATGCCATTGAACAGG 2881
| | | | | | | | | | | | | | | | | | | | |
Db 1 AUCAAUGCCAUUGAGCAGG 19

RESULT 719
US-10-310-914A-145348
; Sequence 145348, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 145348
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-145348

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 7.7e+02;
Matches 17; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 99 GGAGGGACCCCAACTCCAG 117
| | | | | | | | | | | | | | | | | | | | |
Db 1 GGAGGGACCCCAAGUCCAG 19

RESULT 720
US-10-310-914A-176222/c
; Sequence 176222, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 176222
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-176222

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 7.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 4089 GTGTGGGGTGAGGTAGTGA 4107
| | | | | | | | | | | | | | | | | | | | |
Db 19 GTGTGGGGTGAGGCAGTGA 1

RESULT 721
US-10-310-914A-589336/c
; Sequence 589336, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 589336
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-589336

Query Match 0.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 7.7e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 742 GCCACGGCCCTCAGCCAG 760
Db 20 GCCACGGCCCTCAGCCAG 2

RESULT 722

US-10-310-914A-153231/c
; Sequence 153231, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 153231
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-153231

Query Match 0.4%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3891 GTTCCCTTTTGTCT 3907
Db 17 GTTCCCTTTTGTCT 1

RESULT 723

US-10-310-914A-255656
; Sequence 255656, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 255656
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-255656

Query Match 0.4%; Score 17; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 6.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 3014 ACCCGCCAGCTCAAA 3030
Db 1 ACCCGCCAGCTCAAA 17

RESULT 724

US-10-310-914A-687613
; Sequence 687613, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 687613
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-687613

Query Match 0.4%; Score 17; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 6.6e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1847 GGGCAGAGCTCGGGG 1863
Db 2 GGGCAGAGCTCGGGG 18

RESULT 725

US-10-949-720-60/c
; Sequence 60, Application US/10949720
; Publication No. US20050249736A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P02-002
; CURRENT APPLICATION NUMBER: US/10/949,720
; CURRENT FILING DATE: 2004-09-23
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 10/800,350
; PRIOR FILING DATE: 2004-03-12
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 60
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-949-720-60

Query Match 0.4%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1955 AACTGATGAGAGCGAG 1971
Db 19 AACTGATGAGAGCGAG 3

```

RESULT 726
US-11-101-244-4697
; Sequence 4697, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 4697
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-4697

Query Match      0.4%; Score 17; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 7.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 995 TCCCGGAGACTGTGCT 1011
Db 1 UCCCGAGACUGGCCU 17

RESULT 727
US-11-083-784-4697
; Sequence 4697, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 4697
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-4697

Query Match      0.4%; Score 17; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 7.2e+02;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 995 TCCCGGAGACTGTGCT 1011
Db 1 UCCCGAGACUGGCCU 17

```

```

RESULT 728
US-10-750-185-12781/c
; Sequence 12781, Application US/10750185
; Publication No. US20050260603A1
; GENERAL INFORMATION:
; APPLICANT: MMI GENOMICS, INC.
; APPLICANT: Denise, Sue K.
; APPLICANT: KERR, Richard
; APPLICANT: ROSENFELD, David
; APPLICANT: HOLM, Tom
; APPLICANT: BATES, Stephen
; APPLICANT: FANTIN, Dennis
; TITLE OF INVENTION: COMPOSITIONS FOR INFERRING BOVINE TRAITS
; FILE REFERENCE: MM1100-2
; CURRENT APPLICATION NUMBER: US/10/750,185
; CURRENT FILING DATE: 2003-12-31
; PRIOR APPLICATION NUMBER: US 60/437,482
; PRIOR FILING DATE: 2002-12-31
; NUMBER OF SEQ ID NOS: 64922
; SOFTWARE: PatentIN version 3.1
; SEQ ID NO 12781
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Reverse Primer
US-10-750-185-12781

Query Match      0.4%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.8e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 497 AGTGGAGGAACTGAGC 513
Db 19 AGTGGAGGAACTGAGC 3

RESULT 729
US-10-750-623-12781/c
; Sequence 12781, Application US/10750623
; Publication No. US20050287531A1
; GENERAL INFORMATION:
; APPLICANT: MMI GENOMICS, INC.
; APPLICANT: Denise, Sue K.
; APPLICANT: KERR, Richard
; APPLICANT: ROSENFELD, David
; APPLICANT: HOLM, Tom
; APPLICANT: BATES, Stephen
; APPLICANT: FANTIN, Dennis
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR INFERRING BOVINE TRAITS
; FILE REFERENCE: MM1100-1
; CURRENT APPLICATION NUMBER: US/10/750,623
; CURRENT FILING DATE: 2003-12-31
; PRIOR APPLICATION NUMBER: US 60/437,482
; PRIOR FILING DATE: 2002-12-31
; NUMBER OF SEQ ID NOS: 64922
; SOFTWARE: PatentIN version 3.1
; SEQ ID NO 12781
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Reverse Primer
US-10-750-623-12781

Query Match      0.4%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.8e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 497 AGTGGAGGAACTGAGC 513
Db 19 AGTGGAGGAACTGAGC 3

```

```
Db          19 AGTGGGAGGAAGTGCAGC 3

RESULT 730
US-10-770-726-17261
; Sequence 17261, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17261
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17261

Query Match          0.4%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 8.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY          892 GGCTTCTACTGGCCTT 908
          |||:::|||:::|||::|
Db          5 GGCTTCTACTGGCCTT 21

RESULT 731
US-10-770-726-17262
; Sequence 17262, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17262
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-770-726-17262

Query Match          0.4%; Score 17; DB 1; Length 21;
Best Local Similarity 64.7%; Pred. No. 8.4e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY          892 GGCTTCTACTGGCCTT 908
          |||:::|||:::|||::|
Db          3 GGCUUCUACCGGCUU 19

RESULT 732
US-10-310-914A-746199
; Sequence 746199, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 103507
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-103507

Query Match          0.4%; Score 16.8; DB 1; Length 20;

; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 746199
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-746199

Query Match          0.4%; Score 17; DB 1; Length 21;
Best Local Similarity 88.2%; Pred. No. 8.4e+02;
Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY          2966 GGCCCGCGCTTCCCCCGAG 2982
          |||:::|||:::|||::|
Db          1 GGCCCGCGCUUCCCCCAG 17

RESULT 733
US-10-831-286A-34263
; Sequence 34263, Application US/10831286A
; Publication No. US20060046246A1
; GENERAL INFORMATION:
; APPLICANT: ZENG, QIANDONG
; APPLICANT: CHATELIER, SONIA
; APPLICANT: MOIR, DONALD T.
; APPLICANT: LACROIX, BRUNA
; TITLE OF INVENTION: GENUS, GROUP, SPECIES AND/OR STRAIN SPECIFIC 16S rDNA SEQUENCES
; FILE REFERENCE: 032796-174.001
; CURRENT APPLICATION NUMBER: US/10/831,286A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/464,955
; PRIOR FILING DATE: 2003-04-24
; NUMBER OF SEQ ID NOS: 48788
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34263
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Veillonella atypica
US-10-831-286A-34263

Query Match          0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 8.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY          449 TGGAAACTGCTGATCTGAAG 468
          |||:::|||:::|||::|
Db          1 TGGAAACTGCTGATCTAGAG 20

RESULT 734
US-10-310-914A-103507
; Sequence 103507, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 103507
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-103507

Query Match          0.4%; Score 16.8; DB 1; Length 20;
```

```
Best Local Similarity 90.0%; Pred. No. 8.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1061 CCGCCCTGGCCCGCCAGCCCC 1080
      ||||| ||||| |||||
Db 1 CCGCCCGGGCCCGCCGCCCC 20

RESULT 735
US-10-310-914A-183395/c
; Sequence 183395, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 183395
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-183395

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 8.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3702 GGGGGCTGTCCAGGGGCA 3721
      ||||| ||||| |||||
Db 20 GGGGGCTGCCCGGGGGCA 1

RESULT 736
US-10-310-914A-231085
; Sequence 231085, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 231085
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-231085

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 15.0%; Pred. No. 8.1e+02;
Matches 3; Conservative 15; Mismatches 2; Indels 0; Gaps 0;

Qy 3900 TTGTTTCTCGTTTGT 3919
      ::||::: ||:::|:::|
Db 1 UUGUUUUUUUUUUUUUU 20

RESULT 737
US-10-310-914A-231831
; Sequence 231831, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 231831
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-231831

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 8.1e+02;
Matches 15; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 3824 CTCGCCAGCTGTGCCTTC 3843
      |:|||||:|:|:|
Db 1 CUCGCCAGCUGCAGCCUCC 20

RESULT 738
US-10-310-914A-243576/c
; Sequence 243576, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 243576
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-243576

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 8.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1061 CCGCCCTGGCCCGCCAGCCCC 1080
      ||||| ||||| |||||
Db 20 CCGCCCTGGCCCGCCGCCCC 1

RESULT 739
US-10-310-914A-244194
; Sequence 244194, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 244194
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-244194

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 8.1e+02;
```

Matches 15; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1330 CCCTGCACCACTCTCTTC 1349
|||:|||||:|:|:|:|:|:|:|

Db 1 CCCUGACCCUCCUCCUCC 20

RESULT 740

US-10-310-914A-268244
; Sequence 268244, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 268244
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-268244

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 15.0%; Pred. No. 8.1e+02;
Matches 3; Conservative 15; Mismatches 2; Indels 0; Gaps 0;

Qy 3897 TTTTGTCTTCTCTTTTGT 3916
:|:|:|:|:|:|:|:|:|:|:|:|:|

Db 1 UUUUUUUUUUUUUUUUU 20

RESULT 741

US-10-310-914A-310780/G
; Sequence 310780, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 310780
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-310780

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 8.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3897 TTTTGTCTTCTCTTTTGT 3916
|||:|||||:|:|:|:|:|:|:|

Db 20 TTTTGTCTTCTCTTTTGT 1

RESULT 742

US-10-310-914A-332290
; Sequence 332290, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 332290
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-332290

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 8.1e+02;
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1060 CCCGCCCTGCGCCCGAGCCC 1079
|||:|||||:|:|:|:|:|:|:|

Db 1 CCCACCCUAGCCCGAGCCC 20

RESULT 743

US-10-310-914A-332481
; Sequence 332481, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 332481
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-332481

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 8.1e+02;
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1060 CCCGCCCTGCGCCCGAGCCC 1079
|||:|||||:|:|:|:|:|:|:|

Db 1 CCCACCCUAGCCCGAGCCC 20

RESULT 744

US-10-310-914A-359152
; Sequence 359152, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 359152
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-359152

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 15.0%; Pred. No. 8.1e+02;
Matches 3; Conservative 15; Mismatches 2; Indels 0; Gaps 0;


```
QY 3900 TTGTTTCTCGTTTGTGTTT 3919
      ::::: : |:::|:::
Db 1 UGUUUUGUUGUUUUUUUU 20

RESULT 745
US-10-310-914A-409640/c
; Sequence 409640, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 409640
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-409640
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 8.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1726 AGCCTGGCGCTGGCTGTCC 1745
      |||||
Db 20 AGCCTGGCGCTGGCTGTGTC 1

RESULT 746
US-10-310-914A-436758/c
; Sequence 436758, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 436758
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-436758
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 8.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3404 CAGAGGCCGCCAGCCCTGTG 3423
      |||||
Db 20 CCGAGGCCGCCAGCCCACTG 1

RESULT 747
US-10-310-914A-478404
; Sequence 478404, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 478404
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-478404
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 8.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3900 TTGTTTCTCGTTTGTGTTT 3919
      ::::: : |:::|:::
Db 1 UGUUUUGUUGUUUUUUUU 20

RESULT 748
US-10-310-914A-543126/c
; Sequence 543126, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 543126
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-543126
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 8.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3852 GGTTTTGTGAGTTTGTGTTT 3871
      |||||
Db 20 GTTTTGGGTTTGTGTTT 1

RESULT 749
US-10-310-914A-549822
; Sequence 549822, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 549822
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-549822
Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 8.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 1064 CCCCTGGCCCCAGCCCCAGC 1083
Db 1 CCCUCGGCCCCAGCCCCAGC 20

RESULT 750
US-10-310-914A-628964/c
; Sequence 628964, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 628964
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-628964

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 8.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1851 AGAGCTGCGGGCTGAAGC 1870
Db 20 AGAGCTGATGGGCTGAAGC 1

RESULT 751
US-10-310-914A-657369
; Sequence 657369, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 657369
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-657369

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 8.1e+02;
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 4039 CCACATCCCCGGACCCGCC 4058
Db 1 CCACGUCCCCGGACCCGCC 20

RESULT 752
US-10-310-914A-763042
; Sequence 763042, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 763042
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-763042

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 8.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 58 CGGCTCAGCCCGCGCCACCC 77
Db 1 CGGCCCCGCGCCCGCCACCC 20

RESULT 753
US-10-310-914A-824483
; Sequence 824483, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 824483
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-824483

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 8.1e+02;
Matches 15; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2366 AGGCTCTCCATCATGGGCCAG 2385
Db 1 AGGCCUCCAUCCUAGGCCAG 20

RESULT 754
US-10-310-914A-834462
; Sequence 834462, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 834462
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-834462

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 15.0%; Pred. No. 8.1e+02;
Matches 3; Conservative 15; Mismatches 2; Indels 0; Gaps 0;

QY 3900 TTGTTTCTTCGTTTGTGTTT 3919

[illegible]

Db 1 UUGUUUUUUUUUUUUUUU 20

RESULT 760

US-10-310-914A-1290003/c

; Sequence 1209003, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 1209003

; LENGTH: 20

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-1290003

Query Match 0.4%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 8.1e+02;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1066 CCTGGCCCCAGCCCCGCT 1085

||| ||||| ||||| |||||

Db 20 CCTGGCCCCAGCCCCGCT 1

RESULT 761

US-10-310-914A-1230235

; Sequence 1230235, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 1230235

; LENGTH: 20

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-1230235

Query Match 0.4%; Score 16.8; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 8.1e+02;

Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2886 CCGGCTGCCCGCCCCCAG 2905

||||| ||||| ||||| |||||

Db 1 CCGGCTGCCCGCCCCCAG 20

RESULT 762

US-10-310-914A-1290463

; Sequence 1290463, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 1290463

; LENGTH: 20

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-1290463

Query Match 0.4%; Score 16.8; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 8.1e+02;

Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1061 CGCCCCCTGGCCCCCAGCCCC 1080

||||| ||||| ||||| |||||

Db 1 CAGCCCCUGCCCCCAGCGCC 20

RESULT 763

US-10-310-914A-1290469

; Sequence 1290469, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 1290469

; LENGTH: 20

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-1290469

Query Match 0.4%; Score 16.8; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 8.1e+02;

Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1060 CCGCCCCCTGGCCCCCAGCCCC 1079

||||| ||||| ||||| |||||

Db 1 CCAGCCCCUGCCCCCAGCGC 20

RESULT 764

US-10-310-914A-1332047/c

; Sequence 1332047, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 1332047

; LENGTH: 20

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-1332047

Query Match 0.4%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 8.1e+02;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3702 GGGGGCTGTCCAGGGGCA 3721

||||| ||||| ||||| |||||

Db 20 GGGGGCTGTCCAGGGGCA 1

```

; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16898
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-16898

Query Match      0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2626 AACCTGCTCTGCAAGTGTC 2645
Db      1 AACCTGCTCTGCAAGTGTC 20

RESULT 768
US-10-770-726-17246
; Sequence 17246, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17246
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-17246

Query Match      0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      696 CAAGGAGACCTTCACCGTCT 715
Db      1 CAAGGAGACCTTCACCGTCT 20

RESULT 769
US-10-770-726-17508
; Sequence 17508, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING, PREVENTING, AND TREATING
; FILE REFERENCE: AM101079 (031896-010000)
; CURRENT APPLICATION NUMBER: US/10/770,726
; CURRENT FILING DATE: 2004-02-04
; NUMBER OF SEQ ID NOS: 48640
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17508
; LENGTH: 21
; TYPE: RNA

; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: Bloinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1341732
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1341732

Query Match      0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 8.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      667 CTGTCCTGCTCGGCTGG 686
Db      20 CTGTCCTGCTCGGCTGG 1

RESULT 766
US-11-043-752-2628/C
; Sequence 2628, Application US/11043752
; Publication No. US20060014165A1
; GENERAL INFORMATION:
; APPLICANT: Hakonarson, Hakon
; APPLICANT: Gurney, Mark E.
; APPLICANT: Halapi, Eva
; TITLE OF INVENTION: METHODS OF DIAGNOSIS AND TREATMENT FOR
; TITLE OF INVENTION: ASTHMA AND OTHER RESPIRATORY DISEASES BASED ON HAPLOTYPE
; TITLE OF INVENTION: ASSOCIATION
; FILE REFERENCE: 2345.2044-003
; CURRENT APPLICATION NUMBER: US/11/043,752
; CURRENT FILING DATE: 2005-01-26
; PRIOR APPLICATION NUMBER: PCT/US04/022446
; PRIOR FILING DATE: 2004-07-14
; PRIOR APPLICATION NUMBER: 60/487,072
; PRIOR FILING DATE: 2003-07-14
; PRIOR APPLICATION NUMBER: 60/559,611
; PRIOR FILING DATE: 2004-04-05
; NUMBER OF SEQ ID NOS: 4326
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2628
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-11-043-752-2628

Query Match      0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 8.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2065 AGGAAGCAGCAGCAATGGAG 2084
Db      20 AGGAAGCAGCAGCAATGGAG 1

RESULT 767
US-10-770-726-16898
; Sequence 16898, Application US/10770726
; Publication No. US20050266409A1
; GENERAL INFORMATION:
```



```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26045
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-770-726-26045

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1787 ACCATGAGAGGCCGCCGAG 1806
      ||||| ||||| |||||
Db 2 ACCATGAGAGGCCGCCGAG 21

RESULT 775
US-10-310-914A-43024/c
; Sequence 43024, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 43024
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-43024

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1063 GCCCTGTGCCCGCCCGCCGAG 1082
      ||||| ||||| |||||
Db 21 GCCCGAGGCGACCGCCCGCCGAG 2

RESULT 776
US-10-310-914A-94223/c
; Sequence 94223, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 94223
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-94223

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3855 TTTTGAGTTTGTGTTTGGT 3874
      ||||| ||||| |||||
Db 21 TTTTGGGTTTGTGTTTGTG 2

RESULT 777
US-10-310-914A-147724/c
; Sequence 147724, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 147724
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-147724

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3853 GTTTTCAGTTTGTGTTTGG 3872
      ||||| ||||| |||||
Db 21 GTTTTGTGTTTGTGTTTGG 2

RESULT 778
US-10-310-914A-175830/c
; Sequence 175830, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 175830
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-175830

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3898 TTTTGTTCCTTCGTTTGTG 3917
      ||||| ||||| |||||
Db 21 TTTTGTTCCTTCGTTTGTG 2

RESULT 779
US-10-310-914A-239772/c
; Sequence 239772, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
```

; SEQ ID NO 239772
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-239772

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1070 GCCCCAGCCCGCCAGCTCTAC 1089
|||||
Db 21 GCCCCAGCCCGCTGCTCTGC 2

RESULT 780

US-10-310-914A-271797/c
; Sequence 271797, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 271797
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-271797

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 CCGCCCTGCGCCAGCCCC 1080
|||||
Db 20 CCGCCCTGCTGCCAGCCCC 1

RESULT 781

US-10-310-914A-271798/c
; Sequence 271798, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 271798
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-271798

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1061 CCGCCCTGCGCCAGCCCC 1080
|||||
Db 20 CCGCCCTGCTGCCAGCCCC 1

RESULT 782

US-10-310-914A-310403/c
; Sequence 310403, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 310403
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-310403

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1065 CCCTGCGCCCGCCAGCCCC 1084
|||||
Db 21 CCCTGACCCCGCCCTGCC 2

RESULT 783

US-10-310-914A-329952
; Sequence 329952, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 329952
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-329952

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 8.8e+02;
Matches 16; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 3720 CAAGAAGGGGTGTCTAGGGCC 3739
|||||
Db 1 CCAGAAGGGGUGUCAGGGCC 20

RESULT 784

US-10-310-914A-340669/c
; Sequence 340669, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 340669


```
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-340669

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1129 GCGTCAGCTGCTCCGGG 1148
Db 20 GCGCTAGCTGCTCTGGG 1

RESULT 785
US-10-310-914A-406263/c
; Sequence 406263, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 406263
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-406263

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 747 GGCCTCTGCGCAGCCTGGA 766
Db 21 GGCCTCTGCGCAGCCTGGA 2

RESULT 786
US-10-310-914A-426861/c
; Sequence 426861, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 426861
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-426861

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3899 TTGTGTTCTTCGTTGTTT 3918
Db 21 TTGTGTTCTTCGTTGTTT 2

RESULT 787
```

```
US-10-310-914A-481749
; Sequence 481749, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 481749
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-481749

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 166 CGGGCCGCGCGCGCGCGC 185
Db 2 CUGGCGCGCGCGCGCGCGC 21

RESULT 788
US-10-310-914A-497146
; Sequence 497146, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 497146
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-497146

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1064 CCCTGGCCCGCCCGCCCGC 1083
Db 2 CCCCAGCCCGCCCGCCCGC 21

RESULT 789
US-10-310-914A-513444/c
; Sequence 513444, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 513444
; LENGTH: 21
```

```
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-513444

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 37 GGGGGGAGACCGCGGCGG 56
      ||||| ||| ||||| |||||
Db 21 GGGGGGAGAGCGCGGAGCGG 2

RESULT 790
US-10-310-914A-562705
; Sequence 562705, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 562705
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-562705

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 12; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1132 TGCAGCTGTGCTCGGGGTT 1151
      : |||||: |||: |||: |||:
Db 2 UCCAGCUGUCGUCGUGGU 21

RESULT 791
US-10-310-914A-572916/C
; Sequence 572916, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 572916
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-572916

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1716 CAGCAGCTTGAGCTGGCCT 1735
      ||||| ||| ||||| |||||
Db 21 CAGCAGCTTGAGCTGGCAT 2

RESULT 792
US-10-310-914A-628965/C
; Sequence 628965, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 628965
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-628965

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1851 AGAGCTGCGGGGCTGAAGC 1870
      ||||| ||| ||||| |||||
Db 20 AGAGCTGATGGGCTGAAGC 1

RESULT 793
US-10-310-914A-700668
; Sequence 700668, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 700668
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-700668

Query Match          0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 8.8e+02;
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1060 CCGGCCCTGGCCCGCCGCCC 1079
      ||||| ||| ||||| |||||
Db 2 CCGGCCCGUGUCCCGCCGCCC 21

RESULT 794
US-10-310-914A-711740
; Sequence 711740, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 711740
; LENGTH: 21
; TYPE: RNA
```

; ORGANISM: Human
US-10-310-914A-711740

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 8.8e+02;
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 308 AGAGTCACAGCTGGGGGGGC 327
|||||:|||||:|||||
Db 1 AGAGACAGACCCUGGGAGGC 20

RESULT 795

US-10-310-914A-711741
; Sequence 711741, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 711741

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-711741

Query Match

Best Local Similarity 0.4%; Score 16.8; DB 1; Length 21;
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 308 AGAGTCACAGCTGGGGGGGC 327
|||||:|||||:|||||
Db 1 AGAGACAGACCCUGGGAGGC 20

RESULT 796

US-10-310-914A-712558
; Sequence 712558, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 712558

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-712558

Query Match

Best Local Similarity 0.4%; Score 16.8; DB 1; Length 21;
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1063 GCCCCTGGCCCGCCAGCCAG 1082
|||||:|||||:|||||
Db 2 GCCCUCGGCCCGCCAGCCAG 21

RESULT 797

US-10-310-914A-849350/c
; Sequence 849350, Application US/10310914A

; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 849350

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-849350

Query Match

Best Local Similarity 0.4%; Score 16.8; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 498 GTGGGAGGAACCTGAGCGGC 517
|||||:|||||:|||||
Db 21 GTGGGTGGAACAGAGCGGC 2

RESULT 798

US-10-310-914A-853726
; Sequence 853726, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 853726

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-853726

Query Match

Best Local Similarity 0.4%; Score 16.8; DB 1; Length 21;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3056 CCTCACACCTCTCTGGAC 3075
|||||:|||||:|||||
Db 2 CCUCAGACCCUCCUGGC 21

RESULT 799

US-10-310-914A-964814
; Sequence 964814, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 964814

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-964814

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 8.8e+02;
Matches 17; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1067 CTGCCCCCAGCCCGAGCTC 1086
|:|||||:|||||:|||||:
Db 2 CUGGCCCCCGCCCGAGCCCC 21

RESULT 800

US-10-310-914A-1044788/c
; Sequence 1044788, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 1044788

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-1044788

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1073 CCAGCCCCAGCCTCTACTGC 1092
|:|||||:|||||:|||||:
Db 21 CTAGCCCCAGCTTCTACTGC 2

RESULT 801

US-10-310-914A-1044846/c
; Sequence 1044846, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 1044846

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-1044846

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1072 CCCAGCCCCAGCCTCTACTG 1091
|:|||||:|||||:|||||:
Db 20 CCTAGCCCCAGCTTCTACTG 1

RESULT 802

US-10-310-914A-1141569
; Sequence 1141569, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 1141569

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-1141569

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 8.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 830 GGGCCGAGCCACCGGGAAG 849
|:|||||:|||||:|||||:
Db 1 GGGCCGAGCCACCGGGAAG 20

RESULT 803

US-10-310-914A-1329403
; Sequence 1329403, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 1329403

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-1329403

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 8.8e+02;
Matches 16; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 3720 CAAGAGGGGTGTCTAGGGCC 3739
|:|||||:|||||:|||||:
Db 1 CCAGAGGGGGUGUCAGGGGC 20

RESULT 804

US-10-750-185-14487
; Sequence 14487, Application US/10750185
; Publication No. US20050260603A1

; GENERAL INFORMATION:

; APPLICANT: Denise, Sue K.

; APPLICANT: KERR, Richard

; APPLICANT: ROSENFELD, David

; APPLICANT: HOLM, Tom

; APPLICANT: BATES, Stephen

; APPLICANT: FANTIN, Dennis

; TITLE OF INVENTION: COMPOSITIONS FOR INFERRING BOVINE TRAITS

; FILE REFERENCE: MM1100-2

; CURRENT APPLICATION NUMBER: US/10/750,185

; CURRENT FILING DATE: 2003-12-31

; PRIOR APPLICATION NUMBER: US 60/437,482

; NUMBER OF SEQ ID NOS: 64922

```
; SOFTWARE: PatentIN version 3.1
; SEQ ID NO 14487
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Reverse Primer
US-10-185-14487

Query Match          0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 7.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1532 TGGTGGAGCCCTGGGTGG 1549
Db 1 TGGTGGAGCCCTGTGTGG 18

RESULT 805
US-10-750-623-14487
; Sequence 14487, Application US/10750623
; Publication No. US20050287531A1
; GENERAL INFORMATION:
; APPLICANT: MMI GENOMICS, INC.
; APPLICANT: DENISE, Sue K.
; APPLICANT: KERR, Richard
; APPLICANT: ROSENFELD, David
; APPLICANT: HOLM, Tom
; APPLICANT: BATES, Stephen
; APPLICANT: FANTIN, Dennis
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR INFERRING BOVINE TRAITS
; FILE REFERENCE: MM11100-1
; CURRENT APPLICATION NUMBER: US/10/750,623
; CURRENT FILING DATE: 2003-12-31
; PRIOR APPLICATION NUMBER: US 60/437,482
; PRIOR FILING DATE: 2002-12-31
; NUMBER OF SEQ ID NOS: 64922
; SOFTWARE: PatentIN version 3.1
; SEQ ID NO 14487
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Reverse Primer
US-10-750-623-14487

Query Match          0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 7.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1532 TGGTGGAGCCCTGGGTGG 1549
Db 1 TGGTGGAGCCCTGTGTGG 18

RESULT 806
US-10-310-914A-44706/c
; Sequence 44706, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 44706
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
```

```
US-10-310-914A-44706

Query Match          0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 7.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2911 CCCACCTCCTCCACCAG 2928
Db 18 CCCCCCTCCCTCCACCAG 1

RESULT 807
US-10-310-914A-161816
; Sequence 161816, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161816
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-161816

Query Match          0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 7.6e+02;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 3607 AACATCTCCAGCCTCCC 3624
Db 1 AACCTCCAGCCTCC 18

RESULT 808
US-10-310-914A-215670
; Sequence 215670, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 215670
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-215670

Query Match          0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 7.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 171 CCGCGCGCGCGCGCG 188
Db 1 CCGCGCGCGCGCGCG 18

RESULT 809
US-10-310-914A-239735/c
; Sequence 239735, Application US/10310914A
; Publication No. US20060003322A1
```



```
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 702467
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-702467

Query Match      0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 7.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3774 TTGCTGCTGTCCACCACCA 3791
Db 18 TTTCTGCTGTCCACCACCA 1

RESULT 815
US-10-310-914A-806755/c
; Sequence 806755, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 806755
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-806755

Query Match      0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 7.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3381 TTCGGGGGCAGAGTGGGG 3398
Db 18 TTCGGGGGCAGAGTGGGG 1

RESULT 816
US-10-310-914A-815915
; Sequence 815915, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 815915
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-815915
```

```
Query Match      0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 7.6e+02;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1376 TGAACGGCTCTCCCTGC 1393
Db 1 UGAACGGCUCUCCCGCCG 18

RESULT 817
US-10-310-914A-916487/c
; Sequence 916487, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 916487
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-916487

Query Match      0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 7.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1067 CTGCCCCCAGCCCGCCG 1084
Db 18 CTGCCCCCAGCCCGCCG 1

RESULT 818
US-10-310-914A-937535/c
; Sequence 937535, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 937535
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-937535

Query Match      0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 7.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 267 GAGGAGTCCCGCGCGAG 284
Db 18 GAGGAGTCCCGCGCAGAG 1

RESULT 819
US-10-310-914A-1079798/c
; Sequence 1079798, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
```

```
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1079798
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1079798

Query Match      0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 7.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1062 CGCCCTGGCCCGAGCC 1079
      |||||
Db 18 CGCCCTGTCCCGAGCCC 1

RESULT 820
US-10-310-914A-1251971
; Sequence 1251971, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1251971
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1251971

Query Match      0.4%; Score 16.4; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 7.6e+02;
Matches 16; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2075 GCAATGGGAGAGAGCAG 2092
      |||||
Db 1 GCAAGGGAGGGAGAGCAG 18

RESULT 821
US-10-310-914A-161839
; Sequence 161839, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161839
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-161839

Query Match      0.4%; Score 16.4; DB 1; Length 19;
```

```
Best Local Similarity 77.8%; Pred. No. 8.2e+02;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3608 ACATCTCCAGCGCTCCCC 3625
      ||:|||||:||||
Db 1 ACCUCUCCAGCGCUCGCC 18

RESULT 822
US-10-310-914A-161840
; Sequence 161840, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161840
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-161840

Query Match      0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 8.2e+02;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3608 ACATCTCCAGCGCTCCCC 3625
      ||:|||||:||||
Db 1 ACCUCUCCAGCGCUCGCC 18

RESULT 823
US-10-310-914A-225326
; Sequence 225326, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 225326
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-225326

Query Match      0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 8.2e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 754 ACGCCAGCGCTGGATGGAG 771
      |||||
Db 1 ACGCCAGCGCUGGAGGAG 18

RESULT 824
US-10-310-914A-329935
; Sequence 329935, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
```



```
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 329935
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-329935

Query Match      0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 8.2e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 3722 AGAAGGGGTGTGAGGGCC 3739
Db 2 AGAAGGGGUGUCAGGGCC 19

RESULT 825
US-10-310-914A-481752
; Sequence 481752, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 481752
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-481752

Query Match      0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 8.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 168 GGCCCGCGCGCCGCGCGC 185
Db 1 GGCCCGUGCGCCGCGCGC 18

RESULT 826
US-10-310-914A-562468/c
; Sequence 562468, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 562468
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-562468

Query Match      0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 8.2e+02;
```

```
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1059 CCCGCGCCCTGGCCCGCAG 1076
Db 19 CCCGACCCCTGGCCCGCAG 2

RESULT 827
US-10-310-914A-910660
; Sequence 910660, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 910660
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-910660

Query Match      0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 8.2e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1979 GGGAGCAGCTGGCCCTGA 1996
Db 2 GGGAGCAGCUGGCGCCUGA 19

RESULT 828
US-10-310-914A-917658/c
; Sequence 917658, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 917658
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-917658

Query Match      0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 8.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1722 CTTGAGCCTGGCCTGGGC 1739
Db 19 CTTGAGCCTGGCCTGGGC 2

RESULT 829
US-10-310-914A-1011800/c
; Sequence 1011800, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
```

; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1011800
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1011800

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 8.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1069 GGGCCCGAGCCCGGCTC 1086
||| ||||| ||||| |||||
Db 18 GGCACCGAGCCCGGCTC 1

RESULT 830
US-10-310-914A-1024936
; Sequence 1024936, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1024936
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1024936

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 8.2e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 3775 TGTGTGTGTACCAACCAA 3792
: ||| : ||| : ||| : |||
Db 1 UGCUGCUGUCACCAUCAA 18

RESULT 831
US-10-310-914A-1182295
; Sequence 1182295, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1182295
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1182295

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 8.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 219 CGCCCGGTGCGCCGCAAG 236
||| ||||| ||||| |||||
Db 1 CGCCCGGGGGCGCCGCAAG 18
RESULT 832
US-10-310-914A-1313753
; Sequence 1313753, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1313753
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1313753

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 8.2e+02;
Matches 11; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 3095 CAGCTTTTGGCTCTGGG 3112
||| |||| : |||| : |||
Db 1 CAGCAUUUGGUCUCUGG 18

RESULT 833
US-10-310-914A-1329386
; Sequence 1329386, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1329386
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1329386

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 8.2e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3722 AGAAGGGGTGTCAAGGCC 3739
||| ||||| : |||||
Db 2 AGAAGGGGUGUCAGGGGC 19

RESULT 834
US-11-101-244-117533
; Sequence 117533, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 117533
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-117533

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 8.2e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2592 AGACCTGGCTCTCGCAA 2609
DB 1 AGACCGGCGCGCGCAA 18

RESULT 835
US-11-101-244-158322
; Sequence 158322, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158322
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158322

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 8.2e+02;
Matches 11; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 2634 CTGCAAGTGTCTGACTT 2651
DB 2 CUGCAAGGUGUGUGACUU 19

RESULT 836
US-11-101-244-159024
; Sequence 159024, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159024
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159024

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 8.2e+02;
Matches 11; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 2804 TGTGGAGGTGATGTCTAT 2821
DB 1 UGUGGGAGGUGUGUCCU 18

RESULT 837
US-11-101-244-159117
; Sequence 159117, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159117
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159117

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 8.2e+02;
Matches 11; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 2804 TGTGGAGGTGATGTCTAT 2821
DB 1 UGUGGGAGGUGUGUCCU 18

RESULT 838
US-11-101-244-159229
; Sequence 159229, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

```
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159229
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159229

Query Match      0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 8.2e+02;
Matches 16; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy      2841 GGACATGAGCAATCAGGA 2858
Db      1 GGACAUGAGCAACCAGGA 18

RESULT 839
US-11-101-244-159279
; Sequence 159279, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159279
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159279

Query Match      0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 8.2e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy      2625 CAACCTGCTGCAAGT 2642
Db      1 CAACCGUGGUCGCAAGU 18

RESULT 840
US-11-101-244-258796
; Sequence 258796, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 258796
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-258796

Query Match      0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 8.2e+02;
Matches 11; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy      1565 GTCCTGACTTCACCTATA 1582
Db      2 GUCCUGACUUCACUAUA 19

RESULT 841
US-11-101-244-258802
; Sequence 258802, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 258802
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-258802

Query Match      0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 8.2e+02;
Matches 11; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy      1565 GTCCTGACTTCACCTATA 1582
Db      1 GUCCUGACUUCACUAUA 18

RESULT 842
US-11-101-244-317987/c
; Sequence 317987, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
```

```
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 317987
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-317987

Query Match
Best Local Similarity 0.4%; Score 16.4; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2801 TGATGTGGGAGTGATGT 2818
      ||||| ||||| ||||| |||||
Db 19 TGATGTGGGAGTTGATGT 2

RESULT 843
US-11-101-244-325732
; Sequence 325732, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 325732
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-325732

Query Match
Best Local Similarity 0.4%; Score 16.4; DB 1; Length 19;
Matches 16; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 3276 CATGAAGTCCAGGCCAA 3293
      ||||| ||||| ||||| |||||
Db 1 CAAGAAGUCCAGGCCAA 18

RESULT 844
US-11-101-244-495967
; Sequence 495967, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990US
; CURRENT APPLICATION NUMBER: US/11/101,244
```

```
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 495967
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-495967

Query Match
Best Local Similarity 0.4%; Score 16.4; DB 1; Length 19;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2987 TCAGCGCCCTGGACAAGA 3004
      :||| :||| :||| :|||
Db 1 UCAGCGGCCUGGACAAGA 18

RESULT 845
US-11-101-244-520914
; Sequence 520914, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 520914
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-520914

Query Match
Best Local Similarity 0.4%; Score 16.4; DB 1; Length 19;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2580 CTAGTCCACCGAGACCT 2597
      :||| :||| :||| :|||
Db 1 CUACAUCACCGAGACCU 18

RESULT 846
US-11-101-244-521180
; Sequence 521180, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
```

; PRIOR APPLICATION NUMBER: 60/502,050
 ; PRIOR FILING DATE: 2003-09-10
 ; PRIOR APPLICATION NUMBER: 60/426,137
 ; PRIOR FILING DATE: 2002-11-14
 ; NUMBER OF SEQ ID NOS: 1591911
 ; SOFTWARE: Proprietary
 ; SEQ ID NO 521180
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-11-101-244-521180

Query Match 0.4%; Score 16.4; DB 1; Length 19;
 Best Local Similarity 77.8%; Pred. No. 8.2e+02;
 Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2592 AGACCTGGCTGCTCGCAA 2609
 |||||:||||:||||:
 Db 1 AGACCGUGCUGCUGGAA 18

RESULT 847

US-11-101-244-931315
 ; Sequence 931315, Application US/11101244
 ; Publication No. US20050246794A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Dharmacon, Inc.
 ; APPLICANT: Khvorova, Anastasia
 ; APPLICANT: Reynolds, Angela
 ; APPLICANT: Leake, Devin
 ; APPLICANT: Marshall, William
 ; APPLICANT: Scaringe, Stephen
 ; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
 ; FILE REFERENCE: 13499US
 ; CURRENT APPLICATION NUMBER: US/11/101,244
 ; CURRENT FILING DATE: 2005-04-07
 ; PRIOR APPLICATION NUMBER: 60/502,050
 ; PRIOR FILING DATE: 2003-09-10
 ; PRIOR APPLICATION NUMBER: 60/426,137
 ; PRIOR FILING DATE: 2002-11-14
 ; NUMBER OF SEQ ID NOS: 1591911
 ; SOFTWARE: Proprietary
 ; SEQ ID NO 931315
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-11-101-244-931315

Query Match 0.4%; Score 16.4; DB 1; Length 19;
 Best Local Similarity 55.6%; Pred. No. 8.2e+02;
 Matches 10; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 3962 TCACATGGCTCCTCTTG 3979
 :|||:||||:||||:
 Db 1 UGACUAGCCUCCUUG 18

RESULT 848

US-11-101-244-1104821
 ; Sequence 1104821, Application US/11101244
 ; Publication No. US20050246794A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Dharmacon, Inc.
 ; APPLICANT: Khvorova, Anastasia
 ; APPLICANT: Reynolds, Angela
 ; APPLICANT: Leake, Devin
 ; APPLICANT: Marshall, William
 ; APPLICANT: Scaringe, Stephen
 ; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
 ; FILE REFERENCE: 13499US
 ; CURRENT APPLICATION NUMBER: US/11/101,244
 ; CURRENT FILING DATE: 2005-04-07
 ; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10
 ; PRIOR APPLICATION NUMBER: 60/426,137
 ; PRIOR FILING DATE: 2002-11-14
 ; NUMBER OF SEQ ID NOS: 1591911
 ; SOFTWARE: Proprietary
 ; SEQ ID NO 1104821
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-11-101-244-1104821

Query Match 0.4%; Score 16.4; DB 1; Length 19;
 Best Local Similarity 77.8%; Pred. No. 8.2e+02;
 Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2157 CACTTATGAAGACCTTAA 2174
 |||||:||||:||||:
 Db 2 CACUAAUGAAGACCCUA 19

RESULT 849

US-11-101-244-1174362
 ; Sequence 1174362, Application US/11101244
 ; Publication No. US20050246794A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Dharmacon, Inc.
 ; APPLICANT: Khvorova, Anastasia
 ; APPLICANT: Reynolds, Angela
 ; APPLICANT: Leake, Devin
 ; APPLICANT: Marshall, William
 ; APPLICANT: Scaringe, Stephen
 ; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
 ; FILE REFERENCE: 13499US
 ; CURRENT APPLICATION NUMBER: US/11/101,244
 ; CURRENT FILING DATE: 2005-04-07
 ; PRIOR APPLICATION NUMBER: 60/502,050
 ; PRIOR FILING DATE: 2003-09-10
 ; PRIOR APPLICATION NUMBER: 60/426,137
 ; PRIOR FILING DATE: 2002-11-14
 ; NUMBER OF SEQ ID NOS: 1591911
 ; SOFTWARE: Proprietary
 ; SEQ ID NO 1174362
 ; LENGTH: 19
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-11-101-244-1174362

Query Match 0.4%; Score 16.4; DB 1; Length 19;
 Best Local Similarity 72.2%; Pred. No. 8.2e+02;
 Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1386 CTCCTGCACCTGGAATG 1403
 :|||:||||:||||:
 Db 2 CUCCUGCUGCUGGAUG 19

RESULT 850

US-11-101-244-1393142/c
 ; Sequence 1393142, Application US/11101244
 ; Publication No. US20050246794A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Dharmacon, Inc.
 ; APPLICANT: Khvorova, Anastasia
 ; APPLICANT: Reynolds, Angela
 ; APPLICANT: Leake, Devin
 ; APPLICANT: Marshall, William
 ; APPLICANT: Scaringe, Stephen
 ; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
 ; FILE REFERENCE: 13499US
 ; CURRENT APPLICATION NUMBER: US/11/101,244
 ; CURRENT FILING DATE: 2005-04-07
 ; PRIOR APPLICATION NUMBER: 60/502,050
 ; PRIOR FILING DATE: 2003-09-10

; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1393142
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1393142

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 8.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2165 AGACCCCTAATGAGGCTG 2182
Db 18 AAGACCCGAATGAGGCTG 1

RESULT 851
US-11-101-244-1494874/c
; Sequence 1494874, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1494874
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1494874

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 8.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1937 AACATCACAGCCAGACCC 1954
Db 18 AACACCACAGCCAGACCC 1

RESULT 852
US-11-101-244-1529001
; Sequence 1529001, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137

; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1529001
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1529001

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 8.2e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2298 GAGCTGTGTGCAATCAA 2315
Db 1 GAGCUGUGUGCAAUCAA 18

RESULT 853
US-11-083-784-117533
; Sequence 117533, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 117533
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-117533

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 8.2e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2592 AGACCTGGCTGCTGCAA 2609
Db 1 AGACCUGGUGCCGCGCAA 18

RESULT 854
US-11-083-784-158322
; Sequence 158322, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159279
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159279

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 8.2e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2625 CAACCTCGTCGCAAGT 2642
||||| :|:|:|:|:|:
DB 1 CAACCGUGUCGCAAGU 18

RESULT 859
US-11-083-784-258796
; Sequence 258796, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 258796
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-258796

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 8.2e+02;
Matches 11; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1565 GTCCTGACTTCACCTATA 1582
|:|:|:|:|:|:|:|:
DB 2 GUCCUGACUUCACUAUA 19

RESULT 860
US-11-083-784-258802
; Sequence 258802, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 258802
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-258802

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 8.2e+02;
Matches 11; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1565 GTCCTGACTTCACCTATA 1582
|:|:|:|:|:|:|:|:
DB 1 GUCCUGACUUCACUAUA 18

RESULT 861
US-11-083-784-317987/c
; Sequence 317987, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 317987
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-317987

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 8.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2801 TGATGTGGGAGGTGATGT 2818
||||| :|:|:|:|:|:
DB 19 TGATGTGGGAGTTGATGT 2

RESULT 862
US-11-083-784-325732
; Sequence 325732, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:

```
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 325732
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-325732
```

```
Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 8.2e+02;
Matches 16; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 3276 CATGAAGTCCAGGCCAA 3293
Db 1 CAAGAAGUCCAGGCCAA 18
```

RESULT 863

```
US-11-083-784-495967
; Sequence 495967, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 495967
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-495967
```

```
Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 8.2e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2987 TCAGCGCCCTGCACAGA 3004
Db 1 UCAGCGCCUGGACAGA 18
```

RESULT 864

```
US-11-083-784-520914
```

```
; Sequence 520914, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 520914
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-520914
```

```
Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 8.2e+02;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2580 CTACGTCCACCGAGCCT 2597
Db 1 CUACAUCACCGAGACCU 18
```

RESULT 865

```
US-11-083-784-521180
; Sequence 521180, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 521180
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-521180
```

```
Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 8.2e+02;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2592 AGACCTGGCTGCTCGCAA 2609
Db 1 AGACCGGCGUCGCGAA 18
```

```
RESULT 866
US-11-083-784-931315
; Sequence 931315, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 931315
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-931315

Query Match          0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 55.6%; Pred. No. 8.2e+02;
Matches 10; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 3962 TCACATATGCGCTCCTTTG 3979
: ||:|||||:|:|:|
Db 1 UGACUAGGCCUCCUUUG 18

RESULT 867
US-11-083-784-1104821
; Sequence 1104821, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1104821
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1104821

Query Match          0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 8.2e+02;
Matches 14; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2157 CACTTATGAGACCCCTAA 2174
```

```
||||: ||:|||||:|:|:|
Db 2 CACUAGAAGAGACCCUAA 19

RESULT 868
US-11-083-784-1174362
; Sequence 1174362, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1174362
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1174362

Query Match          0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 8.2e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1386 CTCCTGCACCTGGAATG 1403
:|||||:|:|:|:|
Db 2 CUCCUGCUCUUGGAUG 19

RESULT 869
US-11-083-784-1393142/c
; Sequence 1393142, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1393142
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1393142

Query Match          0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 8.2e+02;
```

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2165 AAGACCTATAGGCTG 2182
| | | | | | | | | | | | | | | | | | | | | |
Db 18 AAGACCGAATGAGGCTG 1

RESULT 870

US-11-083-784-1494874/c
; Sequence 1494874, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1494874
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1494874

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 8.2e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1937 AACATCACAGCCAGACC 1954
| | | | | | | | | | | | | | | | | | | | | |
Db 18 AACACACAGCCAGACC 1

RESULT 871

US-11-083-784-1529001
; Sequence 1529001, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1529001
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1529001

Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 8.2e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2298 GAGCTGTGTGCAATCAA 2315
| | | | | | | | | | | | | | | | | | | | | |
Db 1 GAGCUGUUGCAUCA 18

RESULT 872

US-10-310-914A-385316/c
; Sequence 385316, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 385316
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-385316

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 8.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2885 ACCGGCTGCCCGGCC 2902
| | | | | | | | | | | | | | | | | | | | | |
Db 20 ACCGGCTGCCCGGCC 3

RESULT 873

US-10-310-914A-916483/c
; Sequence 916483, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 916483
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-916483

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 8.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1069 GGGCCCGAGCCCGAGCTC 1086
| | | | | | | | | | | | | | | | | | | | | |
Db 19 GGGCCCGAGCCCGAGCTC 2

RESULT 874

US-10-310-914A-1192704/c
; Sequence 1192704, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

```

Query Match      0.4%; Score 16; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 8.3e+02;
Matches 15; Conservative 1; Mismatches 0; Indels

Qy  1071  CCCGAGCCCCGAGCCTC 1086
      ||||| ||||| ||||| |||||
Db   3  CCCGAGCCCCGAGCCUC 18

RESULT 877
US-10-310-914A-916489/c
; Sequence 916489, Application US/10310914A
; Publication No. US20060003322A1

```

```

? APPLICANT: Bentwich, Isaac
?
? APPLICANT: Shiler, Kuzat
?
? TITLE OF INVENTION: Bioinformatically detectable group of n
?
? TITLE OF INVENTION: Uses thereof
?
? FILE REFERENCE: 06087, 0200.CPUS01
?
? CURRENT APPLICATION NUMBER: US/10/310,914A
?
? CURRENT FILING DATE: 2002-12-06
?
? NUMBER OF SEQ ID NOS: 1388402
?
? SOFTWARE: PatentIn version 3.3
?
? SEQ ID NO 916489
?
? LENGTH: 18
?
? TYPE: RNA
?
? ORGANISM: Human
?
? US-10-310-914A-916489

```

```

Query Match      0.4%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. NO. 8.3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels

Qy      1071  CCCACGCCCCCAGCCTC 1086
          |||||
Db       18   CCCACGCCCCCAGCCTC 3

RESULT 878
US-10-310-914A-983472
; Sequence 983472, Application US/10310914A
; Publication No. US2006000332A1

```

```

? APPLICANT: Bentwich, Ishaac
? APPLICANT: Shiler, Kvuzaat
? TITLE OF INVENTION: Bioinformatically detectable group of n
? TITLE OF INVENTION: uses thereof
? FILE REFERENCE: 06087.0200.CPUS01
? CURRENT APPLICATION NUMBER: US/10/310,914A
? CURRENT FILING DATE: 2002-12-06
? NUMBER OF SEQ ID NOS: 1388402
? SOFTWARE: PatentIn version 3.3
? SEQ ID NO 983472
? LENGTH: 18
? TYPE: RNA
? ORGANISM: Human
? US-10-310-914A-983472

```

```

Query Match      0.4%; Score 16; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. NO. 8.3e+02;
Matches 15; Conservative 1; Mismatches 0; Indels

Qy      1065 CCCTGGCCCCCAGCCCC 1080
          |||:|||||
Db      2 CCCUGGCCCCAGCCCC 17

RESULT 879
US-10-310-914A-1088339/C
; Sequence 1088339, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac

```

```

; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1088339
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1088339

Query Match      0.4%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2050 GCAGTTCTCTGCCTCA 2065
Db 16 GCAGTTCTCTGCCTCA 1

RESULT 880
US-10-310-914A-1346847/c
; Sequence 1346847, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1346847
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1346847

Query Match      0.4%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1064 CCCCTGGCCCCAGGCC 1079
Db 17 CCCCTGGCCCCAGGCC 2

RESULT 881
US-10-310-914A-196336
; Sequence 196336, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 196336
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-196336

Query Match      0.4%; Score 16; DB 1; Length 19;

```

```

Best Local Similarity 100.0%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2285 CAGGGAAGAGGAGAG 2300
Db 3 CAGGGAAGAGGAGAG 18

RESULT 882
US-10-310-914A-482672
; Sequence 482672, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 482672
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-482672

Query Match      0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 68.8%; Pred. No. 9e+02;
Matches 11; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2051 CAGTTCTCTGCCTCAG 2066
Db 1 CAGUUCUCUGCCUCAG 16

RESULT 883
US-10-310-914A-1295091/c
; Sequence 1295091, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1295091
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1295091

Query Match      0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3821 CCCCTCCCCCAGCTGC 3836
Db 17 CCCCTCCCCCAGCTGC 2

RESULT 884
US-10-310-914A-1343420/c
; Sequence 1343420, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat

```

```
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1343420
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1343420

Query Match          0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 180 GCGGCGCGGCACAGA 195
Db 16 GCGGCGCGGCACAGA 1

RESULT 885
US-11-101-244-31908/c
; Sequence 31908, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 31908
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-31908

Query Match          0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3264 CAGTGTCCAGCACATG 3279
Db 18 CAGTGTCCAGCACATG 3

RESULT 886
US-11-101-244-159280
; Sequence 159280, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
```

```
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159280
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159280
```

```
Query Match          0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 75.0%; Pred. No. 9e+02;
Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 885 CAAGGCTGGCTTCTAC 900
Db 4 CAAGGCTGGCTTCTAC 19
```

```
RESULT 887
US-11-101-244-704088/c
; Sequence 704088, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 704088
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-704088
```

```
Query Match          0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3608 ACATCTCCAGCCTCC 3623
Db 19 ACATCTCCAGCCTCC 4
```

```
RESULT 888
US-11-101-244-704181/c
; Sequence 704181, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
```

; PRIOR APPLICATION NUMBER: 60/426,137									
; PRIOR FILING DATE: 2002-11-14									
; NUMBER OF SEQ ID NOS: 1591911									
; SOFTWARE: Proprietary									
; SEQ ID NO 931277									
; LENGTH: 19									
; TYPE: RNA									
; ORGANISM: Homo sapiens									
US-11-101-244-931277									
Query Match 0.4%; Score 16; DB 1; Length 19;									
Best Local Similarity 62.5%; Pred. No. 9e+02;									
Matches 10; Conservative 6; Mismatches 0; Indels 0; Gaps 0;									
QY 3964 ACTATGGCTCTCTTG 3979									
: : :									
Db 1 ACUAGGCCUCCUUG 16									
RESULT 891									
US-11-101-244-1365774/c									
; Sequence 1365774, Application US/1101244									
; Publication No. US20050246794A1									
; GENERAL INFORMATION:									
; APPLICANT: Dharmacon, Inc.									
; APPLICANT: Khvorova, Anastasia									
; APPLICANT: Reynolds, Angela									
; APPLICANT: Leake, Devin									
; APPLICANT: Marshall, William									
; APPLICANT: Scaringe, Stephen									
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA									
; FILE REFERENCE: 13499US									
; CURRENT APPLICATION NUMBER: US/11/01,244									
; CURRENT FILING DATE: 2005-04-07									
; PRIOR APPLICATION NUMBER: 60/502,050									
; PRIOR FILING DATE: 2003-09-10									
; PRIOR APPLICATION NUMBER: 60/426,137									
; PRIOR FILING DATE: 2002-11-14									
; NUMBER OF SEQ ID NOS: 1591911									
; SOFTWARE: Proprietary									
; SEQ ID NO 1365774									
; LENGTH: 19									
; TYPE: RNA									
; ORGANISM: Homo sapiens									
US-11-101-244-1365774									
Query Match 0.4%; Score 16; DB 1; Length 19;									
Best Local Similarity 100.0%; Pred. No. 9e+02; 0; Indels 0; Gaps 0;									
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 2656 CTTTCCCGATTCCTGG 2671									
:									
Db 16 CTTTCCCGATTCCTGG 1									
RESULT 892									
US-11-083-784-31908/c									
; Sequence 31908, Application US/11083784									
; Publication No. US20050245475A1									
; GENERAL INFORMATION:									
; APPLICANT: Dharmacon, Inc.									
; APPLICANT: Khvorova, Anastasia									
; APPLICANT: Reynolds, Angela									
; APPLICANT: Leake, Devin									
; APPLICANT: Marshall, William									
; APPLICANT: Scaringe, Stephen									
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA									
; FILE REFERENCE: 13499US									
; CURRENT APPLICATION NUMBER: US/11/083,784									
; CURRENT FILING DATE: 2005-03-18									
; PRIOR APPLICATION NUMBER: US/10/714,333									
; PRIOR FILING DATE: 2003-11-14									
; PRIOR APPLICATION NUMBER: 60/502,050									

; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 31908
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-31908

Query Match 0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3264 CAGTGTCCAGCACATG 3279
|||:|||||
Db 18 CAGTGTCCAGCACATG 3

RESULT 893

US-11-083-784-159280
; Sequence 159280, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159280
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159280

Query Match 0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 75.0%; Pred. No. 9e+02;
Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 885 CAAGGCTGGCTTCTAC 900
|||:|||||
Db 4 CAAGGCTGGCTTCTAC 19

RESULT 894

US-11-083-784-704088/c
; Sequence 704088, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18

; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 704088
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-704088

Query Match 0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3608 ACATCTCCAGCCTCC 3623
|||:|||||
Db 19 ACATCTCCAGCCTCC 4

RESULT 895

US-11-083-784-704181/c
; Sequence 704181, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 704181
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-704181

Query Match 0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3608 ACATCTCCAGCCTCC 3623
|||:|||||
Db 19 ACATCTCCAGCCTCC 4

RESULT 896

US-11-083-784-931267
; Sequence 931267, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 931267
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-931267

Query Match 0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 62.5%; Pred. No. 9e+02;
Matches 10; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 3964 ACTATGGCCTCTTTG 3979
||:|||||:|:|:
Db 2 ACUAGGCCUCCUUG 17

RESULT 897
US-11-083-784-931277
; Sequence 931277, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 931277
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-931277

Query Match 0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 62.5%; Pred. No. 9e+02;
Matches 10; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 3964 ACTATGGCCTCTTTG 3979
||:|||||:|:|:
Db 1 ACUAGGCCUCCUUG 16

RESULT 898
US-11-083-784-1365774/c
; Sequence 1365774, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1365774
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1365774

Query Match 0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2656 CTTTCCCGATTCCTGG 2671
|||||:|:|:
Db 16 CTTTCCCGATTCCTGG 1

RESULT 899
US-10-831-286A-34811
; Sequence 34811, Application US/10831286A
; Publication No. US20060046246A1
; GENERAL INFORMATION:
; APPLICANT: ZENG, QIANDONG
; APPLICANT: CHATELLIER, SONIA
; APPLICANT: MOIR, DONALD T.
; APPLICANT: LACROIX, BRUNA
; APPLICANT: CHILDRESS, DARRELL
; TITLE OF INVENTION: GENUS, GROUP, SPECIES AND/OR STRAIN SPECIFIC 16S rDNA SEQUENCES
; FILE REFERENCE: 032796-174.001
; CURRENT APPLICATION NUMBER: US/10/831,286A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/464,955
; PRIOR FILING DATE: 2003-04-24
; NUMBER OF SEQ ID NOS: 48788
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34811
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Veillonella atypica
US-10-831-286A-34811

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 9.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 449 TGGAAACTGCTGATCT 464
|||||:|:|:
Db 2 TGGAAACTGCTGATCT 17

RESULT 900
US-10-831-286A-37357
; Sequence 37357, Application US/10831286A
; Publication No. US20060046246A1
; GENERAL INFORMATION:
; APPLICANT: ZENG, QIANDONG
; APPLICANT: CHATELLIER, SONIA
; APPLICANT: MOIR, DONALD T.
; APPLICANT: LACROIX, BRUNA
; APPLICANT: CHILDRESS, DARRELL
; TITLE OF INVENTION: GENUS, GROUP, SPECIES AND/OR STRAIN SPECIFIC 16S rDNA SEQUENCES

FILE REFERENCE: 032796-174.001
; CURRENT APPLICATION NUMBER: US/10/831,286A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/464,955
; PRIOR FILING DATE: 2003-04-24
; NUMBER OF SEQ ID NOS: 48788
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37357
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Veillonella atypica
US-10-831-286A-37357

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 9.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 449 TGGAAACTGCTGATCT 464
|||||
DB 4 TGGAAACTGCTGATCT 19

RESULT 901

US-10-831-286A-40915
; Sequence 40915, Application US/10831286A
; Publication No. US20060046246A1
; GENERAL INFORMATION:

; APPLICANT: ZENG, QIANDONG
; APPLICANT: CHATELLIER, SONIA
; APPLICANT: MOIR, DONALD T.
; APPLICANT: LACROIX, BRUNA
; APPLICANT: CHILDRESS, DARRELL
; TITLE OF INVENTION: GENUS, GROUP, SPECIES AND/OR STRAIN SPECIFIC 16S rDNA SEQUENCES
; FILE REFERENCE: 032796-174.001
; CURRENT APPLICATION NUMBER: US/10/831,286A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/464,955
; PRIOR FILING DATE: 2003-04-24
; NUMBER OF SEQ ID NOS: 48788
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40915
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Veillonella atypica
US-10-831-286A-40915

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 9.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 449 TGGAAACTGCTGATCT 464
|||||
DB 3 TGGAAACTGCTGATCT 18

RESULT 902

US-10-831-286A-48457
; Sequence 48457, Application US/10831286A
; Publication No. US20060046246A1
; GENERAL INFORMATION:

; APPLICANT: ZENG, QIANDONG
; APPLICANT: CHATELLIER, SONIA
; APPLICANT: MOIR, DONALD T.
; APPLICANT: LACROIX, BRUNA
; APPLICANT: CHILDRESS, DARRELL
; TITLE OF INVENTION: GENUS, GROUP, SPECIES AND/OR STRAIN SPECIFIC 16S rDNA SEQUENCES
; FILE REFERENCE: 032796-174.001
; CURRENT APPLICATION NUMBER: US/10/831,286A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/464,955
; PRIOR FILING DATE: 2003-04-24
; NUMBER OF SEQ ID NOS: 48788
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 48457
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Veillonella atypica
US-10-831-286A-48457

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 9.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 449 TGGAAACTGCTGATCT 464
|||||
DB 5 TGGAAACTGCTGATCT 20

RESULT 903

US-10-310-914A-196337
; Sequence 196337, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 196337
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-196337

Query Match 0.4%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 9.7e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2285 CAGGGAAGAGGAGAG 2300
|||||
DB 3 CAGGGAAGAGGAGAG 18

RESULT 904

US-10-922-761-87
; Sequence 87, Application US/10922761
; Publication No. US20050267058A1
; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Ueman, Nassim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/223 (MEHB 04-736-A)
; CURRENT APPLICATION NUMBER: US/10/922,761
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: US 10/683,990
; PRIOR FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2004-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 320
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 87
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-922-761-87

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 9.4e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 519 GGATGAGGACACGACGACG 537
|||:|||||
Db 1 GGAUGAGAAACAGCUCGACG 19

RESULT 905

US-10-922-761-184/c
; Sequence 184, Application US/10922761
; Publication No. US20050267058A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/223 (MRHB 04-736-A)
; CURRENT APPLICATION NUMBER: US/10/922,761
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: US 10/683,990
; PRIOR FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2004-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 320
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 184
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-922-761-184

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 519 GGATGAGGACACGACGACG 537
|||:|||||
Db 19 GGATGAGAAACAGCTCAGC 1

RESULT 906

US-10-310-914A-50195
; Sequence 50195, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CFUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 50195
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-50195

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 9.4e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2276 TCAAGGCCCGGGAAGAA 2294
:|||||
Db 1 UCAUGCCCCCGGAAGAA 19

RESULT 907

US-10-310-914A-74610/c
; Sequence 74610, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CFUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 74610
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-74610

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3896 CTTTGTGTTCTCGTTTT 3914
|||||
Db 19 CTTTGTGTTCTGTTTT 1

RESULT 908

US-10-310-914A-81513
; Sequence 81513, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 81513
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-81513

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 9.4e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 3357 CCCAGGACACCGCTCC 3375
| | | | | | | | | | | | | | | | | | | | |
Db 1 CCCAGGACACCGCTCC 3375

RESULT 909
US-10-310-914A-143107/c
; Sequence 143107, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 143107
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-143107

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1669 GAGCTACTCTCTGCGAGTCT 1687
| | | | | | | | | | | | | | | | | | | | |
Db 19 GTGGTCCCTCTGCGAGTGT 1

RESULT 910
US-10-310-914A-143645/c
; Sequence 143645, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 143645
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-143645

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 571 GCCCGGGCCAGCCCACT 589
| | | | | | | | | | | | | | | | | | | | |
Db 19 GCCCGGGCCAGCCCACT 1

RESULT 911
US-10-310-914A-152768/c
; Sequence 152768, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 152768
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-152768

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 131 CGCGCCCGCCGCGCGGC 149
| | | | | | | | | | | | | | | | | | | | |
Db 19 CGCGCCCGCCGCGCGGC 1

RESULT 912
US-10-310-914A-175809/c
; Sequence 175809, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 175809
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-175809

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3898 TTTTGTTCCTGCTTTGT 3916
| | | | | | | | | | | | | | | | | | | | |
Db 19 TTTTGTTCCTGCTTTGT 1

RESULT 913
US-10-310-914A-209753
; Sequence 209753, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 175809
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-143645

; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 209753
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-209753

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 9.4e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 3408 GGCCCCCAGCCCTGTGCCC 3426
|| ||||| ||||| :|||
Db 1 GGACCCAGCCGACGUGCCC 19

RESULT 914

US-10-310-914A-242649/c
; Sequence 242649, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 242649
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-242649

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 494 GGCAGTGGGAGGAACTGAG 512
|| ||||| ||||| |||||
Db 19 GGCAGTGGGTGGAAAGTGAG 1

RESULT 915

US-10-310-914A-271792/c
; Sequence 271792, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 271792
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-271792

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1061 CCGCCCTGTGCCCCAGCCC 1079

Db 19 CCCCCCTGTGCCCCAGCCC 1
|| ||||| ||||| |||||

RESULT 916

US-10-310-914A-376173/c
; Sequence 376173, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 376173
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-376173

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1959 GGATGAGAGCGAGGCTGG 1977
|| ||||| ||||| |||||
Db 19 CGAGGAGAGCGCGGCTGG 1

RESULT 917

US-10-310-914A-402475/c
; Sequence 402475, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 402475
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-402475

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 85 GACCCCGAGCGCCCGGAGG 103
|| ||||| ||||| |||||
Db 19 GCCCTCGAGCGCCCGGAGG 1

RESULT 918

US-10-310-914A-426755/c
; Sequence 426755, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 426755
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-426755

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3899 TTTGTTCTCTCGTTTGT 3917
Db 19 TTTGTTCTCTGTTTATT 1

RESULT 919
US-10-310-914A-427119/c
; Sequence 427119, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 427119
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-427119

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3161 CAGCGCTGGCTTTGGCTC 3179
Db 19 CAGCTGCTGGATTGGCTC 1

RESULT 920
US-10-310-914A-454195
; Sequence 454195, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 454195
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-454195

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 130 GCGCGCCGCGCGGCGG 148
||||| ||||||| |||

Db 1 GCGCGCGCGCGCGGCGG 19
RESULT 921
US-10-310-914A-462107/c
; Sequence 462107, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 462107
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-462107

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3897 TTTTGTCTCTCGTTTGT 3915
Db 19 TTTTGTCTCTGTTTGTG 1

RESULT 922
US-10-310-914A-477363
; Sequence 477363, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 477363
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-477363

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2227 GAAGAGGTGATTGTCGAG 2245
Db 1 GAAGAGGUGAGUGAGCAG 19

RESULT 923
US-10-310-914A-481676/c
; Sequence 481676, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 481676
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-481676

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1964 AGAGCGAGGCTGCGGGA 1982
Db 19 AGAGGAGGCGGCGGGA 1

RESULT 924

US-10-310-914A-496772
; Sequence 496772, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 496772
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-496772

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1753 CCCAGTGGGCTGCTGG 1771
Db 1 CCCAGUGGUGGCGGCGG 19

RESULT 925

US-10-310-914A-497205
; Sequence 497205, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 497205
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-497205

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1064 CCCCTGGCCCCGAGCCAG 1082
Db 1 CCCCCAGCCCCGAGCCAG 19

RESULT 926

US-10-310-914A-520422/c
; Sequence 520422, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 520422
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-520422

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3896 CTTTGTGTTCTCGTTTT 3914
Db 19 CTTTGTGTTGTGTTTT 1

RESULT 927

US-10-310-914A-543953/c
; Sequence 543953, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 543953
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-543953

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2799 TGTGATGTGGAGGTGATG 2817
Db 19 TGTGATGTGGAGGTG 1

RESULT 928

US-10-310-914A-616709
; Sequence 616709, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402


```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 616709
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-616709

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1061 CCGCCCTCGGCCCGCCAGCCC 1079
Db 1 CCGCCCGCCGCCCGCCAGCCC 19

RESULT 929
US-10-310-914A-691544/c
; Sequence 691544, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 691544
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-691544

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1055 CCGTCCCGCCCGCCCTCGGCC 1073
Db 19 CCGTCCCGCCCGCCCTCGGCC 1

RESULT 930
US-10-310-914A-701274
; Sequence 701274, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 701274
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-701274

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 3571 CAGGACTGGGTGTGACCCAG 3589
Db 1 CAGGACUGGGUGACGACUG 19

RESULT 931
US-10-310-914A-735391
; Sequence 735391, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 735391
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-735391

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1531 CTGCTGGAGCCCTGGGTGG 1549
Db 1 CUGGUGAGGCCCGGGCGG 19

RESULT 932
US-10-310-914A-764359/c
; Sequence 764359, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 764359
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-764359

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1847 GGCAGAGCTGCGGGGGCT 1865
Db 19 GGGCGGAGCTGTGGGGCT 1

RESULT 933
US-10-310-914A-778757
; Sequence 778757, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
```



```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1147060

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1530 CCTGGTGGAGCCCTGGTG 1548
Db 19 CCTGGCGGAGCCCTGGTG 1

RESULT 939
US-10-310-914A-1160786
; Sequence 1160786, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310.914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1160786
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1160786

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 9.4e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1057 GTCCCGCCCTGGGCCCA 1075
Db 1 GUCCCCGACCAGGCCCA 19

RESULT 940
US-10-310-914A-1167297/c
; Sequence 1167297, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310.914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1167297
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1167297

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3897 TTTTGTTCCTCGTTTG 3915
Db 19 TTTTGTTCCTCGTTTG 1

RESULT 941
```

```
US-10-310-914A-1249167
; Sequence 1249167, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310.914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1249167
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1249167

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1074 CAGCCCCAGCCTTACTGC 1092
Db 1 CAGCCCCAGCCTTACTGC 19

RESULT 942
US-10-310-914A-1257401
; Sequence 1257401, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310.914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1257401
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1257401

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 15.8%; Pred. No. 9.4e+02;
Matches 3; Conservative 14; Mismatches 2; Indels 0; Gaps 0;

Qy 3904 TTCTCGTTTGTGTTTCT 3922
Db 1 UUCUUUGUUUUUUUUUCU 19

RESULT 943
US-11-101-244-611
; Sequence 611, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101.244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
```

```
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 611
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-611

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 9.4e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2985 GGTGAGCGCCCTGGACAAG 3003
   ||:|||||  |||||
Db 1 GGUCAGCGCCCAAGACAAG 19

RESULT 944
US-11-101-244-31906
; Sequence 31906, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 31906
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-31906

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 3952 GGAACCTGTTTCACTATGG 3970
   |||||:|:|:|:|:|
Db 1 GGAAGCUGAUCACUAUGG 19

RESULT 945
US-11-101-244-51586
; Sequence 51586, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
```

```
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 51586
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-51586

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 9.4e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2985 GGTGAGCGCCCTGGACAAG 3003
   ||:|||||  |||||
Db 1 GGUCAGCGCCCAAGACAAG 19

RESULT 946
US-11-101-244-88135/c
; Sequence 88135, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 88135
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-88135

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2032 CTGTGTCATTCTGTGTCG 2050
   ||:|||||  |||||
Db 19 CTGTGTCATTCTGTGTCG 1

RESULT 947
US-11-101-244-108278
; Sequence 108278, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
```

; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 108278
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-108278

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e-02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2450 TCACAGAGTTTCATGGAGAA 2468
:|||||:|:|:|
Db 1 UCACAGACUCCUGGAGAA 19

RESULT 948

US-11-101-244-108374
; Sequence 108374, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary
; SEQ ID NO 108374
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-108374

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e-02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2450 TCACAGAGTTTCATGGAGAA 2468
:|||||:|:|:|
Db 1 UCACAGACUCCUGGAGAA 19

RESULT 949

US-11-101-244-108473
; Sequence 108473, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 108473
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-108473

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e-02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2450 TCACAGAGTTTCATGGAGAA 2468
:|||||:|:|:|
Db 1 UCACAGACUCCUGGAGAA 19

RESULT 950

US-11-101-244-108571
; Sequence 108571, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary
; SEQ ID NO 108571
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-108571

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e-02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 2450 TCACAGAGTTTCATGGAGAA 2468
:|||||:|:~|:|:|
Db 1 UCACAGACUCCUGGAGAA 19

RESULT 951

US-11-101-244-108671
; Sequence 108671, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 108671
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-108671

```
; SOFTWARE: Proprietary
; SEQ ID NO 108671
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-108671

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTTCATGGAGAA 2468
      :||||| :|| :|||||
      1 UCACAGACUCCUGGAGAA 19

Db

RESULT 952
US-11-101-244-113648/c
; Sequence 113648, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 113648
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-113648

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 974 TGACTGTGAACCTGACTCG 992
      ||| ||||||| |||||
      19 TGAGTGTGAACCTGGCTCG 1

Db

RESULT 953
US-11-101-244-149446
; Sequence 149446, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
```

```
; SEQ ID NO 149446
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-149446

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1979 GGGAGCAGCTGGCCCTGAT 1997
      ||||||| :|| :||| :|||
      1 GGGAGCUGCGGCACUGAU 19

Db

RESULT 954
US-11-101-244-153349
; Sequence 153349, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 153349
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-153349

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTTCATGGAGAA 2468
      :||||| :|| :||| :|||
      1 UCACUGAGUACAUUGGAGAA 19

Db

RESULT 955
US-11-101-244-158289
; Sequence 158289, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158289
```

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158289

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTCATGAGAA 2468
Db 1 UCACAGAAUUAUGGAGAA 19

RESULT 956
US-11-101-244-158376
; Sequence 158376, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158376
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158376

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2846 TGAGCAATCAGACGTGAT 2864
Db 1 UGAGCAAUCAAGGAGGUAAU 19

RESULT 957
US-11-101-244-158377
; Sequence 158377, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158377
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158377

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1777 GAGGTCAATACCATGAGA 1795
Db 1 GAGGUCAAAUACUAUGAAA 19

RESULT 958
US-11-101-244-158451
; Sequence 158451, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158451
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158451

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2710 GGAGGAAGATTCCCATCC 2728
Db 1 GGAGGAAGAUCCCUAUCC 19

RESULT 959
US-11-101-244-158521
; Sequence 158521, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158521
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158521
```

```

; ORGANISM: Homo sapiens
US-11-101-244-158521

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTCATGAGAA 2468
      :|||||:|:|||||
Db 1 UACAGAGUACAGGAGAA 19

RESULT 960
US-11-101-244-158525
; Sequence 158525, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158525
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158525

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2453 CAGAGTTCATGAGACGG 2471
      :|||||:|:|||||
Db 1 CAGAGUACAGGAGAAUGG 19

RESULT 961
US-11-101-244-158535
; Sequence 158535, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158535
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

```

```

US-11-101-244-158535

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2411 TGGAGGGCGTGTCAACAA 2429
      :|||||:|:|||||
Db 1 UGGAGGCGUGGUCACUA 19

RESULT 962
US-11-101-244-158948
; Sequence 158948, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158948
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158948

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 9.4e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 2804 TGTGGAGGTGATGTCTTT 2822
      :|:|||||:|:|||||
Db 1 UGUGGAGAGUCAUGUCAU 19

RESULT 963
US-11-101-244-158952
; Sequence 158952, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158952
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158952

```


Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2445 GATTCTCAGAGTTTCATG 2463
||: |||||: ||: ||
Db 1 GAUCAUCACAGAGUUAUG 19

RESULT 964

US-11-101-244-158958
; Sequence 158958, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158958
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158958

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 2807 GGGAGGTGATGTCATTTGG 2825
||| | : ||| : |||
Db 1 GGGAGUCAUGCAUUGG 19

RESULT 965

US-11-101-244-159005
; Sequence 159005, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159005
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159005

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2500 GACGGACAGTTCACAGTCA 2518
|| || ||| : ||| : ||
Db 1 GAUGGGCAGUUCACAGUCA 19

RESULT 966

US-11-101-244-159035
; Sequence 159035, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159035
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159035

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2807 GGGAGGTGATGTCATTTGG 2825
||| | : ||| : |||
Db 1 GGGAGGUGAUGUCCUAUGG 19

RESULT 967

US-11-101-244-159068
; Sequence 159068, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159068
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159068

Query Match 0.4%; Score 15.8; DB 1; Length 19;

Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2998 GACAGATGATCCGGAACC 3016
|||||:|:|:|:|:|:|
Db 1 GACAAGAGUAGUCCGCAUC 19

RESULT 968

US-11-101-244-159101
; Sequence 159101, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159101
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159101

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2500 GACGACAGTTCACAGTCA 2518
|||||:|:|:|:|:|:|
Db 1 GAUGGGCAGUUCACAGUCA 19

RESULT 969

US-11-101-244-159124
; Sequence 159124, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159124
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159124

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;

Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2807 GCGAGTGCATCTCATTTGG 2825
|||||:|:|:|:|:|:|
Db 1 GCGAGGUGAUGUCCUAUGG 19

RESULT 970

US-11-101-244-159148
; Sequence 159148, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159148
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159148

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2998 GACAAGATGATCCGGAACC 3016
|||||:|:|:|:|:|:|
Db 1 GACAAGAGUAGUCCGCAUC 19

RESULT 971

US-11-101-244-159210
; Sequence 159210, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159210
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159210

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 9.4e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 704 CCTCACCGTCTTCTACTA 722
||:|||||:|:|:|:|:|:|:|:
Db 1 CCUUCACCUUCUUCUACUA 19

RESULT 972
US-11-101-244-159219
; Sequence 159219, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159219
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159219

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
QY 2450 TCACAGAGTTCATGCAGAA 2468
||:|||||:|:|:|:|:|:|:|:
Db 1 UCACUGAGUUCUUGGAAAA 19

RESULT 973
US-11-101-244-159481
; Sequence 159481, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159481
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-159481

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2220 CAAGATTGAAGAGGTGATT 2238
||||:|:|:|:|:|:|:|:
Db 1 CAAGAUUGAGGAGGUCAUU 19

RESULT 974
US-11-101-244-182879/c
; Sequence 182879, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 182879
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-182879

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3876 TTAATTTTCTCCCGTTC 3894
|||||:|:|:|:|:|:|:|:
Db 19 TTAATTTTCTACCGTTC 1

RESULT 975
US-11-101-244-183246/c
; Sequence 183246, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 183246
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-183246

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1585 TTTGAGGTCACTGCATTGA 1603

Db	19	TTTGAGGTGACTTCATTGA	1
RESULT 976			
US-11-101-244-215222			
; Sequence 215222, Application US/11101244			
; Publication No. US20050246794A1			
; GENERAL INFORMATION:			
; APPLICANT: Dharmacon, Inc.			
; APPLICANT: Khvorova, Anastasia			
; APPLICANT: Reynolds, Angela			
; APPLICANT: Leake, Devin			
; APPLICANT: Marshall, William			
; APPLICANT: Scaringe, Stephen			
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA			
; FILE REFERENCE: 13499US			
; CURRENT APPLICATION NUMBER: US/11/101,244			
; CURRENT FILING DATE: 2005-04-07			
; PRIOR APPLICATION NUMBER: 60/502,050			
; PRIOR FILING DATE: 2003-09-10			
; PRIOR APPLICATION NUMBER: 60/426,137			
; PRIOR FILING DATE: 2002-11-14			
; NUMBER OF SEQ ID NOS: 1591911			
; SOFTWARE: Proprietary			
; SEQ ID NO 215222			
; LENGTH: 19			
; TYPE: RNA			
; ORGANISM: Homo sapiens			
US-11-101-244-215222			
Query Match 0.4%; Score 15.8; DB 1; Length 19;			
Best Local Similarity 78.9%; Pred. No. 9.4e+02;			
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;			
QY	3730	TGTCAGGGCCCGAGTACAA	3748
Db	1	UGUCAGGGCCCGAGAGAA	19
RESULT 977			
US-11-101-244-247832/c			
; Sequence 247832, Application US/11101244			
; Publication No. US20050246794A1			
; GENERAL INFORMATION:			
; APPLICANT: Dharmacon, Inc.			
; APPLICANT: Khvorova, Anastasia			
; APPLICANT: Reynolds, Angela			
; APPLICANT: Leake, Devin			
; APPLICANT: Marshall, William			
; APPLICANT: Scaringe, Stephen			
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA			
; FILE REFERENCE: 13499US			
; CURRENT APPLICATION NUMBER: US/11/101,244			
; CURRENT FILING DATE: 2005-04-07			
; PRIOR APPLICATION NUMBER: 60/502,050			
; PRIOR FILING DATE: 2003-09-10			
; PRIOR APPLICATION NUMBER: 60/426,137			
; PRIOR FILING DATE: 2002-11-14			
; NUMBER OF SEQ ID NOS: 1591911			
; SOFTWARE: Proprietary			
; SEQ ID NO 247832			
; LENGTH: 19			
; TYPE: RNA			
; ORGANISM: Homo sapiens			
US-11-101-244-247832			
Query Match 0.4%; Score 15.8; DB 1; Length 19;			
Best Local Similarity 89.5%; Pred. No. 9.4e+02;			
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	1612	TCCTCCTTAGCCACGGGGC	1630
Db	1	TCATGGGCTTCAGCTGTGC	1
RESULT 978			
US-11-101-244-256851/c			
; Sequence 256851, Application US/11101244			
; Publication No. US20050246794A1			
; GENERAL INFORMATION:			
; APPLICANT: Dharmacon, Inc.			
; APPLICANT: Khvorova, Anastasia			
; APPLICANT: Reynolds, Angela			
; APPLICANT: Leake, Devin			
; APPLICANT: Marshall, William			
; APPLICANT: Scaringe, Stephen			
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA			
; FILE REFERENCE: 13499US			
; CURRENT APPLICATION NUMBER: US/11/101,244			
; CURRENT FILING DATE: 2005-04-07			
; PRIOR APPLICATION NUMBER: 60/502,050			
; PRIOR FILING DATE: 2003-09-10			
; PRIOR APPLICATION NUMBER: 60/426,137			
; PRIOR FILING DATE: 2002-11-14			
; NUMBER OF SEQ ID NOS: 1591911			
; SOFTWARE: Proprietary			
; SEQ ID NO 256851			
; LENGTH: 19			
; TYPE: RNA			
; ORGANISM: Homo sapiens			
US-11-101-244-256851			
Query Match 0.4%; Score 15.8; DB 1; Length 19;			
Best Local Similarity 89.5%; Pred. No. 9.4e+02;			
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	2019	TGTGGTCCTGTCCTGGTG	2037
Db	19	TTTGGTCCTGTCCTGTG	1
RESULT 979			
US-11-101-244-314443/c			
; Sequence 314443, Application US/11101244			
; Publication No. US20050246794A1			
; GENERAL INFORMATION:			
; APPLICANT: Dharmacon, Inc.			
; APPLICANT: Khvorova, Anastasia			
; APPLICANT: Reynolds, Angela			
; APPLICANT: Leake, Devin			
; APPLICANT: Marshall, William			
; APPLICANT: Scaringe, Stephen			
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA			
; FILE REFERENCE: 13499US			
; CURRENT APPLICATION NUMBER: US/11/101,244			
; CURRENT FILING DATE: 2005-04-07			
; PRIOR APPLICATION NUMBER: 60/502,050			
; PRIOR FILING DATE: 2003-09-10			
; PRIOR APPLICATION NUMBER: 60/426,137			
; PRIOR FILING DATE: 2002-11-14			
; NUMBER OF SEQ ID NOS: 1591911			
; SOFTWARE: Proprietary			
; SEQ ID NO 314443			
; LENGTH: 19			
; TYPE: RNA			
; ORGANISM: Homo sapiens			
US-11-101-244-314443			
Query Match 0.4%; Score 15.8; DB 1; Length 19;			
Best Local Similarity 89.5%; Pred. No. 9.4e+02;			
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	1124	TCACGGGCTGCAGCTGTGC	1142
Db	19	TCATGGGCTTCAGCTGTGC	1

RESULT 980
US-11-101-244-351839
; Sequence 351839, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 351839
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-351839

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 3779 GCTGTCACCACTCA 3797
||:|||||:|
Db 1 GCUGUCAUCCAAAGUCA 19

RESULT 981
US-11-101-244-351938
; Sequence 351938, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 351938
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-351938

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 3779 GCTGTCACCACTCA 3797
||:|||||:|
Db 1 GCUGUCAUCCAAAGUCA 19

RESULT 982
US-11-101-244-351977
; Sequence 351977, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 351977
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-351977

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 3779 GCTGTCACCACTCA 3797
||:|||||:|
Db 1 GCUGUCAUCCAAAGUCA 19

RESULT 983
US-11-101-244-358726
; Sequence 358726, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 358726
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-358726

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1564 GTCCTGACTTCACCTATA 1582
||:|||||:|
Db 1 CGUACUGACUCCUUAUA 19

Query Match	Best Local Similarity	Score	DB 1	Length	DB 2	Indels	Gaps
US-11-101-244-368735	Sequence 368735, Application US/11101244	0.4%	Score 15.8; DB 1; Length 19;				
US-11-101-244-368735	Publication No. US20050246794A1	78.9%	Pred. No. 9.4e+02;				
US-11-101-244-368735	GENERAL INFORMATION:	Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;					
US-11-101-244-368735	APPLICANT: Dharmacon, Inc.						
US-11-101-244-368735	APPLICANT: Khvorova, Anastasia						
US-11-101-244-368735	APPLICANT: Reynolds, Angela						
US-11-101-244-368735	APPLICANT: Leake, Devin						
US-11-101-244-368735	APPLICANT: Marshall, William						
US-11-101-244-368735	APPLICANT: Scaringe, Stephen						
US-11-101-244-368735	TITLE OF INVENTION: Functional and Hyperfunctional siRNA						
US-11-101-244-368735	FILE REFERENCE: 13499US						
US-11-101-244-368735	CURRENT APPLICATION NUMBER: US/11/101,244						
US-11-101-244-368735	CURRENT FILING DATE: 2005-04-07						
US-11-101-244-368735	PRIOR APPLICATION NUMBER: 60/502,050						
US-11-101-244-368735	PRIOR FILING DATE: 2003-09-10						
US-11-101-244-368735	PRIOR APPLICATION NUMBER: 60/426,137						
US-11-101-244-368735	PRIOR FILING DATE: 2002-11-14						
US-11-101-244-368735	NUMBER OF SEQ ID NOS: 1591911						
US-11-101-244-368735	SOFTWARE: Proprietary						
US-11-101-244-368735	SEQ ID NO 368735						
US-11-101-244-368735	LENGTH: 19						
US-11-101-244-368735	TYPE: RNA						
US-11-101-244-368735	ORGANISM: Homo sapiens						
US-11-101-244-368735	US-11-101-244-368735						
Query Match	Best Local Similarity	Score 15.8; DB 1; Length 19;					
US-11-101-244-368735	Sequence 368735, Application US/11101244	0.4%	Score 15.8; DB 1; Length 19;				
US-11-101-244-368735	Publication No. US20050246794A1	78.9%	Pred. No. 9.4e+02;				
US-11-101-244-368735	GENERAL INFORMATION:	Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;					
US-11-101-244-368735	APPLICANT: Dharmacon, Inc.						
US-11-101-244-368735	APPLICANT: Khvorova, Anastasia						
US-11-101-244-368735	APPLICANT: Reynolds, Angela						
US-11-101-244-368735	APPLICANT: Leake, Devin						
US-11-101-244-368735	APPLICANT: Marshall, William						
US-11-101-244-368735	APPLICANT: Scaringe, Stephen						
US-11-101-244-368735	TITLE OF INVENTION: Functional and Hyperfunctional siRNA						
US-11-101-244-368735	FILE REFERENCE: 13499US						
US-11-101-244-368735	CURRENT APPLICATION NUMBER: US/11/101,244						
US-11-101-244-368735	CURRENT FILING DATE: 2005-04-07						
US-11-101-244-368735	PRIOR APPLICATION NUMBER: 60/502,050						
US-11-101-244-368735	PRIOR FILING DATE: 2003-09-10						
US-11-101-244-368735	PRIOR APPLICATION NUMBER: 60/426,137						
US-11-101-244-368735	PRIOR FILING DATE: 2002-11-14						
US-11-101-244-368735	NUMBER OF SEQ ID NOS: 1591911						
US-11-101-244-368735	SOFTWARE: Proprietary						
US-11-101-244-368735	SEQ ID NO 368735						
US-11-101-244-368735	LENGTH: 19						
US-11-101-244-368735	TYPE: RNA						
US-11-101-244-368735	ORGANISM: Homo sapiens						
US-11-101-244-368735	US-11-101-244-368735						

```
; Sequence 463025, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 463025
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-463025

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2206 GATGTCCTCTAGTCAAGA 2224
||:|:|:|:|:|:|:|:|:|:|
Db 1 GAUGUCACUACGUCAAGA 19

RESULT 989
US-11-101-244-520652
; Sequence 520652, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 520652
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-520652

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTTCATGGAGAA 2468
:|||||:|:|:|:|:|:|
Db 1 UCACAGAGUUCAGGAGAA 19

RESULT 990
US-11-101-244-553895
; Sequence 553895, Application US/11101244
```

```
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 553895
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-553895

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 3593 AAAAGGAAGTGCCCAACAT 3611
|||||:|:|:|:|:|:|
Db 1 AAAAGGAAGUGUCCAUAU 19

RESULT 991
US-11-101-244-558451
; Sequence 558451, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 558451
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-558451

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2288 GGAAGAAGGAGAGCTGTGT 2306
|||||:|:|:|:|:|:|
Db 1 GGAAGAAGGAGAGGAGUGU 19

RESULT 992
US-11-101-244-588523
; Sequence 588523, Application US/11101244
; Publication No. US20050246794A1
```

; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 588523
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-11-101-244-588523

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1564 CGTCCTGACTTCACCTATA 1582
||:||||:||||:
Db 1 CGUACUGACUCCUUAUA 19

RESULT 993
US-11-101-244-602297
; Sequence 602297, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 602297
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-11-101-244-602297

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 9.4e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3239 CGGACACCAAGAGAAAT 3257
|||||
Db 1 CGUGACACCAAGAGAAUAU 19

RESULT 994
US-11-101-244-632602
; Sequence 632602, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 632602
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-11-101-244-632602

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 9.4e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 704 CCTTCACCGTCTTCTACTA 722
|:||||:|:
Db 1 CAUCAACGUCUACUA 19

RESULT 995
US-11-101-244-633003/c
; Sequence 633003, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 633003
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-11-101-244-633003

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2801 TGATGTGGAGGTGATGTC 2819
|||||
Db 19 TGATGTGGAGGTGATGTC 1

RESULT 996
US-11-101-244-645883/c
; Sequence 645883, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 645883
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-645883

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3243 ACACCAGAGAAATCTTG 3261
||| ||||| ||||| |||||
Db 19 ACACAGAGCAATCTTG 1

RESULT 997
US-11-101-244-665485/c
; Sequence 665485, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 665485
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-665485

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2607 CAACATCCTAGTCACAGC 2625
||| ||||| ||||| |||||
Db 19 CAACATCCAGTCAATAGC 1

RESULT 998
US-11-101-244-669877
; Sequence 669877, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 669877
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-669877

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1564 GGTCTGACTTCACCTATA 1582
||: ||||| ||||| |||||
Db 1 CGUACUGACUCCUUA 19

RESULT 999
US-11-101-244-707935/c
; Sequence 707935, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 707935
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-707935

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2029 GTCCTGGTGGTCATTGTGG 2047
||| ||||| ||||| |||||
Db 19 GTACTGGTGGTCTTGCG 1

RESULT 1000
US-11-101-244-722881/c
; Sequence 722881, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela

```
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 722881
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-722881
```

```
Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 2801 TGATGTCGGAGTGTATGTC 2819
Db 19 TGATGTCGGCGTTGATGTC 1
```

```
RESULT 1001
US-11-101-244-729514
; Sequence 729514, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 729514
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-729514
```

```
Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 9.4e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 4003 CATCATGCTGTTTCCAGA 4021
Db 1 CAUGAUGUCUGUUCUAGA 19
```

```
RESULT 1002
US-11-101-244-729613
; Sequence 729613, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
```

```
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 729613
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-729613
```

```
Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 9.4e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 4003 CATCATGCTGTTTCCAGA 4021
Db 1 CAUGAUGUCUGUUCUAGA 19
```

```
RESULT 1003
US-11-101-244-748070
; Sequence 748070, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 748070
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-748070
```

```
Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 455 CTGCTCATCTGAAGTGGGT 473
Db 1 CUGCUGAUCUGUUGGUU 19
```

```
RESULT 1004
US-11-101-244-748086/c
; Sequence 748086, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
```

; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 748086
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-748086

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 3598 GAAGTGGCCCAACATCTCCC 3616
Db 19 GAAGTTTCCACATCTCCC 1

RESULT 1005
US-11-101-244-814212
; Sequence 814212, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 814212
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-814212

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
Qy 893 GCTTCTACCTGCCTTCCA 911
Db 1 GCUUCUACCGGCCCUCA 19

RESULT 1006
US-11-101-244-815617
; Sequence 815617, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 815617
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-815617

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
Qy 2292 GAAGGAGAGCTGTGTGCA 2310
Db 1 GAAGGAAAGCUGUGACA 19

RESULT 1007
US-11-101-244-829676/c
; Sequence 829676, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 829676
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-829676

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2375 TCATGGCCAGTTCGAGCA 2393
Db 19 TCATGGTCCAGTCGAGCA 1

RESULT 1008
US-11-101-244-858962
; Sequence 858962, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 858962
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-858962

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 504 GGAAGTGGCGGCTGGAT 522
|||:|||||:|:
Db 1 GGAAGUCAGCGGCCUGGAU 19

RESULT 1009
US-11-101-244-871328
; Sequence 871328, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 871328
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-871328

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1564 CGTCTGACTTCACCTATA 1582
||:|:|:|:|:|:|:
Db 1 CGUACUGACUUCUCCUAUA 19

RESULT 1010
US-11-101-244-889071/c
; Sequence 889071, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 889071
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-889071

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2644 TCTGACTTTGGCCTTCCC 2662
|||||:|||||:|:
Db 19 TCTGACTTGGGCTCTCCC 1

RESULT 1011
US-11-101-244-903949
; Sequence 903949, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 903949
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-903949

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 9.4e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 3012 GAACCCCGCAGCCTCAAA 3030
|||||:|||||:|:
Db 1 GAACCCAGCCAGCCUAUA 19

RESULT 1012
US-11-101-244-931273/c
; Sequence 931273, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244

; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 931273
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-931273

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 447 ATTGGAACCTGCTGATCTG 465
|||||
Db 19 ATTGGAACCTGCTGAGCTG 1

RESULT 1013

US-11-101-244-931865
; Sequence 931865, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 931865
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-931865

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 3625 CAGGTGCCCTCCCTCACCCTT 3643
|||||
Db 1 CAGTGGCCCTCCACCCU 19

RESULT 1014

US-11-101-244-943735
; Sequence 943735, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 943735
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-943735

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 9.4e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 835 GAGGCCACCGGAGGATGA 853
|||||
Db 1 GAGGCCACCGAGAAUGUGA 19

RESULT 1015

US-11-101-244-959149
; Sequence 959149, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 959149
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-959149

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 768 GGAGAACCCCTACATCAAG 786
|||||
Db 1 GGAGAGGCCCAUCAAG 19

RESULT 1016

US-11-101-244-959179
; Sequence 959179, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050

```
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 959179
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-959179

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 767 TGGAGAACCCCTACATCAA 785
Db 1 UGGAGAGGCCUACAACAA 19

RESULT 1017
US-11-101-244-965862/c
; Sequence 965862, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 965862
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-965862

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2618 TCAACAGCAACCTCGTCTG 2636
Db 19 TCAACAGCAACCTCAACTG 1

RESULT 1018
US-11-101-244-1012257
; Sequence 1012257, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
```

```
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1012257
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1012257

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2619 CAACAGCAACCTCGTCTGC 2637
Db 1 CAACAGCAACCCUUCUUC 19

RESULT 1019
US-11-101-244-1012356
; Sequence 1012356, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1012356
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1012356

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2619 CAACAGCAACCTCGTCTGC 2637
Db 1 CAACAGCAACCCUUCUUC 19

RESULT 1020
US-11-101-244-1029052/c
; Sequence 1029052, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
```



```

; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1111461

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1564 CGTCCTGCATTCACCTATA 1582
    ||: |||||: ||: ||
Db 1 CGUACUGACUUCUCCUAUA 19

RESULT 1029
US-11-101-244-1111653
; Sequence 1111653, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1111653
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1111653

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1564 CGTCCTGCATTCACCTATA 1582
    ||: |||||: ||: ||
Db 1 CGUACUGACUUCUCCUAUA 19

RESULT 1030
US-11-101-244-1111863
; Sequence 1111863, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1111863
; LENGTH: 19

```


QY 452 AAAGTCTGATCTGAAGT 470
||||:||||:|:||||:
Db 1 AAACUGCUGACCUAGUG 19

RESULT 1045
US-11-101-244-1207595
; Sequence 1207595, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1207595
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1207595

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 2808 GGAGGTGATGTCATTGGG 2826
||||:|:||||:|:
Db 1 GGAGGUGGUGCAUUGUG 19

RESULT 1046
US-11-101-244-1277041
; Sequence 1277041, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1277041
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1277041

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2746 GCCATTGCTTCGGAAGT 2764
||||:||||:|:||||:
Db 1 GCCAUUGCCUUCAGAAAGU 19

RESULT 1047
US-11-101-244-1315734
; Sequence 1315734, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1315734
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1315734

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 3828 CCCAGCTGCTGCCCTTCATA 3846
||||:|:||||:|:
Db 1 CCCAGCUCUCCUUCUUA 19

RESULT 1048
US-11-101-244-1355528/c
; Sequence 1355528, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1355528
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1355528

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3469 TTTGGAGACAGGATTG 3487


```

Db      1 GGUCAGCGCCCAAGACAAG 19
|||||
RESULT 1053
US-11-083-784-31906
; Sequence 31906, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 31906
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-31906

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy      3952 GGAACCTGTTTCACATATGG 3970
|||||
Db      1 GGAAGCUGAUAUCACUAUGG 19

RESULT 1054
US-11-083-784-51586
; Sequence 51586, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 51586
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-51586

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Db      1 GGUCAGCGCCCAAGACAAG 19
|||||
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy      2985 GGTACGCGCCTGGACAAG 3003
|||||
Db      1 GGUCAGCGCCCAAGACAAG 19

RESULT 1055
US-11-083-784-88135/C
; Sequence 88135, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 88135
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-88135

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2032 CTGCTGTCATTGTGGTCG 2050
|||||
Db      19 CTTGTGTCATTCTGTCG 1

RESULT 1056
US-11-083-784-108278
; Sequence 108278, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 108278
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-108278
```

```
Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTTCATGGAGAA 2468
:|||||:|:|:|||||
Db 1 UCACAGACUCCUGGAGAA 19

RESULT 1057
US-11-083-784-108374
; Sequence 108374, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 108374
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-108374

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTTCATGGAGAA 2468
:|||||:|:|:|||||
Db 1 UCACAGACUCCUGGAGAA 19

RESULT 1058
US-11-083-784-108473
; Sequence 108473, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 108473
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-108473

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTTCATGGAGAA 2468
:|||||:|:|:|||||
Db 1 UCACAGACUCCUGGAGAA 19

RESULT 1059
US-11-083-784-108571
; Sequence 108571, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 108571
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-108571

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTTCATGGAGAA 2468
:|||||:|:~|:|||||
Db 1 UCACAGACUCCUGGAGAA 19

RESULT 1060
US-11-083-784-108671
; Sequence 108671, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
```



```
; SOFTWARE: Proprietary
; SEQ ID NO 108671
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-108671

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTCATGGAGAA 2468
Db 1 UCACAGACUUCUGGAGAA 19

RESULT 1061
US-11-083-784-113648/c
; Sequence 113648, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 113648
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-113648

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 974 TGACTGTGAACCTGACTCG 992
Db 19 TGAGTGTGAACCTGGCTCG 1

RESULT 1062
US-11-083-784-149446
; Sequence 149446, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
```

```
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 149446
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-149446

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1979 GGGAGCAGCTGGCCCTGAT 1997
Db 1 GGGAGCUGGCGACUGAU 19

RESULT 1063
US-11-083-784-153349
; Sequence 153349, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 153349
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-153349

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTCATGGAGAA 2468
Db 1 UCACUGAGUACUGGAGAA 19

RESULT 1064
US-11-083-784-158289
; Sequence 158289, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
```

```
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158289
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158289

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy      2450 TCACAGAGTTCATGGAGAA 2468
Db      1 UCACAGAAUUUUGGAGAA 19

RESULT 1065
US-11-083-784-158376
; Sequence 158376, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158376
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158376

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy      2846 TGACCAATCAGGCGTGTAT 2864
Db      1 UGACCAUUCAGGAGGUUUAU 19

RESULT 1066
US-11-083-784-158377
; Sequence 158377, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
```

```
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158377
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158377

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy      2710 GGAGGAAGATTCCTCCATCC 2728
Db      1 GGAGGAAGAUCCCUAUCC 19

RESULT 1067
US-11-083-784-158451
; Sequence 158451, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158451
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158451

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy      1777 GAGGTCAATATACCATGAGA 1795
Db      1 GAGGUCAAAUACUAGUAAA 19

RESULT 1068
US-11-083-784-158521
; Sequence 158521, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
```

; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158521
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158521

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2450 TCACAGAGTTCATGGAGAA 2468
:|||||:|||||
Db 1 UAACAGAGUACGAGGAGAA 19

RESULT 1069
US-11-083-784-158525
; Sequence 158525, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158525
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158525

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2453 CAGAGTTCATGGAGAACGG 2471
:|||||:|||||
Db 1 CAGAGUACGAGGAGAAUGG 19

RESULT 1070
US-11-083-784-158535
; Sequence 158535, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158535
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158535

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2411 TGGAGGGCGTGTCTACCAA 2429
:|||||:|||||
Db 1 UGGAAGCGGUGGUCACUAA 19

RESULT 1071
US-11-083-784-158948
; Sequence 158948, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158948
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158948

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 9.4e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 2804 TGTGGAGGTGATGTCATT 2822
:|||||:|||||
Db 1 UGUGGAGGAGUCAGUCAU 19

RESULT 1072
US-11-083-784-158952
; Sequence 158952, Application US/11083784
; Publication No. US20050245475A1

```
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158952
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158952
```

```
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 2445 GATTCTCACAGAGTTCATG 2463
|||:|||||:|:|:|:|:|:|:|
Db 1 GAUCAUCAGAGUUAUG 19
```

RESULT 1073

```
US-11-083-784-158958
; Sequence 158958, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158958
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158958
```

```
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 2807 GGGAGGTGATGTCATTGG 2825
|||||:|:|:|:|:|:|:|
Db 1 GGGAGUAGUAGUUAUGG 19
```

RESULT 1074

```
US-11-083-784-159005
; Sequence 159005, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159005
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159005
```

```
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 2500 GACGACAGTTCACAGTCA 2518
|||:|||||:|:|:|:|:|:|
Db 1 GAUGGCGAGUACAGUCA 19
```

RESULT 1075

```
US-11-083-784-159035
; Sequence 159035, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159035
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159035
```

```
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 2807 GGGAGGTGATGTCATTGG 2825
|||||:|:|:|:|:|:|:|
Db 1 GGGAGGUGAUGUCCUAUGG 19
```

RESULT 1076
US-11-083-784-159068
; Sequence 159068, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159068
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159068

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 2998 GACAAGATGATCCGAACC 3016
Db 1 GACAAGAUGAUGCCGAUC 19

RESULT 1077
US-11-083-784-159101
; Sequence 159101, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159101
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159101

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2500 GACGACAGTTCACAGTCA 2518
Db 1 GAUGGGCAGUUCACAGUCA 19

RESULT 1078
US-11-083-784-159124
; Sequence 159124, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159124
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159124

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2807 GGGAGGTGATGTCATTGG 2825
Db 1 GGGAGGUGAUGUCCUAUGG 19

RESULT 1079
US-11-083-784-159148
; Sequence 159148, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159148
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159148

Query Match 0.4%; Score 15.8; DB 1; Length 19;

Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2998 GACAAGATGATCGGACC 3016
|||||:|:|:|:|:|:|
Db 1 GACAAGAUGAUCGCAUC 19

RESULT 1080
US-11-083-784-159210
; Sequence 159210, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159210
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159210

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 9.4e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 704 CCTTCACCGTCTTACTA 722
||:|:|:|:|:|:|
Db 1 CCUUCACCUUCUACUA 19

RESULT 1081
US-11-083-784-159219
; Sequence 159219, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159219
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-11-083-784-159219

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2450 TCACAGATTTCATGGAGAA 2468
:|:|:|:|:|:|:|:|:|:|:|:|
Db 1 UCACUGAGUUGGAGGAAA 19

RESULT 1082
US-11-083-784-159481
; Sequence 159481, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 159481
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-159481

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2220 CAAGATTGAGAGGTGATT 2238
||:|:|:|:|:|:|:|:|:|:|:|:|
Db 1 CAAGAUGAGGAGGUGCAUU 19

RESULT 1083
US-11-083-784-182879/c
; Sequence 182879, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 182879

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-182879

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3876 TTAATTTTCTCCCGTTC 3894
Db 19 TTAATTTTCTCCCGTTC 1

RESULT 1084
US-11-083-784-183246/c
; Sequence 183246, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 183246
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-183246

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1585 TTTGAGGTCACTGCATTGA 1603
Db 19 TTTGAGGTCACTGCATTGA 1

RESULT 1085
US-11-083-784-215222
; Sequence 215222, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 215222
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-215222

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1612 TCCTCCTTAGCCACGGGC 1630
Db 19 TCATCCTTAGCCACGGTGC 1

RESULT 1087
US-11-083-784-256851/c
; Sequence 256851, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-11-14

; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 247832
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-247832

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3730 TGTGAGGGCCCGAGTGA 3748
Db 1 UGUCAGGGCCCGAGAGAA 19

RESULT 1086
US-11-083-784-247832/c
; Sequence 247832, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 247832
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-247832

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 3730 TGTGAGGGCCCGAGTGA 3748
Db 1 UGUCAGGGCCCGAGAGAA 19
```

```
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 256851
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-256851

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2019 TGTGGTCCTGGTCCTGTGTG 2037
Db 19 TTTGGTCCTGGTCCTGTGTG 1

RESULT 1088
US-11-083-784-314443/c
; Sequence 314443, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 314443
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-314443

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1124 TCACGGGCTCAGCTGTGTC 1142
Db 19 TCATGGGCTTCAGCTGTGTC 1

RESULT 1089
US-11-083-784-351839
; Sequence 351839, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18

; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 351839
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-351839

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 3779 GCTGTCACCACCAACTCA 3797
Db 1 GCUGUCAUCCCAAGUCA 19

RESULT 1090
US-11-083-784-351938
; Sequence 351938, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 351938
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-351938

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 3779 GCTGTCACCACCAACTCA 3797
Db 1 GCUGUCAUCCCAAGUCA 19

RESULT 1091
US-11-083-784-351977
; Sequence 351977, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```



```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 351977
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-351977

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 3779 GCTGTCACCACTCA 3797
||:|||||:|
Db 1 GCUGUCAUCCAAAGUCA 19

RESULT 1092
US-11-083-784-358726
; Sequence 358726, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 358726
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-358726

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1564 CGTCCTGACTTCACCTATA 1582
||:|||||:|
Db 1 CGUACUGACUUCUCCUAU 19

RESULT 1093
US-11-083-784-358909
; Sequence 358909, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
```

```
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 358909
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-358909

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1564 CGTCCTGACTTCACCTATA 1582
||:|||||:|
Db 1 CGUACUGACUUCUCCUAU 19

RESULT 1094
US-11-083-784-367347
; Sequence 367347, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 367347
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-367347

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 9.4e+02;
Matches 10; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 2804 TGTGGAGGTGATCTCATT 2822
:|||||:|:|:|:|:|
Db 1 UGUGGCAGUGAUGUCAU 19

RESULT 1095
US-11-083-784-368735
; Sequence 368735, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
```

```
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 368735
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-368735
```

```
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 510 GAGCGCCTCGATGAGAA 528
      |||||:||||:|||||
Db 1 GAGCUGCCUGGAGAGAA 19
```

RESULT 1096

```
US-11-083-784-401647
; Sequence 401647, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 401647
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-401647
```

```
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 109 CAACCTCAGCCAGCTCTTG 127
      |||||:||||:|||||
Db 1 CAACACCAGCCAGCGAUG 19
```

RESULT 1097

```
US-11-083-784-463025
; Sequence 463025, Application US/11083784
```

```
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 463025
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-463025
```

```
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 2206 GATGTCCTCTAGTCAAGA 2224
      ||:|:|:||||:|||||
Db 1 GAUGUCACUUCAGCUCAAGA 19
```

RESULT 1098

```
US-11-083-784-520652
; Sequence 520652, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 520652
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-520652
```

```
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 2450 TCACAGAGTTTCATGGAGAA 2468
      :|||||:||||:|||||
Db 1 UGACACAGAUUCAUGGAAAA 19
```

```
RESULT 1099
US-11-083-784-553895
; Sequence 553895, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 553895
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-553895

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 3593 AAAAGGAGTGGCCACAT 3611
DB 1 AAAAGGAGUGUCCAAUAU 19

RESULT 1100
US-11-083-784-558451
; Sequence 558451, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 558451
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-558451

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2288 GGAAGAAGGAGAGCTGTGT 2306
DB 1 GGAAGAAGGAGAGCTGTGT 2306
```

```
Db 1 GGAAGAAGGAGAGGAGUGU 19

RESULT 1101
US-11-083-784-588523
; Sequence 588523, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 588523
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-588523

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1564 CGTCCTGACTTCACCTATA 1582
DB 1 CGUACUGACUUCUCCUAUA 19

RESULT 1102
US-11-083-784-602297
; Sequence 602297, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 602297
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-602297

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 9.4e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
```

```

Qy      3239 CCGGACACCAGAGAAAAAT 3257
        ||| ||||| ||||| :
Db      1 CGUGACACCAGAAUAU 19

RESULT 1103
US-11-083-784-632602
; Sequence 632602, Application US//1083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hypo
; FILE REFERENCE: I3499US
; CURRENT APPLICATION NUMBER: US//1083,7
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US//10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 632602
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-632602
```

Query Match	0.4%	Score	15.8	DB	1	Length	19
Best Local Similarity	52.6%	Pred. No.	9.4e+02				
Matches	10	Conservative	7	Mismatches	2	Indels	0
						Gaps	0

Qy 704 CCTTACCGTCTTCTACTA 722
| : : | | : : | : : |
Db 1 CAUUCACGUCUUCUACUA 19

```

RESULT 1104
US-11-083-784-633003/c
; Sequence 633003, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 633003
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-633003

```

```

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. NO. 9.4e-02;
Matches 17; Conservative 0; Mismatches 2; Indels

Qy      2801  TGA TGTGGGAGGTGATGTC 2819
          |||||  |||||  |||||  |||||
Db      19    TGA TGTGGGAGGTGATGTC 1

RESULT 1105
US-11-083-784-645883/c
; Sequence 645883, Application US//11083784
; Publication NO. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US//11083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US//10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 645883
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-645883

```

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels

Qy 3243 ACACGAGAAGAAATCTTG 3261
||| ||||| ||||| |||
pb 19 ACAACGAGAAGCAATCTTG 1

```

RESULT 1106
US-11-083-784-665485/c
; Sequence 665485, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13493US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIORITY APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIORITY APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 665485
; LENGTH: 19
; TYPE: RNA

```

```
; ORGANISM: Homo sapiens
US-11-083-784-665485

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2607 CAACATCTAGTCAACAGC 2625
||||| ||||| |||
Db 19 CAACATCCAGTCATATGC 1

RESULT 1107
US-11-083-784-669877
; Sequence 669877, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 669877
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-669877

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1564 CGTCTGACTTCACCTATA 1582
||:||||:| ||:|
Db 1 CGUACUGACUUCUCCUAUA 19

RESULT 1108
US-11-083-784-707935/c
; Sequence 707935, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
```

```
; SEQ ID NO 707935
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-707935

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2029 GTCTGTGGTTCATTGTGG 2047
|| ||||| ||||| |||||
Db 19 GTACTGTGGTCTTGTGG 1

RESULT 1109
US-11-083-784-722881/c
; Sequence 722881, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 722881
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-722881

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2801 TGATGTGGGAGGTGATGTC 2819
||||| ||||| ||||| |||||
Db 19 TGATGTGGGCGTTGATGTC 1

RESULT 1110
US-11-083-784-729514
; Sequence 729514, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
```



```
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 814212
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-814212

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy      893 GCTTCTACCTGCGCTTCCA 911
Db      1 GCUUCUACCGGCCCUCA 19

RESULT 1115
US-11-083-784-815617
; Sequence 815617, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 815617
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-815617

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy      2292 GAAGGAGAGCTGTGTGGCA 2310
Db      1 GAAGGAAAGCUGUGUGACA 19

RESULT 1116
US-11-083-784-829676/c
; Sequence 829676, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
```

```
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 829676
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-829676

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2375 TCATGGGCCAGTTCGAGCA 2393
Db      19 TCATGGTCCAGCTCGAGCA 1

RESULT 1117
US-11-083-784-858962
; Sequence 858962, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 858962
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-858962

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy      504 GGAAGTGGCGGCGCTGGAT 522
Db      1 GGAAGCAGCGCGCCUGGAU 19

RESULT 1118
US-11-083-784-871328
; Sequence 871328, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
```

```

; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134930US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 871328
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-11-083-784-871328

```

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1564 CGTCCTGACTTCACCTATA 1582
||:|:|:|:|:|:|:|:|:|:
pb 1 CGUACUGACUUCUCCUAA 19

```

RESULT 1119
US-11-083-784-889071/c
; Sequence 889071, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khivotova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsinge, Stephen
; TITLE OF INVENTION: Functional and Hypo
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,7
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 889071
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-889071

```

Query Match	0.4%	Score 15.8;	DB 1;	Length 19;
Best Local Similarity	89.5%	Pred. No. 9.4e+02;		
Matches 17; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;

Qy 2644 TCTGACTTTGGCCCTTTCCC 2662
|||
pb 19 TCTGACTTTGGCCCTCTCCC 1

RESULT 1120
US-11-083-784-903949
; Sequence 903949, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:

```

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Kivoroova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13498US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/456,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 903949
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-11-083-784-903949

```

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 9.4e+02;
Matches 16: Conservative 1; Mismatches 2; Indels

Qy 3012 GAACCCCGCCAGCCTCAAA 3030
|||
Db 1 GAACCCAGCCAGCCUCAUA 19

```

RESULT 1121
US-11-083-784-931273/c
; Sequence 931273, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 931273
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-931273

```

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. NO.9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels

Qy 447 ATTGAAACTGCTGATCTG 465
|||
Db 19 ATTGAAACTGCTCAGCTG 1

RESULT 1122
US-11-083-784-931865


```
; Sequence 931865, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 931865
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-931865

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy      3625 CAGGTGCCCCCTACCTT 3643
Db      1 CAGCUGCCCCCUCACCUU 19

RESULT 1123
US-11-083-784-943735
; Sequence 943735, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 943735
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-943735

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 9.4e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy      835 GAGGCCACCGGAGGTGA 853
Db      1 GAGGCCACCGGAAUGUGA 19
```

```
RESULT 1124
US-11-083-784-959149
; Sequence 959149, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 959149
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-959149

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 9.4e+02;
Matches 15; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy      768 GGAGAACCCCTACATCAA 786
Db      1 GGAGAGGCCCAUCAAG 19

RESULT 1125
US-11-083-784-959179
; Sequence 959179, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 959179
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-959179

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy      767 TGGAGAACCCCTACATCAA 785
```

Db	1	UGGAGGAGGCCUACAUA 19	Matches 14;	Conservative 3;	Mismatches 2;	Indels 0;	Gaps 0;
RESULT 1126							
US-11-083-784-965862/c							
Sequence 965862, Application US/11083784							
Publication No. US20050245475A1							
GENERAL INFORMATION:							
APPLICANT: Dharmakon, Inc.							
APPLICANT: Khvorova, Anastasia							
APPLICANT: Reynolds, Angela							
APPLICANT: Leake, Devin							
APPLICANT: Marshall, William							
APPLICANT: Scaringe, Stephen							
TITLE OF INVENTION: Functional and Hyperfunctional siRNA							
FILE REFERENCE: 13499US							
CURRENT APPLICATION NUMBER: US/11/083,784							
PRIOR FILING DATE: 2005-03-18							
PRIOR APPLICATION NUMBER: 60/502,050							
PRIOR FILING DATE: 2003-09-10							
PRIOR APPLICATION NUMBER: 60/426,137							
PRIOR FILING DATE: 2002-11-14							
NUMBER OF SEQ ID NOS: 1591911							
SOFTWARE: Proprietary							
SEQ ID NO 965862							
LENGTH: 19							
TYPE: RNA							
ORGANISM: Homo sapiens							
US-11-083-784-965862							
Query Match			0.4%;	Score 15.8;	DB 1;	Length 19;	
Best Local Similarity			89.5%;	Pred. No. 9.4e+02;			
Matches 17;			Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;	
QY	2618	TCAACGACCACTCGCTG 2636					
Db	19	TCAACGACCACTCGCTG 1					
RESULT 1127							
US-11-083-784-1012257							
Sequence 1012257, Application US/11083784							
Publication No. US20050245475A1							
GENERAL INFORMATION:							
APPLICANT: Dharmakon, Inc.							
APPLICANT: Khvorova, Anastasia							
APPLICANT: Reynolds, Angela							
APPLICANT: Leake, Devin							
APPLICANT: Marshall, William							
APPLICANT: Scaringe, Stephen							
TITLE OF INVENTION: Functional and Hyperfunctional siRNA							
FILE REFERENCE: 13499US							
CURRENT APPLICATION NUMBER: US/11/083,784							
PRIOR FILING DATE: 2005-03-18							
PRIOR APPLICATION NUMBER: US/10/714,333							
PRIOR FILING DATE: 2003-11-14							
PRIOR APPLICATION NUMBER: 60/502,050							
PRIOR FILING DATE: 2003-09-10							
PRIOR APPLICATION NUMBER: 60/426,137							
PRIOR FILING DATE: 2002-11-14							
NUMBER OF SEQ ID NOS: 1591911							
SOFTWARE: Proprietary							
SEQ ID NO 1012257							
LENGTH: 19							
TYPE: RNA							
ORGANISM: Homo sapiens							
US-11-083-784-1012257							
Query Match			0.4%;	Score 15.8;	DB 1;	Length 19;	
Best Local Similarity			73.7%;	Pred. No. 9.4e+02;			
Matches 14;			Conservative 3;	Mismatches 2;	Indels 0;	Gaps 0;	
QY	2619	CAACGACCACTCGCTGC 2637					
Db	1	CAACGACCACTCGCTGC 19					
RESULT 1128							
US-11-083-784-1012356							
Sequence 1012356, Application US/11083784							
Publication No. US20050245475A1							
GENERAL INFORMATION:							
APPLICANT: Dharmakon, Inc.							
APPLICANT: Khvorova, Anastasia							
APPLICANT: Reynolds, Angela							
APPLICANT: Leake, Devin							
APPLICANT: Marshall, William							
APPLICANT: Scaringe, Stephen							
TITLE OF INVENTION: Functional and Hyperfunctional siRNA							
FILE REFERENCE: 13499US							
CURRENT APPLICATION NUMBER: US/11/083,784							
PRIOR FILING DATE: 2005-03-18							
PRIOR APPLICATION NUMBER: US/10/714,333							
PRIOR FILING DATE: 2003-11-14							
PRIOR APPLICATION NUMBER: 60/502,050							
PRIOR FILING DATE: 2003-09-10							
PRIOR APPLICATION NUMBER: 60/426,137							
PRIOR FILING DATE: 2002-11-14							
NUMBER OF SEQ ID NOS: 1591911							
SOFTWARE: Proprietary							
SEQ ID NO 1012356							
LENGTH: 19							
TYPE: RNA							
ORGANISM: Homo sapiens							
US-11-083-784-1012356							
Query Match			0.4%;	Score 15.8;	DB 1;	Length 19;	
Best Local Similarity			73.7%;	Pred. No. 9.4e+02;			
Matches 14;			Conservative 3;	Mismatches 2;	Indels 0;	Gaps 0;	
QY	2619	CAACGACCACTCGCTGC 2637					
Db	1	CAACGACCACTCGCTGC 19					

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1033475

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2644 TCTGACTTTGGCCTTCC 2662
Db      19 TCTGACTCTGGCCTTTGCC 1

RESULT 1130
US-11-083-784-1030733
; Sequence 1030733, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083.784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714.333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1030733
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1030733

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2176 GAGCGTGTGAGGGAATTG 2194
Db      1 GAGCGUGUGAGAAUUG 19

RESULT 1131
US-11-083-784-1033475/c
; Sequence 1033475, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083.784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714.333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1033475
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1033475

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3960 TTTCACATGCGCTCCTTT 3978
Db      19 TTTCGTATGCGCTCCTTT 1

RESULT 1132
US-11-083-784-1104856
; Sequence 1104856, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083.784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714.333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1104856
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1104856

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 9.4e+02;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2159 CTTATGAAGACCTAATGA 2177
Db      1 CUAAGAAGACCCUAAAGA 19

RESULT 1133
US-11-083-784-1110635
; Sequence 1110635, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083.784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714.333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
```



```

RESULT 1139
US-11-083-784-1111863
; Sequence 1111863, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scarsing, Stephen
; TITLE OF INVENTION: Functional and Hyper-
FILE REFERENCE: 13499US

```

RESULT 1141
US-11-083-784-112255
; Sequence 1112255, Application US/11083784
; Publication NO. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William


```
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1112941
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1112941

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1564 CGTCCTGACTTCACCTATA 1582
Db 1 CGUACUGACUUCUCCUAUA 19

RESULT 1146
US-11-083-784-1113149
; Sequence 1113149, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1113149
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1113149

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1564 CGTCCTGACTTCACCTATA 1582
Db 1 CGUACUGACUUCUCCUAUA 19

RESULT 1147
US-11-083-784-1113149
; Sequence 1113149, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1113149
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1113149

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1564 CGTCCTGACTTCACCTATA 1582
Db 1 CGUACUGACUUCUCCUAUA 19

RESULT 1148
US-11-083-784-1113350
; Sequence 1113350, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1113350
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1113350

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1564 CGTCCTGACTTCACCTATA 1582
Db 1 CGUACUGACUUCUCCUAUA 19

RESULT 1148
US-11-083-784-1113545
; Sequence 1113545, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1113545
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1113545

Query Match      0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1564 CGTCCTGACTTCACCTATA 1582
Db 1 CGUACUGACUUCUCCUAUA 19
```

RESULT 1149
US-11-083-784-1113749
; Sequence 1113749, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1113749
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1113749

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1564 CGTCCTGACTTCACCTATA 1582
||:|:|:|:|:|:|:|:|:|:|:
Db 1 CGUACUGACUUCUCCUAUA 19

RESULT 1150
US-11-083-784-1113949
; Sequence 1113949, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1113949
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1113949

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1564 CGTCCTGACTTCACCTATA 1582
||:|:|:|:|:|:|:|:|:|:|:
Db 1 CGUACUGACUUCUCCUAUA 19

RESULT 1151
US-11-083-784-1114149
; Sequence 1114149, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1114149
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1114149

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1564 CGTCCTGACTTCACCTATA 1582
||:|:~|:|:|:|:|:|:|:|:|:|:
Db 1 CGUACUGACUUCUCCUAUA 19

RESULT 1152
US-11-083-784-1162888/c
; Sequence 1162888, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1162888
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1162888

Query Match 0.4%; Score 15.8; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 9.4e+02; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 AAACCTGCTGATCTGAAGTG 470
||||| ||||| ||||| ||||| |||||
Db 19 AAACCTCCTGATCTCAAGTG 1

RESULT 1153
US-11-083-784-1175693
; Sequence 1175693, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1175693
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1175693

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9.4e+02; DB 1; Length 19;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 452 AAACCTGCTGATCTGAAGTG 470
||||| ||||| ||||| ||||| |||||
Db 1 AAACUGUGACCUCAAGUG 19

RESULT 1154
US-11-083-784-1207595
; Sequence 1207595, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1207595
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens

US-11-083-784-1207595
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 9.4e+02; DB 1; Length 19;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 2808 GGAGGTGATGTCATTTGGG 2826
||||| ||||| ||||| ||||| |||||
Db 1 GGAGGUGUGCAUUCUG 19

RESULT 1155
US-11-083-784-1277041
; Sequence 1277041, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1277041
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1277041

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02; DB 1; Length 19;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2746 GCCATTGCCTTCGGAGT 2764
||||| ||||| ||||| ||||| |||||
Db 1 GCCAUGGCCUUCAGAAAGU 19

RESULT 1156
US-11-083-784-1315734
; Sequence 1315734, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1315734

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1315734

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 3828 CCCAGCTGCTGCCTTCATA 3846
    |||||:|:||||:|:|
Db 1 CCCAGCUCGCGCCTCUUA 19

RESULT 1157
US-11-083-784-1355528/c
; Sequence 1355528, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1355528
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1355528

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3469 TTTGGAGACAGGAGTTTG 3487
    |||||:|||||:|
Db 19 TATGGAGACAGGAGTTG 1

RESULT 1158
US-11-083-784-1377429/c
; Sequence 1377429, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1377429
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1377429

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 466 AAGTGGTGACATTCCTC 484
    |||||:|||||:|
Db 19 AAGTAGTGACACTCCCTC 1

RESULT 1159
US-11-083-784-1380520/c
; Sequence 1380520, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1380520
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1380520

Query Match          0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 9.4e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2799 TGTGATGTGGAGGTGATG 2817
    |||||:|||||:|
Db 19 TGTGATGTGCGTGGTGATG 1

RESULT 1160
US-11-083-784-1563938
; Sequence 1563938, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
```

; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1563938
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1563938

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 9.4e+02;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 702 GACCTTCACCTCTCTAC 720
|||::|||::|::|::|::|
Db 1 GACCTUCAACGUCUAC 19

RESULT 1161
US-10-310-914A-76027/c
; Sequence 76027, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 76027
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-76027

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 4086 GGGGTGTGGGTGGGT 4102
|||||::|||::|::|::|::|
Db 17 GGGGTGTGGGTGGGT 1

RESULT 1162
US-10-310-914A-88249/c
; Sequence 88249, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 88249
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-88249

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 169 GCCCGCGCGCGCGC 185
|||||::|||::|::|::|::|
Db 17 GCCCGCGCGCGCGC 1
|||||::|||::|::|::|::|

RESULT 1163
US-10-310-914A-142074/c
; Sequence 142074, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 142074
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-142074

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3820 GCCCTCCCCCAGCTGC 3836
|||||::|||::|::|::|::|
Db 18 GCCCTCCCCCAGCTCC 2

RESULT 1164
US-10-310-914A-194147/c
; Sequence 194147, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 194147
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-194147

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1530 CCTGGTGGAGCCCTGGG 1546
|||::|||::|::|::|::|
Db 18 CCAGGTGGAGCCCTGGG 2

RESULT 1165
US-10-310-914A-196436/c
; Sequence 196436, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 196436
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-196436

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1230 CCAGCCATGCCCGCCCA 1246
Db 18 CCAGCCAGCCCGCCCA 2

RESULT 1166
US-10-310-914A-215704
; Sequence 215704, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 215704
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-215704

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 171 CCGCGCCCGCGCGCGC 187
Db 2 CCGCGCCCGCGCGCGC 18

RESULT 1167
US-10-310-914A-233017/c
; Sequence 233017, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 233017
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-233017

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3891 GTTCCCTTTTGTCT 3907

Db 17 GTTCCCTCTTGTCT 1

RESULT 1168
US-10-310-914A-239452/c
; Sequence 239452, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 239452
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-239452

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1059 CCGCGCCCTGCGCCCA 1075
Db 18 CCGCGCCCTGCGCCCA 2

RESULT 1169
US-10-310-914A-277041/c
; Sequence 277041, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 277041
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-277041

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 144 CCGCGCCACTGCCAGCA 160
Db 18 CCGCGCTACTGCCAGCA 2

RESULT 1170
US-10-310-914A-291755
; Sequence 291755, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A


```

; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 482383
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-482383

```

Query Match	0.4;	Score	15.4;	DB	1;	Length	18;
Best Local Similarity	94.1;	Pred. No.	9.5e+02;				
Matches	16;	Conservative	0;	Mismatches	1;	Indels	0;
						Gaps	0;

Qy 169 GCCCGCCGCCCGCGGC 185
Db 18 GCCCGCCGCCCGCGGC 2

RESULT 1176
US-10-310-914A-493585/c
; Sequence 493585, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:
 ; APPLICANT: Bentwich, Isaac
 ; APPLICANT: Shiler, Kvyzat

```

, TITLE OF INVENTION: Bioinformatically determined
, TITLE OF INVENTION: uses thereof
, FILE REFERENCE: 06087.02000.CPUS01
, CURRENT APPLICATION NUMBER: US/10/310,914A
, CURRENT FILING DATE: 2002-12-06
, NUMBER OF SEQ ID NOS: 1388402
, SOFTWARE: Patent in version 3.3

```

```

; SEQ ID NO 493585
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-493

```

Query Match	0.4;	Score 15.4;	DB 1;	Length 18;
Best Local Similarity	94.1;	Pred. NO. 9.5e+02;		
Matches 16;	Conservative	0;	Mismatches 1;	Indels 0;
Gaps	0;			

QY 184 GCGGGCACAGACGGG 200
Db 18 GCGGGCACAGGGCGG 2

RESULT 1177
US-10-310-914A-509676
; Sequence 509676, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:
 ; APPLICANT: Bentwich, Isaac
 : APPLICANT: Shiler, Kvyzato

```
,
, CACNA, beta, bioinformatically detectable group of novel regulatory genes and
,
, TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
, TITLE OF INVENTION: uses thereof
, FILE REFERENCE: 06087.0200.CPUS01
, CURRENT APPLICATION NUMBER: US/10/310,914A
, CURRENT FILING DATE: 2002-12-06
, NUMBER OF SEQ ID NOS: 1388402
, SOFTWARE: PatentIn version 3.3
,
```

```

; SOURCE: JACOBSON
; SEQ ID NO 509676
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-509

```

Query Match	0.4%	Score 15.4;	DB 1;	Length 18;
Best Local Similarity	76.5%;	Pred. NO. 9.5e+02;		
Matches 13;	Conservative	3;	Mismatches 1;	Indels 0;
Gaps				

Qy	3823	CCTCCCCAGCTGCTGC	3839
		: : :	
Db	2	CCUCCUCCAGCUGCUGC	18

RESULT 1178
US-10-310-914A-510078
; Sequence 510078, Application US/10310914A
; Publication No. US2006000322A1

```
?
?
? APPLICANT: Bentwich, Isaac
? APPLICANT: Shiler, Kvazat
? TITLE OF INVENTION: Bioinformatically determined
? TITLE OF INVENTION: uses thereof
? FILE REFERENCE: 06087.0200 CPUS01
? CURRENT APPLICATION NUMBER: US/10/310,914A
? CURRENT FILING DATE: 2002-12-06
? NUMBER OF SEQ ID NOS: 1388402
? SOFTWARE: PatentIn version 3.3
?
? SEQ ID NO 510078
?
```

; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-510078

Query Match	0.4%	Score 15.4;	DB 1;	Length 18;
Best Local Similarity	94.1%	Pred. No. 9.5e+02;		
Matches 16;	Conservative	0;	Mismatches 1;	Indels 0;
				Gaps 0;

Qy 572 CCCCGGCCAGGCCAC 588
|||
pb 2 CCACGGGCCAGGCCAC 18

RESULT 1179
US-10-310-914A-562505/c
; Sequence 562505, Application US/10310914A
; Publication No. US2006000322A1

```

, APPLICANT: Bentwich, Isaac
, APPLICANT: Shilar, Kyurat
, TITLE OF INVENTION: Bioinformatically detected
, TITLE OF INVENTION: uses thereof
, FILE REFERENCE: 06087.0200.CPUS01
, CURRENT APPLICATION NUMBER: US/10/310,914A
, CURRENT FILING DATE: 2002-12-06
, NUMBER OF SEQ ID NOS: 1388402
, SOFTWARE: patent in version 3.3

```

```

; SOURCE: GenBank
; SEQ ID NO 562505
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-562505

```

Query Match	0.4%	Score 15.4;	DB 1;	Length 18;
Best Local Similarity	94.1%;	Pred. No. 9.5e+02;		
Matches 16;	Conservative	0;	Mismatches 1;	Indels 0;
				Gaps 0;

Qy 1059 C C C C G C C C C T G G C C C C A 1075
|||
Db 17 C C C C G A C C C T G G C C C C A 1

RESULT 1180
US-10-310-914A-572035/c
; Sequence 572035, Application US/10310914A
; Publication No. US20060003322A1

```

:
: APPLICANT: Bentwich, Isaac
: APPLICANT: Shiler, Kyuzat
:
: TITLE OF INVENTION: Bioinformatically deter
:
: TITLE OF INVENTION: uses thereof
:
: FILE REFERENCE: 06087.0200.CPUS01
:
: CURRENT APPLICATION NUMBER: US/10/310,914A
:
: CURRENT FILING DATE: 2002-12-06
:
: NUMBER OF SEQ ID NOS: 1388402
:
:

```

```
/ SOFTWARE: PatentIn version 3.3
; SEQ ID NO 572035
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-572035

Query Match          0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 66 CCCCGCCACCCGGGCG 82
Db 17 CCCCGCCACCCGGGCG 1

RESULT 1181
US-10-310-914A-572960/c
; Sequence 572960, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310.914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 572960
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-572960

Query Match          0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1717 AGCAGCTTGACCTGGC 1733
Db 18 AGCAGCTTGCTGCTGGC 2

RESULT 1182
US-10-310-914A-621831/c
; Sequence 621831, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310.914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 621831
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-621831

Query Match          0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3820 GCCCCTCCCCAGCTGC 3836
Db 18 GCCCCTCTCCAGCTGC 2

RESULT 1183
US-10-310-914A-705359/c
; Sequence 705359, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310.914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 705359
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-705359

Query Match          0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1833 GAGCTCAGAAACCGGG 1849
Db 17 GAGCTCAGAAACCGGG 1

RESULT 1184
US-10-310-914A-726118/c
; Sequence 726118, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310.914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 726118
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-726118

Query Match          0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3614 CCCAGCTCCCGGAGTG 3630
Db 17 CCCAGCTCCCGGAGTG 1

RESULT 1185
US-10-310-914A-736049/c
; Sequence 736049, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310.914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
```

; SEQ ID NO 736049
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-736049

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1067 CTGCCCCCAGCCCGCAGC 1083
||| ||||| ||||| |||||
Db 18 CTGCCCCCAGCCCGCAGC 2

RESULT 1186

US-10-310-914A-743243/c
; Sequence 743243, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 743243
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-743243

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1970 AGGCTCGCGGAGCAG 1986
||||| ||||| |||||
Db 17 AGGCTCGCGGAGCAG 1

RESULT 1187

US-10-310-914A-839587
; Sequence 839587, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 839587
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-839587

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 9.5e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1340 CCCCTCTTGGCTCCG 1356
||||| ||||| |||||
Db 2 CCCCTCTTGGCTCCG 18

RESULT 1188

US-10-310-914A-842880
; Sequence 842880, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 842880
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-842880

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 9.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 921 TGCCTGCATGGCCCTGC 937
:||| :||| :||| :||| :|||
Db 1 UGCGUGCAUGGCCUCC 17

RESULT 1189

US-10-310-914A-876761/c
; Sequence 876761, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 876761
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-876761

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3832 GCTGCTGCCTTCATTT 3848
||||| ||||| ||||| |||||
Db 18 GCTGCTGCCTTCATTTT 2

RESULT 1190

US-10-310-914A-877410/c
; Sequence 877410, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 877410

; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-877410

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1178 GCGGACCTGTGCCAG 1194
||| ||||| |||||
Db 18 GCCTAGCCTGTGCCAG 2

RESULT 1191

US-10-310-914A-904313
; Sequence 904313, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 904313
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-904313

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 9.5e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1329 ACCCTGCCACCCCTC 1345
|||:||||| |||||
Db 1 ACCCUGCACCCAC 17

RESULT 1192

US-10-310-914A-924563
; Sequence 924563, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 924563
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-924563

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 76.5%; Pred. No. 9.5e+02;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1927 TTCGCCCGGACATCA 1943
::||| ||||| |||||
Db 1 UUCGCCCGGAGCAUCA 17

RESULT 1193

US-10-310-914A-966189
; Sequence 966189, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 966189
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-966189

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 9.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2935 CTGGACTGTTGGCAGAA 2951
|:|||||:|:|||||
Db 2 CUGGACUGUGCGGAA 18

RESULT 1194

US-10-310-914A-1029714
; Sequence 1029714, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1029714
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1029714

Query Match 0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 89.2%; Pred. No. 9.5e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1068 TGGCCCCAGCCCCAGCC 1084
:||||| |||||
Db 1 UGGCCCGCCGCCAGCC 17

RESULT 1195

US-10-310-914A-1043266/c
; Sequence 1043266, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1043266
; LENGTH: 18

```
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1043266

Query Match          0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 577 GGCAGGCCCACTGGCT 593
      |||||
Db 17 GGCAGGCCCACTGGCT 1

RESULT 1196
US-10-310-914A-1071301
; Sequence 1071301, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1071301
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1071301

Query Match          0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 3; Conservative 13; Mismatches 1; Indels 0; Gaps 0;

Qy 3898 TTTGTTCCTTCGTTT 3914
      ::::|:::|:::|:::|
Db 1 UUUUGUUUCUUGUUU 17

RESULT 1197
US-10-310-914A-1175377/c
; Sequence 1175377, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1175377
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1175377

Query Match          0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1059 CCCC GCCCCTGGCCCA 1075
      |||||
Db 17 CCCC GCCCCTGGCCCA 1

RESULT 1198
US-10-310-914A-1199690
; Sequence 1199690, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1199690
; LENGTH: 18
; TYPE: RNA
US-10-310-914A-1199690

Query Match          0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 70.6%; Pred. No. 9.5e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 3680 TCCCTTGCCAGCTCCAG 3696
      :||::|::|::|::|
Db 1 UACCUUGCCAGCUCCAG 17

RESULT 1199
US-10-310-914A-1214992
; Sequence 1214992, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1214992
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1214992

Query Match          0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 9.5e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 3612 CTCGCCAGCTCCAGG 3628
      :||::|::|::|::|
Db 1 CUCCCAACCCUCCAGG 17

RESULT 1200
US-10-310-914A-1253300
; Sequence 1253300, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1253300
; LENGTH: 18
; TYPE: RNA
```

```
; ORGANISM: Human
US-10-310-914A-1253300

Query Match          0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 88.2%; Pred.No. 9.5e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1069 GGCCCCAGCCCGCCT 1085
      |||||
Db 1 GGCCCCAGCCCGCCT 17

RESULT 1201
US-10-310-914A-1296340/c
; Sequence 1296340, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1296340
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1296340

Query Match          0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred.No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 644 TCGCTTCACCATGCTC 660
      |||||
Db 18 TGTGCTTCACCATGCTC 2

RESULT 1202
US-10-310-914A-1312670/c
; Sequence 1312670, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1312670
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1312670

Query Match          0.4%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred.No. 9.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3517 CACCCCCCAGCCACCTC 3533
      |||||
Db 17 CACCCGCGCCACCTC 1

RESULT 1203
US-10-310-914A-42828/c
; Sequence 42828, Application US/10310914A
```

```
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 42828
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-42828

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred.No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1536 GGAGCCCTGGGTGGTGG 1552
      |||||
Db 18 GGCGCCCTGGGTGGTGG 2

RESULT 1204
US-10-310-914A-42829/c
; Sequence 42829, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 42829
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-42829

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred.No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1536 GGAGCCCTGGGTGGTGG 1552
      |||||
Db 18 GGCGCCCTGGGTGGTGG 2

RESULT 1205
US-10-310-914A-44524
; Sequence 44524, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 44524
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
```

US-10-310-914A-44524

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1e+03;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1864 CTGAAGCGGGAGCCAG 1880
|:|||||:|||||:
Db 1 CUGAAGCGGGAGCCAG 17

RESULT 1206

US-10-310-914A-44732/c
; Sequence 44732, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 44732

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-44732

Query Match

Best Local Similarity 0.4%; Score 15.4; DB 1; Length 19;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2912 CCACCTCCCTCCACCAG 2928
|||:|||||:|||||:
Db 19 CCCCTCCCTCCACCAG 3

RESULT 1207

US-10-310-914A-66712/c
; Sequence 66712, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 66712

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-66712

Query Match

Best Local Similarity 0.4%; Score 15.4; DB 1; Length 19;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4086 GGGGTGTGGGTGAGGT 4102
|||||:|||||:|||||:
Db 18 GGGGTGTGGGTGAGGT 2

RESULT 1208

US-10-310-914A-76028/c
; Sequence 76028, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 76028

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-76028

Query Match

Best Local Similarity 0.4%; Score 15.4; DB 1; Length 19;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4086 GGGGTGTGGGTGAGGT 4102
|||||:|||||:|||||:
Db 17 GGGGTGTGGGTGAGGT 1

RESULT 1209

US-10-310-914A-124041
; Sequence 124041, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 124041

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-124041

Query Match

Best Local Similarity 0.4%; Score 15.4; DB 1; Length 19;

Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 730 GATGGGACACGCCAC 746
||:|||||:|||||:
Db 2 GAUGCGGACACGCCAC 18

RESULT 1210

US-10-310-914A-141479/c
; Sequence 141479, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 141479

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-141479

```
Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; 1; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1384 TCCTCCCTGCACCTGGA 1400
Db 17 TCCTCCCTGCCCTGGA 1

RESULT 1211
US-10-310-914A-164314/c
; Sequence 164314, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 164314
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-164314

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; 1; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1531 CTGTGGAGCCCTGGT 1547
Db 17 CTGGGGGAGCCCTGGT 1

RESULT 1212
US-10-310-914A-165319/c
; Sequence 165319, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 165319
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-165319

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; 1; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3823 CCTCCCCCAGCTGCTGC 3839
Db 18 CCTCCCCCTGCTGCTGC 2

RESULT 1213
US-10-310-914A-165325/c
; Sequence 165325, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 165325
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-165325
```

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 1e+03; 1; Indels 0; Gaps 0;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3823 CCTCCCCCAGCTGCTGC 3839

Db 19 CCTCCCCCTGCTGCTGC 3

RESULT 1214

US-10-310-914A-174508

; Sequence 174508, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 174508

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-174508

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 88.2%; Pred. No. 1e+03; 1; Indels 0; Gaps 0;

Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 3383 CCGGGGCAGAGTGGGA 3399

Db 3 CCGGGGCAGAGUGGGGA 19

RESULT 1215

US-10-310-914A-260318/c

; Sequence 260318, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 260318

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-260318

```
Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 681 GGCTGGGCGCTCTGCAC 697
    |||||
Db 19 GGCTGGGCGCCCTGCAC 3

RESULT 1216
US-10-310-914A-332383
; Sequence 332383, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 332383
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-332383

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1e+03;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1064 CCCCTGGCCCGCCAGCCCC 1080
    |||||
Db 3 CCCCUAGCCCGCCAGCCCC 19

RESULT 1217
US-10-310-914A-368914/c
; Sequence 368914, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 368914
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-368914

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 933 CCTGCTATCCTCGACC 949
    |||||
Db 19 CCTGCTATCCTCGACG 3

RESULT 1218
US-10-310-914A-450885
; Sequence 450885, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
```

```
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 450885
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-450885

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 23.5%; Pred. No. 1e+03;
Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

QY 3892 TTCCCTTTTGTTCCT 3908
    :|||:
Db 2 UUUUUUUUUUUUUUU 18

RESULT 1219
US-10-310-914A-476139/c
; Sequence 476139, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 476139
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-476139

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3351 TCCCCACCCCGAGGACA 3367
    |||||
Db 17 TCCCCACCCCGAGGTCA 1

RESULT 1220
US-10-310-914A-478635/c
; Sequence 478635, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 478635
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-478635

Query Match      0.4%; Score 15.4; DB 1; Length 19;
```

```
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 580849
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-580849

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 79 GGCGCGGAGCCCGAGGC 95
Db 17 GGCGCGGAGCCCGAGGC 1

RESULT 1221
US-10-310-914A-567126
; Sequence 567126, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 567126
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-567126

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 494 GGCAGTGGGAGGAACUG 510
Db 2 GGCAGGCGGAGGAACUG 18

RESULT 1222
US-10-310-914A-568323/c
; Sequence 568323, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 568323
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-568323

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 17 GAGCAGACCCACTCCAG 33
Db 17 GAGCAGACCCACTCCAG 1

RESULT 1223
US-10-310-914A-580849
; Sequence 580849, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
```

```
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 580849
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-580849

Query Match
Best Local Similarity 88.2%; Score 15.4; DB 1; Length 19;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 3409 GCCCCAGCCCTGTGCC 3425
Db 2 GCCCCAGCCCTGTGCC 18

RESULT 1224
US-10-310-914A-591068/c
; Sequence 591068, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 591068
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-591068

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3862 TTTTGTGTTTGGTCTTA 3878
Db 19 TTTTGTGTTTGGTCTTA 3

RESULT 1225
US-10-310-914A-621832/c
; Sequence 621832, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 621832
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-621832

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3820 GCCCTCCCCCAGTGCC 3836
Db 18 GCCCTCTCCAGTGCC 2

RESULT 1226

US-10-310-914A-632545
; Sequence 632545, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 632545

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-632545

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 1e+03;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 74 ACCCGGGGGGACCCC 90

Db 2 ACCCGGGGGGACCC 18

RESULT 1227

US-10-310-914A-656960

; Sequence 656960, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 656960

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-656960

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 76.5%; Pred. No. 1e+03;

Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 3730 TGTCAGGGCCAGGAC 3746

Db 1 UCUCAGGGCCAGGAC 17

RESULT 1228

US-10-310-914A-693048

; Sequence 693048, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 693048

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-693048

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 88.2%; Pred. No. 1e+03;

Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 212 GCGCGCGCGCGCGTGC 228

Db 3 GCGCGCGCGCGCGTGC 19

RESULT 1229

US-10-310-914A-693049

; Sequence 693049, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 693049

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-693049

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 88.2%; Pred. No. 1e+03;

Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 212 GCGCGCGCGCGCGTGC 228

Db 3 GCGCGCGCGCGCGTGC 19

RESULT 1230

US-10-310-914A-724817/c

; Sequence 724817, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 724817

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-724817

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 1e+03;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;


```

; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 757318
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-757318

Query Match          0.4%   Score 15.4;  DB 1;   Length 19;
Best Local Similarity 88.2%; Pred. No. 1e+03;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy  4056  GCCTGGGACCCCAAGC 4072
      |||:|||||
Db    2  GCCUGGAGCCCAAGC 18

RESULT 1234
US-10-310-914A-773116
; Sequence 773116, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 773116
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-773116

Query Match          0.4%   Score 15.4;  DB 1;   Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy  923  CCTGCATGGCCCTGCTA 939
      ||:|||||
Db    1  CCUGCAUGGCCUGCAA 17

RESULT 1235
US-10-310-914A-796345
; Sequence 796345, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 796345
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-796345

Query Match          0.4%   Score 15.4;  DB 1;   Length 19;
Best Local Similarity 23.5%; Pred. No. 1e+03;
Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

```

QY 3856 TTGTGAGTTTGTGTTTG 3872
::|||:::|:::|:::|
Db 3 UUGUGUUUGUUUG 19

RESULT 1236

US-10-310-914A-814718/c
; Sequence 814718, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 814718

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-814718

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 1e+03;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1228 TGCCAGCCATGCCCCAGC 1244

|||||:::|:::|:::|

Db 19 TGCCAGCCAGGCCCCAGC 3

RESULT 1237

US-10-310-914A-842885
; Sequence 842885, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 842885

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-842885

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 70.6%; Pred. No. 1e+03;

Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 921 TGCCTGCATGCCCTGC 937

::|||:::|:::|:::|

Db 2 UGCGUGCAUGGCCCUGC 18

RESULT 1238

US-10-310-914A-885145/c
; Sequence 885145, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 885145

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-885145

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 1e+03;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 106 CCCCACTCCAGCCAGC 122

|||||:::|:::|:::|

Db 17 CCCCACTCCAGCCCG 1

RESULT 1239

US-10-310-914A-900173/c
; Sequence 900173, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 900173

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-900173

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 1e+03;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1725 GAGCCTGGCCTGGCGTG 1741

|||||:::|:::|:::|

Db 17 GCGCCTGGCCTGGCGTG 1

RESULT 1240

US-10-310-914A-906770
; Sequence 906770, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 906770

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-906770

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 1e+03;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 77 CGGGCGGGGAGCCCGAG 93

Db 1 CGGGCGGGAGACCCGAG 17
|||||

RESULT 1241

US-10-310-914A-912740
; Sequence 912740, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 912740
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-912740

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03; Mismatches 2; Indels 0; Gaps 0;
Matches 14; Conservative 2;

Qy 1330 CCCTGCACCCCTCC 1346
|||||

Db 1 CCCUGCCACCCCTCC 17
|||||

RESULT 1242

US-10-310-914A-933011
; Sequence 933011, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 933011
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-933011

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 47.1%; Pred. No. 1e+03; Mismatches 8; Indels 0; Gaps 0;
Matches 8; Conservative 8;

Qy 4189 TTTTGTATAAATAAAA 4205
:|||||

Db 2 UUUUUUAUAAUAAACA 18
UUUUUU

RESULT 1243

US-10-310-914A-949706
; Sequence 949706, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 949706
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-949706

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 1e+03; Mismatches 4; Indels 0; Gaps 0;
Matches 12; Conservative 4;

Qy 3192 CAGCCAGATCTCTGCTG 3208
|||||

Db 1 CAGCCAGUUCUCUGUG 17
|||||

RESULT 1244

US-10-310-914A-966440/c
; Sequence 966440, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 966440
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-966440

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; Mismatches 0; Indels 0; Gaps 0;
Matches 16; Conservative 0;

Qy 1230 CCAGCCATGCCAGCCA 1246
|||||

Db 17 CCAGCCAGCCAGCCA 1
|||||

RESULT 1245

US-10-310-914A-1044765/c
; Sequence 1044765, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1044765
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1044765

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; Mismatches 0; Indels 0; Gaps 0;
Matches 16; Conservative 0;

Qy 1076 GCCCCAGCCCTCTACTGC 1092
|||||

Db 19 GCCCCAGCTTCTACTGC 3

RESULT 1246

US-10-310-914A-1127249/c
; Sequence 1127249, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 1127249

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-1127249

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 1e+03; Mismatches 0; Gaps 0;

Matches 16; Conservative 0; Indels 1; Indels 0; Gaps 0;

Qy 1070 GCCCCAGCCCCAGCCTC 1086

|||||

Db 18 GCCCCAGCCCCAGCCCC 2

RESULT 1247

US-10-310-914A-1150255

; Sequence 1150255, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 1150255

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-1150255

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 64.7%; Pred. No. 1e+03; Mismatches 5; Gaps 0;

Matches 11; Conservative 5; Indels 1; Indels 0; Gaps 0;

Qy 3106 TCTGTGGCGAGTGCT 3122

:|:|:|:|:|:|:|:|:|

Db 1 UCUGUGGCGCAGUGGCU 17

RESULT 1248

US-10-310-914A-1150285

; Sequence 1150285, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 1150285

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-1150285

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 64.7%; Pred. No. 1e+03; Mismatches 5; Indels 0; Gaps 0;

Matches 11; Conservative 5; Indels 1; Indels 0; Gaps 0;

Qy 3106 TCTGTGGCGAGTGCT 3122

:|:|:|:|:|:|:|:|:|

Db 1 UCUGUGGCGCAGUGGCU 17

RESULT 1249

US-10-310-914A-1154760

; Sequence 1154760, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 1154760

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-1154760

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 76.5%; Pred. No. 1e+03; Mismatches 3; Indels 0; Gaps 0;

Matches 13; Conservative 3; Indels 1; Indels 0; Gaps 0;

Qy 2910 TCCACCTCCCTCCACC 2926

:|:|:|:|:|:|:|:|:|

Db 1 UCCACCUCUCCUCCAGC 17

RESULT 1250

US-10-310-914A-1187331/c

; Sequence 1187331, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 1187331

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-1187331

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 1e+03; Mismatches 0; Indels 0; Gaps 0;

Matches 16; Conservative 0; Indels 1; Indels 0; Gaps 0;

Qy 1064 CCCTGCCCCCAGCCCC 1080

|||||

Db 18 CCCTGCCCCCAGCCCC 2

```
RESULT 1251
US-10-310-914A-1283822/c
; Sequence 1283822, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiller, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CFUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1283822
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1283822

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4002 TCATCATGTCGTGTTCC 4018
Db 19 TCATCATGTTGTTTCC 3

RESULT 1252
US-11-101-244-51
; Sequence 51, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 51
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-51

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3472 GGAGAGACAGGATTGG 3488
Db 2 GGAGAGAAAGGAUUGG 18

RESULT 1253
US-11-101-244-14393
; Sequence 14393, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 51
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-14393

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3472 GGAGAGACAGGATTGG 3488
Db 2 GGAGAGAAAGGAUUGG 18

RESULT 1254
US-11-101-244-14433
; Sequence 14433, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14433
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-14433

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2606 GCAACATCCTAGTCAAC 2622
Db 1 GCAACUCCUAGUCAUC 17

RESULT 1255
US-11-101-244-38758
; Sequence 38758, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14433
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-38758

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2606 GCAACATCCTAGTCAAC 2622
Db 3 GCAACUCCUAGUCAUC 19
```

```
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 38758
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-38758
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1191 CCAGGCGCCTTCAAGC 1207
Db 1 CCAGGCGCACCUCUCAAAC 17
```

```
RESULT 1256
US-11-101-244-47494/C
; Sequence 47494, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 47494
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-47494
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2120 TCATCGGACATGTTACT 2136
Db 19 TCATCGGACATGTTACT 3
```

```
RESULT 1257
US-11-101-244-88064
; Sequence 88064, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
```

```
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 88064
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-88064
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 1e+03;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 708 CACCGCTTCTACTATG 724
Db 3 CAAAGUCUUCUACUUG 19
```

```
RESULT 1258
US-11-101-244-95986
; Sequence 95986, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 95986
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-95986
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 1e+03;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 3946 TTGGAGGGAACCTGTTT 3962
Db 3 UUGGAGGGUACUGUUU 19
```

```
RESULT 1259
US-11-101-244-124920
; Sequence 124920, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
```

```

; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 124920
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-124920

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 1e+03;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 2222 AGATTGACAGAGTGATT 2238
Db      |||:|||||:|||||:
3 AGAUGAACAGGUGAUU 19

```

```

RESULT 1260
US-11-101-244-158311
; Sequence 158311, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158311
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158311

```

```

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2845 ATGAGCAATCAGACGT 2861
Db      |||:|||||:|||||:
2 AUGAGCAACAGGAGGU 18

```

```

RESULT 1261
US-11-101-244-158978
; Sequence 158978, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William

```

```

; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158978
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-158978

```

```

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 1e+03;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 2815 ATGTCATTTGGGAGAG 2831
Db      |||:|||||:|||||:
2 AUGUCAUUGGAGAG 18

```

```

RESULT 1262
US-11-101-244-165037/c
; Sequence 165037, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165037
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-165037

```

```

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3254 AAATCTTGGCCAGTGTC 3270
Db      |||:|||||:|||||:
18 AAATCTTGGCCATTGTC 2

```

```

RESULT 1263
US-11-101-244-165057/c
; Sequence 165057, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

```

```
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165057
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-165057
```

```
Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 3254 AAATCTTGGCCAGTGC 3270
      ||||| ||||| |||||
Db 17 AAATCTTGGCCATTGTC 1
```

```
RESULT 1264
US-11-101-244-165136/c
; Sequence 165136, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165136
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-165136
```

```
Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 3254 AAATCTTGGCCAGTGC 3270
      ||||| ||||| |||||
Db 18 AAATCTTGGCCATTGTC 2
```

```
RESULT 1265
US-11-101-244-165156/c
; Sequence 165156, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
```

```
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165156
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-165156
```

```
Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 3254 AAATCTTGGCCAGTGC 3270
      ||||| ||||| |||||
Db 17 AAATCTTGGCCATTGTC 1
```

```
RESULT 1266
US-11-101-244-165238/c
; Sequence 165238, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165238
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-165238
```

```
Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 3254 AAATCTTGGCCAGTGC 3270
      ||||| ||||| |||||
Db 18 AAATCTTGGCCATTGTC 2
```

```
RESULT 1267
US-11-101-244-165258/c
; Sequence 165258, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
```


; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165258
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-165258

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; 1; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGC 3270
| | | | | | | | | | | | | | | | | | | | | |
Db 17 AAATCTTGGCCATTGTC 1

RESULT 1268
US-11-101-244-165337/c
; Sequence 165337, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165337
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-165337

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; 1; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGC 3270
| | | | | | | | | | | | | | | | | | | | | |
Db 18 AAATCTTGGCCATTGTC 2

RESULT 1269
US-11-101-244-165357/c
; Sequence 165357, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244

; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165357
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-165357

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; 1; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGC 3270
| | | | | | | | | | | | | | | | | | | | | |
Db 17 AAATCTTGGCCATTGTC 1

RESULT 1270
US-11-101-244-165439/c
; Sequence 165439, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165439
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-165439

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; 1; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGC 3270
| | | | | | | | | | | | | | | | | | | | | |
Db 18 AAATCTTGGCCATTGTC 2

RESULT 1271
US-11-101-244-165462/c
; Sequence 165462, Application US/11/101,244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165462
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-165462

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGC 3270
|||||
Db 17 AAATCTTGGCCATTGTC 1

RESULT 1272
US-11-101-244-223107
; Sequence 223107, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 223107
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-223107

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 1e+03;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 449 TGGAACTGCTGATCTG 465
:|||||:|:|:|:
Db 3 UGGAACUUCUGAUCUG 19

RESULT 1273
US-11-101-244-249657/c
; Sequence 249657, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050

; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 249657
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-249657

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2411 TGGAGGGCGTGTCTACC 2427
|||||
Db 17 TGGAGGGCGTGTCTATC 1

RESULT 1274
US-11-101-244-249676/c
; Sequence 249676, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 249676
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-249676

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2411 TGGAGGGCGTGTCTACC 2427
|||||
Db 17 TGGAGGGCGTGTCTATC 1

RESULT 1275
US-11-101-244-376141
; Sequence 376141, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10

```

; PRIOR APPLICATION NUMBER: 60/426,137
;
; PRIOR FILING DATE: 2002-11-14
;
; NUMBER OF SEQ ID NOS: 1591911
;
; SOFTWARE: Proprietary
;
; SEQ ID NO 376141
;
; LENGTH: 19
;
; TYPE: RNA
;
; ORGANISM: Homo sapiens
US-11-101-244-376141

```

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels

Qy 520 GATGAGGAACAGCACAG 536
Db 1 GAAGAGGAACAGCACAG 17

```

RESULT 1276
US-11-101-244-384878
; Sequence 384878, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional sirna
; FILE REFERENCE: 13498US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 384878
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-384878

```

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 1e+03;
Matches 12: Conservative 4: Mismatches 1: Indels

Qy 2158 ACTTATGAAGACCCTAA 2174
||:|:|:|:|:|:|:
Db 3 ACUUAUGAACACCCUAA 19

```

RESULT 1277
US-11-101-244-388710
; Sequence 388710, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/436,137

```

```
; PRIORITY DATE: 2002-11-14  
; NUMBER OF SEQ ID NOS: 1591911  
; SOFTWARE: Proprietary  
; SEQ ID NO 388710  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-11_101_244-388710
```

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels

Qy 3472 GGAGAGACAGGATTGG 3488
 |||||
 Db 1 GGAGAGAAAGGAUUGG 17

```

RESULT 1278
US-11-101-244-393275/c
; Sequence 393275, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 1349SUS
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 159111
; SOFTWARE: Proprietary
; SEQ ID NO 393275
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-393275

```

Query Match	0.4%	Score 15.4;	DB 1;	Length 19;
Best Local Similarity	94.1%	Pred. No. 1e+03;		
Matches 16: Conservative	0:	Mismatches	1:	Indels

Qy 3133 AAAATGGGAAGATACGA 3149
||| ||||| ||||| |||||
pb 19 AAAGTGGGAAGATACGA 3

RESULT 1279
US-11-101-244-405137
Sequence 405137, Application US/11101244
Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14


```
; SEQ ID NO 446199
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-446199

Query Match      0.4%  Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1612 TCCTCCTTAGCCAGCGG 1628
Db 18 TCCTCCATAGCCAGCGG 2

RESULT 1284
US-11-101-244-448936/c
; Sequence 448936, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 448936
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-448936

Query Match      0.4%  Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1933 CAGGAACATCAGCCCA 1949
Db 17 CAGGAACATCAGCCCA 1

RESULT 1285
US-11-101-244-466442
; Sequence 466442, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 466442
```

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-466442

Query Match      0.4%  Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2187 GGAATTTGCAAAAGAGA 2203
Db 1 GGAUUUGCAAGAGA 17

RESULT 1286
US-11-101-244-478703/c
; Sequence 478703, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 478703
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-478703

Query Match      0.4%  Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2803 ATGTGGAGGTGATGTC 2819
Db 18 ATGTGTGAGGTGATGTC 2

RESULT 1287
US-11-101-244-488729
; Sequence 488729, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 488729
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-488729

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1877 CCAGCTACCTGCTGCAG 1893
    ||| |:|:|:|:|:|
Db 1 CCAACUACUGGUGCAG 17

RESULT 1288
US-11-101-244-499341
; Sequence 499341, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 499341
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-499341

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2290 AAGAAGGAGAGCTGTGT 2306
    ||| ||||| |:|:|
Db 3 AAGAAGGAGAACUGUGU 19

RESULT 1289
US-11-101-244-536642
; Sequence 536642, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 536642
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-536642

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 438 GAACACAAAATTGGAAA 454
    ||||| |:|:|:|:|
Db 1 GAACACAAAATUUGGAAA 17

RESULT 1290
US-11-101-244-586431/c
; Sequence 586431, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 586431
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-586431

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1587 TGAGGTCACTGCATTGA 1603
    ||||| ||||| |:|:|
Db 17 TGAGGTCACTGCCTTGA 1

RESULT 1291
US-11-101-244-593515/c
; Sequence 593515, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 593515
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-593515
```

US-11-101-244-593515

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2475 CCTGACTCCTTCTGCG 2491
|||||
DB 17 CCTGGCTCTCTTCTGCG 1

RESULT 1292

US-11-101-244-604134/c
; Sequence 604134, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 604134
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-604134

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3247 CAGAAGAAATCTTGGC 3263
|||||
DB 17 CAGAAGGAATCTTGGC 1

RESULT 1293

US-11-101-244-618691/c
; Sequence 618691, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 618691
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-618691

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2338 GAGCGCAGCGCGTGA 2354
|||||
DB 17 GAGCAGCAGCGCGTGA 1

RESULT 1294

US-11-101-244-710189
; Sequence 710189, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 710189
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-710189

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03; Indels 0; Gaps 0;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2593 GACCTGGCTGCTCGCA 2609
|||||
DB 2 GACCTGGCTGCTCGCA 18

RESULT 1295

US-11-101-244-772658/c
; Sequence 772658, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 772658
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-772658

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; 1; Indels 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2029 GTCTGGTGGTCAATTGT 2045
|||:|||||:|||||
Db 17 GTCTGGTGGTCTTTGT 1

RESULT 1296
US-11-101-244-778427
; Sequence 778427, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 778427
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-778427

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 1e+03; 1; Indels 0; Gaps 0;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 3934 CATAACTTTTGTGTGGA 3950
|||:|||||:|||||
Db 3 CAUAAACUUGUCUUGGA 19

RESULT 1297
US-11-101-244-778438
; Sequence 778438, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 778438
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-778438

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 52.9%; Pred. No. 1e+03; 1; Indels 0; Gaps 0;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 3934 CATAACTTTTGTGTGGA 3950
|||:|||||:|||||
Db 2 CAUAAACUUGUCUUGGA 18

RESULT 1298
US-11-101-244-788952
; Sequence 788952, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 788952
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-788952

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03; 1; Indels 0; Gaps 0;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2618 TCAACAGCAACCTCGTC 2634
:|||||:|||||:|
Db 3 UCAACAGCAACCCUCUC 19

RESULT 1299
US-11-101-244-789052
; Sequence 789052, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 789052
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-789052

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;

Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2618 TCAACAGCAACCTCGTC 2634
:|||||||:|
Db 3 UCAACAGCAACCUUC 19

RESULT 1300
US-11-101-244-789152
; Sequence 789152, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 789152
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-789152

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2618 TCAACAGCAACCTCGTC 2634
:|||||||:|
Db 3 UCAACAGCAACCUUC 19

RESULT 1301
US-11-101-244-789248
; Sequence 789248, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 789248
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-789248

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2618 TCAACAGCAACCTCGTC 2634
:|||||||:|
Db 3 UCAACAGCAACCUUC 19

RESULT 1302
US-11-101-244-789347
; Sequence 789347, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 789347
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-789347

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2618 TCAACAGCAACCTCGTC 2634
:|||||||:|
Db 3 UCAACAGCAACCUUC 19

RESULT 1303
US-11-101-244-789447
; Sequence 789447, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 789447
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-789447

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

```
QY 2618 TCAACAGCAACCTCGTC 2634
Db :|||||:|:|
3 UCAACAGCAACCUUC 19

RESULT 1304
US-11-101-244-834453/c
; Sequence 834453, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 834453
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-834453

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2205 CGATGCTCCTACGTCA 2221
Db :|||||:|:|
17 CGATGCTCCTACTTCA 1

RESULT 1305
US-11-101-244-837999
; Sequence 837999, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 837999
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-837999

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1e+03;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 3073 GACCAGCGGCGCTCA 3089
Db :|||||:|:|
17 GACCAGCGGCGCTCA 19

RESULT 1306
US-11-101-244-855576
; Sequence 855576, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 855576
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-855576

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 1e+03;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 452 AAACGTCTGATCTGAAG 468
Db :|||||:|:|
3 AAUAUCGUAUCUGAAG 19

RESULT 1307
US-11-101-244-927801/c
; Sequence 927801, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 927801
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-927801

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3168 TGGCTTTGGCTCCTCG 3184
Db :|||||:|:|
17 TGGCTTTGGCTCCTCG 19
```

Db 17 TGGCTTCGGCTCCTTCG 1

RESULT 1308
US-11-101-244-1019444
; Sequence 1019444, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1019444
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1019444

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.1%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 109 CAACTCCAGCCACGCTCT 125
||||:|||||:|:|:
Db 1 CAACUCCAGUCACGUCU 17

RESULT 1309
US-11-101-244-1036594/c
; Sequence 1036594, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1036594
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1036594

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2669 TGGAGGAGAACTCTTCC 2685
|||||:|||||:|||||:
Db 17 TGGTGGAGAACTCTTCC 1

RESULT 1310
US-11-101-244-1071237
; Sequence 1071237, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1071237
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1071237

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 1e+03;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 3831 AGCTGCTGCCTTCATAT 3847
||||:|||||:|:|:
Db 2 AGCUGCGCCUUAUUU 18

RESULT 1311
US-11-101-244-1071275
; Sequence 1071275, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1071275
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1071275

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 1e+03;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 3831 AGCTGCTGCCTTCATAT 3847
||||:|||||:|:|:
Db 3 AGCUGCGCCUUAUUU 19

RESULT 1312
US-11-101-244-1104410
; Sequence 1104410, Application US/1101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1104410
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1104410

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
Qy 1233 GCCATGCCAGCCCAATA 1249
|||||:|||||:|||||:
Db 2 GCCAUGCCCAACCAUA 18

RESULT 1313
US-11-101-244-1104472
; Sequence 1104472, Application US/1101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1104472
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1104472

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
Qy 1233 GCCATGCCAGCCCAATA 1249
|||||:|||||:|||||:
Db 3 GCCAUGCCCAACCAUA 19

RESULT 1314
US-11-101-244-1134517
; Sequence 1134517, Application US/1101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1134517
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1134517

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
Qy 3595 AAGGAGTCCCAACAT 3611
|||||:|||||:|||||:
Db 2 AAGGAGUGCCCAACAU 18

RESULT 1315
US-11-101-244-1136133
; Sequence 1136133, Application US/1101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1136133
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1136133

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 1e+03;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
Qy 3832 GCTGCTGCCTTCATT 3848
||:|:|:|:|:|:|:|:
Db 1 GCUGCUGCCUACAU 17

RESULT 1316

```
US-11-101-244-1207573
; Sequence 1207573, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1207573
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1207573
```

```
Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 1e+03;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2808 GGAGGTGATGTCATTG 2824
      |||||.:|:|:|:|
Db 3 GGAGGUGGUGCAUUG 19
```

```
RESULT 1317
US-11-101-244-1259838
; Sequence 1259838, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1259838
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1259838
```

```
Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 451 GAAACTGCTGATCTGAA 467
      |||||.:|:|:|:|
Db 2 GAAACAGCUGAUCUGAA 18
```

```
RESULT 1318
US-11-101-244-1263543/c
```

```
; Sequence 1263543, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1263543
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1263543
```

```
Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 445 AAATTGGAAACTGCTGA 461
      |||||.:|:|:|:|
Db 19 AAATTGGAAACTTCTGA 3
```

```
RESULT 1319
US-11-101-244-1263597/c
; Sequence 1263597, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990S
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1263597
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1263597
```

```
Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 445 AAATTGGAAACTGCTGA 461
      |||||.:|:|:|:|
Db 17 AAATTGGAAACTTCTGA 1
```

```
RESULT 1320
US-11-101-244-1268095/c
; Sequence 1268095, Application US/11101244
```

; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101.244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1268095
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1268095

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; Indels 1; Mismatches 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 0; Gaps 0;
QY 1044 CGTGGTGGATGCCGCTCC 1060
Db 17 CATGGTGGATGCCGCTCC 1

RESULT 1321
US-11-101-244-1319444/c
; Sequence 1319444, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101.244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1319444
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1319444

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; Indels 1; Mismatches 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 0; Gaps 0;
QY 3780 CTGTCCACCACCAACTC 3796
Db 18 CTGTCCACCACCAAGTC 2

RESULT 1322
US-11-101-244-1323046/c
; Sequence 1323046, Application US/11101244
; Publication No. US20050246794A1

; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101.244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1323046
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1323046

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; Indels 1; Mismatches 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 0; Gaps 0;
QY 2930 TCATGCTGGACTGTTGG 2946
Db 19 TCATGCTGGACTGTTTG 3

RESULT 1323
US-11-101-244-1334142/c
; Sequence 1334142, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101.244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1334142
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1334142

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; Indels 1; Mismatches 0; Gaps 0;
Matches 16; Conservative 0; Mismatches 0; Gaps 0;
QY 4134 CAGAAACGACGCCGGT 4150
Db 18 CAGAAACAGACGCCGGT 2

RESULT 1324
US-11-101-244-1366776
; Sequence 1366776, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1366776
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1366776

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 305 GGGAGAGTCAGACCTGG 321
|||||:|:|:|:|:|:|:|:|:|
Db 1 GGGAGAGUCAGCCUGG 17

RESULT 1325
US-11-101-244-1372964/c
; Sequence 1372964, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1372964
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1372964

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2110 GGACAGTATCTCATCGG 2126
|||||:|:|:|:|:|:|:|:|:|
Db 17 GGACAGTATCTCATCAG 1

RESULT 1326
US-11-101-244-1401474
; Sequence 1401474, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1401474
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1401474

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 1e+03;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 3639 ACCTTGATGGTGGGTT 3655
|||:|:|:|:|:|:|:|:|:|
Db 3 ACCUUGAUGGUGCUUU 19

RESULT 1327
US-11-101-244-1441103/c
; Sequence 1441103, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1441103
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1441103

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3272 AGCACATGAAGTCCCG 3288
|||:|:|:|:|:|:|:|:|:|
Db 18 AGAACATGAAGTCCCG 2

RESULT 1328
US-11-101-244-1444645/c
; Sequence 1444645, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.

; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 144645
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-144645

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1885 CTGGTGCAGGTACGGC 1901
|||||
Db 17 CTGGTGCAGGTACTGGC 1

RESULT 1329
US-11-101-244-1469620/c
; Sequence 1469620, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1469620
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1469620

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 859 AAGACGCTGCTCTGGG 875
|||||
Db 18 AAGAACTGCTCTGGG 2

RESULT 1330
US-11-101-244-1495899/c
; Sequence 1495899, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1495899
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1495899

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2446 ATTCTCAGAGTTTCAT 2462
|||||
Db 18 ATTCTCAGAGTTTCAT 2

RESULT 1331
US-11-101-244-1512077
; Sequence 1512077, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1512077
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1512077

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 1e+03;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 2348 GCGCTGAGTTTCTGAGC 2364
|||||
Db 2 GCGGUGAGUUCUAGC 18

RESULT 1332
US-11-101-244-1525042
; Sequence 1525042, Application US/11101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1525042
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1525042

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 4017 CCAGAACAGTGCCTTGG 4033
|||||:||||:|
Db 1 CCAGAACAGGCCUAG 17

RESULT 1333
US-11-101-244-1575806/c
; Sequence 1575806, Application US/11/101244
; Publication No. US20050246794A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/101,244
; CURRENT FILING DATE: 2005-04-07
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1575806
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-101-244-1575806

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3134 AAATGGGAAGATACGAA 3150
|||||:||||:|
Db 18 AAATGGGAAGATAAGAA 2

RESULT 1334
US-11-083-784-51
; Sequence 51, Application US/11/083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 51
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-51

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3472 GGAGAGACGAGATTGG 3488
|||||:||||:|
Db 2 GGAGAGAAAGGAUUGG 18

RESULT 1335
US-11-083-784-14393
; Sequence 14393, Application US/11/083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14393
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-14393

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2606 GCAACATCCTAGTCAAC 2622
|||||:||||:|
Db 1 GCAACAUCUAGUCAUC 17

RESULT 1336
US-11-083-784-14433
; Sequence 14433, Application US/11/083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmoon, Inc.
; APPLICANT: Khvorova, Anastasia

```
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 14433
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-14433
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2606 GCAACATCCTTAGTCAAC 2622
Db 3 GCAACAUCUUAUCAUC 19
|||||:|:|:|:|:|
```

```
RESULT 1337
US-11-083-784-38758
; Sequence 38758, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 38758
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-38758
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1191 CCAGGCACCTTCAAGC 1207
Db 1 CCAGGCACCUCAAC 17
|||||:|:|:|:|:|
```

```
RESULT 1338
US-11-083-784-47494/c
; Sequence 47494, Application US/11083784
; Publication No. US20050245475A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 47494
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-47494
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2120 TCATCGACATGCTACT 2136
Db 19 TCATCGACATGCTACT 3
|||||:|:|:|:|:|
```

```
RESULT 1339
US-11-083-784-88064
; Sequence 88064, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 88064
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-88064
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 1e+03;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 708 CACCGTCTTCTACTG 724
Db 3 CAACGUCUUCUACUAG 19
|||||:|:|:|:|:|
```

```
RESULT 1340
```

US-11-083-784-95986
; Sequence 95986, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 95986
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-95986

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 1e+03;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 3946 TTGGAGGGGAACCTGTTT 3962
Db 3 UUGGAGGGGUACCGUUU 19

RESULT 1341
US-11-083-784-124920
; Sequence 124920, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 124920
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-124920

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 1e+03;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 2222 AGATTGAAGAGGTGATT 2238
Db 3 AGAUTGAACAGGUAU 19

RESULT 1342
US-11-083-784-158311
; Sequence 158311, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158311
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158311

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2845 ATGCAATCAGGACGT 2861
Db 2 AUGAGCAACAGGAGGU 18

RESULT 1343
US-11-083-784-158978
; Sequence 158978, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 158978
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-158978

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 1e+03;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

```
QY 2815 ATGTCATTGGCGAG 2831
Db 2 AUGUCAUUUGAGAG 18

RESULT 1344
US-11-083-784-165037/c
; Sequence 165037, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165037
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-165037

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3254 AAATCTTGGCAGTGC 3270
Db 18 AAATCTTGGCAGTGC 2

RESULT 1345
US-11-083-784-165057/c
; Sequence 165057, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165057
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-165057

Query Match 0.4%; Score 15.4; DB 1; Length 19;
```

```
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3254 AAATCTTGGCAGTGC 3270
Db 17 AAATCTTGGCAGTGC 1

RESULT 1346
US-11-083-784-165136/c
; Sequence 165136, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165136
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-165136

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3254 AAATCTTGGCAGTGC 3270
Db 18 AAATCTTGGCAGTGC 2

RESULT 1347
US-11-083-784-165156/c
; Sequence 165156, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165156
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
```

US-11-083-784-165156

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGCCAGTGTC 3270
|||||
Db 17 AAATCTTGCCATTGTC 1

RESULT 1348

US-11-083-784-165238/c
; Sequence 165238, Application US/11083784
; Publication No. US20050245475A1

; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/083,784

; PRIOR FILING DATE: 2005-03-18

; PRIOR FILING DATE: 2003-11-14

; PRIOR FILING DATE: 2003-09-10

; PRIOR FILING DATE: 2003-09-10

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 165238

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-083-784-165238

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGCCAGTGTC 3270
|||||
Db 18 AAATCTTGCCATTGTC 2

RESULT 1349

US-11-083-784-165258/c

; Sequence 165258, Application US/11083784

; Publication No. US20050245475A1

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/083,784

; PRIOR FILING DATE: 2005-03-18

; PRIOR FILING DATE: 2003-11-14

; PRIOR FILING DATE: 2003-09-10

; PRIOR FILING DATE: 2003-09-10

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 165258

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-083-784-165258

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGCCAGTGTC 3270
|||||
Db 17 AAATCTTGCCATTGTC 1

RESULT 1350

US-11-083-784-165337/c

; Sequence 165337, Application US/11083784

; Publication No. US20050245475A1

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/083,784

; PRIOR FILING DATE: 2005-03-18

; PRIOR FILING DATE: US/10/714,333

; PRIOR FILING DATE: 2003-11-14

; PRIOR FILING DATE: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR FILING DATE: 2002-11-14

; NUMBER OF SEQ ID NOS: 1591911

; SOFTWARE: Proprietary

; SEQ ID NO 165337

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Homo sapiens

US-11-083-784-165337

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGCCAGTGTC 3270
|||||
Db 18 AAATCTTGCCATTGTC 2

RESULT 1351

US-11-083-784-165357/c

; Sequence 165357, Application US/11083784

; Publication No. US20050245475A1

; GENERAL INFORMATION:

; APPLICANT: Dharmacon, Inc.

; APPLICANT: Khvorova, Anastasia

; APPLICANT: Reynolds, Angela

; APPLICANT: Leake, Devin

; APPLICANT: Marshall, William

; APPLICANT: Scaringe, Stephen

; TITLE OF INVENTION: Functional and Hyperfunctional siRNA

; FILE REFERENCE: 13499US

; CURRENT APPLICATION NUMBER: US/11/083,784

; PRIOR FILING DATE: 2005-03-18

; PRIOR FILING DATE: US/10/714,333

; PRIOR FILING DATE: 2003-11-14

; PRIOR FILING DATE: 60/502,050

; PRIOR FILING DATE: 2003-09-10

; PRIOR FILING DATE: 2002-11-14

```
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165357
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-165357

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGC 3270
Db 17 AAATCTTGGCCATTGTC 1

RESULT 1352
US-11-083-784-165439/c
; Sequence 165439, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165439
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-165439

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGC 3270
Db 18 AAATCTTGGCCATTGTC 2

RESULT 1353
US-11-083-784-165462/c
; Sequence 165462, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050

; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 165462
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-165462

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTGC 3270
Db 17 AAATCTTGGCCATTGTC 1

RESULT 1354
US-11-083-784-223107
; Sequence 223107, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 223107
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-223107

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 1e+03;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 449 TGGAAACTGCTGATCTG 465
Db 3 UGGAAACUUCUGAUCUG 19

RESULT 1355
US-11-083-784-249657/c
; Sequence 249657, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
```

RESULT 1357
US-11-083-784-376141
; Sequence 376141, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Pharmaco, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hypo-

RESULT 1359
US-11-083-7884-388710 Application US/11083784
; Publication NO. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Pharmaco, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin

```
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/083,784
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 388710
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-388710
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 3472 GGAGAGACAGGATTGG 3488
Db 1 GGAGAGAGGAGUUUGG 17
|||||:|||||:|||||
```

```
RESULT 1360
US-11-083-784-393275/c
; Sequence 393275, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 393275
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-393275
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 3133 AAATGGGAGATACGA 3149
Db 19 AAAGTGGGAGATACGA 3
|||||:|||||:|||||
```

```
RESULT 1361
US-11-083-784-405137
; Sequence 405137, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
```

```
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 405137
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-405137
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 1e+03;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 4066 CCCAAGCTGTGTCCTAT 4082
Db 3 CCCAAGCUGUGUCCAAU 19
|||||:|||||:|||||
```

```
RESULT 1362
US-11-083-784-405183
; Sequence 405183, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 405183
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-405183
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 1e+03;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 4066 CCCAAGCTGTGTCCTAT 4082
Db 1 CCCAAGCUGUGUCCAAU 17
|||||:|||||:|||||
```

```
RESULT 1363
US-11-083-784-440347
; Sequence 440347, Application US/11083784
```


RESULT 1364
US-11-083-784-446199/c
; Sequence 446199, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 440347
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-440347

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.1%; Pred. No. 1e+03;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 438 GAACACAAAATTGGAAA 454
|||||:|||||
DB 1 GAACAGAAAUAUUGAAA 17

RESULT 1364
US-11-083-784-442932/c
; Sequence 442932, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 442932
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-442932

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2423 TCACCAACAGCATGCC 2439
|||||:|||||
DB 17 TCACCAACAGCATGACC 1

RESULT 1365
US-11-083-784-446199/c
; Sequence 446199, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 446199
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-446199

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1612 TCCTCCTTAGCCACGGG 1628
|||||:|||||
DB 18 TCCTCCATAGCCACGGG 2

RESULT 1366
US-11-083-784-448936/c
; Sequence 448936, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 448936
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-448936

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1933 CAGGAACATCACAGCCA 1949
|||||:|||||

```
Db      17 CAGGAACATCACTGCCA 1
RESULT 1367
US-11-083-784-466442
; Sequence 466442, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 466442
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-466442
Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      2187 GGAATTTCGAAGAGA 2203
      |||||:|||||
Db      1 GGAAUUGGCAAGAGA 17

RESULT 1368
US-11-083-784-478703/c
; Sequence 478703, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 478703
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-478703
Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db      17 CAGGAACATCACTGCCA 1
RESULT 1367
US-11-083-784-466442
; Sequence 466442, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 466442
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-466442
Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      2803 ATGTGGAGGTGATGTC 2819
      |||||:|||||
Db      18 ATGTGTGAGGTGATGTC 2

RESULT 1369
US-11-083-784-488729
; Sequence 488729, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 488729
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-488729
Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      1877 CCAGCTACCTGCTGCAG 1893
      |||||:|||||
Db      1 CCAACUACCGUGGCAG 17

RESULT 1370
US-11-083-784-499341
; Sequence 499341, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 499341
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-499341
```

```
Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2290 AAGAAGGAGAGTGTGT 2306
Db 3 AAGAAGGAGAACUGUGU 19
|||||||:|:|:|
|:|:|:|:|:|:|

RESULT 1371
US-11-083-784-536642
; Sequence 536642, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 536642
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-536642

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 438 GAACACAAATGGAAA 454
Db 1 GAACAGAAAUAUGGAA 17
|||||:|:|:|
|:|:|:|:|:|:|

RESULT 1372
US-11-083-784-586431/c
; Sequence 586431, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 586431
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-586431

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1587 TGAGGTCACTGCATTGA 1603
Db 17 TGAGGTCACTGCATTGA 1
|||||||:|:|:|
|:|:|:|:|:|:|

RESULT 1373
US-11-083-784-593515/c
; Sequence 593515, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 593515
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-593515

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2475 CCTGGACTCCTTCTGTC 2491
Db 17 CCTGGCTCTCTTCTGTC 1
|||||:|:|:|
|:|:|:|:|:|:|

RESULT 1374
US-11-083-784-604134/c
; Sequence 604134, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 604134
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-604134
```

```
; SEQ ID NO 604134
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-604134

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3247 CAGAGAAAATCTTGGC 3263
      ||||| ||||| |||||
Db 17 CAGAGGGAATCTTGGC 1

RESULT 1375
US-11-083-784-618691/c
; Sequence 618691, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 618691
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-618691

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2338 GAGCGGCGGCGGTGA 2354
      ||||| ||||| |||||
Db 17 GAGCAGCGGCGGTGA 1

RESULT 1376
US-11-083-784-710189
; Sequence 710189, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
```

```
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 710189
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-710189

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2593 GACCTGGCTGCTGCAA 2609
      ||||| ||||| |||||
Db 2 GACCUUGGUGCCGCGCAA 18

RESULT 1377
US-11-083-784-772658/c
; Sequence 772658, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 772658
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-772658

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2029 GTCCTGGTGGTCATTGT 2045
      ||||| ||||| |||||
Db 17 GTCCTGGTGGTCATTGT 1

RESULT 1378
US-11-083-784-778427
; Sequence 778427, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
```

; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 778427
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-778427

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 1e+03;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

Qy 3934 CATAACTTTGGTGGGA 3950
Db 3 CAUAACUUUGUCUUGGA 19

RESULT 1379
US-11-083-784-778438
; Sequence 778438, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 778438
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-778438

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 1e+03;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

Qy 3934 CATAACTTTGGTGGGA 3950
Db 2 CAUAACUUUGUCUUGGA 18

RESULT 1380
US-11-083-784-788952
; Sequence 788952, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784

; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 788952
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-788952

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2618 TCAACAGCAACCTCGTC 2634
Db 3 UCAACAGCAACCUUC 19

RESULT 1381
US-11-083-784-789052
; Sequence 789052, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 789052
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-789052

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 2618 TCAACAGCAACCTCGTC 2634
Db 3 UCAACAGCAACCUUC 19

RESULT 1382
US-11-083-784-789152
; Sequence 789152, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen

```
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 789152
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-789152
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 2618 TCAACAGCAACCTCGTC 2634
:|||||:|:|
Db 3 UCAACAGCAACCCUUC 19
```

```
RESULT 1383
US-11-083-784-789248
; Sequence 789248, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 789248
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-789248
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 2618 TCAACAGCAACCTCGTC 2634
:|||||:|:|
Db 3 UCAACAGCAACCCUUC 19
```

```
RESULT 1384
US-11-083-784-789347
; Sequence 789347, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
```

```
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 789347
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-789347
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 2618 TCAACAGCAACCTCGTC 2634
:|||||:|:|
Db 3 UCAACAGCAACCCUUC 19
```

```
RESULT 1385
US-11-083-784-789447
; Sequence 789447, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 789447
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-789447
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 2618 TCAACAGCAACCTCGTC 2634
:|||||:|:|
Db 3 UCAACAGCAACCCUUC 19
```

```
RESULT 1386
US-11-083-784-834453/c
; Sequence 834453, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
```

; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 834453
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-834453

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; Mismatches 1; Indels 0; Gaps 0;
Matches 16; Conservative 0;

QY 2205 CGATGCTCTCTAGCTCA 2221
Db 17 CGATGCTCTCTACTTCA 1

RESULT 1387

US-11-083-784-837999
; Sequence 837999, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 837999
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-837999

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1e+03; Mismatches 1; Indels 0; Gaps 0;
Matches 15; Conservative 1;

QY 3073 GACCAGCGGCGACCTCA 3089
Db 1 GACCAGCGGCAACCUCA 17

RESULT 1388

US-11-083-784-855576

; Sequence 855576, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 855576
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-855576

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 1e+03; Mismatches 4; Indels 0; Gaps 0;
Matches 12; Conservative 1;

QY 452 AAACCTGCTGATCTGAAG 468
Db 3 AAUUGCUGAUCUGAAG 19

RESULT 1389

US-11-083-784-927801/c
; Sequence 927801, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 927801
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-927801

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; Mismatches 0; Indels 0; Gaps 0;
Matches 16; Conservative 0;

QY 3168 TGGCTTTGGCTCTCTCG 3184
Db 17 TGGCTTCGGCTCTCTCG 1

RESULT 1390
US-11-083-784-1019444
; Sequence 1019444, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1019444
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1019444

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03; DB 1; Length 19;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 109 CAACCTCCAGCCACCTCT 125
|||||
Db 1 CAACUCCAGUACCGUCU 17

RESULT 1391
US-11-083-784-1036594/c
; Sequence 1036594, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1036594
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1036594

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2669 TGGAGGAGAACTCTTCC 2685

Db 17 TGGTGGAGAACTCTTCC 1
|||||
RESULT 1392
US-11-083-784-1071237
; Sequence 1071237, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1071237
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1071237

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 1e+03; DB 1; Length 19;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 3831 AGCTGCTGCCTTCATAT 3847
|||||
Db 2 AGCUGCGUCCUUAUUU 18

RESULT 1393
US-11-083-784-1071275
; Sequence 1071275, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1071275
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1071275

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 1e+03; DB 1; Length 19;

Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 3831 AGCTGTCGCTTCATAT 3847
Best Local Similarity 82.4%; Pred. No. 1e+03; Length 19;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Db 3 AGCUGCGCCUUAUUU 19

RESULT 1394

US-11-083-784-1104410
; Sequence 1104410, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1104410
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1104410

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03; Length 19;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1233 GCCATGCCCAACAATA 1249
Best Local Similarity 82.4%; Pred. No. 1e+03; Length 19;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Db 2 GCCAUGCCCAACCAUA 18

RESULT 1395

US-11-083-784-1104472
; Sequence 1104472, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1104472
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1104472

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03; Length 19;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1233 GCCATGCCCAACAATA 1249
Best Local Similarity 82.4%; Pred. No. 1e+03; Length 19;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Db 3 GCCAUGCCCAACCAUA 19

RESULT 1396

US-11-083-784-1134517
; Sequence 1134517, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1134517
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1134517

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03; Length 19;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3595 AAGGAGTGCACCAAT 3611
Best Local Similarity 82.4%; Pred. No. 1e+03; Length 19;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Db 2 AGGAAGUGCCCAACAU 18

RESULT 1397

US-11-083-784-1136133
; Sequence 1136133, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1136133
; LENGTH: 19

```

; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1136133

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 1e+03;
Matches 10; Conservative 6; Mismatches 1; Indels

QY      3832  GCTGCTGCCTTCATATT 3848
DB      1      GCUGCGGCUUACAUAU 17
          ||:|||||:|:|:|

RESULT 1398
US-11-083-784-1207573
; Sequence 1207573, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1207573
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1207573

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 1e+03;
Matches 10; Conservative 6; Mismatches 1; Indels

QY      2808  GGAGGTGATGTCATTG 2824
DB      3      GGAGGUGUGUCAUUG 19
          |||||:|:|:|:|

RESULT 1399
US-11-083-784-1259838
; Sequence 1259838, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911

```

```

; SOFTWARE: Proprietary
; SEQ ID NO 1259838
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1259838

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      451 GAAACTGCTGATCTGAA 467
      ||||| ||:|:|:|
Db      2 GAAACAGCUGAUCUGAA 18

RESULT 1400
US-11-083-784-1263543/c
; Sequence 1263543, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; PRIOR FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1263543
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1263543

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      445 AAATTGGAAACTGCTGA 461
      ||||| ||||| |||||
Db      19 AAATTGGAAACTTCTGA 3

RESULT 1401
US-11-083-784-1263597/c
; Sequence 1263597, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10

```

; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1263597
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1263597

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 445 AAATTGGAACCTCTGA 461
Db 17 AAATTGGAACCTCTGA 1

RESULT 1402
US-11-083-784-1268095/c
; Sequence 1268095, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1268095
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1268095

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1044 CTTGCTGGATCCGTC 1060
Db 17 CATGCTGGATCCGTC 1

RESULT 1403
US-11-083-784-1319444/c
; Sequence 1319444, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333

; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1319444
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1319444

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3780 CTGTCAACCAAACTC 3796
Db 18 CTGTCAACCAAAAGTC 2

RESULT 1404
US-11-083-784-1323046/c
; Sequence 1323046, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1323046
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1323046

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2930 TCATGCTGGACTGTGG 2946
Db 19 TCATGCTGGACTGTGG 3

RESULT 1405
US-11-083-784-1334142/c
; Sequence 1334142, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 134990US

```
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1334142
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1334142

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 4134 CAGAAACGACGCGCGT 4150
Db 18 CAGAAACGACGCGCGT 2

RESULT 1406
US-11-083-784-1366776
; Sequence 1366776, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1366776
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1366776

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 1e+03;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 305 GGGAGAGTCAGACCTGG 321
Db 1 GGGAGAGTCAGACCTGG 17

RESULT 1407
US-11-083-784-1372964/c
; Sequence 1372964, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
```

```
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1372964
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1372964

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2110 GGACAGTATCTCATCGG 2126
Db 17 GGACAGTATCTCATCAG 1

RESULT 1408
US-11-083-784-1401474
; Sequence 1401474, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1401474
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1401474

Query Match          0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 58.8%; Pred. No. 1e+03;
Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 3639 ACCTTGATGGTGGCTT 3655
Db 3 ACCUUGAUGGUGCUU 19

RESULT 1409
US-11-083-784-1441103/c
; Sequence 1441103, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
```

```
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1441103
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1441103
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 3272 AGCATCATGAGTCCAG 3288
Db 18 AGAATGAGTCCAG 2
```

RESULT 1410

```
US-11-083-784-1444645/c
; Sequence 1444645, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1444645
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1444645
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 1885 CTGGTGACGGTACGGC 1901
Db 17 CTGGTGACGGTACTGCC 1
```

RESULT 1411

```
US-11-083-784-1469620/c
; Sequence 1469620, Application US/11083784
; Publication No. US20050245475A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1469620
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1469620
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 859 AAGACGCTGCGTCTGGG 875
Db 18 AAGAAGCTGCGTCTGGG 2
```

RESULT 1412

```
US-11-083-784-1495899/c
; Sequence 1495899, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmacon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1495899
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1495899
```

```
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2446 ATTCTCACAGTTCAT 2462
Db 18 ATTCTCACAGTTCAT 2
```

RESULT 1413

```
US-11-083-784-1512077
; Sequence 1512077, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1512077
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1512077

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 1e+03;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 2348 GCGGTGAGTTCGAGC 2364
|||||:|:|:|:|:|
Db 2 GCGGUGAGUUCUAGC 18

RESULT 1414
US-11-083-784-1525042
; Sequence 1525042, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1525042
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1525042

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 1e+03;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 4017 CCAGAACAGTCCTTGG 4033
|||||:|:|:|:|:|
Db 1 CCAGAACAGUCCUAGC 17

RESULT 1415
US-11-083-784-1575806/c
; Sequence 1575806, Application US/11083784
; Publication No. US20050245475A1
; GENERAL INFORMATION:
; APPLICANT: Dharmakon, Inc.
; APPLICANT: Khvorova, Anastasia
; APPLICANT: Reynolds, Angela
; APPLICANT: Leake, Devin
; APPLICANT: Marshall, William
; APPLICANT: Scaringe, Stephen
; TITLE OF INVENTION: Functional and Hyperfunctional siRNA
; FILE REFERENCE: 13499US
; CURRENT APPLICATION NUMBER: US/11/083,784
; CURRENT FILING DATE: 2005-03-18
; PRIOR APPLICATION NUMBER: US/10/714,333
; PRIOR FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/502,050
; PRIOR FILING DATE: 2003-09-10
; PRIOR APPLICATION NUMBER: 60/426,137
; PRIOR FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 1591911
; SOFTWARE: Proprietary
; SEQ ID NO 1575806
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-11-083-784-1575806

Query Match      0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3134 AAATGGGAAGATACGAA 3150
|||||:|:|:|:|:|
Db 18 AAATGGGAAGATAAGAA 2

RESULT 1416
US-10-310-914A-326990
; Sequence 326990, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 326990
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-326990

Query Match      0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 12 GCGCGAGCAGAGCC 26
|||||:|:|:|:|:|
Db 3 GCGCGAGCAGAGCC 17

RESULT 1417
US-10-310-914A-350180/c
; Sequence 350180, Application US/10310914A
; Publication No. US20060003322A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 350180
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-350180

Query Match          0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 430 ACCCTGCTGGAACACA 444
Db 18 ACCCTGCTGGAACACA 4

RESULT 1418
US-10-310-914A-392825
; Sequence 392825, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 392825
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-392825

Query Match          0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 66.7%; Pred. No. 1e+03;
Matches 10; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 389 TGCTGCTCTGCTGGG 403
Db 4 UGCUGCUCUGCUGGG 18

RESULT 1419
US-10-310-914A-439882
; Sequence 439882, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 439882
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-439882
```

```
Query Match          0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 92.3%; Pred. No. 1e+03;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 147 GGCCACTGCCAGCAC 161
Db 4 GGCCACUGCCAGCAC 18

RESULT 1420
US-10-310-914A-492615
; Sequence 492615, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 492615
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-492615

Query Match          0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 1e+03;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1709 CCTCACCACGAGCT 1723
Db 3 CCACACCCAGCAGCT 17

RESULT 1421
US-10-310-914A-736192/c
; Sequence 736192, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 736192
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-736192

Query Match          0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1072 CCCAGCCCCAGCCTC 1086
Db 18 CCCAGCCCCAGCCTC 4

RESULT 1422
US-10-310-914A-746225
; Sequence 746225, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 746225
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-746225

Query Match      0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 1e+03;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2966 GGCCCCCGCTTCCCCC 2980
Db 4 GGCCCCCGCUCCCCC 18

RESULT 1423
US-10-310-914A-1154193
; Sequence 1154193, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1154193
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1154193

Query Match      0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 1e+03;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2913 CACCTCCCTCCACCA 2927
Db 3 CACCUCCCUCCACCA 17

RESULT 1424
US-10-310-914A-1198207/c
; Sequence 1198207, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1198207
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1198207
```

```
Query Match      0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1070 GCCCAGCCCCCAGCC 1084
Db 16 GCCCAGCCCCCAGCC 2

RESULT 1425
US-10-310-914A-1202821
; Sequence 1202821, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1202821
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1202821

Query Match      0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 1e+03;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1743 TCCCGCGGCACCCAG 1757
Db 1 UCCCCGCGGCACCCAG 15

RESULT 1426
US-10-310-914A-1218422/c
; Sequence 1218422, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1218422
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1218422

Query Match      0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2985 GGTGACGCCCTTGA 2999
Db 17 GGTGACGCCCTTGA 3

RESULT 1427
US-10-958-999-8/c
; Sequence 8, Application US/10958999
; Publication No. US20060018826A1
; GENERAL INFORMATION:
; APPLICANT: Genesegues, Inc.
```


1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

APPLICANT: Bentwich, Isaac

```
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 44001
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-44001

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1966 AGCGAGGGCTGGCGGGGAG 1983
Db 1 AGGAGGGCGGGCGGGGAG 18

RESULT 1433
US-10-310-914A-49283
; Sequence 49283, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 49283
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-49283

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 170 CCCGCCCGCGCGCGCGC 187
Db 1 CCCGCCCGCGCGCGCGC 18

RESULT 1434
US-10-310-914A-58832
; Sequence 58832, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 58832
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-58832

Query Match      0.3%; Score 14.8; DB 1; Length 18;
```

```
Best Local Similarity 66.7%; Pred. No. 1.1e+03;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 942 CTGCACCTTCTCTACAA 959
Db 1 CCUGCACCUUCCCA 18

RESULT 1435
US-10-310-914A-64741/c
; Sequence 64741, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 64741
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-64741

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2887 CGCTGCCCCCGCCCCCA 2904
Db 18 CCGCTGCGCGCGCCCCCA 1

RESULT 1436
US-10-310-914A-67513/c
; Sequence 67513, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 67513
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-67513

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3856 TTGTAGTTTTGTTTTGG 3873
Db 18 TTGTAGTTTTTTTTTTG 1

RESULT 1437
US-10-310-914A-73628
; Sequence 73628, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
```

```
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 73628
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-73628

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2979 CCAGGTGTCAGCGCCCT 2996
Db 1 CCAGGGGGUCAGAGCCCU 18

RESULT 1438
US-10-310-914A-73629
; Sequence 73629, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 73629
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-73629

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2979 CCAGGTGTCAGCGCCCT 2996
Db 1 CCAGGGGGUCAGAGCCCU 18

RESULT 1439
US-10-310-914A-74614/c
; Sequence 74614, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 74614
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-74614

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3896 CTTTGTGTTCTTCGTTT 3913
Db 18 CTTTGTGTTCTTCGTTT 1

RESULT 1440
US-10-310-914A-76058/c
; Sequence 76058, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 76058
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-76058

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4087 GGGTGTGGGTGAGGTAG 4104
Db 18 GGGTGTGGGTGAGGTAG 1

RESULT 1441
US-10-310-914A-79264/c
; Sequence 79264, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 79264
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-79264

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1383 CTCCTCCCTGCACCTGGA 1400
Db 18 CTCCTCCCTGCACCTGGA 1

RESULT 1442
US-10-310-914A-85575/c
; Sequence 85575, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
```

; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 85575
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-85575

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3898 TTTTGTTCCTGTTTG 3915
DB 18 TTTTGTTCCTGTTTG 1

RESULT 1443
US-10-310-914A-95682/c
; Sequence 95682, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 95682
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-95682

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3168 TGGCTTTGGCTCTCTGA 3185
DB 18 TGGCTTTGGCTCTCTGA 1

RESULT 1444
US-10-310-914A-98379/c
; Sequence 98379, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 98379
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-98379

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3861 GTTTTGTTCCTCTTA 3878
DB 18 GTTTTGTTCCTCTGA 1

RESULT 1445
US-10-310-914A-99217/c
; Sequence 99217, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 99217
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-99217

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3853 GTTTTGTTCCTCTTT 3870
DB 18 GTTTTGTTCCTCTTT 1

RESULT 1446
US-10-310-914A-107712/c
; Sequence 107712, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 107712
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-107712

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 133 CGCCCGCCCGCGCGGCC 150
DB 18 CGCCCGCCCGCGCGGCC 1

RESULT 1447
US-10-310-914A-111236/c
; Sequence 111236, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 98379
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-98379

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310.914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 111236
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-111236

```

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1230 CCAGCCATGCCCAGCCAA 1247
Db 18 CCAGCCAGGCCCAGCCGA 1

RESULT 1448
US-10-310-914A-138164/c
; Sequence 138164, Application US/10310914A
; Publication No. US20060003322A1

```
Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Qy 134 GCCCGCCCGCGCGGCCA 151
Dp 18 GCCCGCCCGCGCGGCCA 1

RESULT 1449
US-10-310-914A-149256/c
; Sequence 149256, Application US/10310914A
; Publication No. US20060003322A1

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

Qy 3622 CCCACGGTGCCTCCCTCA 3639
      |||||
Db 18 CCCCCGAGCCCCCTCA 1

```

Query Match	0.3%	Score 14.8;	DB 1;	Length 18;
Best Local Similarity	72.2%	Pred. No. 1.1e+03;		
Matches 13; Conservative	3;	Mismatches 2;	Indels 0;	Gaps 0;

Qy 3823 CCTCCCCCAGCTGCTGCC 3840
||:|||||:|:|
Db 1 CCUCCUCCAGTUCUGCC 18

RESULT 1451
US-10-310-914A-157171
; Sequence 157171, Application US/10310914A
; Publication No. US2006000322A1

Query Match	0.3%	Score 14.8;	DB 1;	Length 18;
Best Local Similarity	77.8%	Pred. No. 1.le+03;		
Matches 14: Conservative		2; Mismatches 2;	Indels 0;	Gaps 0;

Qy 1442 CCTACGCCCTCCGCTGCC 1459
||: ||||| ||||: |||
pb 1 CCGCGCCCGCGCGGCC 18

RESULT 1452
US-10-310-914A-168059/c
; Sequence 168059, Application US/10310914A
; Publication No. US2006000322A1

; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 168059
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-168059

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 133 CGCCGCGCCGCGCGGCC 150
Db 18 CGCCGCGCCGCGCGGCC 1

RESULT 1453
US-10-310-914A-168733/c
; Sequence 168733, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 168733
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-168733

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3056 CCTCACACCTCTCTCTCG 3073
Db 18 CCTCACATCTCTCCAG 1

RESULT 1454
US-10-310-914A-182752
; Sequence 182752, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 182752
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-182752

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2963 CCCGCGCCGCTTCCCC 2980

Db 1 CCGCGCCCGCGUCCCCAC 18
RESULT 1455
US-10-310-914A-185749
; Sequence 185749, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 185749
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-185749

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 66.7%; Pred. No. 1.1e+03;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1128 GGGCTGCAGCTGTGCTCC 1145
Db 1 GAGCUGCUGCUGGCUCC 18

RESULT 1456
US-10-310-914A-200249
; Sequence 200249, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 200249
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-200249

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 1.1e+03;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 3616 CAGCTTCCCAGTGCC 3633
Db 1 CACCCUCCGCGCGUCCC 18

RESULT 1457
US-10-310-914A-200570
; Sequence 200570, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A

Qy 1330 CCCTGCACCACTCCCTCT 1347

; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 289024
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-289024

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 50.0%; Pred. No. 1.1e+03;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 3677 TAATTTTCTCCCGCTC 3894

Db 1 UAAUUUCUCCCGCGC 18

RESULT 1463

US-10-310-914A-312199
; Sequence 312199, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvazat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 312199

; LENGTH: 18

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-312199

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 89.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1705 CGGTCTTCACCCAGCAGC 1722

Db 1 CUGUCCACCCAGCAGC 18

RESULT 1464

US-10-310-914A-316348/c
; Sequence 316348, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvazat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 316348

; LENGTH: 18

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-316348

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 89.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3072 GGACGAGCGGCGAGCTCA 3089

Db 18 GGGCCAGCGGCGAGCTCA 1

RESULT 1465

US-10-310-914A-318062/c
; Sequence 318062, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvazat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 318062

; LENGTH: 18

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-318062

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4149 GTGCTTGAGGGGTCTT 4166

Db 18 GTGCTTGAGCGTGTCTT 1

RESULT 1466

US-10-310-914A-321907/c
; Sequence 321907, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvazat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 321907

; LENGTH: 18

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-321907

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2886 CCGGCTGCCCGCCCGCC 2903

Db 18 CCGGCTGCCCGCTGCCCGC 1

RESULT 1467

US-10-310-914A-322050
; Sequence 322050, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvazat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402


```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 322050
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-322050

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1062 CGCCCTGGCCACGCC 1079
| ||||| |||||
Db 1 CUCCCCUGGCCUACGCC 18

RESULT 1468
US-10-310-914A-340689/c
; Sequence 340689, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 340689
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-340689

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1127 CGGGCTGACGTGTGCTC 1144
| ||||| |||||
Db 18 CTGGCTGTAGCTGTGCTC 1

RESULT 1469
US-10-310-914A-343588/c
; Sequence 343588, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 343588
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-343588

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1326 TGCACCCCTGCACACCCC 1343
| || ||||| |||||
Db 18 TGCCCCCTGCCACACCCC 1

RESULT 1470
US-10-310-914A-343589/c
; Sequence 343589, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 343589
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-343589

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1326 TGCACCCCTGCACACCCC 1343
| || ||||| |||||
Db 18 TGCCCCCTGCCACACCCC 1

RESULT 1471
US-10-310-914A-353955/c
; Sequence 353955, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 353955
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-353955

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2089 GCAGATATTTCGACAAA 2106
| ||||| |||||
Db 18 GTAGATATTTCGACAAA 1

RESULT 1472
US-10-310-914A-370347/c
; Sequence 370347, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
```

; SEQ ID NO 370347
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-370347

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 158 GCACGCTCCGGCCCGCC 175
||||| ||||| |||||
Db 18 GCACGCCCCGGCCCGCC 1

RESULT 1473
US-10-310-914A-374108/c
; Sequence 374108, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 374108
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-374108

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4015 TTCAGAACAGTGCCTTG 4032
||||| ||||| |||||
Db 18 TTCTAGCACAGTGCCTTG 1

RESULT 1474
US-10-310-914A-392819/c
; Sequence 392819, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 392819
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-392819

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1801 GCCAGAGGTCCAGCAGC 1818
||||| ||||| |||||
Db 18 GCCTAGGCCCCCAGCAGC 1

RESULT 1475
US-10-310-914A-394234/c
; Sequence 394234, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 394234
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-394234

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 245 GCGCCGCGCTGAGGGCC 262
||||| ||||| |||||
Db 18 GCGCCGCGCTGAGGGCC 1

RESULT 1476
US-10-310-914A-399085/c
; Sequence 399085, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 399085
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-399085

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 128 CTGCGCGCCCGCCGCGC 145
||||| ||||| |||||
Db 18 CCGCGCGCCCGCCGCGC 1

RESULT 1477
US-10-310-914A-401700
; Sequence 401700, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 401700

```
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-401700

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 66.7%; Pred. No. 1.1e+03;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1128 GGGCTGCAGCTGTCTCC 1145
      |||:|||||:|:|
Db 1 GCGCCUGCAGCUGAUC 18

RESULT 1478
US-10-310-914A-407421/c
; Sequence 407421, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 407421
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-407421

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 419 CTTTGGAGAGACCTGC 436
      |||:|||||:|
Db 18 CTTTGGAGAGATTCTGC 1

RESULT 1479
US-10-310-914A-472391/c
; Sequence 472391, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 472391
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-472391

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2043 TGTGCTCCAGTTCCTG 2060
      |||:|||||:|
Db 18 TGTGTTACAGTTCCTG 1

RESULT 1480
```

```
US-10-310-914A-479651/c
; Sequence 479651, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 479651
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-479651

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1905 CTCTGAGCGCGCTACGG 1922
      |||:|||||:|
Db 18 CTCTGAGCGCGCTCCTG 1

RESULT 1481
US-10-310-914A-485967/c
; Sequence 485967, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 485967
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-485967

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3879 ATTTTCTCCCGTTCCTCC 3896
      |||:|||||:|
Db 18 ATTTTCTCCCGTTCCTCC 1

RESULT 1482
US-10-310-914A-487136/c
; Sequence 487136, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 487136
; LENGTH: 18
```

```

; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-487136

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3898 TTTTGTTCCTTCGTTTG 3915
    |||||
Db 18 TTTTGTTCCTTCGTTTG 1

RESULT 1483
US-10-310-914A-490510/c
; Sequence 490510, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 490510
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-490510

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1957 CTGATCAGAGCGGCGC 1974
    |||||
Db 18 CAGGAGGAGCGGCGGCGC 1

RESULT 1484
US-10-310-914A-494389/c
; Sequence 494389, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 494389
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-494389

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1151 TCGAGGCGAGCTGAGGGGA 1168
    |||||
Db 18 TCTGGCAGCTGAGGGGA 1

RESULT 1485
US-10-310-914A-510815/c
; Sequence 510815, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 510815
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-510815

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 384 CCGGGTGCTGCTGCTGCTG 401
    |||||
Db 18 CTGGGGCTGCTGCTGCTG 1

RESULT 1486
US-10-310-914A-519334/c
; Sequence 519334, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 519334
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-519334

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 156 CAGCAGCTCCGGGCGCCG 173
    |||||
Db 18 CAGCAGCTCCGGGCGCCG 1

RESULT 1487
US-10-310-914A-521199/c
; Sequence 521199, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 521199
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-521199/c

```

```
; ORGANISM: Human
US-10-310-914A-521199

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3604 CCCACATCTCCACGCT 3621
    ||||| ||||| |||||
Db 18 CCCACATCACCACTCT 1

RESULT 1488
US-10-310-914A-523963
; Sequence 523963, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 523963
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-523963

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 2225 TTGAGAGGTGATTGGTG 2242
    :|||: |||: |||: |||:
Db 1 UUGAAGAAGAUUGUG 18

RESULT 1489
US-10-310-914A-540325/c
; Sequence 540325, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 540325
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-540325

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 20 CAGAGCCACTCCAGGAG 37
    ||||| ||||| |||||
Db 18 CAGAGCCACTCCAGCCAG 1

RESULT 1490
US-10-310-914A-552910/c
; Sequence 552910, Application US/10310914A
```

```
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 552910
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-552910

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4054 CCGCTGGGACCCCAAG 4071
    ||||| ||||| |||||
Db 18 CCGCTGGGATCCCAAG 1

RESULT 1491
US-10-310-914A-559267/c
; Sequence 559267, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 559267
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-559267

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3609 CATCTCCAGCTCCCA 3626
    ||||| ||||| |||||
Db 18 CATCTCCACCTCCCA 1

RESULT 1492
US-10-310-914A-560682/c
; Sequence 560682, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 560682
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
```

US-10-310-914A-560682

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1330 CCTGCACCACTCCCTCT 1347
||| ||||| ||||| |||||
Db 18 CCCAGCACCGCCCTCTCT 1

RESULT 1493

US-10-310-914A-570781
; Sequence 570781, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 570781

; LENGTH: 18

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-570781

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 1.1e+03;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 2290 AAGAGGAGAGCTGTGTG 2307
||||| ||||| ||||| |||||
Db 1 AAGAAAGAGAGCTGGUG 18

RESULT 1494

US-10-310-914A-592815/c

; Sequence 592815, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 592815

; LENGTH: 18

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-592815

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3449 GTGGGTGAGAGTGTGC 3466
||||| ||||| ||||| |||||
Db 18 GTGGGTGAGAGTGTGC 1

RESULT 1495

US-10-310-914A-609105/c

; Sequence 609105, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 609105
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-609105

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1847 GGCAGAGCTCGGGGC 1864
||| ||||| ||||| |||||
Db 18 GGACAGAGCTGTGGGC 1

RESULT 1496

US-10-310-914A-655587

; Sequence 655587, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 655587

; LENGTH: 18

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-655587

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 1.1e+03;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1782 CAAATACCATGAGAGGG 1799
||||| ||||| ||||| |||||
Db 1 CAAAUACCAUGAGCTGGG 18

RESULT 1497

US-10-310-914A-661057/c

; Sequence 661057, Application US/10310914A

; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 661057

; LENGTH: 18

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-661057

```
Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1326 TGCACCTGTGCACCC 1343
Db 18 TGCCTCTGTGCACCC 1

RESULT 1498
US-10-310-914A-675735/c
; Sequence 675735, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 675735
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-675735

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3852 GGTTTTGAGTTTGTTT 3869
Db 18 GGTTTTGAGTTTGTTT 1

RESULT 1499
US-10-310-914A-702256/c
; Sequence 702256, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 702256
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-702256

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 170 CCGCGCGCGCGCGCGC 187
Db 18 CTCGCGCGCGCGCGCGC 1

RESULT 1500
US-10-310-914A-716395
; Sequence 716395, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 716395
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-716395
```

```
Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 2286 AGGAGAGAGAGAGCTG 2303
Db 1 AGGAGAGAGAGAGCTG 18
```

```
RESULT 1501
US-10-310-914A-728016
; Sequence 728016, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 728016
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-728016
```

```
Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 1.1e+03;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 1227 CTCGCGCCATGCCGAGC 1244
Db 1 CUUCCAGCCCGCCGAGC 18
```

```
RESULT 1502
US-10-310-914A-747222
; Sequence 747222, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 747222
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-747222
```

```
Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      85 GACCCCGAGCCCGGGAG 102
      ||||| ||||| |||||
Db      1 GACCCAGGGGCCCGGGAG 18

RESULT 1503
US-10-310-914A-761086/c
; Sequence 761086, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 761086
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-761086

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2977 CCCCAGGTGTCAGCGCC 2994
      ||||| ||||| |||||
Db      18 CCCCAGGTGCTCAGGGCC 1

RESULT 1504
US-10-310-914A-765180
; Sequence 765180, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 765180
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-765180

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1066 CTTGGCCCCAGCCCCCAGC 1083
      || ||||| ||||| |||||
Db      1 CCCCAGCCCCAGCCCCACC 18

RESULT 1505
US-10-310-914A-771537/c
; Sequence 771537, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
```

```
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 771537
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-771537

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1089 CTGCGGTGAGGATGGCCA 1106
      ||||| ||||| |||||
Db      18 CTGGGTGAGGATGGCCA 1

RESULT 1506
US-10-310-914A-778728
; Sequence 778728, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 778728
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-778728

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      187 CGGCACAGCGCGGGGCC 204
      ||||| ||||| |||||
Db      1 CGGCACAGCGCGAGGGCC 18

RESULT 1507
US-10-310-914A-785986/c
; Sequence 785986, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 785986
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-785986

Query Match      0.3%; Score 14.8; DB 1; Length 18;
```



```
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 817270
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-817270

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 3095 CAGCTTTTGGCTCTGTGG 3112
Db 1 CAGGUUUUGCUCUGUGG 18

RESULT 1511
US-10-310-914A-894247
; Sequence 894247, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 894247
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-894247

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1329 ACCCTGCACCCCTCC 1346
Db 1 ACCCUGCACCAAGCCGCC 18

RESULT 1512
US-10-310-914A-894280
; Sequence 894280, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 894280
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-894280

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 3824 CTCCTCCAGCTCTGCT 3841
Db 1 CUCCUCCAGCCGCGCCU 18

RESULT 1510
US-10-310-914A-817270
; Sequence 817270, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 804096
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-804096

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 3342 TGCAGGAACCTCCACCC 3359
Db 1 UGCAGGUAACCCCAACCC 18

RESULT 1509
US-10-310-914A-804096
; Sequence 804096, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 804096
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-804096

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1064 CCCCTGGCCCCAGCCCA 1081
Db 18 CCCCTGACCCAGCCTCA 1
```

```
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 817270
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-817270

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 3095 CAGCTTTTGGCTCTGTGG 3112
Db 1 CAGGUUUUGCUCUGUGG 18

RESULT 1511
US-10-310-914A-894247
; Sequence 894247, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 894247
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-894247

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1329 ACCCTGCACCCCTCC 1346
Db 1 ACCCUGCACCAAGCCGCC 18

RESULT 1512
US-10-310-914A-894280
; Sequence 894280, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 894280
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-894280

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 3824 CTCCTCCAGCTCTGCT 3841
Db 1 CUCCUCCAGCCGCGCCU 18

RESULT 1510
US-10-310-914A-817270
; Sequence 817270, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 804096
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-804096

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 3342 TGCAGGAACCTCCACCC 3359
Db 1 UGCAGGUAACCCCAACCC 18

RESULT 1509
US-10-310-914A-804096
; Sequence 804096, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 804096
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-804096

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1064 CCCCTGGCCCCAGCCCA 1081
Db 18 CCCCTGACCCAGCCTCA 1
```

Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1330 CCTGTGACACCCCTCT 1347
 |||:|||||:|:|:|:
 Db 1 CCCUGCACAGCCCUCCU 18

RESULT 1513

US-10-310-914A-897142
 ; Sequence 897142, Application US/10310914A
 ; Publication No. US20060003322A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bentwich, Isaac
 ; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
 ; FILE REFERENCE: 06087.0200.CPUS01
 ; CURRENT APPLICATION NUMBER: US/10/310,914A
 ; CURRENT FILING DATE: 2002-12-06
 ; NUMBER OF SEQ ID NOS: 1388402
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 897142
 ; LENGTH: 18
 ; TYPE: RNA
 ; ORGANISM: Human
 US-10-310-914A-897142

Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 1.1e+03;
 Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1844 ACCGGGACAGCTCGGG 1861
 |||:|||||:|:|:|:
 Db 1 ACCAGGACAGCGUCGG 18

RESULT 1514

US-10-310-914A-907233/c
 ; Sequence 907233, Application US/10310914A
 ; Publication No. US20060003322A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bentwich, Isaac
 ; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
 ; FILE REFERENCE: 06087.0200.CPUS01
 ; CURRENT APPLICATION NUMBER: US/10/310,914A
 ; CURRENT FILING DATE: 2002-12-06
 ; NUMBER OF SEQ ID NOS: 1388402
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 907233
 ; LENGTH: 18
 ; TYPE: RNA
 ; ORGANISM: Human
 US-10-310-914A-907233

Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 1.1e+03;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1070 GCCCCAGCCCGCTCT 1087
 |||:|||||:|:|:|:
 Db 18 GCCCCAGCCCTGCTCT 1

RESULT 1515

US-10-310-914A-958358
 ; Sequence 958358, Application US/10310914A
 ; Publication No. US20060003322A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bentwich, Isaac
 ; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof
 ; FILE REFERENCE: 06087.0200.CPUS01
 ; CURRENT APPLICATION NUMBER: US/10/310,914A
 ; CURRENT FILING DATE: 2002-12-06
 ; NUMBER OF SEQ ID NOS: 1388402
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 958358
 ; LENGTH: 18
 ; TYPE: RNA
 ; ORGANISM: Human
 US-10-310-914A-958358

Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 77.8%; Pred. No. 1.1e+03;
 Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2910 TCCACCTCCCTCCACCA 2927
 :|||||:|:|:|:
 Db 1 UCCCACTCCCTCCCUCCA 18

RESULT 1516

US-10-310-914A-958514/c
 ; Sequence 958514, Application US/10310914A
 ; Publication No. US20060003322A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bentwich, Isaac
 ; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
 ; FILE REFERENCE: 06087.0200.CPUS01
 ; CURRENT APPLICATION NUMBER: US/10/310,914A
 ; CURRENT FILING DATE: 2002-12-06
 ; NUMBER OF SEQ ID NOS: 1388402
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 958514
 ; LENGTH: 18
 ; TYPE: RNA
 ; ORGANISM: Human
 US-10-310-914A-958514

Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 1.1e+03;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2968 CCCCGCTTCCCCAGGTG 2985
 |||:|||||:|:|:|:
 Db 18 CCCAGCATCCCCCAGGTG 1

RESULT 1517

US-10-310-914A-967635
 ; Sequence 967635, Application US/10310914A
 ; Publication No. US20060003322A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bentwich, Isaac
 ; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
 ; FILE REFERENCE: 06087.0200.CPUS01
 ; CURRENT APPLICATION NUMBER: US/10/310,914A
 ; CURRENT FILING DATE: 2002-12-06
 ; NUMBER OF SEQ ID NOS: 1388402
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 967635
 ; LENGTH: 18
 ; TYPE: RNA
 ; ORGANISM: Human
 US-10-310-914A-967635

Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 72.2%; Pred. No. 1.1e+03;
 Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

QY 2306 TGGCAATCAAGACCTGCA 2323
:|||||: |||||: ||
Db 1 UGCAUGAGACCCUGA 18

RESULT 1518
US-10-310-914A-974099/c
; Sequence 974099, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 974099
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-974099

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1067 CTGGGCCCCAGCCCGGCC 1084
:|||||: |||||: ||
Db 18 CGGGCCCCAGCCCGGCC 1

RESULT 1519
US-10-310-914A-1009356/c
; Sequence 1009356, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1009356
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1009356

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1319 CCGGGGTGCACCTGCA 1336
:|||||: |||||: ||
Db 18 CCGGTGTGCACCTGCA 1

RESULT 1520
US-10-310-914A-1014756
; Sequence 1014756, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1014756
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1014756

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 2963 CCGGCCCCGCTTCCCC 2980
:|||||: |||||: ||
Db 1 CGCGCCCCGCAUCCCC 18

RESULT 1521
US-10-310-914A-1026764/c
; Sequence 1026764, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1026764
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1026764

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3903 TTCTTCGTTTGTTTT 3920
:|||||: |||||: ||
Db 18 TTCTCTGTTTGTTTT 1

RESULT 1522
US-10-310-914A-1030192/c
; Sequence 1030192, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1030192
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1030192

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3823 CCTCCCCAGCTGCTGC 3840
DB 18 CCACCCCCAGCTGCTGC 1

RESULT 1523

US-10-310-914A-1059710
; Sequence 1059710, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1059710
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1059710

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 675 GCCTCGGGCTGGGGCTGC 692
DB 1 GCCUCGGCGGGCGCGC 18

RESULT 1524

US-10-310-914A-1067192
; Sequence 1067192, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1067192
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1067192

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3517 CACCCCCCAGCCACCTCG 3534
DB 1 CAGCCCCCUGCCACCUCG 18

RESULT 1525

US-10-310-914A-1067193
; Sequence 1067193, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1067193
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1067193

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3517 CACCCCCCAGCCACCTCG 3534
DB 1 CAGCCCCCUGCCACCUCG 18

RESULT 1526

US-10-310-914A-1077647
; Sequence 1077647, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1077647
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1077647

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3517 CACCCCCCAGCCACCTCG 3534
DB 1 CAGCCCCCUGCCACCUCG 18

RESULT 1527

US-10-310-914A-1077648
; Sequence 1077648, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1077648
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1077648

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 3517 CACCCCCCAGCCACCTCG 3534

Db 1 CAGCCCCCGGCCACCUCC 18
|| ||||| |||||: ||

RESULT 1528
US-10-310-914A-1079848/c
; Sequence 1079848, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1079848
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1079848

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2964 CCGGCCCGCTTCCCCCA 2981
|| ||||| |||||
Db 18 CCGGCCCGCTTCCCCCA 1

RESULT 1529
US-10-310-914A-1085525
; Sequence 1085525, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1085525
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1085525

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 1.1e+03;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 3260 TGGCCAGTGTCCAGACA 3277
: |||||: |||||
Db 1 UGCCAGUGUGCAGACA 18

RESULT 1530
US-10-310-914A-1087279/c
; Sequence 1087279, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1087279
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1087279

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2811 GGTGATGTCATTGGGGA 2828
|| ||||| |||||
Db 18 GTTGATGTCATTGGGGA 1

RESULT 1531
US-10-310-914A-1087936
; Sequence 1087936, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1087936
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1087936

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 568 CGTGCCCCCGGCCAGGCC 585
|: ||||| |||||
Db 1 CCUGCCCCCGGCCAGGCC 18

RESULT 1532
US-10-310-914A-1090451
; Sequence 1090451, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes, and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1090451
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1090451

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 2963 CCGGCCCGCTTCCCC 2980
|| ||||| |||||

```
Db      1  CCCGCCCCCGUCCGCC 18

RESULT 1533
US-10-310-914A-1091850/c
; Sequence 1091850, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1091850
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1091850

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

YQ      3765 AGTCCCAACTGCTGCTG 3782
        ||||| |||||
Db      18 AGTCCCACTGCTGCTG 1

RESULT 1534
US-10-310-914A-1108672/c
; Sequence 1108672, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1108672
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1108672

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

YQ      3765 AGTCCCAACTGCTGCTG 3782
        ||||| |||||
Db      18 AGTCCCACTGCTGCTG 1

RESULT 1535
US-10-310-914A-1115627/c
; Sequence 1115627, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1115627
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1115627

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

YQ      3821 CCCCTCCCCAGCTGCTG 3838
        ||||| |||||
Db      18 CCCCTCCGCCGCTGCTG 1

RESULT 1536
US-10-310-914A-1134670/c
; Sequence 1134670, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1134670
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1134670

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

YQ      381 GCTCCGGGTGCTGCTG 398
        ||||| |||||
Db      18 GCTCTGGGTGCTGCTTG 1

RESULT 1537
US-10-310-914A-1141714
; Sequence 1141714, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1141714
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1141714

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 1.1e+03;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

YQ      3603 GCCCAACATCTCCAGCC 3620
        ||||| :|||
Db      1 GCACAACCTCCTCCAGCC 18
```

```
RESULT 1538
US-10-310-914A-1150343/c
; Sequence 1150343, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1150343
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1150343

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3765 AGTCCCACTGCTGCTG 3782
Db 18 AGTCCCACTGCTGCTG 1

RESULT 1539
US-10-310-914A-1160776
; Sequence 1160776, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1160776
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1160776

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1060 CCGGCCCTGCCCCAGC 1077
Db 1 CCGGACCCAGGCCCCAGC 18

RESULT 1540
US-10-310-914A-1161317/c
; Sequence 1161317, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
```

```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1161317
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1161317

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2419 GTGCTCACCAACAGCATG 2436
Db 18 GTGCTCACCAACAGCATG 1

RESULT 1541
US-10-310-914A-1168846/c
; Sequence 1168846, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1168846
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1168846

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 244 GGGCCCGGCTGAGGGCC 261
Db 18 GGGCCCGGCTGCGGGCC 1

RESULT 1542
US-10-310-914A-1183773/c
; Sequence 1183773, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1183773
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1183773

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1866 GAACGGGGAGCCAGCTA 1883
Db 18 GAACGGGGAGCCAGCGA 1
```

```
RESULT 1543
US-10-310-914A-1187035/c
; Sequence 1187035, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1187035
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1187035

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2964 CCGGCCCGCTTCCCCA 2981
Db 18 CCAGCCCCGCTGCCCA 1

RESULT 1544
US-10-310-914A-1197636
; Sequence 1197636, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1197636
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1197636

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 1062 CGCCCCCTGGCCCCAGCCC 1079
Db 1 CUCCCCUGGCCUCAGCCC 18

RESULT 1545
US-10-310-914A-1200184
; Sequence 1200184, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
```

```
; SEQ ID NO 1200184
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1200184

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 1.1e+03;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 3469 TTTGAGAGACAGGATTT 3486
Db 1 UUUUAGACAGAGGGUUU 18

RESULT 1546
US-10-310-914A-1201161/c
; Sequence 1201161, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1201161
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1201161

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1066 CTGGCCCCAGCCCCCAGC 1083
Db 18 CTTGGTCGACAGCCCCCAGC 1

RESULT 1547
US-10-310-914A-1212176/c
; Sequence 1212176, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1212176
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1212176

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1062 CGCCCCCTGGCCCCAGCCC 1079
Db 18 CTCCCCCGGCCCCAGCCC 1
```



```
RESULT 1548
US-10-310-914A-1214147/c
; Sequence 1214147, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1214147
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1214147

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3819 TGCCCTCCCTCCAGTGC 3836
Db 18 TGCCCTCCCTCCAGTGC 1

RESULT 1549
US-10-310-914A-1214571/c
; Sequence 1214571, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1214571
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1214571

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 381 GCTCGGGTGTGCTGTG 398
Db 18 GCTCGGGTGTGCTTTG 1

RESULT 1550
US-10-310-914A-1214779/c
; Sequence 1214779, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1214779
```

```
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1214779

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1557 AGGCTACGCTCGCTT 1574
Db 18 AGGCTACGCTCGCTT 1

RESULT 1551
US-10-310-914A-1228679
; Sequence 1228679, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1228679
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1228679

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 1.1e+03;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 763 TGGATGGAGAACCCCTAC 780
Db 1 UGGAUGGAGAGAGCCUCUAC 18

RESULT 1552
US-10-310-914A-1228949/c
; Sequence 1228949, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1228949
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1228949

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3897 TTTTGTCTTCTCGTTT 3914
Db 18 TTTTGTCTTCTGTTT 1

RESULT 1553
```

```
US-10-310-914A-1253710
; Sequence 1253710, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1253710
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1253710

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 1.1e+03;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY      3469 TTTGGAGAGACAGGATTT 3486
        ::||| ||||| ||| ::
Db       1 UUUUGAGAGACAGGGUUU 18

RESULT 1554
US-10-310-914A-1258332/c
; Sequence 1258332, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1258332
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1258332

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      3892 TTCCCTTTTCTTCTTC 3909
        ||||| ||||| |||||
Db       18 TTCCCTTGTCTTCTTC 1

RESULT 1555
US-10-310-914A-1260027
; Sequence 1260027, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1260027
; LENGTH: 18
```

```
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1260027

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 66.7%; Pred. No. 1.1e+03;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      1127 CGGGCTGCAGCTGTGCTC 1144
        ||||| ||||| |||
Db       1 CAGGCUGAGCUGUGCUC 18

RESULT 1556
US-10-310-914A-1263719
; Sequence 1263719, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1263719
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1263719

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      86 ACCCGAGGCGCGGAGG 103
        ||| ||||| ||||| |||
Db       1 ACGCGGCGGCGCGGAGG 18

RESULT 1557
US-10-310-914A-1284973/c
; Sequence 1284973, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1284973
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1284973

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      172 CGCGCGCGCGCGCGCGG 189
        ||| ||||| ||||| |||
Db       18 CGGCGCGCGCGCGCGCGG 1

RESULT 1558
US-10-310-914A-1287424
```

```
; Sequence 1287424, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1287424
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1287424

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 675 GCCTCGGCGTGGCGCTC 692
Db 1 GCCUCGGCGCGGCGCGC 18

RESULT 1559
US-10-310-914A-1296859
; Sequence 1296859, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1296859
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1296859

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 1.1e+03;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1072 CCCAGCCCCAGCTTCTAC 1089
Db 1 CCCUGCCCCAGCCUCC 18

RESULT 1560
US-10-310-914A-1302290
; Sequence 1302290, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1302290
; LENGTH: 18
; TYPE: RNA
```

```
; ORGANISM: Human
US-10-310-914A-1302290

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 3517 CACCCCCCAGCCACCTCG 3534
Db 1 CAGCCCCCUGCCACCUUG 18

RESULT 1561
US-10-310-914A-1302291
; Sequence 1302291, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1302291
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1302291

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 3517 CACCCCCCAGCCACCTCG 3534
Db 1 CAGCCCCCUGCCACCUUG 18

RESULT 1562
US-10-310-914A-1303787/c
; Sequence 1303787, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1303787
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1303787

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2279 AGCCCCCAGGGAAGG 2296
Db 18 AGCCCCCAGAGAGGAGG 1

RESULT 1563
US-10-310-914A-1305050
; Sequence 1305050, Application US/10310914A
```

```
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1305050
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1305050

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 1.1e+03;
Matches 14; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 1803 CGAGGGTCCCGACGCGCT 1820
      |||||:|||||:|
Db 1 CGAGGGUCCCGACGAGCCU 18

RESULT 1564
US-10-310-914A-1305749
; Sequence 1305749, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1305749
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1305749

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.1e+03;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 568 CGTCCCGCGGCGCAGGCC 585
      |:|||||:|||||
Db 1 CCUGCGCCCGGACAGGCC 18

RESULT 1565
US-10-310-914A-1307300/c
; Sequence 1307300, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1307300
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
```

```
US-10-310-914A-1307300

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3822 CCTCCCGCCAGCTGCTGC 3839
      |||:|||||:|||||
Db 18 CCGCGCCCTGCTGCTGC 1

RESULT 1566
US-10-310-914A-1313757/c
; Sequence 1313757, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1313757
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1313757

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1531 CTGGTGGAGCCCTGGGTG 1548
      |||||:|||||:|||||
Db 18 CTGGTGGAGCTCTGGGGG 1

RESULT 1567
US-10-310-914A-1322817/c
; Sequence 1322817, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1322817
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1322817

Query Match          0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3412 CCCAGCCCTGTGCCCGC 3429
      |||||:|||||:|||||
Db 18 CCCAGCCCTGTGCCAGGC 1

RESULT 1568
US-10-310-914A-1330318/c
; Sequence 1330318, Application US/10310914A
; Publication No. US20060003322A1
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ TITLE OF INVENTION: uses thereof
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ CURRENT FILING DATE: 2002-12-06
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 1330318
/ LENGTH: 18
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-1330318

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1959 GGATGAGCGCGGGCTG 1976
Db 18 GGAGGAGCGCGGGCTG 1

RESULT 1569
US-10-310-914A-1345129/c
/ Sequence 1345129, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ TITLE OF INVENTION: uses thereof
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ CURRENT FILING DATE: 2002-12-06
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 1345129
/ LENGTH: 18
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-1345129

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3578 GGGTGTGACACAGGAA 3595
Db 18 GGGTGTGCCAGGCAA 1

RESULT 1570
US-10-310-914A-1360221/c
/ Sequence 1360221, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ TITLE OF INVENTION: uses thereof
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ CURRENT FILING DATE: 2002-12-06
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 1360221
/ LENGTH: 18
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-1360221
```

```
Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1062 CGCCCTGGCCCGCC 1079
Db 18 CGCCCTGTCCCTGCC 1

RESULT 1571
US-10-310-914A-1362557
/ Sequence 1362557, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ TITLE OF INVENTION: uses thereof
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ CURRENT FILING DATE: 2002-12-06
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 1362557
/ LENGTH: 18
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-1362557

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 3469 TTTGAGACAGGATT 3486
Db 1 UUUGAGACAGGGUUU 18

RESULT 1572
US-10-310-914A-1368458
/ Sequence 1368458, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
/ APPLICANT: Bentwich, Isaac
/ TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
/ TITLE OF INVENTION: uses thereof
/ FILE REFERENCE: 06087.0200.CPUS01
/ CURRENT APPLICATION NUMBER: US/10/310,914A
/ CURRENT FILING DATE: 2002-12-06
/ NUMBER OF SEQ ID NOS: 1388402
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 1368458
/ LENGTH: 18
/ TYPE: RNA
/ ORGANISM: Human
US-10-310-914A-1368458

Query Match
Best Local Similarity 0.3%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3514 AATCACCACCCAGCC 3531
Db 1 AACACCCACACAGCC 18

RESULT 1573
US-10-310-914A-1374377
/ Sequence 1374377, Application US/10310914A
/ Publication No. US20060003322A1
/ GENERAL INFORMATION:
```

```
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kruzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1374377
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1374377

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 76 CCGGGGGCGGACCCCGAG 93
Db 1 CCGGGGGCGGACCCCGAG 18

RESULT 1574
US-10-310-914A-1375900/c
; Sequence 1375900, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kruzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1375900
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1375900

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1131 CTGCAGCTGTGCTCCGG 1148
Db 18 CTGCAGGTGTCTCAGG 1

RESULT 1575
US-11-069-908-5922
; Sequence 5922, Application US/11069908
; Publication No. US20050268432A1
; GENERAL INFORMATION:
; APPLICANT: OLIPHANT, ARNOLD
; APPLICANT: MURRAY, SARAH
; TITLE OF INVENTION: HAPLOTYPE MARKERS FOR DIAGNOSING SUSCEPTIBILITY TO IMMUNOLOGICAL
; FILE REFERENCE: 029011-0402
; CURRENT APPLICATION NUMBER: US/11/069,908
; CURRENT FILING DATE: 2005-02-28
; PRIOR APPLICATION NUMBER: 60/547,823
; PRIOR FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 7098
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 5922
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
US-11-069-908-5922

Query Match      0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.1e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1793 AGAAGGGCGCGAGGGTC 1810
Db 1 AGAAGGGTCGAGAGGGTC 18

RESULT 1576
US-11-121-849-151576/c
; Sequence 151576, Application US/11121849
; Publication No. US20050272080A1
; GENERAL INFORMATION:
; APPLICANT: John Palma
; TITLE OF INVENTION: Methods of Genetic Analysis of Formalin Fixed Paraffin Embedded S&
; FILE REFERENCE: 3684.1
; CURRENT APPLICATION NUMBER: US/11/121,849
; CURRENT FILING DATE: 2005-05-03
; PRIOR APPLICATION NUMBER: 60/567,949
; PRIOR FILING DATE: 2004-05-03
; NUMBER OF SEQ ID NOS: 673904
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 151576
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-11-121-849-151576

Query Match      0.3%; Score 14.6; DB 1; Length 25;
Best Local Similarity 81.0%; Pred. No. 1.6e+03;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 2343 GCAGCGCGGTGAGTTTCTGAG 2363
Db 22 GCACCGCGGTCCGTTTCTGGG 2

RESULT 1577
US-10-858-341-1384
; Sequence 1384, Application US/10858341
; Publication No. US20050287667A1
; GENERAL INFORMATION:
; APPLICANT: Sheikhnajad, Reza
; APPLICANT: Sooch, Mina P.
; APPLICANT: Goodwin, Neal
; APPLICANT: Olson, David
; TITLE OF INVENTION: Methods and Compositions for the Inhibition of Gene Expression
; FILE REFERENCE: PRONAI-09053
; CURRENT APPLICATION NUMBER: US/10/858,341
; CURRENT FILING DATE: 2004-06-01
; NUMBER OF SEQ ID NOS: 1439
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1384
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
; NAME/KEY: modified base
; LOCATION: (7)..(7)
; OTHER INFORMATION: methylated C nucleotide
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (10)..(10)
; OTHER INFORMATION: methylated C nucleotide
; FEATURE:
```

NAME/KEY: modified base
LOCATION: (12)..(12)
OTHER INFORMATION: methylated C nucleotide
FEATURE:
NAME/KEY: modified base
LOCATION: (17)..(17)
OTHER INFORMATION: methylated C nucleotide
US-10-858-341-1384

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.1e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5 GCCCGCGCGCGGAGC 20
Db 1 GCCTGGCGCGGAGC 16

RESULT 1578
US-10-310-914A-41907/c
Sequence 41907, Application US/10310914A
Publication No. US20060003322A1
GENERAL INFORMATION:
APPLICANT: Bentwich, Isaac
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310,914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 41907
LENGTH: 18
TYPE: RNA
ORGANISM: Human
US-10-310-914A-41907

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1866 GAAGCGGAGCCAGC 1881
Db 17 GAAGCGGAGCCAGC 2

RESULT 1579
US-10-310-914A-56011
Sequence 56011, Application US/10310914A
Publication No. US20060003322A1
GENERAL INFORMATION:
APPLICANT: Bentwich, Isaac
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310,914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 56011
LENGTH: 18
TYPE: RNA
ORGANISM: Human
US-10-310-914A-56011

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2286 AGGGAAGAGGAGC 2301
Db 1 AGGGAAGAGGAGC 16

Db 1 AGGCAAGAGGAGGAGC 16

RESULT 1580
US-10-310-914A-64680/c
Sequence 64680, Application US/10310914A
Publication No. US20060003322A1
GENERAL INFORMATION:
APPLICANT: Bentwich, Isaac
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310,914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 64680
LENGTH: 18
TYPE: RNA
ORGANISM: Human
US-10-310-914A-64680

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2890 CTGCCCCCGCCCCCAG 2905
Db 18 CTGCCCCCGCCCCCAG 3

RESULT 1581
US-10-310-914A-79204
Sequence 79204, Application US/10310914A
Publication No. US20060003322A1
GENERAL INFORMATION:
APPLICANT: Bentwich, Isaac
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310,914A
CURRENT FILING DATE: 2002-12-06
NUMBER OF SEQ ID NOS: 1388402
SOFTWARE: PatentIn version 3.3
SEQ ID NO 79204
LENGTH: 18
TYPE: RNA
ORGANISM: Human
US-10-310-914A-79204

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.2e+03;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 3612 CTCCAGCCCTCCCGAG 3627
Db 1 CUCCCAGCCUCCCGG 16

RESULT 1582
US-10-310-914A-91195/c
Sequence 91195, Application US/10310914A
Publication No. US20060003322A1
GENERAL INFORMATION:
APPLICANT: Bentwich, Isaac
TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

FILE REFERENCE: 06087.0200.CPUS01
CURRENT APPLICATION NUMBER: US/10/310,914A
CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 91195
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-91195

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1058 TCCCGGCCCTGGGCC 1073
| | | | | | | | | | | | | | | | | |
Db 17 TCCCGGCCCTGGCCCC 2

RESULT 1583
US-10-310-914A-98349
; Sequence 98349, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 98349
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-98349

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2282 CCCCAGGGAAGGA 2297
| | | | | | | | | | | | | | | | | |
Db 1 CCCCAGGCGAGGA 16

RESULT 1584
US-10-310-914A-111218/c
; Sequence 111218, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 111218
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-111218

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1230 CCAGCCATGCCAGCC 1245
| | | | | | | | | | | | | | | | | |
Db 17 CCAGCCAGGCCAGCC 2

RESULT 1585
US-10-310-914A-148286/c
; Sequence 148286, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 148286
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-148286

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3821 CCCTCCCCCAGCTGC 3836
| | | | | | | | | | | | | | | | | |
Db 18 CTCCTCCCCCAGCTGC 3

RESULT 1586
US-10-310-914A-169474/c
; Sequence 169474, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 169474
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-169474

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 170 CCGCGCGCCCGCGCGC 185
| | | | | | | | | | | | | | | | | |
Db 18 CGCGCGCCCGCGCGC 3

RESULT 1587
US-10-310-914A-173307/c
; Sequence 173307, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402


```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 173307
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-173307

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1071 CCCAGCCCCCAGCTCT 1086
    |||||
Db 18 CCCAGCCCCCAGCCCC 3

RESULT 1588
US-10-310-914A-174618/c
; Sequence 174618, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 174618
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-174618

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2467 AACGGCGCCTGGACT 2482
    |||||
Db 18 AGCGCGCCTGGACT 3

RESULT 1589
US-10-310-914A-176334/c
; Sequence 176334, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 176334
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-176334

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3822 CCTTCTCCCGAGCTGCT 3837
    |||||
Db 17 CCTTCTCCCGAGCTGCT 2

RESULT 1590
US-10-310-914A-213603/c
; Sequence 213603, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 213603
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-213603

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3352 CCCACCCCGAGGACA 3367
    |||||
Db 18 CCCACCCCGAGGACA 3

RESULT 1591
US-10-310-914A-213974/c
; Sequence 213974, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 213974
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-213974

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 135 CCCGCCCGCGCGCCC 150
    |||||
Db 17 CCCGCCCGCGCGCCC 2

RESULT 1592
US-10-310-914A-213993
; Sequence 213993, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
```

; SEQ ID NO 213993
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-213993

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.2e+03;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 164 TCCGGGCCCGCCGCC 179
;|||||
Db 1 UCCGGGGCGCCGCC 16

RESULT 1593

US-10-310-914A-216815/c
; Sequence 216815, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 216815
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-216815

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1071 CCCAGCCCGCCGCTC 1086
;|||||
Db 16 CCCAGCCCGCCGCCC 1

RESULT 1594

US-10-310-914A-216816/c
; Sequence 216816, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 216816
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-216816

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1071 CCCAGCCCGCCGCTC 1086
;|||||
Db 16 CCCAGCCCGCCGCCC 1

RESULT 1595

US-10-310-914A-218402/c
; Sequence 218402, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 218402
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-218402

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1980 GGAGCAGCTGGCCCTG 1995
;|||||
Db 16 GGAGCAGCTGGCTCTG 1

RESULT 1596

US-10-310-914A-223481/c
; Sequence 223481, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 223481
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-223481

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3523 CCAGCCACCTCGGGGA 3538
;|||||
Db 16 CCAGCCCACTCGGGGA 1

RESULT 1597

US-10-310-914A-225022
; Sequence 225022, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 225022

```
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-225022

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.2e+03;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 3609 CATCTCCAGCCTCC 3624
    |||:|||||:||||
Db 3 CACCCUCCAGCCUCC 18

RESULT 1598
US-10-310-914A-246025/c
; Sequence 246025, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 246025
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-246025

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3856 TTTGAGTTTCTTTT 3871
    |||||:|||||:||||
Db 18 TTTGGTTTCTTTT 3

RESULT 1599
US-10-310-914A-247428/c
; Sequence 247428, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 247428
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-247428

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3517 CACCCCCCAGCCCT 3532
    |||||:|||||:||||
Db 16 CACCCCCCAGCCCT 1

RESULT 1600
US-10-310-914A-260616/c
; Sequence 260616, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 260616
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-260616

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3799 TCATTTTTCCTTG 3814
    |||||:|||||:||||
Db 17 TCATTTTTCCTTG 2

RESULT 1601
US-10-310-914A-279451/c
; Sequence 279451, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 279451
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-279451

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 169 GCCCGCGCGCGCG 184
    |||||:|||||:||||
Db 16 GCCCGCGCGCGCG 1

RESULT 1602
US-10-310-914A-281381/c
; Sequence 281381, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 281381
; LENGTH: 18
```

```
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-281381

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2064 CAGGAGCAGCAAT 2079
    |||||
Db 18 CAGGAGCAAGCAAT 3

RESULT 1603
US-10-310-914A-283866/c
; Sequence 283866, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 283866
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-283866

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1230 CCAGCCATGCCAGCC 1245
    |||||
Db 16 CCAGCCCTGCCAGCC 1

RESULT 1604
US-10-310-914A-302300
; Sequence 302300, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 302300
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-302300

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.2e+03;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2700 GAGCTCCCTGGGAGGA 2715
    |||||
Db 1 GAGCUCCUUGGAGCA 16

RESULT 1605
US-10-310-914A-312334
; Sequence 312334, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 312334
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-312334

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 835 GAGGCCACGGGAAGG 850
    |||||
Db 2 GCGGCCACCGGAAGG 17

RESULT 1606
US-10-310-914A-345359/c
; Sequence 345359, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 345359
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-345359

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 974 TGACTGTGAACCTGAC 989
    |||||
Db 16 TGGCTGTGAACCTGAC 1

RESULT 1607
US-10-310-914A-360426
; Sequence 360426, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 360426
; LENGTH: 18
; TYPE: RNA
```


US-10-310-914A-405260

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 25 CCACCTCCAGGGAGGGG 40
|||||
DB 18 CCACCTCCCGGAGGGG 3

RESULT 1613

US-10-310-914A-409851/c
; Sequence 409851, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 409851

; LENGTH: 18

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-409851

Query Match

Best Local Similarity 0.3%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1070 GCCCAGCCCGCAGCCT 1085
|||||
DB 16 GCCCAGCCCTCAGCCT 1

RESULT 1614

US-10-310-914A-416008/c

; Sequence 416008, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 416008

; LENGTH: 18

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-416008

Query Match

Best Local Similarity 0.3%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2269 GGGCGGCTCAAGGCC 2284
|||||
DB 16 GGGCGGCTCCAGGCC 1

RESULT 1615

US-10-310-914A-434918

; Sequence 434918, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 434918

; LENGTH: 18

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-434918

Query Match

Best Local Similarity 0.3%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 57 CCGGCTCAGCCCGCGC 72
|||||
DB 3 CCGGCCAGCCCGCGC 18

RESULT 1616

US-10-310-914A-444628/c

; Sequence 444628, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 444628

; LENGTH: 18

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-444628

Query Match

Best Local Similarity 0.3%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3759 GTTTGTAGTCCCACT 3774
|||||
DB 18 GCTTGTAGTCCCACT 3

RESULT 1617

US-10-310-914A-449233

; Sequence 449233, Application US/10310914A
; Publication No. US20060003322A1

; GENERAL INFORMATION:

; APPLICANT: Bentwich, Isaac

; APPLICANT: Shiler, Kvuzat

; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and

; TITLE OF INVENTION: uses thereof

; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 449233

; LENGTH: 18

; TYPE: RNA

; ORGANISM: Human

US-10-310-914A-449233

```
; Query Match
; Best Local Similarity 0.3%; Score 14.4; DB 1; Length 18;
; Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 831 GGCCGAGGCGCCCGGG 846
DB 2 GGCCGAGGCGCCCGGG 17

RESULT 1618
US-10-310-914A-470179/c
; Sequence 470179, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 470179
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-470179

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3904 TTCTCGTTGTTGTTT 3919
DB 17 TTCTGGTTTGGTTT 2

RESULT 1619
US-10-310-914A-476504
; Sequence 476504, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 476504
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-476504

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.2e+03;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1063 GCCCCTGGCCCGCC 1078
DB 3 GCCCCTGGCCCGCC 18

RESULT 1620
US-10-310-914A-477521/c
; Sequence 477521, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 477521
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-477521
```

```
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 896 TCTACCTGGCCTTCCA 911
DB 18 TCTCCCTGGCCTTCCA 3
```

```
RESULT 1621
US-10-310-914A-477522/c
; Sequence 477522, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 477522
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-477522
```

```
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 896 TCTACCTGGCCTTCCA 911
DB 18 TCTCCCTGGCCTTCCA 3
```

```
RESULT 1622
US-10-310-914A-502238/c
; Sequence 502238, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 502238
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-502238
```

```
Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1071 CCCAGCCCCAGCCTC 1086
    |||||
Db 16 CCCAGCCCCAGCCCC 1

RESULT 1623
US-10-310-914A-541085/c
; Sequence 541085, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 541085
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-541085

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3852 GGTTTTGGGTTTGT 3867
    |||||
Db 16 GGTTTTGGGTTTGT 1

RESULT 1624
US-10-310-914A-543962/c
; Sequence 543962, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 543962
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-543962

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2799 TGTGATGGGAGGTG 2814
    |||||
Db 16 TGTGATGGGAGGTG 1

RESULT 1625
US-10-310-914A-545257/c
; Sequence 545257, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
```

```
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 545257
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-545257

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 680 GGGCTGGCGCTCCTG 695
    |||||
Db 16 GGGCCGGCGCTCCTG 1

RESULT 1626
US-10-310-914A-551594/c
; Sequence 551594, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 551594
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-551594

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 753 CAGCCAGCGCTGGATG 768
    |||||
Db 17 CACTCCAGCGCTGGATG 2

RESULT 1627
US-10-310-914A-608856/c
; Sequence 608856, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 608856
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-608856

Query Match          0.3%; Score 14.4; DB 1; Length 18;
```


QY 31 CAGGAGGGGGGAGA 46
|||||
Db 3 CAGGAGGGGGGAGA 18

RESULT 1643

US-10-310-914A-738114/c
; Sequence 738114, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 738114
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-738114

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3821 CCCCTCCCCCAGCTGC 3836
|||||
Db 16 CCCCTCCCCCAGCTCC 1

RESULT 1644

US-10-310-914A-750442
; Sequence 750442, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 750442
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-750442

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 85 GACCCCGAGGCCCGG 100
|||||
Db 3 GGCCCGGAGGCCCGG 18

RESULT 1645

US-10-310-914A-759572
; Sequence 759572, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01

; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 759572
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-759572

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.2e+03;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 824 GCCTGGGGCCGAGGC 839
|||||
Db 2 GCCCUGGGCCGCGGC 17

RESULT 1646

US-10-310-914A-778291
; Sequence 778291, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 778291
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-778291

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.2e+03;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3688 CAGCTCCAGAGTGGG 3703
|||||
Db 3 CAGCUUCAGAGUGGG 18

RESULT 1647

US-10-310-914A-790616
; Sequence 790616, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 790616
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-790616

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.2e+03;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3821 CCCCTCCCCCAGCTGC 3836

Db 3 CCCCTCCCCAGCUCC 18
||||:|||||||:|

RESULT 1648
US-10-310-914A-791845/c
; Sequence 791845, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 791845
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-791845

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1530 CCTGTGGAGCCTGG 1545
||||:|||||||

Db 18 CCTGGGGAGCCTGG 3

RESULT 1649
US-10-310-914A-802146/c
; Sequence 802146, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 802146
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-802146

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 390 GCTGCTCTGGGCT 405
||||:|||||||

Db 16 GCTGCTCTGGGCT 1

RESULT 1650
US-10-310-914A-829295/c
; Sequence 829295, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A

; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 829295
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-829295

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1382 GCTCTCCCTGCCT 1397
||||:|||||||

Db 18 GCTCTCCCTGCCT 3

RESULT 1651
US-10-310-914A-833421
; Sequence 833421, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 833421
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-833421

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1069 GGCCCCAGCCCGCC 1084
||:|||||||

Db 2 GGCCCCAGCCCGCC 17

RESULT 1652
US-10-310-914A-841274
; Sequence 841274, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvazat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 841274
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-841274

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.2e+03;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 750 CCTCAGCCAGCCTGG 765
||:|||||||

```
Db      2 CCUACUCCAGCCUGG 17

RESULT 1653
US-10-310-914A-847213
; Sequence 847213, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 847213
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-847213

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 75.0%; Pred. No. 1.2e+03;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      4083 GAAGGGGTGTGGGTG 4098
      |||||:||||:|
Db      3 GGAGGGGUGUGGGUG 18

RESULT 1654
US-10-310-914A-847214
; Sequence 847214, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 847214
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-847214

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 75.0%; Pred. No. 1.2e+03;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      4083 GAAGGGGTGTGGGTG 4098
      |||||:||||:|
Db      3 GGAGGGGUGUGGGUG 18

RESULT 1655
US-10-310-914A-853825/c
; Sequence 853825, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06

; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 878489
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-878489

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1727 GCCTGGCCTGGGCTGT 1742
      |||||:||||:|
Db      17 GGCTGGCCTGGGCTGT 2

RESULT 1657
US-10-310-914A-878489/c
; Sequence 878489, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 878489
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-878489

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      3828 CCACGCTGCTGCCTTC 3843
      |||||:||||:|
Db      16 CCACGCTGCTGCCTTC 1
```

```
RESULT 1658
US-10-310-914A-892826/c
; Sequence 892826, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 892826
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-892826

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3823 CCTCCCCCAGCTGCTG 3838
Db 18 CCTCCCCCTGCTGCTG 3

RESULT 1659
US-10-310-914A-893437
; Sequence 893437, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 893437
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-893437

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.2e+03;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2704 TCCCTGGGAGGAAAGA 2719
Db 1 UCCUGGGAGGAAGA 16

RESULT 1660
US-10-310-914A-895138
; Sequence 895138, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
```

```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 895138
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-895138

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.2e+03;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1071 CCCAGCCCCAGCCTC 1086
Db 3 CCCAGCCUCAGCCUC 18

RESULT 1661
US-10-310-914A-906603
; Sequence 906603, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 906603
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-906603

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.2e+03;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 2893 CCCCGCCCCCAGACT 2908
Db 2 CCCCCUCCCCCAGACU 17

RESULT 1662
US-10-310-914A-912483/c
; Sequence 912483, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 912483
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-912483

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3862 TTTGTTTTGGTCTT 3877
Db 18 TTTGTTTTGGTTTT 3
```

```
RESULT 1663
US-10-310-914A-912486/c
; Sequence 912486, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 912486
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-912486

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3862 TTTTGTGTTTGGTCTT 3877
      |||||
Db 16 TTTTGTGTTTGGTCTT 1

RESULT 1664
US-10-310-914A-914942
; Sequence 914942, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 914942
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-914942

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.2e+03;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 210 TGGCGCCGCCGCCGG 225
      :|||||
Db 3 UGGCGCCGCCGCCGG 18

RESULT 1665
US-10-310-914A-916502/c
; Sequence 916502, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
```

```
; SEQ ID NO 916502
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-916502

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2890 CTGCCCCCGCCCCCAG 2905
      |||||
Db 18 CTGCCCCCGCCCCCAG 3

RESULT 1666
US-10-310-914A-916686/c
; Sequence 916686, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 916686
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-916686

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3402 CACAGAGCCCCCAGC 3417
      |||||
Db 17 CACAGAGCCCCCAGC 2

RESULT 1667
US-10-310-914A-922634
; Sequence 922634, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 922634
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-922634

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.2e+03;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2879 AGGACTACCGGTGCC 2894
      |||||
Db 2 AGGACTACCGGTGCC 17
```


RESULT 1668

US-10-310-914A-929594/c
; Sequence 929594, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 929594
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-929594

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3855 TTTTGAGTTTGTGTTT 3870

Db 18 TTCTGAGTTTGTGTTT 3

RESULT 1669

US-10-310-914A-964748
; Sequence 964748, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 964748
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-964748

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 62.5%; Pred. No. 1.2e+03;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 4177 TAAAAAGTAACTTT 4192

Db 1 UAAAAAGUACUCUU 16

RESULT 1670

US-10-310-914A-966408/c
; Sequence 966408, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 966408

; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-966408

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1230 CCAGCCATGCCAGCC 1245

Db 16 CCAGCCAAAGCCAGCC 1

RESULT 1671

US-10-310-914A-968397
; Sequence 968397, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 968397
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-968397

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 75.0%; Pred. No. 1.2e+03;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 3185 AGCTGTCAGCCAGAT 3200

Db 2 AGCUGGUCAGCCAGAU 17

RESULT 1672

US-10-310-914A-989400/c
; Sequence 989400, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 989400
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-989400

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3907 TTCGTTTGTGTTTCT 3922

Db 17 TTCTTTTGTGTTTCT 2

RESULT 1673

US-10-310-914A-999098
; Sequence 999098, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 999098
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-999098

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.2e+03;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1331 CTGCACCACTCCCTCC 1346
||:|||||:|
Db 1 CCUGCUCCACCCUCC 16

RESULT 1674
US-10-310-914A-999099
; Sequence 999099, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 999099
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-999099

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.2e+03;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1331 CTGCACCACTCCCTCC 1346
||:|||||:|
Db 1 CCUGCUCCACCCUCC 16

RESULT 1675
US-10-310-914A-999100
; Sequence 999100, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 999100
; LENGTH: 18

; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-999100

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.2e+03;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1331 CTGCACCACTCCCTCC 1346
||:|||||:|
Db 1 CCUGCUCCACCCUCC 16

RESULT 1676
US-10-310-914A-1002209/c
; Sequence 1002209, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1002209
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1002209

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3372 CTCCTCATTTTCGGG 3387
|||||:|
Db 17 CTCCTCATTTTCGGG 2

RESULT 1677
US-10-310-914A-1013145
; Sequence 1013145, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1013145
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1013145

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 137 CGCCCGCGCGGCCAC 152
|||||:|
Db 2 CGCCCGCGCGGCCGC 17

RESULT 1678
US-10-310-914A-1022764/c

```
; Sequence 1022764, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1022764
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1022764

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3907 TTCGTTTGTCTTCT 3922
DB 17 TTCCTTTGTCTTCT 2

RESULT 1679
US-10-310-914A-1027936
; Sequence 1027936, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1027936
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1027936

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 3983 AAGTTGAACAGGGGC 3998
DB 2 AAGUUGAACAGGGGUC 17

RESULT 1680
US-10-310-914A-1041898/c
; Sequence 1041898, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1041898
; LENGTH: 18
; TYPE: RNA
```

```
; ORGANISM: Human
US-10-310-914A-1041898

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 681 GGCTGGGCGTCTCTGC 696
DB 18 GGCTGGGCTCTCTGC 3

RESULT 1681
US-10-310-914A-1060050/c
; Sequence 1060050, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1060050
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1060050

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1070 GCCCCAGCCCGCT 1085
DB 17 GCCCCAGCCCGCT 2

RESULT 1682
US-10-310-914A-1101002
; Sequence 1101002, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1101002
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1101002

Query Match          0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 56.2%; Pred. No. 1.2e+03;
Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 3882 TTTCTCCCCGTTTCT 3897
DB 1 UUUUCUCCCGUCCCU 16

RESULT 1683
US-10-310-914A-1124096/c
; Sequence 1124096, Application US/10310914A
```

; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1124096
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
; US-10-310-914A-1124096

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1425 TGGCCGAGAGGACCTC 1440
||| |||||
Db 16 TGGCGGAGAGGACCTC 1

RESULT 1684

US-10-310-914A-117722/c
; Sequence 117722, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 117722
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
; US-10-310-914A-117722

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1070 GCCCCAGCCCCAGCCT 1085
||| |||||
Db 17 GCCCCAGCCCCATCCT 2

RESULT 1685

US-10-310-914A-1187158/c
; Sequence 1187158, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1187158
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human

US-10-310-914A-1187158

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1063 GCCCTGTGCCCCAGCC 1078
||| |||||
Db 16 GCCCGGGCCCCAGCC 1

RESULT 1686

US-10-310-914A-1187485
; Sequence 1187485, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1187485
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
; US-10-310-914A-1187485

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.2e+03;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1070 GCCCCAGCCCCAGCCT 1085
||| |||||
Db 3 GACCCAGCCCCAGCCU 18

RESULT 1687

US-10-310-914A-1219995/c
; Sequence 1219995, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; TITLE OF INVENTION: uses thereof
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1219995
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
; US-10-310-914A-1219995

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3800 CATTTTTCCTTGT 3815
||| |||||
Db 18 CATTTTTCCTTGT 3

RESULT 1688

US-10-310-914A-1222014
; Sequence 1222014, Application US/10310914A
; Publication No. US20060003322A1

```
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1222014
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1222014

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.2e+03;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2407 CGCCTGGAGGGCGTGG 2422
      |||:|||||:|
Db 1 CCCUGGAGGGGUGG 16

RESULT 1689
US-10-310-914A-1264272/c
; Sequence 1264272, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1264272
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1264272

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 680 GGGCTGGCGCTCCTG 695
      |||||:|||||
Db 16 GGGCGGGCGCTCCTG 1

RESULT 1690
US-10-310-914A-1264496
; Sequence 1264496, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1264496
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1264496
```

```
Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.2e+03;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 750 CCTCAGCCAGCCTGG 765
      |||:|||||:|
Db 2 CCUCACUCCAGCCUGG 17

RESULT 1691
US-10-310-914A-1279584
; Sequence 1279584, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1279584
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1279584

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 131 CGGCGCCCGCGCGC 146
      |||||:|||||
Db 2 CGGCGCCCGCGCGC 17

RESULT 1692
US-10-310-914A-1289326
; Sequence 1289326, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1289326
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1289326

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 75.0%; Pred. No. 1.2e+03;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 3611 TCTCCAGCCTCCCA 3626
      :|:|||||:|
Db 1 UCUCUCCAGCCUCCA 16

RESULT 1693
US-10-310-914A-1289327
; Sequence 1289327, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1289327
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1289327

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 75.0%; Pred. No. 1.2e+03;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 3611 TCTCCGAGCTCCCA 3626
Db 1 UCUCGAGCCUCUCA 16

RESULT 1694
US-10-310-914A-1295076/c
; Sequence 1295076, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1295076
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1295076

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3823 CCTCCCCAGCTGCTG 3838
Db 18 CCTCCCCAGCTGCAG 3

RESULT 1695
US-10-310-914A-1296315/c
; Sequence 1296315, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1296315
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1296315
```

```

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 647 GCTTACCATGCTCGA 662
Db 17 GCTTACCATGCTCCA 2

RESULT 1696
US-10-310-914A-1315876/c
; Sequence 1315876, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1315876
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1315876

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1071 CCCGAGCCCGAGCTC 1086
Db 18 CACGAGCCCGAGCTC 3

RESULT 1697
US-10-310-914A-1347485/c
; Sequence 1347485, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
; APPLICANT: Shiler, Kvuzat
; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
; FILE REFERENCE: 06087.0200.CPUS01
; CURRENT APPLICATION NUMBER: US/10/310,914A
; CURRENT FILING DATE: 2002-12-06
; NUMBER OF SEQ ID NOS: 1388402
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1347485
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Human
US-10-310-914A-1347485

Query Match      0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1515 CCCCGGCCCCGGGAC 1530
Db 16 CCCCGGCCCCGGGCC 1

RESULT 1698
US-10-310-914A-1353530/c
; Sequence 1353530, Application US/10310914A
; Publication No. US20060003322A1
; GENERAL INFORMATION:
; APPLICANT: Bentwich, Isaac
```

; APPLICANT: Shiller, Kvazat
 ; TITLE OF INVENTION: Bioinformatically detectable group of novel regulatory genes and
 ; FILE REFERENCE: 06087.0200.CPUS01
 ; CURRENT APPLICATION NUMBER: US/10/310,914A
 ; NUMBER OF SEQ ID NOS: 1388402
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 1353530
 ; LENGTH: 18
 ; TYPE: RNA
 ; ORGANISM: Human
 US-10-310-914A-1353530

Query Match 0.3%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 753 CACGCCAGCCTGGATG 768
 Db 17 CACTCCAGCCTGGATG 2

RESULT 1699
 US-11-069-908-1263
 ; Sequence 1263, Application US/11069908
 ; Publication No. US20050266432A1
 ; GENERAL INFORMATION:
 ; APPLICANT: OLIPHANT, ARNOLD
 ; APPLICANT: MURRAY, SARAH
 ; TITLE OF INVENTION: HAPLOTYPE MARKERS FOR DIAGNOSING SUSCEPTIBILITY TO IMMUNOLOGICAL
 ; FILE REFERENCE: 029011-0402
 ; CURRENT APPLICATION NUMBER: US/11/069,908
 ; PRIOR FILING DATE: 2005-02-28
 ; PRIOR APPLICATION NUMBER: 60/547,823
 ; PRIOR FILING DATE: 2004-02-26
 ; NUMBER OF SEQ ID NOS: 7098
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 1263
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
 US-11-069-908-1263

Query Match 0.3%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1068 TGGCCCCCAGCCCCAGC 1083
 Db 1 TGGGCCCAGCCCCCAGC 16

RESULT 1700
 US-11-069-908-3629
 ; Sequence 3629, Application US/11069908
 ; Publication No. US20050266432A1
 ; GENERAL INFORMATION:
 ; APPLICANT: OLIPHANT, ARNOLD
 ; APPLICANT: MURRAY, SARAH
 ; TITLE OF INVENTION: HAPLOTYPE MARKERS FOR DIAGNOSING SUSCEPTIBILITY TO IMMUNOLOGICAL
 ; FILE REFERENCE: 029011-0402
 ; CURRENT APPLICATION NUMBER: US/11/069,908
 ; PRIOR FILING DATE: 2005-02-28
 ; PRIOR APPLICATION NUMBER: 60/547,823
 ; PRIOR FILING DATE: 2004-02-26
 ; NUMBER OF SEQ ID NOS: 7098
 ; SOFTWARE: PatentIn version 3.3
 ; SEQ ID NO 3629

; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide
 US-11-069-908-3629

Query Match 0.3%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1068 TGGCCCCCAGCCCCAGC 1083
 Db 1 TGGGCCCAGCCCCCAGC 16

Search completed: March 23, 2006, 11:21:11
 Job time : 92 secs

THIS PAGE BLANK (USPTO)

107	21	0.5	21	1	ADR92518	Human EphB4 antisense	C 180	20	0.5	20	1	ADR86805	Human ephrin B4 an
108	21	0.5	21	1	ADR92529	Human EphB4 antisense	C 181	20	0.5	20	1	ADR86809	Human ephrin B4 an
109	21	0.5	21	1	ADR92537	Human EphB4 antisense	C 182	20	0.5	20	1	ADR86821	Human ephrin B4 an
c 110	21	0.5	21	1	ADR92316	Human EphB4 antisense	C 183	20	0.5	20	1	ADR86824	Human ephrin B4 an
111	21	0.5	21	1	ADR92496	Human EphB4 antisense	C 184	20	0.5	20	1	ADR86840	Human ephrin B4 an
112	21	0.5	21	1	ADR92503	Human EphB4 antisense	C 185	20	0.5	20	1	ADR86841	Human ephrin B4 an
113	21	0.5	21	1	ADR92508	Human EphB4 antisense	C 186	20	0.5	20	1	ADR86777	Human ephrin B4 an
114	21	0.5	21	1	ADR92510	Human EphB4 antisense	C 187	20	0.5	20	1	ADR86787	Human ephrin B4 an
115	21	0.5	21	1	ADR92542	Human EphB4 antisense	C 188	20	0.5	20	1	ADR86808	Human ephrin B4 an
c 116	21	0.5	21	1	ADR92311	Human EphB4 antisense	C 189	20	0.5	20	1	ADR86813	Human ephrin B4 an
c 117	21	0.5	21	1	ADR92317	Human EphB4 antisense	C 190	20	0.5	20	1	ADR86814	Human ephrin B4 an
118	21	0.5	21	1	ADR92499	Human EphB4 antisense	C 191	20	0.5	20	1	ADR86815	Human ephrin B4 an
119	21	0.5	21	1	ADR92509	Human EphB4 antisense	C 192	20	0.5	20	1	ADR86819	Human ephrin B4 an
120	21	0.5	21	1	ADR92520	Human EphB4 antisense	C 193	20	0.5	20	1	ADR86822	Human ephrin B4 an
121	21	0.5	21	1	ADR92492	Human EphB4 antisense	C 194	20	0.5	20	1	ADR86838	Human ephrin B4 an
122	21	0.5	21	1	ADR92504	Human EphB4 antisense	C 195	20	0.5	20	1	ADR86873	Human ephrin B4 an
c 123	21	0.5	21	1	ADR92308	Human EphB4 antisense	C 196	20	0.5	20	1	ADR86899	Human ephrin B4 an
c 124	21	0.5	21	1	ADR92313	Human EphB4 antisense	C 197	20	0.5	20	1	ADR86923	Human ephrin B4 an
c 125	21	0.5	21	1	ADR92482	Human EphB4 antisense	C 198	20	0.5	20	1	ADR86758	Human ephrin B4 pr
c 126	21	0.5	21	1	ADR92486	Human EphB4 antisense	C 199	20	0.5	20	1	ADR86778	Human ephrin B4 an
c 127	21	0.5	21	1	ADR92302	Human EphB4 antisense	C 200	20	0.5	20	1	ADR86796	Human ephrin B4 an
c 128	21	0.5	21	1	ADR92327	Human EphB4 antisense	C 201	20	0.5	20	1	ADR86803	Human ephrin B4 an
129	21	0.5	21	1	ADR92498	Human EphB4 antisense	C 202	20	0.5	20	1	ADR86832	Human ephrin B4 an
130	21	0.5	21	1	ADR92500	Human EphB4 antisense	C 203	20	0.5	20	1	ADR86848	Human ephrin B4 an
131	21	0.5	21	1	ADR92505	Human EphB4 antisense	C 204	20	0.5	20	1	ADR86850	Human ephrin B4 an
132	21	0.5	21	1	ADR92538	Human EphB4 antisense	C 205	20	0.5	20	1	ADR86856	Human ephrin B4 an
c 133	21	0.5	21	1	ADR92487	Human EphB4 antisense	C 206	20	0.5	20	1	ADR86862	Human ephrin B4 an
134	21	0.5	21	1	ADR92491	Human EphB4 antisense	C 207	20	0.5	20	1	ADR86884	Human ephrin B4 an
135	21	0.5	21	1	ADR92517	Human EphB4 antisense	C 208	20	0.5	20	1	ADR86895	Human ephrin B4 an
136	21	0.5	21	1	ADR92522	Human EphB4 antisense	C 209	20	0.5	20	1	ADR86905	Human ephrin B4 an
137	21	0.5	21	1	ADR92528	Human EphB4 antisense	C 210	20	0.5	20	1	ADR86906	Human ephrin B4 an
138	21	0.5	21	1	ADR92530	Human EphB4 antisense	C 211	20	0.5	20	1	ADR86908	Human ephrin B4 an
c 139	21	0.5	21	1	ADR92304	Human EphB4 antisense	C 212	20	0.5	20	1	ADR86918	Human ephrin B4 an
c 140	21	0.5	21	1	ADR92306	Human EphB4 antisense	C 213	20	0.5	20	1	ADR86725	Human ephrin B4 an
c 141	21	0.5	21	1	ADR92312	Human EphB4 antisense	C 214	20	0.5	20	1	ADR86785	Human ephrin B4 an
142	21	0.5	21	1	ADR92511	Human EphB4 antisense	C 215	20	0.5	20	1	ADR86835	Human ephrin B4 an
143	21	0.5	21	1	ADR92533	Human EphB4 antisense	C 216	20	0.5	20	1	ADR86851	Human ephrin B4 an
c 144	21	0.5	21	1	ADR92330	Human EphB4 antisense	C 217	20	0.5	20	1	ADR86864	Human ephrin B4 an
c 145	21	0.5	21	1	ADR92481	Human EphB4 antisense	C 218	20	0.5	20	1	ADR86875	Human ephrin B4 an
146	21	0.5	21	1	ADR92490	Human EphB4 antisense	C 219	20	0.5	20	1	ADR86879	Human ephrin B4 an
147	21	0.5	21	1	ADR92501	Human EphB4 antisense	C 220	20	0.5	20	1	ADR86880	Human ephrin B4 an
148	21	0.5	21	1	ADR92502	Human EphB4 antisense	C 221	20	0.5	20	1	ADR86900	Human ephrin B4 an
149	21	0.5	21	1	ADR92523	Human EphB4 antisense	C 222	20	0.5	20	1	ADR86907	Human ephrin B4 an
150	21	0.5	21	1	ADR92535	Human EphB4 antisense	C 223	20	0.5	20	1	ADR86731	Human ephrin B4 RT
151	21	0.5	21	1	ADR92536	Human EphB4 antisense	C 224	20	0.5	20	1	ADR86779	Human ephrin B4 an
152	21	0.5	21	1	ADR92541	Human EphB4 antisense	C 225	20	0.5	20	1	ADR86784	Human ephrin B4 an
c 153	21	0.5	21	1	ADR92515	Human EphB4 antisense	C 226	20	0.5	20	1	ADR86792	Human ephrin B4 an
c 154	21	0.5	21	1	ADR92309	Human EphB4 antisense	C 227	20	0.5	20	1	ADR86804	Human ephrin B4 an
155	21	0.5	21	1	ADR92497	Human EphB4 antisense	C 228	20	0.5	20	1	ADR86807	Human ephrin B4 an
156	21	0.5	21	1	ADR92521	Human EphB4 antisense	C 229	20	0.5	20	1	ADR86867	Human ephrin B4 an
157	21	0.5	21	1	ADR92539	Human EphB4 antisense	C 230	20	0.5	20	1	ADR86874	Human ephrin B4 an
c 158	21	0.5	21	1	ADR92489	Human EphB4 antisense	C 231	20	0.5	20	1	ADR86881	Human ephrin B4 an
159	21	0.5	21	1	ADR92526	Human EphB4 antisense	C 232	20	0.5	20	1	ADR86892	Human ephrin B4 an
c 160	20.8	0.5	24	1	ADU79893	Antisense oligonucleotide	C 233	20	0.5	20	1	ADR86893	Human ephrin B4 an
161	20.4	0.5	22	1	ADR86761	Human ephrin B4 RT	C 234	20	0.5	20	1	ADR86917	Human ephrin B4 an
162	20.4	0.5	22	1	ADR92667	Human EphB4 RT-PCR	C 235	20	0.5	20	1	ADR86794	Human ephrin B4 an
c 163	20.4	0.5	24	1	ADE79941	Tyrosine kinase antisense	C 236	20	0.5	20	1	ADR86827	Human ephrin B4 an
c 164	20	0.5	20	1	ADR86727	Human ephrin B4 an	C 237	20	0.5	20	1	ADR86839	Human ephrin B4 an
c 165	20	0.5	20	1	ADR86801	Human ephrin B4 an	C 238	20	0.5	20	1	ADR86847	Human ephrin B4 an
c 166	20	0.5	20	1	ADR86860	Human ephrin B4 an	C 239	20	0.5	20	1	ADR86854	Human ephrin B4 an
c 167	20	0.5	20	1	ADR86901	Human ephrin B4 an	C 240	20	0.5	20	1	ADR86855	Human ephrin B4 an
c 168	20	0.5	20	1	ADR87091	Human ephrin B4 PC	C 241	20	0.5	20	1	ADR86888	Human ephrin B4 an
c 169	20	0.5	20	1	ADR86753	Human ephrin B4 an	C 242	20	0.5	20	1	ADR86757	Human ephrin B4 pr
c 170	20	0.5	20	1	ADR86782	Human ephrin B4 an	C 243	20	0.5	20	1	ADR86793	Human ephrin B4 an
c 171	20	0.5	20	1	ADR86823	Human ephrin B4 an	C 244	20	0.5	20	1	ADR86802	Human ephrin B4 an
c 172	20	0.5	20	1	ADR86871	Human ephrin B4 an	C 245	20	0.5	20	1	ADR86806	Human ephrin B4 an
c 173	20	0.5	20	1	ADR86877	Human ephrin B4 an	C 246	20	0.5	20	1	ADR86830	Human ephrin B4 an
c 174	20	0.5	20	1	ADR86894	Human ephrin B4 an	C 247	20	0.5	20	1	ADR86831	Human ephrin B4 an
c 175	20	0.5	20	1	ADR86902	Human ephrin B4 an	C 248	20	0.5	20	1	ADR86878	Human ephrin B4 an
c 176	20	0.5	20	1	ADR86910	Human ephrin B4 an	C 249	20	0.5	20	1	ADR86909	Human ephrin B4 an
c 177	20	0.5	20	1	ADR86915	Human ephrin B4 an	C 250	20	0.5	20	1	ADR86795	Human ephrin B4 an
c 178	20	0.5	20	1	ADR86921	Human ephrin B4 an	C 251	20	0.5	20	1	ADR86818	Human ephrin B4 an
c 179	20	0.5	20	1	ADR86790	Human ephrin B4 an	C 252	20	0.5	20	1	ADR86942	Human ephrin B4 an

C 399	20	0.5	20	1	ADR82431	Human EphB4 antisense	C 472	20	0.5	20	1	ADR82461	Human EphB4 antisense
C 400	20	0.5	20	1	ADR82434	Human EphB4 antisense	C 473	20	0.5	20	1	ADR82473	Human EphB4 antisense
C 401	20	0.5	20	1	ADR82435	Human EphB4 antisense	C 474	20	0.5	20	1	ADR82350	Human EphB4 antisense
C 402	20	0.5	20	1	ADR82449	Human EphB4 antisense	C 475	20	0.5	20	1	ADR82397	Human EphB4 antisense
C 403	20	0.5	20	1	ADR82331	Human EphB4 antisense	C 476	20	0.5	20	1	ADR82400	Human EphB4 antisense
C 404	20	0.5	20	1	ADR82360	Human EphB4 antisense	C 477	20	0.5	20	1	ADR82436	Human EphB4 antisense
C 405	20	0.5	20	1	ADR82371	Human EphB4 antisense	C 478	20	0.5	20	1	ADR82478	Human EphB4 antisense
C 406	20	0.5	20	1	ADR82389	Human EphB4 antisense	C 479	20	0.5	20	1	ADR86990	Human EphrinB4 shRNA
C 407	20	0.5	20	1	ADR82454	Human EphB4 antisense	C 480	20	0.5	20	1	ADR86740	Human EphrinB4 shRNA
C 408	20	0.5	20	1	ADR82470	Human EphB4 antisense	C 481	20	0.5	20	1	ADR82545	Human EphB4 antisense
C 409	20	0.5	20	1	ADR82658	Human EphB4 antisense	C 482	20	0.5	20	1	ADR82305	Human EphB4 antisense
C 410	20	0.5	20	1	ADR82332	Human EphB4 antisense	C 483	19.8	0.5	23	1	ADY89201	VEGF/VEGFR siRNA S
C 411	20	0.5	20	1	ADR82346	Human EphB4 antisense	C 484	19.4	0.5	23	1	ADR86925	Human Ephrin B4 antisense
C 412	20	0.5	20	1	ADR82364	Human EphB4 antisense	C 485	19.4	0.5	21	1	ADR86745	Human Ephrin B4 antisense
C 413	20	0.5	20	1	ADR82369	Human EphB4 antisense	C 486	19.4	0.5	21	1	ADR82480	Human EphB4 antisense
C 414	20	0.5	20	1	ADR82381	Human EphB4 antisense	C 487	19.4	0.5	21	1	ADR82310	Human EphB4 antisense
C 415	20	0.5	20	1	ADR82385	Human EphB4 antisense	C 488	19.4	0.5	21	1	ADU31805	Knock-down target
C 416	20	0.5	20	1	ADR82409	Human EphB4 antisense	C 489	19.4	0.5	21	1	ADU31803	Knock-down target
C 417	20	0.5	20	1	ADR82412	Human EphB4 antisense	C 490	19.4	0.5	21	1	ADU31804	Knock-down target
C 418	20	0.5	20	1	ADR82420	Human EphB4 antisense	C 491	19.4	0.5	22	1	ADU31804	Human CYP2D6 gene
C 419	20	0.5	20	1	ADR82430	Human EphB4 antisense	C 492	19.2	0.5	24	1	ADG75924	Immunostimulatory
C 420	20	0.5	20	1	ADR82437	Human EphB4 antisense	C 493	19.2	0.5	24	1	ADG75971	Immunostimulatory
C 421	20	0.5	20	1	ADR82451	Human EphB4 antisense	C 494	19	0.4	19	1	ADH17042	Reverse PCR primer
C 422	20	0.5	20	1	ADR82458	Human EphB4 antisense	C 495	19	0.4	19	1	ADG60986	Anti-EphB4 siRNA r
C 423	20	0.5	20	1	ADR82460	Human EphB4 antisense	C 496	19	0.4	19	1	ADG60983	Anti-EphB4 siRNA r
C 424	20	0.5	20	1	ADR82477	Human EphB4 antisense	C 497	19	0.4	19	1	ADG60984	Anti-EphB4 siRNA r
C 425	20	0.5	20	1	ADR82664	Human EphB4 antisense	C 498	19	0.4	19	1	ADG60985	Human EphrinB4 shRNA
C 426	20	0.5	20	1	ADR82342	Human EphB4 antisense	C 499	19	0.4	21	1	ADR86728	Human EphrinB4 shRNA
C 427	20	0.5	20	1	ADR82354	Human EphB4 antisense	C 500	19	0.4	21	1	ADR86742	Human EphrinB4 shRNA
C 428	20	0.5	20	1	ADR82372	Human EphB4 antisense	C 501	19	0.4	21	1	ADR86992	Human EphrinB4 shRNA
C 429	20	0.5	20	1	ADR82373	Human EphB4 antisense	C 502	19	0.4	21	1	ADR86989	Human EphrinB4 shRNA
C 430	20	0.5	20	1	ADR82379	Human EphB4 antisense	C 503	19	0.4	21	1	ADR86771	Human EphrinB4 shRNA
C 431	20	0.5	20	1	ADR82391	Human EphB4 antisense	C 504	19	0.4	21	1	ADR86736	Human EphrinB4 shRNA
C 432	20	0.5	20	1	ADR82401	Human EphB4 antisense	C 505	19	0.4	21	1	ADR86729	Human EphrinB4 shRNA
C 433	20	0.5	20	1	ADR82411	Human EphB4 antisense	C 506	19	0.4	21	1	ADR86991	Human EphrinB4 shRNA
C 434	20	0.5	20	1	ADR82414	Human EphB4 antisense	C 507	19	0.4	21	1	ADR86738	Human EphrinB4 shRNA
C 435	20	0.5	20	1	ADR82418	Human EphB4 antisense	C 508	19	0.4	21	1	ADR86988	Human EphrinB4 shRNA
C 436	20	0.5	20	1	ADR82334	Human EphB4 antisense	C 509	19	0.4	21	1	ADR82303	Human EphB4 siRNA
C 437	20	0.5	20	1	ADR82351	Human EphB4 antisense	C 510	19	0.4	21	1	ADR82543	Human EphB4 antisense
C 438	20	0.5	20	1	ADR82357	Human EphB4 antisense	C 511	19	0.4	21	1	ADR82544	Human EphB4 antisense
C 439	20	0.5	20	1	ADR82362	Human EphB4 antisense	C 512	19	0.4	21	1	ADR82307	Human EphB4 siRNA
C 440	20	0.5	20	1	ADR82374	Human EphB4 antisense	C 513	19	0.4	21	1	ADR82301	Human EphB4 siRNA
C 441	20	0.5	20	1	ADR82394	Human EphB4 antisense	C 514	19	0.4	21	1	ADR82326	Human EphB4 siRNA
C 442	20	0.5	20	1	ADR82399	Human EphB4 antisense	C 515	19	0.4	21	1	ADR82295	Human beta-actin R
C 443	20	0.5	20	1	ADR82422	Human EphB4 antisense	C 516	19	0.4	21	1	ADR82294	Human EphB4 siRNA
C 444	20	0.5	20	1	ADR82427	Human EphB4 antisense	C 517	19	0.4	21	1	ADR82546	Human EphB4 antisense
C 445	20	0.5	20	1	ADR82464	Human EphB4 antisense	C 518	19	0.4	21	1	ADR82547	Human EphB4 antisense
C 446	20	0.5	20	1	ADR82467	Human EphB4 antisense	C 519	19	0.4	21	1	ADR82660	Human EphB4 siRNA
C 447	20	0.5	20	1	ADR82468	Human EphB4 antisense	C 520	18.8	0.4	22	1	ADJ14704	Debrisosine 4-hyd
C 448	20	0.5	20	1	ADR82488	Human EphB4 antisense	C 521	18.8	0.4	22	1	ADJ14787	Debrisosine 4-hyd
C 449	20	0.5	20	1	ADR82297	Human beta-actin R	C 522	18.8	0.4	22	1	ADG60807	Human debrisosine
C 450	20	0.5	20	1	ADR82377	Human EphB4 antisense	C 523	18.8	0.4	22	1	ADG60878	Human debrisosine
C 451	20	0.5	20	1	ADR82392	Human EphB4 antisense	C 524	18.8	0.4	22	1	ADY71126	Human CYP2D6 gene-
C 452	20	0.5	20	1	ADR82403	Human EphB4 antisense	C 525	18.8	0.4	23	1	ADY89206	VEGF/VEGFR siRNA S
C 453	20	0.5	20	1	ADR82423	Human EphB4 antisense	C 526	18.8	0.4	23	1	ADY89196	VEGF/VEGFR siRNA S
C 454	20	0.5	20	1	ADR82453	Human EphB4 antisense	C 527	18.4	0.4	23	1	ADY50241	Human beta-globin
C 455	20	0.5	20	1	ADR82456	Human EphB4 antisense	C 528	18	0.4	18	1	ADR86930	Human Ephrin B4 an
C 456	20	0.5	20	1	ADR82339	Human EphB4 antisense	C 529	18	0.4	18	1	ADR86749	Human Ephrin B4 an
C 457	20	0.5	20	1	ADR82341	Human EphB4 antisense	C 530	18	0.4	18	1	ADR86750	Human Ephrin B4 an
C 458	20	0.5	20	1	ADR82358	Human EphB4 antisense	C 531	18	0.4	18	1	ADR86929	Human Ephrin B4 an
C 459	20	0.5	20	1	ADR82382	Human EphB4 antisense	C 532	18	0.4	18	1	ADR82314	Human EphB4 antisense
C 460	20	0.5	20	1	ADR82659	Human EphB4 antisense	C 533	18	0.4	18	1	ADR82484	Human EphB4 antisense
C 461	20	0.5	20	1	ADR82337	Human EphB4 antisense	C 534	18	0.4	18	1	ADR82315	Human EphB4 antisense
C 462	20	0.5	20	1	ADR82349	Human EphB4 antisense	C 535	18	0.4	18	1	ADR82485	Human EphB4 antisense
C 463	20	0.5	20	1	ADR82366	Human EphB4 antisense	C 536	18	0.4	22	1	ADJ16452	Short interfering
C 464	20	0.5	20	1	ADR82375	Human EphB4 antisense	C 537	17.8	0.4	21	1	ADJ78587	Human cytochrome p
C 465	20	0.5	20	1	ADR82378	Human EphB4 antisense	C 538	17.8	0.4	21	1	ADM28915	PCR primer #1 for
C 466	20	0.5	20	1	ADR82398	Human EphB4 antisense	C 539	17.8	0.4	21	1	ADSO0674	Nested PCR primer
C 467	20	0.5	20	1	ADR82404	Human EphB4 antisense	C 540	17.4	0.4	19	1	ADJ14673	Debrisosine 4-hyd
C 468	20	0.5	20	1	ADR82405	Human EphB4 antisense	C 541	17.4	0.4	19	1	ADG60900	Human debrisosine
C 469	20	0.5	20	1	ADR82428	Human EphB4 antisense	C 542	17.4	0.4	19	1	ADG60775	Human debrisosine
C 470	20	0.5	20	1	ADR82448	Human EphB4 antisense	C 543	17.4	0.4	19	1	ADT01293	Novel mutant prote
C 471	20	0.5	20	1	ADR82457	Human EphB4 antisense	C 544	17.4	0.4	20	1	ABL94275	Human C/EBP beta p

545	17.4	0.4	20	1	ADC26603	CYP2D6-specific pr	c 618	15.4	0.4	17	1	ACN64751	Human GMMLP-1 prob
546	17	0.4	19	1	ADR86762	Human ephrin B4 RT	c 619	15.4	0.4	17	1	ACN64752	Human GMMLP-1 prob
547	17	0.4	19	1	ADR82668	Human EphB4 RT-PCR	c 620	15.4	0.4	18	1	ADR87873	Biotinylated prime
548	17	0.4	20	1	AAQ27541	PCR Primer P5(1) c	c 621	15.4	0.4	19	1	ADF36606	Human VEGFR2 short
549	17	0.4	20	1	AAQ64160	Primer for amplify	c 622	15.4	0.4	19	1	ADF36606	Human VEGFR2 short
550	16.8	0.4	20	1	AAZ18209	Tyrosine kinase ge	c 623	15.4	0.4	19	1	ADQ16519	4 synthesis-period
551	16.8	0.4	20	1	AAZ02532	PCR primer used to	c 624	15.4	0.4	19	1	ADQ60352	Anti-Cyclophilin s
552	16.8	0.4	20	1	ADC65757	Human TGF-beta rec	c 625	15.4	0.4	19	1	ADR79853	Human apolipoprote
553	16.8	0.4	20	1	ADU78633	Antisense oligonuc	c 626	15.4	0.4	19	1	ADR79854	Human apolipoprote
554	16.8	0.4	20	1	ADW83103	MAP3K9 marker ampl	c 627	15.4	0.4	19	1	ADR76909	Human apolipoprote
555	16.8	0.4	21	1	AAZ18182	PRK 26 gene specif	c 628	15.4	0.4	19	1	ADR76910	Human apolipoprote
556	16.8	0.4	21	1	AAZ18188	PRK 30 gene specif	c 629	15.4	0.4	19	1	ADT81353	Apolipoprotein B (
557	16.8	0.4	21	1	AAZ18166	PRK 17 gene specif	c 630	15.4	0.4	19	1	ADT84297	Apolipoprotein B (
558	16.8	0.4	21	1	AAZ18172	PRK 20 gene specif	c 631	15.4	0.4	19	1	ADT84296	Apolipoprotein B (
559	16.8	0.4	21	1	AAZ18178	PRK 23 gene specif	c 632	15.4	0.4	19	1	ADT81352	Apolipoprotein B (
560	16.8	0.4	21	1	AAZ07689	Reverse primer for	c 633	15.4	0.4	19	1	ADX00842	Human CYP2D6 gene
561	16.8	0.4	21	1	ABZ58380	Human protein phos	c 634	15.4	0.4	19	1	ADY88183	VEGFR siRNA SEQ ID
562	16.8	0.4	21	1	ACL42990	CACNA1D siRNA anti	c 635	15.4	0.4	19	1	ADY87859	VEGFR siRNA SEQ ID
563	16.4	0.4	18	1	AAH47543	Human Her-3 mRNA i	c 636	15.4	0.4	19	1	ADY89384	VEGFR siRNA target
564	16.4	0.4	18	1	ABX80008	EST polymorphic DN	c 637	15.4	0.4	19	1	ADY90334	VEGFR siRNA SEQ ID
565	16.4	0.4	19	1	ADY82827	VEGFR siRNA target	c 638	15	0.4	15	1	ADH17043	Taqman probe used
566	16.4	0.4	19	1	ADY89385	VEGFR siRNA target	c 639	15	0.4	17	1	AAZ35184	PCR primer used am
567	16.4	0.4	20	1	AAQ20433	Debrisioquine polym	c 640	15	0.4	17	1	ABN01660	Human GMMLP-1 17-m
568	16.4	0.4	20	1	AAZ92799	PCR primer used to	c 641	15	0.4	17	1	ABN01659	Human GMMLP-1 17-m
569	16.4	0.4	20	1	AAZ60967	Human MyD88 antise	c 642	15	0.4	17	1	ABA02896	Human IL-17 RT-PCR
570	16.4	0.4	20	1	ADZ14481	HSP11B1 antisense	c 643	15	0.4	17	1	ACA99869	G-protein coupled
571	16.4	0.4	20	1	ADZ59502	Oligonucleotide of	c 644	15	0.4	17	1	ACA99866	G-protein coupled
572	16.4	0.4	20	1	ABZ29981	SCN5A gene exon 2	c 645	15	0.4	17	1	AD013871	dbv gene cluster p
573	16	0.4	17	1	ACA99868	G-protein coupled	c 646	15	0.4	17	1	ACN64750	Human GMMLP-1 prob
574	16	0.4	17	1	ACA99867	G-protein coupled	c 647	15	0.4	17	1	ACN64749	Human GMMLP-1 prob
575	16	0.4	17	1	ABT37713	Tumour suppression	c 648	15	0.4	17	1	ADZ37574	tcp gene cluster i
576	16	0.4	17	1	AD148271	Human tumour suppress	c 649	15	0.4	18	1	AAZ70292	Human flt1 VEGF re
577	16	0.4	17	1	ACZ53159	Human tumour suppress	c 650	14.8	0.3	18	1	AAQ65270	Antisense oligonuc
578	16	0.4	19	1	AAA82486	cdk1 ribozyme bind	c 651	14.8	0.3	18	1	AAZ09484	Human betaallic po
579	16	0.4	19	1	AAA82487	cdk1 ribozyme bind	c 652	14.8	0.3	18	1	AAZ25485	Primer 39DRD4.SB.P
580	16	0.4	19	1	AAH57648	Cell-cycle depende	c 653	14.8	0.3	18	1	AAZ25567	Human RhoG antisen
581	16	0.4	19	1	AAH57649	Cell-cycle depende	c 654	14.8	0.3	18	1	AAZ55193	Multiple antisense
582	16	0.4	19	1	ABK41169	Human obesity-asso	c 655	14.8	0.3	18	1	AAA34640	Human adenosine re
583	16	0.4	19	1	ADT01526	Novel mutant prote	c 656	14.8	0.3	18	1	AAA09486	Antisense primer f
584	16	0.4	20	1	ABZ99246	Human cytochrome P	c 657	14.8	0.3	18	1	AAF20762	Human multiple tar
585	16	0.4	20	1	ABD32277	Human PDE4C-deri	c 658	14.8	0.3	18	1	AAF21465	Human multiple tar
586	16	0.4	20	1	ADJ61131	Oligonucleotide as	c 659	14.8	0.3	18	1	AAH75205	Human inducible NO
587	15.8	0.4	19	1	AAT00705	Human trkC recepto	c 660	14.8	0.3	18	1	AAF94748	Rho G antisen ph
588	15.8	0.4	19	1	AZ888855	Human trkC recepto	c 661	14.8	0.3	18	1	ABA82492	Zmax1 gene region
589	15.8	0.4	19	1	AAD30287	Human PKD1 gene mu	c 662	14.8	0.3	18	1	ABL44014	Human chromosome 1
590	15.8	0.4	19	1	ABK30165	CYP2D6 gene polymo	c 663	14.8	0.3	18	1	ABL44014	Human c-mos gene p
591	15.8	0.4	19	1	ABZ24394	Human cytochrome P	c 664	14.8	0.3	18	1	ABK23289	Human Zmax1 cdna f
592	15.8	0.4	19	1	ADZ37388	Human VEGFR3 short	c 665	14.8	0.3	18	1	ABZ11106	Haematopoietic cel
593	15.8	0.4	19	1	ADZ37635	Human VEGFR3 short	c 666	14.8	0.3	18	1	ACC45872	Human HBM SPS mark
594	15.8	0.4	19	1	ADZ84250	Human ABL1-targete	c 667	14.8	0.3	18	1	ADZ84250	Sequence tagged si
595	15.8	0.4	19	1	ADZ84250	Human ABL1-targete	c 668	14.8	0.3	18	1	ADZ84250	Casein kinase 2 an
596	15.8	0.4	19	1	ADZ84250	PCR primer SEQ ID	c 669	14.8	0.3	18	1	ADZ84250	CK2-alpha' (prime-1
597	15.8	0.4	19	1	ADZ84250	4 synthesis-period	c 670	14.8	0.3	18	1	ADZ84250	Human nucleic acid
598	15.8	0.4	19	1	ADQ60909	Anti-BLK siRNA rel	c 671	14.8	0.3	18	1	ADZ97159	Human MTA oligonuc
599	15.8	0.4	19	1	ADU03887	Human polycystic k	c 672	14.8	0.3	18	1	ABX10913	Novel human membra
600	15.8	0.4	19	1	ADY88888	VEGFR siRNA SEQ ID	c 673	14.8	0.3	18	1	ACA60574	Antisense inhibiti
601	15.8	0.4	19	1	ADY89258	VEGFR siRNA target	c 674	14.8	0.3	18	1	ABD20418	Human pulmonary an
602	15.8	0.4	19	1	ADY89258	VEGFR siRNA target	c 675	14.8	0.3	18	1	ABD32442	Human MTA oligo SE
603	15.6	0.4	18	1	ADZ58087	Primer Gamma 10 fo	c 676	14.8	0.3	18	1	ADZ34784	Kidney injury mole
604	15.6	0.4	18	1	ADZ58086	Primer Gamma 9 for	c 677	14.8	0.3	18	1	ADZ58087	MS Snupe detection
605	15.4	0.4	17	1	AAT53779	Rat ICAM hammerhea	c 678	14.8	0.3	18	1	ADP47449	Intelligent PCR pr
606	15.4	0.4	17	1	AAV92591	Human A-Raf subutr	c 679	14.8	0.3	18	1	ADQ59807	Intelligent PCR pr
607	15.4	0.4	17	1	AAV92591	Hammerhead ribozym	c 680	14.8	0.3	18	1	ADZ17435	Human chromosome 1
608	15.4	0.4	17	1	ABA81101	LDLR mutation corr	c 681	14.8	0.3	18	1	ADZ17435	Human chromosome 1
609	15.4	0.4	17	1	ABA81101	LDLR mutation corr	c 682	14.8	0.3	18	1	ADZ17435	Human GPR4 DNA RT-
610	15.4	0.4	17	1	ABN01661	Human GMMLP-1 17-m	c 683	14.8	0.3	18	1	ADZ17435	S. carnosus seca p
611	15.4	0.4	17	1	ABN01662	Human GMMLP-1 17-m	c 684	14.8	0.3	18	1	ADZ17435	Human chromosome 1
612	15.4	0.4	17	1	ABQ63403	Human KTN1a portti	c 685	14.8	0.3	18	1	ADZ17435	Small interfering
613	15.4	0.4	17	1	ACN02004	WNV Inozyme subutr	c 686	14.8	0.3	18	1	ADZ17435	Small interfering
614	15.4	0.4	17	1	ACN11465	WNV minus strand I	c 687	14.6	0.3	17	1	ABQ72285	Human CYP2D6 allel
615	15.4	0.4	17	1	ABE58244	Human VEGF recepto	c 688	14.6	0.3	17	1	ABQ72285	Human insulin sens
616	15.4	0.4	17	1	ABE58245	Human VEGF recepto	c 689	14.6	0.3	17	1	ADH23252	Degenerate sense p
617	15.4	0.4	17	1	ABE61660	Human VEGF recepto	c 690	14.4	0.3	16	1	AAQ65268	Antisense oligonuc

c 691	14.4	0.3	16	1	ADCL13653	Human NOVX reverse
c 692	14.4	0.3	16	1	ABE18973	Human leukocyte an
c 693	14.4	0.3	17	1	AAQ85269	Antisense oligonuc
c 694	14.4	0.3	17	1	AAQ65253	Antisense oligonuc
c 695	14.4	0.3	17	1	AAV92592	Human A-Raf substr
c 696	14.4	0.3	17	1	AAFO6057	Hammerhead ribozym
c 697	14.4	0.3	17	1	AAFO2029	Hammerhead ribozym
c 698	14.4	0.3	17	1	ADVO6123	Human BACE DNzyme
c 699	14.4	0.3	17	1	ADU94065	Human TERT NCH rib
c 700	14.4	0.3	17	1	ADVO0664	Human TERT DNzyme
c 701	14.4	0.3	17	1	ADMB9524	Human PTP-B NCH r
c 702	14.4	0.3	17	1	ADMB9525	Human PTP-B NCH r
c 703	14.4	0.3	17	1	ADMO7544	Human BACE amberzy
c 704	14.4	0.3	17	1	ADVO1226	Human TERT DNzyme
c 705	14.4	0.3	17	1	ADU94064	Human TERT NCH rib
c 706	14.4	0.3	17	1	ADVO5221	Human BACE zinzyme
c 707	14.4	0.3	17	1	ADVO7126	Human BACE amberzy
c 708	14.4	0.3	17	1	ABNO2655	Human GMMLP-1 17-m
c 709	14.4	0.3	17	1	ABNO1663	Human GMMLP-1 17-m
c 710	14.4	0.3	17	1	ABNO2656	Human GMMLP-1 17-m
c 711	14.4	0.3	17	1	ABNO0913	Human GMMLP-1 17-m
c 712	14.4	0.3	17	1	ABNO0914	Human GMMLP-1 17-m
c 713	14.4	0.3	17	1	ABQ63402	Human KTMiA porti
c 714	14.4	0.3	17	1	ABQ63404	Human KTMiA porti
c 715	14.4	0.3	17	1	ABL31121	Human HLA genotypl
c 716	14.4	0.3	17	1	ACN04226	WNV Zinzyme subatr
c 717	14.4	0.3	17	1	ACN12772	WNV minus strand Z
c 718	14.4	0.3	17	1	ACN13224	WNV minus strand Z
c 719	14.4	0.3	17	1	ACN05992	WNV Amberzyme subs
c 720	14.4	0.3	17	1	ACN11464	WNV minus strand I
c 721	14.4	0.3	17	1	ABT35221	Tumour suppression
c 722	14.4	0.3	17	1	ACA06540	NFKB sub-unit modu
c 723	14.4	0.3	17	1	ACA06539	NFKB sub-unit modu
c 724	14.4	0.3	17	1	ABZ62068	Human H-Ras DNazym
c 725	14.4	0.3	17	1	ABZ61986	Human H-Ras DNazym
c 726	14.4	0.3	17	1	ACC66601	Murine oligonucleo
c 727	14.4	0.3	17	1	ACC63709	Murine oligonucleo
c 728	14.4	0.3	17	1	ADB44084	Tumour suppression
c 729	14.4	0.3	17	1	ADE25202	Plant growth aescoc
c 730	14.4	0.3	17	1	ACC53156	Human tumour suppr
c 731	14.4	0.3	17	1	ADL48219	Human IXX-gamma su
c 732	14.4	0.3	17	1	ABE60994	Human VEGF recepto
c 733	14.4	0.3	17	1	ADL82216	Human ER+ breast c
c 734	14.4	0.3	17	1	ADL60384	Human organic anio
c 735	14.4	0.3	17	1	ADR27266	Human single nucle
c 736	14.4	0.3	17	1	ACN64003	Human GMMLP-1 prob
c 737	14.4	0.3	17	1	ACN64753	Human GMMLP-1 prob
c 738	14.4	0.3	17	1	ACN64004	Human GMMLP-1 prob
c 739	14.4	0.3	17	1	ACN65746	Human GMMLP-1 prob
c 740	14.4	0.3	17	1	ACN65745	Human GMMLP-1 prob
c 741	14.4	0.3	17	1	ADZ31142	Human H-Ras substr
c 742	14.4	0.3	17	1	ADZ31060	Human H-Ras substr
c 743	14.4	0.3	18	1	AAQ65238	Antisense oligonuc
c 744	14.4	0.3	18	1	AAQ65254	Antisense oligonuc
c 745	14.4	0.3	18	1	AAV48676	JunB gene antisens
c 746	14.4	0.3	18	1	AAAS2892	Human CD44 antisen
c 747	14.4	0.3	18	1	AAAS0403	Human NF-kappa-B p
c 748	14.4	0.3	18	1	ADI94534	Human IL-10 associ
c 749	14.4	0.3	18	1	ADI93071	ARRESTOR oligonuc
c 750	14.4	0.3	18	1	ACA62538	Human MDM2 mutant
c 751	14.4	0.3	18	1	ADB54472	Hybridisation olig
c 752	14.4	0.3	18	1	ADP90215	Human NF-kappa-B p
c 753	14.4	0.3	18	1	ADH94506	Human gene PCR pri
c 754	14.4	0.3	18	1	ADH71082	Human Vbeta micros
c 755	14.4	0.3	18	1	ADMB3057	Human NF-kappa-B p
c 756	14.4	0.3	18	1	ADS90640	Oligonucleotide of
c 757	14.4	0.3	18	1	ADZ66354	DNA methylation an
c 758	14.4	0.3	18	1	AEA12272	Human KIR allele 2

ALIGNMENTS

RESULT 1	
AAI78874/c	
ID AAI78874 standard; DNA; 50 BP.	
XX	
AC AAI78874;	
XX	
DT 09-NOV-2001 (first entry)	
XX	
DE Human silent SNP containing nucleic acid SEQ:5815.	
XX	
KW Human; single nucleotide polymorphism; SNP; genome; gene therapy; protein therapy; vaccine; probe; diagnostic assay; detection; quantitation; restorative therapy; polymorphic; ds.	
KW	
XX	
OS Homo sapiens.	
XX	
PN WO200140521-A2.	
XX	
PD 07-JUN-2001.	
XX	
PF 30-NOV-2000; 2000WO-US032758.	
XX	
PR 30-NOV-1999; 99US-0168138P.	
XX	
PR 29-NOV-2000; 2000US-00726173.	
XX	
PA (CURA-) CURAGEN CORP.	
XX	
PI Shinkets RA, Leach M;	
XX	
DR WPI; 2001-356160/37.	
XX	
PT Polymorphic nucleic acid sequences, useful in genetic testing and therapy.	
XX	
PS Claim 1; Page 2290; 2653pp; English.	
XX	
CC AAI73060 to AAI79867 represent isolated human polymorphic polynucleotide sequences (I), which contain single nucleotide polymorphisms (SNPs).	
CC	
CC AAM53114 to AAM53329 represent peptides related to human polymorphic polynucleotide sequences. The sequences can be used in gene and protein therapy, and in vaccine production. (I) and the polypeptides encoded by them may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate expression of polymorphic polypeptides. For example, (I) may be used to treat disorders by rectifying mutations or deletions in a patient's genome that affect the activity of polypeptides by expressing inactive proteins or to supplement the patient's own production of polypeptide. Additionally, (I) and its complementary sequences may also be used as DNA probes in diagnostic assays to detect and quantitate the presence of similar nucleic acids in samples, and therefore which patients may be in need of restorative therapy. The polypeptides encoded by (I) may be used as antigens in the production of antibodies specific for polymorphic polypeptides. The antibodies may also be used to down regulate expression and activity. The antibodies may also be used as diagnostic agents for detecting the presence of polymorphic polypeptides in samples	
XX	
SQ Sequence 50 BP; 24 A; 11 C; 8 G; 7 T; 0 U; 0 Other;	
Query Match 1.2%; Score 50; DB 1; Length 50;	
Best Local Similarity 100.0%; Pred. No. 0.037;	
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY 3829 CCAGCTGCTGCCTTCATATGTAAGCTTTTGTAGTTTGTGTTTGTGCTTA 3878	
DB 50 CCAGCTGCTGCCTTCATATGTAAGCTTTTGTAGTTTGTGTTTGTGCTTA 1	
RESULT 2	
ADRS2551	
ID ADRS2551 standard; DNA; 48 BP.	
XX	
AC ADRS2551;	
XX	

```
DT 18-NOV-2004 (first entry)
XX
DE Small interfering RNA expression library oligonucleotide #109.
XX
KW ss; siRNA; small interfering RNA; gene expression; gene silencing;
KW expression library; silencing; G coupled receptor; ion channel;
XX receptor tyrosine kinase; non-receptor tyrosine kinases;
KW nuclear hormone receptor; GTPase; ATPase; serine/threonine kinase;
KW protease; matrix metalloproteinase; E3 ubiquitin ligase.
XX
OS Synthetic.
XX
FN WO2004072261-A2.
XX
PD 26-AUG-2004.
XX
PF 10-FEB-2004; 2004WO-US003949.
XX
PR 11-FEB-2003; 2003US-0446714P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Li H, Chatterton JE, Fan W, Ke N, Wong-Staal F;
XX
DR WPI; 2004-625862/60.
XX
DR P-PSDB; ADR52552.
XX
PT Generating a siRNA expression library for selective post-transcriptional
PT silencing of genes encoding a family of proteins comprises identifying a
XX consensus sequence for protein families.
XX
PS Example 2; SEQ ID NO 217; 44pp; English.
XX
CC The invention relates to a method for generating a siRNA expression
CC library for selective post-transcriptional silencing of genes encoding a
CC family of proteins comprising identifying a consensus sequence for the
CC family of proteins. The method comprises: (a) identifying a consensus
CC sequence for the family of proteins; and (b) generating an siRNA
CC expression library whose members encode siRNA molecules that target at
CC least all mRNA encoding all known members of the family of proteins. The
CC tyrosine kinases, non-receptor tyrosine kinases, nuclear hormone
CC receptors, GTPases, ATPases, serine/threonine kinases, proteases, matrix
CC metalloproteinases, GTPase-activating proteins or E3 ubiquitin ligases.
CC Identifying a consensus sequence comprises identifying at least one, two
CC or more signature motif for the family of proteins. The method is useful
CC for generating a siRNA expression library for selective post-
CC transcriptional silencing of genes encoding a family of proteins. The
CC library is useful for identifying genes involved in disease processes.
CC This sequence corresponds to an oligonucleotide used in the method of the
CC invention.
XX
SQ Sequence 48 BP; 12 A; 17 C; 10 G; 9 T; 0 U; 0 Other;
Query Match 1.1%; Score 48; DB 1; Length 48;
Best Local Similarity 100.0%; Pred. No. 0.065;
Matches 48; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2575 ATGAGCTACGTCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 2622
DB 1 ATGAGCTACGTCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 48
RESULT 3
ADR52531
ID ADR52531 standard; DNA; 48 BP.
XX
AC ADR52531;
XX
DT 18-NOV-2004 (first entry)
XX
DE Small interfering RNA expression library oligonucleotide #99.
XX
KW ss; siRNA; small interfering RNA; gene expression; gene silencing;
KW expression library; silencing; G coupled receptor; ion channel;
XX receptor tyrosine kinase; non-receptor tyrosine kinases;
KW nuclear hormone receptor; GTPase; ATPase; serine/threonine kinase;
KW protease; matrix metalloproteinase; E3 ubiquitin ligase.
XX
OS Synthetic.
XX
FN WO2004072261-A2.
XX
PD 26-AUG-2004.
XX
PF 10-FEB-2004; 2004WO-US003949.
XX
PR 11-FEB-2003; 2003US-0446714P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Li H, Chatterton JE, Fan W, Ke N, Wong-Staal F;
XX
DR WPI; 2004-625862/60.
XX
DR P-PSDB; ADR52552.
XX
PT Generating a siRNA expression library for selective post-transcriptional
PT silencing of genes encoding a family of proteins comprises identifying a
XX consensus sequence for protein families.
XX
PS Example 2; SEQ ID NO 217; 44pp; English.
XX
CC The invention relates to a method for generating a siRNA expression
CC library for selective post-transcriptional silencing of genes encoding a
CC family of proteins comprising identifying a consensus sequence for the
CC family of proteins. The method comprises: (a) identifying a consensus
CC sequence for the family of proteins; and (b) generating an siRNA
CC expression library whose members encode siRNA molecules that target at
CC least all mRNA encoding all known members of the family of proteins. The
CC tyrosine kinases, non-receptor tyrosine kinases, nuclear hormone
CC receptors, GTPases, ATPases, serine/threonine kinases, proteases, matrix
CC metalloproteinases, GTPase-activating proteins or E3 ubiquitin ligases.
CC Identifying a consensus sequence comprises identifying at least one, two
CC or more signature motif for the family of proteins. The method is useful
CC for generating a siRNA expression library for selective post-
CC transcriptional silencing of genes encoding a family of proteins. The
CC library is useful for identifying genes involved in disease processes.
CC This sequence corresponds to an oligonucleotide used in the method of the
CC invention.
XX
SQ Sequence 48 BP; 11 A; 16 C; 10 G; 11 T; 0 U; 0 Other;
Query Match 0.9%; Score 40; DB 1; Length 48;
Best Local Similarity 89.6%; Pred. No. 0.86;
Matches 43; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
QY 2575 ATGAGCTACGTCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 2622
DB 1 ATGAGCTACGTCACCGAGACCTGGCTGCTCGCAACATCCTAGTCAAC 48
RESULT 4
ADR52529
ID ADR52529 standard; DNA; 48 BP.
XX
AC ADR52529;
XX
DT 18-NOV-2004 (first entry)
XX
DE Small interfering RNA expression library oligonucleotide #98.
XX
KW ss; siRNA; small interfering RNA; gene expression; gene silencing;
KW expression library; silencing; G coupled receptor; ion channel;
XX receptor tyrosine kinase; non-receptor tyrosine kinases;
KW nuclear hormone receptor; GTPase; ATPase; serine/threonine kinase;
```


KW protease; matrix metalloproteinase; E3 ubiquitin ligase.
XX Synthetic.
OS

PN WO2004072261-A2.

XX 26-AUG-2004.

PF 10-FEB-2004; 2004WO-US0003949.

XX 11-FEB-2003; 2003US-0446714P.

XX (IMMU-) IMMUSOL INC.

PI Li H, Chatterton JE, Fan W, Ke N, Wong-Staal F;

XX WPI; 2004-625862/60.

DR P-PSDB; ADR52530.

XX Generating a siRNA expression library for selective post-transcriptional silencing of genes encoding a family of proteins comprises identifying a consensus sequence for protein families.

PS Example 2; SEQ ID NO 195; 44pp; English.

XX The invention relates to a method for generating a siRNA expression library for selective post-transcriptional silencing of genes encoding a family of proteins comprising identifying a consensus sequence for the family of proteins. The method comprises: (a) identifying a consensus sequence for the family of proteins; and (b) generating an siRNA expression library whose members encode siRNA molecules that target at least all mRNA encoding all known members of the family of proteins. The family of proteins is G coupled receptors, ion channels, receptor tyrosine kinases, non-receptor tyrosine kinases, nuclear hormone receptors, GTPases, ATPases, serine/threonine kinases, proteases, matrix metalloproteinases, GTPase-activating proteins or E3 ubiquitin ligases. CC Identifying a consensus sequences comprises identifying at least one, two or more signature motif for the family of proteins. The method is useful for generating a siRNA expression library for selective post-transcriptional silencing of genes encoding a family of proteins. The library is useful for identifying genes involved in disease processes. CC This sequence corresponds to an oligonucleotide used in the method of the invention.

XX Sequence 48 BP; 11 A; 17 C; 9 G; 11 T; 0 U; 0 Other;

Query Match 0.9%; Score 38.4; DB 1; Length 48;

Best Local Similarity 87.5%; Pred. No. 1.4;

Matches 42; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2575 ATGAGCTACGTCACCGAGACCTGGCTGCGCAACATCCTAGTCAAC 2622

Db 1 ATGAACATATGTTACCGTGACCTGGCTGCGCGCAACATCCTCGTCAAC 48

RESULT 5

ADR52517

ID ADR52517 standard; DNA; 48 BP.

XX ADR52517;

XX 18-NOV-2004 (first entry)

XX Small interfering RNA expression library oligonucleotide #92.

XX ss; siRNA; small interfering RNA; gene expression; gene silencing; expression library; silencing; G coupled receptor; ion channel; receptor tyrosine kinase; non-receptor tyrosine kinases; nuclear hormone receptor; GTPase; ATPase; serine/threonine kinase; protease; matrix metalloproteinase; E3 ubiquitin ligase.

XX Synthetic.

XX

PN WO2004072261-A2.

XX 26-AUG-2004.

XX 10-FEB-2004; 2004WO-US0003949.

XX 11-FEB-2003; 2003US-0446714P.

XX (IMMU-) IMMUSOL INC.

XX Li H, Chatterton JE, Fan W, Ke N, Wong-Staal F;

XX WPI; 2004-625862/60.

DR P-PSDB; ADR52518.

XX Generating a siRNA expression library for selective post-transcriptional silencing of genes encoding a family of proteins comprises identifying a consensus sequence for protein families.

PS Example 2; SEQ ID NO 183; 44pp; English.

XX The invention relates to a method for generating a siRNA expression library for selective post-transcriptional silencing of genes encoding a family of proteins comprising identifying a consensus sequence for the family of proteins. The method comprises: (a) identifying a consensus sequence for the family of proteins; and (b) generating an siRNA expression library whose members encode siRNA molecules that target at least all mRNA encoding all known members of the family of proteins. The family of proteins is G coupled receptors, ion channels, receptor tyrosine kinases, non-receptor tyrosine kinases, nuclear hormone receptors, GTPases, ATPases, serine/threonine kinases, proteases, matrix metalloproteinases, GTPase-activating proteins or E3 ubiquitin ligases. CC Identifying a consensus sequences comprises identifying at least one, two or more signature motif for the family of proteins. The method is useful for generating a siRNA expression library for selective post-transcriptional silencing of genes encoding a family of proteins. The library is useful for identifying genes involved in disease processes. CC This sequence corresponds to an oligonucleotide used in the method of the invention.

XX Sequence 48 BP; 11 A; 17 C; 10 G; 10 T; 0 U; 0 Other;

Query Match 0.9%; Score 38.4; DB 1; Length 48;

Best Local Similarity 87.5%; Pred. No. 1.4;

Matches 42; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2575 ATGAGCTACGTCACCGAGACCTGGCTGCGCAACATCCTAGTCAAC 2622

Db 1 ATGAACATATGTCACCGTGACCTGGCTGCGCGCAACATCCTCGTCAAC 48

RESULT 6

ADR86708/c

ID ADR86708 standard; DNA; 36 BP.

XX ADR86708;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 PCR primer seqid 13.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic; dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2; pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour; angiogenesis-associated disease; inflammatory disorder; chronic articular rheumatism; psoriasis; ocular angiogenic disease; scleroderma; human; ephrin B4; PCR; primer; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX

XX PF 12-MAR-2004; 2004WO-US007755.
 XX PF 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX PA (VASG-) VASGENE THERAPEUTICS INC.
 XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX DR WPI; 2004-668883/65.
 XX XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX PS Example 1; Page 44; 198pp; English.
 XX CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a primer used in the isolation of human ephrin B4 cDNA used in
 CC the creation of an expression vector for producing a soluble Eph B4
 CC derivative.
 XX SQ Sequence 36 BP; 4 A; 18 C; 6 G; 8 T; 0 U; 0 Other;
 Query Match 0.7%; Score 29; DB 1; Length 36;
 Best Local Similarity 100.0%; Pred. No. 17;
 Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1958 TGGATGAGCGAGCGGCTGCGGGAGCAG 1986
 Db |||||
 36 TGGATGAGCGAGCGGCTGCGGGAGCAG 8
 RESULT 7
 ADR82277/c
 ID ADR82277 standard; DNA; 36 BP.
 XX AC ADR82277;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human EphB4 PCR primer #2.
 XX XX human; ss; PCR; primer; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor.
 XX OS Homo sapiens.
 XX PN WO2004080418-A2.

XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007491.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX PA (VASG-) VASGENE THERAPEUTICS INC.
 XX PI Reddy R, Gill P;
 XX DR WPI; 2004-668879/65.
 XX XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX PS Example 1; Page 49; 206pp; English.
 XX CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC PCR primer.
 XX SQ Sequence 36 BP; 4 A; 18 C; 6 G; 8 T; 0 U; 0 Other;
 Query Match 0.7%; Score 29; DB 1; Length 36;
 Best Local Similarity 100.0%; Pred. No. 17;
 Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1958 TGGATGAGCGAGCGGCTGCGGGAGCAG 1986
 Db |||||
 36 TGGATGAGCGAGCGGCTGCGGGAGCAG 8
 RESULT 8
 ADR17041
 ID ADR17041 standard; DNA; 26 BP.
 XX AC ADR17041;
 XX DT 11-MAR-2004 (first entry)
 XX DE Forward PCR primer used to amplify human EphB4 sequence.
 XX XX tyrosine kinase activity; type 1 plasminogen activator inhibitor; PAI-1;
 KW TIMP-1; tissue inhibitor of metalloproteinase 1; vinculin;
 KW vascular endothelial growth factor; VEGF; placental growth factor; PLGF;
 KW migration inhibitory factor; MIG; PCR; primer; ss; human; RT-PCR; EphB4.
 XX OS Homo sapiens.
 XX PN WO2003097854-A2.
 XX PD 27-NOV-2003.
 XX XX 19-MAY-2003; 2003WO-US015711.
 XX XX 17-MAY-2002; 2002US-0380872P.
 XX PR 24-FEB-2003; 2003US-0448874P.
 XX PR 24-FEB-2003; 2003US-0448922P.
 XX XX (SUGE-) SUGEN INC.
 XX PI Morimoto A, Deprimo S, O'farrell A, Smolich BD, Manning WC;

PI Walter SA, Schilling JW, Cherrington J;
 XX WPI; 2004-042604/04.
 XX
 XX
 PT Determining whether a test compound inhibits tyrosine kinase activity in
 PT a mammal by exposing the mammal to the test compound and measuring in the
 PT mammal the level of at least one of the measured proteins or mRNA
 PT transcripts.
 XX
 XX Example K; SEQ ID NO 40; 408pp; English.
 XX
 XX The invention relates to a novel method for determining whether a test
 CC compound inhibits tyrosine kinase activity in a mammal comprising
 CC measuring in the mammal the level of at least one of the proteins and/or
 CC mRNA transcripts or genes for such proteins comprising type 1 plasminogen
 CC activator inhibitor (PAI-1), TIMP-1 (tissue inhibitor of
 CC metalloproteinase 1), vinculin, vascular endothelial growth factor
 CC (VEGF), placental growth factor (PLGF), VEGF/PLGF heterodimers or
 CC migration inhibitory factor (MIG), exposing the mammal to the test
 CC compound and then measuring in the mammal the level of at least one of
 CC the proteins and/or mRNA transcripts previously measured. The method of
 CC the invention may be useful for determining whether a test compound
 CC inhibits tyrosine kinase activity in a mammal. The current sequence is
 CC that of the PCR primer which was used in the exemplification of the
 CC invention.
 XX
 XX Sequence 26 BP; 4 A; 7 C; 4 G; 11 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 24;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 3920 TCTACGCTCTTGTGTCATACCTTTGTG 3945
 Db 1 TCTACGCTCTTGTGTCATACCTTTGTG 26
 RESULT 9
 ADR86707
 ID ADR86707 standard; DNA; 29 BP.
 AC ADR86707;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 XX Human ephrin B4 PCR primer seqid 12.
 DE
 XX
 XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2004080425-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007755.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 PI WPI; 2004-668893/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 XX Example I; Page 44; 198pp; English.
 XX
 XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a primer used in the isolation of human ephrin B4 cDNA used in
 CC the creation of an expression vector for producing a soluble Eph B4
 CC derivative.
 XX
 XX Sequence 29 BP; 3 A; 9 C; 11 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 24.2; DB 1; Length 29;
 Best Local Similarity 89.7%; Pred. No. 52;
 Matches 26; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 367 GGCGCGCCATCGAGCTCGGCTGCTGCT 395
 Db 1 GGATCGCCATCGAGCTCGGCTGCTGCT 29
 RESULT 10
 ADR82276
 ID ADR82276 standard; DNA; 29 BP.
 XX
 XX ADR82276;
 AC
 XX 16-DEC-2004 (first entry)
 DT
 XX Human EphB4 PCR primer #1.
 DE
 XX human; ss; PCR; primer; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor.
 XX
 OS Homo sapiens.
 XX
 XX WO2004080418-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007491.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Reddy R, Gill P;
 PI WPI; 2004-668879/65.
 XX
 XX

CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

XX Sequence 21 BP; 2 A; 10 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 77; Mismatches 0; Indels 0; Gaps 0;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 784 AAGGTGGACACGGTGGCGCG 804

|||||

Db 21 AAGGTGGACACGGTGGCGCG 1

RESULT 13

ADR86956

ID ADR86956 standard; DNA; 21 BP.

XX ADR86956;

AC ADR86956;

XX ADR86956;

DT 16-DEC-2004 (first entry)

XX Human ephrinB4 short interference RNA seqid 261.

XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; short interference RNA; siRNA;

KW RNA interference; gene silencing; ss.

XX Homo sapiens.

OS Homo sapiens.

XX WO2004080425-A2.

PN WO2004080425-A2.

XX 23-SEP-2004.

PD 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

PA (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

DR WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or

PT scleroderma.

XX Example 8; Page 95; 198pp; English.

PS Example 8; Page 95; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.

XX Sequence 21 BP; 8 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 77;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2196 AAAAGAGATCGATGCTCCTA 2216

|||||

Db 1 AAAAGAGATCGATGCTCCTA 21

RESULT 14

ADR86972

ID ADR86972 standard; DNA; 21 BP.

XX ADR86972;

AC ADR86972;

XX 16-DEC-2004 (first entry)

DT 16-DEC-2004 (first entry)

XX Human ephrinB4 short interference RNA seqid 277.

DE cytotatic; antiinflammatory; antirheumatic; antipsoriatic;

XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; short interference RNA; siRNA;

KW RNA interference; gene silencing; ss.

XX Homo sapiens.

OS Homo sapiens.

XX WO2004080425-A2.

PN WO2004080425-A2.

XX 23-SEP-2004.

PD 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

PA (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

DR WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or

PT scleroderma.

XX Example 8; Page 95; 198pp; English.

PS Example 8; Page 95; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.

XX SQ Sequence 21 BP; 3 A; 4 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2639 AAGTGTCTGACTTGGCCTTT 2659

DB 1 AAGTGTCTGACTTGGCCTTT 21

RESULT 15

ADR86981

ID ADR86981 standard; DNA; 21 BP.

AC ADR86981;

DT 16-DEC-2004 (first entry)

DE Human ephrinB4 short interference RNA seqid 286.

KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.

XX OS Homo sapiens.

XX PN WO2004080425-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US007755.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-045432P.

XX PA (VASG-) VASGENE THERAPEUTICS INC.

XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX DR WPI; 2004-668883/65.

XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX PS Example 8; Page 95; 198pp; English.

XX CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.

XX SQ Sequence 21 BP; 8 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 77;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2866 AATGCCATTGACGAGCTAC 2886

DB 1 AATGCCATTGACGAGCTAC 21

RESULT 16

ADR86772/c

ID ADR86772 standard; DNA; 21 BP.

AC ADR86772;

DT 16-DEC-2004 (first entry)

DE Human ephrinB4 short interference RNA seqid 77.

KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.

XX OS Homo sapiens.

XX PN WO2004080425-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US007755.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-045432P.

XX PA (VASG-) VASGENE THERAPEUTICS INC.

XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX DR WPI; 2004-668883/65.

XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX PS Example 6; Page 89; 198pp; English.

CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.

SQ Sequence 21 BP; 2 A; 4 C; 6 G; 0 T; 9 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 425 AAGAGACCCCTGCTGACACAA 445
|||||
DB 21 AAGAGACCCCTGCTGACACAA 1

RESULT 17
ADR86950
ID ADR86950 standard; DNA; 21 BP.
XX
AC ADR86950;
XX
XX 16-DEC-2004 (first entry)
XX Human ephrinB4 short interference RNA seqid 255.
XX
XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
XX RNA interference; gene silencing; ss.
OS Homo sapiens.
XX WO2004080425-A2.
PN
PD 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US0007755.
PF
XX
XX 12-MAR-2003; 2003US-0454300P.
PR
XX 12-MAR-2003; 2003US-0454432P.
PR
XX (VASG-) VASGENE THERAPEUTICS INC.
PA
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.

XX
PS
XX Example 8; Page 95; 198pp; English.
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.

SQ Sequence 21 BP; 10 A; 2 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2068 AAGCAGACCAATGGGAGAGAA 2088
|||||
DB 1 AAGCAGACCAATGGGAGAGAA 21

RESULT 18
ADR86963
ID ADR86963 standard; DNA; 21 BP.
XX
AC ADR86963;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrinB4 short interference RNA seqid 268.
DE
XX
XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
XX RNA interference; gene silencing; ss.
XX Homo sapiens.
XX
XX WO2004080425-A2.
PN
PD 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US0007755.
PF
XX
XX 12-MAR-2003; 2003US-0454300P.
PR
XX 12-MAR-2003; 2003US-0454432P.
PR
XX (VASG-) VASGENE THERAPEUTICS INC.
PA
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
PS Example 8; Page 95; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
XX expression.
SQ Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 2428 AACGATGCGCCGTCATGATT 2448
DB 1 AACGATGCGCCGTCATGATT 21
RESULT 19
ADR86971
ID ADR86971 standard; DNA; 21 BP.
XX ADR86971;
AC ADR86971;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interference RNA seqid 276.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
XX RNA interference; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Kraenoperv V, Zozulya S, Keretes N, Reddy R, Gill P;
XX

DR WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX Example 8; Page 95; 198pp; English.
PS
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
XX expression.
SQ Sequence 21 BP; 5 A; 10 C; 1 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 2677 AACTCTTCGATCCACCTAC 2697
DB 1 AACTCTTCGATCCACCTAC 21
RESULT 20
ADR86979
ID ADR86979 standard; DNA; 21 BP.
XX ADR86979;
AC ADR86979;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interference RNA seqid 284.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
XX RNA interference; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
PI WPI; 2004-668983/65.
XX
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 95; 198pp; English.
PS
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumor; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 9 A; 3 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3141 AAGATACGAGAAAGTTTCGC 3161
|||||
DB 1 AAGATACGAGAAAGTTTCGC 21

RESULT 21
ADR86726/c
ID ADR86726 standard; DNA; 21 BP.
XX
AC ADR86726;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 31.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US0007755.
XX
XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VAGS-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668983/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 3; Page 62; 198pp; English.
PS
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumor; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 928 ATGGCCCTGCTATCCCTGCAC 948
|||||
DB 21 ATGGCCCTGCTATCCCTGCAC 1

RESULT 22
ADR86936
ID ADR86936 standard; DNA; 21 BP.
XX
AC ADR86936;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interference RNA seqid 241.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.

PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
DR
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumor; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 7 A; 3 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 446 AATTGGAAACTGCTGATCTGA 466
Db 1 AATTGGAAACTGCTGATCTGA 21
RESULT 23
ADR86938
ID ADR86938 standard; DNA; 21 BP.
XX
AC ADR86938;
XX
XX 16-DEC-2004 (first entry)
DT
DE Human ephrinB4 short interference RNA seqid 243.
XX
KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
XX RNA interference; gene silencing; ss.
OS Homo sapiens.
XX
PN WO2004080425-A2.

XX 23-SEP-2004.
PD
XX 12-MAR-2004; 2004WO-US007755.
PF
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
PI WPI; 2004-668883/65.
DR
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumor; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 5 A; 3 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 453 AACTGCTGATCTGAAGTGGGT 473
Db 1 AACTGCTGATCTGAAGTGGGT 21
RESULT 24
ADR86957
ID ADR86957 standard; DNA; 21 BP.
XX
AC ADR86957;
XX
XX 16-DEC-2004 (first entry)
DT
DE Human ephrinB4 short interference RNA seqid 262.
XX
KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
XX RNA interference; gene silencing; ss.
OS
XX

OS Homo sapiens.
 XX WO2004080425-A2.
 PN
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 PI WPI; 2004-668883/65.
 DR
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 95; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.
 XX
 SQ Sequence 21 BP; 6 A; 1 C; 8 G; 6 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2173 AATGAGGCTGTGAGGGAATTT 2193
 |||||
 Db 1 AATGAGGCTGTGAGGGAATTT 21
 |||||
 RESULT 25
 ADR86965
 ID ADR86965 standard; DNA; 21 BP.
 XX
 AC ADR86965;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 XX Human ephrinB4 short interference RNA seqid 270.
 DE
 XX cytostatic; antinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 PI WPI; 2004-668883/65.
 DR
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 95; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.
 XX
 SQ Sequence 21 BP; 6 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2293 AAGGAGGCTGTGTGCAATC 2313
 |||||
 Db 1 AAGGAGGCTGTGTGCAATC 21
 |||||
 RESULT 26
 ADR86967
 ID ADR86967 standard; DNA; 21 BP.
 XX
 AC ADR86967;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 XX Human ephrinB4 short interference RNA seqid 272.
 DE
 XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
XX Homo sapiens.
XX WO2004080425-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007755.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX Example 8; Page 95; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumour; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX antibody is useful for manufacturing a medicament for the treatment of
XX cancer or an angiogenesis-associated disease. The composition and methods
XX are useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases, such as inflammatory disorders, chronic articular rheumatism,
XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX represents a human ephrin B4 siRNA that can be used to control EphB4
XX expression.
XX Sequence 21 BP; 8 A; 5 C; 5 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2496 AAACGACGACAGTTCACAGT 2516
DB 1 AAACGACGACAGTTCACAGT 21
RESULT 27
ID ADR86983
XX ADR86983 standard; DNA; 21 BP.
XX ADR86983;
XX 16-DEC-2004 (first entry)
XX Human ephrinB4 short interference RNA seqid 288.
DE

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
XX Homo sapiens.
XX WO2004080425-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007755.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX Example 8; Page 95; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumour; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX antibody is useful for manufacturing a medicament for the treatment of
XX cancer or an angiogenesis-associated disease. The composition and methods
XX are useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases, such as inflammatory disorders, chronic articular rheumatism,
XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX represents a human ephrin B4 siRNA that can be used to control EphB4
XX expression.
XX Sequence 21 BP; 6 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3253 AAAATCTTGCCAGTGTCCAG 3273
DB 1 AAAATCTTGCCAGTGTCCAG 21
RESULT 28
ID ADR86941
XX ADR86941 standard; DNA; 21 BP.
XX ADR86941;
XX

DT 16-DEC-2004 (first entry)
 XX Human ephrinB4 short interference RNA seqid 246.
 DE
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2004080425-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 XX 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 XX
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 XX associated diseases, such as inflammatory disorders, psoriasis or
 XX scleroderma.
 XX
 XX Example 8; Page 94; 198pp; English.
 XX
 XX The invention describes an isolated soluble polypeptide comprising an
 XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 XX described are: an antagonist antibody that binds to an extracellular
 XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 XX diagnostic kit, comprising the above soluble polypeptide or antagonist
 XX antibody, and a method of reducing the growth rate of a tumour; methods for
 XX treating a patient suffering from a cancer or an angiogenesis-associated
 XX disease; and a method for identifying a tumor that is suitable for
 XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 XX antibody is useful for manufacturing a medicament for the treatment of
 XX cancer or an angiogenesis-associated disease. The composition and methods
 XX are useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases, such as inflammatory disorders, chronic articular rheumatism,
 XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 XX represents a human ephrin B4 siRNA that can be used to control EphB4
 XX expression.
 XX
 XX Sequence 21 BP; 7 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
 XX
 XX Query Match 0.5%; Score 21; DB 1; Length 21;
 XX Best Local Similarity 100.0%; Pred. No. 77;
 XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 847 AAGGTGAATGTCAGAGCGTG 867
 DB 1 AAGGTGAATGTCAGAGCGTG 21
 DB
 RESULT 29
 ADR86953
 ID ADR86953 standard; DNA; 21 BP.

XX ADR86953;
 XX 16-DEC-2004 (first entry)
 DT
 XX Human ephrinB4 short interference RNA seqid 258.
 DE
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2004080425-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 XX 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VAG-) VASGENE THERAPEUTICS INC.
 XX
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 XX associated diseases, such as inflammatory disorders, psoriasis or
 XX scleroderma.
 XX
 XX Example 8; Page 95; 198pp; English.
 XX
 XX The invention describes an isolated soluble polypeptide comprising an
 XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 XX described are: an antagonist antibody that binds to an extracellular
 XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 XX diagnostic kit, comprising the above soluble polypeptide or antagonist
 XX antibody, and a pharmaceutical carrier; methods of inhibiting
 XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 XX cell; a method of reducing the growth rate of a tumour; methods for
 XX treating a patient suffering from a cancer or an angiogenesis-associated
 XX disease; and a method for identifying a tumor that is suitable for
 XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 XX antibody is useful for manufacturing a medicament for the treatment of
 XX cancer or an angiogenesis-associated disease. The composition and methods
 XX are useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases, such as inflammatory disorders, chronic articular rheumatism,
 XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 XX represents a human ephrin B4 siRNA that can be used to control EphB4
 XX expression.
 XX
 XX Sequence 21 BP; 9 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
 XX
 XX Query Match 0.5%; Score 21; DB 1; Length 21;
 XX Best Local Similarity 100.0%; Pred. No. 77;
 XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 2093 AATATTCGACAAACACGGAC 2113
 DB 1 AATATTCGACAAACACGGAC 21
 DB

RESULT 30
 ADR86966
 ID ADR86966 standard; DNA; 21 BP.
 AC ADR86966;
 DT 16-DEC-2004 (first entry)
 DE Human ephrinB4 short interference RNA seqid 271.
 DE
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 OS Homo sapiens.
 OS
 PN WO2004080425-A2.
 PN
 PD 23-SEP-2004.
 PD
 PF 12-MAR-2004; 2004WO-US007755.
 PF
 PR 12-MAR-2003; 2003US-0454300P.
 PR
 PR 12-MAR-2003; 2003US-0454432P.
 PR
 PA (VASG-) VASGENE THERAPEUTICS INC.
 PA
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 PI
 XX WPI; 2004-668883/65.
 XX
 DR New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 95; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a method for reducing the growth rate of a tumour, for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.
 XX
 SQ Sequence 21 BP; 7 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 |||||||||||||||||||

Db 1 AATCAAGACCTGAAGGTGG 21
 RESULT 31
 ADR86969
 ID ADR86969 standard; DNA; 21 BP.
 AC ADR86969;
 DT 16-DEC-2004 (first entry)
 DE Human ephrinB4 short interference RNA seqid 274.
 DE
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 OS Homo sapiens.
 OS
 PN WO2004080425-A2.
 PN
 PD 23-SEP-2004.
 PD
 PF 12-MAR-2004; 2004WO-US007755.
 PF
 PR 12-MAR-2003; 2003US-0454300P.
 PR
 PR 12-MAR-2003; 2003US-0454432P.
 PR
 PA (VASG-) VASGENE THERAPEUTICS INC.
 PA
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 PI
 XX WPI; 2004-668883/65.
 XX
 DR New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 95; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a method for reducing the growth rate of a tumour, for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.
 XX
 SQ Sequence 21 BP; 9 A; 7 C; 2 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	2608 AACATCCTAGTCAACAGCAAC 2628	Query Match	0.5%; Score 21; DB 1; Length 21;
		Best Local Similarity	100.0%; Pred.No. 77;
Db	1 AACATCCTAGTCAACAGCAAC 21	Matches	21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
RESULT 32			
ID	ADR86980 standard; DNA; 21 BP.		
XX	ADR86980;		
XX	16-DEC-2004 (first entry)		
DE	Human ephrinB4 short interference RNA seqid 285.		
XX			
KW	cytostatic; antiinflammatory; antirheumatic; antipsoriatic;		
KW	dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;		
KW	pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;		
KW	angiogenesis-associated disease; inflammatory disorder;		
KW	chronic articular rheumatism; psoriasis; ocular angiogenic disease;		
KW	scleroderma; human; ephrin B4; short interference RNA; siRNA;		
XX	RNA interference; gene silencing; ss.		
OS	Homo sapiens.		
XX			
PN	WO2004080425-A2.		
XX			
PD	23-SEP-2004.		
XX			
XX	12-MAR-2004; 2004WO-US007755.		
XX			
PR	12-MAR-2003; 2003US-0454300P.		
PR	12-MAR-2003; 2003US-0454432P.		
XX			
PA	(VASG-) VASGENE THERAPEUTICS INC.		
PI	Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;		
DR	WPI; 2004-668883/65.		
XX			
PT	New soluble polypeptides comprising an extracellular domain of EphB4 or		
PT	Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-		
PT	associated diseases, such as inflammatory disorders, psoriasis or		
PT	scleroderma.		
PS	Example 8; Page 95; 198pp; English.		
XX			
CC	The invention describes an isolated soluble polypeptide comprising an		
CC	amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2		
CC	protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4		
CC	polypeptide binds specifically to the Ephrin B2 polypeptide, and the		
CC	Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also		
CC	described are: an antagonist antibody that binds to an extracellular		
CC	domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the		
CC	EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a		
CC	diagnostic kit, comprising the above soluble polypeptide or antagonist		
CC	antibody, and a pharmaceutical carrier; methods of inhibiting		
CC	angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a		
CC	cell; a method of reducing the growth rate of a tumour; methods for		
CC	treating a patient suffering from a cancer or an angiogenesis-associated		
CC	disease; and a method for identifying a tumor that is suitable for		
CC	treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or		
CC	antibody is useful for manufacturing a medicament for the treatment of		
CC	cancer or an angiogenesis-associated disease. The composition and methods		
CC	are useful for diagnosing or treating cancer or angiogenesis-associated		
CC	diseases, such as inflammatory disorders, chronic articular rheumatism,		
CC	psoriasis, ocular angiogenic diseases or scleroderma. This sequence		
CC	represents a human ephrin B4 siRNA that can be used to control EphB4		
CC	expression.		
XX			
SQ	Sequence 21 BP; 11 A; 1 C; 7 G; 2 T; 0 U; 0 Other;		

XX SQ Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1381 GGCTCCTCCCTGCACCTGGAA 1401
 Db 21 GGCTCCTCCCTGCACCTGGAA 1

RESULT 34
 ADR86924/C
 ID ADR86924 standard; DNA; 21 BP.
 AC ADR86924;
 XX
 DT 16-DEC-2004 (first entry)
 DE Human ephrin B4 antisense oligonucleotide seqid 229.
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX WO2004080425-A2.
 PN
 XX
 FD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 94; 198pp; English.
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX SQ Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 928 ATGGCCCTGCTATCCTGCAC 948
 Db 21 ATGGCCCTGCTATCCTGCAC 1

RESULT 35
 ADR86927/C
 ID ADR86927 standard; DNA; 21 BP.
 AC ADR86927;
 XX
 DT 16-DEC-2004 (first entry)
 DE Human ephrin B4 antisense oligonucleotide seqid 232.
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX WO2004080425-A2.
 PN
 XX
 FD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 94; 198pp; English.
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

SQ Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1641 TGAGCCTGTCAATGTCACAC 1661
Db 21 TGAGCCTGTCAATGTCACAC 1

RESULT 36

ADR86944

ID ADR86944 standard; DNA; 21 BP.

XX AC ADR86944;

XX DT 16-DEC-2004 (first entry)

XX DE Human ephrinB4 short interference RNA seqid 249.

XX KW cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.

XX OS Homo sapiens.

XX PN WO2004080425-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US007755.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-0454432P.

XX PA (VASG-) VASGENE THERAPEUTICS INC.

XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX DR WPI; 2004-668883/65.

XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX PS Example 8; Page 95; 198pp; English.

XX CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated

CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.

SQ Sequence 21 BP; 8 A; 7 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1246 AATAGCCACTCTTAACACCATT 1266

Db 1 AATAGCCACTCTTAACACCATT 21

RESULT 37

ADR86945

ID ADR86945 standard; DNA; 21 BP.

XX AC ADR86945;

XX DT 16-DEC-2004 (first entry)

XX DE Human ephrinB4 short interference RNA seqid 250.

XX KW cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.

XX OS Homo sapiens.

XX PN WO2004080425-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US007755.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-0454432P.

XX PA (VASG-) VASGENE THERAPEUTICS INC.

XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX DR WPI; 2004-668883/65.

XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX PS Example 8; Page 95; 198pp; English.

XX CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.
 XX
 SQ Sequence 21 BP; 6 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1258 AACACATTGGATCAGCGGTC 1278
 |||||
 Db 1 AACACATTGGATCAGCGGTC 21

RESULT 38
 ADR86954
 ID ADR86954 standard; DNA; 21 BP.
 AC ADR86954;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrinB4 short interference RNA seqid 259.
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.

OS Homo sapiens.
 XX WO2004080425-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 XX 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 XX
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 XX associated diseases, such as inflammatory disorders, psoriasis or
 XX scleroderma.
 XX
 XX Example 8; Page 95; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 XX described are: an antagonist antibody that binds to an extracellular
 XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.
 XX
 SQ Sequence 21 BP; 8 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2104 AAACACGACAGTATCTCATC 2124
 |||||
 Db 1 AAACACGACAGTATCTCATC 21

RESULT 39
 ADR86961
 ID ADR86961 standard; DNA; 21 BP.
 AC ADR86961;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrinB4 short interference RNA seqid 266.
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.

OS Homo sapiens.
 XX WO2004080425-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 XX 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 XX
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 XX associated diseases, such as inflammatory disorders, psoriasis or
 XX scleroderma.
 XX
 XX Example 8; Page 95; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 XX described are: an antagonist antibody that binds to an extracellular
 XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumor; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.

XX
SQ Sequence 21 BP; 5 A; 1 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2228 AAGAGGTGATTGGTCAGGTG 2248
|||||
Db 1 AAGAGGTGATTGGTCAGGTG 21

RESULT 40
ADR86948
ID ADR86948 standard; DNA; 21 BP.

AC ADR86948;

DT 16-DEC-2004 (first entry)

DE Human ephrinB4 short interference RNA seqid 253.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.

OS Homo sapiens.

XX WO2004080425-A2.

PN 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.

XX Example 8; Page 95; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumor; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.

XX
SQ Sequence 21 BP; 9 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1831 AAGACGTCAGAAACCGGCA 1851
|||||
Db 1 AAGACGTCAGAAACCGGCA 21

RESULT 41
ADR86968

ID ADR86968 standard; DNA; 21 BP.

AC ADR86968;

DT 16-DEC-2004 (first entry)

DE Human ephrinB4 short interference RNA seqid 273.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.

OS Homo sapiens.

XX WO2004080425-A2.

PN 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.

PS Example 8; Page 95; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumour; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated

CC disease; and a method for identifying a tumor that is suitable for

CC antibody with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence

CC represents a human ephrin B4 siRNA that can be used to control EphB4

CC expression.

XX Sequence 21 BP; 7 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

SQ Query Match 0.5%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 77;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2497 AACGACGACAGTTCACAGTC 2517

|||||

DB 1 AACGACGACAGTTCACAGTC 21

RESULT 42

ADR86987

ID ADR86987 standard; DNA; 21 BP.

XX ADR86987;

XX 16-DEC-2004 (first entry)

XX Human ephrinB4 short interference RNA seqid 292.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; short interference RNA; siRNA;

KW RNA interference; gene silencing; ss.

OS Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or

PT scleroderma.

PS Example 8; Page 96; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumour; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated

CC disease; and a method for identifying a tumor that is suitable for

CC antibody with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence

CC represents a human ephrin B4 siRNA that can be used to control EphB4

CC expression.

XX Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

SQ Query Match 0.5%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 77;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 3255 AATCTTGGCCAGTGTCCAGCA 3275

|||||

DB 1 AATCTTGGCCAGTGTCCAGCA 21

RESULT 43

ADR86775/c

ID ADR86775 standard; DNA; 21 BP.

XX ADR86775;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 80.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; antisense technology;

KW antisense oligonucleotide; ss.

OS Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 91; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumor; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 21 BP; 2 A; 7 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3319 GGACCGCGCCCGCAGTACTGA 3339
Db 21 GGACCGCGCCCGCAGTACTGA 1
|||||
RESULT 44
ADR86928/c
ID ADR86928 standard; DNA; 21 BP.
AC ADR86928;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 233.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
DR
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumor; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 21 BP; 1 A; 5 C; 7 G; 8 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1931 GCCAGGAACATCAGCCGAGA 1951
Db 21 GCCAGGAACATCAGCCGAGA 1
|||||
RESULT 45
ADR86940
ID ADR86940 standard; DNA; 21 BP.
AC ADR86940;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interference RNA seqid 245.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX

```
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX DR WPI; 2004-668883/65.
XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
XX PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX PT associated diseases, such as inflammatory disorders, psoriasis or
XX PT scleroderma.
XX PS Example 8; Page 94; 199pp; English.
XX CC The invention describes an isolated soluble polypeptide comprising an
XX CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX CC described are: an antagonist antibody that binds to an extracellular
XX CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX CC diagnostic kit, comprising the above soluble polypeptide or antagonist
XX CC antibody, and a pharmaceutical carrier; methods of inhibiting
XX CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX CC cell; a method of reducing the growth rate of a tumor; methods for
XX CC treating a patient suffering from a cancer or an angiogenesis-associated
XX CC disease; and a method for identifying a tumor that is suitable for
XX CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX CC antibody is useful for manufacturing a medicament for the treatment of
XX CC cancer or an angiogenesis-associated disease. The composition and methods
XX CC are useful for diagnosing or treating cancer or angiogenesis-associated
XX CC diseases, such as inflammatory disorders, chronic articular rheumatism,
XX CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX CC represents a human ephrin B4 siRNA that can be used to control EphB4
XX CC expression.
XX SQ Sequence 21 BP; 5 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 466 AAGTGGGTGACATTCCTCAG 486
Db |||||
1 AAGTGGGTGACATTCCTCAG 21
RESULT 46
ADR86973
ID ADR86973 standard; DNA; 21 BP.
XX AC ADR86973;
XX DT 16-DEC-2004 (first entry)
XX DE Human ephrinB4 short interference RNA seqid 278.
XX KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
XX KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
XX KW angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
XX KW RNA interference; gene silencing; ss.
XX OS Homo sapiens.
XX PN WO2004080425-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007755.
```

```
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX DR WPI; 2004-668883/65.
XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
XX PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX PT associated diseases, such as inflammatory disorders, psoriasis or
XX PT scleroderma.
XX PS Example 8; Page 95; 198pp; English.
XX CC The invention describes an isolated soluble polypeptide comprising an
XX CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX CC described are: an antagonist antibody that binds to an extracellular
XX CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX CC diagnostic kit, comprising the above soluble polypeptide or antagonist
XX CC antibody, and a pharmaceutical carrier; methods of inhibiting
XX CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX CC cell; a method of reducing the growth rate of a tumor; methods for
XX CC treating a patient suffering from a cancer or an angiogenesis-associated
XX CC disease; and a method for identifying a tumor that is suitable for
XX CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX CC antibody is useful for manufacturing a medicament for the treatment of
XX CC cancer or an angiogenesis-associated disease. The composition and methods
XX CC are useful for diagnosing or treating cancer or angiogenesis-associated
XX CC diseases, such as inflammatory disorders, chronic articular rheumatism,
XX CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX CC represents a human ephrin B4 siRNA that can be used to control EphB4
XX CC expression.
XX SQ Sequence 21 BP; 5 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2626 AACCTGCTGCAAGTGCT 2646
Db |||||
1 AACCTGCTGCAAGTGCT 21
RESULT 47
ADR86975
ID ADR86975 standard; DNA; 21 BP.
XX AC ADR86975;
XX DT 16-DEC-2004 (first entry)
XX DE Human ephrinB4 short interference RNA seqid 280.
XX KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
XX KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
XX KW angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
XX KW RNA interference; gene silencing; ss.
XX OS Homo sapiens.
XX PN WO2004080425-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007755.
```

PD 23-SEP-2004.
XX
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VAGS-) VASGENE THERAPEUTICS INC.
XX
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 95; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
XX expression.
XX
SQ Sequence 21 BP; 7 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2851 AATCAGGACGTCATCAATGCC 2871
Db |||||
1 AATCAGGACGTCATCAATGCC 21
RESULT 48
ADR86952
ID ADR86952 standard; DNA; 21 BP.
XX
AC ADR86952;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrinB4 short interference RNA seqid 257.
XX
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
OS Homo sapiens.

XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VAGS-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 95; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
XX expression.
XX
SQ Sequence 21 BP; 10 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2087 AAGCAGAATATTCGACAAAC 2107
Db |||||
1 AAGCAGAATATTCGACAAAC 21
RESULT 49
ADR86955
ID ADR86955 standard; DNA; 21 BP.
XX
AC ADR86955;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrinB4 short interference RNA seqid 260.
XX
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
XX

KW RNA interference; gene silencing; ss.
XX Homo sapiens.
XX WO2004080425-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007755.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX Example 8; Page 95; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumor; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX antibody is useful for manufacturing a medicament for the treatment of
XX cancer or an angiogenesis-associated disease. The composition and methods
XX are useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases, such as inflammatory disorders, chronic articular rheumatism,
XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX represents a human ephrin B4 siRNA that can be used to control EphB4
XX expression.
XX Sequence 21 BP; 7 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2105 AACACGGACATCTCTACG 2125
Db |||||||||||||||||||
1 AACACGGACATCTCTACG 21
RESULT 50
ADR86960
ID ADR86960 standard; DNA; 21 BP.
XX ADR86960;
XX 16-DEC-2004 (first entry)
XX Human ephrinB4 short interference RNA seqid 265.
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
XX pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
XX RNA interference; gene silencing; ss.
XX Homo sapiens.
XX WO2004080425-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007755.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX Example 8; Page 95; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumor; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX antibody is useful for manufacturing a medicament for the treatment of
XX cancer or an angiogenesis-associated disease. The composition and methods
XX are useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases, such as inflammatory disorders, chronic articular rheumatism,
XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX represents a human ephrin B4 siRNA that can be used to control EphB4
XX expression.
XX Sequence 21 BP; 6 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2198 AAGAGATCGATGTCTCTACG 2218
Db |||||||||||||||||||
1 AAGAGATCGATGTCTCTACG 21
RESULT 51
ADR86962
ID ADR86962 standard; DNA; 21 BP.
XX ADR86962;
XX 16-DEC-2004 (first entry)
XX Human ephrinB4 short interference RNA seqid 267.

KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 XX Homo sapiens.
 OS
 XX WO2004080425-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 PF 12-MAR-2003; 2003US-0454300P.
 XX
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 PI WPI; 2004-668883/65.
 DR
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 XX Example 8; Page 95; 198pp; English.
 PS
 XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.
 XX
 SQ Sequence 21 BP; 7 A; 0 C; 8 G; 6 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2221 AAGATTGAAGGGTGATTGTT 2241
 ||||||||||||||||||||
 Db 1 AAGATTGAAGGGTGATTGTT 21
 RESULT 52
 ADR86976
 ID ADR86976 standard; DNA; 21 BP.
 XX
 AC ADR86976;
 XX
 XX 16-DEC-2004 (first entry)
 DT

XX Human ephrinB4 short interference RNA seqid 281.
 DE
 XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 XX Homo sapiens.
 OS
 XX WO2004080425-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 PF 12-MAR-2003; 2003US-0454300P.
 XX
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 PI WPI; 2004-668883/65.
 DR
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 XX Example 8; Page 95; 198pp; English.
 PS
 XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.
 XX
 SQ Sequence 21 BP; 7 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2715 AAAGATTCCCATCCGATGCAC 2735
 ||||||||||||||||||||
 Db 1 AAAGATTCCCATCCGATGCAC 21
 RESULT 53
 ADR86748/C
 ID ADR86748 standard; DNA; 21 BP.
 XX

AC ADR86748;
 XX 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 53.
 XX
 KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR
 PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 5; Page 79; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 21 BP; 1 A; 5 C; 7 G; 8 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1931 GCCAGGACATCAGCCAGCA 1951
 DB 21 GCCAGGACATCAGCCAGCA 1
 RESULT 54

ADR86931/c
 ID ADR86931 standard; DNA; 21 BP.
 XX
 AC ADR86931;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 DE Human ephrin B4 antisense oligonucleotide seqid 236.
 XX
 KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR
 PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 94; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 21 BP; 2 A; 10 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 784 AAGGTGGACACGGTGGCCGCG 804
 DB 21 AAGGTGGACACGGTGGCCGCG 1

RESULT 55	445	AAATTGGAACCTGCTGATCTG	465
ADR86935	1	AAATTGGAACCTGCTGATCTG	21
ID	ADR86935	standard; DNA; 21 BP.	
AC	ADR86935;		
XX			
DT	16-DEC-2004	(first entry)	
XX			
DE	Human ephrinB4 short interference RNA seqid 240.		
XX			
KW	cytostatic; antiinflammatory; antirheumatic; antipsoriatic;		
KW	dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;		
KW	pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;		
KW	angiogenesis-associated disease; inflammatory disorder;		
KW	chronic articular rheumatism; psoriasis; ocular angiogenic disease;		
KW	scleroderma; human; ephrin B4; short interference RNA; siRNA;		
KW	RNA interference; gene silencing; ss.		
OS	Homo sapiens.		
XX			
PN	WO2004080425-A2.		
XX			
PD	23-SEP-2004.		
XX			
PF	12-MAR-2004; 2004WO-US007755.		
XX			
PR	12-MAR-2003; 2003US-0454300P.		
PR	12-MAR-2003; 2003US-0454432P.		
XX			
PA	(VASC-) VASGENE THERAPEUTICS INC.		
XX			
PI	Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;		
XX			
DR	WPI; 2004-668883/65.		
XX			
PT	New soluble polypeptides comprising an extracellular domain of EphB4 or		
PT	Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-		
PT	associated diseases, such as inflammatory disorders, psoriasis or		
PT	scleroderma.		
XX			
PS	Example 8; Page 94; 198pp; English.		
XX			
CC	The invention describes an isolated soluble polypeptide comprising an		
CC	amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2		
CC	protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4		
CC	polypeptide binds specifically to the Ephrin B2 polypeptide, and the		
CC	Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also		
CC	described are: an antagonist antibody that binds to an extracellular		
CC	domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the		
CC	EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a		
CC	diagnostic kit, comprising the above soluble polypeptide or antagonist		
CC	antibody, and a pharmaceutical carrier; methods of inhibiting		
CC	angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a		
CC	cell; a method of reducing the growth rate of a tumour; methods for		
CC	treating a patient suffering from a cancer or an angiogenesis-associated		
CC	disease; and a method for identifying a tumor that is suitable for		
CC	treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or		
CC	antibody is useful for manufacturing a medicament for the treatment of		
CC	cancer or an angiogenesis-associated disease. The composition and methods		
CC	are useful for diagnosing or treating cancer or angiogenesis-associated		
CC	diseases, such as inflammatory disorders, chronic articular rheumatism,		
CC	psoriasis, ocular angiogenic diseases or scleroderma. This sequence		
CC	represents a human ephrin B4 siRNA that can be used to control EphB4		
CC	expression.		
XX			
SQ	Sequence 21 BP; 7 A; 3 C; 5 G; 6 T; 0 U; 0 Other;		
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0; Gaps
			0;
	Query Match	0.5%;	Score 21; DB 1; Length 21;
	Best Local Similarity	100.0%;	Pred. No. 77;
	Matches	21; Conservative	0; Mismatches
		0; Indels	0;

Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2716 AAGATTCCCATCCGATGACT 2736
|||||
DB 1 AAGATTCCCATCCGATGACT 21

RESULT 57
ADR86978
ID ADR86978 standard; DNA; 21 BP.
XX AC ADR86978;
XX DT 16-DEC-2004 (first entry)
XX DE Human ephrinB4 short interference RNA seqid 283.
XX KW cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX OS Homo sapiens.
XX PN WO2004080425-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007755.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX DR WPI; 2004-668883/65.
XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX PS Example 8; Page 95; 198pp; English.
XX CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.

SQ Sequence 21 BP; 5 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2761 AAGTTCACTTCCGCCAGTGAT 2781
|||||
DB 1 AAGTTCACTTCCGCCAGTGAT 21

RESULT 58
ADR86985
ID ADR86985 standard; DNA; 21 BP.
XX AC ADR86985;
XX DT 16-DEC-2004 (first entry)
XX DE Human ephrinB4 short interference RNA seqid 290.
XX KW cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX OS Homo sapiens.
XX PN WO2004080425-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007755.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX DR WPI; 2004-668883/65.
XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX PS Example 8; Page 96; 198pp; English.
XX CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.

CC represents a human ephrin B4 siRNA that can be used to control EphB4 expression.

XX Sequence 21 BP; 6 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

SQ Sequence 21 BP; 6 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 3149 AAGAAAGTTTCGACGCGCTG 3169
|||||
Db 1 AAGAAAGTTTCGACGCGCTG 21
|||||

RESULT 59
ADR86932/c
ID ADR86932 standard; DNA; 21 BP.
XX
AC ADR86932;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 237.
XX
KW cyostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
PR
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 94; 198pp; English.

CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
XX to control EphB4 expression.

SQ Sequence 21 BP; 3 A; 6 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2305 GTGGCAATCAAGACCTGAAG 2325
|||||
Db 21 GTGGCAATCAAGACCTGAAG 1
|||||

RESULT 60
ADR86943
ID ADR86943 standard; DNA; 21 BP.
XX
AC ADR86943;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interference RNA seqid 248.
XX
KW cyostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
XX Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
PR
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 95; 198pp; English.

CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.

XX Sequence 21 BP; 7 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 958 AAAAGTGGCCGCTGACT 978

Db 1 AAAAAGTGGCCGCTGACT 21

RESULT 61

ADR86958
 ID ADR86958 standard; DNA; 21 BP.

XX ADR86958;

XX 16-DEC-2004 (first entry)

XX Human ephrinB4 short interference RNA seqid 263.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 8; Page 95; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.

XX Sequence 21 BP; 7 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2165 AAGACCTTATGAGCTGTGA 2185

Db 1 AAGACCTTATGAGCTGTGA 21

RESULT 62

ADR86982
 ID ADR86982 standard; DNA; 21 BP.

XX ADR86982;

XX 16-DEC-2004 (first entry)

XX Human ephrinB4 short interference RNA seqid 287.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 8; Page 95; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

PT scleroderma.
XX
PS Example 5; Page 79; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 21 BP; 3 A; 6 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2305 GTGGCAATCAAGACCTTGAAG 2325
Db 21 GTGGCAATCAAGACCTTGAAG 1
RESULT 67
ADR86937
ID ADR86937 standard; DNA; 21 BP.
XX
AC ADR86937;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interference RNA seqid 242.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
OS Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX

PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 6 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 452 AAACGTCTGATCTGAAGTGGG 472
Db 1 AAACGTCTGATCTGAAGTGGG 21
RESULT 68
ADR86939
ID ADR86939 standard; DNA; 21 BP.
XX
AC ADR86939;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interference RNA seqid 244.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
OS Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX

XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 94; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
XX Sequence 21 BP; 5 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 853 AATGTCAGAGCGCTCGTCTG 873
|||||
DB 1 AATGTCAGAGCGCTCGTCTG 21

RESULT 69
ADR86959
ID ADR86959 standard; DNA; 21 BP.
XX
XX ADR86959;
AC
XX 16-DEC-2004 (first entry)
DT
XX Human ephrinB4 short interference RNA seqid 264.
DE
XX
XX cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
XX Homo sapiens.
OS
XX WO2004080425-A2.
FN
XX 23-SEP-2004.
PD
XX 12-MAR-2004; 2004WO-US007755.
PF
XX 12-MAR-2003; 2003US-0454300P.
PR
XX 12-MAR-2003; 2003US-0454432P.
PR

(VASG-) VASGENE THERAPEUTICS INC.
PA Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 95; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
XX Sequence 21 BP; 7 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2197 AAAGATCGATGTCCTCTAC 2217
|||||
DB 1 AAAGATCGATGTCCTCTAC 21

RESULT 70
ADR86964
ID ADR86964 standard; DNA; 21 BP.
XX
XX ADR86964;
AC
XX 16-DEC-2004 (first entry)
DT
XX Human ephrinB4 short interference RNA seqid 269.
DE
XX
XX cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
XX Homo sapiens.
OS
XX WO2004080425-A2.
FN
XX 23-SEP-2004.
PD
XX 12-MAR-2004; 2004WO-US007755.
PF

PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 PA (VAGS-) VASGENE THERAPEUTICS INC.
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX Example 8; Page 95; 198pp; English.
 XX
 XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.
 XX
 SQ Sequence 21 BP; 7 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 2290 AAGAAGGAGAGCTGTGTGGCA 2310
 Db 1 AAGAAGGAGAGCTGTGTGGCA 21
 RESULT 71
 ADR86737/c
 ID ADR86737 standard; RNA; 21 BP.
 XX
 AC ADR86737;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrinB4 short interference RNA seqid 42.
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO2004080425-A2.
 XX
 PD 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US0007755.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VAGS-) VASGENE THERAPEUTICS INC.
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX Example 5; Page 75; 198pp; English.
 XX
 XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.
 XX
 SQ Sequence 21 BP; 2 A; 4 C; 6 G; 0 T; 9 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 425 AAGAGACCCCTGCTGACACAA 445
 Db 21 AAGAGACCCCTGCTGACACAA 1
 RESULT 72
 ADR86741/c
 ID ADR86741 standard; RNA; 21 BP.
 XX
 AC ADR86741;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrinB4 short interference RNA seqid 46.
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 XX
 OS Homo sapiens.
 XX

PN WO2004080425-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007755.
PF 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
PA Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
PI WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX Example 5; Page 75; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumour; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX antibody is useful for manufacturing a medicament for the treatment of
XX cancer or an angiogenesis-associated disease. The composition and methods
XX are useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases, such as inflammatory disorders, chronic articular rheumatism,
XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX represents a human ephrin B4 siRNA that can be used to control EphB4
XX expression.
XX Sequence 21 BP; 1 A; 2 C; 9 G; 0 T; 9 U; 0 Other;
SQ Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1937 AACATCAGCAGCAGACCAAC 1957
Db 21 AACATCAGCAGCAGACCAAC 1
RESULT 73
ADR86942
ID ADR86942 standard; DNA; 21 BP.
XX ADR86942;
XX 16-DEC-2004 (first entry)
DT Human ephrinB4 short interference RNA seqid 247.
DE cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.

XX Homo sapiens.
OS WO2004080425-A2.
PN 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007755.
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
PA Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
PI WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX Example 8; Page 95; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumour; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX antibody is useful for manufacturing a medicament for the treatment of
XX cancer or an angiogenesis-associated disease. The composition and methods
XX are useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases, such as inflammatory disorders, chronic articular rheumatism,
XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX represents a human ephrin B4 siRNA that can be used to control EphB4
XX expression.
XX Sequence 21 BP; 5 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 697 AAGGAGACCTTCACCGCTTC 717
Db 1 AAGGAGACCTTCACCGCTTC 21
RESULT 74
ADR86754/c
ID ADR86754 standard; DNA; 21 BP.
XX ADR86754;
XX 16-DEC-2004 (first entry)
DT Human ephrin B4 antisense oligonucleotide seqid 59.
DE cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
XX antisense oligonucleotide; ss.

OS Homo sapiens.

PN WO2004080425-A2.

XX

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASC-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or

XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

XX associated diseases, such as inflammatory disorders, psoriasis or

XX scleroderma.

XX Example 5; Page 79; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the

XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

XX described are: an antagonist antibody that binds to an extracellular

XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

XX diagnostic kit, comprising the above soluble polypeptide or antagonist

XX antibody, and a pharmaceutical carrier; methods of inhibiting

XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

XX cell; a method of reducing the growth rate of a tumour; methods for

XX treating a patient suffering from a cancer or an angiogenesis-associated

XX disease; and a method for identifying a tumor that is suitable for

XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

XX antibody is useful for manufacturing a medicament for the treatment of

XX cancer or an angiogenesis-associated disease. The composition and methods

XX are useful for diagnosing or treating cancer or angiogenesis-associated

XX diseases, such as inflammatory disorders, chronic articular rheumatism,

XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence

XX represents a human ephrin B4 antisense oligonucleotide that can be used

XX to control EphB4 expression.

SQ Sequence 21 BP; 5 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 77;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2515 GTCATCCAGCTCGTGGGCATG 2535

DB 21 GTCATCCAGCTCGTGGGCATG 1

RESULT 75

ADR86926/c

XX ADR86926 standard; DNA; 21 BP.

XX ADR86926;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 231.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
XX angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
XX antisense oligonucleotide; ss.

OS Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASC-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or

XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

XX associated diseases, such as inflammatory disorders, psoriasis or

XX scleroderma.

XX Example 8; Page 94; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the

XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

XX described are: an antagonist antibody that binds to an extracellular

XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

XX diagnostic kit, comprising the above soluble polypeptide or antagonist

XX antibody, and a pharmaceutical carrier; methods of inhibiting

XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

XX cell; a method of reducing the growth rate of a tumour; methods for

XX treating a patient suffering from a cancer or an angiogenesis-associated

XX disease; and a method for identifying a tumor that is suitable for

XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

XX antibody is useful for manufacturing a medicament for the treatment of

XX cancer or an angiogenesis-associated disease. The composition and methods

XX are useful for diagnosing or treating cancer or angiogenesis-associated

XX diseases, such as inflammatory disorders, chronic articular rheumatism,

XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence

XX represents a human ephrin B4 antisense oligonucleotide that can be used

XX to control EphB4 expression.

SQ Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 77;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1381 GGCTCTCCCTGCACCTGGAA 1401

DB 21 GGCTCTCCCTGCACCTGGAA 1

RESULT 76

ADR86947

XX ADR86947 standard; DNA; 21 BP.

XX ADR86947;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 231.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

DE Human ephrinB4 short interference RNA seqid 252.
 XX
 XX
 KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmacological; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2004080425-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 XX
 XX 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASC-) VASGENE THERAPEUTICS INC.
 XX
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 XX associated diseases, such as inflammatory disorders, psoriasis or
 XX scleroderma.
 XX
 XX Example 8; Page 95; 198pp; English.
 XX
 XX The invention describes an isolated soluble polypeptide comprising an
 XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 XX described are: an antagonist antibody that binds to an extracellular
 XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 XX diagnostic kit, comprising the above soluble polypeptide or antagonist
 XX antibody, and a pharmaceutical carrier; methods of inhibiting
 XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 XX cell; a method of reducing the growth rate of a tumour; methods for
 XX treating a patient suffering from a cancer or an angiogenesis-associated
 XX disease; and a method for identifying a tumor that is suitable for
 XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 XX antibody is useful for manufacturing a medicament for the treatment of
 XX cancer or an angiogenesis-associated disease. The composition and methods
 XX are useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases, such as inflammatory disorders, chronic articular rheumatism,
 XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 XX represents a human ephrin B4 siRNA that can be used to control EphB4
 XX expression.
 XX
 XX Sequence 21 BP; 8 A; 5 C; 6 G; 2 T; 0 U; 0 Other;
 XX
 XX Query Match 0.5%; Score 21; DB 1; Length 21;
 XX Best Local Similarity 100.0%; Pred. No. 77;
 XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 XX 1783 AAATACCATGAGAGGGGCC 1803
 XX ||||||||||||||||
 XX 1 AAATACCATGAGAGGGGCC 21
 XX
 XX RESULT 77
 XX ADR86949
 XX ID ADR86949 standard; DNA; 21 BP.
 XX
 XX ADR86949;

XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrinB4 short interference RNA seqid 254.
 XX
 KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmacological; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2004080425-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 XX
 XX 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASC-) VASGENE THERAPEUTICS INC.
 XX
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 XX associated diseases, such as inflammatory disorders, psoriasis or
 XX scleroderma.
 XX
 XX Example 8; Page 95; 198pp; English.
 XX
 XX The invention describes an isolated soluble polypeptide comprising an
 XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 XX described are: an antagonist antibody that binds to an extracellular
 XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 XX diagnostic kit, comprising the above soluble polypeptide or antagonist
 XX antibody, and a pharmaceutical carrier; methods of inhibiting
 XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 XX cell; a method of reducing the growth rate of a tumour; methods for
 XX treating a patient suffering from a cancer or an angiogenesis-associated
 XX disease; and a method for identifying a tumor that is suitable for
 XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 XX antibody is useful for manufacturing a medicament for the treatment of
 XX cancer or an angiogenesis-associated disease. The composition and methods
 XX are useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases, such as inflammatory disorders, chronic articular rheumatism,
 XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 XX represents a human ephrin B4 siRNA that can be used to control EphB4
 XX expression.
 XX
 XX Sequence 21 BP; 9 A; 9 C; 2 G; 1 T; 0 U; 0 Other;
 XX
 XX Query Match 0.5%; Score 21; DB 1; Length 21;
 XX Best Local Similarity 100.0%; Pred. No. 77;
 XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 XX 1937 AACATCACAGCCAGACCCAAC 1957
 XX ||||||||||||||||
 XX 1 AACATCACAGCCAGACCCAAC 21
 XX
 XX RESULT 78
 XX ADR86744/c

ID ADR86744 standard; DNA; 21 BP.
 AC ADR86744;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 49.
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX
 DR WPI; 2004-668883/65.
 XX
 PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 5; Page 79; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 928 ATGGCCTGCTATCCCTGCAC 948
 |||||
 DB 21 ATGGCCTGCTATCCCTGCAC 1

RESULT 79
 ID ADR86934/C
 XX
 DT ADR86934 standard; DNA; 21 BP.
 XX
 AC ADR86934;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 239.
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX
 DR WPI; 2004-668883/65.
 XX
 PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 94; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 21 BP; 5 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2515 GTCATCCAGCTCGTGGCATG 2535

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2077 AATGGGAGAGACAGAGATAT 2097
|||||
Db 1 AATGGGAGAGACAGAGATAT 21

RESULT 82
ADR86970
ID ADR86970 standard; DNA; 21 BP.
XX
AC ADR86970;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interference RNA seqid 275.
XX
KW cyostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 95; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4

CC expression.
XX
SQ Sequence 21 BP; 8 A; 7 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2620 AACAGCAACCTGCTGCAAA 2640
|||||
Db 1 AACAGCAACCTGCTGCAAA 21

RESULT 83
ADR86984
ID ADR86984 standard; DNA; 21 BP.
XX
AC ADR86984;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interference RNA seqid 289.
XX
KW cyostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 96; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4

CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.

XX SQ Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3254 AAATCTTGGCCAGTCCAGC 3274
 |||||
 Db 1 AAATCTTGGCCAGTCCAGC 21

RESULT 84
 ADR86747/c
 ID ADR86747 standard; DNA; 21 BP.
 XX AC ADR86747;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human ephrin B4 antisense oligonucleotide seqid 52.
 XX KW cytotactic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX OS Homo sapiens.
 XX PN WO2004080425-A2.
 XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007755.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX PA (VASG-) VASGENE THERAPEUTICS INC.
 XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX DR New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX FS Example 5; Page 79; 198pp; English.
 XX CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC described are: a pharmaceutical or cosmetic composition, or a
 CC antibody, and a pharmaceutical carrier, methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX SQ Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1641 TGAGCCTGTCAATGTCACCAC 1661
 |||||
 Db 21 TGAGCCTGTCAATGTCACCAC 1

RESULT 85
 ADR86974
 ID ADR86974 standard; DNA; 21 BP.
 XX AC ADR86974;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human ephrinB4 short interference RNA seqid 279.
 XX KW cytotactic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 XX OS Homo sapiens.
 XX PN WO2004080425-A2.
 XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007755.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX PA (VASG-) VASGENE THERAPEUTICS INC.
 XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX DR New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX FS Example 8; Page 95; 198pp; English.
 XX CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC described are: a pharmaceutical or cosmetic composition, or a
 CC antibody, and a pharmaceutical carrier, methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.

XX
SQ Sequence 21 BP; 4 A; 4 C; 5 G; 8 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2638 AAGTGTCTGACCTTGGCCTT 2658
|||||
Db 1 AAGTGTCTGACCTTGGCCTT 21

RESULT 86
ADR82292/c
ID ADR82292 standard; DNA; 21 BP.
XX
AC ADR82292;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense ODN #1.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.

XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VAGS-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 3; Page 68; 206pp; English.

XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense oligodeoxynucleotide (ODN).

XX
SQ Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 928 ATGGCCCTGCTATCCCTGCAC 948
|||||
Db 21 ATGGCCCTGCTATCCCTGCAC 1

RESULT 87
ADR82495
ID ADR82495 standard; DNA; 21 BP.
XX
AC ADR82495;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense RNAi probe #6.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VAGS-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX
PS Example 8; Page 102; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.

XX
SQ Sequence 21 BP; 5 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 466 AAGTGGTGACATTCCTCAG 486
|||||
Db 1 AAGTGGTGACATTCCTCAG 21

```
RESULT 88
ADR82516
ID ADR82516 standard; DNA; 21 BP.
XX AC
XX ADR82516;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense RNAi probe #27.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
XX Homo sapiens.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX Example 8; Page 102; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense RNAi probe.
XX
XX Sequence 21 BP; 5 A; 1 C; 10 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 77;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 2228 AAGAGGTGATTGGTGCAGGTG 2248
XX ||||||||||||||||
XX 1 AAGAGGTGATTGGTGCAGGTG 21
XX
XX RESULT 89
ADR82524
ID ADR82524 standard; DNA; 21 BP.
XX AC
XX ADR82524;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense RNAi probe #35.
XX
XX
```

```
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
XX Homo sapiens.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX Example 8; Page 102; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense RNAi probe.
XX
XX Sequence 21 BP; 9 A; 7 C; 2 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 77;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 2608 AACATCCTAGTCAACAGCAAC 2628
XX ||||||||||||||||
XX 1 AACATCCTAGTCAACAGCAAC 21
XX
XX RESULT 90
ADR82527
ID ADR82527 standard; DNA; 21 BP.
XX AC
XX ADR82527;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense RNAi probe #38.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
XX Homo sapiens.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
```


CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense RNAi probe.
 XX
 SQ Sequence 21 BP; 6 A; 1 C; 8 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2173 AATGAGGCTGTGAGGGAATTT 2193
 DB 1 AATGAGGCTGTGAGGGAATTT 21

RESULT 93

ADR82531

ID ADR82531 standard; DNA; 21 BP.

XX ADR82531;

DT 16-DEC-2004 (first entry)

DE Human EphB4 antisense RNAi probe #42.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
 XX Homo sapiens.
 OS
 PN WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Reddy R, Gill P;
 XX
 DR WPI; 2004-668879/65.
 XX
 PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 FS Example 8; Page 103; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense RNAi probe.
 XX
 SQ Sequence 21 BP; 7 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

RESULT 94

ADR82319/c

ID ADR82319 standard; DNA; 21 BP.

XX ADR82319;

DT 16-DEC-2004 (first entry)

DE Human EphB4 antisense ODN #13.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor.
 XX Homo sapiens.
 OS Synthetic.
 PN WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Reddy R, Gill P;
 XX
 DR WPI; 2004-668879/65.
 XX
 PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 FS Example 5; Page 85; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense oligodeoxynucleotide (ODN).
 XX
 SQ Sequence 21 BP; 5 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2515 GTCATCCAGCTCTGGGCATG 2535
 DB 21 GTCATCCAGCTCTGGGCATG 1

RESULT 95

ADR82493

ID ADR82493 standard; DNA; 21 BP.
 XX ADR82493;
 XX 16-DEC-2004 (first entry)
 XX Human EphB4 antisense RNAi probe #4.
 DE
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
 XX
 OS Homo sapiens.
 XX
 XX WO2004080418-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 XX 12-MAR-2003; 2003US-0454432P.
 XX (VAGS-) VASGENE THERAPEUTICS INC.
 XX Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX Example 8; Page 102; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense RNAi probe.
 XX Sequence 21 BP; 5 A; 3 C; 7 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 453 AACTGCTGATCTGAAGTGGGT 473
 DB 1 AACTGCTGATCTGAAGTGGGT 21
 RESULT 96
 ADR82494
 ID ADR82494 standard; DNA; 21 BP.
 XX ADR82494;
 XX 16-DEC-2004 (first entry)
 XX Human EphB4 antisense RNAi probe #5.
 DE
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.

KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
 XX Homo sapiens.
 XX WO2004080418-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 XX 12-MAR-2003; 2003US-0454432P.
 XX (VAGS-) VASGENE THERAPEUTICS INC.
 XX Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX Example 8; Page 102; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense RNAi probe.
 XX Sequence 21 BP; 5 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 853 AATGTCACAGCGCTCGCTG 873
 DB 1 AATGTCACAGCGCTCGCTG 21
 RESULT 97
 ADR82519
 ID ADR82519 standard; DNA; 21 BP.
 XX ADR82519;
 XX 16-DEC-2004 (first entry)
 XX Human EphB4 antisense RNAi probe #30.
 DE
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
 XX Homo sapiens.
 XX WO2004080418-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007491.
 XX

PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 102; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 7 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2290 AAGAGGAGAGAGCTGTGGCA 2310
DB 1 AAGAGGAGAGAGCTGTGGCA 21
RESULT 98
ADR82525
ID ADR82525 standard; DNA; 21 BP.
XX ADR82525;
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense RNAi probe #36.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX Homo sapiens.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,

PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 102; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 8 A; 7 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2620 AACAGCAACCTGCTGCAAA 2640
DB 1 AACAGCAACCTGCTGCAAA 21
RESULT 99
ADR82534
ID ADR82534 standard; DNA; 21 BP.
XX ADR82534;
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense RNAi probe #45.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX Homo sapiens.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 103; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or

CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.

XX
SQ Sequence 21 BP; 9 A; 3 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3141 AAGATACGAGAAAGTTTGGC 3161

DB 1 AAGATACGAGAAAGTTTGGC 21

RESULT 100

ADR82506

ID ADR82506 standard; DNA; 21 BP.

XX ADR82506;

XX 16-DEC-2004 (first entry)

XX Human EphB4 antisense RNAi probe #17.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.

XX Homo sapiens.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASC-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX Example 8; Page 102; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.

XX Sequence 21 BP; 10 A; 1 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2077 AATGGGAGAGAGCAGATAT 2097

DB 1 AATGGGAGAGAGCAGATAT 21

RESULT 101

ADR82513

ID ADR82513 standard; DNA; 21 BP.

XX ADR82513;

XX 16-DEC-2004 (first entry)

XX Human EphB4 antisense RNAi probe #24.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.

XX Homo sapiens.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASC-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX Example 8; Page 102; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.

XX Sequence 21 BP; 7 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2165 AAGACCCCTAATGAGCTGTGA 2185

DB 1 AAGACCCCTAATGAGCTGTGA 21

RESULT 102

ADR82540

ID ADR82540 standard; DNA; 21 BP.

XX

XX ADR82540;


```
DT 16-DEC-2004 (first entry)
XX Human EphB4 antisense RNAi probe #51.
DE
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angio genesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX Example 8; Page 103; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense RNAi probe.
XX
XX Sequence 21 BP; 6 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 77;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 3149 AAGAAAGTTTCGACGCCGCTG 3169
XX |||||
XX 1 AAGAAAGTTTCGACGCCGCTG 21
XX
RESULT 103
ADR82479/C
ID ADR82479 standard; DNA; 21 BP.
XX
XX ADR82479;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense probe #150.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angio genesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
XX Homo sapiens.
XX
```

```
OS Synthetic.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX Example 8; Page 101; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
XX
XX Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 77;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 928 ATGGCCCTGCTATCCCTGCAC 948
XX |||||
XX 21 ATGGCCCTGCTATCCCTGCAC 1
XX
RESULT 104
ADR82483/C
ID ADR82483 standard; DNA; 21 BP.
XX
XX ADR82483;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense probe #154.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angio genesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
XX Homo sapiens.
XX
XX Synthetic.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
```

XX (VAG-) VASGENE THERAPEUTICS INC.
PA Reddy R, Gill P;
XX WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 101; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 21 BP; 1 A; 5 C; 7 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1931 GCCAGGACATCATCAGCCAGA 1951
DB 21 GCCAGGAACATCATCAGCCAGA 1
XX
RESULT 105
ADR82507
ID ADR82507 standard; DNA; 21 BP.
XX
XX ADR82507;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense RNAi probe #18.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
XX Homo sapiens.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VAG-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX Example 8; Page 102; 206pp; English.
PS
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 10 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 2087 AAGCAGATATTCGGACAAAC 2107
DB 1 AAGCAGATATTCGGACAAAC 21
XX
RESULT 106
ADR82514
ID ADR82514 standard; DNA; 21 BP.
XX
XX ADR82514;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense RNAi probe #25.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
XX Homo sapiens.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VAG-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 102; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 10 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 2087 AAGCAGATATTCGGACAAAC 2107
DB 1 AAGCAGATATTCGGACAAAC 21
XX
RESULT 106
ADR82514
ID ADR82514 standard; DNA; 21 BP.
XX
XX ADR82514;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense RNAi probe #25.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
XX Homo sapiens.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VAG-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 102; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.

CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense RNAi probe.
 SQ Sequence 21 BP; 7 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2197 AAAGAGATCGATGCTCTCTAC 2217
 |||||
 DB 1 AAAGAGATCGATGCTCTCTAC 21
 RESULT 107
 ADR82518
 ID ADR82518 standard; DNA; 21 BP.
 XX
 AC ADR82518;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense RNAi probe #29.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Reddy R, Gill P;
 XX
 DR WPI; 2004-668879/65.
 XX
 PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 102; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense RNAi probe.
 XX
 SQ Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2428 AACAGCATGCCGTCATGATT 2448
 |||||

Db 1 AACAGCATGCCGTCATGATT 21
 RESULT 108
 ADR82529
 ID ADR82529 standard; DNA; 21 BP.
 XX
 AC ADR82529;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense RNAi probe #40.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Reddy R, Gill P;
 XX
 DR WPI; 2004-668879/65.
 XX
 PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 102; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense RNAi probe.
 XX
 SQ Sequence 21 BP; 4 A; 4 C; 5 G; 8 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2638 AAAGTGCTGACTTTGGCCTT 2658
 |||||
 DB 1 AAAGTGCTGACTTTGGCCTT 21
 RESULT 109
 ADR82537
 ID ADR82537 standard; DNA; 21 BP.
 XX
 AC ADR82537;
 XX
 DT 16-DEC-2004 (first entry)
 XX

```
DE Human EphB4 antisense RNAi probe #48.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VAGS-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX Example 8; Page 103; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense RNAi probe.
XX
XX Sequence 21 BP; 7 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 77;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 3028 AAAATCGTGGCCGGGAGAAAT 3048
Db 1 AAAATCGTGGCCGGGAGAAAT 21
XX
RESULT 110
ADR82316/c
ID ADR82316 standard; DNA; 21 BP.
XX
XX ADR82316;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense ODN #10.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor.
XX
XX Homo sapiens.
XX
XX Synthetic.
XX
```

```
PN WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VAGS-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX Example 5; Page 85; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense oligodeoxynucleotide (ODN).
XX
XX Sequence 21 BP; 2 A; 10 C; 5 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 77;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 784 AAGGTGGACACGGTGGCGCG 804
Db 21 AAGGTGGACACGGTGGCGCG 1
XX
RESULT 111
ADR82496
ID ADR82496 standard; DNA; 21 BP.
XX
XX ADR82496;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense RNAi probe #7.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
XX Homo sapiens.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VAGS-) VASGENE THERAPEUTICS INC.
XX
```



```
SQ Sequence 21 BP; 9 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2093 AATATTGGGACAAACACGGAC 2113
|||||
Db 1 AATATTGGGACAAACACGGAC 21

RESULT 114
ADR82510
ID ADR82510 standard; DNA; 21 BP.
XX
AC ADR82510;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense RNAi probe #21.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VAG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 102; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 7 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2105 AACACGACAGTATCTCATCG 2125
|||||
Db 1 AACACGACAGTATCTCATCG 21

RESULT 115
ADR82542
ID ADR82542 standard; DNA; 21 BP.
XX
AC ADR82542;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense RNAi probe #53.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VAG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 103; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3255 AATCTGGCCAGTGTCCAGCA 3275
|||||
Db 1 AATCTGGCCAGTGTCCAGCA 21

RESULT 116
ADR82311/c
ID ADR82311 standard; DNA; 21 BP.
XX
AC ADR82311;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense ODN #5.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
```

KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor.
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
FN
PD 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
PF
XX 12-MAR-2003; 2003US-0454300P.
PR
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
PA
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX
XX Example 5; Page 85; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense oligodeoxynucleotide (ODN).
XX
XX Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
CC
CC Query Match 0.5%; Score 21; DB 1; Length 21;
CC Best Local Similarity 100.0%; Pred. No. 77;
CC Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1381 GGCTCCTCCCTGCACCTGGAA 1401
Db 21 GGCTCCTCCCTGCACCTGGAA 1
RESULT 117
ADR82317/C
ID ADR82317 standard; DNA; 21 BP.
XX
XX ADR82317;
AC
XX
XX 16-DEC-2004 (first entry)
DT
XX
XX Human EphB4 antisense ODN #11.
DE
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor.
XX
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
FN
XX

PD 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
PR
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
PA
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX
XX Example 5; Page 85; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense oligodeoxynucleotide (ODN).
XX
XX Sequence 21 BP; 3 A; 6 C; 5 G; 7 T; 0 U; 0 Other;
CC
CC Query Match 0.5%; Score 21; DB 1; Length 21;
CC Best Local Similarity 100.0%; Pred. No. 77;
CC Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2305 GTGGCAATCAAGACCCCTGAAG 2325
Db 21 GTGGCAATCAAGACCCCTGAAG 1
RESULT 118
ADR82499
ID ADR82499 standard; DNA; 21 BP.
XX
XX ADR82499;
AC
XX
XX 16-DEC-2004 (first entry)
DT
XX
XX Human EphB4 antisense RNAi probe #10.
DE
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
XX Homo sapiens.
OS
XX WO2004080418-A2.
FN
XX
XX 23-SEP-2004.
PD
XX 12-MAR-2004; 2004WO-US007491.
PF
XX 12-MAR-2003; 2003US-0454300P.
PR
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
PA
XX Reddy R, Gill P;
XX

DR WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 102; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 8 A; 7 C; 1 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1246 AATAGCCACTCTAACACCAT 1266
DB 1 AATAGCCACTCTAACACCAT 21
RESULT 119
ADR82509
ID ADR82509 standard; DNA; 21 BP.
XX
AC ADR82509;
XX
DT 16-DEC-2004 (first entry)
DE Human EphB4 antisense RNAi probe #20.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASC-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 102; 206pp; English.
PS The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under

CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 8 A; 6 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2104 AAACACGGACAGTATCTCATC 2124
DB 1 AAACACGGACAGTATCTCATC 21
RESULT 120
ADR82520
ID ADR82520 standard; DNA; 21 BP.
XX
AC ADR82520;
XX
DT 16-DEC-2004 (first entry)
DE Human EphB4 antisense RNAi probe #31.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASC-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 102; 206pp; English.
PS The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 6 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2293 AAGGAGAGCTGTGGCAATC 2313
|||||
Db 1 AAGGAGAGCTGTGGCAATC 21

RESULT 121

ADR82492

ID ADR82492 standard; DNA; 21 BP.

XX AC ADR82492;

XX DT 16-DEC-2004 (first entry)

XX DE Human EphB4 antisense RNAi probe #3.

XX DX human; ss; antisense; EphB4; EphrinB2; cancer;

XX KW angiogenesis-associated disease; inflammatory disorder;

XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

XX KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;

XX KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.

XX OS Homo sapiens.

XX FN WO2004080418-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US007491.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-0454432P.

XX PA (VASG-) VASGENE THERAPEUTICS INC.

XX FI Reddy R, Gill P;

XX DR WPI; 2004-668879/65.

XX CC New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX PS Example 8; Page 102; 206pp; English.

XX CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.

XX SQ Sequence 21 BP; 6 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.5%; Score 21; DB 1; Length 21;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 452 AAAGTCTGATCTGAAGTGG 472

|||||

Db 1 AAAGTCTGATCTGAAGTGG 21

RESULT 122

ADR82504

ID ADR82504 standard; DNA; 21 BP.

XX AC ADR82504;

XX DT 16-DEC-2004 (first entry)

XX DE Human EphB4 antisense RNAi probe #15.

XX DX human; ss; antisense; EphB4; EphrinB2; cancer;

XX KW angiogenesis-associated disease; inflammatory disorder;

XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

XX KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;

XX KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.

XX OS Homo sapiens.

XX FN WO2004080418-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US007491.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-0454432P.

XX PA (VASG-) VASGENE THERAPEUTICS INC.

XX FI Reddy R, Gill P;

XX DR WPI; 2004-668879/65.

XX CC New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX PS Example 8; Page 102; 206pp; English.

XX CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.

XX SQ Sequence 21 BP; 9 A; 9 C; 2 G; 1 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.5%; Score 21; DB 1; Length 21;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1937 AACATCACGCCAGCCCAAC 1957

|||||

Db 1 AACATCACGCCAGCCCAAC 21

RESULT 123

ADR82308/C

ID ADR82308 standard; RNA; 21 BP.

XX AC ADR82308;

XX DT 16-DEC-2004 (first entry)

XX DE Human EphB4 siRNA #10.

XX KW human; ss; siRNA; small interference RNA; RNA interference;
XX KW gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
XX KW inflammatory disorder; chronic articular rheumatism; psoriasis;

KW ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
 KW antirheumatic; antipsoriatic; dermatological; ophthalmological;
 KW angiogenesis inhibitor.
 XX Homo sapiens.
 OS
 PN WO2004080418-A2.
 XX
 XX 23-SEP-2004.
 PD
 XX
 XX 12-MAR-2004; 2004WO-US007491.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASC-) VASGENE THERAPEUTICS INC.
 XX
 XX Reddy R, Gill P;
 PI
 XX WPI; 2004-668879/65.
 DR
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 XX useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases.
 XX Example 5; Page 81; 206pp; English.
 PS
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC siRNA.
 XX
 XX Sequence 21 BP; 5 A; 1 C; 10 G; 0 T; 5 U; 0 Other;
 SQ
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2677 AACTCTTCGATCCACCTAC 2697
 Db 21 AACTCTTCGATCCACCTAC 1
 |||||
 RESULT 124
 ADR82313/c
 ID ADR82313 standard; DNA; 21 BP.
 XX
 AC ADR82313;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 DE Human EphB4 antisense ODN #7.
 XX
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor.
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO2004080418-A2.
 XX
 XX 23-SEP-2004.

PF 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASC-) VASGENE THERAPEUTICS INC.
 XX
 XX Reddy R, Gill P;
 PI
 XX WPI; 2004-668879/65.
 DR
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 XX useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases.
 XX Example 5; Page 85; 206pp; English.
 PS
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense oligodeoxynucleotide (ODN).
 XX
 XX Sequence 21 BP; 1 A; 5 C; 7 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1931 GCCAGGAACATCACGCCAGA 1951
 Db 21 GCCAGGAACATCACGCCAGA 1
 |||||
 RESULT 125
 ADR82482/c
 ID ADR82482 standard; DNA; 21 BP.
 XX
 AC ADR82482;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 DE Human EphB4 antisense probe #153.
 XX
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO2004080418-A2.
 XX
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007491.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASC-) VASGENE THERAPEUTICS INC.
 XX
 XX Reddy R, Gill P;
 PI
 XX WPI; 2004-668879/65.
 DR

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 101; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1641 TGAGCCTGTCAATGTCACCAC 1661
Db 21 TGAGCCTGTCAATGTCACCAC 1
RESULT 126
ADR82486/c
ID ADR82486 standard; DNA; 21 BP.
XX ADR82486;
AC ADR82486;
XX 16-DEC-2004 (first entry)
DT Human EphB4 antisense probe #157.
DE human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
OS Synthetic.
OS WO2004080418-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 101; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under

CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX Sequence 21 BP; 2 A; 10 C; 5 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 784 AAGGTGCACACGGTGGCCGCG 804
Db 21 AAGGTGCACACGGTGGCCGCG 1
RESULT 127
ADR82302/c
ID ADR82302 standard; RNA; 21 BP.
XX ADR82302;
AC ADR82302;
XX 16-DEC-2004 (first entry)
DT Human EphB4 siRNA #4.
DE human; ss; siRNA; small interference RNA; RNA interference;
KW gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW inflammatory disorder; chronic articular rheumatism; psoriasis;
KW ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW angiogenesis inhibitor.
XX Homo sapiens.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 5; Page 81; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC siRNA.
XX Sequence 21 BP; 2 A; 4 C; 6 G; 0 T; 9 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 425 AAGAGACCCCTGCTGAACACAA 445
|||||
Db 21 AAGAGACCCCTGCTGAACACAA 1

RESULT 128

ADR82327/c

ID ADR82327 standard; RNA; 21 BP.

XX ADR82327;

XX ADR82327;

DT 16-DEC-2004 (first entry)

XX Human EphB4 siRNA #12.

XX human; ss; siRNA; small interference RNA; RNA interference;

XX gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;

XX inflammatory disorder; chronic articular rheumatism; psoriasis;

XX ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;

XX antirheumatic; antipsoriatic; dermatological; ophthalmological;

XX angiogenesis inhibitor.

XX Homo sapiens.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VAGS-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2

XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,

XX useful for diagnosing or treating cancer or angiogenesis-associated

XX diseases.

XX Example 6; Page 96; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at

XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under

XX physiological conditions and decreases the expression of EphB4 or

XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a

XX medicament for the treatment of cancer or angiogenesis-associated

XX diseases. The composition and methods are useful for diagnosing or

XX treating cancer or angiogenesis-associated diseases, such as inflammatory

XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic

XX diseases or scleroderma. The present sequence represents a human EphB4

XX siRNA.

XX Sequence 21 BP; 2 A; 4 C; 6 G; 0 T; 9 U; 0 Other;

XX Query Match 0.5%; Score 21; DB 1; Length 21;

XX Best Local Similarity 100.0%; Pred. No. 77;

XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

RESULT 129

ADR82498

ID ADR82498 standard; DNA; 21 BP.

XX ADR82498;

XX ADR82498;

XX 16-DEC-2004 (first entry)

XX Human EphB4 antisense RNAi probe #9.

XX human; ss; antisense; EphB4; EphrinB2; cancer;

XX angiogenesis-associated disease; inflammatory disorder;

XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;

XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

XX dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.

XX Homo sapiens.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VAGS-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2

XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,

XX useful for diagnosing or treating cancer or angiogenesis-associated

XX diseases.

XX Example 8; Page 102; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at

XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under

XX physiological conditions and decreases the expression of EphB4 or

XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a

XX medicament for the treatment of cancer or angiogenesis-associated

XX diseases. The composition and methods are useful for diagnosing or

XX treating cancer or angiogenesis-associated diseases, such as inflammatory

XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic

XX diseases or scleroderma. The present sequence represents a human EphB4

XX antisense RNAi probe.

XX Sequence 21 BP; 7 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

XX Query Match 0.5%; Score 21; DB 1; Length 21;

XX Best Local Similarity 100.0%; Pred. No. 77;

XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

KW angio genesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
XX OS Homo sapiens.
XX WO2004080418-A2.
XX
XX PD 23-SEP-2004.
XX
XX PF 12-MAR-2004; 2004WO-US007491.
XX
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX
XX PI Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX PS Example 8; Page 102; 206pp; English.
XX
XX CC The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense RNAi probe.
XX
XX SQ Sequence 21 BP; 6 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 77;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 1258 AACACCATGGATCAGCGTC 1278
XX |||||
XX Db 1 AACACCATGGATCAGCGTC 21
XX
XX RESULT 131
XX ADR82505
XX ID ADR82505 standard; DNA; 21 BP.
XX AC ADR82505;
XX
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense RNAi probe #16.
XX
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
XX angio genesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
XX OS Homo sapiens.
XX
XX PN WO2004080418-A2.
XX
XX PD 23-SEP-2004.
XX

PF 12-MAR-2004; 2004WO-US007491.
XX
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX
XX PI Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX PS Example 8; Page 102; 206pp; English.
XX
XX CC The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense RNAi probe.
XX
XX SQ Sequence 21 BP; 10 A; 2 C; 8 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 77;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX Qy 2068 AACGACGACCAATGGAGAGAA 2088
XX |||||
XX Db 1 AACGACGACCAATGGAGAGAA 21
XX
XX RESULT 132
XX ADR82538
XX ID ADR82538 standard; DNA; 21 BP.
XX AC ADR82538;
XX
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense RNAi probe #49.
XX
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
XX angio genesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
XX OS Homo sapiens.
XX
XX PN WO2004080418-A2.
XX
XX PD 23-SEP-2004.
XX
XX PF 12-MAR-2004; 2004WO-US007491.
XX
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX
XX PI Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX

PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 103; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 6 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3253 AAAATCTTGGCCAGTGTCCAG 3273
Db |||||
1 AAAATCTTGGCCAGTGTCCAG 21

RESULT 133
ADR82487/c
ID ADR82487 standard; DNA; 21 BP.
XX
AC ADR82487;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #158.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 101; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or

CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 21 BP; 3 A; 6 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2305 GTGGCAATCAGACCCCTGAAG 2325
Db |||||
21 GTGGCAATCAGACCCCTGAAG 1

RESULT 134
ADR82491
ID ADR82491 standard; DNA; 21 BP.
XX
AC ADR82491;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense RNAi probe #2.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 101; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 7 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 21; DB 1; Length 21;

[illegible]

KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX Homo sapiens.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX PF
XX 12-MAR-2003; 2003US-0454300P.
XX PR
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASC-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX Example 8; Page 102; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense RNAi probe.
XX
XX Sequence 21 BP; 5 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
SQ
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
XX Sequence 21 BP; 5 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2626 AACCTCGTCTGCAAGTGCT 2646
DB 1 AACCTCGTCTGCAAGTGCT 21
RESULT 138
ADR82530
ID ADR82530 standard; DNA; 21 BP.
XX
XX ADR82530;
AC
XX 16-DEC-2004 (first entry)
DT
XX Human EphB4 antisense RNAi probe #41.
DE
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
XX Homo sapiens.
OS
XX WO2004080418-A2.
PN
XX 23-SEP-2004.
PD
XX 12-MAR-2004; 2004WO-US007491.
XX PF
XX 12-MAR-2003; 2003US-0454300P.
XX PR
XX 12-MAR-2003; 2003US-0454300P.
XX
XX (VASC-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX Example 8; Page 102; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense RNAi probe.
XX
XX Sequence 21 BP; 5 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
SQ

PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASC-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX PI
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX Example 8; Page 102; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense RNAi probe.
XX
XX Sequence 21 BP; 7 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2851 AATCAGCAGTCATCAATGCC 2871
DB 1 AATCAGCAGTCATCAATGCC 21
RESULT 139
ADR82304/C
ID ADR82304 standard; RNA; 21 BP.
XX
XX ADR82304;
AC
XX 16-DEC-2004 (first entry)
DT
XX Human EphB4 siRNA #6.
DE
XX human; ss; siRNA; small interference RNA; RNA interference;
KW gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW inflammatory disorder; chronic articular rheumatism; psoriasis;
KW ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW angiogenesis inhibitor.
XX
XX Homo sapiens.
OS
XX WO2004080418-A2.
PN
XX 23-SEP-2004.
PD
XX 12-MAR-2004; 2004WO-US007491.
XX PF
XX 12-MAR-2003; 2003US-0454300P.
XX PR
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASC-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX PI
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX Example 8; Page 102; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense RNAi probe.
XX
XX Sequence 21 BP; 7 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
SQ

PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 5; Page 81; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC siRNA.
XX
SQ Sequence 21 BP; 4 A; 7 C; 3 G; 0 T; 7 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 847 AAGGTGAATGTCAGACGCTG 867
Db 21 AAGGTGAATGTCAGACGCTG 1
RESULT 140
ADR82306/c
ID ADR82306 standard; RNA; 21 BP.
XX
AC ADR82306;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 siRNA #8.
XX
KW human; ss; siRNA; small interference RNA; RNA interference;
KW gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW inflammatory disorder; chronic articular rheumatism; psoriasis;
KW ocular angiogenic disease; scleroderma; cytostatic; antinflammatory;
KW antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW angiogenesis inhibitor.
XX
OS Homo sapiens.
XX
FN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 5; Page 81; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated

CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC siRNA.
XX
SQ Sequence 21 BP; 1 A; 2 C; 9 G; 0 T; 9 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1937 AACATCACGCCAGACCCAC 1957
Db 21 AACATCACGCCAGACCCAC 1
RESULT 141
ADR82312/c
ID ADR82312 standard; DNA; 21 BP.
XX
AC ADR82312;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense ODN #6.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS Homo sapiens.
XX
OS Synthetic.
XX
FN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 5; Page 85; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense oligodeoxynucleotide (ODN).
XX
SQ Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;

```
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1641 TGAGCCTGTCAATGTCACCA 1661
DB 21 TGAGCCTGTCAATGTCACCA 1

RESULT 142
ADR82511
ID ADR82511 standard; DNA; 21 BP.
XX ADR82511;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense RNA1 probe #22.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe; RNA1.
XX
XX Homo sapiens.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX Example 8; Page 102; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense RNA1 probe.
XX
XX Sequence 21 BP; 8 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 77;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2196 AAAAGAGATCGATGTCCTTA 2216
DB 1 AAAAGAGATCGATGTCCTTA 21

RESULT 143
ADR82533
ID ADR82533 standard; DNA; 21 BP.
XX
```

```
AC ADR82533;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense RNA1 probe #44.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe; RNA1.
XX
XX Homo sapiens.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX Example 8; Page 103; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense RNA1 probe.
XX
XX Sequence 21 BP; 5 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 77;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2761 AAGTTCACCTCCGCCAGTGAT 2781
DB 1 AAGTTCACCTCCGCCAGTGAT 21

RESULT 144
ADR82330/c
ID ADR82330 standard; DNA; 21 BP.
XX
XX ADR82330;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense probe #1.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe.
```

OS Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
PN PD 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
PA Reddy R, Gill P;
PI WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX
XX Example 8; Page 98; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
XX Sequence 21 BP; 2 A; 7 C; 8 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 3319 GGACGGCCCGCAGTACTGA 3339
Db 21 GGACGGCCCGCAGTACTGA 1
RESULT 145
ADR82481/C
ID ADR82481 standard; DNA; 21 BP.
XX
XX ADR82481;
AC
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #152.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
PN PD 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX
XX Example 8; Page 98; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
XX Sequence 21 BP; 2 A; 7 C; 8 G; 4 T; 0 U; 0 Other;
SQ

PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX
XX Example 8; Page 101; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
XX Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1381 GGCTCTCTCCCTGCACCTGGAA 1401
Db 21 GGCTCTCTCCCTGCACCTGGAA 1
RESULT 146
ADR82490
ID ADR82490 standard; DNA; 21 BP.
XX
XX ADR82490;
AC
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense RNAi probe #1.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX WO2004080418-A2.
PN PD 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX
XX Example 8; Page 101; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
XX Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
SQ

PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 101; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense RNAi probe.
 XX
 SQ Sequence 21 BP; 7 A; 3 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 445 AAATTGGAAACTGCTGATCTG 465
 DB 1 AAATTGGAAACTGCTGATCTG 21
 RESULT 147
 ADR82501
 ID ADR82501 standard; DNA; 21 BP.
 XX
 AC ADR82501;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense RNAi probe #12.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
 XX
 OS Homo sapiens.
 XX
 WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PP 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASC-) VASGENE THERAPEUTICS INC.
 XX
 PI Reddy R, Gill P;
 XX
 DR WPI; 2004-668879/65.
 XX
 PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 102; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense RNAi probe.

CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense RNAi probe.
 XX
 SQ Sequence 21 BP; 7 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1651 AATGTCACCACTGACCGAG 1671
 DB 1 AATGTCACCACTGACCGAG 21
 RESULT 148
 ADR82502
 ID ADR82502 standard; DNA; 21 BP.
 XX
 AC ADR82502;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense RNAi probe #13.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
 XX
 OS Homo sapiens.
 XX
 WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PP 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASC-) VASGENE THERAPEUTICS INC.
 XX
 PI Reddy R, Gill P;
 XX
 DR WPI; 2004-668879/65.
 XX
 PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 102; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense RNAi probe.
 XX
 SQ Sequence 21 BP; 8 A; 5 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1783 AAATACCATGAGAGGGCGCC 1803
 |||||
 DB 1 AAATACCATGAGAGGGCGCC 21

RESULT 149
 ADR82523

ID ADR82523 standard; DNA; 21 BP.
 XX
 AC ADR82523;
 XX
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense RNAi probe #34.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
 XX
 OS Homo sapiens.
 XX
 FN WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VAGS-) VASGENE THERAPEUTICS INC.
 XX
 PI Reddy R, Gill P;
 XX
 DR WPI; 2004-668879/65.
 XX
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 102; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense RNAi probe.
 XX
 SQ Sequence 21 BP; 7 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2497 AACGACGGACAGTTCACAGTC 2517
 |||||
 DB 1 AACGACGGACAGTTCACAGTC 21

RESULT 150
 ADR82535

ID ADR82535 standard; DNA; 21 BP.
 XX
 AC ADR82535;
 XX
 XX

DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense RNAi probe #46.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
 XX
 OS Homo sapiens.
 XX
 FN WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VAGS-) VASGENE THERAPEUTICS INC.
 XX
 PI Reddy R, Gill P;
 XX
 DR WPI; 2004-668879/65.
 XX
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 103; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense RNAi probe.
 XX
 SQ Sequence 21 BP; 11 A; 1 C; 7 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 0.5%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 77;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 3135 AATGGGAAGATACGAGAAAG 3155
 |||||
 DB 1 AATGGGAAGATACGAGAAAG 21

RESULT 151
 ADR82536

ID ADR82536 standard; DNA; 21 BP.
 XX
 AC ADR82536;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense RNAi probe #47.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
 XX
 OS Homo sapiens.

```
XX PN WO2004080418-A2.
XX PD
XX PF 23-SEP-2004.
XX PP
XX PR 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX PP WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT useful for diagnosing or treating cancer or angiogenesis-associated
XX PT diseases.
XX PS Example 8; Page 103; 206pp; English.
XX SQ The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX SQ Sequence 21 BP; 8 A; 5 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2866 AATGCCATTGACAGGACTAC 2886
DB 1 AATGCCATTGACAGGACTAC 21
RESULT 152
ADR82541
ID ADR82541 standard; DNA; 21 BP.
XX AC ADR82541;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense RNAi probe #52.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
XX KW angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX OS Homo sapiens.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PP 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX PP WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT useful for diagnosing or treating cancer or angiogenesis-associated
XX PT diseases.
```

```
XX PI Reddy R, Gill P;
XX PP WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT useful for diagnosing or treating cancer or angiogenesis-associated
XX PT diseases.
XX PS Example 8; Page 103; 206pp; English.
XX SQ The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX SQ Sequence 21 BP; 7 A; 4 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3250 AAGAAAATCTTGCCAGTGTC 3270
DB 1 AAGAAAATCTTGCCAGTGTC 21
RESULT 153
ADR82515
ID ADR82515 standard; DNA; 21 BP.
XX AC ADR82515;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense RNAi probe #26.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
XX KW angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX OS Homo sapiens.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PP 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX PP WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT useful for diagnosing or treating cancer or angiogenesis-associated
XX PT diseases.
XX PS Example 8; Page 102; 206pp; English.
```

CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.

XX Sequence 21 BP; 6 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
SQ

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2198 AAGAGATCGATGTCCTCTACG 2218
Db 1 AAGAGATCGATGTCCTCTACG 21

RESULT 154
ADR82309/c
ID ADR82309 standard; DNA; 21 BP.
XX
AC ADR82309;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense ODN #3.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO2004080418-A2.
XX
FD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PF New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 5; Page 85; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.

CC antisense oligodeoxynucleotide (ODN).
XX
SQ Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 928 ATGGCCCTGCTATCCCTGCAC 948
Db 21 ATGGCCCTGCTATCCCTGCAC 1

RESULT 155
ADR82497
ID ADR82497 standard; DNA; 21 BP.
XX
AC ADR82497;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense RNAi probe #8.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX
FN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PF New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 102; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.

XX Sequence 21 BP; 5 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
SQ

Query Match 0.5%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 697 AAGGAGACCTTCACCGTCTTC 717
Db 1 AAGGAGACCTTCACCGTCTTC 21

```

XX human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX Example 8; Page 103; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense RNAi probe.
XX
XX Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 77;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3254 AAATCTGGCCAGTGTCAGC 3274
DB 1 AAATCTGGCCAGTGTCAGC 21

RESULT 158
ADR82489/c
ID ADR82489 standard; DNA; 21 BP.
XX
XX ADR82489;
XX AC
XX 16-DEC-2004 (first entry)
XX DT
XX Human EphB4 antisense probe #160.
XX DE
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
XX Homo sapiens.
XX OS
XX Synthetic.
XX OS
XX WO2004080418-A2.
XX PN

```

```

XX human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
XX Example 8; Page 102; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense RNAi probe.
XX
XX Sequence 21 BP; 7 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 77;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2310 AATCAAGACCTGAAGGGTGG 2330
DB 1 AATCAAGACCTGAAGGGTGG 21

RESULT 157
ADR82539
ID ADR82539 standard; DNA; 21 BP.
XX
XX ADR82539;
XX AC
XX 16-DEC-2004 (first entry)
XX DT
XX Human EphB4 antisense RNAi probe #50.
XX DE

```


XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007491.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX PA (VASG-) VASGENE THERAPEUTICS INC.
 XX PI Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
 XX Example 8; Page 101; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
 XX Sequence 21 BP; 5 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 CC Query Match 0.5%; Score 21; DB 1; Length 21;
 CC Best Local Similarity 100.0%; Pred. No. 77;
 CC Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2515 GTCATCCAGCTCGTGGCATG 2535
 DB 21 GTCATCCAGCTCGTGGCATG 1
 RESULT 159
 AD82526
 ID AD82526 standard; DNA; 21 BP.
 XX AC ADR82526;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human EphB4 antisense RNAi probe #37.
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
 XX OS Homo sapiens.
 XX PN WO2004080418-A2.
 XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007491.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX PA (VASG-) VASGENE THERAPEUTICS INC.
 XX PI Reddy R, Gill P;

XX WPI; 2004-668879/65.
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
 XX Example 8; Page 102; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense RNAi probe.
 XX Sequence 21 BP; 5 A; 10 C; 1 G; 5 T; 0 U; 0 Other;
 CC Query Match 0.5%; Score 21; DB 1; Length 21;
 CC Best Local Similarity 100.0%; Pred. No. 77;
 CC Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2677 AACTCTTCCGATCCACCTAC 2697
 DB 1 AACTCTTCCGATCCACCTAC 21
 RESULT 160
 ADU79893/C
 ID ADU79893 standard; DNA; 24 BP.
 XX AC ADU79893;
 XX DT 10-FEB-2005 (first entry)
 XX DE Antisense oligonucleotide #7 specific for human EphA7.
 XX Prostrate cancer; breast cancer; colon cancer; cytostatic;
 KW bone metastasis; EphA2; EphA2 inhibitor; bone injury; bone pain;
 KW analgesic; spinal cord compression; bone surgery; hypercalcemia;
 KW angiogenesis; antisense therapy; antibody therapy; antimetastatic;
 KW Brythropoietin-producing hepatocellular A2 receptor tyrosine kinase; ss.
 XX OS Homo sapiens.
 XX PN WO2004101764-A2.
 XX PD 25-NOV-2004.
 XX PF 12-MAY-2004; 2004WO-US014830.
 XX PR 13-MAY-2003; 2003US-0470006P.
 XX PR 18-SEP-2003; 2003US-0504324P.
 XX PA (CHIR) CHIRON CORP.
 XX PI Zimmerman DL, Hansen R, Winter J, Reinhard C, Fang S;
 XX WPI; 2005-039350/04.
 XX Inhibiting one or more skeletal related events such as bone fracture, spinal cord compression, bone surgery, bone metastasis or hypercalcemia of malignancy in cancer patient, involves administering EphA2 inhibitors to patient.
 XX Example 10; SEQ ID NO 77; 115pp; English.
 XX The present invention relates to metastasis of cancer to bone,

CC identifying molecules that play a role in skeletal related events (SRES)
CC and metastasis, identifying modulators of skeletal related events and
CC metastasis, and inhibiting one or more SRES in a patient. Determining the
CC susceptibility of a cancer patient to one or more SRES comprises
CC detecting evidence of Erythropoietin-producing hepatocellular A2 receptor
CC tyrosine kinase (EphA2) expression in a patient's cancer sample. Evidence
CC of EphA2 expression is indicative of the patient's susceptibility to one
CC or more SRES. The cancer prostate, breast or colon cancer. Inhibiting
CC SRES comprises administering one or more EphA2 inhibitors to the patient.
CC One inhibitor is an antibody that binds EphA2, where the antibody
CC inhibits bone SRES in a patient having bone metastasis, or the antibody
CC is identified by testing for its effectiveness for treating metastasis in
CC bone. The antibody binds at least one region of the EphA2 sequence, and
CC the regions are chosen from 60 sequences given in the specification. The
CC EphA2 inhibitor can also be an oligonucleotide, small molecule, mimetic,
CC or decoy. The methods are useful for determining the susceptibility of a
CC cancer patient to one or more SRES chosen from bone fracture, radiation
CC for bone pain or fracture prevention or treatment, spinal cord
CC compression, bone surgery, bone metastasis or hypercalcemia of
CC malignancy. The methods are useful for ameliorating symptoms of a
CC metastasis to bone in a cancer patient, inhibiting interactions of a
CC cancer cell and a host cell, inhibiting anchorage-dependent cell growth,
CC and inhibiting migration of cancer cell or inhibiting adhesion of cancer
CC cell. The symptoms of metastasis to bone is chosen from pain and bone
CC fractures. The present sequence is antisense oligonucleotide #7 specific
CC for human EphA2.

XX Sequence 24 BP; 4 A; 4 C; 9 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20.8; DB 1; Length 24;
Best Local Similarity 91.7%; Pred. No. 1.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2609 ACATCTCTAGTCAACAGCAACCTCG 2632
||||| |||||||
Db 24 ACATCTCTCTAGTCAACAGCAACCTCG 1

RESULT 161

ADR86761

ID ADR86761 standard; DNA; 22 BP.

XX

AC ADR86761;

XX

DT 16-DEC-2004 (first entry)

XX

DE Human ephrin B4 RT-PCR primer seqid 66.

XX

KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological, gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; reverse transcriptase PCR; primer; ss.

XX

OS Homo sapiens.

XX

FN WO2004080425-A2.

XX

PD 23-SEP-2004.

XX

PF 12-MAR-2004; 2004WO-US0007755.

XX

PR 12-MAR-2003; 2003US-0454300P.

XX

PR 12-MAR-2003; 2003US-0454432P.

XX

PA (VASG-) VASGENE THERAPEUTICS INC.

XX

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX

DR WPI; 2004-668883/65.

XX

PT New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.

XX Example 6; Page 86; 198pp; English.

PS The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a primer used in the isolation of human ephrin B4 CDNA.

XX Sequence 22 BP; 5 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 1e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1587 TCAGTCTACTGTCATTGAACGGG 1608

||||| |||||||

Db 1 TCAGTCTACTGTCATTGAACGGG 22

RESULT 162

ADR82667

ID ADR82667 standard; DNA; 22 BP.

XX

AC ADR82667;

XX

DT 16-DEC-2004 (first entry)

XX

DE Human EphB4 RT-PCR primer #3.

XX

KW human; ss; RT-PCR; primer; reverse transcriptase; EphB4; EphrinB2;

KW cancer; angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; angiogenesis inhibitor.

XX

OS Homo sapiens.

XX

FN WO2004080418-A2.

XX

PD 23-SEP-2004.

XX

PF 12-MAR-2004; 2004WO-US0007491.

XX

PR 12-MAR-2003; 2003US-0454300P.

XX

PR 12-MAR-2003; 2003US-0454432P.

XX

PA (VASG-) VASGENE THERAPEUTICS INC.

XX

PI Reddy R, Gill P;

XX

DR WPI; 2004-668879/65.

XX

PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2

transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 useful for diagnosing or treating cancer or angiogenesis-associated
 diseases.

Example 6; Page 93; 206pp; English.

The invention relates to an isolated nucleic acid compound comprising at
 least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 physiological conditions and decreases the expression of EphB4 or
 EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 medicament for the treatment of cancer or angiogenesis-associated
 diseases. The composition and methods are useful for diagnosing or
 treating cancer or angiogenesis-associated diseases, such as inflammatory
 disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 diseases or scleroderma. The present sequence represents a human EphB4
 reverse transcriptase (RT)-PCR primer.

Sequence 22 BP; 5 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20.4; DB 1; Length 22;
 Best Local Similarity 95.5%; Pred. No. 1e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1587 TGAGTCACTGCTGATGACGGG 1608
 Db 1 TCAGTCACTGCTGATGACGGG 22

RESULT 163
 ADE79941/c
 ID ADE79941 standard; cDNA; 24 BP.

AC ADE79941;
 XX
 XX 29-JAN-2004 (first entry)
 DT
 DE Tyrosine kinase antisense oligonucleotide.
 XX ss; antisense; tyrosine kinase; epithelial type cell tumour.
 KW Synthetic.
 OS
 XX US2003124133-A1.
 FN
 XX 03-JUN-2003.
 PD
 XX 26-AUG-1998; 98US-00140378.
 PF
 XX 14-JUN-1993; 93US-00077254.
 PR
 XX 16-AUG-1994; 94US-00292299.
 PR
 XX (JOHN/) JOHNSON J D.
 PA (RUTT/) RUTTER W J.
 PA (EDMA/) EDMAN J C.
 PA
 XX Johnson JD, Rutter WJ, Edman JC;
 PI WPI; 2004-009136/01.
 DR
 XX A new polypeptide has a discoidin-type ligand binding domain and a
 tyrosine kinase domain and is useful to diagnose and treat a patient
 having tumors of epithelial type cells which express the polypeptide on
 their surface.

Example 1; SEQ ID NO 3; 27pp; English.

The invention relates to a composition comprising a polypeptide having a
 first domain with carbohydrate binding activity and a second domain with
 kinase activity, a first domain with discoidin-type ligand binding
 characteristics and a second domain with tyrosine kinase activity. The
 invention is useful to diagnose, prognose and treat a patient having
 tumours of epithelial type cells which express the polypeptide on their
 surface. The present sequence represents a tyrosine kinase antisense

CC oligonucleotide.
 XX
 SQ Sequence 24 BP; 1 A; 6 C; 7 G; 4 T; 0 U; 6 Other;
 Query Match 0.5%; Score 20.4; DB 1; Length 24;
 Best Local Similarity 75.0%; Pred. No. 1.2e+02;
 Matches 18; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 2587 CACCGAGACTGCTGCTGCGCAAC 2610
 Db 24 CAYCGGAYCTGCGCYCGSAAC 1

RESULT 164
 ADR86727/c
 ID ADR86727 standard; DNA; 20 BP.

XX
 XX ADR86727;
 AC
 XX 16-DEC-2004 (first entry)
 DT
 XX Human ephrin B4 antisense oligonucleotide seqid 32.
 DE
 XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004080425-A2.
 FN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007755.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 XX 12-MAR-2003; 2003US-0454432P.
 PR
 XX (VAG-) VASGENE THERAPEUTICS INC.
 PA
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 PI WPI; 2004-668883/65.
 DR
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 associated diseases, such as inflammatory disorders, psoriasis or
 scleroderma.

Example 3; Page 62; 198pp; English.

The invention describes an isolated soluble polypeptide comprising an
 amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 described are: an antagonist antibody that binds to an extracellular
 domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 diagnostic kit, comprising the above soluble polypeptide or antagonist
 antibody, and a pharmaceutical carrier; methods of inhibiting
 angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 cell; a method of reducing the growth rate of a tumour; methods for
 treating a patient suffering from a cancer or an angiogenesis-associated
 disease; and a method for identifying a tumor that is suitable for
 treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 antibody is useful for manufacturing a medicament for the treatment of
 cancer or an angiogenesis-associated disease. The composition and methods
 are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2356 TTCTGAGCGAGCCTCCAT 2375
|||||
Db 20 TTCTGAGCGAGCCTCCAT 1
RESULT 165
ADR86801/c
ID ADR86801 standard; DNA; 20 BP.
XX
AC ADR86801;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 106.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US0007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
DR New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of
XX the EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumour; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 7 A; 10 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2799 TGTGATGTGGAGGTGATGT 2818
|||||
Db 20 TGTGATGTGGAGGTGATGT 1
RESULT 166
ADR86860/c
ID ADR86860 standard; DNA; 20 BP.
XX
AC ADR86860;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 165.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US0007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
DR New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of
XX the EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumour; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

XX
SQ Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1618 TTAGCCACGGGGCCCGTCCC 1637
Db 20 TTAGCCACGGGGCCCGTCCC 1

RESULT 167
ADR86901/c
ID ADR86901 standard; DNA; 20 BP.

AC ADR86901;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 206.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.

XX Example 8; Page 94; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

XX Sequence 20 BP; 2 A; 6 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 798 GGCGCGGAGCATCTCACCC 817

Db 20 GGCGCGGAGCATCTCACCC 1

RESULT 168

ADR87091/c

ID ADR87091 standard; DNA; 20 BP.

XX ADR87091;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 PCR primer seqid 396.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; PCR; primer; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.

XX Example 4; Page 69; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a primer used in the isolation of human ephrin B4 cDNA used in
CC the creation of an expression vector for producing a soluble Eph B4
CC derivative.

XX
SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 696 CAAGGAGACCTTCACCGTCT 715
DB 20 CAAGGAGACCTTCACCGTCT 1

RESULT 169
ADR86753/c
ID ADR86753 standard; DNA; 20 BP.
XX
AC ADR86753;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 58.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US0007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX
XX Example 5; Page 79; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

XX
SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2356 TTCTGAGCGAGCGCTCCAT 2375
DB 20 TTCTGAGCGAGCGCTCCAT 1

RESULT 170
ADR86782/c
ID ADR86782 standard; DNA; 20 BP.
XX
AC ADR86782;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 87.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US0007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX
XX Example 8; Page 91; 198pp; English.

CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphA4 or Ephrin B2
 CC protein. The EphA4 or Ephrin B2 polypeptide is a monomer, the EphA4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphA4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphA4 or Ephrin B2 protein and inhibits an activity of the
 CC EphA4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphA4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3179 CTTTCGAGCTGTCAGCCAG 3198
 |||||
 DB 20 CTTTCGAGCTGTCAGCCAG 1

RESULT 171
 ADR86823/c
 ID ADR86823 standard; DNA; 20 BP.

AC ADR86823;
 XX
 XX
 XX 16-DEC-2004 (first entry)
 DT
 DE Human ephrin B4 antisense oligonucleotide seqid 128.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.
 OS
 XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 8; Page 92; 198pp; English.
 PS
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphA4 or Ephrin B2
 CC protein. The EphA4 or Ephrin B2 polypeptide is a monomer, the EphA4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphA4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphA4 or Ephrin B2 protein and inhibits an activity of the
 CC EphA4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphA4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphA4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2358 TCTGAGCGAGGCTCCATCA 2377

DB 20 TCTGAGCGAGGCTCCATCA 1

RESULT 172

ADR86871/c
 ID ADR86871 standard; DNA; 20 BP.

XX ADR86871;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 176.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumor; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1398 GGAATGGAGTCCCTGG 1417
DB 20 GGAATGGAGTCCCTGG 1

RESULT 173
ADR86877/c
ID ADR86877 standard; DNA; 20 BP.
XX
AC ADR86877;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 182.
XX
KW cyostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
XX WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US0007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX

DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumor; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 8 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1278 CTGCCAGTCCCGTCGGT 1297
DB 20 CTGCCAGTCCCGTCGGT 1

RESULT 174
ADR86894/c
ID ADR86894 standard; DNA; 20 BP.
XX
AC ADR86894;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 199.
XX
KW cyostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
XX WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US0007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX
XX Example 8; Page 93; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX domain of the EphB4 or Ephrin B2 protein or a cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumor; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX antibody is useful for manufacturing a medicament for the treatment of
XX cancer or an angiogenesis-associated disease. The composition and methods
XX are useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases, such as inflammatory disorders, chronic articular rheumatism,
XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX represents a human ephrin B4 antisense oligonucleotide that can be used
XX to control EphB4 expression.
XX
XX Sequence 20 BP; 7 A; 1 C; 9 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 938 TATCCCTGCACCTCTCTAC 957
DB 20 TATCCCTGCACCTCTCTAC 1
RESULT 175
ADR86902/c
ID ADR86902 standard; DNA; 20 BP.
XX
XX ADR86902;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrin B4 antisense oligonucleotide seqid 207.
XX
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
XX pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; human; ephrin B4; antisense technology;
XX antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASC-) VASCENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX
XX Example 8; Page 94; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX domain of the EphB4 or Ephrin B2 protein or a cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumor; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX antibody is useful for manufacturing a medicament for the treatment of
XX cancer or an angiogenesis-associated disease. The composition and methods
XX are useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases, such as inflammatory disorders, chronic articular rheumatism,
XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX represents a human ephrin B4 antisense oligonucleotide that can be used
XX to control EphB4 expression.
XX
XX Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 778 TACATCAAGGTGCACACGGT 797
DB 20 TACATCAAGGTGCACACGGT 1
RESULT 176
ADR86910/c
ID ADR86910 standard; DNA; 20 BP.
XX
XX ADR86910;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrin B4 antisense oligonucleotide seqid 215.
XX
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
XX pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; human; ephrin B4; antisense technology;
XX antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.

OS Homo sapiens.
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 94; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 5 A; 8 C; 6 G; 1 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 398 GCTGGGCTTCGTTGGCCCA 417
 Db 20 GCTGGGCTTCGTTGGCCCA 1
 RESULT 179
 ADR86790/c
 ID ADR86790 standard; DNA; 20 BP.
 XX
 AC ADR86790;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 XX Human ephrin B4 antisense oligonucleotide seqid 95.
 DE
 XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; antisense technology;
 XX antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 92; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 3019 GCCAGCCTCAAAATCGTGGC 3038
 Db 20 GCCAGCCTCAAAATCGTGGC 1
 RESULT 180
 ADR86805/c
 ID ADR86805 standard; DNA; 20 BP.
 XX
 AC ADR86805;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 XX Human ephrin B4 antisense oligonucleotide seqid 110.
 DE
 XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 OS Homo sapiens.
 XX
 XX WO2004080425-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 XX Example 8; Page 92; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2719 ATTCCTCATCGATGACTGC 2738
 Db 20 ATTCCTCATCGATGACTGC 1
 RESULT 181
 ADR86809/c
 ID ADR86809 standard; DNA; 20 BP.
 XX
 AC ADR86809;
 XX
 XX 16-DEC-2004 (first entry)
 DT Human ephrin B4 antisense oligonucleotide seqid 114.
 DE

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 XX Homo sapiens.
 XX
 XX WO2004080425-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 XX Example 8; Page 92; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 XX Sequence 20 BP; 8 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2639 AAGTGCTGACTTGGCCTT 2658
 Db 20 AAGTGCTGACTTGGCCTT 1
 RESULT 182
 ADR86821/c
 ID ADR86821 standard; DNA; 20 BP.
 XX
 AC ADR86821;
 XX

DT XX 16-DEC-2004 (first entry)

DE XX Human ephrin B4 antisense oligonucleotide seqid 126.

XX KW cytotatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; antisense technology;

XX KW antisense oligonucleotide; ss.

OS Homo sapiens.

XX WO2004080425-A2.

PN 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASC-) VASGENE THERAPEUTICS INC.

PA Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

PI WPI; 2004-668883/65.

DR New soluble polypeptides comprising an extracellular domain of EphB4 or

XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or

PT scleroderma.

XX Example 8; Page 92; 198pp; English.

PS The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC cell; a method of reducing the growth rate of a tumour; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated

CC disease; and a method for identifying a tumor that is suitable for

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC antibody is useful for manufacturing a medicament for the treatment of

CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence

CC represents a human ephrin B4 antisense oligonucleotide that can be used

CC to control EphB4 expression.

XX SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2398 AATATCATCCCTGGAGGG 2417

Db ||||||||||||||||||

20 AATATCATCCCTGGAGGG 1

RESULT 183

ADR86824/c

ID ADR86824 standard; DNA; 20 BP.

XX ADR86824;

AC 16-DEC-2004 (first entry)

DT XX Human ephrin B4 antisense oligonucleotide seqid 129.

DE XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;

XX KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; antisense technology;

XX KW antisense oligonucleotide; ss.

OS Homo sapiens.

XX WO2004080425-A2.

PN 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASC-) VASGENE THERAPEUTICS INC.

PA Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

PI WPI; 2004-668883/65.

DR New soluble polypeptides comprising an extracellular domain of EphB4 or

XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or

PT scleroderma.

XX Example 8; Page 92; 198pp; English.

PS The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC cell; a method of reducing the growth rate of a tumour; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated

CC disease; and a method for identifying a tumor that is suitable for

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC antibody is useful for manufacturing a medicament for the treatment of

CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence

CC represents a human ephrin B4 antisense oligonucleotide that can be used

CC to control EphB4 expression.

XX SQ Sequence 20 BP; 3 A; 10 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2338 GAGCGGACGGCGTGAGTT 2357

Db ||||||||||||||||||

20 GAGCGGACGGCGTGAGTT 1

RESULT 184
ADR86840/c
ID ADR86840 standard; DNA; 20 BP.
XX
AC ADR86840;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 145.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PP 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a method for identifying a tumor that is suitable for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 7 A; 9 C; 4 G; 0 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2018 GTGTGGTCCTGGTCCTGGTG 2037
|||||

Db 20 GTGTGGTCCTGGTCCTGGTG 1
RESULT 185
ADR86841/c
ID ADR86841 standard; DNA; 20 BP.
XX
AC ADR86841;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 146.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PP 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a method for identifying a tumor that is suitable for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 10 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1998 TCGGGGACGCGAGTCGTGG 2017
|||||
Db 20 TCGGGGACGCGAGTCGTGG 1

RESULT 186
ADR86777/c
ID ADR86777 standard; DNA; 20 BP.
XX ADR86777;
XX 16-DEC-2004 (first entry)
XX Human ephrin B4 antisense oligonucleotide seqid 82.
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX Homo sapiens.
XX WO2004080425-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007755.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX Example 8; Page 91; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumour; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX antibody is useful for manufacturing a medicament for the treatment of
XX cancer or an angiogenesis-associated disease. The composition and methods
XX are useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases, such as inflammatory disorders, chronic articular rheumatism,
XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX represents a human ephrin B4 antisense oligonucleotide that can be used
XX to control EphB4 expression.

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 3279 GAAGTCCAGGCCAAGCCGG 3298
|||||
Db 20 GAAGTCCAGGCCAAGCCGG 1

RESULT 187
ADR86787/c
ID ADR86787 standard; DNA; 20 BP.
XX ADR86787;
XX 16-DEC-2004 (first entry)
XX Human ephrin B4 antisense oligonucleotide seqid 92.
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX Homo sapiens.
XX WO2004080425-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007755.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX Example 8; Page 92; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumour; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX antibody is useful for manufacturing a medicament for the treatment of
XX cancer or an angiogenesis-associated disease. The composition and methods
XX are useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases, such as inflammatory disorders, chronic articular rheumatism,
XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX represents a human ephrin B4 antisense oligonucleotide that can be used
XX to control EphB4 expression.

XX SQ Sequence 20 BP; 3 A; 4 C; 9 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3079 CGGCAGCCTCACTACTCAGC 3098
 |||||
 Db 20 CGGCAGCCTCACTACTCAGC 1

RESULT 188
 ADR86808/c
 ID ADR86808 standard; DNA; 20 BP.
 XX AC ADR86808;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human ephrin B4 antisense oligonucleotide seqid 113.
 XX KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX OS Homo sapiens.
 XX PN WO2004080425-A2.
 XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007755.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX PA (VASC-) VASGENE THERAPEUTICS INC.
 XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WIPI; 2004-668883/65.
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, psoriasis or scleroderma.
 XX Example 8; Page 92; 198pp; English.
 XX The invention describes an isolated soluble polypeptide comprising an amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2 protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4 polypeptide binds specifically to the Ephrin B2 polypeptide, and the Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also described are: an antagonist antibody that binds to an extracellular domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a diagnostic kit, comprising the above soluble polypeptide or antagonist antibody, and a pharmaceutical carrier; methods of inhibiting angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a cell; a method of reducing the growth rate of a tumour; methods for treating a patient suffering from a cancer or an angiogenesis-associated disease; and a method for identifying a tumor that is suitable for treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or antibody is useful for manufacturing a medicament for the treatment of cancer or an angiogenesis-associated disease. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence represents a human ephrin B4 antisense oligonucleotide that can be used to control EphB4 expression.
 CC SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2659 TCCCGATTCTCGAGAGAA 2678
 |||||
 Db 20 TCCCGATTCTCGAGAGAA 1

RESULT 189
 ADR86813/c
 ID ADR86813 standard; DNA; 20 BP.
 XX AC ADR86813;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human ephrin B4 antisense oligonucleotide seqid 118.
 XX KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX OS Homo sapiens.
 XX PN WO2004080425-A2.
 XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007755.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX PA (VASC-) VASGENE THERAPEUTICS INC.
 XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WIPI; 2004-668883/65.
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, psoriasis or scleroderma.
 XX Example 8; Page 92; 198pp; English.
 XX The invention describes an isolated soluble polypeptide comprising an amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2 protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4 polypeptide binds specifically to the Ephrin B2 polypeptide, and the Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also described are: an antagonist antibody that binds to an extracellular domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a diagnostic kit, comprising the above soluble polypeptide or antagonist antibody, and a pharmaceutical carrier; methods of inhibiting angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a cell; a method of reducing the growth rate of a tumour; methods for treating a patient suffering from a cancer or an angiogenesis-associated disease; and a method for identifying a tumor that is suitable for treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or antibody is useful for manufacturing a medicament for the treatment of cancer or an angiogenesis-associated disease. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism,

CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2558 TGGCGTACCTTGGCGAGATG 2577
 |||||
 Db 20 TGGCGTACCTTGGCGAGATG 1

RESULT 190

ADR86814/c

ID ADR86814 standard; DNA; 20 BP.

AC ADR86814;

XX 16-DEC-2004 (first entry)

DE Human ephrin B4 antisense oligonucleotide seqid 119.

XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

PS Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated

CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX Sequence 20 BP; 2 A; 9 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2538 GCGGGCATCGCTCGGCA 2557
 |||||
 Db 20 GCGGGCATCGCTCGGCA 1

RESULT 191

ADR86815/c

ID ADR86815 standard; DNA; 20 BP.

XX ADR86815;

XX 16-DEC-2004 (first entry)

DE Human ephrin B4 antisense oligonucleotide seqid 120.

XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

PS Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

XX
SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2518 ATCCAGCTCGTGGCATGCT 2537
Db |||||
20 ATCCAGCTCGTGGCATGCT 1

RESULT 192
ADR86819/c
ID ADR86819 standard; DNA; 20 BP.
XX
AC ADR86819;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 124.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2438 CCGTCATGATTCACAGAG 2457
Db |||||
20 CCGTCATGATTCACAGAG 1

RESULT 193
ADR86822/c
ID ADR86822 standard; DNA; 20 BP.
XX
AC ADR86822;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 127.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease, and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2378 TGGGCCAGTTCGAGCACCCC 2397

Db 20 TGGGCCAGTTCGAGCACCCC 1

RESULT 194

ADR86838/c
 ID ADR86838 standard; DNA; 20 BP.

AC ADR86838;

DT 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 143.

XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2058 CTGCCTCAGGAAGCAGAGCA 2077

Db 20 CTGCCTCAGGAAGCAGAGCA 1

RESULT 195

ADR86873/c
 ID ADR86873 standard; DNA; 20 BP.

AC ADR86873;

DT 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 178.

XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

PS Example 8; Page 93; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumour; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated

CC antibody is useful for manufacturing a medicament for the treatment of

CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence

CC represents a human ephrin B4 antisense oligonucleotide that can be used

CC to control EphB4 expression.

XX Sequence 20 BP; 5 A; 8 C; 6 G; 1 T; 0 U; 0 Other;

SQ

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1358 GGAGCGTGGTTCCGCGCTG 1377

DB 20 GGAGCGGTGGTTCCGCGCTG 1

RESULT 196

ADR86899/c

ID ADR86899 standard; DNA; 20 BP.

XX

AC ADR86899;

XX

DT 16-DEC-2004 (first entry)

XX

DE Human ephrin B4 antisense oligonucleotide seqid 204.

XX

KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; antisense technology;

KW antisense oligonucleotide; ss.

XX

OS Homo sapiens.

XX

PN WO2004080425-A2.

XX

PD 23-SEP-2004.

XX

PF 12-MAR-2004; 2004WO-US0007755.

XX

PR 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX

PA (VASG-) VASGENE THERAPEUTICS INC.

XX

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

DR

PT New soluble polypeptides comprising an extracellular domain of EphB4 or Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or scleroderma.

XX Example 8; Page 94; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumour; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated

CC disease; and a method for identifying a tumor that is suitable for

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC antibody is useful for manufacturing a medicament for the treatment of

CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence

CC represents a human ephrin B4 antisense oligonucleotide that can be used

CC to control EphB4 expression.

XX Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;

SQ

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 838 GCCACCGGAGGTGAATGT 857

DB 20 GCCACCGGAGGTGAATGT 1

RESULT 197

ADR86923/c

ID ADR86923 standard; DNA; 20 BP.

XX

AC ADR86923;

XX

DT 16-DEC-2004 (first entry)

XX

DE Human ephrin B4 antisense oligonucleotide seqid 228.

XX

KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; antisense technology;

KW antisense oligonucleotide; ss.

XX

OS Homo sapiens.

XX

PN WO2004080425-A2.

XX

PD 23-SEP-2004.

XX

PF 12-MAR-2004; 2004WO-US0007755.

XX

PR 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX

PA (VASG-) VASGENE THERAPEUTICS INC.

XX

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

DR

```

XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumor; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 376 ATGGAGCTCCGGTCTGCT 395
DB 20 ATGGAGCTCCGGTCTGCT 1
RESULT 198
ADR86758/c
ID ADR86758 standard; DNA; 20 BP.
AC ADR86758;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrin B4 probe seqid 63.
XX
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
XX pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; human; ephrin B4; probe; ss.
XX
XX Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

```

```

XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 6; Page 86; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumor; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 probe that can be used to detect EphB4
CC expression.
XX
SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 696 CAGGAGACCTTCACCGTCT 715
DB 20 CAGGAGACCTTCACCGTCT 1
RESULT 199
ADR86778/c
ID ADR86778 standard; DNA; 20 BP.
AC ADR86778;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrin B4 antisense oligonucleotide seqid 83.
XX
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
XX pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; human; ephrin B4; antisense technology;
XX antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX

```

PA (VASG-) VASGENE THERAPEUTICS INC.
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 XX Example 8; Page 91; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumor; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 XX Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3259 TTGGCCAGTGTCCAGCACAT 3278
 Db 20 TTGGCCAGTGTCCAGCACAT 1
 RESULT 200
 ADR86796/c
 ID ADR86796 standard; DNA; 20 BP.
 XX
 AC ADR86796;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 101.
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 PN W02004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX

PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 XX Example 8; Page 92; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumor; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 XX Sequence 20 BP; 3 A; 2 C; 12 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2899 CCCCAGACTGTCCACCTC 2918
 Db 20 CCCCAGACTGTCCACCTC 1
 RESULT 201
 ADR86803/c
 ID ADR86803 standard; DNA; 20 BP.
 XX
 AC ADR86803;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 108.
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 PN W02004080425-A2.
 XX
 PD 23-SEP-2004.
 XX

XX PF 12-MAR-2004; 2004WO-US007755.
 XX PF 12-MAR-2003; 2003US-0454300P.
 XX PF 12-MAR-2003; 2003US-0454432P.
 XX PA (VASG-) VASGENE THERAPEUTICS INC.
 XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX DR WPI; 2004-668883/65.
 XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX PS Example 8; Page 92; 198pp; English.
 XX CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumor; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2759 GGAAGTTCACTTCGCCAGT 2778
 Db |||||
 20 GGAAGTTCACTTCGCCAGT 1
 RESULT 202
 ADR86832/c
 ID ADR86832 standard; DNA; 20 BP.
 XX AC ADR86832;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human ephrin B4 antisense oligonucleotide seqid 137.
 XX KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 XX KW antisense oligonucleotide; ss.
 OS Homo sapiens.
 XX

PN WO2004080425-A2.
 XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007755.
 XX PF 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX PA (VASG-) VASGENE THERAPEUTICS INC.
 XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX DR WPI; 2004-668883/65.
 XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX PS Example 8; Page 92; 198pp; English.
 XX CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumor; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX SQ Sequence 20 BP; 5 A; 8 C; 2 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2178 GGCTGTGAGGGAATTTGCAA 2197
 Db |||||
 20 GGCTGTGAGGGAATTTGCAA 1
 RESULT 203
 ADR86848/c
 ID ADR86848 standard; DNA; 20 BP.
 XX AC ADR86848;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human ephrin B4 antisense oligonucleotide seqid 153.
 XX KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 XX KW antisense oligonucleotide; ss.

XX OS Homo sapiens.
 XX PN WO2004080425-A2.
 XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007755.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX PA (VASC-) VASGENE THERAPEUTICS INC.
 XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX DR WPI; 2004-668883/65.
 XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX PS Example 8; Page 93; 198pp; English.
 XX CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumor; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX SQ Sequence 20 BP; 1 A; 12 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1858 CGGGGGCTGAAGCGGGAGC 1877
 Db ||||||||||||||||
 20 CGGGGGCTGAAGCGGGAGC 1
 RESULT 204
 ADR86850/c
 ID ADR86850 standard; DNA; 20 BP.
 XX AC ADR86850;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human ephrin B4 antisense oligonucleotide seqid 155.
 XX KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 XX antisense oligonucleotide; ss.
 XX OS Homo sapiens.
 XX PN WO2004080425-A2.
 XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007755.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX PA (VASC-) VASGENE THERAPEUTICS INC.
 XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX DR WPI; 2004-668883/65.
 XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX PS Example 8; Page 93; 198pp; English.
 XX CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumor; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1818 CGTGGGTTCTCTGAAGACGT 1837
 Db ||||||||||||||||
 20 CGTGGGTTCTCTGAAGACGT 1
 RESULT 205
 ADR86856/c
 ID ADR86856 standard; DNA; 20 BP.
 XX AC ADR86856;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human ephrin B4 antisense oligonucleotide seqid 161.
 XX KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX Homo sapiens.
 OS
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 93; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred.No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1698 GGTGACGGGCTTCACCCA 1717
 Db |||||
 20 GGTGACGGGCTTCACCCA 1
 RESULT 206
 ADR86862/c
 ID ADR86862 standard; DNA; 20 BP.
 XX
 AC ADR86862;
 XX
 DT 16-DEC-2004 (first entry)
 XX

DE Human ephrin B4 antisense oligonucleotide seqid 167.
 XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX Homo sapiens.
 OS
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 93; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred.No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1578 CTATACCTTTGAGGTCACTG 1597
 Db |||||
 20 CTATACCTTTGAGGTCACTG 1
 RESULT 207
 ADR86884/c
 ID ADR86884 standard; DNA; 20 BP.
 XX
 AC ADR86884;
 XX

XX 16-DEC-2004 (first entry)
DT Human ephrin B4 antisense oligonucleotide seqid 189.
XX
XX
DE cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-045432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 93; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 9 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1138 TGTGCTCCGGGGTTCGAGGC 1157
Dbbbbb|
20 TGTGCTCCGGGGTTCGAGGC 1

RESULT 208
ADR86895/c

ID ADR86895 standard; DNA; 20 BP.
XX
AC ADR86895;
XX
DT 16-DEC-2004 (first entry)
XX
XX Human ephrin B4 antisense oligonucleotide seqid 200.
DE
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-045432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 93; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 8 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 918 GGGTGCCTGCATGGCCCTGC 937
Dbbbbb|
20 GGGTGCCTGCATGGCCCTGC 1

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 698 AGGAGACCTTCACCGTCTTC 717
| | | | | | | | | | | | | | | |
Db 20 AGGAGACCTTCACCGTCTTC 1

RESULT 211
ADR86908/c
ID ADR86908 standard; DNA; 20 BP.
XX ADR86908;
AC
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 213.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; disease; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
XX
SQ Sequence 20 BP; 5 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 658 CTCGAGTGCCTGCTCCCTGCC 677
| | | | | | | | | | | | | | | |
Db 20 CTCGAGTGCCTGCTCCCTGCC 1

RESULT 212
ADR86918/c
ID ADR86918 standard; DNA; 20 BP.
XX
XX ADR86918;
AC
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 223.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; disease; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
XX
SQ Sequence 20 BP; 5 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 458 CTGATCTGAAGTGGTGACA 477
|||||
Db 20 CTGATCTGAAGTGGTGACA 1
RESULT 213
ADR86725
ID ADR86725 standard; DNA; 20 BP.
XX
AC ADR86725;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 30.
XX
KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
FN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 3; Page 62; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 691 TCCTGCAAGGAGACCTTCAC 710
|||||
Db 1 TCCTGCAAGGAGACCTTCAC 20
RESULT 214
ADR86785/c
ID ADR86785 standard; DNA; 20 BP.
XX
AC ADR86785;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 90.
XX
KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
FN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX
DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

XX Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

SQ Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3119 GGCTTCGGGCCATCAAAATG 3138

Db 20 GGCTTCGGGCCATCAAAATG 1

RESULT 215

ADR86835/C

ID ADR86835 standard; DNA; 20 BP.

AC ADR86835;

DT 16-DEC-2004 (first entry)

DE Human ephrin B4 antisense oligonucleotide seqid 140.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; antisense technology;

KW antisense oligonucleotide; ss.

XX Homo sapiens.

OS WO2004080425-A2.

PN 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

PF 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

PA Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

PI WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or

PT scleroderma.

XX Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumour; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

XX Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

SQ Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2118 TCTCATCGGACATGCTACTA 2137

Db 20 TCTCATCGGACATGCTACTA 1

RESULT 216

ADR86851/C

ID ADR86851 standard; DNA; 20 BP.

AC ADR86851;

DT 16-DEC-2004 (first entry)

DE Human ephrin B4 antisense oligonucleotide seqid 156.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; antisense technology;

KW antisense oligonucleotide; ss.

XX Homo sapiens.

OS WO2004080425-A2.

PN 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

PF 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

PA Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

PI WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or

PT scleroderma.

XX Example 8; Page 93; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumor; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX
 SQ Sequence 20 BP; 1 A; 9 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1798 GGCGCCGAGGTCACGACG 1817
 Db 20 GGCGCCGAGGTCACGACG 1

RESULT 217
 ADR86864/c
 ID ADR86864 standard; DNA; 20 BP.

AC ADR86864;

DT 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 169.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

OS Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

PS Example 8; Page 93; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumor; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX
 SQ Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1538 AGCCTGGTGGTGGTTTCCA 1557
 Db 20 AGCCTGGTGGTGGTTTCCA 1

RESULT 218

ADR86875/c

ID ADR86875 standard; DNA; 20 BP.

XX ADR86875;

DT 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 180.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

OS Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

PS Example 8; Page 93; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

SQ Sequence 20 BP; 2 A; 6 C; 10 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1318 CCCCGGGTGCACCTGCAC 1337
 Db 20 CCCCGGGTGCACCTGCAC 1

RESULT 219
 ADR86879/c
 ID ADR86879 standard; DNA; 20 BP.
 XX
 AC ADR86879;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 184.
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX
 DR WPI; 2004-668883/65.
 XX
 PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 93; 198pp; English.
 XX

CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX
 SQ Sequence 20 BP; 3 A; 3 C; 9 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1238 GCCCAGCCCAATAGCCACTCT 1257
 Db 20 GCCCAGCCCAATAGCCACTCT 1

RESULT 220
 ADR86880/c
 ID ADR86880 standard; DNA; 20 BP.
 XX
 AC ADR86880;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 185.
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX
 DR WPI; 2004-668883/65.
 XX
 PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 8; Page 93; 198pp; English.

PS The invention describes an isolated soluble polypeptide comprising an

XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumor; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated

CC disease; and a method for identifying a tumor that is suitable for

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC antibody is useful for manufacturing a medicament for the treatment of

CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence

CC represents a human ephrin B4 antisense oligonucleotide that can be used

CC to control EphB4 expression.

XX

SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1218 AGAAGGTCCTGCCAGCCAT 1237

Db 20 AGAAGGTCCTGCCAGCCAT 1

RESULT 221

ADR86900/c

ID ADR86900 standard; DNA; 20 BP.

XX

AC ADR86900;

XX

DT 16-DEC-2004 (first entry)

XX

DE Human ephrin B4 antisense oligonucleotide seqid 205.

XX

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; antisense technology;

XX antisense oligonucleotide; ss.

XX

OS Homo sapiens.

XX

FN WO2004080425-A2.

XX

PD 23-SEP-2004.

XX

PF 12-MAR-2004; 2004WO-US0007755.

XX

PR 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX

PA (VASG-) VASGENE THERAPEUTICS INC.

XX

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX

PT New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or

XX scleroderma.

XX Example 8; Page 94; 198pp; English.

PS The invention describes an isolated soluble polypeptide comprising an

XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumor; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated

CC disease; and a method for identifying a tumor that is suitable for

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC antibody is useful for manufacturing a medicament for the treatment of

CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence

CC represents a human ephrin B4 antisense oligonucleotide that can be used

CC to control EphB4 expression.

XX

SQ Sequence 20 BP; 1 A; 10 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 818 GGAAGCGCCCTGGGCGGAG 837

Db 20 GGAAGCGCCCTGGGCGGAG 1

RESULT 222

ADR86907/c

ID ADR86907 standard; DNA; 20 BP.

XX

AC ADR86907;

XX

DT 16-DEC-2004 (first entry)

XX

DE Human ephrin B4 antisense oligonucleotide seqid 212.

XX

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; antisense technology;

XX antisense oligonucleotide; ss.

XX

OS Homo sapiens.

XX

FN WO2004080425-A2.

XX

PD 23-SEP-2004.

XX

PF 12-MAR-2004; 2004WO-US0007755.

XX

PR 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX

PA (VASG-) VASGENE THERAPEUTICS INC.

XX

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX

DR WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX
PS Example 8; Page 94; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 8 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 678 TCGGGCTGGCGCTCTGCA 697
DB 20 TCGGGCTGGCGCTCTGCA 1

RESULT 223
ADR86731
ID ADR86731 standard; DNA; 20 BP.
XX
AC ADR86731;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 RT-PCR primer seqid 36.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; reverse transcriptase PCR; primer; ss.
OS
XX Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX
PS Example 3; Page 63; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 AAGGAGACCTTCACCGTCTT 716
DB 1 AAGGAGACCTTCACCGTCTT 20

RESULT 224
ADR86779/c
ID ADR86779 standard; DNA; 20 BP.
XX
AC ADR86779;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 84.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
XX
XX antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX

(VASG-) VASGENE THERAPEUTICS INC.
Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
WPI; 2004-668883/65.
New soluble polypeptides comprising an extracellular domain of EphB4 or Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, psoriasis or scleroderma.
Example 8; Page 91; 198pp; English.
The invention describes an isolated soluble polypeptide comprising an amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2 protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4 polypeptide binds specifically to the Ephrin B2 polypeptide, and the Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also described are: an antagonist antibody that binds to an extracellular domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a diagnostic kit, comprising the above soluble polypeptide or antagonist antibody, and a pharmaceutical carrier; methods of inhibiting angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a cell; a method of reducing the growth rate of a tumor; methods for treating a patient suffering from a cancer or an angiogenesis-associated disease; and a method for identifying a tumor that is suitable for treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or antibody is useful for manufacturing a medicament for the treatment of cancer or an angiogenesis-associated disease. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. This sequence represents a human ephrin B4 antisense oligonucleotide that can be used to control EphB4 expression.
Sequence 20 BP; 1 A; 5 C; 5 G; 9 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 3239 CGGGACACACAGAGAAATC 3258
Db 20 CGGGACACACAGAGAAATC 1
RESULT 225
ADR86784/c
ID ADR86784 standard; DNA; 20 BP.
AC ADR86784;
DT 16-DEC-2004 (first entry)
DE Human ephrin B4 antisense oligonucleotide seqid 89.
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic; dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2; pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour; angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease; scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
OS Homo sapiens.
FN WO2004080425-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007755.

12-MAR-2003; 2003US-0454300P.
12-MAR-2003; 2003US-0454432P.
(VASG-) VASGENE THERAPEUTICS INC.
Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
WPI; 2004-668883/65.
New soluble polypeptides comprising an extracellular domain of EphB4 or Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, psoriasis or scleroderma.
Example 8; Page 92; 198pp; English.
The invention describes an isolated soluble polypeptide comprising an amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2 protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4 polypeptide binds specifically to the Ephrin B2 polypeptide, and the Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also described are: an antagonist antibody that binds to an extracellular domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a diagnostic kit, comprising the above soluble polypeptide or antagonist antibody, and a pharmaceutical carrier; methods of inhibiting angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a cell; a method of reducing the growth rate of a tumor; methods for treating a patient suffering from a cancer or an angiogenesis-associated disease; and a method for identifying a tumor that is suitable for treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or antibody is useful for manufacturing a medicament for the treatment of cancer or an angiogenesis-associated disease. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. This sequence represents a human ephrin B4 antisense oligonucleotide that can be used to control EphB4 expression.
Sequence 20 BP; 4 A; 6 C; 1 G; 9 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 3139 GGAAGATACGAGAAAGTTT 3158
Db 20 GGAAGATACGAGAAAGTTT 1
RESULT 226
ADR86792/c
ID ADR86792 standard; DNA; 20 BP.
AC ADR86792;
DT 16-DEC-2004 (first entry)
DE Human ephrin B4 antisense oligonucleotide seqid 97.
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic; dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2; pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour; angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease; scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
OS Homo sapiens.
FN WO2004080425-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2004; 2004WO-US007755.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX Example 8; Page 92; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumour; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX antibody is useful for manufacturing a medicament for the treatment of
XX cancer or an angiogenesis-associated disease. The composition and methods
XX are useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases, such as inflammatory disorders, chronic articular rheumatism,
XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX represents a human ephrin B4 antisense oligonucleotide that can be used
XX to control EphB4 expression.
SQ Sequence 20 BP; 3 A; 8 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2979 CCAGGTGGTCAGCGCCCTGG 2998
Db |||||
20 CCAGGTGGTCAGCGCCCTGG 1
RESULT 227
ADR86804/c
ID ADR86804 standard; DNA; 20 BP.
XX ADR86804;
XX 16-DEC-2004 (first entry)
XX Human ephrin B4 antisense oligonucleotide seqid 109.
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
XX pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; human; ephrin B4; antisense technology;
XX antisense oligonucleotide; ss.
XX Homo sapiens.
XX

PN WO2004080425-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007755.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX Example 8; Page 92; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumour; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX antibody is useful for manufacturing a medicament for the treatment of
XX cancer or an angiogenesis-associated disease. The composition and methods
XX are useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases, such as inflammatory disorders, chronic articular rheumatism,
XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX represents a human ephrin B4 antisense oligonucleotide that can be used
XX to control EphB4 expression.
SQ Sequence 20 BP; 4 A; 5 C; 9 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2739 CCCGAGGCCATTGCTTCC 2758
Db |||||
20 CCCGAGGCCATTGCTTCC 1
RESULT 228
ADR86807/c
ID ADR86807 standard; DNA; 20 BP.
XX ADR86807;
XX 16-DEC-2004 (first entry)
XX Human ephrin B4 antisense oligonucleotide seqid 112.
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
XX pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; human; ephrin B4; antisense technology;
XX antisense oligonucleotide; ss.
XX

KW OS Homo sapiens.
XX FN WO2004080425-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007755.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX DR WPI; 2004-668883/65.
XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
XX PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX PT associated diseases, such as inflammatory disorders, psoriasis or
XX PT scleroderma.
XX PS Example 8; Page 92; 198pp; English.
XX CC The invention describes an isolated soluble polypeptide comprising an
XX CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX CC described are: an antagonist antibody that binds to an extracellular
XX CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX CC diagnostic kit, comprising the above soluble polypeptide or antagonist
XX CC antibody, and a pharmaceutical carrier; methods of inhibiting
XX CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX CC cell; a method of reducing the growth rate of a tumour; methods for
XX CC treating a patient suffering from a cancer or an angiogenesis-associated
XX CC disease; and a method for identifying a tumor that is suitable for
XX CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX CC antibody is useful for manufacturing a medicament for the treatment of
XX CC cancer or an angiogenesis-associated disease. The composition and methods
XX CC are useful for diagnosing or treating cancer or angiogenesis-associated
XX CC diseases, such as inflammatory disorders, chronic articular rheumatism,
XX CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX CC represents a human ephrin B4 antisense oligonucleotide that can be used
XX CC to control EphB4 expression.
XX SQ Sequence 20 BP; 5 A; 1 C; 10 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2679 CTCCTCCGATCCACCTACA 2698
Db 20 CTCCTCCGATCCACCTACA 1
RESULT 229
ADR86867/c
ID ADR86867 standard; DNA; 20 BP.
XX AC ADR86867;
XX DT 16-DEC-2004 (first entry)
XX DE Human ephrin B4 antisense oligonucleotide seqid 172.
XX KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
XX KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
XX KW angiogenesis-associated disease; inflammatory disorder;

KW KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; human; ephrin B4; antisense technology;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX FN WO2004080425-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007755.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX DR WPI; 2004-668883/65.
XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
XX PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX PT associated diseases, such as inflammatory disorders, psoriasis or
XX PT scleroderma.
XX PS Example 8; Page 93; 198pp; English.
XX CC The invention describes an isolated soluble polypeptide comprising an
XX CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX CC described are: an antagonist antibody that binds to an extracellular
XX CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX CC diagnostic kit, comprising the above soluble polypeptide or antagonist
XX CC antibody, and a pharmaceutical carrier; methods of inhibiting
XX CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX CC cell; a method of reducing the growth rate of a tumour; methods for
XX CC treating a patient suffering from a cancer or an angiogenesis-associated
XX CC disease; and a method for identifying a tumor that is suitable for
XX CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX CC antibody is useful for manufacturing a medicament for the treatment of
XX CC cancer or an angiogenesis-associated disease. The composition and methods
XX CC are useful for diagnosing or treating cancer or angiogenesis-associated
XX CC diseases, such as inflammatory disorders, chronic articular rheumatism,
XX CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX CC represents a human ephrin B4 antisense oligonucleotide that can be used
XX CC to control EphB4 expression.
XX SQ Sequence 20 BP; 4 A; 8 C; 8 G; 0 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1478 GCTCCTGTGCGCCTGCGG 1497
Db 20 GCTCCTGTGCGCCTGCGG 1
RESULT 230
ADR86874/c
ID ADR86874 standard; DNA; 20 BP.
XX AC ADR86874;
XX DT 16-DEC-2004 (first entry)
XX DE Human ephrin B4 antisense oligonucleotide seqid 179.
XX KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
XX antisense oligonucleotide; ss.
OS Homo sapiens.
XX WO2004080425-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007755.
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-045432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX Example 8; Page 93; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX Sequence 20 BP; 4 A; 3 C; 12 G; 1 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. NO. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1338 CACCCCTCCCTTCGCTCCG 1357
Db 20 CACCCCTCCCTTCGCTCCG 1
RESULT 231
ADR86881/c
ID ADR86881 standard; DNA; 20 BP.
XX ADR86881;
AC ADR86881;
XX 16-DEC-2004 (first entry)
XX

DE Human ephrin B4 antisense oligonucleotide seqid 186.
XX cytostatic; antiinflammatory; antirheumatic; antiapoptotic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
XX antisense oligonucleotide; ss.
XX Homo sapiens.
XX WO2004080425-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007755.
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-045432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX Example 8; Page 93; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. NO. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1198 ACCTTCAGCCCTGTCCAG 1217
Db 20 ACCTTCAGCCCTGTCCAG 1
RESULT 232
ADR86892/c
ID ADR86892 standard; DNA; 20 BP.
XX ADR86892;
AC ADR86892;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 197.

XX cytosolic; antiinflammatory; antirheumatic; antipsoriatic;

XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

XX pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

XX angiogenesis-associated disease; inflammatory disorder;

XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;

XX scleroderma; human; ephrin B4; antisense technology;

XX antisense oligonucleotide; ss.

OS Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or

XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

XX associated diseases, such as inflammatory disorders, psoriasis or

XX scleroderma.

XX Example 8; Page 93; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the

XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

XX described are: an antagonist antibody that binds to an extracellular

XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

XX diagnostic kit, comprising the above soluble polypeptide or antagonist

XX antibody, and a pharmaceutical carrier; methods of inhibiting

XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

XX cell; a method of reducing the growth rate of a tumour; methods for

XX treating a patient suffering from a cancer or an angiogenesis-associated

XX disease; and a method for identifying a tumor that is suitable for

XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

XX antibody is useful for manufacturing a medicament for the treatment of

XX cancer or an angiogenesis-associated disease. The composition and methods

XX are useful for diagnosing or treating cancer or angiogenesis-associated

XX diseases, such as inflammatory disorders, chronic articular rheumatism,

XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence

XX represents a human ephrin B4 antisense oligonucleotide that can be used

XX to control EphB4 expression.

XX Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 978 TGTGACCTGACTCGATTCC 997

Db 20 TGTGAACCTGACTCGATTCC 1

RESULT 233

ADR86893/c

ID ADR86893 standard; DNA; 20 BP.

XX ADR86893;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 198.

XX cytosolic; antiinflammatory; antirheumatic; antipsoriatic;

XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

XX pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

XX angiogenesis-associated disease; inflammatory disorder;

XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;

XX scleroderma; human; ephrin B4; antisense technology;

XX antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or

XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

XX associated diseases, such as inflammatory disorders, psoriasis or

XX scleroderma.

XX Example 8; Page 93; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the

XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

XX described are: an antagonist antibody that binds to an extracellular

XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

XX diagnostic kit, comprising the above soluble polypeptide or antagonist

XX antibody, and a pharmaceutical carrier; methods of inhibiting

XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

XX cell; a method of reducing the growth rate of a tumour; methods for

XX treating a patient suffering from a cancer or an angiogenesis-associated

XX disease; and a method for identifying a tumor that is suitable for

XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

XX antibody is useful for manufacturing a medicament for the treatment of

XX cancer or an angiogenesis-associated disease. The composition and methods

XX are useful for diagnosing or treating cancer or angiogenesis-associated

XX diseases, such as inflammatory disorders, chronic articular rheumatism,

XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence

XX represents a human ephrin B4 antisense oligonucleotide that can be used

XX to control EphB4 expression.

XX Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 958 AAAAAGTGCGCCCGAGCTGAC 977

Db 20 AAAAAGTGCGCCCGAGCTGAC 1

RESULT 234
 ID ADR86917/C
 AC ADR86917;
 DT 16-DEC-2004 (first entry)
 DE Human ephrin B4 antisense oligonucleotide seqid 222.
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX
 DR WPI; 2004-668883/65.
 XX
 PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 94; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 20 TTCCCTCAGTGGACGGCA 1
 RESULT 235
 ID ADR86794/C
 AC ADR86794;
 DT 16-DEC-2004 (first entry)
 DE Human ephrin B4 antisense oligonucleotide seqid 99.
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX
 DR WPI; 2004-668883/65.
 XX
 PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 92; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;

CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 8 A; 6 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2038 GTCATTGTGGTCCAGTTCT 2057
Db 20 GTCATTGTGGTCCAGTTCT 1
RESULT 238
ADR86847/C
ID ADR86847 standard; DNA; 20 BP.
AC ADR86847;
XX
XX
DT 16-DEC-2004 (first entry)
XX
XX Human ephrin B4 antisense oligonucleotide seqid 152.
DE
XX
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
PI WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 93; 198pp; English.
PS
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1878 CAGCTACCTGCTGCAGGTAC 1897
Db 20 CAGCTACCTGCTGCAGGTAC 1
RESULT 239
ADR86854/C
ID ADR86854 standard; DNA; 20 BP.
XX
XX ADR86854;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrin B4 antisense oligonucleotide seqid 159.
DE
XX
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
PI WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 93; 198pp; English.
PS
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

XX SQ Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1738 GCTGTTCCCGGACCCAG 1757

Db 20 GCTGTTCCCGGACCCAG 1

RESULT 240

ADR86855/c

ID ADR86855 standard; DNA; 20 BP.

XX AC ADR86855;

XX DT 16-DEC-2004 (first entry)

XX DE Human ephrin B4 antisense oligonucleotide seqid 160.

XX KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
XX KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
XX KW angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; human; ephrin B4; antisense technology;
XX KW antisense oligonucleotide; ss.

XX OS Homo sapiens.

XX FN WO2004080425-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US007755.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-0454432P.

XX PA (VASG-) VASGENE THERAPEUTICS INC.

XX FI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX DR WPI; 2004-668883/65.

XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
XX PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX PT associated diseases, such as inflammatory disorders, psoriasis or
XX PT scleroderma.

XX PS Example 8; Page 93; 198pp; English.

XX CC The invention describes an isolated soluble polypeptide comprising an
XX CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX CC described are: an antagonist antibody that binds to an extracellular
XX CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX CC antibody, comprising the above soluble polypeptide or antagonist
XX CC antibody, and a pharmaceutical carrier; methods of inhibiting
XX CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX CC cell; a method of reducing the growth rate of a tumour; methods for.

CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

XX SQ Sequence 20 BP; 4 A; 8 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1718 GCAGCTTGAGCTGGCCTGG 1737

Db 20 GCAGCTTGAGCTGGCCTGG 1

RESULT 241

ADR86888/c

ID ADR86888 standard; DNA; 20 BP.

XX AC ADR86888;

XX DT 16-DEC-2004 (first entry)

XX DE Human ephrin B4 antisense oligonucleotide seqid 193.

XX KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
XX KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
XX KW angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; human; ephrin B4; antisense technology;
XX KW antisense oligonucleotide; ss.

XX OS Homo sapiens.

XX FN WO2004080425-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US007755.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-0454432P.

XX PA (VASG-) VASGENE THERAPEUTICS INC.

XX FI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX DR WPI; 2004-668883/65.

XX PT New soluble polypeptides comprising an extracellular domain of EphB4 or
XX PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX PT associated diseases, such as inflammatory disorders, psoriasis or
XX PT scleroderma.

XX PS Example 8; Page 93; 198pp; English.

XX CC The invention describes an isolated soluble polypeptide comprising an
XX CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX CC described are: an antagonist antibody that binds to an extracellular
XX CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX
 SQ Sequence 20 BP; 2 A; 4 C; 13 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1058 TCCCGGCCCTGGCCCGCAGC 1077
 |||||
 Db 20 TCCCGGCCCTGGCCCGCAGC 1

RESULT 242

ADR86757
 ID ADR86757 standard; DNA; 20 BP.

AC ADR86757;

DT 16-DEC-2004 (first entry)

XX Human ephrin B4 probe seqid 62.

XX
 XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; probe; ss.

OS Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASC-) VASGENE THERAPEUTICS INC.

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

PS Example 6; Page 86; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 probe that can be used to detect EphB4
 CC expression.

XX
 SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 419 CTTTGAAGAGACCCCTGCTG 438
 |||||
 Db 1 CTTTGAAGAGACCCCTGCTG 20

RESULT 243

ADR86793/c

ID ADR86793 standard; DNA; 20 BP.

XX ADR86793;

DT 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 98.

XX
 XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

OS Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASC-) VASGENE THERAPEUTICS INC.

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

PS Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX Sequence 20 BP; 3 A; 4 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2959 AATGCCCGGCCCGCTTCCC 2978

Db 20 AATGCCCGGCCCGCTTCCC 1

RESULT 244

ADR86802/c

ID ADR86802 standard; DNA; 20 BP.

XX ADR86802;

DT 16-DEC-2004 (first entry)

DE Human ephrin B4 antisense oligonucleotide seqid 107.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2779 GATGCTCGGAGTTACGGGAT 2798

Db 20 GATGCTCGGAGTTACGGGAT 1

RESULT 245

ADR86806/c

ID ADR86806 standard; DNA; 20 BP.

XX ADR86806;

DT 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 111.

XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

PS Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumour; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated

CC disease; and a method for identifying a tumor that is suitable for

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC antibody is useful for manufacturing a medicament for the treatment of

CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence

CC represents a human ephrin B4 antisense oligonucleotide that can be used

CC to control EphB4 expression.

XX

SQ Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2699 CGAGCTCCCTGGGAGGNAAG 2718

DB 20 CGAGCTCCCTGGGAGGNAAG 1

RESULT 246

ADR86830/c

ID ADR86830 standard; DNA; 20 BP.

AC ADR86830;

XX

XX 16-DEC-2004 (first entry)

XX

XX Human ephrin B4 antisense oligonucleotide seqid 135.

XX

XX cyostatic; antiinflammatory; antirheumatic; antipsoriatic;

XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

XX pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

XX angiogenesis-associated disease; inflammatory disorder;

XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;

XX scleroderma; human; ephrin B4; antisense technology;

XX antisense oligonucleotide; ss.

XX

OS Homo sapiens.

XX

XX WO2004080425-A2.

XX

XX 23-SEP-2004.

XX

XX 12-MAR-2004; 2004WO-US007755.

XX

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX

XX (VASG-) VASGENE THERAPEUTICS INC.

PA

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX

XX New soluble polypeptides comprising an extracellular domain of EphB4 or

XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT

PT associated diseases, such as inflammatory disorders, psoriasis or

PT scleroderma.

XX

PS Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumour; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated

CC disease; and a method for identifying a tumor that is suitable for

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC antibody is useful for manufacturing a medicament for the treatment of

CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence

CC represents a human ephrin B4 antisense oligonucleotide that can be used

CC to control EphB4 expression.

XX

SQ Sequence 20 BP; 5 A; 7 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2218 GTCAGATTGAAGAGGTGAT 2237

DB 20 GTCAGATTGAAGAGGTGAT 1

RESULT 247

ADR86831/c

ID ADR86831 standard; DNA; 20 BP.

XX

XX ADR86831;

XX

XX 16-DEC-2004 (first entry)

XX

XX Human ephrin B4 antisense oligonucleotide seqid 136.

XX

XX cyostatic; antiinflammatory; antirheumatic; antipsoriatic;

XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

XX pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

XX angiogenesis-associated disease; inflammatory disorder;

XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;

XX scleroderma; human; ephrin B4; antisense technology;

XX antisense oligonucleotide; ss.

XX

OS Homo sapiens.

XX

XX WO2004080425-A2.

XX

XX 23-SEP-2004.

XX

XX 12-MAR-2004; 2004WO-US007755.

PF 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX

XX (VASG-) VASGENE THERAPEUTICS INC.

PA

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX

XX

DR

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2198 AAGAGATCGATGTCCTCTAC 2217
Db |||||
20 AAGAGATCGATGTCCTCTAC 1
RESULT 248
ADR86878/C
ID ADR86878 standard; DNA; 20 BP.
AC ADR86878;
XX
XX 16-DEC-2004 (first entry)
DT
DE Human ephrin B4 antisense oligonucleotide seqid 183.
XX
KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-658883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1258 AACACCATTCGATCAGCCGT 1277
Db |||||
20 AACACCATTCGATCAGCCGT 1
RESULT 249
ADR86909/C
ID ADR86909 standard; DNA; 20 BP.
AC ADR86909;
XX
XX 16-DEC-2004 (first entry)
DT
DE Human ephrin B4 antisense oligonucleotide seqid 214.
XX
KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 94; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 638 CCACGTCGCGCTTCACCATG 657
Db 20 CCACGTCGCGCTTCACCATG 1
RESULT 250
ADR86795/c
ID ADR86795 standard; DNA; 20 BP.
XX ADR86795;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrin B4 antisense oligonucleotide seqid 100.
XX
XX cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
PI WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 92; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2919 CCTCCACCAGCTCATGCTGG 2938
Db 20 CCTCCACCAGCTCATGCTGG 1
RESULT 251
ADR86818/c
ID ADR86818 standard; DNA; 20 BP.
XX ADR86818;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrin B4 antisense oligonucleotide seqid 123.
XX
XX cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.

KW antisense oligonucleotide; ss.
XX Homo sapiens.
OS WO2004080425-A2.
PN 23-SEP-2004.
PD 12-MAR-2004; 2004WO-US007755.
PF 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
PR (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
PI WPI; 2004-668883/65.
DR New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
PS Example 8; Page 93; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell, a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
XX to control EphB4 expression.
SQ Sequence 20 BP; 7 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1638 ATTGAGCCCTCAATGCTCA 1657
Db ||||||||||||||||
20 ATTGAGCCCTCAATGCTCA 1
RESULT 254
ADR86872/c
ID ADR86872 standard; DNA; 20 BP.
XX ADR86872;
XX ADR86872;
XX 16-DEC-2004 (first entry)
XX Human ephrin B4 antisense oligonucleotide seqid 177.
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
XX antisense oligonucleotide; ss.
XX Homo sapiens.
XX WO2004080425-A2.
PN 23-SEP-2004.
PD 12-MAR-2004; 2004WO-US007755.
PF 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
PR (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
PI WPI; 2004-668883/65.
DR New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
PS Example 8; Page 93; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
XX to control EphB4 expression.
SQ Sequence 20 BP; 4 A; 3 C; 10 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1378 AACGGCTCTCCCTGCACCT 1397
Db ||||||||||||||||
20 AACGGCTCTCCCTGCACCT 1
RESULT 255
ADR86885/c
ID ADR86885 standard; DNA; 20 BP.
XX ADR86885;
XX ADR86885;
XX 16-DEC-2004 (first entry)
XX Human ephrin B4 antisense oligonucleotide seqid 190.
XX

KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
OS Homo sapiens.
OS WO2004080425-A2.
PN 23-SEP-2004.
PD 12-MAR-2004; 2004WO-US007755.
PF 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Kraenoperv V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
PS Example 8; Page 93; 198pp; English.
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1118 AGCGGTCACGGGTGCGAC 1137
DB 20 AGCGGTCACGGGTGCGAC 1
RESULT 256
ADR86886/c
ID ADR86886 standard; DNA; 20 BP.
XX
AC ADR86886;
XX
DT 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 191.
DE
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
OS Homo sapiens.
OS WO2004080425-A2.
PN 23-SEP-2004.
PD 12-MAR-2004; 2004WO-US007755.
PF 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Kraenoperv V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
PS Example 8; Page 93; 198pp; English.
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1098 GGATGGCCAGTGGCGGAC 1117
DB 20 GGATGGCCAGTGGCGGAC 1
RESULT 257
ADR86898/c
ID ADR86898 standard; DNA; 20 BP.
XX

```
AC ADR86898;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrin B4 antisense oligonucleotide seqid 203.
XX
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 93; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
XX Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 858 CAAGACGCTGGTCTGGAC 877
| | | | |
DB 20 CAAGACGCTGGTCTGGAC 1

RESULT 258
QY 758 CAGCCTGGATGGAGAACCC 777
| | | | |
DB 20 CAGCCTGGATGGAGAACCC 1
```

RESULT 259
 ADR86911/c
 ID ADR86911 standard; DNA; 20 BP.
 XX
 AC ADR86911;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 216.
 XX
 KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 OS Homo sapiens.
 XX
 FN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX
 DR WPI; 2004-668883/65.
 XX
 PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 94; 198pp; English.
 CC
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 598 ACAGTTGGTCCACGGCG 617
 DB 20 ACAGTTGGTCCACGGCG 1
 RESULT 260
 ADR86933/c
 ID ADR86933 standard; DNA; 20 BP.
 XX
 AC ADR86933;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 238.
 XX
 KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 OS Homo sapiens.
 XX
 FN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX
 DR WPI; 2004-668883/65.
 XX
 PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 94; 198pp; English.
 CC
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2356 TTCTGAGCGAGCGCTCCAT 2375
|||||
20 TTCTGAGCGAGCGCTCCAT 1

Db

RESULT 261
ADR86800/c
ID ADR86800 standard; DNA; 20 BP.
XX ADR86800;
XX
XX
DT 16-DEC-2004 (first entry)
XX
XX Human ephrin B4 antisense oligonucleotide seqid 105.
XX
XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
PI WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 92; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

SQ Sequence 20 BP; 4 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2819 CATTTGGGAGAGCGCGTAC 2838
|||||
20 CATTTGGGAGAGCGCGTAC 1

Db

RESULT 262
ADR86811/c
ID ADR86811 standard; DNA; 20 BP.
XX ADR86811;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrin B4 antisense oligonucleotide seqid 116.
XX
XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
PI WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 92; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2598 GGCTGCTGCAACATCCCTAG 2617
Db 20 GGCTGCTGCAACATCCCTAG 1
RESULT 263
ADR86846/c
ID ADR86846 standard; DNA; 20 BP.
XX
AC ADR86846;
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 151.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
FN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 2 A; 10 C; 7 G; 1 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1898 GGGCGCGCTCTGAGCGCGC 1917
Db 20 GGGCGCGCTCTGAGCGCGC 1
RESULT 264
ADR86882/c
ID ADR86882 standard; DNA; 20 BP.
XX
AC ADR86882;
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 187.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
FN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX Sequence 20 BP; 2 A; 8 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1178 GCCGAGCCTGTGCCAGGC 1197
 |||||
 Db 20 GCCGAGCCTGTGCCAGGC 1

RESULT 265
 ADR86890/c
 ID ADR86890 standard; DNA; 20 BP.

XX ADR86890;

DT 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 195.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

PF 12-MAR-2004; 2004WO-US0007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 8; Page 93; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX Sequence 20 BP; 5 A; 9 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1018 CTGGTTGTGCGCGTGGCGG 1037
 |||||
 Db 20 CTGGTTGTGCGCGTGGCGG 1

RESULT 266

ADR86913/c

ID ADR86913 standard; DNA; 20 BP.

XX ADR86913;

DT 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 218.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

PF 12-MAR-2004; 2004WO-US0007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 8; Page 94; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX
 SQ Sequence 20 BP; 3 A; 8 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 558 TGACGTGCAGCGTGCCCGG 577
 Db 20 TGACGTGCAGCGTGCCCGG 1

RESULT 267
 ADR86914/c
 ID ADR86914 standard; DNA; 20 BP.
 AC ADR86914;
 DT 16-DEC-2004 (first entry)
 DE Human ephrin B4 antisense oligonucleotide seqid 219.
 DE
 KW cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.
 XX WO2004080425-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007755.
 XX 12-MAR-2003; 2003US-0454300P.
 XX 12-MAR-2003; 2003US-0454432P.
 XX (VASG-) VASGENE THERAPEUTICS INC.
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

PS Example 8; Page 94; 198pp; English.
 XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX
 SQ Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 538 GTGGCACCTACGAAGTGTG 557
 Db 20 GTGGCACCTACGAAGTGTG 1

RESULT 268
 ADR86922/c
 ID ADR86922 standard; DNA; 20 BP.
 AC ADR86922;
 DT 16-DEC-2004 (first entry)
 DE Human ephrin B4 antisense oligonucleotide seqid 227.
 DE
 KW cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.
 XX WO2004080425-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007755.
 XX 12-MAR-2003; 2003US-0454300P.
 XX 12-MAR-2003; 2003US-0454432P.
 XX (VASG-) VASGENE THERAPEUTICS INC.
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 PS Example 8; Page 94; 198pp; English.
 XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX
 SQ Sequence 20 BP; 5 A; 8 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 378 GGAGCTCCGGTGCTGCTCT 397
 |||||
 DB 20 GGAGCTCCGGTGCTGCTCT 1

RESULT 269
 ADR86733/c
 ID ADR86733 standard; DNA; 20 BP.

AC ADR86733;

DT 16-DEC-2004 (first entry)

XX Human ephrin B4 RT-PCR primer seqid 38.

DE cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; reverse transcriptase PCR; primer; ss.

XX Homo sapiens.

OS Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or

XX scleroderma.

XX Example 3; Page 63; 198pp; English.

CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a primer used in the isolation of human ephrin B4 CDNA.

XX Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 974 TGACTGTGAACCTGACTCGA 993
 |||||
 DB 20 TGACTGTGAACCTGACTCGA 1

RESULT 270
 ADR86780/c

ID ADR86780 standard; DNA; 20 BP.

XX ADR86780;

DT 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 85.

DE cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;

XX antisense oligonucleotide; ss.

OS Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or

XX scleroderma.

PS Example 8; Page 91; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumor; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated

CC disease; and a method for identifying a tumor that is suitable for

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC antibody is useful for manufacturing a medicament for the treatment of

CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence

CC represents a human ephrin B4 antisense oligonucleotide that can be used

CC to control EphB4 expression.

XX

SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3219 CCGAATCGGACTCTCTGG 3238

Db 20 CCGAATCGGACTCTCTGG 1

RESULT 271

ADR86781/C

ID ADR86781 standard; DNA; 20 BP.

XX

AC ADR86781;

XX

DT 16-DEC-2004 (first entry)

XX

DE Human ephrin B4 antisense oligonucleotide seqid 86.

XX

KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; antisense technology;

XX antisense oligonucleotide; ss.

OS Homo sapiens.

XX

FN WO2004080425-A2.

XX

PD 23-SEP-2004.

XX

PF 12-MAR-2004; 2004WO-US007755.

XX

PR 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX

PA (VASG-) VASGENE THERAPEUTICS INC.

XX

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX

DR WPI; 2004-668883/65.

XX

PT New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or

PT scleroderma.

XX

PS Example 8; Page 91; 198pp; English.

XX

CC The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumor; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated

CC disease; and a method for identifying a tumor that is suitable for

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC antibody is useful for manufacturing a medicament for the treatment of

CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence

CC represents a human ephrin B4 antisense oligonucleotide that can be used

CC to control EphB4 expression.

XX

SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3199 ATCTCTGCTGAGGACCTGCT 3218

Db 20 ATCTCTGCTGAGGACCTGCT 1

RESULT 272

ADR86798/C

ID ADR86798 standard; DNA; 20 BP.

XX

AC ADR86798;

XX

DT 16-DEC-2004 (first entry)

XX

DE Human ephrin B4 antisense oligonucleotide seqid 103.

XX

KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; antisense technology;

XX antisense oligonucleotide; ss.

OS Homo sapiens.

XX

FN WO2004080425-A2.

XX

PD 23-SEP-2004.

XX

PF 12-MAR-2004; 2004WO-US007755.

XX

PR 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX

PA (VASG-) VASGENE THERAPEUTICS INC.

XX

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX

DR WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
XX to control EphB4 expression.
SQ Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2859 CGTGATCAATGCCATTGAAC 2878
Db 20 CGTGATCAATGCCATTGAAC 1
RESULT 273
ADR86812/c
ID ADR86812 standard; DNA; 20 BP.
XX ADR86812;
AC
XX 16-DEC-2004 (first entry)
DT
XX Human ephrin B4 antisense oligonucleotide seqid 117.
DE
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
XX antisense oligonucleotide; ss.
XX Homo sapiens.
XX OS
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX

PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668893/65.
DR
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
XX to control EphB4 expression.
SQ Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2578 AGCTAGTCCACCGAGACCT 2597
Db 20 AGCTAGTCCACCGAGACCT 1
RESULT 274
ADR86845/c
ID ADR86845 standard; DNA; 20 BP.
XX ADR86845;
AC
XX 16-DEC-2004 (first entry)
DT
XX Human ephrin B4 antisense oligonucleotide seqid 150.
DE
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
XX antisense oligonucleotide; ss.
XX Homo sapiens.
XX OS
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.

XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX XX WPI; 2004-668883/65.
XX DR New soluble polypeptides comprising an extracellular domain of EphB4 or
XX PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX PT associated diseases, such as inflammatory disorders, psoriasis or
XX XX scleroderma.
XX PS Example 8; Page 93; 198pp; English.
XX XX The invention describes an isolated soluble polypeptide comprising an
XX CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX CC described are: an antagonist antibody that binds to an extracellular
XX CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX CC diagnostic kit, comprising the above soluble polypeptide or antagonist
XX CC antibody, and a pharmaceutical carrier; methods of inhibiting
XX CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX CC cell; a method of reducing the growth rate of a tumor; methods for
XX CC treating a patient suffering from a cancer or an angiogenesis-associated
XX CC disease; and a method for identifying a tumor that is suitable for
XX CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX CC antibody is useful for manufacturing a medicament for the treatment of
XX CC cancer or an angiogenesis-associated disease. The composition and methods
XX CC are useful for diagnosing or treating cancer or angiogenesis-associated
XX CC diseases, such as inflammatory disorders, chronic articular rheumatism,
XX CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX CC represents a human ephrin B4 antisense oligonucleotide that can be used
XX CC to control EphB4 expression.
XX SQ Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1918 TACGGGCCCTTCGCCAGGA 1937
Db |||||
20 TACGGGCCCTTCGCCAGGA 1
RESULT 275
ADR86865/c
ID ADR86865 standard; DNA; 20 BP.
XX AC ADR86865;
XX XX 16-DEC-2004 (first entry)
XX DT Human ephrin B4 antisense oligonucleotide seqid 170.
XX DE
XX KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
XX KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
XX KW angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; human; ephrin B4; antisense technology;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX XX WO2004080425-A2.
XX PD 23-SEP-2004.
XX XX
XX PF 12-MAR-2004; 2004WO-US007755.

XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-045432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX XX WPI; 2004-668883/65.
XX DR New soluble polypeptides comprising an extracellular domain of EphB4 or
XX XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX PT associated diseases, such as inflammatory disorders, psoriasis or
XX PT scleroderma.
XX PS Example 8; Page 93; 198pp; English.
XX XX The invention describes an isolated soluble polypeptide comprising an
XX CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX CC described are: an antagonist antibody that binds to an extracellular
XX CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX CC diagnostic kit, comprising the above soluble polypeptide or antagonist
XX CC antibody, and a pharmaceutical carrier; methods of inhibiting
XX CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX CC cell; a method of reducing the growth rate of a tumor; methods for
XX CC treating a patient suffering from a cancer or an angiogenesis-associated
XX CC disease; and a method for identifying a tumor that is suitable for
XX CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX CC antibody is useful for manufacturing a medicament for the treatment of
XX CC cancer or an angiogenesis-associated disease. The composition and methods
XX CC are useful for diagnosing or treating cancer or angiogenesis-associated
XX CC diseases, such as inflammatory disorders, chronic articular rheumatism,
XX CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX CC represents a human ephrin B4 antisense oligonucleotide that can be used
XX CC to control EphB4 expression.
XX SQ Sequence 20 BP; 2 A; 9 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1518 CGCCCCCGGACCTGGTGG 1537
Db |||||
20 CGCCCCCGGACCTGGTGG 1
RESULT 276
ADR86876/c
ID ADR86876 standard; DNA; 20 BP.
XX AC ADR86876;
XX XX 16-DEC-2004 (first entry)
XX DT Human ephrin B4 antisense oligonucleotide seqid 181.
XX DE
XX KW cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
XX KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
XX KW angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; human; ephrin B4; antisense technology;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX XX WO2004080425-A2.
XX PD 23-SEP-2004.
XX XX
XX PF 12-MAR-2004; 2004WO-US007755.

PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 XX Example 8; Page 93; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumor; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1298 ACTTCGGGCGCAGCAGAC 1317
 Db | | | | | | | | | | | | | | | | | | | |
 20 ACTTCGGGCGCAGCAGAC 1
 RESULT 277
 ADR86889/c
 ID ADR86889 standard; DNA; 20 BP.
 AC ADR86889;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 XX Human ephrin B4 antisense oligonucleotide seqid 194.
 DE
 XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.

XX WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 XX Example 8; Page 93; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumor; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1038 TAGCTGCGTGGTGATGCG 1057
 Db | | | | | | | | | | | | | | | | | | | |
 20 TAGCTGCGTGGTGATGCG 1
 RESULT 278
 ADR86891/c
 ID ADR86891 standard; DNA; 20 BP.
 AC ADR86891;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 XX Human ephrin B4 antisense oligonucleotide seqid 196.
 DE
 XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

antisense oligonucleotide; ss.
 KW XX Homo sapiens.
 OS XX WO2004080425-A2.
 FN XX 23-SEP-2004.
 PD XX
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 PF XX
 XX 12-MAR-2003; 2003US-0454300P.
 PR XX 12-MAR-2003; 2003US-0454432P.
 PR XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA XX
 FI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 93; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 3 A; 9 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 998 CGGAGACTGTGCTCCGCGGAG 1017
 Db 20 CGGAGACTGTGCTCCGCGGAG 1
 |||||
 RESULT 279
 ADR86904/c
 ID ADR86904 standard; DNA; 20 BP.
 XX
 AC ADR86904;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 209.
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2004080425-A2.
 PN XX
 XX 23-SEP-2004.
 PD XX
 XX 12-MAR-2004; 2004WO-US007755.
 PF XX
 XX 12-MAR-2003; 2003US-0454300P.
 PR XX 12-MAR-2003; 2003US-0454432P.
 PR XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA XX
 FI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 94; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a tumor that is suitable for
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 1 A; 5 C; 11 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 738 CACGGCCACGGCCCTCACGC 757
 Db 20 CACGGCCACGGCCCTCACGC 1
 |||||
 RESULT 280
 ADR86919/c
 ID ADR86919 standard; DNA; 20 BP.
 XX
 AC ADR86919;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 224.

KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX Homo sapiens.
XX WO2004080425-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007755.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX Example 8; Page 94; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX domain of the EphB4 or Ephrin B2 protein or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumour; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX antibody is useful for manufacturing a medicament for the treatment of
XX cancer or an angiogenesis-associated disease. The composition and methods
XX are useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases, such as inflammatory disorders, chronic articular rheumatism,
XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX represents a human ephrin B4 antisense oligonucleotide that can be used
XX to control EphB4 expression.
XX Sequence 20 BP; 3 A; 4 C; 3 G; 10 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 438 GAACACAAATTCGAACTG 457
DB 20 GAACACAAATTCGAACTG 1
RESULT 281
ADR86920/c
ID ADR86920 standard; DNA; 20 BP.
XX ADR86920;
XX ADR86920;
DT 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 225.
DE cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX Homo sapiens.
XX WO2004080425-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007755.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX Example 8; Page 94; 198pp; English.
XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX domain of the EphB4 or Ephrin B2 protein or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumour; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
XX antibody is useful for manufacturing a medicament for the treatment of
XX cancer or an angiogenesis-associated disease. The composition and methods
XX are useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases, such as inflammatory disorders, chronic articular rheumatism,
XX psoriasis, ocular angiogenic diseases or scleroderma. This sequence
XX represents a human ephrin B4 antisense oligonucleotide that can be used
XX to control EphB4 expression.
XX Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 418 GCTTTGGAAGAGACCTGCT 437
DB 20 GCTTTGGAAGAGACCTGCT 1
RESULT 282
ADR86776/c
ID ADR86776 standard; DNA; 20 BP.
XX

AC ADR86776;
 XX 16-DEC-2004 (first entry)
 XX Human ephrin B4 antisense oligonucleotide seqid 81.
 DE cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX Homo sapiens.
 OS
 XX WO2004080425-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007755.
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 PI WPI; 2004-668883/65.
 DR New soluble polypeptides comprising an extracellular domain of EphB4 or
 XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX Example 8; Page 91; 198pp; English.
 PS The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3299 GAACCCCGGTGGACACGGA 3318
 DB 20 GAACCCCGGTGGACACGGA 1
 RESULT 283

ADR86797/c
 ID ADR86797 standard; DNA; 20 BP.
 XX ADR86797;
 XX 16-DEC-2004 (first entry)
 XX Human ephrin B4 antisense oligonucleotide seqid 102.
 DE cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX Homo sapiens.
 OS
 XX WO2004080425-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007755.
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 PI WPI; 2004-668883/65.
 DR New soluble polypeptides comprising an extracellular domain of EphB4 or
 XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX Example 8; Page 92; 198pp; English.
 PS The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 2 A; 6 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2879 AGGACTACCGGTGCCCCCG 2898
 DB 20 AGGACTACCGGTGCCCCCG 1

RESULT 284
ADR86820/c
ID ADR86820 standard; DNA; 20 BP.
XX
AC ADR86820;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 125.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
PI WPI; 2004-668883/65.
XX
DR New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2418 CGTGGTCACCAACAGCATGC 2437
|||||
Db 20 CGTGGTCACCAACAGCATGC 1
|||||
RESULT 285
ADR86825/c
ID ADR86825 standard; DNA; 20 BP.
XX
AC ADR86825;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 130.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
PI WPI; 2004-668883/65.
XX
DR New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;

	Best Local Similarity	100.0%; Pred. No.	96;	Mismatches	20; Conservative	0; Mismatches	0; Indels	0; Gaps	0;
QY	2318 CCTGAAGCGTGGCTACACG	2337 							
Db	20 CCTGAAGCGTGGCTACAG	1							
RESULT	286								
ADR#	86852/c	ID	ADR#	86852 standard; DNA; 20 BP.					
XX	AD	DR	DT	DD					
XX	AC	AA	AT	GC					
XX	TT	TG	CA	TC					
XX	CC	GT	TA	CG					
DE	Human ephrin B4 antisense oligonucleotide seqid 157.								
KW	Cytostatic; antiinflammatory; antirheumatic; antipsoriatic; dermatological; ophthalmologic; gene therapy; EphB4; Ephrin B2; pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour; angiogenesis-associated disease; inflammatory disorder; chronic articular rheumatism; psoriasis; ocular angiogenic disease; scleroderma; human; ephrin B4; antisense technology; antisense oligonucleotide; ss. Homo sapiens.								
OS	Homo sapiens.								
XX	PN	WO	2004080425-A2.						
XX	PD	23-SEP-	2004.						
XX	PP	12-MAR-	2004; 2004WO-US007755.						
XX	PR	12-MAR-	2003; 2003US-0454300P.						
XX	PT	12-MAR-	2003; 2003US-0454432P.						
PA	(VASG-) VASGENE THERAPEUTICS INC.								
PI	Krasnoperov V, Zorulya S, Keretesz N, Reddy R, Gill P;								
PS	WPI; 2004-668883/65.								
XX	New soluble polypeptides comprising an extracellular domain of EphB4 or Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, psoriasis or scleroderma.								
Example	8; Page 93; 199pp; English.								
The invention describes an isolated soluble polypeptide comprising an amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2 protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4 polypeptide binds specifically to the Ephrin B2 polypeptide, and the Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also described are: an antagonist antibody that binds to an extracellular domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a diagnostic kit, comprising the above soluble polypeptide or antagonist antibody, and a pharmaceutical carrier; methods of inhibiting angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a cell; a method of reducing the growth rate of a tumor; methods for treating a patient suffering from a cancer or an angiogenesis-associated disease; and a method for identifying a tumor that is suitable for treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or antibody is useful for manufacturing a medicament for the treatment of cancer or an angiogenesis-associated disease. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic disease or scleroderma. This sequence represents a human ephrin B4 antisense oligonucleotide that can be used to control EphB4 expression.									

SQ Sequence 20 BP; 3 A; 5 C; 3 G; 9 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1778 AGGTCAAAATACCATGAGAAG 1797
 |||||
 DB 20 AGGTCAAAATACCATGAGAAG 1
 RESULT 287
 ADR86866/c
 ADR86866 standard; DNA; 20 BP.
 XX AC AC
 ADR86866;
 XX DT DT
 16-DEC-2004 (first entry)
 XX DE DE
 Human ephrin B4 antisense oligonucleotide seqid 171.
 XX XX
 cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 KW KW
 OS Homo sapiens.
 XX XX
 WO2004080425-A2.
 XX XX
 23-SEP-2004.
 XX XX
 12-MAR-2004; 2004WO-US007755.
 XX XX
 12-MAR-2003; 2003US-0454300P.
 PR PR
 12-MAR-2003; 2003US-0454432P.
 PR PR
 XX XX
 (VASG-) VASGENE THERAPEUTICS INC.
 PA PA
 Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX PI PI
 WPI; 2004-668883/65.
 XX DR
 New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX XX
 Example 8; Page 93; 198pp; English.
 PS PS
 The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence

CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
 SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1498 GGAGACTGACTTTGACCC 1517
 Db 20 GGAGACTGACTTTGACCC 1
 RESULT 288
 ADR86869/c
 ID ADR86869 standard; DNA; 20 BP.
 XX
 AC ADR86869;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 174.
 XX
 KW cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX
 DR New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 93; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX Sequence 20 BP; 4 A; 3 C; 11 G; 2 T; 0 U; 0 Other;
 SQ Sequence 20 BP; 4 A; 3 C; 11 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1438 CTCACCTAGCCCTCGCTG 1457
 Db 20 CTCACCTAGCCCTCGCTG 1
 RESULT 289
 ADR86870/c
 ID ADR86870 standard; DNA; 20 BP.
 XX
 AC ADR86870;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 175.
 XX
 KW cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX
 DR New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 93; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX
 SQ Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1418 AGCTGTTGGCGGAGGAC 1437
 |||||
 Db 20 AGTCTGTTGGCGGAGGAC 1

RESULT 290
 ADR86883/c
 ID ADR86883 standard; DNA; 20 BP.
 XX
 AC ADR86883;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 188.
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX
 DR WPI; 2004-668883/65.
 XX
 PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 93; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX
 SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1158 AGCTGAGGGGACACCAAGT 1177
 |||||
 Db 20 AGCTGAGGGGACACCAAGT 1

RESULT 291
 ADR86887/c
 ID ADR86887 standard; DNA; 20 BP.
 XX
 AC ADR86887;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 192.
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX
 DR WPI; 2004-668883/65.
 XX
 PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 93; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX SQ Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1078 CCCAGCCTTACTGCCGTGA 1097

Db 20 CCCAGCCTTACTGCCGTGA 1

RESULT 292

ADR86896/c

ID ADR86896 standard; DNA; 20 BP.

XX AC ADR86896;

XX DT 16-DEC-2004 (first entry)

XX DE Human ephrin B4 antisense oligonucleotide seqid 201.

XX KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

XX KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

XX KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

XX KW angiogenesis-associated disease; inflammatory disorder;

XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

XX KW scleroderma; human; ephrin B4; antisense technology;

XX KW antisense oligonucleotide; ss.

XX OS Homo sapiens.

XX PN WO2004080425-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US0007755.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-0454432P.

XX PA (VASC-) VASGENE THERAPEUTICS INC.

XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX PI WPI; 2004-668883/65.

XX DR New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or

PT scleroderma.

XX PS Example 8; Page 93; 198pp; English.

XX CC The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX SQ Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 898 TACCTGGCCTCCAGGACCA 917

Db 20 TACCTGGCCTCCAGGACCA 1

RESULT 293

ADR86897/c

ID ADR86897 standard; DNA; 20 BP.

XX AC ADR86897;

XX DT 16-DEC-2004 (first entry)

XX DE Human ephrin B4 antisense oligonucleotide seqid 202.

XX KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

XX KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

XX KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

XX KW angiogenesis-associated disease; inflammatory disorder;

XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

XX KW scleroderma; human; ephrin B4; antisense technology;

XX KW antisense oligonucleotide; ss.

XX OS Homo sapiens.

XX PN WO2004080425-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US0007755.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-0454432P.

XX PA (VASC-) VASGENE THERAPEUTICS INC.

XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX PI WPI; 2004-668883/65.

XX DR New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or

PT scleroderma.

XX PS Example 8; Page 93; 198pp; English.

XX CC The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX SQ Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 878 CGCTCAGCAAGCGTGGCTTC 897
 Db 20 CGCTCAGCAAGCGTGGCTTC 1

RESULT 294

ADR87090
 ID ADR87090 standard; DNA; 20 BP.

AC ADR87090;

DT 16-DEC-2004 (first entry)

DE Human ephrin B4 PCR primer seqid 395.

KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; PCR; primer; ss.

OS Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 4; Page 69; 198pp; English.

CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a primer used in the isolation of human ephrin B4 cDNA used in
 CC the creation of an expression vector for producing a soluble Eph B4
 CC derivative.

XX SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 419 CTTTGAAGAGACCTGCTG 438

Db 1 CTTTGAAGAGACCTGCTG 20

RESULT 295

ADR86788/c

ID ADR86788 standard; DNA; 20 BP.

AC ADR86788;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 93.

DE cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or

PT scleroderma.
 XX Example 8; Page 92; 198pp; English.
 XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 3 A; 3 C; 10 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3059 CACACCTCTCTCGGACCAG 3078
 Db 20 CACACCTCTCTCGGACCAG 1
 RESULT 296
 ADR86789/c
 ID ADR86789 standard; DNA; 20 BP.
 AC ADR86789;
 XX 16-DEC-2004 (first entry)
 DT Human ephrin B4 antisense oligonucleotide seqid 94.
 DE
 XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX Homo sapiens.
 OS
 XX WO2004080425-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007755.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX (VASC-) VASGENE THERAPEUTICS INC.
 PA Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR
 XX

PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX Example 8; Page 92; 198pp; English.
 XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 2 A; 10 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3039 CCGGGAGAAATGCGGGGCT 3058
 Db 20 CCGGGAGAAATGCGGGGCT 1
 RESULT 297
 ADR86791/c
 ID ADR86791 standard; DNA; 20 BP.
 AC ADR86791;
 XX 16-DEC-2004 (first entry)
 DT Human ephrin B4 antisense oligonucleotide seqid 96.
 DE
 XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX Homo sapiens.
 OS
 XX WO2004080425-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007755.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX (VASC-) VASGENE THERAPEUTICS INC.
 PA Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or

PT scleroderma.

XX Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumour; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated

CC disease; and a method for identifying a tumor that is suitable for

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC antibody is useful for manufacturing a medicament for the treatment of

CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence

CC represents a human ephrin B4 antisense oligonucleotide that can be used

CC to control EphB4 expression.

XX Sequence 20 BP; 2 A; 4 C; 7 G; 7 T; 0 U; 0 Other;

SQ Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2999 ACAAGATGATCCGGACCCC 3018

DB 20 ACAAGATGATCCGGACCCC 1

RESULT 298

ADR86817/c

ID ADR86817 standard; DNA; 20 BP.

AC ADR86817;

XX 16-DEC-2004 (first entry)

DT Human ephrin B4 antisense oligonucleotide seqid 122.

DE cytotatic; antiinflammatory; antirheumatic; antipsoriatic;

XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; antisense technology;

XX antisense oligonucleotide; ss.

OS Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

PD 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX

PA (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

DR New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-

PT associated diseases, such as inflammatory disorders, psoriasis or

PT scleroderma.

XX Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an

CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the

CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also

CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the

CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a

CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting

CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a

CC cell; a method of reducing the growth rate of a tumour; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated

CC disease; and a method for identifying a tumor that is suitable for

CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC antibody is useful for manufacturing a medicament for the treatment of

CC cancer or an angiogenesis-associated disease. The composition and methods

CC are useful for diagnosing or treating cancer or angiogenesis-associated

CC diseases, such as inflammatory disorders, chronic articular rheumatism,

CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence

CC represents a human ephrin B4 antisense oligonucleotide that can be used

CC to control EphB4 expression.

XX Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

SQ Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2478 GGACTCTCTCTCTCGGCTAA 2497

DB 20 GGACTCTCTCTCGGCTAA 1

RESULT 299

ADR86833/c

ID ADR86833 standard; DNA; 20 BP.

XX ADR86833;

XX 16-DEC-2004 (first entry)

DT Human ephrin B4 antisense oligonucleotide seqid 138.

DE cytotatic; antiinflammatory; antirheumatic; antipsoriatic;

XX dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;

KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; human; ephrin B4; antisense technology;

XX antisense oligonucleotide; ss.

OS Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

PD 12-MAR-2004; 2004WO-US007755.

XX

```

PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 8; Page 92; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC antibody, and a pharmaceutical or cosmetic composition, or a
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
XX Sequence 20 BP; 5 A; 3 C; 4 G; 8 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2158 ACTTATGAAGACCCCTAATGA 2177
Db 20 ACTTATGAAGACCCCTAATGA 1

RESULT 300
ADR86834/c
ID ADR86834 standard; DNA; 20 BP.
XX
AC ADR86834;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrin B4 antisense oligonucleotide seqid 139.
XX
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX

12-MAR-2004; 2004WO-US0007755.
12-MAR-2003; 2003US-0454300P.
12-MAR-2003; 2003US-0454432P.
(VASG-) VASGENE THERAPEUTICS INC.
Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
WPI; 2004-668883/65.
New soluble polypeptides comprising an extracellular domain of EphB4 or
Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
associated diseases, such as inflammatory disorders, psoriasis or
scleroderma.
Example 8; Page 92; 198pp; English.
The invention describes an isolated soluble polypeptide comprising an
amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
polypeptide binds specifically to the Ephrin B2 polypeptide, and the
Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
described are: an antagonist antibody that binds to an extracellular
domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
antibody, and a pharmaceutical or cosmetic composition, or a
angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
cell; a method of reducing the growth rate of a tumour; methods for
treating a patient suffering from a cancer or an angiogenesis-associated
disease; and a method for identifying a tumor that is suitable for
treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
antibody is useful for manufacturing a medicament for the treatment of
cancer or an angiogenesis-associated disease. The composition and methods
are useful for diagnosing or treating cancer or angiogenesis-associated
diseases, such as inflammatory disorders, chronic articular rheumatism,
psoriasis, ocular angiogenic diseases or scleroderma. This sequence
represents a human ephrin B4 antisense oligonucleotide that can be used
to control EphB4 expression.
Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2138 AGGTCTACATCGACCCCTTC 2157
Db 20 AGGTCTACATCGACCCCTTC 1

RESULT 301
ADR86836/c
ID ADR86836 standard; DNA; 20 BP.
XX
AC ADR86836;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrin B4 antisense oligonucleotide seqid 141.
XX
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
XX
```

PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX
XX WPI; 2004-668883/65.
DR
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX
PS Example 8; Page 92; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2098 TCGGACAAACACGGACAGTA 2117
Db 20 TCGGACAAACACGGACAGTA 1
RESULT 302
ADR86837/c
ID ADR86837 standard; DNA; 20 BP.
XX
AC ADR86837;
XX
XX 16-DEC-2004 (first entry)
DT Human ephrin B4 antisense oligonucleotide seqid 142.
DE
XX
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; 88.

XX Homo sapiens.
OS
XX WO2004080425-A2.
PN
XX 23-SEP-2004.
PD
XX
XX 12-MAR-2004; 2004WO-US007755.
PF
XX
XX 12-MAR-2003; 2003US-0454300P.
PR
XX 12-MAR-2003; 2003US-0454432P.
PR
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
PA
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
DI
XX
XX WPI; 2004-668883/65.
DR
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
PT
XX
XX Example 8; Page 92; 198pp; English.
PS
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.
XX
SQ Sequence 20 BP; 3 A; 7 C; 1 G; 9 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2078 ATGGGAGAGAGCAGCAATAT 2097
Db 20 ATGGGAGAGAGCAGCAATAT 1
RESULT 303
ADR86849/c
ID ADR86849 standard; DNA; 20 BP.
XX
AC ADR86849;
XX
XX 16-DEC-2004 (first entry)
DT Human ephrin B4 antisense oligonucleotide seqid 154.
DE
XX
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; 88.

KW Chronic articular rheumatism; psoriasis; gene therapy; EphB4; Ephrin B2;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

OS Homo sapiens.

PN WO2004080425-A2.

PD 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

PS Example 8; Page 93; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX SQ Sequence 20 BP; 1 A; 7 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1838 CAGAAACCGGCGAGCTG 1857

DB 20 CAGAAACCGGCGAGCTG 1

RESULT 304

ADR86863/c

ID ADR86863 standard; DNA; 20 BP.

AC ADR86863;

DT 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 168.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

OS Homo sapiens.

PN WO2004080425-A2.

PD 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

PS Example 8; Page 93; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX SQ Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1558 GGGCTACGTCCTGACTTCAC 1577

DB 20 GGGCTACGTCCTGACTTCAC 1

RESULT 305

ADR86783/c

ID ADR86783 standard; DNA; 20 BP.

XX ADR86783;

XX 16-DEC-2004 (first entry)

XX

DE Human ephrin B4 antisense oligonucleotide seqid 88.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

OS Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 XX associated diseases, such as inflammatory disorders, psoriasis or
 XX scleroderma.

XX Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX SQ Sequence 20 BP; 5 A; 7 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 3159 CGCAGCCGCTGGCTTGGCT 3178

Db 20 CGCAGCCGCTGGCTTGGCT 1

RESULT 306

ADR86786/c

ID ADR86786 standard; DNA; 20 BP.

XX AC ADR86786;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 91.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

OS Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 XX associated diseases, such as inflammatory disorders, psoriasis or
 XX scleroderma.

XX Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX SQ Sequence 20 BP; 8 A; 8 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 3099 TTTTGGCTCTGGCGGAGT 3118

Db 20 TTTTGGCTCTGGCGGAGT 1

RESULT 307

ADR86828/c

ID ADR86828 standard; DNA; 20 BP.
 XX ADR86828;
 AC
 XX 16-DEC-2004 (first entry)
 DT
 XX Human ephrin B4 antisense oligonucleotide seqid 133.
 DE
 XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2004080425-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 XX 12-MAR-2003; 2003US-0454432P.
 PR
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 PI WPI; 2004-668883/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 92; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 3 A; 11 C; 5 G; 1 T; 0 U; 0 Other;
 XX
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2258 AGGTGTCCGGGGCGGCTC 2277
 Db 20 AGGTGTCCGGGGCGGCTC 1

RESULT 308
 ADR86843/c
 ID ADR86843 standard; DNA; 20 BP.
 XX
 XX ADR86843;
 AC
 XX 16-DEC-2004 (first entry)
 DT
 XX Human ephrin B4 antisense oligonucleotide seqid 148.
 DE
 XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2004080425-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 XX 12-MAR-2003; 2003US-0454432P.
 PR
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 PI WPI; 2004-668883/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 93; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 3 A; 11 C; 2 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1958 TGGATGAGAGCGAGGCTGG 1977

Db 20 TGGATGAGCGGCGGCTGG 1

RESULT 309
 ADR86844/c
 ID ADR86844 standard; DNA; 20 BP.
 XX
 AC ADR86844;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 149.
 XX
 KW cytosatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-045432P.
 PR
 XX (VASG-) VASGENE THERAPEUTICS INC.
 XX
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 XX Example 8; Page 93; 198pp; English.
 XX
 XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 1 A; 2 C; 9 G; 8 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 ACATCAGCCAGCCCAAC 1957
 DB 20 ACATCAGCCAGCCCAAC 1

RESULT 310
 ADR86858/c
 ID ADR86858 standard; DNA; 20 BP.
 XX
 AC ADR86858;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 163.
 XX
 KW cytosatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-045432P.
 PR
 XX (VASG-) VASGENE THERAPEUTICS INC.
 XX
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 XX Example 8; Page 93; 198pp; English.
 XX
 XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;


```
Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1658 CCAGTACCGAGAGGTACCT 1677
    |||||
Db 20 CCAGTACCGAGAGGTACCT 1

RESULT 311
ADR86868/c
ID ADR86868 standard; DNA; 20 BP.
XX
AC ADR86868;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 antisense oligonucleotide seqid 173.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmacological; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 8; Page 93; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
```


CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

XX SQ Sequence 20 BP; 2 A; 10 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 498 GTGGGAGGAACCTGAGCGGCC 517
|||||
Db 20 GTGGGAGGAACCTGAGCGGCC 1

RESULT 313
ADR86799/c
ID ADR86799 standard; DNA; 20 BP.
XX AC ADR86799;
XX DT 16-DEC-2004 (first entry)
XX DE Human ephrin B4 antisense oligonucleotide seqid 104.
XX KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX WO2004080425-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007755.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-045432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX PS New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.

XX Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumour; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

XX SQ Sequence 20 BP; 3 A; 7 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2839 TGGGACATGAGCAATCAGGA 2858
|||||
Db 20 TGGGACATGAGCAATCAGGA 1

RESULT 314
ADR86810/c
ID ADR86810 standard; DNA; 20 BP.
XX AC ADR86810;
XX DT 16-DEC-2004 (first entry)
XX DE Human ephrin B4 antisense oligonucleotide seqid 115.
XX KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX WO2004080425-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007755.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-045432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
XX PS New soluble polypeptides comprising an extracellular domain of EphB4 or
XX Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
XX associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.

XX Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
XX amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
XX protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
XX polypeptide binds specifically to the Ephrin B2 polypeptide, and the
XX Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
XX described are: an antagonist antibody that binds to an extracellular
XX domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
XX EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
XX diagnostic kit, comprising the above soluble polypeptide or antagonist
XX antibody, and a pharmaceutical carrier; methods of inhibiting
XX angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
XX cell; a method of reducing the growth rate of a tumour; methods for
XX treating a patient suffering from a cancer or an angiogenesis-associated
XX disease; and a method for identifying a tumor that is suitable for
XX treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or

CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease, and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2618 TCAACAGCAACCTCGTCTGC 2637
 Db 20 TCAACAGCAACCTCGTCTGC 1

RESULT 315

ADR86816/c

ID ADR86816 standard; DNA; 20 BP.

XX ADR86816;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 121.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2498 ACGACGGACAGTTCACAGTC 2517

Db 20 ACGACGGACAGTTCACAGTC 1

RESULT 316

ADR86826/c

ID ADR86826 standard; DNA; 20 BP.

XX ADR86826;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 131.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX SQ Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2298 GAGCTGTGTGGCAATCAAGA 2317

Db 20 GAGCTGTGTGGCAATCAAGA 1

RESULT 317

ADR86829/c

ID ADR86829 standard; DNA; 20 BP.

XX ADR86829;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 134.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 8; Page 92; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX SQ Sequence 20 BP; 6 A; 10 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2238 TGGTGCAGGTGAGTTGGCG 2257

Db 20 TGGTGCAGGTGAGTTGGCG 1

RESULT 318

ADR86853/c

ID ADR86853 standard; DNA; 20 BP.

XX ADR86853;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 158.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 8; Page 93; 198pp; English.

CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

SQ Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1758 TGGGGCTGCTGCACTACG 1777
 Db |||||

RESULT 319
 ADR86857/c
 ID ADR86857 standard; DNA; 20 BP.
 AC ADR86857;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 162.
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 DR WPI; 2004-668863/65.
 XX
 PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 8; Page 93; 198pp; English.
 PS
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

SQ Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1678 CCTGCAGTCTGCATCCG 1697
 Db |||||

RESULT 320
 ADR86861/c
 ID ADR86861 standard; DNA; 20 BP.
 AC ADR86861;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrin B4 antisense oligonucleotide seqid 166.
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007755.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 DR WPI; 2004-668863/65.
 XX
 PT New soluble polypeptides comprising an extracellular domain of EphB4 or

PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 93; 198pp; English.
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphA4 or Ephrin B2
 CC protein. The EphA4 or Ephrin B2 polypeptide is a monomer, the EphA4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphA4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphA4 or Ephrin B2 protein and inhibits an activity of the
 CC EphA4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphA4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphA4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1598 CATTGACGGGGTATCTCTCC 1617
 Db 20 CATTGACGGGGTATCTCTCC 1

RESULT 321
 ADR86912/c
 ID ADR86912 standard; DNA; 20 BP.
 AC ADR86912;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 DE Human ephrin B4 antisense oligonucleotide seqid 217.
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2004080425-A2.
 FN
 PD 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 FA
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 FI
 XX

DR WPI; 2004-668883/65.
 XX
 PT New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 94; 198pp; English.
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 578 GCCAGGCCCACTGGCTTCG 597
 Db 20 GCCAGGCCCACTGGCTTCG 1

RESULT 322
 ADR82356/c
 ID ADR82356 standard; DNA; 20 BP.
 AC ADR82356;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 DE Human EphB4 antisense probe #27.
 XX
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 XX
 XX Synthetic.
 FN
 PD WO2004080418-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007491.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX

PI Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 DR
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX Example 8; Page 99; 206pp; English.
 PS
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 7 A; 10 C; 0 G; 3 T; 0 U; 0 Other;
 CC
 CC Query Match 0.5%; Score 20; DB 1; Length 20;
 CC Best Local Similarity 100.0%; Pred. No. 96;
 CC Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2799 TGTGATGTGGAGGTGATGT 2818
 DB 20 TGTGATGTGGAGGTGATGT 1
 RESULT 323
 ADR82384/c
 ID ADR82384 standard; DNA; 20 BP.
 AC ADR82384;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 DE Human EphB4 antisense probe #55.
 XX
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007491.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 XX 12-MAR-2003; 2003US-0454432P.
 PR
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Reddy R, Gill P;
 PI
 XX WPI; 2004-668879/65.
 DR
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX Example 8; Page 99; 206pp; English.
 PS

XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 6 A; 10 C; 2 G; 2 T; 0 U; 0 Other;
 CC
 CC Query Match 0.5%; Score 20; DB 1; Length 20;
 CC Best Local Similarity 100.0%; Pred. No. 96;
 CC Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2238 TGGTCAGGTGAGTTTGGCG 2257
 DB 20 TGGTCAGGTGAGTTTGGCG 1
 RESULT 324
 ADR82395/c
 ID ADR82395 standard; DNA; 20 BP.
 XX
 AC ADR82395;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 DE Human EphB4 antisense probe #66.
 XX
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007491.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 XX 12-MAR-2003; 2003US-0454432P.
 PR
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Reddy R, Gill P;
 PI
 XX WPI; 2004-668879/65.
 DR
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX Example 8; Page 99; 206pp; English.
 PS
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.

```
CC antisense probe.
XX Sequence 20 BP; 7 A; 9 C; 4 G; 0 T; 0 U; 0 Other;
SQ

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2018 GTGTGGTCTGCTGCTGCTGCTG 2037
Db 20 GTGTGGTCTGCTGCTGCTGCTG 1

RESULT 325
ADR82438/c
ID ADR82438 standard; DNA; 20 BP.
XX AC ADR82438;
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #109.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
XX Synthetic.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASC-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX Example 8; Page 100; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
XX Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
SQ

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1158 AGCTGAGGGGACACCAAGT 1177
Db 20 GTGTGGTCTGCTGCTGCTGCTG 1

RESULT 326
ADR82474/c
ID ADR82474 standard; DNA; 20 BP.
XX AC ADR82474;
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #145.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
XX Synthetic.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASC-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX Example 8; Page 101; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
XX Sequence 20 BP; 3 A; 4 C; 3 G; 10 T; 0 U; 0 Other;
SQ

Query Match      0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 438 GAACACAAAATTGGAAACTG 457
Db 20 GAACACAAAATTGGAAACTG 1

RESULT 327
ADR82361/c
ID ADR82361 standard; DNA; 20 BP.
XX AC ADR82361;
XX 16-DEC-2004 (first entry)
```



```

XX DE Human EphB4 antisense probe #32.
XX XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX XX
OS Homo sapiens.
OS Synthetic.
XX XX
XX WO2004080418-A2.
XX XX
XX 23-SEP-2004.
XX XX
XX 12-MAR-2004; 2004WO-US007491.
XX XX
XX 12-MAR-2003; 2003US-0454300P.
XX XX
XX 12-MAR-2003; 2003US-0454432P.
XX XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX XX
XX Reddy R, Gill P;
XX PI; 2004-668879/65.
XX XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX XX
XX Example 8; Page 99; 206pp; English.
XX XX
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX XX
XX Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2699 CGAGCTCCCTGGGAGGAAG 2718
Db |||||||
20 CGAGCTCCCTGGGAGGAAG 1

RESULT 328
ADR82367/c
ID ADR82367 standard; DNA; 20 BP.
XX XX
XX ADR82367;
XX XX
XX 16-DEC-2004 (first entry)
XX XX
XX Human EphB4 antisense probe #38.
XX XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX XX
OS Homo sapiens.

```

```

OS Synthetic.
XX XX
XX WO2004080418-A2.
XX XX
XX 23-SEP-2004.
XX XX
XX 12-MAR-2004; 2004WO-US007491.
XX XX
XX 12-MAR-2003; 2003US-0454300P.
XX XX
XX 12-MAR-2003; 2003US-0454432P.
XX XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX XX
XX Reddy R, Gill P;
XX PI; 2004-668879/65.
XX XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX XX
XX Example 8; Page 99; 206pp; English.
XX XX
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX XX
XX Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2578 AGCTAGTCCACCGAGACT 2597
Db |||||||
20 AGCTAGTCCACCGAGACT 1

RESULT 329
ADR82387/c
ID ADR82387 standard; DNA; 20 BP.
XX XX
XX ADR82387;
XX XX
XX 16-DEC-2004 (first entry)
XX XX
XX Human EphB4 antisense probe #58.
XX XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX XX
XX Homo sapiens.
OS Synthetic.
XX XX
XX WO2004080418-A2.
XX XX
XX 23-SEP-2004.
XX XX
XX 12-MAR-2004; 2004WO-US007491.
XX XX
XX 12-MAR-2003; 2003US-0454300P.
XX XX
XX 12-MAR-2003; 2003US-0454432P.
XX XX

```


XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX DR WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT useful for diagnosing or treating cancer or angiogenesis-associated
XX PT diseases.
XX PS Example 8; Page 99; 206pp; English.
XX SQ The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
SQ Sequence 20 BP; 5 A; 8 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2178 GGCTGTGAGGGAATTGCA 2197
DB 20 GGCTGTGAGGGAATTGCA 1
RESULT 330
ADR82388/c
ID ADR82388 standard; DNA; 20 BP.
XX AC ADR82388;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense probe #59.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
XX KW angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX DR WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT useful for diagnosing or treating cancer or angiogenesis-associated
XX PT diseases.

PT diseases.
XX PS Example 8; Page 99; 206pp; English.
XX SQ The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
SQ Sequence 20 BP; 5 A; 3 C; 4 G; 8 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2158 ACTATGACGACCCCTAATGA 2177
DB 20 ACTATGACGACCCCTAATGA 1
RESULT 331
ADR82390/c
ID ADR82390 standard; DNA; 20 BP.
XX AC ADR82390;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense probe #61.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
XX KW angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX DR WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT useful for diagnosing or treating cancer or angiogenesis-associated
XX PT diseases.
XX PS Example 8; Page 99; 206pp; English.
XX SQ The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
XX PT diseases.

CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.

XX
SQ Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2118 TCTCATCGGACATGGTACTA 2137
DB 20 TCTCATCGGACATGGTACTA 1

RESULT 332
ADR82393/c
ID ADR82393 standard; DNA; 20 BP.
XX
AC ADR82393;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #64.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

OS Homo sapiens.
OS Synthetic.

XX WO2004080418-A2.
XX
XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX Example 8; Page 99; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.

XX Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2058 CTGCCTCAGGACGAGCA 2077
DB 20 CTGCCTCAGGACGAGCA 1

RESULT 333
ADR82410/c
ID ADR82410 standard; DNA; 20 BP.

XX
AC ADR82410;

XX 16-DEC-2004 (first entry)

XX Human EphB4 antisense probe #81.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX Homo sapiens.
OS Synthetic.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX Example 8; Page 100; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.

XX Sequence 20 BP; 4 A; 8 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1718 GCAGCTTGAGCCTGCGCTGG 1737
DB 20 GCAGCTTGAGCCTGCGCTGG 1

RESULT 334
ADR82439/c
ID ADR82439 standard; DNA; 20 BP.
XX

AC ADR82439;
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #110.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
PN 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX (VAGS-) VASGENE THERAPEUTICS INC.
PA Reddy R, Gill P;
PI WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX Example 8; Page 100; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
XX Sequence 20 BP; 5 A; 9 C; 5 G; 1 T; 0 U; 0 Other;
XX Query Match 0.5%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 96;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1138 TGTGCTCCGGGTTGAGGC 1157
Db 20 TGTGCTCCGGGTTGAGGC 1
RESULT 335
ADR82440/c
ID ADR82440 standard; DNA; 20 BP.
XX ADR82440;
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #111.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
PN 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX (VAGS-) VASGENE THERAPEUTICS INC.
PA Reddy R, Gill P;
PI WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX Example 8; Page 100; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
XX Sequence 20 BP; 5 A; 9 C; 5 G; 1 T; 0 U; 0 Other;
XX Query Match 0.5%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 96;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1138 TGTGCTCCGGGTTGAGGC 1157
Db 20 TGTGCTCCGGGTTGAGGC 1
RESULT 335
ADR82440/c
ID ADR82440 standard; DNA; 20 BP.
XX ADR82440;
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #111.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
PN 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX (VAGS-) VASGENE THERAPEUTICS INC.
PA Reddy R, Gill P;
PI WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX Example 8; Page 100; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
XX Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;
XX Query Match 0.5%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 96;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1118 AGCGGTCACGGGTCGAGC 1137
Db 20 AGCGGTCACGGGTCGAGC 1
RESULT 336
ADR82452/c
ID ADR82452 standard; DNA; 20 BP.
XX ADR82452;
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #123.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
PN 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX (VAG-) VASGENE THERAPEUTICS INC.
 XX Reddy R, Gill P;
 PI WPI; 2004-668879/65.
 DR
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 101; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 878 CGCTCAGCAGGCTGGCTTC 897
 Db 20 CGCTCAGCAGGCTGGCTTC 1
 RESULT 337
 ADR82463/C
 ID ADR82463 standard; DNA; 20 BP.
 XX
 AC ADR82463;
 XX 16-DEC-2004 (first entry)
 DT Human EphB4 antisense probe #134.
 DE human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 PN 23-SEP-2004.
 PD 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX (VAG-) VASGENE THERAPEUTICS INC.
 PA Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 DR
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX

PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 101; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 5 A; 5 C; 9 G; 1 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 658 CTCGAGTGCCTGCTCCCTGCC 677
 Db 20 CTCGAGTGCCTGCTCCCTGCC 1
 RESULT 338
 ADR82335/C
 ID ADR82335 standard; DNA; 20 BP.
 XX
 AC ADR82335;
 XX 16-DEC-2004 (first entry)
 DT Human EphB4 antisense probe #6.
 DE human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 PN 23-SEP-2004.
 PD 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX (VAG-) VASGENE THERAPEUTICS INC.
 PA Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 DR
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 98; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or

CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.

XX SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3219 CCGAATCGGAGTCACTCTGG 3238
Db 20 CCGAATCGGAGTCACTCTGG 1

RESULT 339
ADR82340/C
ID ADR82340 standard; DNA; 20 BP.

XX AC ADR82340;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense probe #11.

XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
XX KW angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX OS Homo sapiens.
XX OS Synthetic.

XX PN WO2004080418-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US007491.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-0454432P.

XX PA (VASG-) VASGENE THERAPEUTICS INC.

XX PI Reddy R, Gill P;

XX DR WPI; 2004-668879/65.

XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT useful for diagnosing or treating cancer or angiogenesis-associated
XX PT diseases.

XX PS Example 8; Page 98; 206pp; English.

XX CC The invention relates to an isolated nucleic acid compound comprising at
XX CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX CC physiological conditions and decreases the expression of EphB4 or
XX CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX CC medicament for the treatment of cancer or angiogenesis-associated
XX CC diseases. The composition and methods are useful for diagnosing or
XX CC treating cancer or angiogenesis-associated diseases, such as inflammatory
XX CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX CC diseases or scleroderma. The present sequence represents a human EphB4
XX CC antisense probe.

XX SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3119 GGCTTCGGGCATCAAAATG 3138
Db 20 GGCTTCGGGCATCAAAATG 1

RESULT 340
ADR82348/C

ID ADR82348 standard; DNA; 20 BP.

XX AC ADR82348;

XX DT 16-DEC-2004 (first entry)

XX DE Human EphB4 antisense probe #19.

XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
XX KW angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX OS Homo sapiens.
XX OS Synthetic.

XX PN WO2004080418-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US007491.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-0454432P.

XX PA (VASG-) VASGENE THERAPEUTICS INC.

XX PI Reddy R, Gill P;

XX DR WPI; 2004-668879/65.

XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT useful for diagnosing or treating cancer or angiogenesis-associated
XX PT diseases.

XX PS Example 8; Page 99; 206pp; English.

XX CC The invention relates to an isolated nucleic acid compound comprising at
XX CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX CC physiological conditions and decreases the expression of EphB4 or
XX CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX CC medicament for the treatment of cancer or angiogenesis-associated
XX CC diseases. The composition and methods are useful for diagnosing or
XX CC treating cancer or angiogenesis-associated diseases, such as inflammatory
XX CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX CC diseases or scleroderma. The present sequence represents a human EphB4
XX CC antisense probe.

XX SQ Sequence 20 BP; 3 A; 4 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2959 AATGCCCGCCCGCTTCCC 2978
Db 20 AATGCCCGCCCGCTTCCC 1

RESULT 341

ADR82353/c
ID ADR82353 standard; DNA; 20 BP.
XX AC ADR82353;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense probe #24.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
XX
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX (VAGS-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX Example 8; Page 99; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
XX
XX Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2859 CGTGATCAATGCCATTGAAC 2878
DB 20 CGTGATCAATGCCATTGAAC 1

RESULT 342
ADR82408/c
ID ADR82408 standard; DNA; 20 BP.
XX AC ADR82408;
XX
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #79.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW

KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
XX Homo sapiens.
XX Synthetic.
XX WO2004080418-A2.
XX
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX (VAGS-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX Example 8; Page 100; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
XX
XX Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1758 TGGGGCTGTGCTGGACTACG 1777
DB 20 TGGGGCTGTGCTGGACTACG 1

RESULT 343
ADR82415/c
ID ADR82415 standard; DNA; 20 BP.
XX AC ADR82415;
XX
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #86.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
XX Homo sapiens.
XX Synthetic.
XX WO2004080418-A2.
XX

PD 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX
XX Example 8; Page 100; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
XX
XX Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1618 TTAGCCACGGGGCGGTCC 1637
Db 20 TTAGCCACGGGGCGGTCC 1
RESULT 344
ADR82416/C
ID ADR82416 standard; DNA; 20 BP.
XX
AC ADR82416;
XX
DT 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense probe #87.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer; angiogenesis-associated disease; inflammatory disorder; chronic articular rheumatism; psoriasis; ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic; dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
PI

XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX
XX Example 8; Page 100; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
XX
XX Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1598 CATTGAACGGGGTATCTCC 1617
Db 20 CATTGAACGGGGTATCTCC 1
RESULT 345
ADR82441/C
ID ADR82441 standard; DNA; 20 BP.
XX
AC ADR82441;
XX
DT 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense probe #112.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer; angiogenesis-associated disease; inflammatory disorder; chronic articular rheumatism; psoriasis; ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic; dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX
XX Example 8; Page 100; 206pp; English.
XX


```

RESULT 348
ADR82471/c
ID   ADR82471 standard; DNA; 20 BP.
XX   AC   ADR82471;
XX   DT   16-DEC-2004 (first entry)
XX   DE   Human EphB4 antisense probe #142.
XX   KW   human; ss; antisense; EphB4; EphrinB2; cancer;
XX   KW   angiogenesis-associated disease; inflammatory disorder;
XX   KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX   KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX   KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX   OS   Homo sapiens.
XX   OS   Synthetic.
XX   FN   WO2004080418-A2.
XX   PD   23-SEP-2004.
XX   PF   12-MAR-2004; 2004WO-US007491.
XX   PR   12-MAR-2003; 2003US-0454300P.
XX   PR   12-MAR-2003; 2003US-0454432P.
XX   PA   (VASG-) VASGENE THERAPEUTICS INC.
XX   PI   Reddy R, Gill P;
XX   DR   WPI; 2004-668879/65.
XX   CC   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX   PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX   PT   useful for diagnosing or treating cancer or angiogenesis-associated
XX   PS   Example 8; Page 101; 206pp; English.
XX   CC   The invention relates to an isolated nucleic acid compound comprising at
XX   CC   least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX   CC   physiological conditions and decreases the expression of EphB4 or
XX   CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX   CC   medicament for the treatment of cancer or angiogenesis-associated
XX   CC   diseases. The composition and methods are useful for diagnosing or
XX   CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
XX   CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX   CC   diseases or scleroderma. The present sequence represents a human EphB4
XX   SS   antisense probe.
XX   SQ   Sequence 20 BP; 2 A; 10 C; 4 G; 4 T; 0 U; 0 Other;
XX   Query Match 0.5%; Score 20; DB 1; Length 20;
XX   Best Local Similarity 100.0%; Pred. No. 96;
XX   Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY   498 GTGGGAGGAAGTGGCGGCC 517
Db   20 GTGGGAGGAAGTGGCGGCC 1

RESULT 349
ADR82476/c
ID   ADR82476 standard; DNA; 20 BP.
XX   AC   ADR82476;
XX   DT   16-DEC-2004 (first entry)
XX   DE   Human EphB4 antisense probe #7.
XX   KW   human; ss; antisense; EphB4; EphrinB2; cancer;
XX   KW   angiogenesis-associated disease; inflammatory disorder;
XX   KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX   KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX   KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX   OS   Homo sapiens.
XX   OS   Synthetic.

```

```

DE   Human EphB4 antisense probe #147.
XX   KW   human; ss; antisense; EphB4; EphrinB2; cancer;
XX   KW   angiogenesis-associated disease; inflammatory disorder;
XX   KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX   KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX   KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX   OS   Homo sapiens.
XX   OS   Synthetic.
XX   FN   WO2004080418-A2.
XX   PD   23-SEP-2004.
XX   PF   12-MAR-2004; 2004WO-US007491.
XX   PR   12-MAR-2003; 2003US-0454300P.
XX   PR   12-MAR-2003; 2003US-0454432P.
XX   PA   (VASG-) VASGENE THERAPEUTICS INC.
XX   PI   Reddy R, Gill P;
XX   DR   WPI; 2004-668879/65.
XX   CC   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX   PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX   PT   useful for diagnosing or treating cancer or angiogenesis-associated
XX   PS   Example 8; Page 101; 206pp; English.
XX   CC   The invention relates to an isolated nucleic acid compound comprising at
XX   CC   least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX   CC   physiological conditions and decreases the expression of EphB4 or
XX   CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX   CC   medicament for the treatment of cancer or angiogenesis-associated
XX   CC   diseases. The composition and methods are useful for diagnosing or
XX   CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
XX   CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX   CC   diseases or scleroderma. The present sequence represents a human EphB4
XX   SS   antisense probe.
XX   SQ   Sequence 20 BP; 5 A; 8 C; 6 G; 1 T; 0 U; 0 Other;
XX   Query Match 0.5%; Score 20; DB 1; Length 20;
XX   Best Local Similarity 100.0%; Pred. No. 96;
XX   Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY   398 GCTGGGCTTCGTTGGCGGCA 417
Db   20 GCTGGGCTTCGTTGGCGGCA 1

RESULT 350
ADR82336/c
ID   ADR82336 standard; DNA; 20 BP.
XX   AC   ADR82336;
XX   DT   16-DEC-2004 (first entry)
XX   DE   Human EphB4 antisense probe #7.
XX   KW   human; ss; antisense; EphB4; EphrinB2; cancer;
XX   KW   angiogenesis-associated disease; inflammatory disorder;
XX   KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX   KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX   KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX   OS   Homo sapiens.
XX   OS   Synthetic.

```

```

XX PN WO2004080418-A2.
XX PD
XX PF 23-SEP-2004.
XX PR 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VAGS-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX PS WPI; 2004-668879/65.
XX CC New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX CC transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX CC useful for diagnosing or treating cancer or angiogenesis-associated
XX CC diseases.
XX CC Example 8; Page 98; 206pp; English.
XX CC The invention relates to an isolated nucleic acid compound comprising at
XX CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX CC physiological conditions and decreases the expression of EphB4 or
XX CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX CC medicament for the treatment of cancer or angiogenesis-associated
XX CC diseases. The composition and methods are useful for diagnosing or
XX CC treating cancer or angiogenesis-associated diseases, such as inflammatory
XX CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX CC diseases or scleroderma. The present sequence represents a human EphB4
XX CC antisense probe.
XX SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
XX CC
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3199 ATCTCTGCTGAGGACCTGCT 3218
DB 20 ATCTCTGCTGAGGACCTGCT 1

RESULT 351
ADR82343/c
ID ADR82343 standard; DNA; 20 BP.
XX AC ADR82343;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense probe #14.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
XX KW angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VAGS-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX PS WPI; 2004-668879/65.
XX CC New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX CC transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX CC useful for diagnosing or treating cancer or angiogenesis-associated
XX CC diseases.
XX CC Example 8; Page 98; 206pp; English.
XX CC The invention relates to an isolated nucleic acid compound comprising at
XX CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX CC physiological conditions and decreases the expression of EphB4 or
XX CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX CC medicament for the treatment of cancer or angiogenesis-associated
XX CC diseases. The composition and methods are useful for diagnosing or
XX CC treating cancer or angiogenesis-associated diseases, such as inflammatory
XX CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX CC diseases or scleroderma. The present sequence represents a human EphB4
XX CC antisense probe.
XX SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
XX CC
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3059 CACACCCCTCTCTGACCAG 3078
DB 20 CACACCCCTCTCTGACCAG 1

RESULT 352
ADR82345/c
ID ADR82345 standard; DNA; 20 BP.
XX AC ADR82345;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense probe #16.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
XX KW angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VAGS-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX PS WPI; 2004-668879/65.
XX CC New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX CC transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX CC useful for diagnosing or treating cancer or angiogenesis-associated
XX CC diseases.

```

XX PS Example 8; Page 99; 206pp; English.

XX CC The invention relates to an isolated nucleic acid compound comprising at

CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under

CC physiological conditions and decreases the expression of EphB4 or

CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a

CC medicament for the treatment of cancer or angiogenesis-associated

CC diseases. The composition and methods are useful for diagnosing or

CC treating cancer or angiogenesis-associated diseases, such as inflammatory

CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic

CC diseases or scleroderma. The present sequence represents a human EphB4

CC antisense probe.

XX SQ Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3019 GCCAGCCTCAAAATCGTGGC 3038

DB 20 GCCAGCCTCAAAATCGTGGC 1

RESULT 353

ADR82353/c

ID ADR82359 standard; DNA; 20 BP.

XX AC ADR82359;

XX DT 16-DEC-2004 (first entry)

XX DE Human EphB4 antisense probe #30.

XX KW human; ss; antisense; EphB4; EphrinB2; cancer;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX OS Homo sapiens.

OS Synthetic.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX PI Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2

XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,

XX useful for diagnosing or treating cancer or angiogenesis-associated

XX diseases.

XX Example 8; Page 99; 206pp; English.

XX CC The invention relates to an isolated nucleic acid compound comprising at

CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under

CC physiological conditions and decreases the expression of EphB4 or

CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a

CC medicament for the treatment of cancer or angiogenesis-associated

CC diseases. The composition and methods are useful for diagnosing or

CC treating cancer or angiogenesis-associated diseases, such as inflammatory

CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic

CC diseases or scleroderma. The present sequence represents a human EphB4

CC antisense probe.

XX SQ Sequence 20 BP; 4 A; 5 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2739 CCCGAGGCCATTGCCTTCC 2758

DB 20 CCCGAGGCCATTGCCTTCC 1

RESULT 354

ADR82365/c

ID ADR82365 standard; DNA; 20 BP.

XX AC ADR82365;

XX DT 16-DEC-2004 (first entry)

XX DE Human EphB4 antisense probe #36.

XX KW human; ss; antisense; EphB4; EphrinB2; cancer;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX OS Homo sapiens.

OS Synthetic.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX PI Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2

XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,

XX useful for diagnosing or treating cancer or angiogenesis-associated

XX diseases.

XX Example 8; Page 99; 206pp; English.

XX CC The invention relates to an isolated nucleic acid compound comprising at

CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under

CC physiological conditions and decreases the expression of EphB4 or

CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a

CC medicament for the treatment of cancer or angiogenesis-associated

CC diseases. The composition and methods are useful for diagnosing or

CC treating cancer or angiogenesis-associated diseases, such as inflammatory

CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic

CC diseases or scleroderma. The present sequence represents a human EphB4

CC antisense probe.

XX SQ Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2618 TCAACAGCACTCGTCTGC 2637
 Db 20 TCAACAGCACTCGTCTGC 1

RESULT 355
 ADR82370/c
 ID ADR82370 standard; DNA; 20 BP.
 XX
 AC ADR82370;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #41.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 XX
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Reddy R, Gill P;
 XX
 DR WPI; 2004-668879/65.
 XX
 PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 99; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2518 ATCCAGCTCGTGGCATGCT 2537
 Db 20 ATCCAGCTCGTGGCATGCT 1

RESULT 356
 ADR82423/c
 ID ADR82423 standard; DNA; 20 BP.
 XX
 AC ADR82423;

XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #94.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 XX
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Reddy R, Gill P;
 XX
 DR WPI; 2004-668879/65.
 XX
 PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 100; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 1 A; 9 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1458 CCGGGAGTCCGACCCGGAG 1477
 Db 20 CCGGGAGTCCGACCCGGAG 1

RESULT 357
 ADR82432/c
 ID ADR82432 standard; DNA; 20 BP.
 XX
 AC ADR82432;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #103.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

OS Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX
XX Example 8; Page 100; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
XX
XX Sequence 20 BP; 4 A; 8 C; 7 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1278 CTGCCAGTGGCGGCTCGGGT 1297
Db 20 CTGCCAGTGGCGGCTCGGGT 1
RESULT 358
ADR82446/C
ID ADR82446 standard; DNA; 20 BP.
XX
XX ADR82446;
XX
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #117.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
XX Homo sapiens.
XX Synthetic.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX

PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX
XX Example 8; Page 100; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
XX
XX Sequence 20 BP; 3 A; 9 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 998 CGGAGACTGTGCTCGGGAG 1017
Db 20 CGGAGACTGTGCTCGGGAG 1
RESULT 359
ADR82455/C
ID ADR82455 standard; DNA; 20 BP.
XX
XX ADR82455;
XX
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #126.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
XX Homo sapiens.
XX Synthetic.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2

PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 101; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 1 A; 10 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 818 GGAAGCGCCCTGGGCGCAG 837
DB 20 GGAAGCGCCCTGGGCGCAG 1
RESULT 360
ADR82459/c
ID ADR82459 standard; DNA; 20 BP.
AC ADR82459;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #130.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VAGS-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 101; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a

CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 1 A; 5 C; 11 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 738 CACGGCCACGGCCCTCACGC 757
DB 20 CACGGCCACGGCCCTCACGC 1
RESULT 361
ADR82466/c
ID ADR82466 standard; DNA; 20 BP.
AC ADR82466;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #137.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VAGS-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 101; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;

```
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 598 ACAGGTGGGTCCACGCGC 617
Db 20 ACAGGTGGGTCCACGCGC 1

RESULT 362
ADR82472/c
ID ADR82472 standard; DNA; 20 BP.
XX AC ADR82472;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense ODN #12.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
XX KW angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX KW scleroderma; cystostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX KW dermatological; ophthalmological; angiogenesis inhibitor.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004080418-A2.
XX DE 23-SEP-2004.
XX PD 12-MAR-2004; 2004WO-US007491.
XX PF 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PS (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX DT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT useful for diagnosing or treating cancer or angiogenesis-associated
XX PT diseases.
XX PS Example 5; Page 85; 206pp; English.
XX CC The invention relates to an isolated nucleic acid compound comprising at
XX CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX CC physiological conditions and decreases the expression of EphB4 or
XX CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX CC medicament for the treatment of cancer or angiogenesis-associated
XX CC diseases. The composition and methods are useful for diagnosing or
XX CC treating cancer or angiogenesis-associated diseases, such as inflammatory
XX CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX CC diseases or scleroderma. The present sequence represents a human EphB4
XX CC antisense oligodeoxynucleotide (ODN).
XX SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2356 TTCTGAGCGAGCGCTCCAT 2375
Db 20 TTCTGAGCGAGCGCTCCAT 1

RESULT 364
ADR82363/c
ID ADR82363 standard; DNA; 20 BP.
XX AC ADR82363;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense probe #34.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
XX KW angiogenesis-associated disease; inflammatory disorder;

Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 478 TTCCCTCAGGTGGACGGCA 497
Db 20 TTCCCTCAGGTGGACGGCA 1

RESULT 363
ADR82318/c
ID ADR82318 standard; DNA; 20 BP.
XX AC ADR82318;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense ODN #12.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
XX KW angiogenesis-associated disease; inflammatory disorder;
```

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX PF
XX 12-MAR-2003; 2003US-0454300P.
PR
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VAGS-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 99; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2659 TCCCGATTCTCTGGAGGAGAA 2678
DB 20 TCCCGATTCTCTGGAGGAGAA 1
XX
RESULT 365
ADR82406/c
ID ADR82406 standard; DNA; 20 BP.
XX
XX ADR82406;
AC
XX
XX 16-DEC-2004 (first entry)
DT
XX Human EphB4 antisense probe #77.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
XX Homo sapiens.
OS
OS Synthetic.
XX WO2004080418-A2.
XX
XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.
XX PF
XX 12-MAR-2003; 2003US-0454300P.
PR
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VAGS-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 100; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 1 A; 9 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1798 GCGCGCGAGGGTCCCGAGCAG 1817
DB 20 GCGCGCGAGGGTCCCGAGCAG 1
XX
RESULT 366
ADR82429/c
ID ADR82429 standard; DNA; 20 BP.
XX
XX ADR82429;
AC
XX
XX 16-DEC-2004 (first entry)
DT
XX Human EphB4 antisense probe #100.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
XX Homo sapiens.
OS
OS Synthetic.
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
PF
XX 12-MAR-2003; 2003US-0454300P.
PR
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VAGS-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX

DR WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 100; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
SQ Sequence 20 BP; 4 A; 3 C; 12 G; 1 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1338 CACCCCTCTTCGGCTCCGC 1357
DB 20 CACCCCTCTTCGGCTCCGC 1
RESULT 367
ADR82291
ID ADR82291 standard; DNA; 20 BP.
XX
AC ADR82291;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 sense ODN.
XX
KW human; ss; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW inflammatory disorder; chronic articular rheumatism; psoriasis;
KW ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW angiogenesis inhibitor.
OS Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 3; Page 68; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at

CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
XX sense oligodeoxynucleotide (ODN).
SQ Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 691 TCCTGCAAGGAGACCTTCAC 710
DB 1 TCCTGCAAGGAGACCTTCAC 20
RESULT 368
ADR82338/c
ID ADR82338 standard; DNA; 20 BP.
XX
AC ADR82338;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #9.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
OS Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 98; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.

SQ Sequence 20 BP; 5 A; 7 C; 7 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3159 CGCAGCGCTGGCTTGGCT 3178
|||||
DB 20 CGCAGCGCTGGCTTGGCT 1

RESULT 369

ADR82396/c
ID ADR82396 standard; DNA; 20 BP.

XX ADR82396;
XX

DT 16-DEC-2004 (first entry)

DE Human EphB4 antisense probe #67.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX Homo sapiens.
OS Synthetic.

PN WO2004080418-A2.

XX 23-SEP-2004.

PF 12-MAR-2004; 2004WO-US007491.

PR 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.

XX Example 8; Page 99; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.

XX Sequence 20 BP; 3 A; 10 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1998 TGCAGCGCAGTCTGG 2017
|||||
DB 20 TGCAGCGCAGTCTGG 1

RESULT 370

ADR82413/c
ID ADR82413 standard; DNA; 20 BP.

XX ADR82413;

DT 16-DEC-2004 (first entry)

DE Human EphB4 antisense probe #84.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX Homo sapiens.

OS Synthetic.

PN WO2004080418-A2.

XX 23-SEP-2004.

PF 12-MAR-2004; 2004WO-US007491.

PR 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.

XX Example 8; Page 100; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.

XX Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1658 CCACCTGACCGAGAGGTACCT 1677
|||||
DB 20 CCACCTGACCGAGAGGTACCT 1

RESULT 371

ADR82419/c
ID ADR82419 standard; DNA; 20 BP.

XX ADR82419;

DT 16-DEC-2004 (first entry)

XX Human EphB4 antisense probe #90.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 FN
 XX 23-SEP-2004.
 PD
 XX
 XX 12-MAR-2004; 2004WO-US007491.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 XX 12-MAR-2003; 2003US-0454432P.
 PR
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Reddy R, Gill P;
 PI WPI; 2004-668879/65.
 DR
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 100; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1538 AGCCCTGGTGGTGGTTGCA 1557
 Db 20 AGCCCTGGTGGTGGTTGCA 1
 RESULT 372
 ADR82424/C
 ID ADR82424 standard; DNA; 20 BP.
 XX
 AC ADR82424;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #95.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX

PN WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007491.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 XX 12-MAR-2003; 2003US-0454432P.
 PR
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Reddy R, Gill P;
 PI WPI; 2004-668879/65.
 DR
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 100; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 4 A; 3 C; 11 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1438 CTCACCTACGCCCTCCGCTG 1457
 Db 20 CTCACCTACGCCCTCCGCTG 1
 RESULT 373
 ADR82444/C
 ID ADR82444 standard; DNA; 20 BP.
 XX
 AC ADR82444;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #115.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FN WO2004080418-A2.
 PD
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007491.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 XX 12-MAR-2003; 2003US-0454432P.
 PR
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA

XX PI Reddy R, Gill P;
XX DR WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT useful for diagnosing or treating cancer or angiogenesis-associated
XX PT diseases.
XX PS Example 8; Page 100; 206pp; English.
XX CC The invention relates to an isolated nucleic acid compound comprising at
XX CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX CC physiological conditions and decreases the expression of EphB4 or
XX CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX CC medicament for the treatment of cancer or angiogenesis-associated
XX CC diseases. The composition and methods are useful for diagnosing or
XX CC treating cancer or angiogenesis-associated diseases, such as inflammatory
XX CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX CC antisenese probe.
XX SQ Sequence 20 BP; 5 A; 9 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TAGCTGCGTGGTGGATGCCG 1057
DB 20 TAGCTGCGTGGTGGATGCCG 1
RESULT 374
ADR82450/c
ID ADR82450 standard; DNA; 20 BP.
XX AC ADR82450;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense probe #121.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX DR WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT useful for diagnosing or treating cancer or angiogenesis-associated
XX PT diseases.

PS Example 8; Page 100; 206pp; English.
XX CC The invention relates to an isolated nucleic acid compound comprising at
XX CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX CC physiological conditions and decreases the expression of EphB4 or
XX CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX CC medicament for the treatment of cancer or angiogenesis-associated
XX CC diseases. The composition and methods are useful for diagnosing or
XX CC treating cancer or angiogenesis-associated diseases, such as inflammatory
XX CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX CC antisenese probe.
XX SQ Sequence 20 BP; 4 A; 8 C; 7 G; 1 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 918 GGGTGCCTGCATGCCCTGC 937
DB 20 GGGTGCCTGCATGCCCTGC 1
RESULT 375
ADR82465/c
ID ADR82465 standard; DNA; 20 BP.
XX AC ADR82465;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense probe #136.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX DR WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX PT useful for diagnosing or treating cancer or angiogenesis-associated
XX PT diseases.
XX PS Example 8; Page 101; 206pp; English.
XX CC The invention relates to an isolated nucleic acid compound comprising at
XX CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX CC physiological conditions and decreases the expression of EphB4 or
XX CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX CC medicament for the treatment of cancer or angiogenesis-associated
XX CC diseases. The composition and methods are useful for diagnosing or
XX CC treating cancer or angiogenesis-associated diseases, such as inflammatory
XX CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic

CC diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
SQ Sequence 20 BP; 3 A; 8 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 618 GGGCGCGCTCCACGCTAGC 637
DB 20 GGGCGCGCTCCACGCTAGC 1
RESULT 376
ADR82663
ID ADR82663 standard; DNA; 20 BP.
XX
AC ADR82663;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 PCR primer #14.
XX
KW human; ss; PCR; primer; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
WPI; 2004-668879/65.
XX
New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
Example 6; Page 93; 206pp; English.
XX
The invention relates to an isolated nucleic acid compound comprising at
least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC PCR primer.
XX
SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 419 CTTTGAAGAGACCTGCTG 438
|||||

DB 1 CTTTGAAGAGACCTGCTG 20
RESULT 377
ADR82333/C
ID ADR82333 standard; DNA; 20 BP.
XX
AC ADR82333;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #4.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
WPI; 2004-668879/65.
XX
New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
Example 8; Page 98; 206pp; English.
XX
The invention relates to an isolated nucleic acid compound comprising at
least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3259 TTGGCCAGTGTCACGACAT 3278
|||||
DB 20 TTGGCCAGTGTCACGACAT 1
RESULT 378
ADR82347/C
ID ADR82347 standard; DNA; 20 BP.
XX
AC ADR82347;
XX
DT 16-DEC-2004 (first entry)

```

XX DE Human EphB4 antisense probe #18.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VAGS-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 99; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
XX Sequence 20 BP; 3 A; 8 C; 7 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2979 CCAGGTGTCAGCGCCCTGG 2998
Db 20 CCAGGTGTCAGCGCCCTGG 1

RESULT 379
ADR82355/c
ID ADR82355 standard; DNA; 20 BP.
XX
XX ADR82355;
AC
XX
XX 16-DEC-2004 (first entry)
DT
XX
XX Human EphB4 antisense probe #26.
DE
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
XX Homo sapiens.
OS

```

```

OS Synthetic.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VAGS-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 99; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
XX Sequence 20 BP; 4 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2819 CATTGGGGAGAGGCGGTAC 2838
Db 20 CATTGGGGAGAGGCGGTAC 1

RESULT 380
ADR82376/c
ID ADR82376 standard; DNA; 20 BP.
XX
XX ADR82376;
AC
XX
XX 16-DEC-2004 (first entry)
DT
XX
XX Human EphB4 antisense probe #47.
DE
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX

```


CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.

XX
SQ Sequence 20 BP; 3 A; 11 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2258 AGGTGTGCCGGGGCGGCTC 2277
|||||
Db 20 AGGTGTGCCGGGGCGGCTC 1

RESULT 383

ADR82421/c
ID ADR82421 standard; DNA; 20 BP.

XX ADR82421;

DT 16-DEC-2004 (first entry)

DE Human EphB4 antisense probe #92.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX Homo sapiens.

OS Synthetic.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US0007491.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX Example 8; Page 100; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.

XX Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1498 GGAGACCTGACTTTTGACCC 1517
|||||
Db 20 GGAGACCTGACTTTTGACCC 1

RESULT 384

ADR82426/c
ID ADR82426 standard; DNA; 20 BP.

XX ADR82426;

DT 16-DEC-2004 (first entry)

DE Human EphB4 antisense probe #97.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX Homo sapiens.

OS Synthetic.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US0007491.

PR 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX Example 8; Page 100; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.

XX Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1398 GGAATGGAGTCCCCCTGG 1417
|||||
Db 20 GGAATGGAGTCCCCCTGG 1

RESULT 385

ADR82443/c
ID ADR82443 standard; DNA; 20 BP.

XX

AC ADR82443;
 XX 16-DEC-2004 (first entry)
 DT XX
 DE Human EphB4 antisense probe #114.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 OS
 PN WO2004080418-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007491.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 PR 12-MAR-2003; 2003US-045432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Reddy R, Gill P;
 PI
 XX WPI; 2004-668879/65.
 DR
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 XX Example 8; Page 100; 206pp; English.
 PS
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 XX Sequence 20 BP; 2 A; 4 C; 13 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1058 TCCCCGCCCTGGCCCGCAGC 1077
 DB 20 TCCCCGCCCTGGCCCGCAGC 1
 RESULT 386
 ADR82445/C
 ID ADR82445 standard; DNA; 20 BP.
 XX
 AC ADR82445;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 XX Human EphB4 antisense probe #116.
 DE
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 OS
 PN WO2004080418-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007491.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 PR 12-MAR-2003; 2003US-045432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Reddy R, Gill P;
 PI
 XX WPI; 2004-668879/65.
 DR
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 XX Example 8; Page 100; 206pp; English.
 PS
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 XX Sequence 20 BP; 5 A; 9 C; 6 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1018 CTGGTTGTCCTGGCCCG 1037
 DB 20 CTGGTTGTCCTGGCCCG 1
 RESULT 387
 ADR82447/C
 ID ADR82447 standard; DNA; 20 BP.
 XX
 AC ADR82447;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 XX Human EphB4 antisense probe #118.
 DE
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 OS
 PN WO2004080418-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX (VAG-) VASGENE THERAPEUTICS INC.
 PA Reddy R, Gill P;
 PI WPI; 2004-668879/65.
 DR New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX Example 8; Page 100; 206pp; English.
 PS The invention relates to an isolated nucleic acid compound comprising at
 XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 978 TGTGAACCTGACTCGATTCC 997
 Db 20 TGTGAACCTGACTCGATTCC 1
 RESULT 388
 ADR82469/c
 ID ADR82469 standard; DNA; 20 BP.
 XX ADR82469;
 AC 16-DEC-2004 (first entry)
 DT Human EphB4 antisense probe #140.
 DE human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX (VAG-) VASGENE THERAPEUTICS INC.
 PA Reddy R, Gill P;
 PI WPI; 2004-668879/65.
 DR New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX Example 8; Page 101; 206pp; English.
 PS The invention relates to an isolated nucleic acid compound comprising at
 XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX Example 8; Page 101; 206pp; English.
 PS The invention relates to an isolated nucleic acid compound comprising at
 XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 538 GTGCGACCTACGAAGTGTG 557
 Db 20 GTGCGACCTACGAAGTGTG 1
 RESULT 389
 ADR82475/c
 ID ADR82475 standard; DNA; 20 BP.
 XX ADR82475;
 AC 16-DEC-2004 (first entry)
 DT Human EphB4 antisense probe #146.
 DE human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX (VAG-) VASGENE THERAPEUTICS INC.
 PA Reddy R, Gill P;
 PI WPI; 2004-668879/65.
 DR New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX Example 8; Page 101; 206pp; English.
 PS The invention relates to an isolated nucleic acid compound comprising at
 XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 418 GCTTTGGAGAGACCTGCT 437
 Db 20 GCTTTGGAGAGACCTGCT 1

RESULT 390
 ADR82293/C
 ID ADR82293 standard; DNA; 20 BP.
 XX
 AC ADR82293;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense ODN #2.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
 XX angiogenesis-associated disease; inflammatory disorder;
 XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 XX dermatological; ophthalmological; angiogenesis inhibitor.
 XX Homo sapiens.
 OS Synthetic.
 OS WO2004080418-A2.
 FN 23-SEP-2004.
 PD 12-MAR-2004; 2004WO-US007491.
 PF 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA Reddy R, Gill P;
 PI WPI; 2004-668879/65.
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 XX useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases.
 XX Example 3; Page 68; 206pp; English.

CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense oligodeoxynucleotide (ODN).
 XX
 SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2356 TTTCTGAGGAGCGCTCCAT 2375
 Db 20 TTTCTGAGGAGCGCTCCAT 1

RESULT 391
 ADR82344/c
 ID ADR82344 standard; DNA; 20 BP.
 XX
 AC ADR82344;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #15.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
 XX angiogenesis-associated disease; inflammatory disorder;
 XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 XX dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.
 OS WO2004080418-A2.
 FN 23-SEP-2004.
 PD 12-MAR-2004; 2004WO-US007491.
 PF 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA Reddy R, Gill P;
 PI WPI; 2004-668879/65.
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 XX useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases.
 XX Example 8; Page 99; 206pp; English.

CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 2 A; 10 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3039 CCGGAGAAATGGCGGCGCT 3058
 Db 20 CCGGAGAAATGGCGGCGCT 1

RESULT 392

ADR82352/c
ID ADR82352 standard; DNA; 20 BP.
XX
AC ADR82352;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #23.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
PI WPI; 2004-668879/65.
XX
DR New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 2 A; 6 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2879 AGGACTACCGCTGCCCGC 2898
DT
DB 20 AGGACTACCGCTGCCCGC 1
RESULT 393
ADR82368/c
ID ADR82368 standard; DNA; 20 BP.
XX
AC ADR82368;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #39.
XX
DE human; ss; antisense; EphB4; EphrinB2; cancer;
KW

KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
XX Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
PI WPI; 2004-668879/65.
XX
DR New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2558 TGGGTACCTTCCGAGATG 2577
DT
DB 20 TGGGTACCTTCCGAGATG 1
RESULT 394
ADR82386/c
ID ADR82386 standard; DNA; 20 BP.
XX
AC ADR82386;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #57.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
XX Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX

PD 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX Example 8; Page 99; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
XX Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2198 AAGAGATCGATGCTCTCCTAC 2217
DB |||||||||||||||||||
20 AAGAGATCGATGCTCTCCTAC 1
RESULT 395
ADR82401/c
ID ADR82401 standard; DNA; 20 BP.
XX ADR82401;
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #72.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cystostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
PI

XX WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX Example 8; Page 100; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
XX Sequence 20 BP; 2 A; 10 C; 7 G; 1 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1898 GGGCGGCGCTCTGAGCGCGC 1917
DB |||||||||||||||||||
20 GGGCGGCGCTCTGAGCGCGC 1
RESULT 396
ADR82402/c
ID ADR82402 standard; DNA; 20 BP.
XX ADR82402;
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #73.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cystostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX Example 8; Page 100; 206pp; English.
PS

CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.

XX Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1878 CAGCTACCTGGTGCAGGTAC 1897
 |||||
 Db 20 CAGCTACCTGGTGCAGGTAC 1

RESULT 397

ADR82417/c

ID ADR82417 standard; DNA; 20 BP.

XX ADR82417;

AC ADR82417;

XX 16-DEC-2004 (first entry)

DT 16-DEC-2004 (first entry)

DE Human EphB4 antisense probe #88.

XX human; ss; antisense; EphB4; EphrinB2; cancer;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX Homo sapiens.

OS Synthetic.

XX WO2004080418-A2.

PN 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

PA Reddy R, Gill P;

XX WPI; 2004-668879/65.

DR New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2

PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,

PT useful for diagnosing or treating cancer or angiogenesis-associated

PT diseases.

XX Example 8; Page 100; 206pp; English.

PS The invention relates to an isolated nucleic acid compound comprising at

XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under

CC physiological conditions and decreases the expression of EphB4 or

CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a

CC medicament for the treatment of cancer or angiogenesis-associated

CC diseases. The composition and methods are useful for diagnosing or

CC treating cancer or angiogenesis-associated diseases, such as inflammatory

CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic

CC diseases or scleroderma. The present sequence represents a human EphB4

CC antisense probe.

XX Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1578 CTATACCTTTGAGTCACTG 1597
 |||||
 Db 20 CTATACCTTTGAGTCACTG 1

RESULT 398

ADR82425/c

ID ADR82425 standard; DNA; 20 BP.

XX ADR82425;

AC ADR82425;

XX 16-DEC-2004 (first entry)

DT 16-DEC-2004 (first entry)

DE Human EphB4 antisense probe #96.

XX human; ss; antisense; EphB4; EphrinB2; cancer;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX Homo sapiens.

OS Synthetic.

XX WO2004080418-A2.

PN 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

PA Reddy R, Gill P;

XX WPI; 2004-668879/65.

DR New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2

PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,

PT useful for diagnosing or treating cancer or angiogenesis-associated

PT diseases.

XX Example 8; Page 100; 206pp; English.

PS The invention relates to an isolated nucleic acid compound comprising at

XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under

CC physiological conditions and decreases the expression of EphB4 or

CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a

CC medicament for the treatment of cancer or angiogenesis-associated

CC diseases. The composition and methods are useful for diagnosing or

CC treating cancer or angiogenesis-associated diseases, such as inflammatory

CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic

CC diseases or scleroderma. The present sequence represents a human EphB4

CC antisense probe.

XX Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1418 AGTCTGGTGGCCGAGGAC 1437
 |||||
 Db 20 AGTCTGGTGGCCGAGGAC 1

```
RESULT 399
ADR82431/c
ID   ADR82431 standard; DNA; 20 BP.
XX
AC   ADR82431;
XX
DT   16-DEC-2004 (first entry)
XX
DE   Human EphB4 antisense probe #102.
DE
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R, Gill P;
XX
WI   2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 U; 0 Other;
      Query Match      0.5%; Score 20; DB 1; Length 20;
      Best Local Similarity 100.0%; Pred. No. 96;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1298 ACTTCGGGCACGCACAC 1317
      ||||||||||||||||
Db   20 ACTTCGGGCACGCACAG 1

RESULT 400
ADR82434/c
ID   ADR82434 standard; DNA; 20 BP.
XX
AC   ADR82434;
XX
DT   16-DEC-2004 (first entry)
XX
DE   Human EphB4 antisense probe #106.
DE
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
```

```
DE   Human EphB4 antisense probe #105.
XX
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FN   WO2004080418-A2.
XX
PD   23-SEP-2004.
XX
PF   12-MAR-2004; 2004WO-US007491.
XX
PR   12-MAR-2003; 2003US-0454300P.
PR   12-MAR-2003; 2003US-0454432P.
XX
PA   (VASG-) VASGENE THERAPEUTICS INC.
XX
PI   Reddy R, Gill P;
XX
WI   2004-668879/65.
XX
PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT   useful for diagnosing or treating cancer or angiogenesis-associated
PT   diseases.
XX
PS   Example 8; Page 100; 206pp; English.
XX
CC   The invention relates to an isolated nucleic acid compound comprising at
CC   least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC   physiological conditions and decreases the expression of EphB4 or
CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC   medicament for the treatment of cancer or angiogenesis-associated
CC   diseases. The composition and methods are useful for diagnosing or
CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC   diseases or scleroderma. The present sequence represents a human EphB4
CC   antisense probe.
XX
SQ   Sequence 20 BP; 3 A; 3 C; 9 G; 5 T; 0 U; 0 Other;
      Query Match      0.5%; Score 20; DB 1; Length 20;
      Best Local Similarity 100.0%; Pred. No. 96;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy   1238 GCCCAGCCCAATAGCCACTCT 1257
      ||||||||||||||||
Db   20 GCCCAGCCCAATAGCCACTCT 1

RESULT 401
ADR82435/c
ID   ADR82435 standard; DNA; 20 BP.
XX
AC   ADR82435;
XX
DT   16-DEC-2004 (first entry)
XX
DE   Human EphB4 antisense probe #106.
DE
KW   human; ss; antisense; EphB4; EphrinB2; cancer;
KW   angiogenesis-associated disease; inflammatory disorder;
KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW   dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
```

XX PN WO2004080418-A2.
 XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007491.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX PA (VASG-) VASGENE THERAPEUTICS INC.
 XX PI Reddy R, Gill P;
 XX DR WPI; 2004-668879/65.
 XX PF New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
 XX PA Example 8; Page 100; 206pp; English.
 XX PI The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
 XX SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1218 AGAAGGGTCTGCGAGCCAT 1237
 |||||
 DB 20 AGAAGGGTCTGCGAGCCAT 1
 RESULT 402
 ADR82449/c
 ID ADR82449 standard; DNA; 20 BP.
 XX AC ADR82449;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human EphB4 antisense probe #120.
 XX KW human; ss; antisense; EphB4; EphrinB2; cancer; angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic; dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN WO2004080418-A2.
 XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007491.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.

PA (VASG-) VASGENE THERAPEUTICS INC.
 XX Reddy R, Gill P;
 XX DR WPI; 2004-668879/65.
 XX PF New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
 XX PA Example 8; Page 100; 206pp; English.
 XX PI The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
 XX SQ Sequence 20 BP; 7 A; 1 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 938 TATCCCTGCACCTCTTCTAC 957
 |||||
 DB 20 TATCCCTGCACCTCTTCTAC 1
 RESULT 403
 ADR82331/c
 ID ADR82331 standard; DNA; 20 BP.
 XX AC ADR82331;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human EphB4 antisense probe #2.
 XX KW human; ss; antisense; EphB4; EphrinB2; cancer; angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic; dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN WO2004080418-A2.
 XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007491.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX PA (VASG-) VASGENE THERAPEUTICS INC.
 XX Reddy R, Gill P;
 XX DR WPI; 2004-668879/65.
 XX PF New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.

XX PS Example 8; Page 98; 206pp; English.

CC The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.

XX SQ Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3299 GAACCCCGGTGGACAGGA 3318
Db 20 GAACCCCGGTGGACAGGA 1

RESULT 404
ADR82360/C

ID ADR82360 standard; DNA; 20 BP.

XX AC ADR82360;

XX 16-DEC-2004 (first entry)

XX Human EphB4 antisense probe #31.

XX human; ss; antisense; EphB4; EphrinB2; cancer; angiogenesis-associated disease; inflammatory disorder; chronic articular rheumatism; psoriasis; ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic; dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX Homo sapiens.

XX Synthetic.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.

XX Example 8; Page 99; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.

CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.

XX SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2719 ATTCCCATCCGATGACTGC 2738
Db 20 ATTCCCATCCGATGACTGC 1

RESULT 405
ADR82371/C

ID ADR82371 standard; DNA; 20 BP.

XX AC ADR82371;

XX 16-DEC-2004 (first entry)

XX Human EphB4 antisense probe #42.

XX human; ss; antisense; EphB4; EphrinB2; cancer; angiogenesis-associated disease; inflammatory disorder; chronic articular rheumatism; psoriasis; ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic; dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX Homo sapiens.

XX Synthetic.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.

XX Example 8; Page 99; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.

XX SQ Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2498 ACGACGGACAGTTCACAGTC 2517
 |||||
 Db 20 ACGACGGACAGTTCACAGTC 1

RESULT 406
 ADR82389/c
 ID ADR82389 standard; DNA; 20 BP.
 XX
 AC ADR82389;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #60.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Reddy R, Gill P;
 XX
 DR WPI; 2004-668879/65.
 XX
 PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 99; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2138 AGGTCTACATCGACCCCTTC 2157
 |||||
 Db 20 AGGTCTACATCGACCCCTTC 1

RESULT 407
 ADR82454/c
 ID ADR82454 standard; DNA; 20 BP.
 XX
 AC ADR82454;

XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #125.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Reddy R, Gill P;
 XX
 DR WPI; 2004-668879/65.
 XX
 PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 101; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 838 GCCACCGGGAAGTGAATGT 857
 |||||
 Db 20 GCCACCGGGAAGTGAATGT 1

RESULT 408
 ADR82470/c
 ID ADR82470 standard; DNA; 20 BP.
 XX
 AC ADR82470;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #141.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX DR WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX PS Example 8; Page 101; 206pp; English.
XX CC The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
XX SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 518 TGGATGAGGACACACAGC 537
DB 20 TGGATGAGGACACACAGC 1
RESULT 409
ADR82658
ID ADR82658 standard; DNA; 20 BP.
XX AC ADR82658;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 PCR primer #12.
XX KW human; ss; PCR; primer; EphB4; EphrinB2; cancer; angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic; dermatological; ophthalmological; angiogenesis inhibitor.
XX OS Homo sapiens.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX DR WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX PS Example 4; Page 75; 206pp; English.
XX CC The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 PCR primer.
XX SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 419 CTTTGGAGAGACCCCTGCTG 438
DB 1 CTTTGGAGAGACCCCTGCTG 20
RESULT 410
ADR82332/C
ID ADR82332 standard; DNA; 20 BP.
XX AC ADR82332;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense probe #3.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer; angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic; dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX DR WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells,

PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

PS Example 8; Page 98; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.

XX Sequence 20 BP; 1 A; 7 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3279 GAAGTCCCGCCAGCCGCG 3298

DB 20 GAAGTCCCGCCAGCCGCG 1

RESULT 411

ADR82346/c

ID ADR82346 standard; DNA; 20 BP.

XX ADR82346;

XX 16-DEC-2004 (first entry)

XX Human EphB4 antisense probe #17.

XX human; ss; antisense; EphB4; EphrinB2; cancer;

XX angiogenesis-associated disease; inflammatory disorder;

XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;

XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

XX dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX Homo sapiens.

XX Synthetic.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2

XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,

XX useful for diagnosing or treating cancer or angiogenesis-associated

XX diseases.

XX Example 8; Page 99; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at

XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under

XX physiological conditions and decreases the expression of EphB4 or

XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a

XX medicament for the treatment of cancer or angiogenesis-associated

XX diseases.

XX Example 8; Page 99; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at

XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under

XX physiological conditions and decreases the expression of EphB4 or

XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a

XX medicament for the treatment of cancer or angiogenesis-associated

XX diseases.

XX Example 8; Page 99; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at

XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under

XX physiological conditions and decreases the expression of EphB4 or

XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a

XX medicament for the treatment of cancer or angiogenesis-associated

CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.

SQ Sequence 20 BP; 2 A; 4 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2999 ACAAGATGATCCGGAACCCC 3018

DB 20 ACAAGATGATCCGGAACCCC 1

RESULT 412

ADR82364/c

ID ADR82364 standard; DNA; 20 BP.

XX ADR82364;

XX 16-DEC-2004 (first entry)

XX Human EphB4 antisense probe #35.

XX human; ss; antisense; EphB4; EphrinB2; cancer;

XX angiogenesis-associated disease; inflammatory disorder;

XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;

XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

XX dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX Homo sapiens.

XX Synthetic.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2

XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,

XX useful for diagnosing or treating cancer or angiogenesis-associated

XX diseases.

XX Example 8; Page 99; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at

XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under

XX physiological conditions and decreases the expression of EphB4 or

XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a

XX medicament for the treatment of cancer or angiogenesis-associated

XX diseases. The composition and methods are useful for diagnosing or

XX treating cancer or angiogenesis-associated diseases, such as inflammatory

XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic

XX diseases or scleroderma. The present sequence represents a human EphB4

XX antisense probe.

XX Sequence 20 BP; 8 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

SQ Sequence 20 BP; 8 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2639 AAGTGTCTGACTTTGGCCTT 2658
 Db 20 AAGTGTCTGACTTTGGCCTT 1

RESULT 413
 ADR82369/c
 ID ADR82369 standard; DNA; 20 BP.
 XX AC ADR82369;
 XX 16-DEC-2004 (first entry)
 XX Human EphB4 antisense probe #40.
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 XX 12-MAR-2003; 2003US-0454432P.
 XX (VASG-) VASGENE THERAPEUTICS INC.
 XX Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
 XX Example 8; Page 99; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
 XX Sequence 20 BP; 2 A; 9 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2538 GCGGGGCAATCGCTCGGCA 2557
 Db 20 GCGGGGCAATCGCTCGGCA 1

RESULT 414
 ADR82381/c
 ID ADR82381 standard; DNA; 20 BP.

XX ADR82381;
 AC 16-DEC-2004 (first entry)
 DT Human EphB4 antisense probe #52.
 DE human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 XX 12-MAR-2003; 2003US-0454432P.
 XX (VASG-) VASGENE THERAPEUTICS INC.
 XX Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
 XX Example 8; Page 99; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
 XX Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2298 GAGCTGTGTGCAATCAAGA 2317
 Db 20 GAGCTGTGTGCAATCAAGA 1

RESULT 415
 ADR82385/c
 ID ADR82385 standard; DNA; 20 BP.
 XX AC ADR82385;
 XX 16-DEC-2004 (first entry)
 XX Human EphB4 antisense probe #56.
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe.
OS Homo sapiens.
XX Synthetic.
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 99; 206pp; English.
PS
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 7 C; 1 G; 7 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2218 GTCAGATTGACAGAGGTGAT 2237
|||||
DB 20 GTCAGATTGACAGAGGTGAT 1
RESULT 416
ADR82409/c
ID ADR82409 standard; DNA; 20 BP.
XX
AC ADR82409;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #80.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
OS Homo sapiens.
XX Synthetic.
XX WO2004080418-A2.
PN
PD 23-SEP-2004.
XX

PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 100; 206pp; English.
PS
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1738 GCTGTTCCCGGGCACCAG 1757
|||||
DB 20 GCTGTTCCCGGGCACCAG 1
RESULT 417
ADR82412/c
ID ADR82412 standard; DNA; 20 BP.
XX
AC ADR82412;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #83.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
OS Homo sapiens.
XX Synthetic.
XX WO2004080418-A2.
PN
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX WPI; 2004-668879/65.
DR

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 100; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
XX Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1678 CCTGCAGTGTCTGACATCCG 1697
DB 20 CCTGCAGTGTCTGACATCCG 1
RESULT 418
ADR82420/c
ID ADR82420 standard; DNA; 20 BP.
AC ADR82420;
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #91.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 100; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under

CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
XX Sequence 20 BP; 2 A; 9 C; 8 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1518 CGGCCCGGGGACCTGTGGTGG 1537
DB 20 CGGCCCGGGGACCTGTGGTGG 1
RESULT 419
ADR82430/c
ID ADR82430 standard; DNA; 20 BP.
XX ADR82430;
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #101.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 100; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
XX Sequence 20 BP; 2 A; 6 C; 10 G; 2 T; 0 U; 0 Other;
SQ

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CCCCGGGTGCACCTGCAC 1337
 |||||
 Db 20 CCCCGGGTGCACCTGCAC 1

RESULT 420
 ADR82437/c
 ID ADR82437 standard; DNA; 20 BP.
 XX
 AC ADR82437;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #108.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Reddy R, Gill P;
 XX
 DR WPI; 2004-668879/65.
 XX
 PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 100; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 2 A; 8 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1178 GCCAGCCTGTGCCAGGC 1197
 |||||
 Db 20 GCCAGCCTGTGCCAGGC 1

RESULT 422
 ADR82458/c
 ID ADR82458 standard; DNA; 20 BP.
 XX
 AC ADR82458;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #129.
 XX

RESULT 421
 ADR82451/c
 ID ADR82451 standard; DNA; 20 BP.
 XX
 AC ADR82451;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #122.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Reddy R, Gill P;
 XX
 DR WPI; 2004-668879/65.
 XX
 PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 PS Example 8; Page 101; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 898 TACCTGGCCTCCAGGACCA 917
 |||||
 Db 20 TACCTGGCCTCCAGGACCA 1

RESULT 422
 ADR82458/c
 ID ADR82458 standard; DNA; 20 BP.
 XX
 AC ADR82458;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #129.
 XX

KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 DR
 XX
 PF New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PR transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PR useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases.
 XX
 PA Example 8; Page 101; 206pp; English.
 XX
 PI The invention relates to an isolated nucleic acid compound comprising at
 XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 PS Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;
 XX
 CC Query Match 0.5%; Score 20; DB 1; Length 20;
 CC Best Local Similarity 100.0%; Pred. No. 96;
 CC Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 758 CAGCCTGGATGGAGAACCCC 777
 DB |||||
 20 CAGCCTGGATGGAGAACCCC 1
 XX
 RESULT 423
 ADR82460/c
 ID ADR82460 standard; DNA; 20 BP.
 XX
 AC ADR82460;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #131.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 PN

XX 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 DR
 XX
 PF New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PR transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PR useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases.
 XX
 PA Example 8; Page 101; 206pp; English.
 XX
 PI The invention relates to an isolated nucleic acid compound comprising at
 XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 PS Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;
 XX
 CC Query Match 0.5%; Score 20; DB 1; Length 20;
 CC Best Local Similarity 100.0%; Pred. No. 96;
 CC Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 718 TACTATGAGAGCGATGCGGA 737
 DB |||||
 20 TACTATGAGAGCGATGCGGA 1
 XX
 RESULT 424
 ADR82477/c
 ID ADR82477 standard; DNA; 20 BP.
 XX
 AC ADR82477;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #148.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX

PI Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 XX
 PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX
 XX Example 8; Page 101; 206pp; English.
 XX
 PS The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 XX Sequence 20 BP; 5 A; 8 C; 6 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 378 GGAGCTCCGGTGTCTCT 397
 |||||
 Db 20 GGAGCTCCGGTGTCTCT 1
 RESULT 425
 ADR82664/c
 ID ADR82664 standard; DNA; 20 BP.
 XX
 AC ADR82664;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 DE Human EphB4 PCR primer #15.
 XX
 XX human; ss; PCR; primer; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor.
 XX
 OS Homo sapiens.
 XX
 OS Synthetic.
 XX
 XX WO2004080418-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007491.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 XX 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 XX
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 XX useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases.
 XX
 XX Example 6; Page 93; 206pp; English.

CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC PCR primer.
 XX
 XX Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 696 CAAGGAGACCTTCACCGTCT 715
 |||||
 Db 20 CAAGGAGACCTTCACCGTCT 1
 RESULT 426
 ADR82342/c
 ID ADR82342 standard; DNA; 20 BP.
 XX
 AC ADR82342;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 DE Human EphB4 antisense probe #13.
 XX
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO2004080418-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007491.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 XX 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 XX
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 XX useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases.
 XX
 XX Example 8; Page 98; 206pp; English.
 PS
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.

XX SQ Sequence 20 BP; 3 A; 4 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3079 CGGACGCTCACTACTCAGC 3098
|||||
DB 20 CGGACGCTCACTACTCAGC 1

RESULT 427

ADR82354/c

ID ADR82354 standard; DNA; 20 BP.

XX AC

XX ADR82354;

XX DT

XX 16-DEC-2004 (first entry)

XX DE

XX Human EphB4 antisense probe #25.

XX KW

KW human; ss; antisense; EphB4; EphrinB2; cancer;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX OS

OS Homo sapiens.

XX OS

XX Synthetic.

XX PN WO2004080418-A2.

XX XX

XX PD 23-SEP-2004.

XX PF

XX 12-MAR-2004; 2004WO-US007491.

XX PR

PR 12-MAR-2003; 2003US-0454300P.

XX PR

PR 12-MAR-2003; 2003US-0454432P.

XX PA

(VASG-) VASGENE THERAPEUTICS INC.

XX PI

PI Reddy R, Gill P;

XX XX

XX WPI; 2004-668879/65.

XX DR

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.

XX PT

XX PT

XX PT

XX PS

PS Example 8; Page 99; 206pp; English.

XX XX

XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.

XX SQ Sequence 20 BP; 3 A; 7 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2839 TGGGACATGAGCAATCAGGA 2858
|||||
DB 20 TGGGACATGAGCAATCAGGA 1

RESULT 428

ADR82372/c

ID ADR82372 standard; DNA; 20 BP.

XX XX

XX ADR82372;

XX AC

XX 16-DEC-2004 (first entry)

XX DT

XX Human EphB4 antisense probe #43.

XX DE

XX KW human; ss; antisense; EphB4; EphrinB2; cancer;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX KW

XX OS

OS Homo sapiens.

XX OS

XX Synthetic.

XX XX

XX PN WO2004080418-A2.

XX XX

XX PD 23-SEP-2004.

XX PF

PF 12-MAR-2004; 2004WO-US007491.

XX XX

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR

PR 12-MAR-2003; 2003US-0454432P.

XX XX

(VASG-) VASGENE THERAPEUTICS INC.

XX PA

XX PI

PI Reddy R, Gill P;

XX XX

XX WPI; 2004-668879/65.

XX XX

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.

XX PT

XX PT

XX PT

XX PS

PS Example 8; Page 99; 206pp; English.

XX XX

XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.

XX SQ Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2478 GGACTCTCTCTCGGGCTAA 2497
|||||
DB 20 GGACTCTCTCTCGGGCTAA 1

RESULT 429

ADR82373/c

ID ADR82373 standard; DNA; 20 BP.

XX XX

XX ADR82373;

XX AC

XX 16-DEC-2004 (first entry)

XX DT

XX XX

DE Human EphB4 antisense probe #44.
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.
 OS WO2004080418-A2.
 PN 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA Reddy R, Gill P;
 PI WPI; 2004-668879/65.
 DR New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 XX useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases.
 XX Example 8; Page 99; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2458 TTCTATGGAGAACGGCGCCT 2477
 DB 20 TTCTATGGAGAACGGCGCCT 1
 RESULT 430
 ADR82379/C
 ID ADR82379 standard; DNA; 20 BP.
 XX ADR82379;
 AC 16-DEC-2004 (first entry)
 DT Human EphB4 antisense probe #50.
 DE human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.

XX WO2004080418-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA Reddy R, Gill P;
 PI WPI; 2004-668879/65.
 DR New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 XX useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases.
 XX Example 8; Page 99; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX Sequence 20 BP; 3 A; 10 C; 4 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2338 GAGCGCAGCGCGTGAGTT 2357
 DB 20 GAGCGCAGCGCGTGAGTT 1
 RESULT 431
 ADR82391/C
 ID ADR82391 standard; DNA; 20 BP.
 XX ADR82391;
 AC 16-DEC-2004 (first entry)
 DT Human EphB4 antisense probe #62.
 DE human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.
 OS WO2004080418-A2.
 PN 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA Reddy R, Gill P;
 PI WPI; 2004-668879/65.
 DR New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 XX useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases.
 XX Example 8; Page 99; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX Sequence 20 BP; 3 A; 10 C; 4 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2338 GAGCGCAGCGCGTGAGTT 2357
 DB 20 GAGCGCAGCGCGTGAGTT 1

PA (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 99; 206pp; English.
PS The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
XX Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2098 TCGGACAAACACGGACGTA 2117
DB 20 TCGGACAAACACGGACGTA 1
RESULT 432
ADR82407/c
ID ADR82407 standard; DNA; 20 BP.
XX
XX ADR82407;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense probe #78.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
XX Homo sapiens.
OS
OS Synthetic.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 100; 206pp; English.
PS The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
XX Sequence 20 BP; 3 A; 5 C; 3 G; 9 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1778 AGGTCAAATACCATGAGAAG 1797
DB 20 AGGTCAAATACCATGAGAAG 1
RESULT 433
ADR82411/c
ID ADR82411 standard; DNA; 20 BP.
XX
XX ADR82411;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human EphB4 antisense probe #82.
XX
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
XX Homo sapiens.
OS
OS Synthetic.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1698 GGTGACGCGTCTCTCACCA 1717
Db 20 GGTGACGCGTCTCTCACCA 1
RESULT 434
ADR82414/c
ID ADR82414 standard; DNA; 20 BP.
XX
AC ADR82414;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #85.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 7 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1638 ATTGAGCTGTCAATGTCA 1657
Db 20 ATTGAGCTGTCAATGTCA 1
RESULT 435
ADR82418/c
ID ADR82418 standard; DNA; 20 BP.
XX
AC ADR82418;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #89.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1558 GGGCTACGTCCTGACTTCAC 1577
Db 20 GGGCTACGTCCTGACTTCAC 1
RESULT 436
ADR82334/c
ID ADR82334 standard; DNA; 20 BP.
XX
AC ADR82334;

```
XX 16-DEC-2004 (first entry)
DT Human EphB4 antisense probe #5.
DE
XX human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
PN
XX 23-SEP-2004.
FD
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
FR
XX (VASG-) VASGENE THERAPEUTICS INC.
PA
XX Reddy R, Gill P;
PI WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
PT
XX Example 8; Page 98; 206pp; English.
PS
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
SQ Sequence 20 BP; 1 A; 5 C; 5 G; 9 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 3239 CGGACACACAGAGAAATC 3258
Db |||||
20 CGGACACACAGAGAAATC 1
RESULT 437
ADR82351/c
ID ADR82351 standard; DNA; 20 BP.
XX
AC ADR82351;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #22.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
```

```
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
PN
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
FR
XX (VASG-) VASGENE THERAPEUTICS INC.
PA
XX Reddy R, Gill P;
PI WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
PT
XX Example 8; Page 99; 206pp; English.
PS
XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
SQ Sequence 20 BP; 3 A; 2 C; 12 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 2899 CCCCCAGACTGCCACCTC 2918
Db |||||
20 CCCCCAGACTGCCACCTC 1
RESULT 438
ADR82357/c
ID ADR82357 standard; DNA; 20 BP.
XX
AC ADR82357;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #28.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
PN
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX
```

```
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 99; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2779 GATGCTCGAGTTACGGGAT 2798
DB 20 GATGCTCGAGTTACGGGAT 1

RESULT 439
ADR82362/c
ID ADR82362 standard; DNA; 20 BP.
XX AC ADR82362;
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #33.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
XX Synthetic.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 99; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX Sequence 20 BP; 5 A; 1 C; 10 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2679 CTCCTCCGATCCACCTACA 2698
DB 20 CTCCTCCGATCCACCTACA 1

RESULT 440
ADR82374/c
ID ADR82374 standard; DNA; 20 BP.
XX AC ADR82374;
XX 16-DEC-2004 (first entry)
XX Human EphB4 antisense probe #45.
XX human; ss; antisense; EphB4; EphrinB2; cancer;
XX angiogenesis-associated disease; inflammatory disorder;
XX chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
XX Synthetic.
XX WO2004080418-A2.
XX 23-SEP-2004.
XX 12-MAR-2004; 2004WO-US007491.
XX 12-MAR-2003; 2003US-0454300P.
XX 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
XX Reddy R, Gill P;
XX WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 99; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX Sequence 20 BP; 5 A; 1 C; 10 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```


CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.

XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2438 CCGTCATGATTCACAGAG 2457
Db 20 CCGTCATGATTCACAGAG 1

RESULT 441

ADR82394/c
ID ADR82394 standard; DNA; 20 BP.

XX AC ADR82394;

XX DT 16-DEC-2004 (first entry)

XX DE Human EphB4 antisense probe #65.

XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO2004080418-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US007491.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-0454432P.

XX PA (VASG-) VASGENE THERAPEUTICS INC.

XX PI Reddy R, Gill P;

XX DR WPI; 2004-668879/65.

XX CC New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.

XX PS Example 8; Page 99; 206pp; English.

XX CC The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.

XX SQ Sequence 20 BP; 8 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2038 GTCATTGTGTCGAGTTCT 2057
Db 20 GTCATTGTGTCGAGTTCT 1

RESULT 442

ADR82399/c

ID ADR82399 standard; DNA; 20 BP.

XX AC ADR82399;

XX DT 16-DEC-2004 (first entry)

XX DE Human EphB4 antisense probe #70.

XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX OS Homo sapiens.

XX OS Synthetic.

XX PN WO2004080418-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US007491.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-0454432P.

XX PA (VASG-) VASGENE THERAPEUTICS INC.

XX PI Reddy R, Gill P;

XX DR WPI; 2004-668879/65.

XX CC New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.

XX PS Example 8; Page 100; 206pp; English.

XX CC The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.

XX SQ Sequence 20 BP; 1 A; 2 C; 9 G; 8 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 96;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1938 ACATCAGCCAGCCCAAC 1957
Db 20 ACATCAGCCAGCCCAAC 1

RESULT 443

ADR82422/c

ID ADR82422 standard; DNA; 20 BP.
XX ADR82422;
XX 16-DEC-2004 (first entry)
DT Human EphB4 antisense probe #93.
DE
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
PN
XX 23-SEP-2004.
PD
XX 12-MAR-2004; 2004WO-US007491.
PF
XX 12-MAR-2003; 2003US-0454300P.
PR
PR 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
PA
XX Reddy R, Gill P;
PI
XX WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 100; 206pp; English.
PS
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 4 A; 8 C; 8 G; 0 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1478 GCTCCTGTGCGCCCTGCGG 1497
Db 20 GCTCCTGTGCGCCCTGCGG 1
RESULT 444
ADR82427/c
ID ADR82427 standard; DNA; 20 BP.
XX
XX ADR82427;
AC
XX 16-DEC-2004 (first entry)
DT Human EphB4 antisense probe #98.
DE
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
PN
XX 23-SEP-2004.
PD
XX 12-MAR-2004; 2004WO-US007491.
PF
XX 12-MAR-2003; 2003US-0454300P.
PR
PR 12-MAR-2003; 2003US-0454432P.
XX (VASG-) VASGENE THERAPEUTICS INC.
PA
XX Reddy R, Gill P;
PI
XX WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX Example 8; Page 100; 206pp; English.
PS
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 4 A; 3 C; 10 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1378 AACGGCTCTCCCTGCACCT 1397
Db 20 AACGGCTCTCCCTGCACCT 1
RESULT 445
ADR82464/c
ID ADR82464 standard; DNA; 20 BP.
XX
XX ADR82464;
AC
XX 16-DEC-2004 (first entry)
DT Human EphB4 antisense probe #135.
DE
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
PN
XX 23-SEP-2004.
PD

XX PF 12-MAR-2004; 2004WO-US007491.
XX XX
PR 12-MAR-2003; 2003US-0454300P.
XX PF 12-MAR-2003; 2003US-0454432P.
XX XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX WPI; 2004-668879/65.
DR XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX XX
PS Example 8; Page 101; 206pp; English.
XX CC
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX SQ Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 638 CCACGCTGGCTTCACCATG 657
DB 20 CCACGCTGGCTTCACCATG 1
RESULT 446
ADR82467/c
ID ADR82467 standard; DNA; 20 BP.
XX AC ADR82467;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense probe #138.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX WPI; 2004-668879/65.
DR XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX XX
PS Example 8; Page 101; 206pp; English.
XX CC
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX SQ Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 638 CCACGCTGGCTTCACCATG 657
DB 20 CCACGCTGGCTTCACCATG 1
RESULT 446
ADR82467/c
ID ADR82467 standard; DNA; 20 BP.
XX AC ADR82467;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense probe #138.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX WPI; 2004-668879/65.
DR XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX XX
PS Example 8; Page 101; 206pp; English.
XX CC
CC The invention relates to an isolated nucleic acid compound comprising at

DR WPI; 2004-668879/65.
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX XX
PS Example 8; Page 101; 206pp; English.
XX CC
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX SQ Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 578 GCCAGGCCCACTGGCTTCGC 597
DB 20 GCCAGGCCCACTGGCTTCGC 1
RESULT 447
ADR82468/c
ID ADR82468 standard; DNA; 20 BP.
XX AC ADR82468;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense probe #139.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX WPI; 2004-668879/65.
DR XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX XX
PS Example 8; Page 101; 206pp; English.
XX CC
CC The invention relates to an isolated nucleic acid compound comprising at

CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.

XX SQ Sequence 20 BP; 3 A; 8 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 558 TGAGGTGCAGCGTGCCTCCAT 577
 |||||
 Db 20 TGAGGTGCAGCGTGCCTCCAT 1

RESULT 448
 ADR82488/c
 ID ADR82488 standard; DNA; 20 BP.

XX AC ADR82488;

XX DT 16-DEC-2004 (first entry)

XX DE Human EphB4 antisense probe #159.

XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

OS Homo sapiens.
 OS Synthetic.

XX WO2004080418-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US007491.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-0454432P.

XX PA (VASG-) VASGENE THERAPEUTICS INC.

XX PI Reddy R, Gill P;

XX WIPI; 2004-668879/65.

XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.

XX PS Example 8; Page 101; 206pp; English.

XX CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.

SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2356 TTTCGTGAGCGAGCTCCAT 2375
 |||||
 Db 20 TTTCGTGAGCGAGCTCCAT 1

RESULT 449

ADR82297

ID ADR82297 standard; DNA; 20 BP.

XX AC ADR82297;

XX DT 16-DEC-2004 (first entry)

XX DE Human beta-actin RT-PCR primer #2.

XX KW human; ss; RT-PCR; primer; beta-actin; reverse transcriptase; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor.

XX OS Homo sapiens.

XX PN WO2004080418-A2.

XX PD 23-SEP-2004.

XX PF 12-MAR-2004; 2004WO-US007491.

XX PR 12-MAR-2003; 2003US-0454300P.

XX PR 12-MAR-2003; 2003US-0454432P.

XX PA (VASG-) VASGENE THERAPEUTICS INC.

XX PI Reddy R, Gill P;

XX WIPI; 2004-668879/65.

XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.

XX PS Example 3; Page 69; 206pp; English.

XX CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human beta-
 CC actin reverse transcriptase (RT)-PCR primer.

XX SQ Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 697 AAGGAGACCTTCACCGTCTT 716
 |||||
 Db 1 AAGGAGACCTTCACCGTCTT 20

RESULT 450
 ADR82377/c
 ID ADR82377 standard; DNA; 20 BP.
 AC ADR82377;
 DT 16-DEC-2004 (first entry)
 XX Human EphB4 antisense probe #48.
 DE
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007491.
 XX
 PF 12-MAR-2003; 2003US-0454300P.
 XX
 PR 12-MAR-2003; 2003US-0454432P.
 PR
 XX (VAGS-) VASGENE THERAPEUTICS INC.
 PA
 XX Reddy R, Gill P;
 PI
 XX WPI; 2004-668879/65.
 DR
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 PT
 XX Example 8; Page 99; 206pp; English.
 PS
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 2378 TGGGCCAGTTCGAGCACC 2397
 Db 20 TGGGCCAGTTCGAGCACC 1
 RESULT 451
 ADR82392/c
 ID ADR82392 standard; DNA; 20 BP.
 XX
 AC ADR82392;
 XX
 DT 16-DEC-2004 (first entry)
 XX Human EphB4 antisense probe #63.
 DE
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 PN

KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007491.
 XX
 PF 12-MAR-2003; 2003US-0454300P.
 XX
 PR 12-MAR-2003; 2003US-0454432P.
 PR
 XX (VAGS-) VASGENE THERAPEUTICS INC.
 PA
 XX Reddy R, Gill P;
 PI
 XX WPI; 2004-668879/65.
 DR
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 PT
 XX Example 8; Page 99; 206pp; English.
 PS
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX
 SQ Sequence 20 BP; 3 A; 7 C; 1 G; 9 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 2078 ATGGGAGAGAGCAGATAT 2097
 Db 20 ATGGGAGAGAGCAGATAT 1
 RESULT 452
 ADR82403/c
 ID ADR82403 standard; DNA; 20 BP.
 XX
 AC ADR82403;
 XX
 DT 16-DEC-2004 (first entry)
 XX Human EphB4 antisense probe #74.
 DE
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 PN

XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007491.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX (VASC-) VASGENE THERAPEUTICS INC.
 XX PA Reddy R, Gill P;
 XX PI WPI; 2004-668879/65.
 XX DR New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
 XX PT Example 8; Page 100; 206pp; English.
 XX CC The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
 XX SQ Sequence 20 BP; 1 A; 12 C; 4 G; 3 T; 0 U; 0 Other;
 XX Query Match 0.5%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 96;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1858 CGGGGGCTGAAGCGGGGAGC 1877
 DB 20 CGGGGGCTGAAGCGGGGAGC 1
 RESULT 453
 ADR82433/c
 ID ADR82433 standard; DNA; 20 BP.
 XX AC ADR82433;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human EphB4 antisense probe #104.
 XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN WO2004080418-A2.
 XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007491.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX (VASC-) VASGENE THERAPEUTICS INC.
 XX PA Reddy R, Gill P;
 XX PI WPI; 2004-668879/65.
 XX DR New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
 XX PT Example 8; Page 101; 206pp; English.

PI Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
 XX Example 8; Page 100; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
 XX SQ Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;
 XX Query Match 0.5%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 96;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1258 AACACCATTTGGATCAGCCGT 1277
 DB 20 AACACCATTTGGATCAGCCGT 1
 RESULT 454
 ADR82453/c
 ID ADR82453 standard; DNA; 20 BP.
 XX AC ADR82453;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human EphB4 antisense probe #124.
 XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN WO2004080418-A2.
 XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007491.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX (VASC-) VASGENE THERAPEUTICS INC.
 XX PA Reddy R, Gill P;
 XX PI WPI; 2004-668879/65.
 XX DR New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
 XX PT Example 8; Page 101; 206pp; English.

XX CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 858 CAAGACGCTGGCTCTGGGAC 877
 DB 20 CAAGACGCTGGCTCTGGGAC 1
 RESULT 455
 ADR82456/c
 ID ADR82456 standard; DNA; 20 BP.
 XX AC ADR82456;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human EphB4 antisense probe #127.
 XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN WO2004080418-A2.
 XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007491.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX PA (VASG-) VASGENE THERAPEUTICS INC.
 XX PI Reddy R, Gill P;
 XX DR WPI; 2004-668879/65.
 XX PF New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 XX useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases.
 XX Example 8; Page 101; 206pp; English.
 XX PS The invention relates to an isolated nucleic acid compound comprising at
 XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 XX physiological conditions and decreases the expression of EphB4 or
 XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 XX medicament for the treatment of cancer or angiogenesis-associated
 XX diseases. The composition and methods are useful for diagnosing or
 XX treating cancer or angiogenesis-associated diseases, such as inflammatory
 XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 XX diseases or scleroderma. The present sequence represents a human EphB4

CC antisense probe.
 XX SQ Sequence 20 BP; 2 A; 6 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 798 GGCGGGGAGCATCTCACCC 817
 DB 20 GGCGGGGAGCATCTCACCC 1
 RESULT 456
 ADR82339/c
 ID ADR82339 standard; DNA; 20 BP.
 XX AC ADR82339;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human EphB4 antisense probe #10.
 XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN WO2004080418-A2.
 XX PD 23-SEP-2004.
 XX PF 12-MAR-2004; 2004WO-US007491.
 XX PR 12-MAR-2003; 2003US-0454300P.
 XX PR 12-MAR-2003; 2003US-0454432P.
 XX PA (VASG-) VASGENE THERAPEUTICS INC.
 XX PI Reddy R, Gill P;
 XX DR WPI; 2004-668879/65.
 XX PF New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 XX useful for diagnosing or treating cancer or angiogenesis-associated
 XX diseases.
 XX Example 8; Page 98; 206pp; English.
 XX PS The invention relates to an isolated nucleic acid compound comprising at
 XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 XX physiological conditions and decreases the expression of EphB4 or
 XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 XX medicament for the treatment of cancer or angiogenesis-associated
 XX diseases. The composition and methods are useful for diagnosing or
 XX treating cancer or angiogenesis-associated diseases, such as inflammatory
 XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 XX diseases or scleroderma. The present sequence represents a human EphB4
 XX antisense probe.
 XX SQ Sequence 20 BP; 4 A; 6 C; 1 G; 9 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3139 GGAAGATACGAGAAAGTTT 3158
 |||||||||||||||||||||

```
Db          20 GGAAGATACGAGAAAGTTT 1

RESULT 457
ADR82341/c
ID ADR82341 standard; DNA; 20 BP.
XX
AC ADR82341;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #12.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
WIPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 98; 206pp; English.
XX
SQ The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 8 A; 8 C; 3 G; 1 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3099 TTTTGGCTCTGTGGCGAGT 3118
DB 20 TTTTGGCTCTGTGGCGAGT 1

RESULT 458
ADR82358/c
ID ADR82358 standard; DNA; 20 BP.
XX
AC ADR82358;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #53.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
```

```
XX
DE Human EphB4 antisense probe #29.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
WIPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
SQ The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2759 GGAAGTTCACTTCGCGCAGT 2778
DB 20 GGAAGTTCACTTCGCGCAGT 1

RESULT 459
ADR82382/c
ID ADR82382 standard; DNA; 20 BP.
XX
AC ADR82382;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #53.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
```


OS Synthetic.
PN WO2004080418-A2.
XX
XX
PD 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
PF
XX 12-MAR-2003; 2003US-0454300P.
PR
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASC-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
PI
XX WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 99; 206pp; English.
PS
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
XX Sequence 20 BP; 0 A; 8 C; 4 G; 8 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2278 AAGGCCCCAGGAGAGGA 2297
Db 20 AAGGCCCCAGGAGAGGA 1
RESULT 460
ADR82659/c
ID ADR82659 standard; DNA; 20 BP.
AC
AC ADR82659;
XX
XX 16-DEC-2004 (first entry)
DT
XX Human EphB4 PCR primer #13.
DE
XX human; ss; PCR; primer; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor.
XX
OS Homo sapiens.
XX
XX WO2004080418-A2.
PN
XX 23-SEP-2004.
PD
XX 12-MAR-2004; 2004WO-US007491.
PF
XX 12-MAR-2003; 2003US-0454300P.
PR
PR 12-MAR-2003; 2003US-0454432P.
XX

PA (VASC-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
PI
XX WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 4; Page 75; 206pp; English.
PS
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC PCR primer.
XX
XX Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 696 CAAGGAGACCTTCACCGTCT 715
Db 20 CAAGGAGACCTTCACCGTCT 1
RESULT 461
ADR82337/c
ID ADR82337 standard; DNA; 20 BP.
XX
XX ADR82337;
AC
XX 16-DEC-2004 (first entry)
DT
XX Human EphB4 antisense probe #8.
DE
XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
XX
XX Synthetic.
XX
XX WO2004080418-A2.
PN
XX 23-SEP-2004.
PD
XX 12-MAR-2004; 2004WO-US007491.
PF
XX 12-MAR-2003; 2003US-0454300P.
PR
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASC-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
PI
XX WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX

XX PS Example 8; Page 98; 206pp; English.

XX CC The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.

XX SQ Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3179 CCTTCGAGCTGTCAGCCAG 3198
|||||
Db 20 CCTTCGAGCTGTCAGCCAG 1

RESULT 462
ADR82349/c
ID ADR82349 standard; DNA; 20 BP.
XX AC ADR82349;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense probe #20.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer; angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic; dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX DR WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX PS Example 8; Page 99; 206pp; English.
XX PI Reddy R, Gill P;
XX DR WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX PS Example 8; Page 99; 206pp; English.
XX CC The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory

CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.

XX SQ Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2939 ACTGTTGGCAGAAAGACCGG 2958
|||||
Db 20 ACTGTTGGCAGAAAGACCGG 1

RESULT 463
ADR82366/c
ID ADR82366 standard; DNA; 20 BP.
XX AC ADR82366;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense probe #37.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer; angiogenesis-associated disease; inflammatory disorder;
XX KW chronic articular rheumatism; psoriasis; ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic; dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX DR WPI; 2004-668879/65.
XX PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
XX PS Example 8; Page 99; 206pp; English.
XX CC The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
XX SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
OY 2598 GGCTGCTCGCAACATCTCTAG 2617
DB 20 GGCTGCTCGCAACATCTCTAG 1

RESULT 464
ADR82375/c
ID ADR82375 standard; DNA; 20 BP.
XX
AC ADR82375;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #46.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VAGS-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PF New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
XX
SQ Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2418 CGTGTCTACCAACAGCATGC 2437
DB 20 CGTGTCTACCAACAGCATGC 1

RESULT 465
ADR82380/c
ID ADR82380 standard; DNA; 20 BP.
XX
AC ADR82380;
```

```
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #51.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VAGS-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PF New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
PS Example 8; Page 99; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.
XX
SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2318 CCCTGAAGGGTGGCTACACG 2337
DB 20 CCCTGAAGGGTGGCTACACG 1

RESULT 466
ADR82398/c
ID ADR82398 standard; DNA; 20 BP.
XX
AC ADR82398;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #69.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
```

XX Homo sapiens.
OS Synthetic.
XX WO2004080418-A2.
PN
PD 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
PF
XX 12-MAR-2003; 2003US-0454300P.
PR
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
PA
XX Reddy R, Gill P;
PI
XX WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 100; 206pp; English.
PS
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 3 A; 11 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 TGGATGAGCGGCGGCTGG 1977
Db |||||
20 TGGATGAGCGGCGGCTGG 1

RESULT 467
ADR82404/C
ID ADR82404 standard; DNA; 20 BP.
XX
AC ADR82404;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #75.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX

PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
PI
XX WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 8; Page 100; 206pp; English.
PS
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 1 A; 7 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1838 CAGAAAACCGGCGAGCTG 1857
Db |||||
20 CAGAAAACCGGCGAGCTG 1

RESULT 468
ADR82405/C
ID ADR82405 standard; DNA; 20 BP.
XX
AC ADR82405;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #76.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
PA
XX Reddy R, Gill P;
PI
XX WPI; 2004-668879/65.
DR
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT

PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
PS Example 8; Page 100; 206pp; English.
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1818 CGTCGGTTCTCTGAGACGT 1837
Db 20 CGTCGGTTCTCTGAGACGT 1
RESULT 469
ADR82428/c
ID ADR82428 standard; DNA; 20 BP.
XX
AC ADR82428;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #99.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
OS Homo sapiens.
OS Synthetic.
FN WO2004080418-A2.
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PF New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
PT The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a

CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 5 A; 8 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1358 GGAGCGGTTCCTCCGCGCTG 1377
Db 20 GGAGCGGTTCCTCCGCGCTG 1
RESULT 470
ADR82448/c
ID ADR82448 standard; DNA; 20 BP.
XX
AC ADR82448;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #119.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
OS Homo sapiens.
OS Synthetic.
FN WO2004080418-A2.
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PF New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX
PS Example 8; Page 100; 206pp; English.
XX
PT The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;

```
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 958 AAAAAGTGGCCCGACGTGAC 977
   |||||
Db 20 AAAAAGTGGCCCGACGTGAC 1

RESULT 471
ADR82457/c
ID ADR82457 standard; DNA; 20 BP.
XX
AC ADR82457;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #128.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
XX
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 101; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.
XX
SQ Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 778 TACATCAAGTGGACACGGT 797
   |||||
Db 20 TACATCAAGTGGACACGGT 1

RESULT 472
ADR82461/c
ID ADR82461 standard; DNA; 20 BP.
XX
AC ADR82461;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense probe #144.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
```

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 XX dermatological; ophthalmological; angiogenesis inhibitor; probe.
 OS Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 XX 12-MAR-2003; 2003US-0454432P.
 XX (VAGS-) VASGENE THERAPEUTICS INC.
 XX Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX Example 8; Page 101; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
 XX Query Match 0.5%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 96;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 458 CTGATCTGAAGTGGGTGACA 477
 Db 20 CTGATCTGAAGTGGGTGACA 1
 RESULT 474
 ADR82350/c
 ID ADR82350 standard; DNA; 20 BP.
 XX ADR82350;
 XX 16-DEC-2004 (first entry)
 XX Human EphB4 antisense probe #21.
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 XX 12-MAR-2003; 2003US-0454432P.
 XX (VAGS-) VASGENE THERAPEUTICS INC.
 XX Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX Example 8; Page 99; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC antisense probe.
 XX Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
 XX Query Match 0.5%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 96;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 2919 CCTCCACCAGCTCATGCTGG 2938
 Db 20 CCTCCACCAGCTCATGCTGG 1
 RESULT 475
 ADR82397/c
 ID ADR82397 standard; DNA; 20 BP.
 XX ADR82397;
 XX 16-DEC-2004 (first entry)
 XX Human EphB4 antisense probe #68.
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 XX 12-MAR-2003; 2003US-0454432P.
 XX (VAGS-) VASGENE THERAPEUTICS INC.
 XX Reddy R, Gill P;

DR WPI; 2004-668879/65.
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX Example 8; Page 100; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 XX antisense probe.
 SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1978 CCGGAGCAGCTGGCCCTGAT 1997
 Db 20 CCGGAGCAGCTGGCCCTGAT 1
 RESULT 476
 ADR82400/c
 ID ADR82400 standard; DNA; 20 BP.
 XX AC ADR82400;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human EphB4 antisense probe #71.
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 XX 12-MAR-2003; 2003US-0454432P.
 XX (VAGS-) VASGENE THERAPEUTICS INC.
 XX Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX Example 8; Page 100; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at

CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 XX antisense probe.
 SQ Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1918 TACGGGCCCTTGGCCAGGA 1937
 Db 20 TACGGGCCCTTGGCCAGGA 1
 RESULT 477
 ADR82436/c
 ID ADR82436 standard; DNA; 20 BP.
 XX AC ADR82436;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human EphB4 antisense probe #107.
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 XX 23-SEP-2004.
 XX 12-MAR-2004; 2004WO-US007491.
 XX 12-MAR-2003; 2003US-0454300P.
 XX 12-MAR-2003; 2003US-0454432P.
 XX (VAGS-) VASGENE THERAPEUTICS INC.
 XX Reddy R, Gill P;
 XX WPI; 2004-668879/65.
 XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated
 PT diseases.
 XX Example 8; Page 100; 206pp; English.
 XX The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 XX antisense probe.

SQ Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1198 ACCTTCAAGCCCTGTCTCAGG 1217
 |||||
 Db 20 ACCTTCAAGCCCTGTCTCAGG 1

RESULT 478
 ADR82478/c
 ID ADR82478 standard; DNA; 20 BP.
 XX
 AC ADR82478;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human EphB4 antisense probe #149.
 XX
 KW human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor; probe.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO2004080418-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007491.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 XX 12-MAR-2003; 2003US-0454432P.
 XX (VAGS-) VASGENE THERAPEUTICS INC.
 FA
 XX Reddy R, Gill P;
 PI
 XX WPI; 2004-668879/65.
 DR
 XX

New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2 transcripts or decrease the expression of EphB4 or EphrinB2 in cells, useful for diagnosing or treating cancer or angiogenesis-associated diseases.
 Example 8; Page 101; 206pp; English.
 The invention relates to an isolated nucleic acid compound comprising at least a portion that hybridizes to an EphB4 or EphrinB2 transcript under physiological conditions and decreases the expression of EphB4 or EphrinB2 in a cell. The nucleic acid is useful for manufacturing a medicament for the treatment of cancer or angiogenesis-associated diseases. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. The present sequence represents a human EphB4 antisense probe.
 SQ Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 376 ATGGAGCTCCGGGTGCTGCT 395
 |||||
 Db 20 ATGGAGCTCCGGGTGCTGCT 1

RESULT 479
 ADR86990
 ID ADR86990 standard; DNA; 21 BP.
 XX
 AC ADR86990;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrinB4 short interference RNA seqid 295.
 XX
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 XX
 OS Homo sapiens.
 XX WO2004080425-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 12-MAR-2004; 2004WO-US007755.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 XX 12-MAR-2003; 2003US-0454432P.
 XX (VAGS-) VASGENE THERAPEUTICS INC.
 FA
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 PI
 XX WPI; 2004-668883/65.
 DR
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, psoriasis or scleroderma.

Example 8; Page 96; 198pp; English.
 The invention describes an isolated soluble polypeptide comprising an amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2 protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4 polypeptide binds specifically to the Ephrin B2 polypeptide, and the Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also described are: an antagonist antibody that binds to an extracellular domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a diagnostic kit, comprising the above soluble polypeptide or antagonist antibody, and a pharmaceutical carrier; methods of inhibiting angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a cell; a method of reducing the growth rate of a tumour; methods for treating a patient suffering from a cancer or an angiogenesis-associated disease; and a method for identifying a tumor that is suitable for treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or antibody is useful for manufacturing a medicament for the treatment of cancer or an angiogenesis-associated disease. The composition and methods are useful for diagnosing or treating cancer or angiogenesis-associated diseases, such as inflammatory disorders, chronic articular rheumatism, psoriasis, ocular angiogenic diseases or scleroderma. This sequence represents a human ephrin B4 siRNA that can be used to control EphB4 expression.
 SQ Sequence 21 BP; 7 A; 9 C; 2 G; 0 T; 3 U; 0 Other;

Query Match 0.5%; Score 20; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 1.1e+02;
 Matches 18; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 Qy 1939 CATCAGCCAGACCACT 1958

```
Db          ||:|||||:|||||:|||||:
1 CAUCACAGCCAGACCCCAACU 20

RESULT 480
ADR86740
ID ADR86740 standard; RNA; 21 BP.
XX
AC ADR86740;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrinB4 short interference RNA seqid 45.
XX
KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
OS Homo sapiens.
XX
PN WO2004080425-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007755.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASC-) VASGENE THERAPEUTICS INC.
XX
PI Krasnoperov V, Zorulya S, Keretes N, Reddy R, Gill P;
XX
DR WPI; 2004-668893/65.
XX
PT New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 5; Page 75; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 7 A; 9 C; 2 G; 0 T; 3 U; 0 Other;

Query Match          0.5%; Score 20; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.1e+02;

Matches 18; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1939 CATCAGCCAGACCCCAACT 1958
Db          ||:|||||:|||||:|||||:
1 CAUCACAGCCAGACCCCAACU 20

RESULT 481
ADR82545
ID ADR82545 standard; RNA; 21 BP.
XX
AC ADR82545;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 antisense RNAi probe #56.
XX
KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
OS Homo sapiens.
XX
PN WO2004080418-A2.
XX
PD 23-SEP-2004.
XX
PF 12-MAR-2004; 2004WO-US007491.
XX
PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASC-) VASGENE THERAPEUTICS INC.
XX
PI Reddy R, Gill P;
XX
DR WPI; 2004-668879/65.
XX
PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
PS Example 8; Page 103; 206pp; English.
XX
CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense RNAi probe.
XX
SQ Sequence 21 BP; 7 A; 9 C; 2 G; 0 T; 3 U; 0 Other;

Query Match          0.5%; Score 20; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.1e+02;

Matches 18; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1939 CATCAGCCAGACCCCAACT 1958
Db          ||:|||||:|||||:|||||:
1 CAUCACAGCCAGACCCCAACU 20

RESULT 482
ADR82305
ID ADR82305 standard; RNA; 21 BP.
XX
```

AC ADR82305;
XX
XX
DT 16-DEC-2004 (first entry)
XX
DE Human EphB4 siRNA #7.
XX
XX human; ss; siRNA; small interference RNA; RNA interference;
KW gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW inflammatory disorder; chronic articular rheumatism; psoriasis;
KW ocular angiogenic disease; scleroderma; cytostatic; antinflammatory;
KW antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW angiogenesis inhibitor.
XX
OS Homo sapiens.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007491.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Reddy R, Gill P;
XX
XX WPI; 2004-668879/65.
XX
XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.
XX
XX Example 5; Page 81; 206pp; English.
XX
XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC siRNA.
XX
XX Sequence 21 BP; 7 A; 9 C; 2 G; 0 T; 3 U; 0 Other;
SQ
Query Match 0.5%; Score 20; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.1e+02;
Matches 18; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 1939 CATCAGCCAGACCCCACT 1958
Db 1 CAUCACGCCAGACCCCACTU 20
RESULT 483
ADY89201
ID ADY89201 standard; RNA; 23 BP.
XX
AC ADY89201;
XX
XX 16-JUN-2005 (first entry)
XX
XX VEGF/VEGFR siRNA SEQ ID NO 2237.
DE
XX ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
XX Synthetic.

XX WO2005028649-A1.
XX
XX 31-MAR-2005.
XX
XX 16-SEP-2004; 2004WO-US030488.
XX
XX 16-SEP-2003; 2003US-00664767.
XX
XX 16-SEP-2003; 2003US-00665255.
XX
XX 23-SEP-2003; 2003US-00670011.
XX
XX 23-OCT-2003; 2003US-00693059.
XX
XX 24-NOV-2003; 2003US-00720448.
XX
XX 03-DEC-2003; 2003US-00727780.
XX
XX 14-JAN-2004; 2004US-00757803.
XX
XX 26-JAN-2004; 2004US-00764957.
XX
XX 10-FEB-2004; 2004US-0543480P.
XX
XX 13-FEB-2004; 2004US-00780447.
XX
XX 16-APR-2004; 2004US-00826966.
XX
XX 23-APR-2004; 2004US-00831620.
XX
XX 30-APR-2004; 2004US-00013456.
XX
XX 11-MAY-2004; 2004US-00844076.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
XX WPI; 2005-254128/26.
XX
XX New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
XX Disclosure; SEQ ID NO 2237; 396pp; English.
XX
XX The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MP-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGF/VEGFR siRNA.
XX
XX Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;
SQ
Query Match 0.5%; Score 19.8; DB 1; Length 23;
Best Local Similarity 69.6%; Pred. No. 1.3e+02;
Matches 16; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 2926 CAGCTCATGCTGGACTGTGGCA 2948
Db 1 CAGCAUCAUGCUGGACUGGCA 23
RESULT 484
ADR86925/c
ID ADR86925 standard; DNA; 21 BP.
XX
XX ADR86925;
AC
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrin B4 antisense oligonucleotide seqid 230.
DE
XX
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; antisense technology;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
OS

PN WO2004080425-A2.
 XX
 PD 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 PF 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASC-) VASGENE THERAPEUTICS INC.
 PA
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 94; 198pp; English.
 XX
 XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 21 BP; 4 A; 2 C; 12 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 1.3e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1328 CACCCTGCACCCCTCCTT 1348
 |||||
 Db 21 CACCGTGACACCCCTCCTT 1
 |||||
 RESULT 485
 ADR86745/c
 ID ADR86745 standard; DNA; 21 BP.
 AC ADR86745;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 XX Human ephrin B4 antisense oligonucleotide seqid 50.
 DE
 XX
 XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatologic; ophthalmologic; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX OS Homo sapiens.
 XX
 XX WO2004080425-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASC-) VASGENE THERAPEUTICS INC.
 PA
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 XX WPI; 2004-668883/65.
 DR
 XX
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 5; Page 79; 198pp; English.
 XX
 XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.
 XX
 SQ Sequence 21 BP; 4 A; 2 C; 12 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 1.3e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1328 CACCCTGCACCCCTCCTT 1348
 |||||
 Db 21 CACCGTGACACCCCTCCTT 1
 |||||
 RESULT 486
 ADR82480/c
 ID ADR82480 standard; DNA; 21 BP.
 XX ADR82480;
 AC
 XX 16-DEC-2004 (first entry)
 DT
 XX Human EphB4 antisense probe #151.
 DE
 XX human; ss; antisense; EphB4; EphrinB2; cancer;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

OS Homo sapiens.
OS Synthetic.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX Example 8; Page 101; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.

XX Sequence 21 BP; 4 A; 2 C; 12 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 21;

Best Local Similarity 95.2%; Pred. No. 1.3e+02;

Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1328 CACCCTGCACCCCTCCTT 1348

Db 21 CACCGTGCACCCCTCCTT 1

RESULT 487

ADR82310/C

ID ADR82310 standard; DNA; 21 BP.

AC ADR82310;

DT 16-DEC-2004 (first entry)

XX Human EphB4 antisense ODN #4.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor.

OS Homo sapiens.

OS Synthetic.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX

PR 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX Example 5; Page 85; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense oligodeoxynucleotide (ODN).

XX Sequence 21 BP; 4 A; 2 C; 12 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 21;

Best Local Similarity 95.2%; Pred. No. 1.3e+02;

Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1328 CACCCTGCACCCCTCCTT 1348

Db 21 CACCGTGCACCCCTCCTT 1

RESULT 488

ADU31805

ID ADU31805 standard; DNA; 21 BP.

AC ADU31805;

XX 27-JAN-2005 (first entry)

XX Knock-down target sequence #5203.

XX ds; RNA production; protein production; drug development;

XX Knock-down target.

XX Unidentified.

XX WO2004094636-A1.

XX 04-NOV-2004.

XX 24-APR-2003; 2003WO-EF004362.

XX 24-APR-2003; 2003WO-EF004362.

XX (GALA-) GALAPAGOS GENOMICS NV.

XX (VSC/) VAN DER SCHUEREN J.

XX Arts GJF, Lambrecht MJY, Djokic K, Clasen RJ, Mesic E;

XX Griffioen S, Bergs CJL;

XX WPI; 2004-775940/76.

XX New knockdown sequences, useful in lowering the amount of RNA and/or
PT protein production in cells used in drug development process.

PS Claim 11; SEQ ID NO 5219; 402pp; English.

XX AC

XX The invention relates to a polynucleotide comprising an RNA sequence. The

CC polynucleotides, vector, libraries, and method are useful in lowering the

CC amount of RNA and/or protein production in cells used in drug development

CC process. The present sequence represents a knock-down target sequence.

XX SQ Sequence 21 BP; 6 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 21;

Best Local Similarity 95.2%; Pred. No. 1.3e+02;

Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2851 AATCAGGACGTGATCAATGCC 2871

Db 1 ACTCAGGACGTGATCAATGCC 21

RESULT 489

ID ADU31803

XX ADU31803 standard; DNA; 21 BP.

XX AC

XX ADU31803;

XX 27-JAN-2005 (first entry)

XX DE Knock-down target sequence #5201.

XX ds; RNA production; protein production; drug development;

XX knock-down target.

XX Unidentified.

XX WO2004094636-A1.

XX 04-NOV-2004.

XX 24-APR-2003; 2003WO-EP004362.

XX 24-APR-2003; 2003WO-EP004362.

XX (GALA-) GALAPAGOS GENOMICS NV.

XX (VSCH/) VAN DER SCHUEREN J.

XX Arts GJF, Lambrecht MJY, Djokic K, Claesen RJ, Mesic E;

XX Griffioen S, Bergs CJL;

XX WPI; 2004-775940/76.

XX New knockdown sequences, useful in lowering the amount of RNA and/or

PT protein production in cells used in drug development process.

XX Claim 11; SEQ ID NO 5217; 402pp; English.

XX The invention relates to a polynucleotide comprising an RNA sequence. The

CC polynucleotides, vector, libraries, and method are useful in lowering the

CC amount of RNA and/or protein production in cells used in drug development

CC process. The present sequence represents a knock-down target sequence.

XX SQ Sequence 21 BP; 7 A; 6 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 21;

Best Local Similarity 95.2%; Pred. No. 1.3e+02;

Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1783 AAATACCATGAGAGGCGGCC 1803

Db 1 ACATACCATGAGAGGCGGCC 21

RESULT 490

ID ADU31804

XX ADU31804 standard; DNA; 21 BP.

XX ADU31804;

XX 27-JAN-2005 (first entry)

XX Knock-down target sequence #5202.

XX ds; RNA production; protein production; drug development;

XX knock-down target.

XX Unidentified.

XX WO2004094636-A1.

XX 04-NOV-2004.

XX 24-APR-2003; 2003WO-EP004362.

XX 24-APR-2003; 2003WO-EP004362.

XX (GALA-) GALAPAGOS GENOMICS NV.

XX (VSCH/) VAN DER SCHUEREN J.

XX Arts GJF, Lambrecht MJY, Djokic K, Claesen RJ, Mesic E;

XX Griffioen S, Bergs CJL;

XX WPI; 2004-775940/76.

XX New knockdown sequences, useful in lowering the amount of RNA and/or

PT protein production in cells used in drug development process.

XX Claim 11; SEQ ID NO 5218; 402pp; English.

XX The invention relates to a polynucleotide comprising an RNA sequence. The

CC polynucleotides, vector, libraries, and method are useful in lowering the

CC amount of RNA and/or protein production in cells used in drug development

CC process. The present sequence represents a knock-down target sequence.

XX SQ Sequence 21 BP; 6 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 19.4; DB 1; Length 21;

Best Local Similarity 95.2%; Pred. No. 1.3e+02;

Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2715 AAAGATTCCTCCATCCGATGGAC 2735

Db 1 ACAGATTCCTCCATCCGATGGAC 21

RESULT 491

ID ADX00839/c

XX ADX00839 standard; DNA; 22 BP.

XX AC

XX ADX00839;

XX 21-APR-2005 (first entry)

XX Human CYP2D6 gene 2988GtoA mutation detection reverse PCR primer #3.

XX DNA purification; SNP detection; cardiovascular-gen.; hypotensive;

XX neuroleptic; antiarrhythmic; antiepileptic; analgesic; anorectic;

XX tranquilizer; antitumor; antidepressant; allelic variant; CYP2D6 gene;

XX diagnosis; codeine dependence; depression; hepatitis C virus infection;

XX psychosis; schizophrenia; Parkinson's disease; forensic; PCR; ss.

XX Homo sapiens.

XX OS

XX US2005032070-A1.

XX 10-FEB-2005.

XX 05-AUG-2003; 2003US-00635780.

XX

05-AUG-2003; 2003US-00635780.
 (RAIM/) RAIMUNDO S.
 (ZANG/) ZANGER U.
 Raimundo S, Zanger U;
 WPI; 2005-161644/17.
 Novel polynucleotide of molecular variants of Cytochrome P450 2D6
 (CYP2D6) gene, capable of hybridizing to CYP2D6 gene, is useful in
 diagnosing disease related to presence of molecular variant of CYP2D6
 gene.
 Example 1; SEQ ID NO 16; 33pp; English.
 The invention relates to a polynucleotide (I) of molecular variants of
 CYP2D6 gene, chosen from polynucleotide capable of hybridizing to CYP2D6
 gene, where the polynucleotide consists of substitution of one or more
 nucleotides at position corresponding to 4784, 4735 or 4087 of the CYP2D6
 gene having a fully defined sequence (S1) of 9609 base pairs as given in
 the specification. (I) is useful for identifying a diagnostic
 composition, which involves (a) isolating (I) from several subgroups of
 individuals, where one subgroup has no prevalence for CYP2D6 associated
 disease, and one or more further subgroup(s) do have prevalence for a
 CYP2D6 associated disease, and (b) identifying a single nucleotide
 polymorphism by comparing the nucleic acid sequence of the polynucleotide
 or the gene of one subgroup having no prevalence for a CYP2D6 associated
 disease, with one or more further subgroup(s) having a prevalence for a
 CYP2D6 associated disease. (I) is useful for diagnosing a disease related
 to the presence of a molecular variant of a CYP2D6 gene or susceptibility
 to such a disorder, which involves determining the presence of (I) in a
 sample from a subject. (I) is useful for diagnosing whether a subject has
 EM, IM or PM phenotype, and for determining whether an individual is at
 risk for a toxic reaction, non-response, insufficient response, or
 reduced metabolic activity of CYP2D6 to treatment with a CYP2D6
 substrate. (I) is useful in selecting a subject suffering from a CYP2D6
 substrate treatable disease for treatment with the substrate, and in
 treating a subject suffering from a CYP2D6 substrate treatable disease.
 (I) is useful for detecting variant polynucleotide of CYP2D6 gene in a
 sample, which involves contacting (I) with the sample under conditions
 allowing interaction of variant of CYP2D6 gene with several immobilized
 targets on (I), and determining the binding of the polynucleotide or the
 gene to the immobilized targets on (I). (I) is useful for diagnosing a
 disease, which involves binding of the variant polynucleotide of CYP2D6
 gene or the gene to the immobilized targets on (I), where the binding
 indicates the presence or the absence of the disease or a prevalence for
 the disease. The disease is codeine dependence, depression, hepatitis C,
 psychosis, schizophrenia or Parkinson's disease. (I) is useful for
 diagnosing an altered activity of the CYP2D6 enzyme, and for diagnosing a
 polynucleotide associated with IM phenotype of CYP2D6. (I) is useful in
 diagnosing individual's genetic constitution of the CYP2D6 status, useful
 in personalized medicine. (I) is used for prediction of the therapeutic
 outcome of an individual with an established drug and for avoidance of
 side effects/toxicity due to altered activity of CYP2D6 mediated by
 different CYP2D6 alleles. (I) is useful as forensic markers. This
 sequence corresponds to a PCR primer to amplify the exon 6 region of the
 CYP2D6 gene for detection polymorphisms.
 Sequence 22 BP; 2 A; 10 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 0.5%; Score 19.4; DB 1; Length 22;
 Best Local Similarity 95.2%; Pred. No. 1.4e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3718 GCGAAGAGGGGTGTCAGGC 3738
 DB 21 GCGAAGAGGGGTGTCAGGC 1
 RESULT 492
 ADG75924
 ID ADG75924 standard; DNA; 24 BP.
 Query Match 0.5%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 1.7e+02;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 3897 TTTTGTCTTCGTTTGTGTTT 3920
 DB 1 TTTTGTCTTCGTTTGTGTTT 24
 RESULT 493
 ADG75971
 ID ADG75971 standard; DNA; 24 BP.
 XX AC ADG75924;
 XX DT 11-MAR-2004 (first entry)
 XX DE Immunostimulatory non-CpG oligonucleotide IMT 179 SeqID 26.
 XX KW ss; non-CpG; immunostimulatory; non-palindromic; immune response;
 KW proliferation; differentiation; cytokine; antibody production; B-cell;
 KW plasmacytoid dendritic cell; immunomodulator; gene therapy;
 KW chronic myelogenous leukaemia; melanoma; Kaposi's sarcoma;
 KW renal cell carcinoma.
 XX OS Synthetic.
 XX PN WO2003101375-A2.
 XX PD 11-DEC-2003.
 XX PF 30-MAY-2003; 2003WO-EP005691.
 XX PR 30-MAY-2002; 2002CA-02388049.
 XX PA (IMMU-) IMMUNOTECH SA.
 XX PI Lopez RA;
 XX DR WPI; 2004-053333/05.
 XX PT New immunostimulatory oligonucleotide comprising non-palindromic nucleic
 PT acid sequence motif, useful for inducing B-cell activation, treating,
 PT preventing or ameliorating immune system disorder or tumoral disease e.g.
 PT melanoma.
 XX PS Claim 14; SEQ ID NO 26; 139pp; English.
 XX CC This invention relates to novel immunostimulatory oligonucleotides that
 CC contain a non-palindromic sequence motif. Specifically, it refers to DNA
 CC oligonucleotides (without a CpG motif), which can stimulate an immune
 CC response in animals of the order of primates, including humans. The immune
 CC response is characterised by the proliferation, differentiation, cytokine
 CC and antibody production in B-cells, as well as cell differentiation and
 CC cytokine production in plasmacytoid dendritic cells. The present
 CC invention describes immunomodulator compositions that also comprise an
 CC antigen selected from, for example, viruses, bacteria, parasites, tumour
 CC cells and glycolipids. As such, these DNA oligos can be used in gene
 CC therapy for inducing B-cell activation, treating, preventing or
 CC ameliorating an immune system disorder or a tumoural disease including
 CC chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell
 CC carcinoma. This oligonucleotide sequence is an immunostimulatory non-CpG
 CC variant DNA oligo, used in an exemplification of the invention.
 XX SQ Sequence 24 BP; 1 A; 1 C; 1 G; 21 T; 0 U; 0 Other;
 Query Match 0.5%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 1.7e+02;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 3897 TTTTGTCTTCGTTTGTGTTT 3920
 DB 1 TTTTGTCTTCGTTTGTGTTT 24
 RESULT 493
 ADG75971
 ID ADG75971 standard; DNA; 24 BP.
 XX AC ADG75971;
 XX DT 11-MAR-2004 (first entry)
 XX DE Immunostimulatory non-CpG phosphorothioate DNA oligo IMT179 SeqID73.
 XX

KW ss; non-CpG; immunostimulatory; non-palindromic; immune response;
KW proliferation; differentiation; cytokine; antibody production; B-cell;
KW plasmacytoid dendritic cell; immunomodulator; gene therapy;
KW chronic myelogenous leukaemia; melanoma; Kaposi's sarcoma;
KW renal cell carcinoma.
XX
OS Synthetic.
XX
FN WO2003101375-A2.
XX
PD 11-DEC-2003.
XX
XX 30-MAY-2003; 2003WO-EP005691.
XX
XX 30-MAY-2002; 2002CN-02388049.
XX
PA (IMMU-) IMMUNOTECH SA.
XX
XX Lopez RA;
PI
XX WPI; 2004-053333/05.
DR
XX New immunostimulatory oligonucleotide comprising non-palindromic nucleic
PT acid sequence motif, useful for inducing B-cell activation, treating,
PT preventing or ameliorating immune system disorder or tumoral disease e.g.
PT melanoma.
XX
XX Example 5; SEQ ID NO 73; 139pp; English.
PS
XX This invention relates to novel immunostimulatory oligonucleotides that
CC contain a non-palindromic sequence motif. Specifically, it refers to DNA
CC oligonucleotides (without a CpG motif), which can stimulate an immune
CC response in animals of the order of primates, including humans. The immune
CC response is characterised by the proliferation, differentiation, cytokine
CC and antibody production in B-cells, as well as cell differentiation and
CC cytokine production in plasmacytoid dendritic cells. The present
CC invention describes immunomodulator compositions that also comprise an
CC antigen selected from, for example, viruses, bacteria, parasites, tumour
CC cells and glycolipids. As such, these DNA oligos can be used in gene
CC therapy for inducing B-cell activation, treating, preventing or
CC ameliorating an immune system disorder or a tumoural disease including
CC chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell
CC carcinoma. This oligonucleotide sequence is an immunostimulatory
CC phosphorothioate non-CpG variant DNA oligo, used to determine the effect
CC of oligo size on B cell proliferation and IL6 secretion in an
CC exemplification of the invention.
XX
SQ Sequence 24 BP; 1 A; 1 C; 1 G; 21 T; 0 U; 0 Other;
Query Match 0.5%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 1.7e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 3897 TTTTGTGTTTCGTTTGTGTTT 3920
Db 1 TTTTGTGTTTCGTTTGTGTTT 24
RESULT 494
ADH17042/c
ID ADH17042 standard; DNA; 19 BP.
XX
AC ADH17042;
XX
XX 11-MAR-2004 (first entry)
XX
XX Reverse PCR primer used to amplify human EphB4 sequence.
XX
XX tyrosine kinase activity; type 1 plasmalogen activator inhibitor; PAI-1;
KW TIMP-1; tissue inhibitor of metalloproteinase 1; vinculin;
KW vascular endothelial growth factor; VEGF; placental growth factor; PLGF;
KW migration inhibitory factor; MIG; PCR; primer; ss; human; RT-PCR; EphB4.
XX

OS Homo sapiens.
XX WO2003097854-A2.
XX
XX 27-NOV-2003.
XX
XX 19-MAY-2003; 2003WO-US015711.
XX
XX 17-MAY-2002; 2002US-0380872P.
PR 24-FEB-2003; 2003US-0448874P.
PR 24-FEB-2003; 2003US-0448922P.
XX
XX (SUGE-) SUGEN INC.
XX
XX Morimoto A, Deprimo S, O'farrell A, Smolich BD, Manning WC;
PI Walter SA, Schilling JW, Cherrington J;
XX WPI; 2004-042604/04.
DR
XX Determining whether a test compound inhibits tyrosine kinase activity in
PT a mammal by exposing the mammal to the test compound and measuring in the
PT mammal the level of at least one of the measured proteins or mRNA
PT transcripts.
XX
XX Example K; SEQ ID NO 41; 408pp; English.
PS
XX The invention relates to a novel method for determining whether a test
CC compound inhibits tyrosine kinase activity in a mammal comprising
CC measuring in the mammal the level of at least one of the proteins and/or
CC mRNA transcripts or genes for such proteins comprising type 1 plasmalogen
CC activator inhibitor (PAI-1), TIMP-1 (tissue inhibitor of
CC metalloproteinase 1), vinculin, vascular endothelial growth factor
CC (VEGF), placental growth factor (PLGF), VEGF/PLGF heterodimers or
CC migration inhibitory factor (MIG), exposing the mammal to the test
CC compound and then measuring in the mammal the level of at least one of
CC the proteins and/or mRNA transcripts previously measured. The method of
CC the invention may be useful for determining whether a test compound
CC inhibits tyrosine kinase activity in a mammal. The current sequence is
CC that of the PCR primer which was used in the exemplification of the
CC invention.
XX
SQ Sequence 19 BP; 3 A; 4 C; 6 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3990 AACAGGGGCCCCATCATCAT 4008
Db 19 AACAGGGGCCCCATCATCAT 1
RESULT 495
ADQ60986
ID ADQ60986 standard; RNA; 19 BP.
XX
AC ADQ60986;
XX
XX 09-SEP-2004 (first entry)
DT
XX
XX Anti-EphB4 siRNA related DNA sequence SEQ ID NO:688.
DE
XX ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
KW RNA interference.
XX
XX Synthetic.
XX
XX WO2004045543-A2.
XX
XX 03-JUN-2004.
XX
XX 14-NOV-2003; 2003WO-US036787.
XX


```
PR 14-NOV-2002; 2002US-0426137P.
PR 10-SEP-2003; 2003US-0502050P.
XX (DHAR-) DHARMACON INC.
XX
XX Anastasia K, Angela R, Devin L, William M, Stephen S;
XX WPI; 2004-420527/39.
XX
XX Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
XX by selecting a target gene and measuring the functionality of the
XX nucleotide sequences that are complementary to a stretch of nucleotides
XX of the target sequence.
XX
XX Example 12; SEQ ID NO 688; 199pp; English.
XX
XX The invention relates to a novel method for selecting siRNA (short
XX interfering RNA) comprising selecting an siRNA molecule of 19-25
XX nucleoside bases by selecting a target gene and measuring the
XX functionality of sequences of 19-25 nucleotides in length that are
XX substantially complementary to a stretch of nucleotides of the target
XX sequence, where the functionality is dependent upon non-target specific
XX criteria. Also claimed are methods for gene-silencing, developing an
XX siRNA algorithm for selecting siRNA, selecting an siRNA with improved
XX functionality, selecting hyperfunctional siRNA, an siRNA molecule
XX effective at silencing Bcl-2, and a kit for gene silencing comprising the
XX siRNA. The siRNA molecule comprises a sequence substantially similar to a
XX siRNA. The siRNA molecule comprises a sequence substantially similar to a
XX sequence consisting of GGGAGAUGAUGAUGAUGA; GAAGUACAUCCAUUAUAG;
XX GUACGACACCCGGGAUA; AGAUAUGAUGAUGAUGA; GAAGUACAUCCAUUAUAG;
XX GAAGUACAUCCGGGAUA; and GAAGUACUUCGUCAGUUU. The siRNA molecule
XX comprises a sense strand and an anti-sense strand. The siRNA molecule
XX comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
XX pairs. The kit comprises at least two siRNA, comprising a first optimised
XX siRNA and a second optimised siRNA. The method is useful in selecting
XX siRNA for generating a gene silencing reagent. The present sequence is
XX used in the exemplification of the invention. The sequence is shown in
XX the specification as DNA, but described as siRNA.
XX
XX Sequence 19 BP; 7 A; 7 C; 2 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1243 GCCAATAGCCACTCTAACA 1261
Db 1 GCCAATAGCCACTCTAACA 19
RESULT 496
ADQ60983
ID ADQ60983 standard; RNA; 19 BP.
XX
XX AC ADQ60983;
XX
XX 09-SEP-2004 (first entry)
XX
XX Anti-BPHB4 siRNA related DNA sequence SEQ ID NO:685.
XX
XX ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
XX RNA interference.
XX
XX Synthetic.
XX
XX WO2004045543-A2.
XX
XX 03-JUN-2004.
XX
XX 14-NOV-2003; 2003WO-US036787.
XX
XX 14-NOV-2002; 2002US-0426137P.
XX
XX 10-SEP-2003; 2003US-0502050P.
XX
XX (DHAR-) DHARMACON INC.
PA
```

```
XX (DHAR-) DHARMACON INC.
XX
XX Anastasia K, Angela R, Devin L, William M, Stephen S;
XX WPI; 2004-420527/39.
XX
XX Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
XX by selecting a target gene and measuring the functionality of the
XX nucleotide sequences that are complementary to a stretch of nucleotides
XX of the target sequence.
XX
XX Example 12; SEQ ID NO 685; 199pp; English.
XX
XX The invention relates to a novel method for selecting siRNA (short
XX interfering RNA) comprising selecting an siRNA molecule of 19-25
XX nucleoside bases by selecting a target gene and measuring the
XX functionality of sequences of 19-25 nucleotides in length that are
XX substantially complementary to a stretch of nucleotides of the target
XX sequence, where the functionality is dependent upon non-target specific
XX criteria. Also claimed are methods for gene-silencing, developing an
XX siRNA algorithm for selecting siRNA, selecting an siRNA with improved
XX functionality, selecting hyperfunctional siRNA, an siRNA molecule
XX effective at silencing Bcl-2, and a kit for gene silencing comprising the
XX siRNA. The siRNA molecule comprises a sequence substantially similar to a
XX siRNA. The siRNA molecule comprises a sequence substantially similar to a
XX sequence consisting of GGGAGAUGAUGAUGAUGA; GAAGUACAUCCAUUAUAG;
XX GUACGACACCCGGGAUA; AGAUAUGAUGAUGAUGA; GAAGUACAUCCAUUAUAG;
XX GAAGUACAUCCGGGAUA; and GAAGUACUUCGUCAGUUU. The siRNA molecule
XX comprises a sense strand and an anti-sense strand. The siRNA molecule
XX comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
XX pairs. The kit comprises at least two siRNA, comprising a first optimised
XX siRNA and a second optimised siRNA. The method is useful in selecting
XX siRNA for generating a gene silencing reagent. The present sequence is
XX used in the exemplification of the invention. The sequence is shown in
XX the specification as DNA, but described as siRNA.
XX
XX Sequence 19 BP; 8 A; 4 C; 5 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2100 GGACAAACACGGACAGTAT 2118
Db 1 GGACAAACACGGACAGTAT 19
RESULT 497
ADQ60984
ID ADQ60984 standard; RNA; 19 BP.
XX
XX AC ADQ60984;
XX
XX 09-SEP-2004 (first entry)
XX
XX Anti-BPHB4 siRNA related DNA sequence SEQ ID NO:686.
XX
XX ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
XX RNA interference.
XX
XX Synthetic.
XX
XX WO2004045543-A2.
XX
XX 03-JUN-2004.
XX
XX 14-NOV-2003; 2003WO-US036787.
XX
XX 14-NOV-2002; 2002US-0426137P.
XX
XX 10-SEP-2003; 2003US-0502050P.
XX
XX (DHAR-) DHARMACON INC.
PA
```

XX Anastasia K, Angela R, Devin L, William M, Stephen S;
 XX WPI; 2004-420527/39.
 XX
 XX Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
 PT by selecting a target gene and measuring the functionality of the
 PT nucleotide sequences that are complementary to a stretch of nucleotides
 PT of the target sequence.
 XX
 XX Example 12; SEQ ID NO 686; 199pp; English.
 XX
 XX The invention relates to a novel method for selecting siRNA (short
 CC interfering RNA) comprising selecting an siRNA molecule of 19-25
 CC nucleoside bases by selecting a target gene and measuring the
 CC functionality of sequences of 19-25 nucleotides in length that are
 CC substantially complementary to a stretch of nucleotides of the target
 CC sequence, where the functionality is dependent upon non-target specific
 CC criteria. Also claimed are methods for gene-silencing, developing an
 CC siRNA algorithm for selecting siRNA, selecting an siRNA with improved
 CC functionality, selecting hyperfunctional siRNA, an siRNA molecule
 CC effective at silencing Bcl-2, and a kit for gene silencing comprising the
 CC siRNA. The siRNA molecule comprises a sequence substantially similar to a
 CC sequence consisting of GGGAGUAGUGAUGAAGUA; GAAGUACUCCAUUAUAG;
 CC GUACGACACCGGAGUA; AGAUAGUGAUGAAGUA; UGAAGACUCUGCAGUUG;
 CC CAUGCGCCUCUGUUGA; UGCGCCUCUGUUGA; GAGAUGUGAUGAAGUA;
 CC GGAGUAGUGAUGAAGUA; and GAAGACUCUGCAGUUG. The siRNA molecule
 CC comprises a sense strand and an anti-sense strand. The siRNA molecule
 CC comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
 CC pairs. The kit comprises at least two siRNA, comprising a first optimised
 CC siRNA and a second optimised siRNA. The method is useful in selecting
 CC siRNA for generating a gene silencing reagent. The present sequence is
 CC siRNA for generating a gene silencing reagent. The present sequence is
 CC used in the exemplification of the invention. The sequence is shown in
 CC the specification as DNA, but described as siRNA.
 XX
 XX Sequence 19 BP; 6 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2132 GTACTAAGGTCTACATCGA 2150
 |||||
 Db 1 GTACTAAGGTCTACATCGA 19
 RESULT 498
 ADQ60985
 ID ADQ60985 standard; RNA; 19 BP.
 AC ADQ60985;
 XX
 XX 09-SEP-2004 (first entry)
 DT
 XX
 XX Anti-EPHB4 siRNA related DNA sequence SEQ ID NO:687.
 DE
 XX
 XX ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
 KW RNA interference.
 KW
 XX Synthetic.
 OS
 XX WO2004045543-A2.
 PN
 XX
 XX 03-JUN-2004.
 PD
 XX
 XX 14-NOV-2003; 2003WO-US036787.
 PF
 XX
 XX 14-NOV-2002; 2002US-0426137P.
 PR
 XX 10-SEP-2003; 2003US-0502050P.
 PR
 XX (DHAR-) DHARMA CON INC.
 PA
 XX Anastasia K, Angela R, Devin L, William M, Stephen S;
 PI

XX WPI; 2004-420527/39.
 DR
 XX Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
 PT by selecting a target gene and measuring the functionality of the
 PT nucleotide sequences that are complementary to a stretch of nucleotides
 PT of the target sequence.
 XX
 XX Example 12; SEQ ID NO 687; 199pp; English.
 XX
 XX The invention relates to a novel method for selecting siRNA (short
 CC interfering RNA) comprising selecting an siRNA molecule of 19-25
 CC nucleoside bases by selecting a target gene and measuring the
 CC functionality of sequences of 19-25 nucleotides in length that are
 CC substantially complementary to a stretch of nucleotides of the target
 CC sequence, where the functionality is dependent upon non-target specific
 CC criteria. Also claimed are methods for gene-silencing, developing an
 CC siRNA algorithm for selecting siRNA, selecting an siRNA with improved
 CC functionality, selecting hyperfunctional siRNA, an siRNA molecule
 CC effective at silencing Bcl-2, and a kit for gene silencing comprising the
 CC siRNA. The siRNA molecule comprises a sequence substantially similar to a
 CC sequence consisting of GGGAGUAGUGAUGAAGUA; GAAGUACUCCAUUAUAG;
 CC GUACGACACCGGAGUA; AGAUAGUGAUGAAGUA; UGAAGACUCUGCAGUUG;
 CC CAUGCGCCUCUGUUGA; UGCGCCUCUGUUGA; GAGAUGUGAUGAAGUA;
 CC GGAGUAGUGAUGAAGUA; and GAAGACUCUGCAGUUG. The siRNA molecule
 CC comprises a sense strand and an anti-sense strand. The siRNA molecule
 CC comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
 CC pairs. The kit comprises at least two siRNA, comprising a first optimised
 CC siRNA and a second optimised siRNA. The method is useful in selecting
 CC siRNA for generating a gene silencing reagent. The present sequence is
 CC used in the exemplification of the invention. The sequence is shown in
 CC the specification as DNA, but described as siRNA.
 XX
 XX Sequence 19 BP; 8 A; 2 C; 6 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2081 GGAGAGAGCAGATATTC 2099
 |||||
 Db 1 GGAGAGAGCAGATATTC 19
 RESULT 499
 ADR86728
 ID ADR86728 standard; RNA; 21 BP.
 XX
 XX ADR86728;
 AC
 XX 16-DEC-2004 (first entry)
 DT
 XX
 XX Human ephrinB4 short interference RNA seqid 33.
 DE
 XX
 XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004080425-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 PF
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 XX 12-MAR-2003; 2003US-0454432P.
 PR
 XX

PA (VASG-) VASGENE THERAPEUTICS INC.
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
DR
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 3; Page 62; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 5 A; 3 C; 7 G; 0 T; 6 U; 0 Other;
Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.4e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Qy 849 GGTGAATGTCAGACGCTG 867
||:||||:|||||||
Db 1 GGUGAAUGUCAGACGUG 19
RESULT 500
ADR86742
ID ADR86742 standard; RNA; 21 BP.
AC ADR86742;
XX
XX 16-DEC-2004 (first entry)
DT
XX
XX Human ephrinB4 short interference RNA seqid 47.
DE
XX
XX cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
XX Homo sapiens.
XX
XX WO2004080425-A2.
PN
XX 23-SEP-2004.
PD
XX
XX 12-MAR-2004; 2004WO-US007755.

PR 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
PA (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
XX WPI; 2004-668883/65.
DR
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
PS Example 5; Page 75; 198pp; English.
XX
CC The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
SQ Sequence 21 BP; 3 A; 10 C; 1 G; 0 T; 7 U; 0 Other;
Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.4e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
Qy 2679 CTCTTCGATCCACCTAC 2697
||:||||:|||||||
Db 1 CUCUCCGAUCCACCCTAC 19
RESULT 501
ADR86992
ID ADR86992 standard; DNA; 21 BP.
AC ADR86992;
XX
XX 16-DEC-2004 (first entry)
DT
XX
XX Human ephrinB4 short interference RNA seqid 297.
DE
XX
XX cytosolic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
XX Homo sapiens.
XX
XX WO2004080425-A2.
PN
XX 23-SEP-2004.
PD
XX
XX 12-MAR-2004; 2004WO-US007755.

OS Homo sapiens.
FN WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
PI WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX
XX Example 6; Page 89; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
XX Sequence 21 BP; 7 A; 6 C; 4 G; 0 T; 4 U; 0 Other;
SQ
Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.4e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 427 GAGACCCCTGCTGAACACAA 445
DB 1 GAGACCCCGCUGAACACAA 19
RESULT 504
ADR86736
ID ADR86736 standard; RNA; 21 BP.
XX
XX ADR86736;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrinB4 short interference RNA seqid 41.
DE
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
XX RNA interference; gene silencing; ss.
OS Homo sapiens.
FN WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
PR 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Keretesz N, Reddy R, Gill P;
PI WPI; 2004-668883/65.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
XX scleroderma.
XX
XX Example 5; Page 75; 198pp; English.
XX
XX The invention describes an isolated soluble polypeptide comprising an
CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 siRNA that can be used to control EphB4
CC expression.
XX
XX Sequence 21 BP; 7 A; 6 C; 4 G; 0 T; 4 U; 0 Other;
SQ
Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.4e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 427 GAGACCCCTGCTGAACACAA 445
DB 1 GAGACCCCGCUGAACACAA 19
RESULT 505
ADR86729
ID ADR86729 standard; RNA; 21 BP.
XX
XX ADR86729;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human ephrinB4 short interference RNA seqid 34.
DE
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW

XX 16-DEC-2004 (first entry)
 XX Human ephrinB4 short interference RNA seqid 43.
 DE
 XX
 XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 PI WPI; 2004-668883/65.
 DR
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 5; Page 75; 198pp; English.
 XX
 XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.
 XX
 XX Sequence 21 BP; 5 A; 3 C; 7 G; 0 T; 6 U; 0 Other;
 SQ
 Query Match 0.4%; Score 19; DB 1; Length 21;
 Best Local Similarity 78.9%; Pred. No. 1.4e+02;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 849 GGTGAATGCTCAAGACGCTG 867
 DB 1 GGUGAUGUCAGACGCG 19
 RESULT 508
 ADR86988

ID
 XX ADR86988 standard; DNA; 21 BP.
 AC
 XX ADR86988;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human ephrinB4 short interference RNA seqid 293.
 KW
 KW cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; short interference RNA; siRNA;
 KW RNA interference; gene silencing; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080425-A2.
 XX
 XX 23-SEP-2004.
 XX
 XX 12-MAR-2004; 2004WO-US007755.
 XX
 XX 12-MAR-2003; 2003US-0454300P.
 PR
 PR 12-MAR-2003; 2003US-0454432P.
 XX
 XX (VASG-) VASGENE THERAPEUTICS INC.
 PA
 XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
 PI WPI; 2004-668883/65.
 DR
 XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.
 XX
 PS Example 8; Page 96; 198pp; English.
 XX
 XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 siRNA that can be used to control EphB4
 CC expression.
 XX
 XX Sequence 21 BP; 7 A; 6 C; 4 G; 0 T; 4 U; 0 Other;
 SQ
 Query Match 0.4%; Score 19; DB 1; Length 21;
 Best Local Similarity 89.5%; Pred. No. 1.4e+02;
 Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 427 GAGACCTGCTGACACAA 445
 DB 1 GAGACCCUGGACACAA 19


```

RESULT 509
ADR82303
ID   ADR82303 standard; RNA; 21 BP.
XX   AC   ADR82303;
XX   DT   16-DEC-2004 (first entry)
XX   DE   Human EphB4 siRNA #5.
XX   KW   human; ss; siRNA; small interference RNA; RNA interference;
XX   KW   gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
XX   KW   inflammatory disorder; chronic articular rheumatism; psoriasis;
XX   KW   ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
XX   KW   antirheumatic; antipsoriatic; dermatological; ophthalmological;
XX   KW   angiogenesis inhibitor.
XX   OS   Homo sapiens.
XX   PN   WO2004080418-A2.
XX   PD   23-SEP-2004.
XX   PF   12-MAR-2004; 2004WO-US007491.
XX   PR   12-MAR-2003; 2003US-0454300P.
XX   PR   12-MAR-2003; 2003US-0454432P.
XX   PA   (VASG-) VASGENE THERAPEUTICS INC.
XX   PI   Reddy R, Gill P;
XX   DR   WPI; 2004-668879/65.
XX   PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX   PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX   PT   useful for diagnosing or treating cancer or angiogenesis-associated
XX   PT   diseases.
XX   PS   Example 5; Page 81; 206pp; English.
XX   CC   The invention relates to an isolated nucleic acid compound comprising at
XX   CC   least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX   CC   physiological conditions and decreases the expression of EphB4 or
XX   CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX   CC   medicament for the treatment of cancer or angiogenesis-associated
XX   CC   diseases. The composition and methods are useful for diagnosing or
XX   CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
XX   CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX   CC   diseases or scleroderma. The present sequence represents a human EphB4
XX   CC   siRNA.
XX   SQ   Sequence 21 BP; 5 A; 3 C; 7 G; 0 T; 6 U; 0 Other;
XX   Query Match      0.4%; Score 19; DB 1; Length 21;
XX   Best Local Similarity 78.9%; Pred. No. 1.4e+02;
XX   Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY   849 GGTGAATGTCAGACGCTG 867
DB   1 GGUGAUGUCCAGACCGUC 19
|||:||||:|||||:|||||
|:|:|:|:|:|:|:|:|:|:|

RESULT 510
ADR82543
ID   ADR82543 standard; RNA; 21 BP.
XX   AC   ADR82543;
XX   DT   16-DEC-2004 (first entry)
XX   DE   Human EphB4 antisense RNAi probe #54.
XX   KW   human; ss; antisense; EphB4; EphrinB2; cancer;
XX   KW   angiogenesis-associated disease; inflammatory disorder;
XX   KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX   KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX   KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX   OS   Homo sapiens.
XX   PN   WO2004080418-A2.

```

```

XX   KW   human; ss; antisense; EphB4; EphrinB2; cancer;
XX   KW   angiogenesis-associated disease; inflammatory disorder;
XX   KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX   KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX   KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX   OS   Homo sapiens.
XX   PN   WO2004080418-A2.
XX   PD   23-SEP-2004.
XX   PF   12-MAR-2004; 2004WO-US007491.
XX   PR   12-MAR-2003; 2003US-0454300P.
XX   PR   12-MAR-2003; 2003US-0454432P.
XX   PA   (VASG-) VASGENE THERAPEUTICS INC.
XX   PI   Reddy R, Gill P;
XX   DR   WPI; 2004-668879/65.
XX   PT   New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX   PT   transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX   PT   useful for diagnosing or treating cancer or angiogenesis-associated
XX   PT   diseases.
XX   PS   Example 8; Page 103; 206pp; English.
XX   CC   The invention relates to an isolated nucleic acid compound comprising at
XX   CC   least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX   CC   physiological conditions and decreases the expression of EphB4 or
XX   CC   EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX   CC   medicament for the treatment of cancer or angiogenesis-associated
XX   CC   diseases. The composition and methods are useful for diagnosing or
XX   CC   treating cancer or angiogenesis-associated diseases, such as inflammatory
XX   CC   disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX   CC   diseases or scleroderma. The present sequence represents a human EphB4
XX   CC   antisense RNAi probe.
XX   SQ   Sequence 21 BP; 7 A; 6 C; 4 G; 0 T; 4 U; 0 Other;
XX   Query Match      0.4%; Score 19; DB 1; Length 21;
XX   Best Local Similarity 89.5%; Pred. No. 1.4e+02;
XX   Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY   427 GAGACCCCTGCTGACACAA 445
DB   1 GAGACCCGUCGACACAA 19
|||||:|:|:|:|:|:|
|:|:|:|:|:|:|:|

RESULT 511
ADR82544
ID   ADR82544 standard; RNA; 21 BP.
XX   AC   ADR82544;
XX   DT   16-DEC-2004 (first entry)
XX   DE   Human EphB4 antisense RNAi probe #55.
XX   KW   human; ss; antisense; EphB4; EphrinB2; cancer;
XX   KW   angiogenesis-associated disease; inflammatory disorder;
XX   KW   chronic articular rheumatism; psoriasis; ocular angiogenic disease;
XX   KW   scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
XX   KW   dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX   OS   Homo sapiens.
XX   PN   WO2004080418-A2.

```


CC The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC siRNA.

XX
SQ Sequence 21 BP; 7 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.4e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 427 GAGACCCCTGCTGAACACAA 445
|||||:|:|:|:|:|:|
DB 1 GAGACCCUGUGACACAA 19

RESULT 514

ADR82326

ID ADR82326 standard; RNA; 21 BP.

XX ADR82326;

DT 16-DEC-2004 (first entry)

DE Human EphB4 siRNA #11.

XX human; ss; siRNA; small interference RNA; RNA interference;
KW gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW inflammatory disorder; chronic articular rheumatism; psoriasis;
KW ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW angiogenesis inhibitor.

OS Homo sapiens.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX Example 6; Page 96; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC siRNA.

XX
SQ Sequence 21 BP; 7 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.4e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 427 GAGACCCCTGCTGAACACAA 445
|||||:|:|:|:|:|:|
DB 1 GAGACCCUGUGACACAA 19

RESULT 515

ADR82295

ID ADR82295 standard; DNA; 21 BP.

XX ADR82295;

XX 16-DEC-2004 (first entry)

XX Human beta-actin RT-PCR primer #1.

XX human; ss; RT-PCR; primer; beta-actin; reverse transcriptase; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor.

OS Homo sapiens.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX Example 3; Page 69; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human beta-
CC actin reverse transcriptase (RT)-PCR primer.

XX Sequence 21 BP; 3 A; 10 C; 1 G; 0 T; 7 U; 0 Other;

Query Match 0.4%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.4e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2679 CTCCTCCGATCCACCTAC 2697
|:|:|:|:|:|:|:|:|:|:|:|:|
DB 1 CUCUCCGACUCCACCTAC 19

```

RESULT 516
ADR82294
ID ADR82294 standard; RNA; 21 BP.
XX AC ADR82294;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 siRNA #1.
XX KW human; ss; siRNA; small interference RNA; RNA interference;
KW gene silencing; EphB4; EphrinB2; cancer; angiogenesis-associated disease;
KW inflammatory disorder; chronic articular rheumatism; psoriasis;
KW ocular angiogenic disease; scleroderma; cytostatic; antiinflammatory;
KW antirheumatic; antipsoriatic; dermatological; ophthalmological;
KW angiogenesis inhibitor.
XX OS Homo sapiens.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX DR WPI; 2004-668879/65.
XX PF New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX PS Example 3; Page 68; 206pp; English.
XX CC The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX siRNA.
XX SQ Sequence 21 BP; 5 A; 3 C; 7 G; 0 T; 6 U; 0 Other;
XX Query Match 0.4%; Score 19; DB 1; Length 21;
XX Best Local Similarity 78.9%; Pred. No. 1.4e+02;
XX Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
XX QY 849 GGTGAATGTCAGACGCTG 867
XX DB 1 GGUGAUGUCAGACGUG 19
XX DE Human EphB4 antisense RNAi probe #57.

RESULT 517
ADR82546
ID ADR82546 standard; RNA; 21 BP.
XX AC ADR82546;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense RNAi probe #57.

```

```

XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX OS Homo sapiens.
XX PN WO2004080418-A2.
XX PD 23-SEP-2004.
XX PF 12-MAR-2004; 2004WO-US007491.
XX PR 12-MAR-2003; 2003US-0454300P.
XX PR 12-MAR-2003; 2003US-0454432P.
XX PA (VASG-) VASGENE THERAPEUTICS INC.
XX PI Reddy R, Gill P;
XX DR WPI; 2004-668879/65.
XX PF New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.
XX PS Example 8; Page 103; 206pp; English.
XX CC The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense RNAi probe.
XX SQ Sequence 21 BP; 3 A; 10 C; 1 G; 0 T; 7 U; 0 Other;
XX Query Match 0.4%; Score 19; DB 1; Length 21;
XX Best Local Similarity 73.7%; Pred. No. 1.4e+02;
XX Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
XX QY 2679 CTCTCCGATCCACCCTAC 2697
XX DB 1 CUCUUCGUAUCCACCUCAC 19
XX DE Human EphB4 antisense RNAi probe #58.

RESULT 518
ADR82547
ID ADR82547 standard; RNA; 21 BP.
XX AC ADR82547;
XX DT 16-DEC-2004 (first entry)
XX DE Human EphB4 antisense RNAi probe #58.
XX KW human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX OS Homo sapiens.
XX PN WO2004080418-A2.
XX

```


CC footprint region, amplifying the Y target sequences with the primer set
CC and detecting at least one of the footprint regions with the assay probe.
CC The method of the invention may be useful for characterising a cytochrome
CC p450 allele. The current sequence is that of a debriisoquine 4-hydroxylase
CC (cytochrome p450 2D6; CYP2D6)-related PCR primer of the invention.
XX

SQ Sequence 22 BP; 7 A; 2 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3716 GGGGCAAGAGGGGTGTTCAGGG 3737

Db 1 GAGGCAAGAGGAGTGTTCAGGG 22

RESULT 521

ADJ14787

ID ADJ14787 standard; DNA; 22 BP.

XX

AC ADJ14787;

XX 20-MAY-2004 (first entry)

XX Debrisoquine 4-hydroxylase (CYP2D6)-related PCR primer 19.

XX SNP; single nucleotide polymorphism; cytochrome p450; CYP allele;
KW debriisoquine 4-hydroxylase; 2D6; CYP2D6; human; ss; PCR; primer.
XX

OS Unidentified.

XX US2003235848-A1.

XX 25-DEC-2003.

XX 11-APR-2003; 2003US-00411954.

XX 11-APR-2002; 2002US-0371819P.

XX (NEVI/) NEVILLE M.

PA (INDI/) INDIG M D A.

XX Neville M, Indig MDA;

PI WPI; 2004-070577/07.

DR Characterizing a cytochrome p450 allele by amplifying Y target sequences
XX with the primer set and detecting at least one of the footprint regions
XX with the assay probe.

PS Example 1; Fig 5A; 55pp; English.

XX The invention relates to a novel method for characterising a cytochrome
XX p450 (CYP) allele (or single nucleotide polymorphism [SNP]) which
XX comprises providing a sample with at least Y target sequences, a primer
XX set comprising a forward and a reverse primer sequence for each of the Y
XX target sequences and at least one assay probe configured to detect a
XX footprint region, amplifying the Y target sequences with the primer set
XX and detecting at least one of the footprint regions with the assay probe.
XX The method of the invention may be useful for characterising a cytochrome
XX p450 allele. The current sequence is that of a debriisoquine 4-hydroxylase
XX (cytochrome p450 2D6; CYP2D6)-related PCR primer of the invention.

SQ Sequence 22 BP; 7 A; 2 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 18.8; DB 1; Length 22;

Best Local Similarity 90.9%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3716 GGGGCAAGAGGGGTGTTCAGGG 3737

Db 1 GAGGCAAGAGGAGTGTTCAGGG 22

RESULT 522

ADO60807

ID ADO60807 standard; DNA; 22 BP.

XX ADO60807;

AC ADO60807;

XX 12-AUG-2004 (first entry)

XX Human debriisoquine 4-hydroxylase, CYP2D6 PCR primer #5.

XX oligonucleotide detection assay; debriisoquine 4-hydroxylase; CYP2D6;
KW cytochrome p450; human; ss; PCR; primer.
XX

XX Homo sapiens.

XX US2004096874-A1.

XX 20-MAY-2004.

XX 10-JUL-2003; 2003US-00617070.

XX 11-APR-2002; 2002US-0371819P.

PR 11-APR-2003; 2003US-00411954.

XX (THIR-) THIRD WAVE TECHNOLOGIES INC.

XX Neville M, Indig MDA, Cao F, Oldenburg MC, Koelbl JA;
PI Aizenstein BD, Davey K;

XX WPI; 2004-447680/42.

XX New kit comprising an oligonucleotide detection assay for detecting the
XX number of CYP2D6 gene copies in a sample and for identifying CYP2D6
XX associated polymorphisms.

PS Example 1; SEQ ID NO 268; 172pp; English.

XX The invention relates to a kit which comprises an oligonucleotide
XX detection assay configured for detecting the number of debriisoquine 4-
XX hydroxylase, CYP2D6, gene copies present in a sample and configured to
XX identify the presence or absence of at least two CYP2D6 associated
XX polymorphisms. The kit and methods are useful for characterising
XX cytochrome p450 genes and alleles or for developing and optimising
XX nucleic acid detection assays for use in basic research, clinical
XX research and for the development of clinical detection assays. The
XX present sequence represents a human debriisoquine 4-hydroxylase, CYP2D6
XX PCR primer.

SQ Sequence 22 BP; 7 A; 2 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 18.8; DB 1; Length 22;

Best Local Similarity 90.9%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3716 GGGGCAAGAGGGGTGTTCAGGG 3737

Db 1 GAGGCAAGAGGAGTGTTCAGGG 22

RESULT 523

ADO60878

ID ADO60878 standard; DNA; 22 BP.

XX ADO60878;

AC ADO60878;

XX 12-AUG-2004 (first entry)

XX Human debriisoquine 4-hydroxylase, CYP2D6 associated oligonucleotide #7.
DE oligonucleotide detection assay; debriisoquine 4-hydroxylase; CYP2D6;
KW cytochrome p450; human; ss.

XX OS Homo sapiens.
 XX PN US2004096874-A1.
 XX PD 20-MAY-2004.
 XX PF 10-JUL-2003; 2003US-00617070.
 XX PR 11-APR-2002; 2002US-0371819P.
 XX PR 11-APR-2003; 2003US-00411954.
 XX PA (THIR-) THIRD WAVE TECHNOLOGIES INC.
 XX PI Neville M, Indig MDA, Cao F, Oldenburg MC, Koelbl JA;
 XX PI Aizenstein BD, Davey K;
 XX DR WPI; 2004-447680/42.
 XX PT New kit comprising an oligonucleotide detection assay for detecting the
 PT number of CYP2D6 gene copies in a sample and for identifying CYP2D6
 PT associated polymorphisms.
 XX PS Disclosure; SEQ ID NO 339; 172pp; English.
 XX CC The invention relates to a kit which comprises an oligonucleotide
 CC detection assay configured for detecting the number of debrisoquine 4-
 CC hydroxylase, CYP2D6, gene copies present in a sample and configured to
 CC identify the presence or absence of at least two CYP2D6 associated
 CC polymorphisms. The kit and methods are useful for characterising
 CC cytochrome p450 genes and alleles or for developing and optimising
 CC nucleic acid detection assays for use in basic research, clinical
 CC research and for the development of clinical detection assays. The
 CC present sequence represents a human debrisoquine 4-hydroxylase, CYP2D6
 CC associated oligonucleotide.
 XX SQ Sequence 22 BP; 7 A; 2 C; 11 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 18.8; DB 1; Length 22;
 Best Local Similarity 90.9%; Pred. No. 1.7e+02;
 Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3716 GGGGCAAGAGGGGTGTCTCAGGG 3737
 Db 1 GAGGCAAGAGGAGTGTCTCAGGG 22
 RESULT 524
 ADZ71126
 ID ADZ71126 standard; DNA; 22 BP.
 XX AC ADZ71126;
 XX DT 14-JUL-2005 (first entry)
 XX DE Human CYP2D6 gene-specific PCR primer - SEQ ID 9.
 XX KW diabetic retinopathy; antidiabetic; ophthalmological; hepatotoxicity;
 KW CYP2D6; PCR; primer; ss.
 XX OS Homo sapiens.
 XX PN WO2005040415-A1.
 XX PD 06-MAY-2005.
 XX PF 05-OCT-2004; 2004WO-EP011123.
 XX PR 06-OCT-2003; 2003US-0508972P.
 XX PA (NOVS) NOVARTIS AG.
 XX PA (NOVS) NOVARTIS PHARMA GMBH.
 XX

PI McCullough K, Wolfgang CD;
 XX WPI; 2005-346738/35.
 XX PT Use of N-benzoyl-staurosporine in manufacture of medicament for treatment
 PT of diabetic retinopathy with reduced hepatotoxicity in patients selected
 PT based on genotype of patients at IL1A genetic locus predictive of
 PT hepatotoxicity.
 XX PS Example; SEQ ID NO 9; 55pp; English.
 XX CC The invention comprises a method of using N-benzoyl-staurosporine in the
 CC manufacture of a medicament for the treatment of diabetic retinopathy
 CC with reduced hepatotoxicity in a selected patient population. The patient
 CC population is selected on the basis of the genotype of the patients at a
 CC genetic locus within the IL1A gene - the IL1A genetic locus is predictive
 CC of hepatotoxicity. The method of the invention is useful in the
 CC manufacture of a medicament for the treatment of diabetic retinopathy
 CC with reduced hepatotoxicity in a selected patient population. The present
 CC DNA sequence represents a PCR primer that was used to amplify exons 7, 8
 CC and 9 of the human CYP2D6 gene.
 XX SQ Sequence 22 BP; 7 A; 2 C; 11 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 18.8; DB 1; Length 22;
 Best Local Similarity 90.9%; Pred. No. 1.7e+02;
 Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3716 GGGGCAAGAGGGGTGTCTCAGGG 3737
 Db 1 GAGGCAAGAGGAGTGTCTCAGGG 22
 RESULT 525
 ADY89206
 ID ADY89206 standard; RNA; 23 BP.
 XX AC ADY89206;
 XX DT 16-JUN-2005 (first entry)
 XX DE VEGF/VEGFR siRNA SEQ ID NO 2242.
 XX KW ss; siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
 KW pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
 XX OS Synthetic.
 XX PN WO2005028649-A1.
 XX PD 31-MAR-2005.
 XX PF 16-SEP-2004; 2004WO-US030488.
 XX PR 16-SEP-2003; 2003US-00664767.
 PR 16-SEP-2003; 2003US-00665255.
 PR 23-SEP-2003; 2003US-00670011.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 26-JAN-2004; 2004US-00764957.
 PR 10-FEB-2004; 2004US-053480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 16-APR-2004; 2004US-00826966.
 PR 23-APR-2004; 2004US-00831620.
 PR 30-APR-2004; 2004US-00013456.
 PR 11-MAY-2004; 2004US-00844076.
 XX PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
 XX

DR WPI; 2005-254128/26.
XX New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
XX Disclosure; SEQ ID NO 2242; 396pp; English.
XX
XX The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGF/VEGFR siRNA.
XX
SQ Sequence 23 BP; 5 A; 6 C; 7 G; 0 T; 5 U; 0 Other;
Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 68.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
Qy 2927 AGCTCATGCTGGACTGTTGGCA 2948
|| :||:||||:| :|||
Db 1 AGAUCAGUCGACUGCUGGCA 22
RESULT 526
ADY89196
ID ADY89196 standard; RNA; 23 BP.
XX
AC ADY89196;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGF/VEGFR siRNA SEQ ID NO 2232.
XX
KW ss: siRNA; short interfering RNA; RNA interference; gene silencing; VEGF;
KW pharmaceutical; cancer; neoplasm; Cytostatic; VEGFR.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (STRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
PI
XX WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.

XX Disclosure; SEQ ID NO 2232; 396pp; English.
XX
XX The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGF/VEGFR siRNA.
XX
SQ Sequence 23 BP; 4 A; 6 C; 7 G; 0 T; 6 U; 0 Other;
Query Match 0.4%; Score 18.8; DB 1; Length 23;
Best Local Similarity 68.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
Qy 2926 CAGCTCATGCTGGACTGTTGGC 2947
|| :||:||||:| :|||
Db 2 CAGAUCAGUCGACUGCUGGCA 23
RESULT 527
ADY50241
ID ADY50241 standard; DNA; 23 BP.
XX
AC ADY50241;
XX
DT 05-MAY-2005 (first entry)
XX
DE Human beta-globin PCR primer SEQ ID NO 7.
XX
KW DNA purification; elution; beta-globin; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2005007852-A2.
XX
PD 27-JAN-2005.
XX
PF 09-JUL-2004; 2004WO-US022391.
XX
PR 09-JUL-2003; 2003US-0485972P.
XX
PA (GENV-) GENVAULT CORP.
XX
PI Davis JC, Hogan M;
XX
DR WPI; 2005-112868/12.
XX
PT Eluting nucleic acid from nucleic acid-containing sample e.g., human
PT blood sample on storage media, by contacting sample on storage media with
PT elution buffer, eluting nucleic acid from sample and recovering eluted
PT nucleic acid.
XX
PS Example 1; SEQ ID NO 7; 54pp; English.
XX
XX The invention describes a method of eluting nucleic acid from a nucleic
CC acid-containing sample e.g., human blood sample on storage media. The
CC method involves providing a nucleic acid containing sample, preferably
CC human blood sample on storage media, contacting the sample on storage
CC media with an elution buffer comprising 10 mM Tris having a pH of 11.0-
CC 12.0, preferably 11.5-11.7, eluting nucleic acid from the sample on
CC storage media, and recovering eluted nucleic acid, where the human blood
CC sample is contacted with a wash buffer which is then removed before being
CC contacted with the elution buffer. Also described is a kit (I) for
CC eluting nucleic acid from a nucleic acid containing sample on storage
CC media, comprising an elution buffer having a pH of 11.0-12.0 and
CC instruction unit for eluting nucleic acid from a sample on storage media.
CC (M1) is useful for eluting nucleic acid such as DNA or RNA from a nucleic
CC acid-containing sample, preferably a human blood sample on storage media.
CC (M1) and (I) are useful for optimizing nucleic acid recovery depending on
CC the sample storage media and the intended use. The DNA eluted by (M1) is
CC useful for numerous downstream applications including PCR based

CC applications, short tandem repeat (STR) marker analysis, single
 CC nucleotide polymorphism (SNP) analysis and whole genome amplification
 CC (WGA). (M1) is simple, inexpensive and can be performed rapidly (30-60
 CC minutes). (M1) provides high quality DNA that can be used in various
 CC applications. (M1) avoids the use of toxic materials and is automaton-
 CC compatible. This sequence represents a primer used to detect beta-globin
 CC from blood samples.

XX Sequence 23 BP; 7 A; 4 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 18.4; DB 1; Length 23;
 Best Local Similarity 95.0%; Pred. No. 2e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3720 CAAGAAGGGGTGTCAGGGCC 3739

Db 1 CAAGAAGGGGTGTCAGGGCC 20

RESULT 528
 ADR86930/C
 ID ADR86930 standard; DNA; 18 BP.
 AC ADR86930;

DT 16-DEC-2004 (first entry)

DE Human ephrin B4 antisense oligonucleotide seqid 235.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 8; Page 94; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for

CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX Sequence 18 BP; 3 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 692 CCTGCAGGAGACCTTCA 709

Db 18 CCTGCAGGAGACCTTCA 1

RESULT 529
 ADR86749/C

ID ADR86749 standard; DNA; 18 BP.

XX ADR86749;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 54.

XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 5; Page 79; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist

CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 499 TGGGAGGAAGTGGCGGC 516
 Db 18 TGGGAGGAAGTGGCGGC 1
 |||||

RESULT 530
 ADR86750/C
 ID ADR86750 standard; DNA; 18 BP.

XX ADR86750;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 55.

XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 5; Page 79; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular

CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a human ephrin B4 antisense oligonucleotide that can be used
 CC to control EphB4 expression.

XX Sequence 18 BP; 3 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

XX Query Match 0.4%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 692 CCTGCAAGGAGACCTTCA 709
 Db 18 CCTGCAAGGAGACCTTCA 1
 |||||

RESULT 531

ADR86929/C

ID ADR86929 standard; DNA; 18 BP.

XX ADR86929;

XX 16-DEC-2004 (first entry)

XX Human ephrin B4 antisense oligonucleotide seqid 234.

XX cytotatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
 KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
 KW angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; human; ephrin B4; antisense technology;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.

XX WO2004080425-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007755.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;

XX WPI; 2004-668883/65.

XX New soluble polypeptides comprising an extracellular domain of EphB4 or
 PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
 PT associated diseases, such as inflammatory disorders, psoriasis or
 PT scleroderma.

XX Example 8; Page 94; 198pp; English.

XX The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4

CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC EphrinB2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B4 antisense oligonucleotide that can be used
CC to control EphB4 expression.

XX Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 499 TGGGAGGAAGTGGAGCGC 516
|||
DB 18 TGGGAGGAAGTGGAGCGC 1

RESULT 532

ADR82314/c

ID ADR82314 standard; DNA; 18 BP.

XX ADR82314;

XX 16-DEC-2004 (first entry)

XX Human EphB4 antisense ODN #8.

XX human; ss; antisense; EphB4; EphrinB2; cancer;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; angiogenesis inhibitor.

XX Homo sapiens.

OS Synthetic.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.

XX Example 5; Page 85; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at

CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense oligodeoxynucleotide (ODN).

XX Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 1.5e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 499 TGGGAGGAAGTGGAGCGC 516

|||
DB 18 TGGGAGGAAGTGGAGCGC 1

RESULT 533

ADR82484/c

ID ADR82484 standard; DNA; 18 BP.

XX ADR82484;

XX 16-DEC-2004 (first entry)

XX Human EphB4 antisense probe #155.

XX human; ss; antisense; EphB4; EphrinB2; cancer;

KW angiogenesis-associated disease; inflammatory disorder;

KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;

KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;

KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX Homo sapiens.

OS Synthetic.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
XX transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
XX useful for diagnosing or treating cancer or angiogenesis-associated
XX diseases.

XX Example 8; Page 101; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at
XX least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
XX physiological conditions and decreases the expression of EphB4 or
XX EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
XX medicament for the treatment of cancer or angiogenesis-associated
XX diseases. The composition and methods are useful for diagnosing or
XX treating cancer or angiogenesis-associated diseases, such as inflammatory
XX disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
XX diseases or scleroderma. The present sequence represents a human EphB4
XX antisense probe.

SQ Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 499 TGGGAGGAACCTGAGCGGC 516
|||||
Db 18 TGGGAGGAACCTGAGCGGC 1

RESULT 534
ADR82315/c

ID ADR82315 standard; DNA; 18 BP.

XX ADR82315;

XX 16-DEC-2004 (first entry)

XX Human EphB4 antisense ODN #9.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor.

XX Homo sapiens.
OS Synthetic.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX Example 5; Page 85; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense oligodeoxynucleotide (ODN).

SQ Sequence 18 BP; 3 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 692 CCTGCAAGGAGACCTTCA 709
|||||
Db 18 CCTGCAAGGAGACCTTCA 1

RESULT 535
ADR82485/c

ID ADR82485 standard; DNA; 18 BP.

XX ADR82485;

XX 16-DEC-2004 (first entry)

XX Human EphB4 antisense probe #156.

XX human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe.

XX Homo sapiens.
OS Synthetic.

XX WO2004080418-A2.

XX 23-SEP-2004.

XX 12-MAR-2004; 2004WO-US007491.

XX 12-MAR-2003; 2003US-0454300P.

XX 12-MAR-2003; 2003US-0454432P.

XX (VASG-) VASGENE THERAPEUTICS INC.

XX Reddy R, Gill P;

XX WPI; 2004-668879/65.

XX New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

XX Example 8; Page 101; 206pp; English.

XX The invention relates to an isolated nucleic acid compound comprising at
CC least a portion that hybridizes to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphB4
CC antisense probe.

SQ Sequence 18 BP; 3 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 692 CCTGCAAGGAGACCTTCA 709
|||||
Db 18 CCTGCAAGGAGACCTTCA 1

RESULT 536
ADC16452/c

ID ADC16452 standard; RNA; 22 BP.

XX ADC16452;

XX 18-DEC-2003 (first entry)

XX Short interfering double-stranded RNA oligonucleotide SEQ ID NO:177.

XX expression interference; expression inhibition; target gene;
 KW short interfering double stranded RNA; cytosstatic; gene therapy;
 KW proliferative disease; cancer; ds.
 XX Synthetic.
 OS
 XX WO2003012052-A2.
 FN
 XX 13-FEB-2003.
 XX
 PD 30-JUL-2002; 2002WO-US024226.
 XX
 PF 30-JUL-2001; 2001US-0308640P.
 XX
 PR 08-APR-2002; 2002US-0370970P.
 XX
 XX (USSH) US DEPT HEALTH & HUMAN SERVICES.
 PA (CARN-) CARNEGIE INST WASHINGTON.
 PA (IMCO-) IMPERIAL COLLEGE INNOVATIONS LTD.
 XX
 XX Caplen NJ, Morgan RA, Fire A, Parrish S, Mousses S;
 PI Kallioniemi O, Cornelson JR, Alton EW, Griesenbach U;
 PI WPI; 2003-248169/24.
 XX
 DR New RNA comprising double stranded RNA and a 3' or 5' overhang having a
 XX length of 0-nucleotide to 5-nucleotides on each strand, useful as reverse
 PT genetic and/or therapeutic tools for interfering or inhibiting expression
 PT of a target gene.
 PT
 XX
 XX Claim 71; SEQ ID NO 177; 176pp; English.
 PS
 XX The present invention describes an RNA (I) used for the interference or
 CC inhibition of expression of a target gene, where (I) comprises double
 CC stranded RNA of 15-40 nucleotides in length and a 3' or 5' overhang
 CC having a length of 0-nucleotide to 5-nucleotides on each strand, where
 CC the sequence of the double stranded RNA is substantially identical to a
 CC portion of a mRNA or transcript of the target gene. Also described: (1)
 CC interfering with or inhibiting the expression of a target gene in a cell
 CC by exposing the cell to an amount of (I); (2) a gene silencing array
 CC comprising a substantially flat substrate, and addressably arrayed
 CC different double-stranded RNAs; (3) an array-based method of assessing a
 CC phenotypic effect of a double-stranded RNA on a target gene; (4)
 CC validating a gene as a potential drug target for a disease or condition;
 CC (5) selecting an optimised sequence of a double-stranded RNA for
 CC interference with or inhibition of expression of a target gene in a cell;
 CC and (6) a short double-stranded RNA effective for interfering with or
 CC inhibiting expression of a target gene comprising any of 311-20-78
 CC nucleotide sequences (see ADC16276 to ADC16586). (I) has cytostatic
 CC activity, and can be used in gene therapy. The RNAs are useful as reverse
 CC genetic and/or therapeutic tools for interfering or inhibiting expression
 CC of a target gene. They are useful for treating proliferative diseases,
 CC e.g. cancer.
 XX
 XX Sequence 22 BP; 3 A; 6 C; 6 G; 0 T; 7 U; 0 Other;
 SQ
 Query Match 0.4%; Score 18; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 516 CCTGGATGAGGACGCA 533
 DB 21 CCTGGATGAGGACGCA 4
 RESULT 537
 ADJ78587
 ID ADJ78587 standard; DNA; 21 BP.
 XX
 AC ADJ78587;
 XX
 DT 06-MAY-2004 (first entry)
 XX

DE Human cytochrome P450 isoenzyme 2D6 PCR primer SeqID25.
 XX
 KW primer set; variant identification; cytochrome P450 isoenzyme 2D6;
 KW CYP2D6; chromosome 22q13.1; single nucleotide polymorphism; SNP;
 KW low frequency variant; pharmaceutical drugs metabolism; human; PCR;
 KW primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004009760-A2.
 XX
 PD 29-JAN-2004.
 XX
 PF 09-JUL-2003; 2003WO-US021468.
 XX
 PR 18-JUL-2002; 2002US-0397010P.
 XX
 XX (BIOV-) BIOVENTURES INC.
 PA
 XX Dawson EP;
 PI
 XX WPI; 2004-132938/13.
 XX
 DR New primer set useful for screening a polynucleotide sample to detect and
 XX identify variants in the cytochrome P450 isoenzyme 2D6 gene, and for
 PT detecting low frequency variants affecting pharmaceutical drugs
 PT metabolism.
 PT
 XX Claim 1; SEQ ID NO 25; 51pp; English.
 PS
 XX This invention relates to novel primer sets that can be used to screen a
 CC polynucleotide sample to detect and identify variants in the cytochrome
 CC P450 isoenzyme 2D6 (CYP2D6) gene. The gene is located on chromosome
 CC 22q13.1 and contains several single nucleotide polymorphisms, the details
 CC of which are disclosed in the specification. The methods and compositions
 CC of the present invention are useful for screening a polynucleotide sample
 CC to detect and identify variants in the cytochrome P450 isoenzyme 2D6 gene
 CC and detecting low frequency variants affecting pharmaceutical drugs
 CC metabolism. The present sequence is that of a PCR primer which may be
 CC used in the primer sets of the invention.
 XX
 XX Sequence 21 BP; 7 A; 2 C; 10 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 2.1e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3715 GGGGGCAAGAGGGGTGTCTAG 3735
 DB 1 GGAGGCAAGAGGAGTGTCTAG 21
 RESULT 538
 ADM28915
 ID ADM28915 standard; DNA; 21 BP.
 XX
 AC ADM28915;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE PCR primer #1 for human CYP2D6 gene exon 7-9.
 XX
 KW Human; cytochrome P450 isoenzyme 2D6; CYP2D6 isoenzyme;
 KW altered metabolism; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2004072235-A1.
 XX
 PD 15-APR-2004.
 XX
 PF 12-NOV-2003; 2003US-00712363.
 XX

PR 20-JUL-2001; 2001US-0306675P.
 PR 18-JUL-2002; 2002US-00360790.
 PR 09-JUL-2003; 2003WO-US021468.
 XX (DAWS/) DAWSON E P.
 PA Dawson EP;
 PI WPI; 2004-328568/30.
 DR Novel primer set for screening a polynucleotide sample to detect and
 XX identify variants in the cytochrome P450 isoenzyme 2D6 (CYP2D6) gene in a
 PT polynucleotide sample or a population.
 PT Claim 1; SEQ ID NO 25; 47pp; English.
 PS The present invention relates to a primer set that can be used to screen
 XX a polynucleotide sample to detect and identify variants in the human
 CC cytochrome P450 isoenzyme 2D6 (CYP2D6) gene. Also disclosed is a kit for
 CC the above screening method, a method for predicting the potential for
 CC altered metabolism of a substance, including one or more than one
 CC pharmaceutical drug, by a first individual compared to a second control
 CC individual, where the substance is metabolized by the CYP2D6 isoenzyme, a
 CC purified or isolated variant of wild-type CYP2D6 isoenzyme having one or
 CC more than one of the alterations chosen from F-I at position 120, F-F at
 CC position 120, E-K at position 155, R-R at position 194, F-F at position
 CC 219, L-L at position 276, H-H at position 324, R-STOP at position 344, Y-
 CC C at position 355, H-H at position 361, V-FRAMESHIFT at position 363, E-K
 CC at position 418, H-Y at position 478 and F-F at position 483. The primer
 CC set is useful for screening a polynucleotide sample to detect and
 CC identify the presence of one or more than one variant in the CYP2D6 gene
 CC in the sample. The primer set permits amplification from a small
 CC polynucleotide sample of selected portions of the coding portion of the
 CC CYP2D6 gene, or amplification of the entire coding portion of CYP2D6, as
 CC well as the flanking intronic sequences that are relevant to recognition
 CC of splice sites. The primer set further permits the detection of genetic
 CC variants of CYP2D6 without interference from pseudogenes or from
 CC homologous or paralogous genes of non-CYP2D6 cytochrome p450 genes. The
 CC primer set also permits the detection of low frequency variants that
 CC affect pharmaceutical drugs metabolism, thereby decreasing the false
 CC negative rate in variant screening. The present sequence represents a PCR
 CC primer of the invention.
 XX Sequence 21 BP; 7 A; 2 C; 10 G; 2 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 2.1e-02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 3715 GGGGGCAGAGGGGTCTCAG 3735
 Db 1 GGGGGCAGAGGGGTCTCAG 21
 RESULT 539
 ADS00674/C
 ID ADS00674 standard; DNA; 21 BP.
 XX ADS00674;
 AC ADS00674;
 DT 16-DEC-2004 (first entry)
 XX Nested PCR primer SAVI#9.
 DE PCR; ss; RNA transcription profile; exon marker; reverse transcription;
 KW Type IIS restriction enzyme; exon tag; viral vector;
 KW green fluorescent protein; SAVI; Serial analysis of vector integration;
 KW functional genome annotation; high throughput sequencing;
 KW exon-intron boundary; primer.
 OS Unidentified.
 XX US2004191873-A1.
 PN

XX 30-SEP-2004.
 XX 26-MAR-2004; 2004US-00810976.
 XX 27-MAR-2003; 2003US-0458152P.
 XX (YOUNG/) YOUNG W.
 XX (LINK/) LINK C J.
 XX Young W, Link CJ;
 XX WPI; 2004-698722/68.
 XX Elucidating RNA transcription profile in eukaryotic cell by producing
 PT cloned tags using construct having exon marker sequence and comparing
 PT sequence tags to sequence database and identifying RNA transcript
 PT specific to sequenced tags.
 PS Example 2; SEQ ID NO 5; 32pp; English.
 XX The invention relates to elucidating the RNA transcription profile in a
 CC eukaryotic cell by introducing into the cell a polynucleotide construct
 CC comprising an exon marker sequence, subjecting cDNA obtained by reverse
 CC transcription to digestion with a first Type IIS restriction enzyme, self
 CC -ligating the fragments, amplifying a region of the fragment containing
 CC the exon tags, cloning the fragments, and comparing sequence tags to
 CC sequence database. The tags obtained are typically 40 nucleotides in
 CC length compared to 20 nucleotides obtained from prior art methods. Also
 CC included are a polynucleotide construct (comprising, in a 5' to 3'
 CC orientation, a splice acceptor sequence, a type IIS restriction enzyme
 CC recognition site oriented so that it is capable of cleaving DNA fused
 CC upstream of the 5' end of a marker exon, restriction enzyme recognition
 CC site, marker exon, a type IIS restriction enzyme recognition site
 CC oriented so that it is capable of cleaving sequences located downstream
 CC of the 3' end of the marker exon, and splice donor sequence or comprising
 CC a marker exon sequence flanked by a functional 5' splice acceptor
 CC sequences and a 3' splice donor sequence, and where the marker exon
 CC contains at least two RER sites at the 5' end of the marker exon, at
 CC least one the 5' RER sites is recognized by a type IIS restriction enzyme
 CC and oriented in such a way that a type IIS restriction enzyme cuts the
 CC DNA outside the boundaries that define the marker exon, and the marker
 CC exon contains at least two RER sites at the 3' end of the marker exon,
 CC where at least one of the 3' RER sites is recognized by a Type IIS
 CC restriction enzyme and oriented in such a way that a Type IIS restriction
 CC enzyme cuts the DNA outside the boundaries that define the marker exon,
 CC and where the restriction recognition sites are located close from the
 CC border of the marker exon such that after cutting flanking exons generate
 CC sequence tags of at least 8 nucleotides), a vector comprising the above
 CC construct, a polynucleotide construct Pgt13, and a polynucleotide
 CC construct pGfso-M. The method further involves ligating the amplified
 CC fragments together to form a concatamer prior to cloning. In the method,
 CC the polynucleotide construct is contained within a (viral) vector (e.g. a
 CC retroviral vector, a lentiviral vector and an adeno-associated viral
 CC vector, preferably retroviral vector). The marker exon marker sequence
 CC encodes a fluorescent protein, preferably a green fluorescent protein.
 CC The method, referred to as SAVI (Serial analysis of vector (or viral)
 CC integration) is useful for elucidating a RNA transcription profile in a
 CC eukaryotic cell. The method is also useful for functional genome
 CC annotation, high throughput sequencing and characterization of exon-
 CC intron boundaries, and for determining the relative transcriptional level
 CC of tagged RNA variant. The method of the invention was used to analyse
 CC the RNA transcription profile of 107 (unidentified) cells. The present
 CC sequence is a nested PCR primer used to amplify the tags in the above
 CC experiment.
 XX Sequence 21 BP; 3 A; 9 C; 4 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.4%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 2.1e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 2410 CTGGAGGGCGTGTCCACCAAC 2430

Db 21 CTGGAGGGGTGTGACAC 1
 |||||
 RESULT 540
 ADJ14673
 ID ADJ14673 standard; DNA; 19 BP.
 XX AC ADJ14673;
 XX DT 20-MAY-2004 (first entry)
 XX DE Debrisoquine 4-hydroxylase (CYP2D6)-related PCR primer - SEQ ID 236.
 XX SNP; single nucleotide polymorphism; cytochrome p450; CYP allele;
 KW debrisoquine 4-hydroxylase; 2D6; CYP2D6; human; ss; PCR; primer.
 XX OS Unidentified.
 XX PN US2003235848-A1.
 XX PD 25-DEC-2003.
 XX PF 11-APR-2003; 2003US-00411954.
 XX PR 11-APR-2002; 2002US-0371819P.
 XX PA (NEVI/) NEVILLE M.
 XX PI (INDI/) INDIG M D A.
 XX PI Neville M, Indig MDA;
 XX DR WPI; 2004-070577/07.
 XX Characterizing a cytochrome p450 allele by amplifying Y target sequences
 PT with the primer set and detecting at least one of the footprint regions
 PT with the assay probe.
 XX Example 3; SEQ ID NO 236; 55pp; English.
 XX The invention relates to a novel method for characterising a cytochrome
 CC p450 (CYP) allele (or single nucleotide polymorphism [SNP]) which
 CC comprises providing a sample with at least Y target sequences, a primer
 CC set comprising a forward and a reverse primer sequence for each of the Y
 CC target sequences and at least one assay probe configured to detect a
 CC footprint region, amplifying the Y target sequences with the primer set
 CC and detecting at least one of the footprint regions with the assay probe.
 CC The method of the invention may be useful for characterising a cytochrome
 CC p450 allele. The current sequence is that of a debrisoquine 4-hydroxylase
 CC (cytochrome p450 2D6; CYP2D6)-related PCR primer of the invention.
 XX Sequence 19 BP; 6 A; 2 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 2e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3719 GCAAGAAGGGGTGTCTCAGG 3737
 Db 1 GCAAGAAGGGGTGTCTCAGG 19
 |||||
 RESULT 541
 ADO60900
 ID ADO60900 standard; DNA; 19 BP.
 XX AC ADO60900;
 XX DT 12-AUG-2004 (first entry)
 XX DE Human debrisoquine 4-hydroxylase, CYP2D6 associated oligonucleotide #29.
 KW oligonucleotide detection assay; debrisoquine 4-hydroxylase; CYP2D6;
 XX cytochrome p450; human; ss.
 XX OS Homo sapiens.
 XX PN US2004096874-A1.
 XX PD 20-MAY-2004.
 XX PF 10-JUL-2003; 2003US-00617070.
 XX PR 11-APR-2002; 2002US-0371819P.
 XX PR 11-APR-2003; 2003US-00411954.
 XX PA (THIR-) THIRD WAVE TECHNOLOGIES INC.
 KW cytochrome p450; human; ss.
 XX Homo sapiens.
 XX US2004096874-A1.
 XX 20-MAY-2004.
 XX 10-JUL-2003; 2003US-00617070.
 XX 11-APR-2002; 2002US-0371819P.
 XX 11-APR-2003; 2003US-00411954.
 XX (THIR-) THIRD WAVE TECHNOLOGIES INC.

XX Neville M, Indig MDA, Cao F, Oldenburg MC, Koelbl JA;
PI Aizenstein BD, Davey K;
XX WPI; 2004-447680/42.

XX New kit comprising an oligonucleotide detection assay for detecting the
PT number of CYP2D6 gene copies in a sample and for identifying CYP2D6
PT associated polymorphisms.

XX Example 3; SEQ ID NO 236; 172pp; English.

XX The invention relates to a kit which comprises an oligonucleotide
CC detection assay configured for detecting the number of debrisoquine 4-
CC hydroxylase, CYP2D6, gene copies present in a sample and configured to
CC identify the presence or absence of at least two CYP2D6 associated
CC polymorphisms. The kit and methods are useful for characterising
CC cytochrome p450 genes and alleles or for developing and optimising
CC nucleic acid detection assays for use in basic research, clinical
CC research and for the development of clinical detection assays. The
CC present sequence represents a human debrisoquine 4-hydroxylase, CYP2D6
CC oligonucleotide.

XX Sequence 19 BP; 6 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 18; Conservative 0; Mismatches 1;

QY 3719 GCAAGAGGGGTGTCAGGG 3737
|||||||
Db 1 GCAAGAGGAGTGTGTCAGGG 19

RESULT 543

ADT01293/c

ID ADT01293 standard; DNA; 19 BP.

XX ADT01293;

XX 16-DEC-2004 (first entry)

XX Novel mutant protein tyrosine kinase-related oligonucleotide SeqID1281.
XX tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
KW tumorigenesis; somatic alteration; colorectal cancer; NTRK3; FES;
KW GUCY2F; MCKK; MLK4; kinase domain; cytostatic; tyrosine kinase inhibitor;
KW guanylate cyclase stimulator; ss.

XX Homo sapiens.

XX WO2004082458-A2.

XX 30-SEP-2004.

XX 18-FEB-2004; 2004WO-US004452.

XX 21-FEB-2003; 2003US-0448537P.

XX 29-MAY-2003; 2003US-0473895P.

XX (UWJO) UNIV JOHNS HOPKINS.

XX Bardelli A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;

XX WPI; 2004-718702/70.

XX Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCKK) and
PT associated methods for diagnosing cancer and screening for anti-cancer
PT agents.

XX Disclosure; SEQ ID NO 1281; 363pp; English.

XX This invention relates to a novel activated mutant protein tyrosine

CC kinases and associated methods for diagnosing cancer and screening for
CC anti-cancer agents. Protein kinases are signalling molecules involved in
CC tumorigenesis. Mutational analysis of the human tyrosine kinase gene
CC family identified somatic alteration sin 1 in 5 colorectal cancers, with
CC the majority of mutations occurring in the NTRK3, FES, GUCY2F and
CC MCKK/MLK4 genes. Most were identified in the kinase domain. The invention
CC may be useful for the production of compounds with a cytostatic activity
CC acting as protein tyrosine kinase inhibitors or guanylate cyclase
CC stimulators. The invention may be useful for developing methods for
CC detecting mutations involved in cancer or screening for anti-cancer
CC agents. The present sequence is that of a human-derived oligonucleotide
CC which is related to the invention.

XX Sequence 19 BP; 6 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.4; DB 1; Length 19;

Best Local Similarity 94.7%; Pred. No. 2e+02; Indels 0; Gaps 0;

Matches 18; Conservative 0; Mismatches 1;

QY 2928 GCTCATGCTGCTGCTGTTGG 2946

|||||||
Db 19 GCTCATGCTGCTGCTGTTGG 1

RESULT 544

ABL94275

ID ABL94275 standard; DNA; 20 BP.

XX ABL94275;

XX 29-JUL-2002 (first entry)

XX Human C/EBP beta phosphorothioate antisense oligonucleotide, SEQ ID:41.

XX Human; C/EBP beta; CCAAT/enhancer-binding protein beta; C/EBP2; LAP;
KW TCF5; CRP2; NFIL6; IL6DBP; NF-M; AGP/EBP; Apc/EBP; transcription factor;
KW tissue development; cellular function; proliferation; differentiation;
KW hormone responsiveness; oxidative stress response;
KW IL-6 signalling mediator; interleukin-6; carbohydrate metabolism;
KW immunity; Th1 response; female fertility; gluconeogenesis; ovarian;
KW cancer; tumour formation; type II; diabetes; infection; inflammation;
KW expression inhibition; phosphorothioate; antisense oligonucleotide; ss.

XX Homo sapiens.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate linkages"

FT modified_base 1..5

FT /*tag= b

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE

FT cytosines are 5-methylcytosine"

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE

FT cytosines are 5-methylcytosine"

XX US6271030-B1.

XX 07-AUG-2001.

XX 14-JUN-2000; 2000US-00593711.

XX 14-JUN-2000; 2000US-00593711.

XX (ISIS-) ISIS PHARM INC.

XX Monia BP, Butler MM, Wyatt J;

XX

DR WPI; 2002-214451/27.
XX Novel antisense compound targeted to nucleic acids encoding human or
PT mouse CCAAT/enhancer binding protein (C/EBP) beta, useful in vitro for
PT inhibiting expression of human or mouse C/EBP beta in cells/tissues.
XX
PS Claim 1; Col 42; 69pp; English.
XX
XX Sequences ABL94252-ABL94476 represent antisense oligonucleotides targeted
CC to the human or mouse CCAAT/enhancer-binding protein alpha (C/EBP alpha)
CC gene, which inhibit its expression. The antisense oligonucleotides were
CC designed to target different regions of the human and/or mouse C/EBP
CC alpha RNA, and were analysed for their effect on C/EBP alpha mRNA levels
CC by quantitative real-time PCR. The C/EBP family of proteins are a family
CC of transcription factors which regulate the expression of a wide range of
CC genes that control normal tissue development, cellular function, cellular
CC proliferation and functional differentiation. C/EBP beta (also known as
CC C/EBP2, LAP, TCF5, CRP2, NFIL6, IL6DBP, NF-M, AGP/EBP and Apc/EBP)
CC primarily regulates hormone responsiveness and oxidative stress responses
CC and is a mediator of IL-6 (interleukin-6) signalling. C/EBP beta is
CC thought to be involved in carbohydrate metabolism, immunity, the Th1
CC response, female fertility and gluconeogenic pathways. C/EBP beta is
CC expressed in the liver, lung, spleen, kidney, brain, and testis, with the
CC highest expression found in the lung. It is also expressed at a higher
CC level in malignant ovarian tissue compared with normal ovarian tissue.
CC and its expression in pancreas is upregulated in response to chronically
CC elevated levels of glucose, indicating that it is involved in the
CC impairment of insulin secretion in type II diabetes. The oligonucleotides
CC of the invention are useful for diagnosis, prevention and treatment of
CC conditions associated with C/EBP beta expression, such as cancer
CC (particularly ovarian cancer), tumour formation, diabetes (particularly
CC type II diabetes), infection, or inflammation
XX
SQ Sequence 20 BP; 0 A; 12 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 214 GCCGCGCCCGGTGCCCCG 232
|||||||
DB 1 GCCGCGCCCGGTGCCCCG 19

RESULT 545
ADC26603
ID ADC26603 standard; DNA; 20 BP.
AC ADC26603;
XX
DT 18-DEC-2003 (first entry)
XX
DE CYP2D6-specific primer 1 used to identify CYP2D6E7_339 polymorphism.
XX
XX statin response; cytochrome p450 3A4; CYP3A4: 2D6; CYP2D6;
KW 3-hydroxy-3-methylglutaryl-coenzyme A reductase; HMGCR; atorvastatin;
KW simvastatin; serum cholesterol level; heart attack; human; ss; PCR;
KW primer.
XX
XX Homo sapiens.
XX
XX WO2003002721-A2.
PN
XX 09-JAN-2003.
PD
XX 01-JUL-2002; 2002WO-US020847.
PF
XX 29-JUN-2001; 2001US-0301867P.
PR
XX 07-AUG-2001; 2001US-0310783P.
PR
XX 13-SEP-2001; 2001US-0322478P.
XX
XX (DNAP-) DNAPRINT GENOMICS INC.

PI Prudakis T;
XX
DR WPI; 2003-239174/23.
XX
PT Inferring a statin response from a nucleic acid sample, by haplotype
PT allele indicative of statin response, a decrease in total cholesterol, or
PT in low density lipoprotein infers a statin response of the subject.
XX
XX Example 1; SEQ ID NO 13; 323pp; English.
XX
XX The invention relates to a novel method for inferring a statin response
CC from a nucleic acid sample comprising identifying in the nucleic acid
CC sample, at least one haplotype allele indicative of a statin response.
CC The haplotype allele may comprise nucleotides of the cytochrome p450 3A4
CC (CYP3A4) gene, nucleotides of the cytochrome p450 2D6 (CYP2D6) gene or
CC nucleotides of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase
CC (HMGCR) gene. The method of the invention may be useful for inferring a
CC statin response of a human subject from a nucleic acid sample, where the
CC human subject is a Caucasian subject and the statin is atorvastatin or
CC simvastatin. The method may also be useful for determining whether to
CC prescribe statin to a patient with elevated serum cholesterol levels in
CC order to prevent heart attack. The current sequence is that of the PCR
CC primer of the invention which was used to identify the human CYP2D6E7_339
CC polymorphism DNA.
XX
SQ Sequence 20 BP; 7 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3718 GGCAGAGAGGGGTGTCAGG 3736
|||||||
DB 2 GGCAGAGAGGGGTGTCAGG 20

RESULT 546
ADR86762/c
ID ADR86762 standard; DNA; 19 BP.
XX
AC ADR86762;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ephrin B4 RT-PCR primer seqid 67.
XX
XX cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmacological; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B4; reverse transcriptase PCR; primer; ss.
XX
XX Homo sapiens.
XX
XX WO2004080425-A2.
PN
XX 23-SEP-2004.
PD
XX 12-MAR-2004; 2004WO-US007755.
PF
XX 12-MAR-2003; 2003US-0454300P.
PR
XX 12-MAR-2003; 2003US-0454432P.
PR
XX (VASG-) VASGENE THERAPEUTICS INC.
PA
XX Krasnoperov V, Zozulya S, Keretes N, Reddy R, Gill P;
PI WPI; 2004-668983/55.
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or

PT scleroderma.
 PS Example 6; Page 86; 198pp; English.
 XX
 CC The invention describes an isolated soluble polypeptide comprising an
 CC amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2
 CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
 CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
 CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
 CC described are: an antagonist antibody that binds to an extracellular
 CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
 CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
 CC diagnostic kit, comprising the above soluble polypeptide or antagonist
 CC antibody, and a pharmaceutical carrier; methods of inhibiting
 CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
 CC cell; a method of reducing the growth rate of a tumour; methods for
 CC treating a patient suffering from a cancer or an angiogenesis-associated
 CC disease; and a method for identifying a tumor that is suitable for
 CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
 CC antibody is useful for manufacturing a medicament for the treatment of
 CC cancer or an angiogenesis-associated disease. The composition and methods
 CC are useful for diagnosing or treating cancer or angiogenesis-associated
 CC diseases, such as inflammatory disorders, chronic articular rheumatism,
 CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
 CC represents a primer used in the isolation of human ephrin B4 cDNA.
 XX
 SQ Sequence 19 BP; 4 A; 7 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 17; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1955 AACTGGATGAGCGGAG 1971
 DB 19 AACTGGATGAGCGGAG 3
 RESULT 547
 ADR82668/C
 ID ADR82668 standard; DNA; 19 BP.
 AC ADR82668;
 XX
 XX 16-DEC-2004 (first entry)
 DT
 XX Human EphB4 RT-PCR primer #4.
 DE
 XX human; ss; RT-PCR; primer; reverse transcriptase; EphB4; EphrinB2;
 KW cancer; angiogenesis-associated disease; inflammatory disorder;
 KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
 KW scleroderma; cytostatic; antiinflammatory; antirheumatic; antipsoriatic;
 KW dermatological; ophthalmological; angiogenesis inhibitor.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080418-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 12-MAR-2004; 2004WO-US007491.
 XX
 PR 12-MAR-2003; 2003US-0454300P.
 PR 12-MAR-2003; 2003US-04544332P.
 XX
 PA (VASG-) VASGENE THERAPEUTICS INC.
 XX
 PI Reddy R, Gill P;
 XX
 DR WPI; 2004-668879/65.
 XX
 PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
 PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
 PT useful for diagnosing or treating cancer or angiogenesis-associated

PT diseases.
 XX Example 6; Page 93; 206pp; English.
 XX
 CC The invention relates to an isolated nucleic acid compound comprising at
 CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
 CC physiological conditions and decreases the expression of EphB4 or
 CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
 CC medicament for the treatment of cancer or angiogenesis-associated
 CC diseases. The composition and methods are useful for diagnosing or
 CC treating cancer or angiogenesis-associated diseases, such as inflammatory
 CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
 CC diseases or scleroderma. The present sequence represents a human EphB4
 CC reverse transcriptase (RT)-PCR primer.
 XX
 SQ Sequence 19 BP; 4 A; 7 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 17; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1955 AACTGGATGAGCGGAG 1971
 DB 19 AACTGGATGAGCGGAG 3
 RESULT 548
 AAQ27541
 ID AAQ27541 standard; DNA; 20 BP.
 XX
 AC AAQ27541;
 XX
 DT 29-JAN-1993 (first entry)
 XX
 DE PCR Primer P5(1) corresponds to TKF receptor nts. 628-647.
 XX
 KW TKF; tumour diagnosis; polymerase chain reaction; PCR;
 KW fibroblast growth factor; human; Tyrosine Kinase receptor; ss.
 XX
 OS Synthetic.
 XX
 PN DE4104240-A.
 XX
 PD 13-AUG-1992.
 XX
 PF 12-FEB-1991; 91DE-04104240.
 XX
 PR 12-FEB-1991; 91DE-04104240.
 XX
 PA (GEOR-) GEORG-SPEYER-HAUS CHEMOTHERAPEUTISCHES.
 XX
 PI Holtrich U, Braeuninger A, Strebhardt K, Ruebsamen-Waigmann H;
 XX
 DR WPI; 1992-277527/34.
 XX
 PT New tyrosine kinase receptor protein related to EGF receptor proteins -
 PT and corresponding DNA sequences, used in treatment and diagnosis of lung
 PT tumours.
 XX
 PS Example 1; Page 11; 12pp; German.
 XX
 CC Primer P5(1) corresponds to nucleotides 628-647 of a human TKF receptor
 CC (see AAQ27537). P5(1) was used with a second primer (AAQ27540) to amplify
 CC partial sequences of previously unknown TKF receptor genes from cDNA
 CC prepared from human lung tissue RNA. The two primers are based on
 CC sequences which are highly conserved among known members of the TKF
 CC receptor family. See AAQ27539-Q27544
 XX
 SQ Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.4%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2584 GTCCACCGAGACTGGC 2600
 Db 4 GTCCACCGAGACTGGC 20

RESULT 549
 AAQ64160
 ID AAQ64160 standard; DNA; 20 BP.
 XX AC AAQ64160;
 XX AC
 XX 25-MAR-2003 (revised)
 DT 03-FEB-1995 (first entry)
 XX
 XX Primer for amplifying tyrosine kinase receptor coding sequence.
 DE
 XX Tyrosine kinase; receptor; proto-oncogene; trk; detection; diagnosis;
 KW antibody; treatment; tumour; antisense; ss.
 XX Synthetic.
 OS
 XX DB4239817-A1.
 PN
 XX
 XX 01-JUN-1994.
 PD
 XX
 XX 26-NOV-1992; 92DB-04239817.
 PF
 XX
 XX 26-NOV-1992; 92DB-04239817.
 PR
 XX (CHEM-) CHEMOTHERAPEUTISCHES FORSCHUNG.
 PA
 XX Sreberhardt K, Ruebsamen-Waigmann H, Holtrich U;
 PI WPI; 1994-184380/23.
 XX
 DR New protein tyrosine kinase and related nucleic acid - vectors,
 XX transformed cells, etc., useful for diagnosis and treatment of tumours.
 PT
 PT Example 1; Page 9; 9pp; German.
 PS
 XX Three primers (AAQ64159-064161) were used to amplify regions of the
 CC protein tyrosine kinase receptor. The gene encoding the receptor is
 CC related to the trk proto-oncogene. Antibodies against the encoded
 CC polypeptide are useful for diagnosis and for the treatment of tumours.
 CC The antibodies may also be radiolabelled or coupled to a cytotoxin for
 CC destruction of cancer cells. Antisense nucleic acid can be used to
 CC inhibit gene expression. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.4%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2584 GTCCACCGAGACTGGC 2600
 Db 4 GTCCACCGAGACTGGC 20

RESULT 550
 AAZ18209
 ID AAZ18209 standard; DNA; 20 BP.
 XX AC AAZ18209;
 XX
 XX 11-OCT-1999 (first entry)
 DT
 XX Tyrosine kinase gene specific primer 400.
 DE
 XX Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 XX

KW primer; ss.
 XX Synthetic.
 OS Homo sapiens.
 XX
 XX WO9934016-A2.
 PN
 XX 08-JUL-1999.
 PD
 XX 28-DEC-1998; 98WO-IL000625.
 PF
 XX 29-DEC-1997; 97IL-00122793.
 PR 16-OCT-1998; 98IL-00126627.
 XX
 XX (GENE-) GENENA LTD.
 PA
 XX Vider B;
 PI WPI; 1999-419113/35.
 XX P-PSDB; AAY14743.
 DR
 XX Identifying and characterizing cells by comparing the pattern of gene
 PT expression in a selected gene family.
 PS Claim 4; Page 48; 102pp; English.
 XX
 CC The invention provides a new method for identifying and characterising
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for
 CC characterising cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC an individual, e.g. a fetus. They can also be used for determining the
 CC effect of a selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain reaction
 CC (RT-PCR) for determining the pattern of gene expression in a selected
 CC gene family. Sequences AAZ17803-Z18342 represent primers that can be used
 CC in the RT-PCR reactions to determine the pattern of gene expression. The
 CC gene family can be selected from a set of homeobox genes, kinase genes,
 CC protein phosphatase genes, P450 enzyme genes, steroid receptor
 CC superfamily genes or cadherin superfamily genes
 XX
 SQ Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2638 AAAGTGTCTGACTTTGGCCT 2657
 Db 1 AAAGTCTCAGACTTTGGCCT 20

RESULT 551
 AAZ02532/c
 ID AAZ02532 standard; DNA; 20 BP.
 XX AC AAZ02532;
 XX
 XX 07-OCT-1999 (first entry)
 DT
 XX PCR primer used to amplify an ORF of Chlamydia trachomatis.
 DE
 XX Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
 KW paratrachoma; inclusion conjunctivitis; genital disease; perihhepatitis;
 KW nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
 KW Bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
 XX Synthetic.
 OS

OS Chlamydia trachomatis.
 PN WO9928475-A2.
 XX
 PD 10-JUN-1999.
 XX
 PF 27-NOV-1998; 98WO-IB001939.
 XX
 PR 28-NOV-1997; 97FR-00015041.
 PR 17-DEC-1997; 97FR-00016034.
 PR 04-NOV-1998; 98US-0107077P.
 XX
 XX (BEST) GENSET.
 PA
 PI Griffais R;
 XX
 DR WPI; 1999-371125/31.
 XX
 PT Genome sequence of Chlamydia trachomatis.
 XX
 PS Disclosure; Page 1532; 1755pp; English.
 XX
 CC PCR primers AAZ01426-Z06209 were used to amplify open reading frames
 CC (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
 CC encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
 CC against Chlamydia trachomatis. Antisense and ribozyme sequences can also
 CC be used to control growth of the microorganism. Chlamydia trachomatis is
 CC responsible for a large number of diseases, e.g. eye diseases such as
 CC conjunctivitis, genital diseases such as nongonococcal urethritis,
 CC epididymitis, cervicitis, salpingitis, perihepatitis, Bartholinitis;
 CC pneumonia in breast feeding infants; and venereal lymphogranulomatosis.
 CC The polypeptides of the invention may be of use in treating these
 CC diseases
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2714 GAAAGATTCCCATCCGATGG 2733
 Db 20 GAAAGATACCTTCGATGG 1
 RESULT 552
 ADC65757/c
 ID ADC65757 standard; DNA; 20 BP.
 XX
 AC ADC65757;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human TGF-beta receptor II targeted antisense oligonucleotide #34.
 XX
 KW human; antisense oligonucleotide;
 KW transforming growth factor beta receptor II; TGF-beta receptor II;
 KW hyperproliferative disorder; breast cancer; autoimmune disorder;
 KW rheumatoid arthritis; 2'-O-methoxyethyl gapmer;
 KW phosphorothioate backbone; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003000656-A2.
 XX
 PD 03-JAN-2003.
 XX
 PF 19-JUN-2002; 2002WO-US019665.
 XX
 PR 21-JUN-2001; 2001US-00888361.
 XX
 PA (ISIS-) ISIS PHARM INC.

XX Murray SF, Wyatt JR;
 PI
 XX WPI; 2003-175279/17.
 DR
 XX
 PT New compound having a sequence targeted to a nucleic acid encoding
 PT Transforming growth factor beta-receptor II, useful for preparing a
 PT composition for treating hyperproliferative disorder e.g., lung, liver,
 PT colon or gastric cancer.
 XX
 XX Claim 3; SEQ ID NO 53; 141pp; English.
 PS
 XX
 CC The invention comprises antisense oligonucleotides that are targeted to
 CC the nucleic acid encoding transforming growth factor beta (TGF-beta)
 CC receptor II. The antisense oligonucleotides of the invention are useful
 CC for treating: hyperproliferative disorders (e.g. breast cancer); or an
 CC autoimmune disorder (e.g. rheumatoid arthritis). The present DNA sequence
 CC represents a 2'-O-methoxyethyl gapmer oligonucleotide with a
 CC phosphorothioate backbone that is targeted to human TGF-beta receptor II.
 XX
 SQ Sequence 20 BP; 9 A; 6 C; 4 G; 1 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 2.6e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2642 TGCTGTGACTTTGGCTTTCC 2661
 Db 20 TGTGTGACTTTGGCTTTCC 1
 RESULT 553
 ADU78633/c
 ID ADU78633 standard; DNA; 20 BP.
 XX
 AC ADU78633;
 XX
 DT 27-JAN-2005 (first entry)
 XX
 DE Antisense oligonucleotide, SEQ ID 6.
 XX
 KW Neuroprotective; Antidepressant; Neuroleptic; Tranquilizer;
 KW Antiparkinsonian; Nootropic; Antidiabetic; Anorectic;
 KW Cardiovascular-Gen.; Antiarteriosclerotic; Antilipemic;
 KW Alzheimer's disease; neurological disorder; phosphatase; enzyme;
 KW antisense; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2004226056-A1.
 XX
 PD 11-NOV-2004.
 XX
 PF 09-FEB-2004; 2004US-00776013.
 XX
 DE 22-DEC-1998; 98US-0113534P.
 PR 12-MAR-1999; 99US-0124120P.
 PR 30-JUN-1999; 99US-0141243P.
 PR 21-DEC-1999; 99US-0046613P.
 PR 17-OCT-2000; 2000US-0240790P.
 PR 13-JUL-2001; 2001US-0304775P.
 PR 10-SEP-2001; 2001US-00948904.
 PR 12-OCT-2001; 2001US-00975072.
 PR 15-JUL-2002; 2002US-00194967.
 XX
 PA (MYRI-) MYRIAD GENETICS INC.
 XX
 PI Roch J, Bartel P, Heichman K;
 XX
 DR WPI; 2004-794772/78.
 XX
 PT Selecting agents useful for treating Alzheimer's disease comprises
 PT contacting focal adhesion kinase 2 with a test agent and measuring a

PT biological activity related to focal adhesion kinase 2 function with or
PT without the test agent.

XX Disclosure; SEQ ID NO 6; 247pp; English.

XX The present invention relates to a method for selecting agents that are
CC potentially useful for the treatment of Alzheimer's disease. The method
CC comprises contacting Focal Adhesion Kinase 2 (FAK2) with a test agent and
CC measuring a biological activity related to FAK2 function in the presence
CC and absence of the test agent. The method is useful for screening
CC compounds or agents that can be used to treat neurological disorders,
CC ailments and diseases including mild cognitive impairment, depression,
CC schizophrenia, obsessive-compulsive disorder, bipolar disorder, and
CC neurodegenerative diseases and disorders and motor neuron diseases and
CC disorders such as Alzheimer's disease, Parkinson's disease, dementia with
CC Lewy bodies, amyotrophic lateral sclerosis or Lou Gehrig's disease,
CC Alpers' disease, Leigh's disease, Pelizaeus-Merzbacher disease,
CC Olivopontocerebellar atrophy, Friedreich's ataxia, leukodystrophies, Rett
CC syndrome, Ramsay Hunt syndrome type II, and Down's syndrome, as well as
CC for treating or preventing other diseases such as dyslipidemia, diabetes,
CC obesity, cardiovascular diseases such as atherosclerosis and coronary
CC heart disease. Also disclosed is the coding sequence for a novel human
CC phosphatase called PN7740 (ADU78628 and ADU78629). PN7740 contains a
CC protein phosphatase 2C domain, which likely acts to dephosphorylate
CC specific phospho-serine or phospho-threonine residues on particular
CC protein substrates. Although the precise role played by protein
CC phosphatase 2Cs in Alzheimer's disease pathogenesis has yet to be
CC defined, the inventors have discovered that fragments of PN7740 interact
CC with the first phosphotyrosine binding domain (PTB) domain of Fe65 (also
CC known as APPB1(710) or amyloid beta (A4) precursor protein-binding,
CC family B, member 1, isoform E9 (710)), suggesting that PN7740 may well be
CC involved somehow. Fe65 is known to interact with the cytosolic C-terminal
CC region of Amyloid beta (A4) precursor protein (APP) and APP metabolism is
CC critical to the pathogenesis of Alzheimer's disease, because it leads to
CC the release of either toxic Abeta or trophic secreted APP (sAPP)
CC metabolites. The present sequence is an antisense oligonucleotide which
CC can be used in antisense therapy for Alzheimer's disease.

XX Sequence 20 BP; 2 A; 7 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 367 GGCGGGCCCATGAGCTCCG 386
||| |||||
Db 20 GGCCCCGCATGGAGCTCCG 1

RESULT 554
ADW83103/C

ID ADW83103 standard; DNA; 20 BP.

XX AC ADW83103;

XX DT 07-APR-2005 (first entry)

XX DE MAP3K9 marker amplification reverse primer #571.

XX mixed lineage kinase; MLK; asthma; at-risk haplotype; MAP3K9;
KW antiasthmatic; respiratory-gen.; antiinflammatory; antirheumatic;
KW antiarthritic; antipsoriatic; neuroprotective; gastrointestinal-gen.;
KW respiratory disease; chronic obstructive pulmonary disease;
KW chronic bronchitis; inflammation; ps; primer; PCR.

XX Unidentified.

XX WO2005007144-A2.

XX PD 27-JAN-2005.

XX PF 14-JUL-2004; 2004WO-US022446.

PR 14-JUL-2003; 2003US-0487072P.
PR 05-APR-2004; 2004US-0559611P.
XX (DECO-) DECODE GENETICS EHF.
XX Hakonarson H, Gurney ME, Halapi E;
PI WPI; 2005-122681/13.
XX Use of mixed lineage kinase family kinase inhibitor in the manufacture of
PT a medicament for treatment of asthma associated at-risk haplotype for
PT asthma, at-risk haplotype in MAP3K9 gene or increased MLK1 protein
PT expression or activity.
XX Disclosure; Fig 12; 640pp; English.

XX The invention relates to the novel use of a mixed lineage kinase (MLK)
CC family kinase inhibitor for treating asthma. Where the asthma is
CC associated with a risk factor selected from an at-risk haplotype for
CC asthma at-risk haplotype in MAP3K9 gene, polymorphism in MAP3K9 nucleic
CC acid, dysregulation of MAP3K9 mRNA expression, dysregulation of a MAP3K9
CC mRNA isoform, and/or increased MLK1 protein expression. The invention
CC further comprises: a method for the diagnosis or identification of
CC susceptibility to asthma; a method for the use of a first nucleic acid
CC molecule for diagnosing asthma or susceptibility to asthma in a sample; a
CC method for assaying the presence of a first nucleic acid molecule in a
CC sample; a method for assessing the response to treatment with an MLK
CC family kinase nucleic acid inhibitor in a target population or in an
CC individual with an at-risk haplotype for asthma, at-risk haplotype in the
CC MAP3K9 gene, polymorphism in the MAP3K9 nucleic acid, dysregulation of
CC MAP3K9 mRNA expression, dysregulation of MAP3K9 mRNA isoform, increased
CC MLK1 protein expression, increased MLK1 biochemical activity or increased
CC MLK1 protein isoform expression; a method for assessing the response to
CC treatment with an MLK1 inhibitor in a target population including an
CC individual with an at-risk haplotype for asthma, as above; a kit for
CC assaying a sample for the presence or absence of at least one haplotype
CC comprising 2 or more alleles associated with asthma comprising: at least
CC one nucleic acid capable of detecting the presence or absence of at least
CC one specific allele; a reagent kit for assaying the presence of at least
CC one haplotype comprising 2 or more alleles comprising: at least one
CC labeled nucleic acid capable of detecting at least one specific allele of
CC the haplotype, and reagents for detection of the label; and a reagent kit
CC for assaying a sample for the presence of at least one haplotype
CC comprising 2 or more alleles comprising: at least one nucleic acid
CC comprising at least one nucleotide sequence that is at least partially
CC complementary to a part of nucleotide sequence of MAP3K9, capable of
CC acting as a primer for a primer extension reaction and capable of
CC detecting 2 or more specific alleles of the haplotype. The MLK family
CC kinase inhibitor has the following activities: antiasthmatic, respiratory
CC -gen., antiinflammatory, antirheumatic, antiarthritic, antipsoriatic,
CC neuroprotective, and gastrointestinal-gen. The MLK family kinase
CC inhibitor is useful for the treatment of asthma associated with a risk
CC factor selected from at-risk haplotype for asthma, at-risk haplotype in
CC MAP3K9 gene, polymorphism in MAP3K9 nucleic acid, dysregulation of MAP3K9
CC mRNA expression, dysregulation of MAP3K9 mRNA isoform, increased MLK1
CC protein expression, increased MLK1 biochemical activity and/or increased
CC MLK1 protein isoform expression; and in diagnosis or identification of
CC susceptibility to asthma. The inhibitor is also useful for the treatment
CC of other respiratory diseases associated with MAP3K9 or other members of
CC the JNK pathway such as chronic obstructive pulmonary disease, chronic
CC bronchitis and other inflammatory diseases such as rheumatoid arthritis,
CC psoriasis, multiple sclerosis and inflammatory bowel disease. This
CC polynucleotide sequence represents a reverse primer which is used in
CC amplifying a marker of the MAP3K9 kinase, where MAP3K9 is a part of
CC Mitogen-Activated Protein Kinase (MAPK) signal transduction pathways, of
CC the invention.

XX Sequence 20 BP; 0 A; 10 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2065 AGGAGCAGACGATGGGAG 2084
 ID AAZ18182/c
 XX ||||| ||||| |||||
 Db 20 AGGAGGAGAGCAAGGGAG 1

RESULT 555
 AAZ18182/c
 ID AAZ18182 standard; DNA; 21 BP.
 XX
 AC AAZ18182;
 XX
 DT 11-OCT-1999 (first entry)
 XX
 DE PTK 26 gene specific primer.
 XX

Genetic proximity; gene expression; cell characterisation; homeobox gene;
 genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 primer; ss.

Synthetic.
 OS Homo sapiens.
 XX WO9934016-A2.
 XX
 FN 08-JUL-1999.
 XX
 PD 28-DEC-1998; 98WO-IL000625.
 XX
 PF 29-DEC-1997; 97IL-00122793.
 XX
 PR 16-OCT-1998; 98IL-00126627.
 XX
 XX (GENE-) GENENA LTD.
 PA
 XX
 PI Vidar B;
 XX
 DR WPI; 1999-419113/35.
 XX
 DR P-PSDB; AAY14717.
 XX

Identifying and characterizing cells by comparing the pattern of gene
 expression in a selected gene family.

Claim 4; Page 46; 102pp; English.

The invention provides a new method for identifying and characterising
 cells. The method for determining the genetic proximity of a first cell
 and a second cell comprises: (a) obtaining the first cell and the second
 cell; (b) determining in the first cell and the second cell the pattern
 of expression of genes in a selected gene family; and (c) calculating a
 proximity index using a specified formula. The methods can be used for
 characterising cells, e.g. for determining the origin of a cell, its
 genetic status, whether it carries a genetic defect, or whether it is
 transformed. They can be used for detecting a selected genetic defect in
 an individual, e.g. a fetus. They can also be used for determining the
 effect of a selected treatment on a test cell. They can also be used for
 obtaining cells capable of expressing an homeobox related desired
 property. The method uses reverse transcriptase polymerase chain reaction
 (RT-PCR) for determining the pattern of gene expression in a selected
 gene family. Sequences AAZ17803-218342 represent primers that can be used
 in the RT-PCR reactions to determine the pattern of gene expression. The
 gene family can be selected from a set of homeobox genes, kinase genes,
 protein phosphatase genes, P450 enzyme genes, steroid receptor
 superfamily genes or cadherin superfamily genes

Sequence 21 BP; 5 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 2.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2776 AGTGATGCTCGAGTTACGG 2795
 ID 21 AGTGATGCTCGAGTTACGG 2
 XX ||||| ||||| |||||

RESULT 556
 AAZ18188/c
 ID AAZ18188 standard; DNA; 21 BP.
 XX
 AC AAZ18188;
 XX
 DT 11-OCT-1999 (first entry)
 XX
 DE PTK 30 gene specific primer.
 XX

Genetic proximity; gene expression; cell characterisation; homeobox gene;
 genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 primer; ss.

Synthetic.
 OS Homo sapiens.
 XX WO9934016-A2.
 XX
 FN 08-JUL-1999.
 XX
 PD 28-DEC-1998; 98WO-IL000625.
 XX
 PF 29-DEC-1997; 97IL-00122793.
 XX
 PR 16-OCT-1998; 98IL-00126627.
 XX
 XX (GENE-) GENENA LTD.
 PA
 XX
 PI Vidar B;
 XX
 DR WPI; 1999-419113/35.
 XX
 DR P-PSDB; AAY14723.
 XX

Identifying and characterizing cells by comparing the pattern of gene
 expression in a selected gene family.

Claim 4; Page 46; 102pp; English.

The invention provides a new method for identifying and characterising
 cells. The method for determining the genetic proximity of a first cell
 and a second cell comprises: (a) obtaining the first cell and the second
 cell; (b) determining in the first cell and the second cell the pattern
 of expression of genes in a selected gene family; and (c) calculating a
 proximity index using a specified formula. The methods can be used for
 characterising cells, e.g. for determining the origin of a cell, its
 genetic status, whether it carries a genetic defect, or whether it is
 transformed. They can be used for detecting a selected genetic defect in
 an individual, e.g. a fetus. They can also be used for determining the
 effect of a selected treatment on a test cell. They can also be used for
 obtaining cells capable of expressing an homeobox related desired
 property. The method uses reverse transcriptase polymerase chain reaction
 (RT-PCR) for determining the pattern of gene expression in a selected
 gene family. Sequences AAZ17803-218342 represent primers that can be used
 in the RT-PCR reactions to determine the pattern of gene expression. The
 gene family can be selected from a set of homeobox genes, kinase genes,
 protein phosphatase genes, P450 enzyme genes, steroid receptor
 superfamily genes or cadherin superfamily genes

Sequence 21 BP; 5 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 2.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2776 AGTGATGCTCGAGTTACGG 2795
 ID 21 AGTGATGCTCGAGTTACGG 2
 XX ||||| ||||| |||||

RESULT 557

AAZ18166/c
 ID AAZ18166 standard; DNA; 21 BP.
 XX
 AC AAZ18166;
 XX
 DT 11-OCT-1999 (first entry)
 XX
 DE PTK 17 gene specific primer.
 XX
 KW Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9934016-A2.
 XX
 PD 08-JUL-1999.
 XX
 PF 28-DEC-1998; 98WO-IL000625.
 XX
 PR 29-DEC-1997; 97IL-00122793.
 PR 16-OCT-1998; 98IL-00126627.
 XX
 PA (GENE-) GENENA LTD.
 XX
 PI Vidar B;
 XX
 DR WPI; 1999-419113/35.
 DR P-PSDB; AAY14701.
 XX
 PT Identifying and characterizing cells by comparing the pattern of gene
 PT expression in a selected gene family.
 XX
 PS Claim 4; Page 46; 102pp; English.
 XX
 CC The invention provides a new method for identifying and characterising
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for
 CC characterising cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can be used for detecting a selected genetic defect in
 CC an individual, e.g. a fetus. They can also be used for determining the
 CC effect of a selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain reaction
 CC (RT-PCR) for determining the pattern of gene expression in a selected
 CC gene family. Sequences AAZ17803-Z18342 represent primers that can be used
 CC in the RT-PCR reactions to determine the pattern of gene expression. The
 CC gene family can be selected from a set of homeobox genes, kinase genes,
 CC protein phosphatase genes, P450 enzyme genes, steroid receptor
 CC superfamily genes or cadherin superfamily genes
 XX
 SQ Sequence 21 BP; 5 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 2.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2776 AGTGATGCTGGAGTTACGG 2795
 ||||| ||||| ||||| ||||| |||||
 Db 21 AGTGATGCTGGAGTTACGG 2
 RESULT 558
 AAZ18172/c
 ID AAZ18172 standard; DNA; 21 BP.
 XX
 AC AAZ18172;
 XX
 DT 11-OCT-1999 (first entry)
 XX

AC AAZ18172;
 XX
 DT 11-OCT-1999 (first entry)
 XX
 DE PTK 20 gene specific primer.
 XX
 KW Genetic proximity; gene expression; cell characterisation; homeobox gene;
 KW genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;
 KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;
 KW primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9934016-A2.
 XX
 PD 08-JUL-1999.
 XX
 PF 28-DEC-1998; 98WO-IL000625.
 XX
 PR 29-DEC-1997; 97IL-00122793.
 PR 16-OCT-1998; 98IL-00126627.
 XX
 PA (GENE-) GENENA LTD.
 XX
 PI Vidar B;
 XX
 DR WPI; 1999-419113/35.
 DR P-PSDB; AAY14707.
 XX
 PT Identifying and characterizing cells by comparing the pattern of gene
 PT expression in a selected gene family.
 XX
 PS Claim 4; Page 46; 102pp; English.
 XX
 CC The invention provides a new method for identifying and characterising
 CC cells. The method for determining the genetic proximity of a first cell
 CC and a second cell comprises: (a) obtaining the first cell and the second
 CC cell; (b) determining in the first cell and the second cell the pattern
 CC of expression of genes in a selected gene family; and (c) calculating a
 CC proximity index using a specified formula. The methods can be used for
 CC characterising cells, e.g. for determining the origin of a cell, its
 CC genetic status, whether it carries a genetic defect, or whether it is
 CC transformed. They can be used for detecting a selected genetic defect in
 CC an individual, e.g. a fetus. They can also be used for determining the
 CC effect of a selected treatment on a test cell. They can also be used for
 CC obtaining cells capable of expressing an homeobox related desired
 CC property. The method uses reverse transcriptase polymerase chain reaction
 CC (RT-PCR) for determining the pattern of gene expression in a selected
 CC gene family. Sequences AAZ17803-Z18342 represent primers that can be used
 CC in the RT-PCR reactions to determine the pattern of gene expression. The
 CC gene family can be selected from a set of homeobox genes, kinase genes,
 CC protein phosphatase genes, P450 enzyme genes, steroid receptor
 CC superfamily genes or cadherin superfamily genes
 XX
 SQ Sequence 21 BP; 5 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 2.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2776 AGTGATGCTGGAGTTACGG 2795
 ||||| ||||| ||||| ||||| |||||
 Db 21 AGTGATGCTGGAGTTACGG 2
 RESULT 559
 AAZ18178/c
 ID AAZ18178 standard; DNA; 21 BP.
 XX
 AC AAZ18178;
 XX
 DT 11-OCT-1999 (first entry)
 XX

XX PTK 23 gene specific primer.

DE Genetic proximity; gene expression; cell characterisation; homeobox gene;

XX genetic defect; reverse transcriptase polymerase chain reaction; RT-PCR;

KW kinase gene; protein phosphatase; P450; steroid receptor; cadherin;

KW primer; ss.

XX Synthetic.

OS Homo sapiens.

XX WO9934016-A2.

PN 08-JUL-1999.

XX 28-DEC-1998; 98WO-IL000625.

PF 29-DEC-1997; 97IL-00122793.

XX 16-OCT-1998; 98IL-00126627.

PR (GENE-) GENENA LTD.

XX Vider B;

PI WPI; 1999-419113/35.

DR P-PSDB; AAY14713.

DR Identifying and characterizing cells by comparing the pattern of gene

XX expression in a selected gene family.

XX Claim 4; Page 46; 102pp; English.

XX The invention provides a new method for identifying and characterising

CC cells. The method for determining the genetic proximity of a first cell

CC and a second cell comprises: (a) obtaining the first cell and the second

CC cell; (b) determining in the first cell and the second cell the pattern

CC of expression of genes in a selected gene family; and (c) calculating a

CC proximity index using a specified formula. The methods can be used for

CC characterising cells, e.g. for determining the origin of a cell, its

CC genetic status, whether it carries a genetic defect, or whether it is

CC transformed. They can be used for detecting a selected genetic defect in

CC an individual, e.g. a fetus. They can also be used for determining the

CC effect of a selected treatment on a test cell. They can also be used for

CC obtaining cells capable of expressing an homeobox related desired

CC property. The method uses reverse transcriptase polymerase chain reaction

CC (RT-PCR) for determining the pattern of gene expression in a selected

CC gene family. Sequences AA217803-218342 represent primers that can be used

CC in the RT-PCR reactions to determine the pattern of gene expression. The

CC gene family can be selected from a set of homeobox genes, kinase genes,

CC protein phosphatase genes, P450 enzyme genes, steroid receptor

CC superfamily genes or cadherin superfamily genes

XX Sequence 21 BP; 5 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 21;

Best Local Similarity 90.0%; Pred. No. 2.8e+02;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2776 AGTGATGCTGGAGTTACGG 2795

Db 21 AGTGATGCTGGAGTTACGG 2

RESULT 560

AAAA07689/c

ID AAA07689 standard; DNA; 21 BP.

XX AAA07689;

AC AAA07689;

XX 19-JUN-2000 (first entry)

DT Reverse primer for amplifying HERG gene exon 13.

DE Reverse primer for amplifying HERG gene exon 13.

XX

KW HERG; mutation; long QT syndrome; LQT syndrome; gene therapy; human;

KW PCR primer; ss.

XX Homo sapiens.

XX WO200006772-A1.

PN 10-FEB-2000.

PD 20-JUL-1999; 99WO-US016337.

XX 27-JUL-1998; 98US-00122847.

PR 06-JAN-1999; 99US-00226012.

XX (UTAH) UNIV UTAH RES FOUND.

PA Keating MT, Splawski I;

PI WPI; 2000-195319/17.

DR New isolated mutant HERG nucleic acids, useful for developing products

PT for the diagnosis, prevention and treatment of long QT syndrome.

PT Claim 7; Page 72; 163pp; English.

XX The invention relates to a HERG protein having a mutation compared to

CC wild-type HERG, and is useful for developing products for the diagnosis,

CC prevention and treatment of long QT (LQT) syndrome. The products and

CC methods can be used for the diagnosis of subjects with LQT syndrome. They

CC can also be used to screen for drugs for treating or preventing LQT

CC syndrome. The HERG nucleic acids can also be used for gene therapy and

CC HERG peptides can be used for peptide therapy. Sequences AAA07654-693

CC represent primers for amplifying HERG exons

XX Sequence 21 BP; 6 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 21;

Best Local Similarity 90.0%; Pred. No. 2.8e+02;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2018 GTGTGTCCTGGTCTGGTG 2037

Db 20 GTGTGTCCTGGTCTGGTG 1

RESULT 561

ABZ58380

ID ABZ58380 standard; DNA; 21 BP.

XX ABZ58380;

AC ABZ58380;

XX 28-APR-2003 (first entry)

DT Human protein phosphatase 2C-like enzyme forward PCR primer.

DE Human; protein phosphatase 2C-like enzyme; enzyme; nootropic;

KW neuroprotective; pulmonary; anorectic; antidiabetic; analgesic;

KW antiparkinsonian; gene therapy; PCR; primer; ss.

XX Homo sapiens.

XX WO200297074-A2.

PN 05-DEC-2002.

PD 29-MAY-2002; 2002WO-EP005874.

XX 30-MAY-2001; 2001US-0294006P.

PR 11-FEB-2002; 2002US-0354928P.

XX (FARB) BAYER AG.

PA Zhu Z;

PI

XX WPI; 2003-041414/03.
DR
XX
PT Reagent for modulating the activity of a protein phosphatase 2C-like
PT enzyme, used for treating diseases, such as, obesity or diabetes,
PT comprises e.g. a polynucleotide, polypeptide, ribozyme, or antisense
PT oligonucleotide.
XX
PS Example 10; Page 83; 121pp; English.
XX
CC The present sequence is a forward primer for the human protein
CC phosphatase 2C-like enzyme (PP2CLE) gene (see AB258379). The primer was
CC used in a Taqman quantitative analysis to determine expression of PP2CLE
CC in different tissues and cell lines. High expression was observed in
CC spinal cord, uterus, skeletal muscle, mammary gland, kidney, trachea,
CC colon and brain, in primary cultured alveolar type II cells, cultured
CC small airway epithelial cells and in cultured human bronchial epithelial
CC cells. The invention provides PP2CLE polynucleotides, polypeptides,
CC expression vectors, host cells and methods of producing PP2CLE
CC polypeptides and detecting PP2CLE polynucleotides. Also provided are
CC methods of using the polypeptides and polynucleotides to screen for
CC reagents which decrease or modulate the activity of PP2CLE. Claimed
CC pharmaceutical compositions comprising an expression vector or an
CC identified reagent are used to modulate the activity of PP2CLE in a
CC disease, especially central nervous system (CNS) disorders, chronic
CC obstructive pulmonary disorder, obesity and diabetes (Claimed). Other
CC diseases that can be treated include Alzheimer's disease, Parkinson's
CC disease, and pain associated with CNS disorders
XX
SQ Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 585 CCACTGGCTTCGCACAGGTT 604
Db 1 CCACTGGCTACGCAGAGGTT 20

RESULT 562
ACL42990
ID ACL42990 standard; RNA; 21 BP.
XX
AC ACL42990;
XX
DT 24-MAR-2005 (first entry)
XX
DE CACNA1D siRNA antisense sequence, SEQ ID 4062.
XX
KW Cytostatic; Gene therapy; Vaccine; RNA Interference; cancer; ss;
KW short interfering RNA; gene silencing.
XX
OS Synthetic.
XX
FN WO2005001092-A2.
XX
PD 06-JAN-2005.
XX
PF 19-MAY-2004; 2004WO-US015645.
XX
PR 20-MAY-2003; 2003US-0471729P.
XX
PA (AMHP) WYETH.
XX
PI Be X, Wei L, Slonim DK, Howes SH;
XX
XX WPI; 2005-075568/08.
XX
PT Pharmaceutical composition comprising an agent capable of modulating an
PT expression level or protein activity of a gene, e.g. ABCA4, or a T cell
PT activated by the polypeptide or antibody, and a carrier, useful for
PT treating cancer.

XX Claim 3; SEQ ID NO 4062; 113pp; English.
PS
XX
CC The present invention relates to a novel pharmaceutical composition
CC comprising: (a) an agent capable of modulating an expression level or
CC protein activity of a cancer-related transmembrane protein (CRTP) or gene
CC , an antibody specific for a CRTP, or a T cell activated by a CRTP; and
CC (b) a carrier. The pharmaceutical composition may also comprise a
CC polynucleotide capable of inhibiting or decreasing the expression of the
CC CRTP by RNA interference or an antisense mechanism. The CRTPs of the
CC invention are selected from ABCC4, C20orf103, CACNA1D, CDH6, CST, ENPPP3,
CC FLJ11856, GPR54, HAVCR1, SLC6A3, SLC30A4, TRG, and TRPM4. The
CC pharmaceutical composition is useful for treating cancer, e.g. colon
CC cancer, lung cancer, breast cancer, prostate cancer, liver cancer, kidney
CC cancer, stomach cancer, and esophageal cancer. The present sequence is a
CC CRTP short interfering RNAs (siRNA) oligonucleotide. Note: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 21 BP; 1 A; 9 C; 3 G; 0 T; 8 U; 0 Other;

Query Match 0.4%; Score 16.8; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 2.8e+02;
Matches 13; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 3823 CCTCCCCACAGCTGCTGCCTT 3842
Db 2 CCUCUCCUCCAGCUGUCUUU 21

RESULT 563
AAH47543/c
ID AAH47543 standard; DNA; 18 BP.
XX
AC AAH47543;
XX
DT 30-NOV-2001 (first entry)
XX
DE Human Her-3 mRNA inhibiting antisense oligo ISIS # 19558.
XX
KW Her-3; epidermal growth factor; EGF; receptor/tyrosine kinase; human;
KW antinflammatory; cytostatic; antibacterial; antisense; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US6277640-B1.
XX
PD 21-AUG-2001.
XX
PF 31-JUL-2000; 2000US-00630706.
XX
PR 31-JUL-2000; 2000US-00630706.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Cowbert LM;
XX
XX WPI; 2001-535134/59.
XX
XX Antisense compounds capable of modulating expression of human Her-3,
PT member of epidermal growth factor family of receptor/tyrosine kinases,
PT useful for preventing or delaying infection, inflammation or tumor
PT formation.
XX
PS Claim 1; Col 42; 49pp; English.
XX
CC The invention provides antisense compounds capable of inhibiting the
CC expression of human Her-3, a member of epidermal growth factor (EGF)
CC family of receptor/tyrosine kinases. The antisense oligonucleotides are
CC useful for inhibiting the expression of Her-3 in cells or tissues. They
CC are commonly used as research reagents and in diagnostics for example, to

CC elucidate the function of particular genes. The antisense compounds are
 CC also useful for distinguishing between functions of various members of a
 CC biological pathway and for research use. They are also utilized for
 CC diagnostics, therapeutics, prophylaxis and in kits. They are useful
 CC prophylactically, e.g. to prevent or delay infection, inflammation or
 CC tumor formation. Sequences AAH47532-47615 represent chimeric antisense
 CC phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap,
 CC used for the inhibition of Her-3 mRNA expression
 XX
 SQ Sequence 18 BP; 1 A; 2 C; 9 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 105 ACCCAACTCCAGCCAG 122
 DB 18 ACACCAACTCCAGCCAG 1
 RESULT 564
 ABX80008
 ID ABX80008 standard; cDNA; 18 BP.
 AC
 AC ABX80008;
 XX
 DT 17-APR-2003 (first entry)
 XX
 DE EST polymorphic DNA repeat polynucleotide #333.
 XX
 KW EST; expressed sequence tag; ss; polymorphic repeat; tandem repeat;
 KW polymorphic marker prediction of ubiquitous simple sequences; POMPOUS;
 KW Rep-X; human; genetic disease; drug-treatment; Machado-Joseph;
 KW Haw River syndrome; Huntington's disease; fragile-X syndrome;
 KW Friedrich's ataxia; myotonic dystrophy; hyperandrogenaemia;
 KW spinal atrophy; bulbar atrophy; spinocerebellar ataxia.
 XX
 OS Homo sapiens.
 XX
 PN US6472154-B1.
 XX
 PD 29-OCT-2002.
 XX
 PF 31-DEC-1999; 99US-00475947.
 XX
 PR 31-DEC-1999; 99US-00475947.
 XX
 PA (TEXA) UNIV TEXAS SYSTEM.
 XX
 PI Garner HR, Wren JD, Minna JD, Fondon JW;
 XX
 DR WPI; 2003-208818/20.
 XX
 PT Identifying a candidate polymorphic repeat within a coding sequence, for
 PT understanding or treating genetic disease, comprises detecting tandem
 PT repeats in a target coding sequence and scoring the repeats for
 PT polymorphic probability.
 XX
 PS Example; Col 1165; 588pp; English.
 XX
 CC The invention discloses a method for identifying a candidate polymorphic
 CC repeat within a coding sequence (expressed sequence tag, EST), which
 CC comprises detecting tandem repeats in a target coding sequence, scoring
 CC the repeats for polymorphic probability and generating a dataset
 CC correlating the repeats with polymorphic probability to identify a
 CC candidate polymorphic repeat. The computational methods (polymorphic
 CC marker prediction of ubiquitous simple sequences, POMPOUS, and Rep-X) are
 CC useful for identifying and detecting candidate polymorphic repeats in
 CC human genes, which can be used to understand, treat or eliminate genetic
 CC diseases, predispositions or adverse drug-treatment reactions. Examples
 CC of diseases linked to nucleotide repeats are Machado-Joseph, Haw River
 CC syndrome, Huntington's disease, fragile-X syndrome, Friedrich's ataxia,
 CC myotonic dystrophy, hyperandrogenaemia, spinal and bulbar atrophy and

CC spinocerebellar ataxia. The sequences presented in ABX79676-ABX80022 are
 CC the polymorphic repeats identified for a search of human ESTs
 XX
 SQ Sequence 18 BP; 2 A; 10 C; 4 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 2.4e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1069 GGCCCCAGCCCCAGCCTC 1086
 DB 1 GGCCCCAGCTCCAGCCTC 18
 RESULT 565
 ADY89257
 ID ADY89257 standard; RNA; 19 BP.
 XX
 AC ADY89257;
 XX
 DT 16-JUN-2005 (first entry)
 XX
 DE VEGFR siRNA target sequence SEQ ID NO 2293.
 XX
 KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
 XX
 OS Synthetic.
 XX
 PN WO2005028649-A1.
 XX
 PD 31-MAR-2005.
 XX
 PF 16-SEP-2004; 2004WO-US030488.
 XX
 PR 16-SEP-2003; 2003US-00664767.
 PR 16-SEP-2003; 2003US-0065255.
 PR 23-SEP-2003; 2003US-00670011.
 PR 23-OCT-2003; 2003US-00693059.
 PR 24-NOV-2003; 2003US-00720448.
 PR 03-DEC-2003; 2003US-00727780.
 PR 14-JAN-2004; 2004US-00757803.
 PR 26-JAN-2004; 2004US-00764957.
 PR 10-FEB-2004; 2004US-0543480P.
 PR 13-FEB-2004; 2004US-00780447.
 PR 16-APR-2004; 2004US-00825966.
 PR 23-APR-2004; 2004US-00831620.
 PR 30-APR-2004; 2004US-00013456.
 PR 11-MAY-2004; 2004US-00844076.
 XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
 XX
 DR WPI; 2005-254128/26.
 XX
 PT New multifunctional siRNA molecule that directs cleavage of the first and
 PT second VEGF or VEGFR target sequences via RNA interference, useful in
 PT preparing a composition for treating cell proliferative disorders e.g.
 PT cancers.
 XX
 PS Disclosure; SEQ ID NO 2293; 396pp; English.
 XX
 CC The invention relates to a multifunctional siRNA molecule comprising a
 CC structure having formula MF-III and which directs cleavage of the first
 CC and second VEGF or VEGFR target sequences via RNA interference. The
 CC multifunctional siRNA molecule is useful in preparing a pharmaceutical
 CC composition for treating cell proliferative disorders, e.g. cancer. The
 CC present sequence represents a VEGFR siRNA target sequence.
 XX
 SQ Sequence 19 BP; 3 A; 6 C; 6 G; 0 T; 4 U; 0 Other;
 Query Match 0.4%; Score 16.4; DB 1; Length 19;
 Best Local Similarity 72.2%; Pred. No. 2.6e+02;

Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACTGTGGCA 2948
Db 1 CAUGCUGGACUGCUGGCA 18

RESULT 566
ADY89385
ID ADY89385 standard; RNA; 19 BP.
XX AC ADY89385;
XX 16-JUN-2005 (first entry)
XX VEGFR siRNA target sequence SEQ ID NO 2421.
DE ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX OS Synthetic.
XX WO2005028649-A1.
FN 31-MAR-2005.
XX 16-SEP-2004; 2004WO-US030488.
XX 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
PI WPI; 2005-254128/26.
XX New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX Disclosure; SEQ ID NO 2421; 396pp; English.
XX The invention relates to a multifunctional siNA molecule comprising a
CC structure having formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX Sequence 19 BP; 3 A; 6 C; 6 G; 0 T; 4 U; 0 Other;
SQ Query Match 0.4%; Score 16.4; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 2.6e+02;
Matches 13; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 2931 CATGCTGGACTGTGGCA 2948
Db 2 CAUGCUGGACUGCUGGCA 19

RESULT 567
AAQ20433/c
ID AAQ20433 standard; DNA; 20 BP.
XX AC AAQ20433;
XX 07-APR-1992 (first entry)
XX Debrisoquine polymorphism PCR primer.
XX Polymerase chain reaction; ss.
XX Synthetic.
XX EP463395-A.
XX 02-JAN-1992.
XX 29-MAY-1991; 91EP-00108867.
XX 22-JUN-1990; 90EP-00810467.
XX (HOFF) HOFFMANN-LA ROCHE AG.
XX WPI; 1992-009068/02.
XX New PCR primers for detecting poor metaboliser of drugs - useful to
PT highlight cases of debrisoquine, mephenytoin-and acetylation-
PT polymorphism.
XX Claim 11; Page 18; 31pp; English.
XX The sequence is that of an oligonucleotide primer which is used in a
CC polymerase chain reaction (PCR) for the detection of normal and genes
CC coding for drug metabolising enzymes which allow the phenotyping of poor
CC metabolisers. Detection of debrisoquine polymorphism (CY2D6 gene -
CC encodes the P450IID6 enzyme) is possible using this primer. See also
CC AAQ20421-Q20436
SQ Sequence 20 BP; 2 A; 10 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3722 AGAAGGGGTGTCTCAGGGCC 3739
Db 20 AGAAGGGGTGTCTCAGGGCC 3

RESULT 568
AAK92799/c
ID AAK92799 standard; DNA; 20 BP.
XX AC AAK92799;
XX 13-SEP-1999 (first entry)
XX PCR primer used to amplify an ORF of Chlamydia pneumoniae.
DE Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
XX sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
KW neutralising epitope; PCR primer; ss.
XX Synthetic.
OS Chlamydothila pneumoniae.
XX WO9927105-A2.
XX 03-JUN-1999.
XX 20-NOV-1998; 98WO-IB001890.
XX

PR 21-NOV-1997; 97FR-00014673.
 PR 04-NOV-1998; 98US-0107078P.
 PA (GEST) GENSET.
 XX Griffais R;
 PI XX
 DR WPI; 1999-357842/30.
 XX
 XX Genome sequence of Chlamydia pneumoniae.
 PT
 XX Page 1540; Disclosure; 1912pp; English.
 PS
 XX AAX91991-X97517 represent PCR primers used to amplify open reading frames
 CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
 CC (see AAX91990). C. pneumoniae causes respiratory disease such as
 CC pneumonia and bronchitis and is thought to be a contributing factor in
 CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
 CC nodosum or pharyngitis. The polypeptides encoded by the open reading
 CC frames of the C. pneumoniae genome (see AAY34584 - AAY35879) can be used
 CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
 CC nucleotides sequences can also be used as immunogenic compositions,
 CC especially where the vector directs the expression of a neutralising
 CC epitope of C. pneumoniae
 XX
 SQ Sequence 20 BP; 2 A; 8 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 2.9e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3134 AAATGGGAAGATACGAAG 3151
 DB ||||||||||||||||
 19 AAATGGGAAGATCCGAAG 2
 RESULT 569
 AAL60967/c
 ID AAL60967 standard; DNA; 20 BP.
 XX
 AC AAL60967;
 XX
 DT 22-SEP-2003 (first entry)
 XX
 DE Human MyD88 antisense oligonucleotide, ISIS #190947.
 XX
 KW Antisense; human; myeloid differentiation primary response gene 88;
 KW MyD88; Alzheimer's disease; neurodegenerative disease; schizophrenia;
 KW gene therapy; Down's syndrome; phosphorothioate; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX
 FN WO2003046132-A2.
 XX
 XX 05-JUN-2003.
 PD
 XX 20-NOV-2002; 2002WO-US037411.
 PF

XX 23-NOV-2001; 2001US-00021707.
 PR (ISIS-) ISIS PHARM INC.
 PA
 XX Karas JG, Dobie K;
 PI
 XX WPI; 2003-505193/47.
 DR
 XX
 XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding MyD88, useful for preparing a composition for treating
 PT neurodegenerative disease, e.g. Alzheimer's disease.
 XX
 PS Claim 3; Page 76; 106pp; English.
 XX
 CC The invention relates to antisense compounds targetted to a nucleic acid
 CC encoding human MyD88 (myeloid differentiation primary response gene 88)
 CC to inhibit its expression. Antisense compounds of the invention are
 CC useful for preparing a composition for treating neurodegenerative disease
 CC e.g. Alzheimer's disease, Down's syndrome or schizophrenia. The invention
 CC is also useful in gene therapy. The present sequence is an antisense
 CC oligonucleotide targetted to human MyD88 DNA
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 2.9e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2595 CCTGGCTGCTCGCAACAT 2612
 DB ||||||||||||||||
 19 CCTGGCTGCTCTCACAT 2
 RESULT 570
 ADE14481/c
 ID ADE14481 standard; DNA; 20 BP.
 XX
 AC ADE14481;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE HSD11B1 antisense oligonucleotide seq id 83.
 XX
 KW osteopathic; antidiabetic; anorectic; antidiabetic;
 KW antiarteriosclerotic; antilipemic; antisense-therapy;
 KW hydroxysteroid 11-beta dehydrogenase 1; osteoporosis; depression;
 KW metabolic disorder; obesity; HSD11B1; diabetes; atherosclerosis;
 KW hyperlipidaemia; antisense technology; mouse; ss.
 XX
 OS Mus sp.
 XX
 XX US2003198965-A1.
 XX
 PD 23-OCT-2003.
 XX
 PF 19-APR-2002; 2002US-00126355.
 XX
 PR 19-APR-2002; 2002US-00126355.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Freier SM;
 PI
 XX WPI; 2003-852782/79.
 DR
 XX New antisense compounds useful for treating disorders associated with
 PT hydroxysteroid 11-beta dehydrogenase 1 expression, such as osteoporosis,
 PT depression and metabolic disorders like obesity, diabetes and
 PT atherosclerosis.
 XX
 PS Example 16; SEQ ID NO 83; 53pp; English.
 XX

CC The invention describes a compound (I) 8-80 nucleobases in length
CC targeted to a nucleic acid molecule encoding hydroxysteroid 11-beta
CC dehydrogenase 1, inhibiting expression of hydroxysteroid 11-beta
CC dehydrogenase 1. The methods and compositions of the present invention
CC are useful for treating disorders associated with hydroxysteroid 11-beta
CC dehydrogenase 1 expression, such as osteoporosis, depression and
CC metabolic disorders like obesity, diabetes, atherosclerosis and
CC hyperlipidaemia. This sequence represents an antisense oligonucleotide
CC used to control the expression of mouse hydroxysteroid 11-beta
CC dehydrogenase 1.
XX
SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2067 GAAGCAGAGCAATGGGAG 2084
|||||
Db 19 GAAGCAGAGCAATGGGAG 2

RESULT 571
ADY59502/c
ID ADY59502 standard; DNA; 20 BP.
XX
AC ADY59502;
XX
DT 19-MAY-2005 (first entry)
XX
DE Oligonucleotide of the invention PN09.
XX
KW ss; diagnosis; tumor; cytostatic; neoplasm; DNA microarray.
XX
OS Unidentified.
XX
PN CN1472338-A.
XX
PD 04-FEB-2004.
XX
PF 01-AUG-2002; 2002CN-00125892.
XX
PR 01-AUG-2002; 2002CN-00125892.
XX
PA (JUNK-) JUNKUAN BIOLOGICAL TECHNOLOGY CO LTD SHE.
XX
PI Liang P, Ding Y, Zhang X;
XX
DR WPI; 2004-317417/30.
XX
PT Tumor related gene testing method.
XX
PS Disclosure; Page 10; 14pp; Chinese.
XX

CC The invention relates to a novel process for detecting a tumor associated
CC gene in order to diagnose early tumor. The method comprises artificially
CC synthesizing a specific cDNA fragment as a probe, on a solid support to
CC form a DNA array of a tumor associated gene, reverse transcription and
CC labeling, hybridizing the labeled specimen cDNA fragment and tumor
CC associated gene DNA array, and direct quantitative analysis. The present
CC sequence is used in the invention.
XX
SQ Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 256 AGGGCCCCGACGAGGAGT 273
|||||
Db 18 AGGGCCCCGCGGAGGAGT 1

RESULT 572
AEB222981
ID AEB22981 standard; DNA; 20 BP.
XX
AC AEB22981;
XX
DT 22-SEP-2005 (first entry)
XX
DE SCNSA gene exon 2 forward primer.
XX
KW SCNSA; sodium channel; Brugada syndrome; heart arrhythmia;
KW antiarrhythmic; selectable marker; ventricular fibrillation; ss; PCR;
KW primer.
XX
OS Synthetic.
XX
PN JP2005192413-A.
XX
PD 21-JUL-2005.
XX
PF 26-DEC-2003; 2003JP-00435234.
XX
PR 26-DEC-2003; 2003JP-00435234.
XX
PA (DOKU-) DOKURITSU GYOSEI HOJIN KAGAKU GIJUTSU SH.
XX
PI Matsunaga A;
XX
DR WPI; 2005-501993/51.
XX
PT Novel SCNSA gene of sodium channel alpha subunit, with mutations in which
PT glycine being substituted by serine, and serine being substituted by
PT leucine, at specific positions, useful as marker for diagnosing Brugada
PT syndrome.
XX
PS Example 1; Page; 30pp; Japanese.
XX
CC The invention relates to an novel SCNSA gene of a sodium channel alpha
CC subunit. The novel SCNSA gene comprises the mutation G292S between the
CC fifth and sixth membrane passing-through subunits of the first domain;
CC and/or the mutation S835L of the intracellular loop between the fourth
CC and fifth membrane passing-through subunits of the second domain. The
CC novel SCNSA gene can be used as a Brugada syndrome marker, for diagnosing
CC Brugada syndrome. Brugada syndrome causes idiopathic ventricular
CC fibrillation, thus the gene/marker allow for the prevention or treatment
CC of the syndrome. This oligo sequence represents a primer used to amplify
CC an exon of the SCNSA gene of the invention.
XX
SQ Sequence 20 BP; 4 A; 12 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2915 CCTCCCTCCACCAGCTCA 2932
|||||
Db 1 CCTCCCTCCACCAGCACA 18

RESULT 573
ACA99868/c
ID ACA99868 standard; DNA; 17 BP.
XX
AC ACA99868;
XX
DT 28-JUL-2003 (first entry)
XX
DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #361.
XX
KW Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS Homo sapiens.

XX WO2003031621-A2.
PN 17-APR-2003.
XX 11-OCT-2002; 2002WO-US032599.
XX 12-OCT-2001; 2001US-0329000P.
XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
FA Zhang J;
PI WPI; 2003-381720/36.
DR New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
XX investigating and/or treating disorders associated with aberrant
PT expression or activity of GPCR-A-1, such as tumors and cancers.
XX Example 2; SEQ ID NO 385; 156pp; English.
PS The invention describes an isolated nucleic acid encoding a G protein
XX coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 base in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumors and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1
XX
SQ Sequence 17 BP; 3 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1190 CCCAGGGCACCTTCAA 1205
Db 16 CCCAGGGCACCTTCAA 1
RESULT 574
ACA99867/c
ID ACA99867 standard; DNA; 17 BP.
XX ACA99867;
AC 28-JUL-2003 (first entry)
DT G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #360.
DE Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
XX G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
KW Homo sapiens.
OS WO2003031621-A2.
XX 17-APR-2003.
PN 11-OCT-2002; 2002WO-US032599.
XX 12-OCT-2001; 2001US-0329000P.
PR (AMSH) AMERSHAM BIOSCIENCES SV CORP.
XX Zhang J;
PI WPI; 2003-381720/36.
DR

PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT investigating and/or treating disorders associated with aberrant
PT expression or activity of GPCR-A-1, such as tumors and cancers.
XX Example 2; SEQ ID NO 384; 156pp; English.
XX The invention describes an isolated nucleic acid encoding a G protein
CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 base in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumors and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1
XX
SQ Sequence 17 BP; 2 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1190 CCCAGGGCACCTTCAA 1205
Db 17 CCCAGGGCACCTTCAA 2
RESULT 575
ABT37713/c
ID ABT37713 standard; DNA; 17 BP.
XX ABT37713;
AC 12-JUN-2003 (first entry)
DT Tumour suppression related human fukutin oligo SEQ ID No 3350.
DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
XX human fukutin; ds.
OS Homo sapiens.
XX WO2003025175-A2.
PN 27-MAR-2003.
XX 17-SEP-2002; 2002WO-IB004208.
PF 17-SEP-2001; 2001PR-00011978.
PR (MOLE-) MOLECULAR ENGINES LAB.
XX Teerman A, Anson R, Tuijnder M;
PI WPI; 2003-313353/30.
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX Disclosure; Page 425; 720pp; French.
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,

CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 4 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3469 TTTGGAGAGACAGGAT 3484
Db 17 TTTGGAGAGACAGGAT 2
RESULT 576
ADI48271/c
ID ADI48271 standard; DNA; 17 BP.
AC ADI48271;
XX
DT 15-APR-2004 (first entry)
XX
DE Human tumour suppression/reversion-related DNA sequence SeqID774.
XX
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX HQ2003025177-A2.
PN
XX
PD 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004523.
XX
PR 17-SEP-2001; 2001FR-00011980.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
PA Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-313354/30.
DR
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
XX Disclosure; SEQ ID NO 774; 30pp; French.
XX
XX This invention relates to novel isolated nucleic acid sequences involved
CC in the phenomena of tumour suppression, tumour reversion, apoptosis
CC and/or resistance to viruses. The invention may be useful for the
CC development of compounds with a cytostatic, virucide, neuroprotective,
CC nontropic or neuroleptic activity. The DNA sequences may be useful as
CC probes and primers for detecting, indentifying, quantifying and/or
CC amplifying nucleic acid, for example as one component of a gene chip, in
CC vitro as antisense reagents and for production of recombinant
CC polypeptides. The invention may therefore be useful for preparation of

CC pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia. The
CC present sequence is that of a nucleic acid sequence of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/publishedpct_sequences
XX
SQ Sequence 17 BP; 4 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3469 TTTGGAGAGACAGGAT 3484
Db 17 TTTGGAGAGACAGGAT 2
RESULT 577
ACCS3159/c
ID ACCS3159 standard; DNA; 17 BP.
XX
AC ACCS3159;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human tumour suppressor sequence #1926.
XX
KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW tumour regression; apoptosis; virus resistance; diagnosis;
KW cellular degeneration.
XX
OS Homo sapiens.
XX FR2826373-A1.
PN
XX 27-DEC-2002.
XX
XX 20-JUN-2001; 2001FR-00008139.
PF
XX 20-JUN-2001; 2001FR-00008139.
PR
XX (MOLE-) MOLECULAR ENGINES LAB SA.
PA Tuijnder M, Telerman A, Amson R;
PI WPI; 2003-250498/25.
DR
XX New nucleic acid sequences associated with tumor suppression, regression,
PT apoptosis or virus resistance are useful to diagnose and treat viral
PT disease, development of tumor cells and cell degeneration.
XX
XX Claim 1; Page 485; 798pp; French.
XX
XX This sequence represents an isolated nucleic acid sequence associated
CC with tumour suppression or regression, apoptosis or virus resistance. The
CC invention relates to these sequences or sequences having at least 80%
CC identity to them, and polypeptides encoded by the sequences or
CC polypeptides having 80% identity to the polypeptide sequences. The
CC invention is used to diagnose or treat viral disease or disease
CC characterized by development of tumour cells or cellular degeneration
XX
SQ Sequence 17 BP; 4 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 0.4%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3469 TTTGGAGAGACAGGAT 3484
Db 17 TTTGGAGAGACAGGAT 2

PF	06-DEC-1999;	99WO-US028772.	
XX			
PR	04-DEC-1998;	98US-0110954P.	
XX			
PA	(IMMU-) IMMUSOL INC.		
XX			
PI	Tritz R, Welch PJ, Barber JR, Robbins JM;		
XX			
DR	WPI; 2000-412314/35.		
XX			
PT	New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves		
PR	RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,		
PT	PCNA and Cyclin B1.		
XX			
PS	Disclosure; Page 47; 109pp; English.		
XX			
CC	The present invention relates to a hairpin or hammerhead ribozyme,		
CC	designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase		
CC	other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.		
CC	Representative examples of ribozyme recognition sites are given in		
CC	AAH82415 to AAH86787. The ribozyme of the invention is useful for		
CC	inhibiting restenosis by introduction of the ribozyme into cells. The		
CC	ribozyme is resistant to endonuclease activity and hence is efficient in		
CC	restenosis treatment		
XX			
SQ	Sequence 19 BP; 10 A; 1 C; 2 G; 6 T; 0 U; 0 Other;		
	Query Match	0.4%; Score 16; DB 1; Length 19;	
	Best Local Similarity	100.0%; Prod. No. 3e+02;	
	Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps		
Qy	4188 CTTTGTGATAAATAA 4203		
Db			
	19 CTTTGTGATAAATAA 4		
RESULT 580			
AAH57648/c			
ID	AAH57648 standard; DNA; 19 BP.		
XX			
AC	AAH57648;		
XX			
DT	10-SEP-2001 (first entry)		
XX			
DE	Cell-cycle dependent kinase cdk1 ribozyme binding site SEQ ID NO:72.		
XX			
KW	Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;		
KW	recognition site; target; ribozyme binding site; eye disease; vulnery;		
KW	proliferative disease; skin disease; psoriasis; diabetic retinopathy;		
KW	cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;		
KW	matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;		
KW	antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;		
KW	antisickling; ophthalmological; keratolytic; gene therapy; viral wart;		
KW	atopic dermatitis; actinic keratosis; squamous cell carcinoma;		
KW	basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;		
KW	sickle cell retinopathy; ss.		
XX			
OS	Homo sapiens.		
OS	Synthetic.		
XX			
PN	WO200130362-A2.		
XX			
PD	03-MAY-2001.		
XX			
PF	26-OCT-2000; 2000WO-US029500.		
XX			
PR	26-OCT-1999; 99US-0161532P.		
XX			
PA	(IMMU-) IMMUSOL INC.		
XX			
PI	Robbins JM, Tritz R;		
XX			
DR	WPI; 2001-300427/31.		

XX
PT Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS Example 1; Page 77; 408pp; English.
XX
CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 19 BP; 10 A; 1 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 4188 CTTTGTGTAATAA 4203
Db 19 CTTTGTGTAATAA 4
RESULT 581
AAH57649/c
ID AAH57649 standard; DNA; 19 BP.
XX
AC AAH57649;
XX
DT 10-SEP-2001 (first entry)
XX
DE Cell-cycle dependent kinase cdk1 ribozyme binding site SEQ ID NO:73.
XX
KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX WO200130362-A2.
XX
PD 03-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-US029500.
XX
XX 26-OCT-1999; 99US-0161532P.
PR
XX (IMMU-) IMMUSOL INC.
PA
XX Robbins JM, Tritz R;
PI

XX
DR WPI; 2001-300427/31.
XX
XX Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
PS Example 1; Page 77; 408pp; English.
XX
CC The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
SQ Sequence 19 BP; 11 A; 1 C; 1 G; 6 T; 0 U; 0 Other;
Query Match 0.4%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 4188 CTTTGTGTAATAA 4203
Db 17 CTTTGTGTAATAA 2
RESULT 582
ABK41169
ID ABK41169 standard; DNA; 19 BP.
XX
AC ABK41169;
XX
DT 21-MAY-2002 (first entry)
XX
DE Human obesity-associated biallelic marker downstream PCR primer #75.
XX
KW Human; obesity associated-biallelic marker; chromosome 10; obesity; ss;
KW drug response; hyperuricaemia; digestive pathology; hypertension; cancer;
KW hepatic function disorder; cardiovascular disease; hyperlipidaemia; PCR;
KW insulin disorder; atheromatous disease; cardiac insufficiency; primer.
XX
OS Homo sapiens.
OS WO200206525-A2.
XX
PN 24-JAN-2002.
XX
XX 28-JUN-2001; 2001WO-IB001477.
PF
XX 18-JUL-2000; 2000US-0219704P.
PR
XX (GEST) GENSET.
XX
XX Cohen D, Blumenfeld M, Chumakov I, Abderrahim H, Bihain B;
PI
XX WPI; 2002-155043/20.
DR
XX Set of novel map-related biallelic markers, preferably located on obesity
PT disorder-associated chromosomal regions on chromosomes 3, 10 and 19,
PT

PT useful, for e.g. detecting statistical correlations between marker allele
 PT and a phenotype.

XX Example 2; Page 278; 31pp; English.

XX The invention relates to a set of novel map-related biallelic markers,
 CC preferably located on obesity disorder-associated chromosomal regions on
 CC chromosomes 3, 10 and 19. The markers are useful for genotyping or
 CC estimating the frequency of an allele in a population, for detecting an
 CC association between a genotype or haplotype and a phenotype, for detecting an
 CC disease involving drug responses, obesity or disorders related to
 CC obesity, such as hyperuricaemia, digestive pathology, hepatic function
 CC disorders, cancer, cardiovascular disease, hypertension, hyperlipidaemia,
 CC insulin disorders, atheromatous disease and cardiac insufficiency. The
 CC markers are useful for detecting a statistical correlation between a
 CC biallelic marker allele and a phenotype and/or between a biallelic marker
 CC haplotype and a phenotype. This sequence represents a PCR primer used to
 CC amplify a human obesity-associated biallelic marker

XX Sequence 19 BP; 3 A; 1 C; 9 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 16; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 3e+02;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4117 TAGTTGGTGGTGAAC 4132

Db 1 TAGTTGGTGGTGAAC 16

RESULT 583

ADT01526

ID ADT01526 standard; DNA; 19 BP.

AC ADT01526;

XX 16-DEC-2004 (first entry)

XX Novel mutant protein tyrosine kinase-related oligonucleotide SeqID1514.

XX tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
 KW tumorigenesis; somatic alteration; colorectal cancer; NTRK3; FES;
 KW GUCY2F; MCKK; MLK4; kinase domain; cytostatic; tyrosine kinase inhibitor;
 KW guanylate cyclase stimulator; ss.

XX Homo sapiens.

XX WO2004082458-A2.

XX 30-SEP-2004.

XX 18-FEB-2004; 2004WO-US004452.

XX 21-FEB-2003; 2003US-0448537P.

XX 29-MAY-2003; 2003US-0473895P.

XX (UWJO) UNIV JOHNS HOPKINS.

XX Bardelli A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;

XX WPI; 2004-718702/70.

XX Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCKK) and
 PT associated methods for diagnosing cancer and screening for anti-cancer
 PT agents.

XX Disclosure; SEQ ID NO 1514; 363pp; English.

XX This invention relates to a novel activated mutant protein tyrosine
 CC kinases and associated methods for diagnosing cancer and screening for
 CC anti-cancer agents. Protein kinases are signalling molecules involved in
 CC tumorigenesis. Mutational analysis of the human tyrosine kinase gene
 CC family identified somatic alteration sin 1 in 5 colorectal cancers, with

CC the majority of mutations occurring in the NTRK3, FES, GUCY2F and
 CC MCKK/MLK4 genes. Most were identified in the kinase domain. The invention
 CC may be useful for the production of compounds with a cytostatic activity
 CC acting as protein tyrosine kinase inhibitors or guanylate cyclase
 CC stimulators. The invention may be useful for developing methods for
 CC detecting mutations involved in cancer or screening for anti-cancer
 CC agents. The present sequence is that of a human-derived oligonucleotide
 CC which is related to the invention.

XX Sequence 19 BP; 4 A; 2 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 16; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 3e+02;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2235 GATTGGTCAGGTCAG 2250

Db 1 GATTGGTCAGGTCAG 16

RESULT 584

ABZ99246

ID ABZ99246 standard; DNA; 20 BP.

AC ABZ99246;

XX 17-OCT-2003 (first entry)

XX Human PDB4C oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;

KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

KW lung inflammation; respiratory disease; ds.

XX Homo sapiens.

XX WO200285308-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013135.

XX 24-APR-2001; 2001US-0286137P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.

XX Disclosure; SEQ ID NO 14488; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an

CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 3.2e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2048 TCGCAGTTCCTCGCCT 2063
 Db 1 TCGCAGTTCCTCGCCT 16
 RESULT 585
 ID ABD32277 standard; DNA; 20 BP.
 AC ABD32277;
 XX
 XX 29-JUL-2004 (first entry)
 DT Human PDB4C-derived oligonucleotide SEQ ID 14488.
 DE
 DE Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 XX Homo sapiens.
 OS
 XX WO200285309-A2.
 PN
 PD 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 PI
 XX WPI; 2003-093058/08.
 DR
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 14488; 763pp; English.
 PS
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)

CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.4%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 3.2e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2048 TCGCAGTTCCTCGCCT 2063
 Db 1 TCGCAGTTCCTCGCCT 16
 RESULT 586
 ADJ61131
 ID ADJ61131 standard; DNA; 20 BP.
 XX ADJ61131;
 AC
 XX 06-MAY-2004 (first entry)
 DT
 XX
 XX Oligonucleotide associated to PDE4C #197.
 DE
 DE Interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX 05-FEB-2004.
 PD
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 PT
 XX Claim 2; SEQ ID NO 1987; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 3.2e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2048 TCGCAGTTCCTCGCCT 2063

Db 1 TCGCAGTTCCTCGCCT 16

RESULT 587

AAT00705

ID AAT00705 standard; DNA; 19 BP.

AC AAT00705;

XX AAT00705;

DT 08-JUL-1996 (first entry)

DE Human trkC receptor TK insert sense DNA primer.

XX trkC receptor; tyrosine-kinase; enzyme; protease; inflammation; pain;
 KW diagnosis; neurotrophic factor; kidney; lung; psychiatric disorder;
 KW DNA primer; PCR; polymerase chain reaction; ss.

XX Synthetic.

XX WO9525795-A1.

XX 28-SEP-1995.

XX 17-MAR-1995; 95WO-US003426.

XX 18-MAR-1994; 94US-00215139.

PR 05-AUG-1994; 94US-00286846.

PR 20-DEC-1994; 94US-00359705.

XX (GETH) GENENTECH INC.

XX Presta LG, Shelton DL, Urfer R;

XX WPI; 1995-344616/44.

XX New human trkB and trkC polypeptide(s) and fusion proteins contg. them -
 PT also DNA, vectors and transformed cells useful in treatment and diagnosis
 PT of abnormal neurotrophic factor expression, e.g. inflammatory pain.

XX Disclosure; Page 70; 117pp; English.

XX This TK insert sense DNA primer was used in a Northern blot analysis to
 CC examine expression patterns of the trkC receptor in human tissue

XX Sequence 19 BP; 5 A; 5 C; 8 G; 1 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.4%; Score 15.8; DB 1; Length 19;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3539 ACTCCAGACCAAGGTTGAG 3557
 Db 1 ACGCCAGGCCAAGGTTGAG 19

RESULT 588

AAZ88855

ID AAZ88855 standard; DNA; 19 BP.

XX AAZ88855;

AC AAZ88855;

XX 30-MAY-2000 (first entry)

XX Human trkC receptor TK insert sense primer.

XX trkB; human; receptor tyrosine kinase; trkC; diagnosis; neurotrophin;
 KW neurotrophic factor; primer; trkA; ss.

XX Homo sapiens.

XX US6027927-A.

XX 22-FEB-2000.

XX 01-OCT-1997; 97US-00942562.

XX 18-MAR-1994; 94US-00215139.

PR 05-AUG-1994; 94US-00286846.

PR 19-MAY-1995; 95US-00444597.

XX (GETH) GENENTECH INC.

XX Urfer R, Shelton DL, Presta LG;

XX WPI; 2000-194832/17.

XX New human trk receptors useful in the diagnosis of various human
 PT pathological conditions associated with elevated or reduced levels of
 PT neurotrophins capable of binding trkB and/or trkC.
 XX Disclosure; Col 93-94; 78pp; English.

XX This invention describes a novel isolated and purified polypeptide (I),
 CC belonging to the trk family of receptor tyrosine kinases, trkB and trkC.
 CC (I) are useful in the purification of human neurotrophic factors and in
 CC the diagnosis of various human pathological conditions associated with
 CC elevated or reduced levels of neurotrophins capable of binding trkB
 CC and/or trkC. AAZ88843-288868 represent primers used in the isolation of
 CC the trkA, trkB and trkC receptor proteins described in the method of the
 CC invention

XX SQ Sequence 19 BP; 5 A; 5 C; 8 G; 1 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.4%; Score 15.8; DB 1; Length 19;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 3539 ACTCCAGACCAAGGTTGAG 3557

Db 1 ACGCCAGGCCAAGGTTGAG 19

RESULT 589

AAD30287/C

ID AAD30287 standard; DNA; 19 BP.

XX AAD30287;

AC AAD30287;

XX 17-MAY-2002 (first entry)

XX Human PKD1 gene mutation detecting nested PCR primer, 13R.

KW Human; PKD1 gene; autosomal dominant polycystic kidney disease; ADPKD;
 KW acquired cystic disease; transgenic animal; PCR primer; ss.
 XX Homo sapiens.
 OS
 XX
 PN WO200206529-A2.
 XX
 XX
 PD 24-JAN-2002.
 XX
 XX 13-JUL-2001; 2001WO-US022035.
 XX
 XX 13-JUL-2000; 2000US-0218261P.
 PR 13-APR-2001; 2001US-0283691P.
 XX
 XX (UYJO) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
 PA
 XX Germino GG, Watnick TJ, Phakdeekitcharoen B;
 PI WPI; 2002-179805/23.
 XX
 DR
 XX Novel primer for diagnosing polycystic kidney disease-associated
 PT disorder, comprises regions having sequence that selectively hybridizes
 PT to polycystic kidney disease gene sequence.
 XX
 XX Claim 6; Page 101; 192pp; English.
 PS
 XX The present invention relates to compositions and methods useful for the
 CC identification and detection of polycystic kidney disease (PKD1) gene
 CC mutations. The invention also relates to primers comprising a 5' region
 CC having a sequence that selectively hybridizes to a PKD1 gene sequence and
 CC optionally, to a PKD1 homologue sequence and an adjacent 3' region having
 CC a sequence that selectively hybridizes to a PKD1 gene sequence and not to
 CC a PKD1 homologue sequence. Primer pairs of the invention are useful for
 CC detecting the presence or absence of a mutation in a PKD1 polynucleotide
 CC in a sample, for identifying a subject at risk for a PKD1-associated
 CC disorder such as autosomal dominant polycystic kidney disease (ADPKD) or
 CC acquired cystic disease and for diagnosing a PKD1-associated disorder in
 CC a subject. They are useful for selectively amplifying a region of a PKD1
 CC gene. PKD1 DNA fragments are useful for detecting the presence of a mutant
 CC PKD1 polynucleotide in a sample, as a probe for an amplification
 CC reaction, in hybridisation or amplification assays of biological samples
 CC to detect abnormalities of PKD1 expression and for engineering transgenic
 CC animals. The present sequence is a PCR primer used to detect mutation in
 CC human PKD1 gene
 XX
 SQ Sequence 19 BP; 4 A; 3 C; 10 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 3.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1068 TGGCCCCAGCCCGAGCTC 1086
 Db 19 TTGTCCAGCCCGAGCTC 1
 RESULT 590
 ABK30165
 ID ABK30165 standard; DNA; 19 BP.
 XX
 AC ABK30165;
 XX
 XX 23-APR-2002 (first entry)
 DT
 XX CYP2D6 gene polymorphism detection primer #4.
 DE
 XX Human; CYP2D6; primer; single nucleotide polymorphism detection; SNP; ss.
 KW
 XX Homo sapiens.
 OS Synthetic.
 XX
 XX WO200196604-A2.
 PN
 XX

PD 20-DEC-2001.
 XX
 PF 11-JUN-2001; 2001WO-US018912.
 XX
 XX 12-JUN-2000; 2000US-0210988P.
 PR
 XX (GENI-) GENICON SCI CORP.
 PA
 XX Bee G, Kohne DE, Korb L, Peterson T, Yguerabide J;
 PI WPI; 2002-130745/17.
 XX
 DR
 XX Determining the presence of a CYP2D6 target sequence in a DNA sample
 PT containing CYP2D6 nucleic acid, for detecting mutations or polymorphisms,
 PT comprises detecting the scattered light from a particle bound to the
 PT target sequence.
 XX
 XX Claim 14; Page 50; 66pp; English.
 PS
 XX The invention relates to a method of determining the presence or absence
 CC of a CYP2D6 target sequence in a DNA sample containing CYP2D6 nucleic
 CC acid. Determining the presence or absence of a CYP2D6 target sequence in
 CC a sample of DNA containing CYP2D6 nucleic acid comprises contacting the
 CC nucleic acid with a probe under stringent binding conditions, and
 CC detecting the presence or absence of the target sequence bound with the
 CC probe with a scattered light detectable particle, by observing light
 CC scattered from the particle which indicates the presence of the target
 CC sequence. The method is useful for determining the presence or absence of
 CC particular single nucleotide polymorphisms or alleles in genomic nucleic
 CC acid, especially in a pharmacogenetically relevant gene or genes in a DNA
 CC sample, and to detect and measure one or more target sequences in a
 CC sample. The method may also be used to detect specific mutations to
 CC identify the phenotypic classification of an individual. ABK30162-
 CC ABK30230 represent CYP2D6 target sequence-specific primers of the
 CC invention
 XX
 SQ Sequence 19 BP; 4 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 3.1e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1947 CCAGACCCCACTGGATGAG 1965
 Db 1 CCTGACCCAGCTGGATGAG 19
 RESULT 591
 ABZ24394
 ID ABZ24394 standard; DNA; 19 BP.
 XX
 AC ABZ24394;
 XX
 XX 18-MAR-2003 (first entry)
 DT
 XX Human cytochrome P450 CYP2D6*35 specific forward PCR primer.
 DE
 XX Human; cytochrome P450; CYP2D6; CYP2D6*36; enzyme; genotyping; SNP;
 KW single nucleotide polymorphism; drug metabolism; antidepressant;
 KW antiarrhythmic; neuroleptic; morphine; PCR; primer; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200299118-A2.
 PN
 XX 12-DEC-2002.
 PD
 XX 05-JUN-2002; 2002WO-US017938.
 PF
 XX 05-JUN-2001; 2001US-0296252P.
 PR
 XX (DNAS-) DNA LAB SCI INC.
 PA
 XX


```
XX 20-FEB-2003; 2003WO-US005022.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR
XX 11-MAR-2002; 2002US-0363124P.
PR
XX 29-MAY-2002; 2002WO-US017674.
PR
XX 06-JUN-2002; 2002US-0386782P.
PR
XX 03-JUL-2002; 2002US-0393796P.
PR
XX 29-JUL-2002; 2002US-0399348P.
PR
XX 29-AUG-2002; 2002US-0406784P.
PR
XX 05-SEP-2002; 2002US-0408378P.
PR
XX 09-SEP-2002; 2002US-0409293P.
PR
XX 04-NOV-2002; 2002US-00287949.
PR
XX 27-NOV-2002; 2002US-00306747.
PR
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Beigelman L, Pavco P;
PI
XX WPI; 2003-679876/64.
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX
XX Example 3; SEQ ID NO 1924; 207pp; English.
XX
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX
XX Sequence 19 BP; 5 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
SQ
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2596 CTGGCTGCTCGCAACATCC 2614
Db 19 CTGGCTGCTCGGAACATTC 1
RESULT 594
ADF84250/c
ID ADF84250 standard; RNA; 19 BP.
XX
XX ADF84250;
AC
XX
XX 26-FEB-2004 (first entry)
DT
XX
XX Human ABL1-targeted siRNA - SEQ ID 544.
DE
XX short interfering nucleic acid; siNA; breakpoint cluster region;
KW v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
XX Homo sapiens.
OS
```

```
XX WO2003070972-A2.
PN
XX
XX 28-AUG-2003.
PD
XX
XX 20-FEB-2003; 2003WO-US005234.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR
XX 11-MAR-2002; 2002US-0363124P.
PR
XX 06-JUN-2002; 2002US-0386782P.
PR
XX 15-AUG-2002; 2002US-0404039P.
PR
XX 29-AUG-2002; 2002US-0406784P.
PR
XX 05-SEP-2002; 2002US-0408378P.
PR
XX 09-SEP-2002; 2002US-0409293P.
PR
XX 14-JAN-2003; 2003US-0439922P.
PR
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Beigelman L, Chowrira B;
PI
XX WPI; 2003-679889/64.
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT cluster region-Abelson (BCR-ABL) gene.
XX
XX Example 7; SEQ ID NO 544; 197pp; English.
XX
XX The invention relates to a novel double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the breakpoint
CC cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC activity and may be useful for modulating expression of the BCR-ABL gene,
CC as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
CC the human ABL1-targeted siRNA of the invention.
XX
XX Sequence 19 BP; 2 A; 7 C; 9 G; 0 T; 1 U; 0 Other;
SQ
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 155 CCAGCACGCTCGGCGCCG 173
Db 19 CCAGCTCGTCCGCGCCG 1
RESULT 595
ADF84569
ID ADF84569 standard; RNA; 19 BP.
XX
XX ADF84569;
AC
XX
XX 26-FEB-2004 (first entry)
DT
XX
XX Human ABL1-targeted siRNA - SEQ ID 863.
DE
XX short interfering nucleic acid; siNA; breakpoint cluster region;
KW v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
XX Homo sapiens.
OS
XX WO2003070972-A2.
PN
XX
XX 28-AUG-2003.
PD
XX
XX 20-FEB-2003; 2003WO-US005234.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR
```

PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 15-AUG-2002; 2002US-0404039P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 14-JAN-2003; 2003US-0439922P.
PR 15-JAN-2003; 2003US-0440129P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Beigelman L, Chowrira B;
XX WPI; 2003-679889/64.
DR
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT cluster region-Abelson (BCR-ABL) gene.
XX
XX Example 7; SEQ ID NO 863; 197pp; English.
XX
XX The invention relates to a novel double-stranded short interfering
CC nucleic acid (siRNA) that downregulates expression of the breakpoint
CC cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC activity and may be useful for modulating expression of the BCR-ABL gene,
CC as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC screening, target identification and validation, genetic engineering, of
CC gene function studies and gene mapping. The current sequence is that of
CC the human ABL1-targeted siRNA of the invention.
XX
XX Sequence 19 BP; 1 A; 9 C; 7 G; 0 T; 2 U; 0 Other;
SQ

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. NO. 3.1e-02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 155 CCAGCAGCGCTCGGGCCCG 173
||||| : |||||
Db 1 CCAGCUCGGUCGGGCCCG 19

RESULT 596
ADI00303/c
ID ADI00303 standard; DNA; 19 BP.
XX
XX AC ADI00303;
XX
XX 22-APR-2004 (first entry)
XX
XX PCR primer SEQ ID 83 used to amplify human PKD-1 exon 13 DNA.
XX
XX mutation analysis; PKD; polycystic kidney disease; human; PKD-1; ss; PCR;
KW primer.
XX
XX Homo sapiens.
XX
XX US2003152936-A1.
FN
XX 14-AUG-2003.
PD
XX 26-FEB-2002; 2002US-00083246.
PF
XX 12-OCT-2001; 2001US-0328739P.
PR
XX (ATHE-) ATHENA DIAGNOSTICS INC.
XX
XX Jones JG, Hennigan AN, Curran JA, Allen SK, Robichaud NJ, Wang J;
PI Flynn KE, Garces JA, Palatucci CM;
XX
XX WPI; 2003-897708/82.
DR
XX Analyzing mutations of a target nucleic acid by detecting heteroduplexes

PT from generated duplexes, useful for diagnosing patients affected with
PT polycystic kidney disease.
XX
XX Disclosure; SEQ ID NO 83; 126pp; English.
XX
XX The invention relates to a novel method of mutation analysis of a target
CC nucleic acid which comprises incubating a sample having the target
CC nucleic acid in a reaction mixture, in the presence of at least one first
CC and second nucleic acid, where incubation produces amplified products,
CC generating duplexes in the amplified products and detecting the presence
CC or absence of a heteroduplex from the duplexes, where its presence
CC indicates a potential mutation in the target nucleic acid and its absence
CC indicates the absence of mutation in the target nucleic acid. The method
CC and compositions of the invention may be useful for analysing mutation
CC and diagnosing patients affected with PKD (polycystic kidney disease).
CC The current sequence is that of a PCR primer of the invention which was
CC used to amplify human polycystic kidney disease PKD-1 DNA.
XX
XX Sequence 19 BP; 4 A; 3 C; 10 G; 2 T; 0 U; 0 Other;
SQ

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. NO. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1068 TGGCCCGCCAGCCCGAGCTC 1086
||||| : |||||
Db 19 TTGTCCCGCCCGAGCTC 1

RESULT 597
ADO16340
ID ADO16340 standard; DNA; 19 BP.
XX
XX AC ADO16340;
XX
XX 29-JUL-2004 (first entry)
XX
XX 4 synthesis-period of neuroblastoma related primer, SEQ ID 602.
XX
XX Human; 4 synthesis-period; neuroblastoma; stage 4S; primer; ss.
XX
XX Synthetic.
XX
XX WO2004039975-A1.
FN
XX 13-MAY-2004.
PD
XX 30-OCT-2003; 2003WO-JP013932.
PF
XX 30-OCT-2002; 2002JP-00316586.
PR
XX (HISM) HISAMITSU PHARM CO LTD.
PA (CHIB-) CHIBA PREFECTURE.
PA
XX Nakagawara A, Ohira M;
XX
XX WPI; 2004-390323/36.
DR
XX Novel nucleic acid obtained from 4 synthesis-period of neuroblastoma
PT cells useful for prognosing and determining progress stage of
PT neuroblastomas.
XX
XX Claim 8; SEQ ID NO 602; 455pp; Japanese.
XX
XX The present invention relates to human nucleic acid sequences (I;
CC ADO15739-ADO15912) obtained from 4 synthesis-period (stage 4S) of
CC neuroblastoma cell. (I) is useful for prognosing and determining the
CC progress stage of 4 synthesis-period of neuroblastoma. The present
CC sequence is a primer, used to illustrate the invention.
XX
XX Sequence 19 BP; 7 A; 7 C; 4 G; 1 T; 0 U; 0 Other;
SQ

Query Match 0.4%; Score 15.8; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 18 AGCAGAGCCACTCCAGGA 36
|||||
Db 1 AGCAGAGCCACTCCACAGA 19

RESULT 598
ADQ60909
ID ADQ60909 standard; RNA; 19 BP.
XX AC ADQ60909;
XX DT 09-SEP-2004 (first entry)
XX DE Anti-BLK siRNA related DNA sequence SEQ ID NO:611.
XX KW ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
XX KW RNA interference.
XX OS Synthetic.
XX PN WO2004045543-A2.
XX PD 03-JUN-2004.
XX PF 14-NOV-2003; 2003WO-US036787.
XX PR 14-NOV-2002; 2002US-0426137P.
XX PR 10-SEP-2003; 2003US-0502050P.
XX PA (DHAR-) DHARMACON INC.
XX PI Anastasia K, Angela R, Devin L, William M, Stephen S;
XX DR WPI; 2004-420527/39.
XX PT Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
PT by selecting a target gene and measuring the functionality of the
PT nucleotide sequences that are complementary to a stretch of nucleotides
PT of the target sequence.
XX PS Example 12; SEQ ID NO 611; 199pp; English.
XX CC The invention relates to a novel method for selecting siRNA (short
CC interfering RNA) comprising selecting an siRNA molecule of 19-25
CC nucleoside bases by selecting a target gene and measuring the
CC functionality of sequences of 19-25 nucleotides in length that are
CC substantially complementary to a stretch of nucleotides of the target
CC sequence, where the functionality is dependent upon non-target specific
CC criteria. Also claimed are methods for gene-silencing, developing an
CC siRNA algorithm for selecting siRNA, selecting an siRNA with improved
CC functionality, selecting hyperfunctional siRNA, an siRNA molecule
CC effective at silencing Bcl-2, and a kit for gene silencing comprising the
CC siRNA. The siRNA molecule comprises a sequence substantially similar to a
CC sequence consisting of GGAGAUAGUGAUGAAGUA; GAAGACUCUGCCAGUUU;
CC GUACACACCGGAGUA; AGAUGAUGAUGAUGAUAU; UGAAGACUCUGCCAGUUU;
CC CAUGGCCUCUGUUUGA; UCGGCCUCUGUUUGA; GAGAUAUGAUGAUGAUAU;
CC GGAGAUAGUGAUGAUAU; and GAAGACUCUGCCAGUUU. The siRNA molecule
CC comprises a sense strand and an anti-sense strand. The siRNA molecule
CC comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
CC pairs. The kit comprises at least two siRNA, comprising a first optimised
CC siRNA and a second optimised siRNA. The method is useful in selecting
CC siRNA for generating a gene silencing reagent. The present sequence is
CC used in the exemplification of the invention. The sequence is shown in
CC the specification as DNA, but described as siRNA.
XX SQ Sequence 19 BP; 6 A; 6 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2985 GGTGAGCGCCCTGGACAG 3003
|||||
Db 1 GGTGAGCGCCCAAGACAAG 19

RESULT 599
ADU03887/c
ID ADU03887 standard; DNA; 19 BP.
XX AC ADU03887;
XX DT 30-DEC-2004 (first entry)
XX DE Human polycystic kidney disease 1 (PKD-1) gene specific primer, 1X13R.
XX KW mutation detection; polycystic kidney disease; PKD; PKD-1; PKD-2;
XX KW biomarker; autosomal dominant polycystic kidney disease; ADPKD; primer;
XX KW ss.
XX OS Homo sapiens.
XX PN CA2461106-A1.
XX PD 11-OCT-2004.
XX PF 08-APR-2004; 2004CA-02461106.
XX PR 11-APR-2003; 2003US-00411915.
XX PA (ATHE-) ATHENA DIAGNOSTICS INC.
XX PI Jones JG, Hennigan AN, Flynn KE, Garces JA, Seltzer WK;
XX PI Palatucci CM, Wang J, Curran JA, Allen SK, Robichaud NJ;
XX DR WPI; 2004-776219/77.
XX PT Novel nucleic acid comprising specific sequence capable of detecting
PT mutations in polycystic kidney disease-1 (PKD-1) or PKD-2 gene, useful
PT for detecting biomarkers of autosomal dominant polycystic kidney disease.
XX PS Disclosure; Page 41; 195pp; English.
XX CC The invention relates to a novel isolated nucleic acid capable of
CC detecting mutations in polycystic kidney disease (PKD-1) or PKD-2 gene,
CC comprising a specific sequence. The invention further comprises: a
CC nucleic acid biomarker for autosomal dominant polycystic kidney disease
CC (ADPKD), comprising a PKD-1 or PKD-2 nucleic acid sequence having one or
CC more novel nucleotide alterations chosen from identified ADPKD associated
CC alterations, as given in the specification; a polypeptide biomarker for
CC ADPKD, comprising a PKD-1 or PKD-2 polypeptide sequence having one or
CC more novel amino acid alterations chosen from identified ADPKD associated
CC alterations, as given in the specification; a method for diagnosing ADPKD
CC in an individual; and a method for determining in an individual the
CC presence or absence of a mutant PKD gene. The PKD mutation detecting
CC isolated nucleic acid or the ADPKD nucleic acid biomarker is useful in
CC diagnosing ADPKD in an individual, or determining the presence or absence
CC of a mutant PKD gene in an individual. This polynucleotide sequence
CC represents a human polycystic kidney disease specific primer used in the
CC detection method of the invention.
XX SQ Sequence 19 BP; 4 A; 3 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1068 TGGCCCCAGCCCCAGCCTC 1086
|||||
Db 19 TTGTCACGCCCCAGCCTC 1

RESULT 600

ADY8888/c
ID ADY8888 standard; RNA; 19 BP.
XX
AC ADY8888;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA SEQ ID NO 1924.
XX
KW ss; siRNA; short interfering RNA; RNA interference; gene silencing;
KW VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 1924; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA.
XX
SQ Sequence 19 BP; 5 A; 5 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2596 CTGGCTGCTCGACATCC 2614
DB 19 CTGGCTGCTCGAACATTC 1
RESULT 601
ADY89258
ID ADY89258 standard; RNA; 19 BP.
XX
AC ADY89258;
XX
DT 16-JUN-2005 (first entry)

XX
DE VEGFR siRNA target sequence SEQ ID NO 2294.
XX
KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
PN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (SIRN-) SIRNA THERAPEUTICS INC.
XX
PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
DR WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 2294; 396pp; English.
XX
CC The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA target sequence.
XX
SQ Sequence 19 BP; 4 A; 5 C; 6 G; 0 T; 4 U; 0 Other;
Query Match 0.4%; Score 15.8; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 3.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
QY 2932 ATGCTGACCTGTTGGCAGA 2950
DB 1 AUGCUGACUGCGGCACA 19
RESULT 602
ADY88641
ID ADY88641 standard; RNA; 19 BP.
XX
AC ADY88641;
XX
DT 16-JUN-2005 (first entry)
XX
DE VEGFR siRNA SEQ ID NO 1677.
XX
KW ss; siRNA; short interfering RNA; RNA interference; gene silencing;
KW VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.

XX PN WO2005028649-A1.
 XX PD 31-MAR-2005.
 XX PF 16-SEP-2004; 2004WO-US030488.
 XX PR 16-SEP-2003; 2003US-00664767.
 XX PR 16-SEP-2003; 2003US-00665255.
 XX PR 23-SEP-2003; 2003US-00670011.
 XX PR 23-OCT-2003; 2003US-00693059.
 XX PR 24-NOV-2003; 2003US-00720448.
 XX PR 03-DEC-2003; 2003US-00727780.
 XX PR 14-JAN-2004; 2004US-00757803.
 XX PR 26-JAN-2004; 2004US-00764957.
 XX PR 10-FEB-2004; 2004US-0543480P.
 XX PR 13-FEB-2004; 2004US-00780447.
 XX PR 16-APR-2004; 2004US-00826966.
 XX PR 23-APR-2004; 2004US-00831620.
 XX PR 30-APR-2004; 2004US-00013456.
 XX PR 11-MAY-2004; 2004US-00844076.
 XX PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX PI Jadhav V, Koseen K, Zinnen S, Vaish N, Mcswiggen J;
 XX PF WPI; 2005-254128/26.
 XX PR New multifunctional siRNA molecule that directs cleavage of the first and
 PT second VEGF or VEGFR target sequences via RNA interference, useful in
 PT preparing a composition for treating cell proliferative disorders e.g.
 PT cancers.
 XX PR Disclosure; SEQ ID NO 1677; 396pp; English.
 XX PS The invention relates to a multifunctional siRNA molecule comprising a
 CC structure having Formula MF-III and which directs cleavage of the first
 CC and second VEGF or VEGFR target sequences via RNA interference. The
 CC multifunctional siRNA molecule is useful in preparing a pharmaceutical
 CC composition for treating cell proliferative disorders, e.g. cancer. The
 CC present sequence represents a VEGFR siRNA.
 XX SQ Sequence 19 BP; 3 A; 6 C; 5 G; 0 T; 5 U; 0 Other;
 Query Match 0.4%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 68.4%; Pred. No. 3.1e+02;
 Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 2596 CTGGCTGCTGCAACATCC 2614
 Db 1 CUGGCGUCGGAACAUUC 19
 RESULT 603
 ADX58087
 ID ADX58087 standard; DNA; 18 BP.
 AC ADX58087;
 XX 21-APR-2005 (first entry)
 XX Primer Gamma 10 for single chain antibody heavy chain variable fragment.
 XX virucide; vaccine; single chain antibody; HSV; glycoprotein;
 KW glycoprotein D; herpes simplex virus; HSV infection; RT-PCR; primer; ss;
 KW heavy chain.
 XX Synthetic.
 XX WO2005011580-A2.
 XX 10-FEB-2005.

PF 26-JUL-2004; 2004WO-US024013.
 XX 25-JUL-2003; 2003US-0489984P.
 XX (TEXA) UNIV TEXAS SYSTEM.
 XX PI Simmons A, Chen J;
 XX WPI; 2005-142827/15.
 DR New single chain antibody that specifically binds to a Herpes Simplex
 PT Virus (HSV) glycoprotein, useful in preparing a composition for
 PT preventing or treating a HSV infection.
 XX Example 1; SEQ ID NO 25; 99pp; English.
 XX The specification describes a single chain antibody that specifically
 CC binds to a herpes simplex virus (HSV) glycoprotein, e.g. glycoprotein D.
 CC The single chain antibody of the invention is useful for preparing a
 CC composition for preventing or treating a HSV infection. C region RT-PCR
 CC primer ADX58077 with gamma degenerate signal sequence RT-PCR primers
 CC ADX58078-ADX58094 were used to amplify cDNA encoding single chain
 CC antibody heavy chain variable fragments. The amplicons were used to
 CC generate single chain antibodies of the invention.
 XX SQ Sequence 18 BP; 2 A; 7 C; 3 G; 5 T; 0 U; 1 Other;
 Query Match 0.4%; Score 15.6; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 3e+02;
 Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 4067 CCAAGCTGTGCTCTAT 4082
 Db 1 CCAAGCTGTGCTCTT 16
 RESULT 604
 ADX58086
 ID ADX58086 standard; DNA; 18 BP.
 AC ADX58086;
 XX 21-APR-2005 (first entry)
 XX Primer Gamma 9 for a single chain antibody heavy chain variable fragment.
 DE virucide; vaccine; single chain antibody; HSV; glycoprotein;
 KW glycoprotein D; herpes simplex virus; HSV infection; RT-PCR; primer; ss;
 KW heavy chain.
 XX Synthetic.
 XX WO2005011580-A2.
 XX 10-FEB-2005.
 XX 26-JUL-2004; 2004WO-US024013.
 XX 25-JUL-2003; 2003US-0489984P.
 XX (TEXA) UNIV TEXAS SYSTEM.
 XX PI Simmons A, Chen J;
 XX WPI; 2005-142827/15.
 DR New single chain antibody that specifically binds to a Herpes Simplex
 PT Virus (HSV) glycoprotein, useful in preparing a composition for
 PT preventing or treating a HSV infection.
 XX Example 1; SEQ ID NO 24; 99pp; English.
 XX The specification describes a single chain antibody that specifically

CC binds to a herpes simplex virus (HSV) glycoprotein, e.g. glycoprotein D.
CC The single chain antibody of the invention is useful for preparing a
CC composition for preventing or treating a HSV infection. C region RT-PCR
CC primer ADX58077 with gamma degenerate signal sequence RT-PCR primers
CC ADX58078-ADX58094 were used to amplify cDNA encoding single chain
CC antibody heavy chain variable fragments. The amplicons were used to
CC generate single chain antibodies of the invention.
XX Sequence 18 BP; 2 A; 7 C; 3 G; 5 T; 0 U; 1 Other;
SQ
Query Match 0.4%; Score 15.6; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
Qy 4067 CCAAGCTGTGCTCAT 4082
Db 1 CCAAGCTGTGCTCAT 16
RESULT 605
AAT53779
ID AAT53779 standard; RNA; 17 BP.
XX
AC AAT53779;
XX
DT 25-MAR-2003 (revised)
DT 03-APR-1997 (first entry)
XX
DE Rat ICAM hammerhead ribozyme target sequence (nt. position 2659).
XX
KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW intercellular adhesion molecule; rel A; tumour necrosis factor;
KW TNF-alpha; respiratory syncytial virus; RSV; bor-abl; oncogene;
KW translocation; chronic myelogenous leukaemia; CML; cancer;
KW Philadelphia chromosome; inflammation; autoimmune disease;
KW atherosclerosis; myocardial infarction; stroke; restenosis;
KW transplant rejection; rheumatoid arthritis; psoriasis;
KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW ss.
XX
OS Rattus rattus.
XX
PN WO9523225-A2.
XX
PD 31-AUG-1995.
XX
PF 23-FEB-1995; 95WO-IB000156.
XX
PR 23-FEB-1994; 94US-00201109.
PR 29-MAR-1994; 94US-00218934.
PR 04-APR-1994; 94US-00222795.
PR 07-APR-1994; 94US-00224483.
PR 15-APR-1994; 94US-00227958.
PR 15-APR-1994; 94US-00228041.
PR 18-MAY-1994; 94US-00245736.
PR 06-JUL-1994; 94US-00271280.
PR 15-AUG-1994; 94US-00291932.
PR 16-AUG-1994; 94US-00291433.
PR 17-AUG-1994; 94US-00292620.
PR 19-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
PR 23-SEP-1994; 94US-00311486.
PR 23-SEP-1994; 94US-00311749.
PR 28-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00321492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.

PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Uzman N, Wincott FE, Woolf T;
DR WPI; 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
XX
XX Claim 2; Page 204; 407pp; English.
XX
CC The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1 mRNA at the
CC nucleotide base position indicated in the DE line. Regions of the mRNA
CC that do not form secondary folding structures and that contain potential
CC hammerhead and hairpin ribozyme cleavage sites were identified by
CC computer analysis. Ribozymes directed against these mRNA sequences were
CC designed and synthesised with modifications that improve their nucleic
CC resistance. The ribozymes cleave the ICAM-1 target sequences and thereby
CC inhibit ICAM-1 expression, making them useful for reducing transplant
CC rejection and alleviating symptoms in patients with rheumatoid arthritis,
CC asthma and other inflammatory disorders. (Updated on 25-MAR-2003 to
CC correct PI field.)
XX
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.9e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
Qy 1218 AGAAGGCTCGCCAGC 1234
Db 1 AGAAGGCTCGCCAGC 17
RESULT 606
AAV92591
ID AAV92591 standard; RNA; 17 BP.
XX
AC AAV92591;
XX
DT 18-FEB-1999 (first entry)
XX
DE Human A-Raf substrate position 1871.
XX
KW Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW screening; identification; synthesis; deprotection; purification; cancer;
KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW restenosis; rheumatoid arthritis; ss.
XX
OS Homo sapiens.
XX
PN WO9850530-A2.
XX
PD 12-NOV-1998.
XX
PF 05-MAY-1998; 98WO-US009249.
XX
PR 09-MAY-1997; 97US-0046059P.
PR 09-JUN-1997; 97US-0049002P.
PR 03-JUL-1997; 97US-0051718P.
PR 22-AUG-1997; 97US-0056808P.
PR 02-OCT-1997; 97US-0061321P.
PR 02-OCT-1997; 97US-0061324P.
PR 05-NOV-1997; 97US-0064866P.

PR 19-DEC-1997; 97US-0068212P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;
 PI Parry T, Beigelman L, Mcswiggen JA, Karpeisky A, Burgin A;
 PI Thompson J, Workman CT, Beaudry A, Sweedler D;
 XX WPI; 1999-009494/01.
 DR
 XX
 XX Identifying new catalytic nucleic acid that modulates selected processes
 PT - especially ribozymes that cleave Raf RNA for treating cancer,
 PT restenosis, and also new ribozymes and modified nucleoside triphosphates
 PT used as antiviral agents and synthons.
 XX
 PS Claim 177; Page 160; 259pp; English.
 XX
 CC A method has been developed for the identification of a nucleic acid
 CC capable of modulating a process in a biological system. The method
 CC comprises: (a) introducing into the system a random library of nucleic
 CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
 CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
 CC in systems where modulation has occurred and/or determining the sequence
 CC of at least part of the SBDs in such systems. Nucleic acid molecules with
 CC endonuclease activity and catalytic activity, from the present invention,
 CC are used to modulate gene expression in plant and mammalian cells and to
 CC cleave target nucleic acid, particularly for treating systemic diseases
 CC caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
 CC ascites and infection. They may also be used to detect genetic drift and
 CC mutations in diseased cells and to determine c-rat RNA. Specifically NACs
 CC with RNA-cleaving activity that modulate expression of the Raf gene, are
 CC used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
 CC generally any condition associated with the level of c-rat. Introduction
 CC of sugar/phosphate modifications increases stability against nuclease and
 CC activity. AAV90922 to AAV93877 represent NACs that can be used in the
 CC method, specifically for modulating the expression of a Raf gene
 XX
 XX Sequence 17 BP; 1 A; 11 C; 2 G; 0 T; 3 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.9e+02;
 Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 2965 CGGCCCGCTTCCCCCA 2981
 DB 1 CGGCCCGCTTCCCCCA 17
 RESULT 607
 AAF06056
 ID AAF06056 standard; DNA; 17 BP.
 XX
 XX AAF06056;
 AC
 XX
 DT 16-FEB-2001 (first entry)
 XX
 XX Hammerhead ribozyme substrate #2853.
 DE
 XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200061729-A2.
 PN
 XX 19-OCT-2000.
 PD
 XX 11-APR-2000; 2000WO-US009721.
 PF
 XX 12-APR-1999; 99US-0129390P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX

PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
 XX WPI; 2000-647423/62.
 XX
 PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor protein,
 PT interferon alpha and erythropoietin.
 XX
 XX Claim 42; Page 121; 164pp; English.
 PS
 XX The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha
 XX
 SQ Sequence 17 BP; 5 A; 5 C; 1 G; 0 T; 6 U; 0 Other;
 Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 58.8%; Pred. No. 2.9e+02;
 Matches 10; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
 QY 1566 TCCTGACTTCACCTATA 1582
 DB 1 UCCUGACUUCACUAUA 17
 RESULT 608
 ABA81101/c
 ID ABA81101 standard; DNA; 17 BP.
 XX
 AC ABA81101;
 XX
 XX 24-JAN-2002 (first entry)
 DT
 XX
 DE LDLR mutation correcting oligonucleotide SEQ ID NO: 3947.
 XX
 XX Human; gene therapy; adenine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antineoplastic; antianemic; haemostatic;
 KW antileptic; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200173002-A2.
 PN
 XX 04-OCT-2001.
 PD
 XX 27-MAR-2001; 2001WO-US009761.
 PF
 XX 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamper HB, Rice MC;
 PI WPI; 2001-639230/73.
 DR
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.

XX PS Claim 7; Page 256; 294pp; English.

XX CC The present invention provides single-stranded oligonucleotides which can be used for the targeted alteration of genomic sequences, where the oligonucleotide has at least one mismatch compared with the genomic sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BCR1, BCR2, CFTR, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6, apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and presenilin-2 (PSEN2). These can be used in the gene therapy of diseases such as cancer, adenosine deaminase deficiency, cystic fibrosis, haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia, Alzheimer's disease, melanoma, adenomatous polyposis of the colon and various syndromes. The present sequence is one of the gene correcting oligonucleotides of the invention

XX SQ Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2319 CCTGAGGGTGGCTACA 2335
Db 17 CCTGAGGGTGGCTACA 1

RESULT 609

ABA81100

ID ABA81100 standard; DNA; 17 BP.

XX AC ABA81100;

XX DT 24-JAN-2002 (first entry)

XX DE LDLR mutation correcting oligonucleotide SEQ ID NO: 3946.

XX KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin; retinoblastoma; BCR1; BCR2; CFTR; cystic fibrosis; cancer; Factor V; cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2; adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis; haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE; mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR; familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense; UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1; Alzheimer's disease; cytosstatic; antisickling; antianaemic; haemostatic; antilipemic; ss.

XX OS Homo sapiens.

XX PN WO200173002-A2.

XX PD 04-OCT-2001.

XX PF 27-MAR-2001; 2001WO-US009761.

XX PR 27-MAR-2000; 2000US-0192176P.

XX PR 27-MAR-2000; 2000US-0192179P.

XX PR 01-JUN-2000; 2000US-0208538P.

XX PR 30-OCT-2000; 2000US-0244989P.

XX PA (UYDE) UNIV DELAWARE.

XX PI Kmiec EB, Gamper HB, Rice MC;

XX WPI; 2001-639230/73.

XX Oligonucleotide for targeted alterations of genetic sequences and for treating cystic fibrosis, comprises at least one mismatch and chemical

PT modification.

XX Claim 7; Page 256; 294pp; English.

XX CC The present invention provides single-stranded oligonucleotides which can be used for the targeted alteration of genomic sequences, where the oligonucleotide has at least one mismatch compared with the genomic sequence to be altered. In particular, these sequences are directed at the following genes: adenosine deaminase, p53, beta-globin, retinoblastoma, BCR1, BCR2, CFTR, cyclin-dependent kinase inhibitor 2A (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6, apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and presenilin-2 (PSEN2). These can be used in the gene therapy of diseases such as cancer, adenosine deaminase deficiency, cystic fibrosis, haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia, Alzheimer's disease, melanoma, adenomatous polyposis of the colon and various syndromes. The present sequence is one of the gene correcting oligonucleotides of the invention

XX SQ Sequence 17 BP; 3 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2319 CCTGAGGGTGGCTACA 2335
Db 1 CCTGAGGGTGGCTACA 17

RESULT 610

ABN01661/c

ID ABN01661 standard; DNA; 17 BP.

XX AC ABN01661;

XX DT 29-MAY-2002 (first entry)

XX DE Human GDMPL-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1653.

XX KW Human; genome-derived myosin-like protein 1; GDMPL-1; heart; muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease; skeletal muscle disorder; ampicion; screening; ss.

XX OS Homo sapiens.

XX PN WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US016981.

XX PR 26-MAY-2000; 2000US-0207456P.

XX PR 21-SEP-2000; 2000US-0234687P.

XX PR 27-SEP-2000; 2000US-0236359P.

XX PR 04-OCT-2000; 2000GB-00024263.

XX PR 30-JAN-2001; 2001WO-US000661.

XX PR 30-JAN-2001; 2001WO-US000662.

XX PR 30-JAN-2001; 2001WO-US000663.

XX PR 30-JAN-2001; 2001WO-US000664.

XX PR 30-JAN-2001; 2001WO-US000665.

XX PR 30-JAN-2001; 2001WO-US000666.

XX PR 30-JAN-2001; 2001WO-US000667.

XX PR 30-JAN-2001; 2001WO-US000668.

XX PR 30-JAN-2001; 2001WO-US000669.

XX PR 05-FEB-2001; 2001US-026860P.

XX PA (AEOM-) AEOMICA INC.

XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX PF 21-SEP-2001; 2001WO-US029656.
 XX PF 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 28-AUG-2001; 2001US-0315676P.
 XX PA (AEOM-) ABOMICA INC.
 XX FI Zhang J;
 XX DR WPI; 2002-479509/51.
 XX PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
 PT acids encoding the protein, useful for treating subjects having defects
 PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
 PT e.g., liver or bone.
 XX PS Example 2; Page 172; 418pp; English.
 XX CC The invention relates to a novel isolated nucleic acid encoding human
 CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
 CC invention has cytostatic activity. The nucleotide may have a use in gene
 CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
 CC monitor a disease caused by altered expression of human KTOM1.
 CC Compositions comprising the nucleic acids, proteins or antibodies may be
 CC used to treat subjects having defects in KTOM1 which can manifest as
 CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
 CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
 CC function. The sequence represents a probe used in the invention to scan
 CC the nt 1-1001 portion of human KTOM1a (ABQ63232)
 XX SQ Sequence 17 BP; 2 A; 2 C; 10 G; 3 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.9e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 4039 CCACATCCCGGACCC 4055
 Db 17 CCACATCCCGGACTCC 1
 RESULT 613
 ACN02004
 ID ACN02004 standard; RNA; 17 BP.
 AC ACN02004;
 AC ACN02004;
 DT 22-APR-2004 (first entry)
 XX WNV Inozyme substrate SEQ ID NO 1994.
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 XX Amberzyme; Zinzyme; ss.
 XX OS West Nile Virus.

PN WO200268637-A2.
 XX 06-SEP-2002.
 XX 19-OCT-2001; 2001WO-US048350.
 XX 20-OCT-2000; 2000US-0242411P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAY/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX Blatt L, Mcswiggen JA;
 XX WPI; 2002-706994/76.
 XX New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX Claim 23; SEQ ID NO 1994; 495pp; English.
 XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;
 Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.9e+02;
 Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 Qy 3228 AGTCACTCTGGCGGAC 3244
 Db 1 AGUCACACGCGCGGAC 17
 RESULT 614
 ACN11465/C
 ID ACN11465 standard; RNA; 17 BP.
 AC ACN11465;
 AC ACN11465;
 DT 22-APR-2004 (first entry)
 XX WNV minus strand Inozyme substrate SEQ ID NO 11468.
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.
 XX OS West Nile Virus.
 XX WO200268637-A2.
 XX 06-SEP-2002.
 XX 19-OCT-2001; 2001WO-US048350.
 XX 20-OCT-2000; 2000US-0242411P.

```
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 11468; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;
SQ
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3228 AGTCACCTCTGGCGGAC 3244
DB 17 AGTCACACTGGCGGAC 1
RESULT 615
AEB58244
XX AEB58244 standard; mRNA; 17 BP.
AC AEB58244;
XX
XX 22-SEP-2005 (first entry)
XX
XX Human VEGF receptor 1 (flt-1) DNazyme target sequence SEQ ID 822.
XX
XX VEGF receptor; angiogenesis; cancer; tumor; ocular disease;
XX diabetic retinopathy; age related macular degeneration;
XX angiogenesis disorder; rheumatoid arthritis; psoriasis; wound healing;
XX endometriosis; endometroid carcinoma; gynecological bleeding disorder;
XX menstruation disorder; premenstrual syndrome; menopause; gynecological;
XX cytostatic; ophthalmological; antidiabetic; antiangiogenic;
XX Antipsoriatic; Antirheumatic; Antiarthritic; Vulnery; Hemostatic;
XX Contraceptive; ss; enzymatic nucleic acid.
XX
XX Homo sapiens.
XX
XX WO200296927-A2.
XX
XX 05-DEC-2002.
XX
XX 29-MAY-2002; 2002WO-US017674.
XX
XX 29-MAY-2001; 2001US-00870161.
XX 30-NOV-2001; 2001US-0334461P.
XX 03-MAY-2002; 2002US-00138674.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
```

```
PA (CHIR ) CHIRON CORP.
XX
XX Escobedo J, Mcswiggen J, Pavco P, Stinchcomb D, Sandberg J;
PI Gordon G;
XX
XX WPI; 2003-140439/13.
XX
XX Novel enzymatic nucleic acids, ribozymes, which modulate expression of
PT genes encoding vascular endothelial growth factor and/or VEGF receptor,
PT useful for inhibiting tumor angiogenesis in cell, and for treating
PT cancer.
XX
XX Disclosure; SEQ ID NO 822; 172pp; English.
XX
XX The invention relates to enzymatic nucleic acids (I) i.e.
CC ribozymes/DNAzymes/zinzymes that target and modulate expression of, genes
CC encoding vascular endothelial growth factor (VEGF) and/or VEGF receptor
CC (VEGFR1 and 2 encode by the Flt-1 and Kdr genes respectively). Also
CC included are a composition comprising (I) and a carrier, administering
CC (I) to a cell (by contacting the cell with the compound under conditions
CC suitable for the administration), administering (I) to a cell (in
CC conjunction with one or more other drug by contacting the cell with the
CC compound and the other drug under conditions suitable for the
CC administration), administering (I) to a mammal (by contacting the mammal
CC with the compound under conditions suitable for the administration),
CC treating (M1) a subject having endometriosis (by contacting a subject
CC with, or administering to subject, a nucleic acid molecule (II) that
CC modulates expression of VEGF, VEGFR1, and/or VEGFR2), a mammalian cell
CC (III) comprising (I) and administering to a mammal (I) (in conjunction
CC with a chemotherapeutic agent comprising contacting the mammal with the
CC compound and the chemotherapeutic agent under conditions suitable for the
CC administration). (I) is administered to a mammalian cell, preferably
CC human cell in the presence of a delivery reagent which is a lipid such as
CC cationic lipid or phospholipid, or a liposome. The enzymatic nucleic acid
CC molecule has an endonuclease activity to cleave RNA encoded by an VEGFR1
CC and/or VEGFR2 gene, and is in a hammerhead, inozyme, DNazyme, G-cleaver,
CC or Amberzyme configuration. The enzymatic nucleic acids are useful for
CC inhibiting ocular angiogenesis associated with diabetic retinopathy or
CC age-related diabetic retinopathy, in a subject. They are also useful for
CC inhibiting angiogenesis, preferably tumor angiogenesis in cell, and for
CC treating a subject having a condition associated with an increased level
CC of VEGF receptor, where the condition is cancer, e.g. breast cancer, lung
CC cancer (such as non-small cell lung carcinoma), colorectal cancer, renal
CC cancer (such as renal cell carcinoma), pancreatic cancer. The enzymatic
CC nucleic acids are useful for treating a subject (preferably human) having
CC endometriosis, psoriasis, age-related macular degeneration, proliferative
CC diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis,
CC wound healing, endometrial carcinoma, gynecologic bleeding disorders,
CC irregular menstrual cycles, ovulation, premenstrual syndrome, and
CC menopausal dysfunction. The enzymatic nucleic acids are useful for birth
CC control by inhibiting ovulation or embryonic uterine implantation. The
CC present sequence is a target sequence from the human VEGFR1/flt-1 mRNA.
XX
XX Sequence 17 BP; 4 A; 4 C; 5 G; 0 T; 4 U; 0 Other;
SQ
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.9e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
QY 2926 CAGCTTCATGCTGGACTG 2942
DB 1 CAGAUAUGCUGGACUG 17
RESULT 616
AEB58245
XX AEB58245 standard; mRNA; 17 BP.
XX
XX AEB58245;
XX
XX 22-SEP-2005 (first entry)
XX
XX Human VEGF receptor 1 (flt-1) DNazyme target sequence SEQ ID 823.
XX
XX
```


VEGF receptor; angiogenesis; cancer; tumor; ocular disease;
diabetic retinopathy; age related macular degeneration;
angiogenesis disorder; rheumatoid arthritis; psoriasis; wound healing;
endometriosis; endometrial carcinoma; gynecological bleeding disorder;
menstruation disorder; premenstrual syndrome; menopause; Gynecological;
Cytostatic; Ophthalmological; Antidiabetic; antiangiogenic;
Antipsoriatic; Antirheumatic; Antiarthritic; Vulnery; Hemostatic;
Contraceptive; ss; enzymatic nucleic acid.

Homo sapiens.
WO200296927-A2.
05-DEC-2002.
29-MAY-2002; 2002WO-US017674.
29-MAY-2001; 2001US-00870161.
30-NOV-2001; 2001US-0334461P.
03-MAY-2002; 2002US-00138674.
(RIBO-) RIBOZYME PHARM INC.
(CHIR) CHIRON CORP.
Escobedo J, Mcswiggen J, Pavco P, Stinchcomb D, Sandberg J;
Gordon G;
WPI; 2003-140439/13.
Novel enzymatic nucleic acids, ribozymes, which modulate expression of
genes encoding vascular endothelial growth factor and/or VEGF receptor,
useful for inhibiting tumor angiogenesis in cell, and for treating
cancer.

Disclosure; SEQ ID NO 823; 172pp; English.

The invention relates to enzymatic nucleic acids (I) i.e.
ribozymes/DNAzymes/Zinzymes that target and modulate expression of, genes
encoding vascular endothelial growth factor (VEGF) and/or VEGF receptor
(VEGFR1 and 2 encode by the Flt-1 and Kdr genes respectively). Also
included are a composition comprising (I) and a carrier, administering
(I) to a cell (by contacting the cell with the compound under conditions
suitable for the administration), administering (I) to a cell (in
conjunction with one or more other drug by contacting the cell with the
compound and the other drug under conditions suitable for the
administration), administering (I) to a mammal (by contacting the mammal
with the compound under conditions suitable for the administration),
treating (M1) a subject having endometriosis (by contacting a subject
with, or administering to subject, a nucleic acid molecule (II) that
modulates expression of VEGF, VEGFR1, and/or VEGFR2), a mammalian cell
(III) comprising (I) and administering to a mammal (I) (in conjunction
with a chemotherapeutic agent comprising contacting the mammal with the
compound and the chemotherapeutic agent under conditions suitable for the
administration). (I) is administered to a mammalian cell, preferably
human cell in the presence of a delivery reagent which is a lipid such as
cationic lipid or phospholipid, or a liposome. The enzymatic nucleic acid
molecule has an endonuclease activity to cleave RNA encoded by an VEGFR1
and/or VEGFR2 gene, and is in a hammerhead, inozyme, DNAzyme, G-cleaver,
or Amberzyme configuration. The enzymatic nucleic acids are useful for
inhibiting ocular angiogenesis associated with diabetic retinopathy or
age-related diabetic retinopathy, in a subject. They are also useful for
inhibiting angiogenesis, preferably tumor angiogenesis in cell, and for
treating a subject having a condition associated with an increased level
of VEGF receptor, where the condition is cancer, e.g. breast cancer, lung
cancer (such as non-small cell lung carcinoma), colorectal cancer, renal
cancer (such as renal cell carcinoma), pancreatic cancer. The enzymatic
nucleic acids are useful for treating a subject (preferably human) having
endometriosis, psoriasis, age-related macular degeneration, proliferative
diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis,
wound healing, endometrial carcinoma, gynecologic bleeding disorders,
irregular menstrual cycles, ovulation, premenstrual syndrome, and
menopausal dysfunction. The enzymatic nucleic acids are useful for birth

CC control by inhibiting ovulation or embryonic uterine implantation. The
CC present sequence is a target sequence from the human VEGFR1/flt-1 mRNA.
XX
SQ Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.9e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
QY 2931 CATGCTGGACTGTTGGC 2947
Db 1 CAUGCUGGACUGCUGGC 17
RESULT 617
AEB61660
ID AEB61660 standard; mRNA; 17 BP.
XX
AC AEB61660;
XX
DT 22-SEP-2005 (first entry)
XX
DE Human VEGF receptor 21 (Kdr) DNAzyme target sequence SEQ ID 4238.
XX
KW VEGF receptor; angiogenesis; cancer; tumor; ocular disease;
KW diabetic retinopathy; age related macular degeneration;
KW angiogenesis disorder; rheumatoid arthritis; psoriasis; wound healing;
KW endometriosis; endometrial carcinoma; gynecological bleeding disorder;
KW menstruation disorder; premenstrual syndrome; menopause; Gynecological;
KW Cytostatic; Ophthalmological; Antidiabetic; antiangiogenic;
KW Antipsoriatic; Antirheumatic; Antiarthritic; Vulnery; Hemostatic;
KW Contraceptive; ss; enzymatic nucleic acid.
XX
OS Homo sapiens.
XX
PN WO200296927-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US017674.
XX
PR 29-MAY-2001; 2001US-00870161.
PR 30-NOV-2001; 2001US-0334461P.
PR 03-MAY-2002; 2002US-00138674.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
PI Escobedo J, Mcswiggen J, Pavco P, Stinchcomb D, Sandberg J;
PI Gordon G;
PI WPI; 2003-140439/13.
DR
XX
XX Novel enzymatic nucleic acids, ribozymes, which modulate expression of
PT genes encoding vascular endothelial growth factor and/or VEGF receptor,
PT useful for inhibiting tumor angiogenesis in cell, and for treating
PT cancer.
XX
PS Disclosure; SEQ ID NO 4238; 172pp; English.
XX
CC The invention relates to enzymatic nucleic acids (I) i.e.
CC ribozymes/DNAzymes/Zinzymes that target and modulate expression of, genes
CC encoding vascular endothelial growth factor (VEGF) and/or VEGF receptor
CC (VEGFR1 and 2 encode by the Flt-1 and Kdr genes respectively). Also
CC included are a composition comprising (I) and a carrier, administering
CC (I) to a cell (by contacting the cell with the compound under conditions
CC suitable for the administration), administering (I) to a cell (in
CC conjunction with one or more other drug by contacting the cell with the
CC compound and the other drug under conditions suitable for the
CC administration), administering (I) to a mammal (by contacting the mammal
CC with the compound under conditions suitable for the administration),
CC treating (M1) a subject having endometriosis (by contacting a subject
CC with, or administering to subject, a nucleic acid molecule (II) that
CC modulates expression of VEGF, VEGFR1, and/or VEGFR2), a mammalian cell
CC (III) comprising (I) and administering to a mammal (I) (in conjunction
CC with a chemotherapeutic agent comprising contacting the mammal with the
CC compound and the chemotherapeutic agent under conditions suitable for the
CC administration). (I) is administered to a mammalian cell, preferably
CC human cell in the presence of a delivery reagent which is a lipid such as
CC cationic lipid or phospholipid, or a liposome. The enzymatic nucleic acid
CC molecule has an endonuclease activity to cleave RNA encoded by an VEGFR1
CC and/or VEGFR2 gene, and is in a hammerhead, inozyme, DNAzyme, G-cleaver,
CC or Amberzyme configuration. The enzymatic nucleic acids are useful for
CC inhibiting ocular angiogenesis associated with diabetic retinopathy or
CC age-related diabetic retinopathy, in a subject. They are also useful for
CC inhibiting angiogenesis, preferably tumor angiogenesis in cell, and for
CC treating a subject having a condition associated with an increased level
CC of VEGF receptor, where the condition is cancer, e.g. breast cancer, lung
CC cancer (such as non-small cell lung carcinoma), colorectal cancer, renal
CC cancer (such as renal cell carcinoma), pancreatic cancer. The enzymatic
CC nucleic acids are useful for treating a subject (preferably human) having
CC endometriosis, psoriasis, age-related macular degeneration, proliferative
CC diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis,
CC wound healing, endometrial carcinoma, gynecologic bleeding disorders,
CC irregular menstrual cycles, ovulation, premenstrual syndrome, and
CC menopausal dysfunction. The enzymatic nucleic acids are useful for birth

CC modulates expression of VEGF, VEGFR1, and/or VEGFR2], a mammalian cell
 CC (III) comprising (I) and administering to a mammal (I) (in conjunction
 CC with a chemotherapeutic agent comprising contacting the mammal with the
 CC compound and the chemotherapeutic agent under conditions suitable for the
 CC administration). (I) is administered to a mammalian cell, preferably
 CC human cell in the presence of a delivery reagent which is a lipid such as
 CC cationic lipid or phospholipid, or a liposome. The enzymatic nucleic acid
 CC molecule has an endonuclease activity to cleave RNA encoded by an VEGFR1
 CC and/or VEGFR2 gene, and is in a hammerhead, inozyme, DNzyme, G-cleaver,
 CC or Ambenzyme configuration. The enzymatic nucleic acids are useful for
 CC inhibiting ocular angiogenesis associated with diabetic retinopathy or
 CC age-related diabetic retinopathy, in a subject. They are also useful for
 CC inhibiting angiogenesis, preferably tumor angiogenesis in cell, and for
 CC treating a subject having a condition associated with an increased level
 CC of VEGF receptor, where the condition is cancer, e.g. breast cancer, lung
 CC cancer (such as non-small cell lung carcinoma), colorectal cancer, renal
 CC cancer (such as renal cell carcinoma), pancreatic cancer. The enzymatic
 CC nucleic acids are useful for treating a subject (preferably human) having
 CC endometriosis, psoriasis, age-related macular degeneration, proliferative
 CC diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis,
 CC wound healing, endometrial carcinoma, gynecologic bleeding disorders,
 CC irregular menstrual cycles, ovulation, premenstrual syndrome, and
 CC menopausal dysfunction. The enzymatic nucleic acids are useful for birth
 CC control by inhibiting ovulation or embryonic uterine implantation. The
 CC present sequence is a target sequence from the human VEGFR2/Kdr mRNA.

XX SQ Sequence 17 BP; 2 A; 5 C; 6 G; 0 T; 4 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.9e+02;
 Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGGACTGTGGC 2947
 ||:|||||:|
 Db 1 CAUGCUGGACUGCGGC 17

RESULT 618
 ACN64751/c
 ID ACN64751 standard; DNA; 17 BP.
 AC ACN64751;
 XX 02-DEC-2004 (first entry)
 XX Human GDMPLP-1 probe SEQ ID NO:1653.

XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.

XX Homo sapiens.
 XX US2004137589-A1.
 XX 15-JUL-2004.
 XX 26-NOV-2003; 2003US-00723361.

XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.

XX (GUYY/) GU Y.
 XX (JIYY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 PI WPI; 2004-533378/51.

XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.

XX Disclosure; SEQ ID NO 1653; Opp; English.

XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 55% identity to (S1). A polypeptide of the invention acts as a agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63102

XX SQ Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 2.9e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3966 TATGGCCTCCTTTGCC 3982
 |||||||
 Db 17 TCTGGCCTCCTTTGCC 1

RESULT 619
 ACN64752/c
 ID ACN64752 standard; DNA; 17 BP.
 AC ACN64752;
 XX 02-DEC-2004 (first entry)
 XX Human GDMPLP-1 probe SEQ ID NO:1654.
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.

XX Homo sapiens.
 XX US2004137589-A1.
 XX 15-JUL-2004.
 XX 26-NOV-2003; 2003US-00723361.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.

PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY)/ GU Y.
PA (JIY)/ JI Y.
PA (PENN)/ PENN S G.
PA (HANZ)/ HANZEL D K.
PA (RANK)/ RANK D.
PA (CHEN)/ CHEN W.
PA (SHAN)/ SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX
DR WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 1654; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
XX Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.4; DB 1; Length 17;
XX Best Local Similarity 94.1%; Pred. No. 2.9e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
Qy 3965 CTATGGCTCCTTTGCC 3981
Db 17 CTCCTGGCTCCTTTGCC 1
XX
RESULT 620
ADR87873
ID ADR87873 standard; DNA; 18 BP.
XX
AC ADR87873;
XX
XX 04-NOV-2004 (first entry)
XX
XX Biotinylated primer used to amplify human CYP2D6 exon 7 DNA - SEQ ID 51.
XX
XX SNP detection; drug therapy; PCR; primer; ss; human;
XX cytochrome P450 isoenzyme; debrisoquine 4-hydroxylase; CYP2D6 exon 7.
XX
XX Homo sapiens.
XX
XX WO2004069189-A2.
XX
XX 19-AUG-2004.
XX
XX 04-FEB-2004; 2004WO-US002941.
XX
XX 04-FEB-2004; 2004WO-US000663.
XX (INNO-) INNOVACEUTICALS INC.
XX
XX Branch RA, Romkes M;
XX
XX WPI; 2004-604340/58.
XX
XX Measuring the expression or activity of a CYP enzyme in a subject by
PT measuring the expression of the CYP enzyme gene or mRNA expression for
PT the CYP enzyme in whole blood and normalizing the measured CYP enzyme
PT gene or mRNA expression.
XX
XX Example 5; SEQ ID NO 51; 73pp; English.
XX
XX The invention relates to a novel method for measuring the expression or
CC activity of a CYP (cytochrome P450), NAT1 (N-acetyltransferase 1) or NAT2
CC (N-acetyltransferase 2) enzyme in a subject comprising measuring the
CC expression of the enzyme gene or mRNA in whole blood and normalising the
CC measured enzyme gene or mRNA expression, respectively. The method may be
CC useful in measuring the expression or activity of an enzyme in a subject
CC and for detecting and quantifying the presence of SNPs (single nucleotide
CC polymorphisms) within an enzyme. Thus, the method of the invention may be
CC utilised in order to predict the effectiveness or safety of a drug
CC therapy, since the drug metabolising capability of an individual is
CC affected by the isoenzymes present within that individual. The current
CC sequence is that of a 5' biotinylated PCR primer which was used to
CC amplify human CYP2D6 (debrisoquine 4-hydroxylase) DNA of the invention.
XX
XX Sequence 18 BP; 7 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 15.4; DB 1; Length 18;
XX Best Local Similarity 94.1%; Pred. No. 3.2e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
Qy 3718 GGCAAGAGGGGTGTCA 3734
Db 2 GGCAAGAGGGGTGTCA 18
XX
RESULT 621
ADF36606/c
ID ADF36606 standard; RNA; 19 BP.
XX
AC ADF36606;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human VEGFR2 short interfering nucleic acid (siRNA) SEQ ID NO:895.
XX
XX double-stranded short interfering nucleic acid;
XX short interfering nucleic acid; siRNA; downregulation;
XX vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
XX cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
XX nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
XX diabetic retinopathy; macular degeneration; neovascular glaucoma;
XX arthritis; psoriasis; endometriosis; angiofibroma;
XX polycystic kidney disease; ss.
XX
XX Synthetic.
XX
XX Homo sapiens.
XX
XX WO2003070910-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005022.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 29-MAY-2002; 2002WO-US017674.
XX 06-JUN-2002; 2002US-0386782P.

```

PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Beigelman L, Pavco P;
XX WPI; 2003-679876/64.
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
XX PT and diagnosis of cancer, downregulates the vascular endothelial growth
XX PT factor receptor gene.
XX
XX Example 3; SEQ ID NO 895; 207pp; English.
XX
XX The present invention describes a double-stranded short interfering
XX CC nucleic acid (siNA) that downregulates expression of the vascular
XX CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
XX CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
XX CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
XX CC that express siNA; and (5) single-stranded siNA with similar properties.
XX CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
XX CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
XX CC gynaecological activities. The siNA are useful for modulating
XX CC (downregulating) the expression of VEGFR genes. The siNA are potentially
XX CC useful for treating a wide range of angiogenesis-associated conditions,
XX CC particularly cancers, diabetic retinopathy, macular degeneration,
XX CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
XX CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
XX CC drug screening, target identification and validation, genetic
XX CC engineering, studying gene function, and also for gene mapping (e.g. of
XX CC single-nucleotide polymorphisms). The present sequence is used in the
XX CC exemplification of the present invention.
XX
XX SQ Sequence 19 BP; 12 A; 3 C; 3 G; 0 T; 1 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3860 AGTTTGTGTTTGTCT 3876
Db |||||
18 AGTTTGTGTTTGTCT 2

RESULT 622
ADF36930
ID ADF36930 standard; RNA; 19 BP.
XX
XX ADF36930;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human VEGFR2 short interfering nucleic acid (siNA) SEQ ID NO:1219.
XX
XX double-stranded short interfering nucleic acid;
XX KW short interfering nucleic acid; siNA; downregulation;
XX KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
XX KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
XX KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
XX KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
XX KW arthritis; psoriasis; endometriosis; angiofibroma;
XX KW polycystic kidney disease; ss.
XX
XX Synthetic.
XX OS Homo sapiens.
XX

```

```

PN WO2003070910-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005022.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 29-MAY-2002; 2002WO-US017674.
XX 06-JUN-2002; 2002US-0386782P.
XX 03-JUL-2002; 2002US-0393796P.
XX 29-JUL-2002; 2002US-0399348P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 04-NOV-2002; 2002US-00287949.
XX 27-NOV-2002; 2002US-00306747.
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Beigelman L, Pavco P;
XX WPI; 2003-679876/64.
XX
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
XX and diagnosis of cancer, downregulates the vascular endothelial growth
XX PT factor receptor gene.
XX
XX Example 3; SEQ ID NO 1219; 207pp; English.
XX
XX The present invention describes a double-stranded short interfering
XX CC nucleic acid (siNA) that downregulates expression of the vascular
XX CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
XX CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
XX CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
XX CC that express siNA; and (5) single-stranded siNA with similar properties.
XX CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
XX CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
XX CC gynaecological activities. The siNA are useful for modulating
XX CC (downregulating) the expression of VEGFR genes. The siNA are potentially
XX CC useful for treating a wide range of angiogenesis-associated conditions,
XX CC particularly cancers, diabetic retinopathy, macular degeneration,
XX CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
XX CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
XX CC drug screening, target identification and validation, genetic
XX CC engineering, studying gene function, and also for gene mapping (e.g. of
XX CC single-nucleotide polymorphisms). The present sequence is used in the
XX CC exemplification of the present invention.
XX
XX SQ Sequence 19 BP; 1 A; 3 C; 3 G; 0 T; 12 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 29.4%; Pred. No. 3.5e+02;
Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;

QY 3860 AGTTTGTGTTTGTCT 3876
Db |||:||||:|:|:|
2 AGUUUUUUUUUUUUU 18

RESULT 623
AD016519
ID AD016519 standard; DNA; 19 BP.
XX
XX AD016519;
XX
XX 29-JUL-2004 (first entry)
XX
XX 4 synthesis-period of neuroblastoma related primer, SEQ ID 781.
XX DE Human; 4 synthesis-period; neuroblastoma; stage 4S; primer; ss.
XX
XX

```

OS Synthetic.
 PN WO2004039975-A1.
 XX
 PD 13-MAY-2004.
 XX
 XX 30-OCT-2003; 2003WO-JP013932.
 PF
 XX 30-OCT-2002; 2002JP-00316586.
 PR
 XX (HISM) HISAMITSU PHARM CO LTD.
 PA (CHIB-) CHIBA PREFECTURE.
 PA
 XX Nakagawara A, Ohira M;
 PI WPI; 2004-390323/36.
 DR
 XX Novel nucleic acid obtained from 4 synthesis-period of neuroblastoma
 PT cells useful for prognosing and determining progress stage of
 PT neuroblastomas.
 PT
 XX Claim 8; SEQ ID NO 781; 455pp; Japanese.
 PS
 XX The present invention relates to human nucleic acid sequences (I;
 CC ADO15739-ADO15912) obtained from 4 synthesis-period (stage 4S) of
 CC neuroblastoma cell. (I) is useful for prognosing and determining the
 CC progress stage of 4 synthesis-period of neuroblastoma. The present
 CC sequence is a primer, used to illustrate the invention.
 CC
 XX Sequence 19 BP; 8 A; 6 C; 4 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1935 GGAACATCCACAGCCAGA 1951
 DB 3 GGAACATCCACAGCCAGA 19
 RESULT 624
 ADO60352
 ID ADO60352 standard; RNA; 19 BP.
 AC ADO60352;
 XX
 DT 09-SEP-2004 (first entry)
 DE
 DE Anti-Cyclophilin siRNA Cyclo 20 SEQ ID NO:51.
 XX
 XX ss; siRNA; gene silencing; Bcl-2; optimised; short interfering RNA;
 KW RNA interference; cyclophilin.
 KW
 XX Synthetic.
 OS
 XX WO2004045543-A2.
 PN
 XX 03-JUN-2004.
 PD
 XX 14-NOV-2003; 2003WO-US036787.
 PF
 XX 14-NOV-2002; 2002US-0426137P.
 PR 10-SEP-2003; 2003US-0502050P.
 PR
 XX (DHAR-) DHARMA CON INC.
 PA
 XX Anastasia K, Angela R, Devin L, William M, Stephen S;
 PI WPI; 2004-420527/39.
 DR
 XX Selecting siRNA by selecting an siRNA molecule of 19-25 nucleoside bases
 PT by selecting a target gene and measuring the functionality of the
 PT nucleotide sequences that are complementary to a stretch of nucleotides

PT of the target sequence.
 XX
 PS Example 1; SEQ ID NO 51; 199pp; English.
 XX
 CC The invention relates to a novel method for selecting siRNA (short
 CC interfering RNA) comprising selecting an siRNA molecule of 19-25
 CC nucleoside bases by selecting a target gene and measuring the
 CC functionality of sequences of 19-25 nucleotides in length that are
 CC substantially complementary to a stretch of nucleotides of the target
 CC sequence, where the functionality is dependent upon non-target specific
 CC criteria. Also claimed are methods for gene-silencing, developing an
 CC siRNA algorithm for selecting siRNA, selecting an siRNA with improved
 CC functionality, selecting hyperfunctional siRNA, an siRNA molecule
 CC effective at silencing Bcl-2, and a kit for gene silencing comprising the
 CC siRNA. The siRNA molecule comprises a sequence substantially similar to a
 CC sequence consisting of GGGAGUAGUGAUGAGUA; GAAGUACAUCCAUUAUAG;
 CC GUACGACACCCGGGAUA; AGAUGAUGAUGAUGAUAU; UGAAGACUCUGCCAGUUU;
 CC AUGCGCCUCUGUUGA; UCGCGCCUCUGUUGA; and GAGAUUGAUGAUGAUA;
 CC GAGAUUGAUGAUGAUA; and GAGACUCUGCAGUUUG. The siRNA molecule
 CC comprises a sense strand and an anti-sense strand. The siRNA molecule
 CC comprises a hairpin. The siRNA molecule comprises between 18 and 30 base
 CC pairs. The kit comprises at least two siRNA, comprising a first optimised
 CC siRNA and a second optimised siRNA. The method is useful in selecting
 CC siRNA for generating a gene silencing reagent. The present sequence is
 CC used in the exemplification of the invention.
 XX
 SQ Sequence 19 BP; 7 A; 1 C; 8 G; 0 T; 3 U; 0 Other;
 Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 76.5%; Pred. No. 3.5e+02;
 Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
 QY 3472 GGAGACACGATTTGG 3488
 DB 2 GGAGAGAAAGGAUUUGG 18
 RESULT 625
 ADR79853/C
 ID ADR79853 standard; DNA; 19 BP.
 AC ADR79853;
 XX
 DT 16-DEC-2004 (first entry)
 DE
 DE Human apolipoprotein B (ApoB) oligonucleotide seqid 4349.
 XX
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2004080406-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 08-MAR-2004; 2004WO-US007070.
 PF
 XX 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.

PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
PA (ALNY-) ALNYLAM PHARM.
XX
XX Manoharan M, Bumcrot D;
XX WPI; 2004-677362/66.
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
PS Example 5; SEQ ID NO 4349; 378pp; English.
XX
CC The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apob-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apob-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
CC can be used to control ApoB gene expression.
XX
SQ Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3553 GTGAGGCGCGCTTCCC 3569
DB 18 GTGAGGCGCGCTTCCC 2

RESULT 626
ID ADR79854/C
XX ADR79854 standard; DNA; 19 BP.
XX
AC ADR79854;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human apolipoprotein B (ApoB) oligonucleotide seqid 4350.
XX
XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW RNA interference; iRNA; antisense technology; lipid metabolism;

KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apob; ss.
XX
OS Homo sapiens.
XX
XX WO2004080406-A2.
XX 23-SEP-2004.
XX
XX 08-MAR-2004; 2004WO-US007070.
XX
XX 07-MAR-2003; 2003US-0452682P.
PR 12-MAR-2003; 2003US-0454265P.
PR 13-MAR-2003; 2003US-0454962P.
PR 13-MAR-2003; 2003US-0455050P.
PR 14-APR-2003; 2003US-0462894P.
PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 25-APR-2003; 2003US-0465802P.
PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
XX (ALNY-) ALNYLAM PHARM.
XX
XX Manoharan M, Bumcrot D;
XX WPI; 2004-677362/66.
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 4350; 378pp; English.
XX
CC The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apob-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apob-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
CC can be used to control ApoB gene expression.
XX
SQ Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3553 GTGAGGCGCGCTTTCCC 3569
 DB 19 GTGAGGCGCGCTTTCCC 3

RESULT 627
 ADR76909/c
 ID ADR76909 standard; DNA; 19 BP.
 AC ADR76909;
 XX
 DT 16-DEC-2004 (first entry)
 DE Human apolipoprotein B (ApoB) oligonucleotide seqid 1394.
 XX
 KW antilipemic; cardiatic; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytosclastic; anticonvulsant; nootropic; muscular; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080406-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 08-MAR-2004; 2004WO-US007070.
 XX
 PR 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 14-APR-2003; 2003US-0455050P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0456655P.
 PR 25-APR-2003; 2003US-0458022P.
 PR 09-MAY-2003; 2003US-0459612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX
 PA (ALNY-) ALNYLAM PHARM.
 XX
 PI Manoharan M, Bumcrot D;
 XX
 XX WPI; 2004-677362/66.
 XX
 XX Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX
 XX Example 5; SEQ ID NO 1394; 378pp; English.
 XX
 XX The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);

CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.

SQ Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3553 GTGAGGCGCGCTTTCCC 3569

DB 18 GTGAGGCGCGCTTTCCC 2

RESULT 628

ADR76910/c

ID ADR76910 standard; DNA; 19 BP.

AC ADR76910;

DT 16-DEC-2004 (first entry)

DE Human apolipoprotein B (ApoB) oligonucleotide seqid 1395.

KW antilipemic; cardiatic; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytosclastic; anticonvulsant; nootropic; muscular; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.

OS Homo sapiens.

PN WO2004080406-A2.

PD 23-SEP-2004.

PF 08-MAR-2004; 2004WO-US007070.

PR 07-MAR-2003; 2003US-0452682P.

PR 12-MAR-2003; 2003US-0454265P.

PR 13-MAR-2003; 2003US-0454962P.

PR 14-APR-2003; 2003US-0455050P.

PR 17-APR-2003; 2003US-0463772P.

PR 25-APR-2003; 2003US-0465665P.

PR 25-APR-2003; 2003US-0465802P.

PR 09-MAY-2003; 2003US-0469612P.

PR 08-AUG-2003; 2003US-0493986P.

PR 11-AUG-2003; 2003US-0494597P.

PR 26-SEP-2003; 2003US-0506341P.

PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX
 PA (ALNY-) ALNYLAM PHARM.
 PI Manoharan M, Bumerot D;
 XX WPI; 2004-677362/66.
 DR
 XX
 XX Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX
 XX Example 5; SEQ ID NO 1395; 378pp; English.
 XX
 CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (MI) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing (I) or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (MI)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (apoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.
 XX
 SQ Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3553 GTGAGGCGCGCTTTCCC 3569
 Db 19 GTGAGGCGCGCTTTCCC 3
 RESULT 629
 ADT81353/c
 ID ADT81353 standard; DNA; 19 BP.
 XX
 AC ADT81353;
 XX
 DT 13-JAN-2005 (first entry)
 XX
 XX Apolipoprotein B (apoB) antisense inhibition target seqid 1395.
 XX
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW interference RNA; iRNA; cholesterol moiety; apoB; glucose-6-phosphatase;
 KW lipid metabolism; cholesterol imbalance; acquired dyslipidaemia;
 KW familial combined hyperlipidaemia; acquired hyperlipidaemia;
 KW hypercholesterolaemia; statin-resistant hypercholesterolaemia;
 KW coronary artery disease; coronary heart disease; atherosclerosis;
 KW hepatic glucose production; glucose-metabolism-related disorder;

KW type-2 diabetes; glitaxzone-resistant diabetes; human; apolipoprotein B;
 KW antisense inhibition; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004091515-A2.
 XX
 PD 28-OCT-2004.
 XX
 PF 09-APR-2004; 2004WO-US011255.
 XX
 PR 09-APR-2003; 2003US-0462097P.
 PR 10-APR-2003; 2003US-0461915P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0491986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 08-NOV-2003; 2003US-0518453P.
 PR 07-NOV-2004; 2004WO-US007070.
 PR 05-APR-2004; 2004WO-US010586.
 PA (ALNY-) ALNYLAM PHARM INC.
 PI Manoharan M, Elbashir S, Harborth J;
 XX WPI; 2004-766693/75.
 XX
 PT New interference RNA agent comprising sense sequence and antisense
 PT sequence having cholesterol moieties, useful for reducing apoB-100 levels
 or glucose-6-phosphatase levels.
 XX
 PS Claim 2; SEQ ID NO 1395; 324pp; English.
 XX
 CC The invention describes an interference RNA (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequence
 CC comprises one or more cholesterol moieties, and the antisense sequence
 CC targets a human gene sequence. The following are disclosed: a
 CC pharmaceutical composition comprising (I); and a device for administering
 CC (I) into a patient. (I) is useful for reducing apoB-100 levels or glucose
 CC -6-phosphatase levels in a subject. (I) targets a sequence identical to
 CC any one of sequences as given in the specification. (I) comprises a
 CC cholesterol moiety. The cholesterol moiety is coupled to a sense strand.
 CC (I) further comprises a second cholesterol moiety. The second cholesterol
 CC moiety is coupled to a sense strand. (I) has 21 or more nucleotides. The
 CC duplex region of (I) is 19 nucleotides in length. The subject is
 CC suffering from a disorder having elevated or otherwise unwanted
 CC expression of apo-B-100, elevated or otherwise unwanted levels of
 CC cholesterol, and/or dysregulation of lipid metabolism. The disorder is
 CC chosen from HDL/LDL cholesterol imbalance, dyslipidaemia (e.g., familial
 CC combined hyperlipidaemia or acquired hyperlipidaemia),
 CC hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary
 CC artery disease, coronary heart disease and atherosclerosis, preferably
 CC statin-resistant hypercholesterolaemia. (I) is administered to a subject
 CC to inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorders e.g., type-2 diabetes or glitaxzone-resistant diabetes.
 CC (I) has endonuclease or exonuclease resistance. This sequence represents
 CC a human apolipoprotein B (apoB) pallindromic sequence that may be useful
 CC as a target for antisense inhibition.
 XX
 SQ Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 3.5e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3553 GTGAGGCGCGCTTTCCC 3569
 ||||||| |||||||

Db 19 GTGAGGGCGGCTTTCCC 3

RESULT 630

ID ADT84297/c

AC ADT84297 standard; DNA; 19 BP.

XX

AC ADT84297;

XX

DT 13-JAN-2005 (first entry)

XX

DE Apolipoprotein B (apoB) antisense inhibition target seqid 4339.

XX

KW antilipemic; cardiac; vasotropic; antiarteriosclerotic; antidiabetic;

KW interference RNA; iRNA; cholesterol moiety; apoB; glucose-6-phosphatase;

KW lipid metabolism; cholesterol imbalance; dyslipidaemia;

KW familial combined hyperlipidaemia; acquired hyperlipidaemia;

KW hypercholesterolaemia; statin-resistant hypercholesterolaemia;

KW coronary artery disease; coronary heart disease; atherosclerosis;

KW hepatic glucose production; glucose-metabolism-related disorder;

KW type-2 diabetes; glitazone-resistant diabetes; human; apolipoprotein B;

KW antisense inhibition; ss.

XX

OS Homo sapiens.

XX

PN WO2004091515-A2.

XX

PD 28-OCT-2004.

XX

PF 09-APR-2004; 2004WO-US011255.

XX

PR 09-APR-2003; 2003US-0462097P.

PR 10-APR-2003; 2003US-0461915P.

PR 14-APR-2003; 2003US-0462894P.

PR 17-APR-2003; 2003US-0463772P.

PR 25-APR-2003; 2003US-0465665P.

PR 25-APR-2003; 2003US-0465802P.

PR 09-MAY-2003; 2003US-0469612P.

PR 08-AUG-2003; 2003US-0439986P.

PR 11-AUG-2003; 2003US-0494597P.

PR 26-SEP-2003; 2003US-0506341P.

PR 09-OCT-2003; 2003US-0510246P.

PR 10-OCT-2003; 2003US-0510318P.

PR 07-NOV-2003; 2003US-0518453P.

PR 08-MAR-2004; 2004WO-US007070.

PR 05-APR-2004; 2004WO-US010586.

XX

PA (ALNY-) ALNYLAM PHARM INC.

XX

PI Manoharan M, Elbashir S, Harborth J;

XX

DR WPI; 2004-766693/75.

XX

PT New interference RNA agent comprising sense sequence and antisense

PT sequence having cholesterol moieties, useful for reducing apoB-100 levels

PT or glucose-6-phosphatase levels.

XX

PS Claim 2; SEQ ID NO 4339; 324pp; English.

XX

CC The invention describes an interference RNA (iRNA) agent (I) comprising a

CC sense sequence and an antisense sequence, where the sense sequence

CC comprises one or more cholesterol moieties, and the antisense sequence

CC targets a human gene sequence. The following are disclosed: a

CC pharmaceutical composition comprising (I); and a device for administering

CC (I) into a patient. (I) is useful for reducing apoB-100 levels or glucose

CC -6-phosphatase levels in a subject. (I) targets a sequence identical to

CC any one of sequences as given in the specification. (I) comprises a

CC cholesterol moiety. The cholesterol moiety is coupled to a sense strand.

CC (I) further comprises a second cholesterol moiety. The second cholesterol

CC moiety is coupled to a sense strand. (I) has 21 or more nucleotides. The

CC duplex region of (I) is 19 nucleotides in length. The subject is

CC suffering from a disorder having elevated or otherwise unwanted

CC expression of apo-B-100, elevated or otherwise unwanted levels of

CC cholesterol, and/or dysregulation of lipid metabolism. The disorder is

CC chosen from HDL/LDL cholesterol imbalance, dyslipidaemia (e.g., familial

CC combined hyperlipidaemia or acquired hyperlipidaemia),

CC hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary

CC artery disease, coronary heart disease and atherosclerosis, preferably

CC statin-resistant hypercholesterolaemia. (I) is administered to a subject

CC to inhibit hepatic glucose production or for treating glucose-metabolism-

CC related disorders e.g., type-2 diabetes or glitazone-resistant diabetes.

CC (I) has endonuclease or exonuclease resistance. This sequence represents

CC a human apolipoprotein B (apoB) palindromic sequence that may be useful

CC as a target for antisense inhibition.

XX

QQ Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

XX

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 3.5e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3553 GTGAGGGCGGCTTTCCC 3569

DB 19 GTGAGGGCGGCTTTCCC 3

RESULT 631

ADT84296/c

ID ADT84296 standard; DNA; 19 BP.

XX

AC ADT84296;

XX

DT 13-JAN-2005 (first entry)

XX

DE Apolipoprotein B (apoB) antisense inhibition target seqid 4338.

XX

KW antilipemic; cardiac; vasotropic; antiarteriosclerotic; antidiabetic;

KW interference RNA; iRNA; cholesterol moiety; apoB; glucose-6-phosphatase;

KW lipid metabolism; cholesterol imbalance; dyslipidaemia;

KW familial combined hyperlipidaemia; acquired hyperlipidaemia;

KW hypercholesterolaemia; statin-resistant hypercholesterolaemia;

KW coronary artery disease; coronary heart disease; atherosclerosis;

KW hepatic glucose production; glucose-metabolism-related disorder;

KW type-2 diabetes; glitazone-resistant diabetes; human; apolipoprotein B;

KW antisense inhibition; ss.

XX

OS Homo sapiens.

XX

PN WO2004091515-A2.

XX

PD 28-OCT-2004.

XX

PF 09-APR-2004; 2004WO-US011255.

XX

PR 09-APR-2003; 2003US-0462097P.

PR 10-APR-2003; 2003US-0461915P.

PR 14-APR-2003; 2003US-0462894P.

PR 17-APR-2003; 2003US-0463772P.

PR 25-APR-2003; 2003US-0465665P.

PR 25-APR-2003; 2003US-0465802P.

PR 09-MAY-2003; 2003US-0494597P.

PR 08-AUG-2003; 2003US-0439986P.

PR 11-AUG-2003; 2003US-0494597P.

PR 26-SEP-2003; 2003US-0506341P.

PR 09-OCT-2003; 2003US-0510246P.

PR 10-OCT-2003; 2003US-0510318P.

PR 07-NOV-2003; 2003US-0518453P.

PR 08-MAR-2004; 2004WO-US007070.

PR 05-APR-2004; 2004WO-US010586.

XX

PA (ALNY-) ALNYLAM PHARM INC.

XX

PI Manoharan M, Elbashir S, Harborth J;

XX

DR WPI; 2004-766693/75.

XX

PT New interference RNA agent comprising sense sequence and antisense
PT sequence having cholesterol moieties, useful for reducing apoB-100 levels
XX or glucose-6-phosphatase levels.
XX Claim 2; SEQ ID NO 4338; 324pp; English.
XX
CC The invention describes an interference RNA (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequence
CC comprises one or more cholesterol moieties, and the antisense sequence
CC targets a human gene sequence. The following are disclosed: a
CC pharmaceutical composition comprising (I); and a device for administering
CC (I) into a patient. (I) is useful for reducing apoB-100 levels or glucose
CC -6-phosphatase levels in a subject. (I) targets a sequence identical to
CC any one of sequences as given in the specification. (I) comprises a
CC cholesterol moiety. The cholesterol moiety is coupled to a sense strand.
CC (I) further comprises a second cholesterol moiety. The second cholesterol
CC moiety is coupled to a sense strand. (I) has 21 or more nucleotides. The
CC duplex region of (I) is 19 nucleotides in length. The subject is
CC suffering from a disorder having elevated or otherwise unwanted levels of
CC expression of apo-B-100, elevated or otherwise unwanted levels of
CC cholesterol, and/or dysregulation of lipid metabolism. The disorder is
CC chosen from HDL/LDL cholesterol imbalance, dyslipidaemia (e.g., familial
CC combined hyperlipidaemia or acquired hyperlipidaemia),
CC hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary
CC artery disease, coronary heart disease and atherosclerosis, preferably
CC statin-resistant hypercholesterolaemia. (I) is administered to a subject
CC to inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorders e.g., type-2 diabetes or glitaxone-resistant diabetes.
CC (I) has endonuclease or exonuclease resistance. This sequence represents
CC a human apolipoprotein B (apoB) palindromic sequence that may be useful
CC as a target for antisense inhibition.
XX
SQ Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3553 GTGAGGCGCGCTTCC 3569
Db 18 GTGAGGCGCGCTTCC 2
RESULT 632
ADT81352/c
ID ADT81352 standard; DNA; 19 BP.
XX
AC ADT81352;
XX
DT 13-JAN-2005 (first entry)
XX
DE Apolipoprotein B (apoB) antisense inhibition target seqid 1394.
XX
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW interference RNA; iRNA; cholesterol moiety; apoB; glucose-6-phosphatase;
KW lipid metabolism; cholesterol imbalance; dyslipidaemia;
KW familial combined hyperlipidaemia; acquired hyperlipidaemia;
KW hypercholesterolaemia; statin-resistant hypercholesterolaemia;
KW coronary artery disease; coronary heart disease; atherosclerosis;
KW hepatic glucose production; glucose-metabolism-related disorder;
KW type-2 diabetes; glitaxone-resistant diabetes; human; apolipoprotein B;
KW antisense inhibition; ss.
XX
OS Homo sapiens.
XX
PN WO2004091515-A2.
XX
PD 28-OCT-2004.
XX
PF 09-APR-2004; 2004WO-US011255.
XX
PR 09-APR-2003; 2003US-0462097P.
PR 10-APR-2003; 2003US-0461915P.

PR 14-APR-2003; 2003US-0462894P.
PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465663P.
PR 25-APR-2003; 2003US-0465802P.
PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
PR 08-MAR-2004; 2004WO-US007070.
PR 05-APR-2004; 2004WO-US010586.
XX (ALNY-) ALNYLAM PHARM INC.
PA
XX Manoharan M, Elbashir S, Harborth J;
XX WPI; 2004-766693/75.
XX
DR New interference RNA agent comprising sense sequence and antisense
XX sequence having cholesterol moieties, useful for reducing apoB-100 levels
XX or glucose-6-phosphatase levels.
XX Claim 2; SEQ ID NO 1394; 324pp; English.
XX
PS The invention describes an interference RNA (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequence
CC comprises one or more cholesterol moieties, and the antisense sequence
CC targets a human gene sequence. The following are disclosed: a
CC pharmaceutical composition comprising (I); and a device for administering
CC (I) into a patient. (I) is useful for reducing apoB-100 levels or glucose
CC -6-phosphatase levels in a subject. (I) targets a sequence identical to
CC any one of sequences as given in the specification. (I) comprises a
CC cholesterol moiety. The cholesterol moiety is coupled to a sense strand.
CC (I) further comprises a second cholesterol moiety. The second cholesterol
CC moiety is coupled to a sense strand. (I) has 21 or more nucleotides. The
CC duplex region of (I) is 19 nucleotides in length. The subject is
CC suffering from a disorder having elevated or otherwise unwanted levels of
CC expression of apo-B-100, elevated or otherwise unwanted levels of
CC cholesterol, and/or dysregulation of lipid metabolism. The disorder is
CC chosen from HDL/LDL cholesterol imbalance, dyslipidaemia (e.g., familial
CC combined hyperlipidaemia or acquired hyperlipidaemia),
CC hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary
CC artery disease, coronary heart disease and atherosclerosis, preferably
CC statin-resistant hypercholesterolaemia. (I) is administered to a subject
CC to inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorders e.g., type-2 diabetes or glitaxone-resistant diabetes.
CC (I) has endonuclease or exonuclease resistance. This sequence represents
CC a human apolipoprotein B (apoB) palindromic sequence that may be useful
CC as a target for antisense inhibition.
XX
SQ Sequence 19 BP; 5 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3553 GTGAGGCGCGCTTCC 3569
Db 18 GTGAGGCGCGCTTCC 2
RESULT 633
ADX00842/c
ID ADX00842 standard; DNA; 19 BP.
XX
AC ADX00842;
XX
DT 21-APR-2005 (first entry)
XX
DE Human CYP2D6 gene 2988GtoA mutation detection reverse PCR primer #6.
XX

DNA purification; SNP detection; cardiovascular-gen.; hypotensive; neuroleptic; antiarrhythmic; antiemetic; analgesic; anorectic; tranquilizer; antimanic; antidepressant; allelic variant; CYP2D6 gene; diagnosis; codeine dependence; depression; hepatitis C virus infection; psychosis; schizophrenia; Parkinsons disease; forensic; primer; PCR; ss.

Homo sapiens.

US2005032070-A1.

10-FEB-2005.

05-AUG-2003; 2003US-00635780.

05-AUG-2003; 2003US-00635780.

(RAIM//) RAIMUNDO S.
(ZANG//) ZANGER U.

Raimundo S, Zanger U;

WPI; 2005-161644/17.

Novel polynucleotide of molecular variants of Cytochrome P450 2D6 (CYP2D6) gene, capable of hybridizing to CYP2D6 gene, is useful in diagnosing disease related to presence of molecular variant of CYP2D6 gene.

Example 1; SEQ ID NO 19; 33pp; English.

The invention relates to a polynucleotide (I) of molecular variants of CYP2D6 gene, chosen from polynucleotide capable of hybridizing to CYP2D6 gene, where the polynucleotide consists of substitution of one or more nucleotides at position corresponding to 4784, 4735 or 4087 of the CYP2D6 gene having a fully defined sequence (S1) of 9609 base pairs as given in the specification. (I) is useful for identifying a diagnostic composition, which involves (a) isolating (I) from several subgroups of individuals, where one subgroup has no prevalence for CYP2D6 associated disease, and one or more further subgroup(s) do have prevalence for a CYP2D6 associated disease, and (b) identifying a single nucleotide polymorphism by comparing the nucleic acid sequence of the polynucleotide or the gene of one subgroup having no prevalence for a CYP2D6 associated disease, with one or more further subgroup(s) having a prevalence for a CYP2D6 associated disease. (I) is useful for diagnosing a disease related to the presence of a molecular variant of a CYP2D6 gene or susceptibility to such a disorder, which involves determining the presence of (I) in a sample from a subject. (I) is useful for diagnosing whether a subject has EM, IM or PM phenotype, and for determining whether an individual is at risk for a toxic reaction, non-response, insufficient response, or reduced metabolic activity of CYP2D6 to treatment with a CYP2D6 substrate. (I) is useful in selecting a subject suffering from a CYP2D6 substrate treatable disease for treatment with the substrate, and in treating a subject suffering from a CYP2D6 substrate treatable disease. (I) is useful for detecting variant polynucleotide of CYP2D6 gene in a sample, which involves contacting (I) with the sample under conditions allowing interaction of variant of CYP2D6 gene with several immobilized targets on (I), and determining the binding of the polynucleotide or the gene to the immobilized targets on (I). (I) is useful for diagnosing a disease, which involves binding of the variant polynucleotide of CYP2D6 gene or the gene to the immobilized targets on (I), where the binding indicates the presence or the absence of the disease or a prevalence for the disease. The disease is codeine dependence, depression, hepatitis C, psychosis, schizophrenia or Parkinson's disease. (I) is useful for diagnosing an altered activity of the CYP2D6 enzyme, and for diagnosing a polynucleotide associated with IM phenotype of CYP2D6. (I) is useful in diagnosing individual's genetic constitution of the CYP2D6 status, useful in personalized medicine. (I) is used for prediction of the therapeutic outcome of an individual with an established drug and for avoidance of side effects/toxicity due to altered activity of CYP2D6 mediated by different CYP2D6 alleles. (I) is useful as forensic markers. This sequence corresponds to a PCR primer to amplify the exon 6 region of the CYP2D6 gene for detection polymorphisms.

SQ Sequence 19 BP; 2 A; 10 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. NO. 3.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3723 GAAGGGGTGTGAGGGCC 3739

Db 19 GAAGGAGTGTGAGGGCC 3

RESULT 634

ADY88183

ID ADY88183 standard; RNA; 19 BP.

XX AC ADY88183;

XX DT 16-JUN-2005 (first entry)

XX DE VEGFR siRNA SEQ ID NO 1219.

XX KW ss; siRNA; short interfering RNA; RNA interference; gene silencing;
XX KW VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.

XX OS Synthetic.

XX PN WO2005028649-A1.

XX PD 31-MAR-2005.

XX PF 16-SEP-2004; 2004WO-US030488.

XX PR 16-SEP-2003; 2003US-00664767.

XX PR 16-SEP-2003; 2003US-00665255.

XX PR 23-SEP-2003; 2003US-00670011.

XX PR 23-OCT-2003; 2003US-00693059.

XX PR 24-NOV-2003; 2003US-00720448.

XX PR 03-DEC-2003; 2003US-00727780.

XX PR 14-JAN-2004; 2004US-00757803.

XX PR 28-JAN-2004; 2004US-00764957.

XX PR 10-FEB-2004; 2004US-0543480P.

XX PR 13-FEB-2004; 2004US-00780447.

XX PR 16-APR-2004; 2004US-00826966.

XX PR 23-APR-2004; 2004US-00831620.

XX PR 30-APR-2004; 2004US-00013456.

XX PR 11-MAY-2004; 2004US-00844076.

XX (SIRN-) SIRNA THERAPEUTICS INC.

XX PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;

XX DR WPI; 2005-254128/26.

XX PT New multifunctional siNA molecule that directs cleavage of the first and second VEGF or VEGFR target sequences via RNA interference, useful in preparing a composition for treating cell proliferative disorders e.g. cancers.

XX PS Disclosure; SEQ ID NO 1219; 396pp; English.

XX CC The invention relates to a multifunctional siNA molecule comprising a structure having Formula MF-III and which directs cleavage of the first and second VEGF or VEGFR target sequences via RNA interference. The CC multifunctional siNA molecule is useful in preparing a pharmaceutical CC composition for treating cell proliferative disorders, e.g. cancer. The CC present sequence represents a VEGFR siRNA.

XX SQ Sequence 19 BP; 1 A; 3 C; 3 G; 0 T; 12 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;

Best Local Similarity 29.4%; Pred. NO. 3.5e+02;

Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;

QY 3860 AGTTTGTGTTTGTCT 3876
 ||:::|:|:::|:|:
 Db 2 AGUUUUUUUUUUUUU 18

RESULT 635

ADY87859/c

ID ADY87859 standard; RNA; 19 BP.

XX

AC ADY87859;

XX

DT 16-JUN-2005 (first entry)

XX

DE VEGFR siRNA SEQ ID NO 895.

XX

KW ss; siRNA; short interfering RNA; RNA interference; gene silencing;

KW VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.

XX

OS Synthetic.

XX

PN WO2005028649-A1.

XX

PD 31-MAR-2005.

XX

PF 16-SEP-2004; 2004WO-US030488.

XX

PR 16-SEP-2003; 2003US-00664767.

PR

PR 16-SEP-2003; 2003US-00665255.

PR

PR 23-SEP-2003; 2003US-00670011.

PR

PR 23-OCT-2003; 2003US-00693059.

PR

PR 24-NOV-2003; 2003US-00720448.

PR

PR 03-DEC-2003; 2003US-00727780.

PR

PR 14-JAN-2004; 2004US-00757803.

PR

PR 26-JAN-2004; 2004US-00764957.

PR

PR 10-FEB-2004; 2004US-0543480P.

PR

PR 13-FEB-2004; 2004US-00780447.

PR

PR 16-APR-2004; 2004US-00826966.

PR

PR 23-APR-2004; 2004US-00831620.

PR

PR 30-APR-2004; 2004US-00013456.

PR

PR 11-MAY-2004; 2004US-00844076.

XX

XX (SIRN-) SIRNA THERAPEUTICS INC.

PA

PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;

XX

PI WPI; 2005-254128/26.

XX

DR

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

ADY89384
 ID ADY89384 standard; RNA; 19 BP.

XX

AC ADY89384;

XX

DT 16-JUN-2005 (first entry)

XX

DE VEGFR siRNA target sequence SEQ ID NO 2420.

XX

KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.

XX

OS Synthetic.

XX

PN WO2005028649-A1.

XX

PD 31-MAR-2005.

XX

PF 16-SEP-2004; 2004WO-US030488.

XX

PR 16-SEP-2003; 2003US-00664767.

PR

PR 16-SEP-2003; 2003US-00665255.

PR

PR 23-SEP-2003; 2003US-00670011.

PR

PR 23-OCT-2003; 2003US-00693059.

PR

PR 24-NOV-2003; 2003US-00720448.

PR

PR 03-DEC-2003; 2003US-00727780.

PR

PR 14-JAN-2004; 2004US-00757803.

PR

PR 26-JAN-2004; 2004US-00764957.

PR

PR 10-FEB-2004; 2004US-0543480P.

PR

PR 13-FEB-2004; 2004US-00780447.

PR

PR 16-APR-2004; 2004US-00826966.

PR

PR 23-APR-2004; 2004US-00831620.

PR

PR 30-APR-2004; 2004US-00013456.

PR

PR 11-MAY-2004; 2004US-00844076.

XX

XX (SIRN-) SIRNA THERAPEUTICS INC.

PA

PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;

XX

PI WPI; 2005-254128/26.

XX

DR

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

ADY89384
 ID ADY89384 standard; RNA; 19 BP.

XX

AC ADY89384;

XX

DT 16-JUN-2005 (first entry)

XX

DE VEGFR siRNA target sequence SEQ ID NO 2420.

XX

KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.

XX

OS Synthetic.

XX

PN WO2005028649-A1.

XX

PD 31-MAR-2005.

XX

PF 16-SEP-2004; 2004WO-US030488.

XX

PR 16-SEP-2003; 2003US-00664767.

PR

PR 16-SEP-2003; 2003US-00665255.

PR

PR 23-SEP-2003; 2003US-00670011.

PR

PR 23-OCT-2003; 2003US-00693059.

PR

PR 24-NOV-2003; 2003US-00720448.

PR

PR 03-DEC-2003; 2003US-00727780.

PR

PR 14-JAN-2004; 2004US-00757803.

PR

PR 26-JAN-2004; 2004US-00764957.

PR

PR 10-FEB-2004; 2004US-0543480P.

PR

PR 13-FEB-2004; 2004US-00780447.

PR

PR 16-APR-2004; 2004US-00826966.

PR

PR 23-APR-2004; 2004US-00831620.

PR

PR 30-APR-2004; 2004US-00013456.

PR

PR 11-MAY-2004; 2004US-00844076.

XX

XX (SIRN-) SIRNA THERAPEUTICS INC.

PA

PI Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;

XX

PI WPI; 2005-254128/26.

XX

DR

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

ADY89384
 ID ADY89384 standard; RNA; 19 BP.

XX

AC ADY89384;

XX

DT 16-JUN-2005 (first entry)

XX

DE VEGFR siRNA target sequence SEQ ID NO 2420.

XX

KW ss; VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.

XX

OS Synthetic.

XX

PN WO2005028649-A1.

XX

PD 31-MAR-2005.

XX

PF 16-SEP-2004; 2004WO-US030488.

XX

PR 16-SEP-2003; 2003US-00664767.

PR

PR 16-SEP-2003; 2003US-00665255.

PR

PR 23-SEP-2003; 2003US-00670011.

PR

PR 23-OCT-2003; 2003US-00693059.

PR

PR 24-NOV-2003; 2003US-00720448.

PR

PR 03-DEC-2003; 2003US-00727780.

PR

PR 14-JAN-2004; 2004US-00757803.

PR

PR 26-JAN-2004; 2004US-00764957.

PR

PR 10-FEB-2004; 2004US-0543480P.

PR

PR 13-FEB-2004;

DE VEGFR siRNA SEQ ID NO 3371.
XX
KW ss: siRNA; short interfering RNA; RNA interference; gene silencing;
KW VEGFR; pharmaceutical; cancer; neoplasm; Cytostatic.
XX
OS Synthetic.
XX
FN WO2005028649-A1.
XX
PD 31-MAR-2005.
XX
PF 16-SEP-2004; 2004WO-US030488.
XX
PR 16-SEP-2003; 2003US-00664767.
PR 16-SEP-2003; 2003US-00665255.
PR 23-SEP-2003; 2003US-00670011.
PR 23-OCT-2003; 2003US-00693059.
PR 24-NOV-2003; 2003US-00720448.
PR 03-DEC-2003; 2003US-00727780.
PR 14-JAN-2004; 2004US-00757803.
PR 26-JAN-2004; 2004US-00764957.
PR 10-FEB-2004; 2004US-0543480P.
PR 13-FEB-2004; 2004US-00780447.
PR 16-APR-2004; 2004US-00826966.
PR 23-APR-2004; 2004US-00831620.
PR 30-APR-2004; 2004US-00013456.
PR 11-MAY-2004; 2004US-00844076.
XX
PA (STRN-) SIRNA THERAPEUTICS INC.
XX
XX Jadhav V, Kossen K, Zinnen S, Vaish N, Mcswiggen J;
XX
XX WPI; 2005-254128/26.
XX
PT New multifunctional siNA molecule that directs cleavage of the first and
PT second VEGF or VEGFR target sequences via RNA interference, useful in
PT preparing a composition for treating cell proliferative disorders e.g.
PT cancers.
XX
PS Disclosure; SEQ ID NO 3371; 396pp; English.
XX
XX The invention relates to a multifunctional siNA molecule comprising a
CC structure having Formula MF-III and which directs cleavage of the first
CC and second VEGF or VEGFR target sequences via RNA interference. The
CC multifunctional siNA molecule is useful in preparing a pharmaceutical
CC composition for treating cell proliferative disorders, e.g. cancer. The
CC present sequence represents a VEGFR siRNA.
XX
SQ Sequence 19 BP; 4 A; 6 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 0.4%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 3.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2931 CATGCTGACGTGTGGC 2947
DB 17 CATGCTGACGTGTGGC 1

RESULT 638
ADH17043
ID ADH17043 standard; DNA; 15 BP.
XX
AC ADH17043;
XX
DT 11-MAR-2004 (first entry)
XX
DE Tagman probe used to analyse human EphB4 sequence.
XX
KW tyrosine kinase activity; type 1 plasminogen activator inhibitor; PAI-1;
KW TIMP-1; tissue inhibitor of metalloproteinase 1; vinculin;
KW vascular endothelial growth factor; VEGF; placental growth factor; PLGF;
KW migration inhibitory factor; MIG; probe; ss; human; EphB4.

XX Homo sapiens.
OS
XX WO2003097854-A2.
PN
XX 27-NOV-2003.
PD
XX 19-MAY-2003; 2003WO-US015711.
PF
XX 17-MAY-2002; 2002US-0380872P.
PR
XX 24-FEB-2003; 2003US-0448874P.
PR
XX 24-FEB-2003; 2003US-0448922P.
XX
PA (SUGB-) SUGEN INC.
XX
PI Morimoto A, Deprimo S, O'farrell A, Smolich BD, Manning WC;
PI Walter SA, Schilling JW, Cherrington J;
XX
XX WPI; 2004-042604/04.
XX
PT Determining whether a test compound inhibits tyrosine kinase activity in
PT a mammal by exposing the mammal to the test compound and measuring in the
PT mammal the level of at least one of the measured proteins or mRNA
PT transcripts.
XX
PS Example K; SEQ ID NO 42; 408pp; English.
XX
XX The invention relates to a novel method for determining whether a test
CC compound inhibits tyrosine kinase activity in a mammal comprising
CC measuring in the mammal the level of at least one of the proteins and/or
CC mRNA transcripts or genes for such proteins comprising type 1 plasminogen
CC activator inhibitor (PAI-1), TIMP-1 (tissue inhibitor of
CC metalloproteinase 1), vinculin, vascular endothelial growth factor
CC (VEGF), placental growth factor (PLGF), VEGF/PLGF heterodimers or
CC migration inhibitory factor (MIG), exposing the mammal to the test
CC compound and then measuring in the mammal the level of at least one of
CC the proteins and/or mRNA transcripts previously measured. The method of
CC the invention may be useful for determining whether a test compound
CC inhibits tyrosine kinase activity in a mammal. The current sequence is
CC that of the Tagman probe which was used in the exemplification of the
CC invention.
XX
SQ Sequence 15 BP; 2 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3974 CCTTGTGCCCAAGTTG 3988
DB 1 CCTTGTGCCCAAGTTG 15

RESULT 639
AAX35184/c
ID AAX35184 standard; DNA; 17 BP.
XX
XX AAX35184;
AC
XX
DT 01-JUL-1999 (first entry)
XX
XX PCR primer used amplify and thus quantify an interleukin-17 gene.
DE
XX Evaluation; transplant rejection; immune activation marker gene;
KW perforin; granzyme B; Fas ligand; acute rejection; renal allograft;
KW sequential evaluation; simultaneous evaluation; infection;
KW interleukin-17; IL-17; PCR primer; ss.
XX
OS Synthetic.
XX
XX WO9915700-A1.
XX
PD 01-APR-1999.

XX 22-SEP-1998; 98WO-US019549.
XX
XX 24-SEP-1997; 97US-00937063.
XX
XX (BETH-) BETH ISRAEL DEACONESS MEDICAL CENT.
XX (CORR) CORNELL RES FOUND INC.
XX
XX Strom TB, Vasconcellos L, Suthanthiran M;
XX WPI; 1999-254724/21.
XX
XX Methods of evaluating transplant rejection.
XX
XX Example 1; Page 17; 40pp; English.
XX
XX The specification describes a method for evaluating transplant rejection
CC in a host by detecting up-regulation of the expression of at least two
CC immune activation marker genes chosen from perforin, granzyme B and Fas
CC ligand. The method is particularly used for evaluation of acute rejection
CC of a renal allograft. Simultaneous, or sequential evaluation of the
CC biological sample for the presence or absence of an infectious agent acts
CC a screening test, which is useful to differentially distinguish between
CC acute rejection of the transplant or infection. PCR primers AAX35184-85
CC were used to quantify the expression of a specific gene transcript
XX
XX Sequence 17 BP; 5 A; 2 C; 8 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3961 TTCACTATGGCCTCC 3975
DB 15 TTCACTATGGCCTCC 1
RESULT 640
ABN01660/c
ID ABN01660 standard; DNA; 17 BP.
XX
XX AC ABN01660;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1652.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 1652; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3968 TGGCCTCTTGGCCC 3982
DB 16 TGGCCTCTTGGCCC 2
RESULT 641
ABN01659/c
ID ABN01659 standard; DNA; 17 BP.
XX
XX AC ABN01659;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1651.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.


```

RESULT 643
ACA99869/c
ID ACA99869 standard; DNA; 17 BP.
XX
AC ACA99869;
XX
DT 28-JUL-2003 (first entry)
XX
DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #362.
XX
KW Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS Homo sapiens.
XX
PN WO2003031621-A2.
XX
PD 17-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032599.
XX
PR 12-OCT-2001; 2001US-0329000P.
XX
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Zhang J;
XX
DR WPI; 2003-381720/36.
XX
PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT investigating and/or treating disorders associated with aberrant
PT expression or activity of GPCR-A-1, such as tumors and cancers.
XX
PS Example 2; SEQ ID NO 386; 156pp; English.
XX
CC The invention describes an isolated nucleic acid encoding a G protein
CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 kb in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumors and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1
XX
SQ Sequence 17 BP; 3 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
PS
XX
PT The invention describes an isolated nucleic acid encoding a G protein
PT coupled receptor (GPCR), mutations of which cause cancer, comprising a
PT 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
PT 409 residue amino acid sequence, all given in the specification, with or
PT without conservative amino acid substitutions, or complements of the
PT sequence of them. The encoding nucleic acid is not more than 100 kb in
PT length. The methods and compositions of the present invention are useful
PT for diagnosing, investigating and/or treating disorders associated with
PT aberrant expression or activity of GPCR-A-1, such as tumors and cancers.
PT This sequence represents an oligonucleotide used to analyse the gene
PT encoding human G-protein coupled receptor GPCR-A-1
XX
SQ Sequence 17 BP; 3 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1190 CCCAGGGCACCTTCA 1204
Db 15 CCCAGGGCACCTTCA 1
RESULT 644
ACA99866/c
ID ACA99866 standard; DNA; 17 BP.
XX
AC ACA99866;
XX
DT 28-JUL-2003 (first entry)
XX
DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #359.
XX
KW Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS Homo sapiens.
XX

```

```

PN WO2003031621-A2.
XX
PD 17-APR-2003.
XX
PF 11-OCT-2002; 2002WO-US032599.
XX
PR 12-OCT-2001; 2001US-0329000P.
XX
PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX
PI Zhang J;
XX
DR WPI; 2003-381720/36.
XX
PT New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
PT investigating and/or treating disorders associated with aberrant
PT expression or activity of GPCR-A-1, such as tumors and cancers.
XX
PS Example 2; SEQ ID NO 383; 156pp; English.
XX
CC The invention describes an isolated nucleic acid encoding a G protein
CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
CC 409 residue amino acid sequence, all given in the specification, with or
CC without conservative amino acid substitutions, or complements of the
CC sequence of them. The encoding nucleic acid is not more than 100 kb in
CC length. The methods and compositions of the present invention are useful
CC for diagnosing, investigating and/or treating disorders associated with
CC aberrant expression or activity of GPCR-A-1, such as tumors and cancers.
CC This sequence represents an oligonucleotide used to analyse the gene
CC encoding human G-protein coupled receptor GPCR-A-1
XX
SQ Sequence 17 BP; 2 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1191 CCAGGGCACCTTCAA 1205
Db 17 CCAGGGCACCTTCAA 3
RESULT 645
ADO13871
ID ADO13871 standard; DNA; 17 BP.
XX
AC ADO13871;
XX
DT 15-JUL-2004 (first entry)
XX
DE dbv gene cluster probe dpgh, primer #2.
XX
KW ss; dbv; gene cluster; Actinomadura sp.; biosynthesis; glycopeptide;
KW A40926; 4-hydroxy-phenylglycine; 3; 5-dihydroxy-phenylglycine;
KW heptapeptide skeleton; chlorination; aromatic residue;
KW beta-hydroxylation; tyrosine; cross-linking; N-acetyl glucuroamine;
KW mannosyl; export; antibiotic; primer.
XX
OS Actinomadura sp. ATCC 39727.
XX
SYNTHETIC.
XX
PN EP1413626-A1.
XX
PD 28-APR-2004.
XX
PF 23-OCT-2002; 2002EP-00023597.
XX
PR 23-OCT-2002; 2002EP-00023597.
XX
PA (VICU-) VICURON PHARM INC.
XX
PI Donadio S, Sosio M, Beltrametti F;

```


XX WPI; 2004-332813/31.

XX Novel isolated polypeptide A40926, comprising polypeptide sequence or

PT open reading frame polypeptide involved in biosynthetic pathway of

PT A409626, useful for synthesizing glycopeptide antibiotic A409626.

XX Example 1; Page 16; 164pp; English.

XX This sequence is a primer which as used in the amplification of a probe

CC which was used in the isolation of the dbv gene cluster from *Nonomura*

CC sp. ATCC39727 (formerly *Actinomyces* sp. ATCC39727). The 37 proteins

CC encoded by the dbv gene cluster are involved in the biosynthesis of the

CC glycopeptide A40926. dbv ORF 1, 2, 5, and 37 encode polypeptides required

CC for the synthesis of 4-hydroxy-phenylglycine residues of A40926. dbv ORF

CC 30-34 and 37 encode polypeptides required for the synthesis of 3, 5-

CC dihydroxy-phenylglycine residues of A40926. dbv ORF 16, 17, 25, 26 and 36

CC encode polypeptides required for the synthesis of heptapeptide skeleton

CC of A40926. dbv ORF 10 encodes polypeptide required for the chlorination

CC of the aromatic residues of A40926. dbv ORF 28 encodes a polypeptide

CC required for the beta-hydroxylation of the tyrosine residue of amino acid

CC 6 of A40926. dbv ORF 11-14 encode polypeptides required for cross-linking

CC of the aromatic residues of amino acids at positions 2 and 4, 4 and 6, 1

CC and 3, and 5 and 7 of A40926. dbv ORF 9, 23 and 29 encode polypeptides

CC required for addition and formation of N-acetyl glucosamine residue of

CC A40926. dbv ORF 20 or 27 encode polypeptides required for the attachment

CC of mannose residues or N-methylation of A40926. dbv ORF 7, 18, 19, 24

CC and 35 encode polypeptides required for the export of A40926 or its

CC precursors. dbv ORF 3, 4, 6, and 22 encode polypeptides required for

CC regulating the expression of one or more genes of the dbv gene cluster.

CC The dbv gene cluster and the proteins encoded by it are useful for

CC producing glycopeptide antibiotic A40926 or its precursor.

XX

SQ Sequence 17 BP; 4 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 15; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 3.3e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1260 CACCATTGGATCAGC 1274

Db 2 CACCATTGGATCAGC 16

RESULT 646

ACN64750/c

ID ACN64750 standard; DNA; 17 BP.

AC ACN64750;

XX 02-DEC-2004 (first entry)

XX Human GDMPLP-1 probe SEQ ID NO:1652.

DE

XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;

XX hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;

KW skeletal muscle function.

XX Homo sapiens.

OS

XX US2004137589-A1.

PN

XX 15-JUL-2004.

PD

XX 26-NOV-2003; 2003US-00723361.

PF

XX 26-MAY-2000; 2000US-0207456P.

PR

XX 21-SEP-2000; 2000US-0234687P.

PR

XX 27-SEP-2000; 2000US-0236359P.

PR

XX 04-OCT-2000; 2000GB-00024263.

PR

XX 30-JAN-2001; 2001WO-US000661.

PR

XX 30-JAN-2001; 2001WO-US000662.

PR

XX 30-JAN-2001; 2001WO-US000663.

PR

PR 30-JAN-2001; 2001WO-US000664.

PR 30-JAN-2001; 2001WO-US000665.

PR 30-JAN-2001; 2001WO-US000666.

PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.

PR 30-JAN-2001; 2001WO-US000670.

PR 05-FEB-2001; 2001US-0266860P.

PR 25-MAY-2001; 2001US-00866108.

XX

PA (GUY/) GU Y.

PA (JIY/) JI Y.

PA (PENN/) PENN S G.

PA (HANZ/) HANZEL D K.

PA (RANK/) RANK D.

PA (CHEN/) CHEN W.

PA (SHAN/) SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

PI WPI; 2004-533378/51.

XX

DR Novel myosin-like protein-1, useful for treating or preventing disorder

XX associated with decreased expression or activity of human genome-derived

PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle

PT function.

XX

PS Disclosure; SEQ ID NO 1652; Opp; English.

XX

CC The invention relates to a novel polypeptide (I) comprising a sequence

CC (SI) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully

CC defined in the specification, a fragment of at least 8 amino acids of

CC (SI), 95% deviation from (SI) which are conservative substitutions, and

CC 6% identity to (SI). A polypeptide of the invention acts as a agonist or

CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A

CC pharmaceutical composition of the invention is useful for treating or

CC preventing a disorder associated with decreased expression or activity of

CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.

CC The present sequence represents a 17-mer nucleotide, used in the

CC invention for scanning the sequence represented in ACN63102

XX

SQ Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 0.4%; Score 15; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 3.3e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3968 TGGCCTCCTTTGCC 3982

Db 16 TGGCCTCCTTTGCC 2

RESULT 647

ACN64749/c

ID ACN64749 standard; DNA; 17 BP.

XX ACN64749;

XX 02-DEC-2004 (first entry)

XX Human GDMPLP-1 probe SEQ ID NO:1651.

DE

XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;

XX hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;

KW skeletal muscle function.

XX Homo sapiens.

OS

XX US2004137589-A1.

PN

XX 15-JUL-2004.

PD

XX 26-NOV-2003; 2003US-00723361.

PF

XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US0000661.
 PR 30-JAN-2001; 2001WO-US0000662.
 PR 30-JAN-2001; 2001WO-US0000663.
 PR 30-JAN-2001; 2001WO-US0000664.
 PR 30-JAN-2001; 2001WO-US0000665.
 PR 30-JAN-2001; 2001WO-US0000666.
 PR 30-JAN-2001; 2001WO-US0000667.
 PR 30-JAN-2001; 2001WO-US0000668.
 PR 30-JAN-2001; 2001WO-US0000669.
 PR 30-JAN-2001; 2001WO-US0000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUYV/) GU Y.
 PA (JIYV/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANK/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX
 DR WPI; 2004-533378/51.
 XX
 PT Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 1651; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (SI) of myosin-like protein-1 (hGDMPL-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (SI), 95% deviation from (SI) which are conservative substitutions, and
 CC 65% identity to (SI). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPL-1, or as an inhibitor of hGDMPL-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPL-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63102
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 8 G; 0 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.3e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3968 TGGCCTCCCTTGCCC 3982
 DB 17 TGGCCTCCCTTGCCC 3
 RESULT 648
 AD873574
 ID ADS73574 standard; DNA; 17 BP.
 XX
 AC ADS73574;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE tcp gene cluster isolation probe dp9A, primer #2.
 XX
 KW ss; tcp; gene cluster; biosynthesis; glycopeptide; teicoplanin;
 KW antibiotic; bal; cep; com; sta; 4-hydroxy-phenylglycine; 3;
 KW 5-dihydroxy-phenylglycine; heptapeptide skeleton; cross-linking;

KW aromatic residue; N-acyl-beta-D-glucosamine; core structure; export;
 KW resistance; chlorination; alpha-hydroxylation; mannosyl attachment;
 KW primer; probe.
 XX
 OS Actinoplanes teichomyceticus; ATCC31121.
 OS Synthetic.
 XX
 PN EP1460085-A1.
 XX
 PD 22-SEP-2004.
 XX
 PF 20-MAR-2003; 2003EP-00006341.
 XX
 PR 20-MAR-2003; 2003EP-00006341.
 XX
 PA (VICU-) VICURON PHARM INC.
 XX
 PI Donadio S, Sosio M, Bianchi A;
 XX
 DR WPI; 2004-663557/65.
 XX
 PT Novel open reading frame polypeptide involved in biosynthetic pathway of
 PT teicoplanin, useful for producing glycopeptide antibiotic teicoplanin.
 XX
 PS Example 1; SEQ ID NO 44; 175pp; English.
 XX
 CC This sequence represents a primer which was used in the amplification of
 CC the probe dp9A. The amplified probe was used in the isolation of the tcp
 CC gene cluster which is involved in the biosynthesis of the glycopeptide
 CC teicoplanin. The isolated tcp sequence consists of 39 ORFs. Teicoplanin
 CC is a complex of closely related glycopeptide antibiotics produced by A.
 CC teichomyceticus. The tcp cluster is characterised by the presence of
 CC several ORFs that do not find homologues in the bal, cep, com and sta
 CC clusters. The glycopeptides encoded by the tcp cluster are useful for
 CC producing glycopeptide antibiotic teicoplanin. Fragments of the tcp
 CC cluster may be used for synthesizing 4-hydroxy-phenylglycine residues of
 CC teicoplanin, 3,5-dihydroxy-phenylglycine residue, heptapeptide skeleton
 CC of teicoplanin, for cross-linking of the aromatic residues of amino acids
 CC of teicoplanin, for the addition and formation of the two N-acyl-beta-D-
 CC glucosamine residues to the core structure of teicoplanin, for exporting
 CC teicoplanin or some of its precursors outside of the cytoplasm and for
 CC conferring resistance to teicoplanin to the producing strain, for
 CC regulating the expression of one or more genes of the tcp gene cluster,
 CC for the chlorination of the aromatic residues of amino acids of
 CC teicoplanin, for alpha-hydroxylation of the tyrosine residue of amino
 CC acid of teicoplanin, for attaching mannosyl residue of teicoplanin, and
 CC for the synthesis of teicoplanin.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.4%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 3.3e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1260 CACCATTTGGATCAGC 1274
 DB 2 CACCATTTGGATCAGC 16
 RESULT 649
 AAX70292
 ID AAX70292 standard; RNA; 18 BP.
 XX
 AC AAX70292;
 XX
 DT 28-JUL-1999 (first entry)
 XX
 DE Human flt1 VEGF receptor hairpin ribozyme substrate #60.
 XX
 KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;

KW foetal liver kinase 1; ss.
XX
OS Homo sapiens.
XX
FN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
FI WPI; 1997-259017/23.
XX
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
XX Claim 4; Page 94; 218pp; English.
XX
XX The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 18 BP; 2 A; 11 C; 3 G; 0 T; 2 U; 0 Other;
Query Match 0.4%; Score 15; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 3.6e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 2894 CCCCCCCCCCAGACT 2908
Db |||||||||||:
4 CCCCCCCCCCAGACU 18
RESULT 650
AAQ65270
ID AAQ65270 standard; DNA; 18 BP.
XX
AC AAQ65270;
XX
DT 23-DEC-1994 (first entry)
XX
DE Antisense oligonucleotide complementary to Hepatitis C Virus genome.
XX
KW Hepatitis C Virus; Non-A, non-B hepatitis virus; HCV; antisense; therapy;
KW inhibition; viral protein precursor; ss.
XX
OS Synthetic.
XX
FN CA2104649-A.
XX
PD 26-FEB-1994.
XX
PF 23-AUG-1993; 93CA-02104649.
XX
PR 25-AUG-1992; 92JP-00248796.
PR 03-MAR-1993; 93JP-00042736.
XX
PA (SEKI/) SEKI M.

XX Seki M, Honda Y, Yamada E;
PI WPI; 1994-151836/19.
XX
DR Anti-sense oligo:nucleotide(s) complementary to the hepatitis C virus
XX genome - are useful as antiviral agents.
PT
PT Claim 5; Page 219; 262pp; English.
PS
XX This oligonucleotide is an example of a preferred antisense compound i.e.
CC it has a base sequence of 15-30 bases which is included within the 49
CC bases from G at position 127 to C at position 175 of AAQ64913 and which
CC contains at least 7 bases from C at position 147 to C at position 153.
CC The antisense oligonucleotide is useful for inhibiting translation of HCV
CC genes
XX
SQ Sequence 18 BP; 1 A; 5 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 26 CACTCCAGGAGGGGGG 43
Db |||||||||||:
1 CTCCTCCGGGAGGGGGG 18
RESULT 651
AAX09464/c
ID AAX09464 standard; DNA; 18 BP.
XX
AC AAX09464;
XX
DT 24-MAR-1999 (first entry)
XX
DE Human biallelic polymorphic marker upstream primer #344.
XX
KW Polymorphism; biallelic; human; forensic; paternity testing; disease;
KW detection; phenotypic typing; characteristic; infection; hereditary;
KW autoimmune disease; cancer; inflammation; drug; therapy; medicament;
KW treatment; marker; primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
FN WO9820165-A2.
XX
PD 14-MAY-1998.
XX
PF 05-NOV-1997; 97WO-US020313.
XX
PR 06-NOV-1996; 96US-0030455P.
XX
XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
XX
PI Lander ES, Wang D, Hudson T;
XX
XX WPI; 1998-286974/25.
XX
XX New isolated nucleic acid segments from the human genome - used for
PT determining polymorphic forms for use in e.g. forensics, paternity
PT testing or phenotypic typing for disease.
XX
XX Claim 15; Page 94; 310pp; English.
XX
CC AAX09121-X10268 are allele-specific oligonucleotide primers used in the
CC isolation of various biallelic polymorphic markers found in the human
CC genome (represented in AAX10269-X1937). These primers can be used in a
CC method for determining polymorphic forms in an individual for use in e.g.
CC forensics, paternity testing or for phenotypic typing for diseases such
CC as agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial

CC hypercholesterolemia, polycystic kidney disease, hereditary
 CC spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary
 CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
 CC syndrome, osteogenesis imperfecta, acute intermittent porphyria,
 CC autoimmune diseases, inflammation, cancer, diseases of the nervous
 CC system, infection by pathogenic microorganisms, and characteristics such
 CC as longevity, appearance (e.g. baldness, obesity), strength, speed,
 CC endurance, fertility, and susceptibility or receptivity to particular
 CC drugs or therapeutic treatments. The isolated polymorphic nucleic acid
 CC segments can also be used to produce medicaments for the treatment or
 CC prophylaxis of such diseases
 XX
 SQ Sequence 18 BP; 3 A; 3 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3990 AACAGGGGCCCATCATCA 4007

Db 18 AACAGGGGCCCATTAICA 1

RESULT 652

AAV25485

ID AAV25485 standard; DNA; 18 BP.

AC AAV25485;

XX

09-JUL-1998 (first entry)

DT

XX Primer 39DRD4.SB.PCR4 for DRD4 gene.

DE

XX

KW PCR primer; dopaminergic gene; DRD4; susceptibility diagnosis;
 KW migraine with aura; depression; anxiety; variant allele detection;
 KW differentiation; ss.

XX

XX Synthetic.

OS Homo sapiens.

XX WO9807426-A1.

PN

XX 26-FEB-1998.

PD

XX 21-AUG-1997; 97WO-US014830.

PF

XX 22-AUG-1996; 96US-0024399P.

PR

XX 17-JAN-1997; 97US-0036091P.

PS

XX (GLAX) GLAXO GROUP LTD.

PA

XX Peroutka SJ;

PI

XX WPI; 1998-168887/15.

DR

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 387 GGTGCTGCTGCTGGGC 404

Db 1 GCTGCTGCTACTGGGC 18

RESULT 653

AAZ25567

ID AAZ25567 standard; DNA; 18 BP.

XX

AC AAZ25567;

XX

DT 21-DEC-1999 (first entry)

XX

DE Human RhoG antisense phosphorothioate oligonucleotide #15.

XX

KW Human; RhoG; inhibition; antisense; phosphorothioate; expression; GTPase;
 KW mitosis; mitogen; DNA synthesis; cell cycle; cancer;
 KW dynamic organisation; actin cytoskeleton; ras-mediated transformation;
 KW diagnosis; ss.

XX

OS Synthetic.

OS Homo sapiens.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Query Match 0.3%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 3.8e+02;

Antisense oligonucleotides useful for inhibiting the expression of the human RhoG gene.

Claim 3; Col 27; 24pp; English.

AAZ25553 to AAZ25582 represent specifically claimed antisense oligonucleotides targeted to, and capable of inhibiting the expression of nucleic acids encoding human RhoG. RhoG is a member of the Rho subfamily of small GTPases the expression of which is associated with the induction of mitosis by mitogens. RhoG is thought to be required for entry into the DNA synthesis step of the cell cycle. It also effects the dynamic organisation of the actin cytoskeleton which regulates changes during cell cycle progression (e.g. cell rounding and pinching off during mitosis) and with determining the density to which cells will proliferate (RhoG affects an actin-dependent signal transduction pathway mediating the level of contact inhibition through surface signals). Additionally, RhoG is associated with the development of cancers (RhoG participates in a signalling pathway involving ras-mediated transformation). Antisense compounds from the present invention may be used for inhibiting the expression of human RhoG in cells and tissues in vitro and may be used diagnostically to determine the role of RhoG in various biochemical pathways (e.g. its role in mitosis, the organisation of the actin cytoskeleton and in cancer development)

Sequence 18 BP; 1 A; 7 C; 7 G; 3 T; 0 U; 0 Other;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 658 CTCGAGTGCCTGTCCCTG 675
| ||||| |||||
Db 1 CGCGAGTGCCTGTCCCTG 18

RESULT 654
AA55193/C
ID AA55193 standard; DNA; 18 BP.
XX AC AA55193;
XX DT 05-JUL-1999 (first entry)
XX DE Multiple antisense oligonucleotide 14.
XX Antisense oligonucleotide; multiple target; antisense treatment;
KW impaired respiration; inflammation; lung disease;
KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
KW acute asthma; allergy; asthma; impeded respiration;
KW respiratory distress syndrome; pain; cystic fibrosis;
KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
KW prostate cancer; ss.
XX OS Synthetic.
XX WO9913886-A1.
XX PD 25-MAR-1999.
XX 17-SEP-1998; 98WO-US019419.
XX 17-SEP-1997; 97US-0059160P.
XX 09-JUN-1998; 98US-00093972.
XX (UYEC-) UNIV EAST CAROLINA.
XX Nyce JW;
XX WPI; 1999-229400/19.
XX New antisense oligonucleotides used in treatment of, e.g. pulmonary
PT vasoconstriction.
XX Disclosure; Page 74; 120pp; English.
XX The specification describes antisense oligonucleotides (AA52869-X55271)
CC directed against at least 2 mRNAs selected from target genes, coding and
CC non-coding regions of RNAs corresponding to target genes, gene initiation
CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-
CC end and the juxta-section between coding and non-coding regions and all
CC segments of RNAs encoding proteins associated with one or more diseases,
CC conditions or mixtures. The antisense oligonucleotides may be derived
CC from sequences AA55272-74. These multiple target oligonucleotides
CC (specifically AA55180-271) can be used for the antisense treatment of
CC diseases and conditions. Typical diseases and conditions are those
CC associated with impaired respiration and inflammation, including lung
CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
CC acute asthma, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
CC colon cancer, breast cancer, lung cancer, pancreatic cancer,
CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
CC well as all types of cancers which may metastasize or have metastasized
CC to the lungs, including breast and prostate cancer
XX Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1063 GCCCTGTGCCCCAGCCCC 1080
| ||||| ||||| |||||
Db 18 GGCCAGGCCGCCAGCCCC 1

RESULT 655
AAA34640/C
ID AAA34640 standard; DNA; 18 BP.
XX AC AAA34640;
XX DT 28-JUL-2000 (first entry)
XX DE Human adenosine receptor related polynucleotide SEQ ID NO:2329.
XX Human; adenosine receptor; low adenosine antisense oligonucleotide;
KW phosphorothioate; impaired respiration; inflammation; allergy;
KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW antiallergic; antiasthmatic; cytosstatic; analgesic; impaired airway;
KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW cancer; leukemia; lymphoma; carcinoma; metastasis; ss.
XX OS Homo sapiens.
XX WO200009525-A2.
XX PD 24-FEB-2000.
XX 03-AUG-1999; 99WO-US017712.
XX 03-AUG-1998; 98US-0095212P.
XX (UYEC-) UNIV EAST CAROLINA.
XX Nyce JW;
XX WPI; 2000-205971/18.
XX New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstriction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers.
XX Disclosure; Page 556; 1343pp; English.
XX The present invention describes a new composition comprising an antisense
CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
CC nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiallergic,
CC antisthmatic, cytosstatic and analgesic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
CC impeded respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,
CC carcinomas, and cancers which may metastasize to the lungs, including
CC breast and prostate cancer. The reduction of the adenosine content of
CC ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. AAA32313 to AAA3512 represent the
CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
CC AAA33992) are specifically claimed ONs from the present invention. N.B.

Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1063 GCCCTGGCCCCAGCCCC 1080
 | | | | | | | | | | | | | | | | | |
 Db 18 GGCCAGGCCCCAGCCCC 1

RESULT 658
 ID AAF21465/c
 XX AAF21465 standard; DNA; 18 BP.
 AC AAF21465;
 XX
 DT 14-MAR-2001 (first entry)
 XX
 DE Human multiple target antisense (MTA) oligonucleotide #3032.
 XX
 KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200062736-A2.
 XX
 XX 26-OCT-2000.
 PD
 XX
 PF 24-MAR-2000; 2000WO-US008020.
 PR
 XX
 PR 06-APR-1999; 99US-0127958P.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 PA (NYCE/) NYCE J W.
 XX
 FI Nyce JW;
 XX
 XX WPI; 2000-679539/66.
 DR
 XX
 XX Low adenosine (A) content antisense oligonucleotides which do not trigger
 PT adenosine receptors during metabolism, useful e.g. for treating cancers
 PT and respiratory obstructions.
 PT
 XX
 PS Disclosure; Page 297; 1592pp; English.

The present invention describes low adenosine (A) content antisense oligonucleotides and compositions (I) comprising them. In the antisense oligonucleotides the A is replaced by a 'universal' or alternative base. (I) can have respiratory, bronchodilator, antiinflammatory, analgesic, immunosuppressive, antiasthmatic, hypotensive and cytostatic activities. The antisense oligonucleotides and (I) can be used to down-regulate the expression and or activity of target polypeptides associated with lung/respiratory disorders and malignancies, such as stimulating and activating peptide factors and transmitters, transcription factors, immunoglobulins and antibodies, antibody receptors, cytokines and chemokines, endogenously produced specific and non-specific enzymes, binding proteins, adhesion molecules and their receptors, cytokine and chemokine receptors, adenosine receptors, bradykinin receptors, central nervous system (CNS) and peripheral nervous and non-nervous system receptors, CNS and peripheral nervous and non-nervous system peptide transmitters, defensins, growth factors, vasoactive peptides and receptors, binding proteins and malignancy associated proteins. The antisense oligonucleotides may be used in this way to treat disorders including respiratory obstruction (especially pulmonary obstruction

CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
 CC surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
 CC fragments and antisense oligonucleotides used in the exemplification of
 CC the present invention
 XX
 SQ Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1063 GCCCTGGCCCCAGCCCC 1080
 | | | | | | | | | | | | | | | | | |
 Db 18 GGCCAGGCCCCAGCCCC 1

RESULT 659
 ID AAF75205/c
 XX AAF75205 standard; DNA; 18 BP.
 AC AAF75205;
 XX
 DT 02-OCT-2001 (first entry)
 XX
 DE Human inducible NOS antisense oligonucleotide SEQ ID NO 49.
 XX
 KW Antisense oligonucleotide; inducible nitric oxide synthase; NOS;
 KW modulate expression; immunomodulator; antidiabetic; cardiovascular;
 KW cardiac; neuroprotective; vasotropic; ischaemia; reperfusion injury;
 KW 2'-O-methoxyethyl; phosphorothioate; human; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..18
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone, 5' and 3' four
 FT nucleotide 2'-MOE (2'-O-methoxyethyl) wings (the cytidine
 FT residues in the 2'-MOE wings are 5-methylcytidines) and a
 FT deoxy gap"
 FT
 FT
 XX WO200152902-A1.
 PN
 XX
 XX 26-JUL-2001.
 PD
 XX
 XX 15-JAN-2001; 2001WO-US001381.
 PF
 XX
 XX 24-JAN-2000; 2000US-00490208.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Bennett CF, Dean NM, Cowser LM;
 PI
 XX WPI; 2001-465340/50.
 DR
 XX New antisense oligonucleotides for modulating the expression of inducible
 PT nitric oxide synthase in cells or tissues, particularly useful for
 PT treating e.g. immunological, cardiovascular or neurological disorders, or
 PT ischemia.
 PT
 XX
 PS Claim 3; Page 84; 144pp; English.

The invention relates to antisense compounds, especially oligonucleotides, which are targeted to a nucleic acid encoding inducible nitric oxide synthase and which specifically hybridise to and modulate expression of inducible nitric oxide synthase. The antisense compounds

CC have immunomodulator, antidiabetic, cardiovascular, cardiac,
CC neuroprotective, disorder and vasotropic activity. The antisense
CC oligonucleotides are useful for inhibiting the expression of inducible
CC nitric oxide synthase in cells or tissues. In particular, the antisense
CC oligonucleotides are useful for treating diseases or disorders associated
CC with inducible nitric oxide synthase, e.g. diabetes, immunological
CC disorder, cardiovascular disorder, neurological disorder or
CC ischaemia/reperfusion injury. The antisense oligonucleotides are also
CC useful for research and diagnostics. The present sequence is that of an
CC antisense 2'-O-methoxyethyl gapped oligonucleotide with a
CC phosphorothioate backbone, a central "gap" region of ten nucleotides
CC flanked by four nucleotide 2'-MOE (2'-methoxyethyl) wings (cytidine
CC residues in the 2'-MOE wings are 5-methylcytidines) and targeted to human
CC inducible nitric oxide synthase (NOS) mRNA (AAH47959)
XX
XX Sequence 18 BP; 2 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 511 AGCGGCGCTGGATGAGGAA 528
DB 18 AGCTGCTGGAGGAGAA 1
RESULT 660
AAF94748
ID AAF94748 standard; DNA; 18 BP.
AC AAF94748;
XX
XX 23-MAY-2001 (first entry)
XX
XX Rho G antisense phosphorothioate oligonucleotide SEQ ID 172.
XX
XX Rho; GTP binding protein; phosphorothioate antisense oligonucleotide;
KW RhoA; RhoB; RhoC; Rac 1; cdc42; hyperproliferative condition;
KW cancer; wound healing; clotting; ischaemia; reperfusion; reoxygenation;
KW ss.
XX
XX Homo sapiens.
OS
XX WO200115739-A1.
PN
XX 08-MAR-2001.
PD
XX 18-AUG-2000; 2000WO-US022808.
PF
XX 31-AUG-1999; 99US-00387341.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Roberts ML, Cowsett LM;
PI
XX WPI; 2001-191677/19.
DR
XX An antisense compound targeted to a nucleic acid molecule encoding a
PT member of the human Rho family of small GTP binding proteins useful for
PT treating e.g. cancer and ischemia.
PT
XX Example 18; Page 81; 156pp; English.
PS
XX This invention relates to an antisense compound targeted to a nucleic
CC acid molecule encoding a member of the human Rho family of small GTP
CC binding proteins, where the antisense compound inhibits the expression of
CC the member of the human Rho family. The invention includes antisense
CC oligonucleotides AAF94580 - AAF94637 which target a RhoA nucleotide
CC sequence, AAF94645 - AAF94684 which target a RhoB nucleotide sequence,
CC AAF94686 - AAF94725 which target a RhoC nucleotide sequence, AAF94727 -
CC AAF94766 which target RhoG nucleotide sequence, AAF94769 - AAF94790 which
CC target a Rac 1 nucleotide sequence and AAF94795 - AAF94809 which target
CC cdc42 nucleotide sequence. The antisense compound is useful for treating

CC hyperproliferative conditions, especially cancer, abnormal wound healing
CC or clotting conditions and ischaemia/reperfusion or reoxygenation injury.
CC The compound may also be used to diagnose the above conditions
XX
SQ Sequence 18 BP; 1 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 658 CTCGAGTGCCTGTCCTG 675
DB 1 CGCGAGTGCCTGGCCCTG 18
RESULT 661
ABA82492
ID ABA82492 standard; DNA; 18 BP.
XX
XX ABA82492;
AC
XX 25-JAN-2002 (first entry)
DT
XX Zmax1 gene region physical map preparation STS marker #451.
DE
XX Human; high bone mass; HBM gene; Zmax1 gene; chromosome 11; 11q13.3;
KW sequence tagged site; STS; osteoporosis; osteopathic; gene therapy;
KW antisense therapy; vaccine; bone disorder; Paget's disease; adapter;
KW sclerostosis; osteomalacia; fibrous dysplasia; PCR primer; linker; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
OS
XX WO200177327-A1.
PN
XX 18-OCT-2001.
PD
XX 21-JUN-2000; 2000WO-US016951.
PF
XX 05-APR-2000; 2000US-00543771.
PR
XX 05-APR-2000; 2000US-00544398.
PR
XX (GENO-) GENOME THERAPEUTICS CORP.
PA
XX Carulli JP, Little RD, Recker RR, Johnson ML;
PI
XX WPI; 2001-657171/75.
DR
XX New high bone mass (HBM) and Zmax1 genes and proteins useful for
PT modulating bone mass for the treatment of e.g. osteoporosis.
PT
XX Disclosure; Page 36; 443pp; English.
PS
XX The present invention describes the human Zmax1 gene and the high bone
CC mass (HBM) gene, which are found on chromosome 11q13.3. The Zmax1 and HBM
CC genes have osteopathic activities. The genes can be used in gene therapy,
CC antisense therapy and in the production of vaccines. They can be used in
CC the diagnosis and treatment of bone disorders including osteoporosis,
CC Paget's disease, sclerostosis, osteomalacia and fibrous dysplasia.
CC ABA82038 to ABA82700 and AAG68168 to AAG68193 represent sequences used in
CC the exemplification of the present invention
XX
XX Sequence 18 BP; 2 A; 4 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3093 CTCAGCTTTTGGCTCTGT 3110
DB 1 CTGAGCTTTTGGCACTGT 18

RESULT 662
 ABL44014
 ID ABL44014 standard; DNA; 18 BP.
 XX
 AC ABL44014;
 DT 11-APR-2002 (first entry)
 XX
 DE Human chromosome 1p36-35 PCR primer SEQ ID NO:1058.
 XX
 KW Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
 KW PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN JP2001321190-A.
 XX
 PD 20-NOV-2001.
 XX
 PF 12-MAR-2001; 2001JP-00068285.
 XX
 PR 10-MAR-2000; 2000JP-00066716.
 XX
 XX (RIKA) RIKAGAKU KENKYUSHO.
 PA (GENO-) GENOTEX YG.
 XX
 DR WPI; 2002-144136/19.
 XX
 PT Arraying genome clones.
 PS Claim 4; Page 25; 528pp; Japanese.
 CC The present invention describes a method of arraying genome clones. The
 CC method comprises: (a) clones of the genomic libraries contained in
 CC multiwell plates numbered for discrimination are mixed in each of the
 CC multiwell plates; (b) a primer designed based on the chromosome marker
 CC sequence is added to the mixture to carry out an amplification reaction;
 CC (c) a signal corresponding to the marker is detected from the resultant
 CC amplified product to specify the discrimination Nos. of the multiwell
 CC plates containing the clones having said marker sequence; (d) the order
 CC of the markers is changed so that the same discrimination Nos. succeed to
 CC the maximum in the specified discrimination Nos. to array the multiwell
 CC plates; (e) the clones in the multiwell plates of the specified
 CC discrimination Nos. are mixed respectively in each wells of longitudinal
 CC and lateral directions; (f) the mixed clones are cultured and the
 CC resultant cultures are amplified by using the above primer; (g) signals
 CC are detected from the amplified products; (h) the clones in the multiwell
 CC plates are specified from the detected result; and (i) the clones are
 CC reconstituted as the positions on the chromosome and arrayed. The
 CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
 CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
 CC represent PCR primers for human chromosome 21q22.1, which are
 CC specifically claimed for use in the present invention
 XX
 SQ Sequence 18 BP; 4 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2554 GGCATGGGTACCTTGCC 2571
 ||||| ||||| ||||| |||||
 Db 1 GGCATGGGTACCTTGCC 18
 RESULT 663
 AAL48393
 ID AAL48393 standard; DNA; 18 BP.
 XX
 AC AAL48393;
 XX
 DT 01-OCT-2002 (first entry)
 XX

DE Human c-mos gene PCR primer SEQ ID NO: 10.
 XX
 KW Human; c-mos; cytosine methylation; cytostatic; cancer; carcinoma;
 KW cytostatic; leukaemia; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200236604-A2.
 XX
 PD 10-MAY-2002.
 XX
 PF 06-NOV-2001; 2001WO-EP012831.
 XX
 PR 06-NOV-2000; 2000DE-01054972.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2002-566498/60.
 DR
 XX New chemically pretreated nucleic acid of the human c-mos gene, useful in
 PT diagnosis and treatment of e.g. cancers, and related oligomers for
 PT determining cytosine methylation.
 XX
 PS Claim 29; Page 36; 42pp; German.
 XX
 CC The present invention provides chemically pretreated DNA sequences
 CC derived from the human c-mos gene. These can be used in the diagnosis and
 CC treatment of lung carcinoma, throat cancer, acute myeloid leukaemia,
 CC chronic myelocytic leukaemia and Burkitt lymphoma, and to differentiate
 CC between different forms and stages of acute lymphatic leukaemia. The
 CC present difference is a PCR primer for the human c-mos sequence
 XX
 SQ Sequence 18 BP; 6 A; 7 C; 1 G; 4 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3782 GTCACACCAACTCAAT 3799
 ||||| ||||| ||||| |||||
 Db 1 GTTACCACCAACTCCAT 18
 RESULT 664
 ABK23289
 ID ABK23289 standard; DNA; 18 BP.
 XX
 AC ABK23289;
 XX
 DT 09-APR-2002 (first entry)
 XX
 DE Human Zmax1 cDNA forward PCR primer #226.
 XX
 KW Human; mouse; Zmax1; HBM; high bone mass gene; lipid regulation; stroke;
 KW lipid-associated condition; arteriosclerosis; cardiovascular disease; ss;
 KW osteoporosis; atherosclerosis; diabetic atherosclerosis; plaque build-up;
 KW neurovascular condition; wound healing; gene therapy; PCR primer; probe;
 KW bone development disorder; arteriosclerosis; cardiovascular;
 KW osteopathic; cerebroprotective.
 XX
 OS Homo sapiens.
 XX
 PN WO200192891-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016946.
 XX
 PR 26-MAY-2000; 2000US-00578900.
 XX
 PA (GENO-) GENOME THERAPEUTICS CORP.

PA (UYCR-) UNIV CREIGHTON SCHOOL MEDICINE.
 XX
 PI Carulli JP, Little RD, Recker RR, Johnson ML;
 XX
 DR WPI; 2002-097784/13.
 XX
 XX Identifying molecules involved in lipid regulation, useful for
 PT diagnosing, treating or preventing e.g., arteriosclerosis, comprises
 PT identifying a molecule that binds to high bone mass gene or its
 PT corresponding wild type gene.
 XX
 XX Disclosure; Page 41; 409pp; English.
 PS
 XX
 CC The invention relates to a method for identifying a molecule involved in
 CC lipid regulation comprising identifying a molecule that binds to or
 CC inhibits binding of a molecule to high bone mass (HBM) or its wild type
 CC gene, Zmax1. Compounds identified by the method are useful for treating,
 CC diagnosing, preventing or screening for normal and abnormal lipid-
 CC associated conditions, including arteriosclerosis, cardiovascular
 CC disease, stroke, and osteoporosis. The compounds may also be used in the
 CC treatment or prevention of diabetic atherosclerosis, neurovascular
 CC conditions caused by plaque build-up, poor circulation due to plaque
 CC build-up and associated poor wound healing. The methods may be used in
 CC gene therapy, pharmaceutical development, and diagnostic assays for bone
 CC development disorders. Molecules identified by comparison of Zmax1 and
 CC HBM systems can be used as surrogate markers in pharmaceutical
 CC development, in diagnosis of human or animal bone disease, and in the
 CC treatment of bone diseases. Sequences ABK22776-ABK23411 represent cDNA
 CC molecules encoding human Zmax1 and HBM, and PCR primers, probes, linkers
 CC and adapters of the invention
 XX
 SQ Sequence 18 BP; 2 A; 4 C; 5 G; 7 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3093 CTCAGCTTTTGGCTCTGT 3110
 Db 1 CTCAGCTTTTGGCCTGT 18
 RESULT 665
 ABZ11106
 ID ABZ11106 standard; DNA; 18 BP.
 XX
 AC ABZ11106;
 XX
 XX 16-JAN-2003 (first entry)
 DT
 XX
 DE Haematopoietic cell proliferation disorder related oligonucleotide #1246.
 XX
 KW Human; haematopoietic cell proliferation disorder; cytostatic;
 KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
 KW cytosine methylation state; probe; primer; ss.
 XX
 XX Homo sapiens.
 OS Synthetic.
 OS
 XX WO20027272-A2.
 XX
 XX 03-OCT-2002.
 PD
 XX 26-MAR-2002; 2002WO-EP003401.
 PF
 XX 26-MAR-2001; 2001US-0278333P.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
 PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
 PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T, Pelet C;
 PI Schwöpe I, Ziebarth H;

XX WPI; 2003-018942/01.
 DR
 XX Detecting and differentiating between hematopoietic cell proliferative
 PT disorders, comprises contacting a target nucleic acid with a reagent that
 PT distinguishes between methylated and non-methylated CpG dinucleotides.
 PT
 XX Claim 15; Page 76; 117pp; English.
 PS
 XX The present invention describes a method for detecting and
 CC differentiating between haematopoietic cell proliferative disorders
 CC associated with at least 1 gene and/or their regulatory regions in a
 CC subject. The method comprises contacting a target nucleic acid in a
 CC biological sample obtained from the subject with at least 1 reagent,
 CC which distinguishes between methylated and non-methylated CpG
 CC dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
 CC represent specifically claimed nucleotide sequences from the present
 CC invention. Oligonucleotides from the present invention can be used: for
 CC differentiating between healthy haematopoietic cells and proliferative
 CC disorder haematopoietic cells; for differentiating between acute
 CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
 CC determining the cytosine methylation state and/or single nucleotide
 CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
 CC related sequences and their complements; and as primers for the
 CC amplification of haematopoietic cell proliferation disorder related DNA
 CC sequences. The nucleotide sequences from the present invention can also
 CC be used for detecting a predisposition to, differentiation between
 CC subclases, diagnosis, prognosis, treatment and/or monitoring of
 CC haematopoietic cell proliferative disorders. The present method enables a
 CC highly specific classification of haematopoietic cell proliferative
 CC disorders allowing for improved and informed treatment of patients
 XX
 SQ Sequence 18 BP; 6 A; 7 C; 1 G; 4 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3782 GTCACCCACCAACTCAAT 3799
 Db 1 GTTACCACCAACTCCAT 18
 RESULT 666
 ACC45872
 ID ACC45872 standard; DNA; 18 BP.
 XX
 AC ACC45872;
 XX
 XX 02-JUN-2003 (first entry)
 DT
 XX
 DE Human HBM STS marker forward primer #226.
 XX
 KW Human; high bone mass; HBM; LRP5; LRP6; transgenic; bone mass modulation;
 KW gene therapy; bone density modulation; bone strength; trabecular number;
 KW bone size; bone tissue connectivity; bone disease; osteoporosis; PCR;
 KW osteomalacia; rickets; Paget's disease; neoplasm of the bone; primer; ss.
 XX
 OS Homo sapiens.
 OS
 XX WO200292764-A2.
 XX
 XX 21-NOV-2002.
 PD
 XX 13-MAY-2002; 2002WO-US014876.
 PF
 XX 11-MAY-2001; 2001US-0290071P.
 PR 17-MAY-2001; 2001US-0291311P.
 PR 01-FEB-2002; 2002US-0353058P.
 PR 04-MAR-2002; 2002US-0361293P.
 XX
 XX (GENO-) GENOME THERAPEUTICS CORP.
 PA (AMHP) WYETH.

DR WPI; 2003-845336/78.
 XX
 PT New nanoparticles of less than 100 nm comprising an antisense
 PT polynucleotide, useful for targeted treatment of cancerous cells, e.g.
 PT leukemic blasts, ovarian or breast cancer cells or other
 PT hyperproliferative disorders.
 XX
 PS Example 6; SEQ ID NO 8; 92pp; English.
 XX
 CC The present sequence is that of a 3' butanol end-blocked antisense
 CC oligonucleotide targeted to the casein kinase 2 alpha' subunit. In an
 CC example from the invention, this oligonucleotide was encapsulated in
 CC nanoparticles and examined for antitumour activity. An IC50 value against
 CC chemoresistant head neck carcinoma SCC-15 cells of 5.5 μ cisplatin IC50
 CC (molar basis) was determined. This is an example of antisense
 CC oligonucleotides of the invention that suppress the expression of protein
 CC kinase CK2 alpha', CK2 beta or CK2 alpha. Such oligonucleotides can be
 CC encapsulated in nanoparticles and delivered to a cell or tissue for use
 CC in cancer therapy. The cells are selected from glial cells, astrocytes,
 CC smooth muscle cells, myofibroblasts, vascular endothelial cells, B-cell
 CC leukaemic blasts, vascular endothelial cells in solid tumours, B-cell
 CC lymphoproliferative disease cells, acute myeloid leukaemic cells, glial
 CC tumour cells, breast cancer cells, small-cell lung cancer cells, ovarian
 CC cancer cells, colorectal cancer cells, blood vessel media cells, squamous
 CC cell carcinoma cells or epithelial-derived cancer cells (claimed).
 XX
 SQ Sequence 18 BP; 2 A; 5 C; 10 G; 1 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1223 GGTCTGTCGCGCCATGCC 1240
 Db 18 GGTCTGTCGCGCCATGCC 1
 RESULT 669
 ADD93278/c
 ID ADD93278 standard; RNA; 18 BP.
 AC ADD93278;
 DT 29-JAN-2004 (first entry)
 XX CK2-alpha' (Prime-1) target for growth inhibition.
 DE
 XX 98; casein kinase II; CK2; alpha subunit; molecular target;
 KW growth inhibition; cell adhesion molecule; immunoglobulin superfamily;
 KW cell adhesion molecule; integrin; cadherin; selectin;
 KW growth factor receptor; collagen receptor; laminin receptor;
 KW fibronectin receptor; chondroitin sulphate receptor;
 KW keratan sulphate receptor; heparin sulphate receptor;
 KW cancer; antisense; doxorubicin; apoptosis.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 18
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER = c-butanol"
 XX
 PN WO2003087323-A2.
 XX
 PD 23-OCT-2003.
 XX
 PF 08-APR-2003; 2003WO-US010850.
 XX
 PR 08-APR-2002; 2002US-0370882P.
 PR 08-JUL-2002; 2002US-0394315P.
 PR 22-NOV-2002; 2002US-0428296P.

PR 28-FEB-2003; 2003US-00378044.
 XX (GENE-) GENESEQUES INC.
 PA Unger GM;
 PI WPI; 2003-853949/79.
 XX
 DR New collection of particles comprising a bioactive component, a
 XX surfactant molecule having an HLB value of less than about 6.0 units, a
 PT biocompatible polymer, and a cell recognition component, useful for
 PT treating cancer.
 XX
 PS Example 6; Page 64; 90pp; English.
 XX
 CC This sequence represents a fragment of a human casein kinase II (CK2)
 CC alpha subunit gene which was used as a molecular target for growth
 CC inhibition. These sequences were used in the new collection of particles
 CC of the invention which comprises a bioactive component, a surfactant
 CC molecule having an HLB value of less than about 6.0 units, a
 CC biocompatible polymer, and a cell recognition component. The collection
 CC has an average diameter of less than about 200 nanometers as measured by
 CC atomic force microscopy following drying of the collection of particles.
 CC The cell recognition component has a binding affinity for a cell
 CC recognition target consisting of cell adhesion molecules, immunoglobulin
 CC superfamily, cell adhesion molecules, integrins, cadherins, selectins,
 CC growth factor receptors, collagen receptors, laminin receptors, dermatan sulphate
 CC fibronectin receptors, chondroitin sulphate receptors, heparan sulphate
 CC receptors, heparin sulphate receptors, keratan sulphate receptors,
 CC elastin receptors or vitronectin receptors. The particles may be used for
 CC delivering an anti-cancer agent to cancer cells by contacting the cancer
 CC cells with the collection of particles comprising the anticancer agent,
 CC a surfactant having an HLB value less than about 6.0 milts and a
 CC biocompatible polymer. The anticancer agent comprises a nucleic acid. The
 CC nucleic acid comprises an antisense sequence to a native human nucleic
 CC acid sequence. The antisense sequence is effective to inhibit expression
 CC of CK2. The anticancer agent comprises doxorubicin or an apoptotic agent.
 XX
 SQ Sequence 18 BP; 2 A; 5 C; 10 G; 1 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1223 GGTCTGTCGCGCCATGCC 1240
 Db 18 GGTCTGTCGCGCCATGCC 1
 RESULT 670
 ABZ96456/c
 ID ABZ96456 standard; DNA; 18 BP.
 XX
 AC ABZ96456;
 XX 17-OCT-2003 (first entry)
 DT
 XX Human nucleic acid sequence.
 DE
 XX Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013135.

XX 24-APR-2001; 2001US-0286137P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-229219/22.
 DR
 XX
 PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 PS Disclosure; SEQ ID NO 11699; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1063 GCCCTGGCCCCAGCCCC 1080
 DB 18 GGCCCGAGCCCCAGCCCC 1
 RESULT 671
 ABZ97159/C
 ID ABZ97159 standard; DNA; 18 BP.
 XX
 AC ABZ97159;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human MTA oligonucleotide.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; lung; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 FN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PP 23-APR-2002; 2002WO-US013135.

XX 24-APR-2001; 2001US-0286137P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-229219/22.
 DR
 XX
 PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 PS Disclosure; SEQ ID NO 12401; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1063 GCCCTGGCCCCAGCCCC 1080
 DB 18 GGCCCGAGCCCCAGCCCC 1
 RESULT 672
 ABX10913
 ID ABX10913 standard; DNA; 18 BP.
 XX
 AC ABX10913;
 XX
 DT 28-APR-2003 (first entry)
 XX
 DE Novel human membrane associated protein Zsig24, antisense primer.
 XX
 KW Human; membrane associated protein; Zsig24; metabolic disease; obesity;
 KW diabetes; type II diabetes; Pima Indian; polymorphism identification;
 KW chromosome 11q23-q24; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 FN US2002164701-A1.
 XX
 PD 07-NOV-2002.
 XX
 PF 25-OCT-2001; 2001US-00001631.
 XX
 PR 23-OCT-1998; 98US-0105450P.
 PR 23-JUN-1999; 99US-0141519P.

```
PR 20-OCT-1999; 99US-00422052.
XX (SHEP/) SHEPPARD P O.
PA (JELI/) JELINEK L J.
PA (WHIT/) WHITMORE T E.
XX
XX Sheppard PO, Jelinek LJ, Whitmore TE;
XX WPI; 2003-247256/24.
XX
XX New isolated Zsig24 polypeptide and polynucleotides encoding the
PT polypeptide, useful for diagnosing chromosome 11 abnormalities, or for
PT diagnosing obesity or type II diabetes in an individual e.g., Pima
PT Indian.
XX
XX Example 2; Page 29; 34pp; English.
XX
XX The invention describes an isolated polypeptide (I) comprising an amino
XX acid sequence which shares at least 70% or greater than 95% percent
XX identity with a fully defined human Zsig24 polypeptide sequence (S1). The
XX polynucleotide encoding Zsig24 is useful as a diagnostic reagent for
XX detecting a chromosome 11 abnormality in a subject, involving amplifying
XX nucleic acid molecules that encode Zsig24 from RNA isolated from a
XX biological sample of the subject, and detecting a mutation in the
XX amplified nucleic acid molecules, where the presence of a mutation
XX indicates a chromosome 11 abnormality. The polynucleotide is also useful
XX for diagnosing a metabolic disease (e.g., obesity or diabetes, preferably
XX type II diabetes) or susceptibility to a metabolic disease in an
XX individual (e.g., Pima Indian), where the disease is related to the
XX expression or activity of Zsig24 polypeptide comprising sequence of (S1)
XX in that individual. The method optionally involves amplifying nucleic
XX acid molecules that encode Zsig24 from RNA isolated from a biological
XX sample of the individual, and detecting a mutation in the amplified
XX nucleic acid molecules, where the presence of a mutation indicates
XX a metabolic disease or susceptibility to a metabolic disease or amplifying
XX nucleic acid molecules that encode Zsig24 from RNA isolated from a
XX biological sample of the subject, and transcribing the amplified nucleic
XX acid molecules to produce Zsig24 mRNA, translating Zsig24 mRNA to produce
XX (I), and detecting a mutation (I). The methods are for identifying
XX polymorphisms in a new human gene that resides on chromosome 11q23-q24, a
XX locus linked with a heritable form of diabetes. This sequence represents
XX a primer used to locate the novel human membrane associated protein
XX Zsig24 gene to chromosome 11
XX
XX Sequence 18 BP; 2 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3629 TGGCCGCCCTCACCTTGAT 3646
DB 1 TGGCCGCCCTTCACCTGGAT 18
RESULT 673
ACA60574
ID ACA60574 standard; DNA; 18 BP.
XX
XX ACA60574;
XX
XX 11-JUN-2003 (first entry)
XX
XX Antisense inhibition of human cyclin D2 related oligonucleotide #11.
DE Human; cyclin D2; diagnostic; therapeutic; prophylaxis;
XX cyclin 2 inhibition; ss.
XX
XX Homo sapiens.
OS
XX US6492173-B1.
XX
XX 10-DEC-2002.
XX
```

```
XX 01-AUG-2001; 2001US-00920760.
XX
XX 01-AUG-2001; 2001US-00920760.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cowsert LM;
XX
XX WPI; 2003-361492/34.
XX
XX Novel antisense compound useful for treating diseases associated with
PT Cyclin D2 expression, comprises an oligonucleotide comprising up to 50
PT nucleobases in length, which inhibits expression of Cyclin D2 in cells or
PT tissues in vitro.
XX
XX Example 15; Col 45-46; 40pp; English.
XX
XX The invention describes a compound (I) of up to 50 nucleobases in length,
XX which inhibits the expression of Cyclin D2. (I) is useful for inhibiting
XX the expression of Cyclin D2 in cells or tissues in vitro. (I) is thus
XX useful for treating disease associated with Cyclin D2 expression. (I) is
XX useful for diagnostics, therapeutics, prophylaxis and as research
XX reagents and kits. This sequence represents human cyclin D2 inhibition
XX associated oligonucleotide
XX
XX Sequence 18 BP; 3 A; 6 C; 2 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2481 CTCCTTCCTCGGCTAAA 2498
DB 1 CTCCTTCCTTGGCTAAA 18
RESULT 674
ABD20418/c
ID ABD20418 standard; DNA; 18 BP.
XX
XX ABD20418;
XX
XX 29-JUL-2004 (first entry)
XX
XX Human pulmonary and inflammatory target DNA #29.
DE
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ds.
XX
XX Homo sapiens.
OS
XX WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandraagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
```


KW epidermal growth factor; clusterin; VEGF;
KW vascular endothelial growth factor; alpha-2u globulin related-protein;
KW complement component 4; C4; kidney-specific organic anion transporter-K1;
KW OAR-K1; aldolase A; aldolase B; podocin; lipocalin 2; nephrotropic; PCR;
KW primer; ss.
XX
OS Rattus sp.
OS Synthetic.
XX
XX WO2004005544-A2.
XX
XX 15-JAN-2004.
XX
XX 03-JUL-2003; 2003WO-EP007111.
XX
XX 04-JUL-2002; 2002GB-00015509.
XX
XX (NOVS) NOVARTIS AG.
XX (NOVS) NOVARTIS PHARMA GMBH.
XX
XX Chibout S, Grenet O, Imbert G, Kehren J, Staedtler P;
XX Wolfgang CD;
XX
XX WPI; 2004-091386/09.
XX
XX Use of marker genes for monitoring, prognosing, diagnosing or treating
PT renal disorders, e.g. renal diseases, injuries or toxicities, or for
PT identifying agents for treating renal toxicity.
XX
XX Example 1; Page 36; 58pp; English.
XX
XX The invention relates to the use of marker genes for monitoring,
CC prognosing, diagnosing or treating renal toxicity, identifying agents for
CC treatment of renal toxicity or identifying agents that do not induce
CC renal toxicity. The marker genes are selected from Calbindin-D28k, KIM-1
CC (kidney injury molecule 1), OPN (osteopontin), EGF1 (epidermal growth
CC factor), Clusterin, VEGF (Vascular Endothelial Growth Factor), Alpha-2u
CC globulin related-protein, Complement component 4 (C4), Kidney-specific
CC Organic Anion transporter-K1 (OAR-K1), Aldolase A, Aldolase B, Podocin
CC and Alpha-2u (lipocalin 2). The marker genes are useful for monitoring,
CC prognosing, diagnosing or treating renal toxicity, identifying agents for
CC treatment of renal toxicity or identifying agents that do not induce
CC renal toxicity. The polymorphism in a gene is useful for the diagnostic
CC of renal toxicity. The method also provides a test useful for determining
CC whether a renal toxicity in a patient will respond to therapy. The
CC present sequence represents a primer used in real-time quantitative PCR
CC analysis of KIM-1 gene.
XX
XX Sequence 18 BP; 2 A; 9 C; 3 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1377 GAACGCTCTCTCCCTGCA 1394
Db 1 GCACGTCCTCTCCCTGCA 18
RESULT 677
ADI20875
ID ADI20875 standard; DNA; 18 BP.
XX
AC ADI20875;
XX
XX 06-MAY-2004 (first entry)
XX
XX MS SnuPE detection oligonucleotide for DD3 #15.
XX DD3; CpG dinucleotide; cell proliferative disorder; ss.
XX Synthetic.
XX
XX

PN WO2004005543-A1.
XX
PD 15-JAN-2004.
XX
XX 25-JUN-2003; 2003WO-EP006690.
XX
XX 08-JUL-2002; 2002DE-01030692.
XX (EPIG-) EPIGENOMICS AG.
XX
XX Horns T;
XX
XX WPI; 2004-091385/09.
XX
XX Detecting methylation of 5' and promoter region of DD3 gene for
PT diagnosing proliferative disorders comprising contacting target nucleic
PT acid with a reagent that distinguishes between methylated and non-
PT methylated CpG dinucleotide.
XX
XX Claim 6; SEQ ID NO 78; 56pp; English.
XX
XX The present invention relates to detecting the methylation state of the
CC 5' and promoter region of the gene DD3 within a subject comprising
CC contacting a target nucleic acid having one or more sequences selected
CC from 5 3581 base pair sequences in a biological sample with at least one
CC reagent or a series of reagents. The method is useful for detecting the
CC methylation state of the 5' and promoter region of the gene DD3 within a
CC subject. The set of oligonucleotides comprising at least three of the
CC oligomers is useful for detecting the cytosine methylation state and/or
CC single nucleotide polymorphisms (SNPs) within SEQ. ID NO. 1-5 and its
CC complementary sequences. The set of oligomers is also useful for
CC detecting the methylation state of all CpG dinucleotides within SEQ ID
CC NO. 1 and its complementary sequences. The set of at least two
CC oligonucleotides can be used as primer oligonucleotides for the
CC amplification of DNA sequences selected from SEQ ID NO. 1-5 and its
CC complementary sequences. The DNA- and/or PNA-array is useful for
CC analyzing diseases associated with the methylation state of the gene DD3
CC comprising at least one nucleic acid. The methods, nucleic acids,
CC oligonucleotide or PNA-oligomer, kit, array or the set of
CC oligonucleotides is useful for the characterization, classification,
CC differentiation, grading, staging, and/or diagnosis of cell proliferative
CC disorders, or the predisposition to cell proliferative disorders. It can
CC also be used for the therapy of cell proliferative disorders. The present
CC sequence represents a detection oligonucleotide of the invention.
XX
XX Sequence 18 BP; 1 A; 0 C; 5 G; 12 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3857 TTGAGTTTGTGTTTGGT 3874
Db 1 TTGAGTTTGTGTTTGGT 18
RESULT 678
ADP47449
ID ADP47449 standard; DNA; 18 BP.
XX
AC ADP47449;
XX
XX 09-SEP-2004 (first entry)
XX
XX Intelligent PCR primer for the identification of bacteria SeqID 104.
XX PCR; ss; primer; pharmacogenetic analysis; medical diagnosis; cancer;
KW blood typing; virus stereotyping; pathogen; mass spectroscopy;
KW etiologic agent.
XX
XX Synthetic.
XX
XX WO2004052175-A2.
XX

XX PD 24-JUN-2004.
 XX PF 05-DEC-2003; 2003WO-US038830.
 XX PR 06-DEC-2002; 2002US-0431319P.
 PR 18-DEC-2002; 2002US-00323233.
 PR 18-DEC-2002; 2002US-00325526.
 PR 18-DEC-2002; 2002US-00325527.
 PR 18-DEC-2002; 2002US-00326051.
 PR 29-JAN-2003; 2003US-0443443P.
 PR 30-JAN-2003; 2003US-0443788P.
 PR 14-FEB-2003; 2003US-0447529P.
 PR 11-SEP-2003; 2003US-00660122.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Ecker DJ, Griffey RH, Hofstadler SA, Sampath R, Mcneil J;
 PI Crooke ST;
 XX DR WPI; 2004-468672/44.
 XX PT Identifying a pathogen in a biological sample, useful in medical
 PT diagnosis, comprises amplifying a nucleic acid from the sample with a
 PT pair of intelligent primers, and determining the molecular mass of the
 PT amplification product.
 XX PS Example 15; SEQ ID NO 104; 228pp; English.
 XX CC This invention relates to a novel method for the rapid identification of
 CC pathogens occurring in environmental samples or biological samples
 CC derived from humans and animals. Specifically, it refers to using
 CC intelligent primers to obtain an amplification product in order that the
 CC molecular mass of the amplicon can be determined by mass spectroscopy,
 CC which in turn identifies the pathogen found in the sample. The present
 CC invention describes the rapid detection and identification of an
 CC etiologic agent that does not require nucleic acid sequencing, and
 CC instead relies on the use of intelligent primers to target ribosomal RNA
 CC or housekeeping genes. Accordingly, this method can be used to identify a
 CC pathogen or infectious agent in a biological sample, which is useful in
 CC pharmacogenetic analysis and medical diagnosis (including cancer
 CC diagnosis based on mutations and polymorphisms), or for detecting single
 CC nucleotide polymorphisms in blood typing or stereotyping of viruses. This
 CC oligonucleotide sequence is an intelligent PCR primer used to identify
 CC different bacterial strains, given in an exemplification of the
 CC invention.
 XX SQ Sequence 18 BP; 2 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 636 CGCCACGCTGCGCTTCAC 653
 Db 1 CGACGCGCTGCGCTTCAC 18
 RESULT 679
 AD059807
 ID AD059807 standard; DNA; 18 BP.
 XX AC AD059807;
 XX DT 07-OCT-2004 (first entry)
 XX DE Intelligent PCR primer VALS_EC_1833_1943 forward SEQ ID NO:104.
 XX ss; etiologic agent; disease; intelligent primer;
 KW pathogen identification; PCR; primer.
 XX OS Synthetic.

PN WO2004060278-A2.
 XX 22-JUL-2004.
 XX PF 05-DEC-2003; 2003WO-US038761.
 XX PR 06-DEC-2002; 2002US-0431319P.
 PR 18-DEC-2002; 2002US-00323233.
 PR 18-DEC-2002; 2002US-00325526.
 PR 18-DEC-2002; 2002US-00325527.
 PR 18-DEC-2002; 2002US-00326051.
 PR 29-JAN-2003; 2003US-0443443P.
 PR 30-JAN-2003; 2003US-0443788P.
 PR 14-FEB-2003; 2003US-0447529P.
 PR 11-SEP-2003; 2003US-0501926P.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Ecker DJ, Griffey RH, Sampath R, Hofstadler SA, Mcneil J;
 PI Crooke ST, Blyn LB, Ranken R, Hall TA;
 XX DR WPI; 2004-534302/51.
 XX PT Identifying pathogens in humans or animals comprises amplifying a nucleic
 PT acid molecule from the individual with intelligent primers to obtain
 PT amplification products, and determining molecular masses of the
 PT amplification products.
 XX PS Claim 40; SEQ ID NO 104; 184pp; English.
 XX CC The invention relates to a novel method for identifying etiologic agents
 CC of disease in an individual comprising amplifying a nucleic acid from a
 CC biological sample of the individual with intelligent primers to obtain
 CC amplification products corresponding to the etiologic agents, and
 CC determining the molecular masses of the amplification products. The
 CC composition and methods of the invention are useful for identifying
 CC pathogens in biological samples from humans and animals, resolving
 CC etiologic agents present in samples obtained from humans and animals,
 CC determining detailed genetic information about such pathogens or
 CC etiologic agents, and for rapidly detecting and identifying bioagents
 CC from environmental, clinical or other samples. The present sequence
 CC represents an intelligent PCR primer of the invention.
 XX SQ Sequence 18 BP; 2 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 636 CGCCACGCTGCGCTTCAC 653
 Db 1 CGACGCGCTGCGCTTCAC 18
 RESULT 680
 ADRL7435
 ID ADRL7435 standard; DNA; 18 BP.
 XX AC ADRL7435;
 XX DT 04-NOV-2004 (first entry)
 XX DE Human chromosome 11 Zmax1 region forward mapping primer #226.
 XX Human; high bone mass; Zmax1; ss; primer; HBM; osteoporosis;
 KW LDL receptor; bone development; metabolic bone disease; PCR.
 XX Homo sapiens.
 XX US6780609-B1.
 XX 24-AUG-2004.

PF 05-APR-2000; 2000US-00543771.
XX
PR 13-JAN-1998; 98US-0071449P.
PR 23-OCT-1998; 98US-0105511P.
PR 13-JAN-1999; 99US-00229319.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
XX
PI Carulli JP, Little RD, Recker RR, Johnson ML;
XX
DR WPI; 2004-623529/60.
XX
XX New high bone mass gene of chromosome 1.1013.3, encoding protein useful
PT for treating, diagnosing, preventing, or screening for normal and
PT abnormal conditions of bone, including metabolic bone diseases, e.g.
PT osteoporosis.
XX
PS Disclosure; SEQ ID NO 517; 284pp; English.
XX
CC The invention relates to an isolated amino acid protein sequence selected
CC from an amino acid sequence appearing as ADR16922 or an amino acid
CC sequence comprising or consisting of the extracellular domain of
CC ADR16922(amino acids 23-1385). ADR16922 is encoded by the HBM (high bone
CC mass) allele of the human Zmax1 gene and has sequence similarity to LDL
CC receptors. Also disclosed are nucleic acids, proteins, cloning vectors,
CC expression vectors, transformed hosts, methods of developing
CC pharmaceutical compositions, methods of identifying molecules involved in
CC bone development, and methods of diagnosing and treating diseases
CC involved in bone development. Specifically disclosed is the Zmax1 gene
CC and the high bone mass (HBM) allele on chromosome 11q13.3 encoding
CC ADR16922. The protein is useful for treating, diagnosing, preventing, or
CC screening for normal and abnormal conditions of bone, including metabolic
CC bone diseases, e.g. osteoporosis. The present sequence is a PCR primer
CC used in the mapping of the Zmax1/HBM gene.
XX
SQ Sequence 18 BP; 2 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3093 CTCAGCTTTGGCTCTGT 3110
Db |||||
1 CTGAGCTTTGGCACTGT 18

RESULT 681
ADR48086
ID ADR48086 standard; DNA; 18 BP.
XX
AC ADR48086;
XX
XX 02-DEC-2004 (first entry)
DT Human chromosome 11 Zmax1 region forward mapping primer #226.
DE
XX Human; ss; PCR; high bone mass; Zmax1; HBM; bone modulation;
KW bone development disorder; osteoporosis; chromosome 11; gene therapy;
KW primer.
XX
XX Homo sapiens.
OS
XX US2004176582-A1.
FN
XX
XX 09-SEP-2004.
PD
XX 10-DEC-2003; 2003US-00731739.
PF
XX 13-JAN-1998; 98US-0071449P.
PR 23-OCT-1998; 98US-0105511P.
PR 13-JAN-1999; 99US-00229319.
PR 05-APR-2000; 2000US-00544398.
XX

PA (GENO-) GENOME THERAPEUTICS CORP.
PA (UYCR-) UNIV CREIGHTON.
XX
PI Carulli JP, Little RD, Recker RR, Johnson ML;
XX
DR WPI; 2004-661408/64.
XX
XX New nucleic acid sequence encoding high bone mass, useful in diagnosing,
PT treating and/or preventing osteoporosis.
PT
XX Disclosure; SEQ ID NO 517; 303pp; English.
XX
CC The invention relates to an isolated nucleic acid sequence encoding a
CC high bone mass protein (HBM). The gene exists in two alleles, Zmax1, the
CC notional wild-type (the cDNA for which appears as ADR47570 encoding
CC ADR47572) and the HBM allele (the cDNA for which appears as ADR47571
CC encoding ADR47573). The two alleles differ by a single nucleotide
CC polymorphism (G to T at position 582 of ADR47570) causing a Gly to Val
CC change at position 171 of the protein. Also included are a replicative
CC cloning vector comprising HBM/Zmax1 (and a replicon operative in an
CC isolated host cell), an expression vector comprising HBM/Zmax1 operably
CC linked to a transcription regulatory region, an isolated host cell
CC transformed with the vector(s), a method for testing a substance as a
CC therapeutic agent for bone modulation in a host, a method of identifying
CC a molecule involved in bone modulation, a method for identifying a
CC (candidate) protein involved in bone modulation, a method of testing for
CC HBM activity, a method of developing a pharmaceutical for the treatment
CC of bone development disorders, a method for treating a bone development
CC disorder in an animal, a method of altering bone development in a host, a
CC method for diagnostic screening for a genetic predisposition to a bone
CC development disorder, a diagnostic assay for bone development disorders,
CC a method of expressing the HBM protein in bone tissue, a bacterial
CC artificial chromosome comprising HBM/Zmax1 sequence (appearing as
CC ADR47574-ADR47580), a method for amplifying a nucleotide polymorphism in
CC the Zmax1 or HBM gene, a method for identifying a regulatory element of a
CC HBM gene and an isolated nucleic acid segment of at least 15 contiguous
CC nucleotides including a polymorphic site from HBM/Zmax1. The nucleic acid
CC molecule and the encoded polypeptide, composition, and methods are useful
CC in diagnosing, treating and preventing a bone development disorder, i.e.
CC osteoporosis. The gene for HBM/Zmax1 is located on chromosome 11q13.3.
CC The present sequence is a primer used in the mapping of the HBM/Zmax1
CC gene.
XX
SQ Sequence 18 BP; 2 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3093 CTCAGCTTTGGCTCTGT 3110
Db |||||
1 CTGAGCTTTGGCACTGT 18

RESULT 682
ADW37806/c
ID ADW37806 standard; DNA; 18 BP.
XX
AC ADW37806;
XX
XX 10-MAR-2005 (first entry)
DT Human GPR4 DNA RT-PCR primer #2.
DE
XX
XX GPR4; osteoporosis; osteopathic; degeneration; endocrine disease;
KW musculoskeletal disease; diagnosis; RT-PCR; primer; ss;
KW reverse transcriptase PCR.
XX
XX Homo sapiens.
OS
XX WO2004112823-A1.
FN
XX 29-DEC-2004.
PD

XX PF 18-JUN-2004; 2004WO-EP006625.
 XX PR 20-JUN-2003; 2003US-0480245P.
 XX PR 02-SEP-2003; 2003US-0499549P.
 XX PA (NOVS) NOVARTIS AG.
 XX PA (NOVS) NOVARTIS PHARMA GMBH.
 XX PI Baumgarten B, Jones CE, Ludwig M, Martiny-Baron G, Seuwen K;
 XX PI Wolf R, Wyder L, Suply T;
 XX DR WPI; 2005-048763/05.
 XX PF Use of an isolated proton-sensing GPCR polypeptide or polynucleotide in
 XX PT developing a medicament for treating medical conditions in which proton
 XX PT homeostasis is imbalanced.
 XX XX Example 11; Page 42; 83pp; English.
 XX CC The invention relates to isolated proton-sensing GPCR polypeptides and
 XX CC polynucleotides useful in developing a medicament for treating diseases
 XX CC and medical conditions in which proton homeostasis is imbalanced. The
 XX CC invention also relates to a pharmaceutical composition comprising the
 XX CC antibody, or agonist or antagonist of a proton-sensing GPCR polypeptide
 XX CC for treating or preventing diseases and medical conditions in which
 XX CC proton homeostasis is imbalanced, a method of screening for compounds
 XX CC that stimulate or inhibit the function or expression level of the proton-
 XX CC sensing GPCR polypeptides, a method of screening for compounds that
 XX CC agonize or antagonize the proton-sensing activity of the GPCR
 XX CC polypeptides and a diagnostic kit comprising the antibody against a
 XX CC proton-sensing GPCR polypeptide or pharmaceutical preparation comprising
 XX CC the antibody. Treating or preventing diseases and medical conditions in
 XX CC which proton homeostasis is imbalanced comprises administering to a
 XX CC subject the antibody, or agonist or antagonist of a proton-sensing GPCR
 XX CC polypeptide. Screening for compounds that stimulate or inhibit the
 XX CC function or expression level of a proton-sensing GPCR polypeptide
 XX CC comprises measuring or detecting, quantitatively or qualitatively, the
 XX CC binding of a candidate compound to the polypeptide (or to the cells or
 XX CC membranes expressing the polypeptide) or its fusion protein by means of a
 XX CC label directly or indirectly associated with the candidate compound,
 XX CC measuring the competition of binding of a candidate compound to the
 XX CC polypeptide (or to the cells or membranes expressing the polypeptide) or
 XX CC a fusion protein thereof in the presence of a labeled competitor, testing
 XX CC whether the candidate compound results in a signal generated by
 XX CC activation or inhibition of the polypeptide using detection systems
 XX CC appropriate to the cells or cell membranes expressing the polypeptide,
 XX CC and detecting the effect of a candidate compound on the production of
 XX CC mRNA encoding the polypeptide or the polypeptide in cells, using for
 XX CC instance, an ELISA assay. The isolated proton-sensing GPCR polypeptides,
 XX CC polynucleotides and antibodies that bind to the polypeptides are useful
 XX CC in developing a medicament for treating or preventing diseases and
 XX CC medical conditions in which proton homeostasis is imbalanced, e.g.,
 XX CC osteoporosis. This sequence represents a reverse transcriptase PCR (RT-
 XX CC PCR) primer used in expression profiling of human GPR4, used in the scope
 XX CC of the invention.
 XX SQ Sequence 18 BP; 0 A; 2 C; 8 G; 8 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 1937 AACATCACAGCAGCACCC 1954
 ||||| ||||| ||||| |||||
 Db 18 AACAGCACAGCAGCAACC 1
 RESULT 683
 ADV66866
 ID ADV66866 standard; DNA; 18 BP.
 XX AC ADV66866;

XX DT 10-MAR-2005 (first entry)
 XX DE S. carnosus secA PCR primer SecAS.c.H4.
 XX KW SecA; translocation ATPase; protein secretion; protein purification; ss;
 XX KW primer; PCR.
 XX OS Staphylococcus carnosus.
 XX PN WO2004108932-A1.
 XX PD 16-DEC-2004.
 XX PF 28-MAY-2004; 2004WO-DE001107.
 XX PR 02-JUN-2003; 2003DE-01025026.
 XX PA (KERJ) FORSCHUNGSZENTRUM JUELICH GMBH.
 XX PI Koerberling O, Freudl R;
 XX DR WPI; 2005-031709/03.
 XX PT New modified SecA protein, useful in microbial production of proteins,
 XX PT provides a higher level of protein secretion than wild-type protein.
 XX PF Example; Page 33; 71pp; German.
 XX CC This invention describes a novel variant SecA protein (a translocation
 XX CC ATPase) and its encoding polynucleotide which provides an increased level
 XX CC of protein secretion, particularly hormones, enzymes, growth factors,
 XX CC pharmaceutical proteins, or cytokines. The protein includes at least one
 XX CC alteration in the amino acid regions that form the regulatory elements
 XX CC IRA-1 and/or IRA-2, and is derived from Bacillus subtilis, B.
 XX CC licheniformis, B. amyloliquefaciens, Staphylococcus carnosus, Escherichia
 XX CC coli or Corynebacterium glutamicum. Most preferably the alterations are
 XX CC in the 198-772 region of the S. carnosus protein or in region 442-767 of
 XX CC the B. subtilis protein. Even a single mutation in secA can significantly
 XX CC improve secretory activity. The invention also describes a method for
 XX CC microbial production of proteins that includes expression of mutant secA
 XX CC in a host cell which improves secretion and yield of the protein, and may
 XX CC make possible secretion of proteins that are not normally secreted at
 XX CC all. Preferably the microorganisms are the same species as those from
 XX CC which the secA polypeptides are derived. The secA polynucleotides can be
 XX CC labeled and used as probes for identification and/or isolation of genes
 XX CC that encode proteins involved in protein secretion. A strain of B.
 XX CC subtilis, designated RMA, was constructed in which the normal secA gene
 XX CC was replaced by secA from S. carnosus. Suppressor mutants of RMA were
 XX CC selected for inability to grow at 25degC and/or inability to produce
 XX CC spores, indicative of changes in the inserted secA gene. The mutations
 XX CC present in the suppressor mutants were identified, then transferred to
 XX CC the secA gene of B. subtilis. The mutant strains of B. subtilis were then
 XX CC tested for expression of alkaline phosphatase PhoB containing the
 XX CC Leu501n mutation, which is normally secreted only very inefficiently in
 XX CC the wild-type. This protein was secreted much more effectively by the
 XX CC mutant strain. This sequence represents a PCR primer used to amplify the
 XX CC S. carnosus wild type secA gene.
 XX SQ Sequence 18 BP; 5 A; 4 C; 8 G; 1 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3.8e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 790 GACACGGTGGCGCGGAG 807
 ||||| ||||| ||||| |||||
 Db 1 GACAGGTGACCGCGAG 18
 RESULT 684
 AEB69814
 ID AEB69814 standard; DNA; 18 BP.

XX AEB69814;
AC
XX
DT 22-SEP-2005 (first entry)
DE Human chromosome 11 Zmax1 region forward mapping primer, SEQ ID 517.
XX
XX Osteopathic; high bone mass; Zmax1; bone disease; osteoporosis;
KW osteomalacia; bone injury; Pagets disease; PCR; primer; ss;
XX sequence-tagged site.
XX
OS Homo sapiens.
XX
XX US2005142617-A1.
PN
XX
XX 30-JUN-2005.
PD
XX 29-APR-2004; 2004US-00834377.
PF
XX 13-JAN-1998; 98US-0071449P.
PR
XX 23-OCT-1998; 98US-0105511P.
PR
XX 13-JAN-1999; 99US-00229319.
PR
XX 05-APR-2000; 2000US-00543771.
PR
XX (GENO-) GENOME THERAPEUTICS CORP.
PA (UYCR-) UNIV CREIGHTON SCHOOL MEDICINE.
PA
XX Carulli JP, Little RD, Recker RR, Johnson ML;
XX WPI; 2005-496364/50.
XX
XX Identifying candidate molecule involved in bone modulation, comprises
PT identifying molecule that binds to Zmax1, high bone mass (HBM) protein,
PT or both Zmax1 and HBM protein.
XX
XX Disclosure; SEQ ID NO 517; 308pp; English.
XX
XX The present invention relates to a method (M1) for identifying a
CC candidate molecule involved in bone modulation. The method comprises
CC identifying a molecule that binds to High Bone Mass protein (HBM) and/ or
CC Zmax1 protein. The HBM gene exists in two alleles: Zmax1, the notional
CC wild-type (the cDNA for which appears as AEB69299 encoding AEB69301 and
CC AEB69939 encoding AEB69940) and the HBM allele (the cDNA for which
CC appears as AEB69300 encoding AEB69302). The two alleles differ by a
CC single nucleotide polymorphism (T to G at position 582 of AEB69299)
CC causing a Gly to Val change at position 171 of the protein. The HBM
CC protein has the property of causing elevated bone mass, while the Zmax1
CC protein does not. The gene for HBM/Zmax1 is located on chromosome
CC 11q13.3. Also claimed is a method of pharmaceutical development for
CC treating of bone development disorders, such as osteoporosis,
CC osteomalacia, bone fractures, Paget's disease, etc., which comprises
CC identifying a molecule that binds to the Zmax1 protein, or to HBM, or
CC both. PCR primers AEB69364 - AEB69923 are for sequence-tagged site (STS)
CC markers in the HBM region on chromosome 11q13.3, which were used to
CC prepare a physical map of the Zmax1 region.
XX
XX Sequence 18 BP; 2 A; 4 C; 5 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.8e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 3093 CTCAGCTTTTGGCTCTGT 3110
DB 1 CTCAGCTTTTGGCACTGT 18
RESULT 685
ADR52529/c
ID ADR52529 standard; DNA; 48 BP.
XX
XX ADR52529;
AC
XX

DT 18-NOV-2004 (first entry)
XX
XX Small interfering RNA expression library oligonucleotide #98.
DE
XX
KW ss; siRNA; small interfering RNA; gene expression; gene silencing;
KW expression library; silencing; G coupled receptor; ion channel;
KW receptor tyrosine kinase; non-receptor tyrosine kinases;
KW nuclear hormone receptor; GTPase; ATPase; serine/threonine kinase;
KW protease; matrix metalloproteinase; E3 ubiquitin ligase.
XX
OS Synthetic.
XX
XX WO2004072261-A2.
PN
XX 26-AUG-2004.
PD
XX 10-FEB-2004; 2004WO-US003949.
PF
XX 11-FEB-2003; 2003US-0446714P.
PR
XX (IMMU-) IMMUSOL INC.
PA
XX Li H, Chatterton JE, Fan W, Ke N, Wong-Staal F;
PI WPI; 2004-625862/50.
XX P-PSDB; ADR52530.
DR
XX Generating a siRNA expression library for selective post-transcriptional
PT silencing of genes encoding a family of proteins comprises identifying a
PT consensus sequence for protein families.
XX
XX Example 2; SEQ ID NO 195; 44pp; English.
XX
XX The invention relates to a method for generating a siRNA expression
CC library for selective post-transcriptional silencing of genes encoding a
CC family of proteins comprising identifying a consensus sequence for the
CC family of proteins. The method comprises: (a) identifying a consensus
CC sequence for the family of proteins; and (b) generating an siRNA
CC expression library whose members encode siRNA molecules that target at
CC least all mRNA encoding all known members of the family of proteins. The
CC family of proteins is G coupled receptors, ion channels, receptor
CC tyrosine kinases, non-receptor tyrosine kinases, nuclear hormone
CC receptors, GTPases, ATPases, serine/threonine kinases, proteases, matrix
CC metalloproteinases, GTPase-activating proteins or E3 ubiquitin ligases.
CC Identifying a consensus sequence comprises identifying at least one, two
CC or more signature motif for the family of proteins. The method is useful
CC for generating a siRNA expression library for selective post-
CC transcriptional silencing of genes encoding a family of proteins. The
CC library is useful for identifying genes involved in disease processes.
CC This sequence corresponds to an oligonucleotide used in the method of the
CC invention.
XX
SQ Sequence 48 BP; 11 A; 17 C; 9 G; 11 T; 0 U; 0 Other;
Query Match 0.3%; Score 14.8; DB 1; Length 48;
Best Local Similarity 64.7%; Pred. No. 6.2e+02;
Matches 22; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
QY 1854 GTCGCGGGGCTGAAGCGGGGAGCCAGCTACTGT 1887
DB 48 GTTGACGAGGATGTTGCGGCGAGCCAGGTCACGG 15
RESULT 686
ADR52517/c
ID ADR52517 standard; DNA; 48 BP.
XX
XX ADR52517;
AC
XX
XX 18-NOV-2004 (first entry)
DT
XX Small interfering RNA expression library oligonucleotide #92.
DE
XX

ss; siRNA; small interfering RNA; gene expression; gene silencing; expression library; silencing; G coupled receptor; ion channel; receptor tyrosine kinase; non-receptor tyrosine kinases; nuclear hormone receptor; GTPase; ATPase; serine/threonine kinase; protease; matrix metalloproteinase; E3 ubiquitin ligase.

XX OS Synthetic.
XX PN WO2004072261-A2.
XX PD 26-AUG-2004.
XX PF 10-FEB-2004; 2004WO-US003949.
XX PR 11-FEB-2003; 2003US-0446714P.
XX PA (IMMU-) IMMUSOL INC.
XX PI Li H, Chatterton JE, Fan W, Ke N, Wong-Staal P;
XX DR WPI; 2004-625862/60.
XX DR P-PSDB; ADR52518.
XX PT Generating a siRNA expression library for selective post-transcriptional silencing of genes encoding a family of proteins comprises identifying a consensus sequence for protein families.
XX PS Example 2; SEQ ID NO 183; 44pp; English.

XX CC The invention relates to a method for generating a siRNA expression library for selective post-transcriptional silencing of genes encoding a family of proteins comprising identifying a consensus sequence for the family of proteins. The method comprises: (a) identifying a consensus sequence for the family of proteins; and (b) generating an siRNA expression library whose members encode siRNA molecules that target at least all mRNA encoding all known members of the family of proteins. The family of proteins is G coupled receptors, ion channels, receptor tyrosine kinases, non-receptor tyrosine kinases, nuclear hormone receptors, GTPases, ATPases, serine/threonine kinases, proteases, matrix metalloproteinases, GTPase-activating proteins or E3 ubiquitin ligases. CC Identifying a consensus sequence comprises identifying at least one, two or more signature motif for the family of proteins. The method is useful for generating a siRNA expression library for selective post-transcriptional silencing of genes encoding a family of proteins. The library is useful for identifying genes involved in disease processes. CC This sequence corresponds to an oligonucleotide used in the method of the invention.

XX SQ Sequence 48 BP; 11 A; 17 C; 10 G; 10 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.8; DB 1; Length 48;
Best Local Similarity 64.7%; Pred. No. 6.2e+02;
Matches 22; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy 1854 GCTCGGGGGCTGAAGCGGGGAGCCAGTACTCTG 1887
Db 48 GTTACGAGGATGTTGCGGCGAGCCAGGTCACGG 15

RESULT 687

ID ABQ72285/c
XX ABQ72285 standard; DNA; 15 BP.

AC ABQ72285;

XX 02-SEP-2002 (first entry)

XX DE Human CYP2D6 allele-specific oligonucleotide (ASO) primer, SEQ ID NO:72.

XX KW Human; cytochrome P450; subfamily IID polypeptide 6; CYP2D6; enzyme; chromosome 22q13.1; drug metabolism; detoxification; mono-oxygenase; anti-arrhythmic; arrhythmia; adrenoceptor antagonist; hypertension; tricyclic antidepressant; procainamide; drug induced lupus syndrome;

KW environmentally linked disease; Parkinson's disease; haplotyping; genotyping; haplotype; genetic variant; single nucleotide polymorphism; SNP; drug screening; drug discovery; allele-specific oligonucleotide; ASO; primer; ss.

XX OS Homo sapiens.
XX PN WO200238589-A2.
XX PD 16-MAY-2002.
XX PF 09-NOV-2001; 2001WO-US047396.
XX PR 09-NOV-2000; 2000US-0247943P.
XX PA (GENA-) GENAISANCE PHARM INC.

XX PI Anastasio AE, Chew A, Choi JY, Denton RR, Nandabalan K;
XX PI Petersen N, Rounds E;
XX DR WPI; 2002-519292/55.

XX PT Novel genetic variants of Cytochrome P450, Subfamily IID, Polypeptide 6 isogenes, useful for improving efficiency and reliability in drug development for treating hypertension, arrhythmias and Parkinson's disease.

XX PS Claim 15; Page 18; 158pp; English.

XX CC The invention relates to a method for haplotyping the cytochrome P450, subfamily IID, polypeptide 6 (CYP2D6) gene (ABQ72215, ABQ72364) of an individual, and also describes 29 novel polymorphic sites within the human CYP2D6 gene. The CYP2D6 gene is located on chromosome 22q13.1 and contains 9 exons which encode a 497 amino acid protein (ABQ09563). CYP2D6 is a mono-oxygenase involved in the detoxification of many drugs and environmental chemicals. It plays a role in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists and tricyclic antidepressants, and is also involved in the formation of a metabolite linked to the drug-induced lupus syndrome observed with procainamide. Variations in CYP2D6 activity or expression may also influence an individual's susceptibility to environmentally-linked diseases, and it has been demonstrated that CYP2D6 activity may be involved in the pathogenesis of Parkinson's disease, with individuals with a less active form of the enzyme tending to have an earlier onset of this condition. CYP2D6 nucleic acid sequences are useful in studying the expression and function of CYP2D6, and in expressing CYP2D6 protein for use in screening drugs for the treatment of CYP2D6-associated diseases (e.g., hypertension, atrial and ventricular arrhythmias, Parkinson's disease, and drug-induced lupus syndrome) or which are metabolised by CYP2D6. CYP2D6 nucleic acids and proteins are also useful in studying the effect of polymorphisms on the biological activity of CYP2D6. Polymorphisms in the target region may be determined by the use of allele-specific oligonucleotides (ASOs; ABQ72217-ABQ72303) as probes and primers, and by primer extension using oligonucleotide primers comprising sequences ABQ72304-ABQ72361. The method of the invention is useful for haplotyping the CYP2D6 gene in populations and in individuals, enabling decisions to be made as to whether CYP2D6 is a likely therapeutic target for a disease of interest, and to control for genetically-based bias in the design of drugs that target or are metabolised by CYP2D6. In addition, transgenic animals comprising a human CYP2D6 gene are useful for studying the expression of CYP2D6 isogenes in vivo, for in vivo screening and testing of drugs targeted to or metabolised by CYP2D6, and for testing the efficacy of therapeutic agents and compounds for treating CYP2D6-associated conditions in a biological system. Sequences ABQ72246-ABQ72303 represent specifically claimed allele-specific oligonucleotide (ASO) primers used for detecting polymorphisms in the CYP2D6 gene

XX SQ Sequence 15 BP; 0 A; 8 C; 3 G; 3 T; 0 U; 1 Other;

Query Match 0.3%; Score 14.6; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 3e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 10 GCGGCGGAGCAG 24
|:|||||
Db 15 GYGCGGAGCAG 1

RESULT 688

AAA29598
ID AAA29598 standard; DNA; 17 BP.

AC AAA29598;

DT 10-AUG-2000 (first entry)

XX Human insulin sense PCR primer.

XX Hormone dependent cancer; hormone independent cancer; hormonal drug;
KW prostate cancer; breast cancer; cervical cancer; ovarian cancer;
KW PCR primer; ss.

OS Homo sapiens.

XX WO200020034-A1.

PN 13-APR-2000.

XX 07-OCT-1999; 99WO-JP005533.

XX 08-OCT-1998; 98JP-00286793.

XX (TAKE) TAKEDA CHEM IND LTD.

PA Matsutani E, Naito K;

PI WPI; 2000-303644/26.

XX Hormonal drug-containing agents for retarding conversion of hormone-
PT dependent cancers into hormone-independent cancers, useful e.g. for
PT treating prostate and breast cancers.

XX Example 1; Page 19; 31pp; Japanese.

XX The present invention describes a hormonal drug-containing agent (I) for
CC retarding the conversion of a hormone-dependent cancer into a hormone-
CC independent cancer. The agents can be used to treat prostate, breast,
CC cervical and ovarian cancers and to make hormonal drugs for retarding the
CC conversion of a hormone-dependent cancer into a hormone-independent
CC cancer. The drug can retard the change of hormone-dependent cancers into
CC hormone-independent cancers effectively. The present sequence represents
CC a PCR primer which is used in an example from the present invention
XX

XX Sequence 17 BP; 2 A; 4 C; 4 G; 1 T; 0 U; 6 Other;

Query Match 0.3%; Score 14.6; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.7e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2587 CACGAGACCTGGCTGC 2603

||:|:|:|:|:|:|
Db 1 CAYMGRGACYTRKGCWG 17

RESULT 689

ADH23252
ID ADH23252 standard; DNA; 17 BP.

AC ADH23252;

XX 25-MAR-2004 (first entry)

XX Degenerate sense PCR primer used to amplify the insulin receptor.

XX hormone dependent cancer; hormone; differentiation inducing agent;
KW luteinising hormone-releasing hormone; LH-RH; fat soluble vitamin;

KW prostate; ovarian; uterine; breast cancer; hormone independent cancer;
KW anti-tumour; PCR; primer; ss; insulin receptor.

XX Synthetic.

OS Unidentified.

XX JP2004002240-A.

XX 08-JAN-2004.

XX 31-MAY-2002; 2002JP-00160837.

XX 31-MAY-2002; 2002JP-00160837.

XX (TAKE) TAKEDA CHEM IND LTD.

XX WPI; 2004-113108/12.

XX Novel therapeutic agent of hormone dependent cancer, comprising hormone
PT group, chemical agent and differentiation inducing agent, useful for
PT treating hormone dependent cancer in mammal.

XX Example 1; Page 14; 15pp; Japanese.

XX This invention relates to a novel therapeutic agent for the treatment of
CC hormone dependent cancer that comprises a hormone group chemical agent
CC and a differentiation inducing agent. Specifically, the hormone group
CC chemical agent refers to an agonist derived from the luteinising hormone-
CC releasing hormone (LH-RH), whereas the differentiation inducing agent is
CC preferably a fat soluble vitamin, or can be a nuclear receptor ligand,
CC histone acetylation regulation drug or a DNA methylation regulation drug.
CC The present invention describes using the LH-RH agonist as a preventative
CC or therapeutic agent for hormone dependent prostate, ovarian, uterine or
CC breast cancer, and can also delay change in hormone independent cancer.
CC Accordingly, the compositions of the invention are described as
CC exhibiting high anti-tumour activity. This oligonucleotide sequence is a
CC degenerate PCR primer used to amplify the insulin receptor, in an
CC exemplification of the invention.

XX Sequence 17 BP; 2 A; 4 C; 4 G; 1 T; 0 U; 6 Other;

Query Match 0.3%; Score 14.6; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.7e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2587 CACGAGACCTGGCTGC 2603

||:|:|:|:|:|:|
Db 1 CAYMGRGACYTRKGCWG 17

RESULT 690

AAQ65268

ID AAQ65268 standard; DNA; 16 BP.

XX AAQ65268;

XX 23-DEC-1994 (first entry)

XX Antisense oligonucleotide complementary to Hepatitis C Virus genome.

XX Hepatitis C Virus; Non-A, non-B hepatitis virus; HCV; antisense; therapy;
KW inhibition; viral protein precursor; ss.

XX Synthetic.

XX CA2104649-A.

XX 26-FEB-1994.

XX 23-AUG-1993; 93CA-02104649.

XX 25-AUG-1992; 92JP-00248796.

PR 03-MAR-1993; 93JP-00042736.

XX PA (SEKI/) SEKI M.
 XX PI Seki M, Honda Y, Yamada E;
 XX DR WPI; 1994-151836/19.
 XX PT Anti-sense oligo:nucleotide(s) complementary to the hepatitis C virus
 genome - are useful as antiviral agents.
 XX PS Claim 5; Page 218; 262pp; English.
 CC This oligonucleotide is an example of a preferred antisense compound i.e.
 CC it has a base sequence of 15-30 bases which is included within the 49
 CC bases from G at position 127 to C at position 175 of AAQ64913 and which
 CC contains at least 7 bases from C at position 147 to C at position 153.
 CC The antisense oligonucleotide is useful for inhibiting translation of HCV
 CC genes
 XX SQ Sequence 16 BP; 1 A; 4 C; 10 G; 1 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 16;
 Best Local Similarity 93.8%; Pred. No. 3.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 28 CTCGAGGAGGGGGG 43
 Db 1 CTCGAGGAGGGGGG 16
 RESULT 691
 ID ADC13653/c standard; DNA; 16 BP.
 XX AC ADC13653;
 XX 18-DEC-2003 (first entry)
 XX Human NOVX reverse primer, SEQ ID NO 138.
 XX NOVX; FADD interacting protein; ATPase; H+ Transporting; Lysosomal;
 KW FGF 17; Single Pass Transmembrane; Beta-Ketoacyl Synthase; Neuramin 2;
 KW Glutamate Receptor Interacting Protein 2; Chr-Methyltransferase;
 KW NP25 Variant; GTPase-Activating Protein; ELKS; Sim2; RhoGAP;
 KW Phospholipase; Scavenger Receptor Domain Containing Protein;
 KW Metallothionein IA; NOGO receptor; FYVE; NOELIN;
 KW Cyclin Regulatory Subunit; Tetrairico Peptide Repeat Protein;
 KW Immunoglobulin Domain Containing Protein; PA Domain Containing Protein;
 KW Phenylalanine; Histidine Ammonia-Lyase; Cellular Retinaldehyde-Binding;
 KW Glutamine Repeat Containing Protein; TNF Receptor Associated Factor2;
 KW Vacuolar Protein Sorting Homologue R-VPS33A;
 KW BOLA Domain Containing Protein; Neurotrophin Receptor;
 KW RAL Guanine Nucleotide Dissociation Stimulator; Armadillo/Beta-Catenin;
 KW Metalloprotease; T10 Ser/Thr-rich; Ring finger-like; cytosstatic;
 KW gene therapy; vaccine; cancer; primer; ss.
 XX OS Homo sapiens.
 XX WO2003004617-A2.
 XX 16-JAN-2003.
 XX 03-JUL-2002; 2002WO-US021359.
 XX 05-JUL-2001; 2001US-0303046P.
 PR 09-JUL-2001; 2001US-0303828P.
 PR 11-JUL-2001; 2001US-0304502P.
 PR 12-JUL-2001; 2001US-0305011P.
 PR 13-JUL-2001; 2001US-0305262P.
 PR 17-JUL-2001; 2001US-0306085P.
 PR 24-JUL-2001; 2001US-0307536P.
 PR 27-JUL-2001; 2001US-0308228P.
 PR 30-JUL-2001; 2001US-0308877P.

PR 01-AUG-2001; 2001US-0309255P.
 PR 10-AUG-2001; 2001US-0311753P.
 PR 19-SEP-2001; 2001US-0323449P.
 PR 22-FEB-2002; 2002US-0358332P.
 PR 05-MAR-2002; 2002US-0361765P.
 PR 02-JUL-2002; 2002US-00188248.
 XX (CURA-) CURAGEN CORP.
 XX Patturajan M, Gerlach VL, Anderson DW, Taupier RJ, Zerhusen BD;
 PI Guo X, Casman SJ, Hjalt T, Miller CE, Kekuda R, Shimkets RA;
 PI Malyankar UM, Zhong M, Padigaru M, Li L, Shenoy SG, Gorman L;
 PI Edinger SR;
 XX WPI; 2003-201550/19.
 XX New NOVX polypeptide, useful for preparing a composition for treating or
 PT preventing cancer.
 XX Example 37; Page 241; 393pp; English.
 CC The invention relates to a novel isolated NOVX polypeptide comprising: a
 CC sequence of 57-1149 amino acids as defined in the specification, or its
 CC mature form; a sequence that is at least 95% identical to the 57-1149
 CC amino acid polypeptide; or a sequence comprising one or more conservative
 CC substitutions in the 57-1149 amino acid polypeptide. The NOVX proteins of
 CC the invention include the following protein families: FADD interacting
 CC protein-like, ATPase, H+ Transporting, Lysosomal (vacuolar Proton Pump)-
 CC like, FGF 17-like, Single Pass Transmembrane-like, Beta-Ketoacyl Synthase
 CC like, Neuramin 2-like, Glutamate Receptor Interacting Protein 2-like,
 CC Chr-Methyltransferase-like, NP25 Variant-like, GTPase-Activating Protein-
 CC like, ELKS-like, Sim2-like, RhoGAP-like, Phospholipase-like, Scavenger
 CC Receptor Domain Containing Protein-like, Metallothionein IA-like, NOGO
 CC receptor-like, FYVE repeat protein, NOELIN-like, Cyclin Regulatory Subunit-like,
 CC Tetrairico Peptide Repeat Protein-like, Immunoglobulin Domain Containing
 CC Protein-like, PA Domain Containing Protein-like, Phenylalanine and
 CC Histidine Ammonia-Lyase-like, Cellular Retinaldehyde-Binding-like,
 CC Glutamine Repeat Containing Protein-like, TNF Receptor Associated Factor2
 CC like, Vacuolar Protein Sorting Homologue R-VPS33A, BOLA Domain
 CC Containing Protein-like, Neurotrophin Receptor-like, RAL Guanine
 CC Nucleotide Dissociation Stimulator-like, Armadillo/Beta-Catenin-like,
 CC Metalloprotease-like, T10 Ser/Thr-rich-like, and Ring finger-like
 CC protein. The NOVX proteins and the encoding polynucleotides have
 CC cytosstatic activity and can be used in gene therapy or a vaccine. The
 CC NOVX polypeptide is useful for preparing a composition for treating or
 CC preventing cancer. This polynucleotide sequence represents a reverse
 CC primer of a gene encoding a NOVX protein of the invention.
 XX SQ Sequence 16 BP; 5 A; 7 C; 4 G; 0 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 16;
 Best Local Similarity 93.8%; Pred. No. 3.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2019 TGTGGTCTGCTGCTG 2034
 Db 16 TGTGGTCTGCTGCTG 1
 RESULT 692
 AEB18973
 ID AEB18973 standard; DNA; 16 BP.
 XX AC AEB18973;
 XX 22-SEP-2005 (first entry)
 XX Human leukocyte antigen-DR allele probe SeqID749.
 KW human leukocyte antigen; hla; diagnostic; transplant rejection; cancer;
 KW diabetes; ss; probe.
 XX Homo sapiens.
 OS

XX JP2005185171-A.
 XX 14-JUL-2005.
 XX
 XX 25-DEC-2003; 2003JP-00430553.
 XX
 XX 25-DEC-2003; 2003JP-00430553.
 XX
 XX (CANO) CANON KK.
 XX
 XX Teukada M;
 XX
 XX WPI; 2005-483346/49.
 XX
 XX Probe set for identifying human leukocyte antigen-DR allele in test
 PT sample of patients with e.g. cancer and diabetes, comprises probes
 PT corresponding to sequences such as DRB1.010101 or DRB1.0104.
 XX
 XX Claim 2; SEQ ID NO 749; 87pp; Japanese.
 XX
 XX This invention relates to a novel probe set for identifying a human
 CC leukocyte antigen (HLA)-DR allele in a test substance, which comprises
 CC probes with partial sequence containing base written in capital letter as
 CC fully defined in the HLA-DR allele list given in the specification. The
 CC invention is useful for identifying HLA-DR allele in a test sample. The
 CC probe set can identify HLA-DR alleles in patients with organ transplant,
 CC cancer, diabetes and other multiple-factor diseases, and enables
 CC provision of tailored medical treatment to individual patients. The
 CC present sequence is that of a probe which is a member of a novel probe
 CC set of the invention.
 XX
 XX Sequence 16 BP; 2 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.3%; Score 14.4; DB 1; Length 16;
 Best Local Similarity 93.8%; Pred. No. 3.6e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 1819 GTGCGGTTCTGGAAGA 1834
 Db 1 GTGCGGTTCTGGAAGA 16
 XX
 RESULT 693
 AAQ65269
 ID AAQ65269 standard; DNA; 17 BP.
 XX
 AC AAQ65269;
 XX
 XX 23-DEC-1994 (first entry)
 XX
 DE Antisense oligonucleotide complementary to Hepatitis C Virus genome.
 XX
 KW Hepatitis C Virus; Non-A, non-B hepatitis virus; HCV; antisense; therapy;
 KW inhibition; viral protein precursor; ss.
 XX
 OS Synthetic.
 XX
 XX CA2104649-A.
 XX
 XX 26-FEB-1994.
 XX
 XX 23-AUG-1993; 93CA-02104649.
 XX
 XX 25-AUG-1992; 92JP-00248796.
 XX
 XX 03-MAR-1993; 93JP-00042736.
 XX
 XX (SEKI/) SEKI M.
 XX
 XX Seki M, Honda Y, Yamada E;
 XX
 XX WPI; 1994-151836/19.
 XX
 DE Antisense oligonucleotide complementary to Hepatitis C Virus genome.
 XX
 KW Hepatitis C Virus; Non-A, non-B hepatitis virus; HCV; antisense; therapy;
 KW inhibition; viral protein precursor; ss.
 XX
 OS Synthetic.
 XX
 XX CA2104649-A.
 XX
 XX 26-FEB-1994.
 XX
 XX 23-AUG-1993; 93CA-02104649.
 XX
 XX 25-AUG-1992; 92JP-00248796.
 XX
 XX 03-MAR-1993; 93JP-00042736.
 XX
 XX (SEKI/) SEKI M.
 XX
 XX Seki M, Honda Y, Yamada E;
 XX
 XX WPI; 1994-151836/19.
 XX

PT Anti-sense oligo:nucleotide(s) complementary to the hepatitis C virus
 PT genome - are useful as antiviral agents.
 XX
 XX Claim 5; Page 219; 262pp; English.
 XX
 XX This oligonucleotide is an example of a preferred antisense compound i.e.
 CC it has a base sequence of 15-30 bases which is included within the 49
 CC bases from G at position 127 to C at position 175 of AAQ64913 and which
 CC contains at least 7 bases from C at position 147 to C at position 153.
 CC The antisense oligonucleotide is useful for inhibiting translation of HCV
 CC genes
 XX
 XX Sequence 17 BP; 1 A; 4 C; 10 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 28 CTCACGGGAGGGGGG 43
 Db 2 CTCACGGGAGGGGGG 17
 XX
 RESULT 694
 AAQ65253
 ID AAQ65253 standard; DNA; 17 BP.
 XX
 AC AAQ65253;
 XX
 XX 21-DEC-1994 (first entry)
 XX
 XX Antisense oligonucleotide complementary to Hepatitis C Virus genome.
 XX
 KW Hepatitis C Virus; Non-A, non-B hepatitis virus; HCV; antisense; therapy;
 KW inhibition; viral protein precursor; ss.
 XX
 OS Synthetic.
 XX
 XX CA2104649-A.
 XX
 XX 26-FEB-1994.
 XX
 XX 23-AUG-1993; 93CA-02104649.
 XX
 XX 25-AUG-1992; 92JP-00248796.
 XX
 XX 03-MAR-1993; 93JP-00042736.
 XX
 XX (SEKI/) SEKI M.
 XX
 XX Seki M, Honda Y, Yamada E;
 XX
 XX WPI; 1994-151836/19.
 XX
 DE Antisense oligo:nucleotide(s) complementary to the hepatitis C virus
 PT genome - are useful as antiviral agents.
 XX
 XX Claim 5; Page 212; 262pp; English.
 XX
 XX This oligonucleotide is an example of a preferred antisense compound i.e.
 CC it has a base sequence of 15-30 bases which is included within the 49
 CC bases from G at position 127 to C at position 175 of AAQ64913 and which
 CC contains at least 7 bases from C at position 147 to C at position 153.
 CC The antisense oligonucleotide is useful for inhibiting translation of HCV
 CC genes
 XX
 XX Sequence 17 BP; 1 A; 4 C; 10 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 28 CTCACGGGAGGGGGG 43
 Db 2 CTCACGGGAGGGGGG 17
 XX

Db 1 CTCCCGGAGGGGGG 16

RESULT 695

AAV92592

ID AAV92592 standard; RNA; 17 BP.

XX AC AAV92592;

XX DT 18-FEB-1999 (first entry)

XX DE Human A-Raf substrate position 1873.

XX KW Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme; target; substrate; catalyst; modulation; expression; Raf gene; delivery; screening; identification; synthesis; deprotection; purification; cancer; inflammation; psoriasis; non-hepatic ascites; infection; genetic drift; rheumatoid arthritis; ss.

XX OS Homo sapiens.

XX PN WO9850530-A2.

XX PD 12-NOV-1998.

XX PF 05-MAY-1998; 98WO-US009249.

XX PR 09-MAY-1997; 97US-0046059P.

XX PR 09-JUN-1997; 97US-0049002P.

XX PR 03-JUL-1997; 97US-0051718P.

XX PR 22-AUG-1997; 97US-0056808P.

XX PR 02-OCT-1997; 97US-0061321P.

XX PR 02-OCT-1997; 97US-0061324P.

XX PR 05-NOV-1997; 97US-0064866P.

XX PR 19-DEC-1997; 97US-0068212P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L; Parry T, Belgelman L, Mcswiggen JA, Karpeisky A, Burgin A; Thompson J, Workman CT, Beaudry A, Sweedler D;

XX WPI; 1999-009494/01.

XX PT Identifying new catalytic nucleic acid that modulates selected processes - especially ribozymes that cleave Raf RNA for treating cancer, restenosis, and also new ribozymes and modified nucleoside triphosphates used as antiviral agents and synthons.

XX PS Claim 177; Page 160; 259pp; English.

XX CC A method has been developed for the identification of a nucleic acid capable of modulating a process in a biological system. The method comprises: (a) introducing into the system a random library of nucleic acid catalysts (NAC) having a substrate binding domain (SBD), comprising a random sequence, and a catalytic domain (CD); and (b) identifying NAC in systems where modulation has occurred and/or determining the sequence of at least part of the SBDs in such systems. Nucleic acid molecules with endonuclease activity and catalytic activity, from the present invention, are used to modulate gene expression in plant and mammalian cells and to cleave target nucleic acid, particularly for treating systemic diseases caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic ascites and infection. They may also be used to detect genetic drift and mutations in diseased cells and to determine c-raf RNA. Specifically NACs with RNA-cleaving activity that modulate expression of the Raf gene, are used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or generally any condition associated with the level of c-raf. Introduction of sugar/phosphate modifications increases stability against nuclease and activity. AAV90922 to AAV93877 represent NACs that can be used in the method, specifically for modulating the expression of a Raf gene

XX SQ Sequence 17 BP; 2 A; 10 C; 2 G; 0 T; 3 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2967 GCCCGCTTCCCCAG 2982
||||| : : |||||
Db 1 GCCCCUUCUCCCGAG 16

RESULT 696

AAF06057

ID AAF06057 standard; DNA; 17 BP.

XX AC AAF06057;

XX DT 16-FEB-2001 (first entry)

XX DE Hammerhead ribozyme substrate #2854.

XX KW Ribozyme; erythropoietin; granulocyte colony stimulating factor; interferon alpha; ss.

XX OS Homo sapiens.

XX PN WO200061729-A2.

XX PD 19-OCT-2000.

XX PF 11-APR-2000; 2000WO-US009721.

XX PR 12-APR-1999; 99US-0129390P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Zwick M, Pavco P, Mcswiggen J;

XX WPI; 2000-647423/62.

XX PT Enzymatic and antisense nucleic acid inhibition of repressor genes, useful for producing e.g. granulocyte colony stimulating factor protein, interferon alpha and erythropoietin.

XX PS Claim 42; Page 121; 164pp; English.

XX CC The present invention relates to enzymatic and antisense nucleic acid molecules that act as inhibitors of the expression of repressor genes encoding the Trk2 Orphan receptor, EGR3/COUP-TF-1, the GATA transcription factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP). Inhibition of the repressors removes prevents inhibition (and consequently increases expression of) genes involved in the production of erythropoietin, granulocyte colony stimulating factor protein and interferon alpha

XX SQ Sequence 17 BP; 6 A; 5 C; 1 G; 0 T; 5 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 3.9e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1567 CCTGACTTCACCTATA 1582
||:||||| : : |||
Db 1 CCUGACUUCACUAUA 16

RESULT 697

AAF02029

ID AAF02029 standard; DNA; 17 BP.

XX AC AAF02029;

XX DT 16-FEB-2001 (first entry)

XX DE Hammerhead ribozyme substrate #324.

XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX Homo sapiens.
 OS
 PN WO200061729-A2.
 PD 19-OCT-2000.
 XX
 PF 11-APR-2000; 2000WO-US009721.
 XX
 PR 12-APR-1999; 99US-0129390P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Zwick M, Pavco P, Mcswiggen J;
 XX WPI; 2000-647423/62.
 DR
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor protein,
 PT interferon alpha and erythropoietin.
 XX
 PS Claim 37; Page 63; 164pp; English.
 XX
 CC The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha
 XX
 SQ Sequence 17 BP; 2 A; 9 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3059 CACACCCCTCTCCTGGA 3074
 DB 1 CACCCCTCTCCTGGA 16
 RESULT 698
 ADV06123
 ID ADV06123 standard; RNA; 17 BP.
 XX
 AC ADV06123;
 XX
 DT 10-FEB-2005 (first entry)
 XX
 DE Human BACE DNzyme substrate sequence #287.
 XX
 KW Enzymatic nucleic acid molecule; gene expression; down regulation;
 KW protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
 KW MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
 KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
 KW c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
 KW hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
 KW amberyzyme; zinzyme; DNzyme; cancer; breast cancer; Alzheimer's disease;
 KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
 KW hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
 KW ss.
 XX Homo sapiens.
 OS
 XX WO200116312-A2.
 PN
 PD 08-MAR-2001.
 XX

PF 30-AUG-2000; 2000WO-US023998.
 XX
 PR 31-AUG-1999; 99US-0151713P.
 PR 27-SEP-1999; 99US-00406643.
 PR 27-SEP-1999; 99US-0156236P.
 PR 27-SEP-1999; 99US-0156467P.
 PR 08-NOV-1999; 99US-00436430.
 PR 06-DEC-1999; 99US-0169100P.
 PR 29-DEC-1999; 99US-00474432.
 PR 29-DEC-1999; 99US-0173612P.
 PR 30-DEC-1999; 99US-00476387.
 PR 04-FEB-2000; 2000US-00498824.
 PR 20-MAR-2000; 2000US-00531025.
 PR 14-APR-2000; 2000US-0197769P.
 PR 23-MAY-2000; 2000US-00578223.
 PR 09-AUG-2000; 2000US-00636385.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswiggen J, Usman N, Blatt L, Beigelman L, Burgin A;
 PI Karpeisky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B;
 PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
 XX
 DR WPI; 2001-244406/25.
 XX
 XX Enzymatic nucleic acid molecules able to cleave separate RNA molecules
 PT are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
 PT obesity and heart disease.
 XX
 PS Example 4; Page 382; 717pp; English.
 XX
 CC The present invention relates to the use of enzymatic nucleic acid
 CC molecules (e.g. ribozymes) to modulate gene expression. The invention
 CC also methods for their use to down regulate or inhibit the expression of
 CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine
 CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
 CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
 CC receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
 CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
 CC nucleic acid molecules used to inhibit the expression of the said genes
 CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberyzyme,
 CC for treating cancer, in particular breast cancer, Alzheimer's disease,
 CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
 CC diseases, hepatitis B infections, and hepatitis and hepatocellular
 CC carcinoma. The enzymatic nucleic acid molecules can also be used as
 CC diagnostic tools to examine genetic drift and mutations within diseased
 CC cells and to detect the presence of specific RNA in a cell. The present
 CC sequence represents a substrate/target sequence for a DNzyme used in the
 CC examples of the present invention. Note: Some SEQ ID Nos are repeated
 CC more than once in the specification, but these have different sequences
 CC associated with them.
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 10 G; 0 T; 1 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 3.9e+02;
 Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 3702 GGGGGCTGTCCAGGG 3717
 DB 1 GGGGGCGUGCCAGGG 16
 RESULT 699
 ADU94065
 ID ADU94065 standard; DNA; 17 BP.
 XX
 AC ADU94065;
 XX
 DT 10-FEB-2005 (first entry)
 XX
 DE Human TERT NCH ribozyme substrate sequence #888.

Enzymatic nucleic acid molecule; gene expression; down regulation;
protein-tyrosine-phosphatase-1b; PTB-1B; methionine aminopeptidase;
MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
ambersyme; zinzyme; DNazyme; cancer; breast cancer; Alzheimer's disease;
diabetes; obesity; cardiac disease; heart disease; age-related disease;
hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
ds.

Homo sapiens.

WO200116312-A2.

08-MAR-2001.

30-AUG-2000; 2000WO-US023998.

31-AUG-1999; 99US-0151713P.

27-SEP-1999; 99US-00406643.

27-SEP-1999; 99US-0156236P.

27-SEP-1999; 99US-0156467P.

08-NOV-1999; 99US-00436430.

06-DEC-1999; 99US-0169100P.

29-DEC-1999; 99US-00474432.

29-DEC-1999; 99US-0173612P.

30-DEC-1999; 99US-00476387.

04-FEB-2000; 2000US-00498824.

20-MAR-2000; 2000US-00531025.

14-APR-2000; 2000US-0197769P.

23-MAY-2000; 2000US-00578223.

09-AUG-2000; 2000US-00636385.

(RIBO-) RIBOZYME PHARM INC.

McSwiggen J, Usman N, Blatt L, Beigelman L, Burgin A;

Karpelsky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B;

Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;

WPI; 2001-244406/25.

Enzymatic nucleic acid molecules able to cleave separate RNA molecules

are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,

obesity and heart disease.

Example 1; Page 294; 717pp; English.

The present invention relates to the use of enzymatic nucleic acid

molecules (e.g. ribozymes) to modulate gene expression. The invention of

also methods for their use to down regulate or inhibit the expression of

genes encoding protein-tyrosine-phosphatase-1b (PTB-1B), methionine

aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C

alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor

receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),

presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic

nucleic acid molecules used to inhibit the expression of the said genes

include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, ambersyme,

zinzyme, and/or DNazyme motifs. The methods of the invention are useful

for treating cancer, in particular breast cancer, Alzheimer's disease,

diabetes, obesity, cardiac diseases e.g. heart disease, age-related

diseases, hepatitis B infections, and hepatitis and hepatocellular

carcinoma. The enzymatic nucleic acid molecules can also be used as

diagnostic tools to examine genetic drift and mutations within diseased

cells and to detect the presence of specific RNA in a cell. The present

invention represents a substrate/target sequence for a ribozyme used in

the examples of the present invention. Note: Some SEQ ID Nos are repeated

more than once in the specification, but these have different sequences

associated with them.

Sequence 17 BP; 2 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

Query Match

Best Local Similarity

Matches

Conservative

0.3%;

Score 14.4;

DB 1;

Length 17;

93.8%;

Pred. No. 3.9e+02;

Mismatches

0;

Indels

1;

Gaps

0;

2733

GACTGCCCGAGGCC

2748

1

GACTGCCCGAGGCC

16

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

CC receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC nucleic acid molecules used to inhibit the expression of the said genes
CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
CC zynzyme, and/or DNzyme motifs. The methods of the invention are useful
CC for treating cancer, in particular breast cancer, Alzheimer's disease,
CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC diseases, hepatitis B infections, and hepatitis and hepatocellular
CC carcinoma. The enzymatic nucleic acid molecules can also be used as
CC diagnostic tools to examine genetic drift and mutations within diseased
CC cells and to detect the presence of specific RNA in a cell. The present
CC sequence represents a substrate/target sequence for a DNzyme used in the
CC examples of the present invention. Note: Some SEQ ID Nos are repeated
CC more than once in the specification, but these have different sequences
CC associated with them.

XX
SQ Sequence 17 BP; 3 A; 7 C; 7 G; 0 T; 0 U; 0 Other;
Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 72 CCACCCGGGGGGGAC 87
|||||
Db 1 CCACCCGGGGGGGAC 16

RESULT 701
ADM89524/c
ID ADM89524 standard; DNA; 17 BP.
XX
AC ADM89524;
XX
DT 10-FEB-2005 (first entry)
XX
DE Human PTP-1B NCH ribozyme substrate sequence #390.
XX
KW Enzymatic nucleic acid molecule; gene expression; down regulation;
KW protein-tyrosine-phosphatase-1b; PTP-1B; methionine aminopeptidase;
KW MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
KW hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW amberzyme; zynzyme; DNzyme; cancer; breast cancer; Alzheimer's disease;
KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
KW ds.
XX
OS Homo sapiens.
XX
PN WO200116312-A2.
XX
PD 08-MAR-2001.
XX
PF 30-AUG-2000; 2000WO-US023998.
XX
PR 31-AUG-1999; 99US-0151713P.
PR 27-SEP-1999; 99US-00406643.
PR 27-SEP-1999; 99US-0156236P.
PR 27-SEP-1999; 99US-0156467P.
PR 08-NOV-1999; 99US-00436430.
PR 06-DEC-1999; 99US-0169100P.
PR 23-DEC-1999; 99US-00474432.
PR 23-DEC-1999; 99US-0173612P.
PR 30-DEC-1999; 99US-00476387.
PR 04-FEB-2000; 2000US-00498824.
PR 20-MAR-2000; 2000US-00531025.
PR 14-APR-2000; 2000US-0197769P.
PR 23-MAY-2000; 2000US-00578223.
PR 09-AUG-2000; 2000US-00636385.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX

PI Mcswiggen J, Usman N, Blatt L, Beigelman L, Burgin A,
PI Karpeisky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B;
PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
XX WPI; 2001-244406/25.
DR Enzymatic nucleic acid molecules able to cleave separate RNA molecules
PT are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
PT obesity and heart disease.
XX Example 2; Page 200; 717pp; English.
XX The present invention relates to the use of enzymatic nucleic acid
CC molecules (e.g. ribozymes) to modulate gene expression. The invention
CC also methods for their use to down regulate or inhibit the expression of
CC genes encoding protein-tyrosine-phosphatase-1b (PTP-1B), methionine
CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
CC receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC nucleic acid molecules used to inhibit the expression of the said genes
CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
CC zynzyme, and/or DNzyme motifs. The methods of the invention are useful
CC for treating cancer, in particular breast cancer, Alzheimer's disease,
CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC diseases, hepatitis B infections, and hepatitis and hepatocellular
CC carcinoma. The enzymatic nucleic acid molecules can also be used as
CC diagnostic tools to examine genetic drift and mutations within diseased
CC cells and to detect the presence of specific RNA in a cell. The present
CC sequence represents a substrate/target sequence for a ribozyme used in
CC the examples of the present invention. Note: Some SEQ ID Nos are repeated
CC more than once in the specification, but these have different sequences
CC associated with them.

XX
SQ Sequence 17 BP; 2 A; 10 C; 4 G; 1 T; 0 U; 0 Other;
Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1536 GGAGCCCTGGGTGGTG 1551
|||||
Db 17 GGAGCCCTGGGTGGGG 2

RESULT 702
ADM89525/c
ID ADM89525 standard; DNA; 17 BP.
XX
AC ADM89525;
XX
DT 10-FEB-2005 (first entry)
XX
DE Human PTP-1B NCH ribozyme substrate sequence #391.
XX
KW Enzymatic nucleic acid molecule; gene expression; down regulation;
KW protein-tyrosine-phosphatase-1b; PTP-1B; methionine aminopeptidase;
KW MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
KW hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW amberzyme; zynzyme; DNzyme; cancer; breast cancer; Alzheimer's disease;
KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
KW ds.
XX
OS Homo sapiens.
XX
PN WO200116312-A2.
XX
PD 08-MAR-2001.
XX
PF 30-AUG-2000; 2000WO-US023998.

XX 31-AUG-1999; 99US-0151713P.
 PR 27-SEP-1999; 99US-00406643.
 PR 27-SEP-1999; 99US-0156236P.
 PR 27-SEP-1999; 99US-0156467P.
 PR 08-NOV-1999; 99US-00436430.
 PR 06-DEC-1999; 99US-0169100P.
 PR 29-DEC-1999; 99US-00474432.
 PR 29-DEC-1999; 99US-0173612P.
 PR 30-DEC-1999; 99US-00476387.
 PR 04-FEB-2000; 2000US-00498824.
 PR 20-MAR-2000; 2000US-00531025.
 PR 14-APR-2000; 2000US-0197769P.
 PR 23-MAY-2000; 2000US-00578223.
 PR 09-AUG-2000; 2000US-00636385.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX McSwiggen J, Usman N, Blatt L, Beigelman L, Burgin A,
 PI Karpelisky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B;
 PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
 XX WPI; 2001-244406/25.
 XX Enzymatic nucleic acid molecules able to cleave separate RNA molecules
 PT are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
 PT obesity and heart disease.
 XX Example 2; Page 200; 717pp; English.
 XX The present invention relates to the use of enzymatic nucleic acid
 CC molecules (e.g. ribozymes) to modulate gene expression. The invention
 CC also methods for their use to down regulate or inhibit the expression of
 CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine
 CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
 CC receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
 CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
 CC nucleic acid molecules used to inhibit the expression of the said genes
 CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
 CC zinyne, and/or DNzyme motifs. The methods of the invention are useful
 CC for treating cancer, in particular breast cancer, Alzheimer's disease,
 CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
 CC diseases, hepatitis B infections, and hepatitis and hepatocellular
 CC carcinoma. The enzymatic nucleic acid molecules can also be used as
 CC diagnostic tools to examine genetic drift and mutations within diseased
 CC cells and to detect the presence of specific RNA in a cell. The present
 CC sequence represents a substrate/target sequence for a ribozyme used in
 CC the examples of the present invention. Note: Some SEQ ID Nos are repeated
 CC more than once in the specification, but these have different sequences
 CC associated with them.
 XX SQ Sequence 17 BP; 2 A; 11 C; 3 G; 1 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 1536 GGAGCCCTGGGTGGTG 1551
 Db 16 GGAGCCCTGGGTGGG 1
 RESULT 703
 ADV07544
 ID ADV07544 standard; RNA; 17 BP.
 XX ADV07544;
 AC ADV07544;
 XX 10-FEB-2005 (first entry)
 DT Human BACE amberzyme ribozyme substrate sequence #425.
 XX

KW Enzymatic nucleic acid molecule; gene expression; down regulation;
 KW protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
 KW MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
 KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
 KW c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
 KW hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
 KW amberzyme; zinyne; DNzyme; cancer; breast cancer; Alzheimer's disease;
 KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
 KW hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
 ss.
 XX Homo sapiens.
 OS WO200116312-A2.
 PN 08-MAR-2001.
 PD 30-AUG-2000; 2000WO-US023998.
 PF 31-AUG-1999; 99US-0151713P.
 XX 27-SEP-1999; 99US-00406643.
 PR 27-SEP-1999; 99US-0156236P.
 PR 27-SEP-1999; 99US-0156467P.
 PR 08-NOV-1999; 99US-00436430.
 PR 06-DEC-1999; 99US-0169100P.
 PR 29-DEC-1999; 99US-00474432.
 PR 29-DEC-1999; 99US-0173612P.
 PR 30-DEC-1999; 99US-00476387.
 PR 04-FEB-2000; 2000US-00498824.
 PR 20-MAR-2000; 2000US-00531025.
 PR 14-APR-2000; 2000US-0197769P.
 PR 23-MAY-2000; 2000US-00578223.
 PR 09-AUG-2000; 2000US-00636385.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA McSwiggen J, Usman N, Blatt L, Beigelman L, Burgin A,
 XX Karpelisky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B;
 PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
 XX WPI; 2001-244406/25.
 XX Enzymatic nucleic acid molecules able to cleave separate RNA molecules
 PT are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
 PT obesity and heart disease.
 XX Example 4; Page 401; 717pp; English.
 XX The present invention relates to the use of enzymatic nucleic acid
 CC molecules (e.g. ribozymes) to modulate gene expression. The invention
 CC also methods for their use to down regulate or inhibit the expression of
 CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine
 CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
 CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
 CC receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
 CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
 CC nucleic acid molecules used to inhibit the expression of the said genes
 CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
 CC zinyne, and/or DNzyme motifs. The methods of the invention are useful
 CC for treating cancer, in particular breast cancer, Alzheimer's disease,
 CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
 CC diseases, hepatitis B infections, and hepatitis and hepatocellular
 CC carcinoma. The enzymatic nucleic acid molecules can also be used as
 CC diagnostic tools to examine genetic drift and mutations within diseased
 CC cells and to detect the presence of specific RNA in a cell. The present
 CC sequence represents a substrate/target sequence for a ribozyme used in
 CC the examples of the present invention. Note: Some SEQ ID Nos are repeated
 CC more than once in the specification, but these have different sequences
 CC associated with them.
 XX SQ Sequence 17 BP; 1 A; 5 C; 10 G; 0 T; 1 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 3.9e+02; Mismatches 1; Indels 0; Gaps 0;
 Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 3702 GGGGGTGTCCACGGG 3717
 |||||:|||||
 Db 2 GGGGGCUGGCCACGGG 17

RESULT 704
 ADV01226/c
 ID ADV01226 standard; DNA; 17 BP.
 AC ADV01226;
 XX
 XX 10-FEB-2005 (first entry)
 DT
 DE Human TERT DNazyme substrate sequence #497.
 DE Enzymatic nucleic acid molecule; gene expression; down regulation;
 KW protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
 KW MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
 KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
 KW c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
 KW hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
 KW amberszyme; zinzyme; DNazyme; cancer; breast cancer; Alzheimer's disease;
 KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
 KW hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
 KW ds.
 XX Homo sapiens.
 OS
 XX WO200116312-A2.
 PN
 XX 08-MAR-2001.
 PD
 XX 30-AUG-2000; 2000WO-US023998.
 PF
 XX 31-AUG-1999; 99US-0151713P.
 PR 27-SEP-1999; 99US-00406643.
 PR 27-SEP-1999; 99US-0156236P.
 PR 08-NOV-1999; 99US-0156467P.
 PR 06-DEC-1999; 99US-00436430.
 PR 29-DEC-1999; 99US-0169100P.
 PR 29-DEC-1999; 99US-00474432.
 PR 30-DEC-1999; 99US-0173612P.
 PR 04-FEB-2000; 99US-00476387.
 PR 20-MAR-2000; 2000US-00498824.
 PR 14-APR-2000; 2000US-00531025.
 PR 23-MAY-2000; 2000US-0197769P.
 PR 09-AUG-2000; 2000US-00578223.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Mcswiggen J, Usman N, Blatt L, Beigelman L, Burgin A;
 PI Karpelsky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B;
 PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
 XX WPI; 2001-244406/25.
 DR Enzymatic nucleic acid molecules able to cleave separate RNA molecules
 XX are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
 PT obesity and heart disease.
 PT
 XX Example 1; Page 328; 717pp; English.
 PS
 XX The present invention relates to the use of enzymatic nucleic acid
 CC molecules (e.g. ribozymes) to modulate gene expression. The invention
 CC also methods for their use to down regulate or inhibit the expression of
 CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine
 CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
 CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
 CC receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),

CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
 CC nucleic acid molecules used to inhibit the expression of the said genes
 CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberszyme,
 CC zinzyme, and/or DNazyme motifs. The methods of the invention are useful
 CC for treating cancer, in particular breast cancer, Alzheimer's disease,
 CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
 CC diseases, hepatitis B infections, and hepatitis and hepatocellular
 CC carcinoma. The enzymatic nucleic acid molecules can also be used as
 CC diagnostic tools to examine genetic drift and mutations within diseased
 CC cells and to detect the presence of specific RNA in a cell. The present
 CC sequence represents a substrate/target sequence for a DNazyme used in the
 CC examples of the present invention. Note: Some SEQ ID Nos are repeated
 CC more than once in the specification, but these have different sequences
 CC associated with them.
 XX
 XX Sequence 17 BP; 1 A; 6 C; 10 G; 0 T; 0 U; 0 Other;
 SQ Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 211 GCGCGCGCGCCGCT 226
 |||||:|||||
 Db 17 GCGCGCGCGCCGCT 2

RESULT 705
 ADU94064
 ID ADU94064 standard; DNA; 17 BP.
 XX
 XX AC ADU94064;
 XX
 XX 10-FEB-2005 (first entry)
 DT
 DE Human TERT NCH ribozyme substrate sequence #887.
 DE Enzymatic nucleic acid molecule; gene expression; down regulation;
 KW protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
 KW MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
 KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
 KW c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
 KW hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
 KW amberszyme; zinzyme; DNazyme; cancer; breast cancer; Alzheimer's disease;
 KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
 KW hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
 KW ds.
 XX Homo sapiens.
 OS
 XX WO200116312-A2.
 PN
 XX 08-MAR-2001.
 PD
 XX 30-AUG-2000; 2000WO-US023998.
 PF
 XX 31-AUG-1999; 99US-0151713P.
 PR 27-SEP-1999; 99US-00406643.
 PR 27-SEP-1999; 99US-0156236P.
 PR 27-SEP-1999; 99US-0156467P.
 PR 08-NOV-1999; 99US-00436430.
 PR 06-DEC-1999; 99US-0169100P.
 PR 29-DEC-1999; 99US-00474432.
 PR 29-DEC-1999; 99US-0173612P.
 PR 30-DEC-1999; 99US-00476387.
 PR 04-FEB-2000; 2000US-00498824.
 PR 20-MAR-2000; 2000US-00531025.
 PR 14-APR-2000; 2000US-0197769P.
 PR 23-MAY-2000; 2000US-00578223.
 PR 09-AUG-2000; 2000US-00636385.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Mcswiggen J, Usman N, Blatt L, Beigelman L, Burgin A;
 PI Karpelsky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B;
 PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
 XX WPI; 2001-244406/25.
 DR Enzymatic nucleic acid molecules able to cleave separate RNA molecules
 XX are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
 PT obesity and heart disease.
 PT
 XX Example 1; Page 328; 717pp; English.
 PS
 XX The present invention relates to the use of enzymatic nucleic acid
 CC molecules (e.g. ribozymes) to modulate gene expression. The invention
 CC also methods for their use to down regulate or inhibit the expression of
 CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine
 CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
 CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
 CC receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),

PI Karpeisky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B;
 PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
 XX WPI; 2001-244406/25.
 XX Enzymatic nucleic acid molecules able to cleave separate RNA molecules
 PT are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
 PT obesity and heart disease.
 XX Example 1; Page 294; 717pp; English.
 XX The present invention relates to the use of enzymatic nucleic acid
 CC molecules (e.g. ribozymes) to modulate gene expression. The invention
 CC also methods for their use to down regulate or inhibit the expression of
 CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine C
 CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
 CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
 CC receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
 CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
 CC nucleic acid molecules used to inhibit the expression of the said genes
 CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
 CC zynzyme, and/or DNAzyme motifs. The methods of the invention are useful
 CC for treating cancer, in particular breast cancer, Alzheimer's disease,
 CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
 CC diseases, hepatitis B infections, and hepatitis and hepatocellular
 CC carcinoma. The enzymatic nucleic acid molecules can also be used as
 CC diagnostic tools to examine genetic drift and mutations within diseased
 CC cells and to detect the presence of specific RNA in a cell. The present
 CC sequence represents a substrate/target sequence for a ribozyme used in
 CC the examples of the present invention. Note: Some SEQ ID Nos are repeated
 CC more than once in the specification, but these have different sequences
 CC associated with them.
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2733 GACTGCCCCGGAGGCC 2748
 Db ||||| |||||
 2 GACTGCCCCGGAGGCC 17
 RESULT 706
 ADV05221
 ID ADV05221 standard; RNA; 17 BP.
 AC ADV05221;
 XX
 DT 10-FEB-2005 (first entry)
 XX
 DE Human BACE zynzyme ribozyme substrate sequence #163.
 XX Enzymatic nucleic acid molecule; gene expression; down regulation;
 KW protein-tyrosine-phosphatase-1b; PTB-1b; methionine aminopeptidase;
 KW MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
 KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
 KW c-erb2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
 KW hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
 KW amberzyme; zynzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
 KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
 KW hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
 KW ss.
 OS Homo sapiens.
 XX
 XX WO200116312-A2.
 PN
 XX 08-MAR-2001.
 PD
 XX 30-AUG-2000; 2000WO-US023998.
 PF
 XX Enzymatic nucleic acid molecule; gene expression; down regulation;

PR 31-AUG-1999; 99US-0151713P.
 PR 27-SEP-1999; 99US-00406643.
 PR 27-SEP-1999; 99US-0156236P.
 PR 27-SEP-1999; 99US-0156467P.
 PR 08-NOV-1999; 99US-00436430.
 PR 06-DEC-1999; 99US-0169100P.
 PR 29-DEC-1999; 99US-00474432.
 PR 29-DEC-1999; 99US-0173612P.
 PR 30-DEC-1999; 99US-00476387.
 PR 04-FEB-2000; 2000US-00498824.
 PR 20-MAR-2000; 2000US-00531025.
 PR 14-APR-2000; 2000US-0197769P.
 PR 23-MAY-2000; 2000US-00578223.
 PR 09-AUG-2000; 2000US-00636385.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA McSwiggen J, Usman N, Blatt L, Beigelman L, Burgin A;
 XX Karpeisky A, Matulic-Adamic J, Sweedler D, Draper K, Chowrira B;
 PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
 XX WPI; 2001-244406/25.
 DR Enzymatic nucleic acid molecules able to cleave separate RNA molecules
 XX are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
 PT obesity and heart disease.
 XX Example 4; Page 373; 717pp; English.
 XX The present invention relates to the use of enzymatic nucleic acid
 CC molecules (e.g. ribozymes) to modulate gene expression. The invention
 CC also methods for their use to down regulate or inhibit the expression of
 CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1b), methionine C
 CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
 CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
 CC receptor-2 (HER2/c-erb2/neu), phospholamban (PLN), presenilin-1 (ps-1),
 CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
 CC nucleic acid molecules used to inhibit the expression of the said genes
 CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberzyme,
 CC zynzyme, and/or DNAzyme motifs. The methods of the invention are useful
 CC for treating cancer, in particular breast cancer, Alzheimer's disease,
 CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
 CC diseases, hepatitis B infections, and hepatitis and hepatocellular
 CC carcinoma. The enzymatic nucleic acid molecules can also be used as
 CC diagnostic tools to examine genetic drift and mutations within diseased
 CC cells and to detect the presence of specific RNA in a cell. The present
 CC sequence represents a substrate/target sequence for a ribozyme used in
 CC the examples of the present invention. Note: Some SEQ ID Nos are repeated
 CC more than once in the specification, but these have different sequences
 CC associated with them.
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 10 G; 0 T; 1 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 3.9e+02;
 Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Qy 3702 GGGGGCTGTCCTCCAGGG 3717
 Db |||||:|||||
 1 GGGGGCTGTCCTCCAGGG 16
 RESULT 707
 ADV07126
 ID ADV07126 standard; RNA; 17 BP.
 XX
 AC ADV07126;
 XX
 DT 10-FEB-2005 (first entry)
 XX
 DE Human BACE amberzyme ribozyme substrate sequence #211.
 XX Enzymatic nucleic acid molecule; gene expression; down regulation;

KW protein-tyrosine-phosphatase-1b; PTB-1B; methionine aminopeptidase;
KW MetAP-2; human telomerase; hTERT; protein kinase C alpha; PKC alpha;
KW beta-secretase; BACE; human epidermal growth factor receptor-2; HER2;
KW c-erbB2; neu; phospholamban; PLN; presenilin-1; ps-1; presenilin-2; ps-2;
KW hepatitis B virus; HBV; hammerhead; HH; hairpin; NCH; inozyme; G-cleaver;
KW amberyzyme; zinzyme; DNAzyme; cancer; breast cancer; Alzheimer's disease;
KW diabetes; obesity; cardiac disease; heart disease; age-related disease;
KW hepatitis B infection; hepatocellular carcinoma; genetic drift; human;
KW SS.
XX
XX Homo sapiens.
XX WO200116312-A2.
XX
XX 08-MAR-2001.
XX
XX 30-AUG-2000; 2000WO-US023998.
XX
XX 31-AUG-1999; 99US-0151713P.
XX 27-SEP-1999; 99US-00406643.
XX 27-SEP-1999; 99US-0156236P.
XX 27-SEP-1999; 99US-0156467P.
XX 08-NOV-1999; 99US-00436430.
XX 06-DEC-1999; 99US-0169100P.
XX 28-DEC-1999; 99US-00474432.
XX 28-DEC-1999; 99US-0173612P.
XX 30-DEC-1999; 99US-00476387.
XX 04-FEB-2000; 2000US-00498824.
XX 20-MAR-2000; 2000US-00531025.
XX 14-APR-2000; 2000US-0197769P.
XX 23-MAY-2000; 2000US-00578223.
XX 09-AUG-2000; 2000US-00638385.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J, Usman N, Blatt L, Beigelman L, Burgin A;
PI Karpiski A, Matulic-Adamic J, Seedler D, Draper K, Chowrira B;
PI Stinchcomb D, Beaudry A, Zinnen S, Ludwig J, Sproat BS;
XX
XX WPI; 2001-244406/25.
XX
XX Enzymatic nucleic acid molecules able to cleave separate RNA molecules
PT are used for treating cancer, Alzheimer's disease, hepatitis, diabetes,
PT obesity and heart disease.
XX
XX Example 4; Page 395; 717pp; English.
XX
XX The present invention relates to the use of enzymatic nucleic acid
CC molecules (e.g. ribozymes) to modulate gene expression. The invention
CC also methods for their use to down regulate or inhibit the expression of
CC genes encoding protein-tyrosine-phosphatase-1b (PTB-1B), methionine
CC aminopeptidase (MetAP-2), human telomerase (hTERT), protein kinase C
CC alpha (PKC alpha), beta-secretase (BACE), human epidermal growth factor
CC receptor-2 (HER2/c-erbB2/neu), phospholamban (PLN), presenilin-1 (ps-1),
CC presenilin-2 (ps-2), and hepatitis B virus (HBV) proteins. The enzymatic
CC nucleic acid molecules used to inhibit the expression of the said genes
CC include hammerhead (HH), hairpin, NCH (inozyme), G-cleaver, amberyzyme,
CC zinzyme, and/or DNAzyme motifs. The methods of the invention are useful
CC for treating cancer, in particular breast cancer, Alzheimer's disease,
CC diabetes, obesity, cardiac diseases e.g. heart disease, age-related
CC diseases, hepatitis B infections, and hepatitis and hepatocellular
CC carcinoma. The enzymatic nucleic acid molecules can also be used as
CC diagnostic tools to examine genetic drift and mutations within diseased
CC cells and to detect the presence of specific RNA in a cell. The present
CC sequence represents a substrate/target sequence for a ribozyme used in
CC the examples of the present invention. Note: Some SEQ ID Nos are repeated
CC more than once in the specification, but these have different sequences
CC associated with them.
XX
XX Sequence 17 BP; 1 A; 5 C; 10 G; 0 T; 1 U; 0 Other;
SQ

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;

Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 3702 GGGGGCTGCCAGGG 3717
DB 1 GGGGCGUGGCCAGGG 16
RESULT 708
ABN02855
ID ABN02655 standard; DNA; 17 BP.
XX
XX AC ABN02655;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2647.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024283.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 2647; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart

CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1222 GGGTCTCCGACCCAT 1237
 DB 2 GGGTCTCCGACCCAT 17
 RESULT 709
 ABN01663/c
 ID ABN01663 standard; DNA; 17 BP.
 XX
 AC ABN01663;
 XX
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1655.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 FA (AEOM-) AEOMICA INC.
 XX
 FI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 DR
 XX
 XX
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
 XX
 XX
 PS Disclosure; SEQ ID NO 1655; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 7 G; 0 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3965 CTATGGCTCTCTTGC 3980
 DB 16 CTCTGGCTCTCTTGC 1
 RESULT 710
 ABN02656
 ID ABN02656 standard; DNA; 17 BP.
 XX
 AC ABN02656;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2648.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 FA (AEOM-) AEOMICA INC.
 XX
 FI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX
 DR
 XX
 XX

PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX
XX Disclosure; SEQ ID NO 2648; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1222 GGGTCTCTGGCAGGCAT 1237
Db 1 GGGTCTCTGGCAGGCAT 16
|||||
|||

RESULT 711
ABN00913
ID ABN00913 standard; DNA; 17 BP.
AC ABN00913;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:905.
XX
XX Human, genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
PN
PD 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US0016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR
PR 21-SEP-2000; 2000US-0234687P.
PR
PR 27-SEP-2000; 2000US-0236359P.
PR
PR 04-OCT-2000; 2000GB-00024263.
PR
PR 30-JAN-2001; 2001WO-US000661.
PR
PR 30-JAN-2001; 2001WO-US000662.
PR
PR 30-JAN-2001; 2001WO-US000663.
PR
PR 30-JAN-2001; 2001WO-US000664.
PR
PR 30-JAN-2001; 2001WO-US000665.
PR
PR 30-JAN-2001; 2001WO-US000666.
PR
PR 30-JAN-2001; 2001WO-US000667.

PR 30-JAN-2001; 2001WO-US000668.
PR
PR 30-JAN-2001; 2001WO-US000669.
PR
PR 30-JAN-2001; 2001WO-US000670.
PR
PR 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
PI
XX WPI; 2002-179446/23.
DR
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 905; 214pp; English.
PS
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
SQ Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4056 GCCTGGACCCCAAG 4071
Db 2 GCCTGGACCCCAAG 17
|||||
|||

RESULT 712
ABN00914
ID ABN00914 standard; DNA; 17 BP.
XX
XX ABN00914;
AC
XX
XX 29-MAY-2002 (first entry)
DT
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:906.
DE
XX
XX Human, genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
PN
PD 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX

PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024283.
 PR 30-JAN-2001; 2001WO-US0000661.
 PR 30-JAN-2001; 2001WO-US0000662.
 PR 30-JAN-2001; 2001WO-US0000663.
 PR 30-JAN-2001; 2001WO-US0000664.
 PR 30-JAN-2001; 2001WO-US0000665.
 PR 30-JAN-2001; 2001WO-US0000666.
 PR 30-JAN-2001; 2001WO-US0000667.
 PR 30-JAN-2001; 2001WO-US0000668.
 PR 30-JAN-2001; 2001WO-US0000669.
 PR 30-JAN-2001; 2001WO-US0000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 FA (AEOM-) AEOMICA INC.
 XX
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 DR
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 PT
 XX
 PS Disclosure; SEQ ID NO 906; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 4056 GCCTGGGACCCCAAG 4071
 Db 1 GCTTGGGACCCCAAG 16
 RESULT 713
 ABQ63402/c
 ID ABQ63402 standard; DNA; 17 BP.
 XX
 AC ABQ63402;
 XX
 DT 20-AUG-2002 (first entry)
 XX
 DE Human KTOM1a portion (ABQ63232) probe # 115.
 XX
 KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;

KW Gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
 KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
 OS Homo sapiens.
 XX WO200224750-A2.
 PN
 XX
 PD 28-MAR-2002.
 XX
 PF 21-SEP-2001; 2001WO-US029656.
 XX
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024283.
 PR 30-JAN-2001; 2001WO-US0000661.
 PR 30-JAN-2001; 2001WO-US0000662.
 PR 30-JAN-2001; 2001WO-US0000663.
 PR 30-JAN-2001; 2001WO-US0000664.
 PR 30-JAN-2001; 2001WO-US0000665.
 PR 30-JAN-2001; 2001WO-US0000666.
 PR 30-JAN-2001; 2001WO-US0000667.
 PR 30-JAN-2001; 2001WO-US0000668.
 PR 30-JAN-2001; 2001WO-US0000669.
 PR 30-JAN-2001; 2001WO-US0000670.
 PR 23-MAY-2001; 2001US-00864761.
 PR 28-AUG-2001; 2001US-0315676P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 XX Zhang J;
 XX WPI; 2002-479509/51.
 DR
 XX
 PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
 PT acids encoding the protein, useful for treating subjects having defects
 PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
 PT e.g., liver or bone.
 XX
 PS Example 2; Page 172; 418pp; English.
 XX
 CC The invention relates to a novel isolated nucleic acid encoding human
 CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
 CC invention has cytostatic activity. The nucleotide may have a use in gene
 CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
 CC monitor a disease caused by altered expression of human KTOM1
 CC Compositions comprising the nucleic acids, proteins or antibodies may be
 CC used to treat subjects having defects in KTOM1 which can manifest as
 CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
 CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
 CC function. The sequence represents a probe used in the invention to scan
 CC the nt 1-1001 portion of human KTOM1a (ABQ63232)
 XX
 SQ Sequence 17 BP; 2 A; 2 C; 10 G; 3 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 4040 CACATCCCCGGACCCC 4055
 Db 17 CACATCCCCGGACTCC 2
 RESULT 714
 ABQ63404/c
 ID ABQ63404 standard; DNA; 17 BP.
 XX
 AC ABQ63404;
 XX
 DT 20-AUG-2002 (first entry)
 XX
 DE Human KTOM1a portion (ABQ63232) probe # 117.

KW Human; KTM01a; KTM01; kidney tumour overexpressed membrane; cytostatic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
XX Homo sapiens.
XX WO200224750-A2.
XX
XX
PD 28-MAR-2002.
XX
XX
PF 21-SEP-2001; 2001WO-US023656.
XX
XX 21-SEP-2000; 2000US-0234587P.
XX 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
XX (AEOM-) AEOMICA INC.
PA
XX Zhang J;
XX
XX WPI; 2002-479509/51.
XX
XX New human kidney tumor overexpressed membrane (KTM01) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTM01 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
XX
PS Example 2; Page 173; 418pp; English.
XX
XX The invention relates to a novel isolated nucleic acid encoding human
CC KTM01 (kidney tumour overexpressed membrane) protein. The protein of the
CC invention has cytostatic activity. The nucleotide may have a use in gene
CC therapy. The KTM01 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTM01.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTM01 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTM01a (AB063232)
XX
XX Sequence 17 BP; 2 A; 2 C; 9 G; 4 T; 0 U; 0 Other;
Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 4039 CCACATCCCCCGAGCC 4054
DB 16 CCACATCCCCGGACTC 1
RESULT 715
ABL31121
ID ABL31121 standard; DNA; 17 BP.
AC ABL31121;
XX
XX 21-MAR-2002 (first entry)
DT
XX Human HLA genotyping oligonucleotide SEQ ID NO 610.

XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
KW immunogenetic; transplantation; genetic disease; ss.
XX
XX Homo sapiens.
XX WO200192572-A1.
XX
XX 06-DEC-2001.
XX
XX 01-JUN-2001; 2001WO-JP004662.
XX
XX 01-JUN-2000; 2000JP-00164798.
XX (NISN) NISSHINBO IND INC.
XX (SYST-) SYSTEM RES INC.
XX
XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX WPI; 2002-122074/16.
XX
XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
PT individuals e.g. by determining immunogenetic differences when
PT transplanting between them.
XX
XX Claim 10; Page 209; 345pp; Japanese.
XX
XX The invention relates to a typing kit for judging human leukocyte antigen
CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
CC genes e.g. belonging to HLA class I antigens on human genome and
CC containing gene polymorphisms as alloantigens have been immobilised as
CC primers for amplification of cleaved nucleic acids relating to gene
CC polymorphisms. The method is useful for judging HLA genotypes of
CC individuals by determining immunogenetic differences before transplanting
CC between them, providing genetic information to decide compatibility of
CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC diagnosis of genetic diseases and identifying individuals
XX
XX Sequence 17 BP; 2 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1819 GTGCGGTTCTTGAGCA 1834
DB 1 GTGCGGTTCTTGAGCA 16
RESULT 716
ACN04226/c
ID ACN04226 standard; RNA; 17 BP.
XX
XX ACN04226;
XX
XX 22-APR-2004 (first entry)
DT
XX WNV Zinzyme substrate SEQ ID NO 4229.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAAzyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX

PF 19-OCT-2001; 2001WO-US048350.
 PR 20-OCT-2000; 2000US-0242411P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX Blatt L, Mcswiggen JA;
 PI WPI; 2002-706994/76.
 DR
 XX New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX
 XX Claim 23; SEQ ID NO 4229; 495pp; English.
 PS
 XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 4 G; 0 T; 3 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. NO. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2054 TTCTCTGCCTCAGGAA 2069
 DB 17 TTCTCTGCCTCAGGAA 2
 RESULT 717
 ACN12772
 ID ACN12772 standard; RNA; 17 BP.
 XX
 AC ACN12772;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE WNV minus strand Zinzyne substrate SEQ ID NO 12775.
 XX
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyne; ss.
 XX
 OS West Nile Virus.
 XX
 XX WO200268637-A2.
 PN
 XX 06-SEP-2002.
 PD
 XX 19-OCT-2001; 2001WO-US048350.
 PF
 XX 20-OCT-2000; 2000US-0242411P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX Blatt L, Mcswiggen JA;
 PI WPI; 2002-706994/76.
 DR
 XX New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX
 XX Claim 23; SEQ ID NO 4229; 495pp; English.
 PS
 XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 4 G; 0 T; 3 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. NO. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2054 TTCTCTGCCTCAGGAA 2069
 DB 17 TTCTCTGCCTCAGGAA 2

XX Blatt L, Mcswiggen JA;
 PI WPI; 2002-706994/76.
 DR
 XX New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX
 XX Claim 23; SEQ ID NO 12775; 495pp; English.
 PS
 XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX
 SQ Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 62.5%; Pred. NO. 3.9e+02;
 Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
 QY 2054 TTCTCTGCCTCAGGAA 2069
 DB 2 UUCUCUGGCUACAGGAA 17
 RESULT 718
 ACN13224/C
 ID ACN13224 standard; RNA; 17 BP.
 XX
 AC ACN13224;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE WNV minus strand Zinzyne substrate SEQ ID NO 13227.
 XX
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyne; ss.
 XX
 OS West Nile Virus.
 XX
 XX WO200268637-A2.
 PN
 XX 06-SEP-2002.
 PD
 XX 19-OCT-2001; 2001WO-US048350.
 PF
 XX 20-OCT-2000; 2000US-0242411P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX Blatt L, Mcswiggen JA;
 PI WPI; 2002-706994/76.
 DR
 XX New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX

PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 13227; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;
Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3228 AGTCACTCTGGCGGGA 3243
DB 16 AGTCACTCTGGCGGGA 1
RESULT 719
ACN05992
ID ACN05992 standard; RNA; 17 BP.
XX
AC ACN05992;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV Amberzyme substrate SEQ ID NO 5995.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic; virucide; neuroprotective; antibacterial; replication; pancreatitis; encephalitis; myocarditis; meningitis; infection; hepatitis; liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme; Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
CC New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 5995; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention
XX
SQ Sequence 17 BP; 3 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 3.9e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 3229 GTCACCTCTGGCGGAC 3244
DB 1 GUCACACUGGCGGAC 16
RESULT 720
ACN11464/c
ID ACN11464 standard; RNA; 17 BP.
XX
AC ACN11464;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Inozyme substrate SEQ ID NO 11467.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic; virucide; neuroprotective; antibacterial; replication; pancreatitis; encephalitis; myocarditis; meningitis; infection; hepatitis; liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme; Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
CC New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 11467; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a

CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention

XX Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;
SQ
Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 3229 GTCACCTCTGGCGGAC 3244
|||||
Db 17 GTCACACTGGCGGAC 2

RESULT 721
ABT35221
ID ABT35221 standard; DNA; 17 BP.

XX AC ABT35221;

XX DT 12-JUN-2003 (first entry)

XX DE Tumour suppression related human fukutin oligo SEQ ID No 858.

XX KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.

XX OS Homo sapiens.

XX FN WO2003025175-A2.

XX PD 27-MAR-2003.

XX PF 17-SEP-2002; 2002WO-IB004208.

XX PR 17-SEP-2001; 2001FR-00011978.

XX PA (MOLE-) MOLECULAR ENGINES LAB.

XX PI Telerman A, Amson R, Tuijnder M;

XX DR WPI; 2003-313353/30.

XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.

XX PS Disclosure; Page 133; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15 consecutive
XX nucleotides from the 17 mer sequence, a sequence with, after optimal
XX alignment, at least 80 % identity to the 17 mer sequence, a sequence that
XX hybridizes to them under highly stringent conditions, or the complement
XX of any of them, or the corresponding RNA. The novel isolated nucleic
XX acids of the invention are useful as probes and primers for detecting,
XX identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
XX component of a gene chip, in vitro as (anti)sense reagents, and for
XX production of recombinant polypeptides. Any of the nucleic acids,
XX polypeptides, vectors containing the nucleic acids, cells containing the
XX vector or antibodies directed against the polypeptides are useful for
XX preparation of pharmaceuticals for prevention and/or treatment of viral
XX diseases that are characterised by development of tumours or cell
XX degeneration, specifically cancer but also Alzheimer's disease and
XX schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
XX patient samples is useful for diagnosis and/or prognosis of these
XX diseases. The polypeptides can also be used to generate antibodies, and
XX both the polypeptide and antibodies are useful as components of protein
XX chips. The nucleic acid sequences of the invention can be used in gene

CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention
XX
SQ Sequence 17 BP; 9 A; 2 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 4174 ATTAAAAAGTAACT 4189
|||||
Db 2 ATCTAAAAAGTAACT 17

RESULT 722
ACA06540

ID ACA06540 standard; RNA; 17 BP.

XX AC ACA06540;

XX DT 03-JUN-2003 (first entry)

XX DE NFkB sub-unit modulating inozyme substrate #359.

XX KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.

XX OS Homo sapiens.

XX FN US2002177568-A1.

XX PD 28-NOV-2002.

XX PF 23-MAY-2001; 2001US-00864785.

XX PR 07-DEC-1992; 92US-00987132.

XX PR 18-MAY-1994; 94US-00245466.

XX PR 15-AUG-1994; 94US-00291932.

XX PR 23-DEC-1996; 96US-00777916.

XX PA (STIN/) STINCHCOMB D T.

XX PA (MCSW/) MCSWIGGEN J.

XX PA (DRAP/) DRAPER K G.

XX PI Stinchcomb DT, Mcswiggen J, Draper KG;

XX DR WPI; 2003-340953/32.

XX Novel enzymatic nucleic acid molecules which down regulates expression of
XX a sequence encoding a subunit of nuclear factor kappa B useful for
XX treating cancer, inflammatory disorders and autoimmune diseases.

XX Claim 3; Page 32; 72pp; English.

XX The invention describes an enzymatic nucleic acid molecule (I) which down
XX regulates expression of a sequence encoding a subunit of nuclear factor
XX kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
XX configuration. The enzymatic nucleic acid molecule is adapted to treat
XX cancer and is useful for down-regulating REL-A activity in a cell, for
XX treating a patient having a condition associated with the level of REL-A.
XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
XX the presence of a divalent cation, especially Mg²⁺. The enzymatic and

CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 XX
 XX Sequence 17 BP; 2 A; 11 C; 3 G; 0 T; 1 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1065 CCTGGCCCCCAGCCCC 1080
 DB 1 CCCAGCCCCCAGCCCC 16
 RESULT 723
 ACA06539
 ID ACA06539 standard; RNA; 17 BP.
 AC ACA06539;
 XX
 XX 03-JUN-2003 (first entry)
 XX
 XX NFKB sub-unit modulating inozyme substrate #358.
 XX
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
 XX
 OS Homo sapiens.
 XX
 XX US2002177568-A1.
 PN
 XX 28-NOV-2002.
 PD
 XX
 XX 23-MAY-2001; 2001US-00864785.
 XX
 XX 07-DEC-1992; 92US-00987132.
 PR 18-MAY-1994; 94US-00245466.
 PR 15-AUG-1994; 94US-00291932.
 PR 23-DEC-1996; 96US-00777916.
 XX
 XX (STIN/) STINCHCOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 PI
 XX WPI; 2003-340953/32.
 DR
 XX

PT Novel enzymatic nucleic acid molecules which down regulates expression of
 PT a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases.
 XX
 XX Claim 3; Page 32; 72pp; English.
 XX
 CC The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel enzymatic
 CC nucleic acid molecule
 XX
 XX Sequence 17 BP; 2 A; 11 C; 4 G; 0 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1065 CCTGGCCCCCAGCCCC 1080
 DB 2 CCAGCCCCCAGCCCC 17
 RESULT 724
 ABZ62068/c
 ID ABZ62068 standard; RNA; 17 BP.
 XX
 XX ABZ62068;
 XX
 XX 21-MAR-2003 (first entry)
 XX
 XX Human H-Ras DNAzyme target #859.
 DE
 XX
 XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
 KW anti-rheumatic; cancer; AIDS; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200297114-A2.
 PN
 XX 05-DEC-2002.
 PD
 XX 29-MAY-2002; 2002WO-US016840.
 PF
 XX 29-MAY-2001; 2001US-0294140P.
 PR 06-JUN-2001; 2001US-0296249P.
 PR 10-SEP-2001; 2001US-0318471P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Mcswiggen J;
 PI
 XX WPI; 2003-140484/13.
 DR

XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 129; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;
Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1668 AGAGGTACTCTCTGCA 1683
Db 16 AGAGATACCTCTCTGCA 1
|||||
RESULT 725
ABZ61986
ID ABZ61986 standard; RNA; 17 BP.
XX
AC ABZ61986;
XX
XX
XX 21-MAR-2003 (first entry)
XX
DE Human H-Ras DNzyme target #777.
XX
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
XX Homo sapiens.
OS
XX WO200297114-A2.
PN
XX
XX 05-DEC-2002.
PD
XX 29-MAY-2002; 2002WO-US016840.
PF
XX 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
FA
XX
XX Mcswiggen J;
PI
XX
XX WPI; 2003-140484/13.
DR
XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 126; 185pp; English.
XX
XX The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic

CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 1 A; 6 C; 7 G; 0 T; 3 U; 0 Other;
Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
Qy 576 GGGCCAGGCCCACTGG 591
Db 2 GGGCCAGGCCCACTGG 17
|||||
RESULT 726
ACC66601
ID ACC66601 standard; DNA; 17 BP.
XX
AC ACC66601;
XX
XX
XX 01-JUL-2003 (first entry)
XX
XX Murine oligonucleotide associated with tumour suppression, SEQ ID 3848.
DE
XX
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
XX Mus musculus.
OS
XX WO2003025176-A2.
PN
XX 27-MAR-2003.
PD
XX 17-SEP-2002; 2002WO-IB004210.
PF
XX 17-SEP-2001; 2001FR-00011979.
PR
XX (MOLE-) MOLECULAR ENGINES LAB.
PA
XX Telerman A, Amson R, Tuijnder M;
PI
XX WPI; 2003-333167/31.
DR
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
XX Disclosure; Page 480; 738pp; French.
PS
XX The present invention relates to murine oligonucleotides (ACC62754-
CC ACC68806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 2 A; 4 C; 2 G; 9 T; 0 U; 0 Other;
Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3798 ATCATTTTTCCTT 3813
 Db 2 ATCATGTTTTCCTT 17

RESULT 727
 ACC63709/c
 ID ACC63709 standard; DNA; 17 BP.
 XX AC ACC63709;
 XX AC ACC63709;
 DT 01-JUL-2003 (first entry)
 XX DE Murine oligonucleotide associated with tumour suppression, SEQ ID 956.
 XX KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; ss.
 XX OS Mus musculus.
 XX PN WO2003025176-A2.
 XX PD 27-MAR-2003.
 XX PF 17-SEP-2002; 2002WO-IB004210.
 XX PR 17-SEP-2001; 2001FR-00011979.
 XX PA (MOLE-) MOLECULAR ENGINES LAB.
 XX PI Telerman A, Amson R, Tuijnder M;
 XX WPI; 2003-333167/31.
 XX PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX PS Disclosure; Page 142; 730pp; French.
 XX CC The present invention relates to murine oligonucleotides (ACC62754-
 CC ACC6806), which are associated with tumour suppression, tumour
 CC reversion, apoptosis and virus resistance. The oligonucleotides are
 CC useful as (1) as probes and primers for detecting, identifying,
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
 CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
 CC recombinant polypeptides. The oligonucleotides are useful for preparation
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia
 XX SQ Sequence 17 BP; 4 A; 3 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2850 CAATCAGGACGTGATC 2865
 Db 16 CAATCAGACGTGATC 1

RESULT 728
 ADB44084
 ID ADB44084 standard; DNA; 17 BP.
 XX AC ADB44084;
 XX AC ADB44084;
 DT 18-DEC-2003 (revised)
 DT 04-DEC-2003 (first entry)

XX DE Tumour suppression/reversion associated nucleotide #4407.
 XX KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
 KW primer; probe; tumour suppression; tumour reversion; apoptosis;
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
 KW diagnosis.
 XX OS Homo sapiens.
 XX PN WO2003040369-A2.
 XX PD 15-MAY-2003.
 XX PF 17-SEP-2002; 2002WO-IB004219.
 XX PR 17-SEP-2001; 2001FR-00011981.
 XX PA (MOLE-) MOLECULAR ENGINES LAB.
 XX PI Telerman A, Amson R, Tuijnder M;
 XX WPI; 2003-441574/41.
 XX PT New nucleic acid encoding human prostate membrane-specific antigen,
 PT useful e.g. for treatment of tumors and viral infection, also related
 PT polypeptide and antibodies.
 XX PS Disclosure; Page 547; 771pp; French.
 XX CC The invention relates to the isolation of 6327 nucleotide sequences,
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
 CC sequence having at least 80% identity, after optimal alignment, with the
 CC nucleotides, a sequence that hybridizes under stringent conditions with
 CC the nucleotides, or the complement, or corresponding RNA, of the
 CC nucleotides. The nucleotides are used as probes or primers for detecting,
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
 CC sense and antisense sequences, of nucleotides involved in tumour
 CC suppression or reversion, apoptosis and/or viral resistance, to produce
 CC recombinant polypeptides, and to prepare transgenic animals, as
 CC experimental models. The nucleotides (also vectors containing them and
 CC cells containing the vectors), the encoded polypeptides and antibodies
 CC (Ab) against the polypeptide are useful for prevention and/or treatment
 CC of viral infections or diseases characterized by development of tumours
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
 CC Analysis of the expression of the nucleotides can be used for diagnosis
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can
 CC also be used to screen for their specific interactive molecules,
 CC potentially useful for treating diseases associated with abnormal
 CC expression of the nucleotides.
 XX SQ Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2545 ATCGCTCCGGCATGC 2560
 Db 2 ATCGCTCCGGCATGC 17

RESULT 729
 ADE25202
 ID ADE25202 standard; DNA; 17 BP.
 XX AC ADE25202;
 XX AC ADE25202;
 DT 29-JAN-2004 (first entry)
 XX DE Plant growth associated polynucleotide seq id 177.
 XX KW plant growth; plant growth trait modulation; Brassicaceae; Arabidopsis;

DR WPI; 2003-058513/05.
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 1752; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 5 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 882 CAGCAAGGCTGGCTTC 897
DB 17 CAGCATGGCTGGCTTC 2

RESULT 732
AEB60994/C
ID AEB60994 standard; mRNA; 17 BP.
AC AEB60994;
XX
XX 22-SRP-2005 (first entry)
DE Human VEGF receptor 21 (Kdr) DNzyme target sequence SEQ ID 3572.
XX
KW VEGF receptor; angiogenesis; cancer; tumor; ocular disease;
KW diabetic retinopathy; age related macular degeneration;
KW angiogenesis disorder; rheumatoid arthritis; psoriasis; wound healing;
KW endometriosis; endometroid carcinoma; gynecological bleeding disorder;
KW menstruation disorder; premenstrual syndrome; menopause; gynecological;
KW cytotatic; Ophthalmological; Antidiabetic; antiangiogenic;
KW Antipsoriatic; Antirheumatic; Antiarthritic; Vulnery; Hemostatic;
KW Contraceptive; ss; enzymatic nucleic acid.
XX
OS Homo sapiens.
XX
XX WO200296927-A2.
XX
XX 05-DEC-2002.
XX
XX 29-MAY-2002; 2002WO-US017674.
XX
XX 29-MAY-2001; 2001US-00870161.
XX 30-NOV-2001; 2001US-0334461P.
XX 03-MAY-2002; 2002US-00136674.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (CHIR) CHIRON CORP.
XX
XX Escobedo J, Mcswiggen J, Pavco P, Stinchcomb D, Sandberg J;
PI Gordon G;
XX

DR WPI; 2003-140439/13.
XX Novel enzymatic nucleic acids, ribozymes, which modulate expression of
PT genes encoding vascular endothelial growth factor and/or VEGF receptor,
PT useful for inhibiting tumor angiogenesis in cell, and for treating
PT cancer.
XX
PS Disclosure; SEQ ID NO 3572; 172pp; English.
XX
CC The invention relates to enzymatic nucleic acids (I) i.e.
CC ribozymes/DNAzymes/zinczymes that target and modulate expression of, genes
CC encoding vascular endothelial growth factor (VEGF) and/or VEGF receptor
CC (VEGFR1 and 2 encode by the FLT-1 and Kdr genes respectively). Also
CC included are a composition comprising (I) and a carrier, administering
CC (I) to a cell (by contacting the cell with the compound under conditions
CC suitable for the administration), administering (I) to a cell (in
CC conjunction with one or more other drug by contacting the cell with the
CC compound and the other drug under conditions suitable for the
CC administration), administering (I) to a mammal (by contacting the mammal
CC with the compound under conditions suitable for the administration),
CC treating (M1) a subject having endometriosis (by contacting a subject
CC with, or administering to subject, a nucleic acid molecule (II) that
CC modulates expression of VEGF, VEGFR1, and/or VEGFR2), a mammalian cell
CC (III) comprising (I) and administering to a mammal (I) (in conjunction
CC with a chemotherapeutic agent comprising contacting the mammal with the
CC compound and the chemotherapeutic agent under conditions suitable for the
CC administration). (I) is administered to a mammalian cell, preferably
CC human cell in the presence of a delivery reagent which is a lipid such as
CC cationic lipid or phospholipid, or a liposome. The enzymatic nucleic acid
CC molecule has an endonuclease activity to cleave RNA encoded by an VEGFR1
CC and/or VEGFR2 gene, and is in a hammerhead, inozyme, DNzyme, G-cleaver,
CC or Amberzyme configuration. The enzymatic nucleic acids are useful for
CC inhibiting ocular angiogenesis associated with diabetic retinopathy or
CC age-related diabetic retinopathy, in a subject. They are also useful for
CC inhibiting angiogenesis, preferably tumor angiogenesis in cell, and for
CC treating a subject having a condition associated with an increased level
CC of VEGF receptor, where the condition is cancer, e.g. breast cancer, lung
CC cancer (such as non-small cell lung carcinoma), colorectal cancer, renal
CC cancer (such as renal cell carcinoma), pancreatic cancer. The enzymatic
CC nucleic acids are useful for treating a subject (preferably human) having
CC endometriosis, psoriasis, age-related macular degeneration, proliferative
CC diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis,
CC wound healing, endometrial carcinoma, gynecologic bleeding disorders,
CC irregular menstrual cycles, ovulation, premenstrual syndrome, and
CC menopausal dysfunction. The enzymatic nucleic acids are useful for birth
CC control by inhibiting ovulation or embryonic uterine implantation. The
CC present sequence is a target sequence from the human VEGFR2/Kdr mRNA.
XX
SQ Sequence 17 BP; 11 A; 3 C; 2 G; 0 T; 1 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3860 AGTTTGTGTTTGGTC 3875
DB 16 AGTTTGTGTTTGGTC 1

RESULT 733
ADL82216
ID ADL82216 standard; DNA; 17 BP.
XX
AC ADL82216;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human ER+ breast cancer differentially expressed sequence #186.
XX gene therapy; ds; breast cancer; human; ER+ breast cancer.
XX Homo sapiens.
XX

PN US2003166026-A1.
 PD 04-SEP-2003.
 XX 08-JAN-2003; 2003US-00339782.
 PF 09-JAN-2002; 2002US-0348053P.
 PR (LYNX-) LYNX THERAPEUTICS INC.
 PA Goodman LJ, Bowen BA;
 PI WPI; 2004-069003/07.
 DR Vector containing nucleic acid associated with breast cancer, useful for
 XX treating, diagnosing and characterizing breast cancer, also related
 PT polypeptides and antibodies.
 XX Claim 1; SEQ ID NO 187; 61pp; English.
 XX The invention relates to a composition which contains at least one vector
 CC (B) containing a nucleic acid (I) associated with breast cancer. The
 CC vector (B), also polypeptides (II) encoded by (I), are used for treatment
 CC of breast cancer. Arrays based on (I), (II), or their fragments, and (II)
 CC -specific antibodies (Ab) are used to predict characteristics (e.g.
 CC invasiveness or stage) of breast cancer, and (I), or its fragments, are
 CC used to modulate characteristics of such cells; to identify breast cancer
 CC genes and to detect breast cancer (by detecting polymorphic nucleic acid
 CC or its products). The present sequence represents a human ER+ breast
 CC cancer differentially expressed sequence.
 XX SQ Sequence 17 BP; 9 A; 2 C; 2 G; 4 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 4174 ATTTAAAAAAGTAACT 4189
 ||| ||||| ||||| |||||
 Db 2 ATCTAAAAAAGTAACT 17
 RESULT 734
 ADL60384
 ID ADL60384 standard; DNA; 17 BP.
 AC ADL60384;
 XX 01-JUL-2004 (first entry)
 DT Human organic anion transport protein SNP region #110.
 DE gene therapy; human; OATP2; cMOAT; hepatic disease; metabolic disease;
 KW inflammatory disease; cardiovascular disease; hyperproliferative disease;
 KW neurological disease; infectious disease; liver disease;
 KW high cholesterol; hypertension; congestive heart failure;
 KW coronary heart disease; cancer; wound healing; ds; SNP;
 KW single nucleotide polymorphism.
 XX Homo sapiens.
 OS US2004068096-A1.
 PN 08-APR-2004.
 PD 20-SEP-2002; 2002US-00252155.
 PF 21-SEP-2001; 2001US-0324172P.
 PR 27-NOV-2001; 2001US-0333700P.
 XX (TSUC/) TSUCHIHASHI Z.
 PA (HUIL/) HUI L.
 PA (KIRC/) KIRCHGESSNER T.

XX Tsuchihaashi Z, Hui L, Kirchgesner T;
 PI WPI; 2004-304621/28.
 XX New nucleic acid encoding human OATP2 or cMOAT protein, useful in
 PT diagnosing, treating or preventing diseases or disorders, e.g.
 PT inflammatory, cardiovascular, hyperproliferative, neurological or
 PT infectious diseases.
 XX PS Claim 3; SEQ ID NO 160; 296pp; English.
 XX The invention relates to an isolated nucleic acid derived from a human
 CC gene encoding a protein, i.e. human OATP2 protein or human cMOAT protein,
 CC where the nucleic acid comprises at least one polymorphic position. The
 CC nucleic acid and the encoded protein, kits and composition are useful in
 CC diagnosing, treating or preventing diseases or disorders, e.g. hepatic,
 CC metabolic, inflammatory, cardiovascular, hyperproliferative,
 CC neurological, infectious diseases, liver disease, high cholesterol,
 CC hypertension, congestive heart failure or coronary heart disease and
 CC cancer and promotes wound healing. The present sequence represents the a
 CC human organic anion transport protein SNP region.
 XX SQ Sequence 17 BP; 3 A; 8 C; 4 G; 2 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3073 GACCAGCGGCGCCTC 3088
 ||||| ||||| ||||| |||||
 Db 2 GACCAGCGGCGCCTC 17
 RESULT 735
 ADR27266
 ID ADR27266 standard; DNA; 17 BP.
 AC ADR27266;
 XX 04-NOV-2004 (first entry)
 DT Human single nucleotide polymorphism detection primer #356.
 DE ss; primer; single nucleotide polymorphism; SNP; diagnosis;
 KW disease association; linkage analysis; autoimmune disease;
 KW rheumatoid arthritis; diabetes; multiple sclerosis;
 KW systemic lupus erythematosus; inflammatory bowel disease; psoriasis;
 KW thyroiditis; celiac disease; pernicious anaemia; asthma; vitiligo;
 KW glomerulonephritis; Graves' disease; myocarditis; Sjogren disease;
 KW primary systemic vasculitis; genotyping; gene therapy; PCR primer.
 XX Homo sapiens.
 OS WO2004067779-A2.
 PN 12-AUG-2004.
 PD 30-JAN-2004; 2004WO-US002652.
 PF 30-JAN-2003; 2003US-0443566P.
 PR 18-MAR-2003; 2003US-0455444P.
 PR 25-APR-2003; 2003US-0465241P.
 PR 15-AUG-2003; 2003US-0495115P.
 PR 13-NOV-2003; 2003US-0519270P.
 XX (APPL-) APPLERA CORP.
 PA Cargill M, Begovich AB, Carlton VE, Schrodi SJ, Alexander HC;
 PI WPI; 2004-594223/57.
 XX New single nucleotide polymorphisms (SNPs) associated with rheumatoid

PT arthritis (RA), useful in identification of individuals at risk of
 PT developing RA or other autoimmune disease, and in development of
 PT therapeutic agents.

XX Claim 21; SEQ ID NO 49938; 141bp; English.

XX The invention relates to an isolated nucleic acid molecule comprising at
 CC least 8 contiguous nucleotides where one of the nucleotides is a single
 CC nucleotide polymorphism (SNP) selected from any one of the nucleotide
 CC sequences of SEQ ID NOs:1-669 and 1339-49582, or their complements. The
 CC SNPs are useful as targets for the design of diagnostic reagents and the
 CC development of therapeutic agents, as well as for disease association and
 CC linkage analysis. In particular, the SNPs are useful for identifying an
 CC individual who is at an increased or decreased risk for developing an
 CC autoimmune disease such as rheumatoid arthritis, type 1 diabetes,
 CC multiple sclerosis, systemic lupus erythematosus, inflammatory bowel
 CC diseases, psoriasis, thyroiditis, celiac disease, pernicious anaemia,
 CC asthma, vitiligo, glomerulonephritis, Graves' disease, myocarditis,
 CC Sjogren disease, or primary systemic vasculitis. Methods associated with
 CC the SNPs are useful for early detection of the disease, for providing of
 CC clinically important information for the prevention and/or treatment of
 CC the autoimmune diseases particularly rheumatoid arthritis, and for
 CC screening and selecting therapeutic agents. The SNPs are useful for human
 CC identification applications. The genes containing the SNPs are useful for
 CC treating the diseases defined above. The nucleic acid molecules are
 CC useful as hybridization probes for genotyping SNPs in messenger RNA,
 CC cDNA, genomic DNA, and genomic clones. The nucleic acid molecules are
 CC useful for constructing host cells expressing a part or all of the
 CC nucleic acid molecules and variant peptides, for constructing transgenic
 CC animals, for assaying or screening drugs that modulate nucleic acid
 CC expression, or for gene therapy in patients whose cells have aberrant
 CC gene expression. This sequence corresponds to a PCR primer which
 CC hybridises to the nucleic acids of the invention to amplify the SNP
 CC containing region. (Note: SEQ ID NOs 1-49582 are claimed and stated as
 CC being provided in the specification, however these sequences are not
 CC provided in the printed specification).

SQ Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3062 ACCCTCTCTCGACCA 3077
 Db 2 AGCCTCTCTCGACCA 17

RESULT 736

ACN64003
 ID ACN64003 standard; DNA; 17 BP.

XX ACN64003;

DT 02-DEC-2004 (first entry)

DE Human GDMPLP-1 probe SEQ ID NO:905.

XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.

XX Homo sapiens.

XX US2004137589-A1.

XX 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-026860P.
 PR 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.

Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 WPI; 2004-533378/51.

XX Novel myosin-like protein-1, useful for treating or preventing disorder,
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.

XX Disclosure; SEQ ID NO 905; Opp; English.

XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63102

XX Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4056 GCCTGGACCCCAAG 4071
 Db 2 GCTTGGACCCCAAG 17

RESULT 737
 ACN64753/c

ID ACN64753 standard; DNA; 17 BP.

XX ACN64753;

XX 02-DEC-2004 (first entry)

XX Human GDMPLP-1 probe SEQ ID NO:1655.

XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.

XX Homo sapiens.

XX US2004137589-A1.

XX PD 15-JUL-2004.
 XX PF 26-NOV-2003; 2003US-00723361.
 XX PR 26-MAY-2000; 2000US-0207456P.
 XX PR 21-SEP-2000; 2000US-0234687P.
 XX PR 27-SEP-2000; 2000US-0236359P.
 XX PR 04-OCT-2000; 2000GB-00024263.
 XX PR 30-JAN-2001; 2001WO-US000661.
 XX PR 30-JAN-2001; 2001WO-US000662.
 XX PR 30-JAN-2001; 2001WO-US000663.
 XX PR 30-JAN-2001; 2001WO-US000664.
 XX PR 30-JAN-2001; 2001WO-US000665.
 XX PR 30-JAN-2001; 2001WO-US000666.
 XX PR 30-JAN-2001; 2001WO-US000667.
 XX PR 30-JAN-2001; 2001WO-US000668.
 XX PR 30-JAN-2001; 2001WO-US000669.
 XX PR 30-JAN-2001; 2001WO-US000670.
 XX PR 05-FEB-2001; 2001US-0266860P.
 XX PR 25-MAY-2001; 2001US-00866108.
 XX PA (GUYV/) GU Y.
 XX PA (JIYV/) JI Y.
 XX PA (PENN/) PENN S G.
 XX PA (HANZ/) HANZEL D K.
 XX PA (RANK/) RANK D.
 XX PA (CHEN/) CHEN W.
 XX PA (SHAN/) SHANNON M E.
 XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX DR WPI; 2004-533378/51.
 XX PT Novel myosin-like protein-1, useful for treating or preventing disorder
 XX PT associated with decreased expression or activity of human genome-derived
 XX PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 XX PT function.
 XX PS Disclosure; SEQ ID NO 1655; Opp; English.
 XX CC The invention relates to a novel polypeptide (I) comprising a sequence
 XX CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 XX CC defined in the specification, a fragment of at least 8 amino acids of
 XX CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 XX CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 XX CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 XX CC pharmaceutical composition of the invention is useful for treating or
 XX CC preventing a disorder associated with decreased expression or activity of
 XX CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 XX CC The present sequence represents a 17-mer nucleotide, used in the
 XX CC invention for scanning the sequence represented in ACN63102
 XX SQ Sequence 17 BP; 6 A; 4 C; 7 G; 0 T; 0 U; 0 Other;
 XX Query Match 0.3%; Score 14.4; DB 1; Length 17;
 XX Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3965 CTATGGCTCTCTTGC 3980
 DB 16 CTCCTGGCTCTCTTGC 1
 RESULT 738
 ACN64004
 ID ACN64004 standard; DNA; 17 BP.
 XX AC ACN64004;
 XX DT 02-DEC-2004 (first entry)
 XX DE Human GDMPLP-1 probe SEQ ID NO:906.

XX KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist; hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX OS Homo sapiens.
 XX US2004137589-A1.
 XX PD 15-JUL-2004.
 XX PF 26-NOV-2003; 2003US-00723361.
 XX PR 26-MAY-2000; 2000US-0207456P.
 XX PR 21-SEP-2000; 2000US-0234687P.
 XX PR 27-SEP-2000; 2000US-0236359P.
 XX PR 04-OCT-2000; 2000GB-00024263.
 XX PR 30-JAN-2001; 2001WO-US000661.
 XX PR 30-JAN-2001; 2001WO-US000662.
 XX PR 30-JAN-2001; 2001WO-US000663.
 XX PR 30-JAN-2001; 2001WO-US000664.
 XX PR 30-JAN-2001; 2001WO-US000665.
 XX PR 30-JAN-2001; 2001WO-US000666.
 XX PR 30-JAN-2001; 2001WO-US000667.
 XX PR 30-JAN-2001; 2001WO-US000668.
 XX PR 30-JAN-2001; 2001WO-US000669.
 XX PR 30-JAN-2001; 2001WO-US000670.
 XX PR 05-FEB-2001; 2001US-0266860P.
 XX PR 25-MAY-2001; 2001US-00866108.
 XX PA (GUYV/) GU Y.
 XX PA (JIYV/) JI Y.
 XX PA (PENN/) PENN S G.
 XX PA (HANZ/) HANZEL D K.
 XX PA (RANK/) RANK D.
 XX PA (CHEN/) CHEN W.
 XX PA (SHAN/) SHANNON M E.
 XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX DR WPI; 2004-533378/51.
 XX PT Novel myosin-like protein-1, useful for treating or preventing disorder
 XX PT associated with decreased expression or activity of human genome-derived
 XX PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 XX PT function.
 XX PS Disclosure; SEQ ID NO 906; Opp; English.
 XX CC The invention relates to a novel polypeptide (I) comprising a sequence
 XX CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 XX CC defined in the specification, a fragment of at least 8 amino acids of
 XX CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 XX CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 XX CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 XX CC pharmaceutical composition of the invention is useful for treating or
 XX CC preventing a disorder associated with decreased expression or activity of
 XX CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 XX CC The present sequence represents a 17-mer nucleotide, used in the
 XX CC invention for scanning the sequence represented in ACN63102
 XX SQ Sequence 17 BP; 4 A; 6 C; 5 G; 2 T; 0 U; 0 Other;
 XX Query Match 0.3%; Score 14.4; DB 1; Length 17;
 XX Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 4056 GCCTGGGACCCCAAG 4071
 DB 1 GCTTGGGACCCCAAG 16
 RESULT 739

ACN65746	ID	ACN65746 standard; DNA; 17 BP.	Matches	15;	Conservative	0;	Mismatches	1;	Indels	0;	Gaps	0;
XX	AC	ACN65746;	QY	1222	GGGTCTCTGCCAGCCAT	1237						
XX	AC	ACN65746;	DB	1	GGGTCTCTGCCAGCCAT	16						
XX	DT	02-DEC-2004 (first entry)										
XX	DE	Human GDMLP-1 probe SEQ ID NO:2648.	RESULT	740								
XX	DE	Human; ss; probe; myosin-like protein-1; hGDMLP-1;	ACN65745									
KW	KW	hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;	ID	ACN65745 standard; DNA; 17 BP.								
KW	KW	skeletal muscle function.	XX	AC	ACN65745;							
XX	OS	Homo sapiens.	XX	DT	02-DEC-2004 (first entry)							
XX	XX	US2004137589-A1.	XX	DE	Human GDMLP-1 probe SEQ ID NO:2647.							
XX	PD	15-JUL-2004.	XX	KW	Human; ss; probe; myosin-like protein-1; hGDMLP-1;							
XX	PF	26-NOV-2003; 2003US-00723361.	KW	KW	hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;							
XX	PR	26-MAY-2000; 2000US-0207456P.	XX	XX	skeletal muscle function.							
PR	PR	21-SEP-2000; 2000US-0234687P.	OS	OS	Homo sapiens.							
PR	PR	27-SEP-2000; 2000US-0236359P.	XX	XX	US2004137589-A1.							
PR	PR	04-OCT-2000; 2000GB-00024263.	XX	PD	15-JUL-2004.							
PR	PR	30-JAN-2001; 2001WO-US000661.	XX	PF	26-NOV-2003; 2003US-00723361.							
PR	PR	30-JAN-2001; 2001WO-US000662.	XX	XX	26-MAY-2000; 2000US-0207456P.							
PR	PR	30-JAN-2001; 2001WO-US000663.	PR	PR	21-SEP-2000; 2000US-0234687P.							
PR	PR	30-JAN-2001; 2001WO-US000664.	PR	PR	27-SEP-2000; 2000US-0236359P.							
PR	PR	30-JAN-2001; 2001WO-US000665.	PR	PR	04-OCT-2000; 2000GB-00024263.							
PR	PR	30-JAN-2001; 2001WO-US000666.	PR	PR	30-JAN-2001; 2001WO-US000661.							
PR	PR	30-JAN-2001; 2001WO-US000667.	PR	PR	30-JAN-2001; 2001WO-US000662.							
PR	PR	30-JAN-2001; 2001WO-US000668.	PR	PR	30-JAN-2001; 2001WO-US000663.							
PR	PR	30-JAN-2001; 2001WO-US000669.	PR	PR	30-JAN-2001; 2001WO-US000664.							
PR	PR	05-FEB-2001; 2001US-0266860P.	PR	PR	30-JAN-2001; 2001WO-US000665.							
PR	PR	25-MAY-2001; 2001US-00866108.	PR	PR	30-JAN-2001; 2001WO-US000666.							
XX	PA	(GUY/) GU Y.	PR	PR	30-JAN-2001; 2001WO-US000667.							
PA	PA	(JIY/) JI Y.	PR	PR	30-JAN-2001; 2001WO-US000668.							
PA	PA	(PENN/) PENN S G.	PR	PR	30-JAN-2001; 2001WO-US000669.							
PA	PA	(HANZ/) HANZEL D K.	PR	PR	30-JAN-2001; 2001WO-US000670.							
PA	PA	(RANK/) RANK D.	PR	PR	05-FEB-2001; 2001US-0266860P.							
PA	PA	(CHEN/) CHEN W.	PR	PR	25-MAY-2001; 2001US-00866108.							
PA	PA	(SHAN/) SHANNON M E.	XX	XX	(GUY/) GU Y.							
XX	PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;	PA	PA	(JIY/) JI Y.							
XX	XX	WPI; 2004-533378/51.	PA	PA	(PENN/) PENN S G.							
XX	XX	Novel myosin-like protein-1, useful for treating or preventing disorder	PA	PA	(HANZ/) HANZEL D K.							
PT	PT	associated with decreased expression or activity of human genome-derived	PA	PA	(RANK/) RANK D.							
PT	PT	myosin-like protein-1 such as disorder of heart and/or skeletal muscle	PA	PA	(CHEN/) CHEN W.							
PT	PT	function.	PA	PA	(SHAN/) SHANNON M E.							
XX	XX	Disclosure; SEQ ID NO 2648; Opp; English.	XX	XX	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;							
PS	PS		PI	PI	WPI; 2004-533378/51.							
XX	XX	The invention relates to a novel polypeptide (I) comprising a sequence	XX	XX	Novel myosin-like protein-1, useful for treating or preventing disorder							
CC	CC	(S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully	XX	XX	associated with decreased expression or activity of human genome-derived							
CC	CC	defined in the specification, a fragment of at least 8 amino acids of	PT	PT	myosin-like protein-1 such as disorder of heart and/or skeletal muscle							
CC	CC	(S1), 95% deviation from (S1) which are conservative substitutions, and	PT	PT	function.							
CC	CC	65% identity to (S1). A polypeptide of the invention acts as an agonist or	XX	XX	Disclosure; SEQ ID NO 2647; Opp; English.							
CC	CC	antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A	PS	PS								
CC	CC	pharmaceutical composition of the invention is useful for treating or	XX	XX	The invention relates to a novel polypeptide (I) comprising a sequence							
CC	CC	hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.	CC	CC	(S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully							
CC	CC	The present sequence represents a 17-mer nucleotide, used in the	CC	CC	defined in the specification, a fragment of at least 8 amino acids of							
CC	CC	invention for scanning the sequence represented in ACN63102	CC	CC	(S1), 95% deviation from (S1) which are conservative substitutions, and							
XX	XX	Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;	CC	CC	65% identity to (S1). A polypeptide of the invention acts as an agonist or							
SQ	SQ		CC	CC	antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A							
			CC	CC	pharmaceutical composition of the invention is useful for treating or							
			CC	CC	preventing a disorder associated with decreased expression or activity of							
			CC	CC	hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.							
			CC	CC	The present sequence represents a 17-mer nucleotide, used in the							
			CC	CC	invention for scanning the sequence represented in ACN63102							
			XX	XX	Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;							
					Query Match							
					Best Local Similarity							
					0.3%; Score 14.4; DB 1; Length 17;							
					93.8%; Pred. No. 3.9e+02;							

CC hGDMPL-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63102

XX
 SO Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1222 GGGTCTGCGCCAT 1237
 Db 2 GGGTCTGCGCCAT 17
 |||||

RESULT 741
 ADZ31142/C
 ID ADZ31142 standard; RNA; 17 BP.
 AC ADZ31142;
 XX

DT 30-JUN-2005 (first entry)
 XX Human H-Ras substrate RNA sequence SEQ ID NO:2180.
 DE short interfering RNA; siRNA; RNA interference; gene silencing;
 KW cytosstatic; cancer; Ras gene; substrate; ss.
 KW Homo sapiens.

OS
 XX US2005080031-A1.
 XX 14-APR-2005.
 XX

XX 26-NOV-2003; 2003US-00724270.

XX 18-MAY-2001; 2001US-0292217P.
 XX 29-MAY-2001; 2001US-0294140P.
 XX 06-JUN-2001; 2001US-0296249P.
 XX 20-JUL-2001; 2001US-0306883P.
 XX 13-AUG-2001; 2001US-0311865P.
 XX 10-SEP-2001; 2001US-0318471P.
 XX 20-FEB-2002; 2002US-0358580P.
 XX 06-MAR-2002; 2002US-0362016P.
 XX 11-MAR-2002; 2002US-0363124P.
 XX 20-MAY-2002; 2002WO-US015876.
 XX 29-MAY-2002; 2002US-00157580.
 XX 29-MAY-2002; 2002WO-US016840.
 XX 06-JUN-2002; 2002US-00163552.
 XX 29-AUG-2002; 2002US-0386782P.
 XX 05-SEP-2002; 2002US-0408378P.
 XX 09-SEP-2002; 2002US-0409293P.
 XX 10-SEP-2002; 2002US-00238700.
 XX 15-JAN-2003; 2003US-0440129P.
 XX 20-FEB-2003; 2003WO-US005028.
 XX 20-FEB-2003; 2003WO-US005346.
 XX 16-APR-2003; 2003US-00417012.
 XX 24-APR-2003; 2003US-00427160.
 XX 30-APR-2003; 2003US-00444853.
 XX 29-AUG-2003; 2003US-0052791.
 XX 23-OCT-2003; 2003US-00693059.

(SIRN-) SIRNA THERAPEUTICS INC.

PI Mcswiggen J;

XX WPI; 2005-331166/34.

XX Novel double-stranded short interfering RNA molecule having first
 PT nucleotide sequence complementary to RNA encoding HER2 or its portion,
 PT and second nucleotide sequence having complementarity to first sequence,

PT useful for treating cancer.
 XX Example 1; SEQ ID NO 2180; 143pp; English.
 XX
 CC The invention relates to a double-stranded short interfering RNA (siRNA)
 CC molecule (I) comprising a first nucleotide sequence having 19-23
 CC nucleotides complementary to an RNA sequence encoding HER2 or its
 CC portion, and a second nucleotide sequence having 19-23 nucleotides
 CC exhibiting complementarity to the first sequence, and including at least
 CC one nucleotide that is not a 2'-OH containing ribonucleotide. Also
 CC described is a method of producing a class of nucleic acid-based gene
 CC modulating agents that exhibit a high degree of specificity for RNA of a
 CC desired target. (I) is useful for modulating HER2 activity in a cell, and
 CC for treating diseases or conditions related to levels of HER2 gene
 CC expression. (I) is useful for treating cancer, such as pancreatic cancer,
 CC bladder cancer, lung cancer, breast cancer or prostate cancer. The
 CC present sequence represents a human H-Ras substrate RNA sequence for a
 CC DNzyme (ribozyme), which is used in an example from the present
 CC invention for the identification of potential target sites in human Ras
 CC RNA.

XX
 SQ Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 3.9e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1668 AGAGGTACCTCTGCA 1683
 Db 16 AGAGTACCTCTGCA 1
 |||||

RESULT 742

ADZ31060
 ID ADZ31060 standard; RNA; 17 BP.

XX
 AC ADZ31060;
 XX
 DT 30-JUN-2005 (first entry)

XX Human H-Ras substrate RNA sequence SEQ ID NO:2098.
 DE short interfering RNA; siRNA; RNA interference; gene silencing;
 KW cytosstatic; cancer; Ras gene; substrate; ss.
 KW Homo sapiens.

OS
 XX US2005080031-A1.
 XX 14-APR-2005.
 XX

XX 26-NOV-2003; 2003US-00724270.

XX 18-MAY-2001; 2001US-0292217P.
 XX 29-MAY-2001; 2001US-0294140P.
 XX 06-JUN-2001; 2001US-0296249P.
 XX 20-JUL-2001; 2001US-0306883P.
 XX 13-AUG-2001; 2001US-0311865P.
 XX 10-SEP-2001; 2001US-0318471P.
 XX 20-FEB-2002; 2002US-0358580P.
 XX 06-MAR-2002; 2002US-0362016P.
 XX 11-MAR-2002; 2002US-0363124P.
 XX 20-MAY-2002; 2002WO-US015876.
 XX 29-MAY-2002; 2002US-00157580.
 XX 29-MAY-2002; 2002WO-US016840.
 XX 06-JUN-2002; 2002US-00163552.
 XX 29-AUG-2002; 2002US-0386782P.
 XX 05-SEP-2002; 2002US-0408378P.
 XX 09-SEP-2002; 2002US-0409293P.
 XX 10-SEP-2002; 2002US-00238700.
 XX 15-JAN-2003; 2003US-0440129P.
 XX 20-FEB-2003; 2003WO-US005028.

PR 20-FEB-2003; 2003WO-US005346.
PR 16-APR-2003; 2003US-00417012.
PR 24-APR-2003; 2003US-00422704.
PR 30-APR-2003; 2003US-00427160.
PR 23-MAY-2003; 2003US-00444853.
PR 29-AUG-2003; 2003US-00652791.
PR 23-OCT-2003; 2003US-00693059.
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Mcswiggen J;
PI
XX WPI; 2005-331166/34.
DR
XX Novel double-stranded short interfering RNA molecule having first
PT nucleotide sequence complementary to RNA encoding HER2 or its portion,
PT and second nucleotide sequence having complementarity to first sequence,
PT useful for treating cancer.
XX
XX Example 1; SEQ ID NO 2098; 143pp; English.
PS
XX The invention relates to a double-stranded short interfering RNA (siRNA)
CC molecule (I) comprising a first nucleotide sequence having 19-23
CC nucleotides complementary to an RNA sequence encoding HER2 or its
CC portion, and a second nucleotide sequence having 19-23 nucleotides
CC exhibiting complementarity to the first sequence, and including at least
CC one nucleotide that is not a 2'-OH containing ribonucleotide. Also
CC described is a method of producing a class of nucleic acid-based gene
CC modulating agents that exhibit a high degree of specificity for RNA of a
CC desired target. (I) is useful for modulating HER2 activity in a cell, and
CC for treating diseases or conditions related to levels of HER2 gene
CC expression. (II) is useful for treating cancer, such as pancreatic cancer,
CC bladder cancer, lung cancer, breast cancer or prostate cancer. The
CC present sequence represents a human H-Ras substrate RNA sequence for a
CC DNzyme (ribozyme), which is used in an example from the present
CC invention for the identification of potential target sites in human Ras
CC RNA.
XX
XX Sequence 17 BP; 1 A; 6 C; 7 G; 0 T; 3 U; 0 Other;
SQ
Query Match 0.3%; Score 14.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 3.9e+02;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 576 GGGCCAGGCCCATGG 591
Db |||||
2 GGGCCAGGCCCATGG 17
RESULT 743
AAQ65238
ID AAQ65238 standard; DNA; 18 BP.
XX
XX AAQ65238;
AC
XX
XX 21-DEC-1994 (first entry)
DT
XX
XX Antisense oligonucleotide complementary to Hepatitis C Virus genome.
DE
XX Hepatitis C Virus; Non-A, non-B hepatitis virus; HCV; antisense; therapy;
KW inhibition; viral protein precursor; ss.
XX
XX Synthetic.
OS
XX CA2104649-A.
PN
XX
XX 26-FEB-1994.
PD
XX
XX 23-AUG-1993; 93CA-02104649.
PF
XX
XX 25-AUG-1992; 92JP-00248796.
PR
XX 03-MAR-1993; 93JP-00042736.
PR
XX
XX (SEKI/) SEKI M.
PA
XX
XX Seki M, Honda Y, Yamada E;
PI
XX WPI; 1994-151836/19.
DR
XX Antisense oligonucleotide complementary to Hepatitis C Virus
DE genome - are useful as antiviral agents.
XX
XX Synthetic.
OS
XX CA2104649-A.
PN
XX
XX 26-FEB-1994.
PD
XX
XX 23-AUG-1993; 93CA-02104649.
PF
XX
XX 25-AUG-1992; 92JP-00248796.
PR
XX 03-MAR-1993; 93JP-00042736.
PR
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Mcswiggen J;
PI
XX WPI; 2005-331166/34.
DR
XX Novel double-stranded short interfering RNA molecule having first
PT nucleotide sequence complementary to RNA encoding HER2 or its portion,
PT and second nucleotide sequence having complementarity to first sequence,
PT useful for treating cancer.
XX
XX Example 1; SEQ ID NO 2098; 143pp; English.
PS
XX The invention relates to a double-stranded short interfering RNA (siRNA)
CC molecule (I) comprising a first nucleotide sequence having 19-23
CC nucleotides complementary to an RNA sequence encoding HER2 or its
CC portion, and a second nucleotide sequence having 19-23 nucleotides
CC exhibiting complementarity to the first sequence, and including at least
CC one nucleotide that is not a 2'-OH containing ribonucleotide. Also
CC described is a method of producing a class of nucleic acid-based gene
CC modulating agents that exhibit a high degree of specificity for RNA of a
CC desired target. (I) is useful for modulating HER2 activity in a cell, and
CC for treating diseases or conditions related to levels of HER2 gene
CC expression. (II) is useful for treating cancer, such as pancreatic cancer,
CC bladder cancer, lung cancer, breast cancer or prostate cancer. The
CC present sequence represents a human H-Ras substrate RNA sequence for a
CC DNzyme (ribozyme), which is used in an example from the present
CC invention for the identification of potential target sites in human Ras
CC RNA.
XX
XX Sequence 17 BP; 1 A; 6 C; 7 G; 0 T; 3 U; 0 Other;
SQ

PA (SEKI/) SEKI M.
XX
XX Seki M, Honda Y, Yamada E;
PI
XX WPI; 1994-151836/19.
DR
XX Antisense oligo:nucleotide(s) complementary to the hepatitis C virus
PT genome - are useful as antiviral agents.
PT
XX Claim 5; Page 205; 262pp; English.
PS
XX This oligonucleotide is an example of a preferred antisense compound i.e.
CC it has a base sequence of 15-30 bases which is included within the 49
CC bases from G at position 127 to C at position 175 of AAQ64913 and which
CC contains at least 7 bases from C at position 147 to C at position 153.
CC The antisense oligonucleotide is useful for inhibiting translation of HCV
CC genes
XX
XX Sequence 18 BP; 1 A; 5 C; 10 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 28 CTCACAGGAGGGGGG 43
Db |||||
1 CTCACAGGAGGGGGG 16
RESULT 744
AAQ65254
ID AAQ65254 standard; DNA; 18 BP.
XX
XX AAQ65254;
AC
XX
XX 21-DEC-1994 (first entry)
DT
XX
XX Antisense oligonucleotide complementary to Hepatitis C Virus genome.
DE
XX Hepatitis C Virus; Non-A, non-B hepatitis virus; HCV; antisense; therapy;
KW inhibition; viral protein precursor; ss.
XX
XX Synthetic.
OS
XX CA2104649-A.
PN
XX
XX 26-FEB-1994.
PD
XX
XX 23-AUG-1993; 93CA-02104649.
PF
XX
XX 25-AUG-1992; 92JP-00248796.
PR
XX 03-MAR-1993; 93JP-00042736.
PR
XX
XX (SEKI/) SEKI M.
PA
XX
XX Seki M, Honda Y, Yamada E;
PI
XX WPI; 1994-151836/19.
DR
XX Antisense oligo:nucleotide(s) complementary to the hepatitis C virus
PT genome - are useful as antiviral agents.
PT
XX Claim 5; Page 212; 262pp; English.
PS
XX This oligonucleotide is an example of a preferred antisense compound i.e.
CC it has a base sequence of 15-30 bases which is included within the 49
CC bases from G at position 127 to C at position 175 of AAQ64913 and which
CC contains at least 7 bases from C at position 147 to C at position 153.
CC The antisense oligonucleotide is useful for inhibiting translation of HCV
CC genes
XX
XX Sequence 18 BP; 1 A; 4 C; 10 G; 3 T; 0 U; 0 Other;
SQ

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 CTCACGGGAGGGGGG 43
DB 2 CTCACGGGAGGGGGG 17

RESULT 745
AAV48676/c
ID AAV48676 standard; DNA; 18 BP.

XX AC AAV48676;

DT 15-OCT-1998 (first entry)

DE junB gene antisense oligonucleotide JunB-T-5.

XX junB; junB; antisense oligonucleotide; modulate; gene expression; ss.

XX Synthetic.

XX Homo sapiens.

XX EP856579-A1.

XX 05-AUG-1998.

XX 31-JAN-1997; 97EP-00101531.

XX 31-JAN-1997; 97EP-00101531.

XX (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.

XX Schlingensiepen K, Brysch W;

XX WPI; 1998-400910/35.

PT Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT consecutive guanosine or inosine - and have specific ratio of residues
PT able to form two or three hydrogen bonds, have greater activity and
PT reduced toxicity, used therapeutically or to modulate growth of cells in
PT culture.

XX Example 3; Fig 5c; 286pp; English.

CC AAV48564-708 represent antisense oligonucleotides directed against the
CC junB and junD genes. Of these, only oligonucleotides AAV48565-614
CC resulted in effective downregulation of negative growth control by JunB
CC or JunD, while AAV48615-708 had little effect. The oligonucleotides
CC exemplify the invention. The specification describes oligonucleotides
CC that contain 8-30 nucleotides, which contain at most 8 nucleotides that
CC can each form three hydrogen bonds to cytosine; do not contain four
CC consecutive nucleotides able to form three H-bonds each to four
CC consecutive cytosines; do not contain two sequences of three consecutive
CC nucleotides each able to form three H-bonds to three consecutive
CC cytosines, and the ratio between residues able to form two H-bonds each
CC (2R) or three such bonds (3R) is given by $2R/3R = 0.33-0.72$. The
CC oligonucleotides are used to modulate expression of genes, particularly
CC the genes for p53, ErbB-2, junB, junD, TGF-beta 1 or beta 2 to control
CC proliferation of primary cell cultures (e.g. bone marrow stem, liver or
CC kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The
CC oligonucleotides can also be used to analyse function of proteins (by
CC altering their expression or activity) and therapeutically, e.g. in cases
CC of cancer or (targeting TGF) for stimulating the immune system

XX Sequence 18 BP; 1 A; 6 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 93 GGGCCCGGAGGGGACC 108

DB 17 GGGCCCGGAGGGACC 2

RESULT 746
AAA52892/c

ID AAA52892 standard; DNA; 18 BP.

XX AC AAA52892;

DT 15-SEP-2000 (first entry)

DE Human CD44 antisense oligonucleotide ISIS# 18781.

XX Human; CD44; cell surface adhesion receptor; cytostatic; antirheumatic;
XX antiinflammatory; antiarthritic; CD44 antisense inhibition;
XX hyperproliferative disorder; cancer; inflammatory disorder;
XX rheumatoid arthritis; ss.

XX Homo sapiens.

XX WO200035935-A1.

XX 22-JUN-2000.

XX 14-DEC-1999; 99WO-US029576.

XX 17-DEC-1998; 98US-00213719.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Cowsett LM;

XX WPI; 2000-431564/37.

XX New antisense compound, that inhibits the expression of human cell
PT surface adhesion receptor CD44, for treating hyperproliferative disorders
PT and inflammatory conditions, such as cancer and rheumatoid arthritis.

XX Example 15; Page 77; 105pp; English.

XX The present sequence is one of a large number of antisense
CC oligonucleotides designed to target different regions of the human CD44
CC mRNA. CD44 is a multifunctional human cell surface adhesion receptor. The
CC oligonucleotides were analysed for effect on CD44 mRNA levels by that
CC quantitative real-time PCR analysis. Antisense oligonucleotides that
CC inhibit CD44 expression can be used to treat CD44-associated conditions
CC including hyperproliferative disorders, such as cancer, and inflammatory
CC conditions, such as rheumatoid arthritis. The antisense compounds
CC hybridise to CD44 nucleic acids, thus allowing sandwich and other assays
CC to be easily constructed. Note: The sequence has a phosphorothioate
CC backbone and may be either an oligodeoxynucleotide or a chimeric
CC oligonucleotide containing 2'-methoxyethyl (2'-MOE) wings and a deoxy
CC gap. The ISIS number given above corresponds to the oligodeoxynucleotide
CC sequence

XX Sequence 18 BP; 3 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2702 GCTCCCTGGGAGAAA 2717

DB 16 GGTCCCTGGGAGAAA 1

RESULT 747

AAA30403

ID AAA30403 standard; DNA; 18 BP.

XX AC AAA30403;

XX

DT 21-AUG-2000 (first entry)
XX
XX Human NF-kappa-B p65 subunit antisense oligodeoxynucleotide ISIS# 23770.
DE
XX Human; anti-inflammatory; cytostatic; antimicrobial; infection;
KW antisense inhibition; inflammation; transcription factor; apoptosis;
KW cancer; ss.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..18
FT /tag= a
FT /note= "all or some internucleoside bonds are
FT phosphorothioate and optionally some sugars may be 2'
FT methoxyethyl"
XX
XX US6069008-A.
PN
XX 30-MAY-2000.
PD
XX 25-NOV-1998; 98US-00199859.
XX
XX 25-NOV-1998; 98US-00199859.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Bennett CF, Cowsett LM, Monia BP;
PI WPI; 2000-410858/35.
XX
XX Antisense compounds which inhibit the expression of the human NF-kappa-B
PT p65 subunit (p65) useful for treating diseases associated with p65
PT expression and as prophylaxis to prevent of delay infection, inflammation
PT or tumor formation.
XX
XX Example 15; Col 41; 33pp; English.
PS
XX The present sequence is one of a number of oligonucleotides designed to
CC target different regions of the human NF-kappa-B p65 subunit, which is a
CC member of the Rel/NF-kappa-B family of transcription factors. Rel/NF-
CC kappa-B proteins are involved in a diverse set of signaling pathways
CC involving stress, apoptosis, cancer, growth, infection and inflammation.
CC Antisense oligonucleotides are able to inhibit expression of the p65
CC subunit and may therefore be used in the treatment of disorders
CC associated with NF-kappa-B p65 subunit expression. They may be used as a
CC prophylaxis to prevent or delay infection, inflammation or tumor
CC formation. Antisense compounds may also be used for research and
CC diagnostics because they hybridise to nucleic acids encoding NF-kappa-B
CC p65 subunit. The effect of antisense oligonucleotides on NF-kappa-B p65
CC subunit mRNA levels was measured using real-time quantitative PCR and
CC Northern blot analysis. Antisense oligonucleotides were synthesised on an
CC automated DNA synthesiser
XX
XX Sequence 18 BP; 6 A; 2 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2669 TGGAGGAGAACTCTTC 2684
Db |||||||
2 TGGAGGAGAACTCTTC 17
RESULT 748
AD194534/c
ID AD194534 standard; DNA; 18 BP.
XX
XX AD194534;
AC
XX 04-NOV-2004 (first entry)
DT
XX

DE Human IL-10 associated probe SEQ ID 2087.
XX
XX functional domain; nucleic acid cleavage assay; nuclease; polymerase;
KW detection; microorganism; RNA genome; hepatitis C;
KW human immunodeficiency virus; ss; probe.
XX
XX Homo sapiens.
OS
XX WO200190337-A2.
PN
XX 29-NOV-2001.
PD
XX 24-MAY-2001; 2001WO-US017086.
PF
XX 24-MAY-2000; 2000US-00577304.
PR 11-JAN-2001; 2001US-00758282.
PR 24-MAY-2001; 2001US-00864426.
PR 24-MAY-2001; 2001US-00864636.
PR
XX (THIR-) THIRD WAVE TECHNOLOGIES INC.
PA
XX Allawi H, Bartholomay CT, Chehak L, Curtis ML, Eis PS, Hall JG;
PI Ip HS, Kaiser M, Kwiatkowski RW, Lukowiak AA, Lyamichev V, Ma W;
PI Olson-Munoz MC, Olson SM, Schaefer JJ, Skrzypczynski Z, Takova TY;
PI Vedvik KL, Lyamichev NE, Neri BP;
XX WPI; 2002-083110/11.
DR
XX Composition comprising enzyme which comprises heterologous functional
PT domain that provides altered functionality in nucleic acid cleavage
PT assay, useful for cleaving nucleic acid, and detecting presence of RNA
PT target.
XX
XX Claim 95; SEQ ID NO 2087; 1266pp; English.
PS
XX This invention describes a novel composition comprising an enzyme which
CC contains a heterologous functional domain that provides altered
CC functionality in a nucleic acid cleavage assay. The enzyme comprises a 5'
CC nuclease, preferably a thermostable 5' nuclease, or a polymerase which is
CC altered in sequence related to a naturally occurring sequence of a
CC polymerase such that it exhibits reduced DNA synthetic activity from that
CC of the naturally occurring polymerase. Preferably the polymerase is a
CC thermostable polymerase from a Thermus species such as T. aquaticus, T.
CC flavus, T. thermophilus, T. filiformis or T. scotoductus. The enzyme
CC comprises a heterologous functional domain, an amino acid sequence that
CC provides an improved substrate binding activity in the nucleic acid
CC cleavage assay and an amino acid sequence that provides improved
CC background specificity in the nucleic acid cleavage assay. The invasive
CC cleavage structure comprises a RNA target nucleic acid (a cytochrome
CC P450, or cytokine RNA). Cleavage of the invasive cleavage structure
CC generates a non-target cleavage product, which is then detected by
CC detecting fluorescence, mass or fluorescence energy transfer or by
CC detecting radioactivity luminescence, phosphorescence, fluorescence
CC polarisation or charge. The enzyme is useful for cleaving a nucleic acid
CC which involves exposing a sample (a cell lysate) comprising substrate
CC nucleic acid to the enzyme which produces at least one detectable
CC cleavage product. The enzyme is employed for detecting target DNAs and
CC RNAs comprising wild-type and mutant alleles of genes including genes
CC from humans, other animal or plants that are or may be associated with
CC disease or other conditions. In addition, the enzymes may be useful for
CC detecting and identifying strains of microorganisms including bacteria,
CC fungi, protozoa, ciliates and viruses, preferably detecting and
CC identifying viruses having RNA genomes, such as hepatitis C and human
CC immunodeficiency virus.
XX
XX Sequence 18 BP; 3 A; 1 C; 8 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3787 CACCAAACTCAATCAT 3802
|||||
|||||

Db 16 CACCAAACTCACTCAT 1

RESULT 749
AD193071/c
ID AD193071 standard; DNA; 18 BP.
AC AD193071;
XX
XX
XX 04-NOV-2004 (first entry)
XX
XX
XX ARRESTOR oligonucleotide SEQ ID 624.
XX
XX functional domain; nucleic acid cleavage assay; nuclease; polymerase;
KW detection; microorganism; RNA genome; hepatitis C;
KW human immunodeficiency virus; ss; probe.
XX
XX Synthetic.
XX
XX WO200190337-A2.
XX
XX 29-NOV-2001.
XX
XX 24-MAY-2001; 2001WO-US017086.
XX
XX 24-MAY-2000; 2000US-00577304.
PR 11-JAN-2001; 2001US-00758282.
PR 24-MAY-2001; 2001US-00864426.
PR 24-MAY-2001; 2001US-00864636.
XX
XX (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX
XX Allawi H, Bartholomay CT, Chehak L, Curtis ML, Eis PS, Hall JG;
PI Ip HS, Kaiser M, Kwiatkowski RW, Lukowiak AA, Lyamichev V, Ma W;
PI Olson-Munoz MC, Olson SM, Schaefer JJ, Skrzypczynski Z, Takova TY;
PI Vedvik KL, Lyamichev NE, Neri BP;
XX
XX WPI; 2002-083110/11.
XX
XX
XX Composition comprising enzyme which comprises heterologous functional
PT domain that provides altered functionality in nucleic acid cleavage
PT assay, useful for cleaving nucleic acid, and detecting presence of RNA
PT target.
XX
XX Claim 96; SEQ ID NO 624; 1266pp; English.

This invention describes a novel composition comprising an enzyme which contains a heterologous functional domain that provides altered functionality in a nucleic acid cleavage assay. The enzyme comprises a 5' nuclease, preferably a thermostable 5' nuclease, or a polymerase which is altered in sequence related to a naturally occurring sequence of a polymerase such that it exhibits reduced DNA synthetic activity from that of the naturally occurring polymerase. Preferably the polymerase is a thermostable polymerase from a thermus species such as T. aquaticus, T. flavus, T. thermophilus, T. filiformis or T. scotoductus. The enzyme comprises a heterologous functional domain, an amino acid sequence that provides an improved substrate binding activity in the nucleic acid cleavage assay and an amino acid sequence that provides improved background specificity in the nucleic acid cleavage assay. The invasive cleavage structure comprises a RNA target nucleic acid (a cytochrome P450, or cytokine RNA). Cleavage of the invasive cleavage structure generates a non-target cleavage product, which is then detected by detecting fluorescence, mass or fluorescence energy transfer or by detecting radioactivity luminescence, phosphorescence, fluorescence polarisation or charge. The enzyme is useful for cleaving a nucleic acid which involves exposing a sample (a cell lysate) comprising substrate nucleic acid to the enzyme which produces at least one detectable cleavage product. The enzyme is employed for detecting target DNAs and RNAs comprising wild-type and mutant alleles of genes including genes from humans, other animal or plants that are or may be associated with disease or other conditions. In addition, the enzymes may be useful for detecting and identifying strains of microorganisms including bacteria, fungi, protozoa, ciliates and viruses, preferably detecting and

CC identifying viruses having RNA genomes, such as hepatitis C and human
CC immunodeficiency virus.
XX
SQ Sequence 18 BP; 3 A; 1 C; 8 G; 6 T; 0 U; 0 Other;
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 3787 CACCAAACTCACTCAT 3802
Db 16 CACCAAACTCACTCAT 1

RESULT 750
ACA62538
ID ACA62538 standard; DNA; 18 BP.
XX
XX ACA62538;
XX
XX 18-AUG-2003 (first entry)
XX
XX Human MDM2 mutant 156-221 PCR primer #2.
XX
XX Human; ss; PCR; primer; MDM2; cancer; tumour; cytostatic; p19(ARF); p53;
KW Rb; oncoprotein; oncogenic transformation; proteosomal degradation.
XX
XX Homo sapiens.
XX
XX US2002193325-A1.
XX
XX 19-DEC-2002.
XX
XX 19-MAR-1998; 98US-00044602.
XX
XX 19-MAR-1998; 98US-00044602.
XX
XX (DEPI/) DEPINHO R A.
XX
XX Depinho RA;
XX
XX WPI; 2003-512091/48.
XX
XX Inhibiting growth of a tumor cell, involves introducing to the cell, an
PT antioncogene protein or nucleic acid encoding the proteins, to inhibit
PT growth of the tumor cell.
XX
XX Disclosure; Page 7; 28pp; English.

The invention relates to inhibiting growth of a tumour cell, involving introducing to the cell, p19(ARF) (or its mimetics), and p53 to inhibit growth of the tumour cell. p19(ARF) acts as a suppressor of oncogenic transformation by binding to the MDM2 (not defined) oncoprotein and blocking its ability to target associated proteins (such as Rb and p53) for proteosomal degradation. Also included is a pharmaceutical composition comprising p19(ARF), or comprising a nucleic acid encoding p19(ARF). The method is useful for inhibiting the growth of a tumour cell, and the treatment of cancer. A mutant of MDM2 was created (lacking amino acids 156-221) which was used to investigate the binding of p19(ARF) to MDM2. The present sequence is a PCR primer used to create a nucleic acid encoding the MDM2 mutant protein

Qy 3598 GAAGTGCCCAACATCT 3613
Db 2 GAAGGCGCCCAACATCT 17

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 751
ADB54472
ID ADB54472 standard; DNA; 18 BP.
XX AC ADB54472;
XX AC ADB54472;
XX 04-DEC-2003 (first entry)
XX DE Hybridisation oligonucleotide 10 used to analyse genomic DNA region.
XX KW colon cell proliferative disorder; non methylated CpG dinucleotide;
XX KW cytosstatic; cancer; adenoma; carcinoma; cytosine methylation state; ss;
XX KW probe.
XX OS Unidentified.
XX PN WO2003072821-A2.
XX PD 04-SEP-2003.
XX PF 27-FEB-2003; 2003WO-EP002035.
XX PR 27-FEB-2002; 2002EP-00004551.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Adorian P, Burger M, Maier S, Nimrich I, Becker E, Lesche R;
XX PI Rujan T, Schmitt A;
XX DR WPI; 2003-731620/69.
XX PT Detecting and differentiating between colon cell proliferative disorders
XX PT associated with a gene or its regulatory regions comprises contacting a
XX PT target nucleic acid in a biological sample obtained from the subject with
XX PT a reagent.
XX PS Claim 36; Page 27; 74pp; English.
XX CC The invention relates to a novel method for detecting and differentiating
XX CC between colon cell proliferative disorders associated with at least one
XX CC gene or its regulatory regions. The method comprises contacting a target
XX CC nucleic acid in a biological sample obtained from the subject with at
XX CC least one reagent or a series of reagents, where the reagent or series of
XX CC reagents, distinguishes between methylated and non methylated CpG
XX CC dinucleotides within the target nucleic acid. The molecules of the
XX CC invention demonstrate cytosstatic activity whilst the method may useful
XX CC for detecting and differentiating between colon cell proliferative
XX CC disorders, including cancers such as colon adenoma and colon carcinoma.
XX CC The DNA (peptide nucleic acid)-oligomers are useful as probes for
XX CC determining cytosine methylation state or single nucleotide
XX CC polymorphisms. The current sequence is that of the hybridisation
XX CC oligonucleotide of the invention which was used to analyse the genomic
XX CC DNA region.
XX SQ Sequence 18 BP; 2 A; 0 C; 5 G; 11 T; 0 U; 0 Other;
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 3859 GAGTTTGTGTTTGGT 3874
Db |||||||||||||
3 GAGTTTGTGTTTGGT 18
RESULT 752
ADF90215
ID ADF90215 standard; DNA; 18 BP.
XX AC ADF90215;
XX 26-FEB-2004 (first entry)
XX DT
XX

DE Human NF-kappa-B p65 subunit antisense oligonucleotide #39.
XX Human; NF-kappa-B p65 subunit; ss; antisense; stress; cancer;
KW autoimmune disease; multiple sclerosis; hyperproliferative disorder;
KW apoptosis-related disease; inflammation; infection; growth disorder.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT modified_base 1..18
FT /tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT modified_base 1..4
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl residue and all cytidines are 5-
FT methylcytidines"
FT modified_base 15..18
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl residue and all cytidines are 5-
FT methylcytidines"
XX PN US2003175793-A1.
XX PD 18-SEP-2003.
XX PF 25-APR-2003; 2003US-00424211.
XX PR 25-NOV-1998; 98US-00199859.
XX PR 23-NOV-1999; 99WO-US027762.
XX PR 24-MAY-2001; 2001US-00856747.
XX PA (BENN/) BENNETT C F.
XX PA (MONI/) MONIA B P.
XX PA (COWS/) COWSERT L M.
XX PI Bennett CF, Monia BP, Cowsert LM;
XX WPI; 2003-898531/82.
XX DR New antisense compound, having a sequence targeted to a nucleic acid
XX PT encoding human NF-kappa-B p65 subunit, useful for preparing a composition
XX PT for treating e.g., autoimmune disease or hyperproliferative disorder.
XX PS Claim 3; SEQ ID NO 46; 33pp; English.
XX CC The invention relates a new antisense compound, having a sequence
XX CC comprising 8-50 bp targeted to a nucleic acid encoding human NF-kappa-B
XX CC p65 subunit, specifically hybridises with the nucleic acid encoding human
XX CC NF-kappa-B p65 subunit and inhibits its expression. Also included are a
XX CC pharmaceutical composition, a method of inhibiting the expression of
XX CC human NF-kappa-B p65 subunit in cells or tissues, and a method of
XX CC treating an animal having or suspected of having a disease or condition
XX CC associated with human NF-kappa-B p65 subunit. The compound is useful for
XX CC preparing a composition for treating autoimmune disease e.g., multiple
XX CC sclerosis or hyperproliferative disorder e.g., cancer, stress, apoptosis-
XX CC related disease, inflammation, infection and growth disorders. The
XX CC present sequence is a Human NF-kappa-B p65 subunit antisense
XX CC oligonucleotide of the invention.
XX SQ Sequence 18 BP; 6 A; 2 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2669 TGGAGGAGAACTCTTC 2684
Db |||||||||||||
2 TGGAGGAGAACTCTTC 17

RESULT 753
ADH94506/c
ID ADH94506 standard; DNA; 18 BP.
XX AC ADH94506;
XX DT 22-APR-2004 (first entry)
XX DE Human gene PCR primer #1351.
XX KW human; gene sequence; single nucleotide polymorphism; SNP;
XX KW disease diagnosis; ss; PCR; primer.
XX OS Homo sapiens.
XX PN JP2003174883-A.
XX PD 24-JUN-2003.
XX PF 11-DEC-2001; 2001JP-00377637.
XX PR 11-DEC-2001; 2001JP-00377637.
XX PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX DR WPI; 2003-819215/77.
XX FT Polynucleotide for detecting single nucleotide polymorphisms existing in
XX FT human gene, contains isolated human gene having specified sequence.
XX PS Claim 2; SEQ ID NO 2343; 529pp; Japanese.
XX CC The invention comprises isolated human gene sequences and PCR primer
XX CC sequences which can be used to detect single nucleotide polymorphisms
XX CC (SNPs). The DNA sequences of the invention are useful for detecting SNPs
XX CC existing in human genes and for the diagnosis of human disease. The
XX CC present DNA sequence represents a human gene PCR primer of the invention.
XX SQ Sequence 18 BP; 5 A; 3 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 3769 CCAACTTGTCTGCTGTC 3784
Db 16 CCAACTTGTCTGCTGCC 1
RESULT 754
ADH71082
ID ADH71082 standard; DNA; 18 BP.
XX AC ADH71082;
XX DT 25-MAR-2004 (first entry)
XX DE Human Vbeta microsatellite primer #25.
XX KW human; T-cell associated disease; Vbeta; autoimmune disease;
XX KW degenerative nervous system disease; graft versus host disease;
XX KW hypersensitivity disease; infectious disease; neoplastic disease;
XX KW Addison's disease; atrophic gastritis;
XX KW degenerative nervous system disease; multiple sclerosis;
XX KW Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
XX KW allergy; type II hypersensitivity; Goodpasture's syndrome;
XX KW type IV hypersensitivity; leprosy; infectious disease; viral infection;
XX KW HIV; fungal infection; Candida; parasitic infection; schistosoma;
XX KW filaria; bacterial infection; Mycobacterium; neoplastic disease;
XX KW lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
XX KW breast cancer; ss; primer; microsatellite.
XX OS Homo sapiens.

XX PN US2002150891-A1.
XX PD 17-OCT-2002.
XX PF 05-MAR-1999; 99US-002639959.
XX PR 19-SEP-1994; 94US-00309335.
XX PR 19-SEP-1995; 95US-00531241.
XX KW (HOOD/) HOOD L E.
XX KW (ROWE/) ROWEN L.
XX PI Hood LE, Rowen L;
XX DR WPI; 2004-059052/06.
XX FT Kit for diagnosing and treating T-cell associated diseases e.g.
XX FT autoimmune, degenerative nervous system and infectious disease, comprises
XX FT nucleic acid primers specifically priming and allowing amplification of a
XX FT Vbeta gene.
XX PS Disclosure; SEQ ID NO 1276; 164pp; English.
XX CC The invention relates to a kit for diagnosing and treating T-cell
XX CC associated diseases which comprises a panel of nucleic acid primers
XX CC specifically priming and allowing amplification of each Vbeta gene,
XX CC Vbetakna or cDNA. The kit is useful for diagnosing organ transplant
XX CC rejection and diagnosing and treating T-cell associated diseases
XX CC including autoimmune diseases, degenerative nervous system diseases,
XX CC graft versus host disease, hypersensitivity diseases, infectious diseases,
XX CC and neoplastic diseases. Autoimmune diseases include Addison's disease,
XX CC atrophic gastritis. Degenerative nervous system diseases include multiple
XX CC sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
XX CC I hypersensitivities such as contact with allergens that lead to
XX CC allergies, Type II hypersensitivities such as those present in
XX CC Goodpasture's syndrome and Type IV hypersensitivities such as those
XX CC manifested in leprosy. Infectious diseases include viral infections
XX CC caused by viruses such as HIV, fungal infections such as those caused by
XX CC the yeast genus Candida, parasitic infections such as those caused by
XX CC schistosomes, filaria and bacterial infections such as those caused by
XX CC Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
XX CC such as leukaemias, lymphomas and cancers such as cancer of the brain,
XX CC breast. The present sequence represents a Vbeta microsatellite primer.
XX SQ Sequence 18 BP; 3 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 753 CAGCCAGCCTGGATG 769
Db 3 CACTCCAGCCTGGATG 18
RESULT 755
ADM83057
ID ADM83057 standard; DNA; 18 BP.
XX AC ADM83057;
XX DT 03-JUN-2004 (first entry)
XX DE Human NF-kappa-B p65 sub-unit antisense oligonucleotide ISIS 23770.
XX KW ss; antisense; human; NF-kappa-B p65 sub-unit; infection; inflammation;
XX KW tumour formation.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX FT modified_base 1. .18

```

FT FT /*tag= a
FT FT /mod_base= OTHER
FT FT /note= "OTHER = phosphorothioate backbone. Optionally 1-4
FT FT and 15-18 are 2'-methoxyethyl (2'-MOE) nucleotides. All
FT FT 2'-MOE cytidines are 5-methylcytidines"
XX PN US6656688-B1.
XX PD 02-DEC-2003.
XX XX
XX PF 24-MAY-2001; 2001US-00856747.
XX XX
XX PR 25-NOV-1998; 98US-00193859.
XX PR 23-NOV-1999; 99WO-US027762.
XX XX
XX PA (ISIS-) ISIS PHARM INC.
XX XX
XX PI Bennett CF, Monia BP, Cowseert LM;
XX XX
XX DR WPI; 2004-058362/06.
XX XX
XX PT New antisense oligonucleotides inhibiting the expression of human NF-
XX PT kappa-B p65 subunit, useful for treating diseases associated with p65
XX PT expression, or for preventing or delaying infection, inflammation or
XX PT tumor formation.
XX XX
XX PS Example 15; SEQ ID NO 46; 32pp; English.
XX XX
XX CC The invention relates to an antisense compound targeted to a nucleic acid
XX CC molecule encoding human NF-kappa-B p65 sub-unit. The antisense compound
XX CC may be used as a prophylaxis to prevent or delay infection, inflammation or
XX CC tumour formation; used for the treatment of disease or disorder
XX CC associated with the expression of NF-kappa-B p65 sub-unit; for research
XX CC and diagnostics; or as reagents and kits. Antisense compounds may be used
XX CC as research reagents and diagnostics, to elucidate the function of
XX CC particular genes, to distinguish between functions of various members of
XX CC biological pathway, and in treatment regimes of cells, tissues, and
XX CC animals. The present sequence represents a human NF-kappa-B p65 sub-unit
XX CC antisense oligonucleotide.
XX SQ Sequence 18 BP; 6 A; 2 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2669 TGGAGGAGGAGTCTTC 2684
Db ||||| ||||| |||||
2 TGGAGGAGGAGTCTTC 17

RESULT 756
AD90640/c
ID ADS90640 standard; DNA; 18 BP.
XX AC ADS90640;
XX XX
XX DT 18-NOV-2004 (first entry)
XX XX
XX DE Oligonucleotide of the invention SEQ ID NO:1656.
XX XX
XX KW ss; cell proliferative disorder; breast; methylation; cytostatic;
XX KW gene therapy; single nucleotide polymorphism; SNP.
XX XX
XX OS Unidentified.
XX XX
XX PN WO2004035803-A2.
XX PD 29-APR-2004.
XX XX
XX PF 01-OCT-2003; 2003WO-EP010881.
XX XX
XX PR 01-OCT-2002; 2002DE-01045779.

```

```

PR 07-JAN-2003; 2003DE-01000096.
PR 17-APR-2003; 2003DE-01017955.
XX PA (EPITG-) EPIGENOMICS AG.
XX XX
XX PI Foekens J, Harbeck N, Koenig T, Maier S, Martens J, Model F;
XX PI Nimmrich I, Rujan T, Schmitt A, Schmitt M, Look MP, Marx A;
XX DR WPI; 2004-348468/32.
XX XX
XX PT Predicting responsiveness of a subject with breast cell proliferative
XX PT disorder, useful for treating or differentiating breast cell
XX PT proliferative disorders comprises analyzing methylation pattern of a
XX PT genomic DNA from the subject.
XX PS Disclosure; SEQ ID NO 1656; 104pp; English.
XX XX
XX CC The invention relates to a novel method for predicting the responsiveness
XX CC of a subject with a cell proliferative disorder of the breast tissues to
XX CC a therapy comprising analysing the methylation pattern of a target
XX CC nucleic acid by contacting at least one of the target nucleic acids in a
XX CC biological sample obtained from the subject prior to or during treatment.
XX CC The method of the invention has cytostatic activity, and may have a use
XX CC in gene therapy. The set of oligonucleotides comprising at least two of
XX CC the oligomers are useful for detecting the cytosine methylation state
XX CC and/or single nucleotide polymorphisms (SNPs) within the sequences. The
XX CC methods, nucleic acid, oligonucleotide, and kit are useful for the
XX CC treatment, characterisation, classification and/or differentiation, of
XX CC breast cell proliferative disorders. The method is also useful for
XX CC predicting the responsiveness of a subject with a cell proliferative
XX CC disorder of the breast tissues to a therapy. The present sequence is used
XX CC in the exemplification of the invention.
XX SQ Sequence 18 BP; 7 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3789 CCAAACTCAATCATTT 3804
Db ||||| ||||| |||||
16 CCAAACTCAATCATTT 1

RESULT 757
ADZ66354/c
ID ADZ66354 standard; DNA; 18 BP.
XX AC ADZ66354;
XX XX
XX DT 14-JUL-2005 (first entry)
XX XX
XX DE DNA methylation analysis method-related human CBFA2T3 PCR primer SeqID37.
XX XX
XX KW DNA methylation; gene expression; cancer; breast tumor; prostate tumor;
XX KW ovary tumor; hepatocellular carcinoma; CBFA2T3; PCR; primer; ss.
XX XX
XX OS Homo sapiens.
XX XX
XX PN WO2005038046-A1.
XX XX
XX PD 28-APR-2005.
XX XX
XX PF 14-OCT-2004; 2004WO-AU001398.
XX XX
XX PR 14-OCT-2003; 2003AU-00905593.
XX XX
XX PA (BION-) BIONOMICS LTD.
XX XX
XX PI Bais AJ, Kremmidiotis G;
XX DR WPI; 2005-322870/33.
XX XX

```


PT Identifying normal cell methylation range in locus of interest by
PT modifying nucleic acids by cytosine-conversion, identifying sample with
PT methylated CpG sites, producing methylation map, quantifying methylation
XX ratio, establishing range.
XX Example 1; SEQ ID NO 37; 80pp; English.
XX This invention relates to a novel method of identifying a normal cell
CC methylation range in a locus of interest. The method involves providing
CC separately nucleic acids from samples and modifying the nucleic acids by
CC cytosine-conversion, identifying samples with high to moderately
CC methylated CpG sites, generating a methylation map, performing
CC amplification of specific CpG sites, quantifying the unmethylated to
CC methylated ratio and establishing a correlation between methylation and
CC mRNA expression levels. The method is useful for identifying a normal
CC cell methylation range, in order to allow for the detection of aberrant
CC methylation, in a locus of interest in a nucleic acid, particularly at a
CC CpG island. The invention is useful for detecting aberrant methylation in
CC a locus of interest in a nucleic acid, particularly at a CpG island, of a
CC subject and may be useful for diagnosis or prognosis of a disease in a
CC subject. The disease is cancer chosen from breast cancer, prostate
CC cancer, ovarian cancer, hepatocellular cancer and primitive
CC neuroectodermal cancer. The invented method is preferably useful for
CC screening samples for aberrant methylation of the CBFA2T3 gene and
CC enables high sensitive and accurate quantification of CpG methylation at
CC any given genetics locus. The present sequence is that of a PCR primer
CC which was used for amplification of a region of the human CBFA2T3 gene in
CC the exemplification of the invention.
XX
XX SQ Sequence 18 BP; 2 A; 10 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2700 GAGCTCCCTGGGAGGA 2715
|||||
Db 18 GAGCTGCTGGGAGGA 3

RESULT 758
AE12272/c
ID AE12272 standard; DNA; 18 BP.
XX
XX AC AE12272;
XX
XX 28-JUL-2005 (first entry)
XX Human KIR allele 2DS4*00101/00102/002 sense PCR primer.
XX
XX ss; primer; PCR; killer-cell immunoglobulin-like receptor;
XX allelic variation; DNA detection.
XX
XX OS Homo sapiens.
XX
XX WO2005046459-A2.
XX
XX 26-MAY-2005.
XX
XX 15-MAR-2004; 2004WO-US007925.
XX
XX 22-OCT-2003; 2003US-0513307P.
XX
XX (PELF-) PEL-FREEZ CLINICAL SYSTEMS INC.
XX
XX Dinauer D, Wang L;
XX
XX WPI; 2005-417488/42.
XX

Primer set for identifying killer-cell immunoglobulin-like receptor KIR
allele or all of presently known KIR alleles, comprises primer pairs
capable of producing amplicon having specific length from nucleic acid
encoding KIR.

XX Example 1; Page 23; 32pp; English.
XX The invention relates to a novel primer set for identifying a killer-cell
CC immunoglobulin-like receptor (KIR) allele or identifying all of the
CC presently known KIR alleles, comprising a first primer pair that
CC comprises a first primer and second primer, or several primer pairs
CC capable of identifying all presently known KIR alleles, where the primer
CC pairs are capable of producing an amplicon that is less than or 1000
CC bases in length from a nucleic acid that encodes a KIR. The primer set is
CC useful for detecting a KIR allele, in carrying out reverse transcriptase
CC (RT)-PCR of KIR mRNA for expression analysis, and for identifying single
CC KIR allele. The primer set is useful for defining or identifying KIR
CC haplotypes, genotypes and polymorphic variations in an individual or in
CC different populations, for identifying KIR compatible and incompatible
CC stem cell transplant donor-recipient pairs and for studying if KIR
CC mismatching between donor and recipient correlates with KIR epitope
CC mismatch predicted by human leukocyte antigen (HLA). The primer set
CC provides high resolution or allele level genotyping that primarily target
CC polymorphism in the extracellular domains of the KIR genes. The sequences
CC shown in (AE12251-AE12290) represent the primer set of the invention.
XX
XX SQ Sequence 18 BP; 3 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 4.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 378 GGAGCTCCGGGTGCTG 393
|||||
Db 16 GGAGCTCCGGGTGCTG 1

Search completed: March 23, 2006, 11:10:29
Job time : 43 secs

THIS PAGE BLANK (USPTO)